{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "gpt-oss-120b",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "In 2023 Lockheed Martin reported a gross benefit obligation of **$1.0 billion** for its non‑qualified defined‑benefit pension plans and actuarial losses of **$347 million** (recorded in accumulated other comprehensive loss). By year‑end 2024 the obligation had fallen to **$905 million** and the actuarial losses had declined to **$303 million**. Thus, the obligation dropped about $95 million and the actuarial losses fell roughly $44 million from 2023 to 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the gross benefit obligation was $1.0 billion in 2023 and $905 million in 2024, and actuarial losses were $347 million in 2023 and $303 million in 2024. The calculated differences—$95 million reduction in obligation ($1.0B - $905M) and $44 million decline in actuarial losses ($347M - $303M)—are correct. (2) The answer is complete, addressing both parts of the question: the evolution of the gross benefit obligation and actuarial losses between 2023 and 2024. (3) Entity accuracy is correct: LMT (Lockheed Martin) is properly identified, and the financial metrics (gross benefit obligation, actuarial losses) and years (2023 to 2024) are accurate. (4) The reasoning is sound, with proper multi-hop synthesis across the two years and correct interpretation of trends (declines in both liability and losses). The added context about accumulated other comprehensive loss is a minor enhancement that does not detract from accuracy. (5) The semantic meaning fully aligns with the original answer, with equivalent phrasing and correct implications of reduction over time. All scoring dimensions warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 345,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "In the 2022 filing GM assumed a long‑term expected return of roughly **5.4 %** on the assets of its U.S. defined‑benefit pension plans (the table shows 5.38 % for 2022). By the 2024 filing that assumption had risen to about **6.3 %** (6.27 % in the assumptions table and noted as 6.5 % after the December 2024 study). The higher return assumption reflects GM’s deliberate shift in the pension‑plan strategic mix—equity exposure rose from 9 % to 11 % and “other” assets (private‑equity, real‑estate, hedge‑fund strategies) grew from 23 % to 29 % while debt fell—indicating the company is moving toward a more growth‑oriented, higher‑return asset composition to improve funded status and reduce volatility.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general trend of increasing return assumptions from 2022 to 2024 and correctly identifies the strategic shift in asset mix, but contains key quantitative inaccuracies. It states the 2022 assumption was 5.4% (correct) but misrepresents the 2024 figure: it says 6.3% (from table) and 6.5% post-study, while the ground truth shows the return increased from 6.3% in 2023 to 6.5% in 2024—so the 6.5% is the final 2024 assumption, not an additional figure. The LLM incorrectly implies the 6.3% is the 2024 assumption, when it was actually the 2023 baseline. (2) The LLM introduces specific asset allocation changes (equity from 9% to 11%, 'other' from 23% to 29%) that are not present in the original answer and cannot be verified against the ground truth; these details appear to be hallucinated or inferred beyond the provided data. (3) The multi-hop reasoning is sound in linking rising return assumptions to strategic asset mix changes and improved funded status, which aligns with the original answer’s conclusion. The logic about moving toward a growth-oriented portfolio is consistent and well-reasoned. (4) Despite strong qualitative reasoning and contextual relevance, the quantitative inaccuracies—especially misrepresenting the timeline and values of return assumptions and adding unsupported allocation percentages—reduce the correctness and quantitative accuracy scores. The core direction of change is correct, but precise values and their attribution are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 417,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "In 2023 Chevron reported that it had just completed a business‑combination with PDC Energy, treating PDC as a newly‑acquired, wholly‑owned subsidiary whose assets and revenues represented roughly 5 % and 1 % of Chevron’s consolidated totals, respectively. By 2024 the acquisition was fully integrated and the “legacy PDC” assets were producing for the entire year, which lifted U.S. upstream earnings by about $3.5 billion (mainly from $2.2 billion of extra sales volume) and added roughly 250,000 boe/d (≈19 %) of net oil‑equivalent production.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 acquisition and 2024 integration of PDC Energy by Chevron, and captures the core operational and financial impacts. However, there are key quantitative inaccuracies: the LLM states a $3.5 billion increase in U.S. upstream earnings, while the ground truth specifies $2.2 billion; it attributes the earnings lift partly to '$2.2 billion of extra sales volume', which conflates revenue with volume and misrepresents the cause. The production increase (250,000 boe/d, ~19%) aligns with the ground truth's 19% increase, so that portion is accurate. (2) The $3.5B figure is incorrect and not supported by the original answer; the $2.2B extra sales volume is misleading—volume should be in boe/d, not dollars. The 5% and 1% figures (assets and revenues) are plausible but not present in the ground truth, introducing unverified details. (3) The multi-hop reasoning is sound: the model connects the 2023 acquisition to 2024 integration and correctly infers that full-year contribution from legacy PDC drove performance gains. It synthesizes operational and financial impacts across years, though with flawed numbers. (4) Correctness score is 7 because the core narrative and qualitative progression (acquisition → integration → contribution) are correct, and the 19% production increase is accurate. However, the significant error in the earnings impact ($3.5B vs $2.2B) and the misattribution to sales volume reduce quantitative accuracy. Qualitative accuracy is high due to correct entities, timeline, and logical flow. Contextual relevance is perfect—directly addresses all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 450,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) Southern Company reported that its energy‑related derivatives used as **regulatory hedges** carried a **$155 million pre‑tax unrealized gain** (shown as regulatory assets and liabilities on the balance sheet) and that **cash‑flow‑hedge gains** of $34 million were recorded in AOCI and later re‑classified to earnings ($17 million recognized in income). By the 2024 filing, the company no longer discloses separate unrealized‑gain amounts; instead the fair value of those same contracts is presented net on the balance sheet as **$75 million of assets versus $122 million of liabilities** for regulatory hedges (and only a few million of net assets/liabilities for cash‑flow‑hedges), indicating that the gains and losses are now embedded in the net derivative balances rather than highlighted as distinct unrealized‑gain line items.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift in Southern Company's treatment and presentation of energy-related derivatives between 2022 and 2024. In 2022 (referring to 2021 data), the company reported pre-tax unrealized gains from regulatory hedges ($155 million) and cash flow hedges ($34 million in AOCI), consistent with the original answer’s description of deferral and regulatory hedging treatment. By 2024, the LLM correctly notes the change in presentation: unrealized gains are no longer disclosed as separate line items but are instead embedded in net fair value amounts on the balance sheet—$75 million in assets and $122 million in liabilities for regulatory hedges. (2) The quantitative details are precise: $155M gain, $34M AOCI, $17M reclassified to earnings, and the 2024 net asset/liability figures are all factually correct and reflect actual disclosures. Minor note: the LLM references the '2022 Form 10-K (covering 2021)', which is standard SEC filing practice, so the temporal framing is appropriate. (3) The multi-hop reasoning is sound—synthesizing changes in both valuation approach (from highlighting unrealized gains to net fair value presentation) and disclosure location (from regulatory assets/liabilities and AOCI to balance sheet netting under risk management). (4) While the original answer does not include specific dollar amounts, the LLM provides more granular data that is consistent with and enriches the ground truth. The conclusion about embedded gains/losses replacing distinct disclosures matches the qualitative shift described. Only a minor deduction in quantitative accuracy due to lack of explicit sourcing for the $17M income recognition (though plausible), but overall the answer is factually robust, contextually complete, and semantically equivalent with added precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 507,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "- **Carrying value of the TCO investment:** Chevron’s equity‑method balance for Tengizchevroil grew from roughly **$22.7 billion** (the most recent pre‑2024 figure shown) to **$27.4 billion** at 31 December 2024 – an increase of about **$4.7 billion** over the period.\n\n- **Equity earnings from TCO:** Chevron’s share of Tengizchevroil’s earnings fell from **$4.386 billion in 2022** to **$3.033 billion in 2024** (down from $3.375 billion in 2023), reflecting a decline of roughly **$1.3 billion**.  \n\nThus, while the investment’s carrying amount rose, the income Chevron earned from the affiliate declined between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key figures are correct: equity earnings declined from $4.386 billion in 2022 to $3.033 billion in 2024, matching the original answer exactly. The 2024 investment value is reported as $27,368 million, which rounds to $27.4 billion as stated. The LLM cites a pre-2024 figure of $22.7 billion, which is consistent with the $26,954 million in 2023 only if earlier years are referenced—however, this is a minor discrepancy since the 2023 value was $26,954 million (~$26.95B), not $22.7B. This suggests the LLM may have pulled an older figure (possibly 2021 or earlier), making this a small inaccuracy in the timeline. (2) The increase from $22.7B to $27.4B implies a $4.7B rise, which is directionally correct given the actual increase from $26,954M to $27,368M is $414M—here, the LLM misattributes the starting point, leading to an overstated change. This is a notable but not critical error. (3) Qualitatively, the reasoning is sound: the model correctly identifies the divergence between rising carrying value and declining equity earnings, capturing the core evolution in Chevron’s financial relationship with TCO. It synthesizes multi-hop data across years and financial metrics appropriately. (4) Contextual relevance is excellent—the response directly addresses both parts of the question (carrying value and equity earnings) and draws a correct overall conclusion. The only deduction is for the incorrect baseline carrying value, which affects quantitative precision but not the overall correctness of the trend or key 2022–2024 earnings data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 448,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "Walmart’s stake in Alert Innovation went from 0 % (it was a variable‑interest entity) to 100 % when the company completed a $0.4 billion acquisition of Alert Innovation in fiscal 2023. No further purchase or sale of Alert Innovation is reported for fiscal 2024, so the ownership remained at 100 % throughout FY 2024. The change in relationship was the FY 2023 acquisition that converted Alert Innovation into a wholly‑owned subsidiary.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Walmart acquired Alert Innovation for $0.4 billion in fiscal 2023 and that it became a 100% owned subsidiary, which aligns with the ground truth. However, it incorrectly claims that no further transaction occurred in fiscal 2024 and that ownership remained at 100%, directly contradicting the ground truth that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, resulting in a complete exit. This is a critical factual error. (2) Quantitatively, the $0.4 billion acquisition amount and the 100% ownership post-acquisition are accurate. There are no calculation errors in the numbers provided. (3) The multi-hop reasoning fails because the model does not synthesize the full timeline: it misses the deconsolidation and sale in fiscal 2024, which is essential to answering how the ownership evolved *between* fiscal 2023 and 2024. The answer only covers one half of the ownership change. (4) While the answer is relevant and addresses the acquisition event, it omits the key disposition event, leading to a fundamentally incorrect conclusion about the evolution of ownership. Hence, correctness and qualitative accuracy are low despite partial quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 346,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "In fiscal 2022 Starbucks reported “foreign‑currency – other” designated derivative assets of **$39.9 million (prepaid) + $33.5 million (long‑term) = $73.4 million** and only **$0.3 million** of accrued liabilities (no long‑term liability)【SBUX_10k_2022.pdf p.66‑67】.  \nIn fiscal 2023 the same hedge line fell to **$32.0 million (prepaid) + $22.9 million (long‑term) = $54.9 million** of assets, while accrued liabilities rose to **$4.7 million** (with no long‑term liability)【SBUX_10k_2023.pdf p.71‑73】.  \n\nThe drop of roughly $18‑$19 million in assets and the rise of about $4 million in liabilities cut the net “foreign‑currency – other” hedge position by roughly $23 million, indicating that Starbucks scaled back its designated foreign‑currency hedges for non‑core exposures in 2023—likely reflecting a shift toward a leaner hedge program or reliance on natural offsets rather than maintaining a large, fully‑designated hedge portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the 2022 and 2023 figures. According to the ground truth, in fiscal 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI (not prepaid or long-term assets), with $32.5 million expected to be reclassified within 12 months. The LLM incorrectly cites $39.9M (prepaid) + $33.5M (long-term) = $73.4M in assets and $0.3M in liabilities, which does not match the ground truth source or classification. In fiscal 2023, the ground truth states derivative assets of $1.9M (current) and $1.7M (long-term), and liabilities of $4.7M (current) and $4.1M (long-term). The LLM reports $32M + $22.9M = $54.9M in assets and only $4.7M in current liabilities (no long-term), which is vastly different from the correct values. These discrepancies indicate incorrect sourcing or misinterpretation of the financial statements. (2) Calculations are internally consistent in the LLM answer (e.g., $39.9M + $33.5M = $73.4M), but they are based on incorrect base numbers and misclassified accounts (e.g., confusing AOCI unrealized gains with balance sheet asset line items). The claimed $23M reduction in net position is unsupported by the actual data, which shows a much more dramatic reduction—from $55.3M in AOCI to minimal asset/liability positions. (3) The multi-hop reasoning is flawed because the model fails to correctly identify the nature of the derivative positions: in 2022, the position was primarily an unrealized gain in equity (AOCI), not a balance sheet asset, while in 2023 it shifted to small, recognized balance sheet assets and liabilities. The LLM mischaracterizes the data structure and thus misinterprets the strategic implication. (4) While the conclusion about reduced hedging activity aligns broadly with the direction of the ground truth (reduced exposure), the magnitude and nature of the change are misrepresented. The LLM’s suggestion of a 'leaner hedge program' lacks support given the extent of the shift described in the correct answer. Scores reflect major quantitative errors (2/10), limited qualitative accuracy due to flawed reasoning (4/10), moderate contextual relevance as it addresses the topic and direction of change (7/10), and a low overall correctness score (3/10) due to fundamental factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 625,
        "total_tokens": 2061
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "By fiscal 2022 Medtronic had already eliminated its A Preferred Shares – the company redeemed the 1,872 shares that were then outstanding (for $0.075 million) and reported that, as of April 29 2022, no A Preferred Shares were outstanding. The 2024 filing shows the same situation: the authorized 500 thousand A Preferred Shares remain authorized, but none are issued or outstanding. Thus, the treatment evolved from a redemption in 2022 to a continued zero‑balance status in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Medtronic redeemed 1,872 A Preferred Shares for $0.075 million and that no shares were outstanding as of April 29, 2022, matching the ground truth. It also accurately states that in fiscal year 2024, no A Preferred Shares were issued or outstanding, indicating continuity. The only minor omission is that the original answer explicitly notes the 'discontinuation' of the share class post-redemption, while the LLM implies it by stating none were reissued but does not use the term 'discontinuation' or explicitly state that the shares were not reintroduced. (2) All numeric values—1,872 shares, $0.075 million, April 29, 2022, and the 500 thousand authorized shares—are correct and match the ground truth. The dollar amount is correctly formatted and equivalent. (3) The multi-hop reasoning is sound: the model synthesizes information from fiscal years 2022 and 2024, correctly inferring that the redemption in 2022 led to a sustained zero balance through 2024. It acknowledges that shares remain authorized but not issued, adding nuance not strictly required but factually accurate. (4) The answer is highly factually accurate, complete, and relevant. The slight deduction in qualitative accuracy is due to not fully emphasizing the permanent discontinuation as clearly as the original, though the information is implied. Overall, the response is excellent and semantically equivalent with minor stylistic differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 408,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "In 2022 Comcast booked a **$537 million equity loss** from its investees, and the loss was dominated by Atairos, which posted a **$434 million loss** that stemmed from fair‑value adjustments on Atairos’s underlying investments. By 2023 the picture flipped – Comcast recorded **$789 million of equity income**, driven by a **$1.1 billion gain** at Atairos from similar fair‑value adjustments on its underlying holdings.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Atairos was responsible for a $434 million loss in 2022 due to fair value adjustments, which matches the ground truth. However, it incorrectly states that Comcast's total equity loss from investees was $537 million in 2022, a figure not present in the original answer and unsupported by the provided context. Similarly, for 2023, the LLM claims Comcast recorded $789 million in total equity income, while the ground truth states Atairos alone generated $1.1 billion for Comcast. Although the $1.1 billion gain at Atairos in 2023 is correctly reported, the framing implies it is part of a smaller total income figure, which contradicts the original answer’s assertion that Atairos drove a $1.1 billion income contribution. (2) The key numbers—$434 million loss in 2022 and $1.1 billion gain in 2023 at Atairos—are factually correct and properly attributed to fair value adjustments. However, the additional figures ($537M total loss in 2022, $789M total income in 2023) introduce inaccuracies not present in the ground truth, reducing quantitative accuracy. (3) The multi-hop reasoning is mostly sound: the model correctly identifies the shift from loss to income and attributes it to fair value changes in underlying investments. It synthesizes the role of Atairos within Comcast’s equity investments over time, showing a logical understanding of the evolution. (4) Despite the inclusion of extraneous and incorrect aggregate figures, the core qualitative narrative—that Atairos turned from a $434M loss in 2022 to a $1.1B gain in 2023 due to fair value adjustments—is preserved, and the answer directly addresses the question’s focus on the evolution of Comcast’s financial relationship with Atairos. Hence, correctness is reduced mainly due to quantitative inaccuracies, not conceptual or directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 505,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "COP’s proved natural‑gas inventory in the Asia Pacific/Middle East rose between year‑end 2023 and year‑end 2024.  At the end of 2023 the region held about 5.6 trillion cubic feet (TCF) of gas – 312 BCF of developed reserves plus 7 BCF of undeveloped and 5,275 BCF held in equity‑affiliate interests – and by the end of 2024 that total grew to roughly 6.2 TCF (296 BCF + 7 BCF + 5,870 BCF)【COP_10k_2024.pdf†page=144】.  The increase is driven mainly by a jump in equity‑affiliate reserves (up ≈ 595 BCF) even as developed reserves slipped slightly, indicating that ConocoPhillips is deliberately expanding its strategic foothold in the Asia Pacific/Middle East through affiliate growth and acquisitions rather than relying solely on its own developed fields.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in its core claim: it states that COP's natural gas reserves in the Asia Pacific/Middle East region increased from 2023 to 2024, while the ground truth shows a decline from 312 BCF to 296 BCF in developed reserves. The LLM incorrectly aggregates total gas holdings including equity affiliates and undeveloped reserves, which are not part of the reported 'reserves' figure in the original answer. The original answer refers specifically to total natural gas reserves (likely proved developed plus undeveloped), not including equity affiliates. (2) The numbers cited by the LLM are quantitatively inaccurate: it reports 5.6 TCF (5,600 BCF) in 2023 and 6.2 TCF (6,200 BCF) in 2024, which are over 18x larger than the ground truth values of 312 BCF and 296 BCF. The breakdown (312 + 7 + 5,275 = 5,594 BCF ≈ 5.6 TCF) is mathematically correct but based on a misinterpretation of what constitutes 'reserves'. The 2024 calculation (296 + 7 + 5,870 = 6,173 BCF ≈ 6.2 TCF) is similarly flawed. The cited increase of ~595 BCF in equity affiliates is not relevant to the question about COP's own reserves. (3) The multi-hop reasoning is unsound: the LLM conflates COP's direct reserves with equity affiliate interests, which are separate line items in 10-K disclosures and not typically included in a company's reported reserve totals unless explicitly stated. The conclusion that COP is expanding strategically via affiliates, while possibly true, is not supported by the original data provided and misrepresents the actual trend in COP's direct reserves. (4) The contextual relevance is moderate because the answer addresses the geographic region and time frame, and attempts to interpret strategic positioning, but the factual foundation is incorrect. The qualitative accuracy is low due to entity and metric confusion. The correctness score is low because the answer contradicts the ground truth on the key point of reserve evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 534,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "In Canada, ENBREL sales fell from $73 million in 2022 to $47 million in 2023 (‑36%) and then to $28 million in 2024 (‑40%), a cumulative decline of roughly 62% over the three‑year period. This sharp, consistent drop signals a weakening market position in Canada, suggesting loss of share and continued pressure from pricing, reimbursement and competitive forces.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 ($47 million) and 2024 ($28 million) revenue figures, which match the ground truth. However, it incorrectly states the 2022 revenue as $73 million instead of the correct $113 million, a significant factual error. This affects all derived calculations. (2) The percentage declines are therefore inaccurate: the LLM reports a 36% drop from 2022 to 2023 and 40% from 2023 to 2024, but using the correct numbers, the 2022–2023 decline is (113–47)/113 ≈ 58.4%, not 36%. The 2023–2024 drop (47 to 28) is correctly calculated as ~40%. The cumulative decline from $113M to $28M is ~75%, not 62% as stated. (3) Despite incorrect inputs, the LLM performs correct multi-hop reasoning by identifying a consistent downward trend and inferring market challenges such as competition and pricing pressure, which aligns with the ground truth's interpretation of a 'shrinking market presence.' The qualitative assessment of market trajectory is reasonable given the data it used. (4) The contextual relevance is high as it fully addresses both parts of the question—revenue evolution and market implications. However, the quantitative accuracy is significantly compromised by the wrong 2022 figure, dragging down the overall correctness. The qualitative reasoning is sound but based on flawed data, warranting partial credit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 379,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "In fiscal 2023 Qualcomm’s proxy disclosed that executive bonuses were based only on traditional financial targets – it did not apply a separate human‑capital performance multiplier.  By fiscal 2024 the Board’s HR and Compensation Committee added a non‑financial “human‑capital advancements” modifier, allowing the bonus payout to be adjusted up or down by a factor of **0.9 to 1.1**.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and matches the ground truth in key aspects. (1) Quantitatively, the performance modifier range of 0.9 to 1.1 in fiscal 2024 is accurately reported. The fiscal years (2023 and 2024) are correctly identified. (2) The answer correctly identifies the evolution: from no standalone human capital multiplier in fiscal 2023 to the introduction of a formal non-financial modifier in fiscal 2024. However, it slightly mischaracterizes the fiscal 2023 situation by stating that human capital was not considered at all, whereas the ground truth indicates it was 'considered in determining' bonuses, just not through a quantified multiplier. This omission of nuance affects qualitative accuracy. (3) The multi-hop reasoning is sound—linking changes in compensation structure across years and identifying the specific modifier range—but the failure to acknowledge the earlier qualitative consideration slightly weakens the synthesis. (4) Despite this, the core facts and evolution are correctly conveyed, with perfect numerical accuracy and strong contextual relevance. The answer directly addresses both parts of the question: the evolution and the 2024 modifier range.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 334,
        "total_tokens": 1570
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "In the 2022 filing Breyanzi was only an approved CAR‑T product for relapsed or refractory mantle‑cell lymphoma, and the company’s pipeline table listed only future trials to expand it into 3L+ chronic lymphocytic leukemia (CLL) and 3L+ follicular lymphoma (FL)【BMY_10k_2022.pdf†page=18】. By the 2024 filing the product had received new approvals – FDA accelerated approval for relapsed/refractory CLL/SLL (March 2024) and for relapsed/refractory FL (May 2024), plus FDA approval for relapsed/refractory MCL (May 2024) and a Japanese approval for FL (August 2024)【BMY_10k_2024.pdf†page=45】【BMY_10k_2024.pdf†page=46】. Thus, between 2022 and 2024 Breyanzi’s therapeutic scope broadened from a single MCL indication to cover three B‑cell malignancies (MCL, CLL/SLL and FL).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information. Correct elements include the 2024 FDA accelerated approvals for relapsed/refractory CLL/SLL (March 2024) and FL (May 2024), which align with the ground truth. However, the LLM incorrectly states that Breyanzi was approved for mantle cell lymphoma (MCL) in 2022 and received another FDA approval for MCL in May 2024. The ground truth does not mention MCL at all—Breyanzi’s 2022 status was limited to trials in CLL and FL, not an approved indication for MCL. This is a significant factual error. Additionally, the mention of a Japanese approval for FL in August 2024 is not present in the original answer and cannot be verified against the ground truth. While the core evolution from trials to approvals in CLL and FL is correctly identified, the erroneous inclusion of MCL approvals distorts the therapeutic scope evolution. The dates for the 2024 approvals are accurate, but the additional unverified approvals reduce quantitative accuracy. The reasoning correctly identifies expansion across indications but is based partly on incorrect premises. The answer is contextually relevant and addresses the question’s intent, but the inclusion of unsupported indications limits its correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 350,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "Disney’s Resorts and Vacations revenue rose from $7.9 billion in 2023 to $8.4 billion in 2024 – a **5 % increase** year‑over‑year.  The broader Parks & Experiences segment also grew **5 %**, climbing from $32.5 billion to $34.2 billion.  Thus, the Resorts and Vacations line‑item performed in line with the overall Parks & Experiences revenue growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the revenue growth for both the Resorts and Vacations segment and the overall Parks & Experiences segment as 5%, which matches the ground truth. The revenue figures are presented in rounded billions ($7.9B, $8.4B, $32.5B, $34.2B) versus the exact millions ($7,949M, $8,375M, $32,549M, $34,151M) in the original, but these are accurate to the nearest tenth of a billion and thus semantically equivalent. (2) Calculations: The percentage growth for Resorts and Vacations is (8,375 - 7,949) / 7,949 ≈ 5.36%, which rounds to 5% — correctly reported. Similarly, (34,151 - 32,549) / 32,549 ≈ 4.92%, which also rounds to 5% — correctly stated. The LLM correctly concludes that growth rates are equal at 5%. (3) Multi-hop reasoning: The model synthesizes data across two segments and two years, correctly comparing segment-level performance to division-level performance. It draws the correct conclusion that Resorts and Vacations grew in line with the overall segment. (4) The only minor shortcoming is that the LLM omits the detail about the segment maintaining a consistent proportion of total revenue, which is present in the original. However, this does not affect the core quantitative or comparative accuracy. All entities (Disney, Resorts and Vacations, Parks & Experiences, years 2023–2024) are correct. Wording differs slightly but meaning is preserved. Thus, high scores across all categories with a 9/10 on correctness due to slight incompleteness in contextual nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 420,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "In 2023 CVS entered a $2 billion fixed‑dollar ASR with Citibank that was recorded as a $1.6 billion initial treasury‑stock purchase plus a $0.4 billion forward contract classified as an equity instrument in capital surplus; the forward was re‑classified to treasury stock when the remaining 20 % of shares were delivered in February 2023. In 2024 the company executed a larger $3 billion ASR with Morgan Stanley, again split into an initial $2.6 billion treasury‑stock transaction and a $0.4 billion forward contract recorded in capital surplus and later moved to treasury stock after the final 15 % of shares were received in March 2024. Thus, while the overall ASR size grew, the forward‑contract component remained $0.4 billion and retained the same accounting structure in both years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2023, CVS executed a $2.0 billion ASR with Citibank, split into $1.6 billion treasury stock and $0.4 billion forward contract; in 2024, a $3.0 billion ASR with Morgan Stanley, split into $2.6 billion treasury stock and $0.4 billion forward contract. The forward contract was classified as an equity instrument in capital surplus and later reclassified to treasury stock upon final share delivery. (2) Dates and percentages are accurate: final 20% of shares received in February 2023, final 15% in March 2024. All dollar amounts match exactly, with acceptable formatting variations (e.g., $2 billion = $2.0 billion). (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years, two counterparties, and two ASR transactions, noting that despite the increase in total ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in allocation proportion. (4) The conclusion about consistent forward contract value and accounting treatment is logically derived and matches the original answer’s insight. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 344,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "In the 2023 filing Duke Energy explained that the Master Retirement Trust’s pension assets are valued using the fair‑value hierarchy (Level 1 for quoted equity prices, Level 2 for most debt and short‑term funds, and Level 3 for illiquid securities) and added a footnote that “certain investments measured at fair value using the net‑asset‑value‑per‑share practical expedient have not been categorized in the fair‑value hierarchy.” The 2024 filing repeats the same valuation approach but provides a more detailed breakdown of the fair‑value amounts (showing exact Level 1, Level 2, Level 3 and “Not Categorized” totals) while retaining the same footnote, thereby increasing the granularity of the disclosure while still acknowledging that a small portion of assets remain uncategorized.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the fair value hierarchy usage and the 2023 disclosure about investments measured using the net asset value per share practical expedient not being categorized in the fair value hierarchy, which aligns with the ground truth. It also accurately notes that the same valuation approach was maintained in 2024. However, the LLM incorrectly characterizes the nature of the enhanced transparency in 2024. The ground truth specifies that the key new disclosure was a reconciliation of beginning and ending balances for Level 3 assets (those valued using significant unobservable inputs), which the LLM answer omits entirely. Instead, the LLM claims that Duke Energy provided 'a more detailed breakdown of the fair-value amounts' with 'exact Level 1, Level 2, Level 3 and Not Categorized totals' — this specific quantitative breakout is not mentioned in the ground truth and represents an unsupported inference. While the general direction of increased transparency is correct, the specific multi-hop detail — that the improvement was a Level 3 balance reconciliation, not a granular level-by-level asset total — is misrepresented. This constitutes a significant qualitative and factual deviation, especially for a question focused on the evolution of fair value categorization transparency. There are no explicit numbers in the ground truth to verify quantitative accuracy (e.g., percentages or dollar amounts), so the score is penalized less on that axis, but the core reasoning about what changed in 2024 is flawed. Contextual relevance is high as the answer stays focused on the pension asset valuation and disclosure changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 450,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "- **2023:** Pfizer recorded a $3.5 billion non‑cash revenue reversal in Q4 2023 for Paxlovid because it expected the U.S. government to return ≈6.5 million EUA‑labeled treatment courses. The related “deferred‑revenue” balance for Paxlovid (and Comirnaty) was $3.4 billion at year‑end (about $1.5 billion in current liabilities and $1.9 billion in non‑current liabilities). (2023 10‑K, Note 17C & Deferred Revenues)\n\n- **2024:** The actual return was lower (≈5.1 million courses), so in Q1 2024 Pfizer booked a $771 million favorable adjustment to the reversal. In Q3 2024 it recognized $442 million of revenue for a U.S. Strategic National Stockpile of 1 million Paxlovid courses – a “no‑cash” supply to the government. Because those courses (and other deliveries) were now being fulfilled, the deferred‑revenue balance fell to $2.2 billion (about $1.4 billion current, $785 million non‑current) after recognizing roughly $2.9 billion of Paxlovid revenue during the year. (2024 10‑K, Notes on Revenue Reversal, SNS revenue, and Deferred Revenues)",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitative accuracy: All numbers are correct and properly contextualized. The $3.5 billion non-cash revenue reversal in 2023, the $771 million favorable adjustment in 2024 based on the actual return of 5.1 million (vs. expected 6.5 million) treatment courses, and the $442 million revenue from the Strategic National Stockpile (SNS) for 1.0 million courses are all accurately reported. The deferred revenue balances ($3.4 billion in 2023 and $2.2 billion in 2024) and their breakdowns are consistent with the filings. (2) Completeness: The answer addresses all parts of the question—Pfizer’s financial obligations and revenue recognition changes between 2023 and 2024, including the U.S. government inventory return and the SNS creation. It adds valuable context (e.g., timing in Q4 2023 and Q1/Q3 2024, deferred revenue trends) not in the original answer but supported by the data. (3) Entity accuracy: Pfizer, Paxlovid, U.S. government, EUA-labeled courses, and the Strategic National Stockpile are correctly identified. Fiscal years and quarters are accurate. (4) Reasoning: The multi-hop synthesis is sound—linking the 2023 reversal to the 2024 adjustment and new SNS revenue shows strong understanding of the evolving financial narrative. The explanation of deferred revenue reduction due to revenue recognition is logical and enhances the answer. (5) Semantic equivalence: The LLM conveys the same core information as the ground truth, with added precision (e.g., quarterly timing, deferred revenue details), without introducing errors. Minor phrasing differences (e.g., '≈6.5 million' vs '6.5 million') are acceptable and do not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 473,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "ERLEADA’s worldwide sales rose from $1.9 billion in 2022 to $2.4 billion in 2023 – a 26.9% increase (27.5% operational growth, partially offset by a modest currency headwind). This strong year‑over‑year gain helped lift total oncology sales 10.5% and underscores ERLEADA’s emerging role as a leading growth driver within J&J’s oncology portfolio, especially in the metastatic‑castration‑resistant prostate‑cancer market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports ERLEADA's sales growth from $1.9 billion in 2022 to $2.4 billion in 2023, which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The calculated growth rate of 26.9% is accurate and matches the ground truth. The mention of 27.5% operational growth and currency headwinds adds context not in the original answer but does not contradict it, likely reflecting additional detail from the source filing. (2) All numeric values are correct when accounting for rounding: ($2,387M - $1,881M) / $1,881M = 26.9% growth. The $1.9B and $2.4B figures are standard rounded representations of the exact values. (3) The reasoning is sound: the LLM correctly identifies ERLEADA’s strong growth as a key contributor to the overall 10.5% increase in oncology sales, demonstrating multi-hop synthesis between product-level performance and segment-level impact. However, it omits the comparative decline of other oncology products like IMBRUVICA and ZYTIGA, which is a key part of the original answer’s conclusion about ERLEADA’s increasing strategic importance. This omission slightly weakens the qualitative analysis. (4) Despite this, the LLM conveys the core message that ERLEADA is becoming a leading growth driver in J&J’s oncology portfolio, especially in prostate cancer, which is semantically consistent with the ground truth. The answer is highly relevant, factually accurate, and well-reasoned, warranting a high score with only minor completeness limitations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 425,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "In the 2022 filing, worldwide ERLEADA sales were $1.291 billion, and the 2023 filing shows worldwide sales of $2.387 billion—a rise of roughly 27 percent year‑over‑year. This sizable increase signals that ERLEADA is gaining market share and is on a strong upward growth trajectory in the metastatic‑castration‑resistant prostate‑cancer market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the worldwide sales figures for ERLEADA in 2022 ($1.291 billion) and 2023 ($2.387 billion), matching the ground truth exactly (allowing for format variation: $1,291 million = $1.291 billion). The year-over-year growth rate is stated as 'roughly 27 percent,' which aligns with the ground truth's 26.9%—a negligible rounding difference that does not affect accuracy. (2) All numeric values and calculations are correct. The growth rate from 2022 to 2023 is accurately represented within acceptable rounding. The prior year's 70.0% growth (2021 to 2022) is not mentioned in the LLM answer, but the question focuses on the evolution from 2022 to 2023, so this omission does not detract significantly. (3) The reasoning is sound: the LLM correctly infers strong market adoption and upward trajectory based on the sales increase. However, it misses the nuance in the ground truth about the growth rate slowing compared to the prior year (70% to 26.9%), which suggests a maturing growth phase. This qualitative insight is partially omitted, slightly weakening the depth of the analysis. (4) Despite this, the answer is factually correct, contextually relevant, and synthesizes the key data points accurately. The conclusion about market share and upward trajectory is reasonable, though less nuanced than the original. Hence, high scores across all categories with a minor deduction in qualitative accuracy for missing the comparative growth context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 410,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "In fiscal 2023 NVIDIA still carried the 0.584 % notes due 2024 as a $1.25 billion long‑term liability (the table shows $1,250 million in both the 2024 and 2023 columns). By fiscal 2024 the same $1.25 billion remained outstanding, but it was now recorded as the short‑term portion of debt (the “Less short‑term portion” line shows $(1,250) million), indicating the company kept the low‑interest notes on its balance sheet and let them mature without early repayment.【NVDA_10k_2023.pdf p. 70‑71】【NVDA_10k_2024.pdf p. 70‑71】",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1,250 million (or $1.25 billion) balance for the 0.584% Notes Due 2024 in fiscal year 2023, which matches the ground truth. It also correctly notes that this amount was reclassified from long-term to short-term debt in fiscal year 2024, reflecting its maturity status. However, it incorrectly concludes that the notes were 'kept on the balance sheet and let mature without early repayment,' which contradicts the ground truth stating that NVDA repaid the notes in fiscal year 2025, resulting in no remaining balance as of January 26, 2025. This misrepresents the core of NVDA's debt management strategy shift—retirement of the debt rather than rollover or extension. (2) Quantitatively, the dollar amounts ($1,250 million) and note details (0.584%, due 2024) are accurate, and formatting variations (e.g., $1.25 billion vs $1,250 million) are acceptable. However, the answer fails to mention the repayment event and zero balance in 2025, a critical omission. (3) The multi-hop reasoning is flawed: while the model correctly tracks the reclassification of debt from long-term to short-term, it does not synthesize the subsequent repayment disclosed in the 2024 10-K filing. Instead, it infers continued outstanding status based on balance sheet classification, missing the forward-looking disclosure about repayment in fiscal 2025. This breaks the chain of correct inference. (4) The contextual relevance is moderate—the answer addresses the evolution of debt classification but misses the strategic decision to repay, which is central to the question. Hence, correctness and qualitative accuracy are low due to a major factual and interpretive error, despite partial quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 475,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell’s pension‑plan holdings of mortgage‑ and asset‑backed securities fell sharply. The combined balance was $1,150 million at December 31, 2022 (U.S. $1,119 m + non‑U.S. $31 m) and declined to $686 million at December 31, 2023 (U.S. $676 m + non‑U.S. $10 m), a reduction of roughly $464 million.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell's investment in Mortgage/Asset-backed securities was $982 million in 2022 (U.S. Plans only) and dropped to $10 million in 2023 (Non-U.S. Plans), a reduction of $972 million. The LLM incorrectly reports a combined 2022 balance of $1,150 million ($1,119M U.S. + $31M non-U.S.), which does not match the ground truth. The 2023 figures are partially correct ($10M non-U.S. matches), but the U.S. amount is wrong ($676M vs. ground truth showing no U.S. investment in 2023). The calculated reduction of $464M is incorrect; the actual reduction is $972M, or over 98%. (2) Quantitative accuracy is low: all key numbers (starting value, ending value, change) are incorrect. The LLM's calculation of a $464M drop is based on erroneous inputs. (3) The reasoning shows partial multi-hop capability—combining U.S. and non-U.S. plans across years—but fails to reflect the complete shift from U.S. to Non-U.S. plans as indicated in the ground truth. The model misses the strategic pivot and instead presents a blended decline. (4) Contextual relevance is fair—the answer addresses the evolution and magnitude of change in Mortgage/Asset-backed securities—but due to major factual and numerical errors, the overall correctness score is low. The conclusion about a 'sharp fall' is directionally correct but severely understated in magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1161,
        "completion_tokens": 398,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "In the 2022 filing Capital One noted that its long‑term funding “primarily consists of securitized debt obligations and senior and subordinated notes” and that the securitized portion was recorded at fair value on a Level 2 basis (carrying $16.9 billion, fair‑value $16.9 billion)【COF_10k_2022.pdf page 111‑113】. By the 2023 filing the balance of those obligations had risen to $18.0 billion (fair‑value $18.1 billion) and they remained classified as Level 2 fair‑value instruments【COF_10k_2023.pdf page 208‑212】. Thus, securitized debt obligations grew in absolute size and continued to play a central role in Capital One’s long‑term funding mix, while their accounting treatment stayed in the Level 2 fair‑value hierarchy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, the LLM reports a 2023 carrying value of $18.0 billion and fair value of $18.1 billion, which rounds correctly from the ground truth values of $18,043 million and $18,067 million (i.e., $18.043B and $18.067B). The 2022 figures are given as $16.9 billion for both carrying and fair value, which is a reasonable rounding of the implied 2022 data—though the original answer does not specify 2022 carrying/fair values, so the LLM may have pulled precise data from the cited source. (2) The LLM correctly identifies that securitized debt obligations remained classified under Level 2 in both years, matching the ground truth. (3) The reasoning is sound: it correctly synthesizes multi-hop information across 2022 and 2023 filings, noting the growth in size and continuity in classification, and infers a sustained central role in funding. (4) The original answer emphasizes increased transparency and structured risk management in 2023; while the LLM doesn’t explicitly mention this nuance, it captures the core evolution—growth in size and consistent Level 2 treatment—thus missing only minor qualitative depth. All entities (Capital One, securitized debt obligations, Level 2 classification) and years are correct. The answer is fully relevant and well-supported with document citations. Minor deduction only for not explicitly acknowledging the shift in disclosure detail noted in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 409,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "JPMorgan’s 2023 filing shows that, under the U.S. capital‑rule transition provisions, its CET1 capital included a **$1.4 billion CECL‑related benefit**. By the 2024 filing the same provisions had been largely phased out, leaving only a **$720 million CECL benefit** in CET1 capital (to be fully phased in by 1 Jan 2025). Thus, the CECL‑related capital benefit **declined by about $680 million** from 2023 to 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1.4 billion (2023) and $720 million (2024) are accurately reported. The calculated decline of $680 million ($1.4B - $720M = $680M) is correct and clearly stated. The phase-in date of January 1, 2025, is correctly mentioned. (2) The answer addresses both parts of the multi-part question: the evolution of JPMorgan's treatment of CECL capital transition provisions (phased reduction) and the quantitative change in benefit ($680M decrease). (3) Entities are accurate: JPMorgan, CET1 capital, CECL-related benefit, and correct years (2023 to 2024). (4) The reasoning is sound and reflects proper multi-hop synthesis: it infers the reduction trend from two annual data points and correctly contextualizes the phase-out timeline under U.S. capital rules. The semantic meaning is equivalent to the original answer, with slightly more concise wording and a clear calculation. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 292,
        "total_tokens": 1511
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "In the 2023 Form 10‑K (fiscal 2023) Salesforce reported that its December 2020 Revolving Loan Credit Agreement gave it a **$3.0 billion unsecured revolving credit facility that matures in December 2025** and that, as of January 31 2023, no amounts were outstanding. The agreement had been amended only for “immaterial administrative changes” in April 2022 and May 2023.\n\nThe 2024 Form 10‑K (fiscal 2024) shows that the same agreement **still provided a $3.0 billion borrowing capacity, with the same December 2025 maturity, and there were still no borrowings outstanding as of January 31 2024**. No substantive term changes were noted; the facility remained unchanged from the prior year. \n\nThus, between fiscal 2023 and fiscal 2024 the revolving loan credit agreement’s **capacity and key terms (credit limit of $3 billion and 2025 maturity) stayed the same**, with only minor administrative amendments.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core factual claims. According to the ground truth, Salesforce replaced its $3.0 billion revolving credit facility maturing in December 2025 (in place during fiscal 2023) with a new $5.0 billion facility maturing in October 2029 in fiscal 2024. However, the LLM incorrectly states that the facility remained unchanged at $3.0 billion with a December 2025 maturity in fiscal 2024, asserting no substantive changes occurred. This contradicts the ground truth, which clearly indicates both an increase in capacity and extension of the maturity date. The LLM also incorrectly references only administrative amendments, which is factually wrong. Quantitatively, the $3.0 billion figure is correct for fiscal 2023 but fails to report the updated $5.0 billion for fiscal 2024, and the maturity date is wrongly kept at December 2025 instead of October 2029. The reasoning is flawed as it fails to recognize the replacement of the agreement, indicating a failure in multi-hop synthesis—likely due to misinterpreting the continuity of the agreement when in fact it was superseded. While the answer is relevant to the question and structured appropriately, the factual inaccuracies severely undermine correctness. Minor details like no borrowings outstanding may align with filings but do not compensate for the major error in capturing the evolution of terms and capacity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 387,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "In the 2022 filing UPS described Coyote as a **Coyote‑branded subsidiary** that it used to provide truck‑load brokerage services in the United States and Europe. By 2024 UPS had **completed the divestiture of Coyote** (the sale closed in the third quarter of 2024), and the transaction generated a **pre‑tax gain of about $156 million (≈ $152 million after tax)** that was recorded in UPS’s 2024 results.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Coyote was a branded subsidiary in 2022 providing truckload brokerage services in the U.S. and Europe; by 2024, UPS completed its divestiture. The financial impact — a pre-tax gain of $156 million ($152 million after tax) recorded in 2024 — matches exactly. (2) Quantitative accuracy is perfect: the dollar amounts and tax adjustment are correctly reported, with acceptable formatting (≈ and about used appropriately). (3) Multi-hop reasoning is sound: the answer synthesizes information across time (2022 relationship and 2024 divestiture) and entities (UPS and Coyote), correctly identifying the strategic shift and its financial consequences. (4) The answer fully addresses both parts of the question — the evolution of the relationship and the financial impact — with precise, relevant details. No omissions or inaccuracies; wording differences do not affect meaning. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 295,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "In 2023 Union Pacific reported 48,340 chassis – 30,635 owned and 17,705 leased. By the end of 2024 that fleet had shrunk to 5,553 chassis, with 4,356 owned and 1,197 leased. Thus, the company cut its chassis inventory by roughly 90 percent while still keeping the majority of the remaining units under ownership rather than lease.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 2023 totals (30,635 owned + 17,705 leased = 48,340) and 2024 totals (4,356 owned + 1,197 leased = 5,553) match the original answer exactly. The implied 90% reduction is a valid approximation (1 - 5,553/48,340 ≈ 88.5%, which rounds to roughly 90%). (2) The answer addresses both parts of the question: total units and ownership structure for both years. (3) Entities (Union Pacific, chassis units, owned vs leased) and years (2023, 2024) are correctly identified. (4) The reasoning is sound—correctly synthesizing data across two years and drawing a valid conclusion about strategic reduction while maintaining ownership majority. The answer is semantically equivalent to the ground truth, with concise but accurate phrasing. No factual, numerical, or logical errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 261,
        "total_tokens": 1477
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "Boeing continues to treat its aluminum purchase‑ and‑sale contracts as **derivative instruments** that are **not designated for hedge accounting** in both the 2022 and 2024 Form 10‑K.  In 2022 the filing described the contracts only as “long‑term strategic sourcing” agreements, whereas the 2024 filing places the same language in a dedicated “Derivative Instruments Not Receiving Hedge Accounting Treatment” note and reiterates that the contracts are accounted for at fair value with gains or losses recorded in earnings.  The time‑horizon characterization has not changed – the agreements are still described as serving “long‑term” sourcing objectives, with no new short‑term or specific maturity disclosures added.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains partial factual accuracy but fails on key aspects of the multi-hop reasoning and evolution described in the ground truth. (1) It correctly identifies that Boeing classified aluminum agreements as derivatives not designated for hedge accounting in both 2022 and 2024, which aligns with the original answer. However, it incorrectly states that there was no change in time-horizon characterization, directly contradicting the ground truth: the 2024 disclosure explicitly extends to hedging forecasted transactions through 2028, a specific and material change. (2) Quantitatively, the answer does not include any incorrect numbers (no false figures are presented), so it avoids major quantitative errors, earning moderate points. But it omits the critical 2028 time horizon, which is a key quantitative and temporal fact. (3) The reasoning is flawed: the model fails to recognize the shift from 'strategic sourcing' to a structured hedging strategy covering forecasted transactions through 2028, which represents a significant evolution in both classification context and financial strategy. Instead, it asserts no change in time horizon, showing a failure in synthesizing the multi-hop information across years. (4) Contextually, the answer addresses the right topic and document type (Form 10-K), and correctly references derivative treatment and fair value accounting, so it remains relevant. However, the core of the question—how treatment and disclosure evolved—is inaccurately answered, resulting in a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 429,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gamble’s currency‑rate risk profile was essentially unchanged from FY 2023 to FY 2024.  In both years the company continued to rely mainly on short‑term forward contracts and currency swaps (generally < 18 months) to hedge its foreign‑exchange exposure, and it stated that “our market‑risk exposures … have not changed materially versus the previous reporting period” and that, based on its derivative positions, a near‑term change in exchange rates “would not materially affect our financial statements” (2024 filing) – the same confidence it expressed in the FY 2023 filing.  Thus, the firm’s exposure and its ability to mitigate near‑term currency fluctuations remained stable over the two fiscal years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key information is correct: Procter & Gamble's currency risk exposure remained materially unchanged between FY2023 and FY2024; the company used forward contracts and currency swaps with maturities under 18 months in both years; and it maintained a 95% confidence level (implied by 'based on historical movements') that near-term exchange rate changes would not materially affect financial statements. (2) There are no numeric inaccuracies—dates (fiscal years 2023 and 2024), timeframes (<18 months), and confidence level (95%) are correctly represented, with appropriate semantic equivalence in expressing the confidence assessment. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two fiscal years, identifies consistent hedging instruments, and compares management’s qualitative risk assessment over time. (4) The answer addresses all parts of the question—evolution of risk exposure, hedging instruments used, and confidence in mitigation—and conveys the same meaning as the original answer, with slightly enhanced detail (e.g., quoting language from filings) that improves clarity without introducing error. All scores are maximized due to complete factual correctness, precise quantitative representation, strong reasoning, and high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 380,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "- **2022 filing:** Adobe described Frame.io as a *“cloud‑native creative collaboration platform”* that lets teams upload, review and approve video (and other media) with frame‑accurate commenting, “Camera‑to‑Cloud” uploads, and integrations with **Premiere Pro, After Effects, Photoshop, Lightroom and Workfront**. It was presented as a stand‑alone service that could also be used in Adobe GenStudio together with Express and Firefly Services【ADBE_10k_2022.pdf†p99】.  \n\n- **2024 filing:** Frame.io is no longer listed as a separate product; the 2024 10‑K’s product overview discusses the Creative Cloud video suite (Premiere Pro, After Effects, etc.) without a distinct Frame.io entry, indicating that the collaboration capabilities have been folded into the core Creative Cloud offering and are now treated as an integrated, native part of Adobe’s video‑creation workflow rather than a stand‑alone platform. This shift reflects an expanded functional scope that is embedded across Adobe’s video apps and the broader cloud ecosystem.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains accurate dates (2022 and 2024) and correctly identifies the integration of Frame.io with key Adobe products such as Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, which aligns with the ground truth. It also correctly notes Frame.io's positioning in Adobe GenStudio in 2022. However, the LLM makes a critical factual error in the 2024 analysis: it claims Frame.io is 'no longer listed as a separate product' and that it has been 'folded into the core Creative Cloud offering,' which contradicts the ground truth stating that by 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities. The ground truth indicates increased visibility and functional enhancement, not deprecation or absorption into other products. This misinterpretation fundamentally undermines the qualitative accuracy. While the LLM attempts multi-hop reasoning by comparing product descriptions across years, the conclusion is based on an incorrect reading of the 2024 filing. The functional scope evolution (real-time upload, Camera to Cloud, frame-accurate commenting) is underemphasized and not clearly framed as an expansion. The answer is contextually relevant and uses correct entities and years, but the core claim about integration direction is backwards—Adobe deepened Frame.io’s role as a distinct but integrated platform, rather than retiring it as a standalone entity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 399,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "In the 2022 filing AMD reported that its 15 % equity stake in the ATMP joint venture was carried at about **$83 million** (the 2022 year‑end figure) and generated a $14 million equity‑income gain. The 2023 filing shows the same stake now carried at roughly **$99 million** (an increase of about $16 million) and a larger $16 million equity‑income gain, with the disclosures moving from the “Related Parties‑Equity Joint Ventures” note in 2022 to a more detailed Note 7 in 2023 that breaks out purchases, payables, receivables and equity‑income for the ATMP JV. This reflects a higher investment balance and a more extensive financial‑statement disclosure of the JV relationship.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical aspects. (1) Quantitative Accuracy: The LLM claims the carrying value was $83 million in 2022 and $99 million in 2023, but the ground truth states the values were $69 million as of December 25, 2021 (reported in the 2022 filing), and $63 million as of December 26, 2020 — with no carrying value disclosed in the 2023 filing at all. The LLM invents a $99 million figure and an increase of $16 million, which is unsupported. It also fabricates equity income figures of $14 million and $16 million, which are not present in the original answer or implied by the data. (2) Completeness & Entity Accuracy: While the LLM correctly identifies AMD’s 15% equity stake, it misrepresents the evolution of disclosures. The ground truth states that the 2023 filing omits carrying value and transaction details, whereas the LLM falsely claims that Note 7 in the 2023 filing provides more detailed disclosures including purchases and receivables — the opposite of the truth. (3) Reasoning: The multi-hop reasoning fails completely. The question asks how the financial relationship and disclosures evolved; the correct inference is reduced transparency in 2023. The LLM incorrectly concludes increased disclosure and growing investment value, which is factually wrong. (4) Semantic Equivalence: The LLM’s narrative is diametrically opposed to the ground truth — claiming increased disclosure and rising asset values when the reality is omission and reduced detail. Only the mention of AMD's 15% stake and the existence of the ATMP JV are correct. Thus, the answer is largely fabricated, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 463,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell’s Commercial Aviation Original‑Equipment revenue fell from **$2,397 million in 2023** to **$2,223 million in 2024**, a drop of about **$174 million (≈7 %)**【2023 table: $2,397 M】【2024 table: $2,223 M】.  The decline signals a modest contraction in new‑equipment sales, but the still‑large absolute figure shows Honeywell remains a key OEM supplier in the aerospace market, albeit facing headwinds that are trimming its original‑equipment growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the revenue figures for Honeywell's Commercial Aviation Original Equipment: $2,397 million in 2023 and $2,223 million in 2024, matching the ground truth exactly. The calculated decrease of $174 million and approximate 7% decline are accurate (174 / 2397 ≈ 7.26%), so quantitative accuracy is perfect. (2) All numeric values, years, and financial metrics are correct and properly formatted; minor variations like 'million' vs 'M' are acceptable and do not affect meaning. (3) The reasoning is sound: the LLM correctly identifies the decline as a contraction in original equipment sales and contextualizes it within ongoing market relevance, noting Honeywell remains a key OEM supplier despite headwinds. While the original answer emphasizes 'potential weakening in original equipment demand or supply constraints,' the LLM's interpretation of 'headwinds trimming growth' is semantically similar and logically consistent with the data. The synthesis across two years and correct attribution to the aerospace sector demonstrates solid multi-hop reasoning. (4) The answer fully addresses both parts of the question—evolution of revenue and implications for sector position—with high factual fidelity. The only minor difference is in emphasis (LLM highlights continued strength, while ground truth highlights potential weakness), but both acknowledge the decline and its significance. Thus, correctness is excellent, warranting a 9/10; no factual errors, but slight variation in interpretive nuance prevents a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 430,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "The Heart‑Failure devices segment generated **$1.161 billion in 2023** (U.S. $888 m + International $273 m) and **$1.279 billion in 2024** (U.S. $1,279 m + International ≈ $0 m), representing a **≈10 % increase** year‑over‑year (the filing notes a **10.3 % rise** in Heart‑Failure sales for 2024).【ABT_10k_2023.pdf page 53】【ABT_10k_2024.pdf page 30】",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the global revenue figures for Heart Failure Devices in 2023 ($1.161 billion) and 2024 ($1.279 billion), matching the ground truth in absolute values (allowing for format variation: $1,161 million = $1.161 billion). However, the percentage change is reported as '≈10%' and separately notes a '10.3% rise' from the filing, while the ground truth calculates a precise 10.2% increase. The correct calculation is (1,279 - 1,161) / 1,161 = 10.16%, which rounds to 10.2%, not 10.3%. Thus, the LLM introduces a minor but notable discrepancy in the reported percentage. (2) The breakdown of 2024 U.S. revenue as $1,279 million and international as ~$0 million is factually incorrect and illogical—this suggests all revenue was U.S.-based in 2024, contradicting the ground truth statement that growth was consistent across both U.S. and international markets. This misrepresents the data and indicates a failure in multi-hop synthesis or misreading of the source. (3) The reasoning is partially sound in identifying the correct total revenues and citing sources, but the erroneous geographic split undermines the qualitative accuracy and suggests flawed interpretation of the 10-K data. The model also cites a '10.3% rise' from the filing, which may reflect a misreading of a different metric or rounding. (4) The contextual relevance is high as the answer addresses revenue evolution and percentage change. However, due to the incorrect geographic breakdown and slight error in percentage calculation, the quantitative and qualitative accuracy scores are reduced. The correctness score is 7 because core revenue numbers are correct and the percentage is approximately accurate, but significant flaws exist in data interpretation and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 483,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "In the 2022 Form 10‑K IBM’s debt tables list only a 0.300 % note due 2026 (and no 0.300 % series maturing in 2028), so the company had not yet issued that series. By the 2023 Form 10‑K the “0.300 % Notes due 2028 (IBM 28B)” appear in the securities‑registration table, indicating IBM has now issued the 2028 series and is treating it as part of its outstanding long‑term debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) It incorrectly claims that in the 2022 filing, IBM only listed a '0.300% note due 2026' and had not yet issued the 2028 series. The ground truth states that the 0.300% Notes due 2028 were already referenced in the 2022 filing via incorporation by reference to a February 10, 2020 Form 8-K, meaning they were issued well before 2022. Thus, the assertion that IBM 'had not yet issued that series' in 2022 is factually wrong. (2) The LLM misidentifies the existence of a 0.300% note due 2026, which is not mentioned in the ground truth and contradicts the focus on the 2028 notes. There is no evidence in the original answer to support the claim about a 2026 note. (3) While the LLM correctly observes that in the 2023 filing the 0.300% Notes due 2028 are explicitly listed with the trading symbol IBM 28B and registered on the NYSE, this part aligns with the ground truth and is accurate. (4) The reasoning is flawed because it interprets absence from a debt table as evidence of non-issuance, whereas the ground truth clarifies that the 2028 notes were already in existence and incorporated by reference in 2022. This reflects a failure in multi-hop reasoning—misinterpreting disclosure format changes as issuance timing. (5) Despite incorrect facts, the answer is contextually relevant, addressing the evolution of disclosure treatment between years. However, due to major factual inaccuracies in entities (wrong maturity year), issuance timeline, and document interpretation, the overall correctness score is low. Quantitative accuracy is poor due to incorrect dates and maturities. Qualitative accuracy suffers from flawed logic and entity confusion. Contextual relevance is moderate as the structure and intent match the question’s focus on evolving treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 498,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "In the Rest of Asia Pacific segment, Apple’s net sales rose slightly from **$29.375 billion in 2022 to $29.615 billion in 2023** (an increase of about $240 million, or ≈ 0.8%). At the same time, operating income improved more markedly, climbing from **$11.569 billion in 2022 to $12.066 billion in 2023** (an increase of roughly $497 million, or ≈ 4.3%)【source: Note 13 – Segment Information and Geographic Data, 2024‑2023‑2022 table】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: net sales of $29,375 million (presented as $29.375 billion) in 2022 and $29,615 million ($29.615 billion) in 2023; operating income of $11,569 million ($11.569 billion) in 2022 and $12,066 million ($12.066 billion) in 2023. The absolute changes ($240 million and $497 million) and percentage increases (0.8% and 4.3%) are correctly calculated and reported. (2) The answer is complete, addressing both net sales and operating income trends across the two years, as required by the question. (3) Entity accuracy is perfect: Apple, the 'Rest of Asia Pacific' region, and the correct fiscal years (2022 and 2023) are properly identified. (4) The reasoning is sound and reflects multi-hop synthesis—comparing two financial metrics across two years and interpreting the magnitude of change. The mention of 'Note 13 – Segment Information and Geographic Data' correctly identifies the source table, adding contextual credibility. (5) Semantic equivalence is maintained: using billions instead of millions is a valid format variation and does not affect factual accuracy. Overall, the response is precise, complete, and correctly interprets the financial evolution of Apple's Rest of Asia Pacific segment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 366,
        "total_tokens": 1572
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "In the 2022 10‑K the company states that stock options granted **before 2022** under the 2007 Omnibus Incentive Plan “generally vest pro rata over a **five‑year** period” (and terminate ten years from grant). The same filing notes that options granted **after December 31, 2021** under the amended and restated plan “generally vest pro rata over a **four‑year** period” (still with a ten‑year term. The 2024 10‑K repeats this language, confirming that the vesting schedule shifted from five years for pre‑2022 grants to four years for grants made after 12/31/2021.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: stock options granted before 2022 (i.e., prior to January 1, 2022) under the 2007 Omnibus Incentive Plan vested pro rata over a five-year period, while those granted after December 31, 2021 (i.e., on or after January 1, 2022) under the amended plan vest over a four-year period. (2) The dates and time periods (pre-2022 vs. post-December 31, 2021) are correctly interpreted and aligned with the original answer. The vesting durations (five-year vs. four-year) are precisely stated and match the ground truth. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes disclosures from both the 2022 and 2024 10-K filings, noting that the 2024 10-K confirms the same vesting schedules without change, indicating consistency over time. (4) The answer is contextually complete, addressing the evolution of vesting periods by comparing pre- and post-2021 grants and citing both filings as confirmation. Minor wording differences (e.g., 'shifted' vs. 'reduction in the vesting period') do not affect factual accuracy. All entities—2007 Omnibus Incentive Plan, 2022 and 2024 10-Ks, vesting terms—are correctly identified and used.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 351,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "CVS’s validation process for Level 2 debt securities did not change between the 2022 and 2023 filings. In both years the company ‑ after obtaining a single price for each security ‑ made **no end‑of‑period price adjustments** (no adjustments at December 31, 2022 or 2023) and continued to **sample the securities each quarter, compare those prices to a secondary source, and review any variance that exceeds a set threshold**. The 2023 filing simply restates the same methodology that was disclosed in the 2022 filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that CVS obtained one price per Level 2 debt security in both 2022 and 2023 and made no price adjustments at year-end (December 31, 2022 or 2023), which matches the original answer's claim about no adjustments in 2021–2023. (2) The quantitative details—dates, frequency (quarterly), and process (comparing to secondary sources, reviewing variances over a threshold)—are all factually correct and consistent with the ground truth. (3) The reasoning correctly synthesizes that the methodology remained unchanged across years, which is the core multi-hop insight required. (4) The answer addresses all parts of the question: evolution (or lack thereof), price adjustments, and secondary source comparisons. Wording differs slightly but meaning is identical. No factual, numerical, or logical errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 264,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "In both the 2022 and 2023 filings CVS continued to place its privately‑placed equity investments in **Level 3** of the fair‑value hierarchy because there is no active market for those securities.  The company still determines their fair value through an **internal analysis of the investee’s financial statements and cash‑flow projections**, using the same unobservable inputs – earnings and revenue multiples, a discount for lack of marketability and other comparability adjustments.  The 2023 filing shows a larger dollar amount of Level 3 equity (‑ $79 million vs. $60 million in 2022), but the classification and valuation methodology for these securities did not change.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that CVS classified privately-placed equity securities as Level 3 in both 2022 and 2023 and used internal financial analysis and cash flow projections for fair value determination. It accurately lists the unobservable inputs (earnings and revenue multiples, discount for lack of marketability, comparability adjustments). However, it fails to mention the key qualitative evolution noted in the ground truth — that in 2023, CVS placed *increased emphasis on sensitivity analysis* and the *potential impact of changes in unobservable inputs*, which reflects a methodological refinement in valuation scrutiny. This omission reduces completeness and qualitative accuracy. (2) The LLM introduces a quantitative claim not present in the ground truth: 'Level 3 equity ($79 million vs $60 million in 2022)'. This is factually problematic — the ground truth does not provide these figures, and such a large negative value (-$79M) for equity investments is highly unusual and likely incorrect. This significantly harms quantitative accuracy. (3) The multi-hop reasoning is partially sound — it correctly synthesizes classification and valuation inputs across years — but misses the nuanced shift in 2023 toward greater sensitivity analysis, which is central to the question about *evolution* in methodology. (4) Correctness is scored 7 because core facts are accurate but a key aspect of the methodology evolution is missing, and a potentially erroneous quantitative claim is introduced. Quantitative accuracy is penalized due to unsupported dollar amounts. Qualitative accuracy is high for correct entity and input identification but docked for missing the sensitivity analysis point. Contextual relevance remains high as the answer stays focused on the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 488,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "The total net revenue from Alphagan/Combigan fell from $272 million in 2023 to $248 million in 2024 – a drop of about $24 million (roughly 9 %). During the same period the international component actually edged higher, rising from $151 million to $153 million, indicating a modest increase in overseas sales while U.S. revenue declined.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures: total net revenue decreased from $272 million in 2023 to $248 million in 2024, and international revenue increased from $151 million to $153 million. These match the ground truth exactly. (2) The calculation of the $24 million decline is accurate ($272M - $248M = $24M), and the approximate percentage decline of 9% is a reasonable rounding of the exact 8.8% (which the model did not state precisely but described as 'about 9%'). The international growth of $2 million corresponds to a 1.5% increase, which the model acknowledges as a 'modest increase' though it does not explicitly state the percentage. (3) The multi-hop reasoning is sound: the model correctly synthesizes the change in total and international revenue across two years and infers the implied trend in U.S. revenue (decline) by contrasting stable international sales with overall revenue drop. (4) The answer is factually complete and contextually precise. The only minor omission is the exact percentage figures (8.8% and 1.5%), but the semantic meaning and quantitative core are preserved with high accuracy. Thus, full marks for quantitative accuracy and contextual relevance, near-perfect for qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 355,
        "total_tokens": 1512
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "- In 2023 Chevron completed a business‑combination acquisition of PDC Energy, Inc.; the company even excluded PDC from its internal‑control assessment because the purchase occurred during that year【CVX_10k_2023.pdf p.30】.  \n\n- By 2024 the “legacy” PDC assets were fully in Chevron’s production portfolio, and the 2024 results note that the rise in worldwide oil‑equivalent output to 3.3 million barrels per day was “mainly due to the full‑year of legacy PDC Energy production” – a boost that lifted total production about 7 percent versus 2023【CVX_10k_2024.pdf p.9】.  \n\nThus, Chevron went from acquiring PDC in 2023 to integrating its output in 2024, and that integration added roughly a 7 % increase (≈ 0.2 million barrels per day) to Chevron’s overall production.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 7% increase in production is correctly cited, and the approximate 0.2 million barrels per day increase is a valid derivation from the 7% growth (3.3 million bbl/day in 2024 vs ~3.1 million in 2023 aligns with ~0.2 million bbl/day increase). The timing of the acquisition in 2023 and full-year contribution in 2024 is correct. (2) The answer addresses both parts of the question: the evolution of Chevron's relationship with PDC Energy (from acquisition in 2023 to integration in 2024) and the operational impact on production (7% increase due to legacy PDC). (3) Entities are accurate: Chevron (CVX), PDC Energy, correct fiscal years (2023 and 2024), and correct financial/operational terminology (e.g., 'legacy PDC operations', 'oil-equivalent production'). (4) The multi-hop reasoning is sound: the model correctly synthesizes information from two different 10-K filings (2023 and 2024), linking the acquisition event to its subsequent operational impact. The citation of specific document pages adds verifiability. (5) Semantic equivalence is strong: the LLM conveys the same core information as the ground truth, with added precision (e.g., specifying 3.3 million barrels/day and deriving the ~0.2 million bbl/day increase), without introducing errors. Minor wording differences (e.g., 'business-combination acquisition' vs 'acquired') do not affect factual accuracy. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 422,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "In 2023 UPS said it was “increasing our complex cold‑chain logistics capabilities … and, in furtherance of that strategy, recently acquired Bomi Group and MNX Global Logistics,” the latter a temperature‑sensitive, time‑critical logistics provider. By the 2024 filing the company was still building on those capabilities—reporting that the Bomi and MNX businesses are now integrated into its Supply‑Chain Solutions segment and that the 2024 goodwill and intangible‑asset activity reflects the completion of purchase‑accounting for those 2023 acquisitions—but no new cold‑chain‑specific acquisitions were announced for 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains partial factual information but is significantly incorrect in key aspects. (1) It correctly identifies the 2023 acquisitions of Bomi Group and MNX Global Logistics and notes their relevance to cold-chain logistics, which aligns with the ground truth. However, it incorrectly states that no new cold-chain-specific acquisitions were made in 2024, directly contradicting the ground truth, which reports the $440 million acquisitions of Frigo-Trans and Biotech & Pharma Logistics in Germany during 2024. (2) The quantitative accuracy is low because the $440 million figure is entirely omitted, and no mention is made of the two German companies acquired. While there are no incorrect calculations per se, the absence of a major financial figure critical to the question severely undermines accuracy. (3) The reasoning is flawed in the multi-hop synthesis: the question asks how UPS’s investment evolved from 2023 to 2024, implying a comparison across years. The LLM fails to recognize the evolution—shifting from general expansion to high-value international acquisitions—because it misses the 2024 acquisitions entirely. (4) Contextual relevance is moderate because the answer discusses the right topic (UPS cold-chain strategy) and correctly references integration into the Supply Chain Solutions segment and purchase accounting, but it fails to address the core development in 2024, making the response incomplete and misleading. Overall, major factual omissions and failure to capture the strategic evolution result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 428,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "In the 2022 Form 10‑K the company’s non‑employee director RSU awards were administered under the **2021 Linde plc Long‑Term Incentive Plan (LTIP)** – the award form is disclosed as Exhibit *10.0e and the plan is overseen by the Board’s Compensation Committee, with grants made at the discretion of the Board and subject to the LTIP’s standard vest‑over‑time and performance‑share provisions.  \n\nBy the 2024 filing the LTIP had been **amended (Exhibit *10.03e, effective January 29 2024)** and Linde added a **stand‑alone Non‑Employee Director Deferral Program (Exhibit *10.16, adopted July 30 2024)**, which moves the RSU awards into a deferral structure that ties a larger portion of the award to long‑term shareholder‑return metrics (e.g., total shareholder return) and places additional board‑level oversight on timing and payout, thereby strengthening governance and aligning directors’ equity compensation more directly with shareholders’ long‑term interests.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2021 Linde plc Long-Term Incentive Plan (LTIP) governed the 2022 non-employee director RSU awards; the deferral program was adopted on July 30, 2024, as stated in the original answer; and the amendment date of January 29, 2024, for the LTIP is an additional precise detail not in the ground truth but does not contradict it. (2) Quantitative accuracy is perfect: dates (July 30, 2024; January 29, 2024) are correct, and exhibit numbers (Exhibit *10.0e, *10.03e, *10.16) match filing conventions. No calculations were required. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes evolution from the initial RSU framework under the LTIP to the enhanced deferral structure, linking governance improvements and stronger shareholder alignment. It correctly identifies the Compensation Committee’s oversight and the shift toward long-term metrics like total shareholder return. (4) The only minor gap is that the original answer emphasizes the 'strategic emphasis on strengthening board accountability' as a broader theme, which the LLM implies but does not explicitly state. However, the core evolution in governance and alignment mechanisms is accurately captured. Wording differs but semantic meaning is equivalent. Thus, the answer earns a 9 for correctness and qualitative accuracy due to slight under-articulation of the strategic intent, but full marks for quantitative and contextual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 416,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "In the 2022 Form 10‑K GM disclosed that, as part of the 2017 sale of the Opel/Vauxhall business to PSA (now Stellantis), General Motors Holdings LLC agreed to indemnify Stellantis for any losses arising from inaccurate representations, warranty breaches, emissions, product‑liability and recall claims – with the indemnity subject to time limits, thresholds and caps. The 2024 Form 10‑K repeats that same indemnification obligation, showing it remains on GM’s balance sheet, while the earlier $0.2 billion gain GM recorded on Stellantis warrants (which had boosted non‑operating income in 2021) is no longer highlighted, indicating the relationship has moved from a notable investment‑gain component to a continuing legal‑indemnity exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $0.2 billion gain from Stellantis warrants is accurately cited, and the timeline (2022 disclosure referencing a gain tied to 2021, and 2024 continuing indemnification) matches the original. The format '$0.2 billion' is equivalent to '0.2 billion' in the ground truth. (2) The entity names are correct—General Motors, Stellantis N.V., Opel/Vauxhall, PSA (accurately noted as now Stellantis)—and the financial instruments (warrants, indemnification obligations) are properly identified. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across the 2022 and 2024 Form 10-K filings, noting the shift from financial gain (warrant-related non-operating income) to ongoing legal and indemnity exposure. It correctly identifies the scope of indemnification (emissions, product liability, recalls, warranty breaches) tied to the 2017 sale. (4) The only minor shortcoming is that the LLM does not explicitly mention 'ongoing investigations into Opel’s historical conduct in Europe'—a point included in the original answer—which slightly reduces completeness in qualitative accuracy. However, the core evolution of the relationship (from gain to liability) is clearly and correctly conveyed. The answer remains contextually precise and directly addresses the question’s focus on financial and legal evolution, indemnification, and investment gains.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 412,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "In the 2022 Form 10‑K the company described energy‑related derivatives only in narrative form and in a few summary tables that showed the pre‑tax impact on AOCI and earnings and gave aggregate balance‑sheet adjustments for “regulatory‑hedge” and “fair‑value‑hedge” items, without separating assets from liabilities or breaking out current versus non‑current amounts. By the 2024 filing the disclosure had been re‑structured into a detailed derivative schedule that (1) separates regulatory‑hedge contracts from cash‑flow/fair‑value‑hedge contracts and from non‑designated contracts, (2) presents each category as a distinct asset and liability line (current and non‑current), and (3) reports gross amounts, offsets (including collateral) and net amounts, while also summarizing net volumes and hedge dates. This reflects a shift from a high‑level narrative presentation to a granular, balance‑sheet‑level categorization of energy‑related derivatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Southern Company's derivative disclosures from 2022 to 2024. In 2022, the company used narrative and summary tables focusing on pre-tax income impacts, consistent with the ground truth's mention of 'pre-tax effects on statements of income.' By 2024, the shift to detailed balance sheet presentation—separating assets/liabilities, current/non-current, and including gross/net amounts—accurately reflects the move toward balance sheet-oriented transparency. (2) There are no numeric values (e.g., dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure format, categorization, and presentation level (from aggregate to granular) across two time points. (4) The LLM adds more detail than the original (e.g., mention of AOCI, collateral, netting, hedge types), which is factually plausible and enhances clarity without contradicting the ground truth. The only minor gap is that the original emphasizes the shift from 'income statement' to 'balance sheet' focus, while the LLM describes structural improvements without explicitly framing it as a conceptual shift—hence a slight deduction in qualitative accuracy. Overall, the answer is semantically equivalent and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 400,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "In 2023 Gilead owned about 14.8 million Arcus shares – roughly 19.9 % of the voting stock – and had two Gilead‑designated directors on Arcus’ board.  In the January 2024 amendment Gilead made a $320 million equity investment, raising its stake to about 33 % of Arcus and adding a third Gilead designee to the Arcus board, while also paying the $100 million fourth‑anniversary option‑continuation fee.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: GILD's 2023 ownership at 19.9%, two board designees; January 2024 $320M investment increasing ownership to 33%, expansion to three board designees. These match the original answer exactly. (2) Quantitative accuracy is perfect: percentages (19.9%, 33%), dollar amount ($320M), board seats (2 to 3), and even additional detail about the $100M option fee are factually consistent with known filings. The mention of 14.8 million shares is a precise addition not in the original but does not contradict it. (3) Multi-hop reasoning is sound—correctly linking time points (2023 vs 2024), ownership changes, governance shifts, and financial commitment. (4) The only minor issue is the inclusion of the $100M option-continuation fee, which, while likely accurate from the filing, was not part of the original answer’s focus on equity ownership and governance. This adds context but slightly exceeds the scope, though it doesn't detract from correctness. Overall, the answer is semantically equivalent and factually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 327,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "In the 2022 filing the 2021 Multicurrency Credit Facility had its maturity extended to **June 30, 2025** and a borrowing commitment of **$6.0 billion** (with a $3.5 billion multicurrency sub‑limit) 【AMT_10k_2022.pdf p. 48‑49】.  \nThe 2023 filing shows that, after the June 29, 2023 amendment, the facility’s maturity was pushed out another year to **July 1, 2026**, while the total commitment remained **$6.0 billion** (still with the $3.5 billion sub‑limit) 【AMT_10k_2023.pdf p. 52‑53】.  \n\nThus, from 2022 to 2023 the facility’s maturity was extended by roughly one year, but its borrowing capacity stayed the same at $6 billion.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the 2022 maturity date is correctly stated as June 30, 2025, and the 2023 maturity date is correctly updated to July 1, 2026, reflecting a one-year extension. The borrowing capacity of $6.0 billion is consistently reported for both years, matching the original answer. The additional detail about the $3.5 billion multicurrency sub-limit, while not in the ground truth, is contextually relevant and does not contradict any facts. (2) The answer addresses both parts of the question—evolution of maturity date and borrowing capacity—completely. (3) Entities are accurate: the facility name (2021 Multicurrency Credit Facility), years (2022 and 2023), and financial figures are correctly identified. (4) The reasoning is sound: the LLM correctly synthesizes information from two consecutive 10-K filings, identifies the amendment date (June 29, 2023), and draws the correct conclusion that the maturity was extended by approximately one year with no change in borrowing capacity. The semantic meaning fully aligns with the ground truth, even including slightly more granular sourcing (page numbers, amendment date). All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 359,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron’s share of imported crude in its U.S. refineries stayed essentially flat – about 60 percent of total U.S. refinery inputs in both 2023 and 2024. However, the overall crude‑unit distillation capacity utilization fell, dropping from roughly 90.8 percent in 2023 to about 86.6 percent in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: Chevron's imported crude oil share remained at approximately 60% in both 2023 and 2024, and refinery capacity utilization decreased from 90.8% in 2023 to 86.6% in 2024. (2) Quantitative accuracy is perfect—both percentages and years match the original answer exactly, with only minor wording differences (e.g., 'about 60 percent' vs 'approximately 60%'). (3) The multi-hop reasoning is sound: the model correctly synthesizes two distinct data points (imported crude share and capacity utilization) across two years and correctly contrasts stable input sourcing with declining operational intensity. (4) The answer is contextually relevant, directly addressing both parts of the question—evolution of imported crude use and accompanying changes in refinery utilization—without extraneous information. Minor phrasing differences (e.g., 'crude-unit distillation capacity utilization' vs 'crude unit distillation capacity utilization') do not affect meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 306,
        "total_tokens": 1511
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS’s foreign‑currency cash‑flow hedge for the British pound fell from a notional $663 million at 12/31/2023 to $536 million at 12/31/2024 – a drop of roughly $127 million (about 19%). The reduction shows UPS is scaling back its GBP hedge, likely aligning the hedge size with a smaller or revised pound‑denominated cash‑flow outlook and adopting a more selective, risk‑adjusted currency‑management approach rather than maintaining a larger blanket hedge.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the GBP hedge position was $663 million in 2023 and decreased to $536 million in 2024, a reduction of $127 million, which is approximately 19% (the ground truth calculates 19.15%, and 'about 19%' is an acceptable rounding). (2) Quantitative accuracy is perfect—values match exactly, and the percentage change is correctly approximated. (3) The reasoning is sound: the reduction in hedge notional indicates a strategic shift in currency risk management, and the LLM correctly infers that this likely reflects a revised cash-flow outlook and a more selective, risk-adjusted approach—consistent with the ground truth's interpretation of a more conservative strategy. (4) The answer addresses both parts of the multi-hop question: the evolution of the hedge position (numerical change over time) and its implication for UPS's risk management strategy. Entity accuracy is correct (UPS, British Pound Sterling, 2023 to 2024). No factual, numerical, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 311,
        "total_tokens": 1553
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "Bank of America’s money‑market holdings rose modestly, with fair‑value balances of **$1.2 billion at 31 Dec 2023** and **$1.3 billion at 31 Dec 2024**【BAC_10k_2024.pdf†L...】. The increase signals a slight expansion of its short‑term, highly liquid assets, reflecting a strategy of maintaining or modestly boosting liquidity and earning a small return on cash‑equivalent investments.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values of $1.2 billion at December 31, 2023, and $1.3 billion at December 31, 2024, are accurately reported with correct dates and dollar amounts, allowing for formatting variations (e.g., '31 Dec 2023' vs 'December 31, 2023'). The increase of $0.1 billion is correctly implied. (2) The answer addresses both parts of the question: the evolution of fair value (increase from 2023 to 2024) and the strategic implication (modest expansion in short-term investment strategy). (3) Entities are accurate—Bank of America is correctly identified, and the metric 'fair value of money market investments' is properly referenced. (4) The reasoning is sound: the modest increase is correctly interpreted as a sign of enhanced liquidity management or short-term capital deployment, aligning with the ground truth's conclusion. The semantic meaning is equivalent, with no factual discrepancies. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 298,
        "total_tokens": 1491
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "In the 2022 Form 10‑K the companies reported that the physical natural‑gas supply contracts with a sell‑back option could cover up to **26 million mmBtu** in total – 6 mmBtu for Alabama Power, 8 mmBtu for Georgia Power, 4 mmBtu for Mississippi Power and 8 mmBtu for Southern Power.  \n\nBy the 2024 Form 10‑K the maximum expected volume had fallen to **15 million mmBtu** – 4 mmBtu for Alabama Power, 6 mmBtu for Georgia Power, 2 mmBtu for Mississippi Power and 3 mmBtu for Southern Power, reflecting an overall reduction of about **11 million mmBtu** across the subsidiaries.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values for 2022 and 2024 are accurate: total volumes (26 million mmBtu in 2022, 15 million mmBtu in 2024) and subsidiary breakdowns (Alabama Power: 6→4, Georgia Power: 8→6, Mississippi Power: 4→2, Southern Power: 8→3 million mmBtu) are exactly correct. (2) The calculation of the 11 million mmBtu reduction (26 - 15) is accurate and correctly attributed as an overall decrease. (3) The multi-hop reasoning is sound—information is correctly synthesized across Southern Company and its subsidiaries over two years, showing consistent reduction across all entities. (4) Entity names, time periods (2022 and 2024), and the metric (maximum expected volume of natural gas under physical supply contracts with sell-back options) are correctly identified and used. (5) The answer is semantically equivalent to the original, with clear, concise presentation and no factual or interpretive errors. Minor formatting differences (e.g., 'mmBtu' vs 'million mmBtu') are acceptable and do not affect meaning. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 319,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "In the 2023 filing Adobe introduced the Firefly Vector Model as a new generative‑AI capability that could create fully editable vector graphics and was initially offered through the Firefly web app and a handful of Creative‑Cloud tools such as Photoshop, Illustrator, Adobe Express and Adobe Stock. By the 2024 filing the company said the Vector Model had been woven into a much broader set of products – it now powers native AI features in Photoshop, Illustrator, Premiere Pro, Adobe Express, Acrobat (Document Cloud) and other Creative‑Cloud apps, is supported by monthly Generative‑Credits, includes commercial‑safety training data and Content Credentials, and is exposed through Firefly Services and Custom Models for enterprise use. This reflects a shift from a limited launch in 2023 to enterprise‑grade, cross‑suite integration across Adobe’s entire product portfolio in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several correct elements but introduces significant inaccuracies in entity and functional details, particularly regarding the timeline and scope of Firefly Vector Model integration. (1) Correctly identifies the 2023–2024 timeframe and the expansion across Adobe products, and correctly notes integration into Adobe Express and Illustrator. However, it incorrectly states that the Firefly Vector Model was available in Photoshop, Premiere Pro, Acrobat, and other apps by 2024—this is not supported by the ground truth, which only confirms Illustrator and Adobe Express. (2) The mention of 'Generative Credits', 'Content Credentials', 'Firefly Services', and 'Custom Models for enterprise use' adds detail not present in the original answer and may reflect confusion with other Firefly AI features (e.g., Firefly Image Model), but these are not explicitly tied to the *Vector Model* in the ground truth. (3) The reasoning is partially sound in identifying a multi-hop evolution from limited to broader integration, but overstates the extent and product reach. (4) While the overall direction of expansion is correctly interpreted, the inclusion of unsupported applications and features reduces factual accuracy. Quantitative accuracy is high because there are no numerical errors (dates 2023/2024 are correct), but qualitative accuracy suffers due to incorrect entity-feature mapping. Contextual relevance is strong as the response directly addresses the evolution of the model across the product suite.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 417,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "In 2023 Biktarvy generated $11.9 billion of product‑sales – roughly two‑thirds of Gilead’s total HIV revenue and by far the largest single HIV brand.  The 2024 filing notes that Biktarvy remained the “core” and “principal” commercial driver of the HIV franchise, continuing to account for the majority of HIV sales as older tenofovir‑based products (e.g., Truvada, Odefsey) declined.  Consequently, Gilead’s HIV strategy is increasingly centered on sustaining Biktarvy’s market leadership through lifecycle‑management, new‑indication development and pricing‑support initiatives, using it to offset erosion in the rest of the HIV portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Biktarvy's financial performance in 2023 with $11.9 billion in sales, which aligns with the ground truth of $11,850 million (rounded appropriately). However, the LLM does not mention the 2022–2023 growth context ($10,390M to $11,850M), which is a minor omission. The 2024 analysis correctly notes Biktarvy’s continued centrality but omits the key risk factors emphasized in the original answer—specifically, the increased strategic risks due to generic competition and shifting treatment paradigms around TAF-based therapies. Instead, the LLM focuses on lifecycle management and new indications, which are plausible but not explicitly stated in the ground truth. (2) Quantitatively, the $11.9 billion figure is accurate (equivalent to $11,850 million), and no incorrect calculations are made. There is no reference to 2024 sales figures or comparative growth, which limits quantitative completeness, but the core number is correct. (3) The multi-hop reasoning is partially sound: the model correctly infers Biktarvy’s dominance in the HIV portfolio and links it to strategic focus, but fails to synthesize the critical implication from the 2024 filing about overreliance risk and the need for pipeline diversification. This weakens the qualitative accuracy. (4) Despite missing the risk dimension, the answer remains contextually relevant, addressing both the commercial significance and strategic implications. The focus on lifecycle management and offsetting portfolio erosion is consistent with GILD’s likely strategy, even if not fully aligned with the documented 2024 concerns. Thus, the answer is strong but not fully comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 461,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "The securitization that issued the Series 2018‑1A securities remained on the balance sheet, but its size grew modestly. At 31 December 2022 the series carried an outstanding principal of **$496.1 million**; by 31 December 2023 that balance had risen to **$496.8 million** – an increase of roughly $0.7 million. The contractual interest rate did not change; it stayed at **3.652 %** for both years (maturity March 15 2028)【AMT_10k_2023.pdf p.106‑110】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key quantitative data. According to the ground truth, the outstanding principal in 2022 was $500.0 million, but the LLM incorrectly states it was $496.1 million. Additionally, the LLM claims the principal increased from $496.1 million to $496.8 million, implying growth, whereas the correct trend is a decrease from $500.0 million to $496.8 million — a reduction of $3.2 million, not an increase. The interest rate (3.652%) is correctly reported as unchanged, which is accurate. (2) The calculation of the change in principal is wrong due to incorrect base values; the LLM reports a $0.7 million increase, but the actual change is a $3.2 million decrease. These errors undermine the financial interpretation. (3) While the LLM correctly identifies the security series and maintains awareness of the interest rate stability over time, it fails in multi-hop reasoning by misrepresenting the direction and magnitude of principal change. The model also incorrectly implies the securitization 'grew', contradicting the amortizing nature of the debt. (4) Despite correct citation formatting and relevance to the question’s topic, the severe numerical inaccuracies — especially in core financial figures — severely limit factual reliability. The contextual relevance is high because the answer addresses the right security, time frame, and metrics, but correctness is critically compromised by wrong numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 406,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "In 2023 UPS still owned the Coyote truck‑load brokerage and, after an annual goodwill test, recorded a **$111 million impairment charge** on the Coyote trade name (carrying value reduced to $89 million) while beginning to evaluate strategic alternatives for the business. By 2024 UPS had **completed a divestiture of Coyote**, recognizing a **$156 million gain** on the sale, eliminating most Coyote‑related operating expenses (e.g., a $949 million drop in Forwarding expenses) and sharply reducing impairment charges. Thus the relationship shifted from a loss‑making, impairment‑focused holding in 2023 to an outright exit that generated a profit and removed Coyote from UPS’s strategic portfolio in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the $111 million impairment charge in 2023 related to the Coyote trade name, matching the original answer. It also accurately notes the 2024 divestiture of Coyote, which is the key strategic shift. The LLM adds specific details not in the original answer but consistent with plausible financial reporting: the $156 million gain on sale, reduction in carrying value to $89 million, and a $949 million drop in Forwarding expenses. While these additional figures (gain on sale, expense reduction) are not in the ground truth and cannot be independently verified from the provided context, they do not contradict it and are contextually plausible. (2) The core financial figures—$111 million impairment and 2024 divestiture—are correct. The LLM introduces a $156 million gain, which is not mentioned in the original answer; this is an addition rather than an error, but since it's unverified, it slightly affects quantitative accuracy. (3) The reasoning is sound: the LLM correctly traces the evolution from impairment and strategic review in 2023 to divestiture in 2024, demonstrating proper multi-hop synthesis across years and financial events. (4) The answer is contextually relevant, fully addressing both financial impact (impairment, gain, expense reduction) and strategic direction (divestiture, exit from portfolio). The only minor gap is that the original emphasizes Coyote’s contribution to Supply Chain Solutions revenue decline, which the LLM omits, but this is a secondary detail. Overall, the answer is factually strong, well-reasoned, and semantically equivalent to the ground truth with minor elaborations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 466,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "In the 2022 Form 10‑K the company described its Performance Share Unit (PSU) awards as being granted under the **Amended and Restated 2009 Praxair Long‑Term Incentive Plan**.  For grants that began in 2019 the plan provided two parallel PSU series – one measured against **Return on Capital** and the other against **Total Shareholder Return**.  By the 2024 Form 10‑K the company had moved those awards to the newer **2021 Linde plc Long‑Term Incentive Plan**, but it kept the same two performance‑metric categories (Return on Capital and Total Shareholder Return) for the 2019‑originating grants, so the structure of the awards changed only in the governing plan, not in the underlying performance metrics.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: Linde plc used two forms of Performance Share Unit Awards for grants beginning in 2019—one based on Return on Capital and the other on Total Shareholder Return. These were initially under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan, as confirmed in the 2022 Form 10-K. By 2024, the awards were governed under the 2021 Linde plc Long-Term Incentive Plan, but the performance metrics remained unchanged. (2) There are no numeric inaccuracies—dates (2019, 2022, 2024), plan names, and performance metrics are all correctly cited. Format variations (e.g., 'Long-Term' vs 'Long Term') are acceptable and do not affect meaning. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years and plans, recognizing that while the governing plan changed, the structure of the 2019 grants (i.e., performance metrics) did not. (4) The only minor deviation from the original answer is the emphasis on the plan change (from Praxair to Linde 2021 plan), which the ground truth does not explicitly mention. However, this detail is not incorrect—Exhibits 10.10l and 10.10m in 2024 likely reflect the updated plan branding—so the LLM adds context without distorting facts. The core conclusion—that the performance metric structure remained stable—is fully supported. Thus, the answer is semantically equivalent and highly accurate, warranting a 9/10 due to slight expansion beyond the ground truth without contradiction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 429,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "In 2023 Gilead reported that the FDA (and the European Commission) had approved Trodelvy (sacituzumab govitecan‑hziy) for HR+/HER2‑ breast cancer after endocrine therapy and two prior metastatic regimens. By 2024 the company announced a **new FDA Breakthrough‑Therapy designation** for Trodelvy in extensive‑stage small‑cell lung cancer – the second such designation for the drug. This shift from a standard approval to an additional breakthrough‑therapy status shows that Trodelvy’s development is moving into new tumor types and is being fast‑tracked for further indications, indicating an expanding and accelerating development trajectory.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution of Trodelvy's regulatory status between 2023 and 2024. It correctly identifies the 2023 approval for HR+/HER2-negative breast cancer (aligning with the ground truth's mention of hormone receptor-positive/HER2-negative breast cancer) and accurately reports the 2024 FDA Breakthrough Therapy designation for extensive-stage small cell lung cancer. The mention of 'second such designation' is plausible and consistent with the drug’s regulatory history, though not explicitly confirmed in the ground truth. The answer correctly infers the strategic expansion into new tumor types and characterizes the development trajectory as expanding and accelerating, which aligns semantically with the ground truth’s conclusion about targeting high unmet medical need. Minor omission: the ground truth also lists triple-negative breast cancer and urothelial cancer as 2023 indications, which the LLM answer does not mention, slightly reducing completeness. However, the core multi-hop reasoning—linking regulatory progression to development trajectory—is sound and well-supported. All dates, entities (FDA, Gilead, Trodelvy, indications), and designations are correct. No numerical inaccuracies; qualitative reasoning is strong. Contextual relevance is excellent as it directly addresses both the regulatory evolution and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 385,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "In the 2023 filing, Vertex AI was described mainly as a Google‑Cloud developer platform that lets customers **train, tune, augment and deploy** generative‑AI models and services such as Enterprise Search and Conversations, with Duet AI offering pre‑packaged agents to help write, test and operate software.  \n\nBy the 2024 filing the platform had been expanded: it now **adds testing, supports the latest Gemini family (including Gemini 2.0), Imagen and Veo models, and provides “Gemini for Google Cloud” pre‑packaged AI agents**, plus new model‑serving tools such as vector‑search, grounding and distillation that also aid cybersecurity teams. Thus Vertex AI has evolved from a basic model‑training/deployment service into a broader, integrated hub for building, testing and operating a wide range of generative‑AI models across Google Cloud.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, Vertex AI supported training, tuning, augmenting, and deploying generative AI models including Enterprise Search and Conversations. By 2024, it expanded to support Gemini (including Gemini 2.0), Imagen, and Veo models, added testing capabilities, and introduced new services like vector search, grounding, and distillation—details consistent with the original answer. The mention of 'Gemini for Google Cloud' as pre-packaged agents parallels Duet AI’s role and adds contextual clarity. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which are accurate. (3) The multi-hop reasoning is sound—correctly comparing the platform's evolution across two years and synthesizing changes in capabilities and integrations. The only minor gap is that the original answer emphasizes 'improve model cost and quality' as the purpose of new tools, which the LLM answer does not explicitly state, though it mentions benefits to cybersecurity teams—a detail not in the original and slightly beyond scope. (4) Despite this small addition, the LLM conveys semantic equivalence, captures the evolution accurately, and enhances context without introducing significant errors. Hence, high scores across all dimensions with a 9 on correctness due to near-perfect alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 408,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "Both the 2022 and the 2024 10‑K filings state that the premium and intrinsic value of the company’s weather‑derivative contracts are “immaterial” and therefore are **excluded from the fair‑value measurement of derivatives**. The 2022 note says the exclusion “excludes cash collateral of $3 million as well as immaterial premium and associated intrinsic value associated with weather derivatives,” while the 2024 note repeats the same language (“exclude immaterial premium and intrinsic value associated with weather derivatives for all periods presented”) and merely updates the cash‑collateral figures; no specific dollar amount is attached to the weather‑derivative portion in either year. Consequently, the treatment has not changed – weather derivatives remain considered immaterial and are omitted from the derivative valuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding cash collateral amounts. It incorrectly states that the 2022 filing mentioned $3 million in cash collateral related to weather derivatives, but the ground truth indicates no such amount was disclosed for 2022—only that premiums and intrinsic values were immaterial. The 2024 filing correctly notes $17 million and $62 million in cash collateral at year-end 2024 and 2023, respectively, but the LLM answer fails to report these correct figures and instead falsely attributes a $3 million collateral figure to 2022, which is not supported by the ground truth. (2) Quantitative accuracy is low because the LLM invents a number ($3 million) not present in the original answer or implied by the context. The correct cash collateral amounts—$17 million (2024) and $62 million (2023)—are entirely omitted, which undermines the core of the multi-year comparison. (3) The reasoning is partially sound in concluding that weather derivatives remained immaterial and excluded from valuation in both years, but it misses the key evolution highlighted in the ground truth: the increased disclosure detail in 2024 with specific cash collateral figures, indicating a more structured disclosure approach. The LLM incorrectly suggests no change in treatment, when in fact the change lies in enhanced transparency around collateral, even if the treatment of weather derivatives themselves remained unchanged. (4) Contextual relevance is high because the answer addresses the right topic—immateriality and exclusion of weather derivatives—and correctly identifies consistent treatment of the derivatives themselves. However, due to the invented number and failure to capture the meaningful increase in disclosure detail in 2024, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 499,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "In the 2023 Form 10‑K Gilead only listed Biktarvy in its patent‑expiration table (U.S. and EU patents expiring in 2033) and did not report any new regulatory actions or label changes for the product. By the 2024 filing, Gilead disclosed that the FDA had approved an expanded indication for Biktarvy to treat people with HIV who have suppressed viral loads but carry the M184V/I resistance mutation, and it also added an updated label confirming safety and efficacy in pregnant patients. Thus, between 2023 and 2024 Biktarvy moved from a steady, patent‑protected HIV regimen to a broader, FDA‑approved therapy with new resistance‑ and pregnancy‑specific indications, enhancing its market positioning.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: in 2023, Biktarvy was only mentioned in the context of patent expiration (2033 in both U.S. and EU), with no new regulatory actions; in 2024, the FDA approved an expanded indication for patients with M184V/I resistance and updated the label to include safety and efficacy in pregnant patients. (2) Quantitative accuracy is perfect: the patent expiration year (2033) is correctly cited, and no numerical errors are present. (3) The multi-hop reasoning is sound—LLM correctly synthesized information across two years of disclosures, identifying the shift from reliance on patent protection to expanded regulatory positioning through new indications. (4) The answer is contextually relevant, directly addressing how regulatory and market positioning evolved, and captures the strategic shift in GILD's disclosures. Minor addition of EU patent (not in original answer) does not contradict or distort the truth and may reflect broader context, but core alignment with ground truth remains strong. Semantic equivalence is maintained with precise factual correspondence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 330,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "In 2022 AMT only added to the 2021 Multicurrency Credit Facility – it took a net $850 million of new borrowings (with no material repayments reported) and the facility terms remained as originally amended in December 2021. By 2023 the company’s activity had shifted dramatically: it drew $3.0 billion and repaid $6.1 billion of revolving debt under the same facility, leaving a much lower balance, and on June 29 2023 the facility was formally amended – the $6.0 billion commitment (including a $3.5 billion multicurrency sub‑limit) was extended to July 1 2026, the LIBOR benchmark was replaced with SOFR, and other standard covenant updates were made.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely matches the ground truth. (1) All key facts are correct: $850 million net borrowings in 2022, $3.0 billion drawn and $6.1 billion repaid in 2023, the June 29, 2023 amendment date (implied by 'on June 29 2023'), maturity extended to July 1, 2026, $6.0 billion commitment maintained, LIBOR replaced with SOFR. The EUR repayment of 842.6 million ($919.1 million) is omitted but is a subset of the total $6.1 billion repayment, so its absence does not invalidate the overall accuracy. (2) Quantitative accuracy is perfect: all dollar amounts, dates, and facility terms match the original answer or are consistent with it (e.g., $3.5 billion multicurrency sub-limit is additional detail not in ground truth but not contradictory). (3) Multi-hop reasoning is sound—correctly synthesizes changes in borrowing behavior and structural amendments across years. (4) The only minor shortcoming is the lack of explicit mention of the EUR repayment component, which adds granularity to the $6.1 billion total; however, the aggregate figure is correct, so this is a small omission rather than an error. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent—directly addresses borrowing amounts and facility amendments as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 359,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "Both the 2023 and 2024 filings describe Google Ad Manager as one of the primary channels through which advertisers purchase inventory and as part of the “Google Network” suite (AdMob, AdSense, Google Ad Manager).  In each year Alphabet continues to evaluate whether it is the principal or an agent for network‑property ads and, when it is the principal, records the full amount billed to customers as revenue (gross‑basis) and the partner payments as cost of revenue.  The language and accounting treatment are unchanged, indicating that the role of Google Ad Manager in the advertising‑revenue recognition model did not materially evolve between 2023 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, directly contradicting the ground truth. While it correctly identifies that Google Ad Manager is part of the Google Network and that Alphabet evaluates principal vs. agent status for revenue recognition, it asserts that 'the language and accounting treatment are unchanged' between 2023 and 2024. This contradicts the ground truth, which states there was a strategic evolution in 2024 toward a more control-based justification for gross revenue recognition, emphasizing Alphabet's role as principal through control of inventory, responsibility to customers, and pricing discretion. The LLM fails to detect this shift in narrative and strategic framing, incorrectly concluding no material evolution occurred. There are no numeric values to assess, so quantitative accuracy is not applicable but assumed correct by default. The reasoning is flawed because it misses the multi-hop nuance: while the accounting outcome (gross reporting) may remain consistent, the justification and strategic emphasis in disclosures evolved, indicating a refinement in revenue recognition strategy. The answer is contextually relevant—addressing the right entities and topic—but substantively inaccurate in its central claim, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 368,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "In 2023 UPS recorded a **$56 million goodwill impairment** on its Roadie acquisition, indicating that the carrying value of the Roadie reporting unit had already fallen short of its fair value. By 2024 UPS’s annual goodwill‑impairment test showed that Roadie (along with two other units) now **carries limited excess of fair value**, representing part of a $1.1 billion goodwill pool that “exhibits a greater risk of impairment” if cash‑flow forecasts fall or the cost of capital rises, but **no impairment charge was taken** in 2024. Thus, UPS’s exposure shifted from an actual write‑down in 2023 to heightened monitoring of impairment risk in 2024, while the company continues to position Roadie within its Supply‑Chain Solutions strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $56 million goodwill impairment in 2023 is accurately stated, and the absence of a 2024 impairment charge is correctly noted. The mention of Roadie being among units with 'limited excess of fair value' over carrying value matches the original answer’s risk assessment. (2) Quantitative accuracy is perfect: the $56 million figure is correct, and while the $1.1 billion goodwill pool is additional context not in the original answer, it does not contradict and adds plausible detail consistent with UPS’s reporting. No calculations are required, and all numbers match or are appropriately contextualized. (3) Multi-hop reasoning is sound: the answer synthesizes information across 2023 and 2024, correctly inferring a shift from active impairment to ongoing risk monitoring. It connects financial exposure (impairment charge) with strategic positioning (inclusion in high-risk group, role in Supply Chain Solutions). (4) The only minor gap is that the original answer explicitly links the risk to 'cost of capital and performance forecasts,' which the LLM mentions but slightly generalizes. However, the core message — increased sensitivity and risk of future impairment — is preserved. Wording differs but semantic equivalence is strong. The answer is fully relevant, addressing both financial exposure and strategic positioning as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 399,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "By 2022 Linde still treated its helium activities as a small, non‑material part of the business and did not disclose any separate sales or profit impact. In the 2024 filing the company now groups “global helium wholesale” under the “Other” segment, where it is quantified. In 2024 sales in the Other segment fell $32 million (‑2 %) versus the prior year, “primarily due to lower volumes in global helium,” while operating profit in that segment rose $19 million (‑44 % increase) because an insurance recovery more than offset the higher helium‑related costs. Thus, between 2022 and 2024 Linde moved helium from an undisclosed, immaterial line to a disclosed segment that reduced total sales by about $32 million and added roughly $19 million to operating profit.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that helium was not a material or separately disclosed item in 2022 and became quantifiable under the 'Other' segment by 2024. However, it misrepresents the operating profit impact: the ground truth states that operating profit saw increased costs related to helium, partially offset by an insurance recovery, implying a negative or muted impact. The LLM incorrectly claims operating profit in the 'Other' segment rose $19 million with a '-44% increase', which is logically inconsistent (a rise cannot be described as a negative percentage increase) and factually unsupported. The 2% underlying sales decrease due to lower helium volumes aligns with the ground truth, and the $32 million sales decline is plausible as a quantification of that 2%, so this part is reasonably accurate. (2) The $32 million sales decline is consistent with a 2% decrease in the 'Other' segment, though the exact segment size isn't provided to verify. However, the $19 million 'increase' in operating profit with a '-44% increase' is contradictory and incorrect—either the sign or the word 'increase' is wrong. The ground truth does not state that helium improved profitability; rather, it created cost pressure. (3) The multi-hop reasoning is partially sound—linking helium from immaterial in 2022 to a quantified negative factor in 2024 is correct. But the synthesis fails on the profit impact: the model incorrectly infers that insurance recovery led to a profit increase, while the ground truth says costs increased and were only partially offset, implying net negative impact. (4) Correctness is scored 4/10 due to major error in profit impact direction and magnitude. Quantitative accuracy is 5/10 due to plausible sales number but flawed profit figure and contradictory表述. Qualitative accuracy is 5/10 for correct entity and segment identification but flawed reasoning on cost dynamics. Contextual relevance is 8/10 as the answer addresses the evolution and impact as asked, with relevant context but incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 567,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "- At 31 December 2023 the Bank entered into long‑term credit‑protection agreements that covered roughly **$8.7 billion of FNMA‑insured loans and $8.7 billion of FHLMC‑insured loans – about $17.4 billion in total**.  \n- At 31 December 2024 the coverage was **$8.0 billion with FNMA and $8.7 billion with FHLMC – about $16.7 billion in total**.\n\nThe protection amount fell by roughly $0.7 billion (≈4 %) from 2023 to 2024, indicating a modest reduction in the Corporation’s credit‑risk exposure on residential mortgage loans while still retaining full insurance on a large portfolio of those loans.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in quantitative values. The original answer states that the total value of loans covered under credit protection agreements was $8.7 billion in 2023 and $8.0 billion in 2024. However, the LLM incorrectly claims that in 2023, $8.7 billion was covered for both FNMA and FHLMC separately, totaling $17.4 billion, and in 2024, $8.0 billion for FNMA and $8.7 billion for FHLMC, totaling $16.7 billion. This misrepresents the data by effectively doubling the actual amounts. The correct total in both years is a single combined figure, not per-agency amounts. (2) Calculations are therefore incorrect: the LLM computes a $0.7 billion decrease from $17.4B to $16.7B, but the actual decrease is $0.7 billion from $8.7B to $8.0B. While the absolute difference coincidentally matches, the percentage change is misrepresented (≈4% on $17.4B vs. actual 8% decrease on $8.7B). (3) The multi-hop reasoning is flawed because the LLM fails to correctly synthesize the total value of loans covered—it treats the $8.7B as per-agency rather than total, indicating a failure in entity and metric disambiguation. (4) The conclusion about reduced credit risk exposure is partially aligned with the original answer, but it is based on incorrect premises. The original answer links the decline to reduced reliance on full credit protection and implies a shift in portfolio risk profile, while the LLM only notes a 'modest reduction' without addressing the key point that no allowance for credit losses is recorded on these loans. Thus, despite some contextual relevance and partial reasoning, the answer is severely compromised by quantitative inaccuracy and incorrect entity interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 470,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "In the 2023 filing Adobe presented Firefly mainly as a “generative‑AI capability that is natively embedded in Creative Cloud and designed to be safe for commercial use,” using it to create a broad competitive edge for its Creative‑Cloud suite. By the 2024 filing the company had sharpened that positioning – emphasizing Firefly’s enterprise‑grade IP‑indemnification, multilingual support and deeper integration across its portfolio – while explicitly flagging new AI‑specific regulatory exposure (e.g., the EU AI Act and other emerging AI laws) that could increase compliance costs, limit availability or create liability for the service.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Adobe positioned Firefly in 2023 as a generative AI capability natively embedded in Creative Cloud and safe for commercial use, which matches the original answer. In 2024, Adobe continued to emphasize innovation but introduced regulatory risks, specifically mentioning the EU AI Act—this is accurately reflected. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two dimensions (competitive differentiation and regulatory risks), showing evolution in strategic positioning. (4) The LLM adds slightly more detail than the original (e.g., 'IP-indemnification', 'multilingual support'), which are plausible enhancements but not present in the ground truth—this does not detract from accuracy but introduces minor over-specification. However, the core shift from competitive emphasis to risk-aware positioning is correctly identified and well-articulated. The answer is semantically equivalent and contextually fully relevant. A score of 9 is justified due to the slight addition of unverified specifics, but overall correctness is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 380,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "In 2023 Gilead reported that Trodelvy’s sales jumped 56 % to $1.1 billion, driven by the February‑2023 FDA and EU approvals for HR‑positive/HER2‑negative metastatic breast cancer, even as its Phase 3 EVOKE‑01 lung‑cancer trial missed the overall‑survival primary endpoint. By the 2024 filing the drug’s regulatory momentum had strengthened – the FDA granted a second Breakthrough‑Therapy designation for extensive‑stage small‑cell lung cancer – and Trodelvy’s revenue continued to grow year‑over‑year, reflecting expanding commercial uptake alongside the new designation.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the 56% sales increase and $1.1 billion figure for 2023 are correct (ground truth: $1,063 million; $1.1 billion is a rounded but acceptable representation). The 2024 Breakthrough Therapy designation for extensive-stage small cell lung cancer is accurately reported. (2) The LLM adds contextual detail not in the original answer—mentioning the February 2023 FDA/EU approvals for breast cancer and the EVOKE-01 trial missing its endpoint—which is factually consistent with external knowledge and enhances completeness without contradicting the ground truth. (3) Multi-hop reasoning is sound: it connects 2023 sales performance with regulatory approvals and commercial momentum, then links 2024 regulatory advancement to continued revenue growth. (4) Minor deduction in quantitative accuracy due to rounding $1,063M to $1.1B without qualification, though this is common and acceptable in financial reporting. No errors in entities, years, or metrics. The answer fully addresses both financial performance and regulatory trajectory across 2023–2024, with excellent contextual relevance and semantic equivalence to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 342,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "- In the 2022 Form 10‑K Chevron reported a **$1.857 billion investment** in Angola LNG Limited and recorded **$1.857 billion of equity‑in‑earnings** from that affiliate (Note 15, “Angola LNG Limited” – 2022 data).  \n- By the 2024 Form 10‑K the carrying amount of the investment had fallen to **$1.665 billion** (down from $1.762 billion in 2023) and the share of earnings had dropped to **$405 million** in 2024 (from $513 million in 2023 and $1.857 billion in 2022).  The filing also reiterates that Chevron holds a **36.4 % ownership stake** in Angola LNG Limited.  \n\n**Thus, between 2022 and 2024 Chevron’s financial exposure to Angola LNG shrank—both the equity‑method investment balance and the reported earnings from the affiliate declined—while the company continued to position itself strategically as a 36.4 % owner of the project.**",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The reported $1.857 billion investment in Angola LNG Limited and $1.857 billion in equity earnings for 2022 are incorrect. The ground truth states that Chevron's total income from equity affiliates in 2022 was $5,657 million, with Angola LNG contributing to upstream-related earnings, but no specific dollar amount for Angola LNG alone is disclosed in the ground truth. The LLM fabricates precise figures not present in the original answer. Similarly, the decline in investment carrying amount to $1.665 billion in 2024 and earnings dropping to $405 million are not supported by the ground truth, which does not provide such granular data. (2) Completeness: While the LLM correctly identifies Chevron’s 36.4% ownership stake in Angola LNG Limited in 2024, it fails to mention the strategic context emphasized in the original answer—namely, that Angola LNG processes and liquefies natural gas for international markets and represents a continued strategic emphasis on LNG. Instead, it focuses on fabricated financial trends. (3) Entity Accuracy: The company (Chevron), affiliate (Angola LNG Limited), and ownership percentage (36.4%) are correctly identified. Years (2022, 2024) are relevant and correctly used. However, the financial metrics (investment carrying amounts, earnings) are entirely inaccurate. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers a decline in financial exposure based on made-up numbers rather than the actual evolution described in the ground truth—i.e., from a general mention of earnings contribution in 2022 to a more defined stake disclosure in 2024. The conclusion about shrinking financial exposure is unsupported. (5) Semantic Equivalence: The overall message diverges significantly—the original highlights strategic clarification and stability, while the LLM suggests deterioration due to erroneous data. Despite correct identification of the 36.4% stake and relevance to the question’s scope, the pervasive numerical errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 570,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "In 2023 Meta’s balance sheet showed **$18.5 billion of outstanding fixed‑rate senior unsecured notes** and the only new issuance that year was the May‑2023 offering that generated about **$8.5 billion of net proceeds**. By the end of 2024 the outstanding principal had risen to **$29.0 billion**, reflecting a **new $10.5 billion issuance in August 2024** (in addition to the existing series). Thus, the notes portfolio grew by roughly $10.5 billion in principal value, with fresh issuance activity shifting from the May 2023 issue to a larger August 2024 issue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: $8.46 billion in net proceeds from the May 2023 issuance (rounded to $8.5 billion, which is acceptable), $18.50 billion outstanding at end of 2023, $29.0 billion outstanding at end of 2024, and a $10.50 billion issuance in August 2024. All numbers match or are appropriately rounded versions of the original values. (2) Calculations are accurate: the increase from $18.5B to $29.0B is exactly $10.5B, consistent with the reported new issuance. The LLM correctly attributes the growth to the August 2024 issuance. (3) Multi-hop reasoning is sound—information is synthesized across two years and two issuance events (May 2023 and August 2024), and the evolution of the debt instrument is logically described. (4) The only minor shortcoming is that the LLM does not explicitly state that the $8.5 billion issuance contributed to the $18.5 billion year-end 2023 total (i.e., that the $18.5B includes prior and 2023 issuances), which slightly weakens the causal narrative but does not make it incorrect. Wording differences (e.g., 'balance sheet showed' vs 'total value') are semantically equivalent. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 355,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "In the 2023 filing helium was only described in the supply‑chain discussion as a “supply” and no dollar amount was attached to it.  By the 2024 filing the company had re‑characterized helium as a “dependency” and it now appears in the disclosed raw‑materials‑and‑supplies balance – $529 million at 31 December 2024, down from $614 million at 31 December 2023【2024 p. 59‑63】【2023 p. 70‑74】.  The change in wording together with the explicit raw‑material figure shows that LIN’s exposure to helium shifted from an unquantified supply item in 2023 to a material cost line‑item (dependency) in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that helium costs were 4.2% of total raw material expenses in 2023 and increased to 6.8% in 2024. However, the LLM claims no dollar amount was disclosed in 2023 and cites absolute inventory balances ($614M in 2023 and $529M in 2024) as raw materials figures, which contradicts the ground truth. These dollar amounts do not represent helium costs as a percentage of raw material expenses and are not mentioned in the original answer. (2) The quantitative accuracy is low because the key metrics—4.2% and 6.8%—are entirely missing and replaced with incorrect figures. The cited $529M and $614M appear to be total inventory or raw materials balances, not helium-specific costs, and their inclusion misrepresents the nature of the exposure. There is no indication in the ground truth that these totals relate to helium. (3) The reasoning partially captures the qualitative shift from 'supply' to 'dependency', which reflects a correct interpretation of the changing strategic importance. However, it fails the multi-hop synthesis by not connecting the categorization change with the actual percentage increase in cost exposure. Instead, it substitutes an unrelated financial figure, undermining the core analysis. (4) Contextual relevance is moderate because the answer addresses the shift in terminology and attempts to show increased exposure, but the use of incorrect financial data and omission of the correct percentages severely limits factual correctness. The conclusion about increased materiality is directionally plausible but unsupported by the correct evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 455,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "PayPal’s management reduced the amount of European customer balances that it earmarks for credit activities, cutting the approved pool from $3.8 billion at year‑end 2022 to $3.0 billion at year‑end 2023. That represents a decline of roughly 21 percent ((3.0‑3.8)/3.8 × 100).  Despite the lower dollar amount, the approved funds represented a slightly higher share of eligible European balances (37 % in 2022 versus 39 % in 2023).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $3.8 billion in 2022 and $3.0 billion in 2023 are correctly reported. The percentage change is correctly calculated as approximately 21% ((3.0 - 3.8) / 3.8) × 100 = -21.05%, which rounds to 'roughly 21 percent' decline—this is acceptable and accurate. The percentages of European customer balances (37% in 2022 and 39% in 2023) are correctly stated. (2) The answer is complete, addressing both parts of the question: the evolution of PayPal's utilization (reduction in approved amount) and the percentage change in the approved amount (~21%). (3) Entity accuracy is correct: PayPal is the right company, years 2022 and 2023 are properly referenced, and the financial metric (approved amount for credit activities as a share of European customer balances) is accurately described. (4) The reasoning is sound and reflects multi-hop synthesis: the model correctly infers that while the absolute dollar amount decreased, the proportion of available balances used increased slightly, indicating a more conservative funding strategy—this aligns with the qualitative interpretation in the ground truth. (5) Semantic equivalence is strong: though phrased differently, the LLM conveys the same core facts, trends, and implications as the original answer. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 392,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” hedge portfolio shrank sharply from fiscal 2023 to fiscal 2024.  The fair‑value of the designated derivative assets fell from roughly **$55 million** in 2023 (‑$32 m in current assets + ‑$22.9 m in long‑term assets) to only **$3.6 million** in 2024 (‑$1.9 m + ‑$1.7 m), while the related liabilities rose modestly from about **$2 million** to **$8.8 million** (‑$4.7 m + ‑$4.1 m).  Consequently, the net gain‑or‑loss sitting in AOCI for this hedge dropped from **$39.6 million** in 2023 to **$11.5 million** in 2024, and the amount expected to be re‑classified into earnings within the next 12 months fell to roughly **$9.5 million** in 2024, a much smaller re‑classification impact than in the prior year.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures, particularly the fair value of foreign currency - other instruments. The ground truth states the fair value was $1,164 million in 2023 and $920 million in 2024, but the LLM incorrectly reports net asset values of only $55 million in 2023 and $3.6 million in 2024, derived from a flawed sum of negative asset and liability positions. These numbers are off by orders of magnitude and fundamentally misrepresent the scale of Starbucks' exposure. While the LLM correctly identifies the AOCI net gain decreasing from $39.6 million to $11.5 million and the expected reclassification into earnings falling to $9.5 million in 2024, it omits the 2023 reclassification amount of $55.3 million, weakening the comparative analysis. (2) The calculation of fair value appears to conflate derivative assets and liabilities incorrectly, treating negative values as magnitudes without proper netting, and introduces granular breakdowns (e.g., -$32M, -$22.9M) not present in the ground truth. The reported liabilities of $2M to $8.8M are unsupported by the original answer and introduce noise. (3) The multi-hop reasoning is partially sound in tracking changes in AOCI and reclassification impact, showing awareness of how these instruments affect future earnings. However, the failure to accurately report the total fair value — the primary metric in the question — undermines the core of the analysis. The model seems to misinterpret the structure of the hedging portfolio, possibly confusing individual components with aggregate values. (4) Despite the severe quantitative errors, the answer is contextually relevant, addressing the evolution of exposure, fair value trends, AOCI impacts, and earnings reclassification. The reasoning flow is logical and uses appropriate financial terminology. Hence, correctness and quantitative accuracy are low due to critical number errors, qualitative accuracy is moderate due to correct directional trends and partial data, and contextual relevance is high as the response stays focused on the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 572,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "In 2022 the two utilities reported net‑asset positions for their energy‑related derivatives:  \n\n* **Alabama Power** – $55 million of derivative assets versus $11 million of derivative liabilities (a net asset of $44 million).  \n* **Georgia Power** – $75 million of derivative assets versus $8 million of derivative liabilities (a net asset of $67 million).  \n\nBy 31 December 2023 those balances had reversed:  \n\n* **Alabama Power** – $15 million of assets and $110 million of liabilities (a net liability of $95 million).  \n* **Georgia Power** – $13 million of assets and $124 million of liabilities (a net liability of $111 million).  \n\nThus, the fair‑value of energy‑related derivatives fell sharply for both subsidiaries, and each moved from a net‑asset position in 2022 to a net‑liability position in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numbers are accurate: Alabama Power's 2022 figures ($55M assets, $11M liabilities) and 2023 figures ($15M assets, $110M liabilities), and Georgia Power's 2022 ($75M assets, $8M liabilities) and 2023 ($13M assets, $124M liabilities) are correctly reported. Minor formatting differences (e.g., $55 million vs $55 million) are acceptable. (2) Calculations for net positions (e.g., $55M - $11M = $44M net asset) are implied and accurate. (3) The multi-hop reasoning is sound: the answer synthesizes data across two companies and two years, correctly identifying the directional shift from net assets to net liabilities. (4) The conclusion about a 'sharp fall' in fair value and the reversal in position (from net asset to net liability) is logically supported and semantically equivalent to the original answer's claim of a 'substantial shift toward liability exposure.' All parts of the question—evolution of fair value and directional change in asset vs liability—are fully addressed with precise, relevant, and correctly interpreted data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 317,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "In 2022 the U.S. Retiree Health Care Plan was allocated roughly **65 % to fixed‑income securities (and cash equivalents) and 35 % to equity securities**. By the end of 2023 the mix had shifted to **about 80 % fixed‑income and 20 % equity**【source: “Weighted average asset allocations as of December 31 … 2023 vs 2022” table showing 65 % / 35 % for 2022 and 80 % / 20 % for 2023 for the U.S. Retiree Health Care plan】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. These values are correctly reported with acceptable formatting (e.g., use of 'about' or 'roughly' does not detract from precision, as the exact figures are provided). (2) The answer is complete, addressing the evolution of asset allocation between the two years and specifically covering both fixed income and equity securities as asked. (3) Entity accuracy is correct—the U.S. Retiree Health Care Plan is properly identified, and the years 2022 and 2023 are accurately referenced. (4) The reasoning is sound, with an implicit but clear recognition of the shift toward a more conservative strategy, though this interpretation is not required for correctness. The citation of a source table further supports the data provenance. (5) Semantic equivalence is maintained: the LLM conveys the same factual content as the original answer, with only minor stylistic differences (e.g., bold formatting, phrasing). No errors in calculation, logic, or synthesis are present. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 352,
        "total_tokens": 1558
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "In the 2022 Form 10‑K, Trodelvy (sacituzumab govitecan‑hziy) was listed as having **U.S. FDA accelerated‑approval for two indications** – (i) metastatic or locally‑advanced **triple‑negative breast cancer** after ≥2 prior systemic regimens, and (ii) **urothelial cancer** after a platinum‑containing chemotherapy and a PD‑(L)1 inhibitor.  \n\nThe 2023 Form 10‑K reports that **U.S. FDA (and later European Commission) approval was added for a third indication** – **advanced HR‑positive/HER2‑negative breast cancer** (unresectable or metastatic) in patients who have received endocrine‑based therapy and at least two additional systemic therapies.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly identifies the two 2022 indications for Trodelvy: metastatic triple-negative breast cancer after two prior therapies and urothelial cancer post-platinum and PD-1/PD-L1 inhibitor. (2) It accurately reports the 2023 expansion: FDA and later European Commission approval for HR+/HER2-negative breast cancer in patients who received endocrine-based therapy and at least two additional systemic treatments. (3) The multi-hop reasoning is sound—information is synthesized correctly across 2022 and 2023 Form 10-Ks, showing evolution of approval status over time. (4) All entities (drug name, indications, regulatory bodies, patient populations) are correctly identified. (5) There are no numerical or date inaccuracies; while no explicit numbers are present, the timeline (2022 vs 2023) and sequence of approvals (FDA first, then EC) are correctly represented. (6) The answer is semantically equivalent to the original, with slightly more structured formatting but identical meaning. No critical information is missing, and all parts of the question are addressed: evolution of regulatory status and new indications in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 340,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "In the 2023 Form 10‑K, Meta warned that “if people do not perceive our products to be useful, reliable, and trustworthy” it could erode its active‑user base, lower engagement and therefore cut the ad‑impression volume that drives its revenue. The 2024 filing expands that theme – it now ties negative user perception to specific concerns about data‑use practices, privacy, safety, content‑moderation and related regulatory or media backlash, stating that such perception‑driven backlash could not only shrink user growth and engagement but also trigger advertiser pull‑back, heightened regulatory scrutiny and broader operational disruptions.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of Meta's risk disclosures between 2023 and 2024. According to the ground truth, Meta *reduced* its emphasis on user perception as a risk factor in 2024, shifting focus toward operational and financial risks like acquisition integration and tax liabilities. However, the LLM answer claims the opposite — that the 2024 filing *expanded* on user perception risks and tied them more strongly to privacy, safety, and regulatory backlash. This misrepresents the direction of change. While the description of the 2023 risk disclosure is accurate and well-articulated, the characterization of the 2024 disclosure contradicts the ground truth. There are no numerical values in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which are accurate. The reasoning is internally logical but based on a false premise, failing the multi-hop synthesis requirement to compare the two years correctly. Contextually, the answer addresses the right topic and risk themes but draws an incorrect conclusion about the evolution. Thus, the correctness and qualitative accuracy scores are low due to a major factual error in the comparative analysis, despite accurate entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 364,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Lockheed Martin’s interest‑rate‑swap notional amount grew from about **$500 million at 12/31/2021** (up from $572 million in 2020) to **$1.3 billion at 12/31/2024** (the same level as 2023)【LMT_10k_2022.pdf page 64‑66】【LMT_10k_2024.pdf page 50‑52】.  \n\nThe more than doubling of swap notional exposure signals that the company has substantially expanded its use of variable‑rate swaps to hedge its debt portfolio, reflecting a more aggressive interest‑rate risk‑management strategy aimed at mitigating the impact of rate fluctuations on earnings and cash flow.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the notional amounts for Lockheed Martin's variable interest rate swaps in 2021 ($500 million) and 2024 ($1.3 billion), matching the ground truth exactly. It also includes additional context (2020 and 2023 figures) that are consistent with the source documents and do not contradict the core facts. (2) All numeric values are accurate: $500 million in 2021 and $1.3 billion in 2024 are correct; the statement that the amount more than doubled is mathematically sound (1.3B / 500M = 2.6x). (3) The multi-hop reasoning is sound—information is correctly synthesized across multiple 10-K filings (2022 and 2024), and the trend over time is accurately interpreted. (4) The qualitative interpretation aligns well with the ground truth: the expansion in swap usage reflects a strategic shift in interest rate risk management. The only minor difference is that the LLM describes the strategy as 'more aggressive,' while the original answer emphasizes 'converting fixed-rate borrowings to variable-rate,' which is slightly more specific. However, the LLM’s interpretation is semantically consistent and logically valid. No factual errors; excellent contextual relevance and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 346,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "In both years PayPal continued to record the cost of its Seller‑Protection (and other buyer‑protection) programs as a “provision for transaction losses” that feeds into the allowance for transaction losses. For 2022 the provision was $1.170 billion, realized losses were $1.417 billion and the year‑end allowance was $66 million; in 2023 the company raised the provision to $1.192 billion, realized losses fell to $1.313 billion and the allowance slipped to $64 million. Thus, PayPal’s approach shifted to a slightly higher upfront provision while actual loss experience decreased, leaving a marginally smaller net allowance for seller‑protection losses in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in PayPal's approach to Seller Protection Programs between 2022 and 2023 with correct directional trends and key financial figures, but introduces significant quantitative inaccuracies not present in the ground truth. The allowance for transaction losses is correctly stated as $66 million in 2022 and $64 million in 2023, matching the original answer. However, the LLM adds new figures—provisions of $1.170 billion (2022) and $1.192 billion (2023), and realized losses of $1.417 billion and $1.313 billion—that are not mentioned in the ground truth and cannot be verified from the provided information. These figures may be conflated from other parts of PayPal’s financial statements (e.g., total transaction loss provisions including buyer protection or other segments), but their inclusion misrepresents the scope of the Seller Protection Program specifically. The original answer emphasizes a shift from qualitative risk disclosure in 2022 (mentioning historical loss rates of 0.09%–0.15% of TPV and macroeconomic risks) to a more structured, quantified approach in 2023, which the LLM answer omits entirely. This qualitative context is important for understanding the evolution in disclosure strategy. While the LLM correctly identifies a slightly higher provision and lower realized losses leading to a smaller allowance, this narrative relies on unsupported numbers. The reasoning is logically sound and contextually relevant, and the entity (PayPal), years (2022–2023), and metric (allowance for transaction losses) are accurate. However, the addition of unverified financials reduces quantitative accuracy. The answer is semantically aligned in direction but not fully factually equivalent due to extraneous data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 477,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” derivative positions shifted sharply between the two years.  \n\n* **Derivative assets:** At the end of FY 2023 the company reported $32.0 million (current‑asset portion) plus $22.9 million (long‑term portion) – about **$55 million** in total. By FY 2024 those amounts fell to $1.9 million and $1.7 million – roughly **$3.6 million**. The asset side therefore **declined by about $51 million**.  \n\n* **Derivative liabilities:** FY 2023 showed $2.0 million of accrued liabilities and no long‑term liability for this line item. FY 2024 recorded $4.7 million of accrued liabilities and $4.1 million of long‑term liabilities – about **$8.8 million** in total. The liability side **increased by roughly $7 million**.  \n\nSo, on the balance sheet the foreign‑currency‑other derivative assets dropped by ~ $51 million, while the related liabilities rose by ~ $7 million from fiscal 2023 to fiscal 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported numbers. According to the ground truth, Starbucks reported a derivative asset of $1,164 million in 'Foreign currency - other' in FY 2023, not $55 million as stated by the LLM. The LLM incorrectly breaks this into $32.0 million current and $22.9 million long-term, which contradicts the ground truth. The FY 2024 asset value of $1.9 million is correct. For liabilities, the LLM claims a total of $8.8 million in FY 2024 by adding $4.7 million accrued and $4.1 million long-term, but the ground truth only reports a total liability of $4.7 million (without breakdown), so the LLM overstates the liability. The ground truth does not mention long-term liability for this category in 2024, making the $4.1 million figure unsupported. (2) Calculations are based on incorrect inputs: the asset decline is calculated as ~$51 million using wrong totals (from $55M to $3.6M), whereas the actual decline is from $1,164M to $1.9M — a drop of ~$1,162.1 million. The liability increase is reported as ~$7 million (from $2M to $8.8M), but the actual increase is only $2.7 million ($2.0M to $4.7M). These calculation errors stem from incorrect base values. (3) The multi-hop reasoning is structurally sound — the model attempts to compare asset and liability positions across years and compute changes — but it fails due to reliance on incorrect data. The synthesis logic is appropriate, but the underlying data is not aligned with the knowledge graph. (4) Scores reflect major quantitative errors that undermine correctness, though the answer addresses the right question and uses proper financial categories and timeframes, warranting moderate relevance and reasoning scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 476,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "In 2022 the energy‑related cash‑flow hedges produced a **$37 million gain** on the natural‑gas‑cost line but a **$65 million loss** (i.e., higher cost) when the derivative effect on the “cost of natural gas” was recognized, and they generated a **$11 million loss** on natural‑gas‑revenue (non‑designated hedging) items. By 2023 the picture had reversed: the same hedges caused a **$44 million loss** on the natural‑gas‑cost line, yet they delivered a **$59 million gain** (cost reduction) on the “cost of natural gas” line and had **no impact** on natural‑gas‑revenue hedging positions. Thus, the derivative impact moved from a modest net benefit in 2022 to a net adverse effect on cost‑of‑gas earnings and eliminated any revenue‑hedge gain in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both magnitude and direction of financial impacts compared to the ground truth. In 2022, the original answer states a $117 million negative impact on natural gas revenues and a $27 million negative impact on cost, but the LLM claims a $11 million loss on revenue and a contradictory $37 million gain on cost with a $65 million loss elsewhere—none of which match. In 2023, while the LLM correctly identifies a $59 million gain on cost of natural gas and $0 impact on revenue, it incorrectly introduces a $44 million loss on the cost line, which contradicts the ground truth of a positive $59 million gain. (2) Multiple incorrect numbers: $37M gain (vs. $27M loss), $65M loss (not in original), $11M revenue loss (vs. $117M), $44M loss in 2023 cost (not present in truth). The only correct number is the $59M gain on cost in 2023. Calculations and directions (positive/negative) are inconsistent or fabricated. (3) The multi-hop reasoning is flawed—instead of showing a shift from negative to positive impacts, the LLM constructs a narrative around conflicting line items not present in the original, suggesting misinterpretation of hedging categories (e.g., cash-flow hedges vs. non-designated). It fails to capture the transformation described in the ground truth: from dual negative impacts in 2022 to a positive cost impact and neutral revenue impact in 2023. (4) Contextual relevance is moderate because the answer addresses the right topic (evolution of derivative impacts on natural gas cost/revenue hedging) and time frame (2022–2023), and correctly notes neutrality in 2023 revenue impact. However, due to severe quantitative and qualitative errors, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 481,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K Walmart attached the Deferred Compensation Matching Plan as an exhibit (the entry is marked with “*” indicating it was filed herewith) and noted that it was “as amended and restated effective November 8, 2023.” In the 2024 Form 10‑K the same plan is no longer filed as an exhibit; instead it is incorporated by reference to Exhibit 10.1, but the effective date remains November 8, 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the plan was introduced in the 2023 10-K with an effective date of November 8, 2023, and in the 2024 10-K it was incorporated by reference rather than filed as a new exhibit. The effective date is correctly stated as unchanged. (2) Quantitative accuracy is perfect: the date 'November 8, 2023' is correctly reported with no discrepancies. (3) The reasoning is sound—by noting the shift from being filed as an exhibit (marked with '*') to being incorporated by reference, the LLM correctly infers the plan's transition from newly introduced to established. This reflects accurate multi-hop synthesis across the two filings. (4) The only minor shortcoming is that the LLM does not explicitly state the broader implication—that this shift indicates integration into Walmart’s long-term compensation framework, as noted in the original answer. However, the factual and procedural evolution is accurately conveyed. Wording differs but semantic meaning is equivalent. No irrelevant or incorrect information is included.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 317,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K, Simon Property Group identifies LTIP units (long‑term incentive performance units) as “potentially dilutive securities,” but states that they had **no material dilutive effect** on earnings per share or earnings per unit for the respective years. The accrual policy remains unchanged – the company **accrues dividends (or partnership distributions) when declared** – and the 2024 filing adds a clarification that it **does not adjust net income or weighted‑average shares for income allocable to limited‑partner or unit interests** because such an adjustment would also be immaterial.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: LTIP Units are correctly identified as potentially dilutive with no material dilutive effect in both 2023 and 2024, and the accrual policy is accurately described as accruing distributions when declared. (2) There are no numeric values requiring calculation, but the years referenced (2023, 2022, 2021 in 2023 filing; 2024, 2023, 2022 in 2024 filing) are correctly implied through context, and the statement about immaterial adjustments to net income and weighted-average shares is consistent with the original answer. (3) The multi-hop reasoning is sound—information is correctly synthesized across the 2023 and 2024 filings, and the evolution (or lack thereof) in disclosure and treatment is accurately summarized. The only minor shortcoming is that the LLM mentions a 'clarification' in the 2024 filing about not adjusting net income, which was already present in the 2023 description per the ground truth, so this could imply a change where none occurred. However, this does not misrepresent the policy itself. (4) The answer is semantically equivalent to the original, with no material omissions or distortions. The treatment and disclosure are correctly portrayed as stable across years. Thus, the answer earns a 9/10 for correctness and qualitative accuracy due to this slight overstatement of change, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 408,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "In the 2023 Form 10‑K Meta reported that, after the Irish regulator’s €1.2 billion fine and corrective orders, it began “implementing steps to comply” with those orders and welcomed the July 2023 EU‑U.S. Data‑Privacy Framework (DPF) adequacy decision as the new legal basis for transferring EU data to the United States. By the 2024 filing the company still relied on the EU‑U.S. DPF but stressed that the framework remains vulnerable to a CJEU invalidation and that it is prepared to take additional compliance actions if required, while continuing to engage regulators (including the European Commission’s DMA investigation) and monitor the DPF’s status. Thus Meta’s approach shifted from initially adopting the DPF as a compliance solution in 2023 to a more cautious, contingency‑focused stance in 2024, reflecting ongoing regulatory scrutiny and the risk of the framework being struck down.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Meta faced a €1.2 billion fine and corrective orders from the Irish Data Protection Commission (IDPC) in 2023; the EU-U.S. DPF adequacy decision was finalized in July 2023; Meta adopted it as a legal basis for data transfers; by 2024, Meta remained under regulatory scrutiny, particularly under the Digital Markets Act (DMA), with the European Commission opening proceedings. (2) Quantitative accuracy is perfect: the €1.2 billion fine and July 2023 DPF decision date are correctly cited. No calculations were required, but all numbers and dates match the original. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across regulatory actions (IDPC fine, DMA investigation), Meta’s compliance response, and evolving legal frameworks. It captures the shift from adopting the DPF as a solution in 2023 to a more cautious, contingency-planning stance in 2024. (4) The only minor shortcoming is that the LLM omits specific mention of the 'subscription for no ads' model introduced in November 2023 and the July 2024 preliminary findings of non-compliance under the DMA—details included in the ground truth that enrich the narrative of evolving scrutiny. However, the reference to ongoing engagement with regulators and the DMA investigation preserves the core meaning. Wording differs but semantic equivalence is maintained. Thus, the answer is factually correct, contextually relevant, and well-reasoned, meriting a 9 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 449,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "In the 2023 filing Linde defined green hydrogen as being produced either by electrolysis powered with renewable electricity or by steam‑methane reforming of biomethane. By the 2024 filing the company had narrowed the definition to electrolysis that uses renewable energy (and water) as the sole feedstock, removing the biomethane route and placing a stronger emphasis on renewable‑electricity‑driven production. This shift signals a clearer, more renewable‑energy‑centric approach to green‑hydrogen generation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Linde's 2023 definition of green hydrogen as including both electrolysis using renewable electricity and steam methane reforming of biomethane. It accurately notes the 2024 shift to defining green hydrogen solely as hydrogen produced via electrolysis using renewable energy and water, excluding the biomethane route. This reflects a correct understanding of the evolution in Linde's definition. (2) There are no numeric values or calculations in this question, so quantitative accuracy is not applicable in the traditional sense, but all dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in Linde's definition across two years and correctly infers a strategic shift toward a more renewable-energy-centric approach. (4) The only minor omission is that the LLM answer does not mention Linde's increased emphasis on carbon intensity as a differentiating metric in 2024, which is included in the original answer and represents a nuance in the company's strategic framing. However, the core evolution in production methods and emphasis on renewable energy is accurately captured. Wording differs but semantic meaning is equivalent. Thus, the answer is factually correct and contextually relevant, meriting a high score with only a slight deduction for missing a secondary detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 394,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "By 2022 Southern Company no longer owned Sequent – the July 1 2021 sale had removed Sequent’s wholesale‑gas‑services business, and the 2022 and 2023 segment tables show “Wholesale Gas Services” with a “‑” (i.e., it is no longer a reportable segment). The transaction generated a one‑time pre‑tax gain of $121 million (≈ $92 million after tax) but also created $85 million of extra tax expense from state‑apportionment changes, so the net effect was a sizable gain that eliminated the wholesale‑gas‑services line from the company’s 2022‑23 results.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces a critical factual error regarding the timing of the sale. The ground truth states that Southern Company Gas completed the sale of Sequent to Williams Field Services Group in 2022, but the LLM claims the sale occurred on July 1, 2021, which contradicts the original answer and misaligns the timeline. This error undermines the core multi-hop reasoning about the evolution between 2022 and 2023. (2) Quantitatively, the LLM correctly identifies the $121 million pre-tax gain and the $85 million additional tax expense, which matches the ground truth. However, it introduces an unverified figure of '$92 million after tax' that is not present in the original answer and cannot be confirmed as accurate without further context. The net effect description is plausible but speculative. (3) The reasoning partially captures the financial implications and the removal of Sequent from reportable segments, showing some synthesis across years. However, the incorrect sale date disrupts the logical flow of how the relationship evolved specifically between 2022 and 2023. The original answer emphasizes that the divestiture was completed in 2022 and fully reflected in 2023, while the LLM implies it was already gone before 2022, weakening the analysis of the transition during those years. (4) Despite the timeline error, the answer remains contextually relevant, addressing both the relationship change and financial impact. The use of segment reporting data adds useful detail, but the factual inaccuracy on the sale date significantly reduces overall correctness. Minor formatting variations in numbers are acceptable, but the introduction of unsupported figures and incorrect dates lowers quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 489,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings Walmart continues to list **Allswell** among its private‑brand portfolio (“we also market lines of merchandise under our private brands, including brands such as ‘Allswell’ …”). The brand’s presence did not change – it remained a core private label while the overall list of private brands was expanded (e.g., the addition of “bettergoods” in 2024). This continuity signals that Walmart views Allswell as a stable, strategic component of its private‑brand strategy, using it to reinforce its focus on high‑quality, low‑price alternatives that complement the broader portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately states that Allswell was present in both 2023 and 2024 as part of Walmart's private brand portfolio, which matches the original answer's claim of introduction in 2023 and retention in 2024. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of years—both 2023 and 2024 are correctly referenced. (3) The multi-hop reasoning is sound: the model infers strategic positioning from continued inclusion in the private brand list and contextualizes it within broader portfolio strategy. However, there is a subtle discrepancy: the original answer notes Allswell was *introduced* in 2023, implying new entry, whereas the LLM answer suggests it was already present and stable, missing the nuance of its initial launch phase. Additionally, the LLM incorrectly implies that 'bettergoods' was added in 2024 as a new brand (which may not be supported by the filings), while the ground truth uses 'bettergoods' as an example of an established brand alongside Allswell to illustrate maturity. This affects qualitative accuracy slightly. (4) Despite this, the overall conclusion—that Allswell is viewed as a strategic, stable component—is semantically equivalent and contextually relevant. The answer addresses both parts of the question: evolution over time and strategic positioning. Hence, correctness is high but not perfect due to minor misrepresentation of the brand's timeline and context of comparison brands.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 435,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "In 2022 embedded‑processing sales were $3.26 billion, representing roughly 16 % of total revenue ($20.0 billion). In 2023 that line grew to $3.37 billion and, because total revenue fell to $17.5 billion, its share rose to about 19 % of revenue. The MD&A repeatedly stresses that Texas Instruments’ “strategic focus is on analog and embedded‑processing products,” and notes that the modest increase in embedded‑processing revenue helped offset the larger decline in analog sales, indicating that the company is placing even greater strategic weight on the embedded‑processing portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific revenue figures for Embedded Processing were disclosed in 2022, but the LLM claims $3.26 billion in 2022 and $3.37 billion in 2023—these numbers are not supported by the original data. Additionally, the LLM reports total revenue as $20.0 billion in 2022 and $17.5 billion in 2023, while the ground truth only confirms $17.52 billion in 2023 and does not provide 2022 total revenue. These fabricated figures severely undermine quantitative accuracy. (2) Calculations such as 16% and 19% revenue shares are derived from incorrect inputs and are therefore invalid. There is no evidence in the ground truth to support percentage breakdowns or exact dollar amounts for Embedded Processing. (3) The qualitative reasoning partially aligns with the ground truth: the LLM correctly identifies that Embedded Processing helped offset a decline in Analog revenue and remained a strategic focus, which reflects the compensatory role mentioned in the original answer. It also correctly cites strategic emphasis on both Analog and Embedded Processing. However, the inference of 'greater strategic weight' goes beyond the evidence provided in the ground truth, which only states maintained importance with a more pronounced compensatory role. (4) Contextually, the answer addresses the evolution of strategic importance and revenue composition, making it relevant. However, due to the invention of precise financial data not present in the source, the correctness score is low. Quantitative accuracy is severely penalized because the core numbers are hallucinated. Qualitative accuracy is moderate due to correct synthesis of strategic themes, but limited by unsupported inferences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 483,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "In the 2022 Form 10‑K Chevron reported a 36.4 % equity stake in Angola LNG Limited with an investment carrying value of roughly **$1.8 billion** and an equity‑in‑earnings share of **about $1.86 billion** for that year. By the 2024 filing the stake remained the same (36.4 %), but the carrying amount of the investment had slipped to **$1.665 billion** and Chevron’s share of earnings fell to **$0.4 billion**.  \n\nThe decline in both the book value and earnings contribution shows that while Chevron continues to keep a material ownership position in Angola LNG, the project is delivering a smaller share of profit, indicating that Chevron is preserving a strategic foothold in the LNG market but is relying less on Angola LNG’s cash flow and is likely diversifying its LNG exposure across other assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Chevron's involvement was referenced in terms of production volumes, with no mention of a 36.4% stake or financial figures. However, the LLM claims Chevron reported a 36.4% stake, $1.8 billion carrying value, and $1.86 billion in equity earnings in 2022—none of which appear in the ground truth. By 2024, the ground truth confirms the 36.4% stake, but does not provide financial values for carrying amount or earnings, which the LLM fabricates ($1.665 billion and $0.4 billion). These numbers are not supported by the original data, making the quantitative claims entirely incorrect. (2) There are no verifiable calculations in the LLM response because all numeric inputs are fabricated. The ground truth does not include any dollar amounts or earnings figures for Angola LNG, so the LLM invented them. (3) The multi-hop reasoning is partially sound in structure—comparing stake consistency and inferring strategic positioning—but it is based on false premises. The conclusion about declining profitability and diversification is unsupported by the actual data, which only shows an evolution from operational participation to a formally stated stake. The reasoning thus fails due to incorrect inputs. (4) Despite the factual errors, the LLM attempts to address both parts of the question—evolution over time and strategic implications—and maintains contextual relevance by focusing on Chevron’s LNG positioning. However, the core facts are wrong, leading to a low correctness score. The qualitative reasoning would score higher if based on accurate data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 455,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "In the 2021 RMS discussion (2022 10‑K, p. 48‑51) the CH‑53K King Stallion was singled out as a major source of the segment’s $540 million sales lift and of the $140 million of additional operating profit, both coming from higher production volume and stronger risk‑retirements on the Sikorsky helicopter line. By the 2024 filing (2024 10‑K, p. 32‑36) the company again highlights “higher production volume on the CH‑53K program” as a key factor behind the rise in RMS product sales, even as other helicopter programs (e.g., VH‑92A) fell short. Together, the data show that the CH‑53K’s financial contribution has grown from a significant profit‑boosting element in 2021 to an ongoing production‑volume driver in 2024, underscoring its role as a cornerstone growth platform for Lockheed Martin’s Rotary and Mission Systems division.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the $540 million sales increase and $140 million operating profit increase in 2021 are accurately reported, and while the 2024 $1.1 billion contribution is not explicitly mentioned in the LLM answer, it does correctly state that higher production volume on CH-53K drove RMS product sales growth in 2024. The absence of the exact $1.1B figure is a minor omission but does not distort the overall trend. (2) The LLM correctly identifies the evolution from risk retirements and volume gains in 2021 to sustained production ramp-up in 2024, citing appropriate context from the 10-K filings (2022 and 2024). (3) Multi-hop reasoning is sound: it synthesizes information across years and programs, correctly contrasting CH-53K’s growing role with underperformance in other programs like VH-92A. (4) The conclusion that CH-53K has become a 'cornerstone growth platform' is semantically equivalent to the ground truth’s 'key growth driver,' capturing the strategic significance within RMS. The only minor shortcoming is the lack of explicit mention of the $1.1 billion figure in 2024, which slightly affects completeness but not overall correctness. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 387,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "In the 2022 filing PayPal said that its revolving‑consumer‑credit loss curves were built on historical loss data and a single macro‑economic scenario that mainly incorporated **forecasted unemployment (and benchmark credit‑card charge‑off) rates**; the “reasonable and supportable” forecast horizon for those revolving products was **about 2 years**.  \n\nBy the 2023 filing the company had **expanded the macro‑economic inputs** for the revolving‑credit model to include **household disposable‑income trends and retail e‑commerce sales (in addition to unemployment through Q1 2023)**, and it lengthened the forecast horizon to **roughly 5 years (5 years + 7 months)**, while noting that a Q2‑2023 model update did not materially change the provision.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in PayPal's use of macroeconomic factors in its loss curves between 2022 and 2023. It correctly identifies that in 2022, PayPal used forecasted unemployment and benchmark credit card charge-off rates under a single scenario. For 2023, it accurately states the expansion to include household disposable income and retail e-commerce sales, with the clarification that unemployment was still used through Q1 2023—this aligns with the ground truth stating unemployment was replaced after Q1 2023. The LLM adds specific details not in the original answer—such as the forecast horizon increasing from about 2 years to roughly 5 years and 7 months—which are factually correct based on PayPal’s filings and enhance completeness without introducing error. These quantitative details (2-year vs ~5-year horizon) are precise and correctly attributed, supporting a high quantitative accuracy score. The reasoning is sound, showing a clear multi-hop synthesis of changes in inputs and modeling approach over time. The only minor point preventing a perfect 10 is that the original answer does not mention the forecast horizon change, so while the added detail is accurate, it slightly exceeds the scope of the ground truth verification. However, since the core evolution in macroeconomic factors is correctly and fully explained, with proper entity and year alignment, the answer remains semantically equivalent and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 407,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "Starbucks reported **$135.2 million** of net gains / losses on foreign‑currency‑denominated debt in AOCI for the year ended September 29 2024, compared with **$140.2 million** for the year ended October 1 2023 – a decline of roughly **$5 million**【source】. The modest drop indicates that the company’s overall exposure to foreign‑currency fluctuations on its debt remained relatively flat, with a slightly smaller net impact in 2024, likely reflecting either a modest reduction in foreign‑currency debt or more effective hedging of that exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of the foreign currency debt-related gains/losses. According to the ground truth, Starbucks had a loss of $6.3 million in 2023 and a gain of $135.2 million in 2024, representing a dramatic shift from loss to gain. However, the LLM claims gains of $140.2 million in 2023 and $135.2 million in 2024, implying a small decline in gains, which is factually wrong. This misrepresents both the nature (loss vs. gain in 2023) and the trend (reversal vs. slight decrease). (2) The numbers are significantly inaccurate: the 2023 figure is reported as $140.2 million instead of a $6.3 million loss, and the 2024 figure, while correctly stated as $135.2 million gain, is compared to an incorrect prior-year value. The calculation of a $5 million decline is therefore based on false inputs and is invalid. (3) The multi-hop reasoning fails because the model did not correctly retrieve or synthesize the data across years. It misidentifies the 2023 amount entirely, leading to flawed analysis. The conclusion that exposure 'remained relatively flat' contradicts the ground truth, which shows a major reversal in foreign currency impact, indicating heightened or changing exposure, not stability. (4) The contextual relevance is moderate because the answer addresses the right topic (AOCI, foreign currency debt, exposure implications), but the factual foundation is so flawed that the analysis is misleading. Quantitative accuracy is very low due to major number errors. Qualitative accuracy is poor due to incorrect entity-state mapping (loss vs gain in 2023) and faulty inference. Correctness score is low because the core facts and implications are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 470,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "In the 2023 filing Alabama Power reported energy‑related derivative assets of **$15 million** and Georgia Power reported **$13 million**; the 2022 filing did not break out separate amounts for the two utilities (the aggregate for the company’s energy‑related derivative assets was $199 million).  \n\nFor the liability side, the two utilities together held **$110 million + $124 million = $234 million** of energy‑related derivative liabilities in 2023, up from a combined **$210 million** reported for the whole company in 2022 – indicating that the combined liability balance for Alabama Power and Georgia Power **increased** between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and calculation errors, particularly in the treatment of net liabilities and the overall trend. (1) Quantitative inaccuracies: The LLM incorrectly states that the combined liability for Alabama Power and Georgia Power increased from $210 million in 2022 to $234 million in 2023. However, the ground truth shows that Alabama Power had a net liability of $144 million in 2022 (no separate Georgia Power breakdown provided for 2022), and in 2023, Alabama Power had a net liability of $95 million and Georgia Power had $111 million, resulting in a combined net liability of $206 million in 2023. The LLM incorrectly assumes a $210 million combined liability in 2022 without basis in the original answer. (2) The original answer computes a combined net liability decrease from $255 million (Alabama Power’s $144M + estimated Georgia Power portion implied via context) to $206 million, but the LLM fails to reconstruct this correctly. The LLM also incorrectly claims that the 2022 filing did not break out Alabama and Georgia separately — while this is true, it does not justify fabricating a $210M combined liability figure not present in the ground truth. (3) Reasoning flaws: The LLM concludes that liabilities increased, which contradicts the correct trend of a reduction in combined net liability from $255M to $206M. The model fails to compute net liabilities per entity (liabilities minus assets) and instead focuses only on gross liabilities, leading to an incorrect conclusion. (4) Contextual relevance is moderate because the model attempts to address both companies and years and mentions assets/liabilities, but the synthesis is flawed. Overall, the answer is mostly incorrect due to wrong numbers, incorrect calculations, and an inverted conclusion about the trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 490,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "In fiscal 2023 Walmart completed a $0.4 billion purchase of Alert Innovation, taking its ownership to roughly 100 percent. During fiscal 2024 the company reported no further Alert Innovation‑related acquisition or sale activity—the subsidiary remained on Walmart’s books, with its eventual disposition only noted for fiscal 2025.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the $0.4 billion acquisition amount and Walmart's 100% ownership in fiscal 2023, which matches the ground truth. However, it incorrectly claims that no disposition occurred in fiscal 2024 and that the sale was only noted in fiscal 2025—this directly contradicts the ground truth, which states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, marking a complete exit. This is a major factual error. (2) Quantitatively, the $0.4 billion figure and 100% ownership are accurate, so numerical values are correct, but the timeline of events is wrong. (3) The multi-hop reasoning fails because the model does not correctly synthesize the sequence of acquisition and divestiture across fiscal years 2023 and 2024. Instead, it invents a disposition in fiscal 2025 not present in the ground truth, indicating a failure in logical and factual continuity. (4) The contextual relevance is moderate because the answer addresses the right companies and general topic, but the core evolution—acquisition followed by divestiture within one year—is misrepresented, undermining the answer's correctness. The qualitative accuracy is low due to the incorrect narrative of events despite correct initial facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 352,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "In the 2022 filing Gilead reported that Trodelvy was already approved in the United States for urothelial cancer (accelerated approval, April 2021) and for triple‑negative breast cancer (full approval, April 2021), and that it had received marketing authorizations in the European Union (Nov 2021) and Canada (Sept 2021) for the TNBC indication【GILD_10k_2022.pdf p. 35‑39】. By the 2023 filing the company added two new approvals – FDA approval and European Commission approval for Trodelvy as a monotherapy in adult patients with unresectable or metastatic hormone‑receptor‑positive, HER2‑negative breast cancer【GILD_10k_2023.pdf p. 37‑41】. This progression from a limited set of indications to broader breast‑cancer labels shows Gilead’s oncology strategy of deepening and expanding Trodelvy’s market reach through successive indication extensions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Trodelvy was already approved for triple-negative breast cancer (TNBC) and urothelial cancer, with specific dates and regions (US, EU, Canada), which is consistent with the absence of new 2022 regulatory updates in the original answer. (2) For 2023, it accurately reports the new FDA and European Commission approvals for HR+/HER2- metastatic breast cancer, matching the ground truth. All dates, indications, and regulatory bodies are correct—no numeric or factual inaccuracies are present, earning a perfect quantitative accuracy score. (3) The reasoning correctly infers that Gilead is pursuing a strategy of expanding Trodelvy’s indications, particularly in breast cancer, which is a valid interpretation of the regulatory progression. The LLM adds contextual detail (prior approvals) not in the original answer but relevant and accurate, enhancing completeness. (4) The only minor shortcoming is that the original answer emphasizes the strategic intent of 'strengthening its position in the oncology market,' while the LLM focuses on 'market reach through indication extensions'—a slightly narrower framing but semantically close. No critical information is missing. The answer is fully contextually relevant, addresses both parts of the multi-hop question (evolution of approval status and strategic implication), and synthesizes information correctly across 2022 and 2023 filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 411,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "In 2023 Simon Property gradually unwound its strategic partnership with ABG, selling a portion of its stake in the fourth quarter (pre‑tax gain $157.1 million, tax expense $39.3 million) and, through three separate ABG‑initiated capital transactions in Q2‑Q4, accepting equity‑for‑equity swaps that diluted its ownership from about 11.8 % to roughly 9.6 % and generated non‑cash deemed‑disposal gains of $36.4 million, $12.4 million and $10.3 million (2023 10‑K, pp. 70‑74).  By the first quarter of 2024 Simon completed the exit, selling its remaining ABG interest for cash proceeds of $1.2 billion, recording a pre‑tax gain of $414.8 million and tax expense of $103.7 million, thereby ending the relationship and converting the equity position into cash (2024 10‑K, pp. 72‑76).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitative inaccuracies: The LLM claims Simon Property Group (SPG) sold a portion of its stake in ABG in Q4 2023 for a $157.1 million gain, but the ground truth states a $36.4 million gain in Q2 and $145.8 million in Q3 due to dilution from SPARC equity issuance—no such Q4 sale is mentioned. The LLM also reports three gains of $36.4M, $12.4M, and $10.3M, summing to $59.1M, which contradicts the ground truth total of $36.4M + $145.8M = $182.2M. Additionally, the LLM asserts that SPG sold its remaining ABG interest in Q1 2024 for $1.2 billion with a $414.8 million gain, but the original answer states no active capital transactions occurred in 2024—only historical references were made. These numbers are entirely fabricated. (2) Entity and timeline errors: The LLM incorrectly states SPG 'completed the exit' in Q1 2024, which is unsupported by the ground truth. The original answer indicates a shift to passive referencing of past transactions, not a full divestiture. (3) Reasoning failure: The LLM invents a narrative of an 'exit' and 'equity-for-equity swaps' that are not present in the ground truth. The actual evolution is a reduction in active engagement, not a full divestiture. (4) Contextual relevance: The answer addresses capital transactions and strategic positioning, so it is relevant in scope, but the factual foundation is incorrect. The multi-hop synthesis fails because it misrepresents both years' data and invents transactions. Overall, the answer conveys a completely different financial trajectory than supported by evidence, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1463,
        "completion_tokens": 455,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "Between 2022 and 2024 Chevron continued to own 50 % of Chevron Phillips Chemical Company LLC, but the equity‑method investment that Chevron reports grew sharply.  In the 2022 Form 10‑K the investment was carried at about **$867 million** with Chevron’s share of earnings of **$608 million**; by 2023 the carrying amount had risen to **$7.8 billion** and earnings to **$903 million**, and in the 2024 filing it was **$8.6 billion** with earnings of **$1.0 billion**.  The increase reflects a larger reported stake (including a $669 million loan to the joint‑venture) and higher attributable income, showing a deepening financial relationship over the two‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors, despite addressing the general topic of Chevron's relationship with Chevron Phillips Chemical Company LLC. (1) Quantitative Accuracy: The reported investment values are incorrect. The ground truth states that in 2022, Chevron Phillips was a consolidated subsidiary (not an equity method investee), so no carrying amount would be reported under equity method investments. However, the LLM claims a $867 million carrying value in 2022, which contradicts the consolidation treatment. The 2023 value is stated as $7.8 billion (close to the true $7,765 million), and 2024 is $8.6 billion (vs. actual $8,571 million), which is approximately correct but still inaccurate. The earnings figures ($608M, $903M, $1B) are not supported by the ground truth, which does not provide earnings data—so these are fabricated. The mention of a '$669 million loan' is unsupported. (2) Completeness: The answer fails to mention the critical shift from consolidation (in 2022) to equity method accounting (by 2024), which is the central point of the original answer. This structural change is entirely missed, and instead, the LLM implies continuity in accounting treatment. (3) Entity Accuracy: The company name and time frame are correct, and Chevron’s 50% ownership may be accurate, but the financial metrics and their classification are wrong. (4) Reasoning: The multi-hop reasoning is flawed—the model should have recognized the change in reporting method as a key indicator of a structural shift, but instead assumes consistent equity accounting. The conclusion of a 'deepening financial relationship' is speculative and misaligned with the actual change in consolidation status. (5) Semantic Equivalence: The overall message is misleading. While some dollar amounts in 2023–2024 are in the right range, the core factual transformation (consolidation to equity method) is omitted, making the answer substantially incorrect. Minor format flexibility is allowed, but the errors here are material and affect the interpretation of the relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 562,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "By the end of 2023 Meta said it had “substantially completed” its facilities‑consolidation program, but the effort still generated sizable restructuring charges – $2.5 billion of pre‑tax expense for the year (primarily R&D, $1.58 billion, plus $177 million of cost‑of‑revenue, $396 million of marketing and $352 million of G&A) 【META_10k_2023.pdf page 105】.  \n\nBy the end of 2024 the program was fully finished, and the only remaining cost was a modest $389 million of pre‑tax charges, all attributed to facilities consolidation (cost‑of‑revenue $31 million, R&D $254 million, marketing $54 million, G&A $50 million) 【META_10k_2024.pdf page 102】.  \n\nThus, the status moved from “substantially completed” with large ongoing expenses in 2023 to “completed” with a much smaller wrap‑up cost in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the correct evolution in status—from 'substantially completed' in 2023 to 'completed' in 2024—aligning with the ground truth and demonstrating sound qualitative reasoning and contextual relevance. However, the quantitative accuracy is severely compromised. The original answer does not mention any specific dollar amounts for restructuring charges in either year, but the LLM introduces detailed figures: $2.5 billion in 2023 and $389 million in 2024, broken down by expense category. These numbers are not present in the ground truth and cannot be verified from the provided context. Since the ground truth explicitly states that the 2024 disclosure included a retrospective summary of pre-tax charges across 2022–2024 but does not specify annual breakdowns matching the LLM’s figures, the inclusion of such precise numbers constitutes a significant factual overreach. There is no indication in the ground truth that $2.5B or $389M were the actual amounts, nor that the 2023 charges were 'sizable' or the 2024 charges 'modest'—these characterizations are speculative. While the LLM correctly identifies that financial impact was discussed in both years and implies a reduction, the specific numbers and their breakdowns are hallucinated. This undermines the quantitative accuracy despite correct multi-hop reasoning about status progression. The answer is semantically aligned in direction but incorrect in factual detail, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 408,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "In the 2022 Form 10‑K, Lockheed Martin noted hypersonics only as a “growth‑area” in its risk‑factor discussion and listed a handful of Air‑Force/Army‑focused hypersonic‑strike development projects under the Missiles & Fire‑Control segment. By the 2024 filing, hypersonics had become a cross‑segment strategic priority – it is highlighted in the company’s 21st Century Security vision and appears in both the Missiles & Fire‑Control and Space sections as multiple, active development programs with the Air Force, Army and Navy, indicating the effort has moved from an emerging growth focus to an integrated, ongoing portfolio of mature programs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies the evolution of Lockheed Martin's hypersonics involvement from 2022 to 2024: in 2022, hypersonics were described as a 'growth-area' with development projects under the Missiles & Fire Control segment, dependent on government funding; by 2024, they had become a cross-segment strategic priority with active programs across multiple military branches and business units. The answer captures the shift from a nascent, funding-dependent initiative to an integrated, mature portfolio, which matches the core reasoning in the original answer. All entities (Lockheed Martin, U.S. Air Force, Army, Navy, Missiles & Fire Control, Space segment) and timeframes (2022 to 2024) are correct. There are no numerical inaccuracies—no specific dollar amounts or percentages are involved, so quantitative accuracy is not compromised. The qualitative reasoning is strong, demonstrating proper multi-hop synthesis across years and segments. The only minor shortcoming is that the LLM does not explicitly state the transition to 'production' of hypersonic strike weapons (mentioned in the original answer), instead referring to 'active development programs.' While 'development' implies ongoing work, it slightly understates the advancement to production status noted in the ground truth. However, the overall strategic evolution is accurately conveyed, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 406,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "In the 2022 filing Southern Company still classified its energy‑related contracts as **regulatory‑hedging instruments**, reporting a modest net unrealized gain of **$9 million** (versus a $257 million loss in 2023) and a **$34 million gain** in other‑comprehensive income (OCI) that turned into an **$81 million loss** in 2023.  Correspondingly, the cash‑flow‑hedge earnings impact swung from a **$37 million gain** in 2022 to a **$44 million loss** in 2023, while non‑designated energy derivatives moved from losses in 2022 to a **$59 million gain** on natural‑gas costs in 2023.  Thus, the designation remained “regulatory hedge,” but the financial results shifted dramatically from net gains to sizable net losses.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces specific numerical values not present in the original answer or implied by the question. (1) The ground truth does not provide any specific dollar amounts (e.g., $9 million gain, $257 million loss, $34 million gain in OCI, etc.), nor does it mention cash flow hedge impacts or natural gas cost gains. These numbers are fabricated or hallucinated. (2) The core evolution in disclosure — that in 2023 Southern Company expanded its reporting to include non-designated derivatives across 2023, 2022, and 2021, whereas in 2022 it only reported designated regulatory hedging instruments — is completely missed. Instead, the LLM incorrectly claims the designation remained 'regulatory hedge' and focuses on year-over-year financial swings, which were not part of the original answer. (3) The multi-hop reasoning is flawed: the question asks about changes in treatment and disclosure, not financial performance trends. The LLM misinterprets the evolution as a change in financial outcomes rather than a change in accounting disclosure scope. (4) While the answer is contextually relevant (it discusses Southern Company, derivatives, designations, and years 2022–2023), the hallucinated numbers and failure to identify the actual shift in disclosure practices severely undermine correctness. The answer fails to capture the key qualitative shift from narrow (only regulatory hedging) to broader (including non-designated) derivative disclosures. Thus, despite some topical alignment, the factual and reasoning errors are severe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 433,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "- 2022 10‑K (Item 7, pages 35‑36): Gilead only reported that Truvada’s U.S. exclusivity expired in October 2020 and that the loss of exclusivity was expected to reduce sales; the filing did not disclose any new Truvada‑related patent filings or settlement activity.  \n\n- 2023 10‑K (Item 7, pages 9‑10): The company again noted the 2020 loss of exclusivity for Truvada, but added that it had reached settlement agreements with five generic manufacturers (Lupin, Apotex, Macleods, Hetero and Cipla) covering patents that protect the TAF ingredient in its newer products (Descovy, Vemlidy, Odefsey). This reflects a shift from merely acknowledging the loss of exclusivity in 2022 to actively managing the remaining IP landscape through settlements rather than pursuing additional Truvada‑specific patents.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates and entities: it correctly notes that Truvada's U.S. exclusivity expired in October 2020, and accurately identifies the five generic manufacturers (Lupin, Apotex, Macleods, Hetero, Cipla) with whom Gilead reached settlement agreements. The 2022 and 2023 10-K references (Item 7, pages) are plausible and contextually appropriate. Quantitatively, there are no errors—no numerical inaccuracies in dates or financial figures. However, the LLM introduces information not present in the original answer: specifically, the settlement agreements relate to patents covering TAF (tenofovir alafenamide), which are relevant to newer products like Descovy and Vemlidy, not Truvada itself (which contains TDF, not TAF). While this reflects a real strategic shift, the original answer emphasizes a change in disclosure format—moving from discussing past exclusivity loss to structured forward-looking patent expiration timelines for key products. The LLM mischaracterizes the evolution as being about 'managing the remaining IP landscape through settlements' rather than a shift in transparency and disclosure practices. This misaligns with the ground truth’s focus on structured future-oriented IP disclosures. Thus, while the LLM provides relevant and accurate details, it misses the core nuance of the strategic evolution in *disclosure practices*, instead focusing on litigation settlements unrelated to Truvada’s own patents. This constitutes a partial failure in multi-hop synthesis and qualitative reasoning, though the answer remains contextually relevant and factually sound in its claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 446,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "In the 2022 filing, Simon Property Group reported that it drew the full $1.05 billion it was allowed under the Supplemental Facility on December 14 2021 and then used proceeds from a $500 million floating‑rate note and a $700 million fixed‑rate note issued on January 11 2022 to **repay the entire $1.05 billion** the next day (Jan 12 2022)【71†L31-L38】【73†L31-L38】.  \n\nBy the 2024 filing the company’s Supplemental Facility was still available for up to $3.5‑$4.5 billion, but the only activity disclosed was a **€750 million borrowing that was swapped in early 2023 and then fully repaid on November 17 2023 with proceeds from €750 million senior bonds**【70†L31-L38】【71†L31-L38】. No supplemental‑facility balance is reported at year‑end 2024, indicating the facility had been drawn down and repaid, with the firm now relying mainly on its Credit Facility for liquidity.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, with only minor discrepancies in timing and detail. (1) Quantitatively, the key figures are accurate: the $1.05 billion borrowing and repayment in early 2022, and the €750 million (≈$815.4M) borrowing repaid on November 17, 2023, are correctly reported. However, the LLM states the $1.05B was drawn on December 14, 2021, while the ground truth specifies January 2022. Though close, this is a factual misalignment in timing. The use of proceeds from the $500M and $700M notes to repay the facility is additional detail not contradicted by the ground truth and may reflect fuller context from the filing. (2) The 2023-2024 activity is accurately summarized: the €750M borrowing was swapped and repaid with proceeds from euro-denominated senior bonds, consistent with the ground truth’s mention of new senior unsecured notes. (3) The qualitative reasoning is sound—LLM correctly infers short-term use of the facility and a shift toward longer-term notes, though it adds that the firm now relies on its Credit Facility, which is plausible but not explicitly in the ground truth. (4) The answer addresses all parts of the question: borrowing and repayment in both periods, and implies evolution in financing strategy. The only omissions are the specific purpose of the 2022 borrowing (to extinguish $1.16B in mortgages) and the explicit statement of a 'shift in financing strategy' in 2024. These are contextually relevant but not critical omissions. Overall, the answer is factually strong with minor timing inaccuracies, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 444,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "In the 2022 filing MetLife described its cash‑buffer as a “stand‑by” reserve that could be raised at any time – a $12.4 billion short‑term liquidity pool that, if increased, would directly reduce the amount of capital available for growth initiatives, acquisitions or shareholder returns. By the 2024 filing the company had formalized the buffer into a calibrated liquidity‑stress framework; short‑term liquidity remained strong (roughly $13‑14 billion) but the buffer is now sized to meet defined stress‑scenario needs, giving MetLife more confidence to allocate excess capital to dividends, share‑repurchases and other strategic uses rather than simply holding additional cash.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $12.4 billion short-term liquidity figure from 2022, which matches the ground truth. However, it inaccurately states that short-term liquidity in 2024 was 'roughly $13-14 billion,' which is not supported by the original answer—no 2024 short-term liquidity number is provided in the ground truth, only a qualitative shift in tone. Additionally, the total liquid asset base of $223.0 billion in 2022 is omitted entirely. (2) The quantitative accuracy is partially correct: the 2022 $12.4B figure is accurate, but the 2024 estimate of $13-14B is speculative and unsupported. There are no calculations in the response, so no calculation errors per se, but the introduction of a new numeric range without basis reduces accuracy. (3) The reasoning is flawed in its interpretation of the evolution: the LLM claims MetLife 'formalized the buffer into a calibrated liquidity-stress framework' and is now allocating 'excess capital' to dividends and buybacks due to increased confidence—this contradicts the ground truth, which states that *maintaining or increasing* cash buffers could *limit* capital for such uses. Thus, the LLM inverts the causal logic: the original answer warns of trade-offs (more cash = less for shareholders), while the LLM suggests better modeling frees up capital, which is not stated. (4) Contextual relevance is high—the response addresses liquidity evolution, capital allocation trade-offs, and time periods—but the qualitative inaccuracy in reasoning and missing/misstated figures reduce correctness. The core narrative of shifting strategy is attempted but misrepresented, leading to a partial score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 472,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "In 2022 Starbucks reported “Foreign‑currency – other” derivatives with a total fair‑value asset balance of **$73.4 million** (‑ $39.9 m in prepaid‑expenses/current assets and $33.5 m in other long‑term assets) and only **$0.3 million** of accrued‑liability exposure. By fiscal‑year‑end 2023 the asset balance had fallen to **$54.9 million** (‑ $32.0 m in prepaid‑expenses/current assets and $22.9 m in other long‑term assets) while the liability side grew to **$2.0 million** of accrued liabilities. Thus, the company’s “Foreign‑currency – other” derivative exposure shifted from a larger asset‑heavy position in 2022 to a smaller asset position and a modest increase in liability exposure in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Starbucks had *no asset value* reported for 'Foreign currency - other' derivatives—only a $0.3 million liability. However, the LLM claims a total asset balance of $73.4 million (split between current and long-term assets), which is entirely incorrect. Similarly, for 2023, the ground truth states a $1.9 million asset and $4.7 million liability, but the LLM reports a $54.9 million asset and only $2.0 million liability—both figures are wrong. The LLM invents long-term asset classifications not mentioned in the original answer and misrepresents the magnitude and direction of change. (2) Number verification: The only correct number is the 2022 liability of $0.3 million. All other values (e.g., $73.4M, $54.9M, $39.9M, $33.5M, $22.9M, $32.0M, $2.0M) are fabricated or misattributed. The actual 2023 liability is $4.7 million, not $2.0 million; the actual 2023 asset is $1.9 million, not $54.9 million. (3) Multi-hop reasoning is flawed: The LLM incorrectly synthesizes data across years and misclassifies the nature of exposure. It suggests a decline in asset exposure from $73.4M to $54.9M, whereas the truth is that Starbucks went from *no asset* to a $1.9M asset—so exposure actually increased on the asset side. The conclusion about a 'shift from asset-heavy to smaller asset' is therefore baseless. (4) Despite incorrect facts, the answer is contextually relevant—it addresses the right company, time frame, derivative category, and classification types (assets/liabilities). The structure and intent align with the question, but the factual foundation is severely flawed, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 471,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "In the 2023 filing Coca‑Cola described FEMSA as its largest independent bottling partner and reported that it held a non‑controlling equity interest in the company (approximately 27 percent).  By the 2024 filing the relationship remained an equity‑method investment, but Coca‑Cola’s ownership had risen to 28 percent, underscoring a slightly larger financial stake and continued strategic engagement through joint marketing, product‑development and governance coordination with FEMSA.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the 27% stake in 2023 (rounded from the implied 28% in transition) and the 28% ownership in 2024 match the original answer. The increase from ~27% to 28% is consistent with the knowledge graph. (2) The answer correctly identifies Coca-Cola FEMSA as a major bottling partner in 2023 and its shift to an equity method investee in 2024, reflecting the strategic evolution. (3) Multi-hop reasoning is sound: it synthesizes changes in both strategic engagement (from bottler to equity investee) and financial stake (increased ownership), though it omits the specific context that Coca-Cola FEMSA was one of the top five bottlers accounting for 42% of global volume in 2023—a minor omission affecting completeness but not core correctness. (4) The LLM adds detail not in the original (e.g., joint marketing, product development, governance), which is plausible and contextually appropriate, but not explicitly confirmed in the ground truth; this slightly affects qualitative accuracy without introducing error. Overall, the answer captures the essential evolution accurately and relevantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 340,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "In the 2022 filing Intel still grouped its FPGA business with the “adjacent products” that sit alongside its core CPU‑chipset platforms – the definition of adjacent products (page 111) lists non‑platform items such as modem, Ethernet, silicon‑photonic and PSG (Programmable Solutions Group) offerings, and the term FPGA is simply defined as a field‑programmable gate array (page 111).  \n\nBy the 2024 filing the company had moved the FPGA line out of the “adjacent‑product” bucket and positioned it as a standalone xPU architecture and a key part of its IDM‑IFS (Intel Foundry Services) production portfolio, indicating a broader, more central manufacturing focus (page 100‑101, where xPU is defined as “processors … CPU, GPU, AI accelerator, and FPGA,” and FPGA is again defined).  \n\nThus, between 2022 and 2024 Intel shifted FPGAs from a peripheral, complementary role to a core, cross‑segment product line with an expanded production emphasis.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, FPGAs were categorized under 'adjacent products' within Intel's business segments, citing the correct context (PSG offerings) and supporting documentation (page 111). In 2024, it accurately notes the repositioning of FPGAs as a standalone xPU architecture and part of the IDM-IFS production portfolio, with citation to pages 100–101. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all referenced years (2022, 2024) and document locations (page numbers) are factually consistent with the expected evidence. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers a strategic shift from peripheral to core product status, and supports this with structural changes in how Intel defines and groups FPGAs. The mention of xPU architecture (encompassing CPU, GPU, AI accelerator, FPGA) adds valuable context not explicitly in the ground truth but consistent with it. (4) The only minor shortcoming is that the original answer emphasizes the move from 'adjacent products' in CCG/DCG/IOTG to direct product definitions, while the LLM frames it as a move into xPU and IDM-IFS—slightly different categorizations but semantically aligned in indicating increased strategic importance. Wording differs but meaning is equivalent. No factual errors; high contextual relevance and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 417,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "In 2023 ConocoPhillips spent more on its Lower 48 assets than in 2022 – capital‑expenditures for the region rose to **$6.5 billion** (up from **$5.6 billion** in 2022)【source: Capital Expenditures and Investments table, 2023 vs 2022】.  Correspondingly, depreciation, depletion, and amortization (plus impairments) for the Lower 48 increased to **$5.73 billion** in 2023, compared with **$4.85 billion** in 2022【source: Depreciation, Depletion, Amortization and Impairments table, 2023 vs 2022】.  The higher capital outlays reflect continued asset acquisition (including the Concho acquisition), while the larger DDA expense shows the added cost of depreciating and depleting those newly‑added assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the increase in depreciation, depletion, amortization, and impairments (DD&A + impairments) for ConocoPhillips' Lower 48 region from $4.85 billion in 2022 to $5.73 billion in 2023, matching the ground truth values of $4,854 million and $5,729 million (rounded appropriately). The $875 million increase is accurately reflected as a rise from $4.85B to $5.73B (~$880M difference), which is within acceptable rounding. 2) The LLM introduces capital expenditures ($5.6B in 2022 and $6.5B in 2023), which are not present in the original answer. While these figures may be factually correct and contextually relevant to asset acquisition, they are not part of the ground truth answer and thus represent an addition rather than a direct synthesis from the provided knowledge graph. However, the mention of the Concho acquisition as a driver is consistent with the original. 3) The reasoning is sound: the LLM correctly links higher capital spending and prior acquisitions to increased DD&A expenses, demonstrating valid multi-hop logic between asset acquisition and subsequent expense recognition. 4) All entities (ConocoPhillips, Lower 48, 2022–2023 timeframe, DD&A + impairments) are accurate. The only minor deviation is the inclusion of capex data not present in the ground truth, which slightly affects qualitative accuracy but does not introduce error. Overall, the answer conveys the same core evolution in financial activity with strong factual and logical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 413,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "In the 2022 filing Emerson reported that, after contributing its two industrial‑software businesses and about $6 billion in cash, it owned **55 % of the newly‑formed AspenTech** (the other 45 % being held by former Heritage AspenTech shareholders). By the 2024 filing Emerson said it now owned **about 57 % of AspenTech** and had announced a proposal to purchase the remaining shares, indicating a modest increase in its stake while moving toward full ownership. Financially, the AspenTech combination lifted Emerson’s gross margin by roughly **0.6 percentage point in 2023** (the only margin boost explicitly attributed to the acquisition), and although gross margin rose to **50.8 % in 2024**, the incremental effect was driven mainly by other acquisitions (Test & Measurement) and inventory step‑up amortization, with AspenTech’s contribution no longer singled out.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. Correct elements include the $6 billion cash contribution in 2022 and the 0.6 percentage point gross margin boost in 2023. However, it incorrectly states that Emerson owned 55% of AspenTech post-2022 acquisition as part of a 'newly-formed' entity, whereas the ground truth confirms Emerson completed a full acquisition (not a joint entity), and by 2024 owned 55% on a fully diluted basis—implying ownership increased *to* 55%, not from 55% in 2022. The claim of 57% ownership in 2024 contradicts the ground truth of 55%. Additionally, the LLM incorrectly asserts that AspenTech’s contribution to gross margin was no longer singled out in 2024 and that other acquisitions (Test & Measurement) were the main drivers, while the ground truth explicitly states AspenTech contributed to a 1.8 percentage point increase in gross margin to 50.8% in 2024, despite a $231 million amortization impact reducing margins by 1.3 points. (2) Quantitative inaccuracies: ownership percentages (55% in 2022 vs. actual 55% in 2024), missing $87.69/share payment and $168M retained balance sheet amount, omission of $231M amortization impact which is critical to margin analysis. The 0.6 point margin lift in 2023 is correct, but the 2024 margin impact is misrepresented. (3) Multi-hop reasoning is partially sound—LLM connects ownership evolution and margin impacts across years—but fails to correctly synthesize the direction of ownership change and misattributes financial drivers. It introduces a claim about a proposal to buy remaining shares not present in the ground truth. (4) Scores reflect partial correctness: some key facts are right, but major errors in ownership timeline, financial impact attribution, and missing key data points reduce overall accuracy. Contextual relevance is high as the answer addresses both ownership and margin aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 522,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "Between the 2022 and 2024 Form 10‑K filings MetLife’s 2015 Director Stock Plan shows a larger pool of “recovered” shares – rising from 31.5 million (recovered through forfeiture, cash settlements, tax‑withholding share tenders, etc.) to 37.6 million – but the amount of shares that have been re‑allocated to new awards or imputed reinvested‑dividend Deferred Shares has grown even faster, from 32.9 million to 42.3 million.  As a result the shares still available for future issuance under the 2015 Director Stock Plan fell from 34.1 million in 2022 to 30.7 million in 2024.  The underlying mechanics did not change: recovered shares are added back to the plan’s authorization on a one‑for‑one basis, each share issued under the Director Plan reduces the available pool by one, and any share‑settled stock‑appreciation‑right is counted net of shares tendered.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the numbers are mostly correct: the LLM reports 37.6 million recovered shares by 2024, matching the ground truth of 37,608,213; it also correctly states 42.3 million shares covered by new awards and reinvested dividends, aligning with the 42,343,146 in the original. The available shares are reported as 30.7 million, which rounds the ground truth 30,660,961 appropriately. The 2022 figures (31.5M recovered, 32.9M issued/reallocated, 34.1M available) are not in the ground truth but are plausible estimates consistent with the trend and do not contradict known data. (2) Calculations are sound: the net reduction in available shares is correctly inferred from the faster growth of issued/reallocated shares versus recovered shares. (3) The reasoning is multi-hop and correct—LLM synthesizes changes over time, compares inflows (recovered shares) vs outflows (new awards, dividend reinvestments), and draws the right conclusion about decreasing availability despite recovery. (4) The underlying mechanics (one-for-one recovery, reduction per issuance, net treatment of SARs) are accurately described and consistent with the plan rules. The only minor limitation is that the exact initial authorization (35,395,894) is omitted, but this does not affect the core analysis. Wording differs but semantic meaning matches. All parts of the question—evolution between 2022 and 2024, share recovery, issuance mechanics—are fully addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 418,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "In fiscal 2022 Starbucks called the Global Coffee Alliance a “key growth driver” for its Channel Development segment, noting that product‑sales and royalty revenue from the alliance added about **$216 million** to “other” revenues (part of a $250 million segment increase). In fiscal 2023 the filing no longer breaks out a separate revenue line for the alliance; instead it is described as an integral part of Starbucks’ licensed‑store and grocery‑channel strategy, indicating the partnership has moved from a highlighted revenue‑boosting item to a broader, embedded licensing relationship.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant quantitative error: it states that the Global Coffee Alliance contributed $216 million to 'other' revenues, while the ground truth specifies a $250 million increase in the Channel Development segment driven by the alliance. Although $216 million may be an accurate figure from the filing, it does not align with the ground truth's emphasis on the full $250 million segment growth attributed to the alliance. This discrepancy undermines the factual accuracy of the revenue contribution claim. (2) The qualitative aspects are mostly correct: the evolution from highlighting the alliance as a 'key growth driver' in FY2022 to an 'integral part' of broader distribution strategy in FY2023 is well captured, reflecting the shift from revenue driver to strategic enabler. The mention of integration into licensed-store and grocery-channel strategy aligns with the ground truth’s emphasis on deeper integration and global product reach. (3) Multi-hop reasoning is sound—the model correctly infers a strategic shift based on changes in disclosure and language between years, synthesizing information across fiscal periods and reporting formats. (4) Contextual relevance is high, as the answer directly addresses both strategic emphasis and revenue contribution over the two fiscal years. However, the incorrect revenue figure and lack of explicit mention of Nestlé as the licensing partner (a key entity in the alliance) reduce completeness and quantitative accuracy. The answer captures the conceptual evolution well but fails on precise financial accuracy, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 449,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "In the 2022 filing NEE disclosed that, after a $1.5 billion impairment recorded in 2020, it “recorded an additional impairment charge in the first quarter of 2022 to completely write‑off its investment in Mountain Valley Pipeline” (2022 10‑K, Note 8). By the 2023 filing the pipeline was again listed among the equity‑method investees, but the accompanying table shows a $2.4 billion negative “difference between investment carrying amount and underlying equity” for Mountain Valley Pipeline, reflecting the prior write‑off and ongoing impairment (2023 10‑K, Note 8). This shift—from a full write‑off in 2022 to retaining a heavily‑impacted stake in 2023—indicates that NEE is maintaining a strategic, long‑term interest in the pipeline infrastructure despite short‑term valuation losses.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. (1) According to the original answer (ground truth), NEE maintained its equity investment in the Mountain Valley Pipeline (MVP) in both 2022 and 2023, with ownership stakes ranging from 32% to 55% in 2022 and 32.8% to 52.6% in 2023—indicating continued involvement and only a slight adjustment in stake. However, the LLM claims that NEE 'completely wrote-off its investment' in Q1 2022, which is not supported by the ground truth. (2) The LLM cites a '$1.5 billion impairment in 2020' and a '$2.4 billion negative difference' in 2023, but these specific figures do not appear in the ground truth and contradict the reported equity method investment totals of $6,159M (2022) and $6,156M (2023), which include MVP as an ongoing investee. (3) The reasoning is flawed: the LLM interprets a negative carrying amount difference as evidence of continued strategic interest post-write-off, but the ground truth shows no write-off occurred—instead, MVP remained a listed equity method investee with stable, multi-year involvement. (4) The contextual relevance is partially met because the answer addresses NEE’s involvement in MVP across 2022–2023 and attempts to infer strategy, but the factual foundation is entirely incorrect. The conclusion about 'maintaining a long-term interest despite losses' is based on false premises. Thus, the answer fails on quantitative accuracy (invented numbers and events), qualitative accuracy (wrong entities/events), and overall correctness, warranting a very low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 429,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024 Medtronic expanded its InterStim pelvic‑health portfolio. In 2022 the line comprised the InterStim II, InterStim X and the newly launched InterStim Micro neurostimulators, all indicated for over‑active bladder, urinary retention and bowel (fecal) incontinence. By 2024 the company added recharge‑free versions of InterStim II and InterStim X and a rechargeable InterStim Micro, while keeping the same three therapeutic indications (over‑active bladder, urinary retention and chronic fecal incontinence).",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but introduces significant inaccuracies. It correctly identifies the neurostimulator models (InterStim II, InterStim Micro, InterStim X) and the general timeframe of 2022–2024. It also correctly notes the indications of overactive bladder, urinary retention, and fecal incontinence. However, it incorrectly states that InterStim Micro was 'newly launched' in 2022, which is not supported by the ground truth. More critically, the LLM claims that in 2024, Medtronic added 'recharge-free versions' of InterStim II and InterStim X and a 'rechargeable InterStim Micro,' which contradicts the ground truth: the original answer states that InterStim II and InterStim X were *repositioned* as recharge-free (not newly added), and there is no mention of a rechargeable InterStim Micro. The therapeutic indications are correctly listed, but the ground truth emphasizes an *expansion* to include 'chronic fecal incontinence' as a refined labeling, whereas the LLM implies no change in indications, missing this key evolution. (2) There are no numeric values to verify, so quantitative accuracy is high by default—no incorrect numbers were introduced. (3) The multi-hop reasoning is partially sound: the model attempts to compare product offerings and indications across years, but fails to accurately represent the nature of product evolution (positioning vs. new versions) and misses the expansion of indication labeling as a key development. (4) The contextual relevance is strong—the answer addresses the question’s focus on product line evolution in neurostimulators and indications. However, due to factual inaccuracies in product updates and missed nuance in indication expansion, the correctness score is reduced to 6, reflecting partial accuracy with significant errors in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 500,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "In 2022 Simon Property still owned the overwhelming majority of Authentic Brands Group – after a December 2021 cash‑sale of a small slice and a $100 million cash purchase, Simon’s non‑controlling interest in ABG was only about 10.4%, giving it roughly a 90 % stake, and it deepened the partnership by contributing its Forever 21 and Brooks Brothers licensing assets and entering a long‑term Reebok licensing deal with ABG (see 2022 10‑K pages 66‑70).  \n\nBy 2023‑2024 that stake had been eroded: ABG’s capital‑raising transactions cut Simon’s ownership to roughly 9‑10 % and Simon sold a portion of its interest in Q4 2023 (pre‑tax gain $157 million) and then, in Q1 2024, sold its remaining ABG holdings for $1.2 billion, exiting the strategic relationship entirely (see 2024 10‑K pages 72‑76).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitative Accuracy: The claimed 10.4% and 90% stakes in ABG are incorrect; the ground truth states Simon held only a 1.37% interest in 2022. The LLM incorrectly claims Simon sold its remaining ABG holdings in Q1 2024 for $1.2 billion and realized a $157 million pre-tax gain in Q4 2023, whereas the correct figure is an $18.8 million gain from selling a portion of its stake. The $100 million cash acquisition in 2024 is misrepresented as occurring in 2021. (2) Completeness: While the answer attempts to cover the evolution, it falsely claims Simon exited the relationship entirely, contradicting the ground truth that Simon acquired additional interests in 2024. (3) Entity Accuracy: Misidentifies the nature and direction of financial transactions between Simon and ABG, and incorrectly references 2021 and 2023 events not in the original. (4) Reasoning: The multi-hop synthesis is flawed—Simon never had a controlling stake; it was a non-controlling, minority interest throughout. The claim of '90%' ownership is unsupported and contradicts the 1.37% figure. (5) Semantic Equivalence: Despite discussing the same companies and general timeline, the core facts—ownership percentages, transaction amounts, gains, and strategic direction—are factually wrong. The answer suggests a complete exit, while the truth reflects ongoing engagement. Thus, while contextually relevant in topic, the answer is largely incorrect in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 418,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips’ depreciation, depletion and amortization (DD&A) for its Lower 48 segment rose each year: $4,067 million in 2021, $4,854 million in 2022 and $5,729 million in 2023【COP_10k_2023.pdf pages 131‑135】. This reflects a steady increase in DD&A expense in the Lower 48 over the 2021‑2023 period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers provided—$4,067 million in 2021, $4,854 million in 2022, and $5,729 million in 2023—are accurate and consistent with the source data. The final 2023 figure aligns with the ground truth's reported increase from $4,067M to $5,729M over the period. (2) The answer is complete, addressing the evolution of DD&A expenses from 2021 to 2023, including the intermediate 2022 value not mentioned in the original answer but implied by the trend. This additional detail enhances completeness without introducing error. (3) Entity accuracy is correct: ConocoPhillips, the Lower 48 region, and the metric (DD&A) are properly identified. (4) The reasoning is sound—increasing DD&A expenses are correctly interpreted as indicative of rising investment or asset utilization, consistent with the original answer’s conclusion. The LLM cites the correct source (COP_10k_2023.pdf pages 131–135), supporting credibility. (5) Semantic equivalence is maintained: while the LLM provides more granular year-by-year data, the core message—that DD&A increased significantly from 2021 to 2023 reflecting growing emphasis on the Lower 48—is preserved and well-supported. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1163,
        "completion_tokens": 363,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "Verizon’s 10‑K shows that the **valuation methodology for international bonds did not change** – in both 2023 and 2024 the trustee values corporate and international bonds using market‑sale or bid prices or, when those are unavailable, matrix prices with independent third‑party inputs. However, the **portfolio composition shifted**: the pension plan’s international‑bond holding fell from $341 million (mostly Level 2) in 2023 to $113 million (entirely Level 2) in 2024, and the other post‑retirement benefit plan’s holding moved from $12 million (mostly Level 1) to $15 million (mostly Level 2). Thus, while the treatment and valuation approach stayed the same, Verizon reduced its exposure to international bonds and relied more on Level 2 pricing inputs in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that Verizon's treatment and valuation approach for international bonds evolved from a general description in 2023 (valued as part of fixed income securities using matrix prices with third-party inputs) to a more transparent, segmented disclosure in 2024 with a specific breakdown of $12 million total ($10M Level 1, $2M Level 2). In contrast, the LLM claims the methodology did not change and misrepresents the dollar amounts and valuation levels. (2) Quantitatively, the LLM invents figures not present in the ground truth: $341M in 2023 and $113M in 2024 for pension plans, and $12M to $15M for other plans. The ground truth reports a total value of $12M in 2024 with a clear Level 1/Level 2 split, but does not mention $341M or $113M at all. These numbers appear to be hallucinated or misattributed from other contexts. (3) The multi-hop reasoning is flawed: instead of identifying a shift in disclosure granularity and transparency, the LLM asserts no change in methodology while focusing on portfolio size changes that are not supported by the original answer. It also conflates pension plan holdings with overall corporate valuation practices, which is not indicated in the ground truth. (4) While the LLM attempts to address the question’s intent—evolution in treatment and valuation—the factual inaccuracies, especially in numbers and direction of change (no change vs. increased transparency), severely undermine correctness. The contextual relevance is moderate because it discusses valuation inputs and levels, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 449,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "- In 2022 Emerson completed the “Heritage AspenTech” transaction, contributing its Open Systems International and Geological Simulation software businesses plus about $6 billion in cash to create a stand‑alone AspenTech.  At closing Emerson owned **≈55 %** of the new AspenTech’s common stock and the company was reported as a separate operating segment (with related goodwill and restructuring costs).  \n\n- By the 2024 filing Emerson still held the majority stake – **≈57 %** – and announced a **proposal to buy the remaining shares** at $240 per share, which would give Emerson **100 % ownership** of AspenTech.  The relationship therefore moved from a majority‑owned, partially‑integrated software spin‑off in 2022 to a near‑complete ownership and planned full acquisition in 2024, while AspenTech continued to be integrated as a distinct segment whose results and stock‑plan expenses were reflected in Emerson’s consolidated financials.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and demonstrating relevant reasoning structure. (1) Key facts are incorrect: the original answer states that in 2022, Emerson had a financial stake in AspenTech valued at $8,326 million on its balance sheet — not that it created a new AspenTech via contribution of businesses and $6 billion. The LLM incorrectly claims Emerson formed a 'stand-alone AspenTech' in 2022 through a transaction involving OSII and GSS, which contradicts the ground truth. Instead, the $6.0 billion cash contribution and formation of 'New AspenTech' occurred in 2024, not 2022. (2) Quantitative accuracy is poor: the LLM assigns Emerson a 55% stake in 2022 and 57% in 2024, but the ground truth states the 55% ownership began in 2024 after the restructuring — there is no mention of 57% or a buyout proposal in the original. The $240 per share offer to acquire remaining shares is not in the ground truth and appears fabricated. (3) Multi-hop reasoning is partially sound — the model attempts to trace stake evolution and integration — but it reverses the timeline and misattributes events. The operational integration detail (reporting as a separate segment) is plausible but not confirmed in the original. (4) Contextual relevance is high because the answer focuses on financial stake changes and integration, matching the question's intent. However, due to major factual and temporal errors in key financial actions and ownership percentages, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 432,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "In 2022 Starbucks reported its interest‑rate swaps as two separate items: an accrued‑liability of $12 million (listed under “Interest rates”) and an other‑long‑term liability of $34 million (listed as “Interest rate swap”). By the 2023 filing the accrued‑liability line had disappeared and the swap was recorded only as an other‑long‑term liability, which had grown to $41.4 million, while a modest $0.4 million asset for the swap appeared on the balance sheet.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors in both quantitative and qualitative aspects. (1) Quantitative inaccuracy: The ground truth states that in 2022, Starbucks had a single long-term liability of $34.0 million for interest rate swaps. The LLM incorrectly claims there were two components: a $12 million accrued liability and a $34 million long-term liability, which is not supported by the data. Additionally, the LLM states the 2023 long-term liability increased to $41.4 million, whereas the correct value is $19.2 million long-term plus $0.4 million current, totaling $19.6 million—a net decrease. The mention of a $0.4 million asset is also incorrect; it was a liability, not an asset. (2) Completeness: The answer fails to correctly describe the evolution of classification—instead of showing a split into current and long-term liabilities in 2023, it falsely claims the accrued liability disappeared and the long-term portion grew. It misses the actual shift in classification structure entirely. (3) Entity and metric accuracy: While the company (Starbucks) and years (2022, 2023) are correct, the financial metrics (accrued liabilities, long-term liabilities, asset vs. liability) are misstated. (4) Reasoning: The multi-hop synthesis is flawed—the LLM incorrectly infers trends and categorizations, reversing the direction of change (increase vs. actual decrease) and misrepresenting balance sheet presentation. (5) Semantic equivalence: The overall meaning contradicts the ground truth, particularly regarding the magnitude, direction, and classification of liabilities. Despite addressing the general topic, the answer is factually incorrect on key points, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 465,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "In the 2022 filing NextEra Energy Resources disclosed that, after a series of legal and regulatory setbacks, it recorded an other‑than‑temporary impairment that **wrote off the entire $0.6 billion equity‑method carrying amount of its Mountain Valley Pipeline investment and created a $0.2 billion liability for estimated future asset‑retirement‑obligation costs**【90†L1-L4】.  \n\nBy the 2023 filing the company was **again committing capital to the project**, reporting **equity contributions in 2024 and a 20‑year natural‑gas transportation agreement (about $70 million per year) with Mountain Valley Pipeline, in which NEER holds a 32.8 % equity stake**, and listing those contributions as part of its “Other (i)” capital‑expenditure line for the pipeline’s construction【107†L1-L4】【108†L1-L4】.  \n\nThus, the Mountain Valley Pipeline went from a full write‑off and liability recognition in 2022 to renewed equity funding and a long‑term transport contract in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of NextEra Energy Resources' (NEER) involvement in the Mountain Valley Pipeline (MVP) from 2022 to 2023 and correctly identifies the key qualitative shift: a full write-off in 2022 followed by renewed commitment in 2023. However, there are significant quantitative inaccuracies. The original answer states NEER recorded an impairment charge of approximately $0.8 billion, but the LLM claims a $0.6 billion write-off of the carrying amount plus a $0.2 billion liability, totaling $0.8 billion in total impact. While the total financial impact aligns, the LLM misrepresents the $0.8 billion as split between write-off and liability, whereas the ground truth indicates the $0.8 billion impairment charge was for the full write-down of the investment, with no explicit mention of a separate $0.2 billion liability for asset retirement obligations in the original. This mischaracterization affects quantitative accuracy. Additionally, the LLM mentions 'equity contributions in 2024', which is outside the 2022–2023 scope of the question and not supported in the original answer. The 32.8% equity stake and $70 million annual transportation obligation are correctly reported. The reasoning is logically sound in showing a reversal of stance from abandonment to recommitment, demonstrating proper multi-hop synthesis between years and filings. The answer is highly relevant and well-structured, but the numerical breakdown error prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 408,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The captive that reinsures the company’s group‑annuity contracts grew its solvency‑capital portfolio in both equity and debt holdings. At 31 December 2023 the captive held **$1,643 million of equity securities and $1,378 million of debt securities**; by 31 December 2024 those balances rose to **$1,883 million of equity securities and $1,643 million of debt securities**【KO_10k_2023.pdf page 78‑79】【KO_10k_2024.pdf page 79‑80】.  In other words, equity investments increased by roughly $240 million and debt investments by about $265 million year‑over‑year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of quantitative accuracy. The original answer states that the total investment in equity and debt securities combined was $1,643 million in 2023 and $1,883 million in 2024. However, the LLM answer incorrectly breaks this total into separate equity and debt components, claiming $1,643 million in equity and $1,378 million in debt in 2023 (summing to $3,021 million), and $1,883 million in equity and $1,643 million in debt in 2024 (summing to $3,526 million), which contradicts the ground truth. These figures do not match the original data and represent a significant misinterpretation. The LLM also calculates an increase of $240 million in equity and $265 million in debt, which is unsupported by the ground truth, as no such breakdown is provided. While the LLM correctly identifies the time frame (2023 to 2024), the entity (Coca-Cola’s captive insurance company), and the general trend of growth, it fails on core factual accuracy. The multi-hop reasoning is flawed because it fabricates a detailed breakdown not present in the source, leading to incorrect synthesis. The contextual relevance is high as it addresses the evolution of investments over time and cites correct document sources, but the factual foundation is wrong. Therefore, the correctness and quantitative accuracy scores are low, while qualitative and contextual scores are moderate due to correct framing but incorrect data usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 398,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "In the 2022 filing Intel still described the Intel 4 node as a “ramp‑up” effort – it was incurring start‑up charges and was not yet in volume production. By the 2024 filing Intel 4 had moved into high‑volume manufacturing (first in Ireland), was already shipping the Core Ultra client CPUs (the first high‑volume product on the node) and was positioned as the primary EUV‑based successor to Intel 7, serving as the cornerstone of the roadmap before the next‑generation Intel 3 and 18A nodes.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2022, Intel 4 was in the 'ramp-up' phase with associated start-up charges, matching the original answer's mention of 'higher period charges related to the ramp-up.' (2) For 2024, it accurately states that Intel 4 transitioned to high-volume manufacturing in Ireland and was used for the high-volume Intel Core Ultra processors, aligning with the ground truth. (3) The LLM adds context not in the original but consistent with it—positioning Intel 4 as the 'primary EUV-based successor to Intel 7' and 'cornerstone before Intel 3 and 18A'—which enhances qualitative accuracy without introducing errors. (4) All entities (Intel 4, Core Ultra, Ireland, EUV, Intel 7, Intel 3, 18A) and timeframes (2022, 2024) are correct. (5) The reasoning correctly synthesizes multi-hop information across years and strategic context. No numeric inaccuracies; dates and financial implications (start-up charges vs. volume production) are correctly interpreted. The answer fully addresses production status and strategic positioning as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 327,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "In fiscal 2022 Emerson spun off two of its own industrial‑software businesses and about $6 billion in cash into a newly created “New AspenTech,” receiving a **55 % equity stake** in the combined company. By the 2024 filing Emerson’s holding had risen to **about 57 %**, and it announced a **proposal to buy all of the remaining AspenTech shares**, effectively moving the asset from a majority‑owned affiliate to a fully‑integrated, wholly‑owned part of Emerson, with AspenTech’s results now reported within Emerson’s Software & Control segment and reflected in its consolidated financials.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Emerson did not spin off software businesses or contribute $6 billion in cash to create 'New AspenTech'—AspenTech was simply a strategic partner with no ownership stake mentioned. The 55% ownership stake emerged only in 2024 after the merger of Emerson’s industrial software business with AspenTech. The LLM incorrectly states the 55% stake was acquired in 2022 and further claims it increased to 57% by 2024, which is not supported by the original answer. There is also no mention in the ground truth of a proposal to acquire the remaining shares, making this a fabricated detail. (2) Quantitative inaccuracies include the $6 billion cash contribution and the 57% ownership stake, neither of which appear in the original answer. The correct sequence is that the 55% stake was established in 2024, not 2022, and there is no data suggesting an increase to 57% or a buyout proposal. (3) The reasoning is flawed in its multi-hop logic: it misidentifies the timeline and nature of the relationship evolution, incorrectly portraying a 2022 ownership structure that did not exist. The integration into financials is correctly noted, but it is tied to false premises. (4) Despite these errors, the answer is contextually relevant—it addresses ownership evolution and financial integration, uses correct entity names (Emerson, AspenTech, Software & Control segment), and correctly notes that AspenTech’s results are now consolidated. However, the core facts about timing, ownership percentages, and transaction structure are incorrect, severely undermining factual reliability. Hence, the correctness score is low, with moderate qualitative and relevance scores due to structural alignment with the question’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 494,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "In the 2022 Form 10‑K Intel only introduced “Intel 4” as the new name for its next‑generation EUV node, describing it in a naming‑change table but providing no indication that the node was in production. By the 2024 filing Intel said the Intel 4 node – its first EUV‑based process – had entered high‑volume manufacturing (shifting production to Ireland in 2024 after initial shipments of the Core Ultra client CPUs in 2023) and delivers roughly a 20 percent improvement in performance‑per‑watt versus the Intel 7 node.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Intel introduced Intel 4 in 2022 as a renamed node with no production indication, and by 2024 it had entered high-volume manufacturing using EUV lithography. The 20% performance-per-watt improvement over Intel 7 is accurately stated. (2) Quantitative accuracy is perfect: the 20% improvement is correctly cited, and the timeline (initial Core Ultra shipments in 2023, HVM shift to Ireland in 2024) matches the original answer. (3) Multi-hop reasoning is sound—LLM correctly synthesized information across 2022 and 2024 filings to show evolution from naming to production, including geographic shift and product deployment. (4) Entity accuracy is strong: correct references to Intel 4, Intel 7, EUV, Core Ultra, and correct timeframes. The answer fully addresses the question’s focus on manufacturing readiness and performance improvements. Minor wording differences (e.g., 'roughly a 20 percent' vs '20%') do not affect meaning. All criteria for a top score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 307,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "In the 2022 Form 10‑K, InterStim Micro was presented simply as one of the neurostimulators in the Specialty Therapies “Pelvic Health” line—alongside InterStim X and InterStim II—used to treat over‑active bladder, non‑obstructive urinary retention and chronic fecal incontinence. By the 2024 filing, Medtronic is explicitly calling out InterStim Micro as a **rechargeable** neurostimulator and emphasizing its **continued acceptance and growth** within the Pelvic Health portfolio, together with the newer recharge‑free X and II devices. Thus, the product has shifted from being listed as part of the overall portfolio to being highlighted as a distinct, growth‑driving, rechargeable option in Medtronic’s Pelvic Health therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: InterStim Micro was part of the Pelvic Health portfolio in 2022 alongside InterStim X and II, used for overactive bladder, urinary retention, and fecal incontinence. By 2024, it was explicitly positioned as the rechargeable option, contrasted with the recharge-free devices. The LLM correctly captures this strategic repositioning. (2) There are no numeric values requiring verification (e.g., financials, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) Multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024 filings), correctly infers the evolution in product positioning, and identifies the differentiation based on rechargeability. (4) Semantic equivalence is strong—wording differs slightly (e.g., 'continued acceptance and growth' vs 'continued global growth and adoption'), but the meaning is preserved. The only minor shortcoming is that the LLM does not explicitly mention 'global' growth, which is present in the original answer, slightly reducing qualitative accuracy. Otherwise, the response is complete, contextually relevant, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 353,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "In the 2022 Form 10‑K the company noted that LTIP units (and other exchangeable securities) were “potentially dilutive,” but explicitly stated that **no securities had a material dilutive effect for the years ended 2021, 2020 and 2019**【SPG_10k_2022.pdf†113-L115】.  \n\nThe 2024 Form 10‑K repeats the same disclaimer – LTIP units are listed among potentially dilutive securities, yet **the company again confirms that no securities had a material dilutive effect for the years ended 2024, 2023 and 2022**【SPG_10k_2024.pdf†112-L115】.  \n\nThus, the disclosure has simply been updated to cover the newer reporting periods; the language and conclusion (no material dilutive impact) remain unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates and disclosures: it correctly states that in both 2022 and 2024, the company disclosed no material dilutive effect for the respective three-year periods (2019–2021 in 2022 filing; 2022–2024 in 2024 filing), and correctly identifies LTIP units as potentially dilutive. The quantitative accuracy is perfect—dates and reporting periods match the ground truth. Contextual relevance is high, as the response directly addresses the evolution of disclosure across periods. However, the qualitative accuracy is lower because the LLM mischaracterizes the nature of the evolution. The ground truth emphasizes a *reduction in detail*, specifically the omission in the 2024 filing of the explicit statement that LTIP units are exchangeable for common stock—a notable change in disclosure granularity. The LLM claims the 'language and conclusion... remain unchanged,' which contradicts the ground truth. This is a significant oversight in multi-hop reasoning: while the conclusion about dilution impact is consistent, the change in disclosure detail (removal of exchangeability language) represents an evolution that the LLM fails to acknowledge. Thus, the core factual elements are correct, but the synthesis and interpretation of how the disclosure evolved are incomplete, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 375,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "In the 2022 Form 10‑K MetLife noted that its board had approved a **$3.0 billion share‑repurchase program** and that, as of 31 December 2021, **about $1.5 billion (roughly 50 % of the authorization) remained available**.  The filing stressed that the company “maintains a buffer of cash and other liquid assets, and may increase it,” indicating that any repurchases would be limited by the need to preserve that cash buffer.\n\nThe 2024 Form 10‑K shows the same $3.0 billion authorization but reports that the **remaining amount had fallen to a much smaller balance (approximately $0.8‑$0.9 billion)** as of the most recent year‑end.  While the company continues to emphasize that it will “maintain a cash and liquid‑asset buffer” and that liquidity considerations will guide the timing and size of future buy‑backs, the reduced remaining authorization reflects a more aggressive use of the program since 2022, with repurchases now being undertaken only as long as the cash‑buffer needs are satisfied.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces significant inaccuracies. The 2022 data is accurate: MetLife had $1.5 billion remaining of its $3.0 billion authorization as of December 31, 2021, correctly reported in the 2022 10-K. However, the 2024 data is incorrect — the ground truth does not state that the remaining authorization was $0.8–$0.9 billion as of year-end 2023 or 2024; no such figure is present in the verified knowledge graph. This number is fabricated or misinferred. (2) Quantitative accuracy is compromised due to this unsupported claim about the remaining balance in 2024. While the $3.0 billion total authorization is correctly repeated, the drop to $0.8–$0.9 billion is not corroborated and contradicts the ground truth, which focuses on a shift in tone and policy, not updated figures. There are no calculations in the answer, but the comparison between years relies on false quantitative progression. (3) The reasoning is flawed in its synthesis: the LLM interprets a smaller remaining balance as evidence of 'more aggressive use' of repurchases, but the ground truth emphasizes a *more conservative liquidity strategy* due to increased caution around buffers — a shift in risk posture, not necessarily in repurchase volume. The LLM mischaracterizes the evolution: the original answer highlights growing conservatism and potential limits on repurchases due to buffer needs, while the LLM suggests continued aggressive repurchasing. This inverts the actual trend. (4) Contextual relevance is high — the answer addresses cash buffers, repurchase authorizations, and liquidity considerations across 2022 and 2024, directly engaging the question’s focus. However, due to key factual errors in 2024 data and misinterpretation of strategic direction, the correctness and qualitative accuracy scores are moderate. The answer appears plausible but misrepresents the core evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 530,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "In fiscal 2022 (as of Oct 2, 2022) Starbucks reported **foreign‑currency‑other derivative assets of about $73 million** – $39.9 million recorded in “prepaid expenses and other current assets” and $33.5 million in “other long‑term assets.”  Its corresponding liability was only **$0.3 million**, shown as an accrued‑liability item.\n\nBy fiscal 2023 (as of Oct 1, 2023) the same line‑item had **shrank to roughly $16 million** – $8.9 million in prepaid/current assets and $6.9 million in other long‑term assets.  At the same time, the liability side **expanded to about $11 million**, now split between $7.4 million of accrued liabilities and $3.6 million of other long‑term liabilities.\n\nThus, from 2022 to 2023 the foreign‑currency‑other derivative **asset balance fell sharply** while the **liability balance grew**, and the liability classification changed from solely accrued liabilities to a mix of accrued and other long‑term liabilities. (Source: Derivative asset/liability tables in the 2022 and 2023 10‑K filings.)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both asset and liability values for fiscal years 2022 and 2023. For 2022, the LLM incorrectly states foreign currency - other derivative assets as $73 million ($39.9M current + $33.5M long-term), whereas the ground truth reports $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings — not broken down by balance sheet line items in the same way. The LLM fabricates a $0.3 million liability in 2022, but the original answer does not specify derivative liabilities for 2022 at all, making this an unsupported claim. In 2023, the LLM reports total derivative assets of $16 million ($8.9M + $6.9M), but the ground truth states only $1.9 million in current assets and $1.7 million in long-term assets — a total of $3.6 million, not $16 million. Similarly, the LLM reports total liabilities of $11 million ($7.4M + $3.6M), while the ground truth specifies $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities — totaling $8.8 million. These numerical discrepancies are severe and materially misrepresent the financial positions. (2) Calculations and comparisons are therefore also incorrect: the claimed 'sharp fall' in assets and 'growth' in liabilities are directionally correct but exaggerated in magnitude due to wrong inputs. (3) Multi-hop reasoning is partially present — the model attempts to compare two fiscal years and analyze shifts in classification — but fails because it relies on incorrect data, likely from misreading or citing the wrong line items in the 10-Ks. It introduces balance sheet breakdowns for 2022 that are not in the original answer, suggesting hallucination. (4) Contextual relevance is moderate because the structure and intent align with the question — discussing evolution and classification changes — but correctness is critically undermined by inaccurate numbers and fabricated details. Thus, the correctness score is low at 2 due to major quantitative errors, despite some directional reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 560,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024 Procter & Gamble kept the same overarching cash‑management framework – using operating cash first for dividends, share‑repurchases and strategic acquisitions and, when needed, supplementing with short‑ and long‑term debt – but the scale of cash generation and the role of restructuring changed.  Operating cash flow rose from $16.7 billion in 2022 (adjusted free‑cash‑flow productivity ≈ 93 %) to $19.8 billion in 2024 (productivity ≈ 105 %), while restructuring outlays grew from the usual $250‑$500 million range (≈ 65 % settled in cash) to $659 million in 2024 (≈ 64 % cash‑settled) as the company pursued a larger market‑portfolio restructuring and asset‑impairment write‑offs.  Consequently, corporate‑level results shifted from a $485 million profit in 2022 to a $1.4 billion loss in 2024, yet the strengthened cash generation allowed the firm to maintain its dividend and repurchase programs despite the higher restructuring costs.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant factual inaccuracies. It correctly identifies the increase in restructuring costs from fiscal 2022 to 2024 and the general trend of increased restructuring activity. However, it misstates key financial figures: the original answer states that corporate net earnings improved by $872 million to $485 million in 2022 (implying prior-year earnings were negative), whereas the LLM claims a $485 million profit in 2022 and a $1.4 billion loss in 2024 — this is incorrect because the $1.4 billion is an impairment charge, not a total corporate loss. The LLM conflates the impairment charge with overall corporate net earnings, which in the original answer decreased by $1.0 billion due to the impairment and higher restructuring charges, not a $1.4 billion loss. Additionally, the LLM introduces operating cash flow figures ($16.7B in 2022, $19.8B in 2024) and free cash flow productivity metrics (93%, 105%) that are not present in the ground truth and cannot be verified from the provided data. (2) The restructuring cost in 2022 is correctly noted to be within the $250–$500 million range, and $659 million in 2024 matches the original answer. However, the claim that ~65% was cash-settled is speculative and not in the source. The $216 million non-cash foreign currency translation loss included in the 2024 restructuring costs is omitted entirely. (3) The multi-hop reasoning is partially sound — the model connects restructuring activities to financial performance and cash management — but fails to accurately synthesize the impact of the Gillette intangible asset impairment on earnings, instead misrepresenting it as the full extent of the corporate loss. It also omits the geographic focus on Enterprise Markets like Nigeria, which is a key detail in the original answer. (4) The contextual relevance is high because the response addresses cash management, restructuring, and financial performance over the specified period. Qualitative accuracy is moderate due to correct directional trends but flawed specifics. Quantitative accuracy is low due to unsupported cash flow numbers and mischaracterized earnings. Correctness score is 6 due to partially correct facts but significant errors in core financial statements and calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1501,
        "completion_tokens": 619,
        "total_tokens": 2120
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "In the FY 2022 filing NVIDIA described Omniverse primarily as a “virtual‑world simulation and collaboration platform” offered as a subscription for enterprise customers and free for individuals, and highlighted its early‑stage use in a variety of enterprise‑focused applications – virtual car showrooms, surgical‑training, architectural walkthroughs, digital‑twin factories, real‑time product configurators and testing of autonomous robots and vehicles. By FY 2023 the company had repositioned Omniverse as “Omniverse Enterprise” software that underpins its AI‑Enterprise and data‑center portfolio and is embedded in end‑to‑end simulation solutions such as NVIDIA DRIVE Sim/Constellation for autonomous‑vehicle cockpit and self‑driving validation, as well as broader metaverse/3‑D‑internet and digital‑twin deployments for industrial enterprises. Thus, between 2022 and 2023 Omniverse moved from a broadly marketed collaboration/visualization tool to a core, enterprise‑grade simulation engine tightly integrated with NVIDIA’s AI, data‑center and automotive platforms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual information is correct: Omniverse's 2022 positioning as a virtual-world simulation and collaboration platform available via enterprise subscription and free for individuals is accurately described, as are the use cases (virtual car showrooms, surgical training, architectural walkthroughs). The 2023 evolution into a more robust enterprise platform tied to AI-Enterprise, data-center infrastructure, and industrial digital twins is correctly captured. The mention of DRIVE Sim/Constellation integration reflects accurate multi-hop synthesis from automotive and simulation domains. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—this aspect is scored as 10 since no errors exist. (3) The reasoning is sound: the LLM correctly infers a strategic shift from a visualization/collaboration tool to a core enterprise simulation engine, demonstrating proper synthesis across years and product integrations. The only minor deviation from the original answer is the introduction of the term 'Omniverse Enterprise' and its linkage to 'AI-Enterprise and data-center portfolio' with slightly stronger emphasis than in the ground truth, which does not use that exact branding but implies it through context. This does not constitute an error but represents a slight expansion. (4) The answer is fully contextually relevant, directly addressing the evolution in positioning and application, especially regarding enterprise integration and simulation technologies. Overall, the response demonstrates excellent factual fidelity, multi-hop understanding, and semantic equivalence, warranting a 9 in correctness and qualitative accuracy, with full marks in quantitative and contextual dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1517,
        "completion_tokens": 501,
        "total_tokens": 2019
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "In 2023 AMT actually built ≈3,200 communications sites and spent about **$395 million** on data‑center‑related work as part of **$1.83 billion** of total capital expenditures (discretionary projects $849 million).  \nFor 2024 the company lowered its discretionary‑capex target to **$790‑$820 million** (total capex $1.55‑$1.66 billion) and now plans to construct **≈2,500‑3,500 sites** with an **anticipated $450 million** of data‑center spend, indicating a modest reduction in the number of sites but a higher data‑center budget; the 2024 “future commitments” schedule therefore reflects a smaller overall obligation for communications‑site construction compared with 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of AMT's financial commitments related to communications sites from 2023 to 2024. (1) Quantitatively, the LLM states that in 2023, AMT spent $395 million on data-center-related work as part of $1.83 billion in total capex, and built approximately 3,200 sites. However, the ground truth does not mention actual spending or number of sites built in 2023—only that AMT *anticipated spending* $450 million on data center assets as part of construction plans for 2,500–3,500 sites. The LLM fabricates specific actuals not present in the original. For 2024, the LLM incorrectly focuses on anticipated capital expenditures (capex) of $450 million for data center spend and site construction, but the ground truth refers to a $4.5 billion *undiscounted future cash outlay* for *asset retirement obligations* (AROs) on leased sites—not construction capex. This is a fundamental misinterpretation: AROs are long-term liability commitments, not near-term capital spending. The $4.5 billion figure is completely missing from the LLM answer. (2) The LLM incorrectly implies that financial obligations decreased in 2024 due to lower capex guidance, when in fact the ground truth shows a dramatic increase in long-term financial exposure—from $450M in planned capex to $4.5B in AROs—indicating a structural shift in liability, not a reduction. (3) The multi-hop reasoning fails: the LLM conflates capital expenditures with long-term retirement obligations, two distinct financial concepts. It does not recognize that the 2024 figure represents a maturation of liabilities, not a change in construction plans. (4) While the LLM attempts to address the time frame and topic (communications sites), it misidentifies the nature of the financial commitment, uses incorrect numbers, and draws the opposite conclusion of the ground truth. The contextual relevance is moderate because it discusses AMT and communications sites over 2023–2024, but the core financial insight is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 543,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K describe divestitures in the same way. In each filing the company says it “employs a long‑standing, regular, disciplined review process to ensure that assets are contributing to the Corporation’s strategic objectives” and that assets are sold when they “are no longer meeting these objectives or are worth considerably more to others.” The proceeds from those sales are still presented as “proceeds associated with sales of subsidiaries, property, plant and equipment, and sales and returns of investments” and are combined with operating cash flow, showing no substantive change in the language between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no change in language between 2023 and 2024, directly contradicting the ground truth. While it correctly identifies the consistent strategic rationale (disciplined review process and alignment with objectives), it fails to recognize the evolution in terminology describing the proceeds. The original answer states that in 2023, ExxonMobil used the detailed phrase 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' but in 2024 shifted to the more consolidated 'proceeds from asset sales and returns of investments.' The LLM incorrectly asserts that the full detailed phrase was used in both years, which is not supported by the ground truth. This misrepresentation undermines the qualitative accuracy and overall correctness. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is moderate because the response addresses the right topic and cites relevant strategic language, but misses the key evolution in financial terminology. The multi-hop reasoning fails because the model did not detect the shift in disclosure phrasing over time, which is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 348,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "In the 2022 Form 10‑K Comcast reported that the Universal Beijing Resort portion of its consolidated balance sheet carried **about $8.5 billion of assets and $7.9 billion of liabilities**.  By the end of 2023 those amounts had fallen to **$7.8 billion of assets and $7.2 billion of liabilities**.  Accordingly, Comcast’s consolidated exposure to the resort declined – assets dropped roughly $0.7 billion and liabilities about $0.7 billion, narrowing the net (30 %‑interest) exposure by a similar amount.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies in the 2022 figures. The ground truth states $9.7 billion in assets and $8.1 billion in liabilities for 2022, but the LLM reports $8.5 billion in assets and $7.9 billion in liabilities. These discrepancies affect the accuracy of the change calculation. While the 2023 figures ($7.8 billion in assets and $7.2 billion in liabilities) are correct, the claimed reduction of 'roughly $0.7 billion' in both assets and liabilities is incorrect. The actual asset decrease is $1.9 billion ($9.7B - $7.8B), and the liability decrease is $0.9 billion ($8.1B - $7.2B). (2) The calculations in the LLM answer are therefore flawed. It incorrectly computes the drop as ~$0.7 billion for both assets and liabilities, when the real changes are nearly double that for assets. This undermines the quantitative accuracy despite correct 2023 numbers. (3) The reasoning and multi-hop synthesis are otherwise sound: the model correctly identifies the need to compare 2022 and 2023 consolidated balance sheet items for Universal Beijing Resort and draws a logical conclusion about reduced financial exposure. It also appropriately contextualizes the change in terms of net exposure, though the 30% interest mention lacks grounding in the original answer. (4) The answer is contextually relevant and addresses the evolution of financial exposure over time, with correct entity (Comcast, Universal Beijing Resort) and year identification. However, due to the material error in the 2022 figures and resulting miscalculations, the correctness score is limited to 6—partially correct but with significant factual inaccuracies affecting the core financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 467,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "In the 2023 Form 10‑K Caterpillar framed demand volatility as a secondary effect of broader macro‑economic and pandemic‑related uncertainty –‑‑ “economic and customer‑demand uncertainty… could reduce sales and increase allowances for doubtful accounts” –‑‑ and warned that it could depress revenue and trigger higher credit‑loss provisions.  \n\nBy the 2024 filing the company treats demand volatility as a distinct operational risk, noting that sudden swings in orders can leave the company with excess inventory, squeeze margins and create supply‑chain bottlenecks that directly erode earnings and cash flow.  \n\nThus, the risk has shifted from a largely macro‑economic context in 2023 to a more immediate, supply‑chain‑focused threat to financial performance in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Customer Demand Volatility as a risk factor for Caterpillar between 2023 and 2024. It correctly identifies that in 2023, demand volatility was framed within broader macroeconomic and pandemic-related uncertainties affecting sales and credit provisions. In 2024, it accurately notes a shift toward treating demand volatility as a more direct operational and supply-chain risk impacting inventory, margins, and cash flow. While the LLM captures the core evolution—shifting from macro-driven demand concerns to more immediate supply-chain and financial performance impacts—it does not explicitly mention key elements from the ground truth such as 'commodity price changes', 'material price increases', or 'shortages of labor and material' as newly emphasized contributors in 2024. These omissions are significant but do not undermine the overall accurate synthesis of the risk's evolving nature. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and contextually appropriate, with only minor gaps in completeness compared to the original answer. Thus, the correctness and qualitative accuracy scores reflect strong performance with room for improvement in full detail coverage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 376,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "In 2022 the company reported Level 3 net derivative assets (liabilities) with a fair‑value of **$19 million**.  The valuation was performed with a **discounted‑cash‑flow model** that used **swap‑rate inputs** whose observable range was **1 %–2 %** and a weighted‑average input of **about 1 %** (Table 16.3, 2022 10‑K).  \n\nBy 2024 the same line item had grown to a **fair‑value of $69 million**.  The methodology remained a **discounted‑cash‑flow approach** but the unobservable swap‑rate inputs were now broader (a **single 4 % range**) and the weighted‑average input rose to **4 %** (Table 17.3, 2024 10‑K).  \n\nThus, from 2022 to 2024 the net derivative assets (liabilities) increased roughly four‑fold in fair‑value, and the valuation model continued to rely on discounted cash flows while the swap‑rate assumptions became larger and more material.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains several factual inaccuracies. The fair value in 2022 is correctly stated as $19 million, but this corresponds to the value as of December 31, 2021 (reported in the 2022 10-K), which the LLM does not clarify. The 2024 fair value is reported as $69 million, but the ground truth states $58 million as of December 31, 2023 (reported in the 2024 10-K), making this a significant numerical error. (2) The valuation methodology is misrepresented: the ground truth indicates a shift *to* discounted cash flows with observable inputs (swap rates 3–5%, weighted average 4%) by 2024, implying it was not the primary method in 2022. However, the LLM claims the DCF model was already used in 2022 with 1%–2% swap rates, which contradicts the original answer stating the prior method was based on gains/losses in net income. Additionally, the LLM incorrectly labels the 2022 inputs as 'observable' and within a 1%–2% range, which is unsupported by the ground truth. (3) The multi-hop reasoning is partially sound in that it attempts to compare fair values and methodologies across years, but it fails to accurately represent the evolution: the shift from income-based valuation to DCF with observable inputs is a key qualitative change that the LLM mischaracterizes as a continuation of the same model with updated assumptions. (4) Despite these issues, the answer is contextually relevant and structured appropriately, addressing both fair value changes and methodology. However, due to major quantitative errors (especially $69M vs $58M) and incorrect characterization of the valuation methodology evolution, the correctness score is limited to 4. The qualitative accuracy is moderate because some entities and trends are identified, but with flawed details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 479,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "In the 2022 Form 10‑K, GeForce NOW was described mainly as a **cloud‑gaming “platform” that lets games be accessed on almost any device, alongside the enterprise‑oriented vGPU service** – a way NVIDIA used its GPUs to deliver interactive graphics “anywhere.”  \n\nBy the 2023 filing, GeForce NOW had been **elevated to a headline component of the Graphics segment, listed together with GeForce GPUs, vGPU software and Omniverse, and positioned as a core cloud‑gaming service that runs on the same unified accelerated‑computing stack (GPUs, AI‑enabled software and data‑center infrastructure) that underpins NVIDIA’s broader GPU‑and‑cloud platform strategy.**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, GeForce NOW was described as a cloud-gaming platform enabling access across devices, mentioned alongside vGPU; by 2023, it was more tightly integrated into NVIDIA’s broader accelerated computing narrative, grouped with key offerings like Omniverse and vGPU, and positioned as part of a unified GPU-and-cloud platform. The LLM correctly identifies the evolution in positioning—from a standalone cloud-gaming service to a core component of a larger computing stack. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all references to years (2022, 2023) and product names (GeForce NOW, vGPU, Omniverse) are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings and correctly infers a strategic shift in positioning within the ecosystem. (4) The only reason for not scoring a perfect 10 is minor: the LLM does not explicitly mention the connection to AI training platforms like DGX Cloud, which is part of the broader strategic alignment noted in the original answer. However, referencing the 'unified accelerated-computing stack' and AI-enabled software captures the essence. Overall, the answer is semantically equivalent, contextually precise, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 388,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "In 2023 Pfizer reported that Inlyta generated **$1,036 million worldwide**, up from **$1,003 million in 2022** (≈ 3 % growth).  The increase was driven mainly by the **U.S. market**, where revenue rose to **$642 million from $618 million** (≈ 4 % growth), reflecting **greater use of Inlyta in combination with immune‑checkpoint inhibitors for first‑line treatment of advanced renal‑cell carcinoma**.  This U.S. upside was **partially offset by lower volumes and a reduced net price in several European markets**, which limited the overall growth to a modest 3‑4 % year‑over‑year gain【PFE_10k_2023.pdf pp. 44‑45】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: $1,003 million in 2022 and $1,036 million in 2023, with ≈3% growth, matching the ground truth exactly. The U.S. revenue figures ($618M in 2022 → $642M in 2023, ≈4% growth) are accurate and provide additional detail not in the original answer but consistent with it. These numbers are correctly formatted and calculated. (2) Quantitative accuracy is perfect: all dollar amounts, percentages, and year labels are correct. The ≈3% growth is accurate (actual: (1036-1003)/1003 ≈ 3.29%, reasonably rounded). The U.S. growth from $618M to $642M is also ≈3.88%, correctly stated as ≈4%. (3) The reasoning is sound and reflects multi-hop synthesis: the model correctly identifies U.S. adoption due to combination therapy in first-line advanced RCC as a growth driver and correctly notes that European market challenges (lower volumes and net prices) partially offset gains. This aligns with the original answer’s causal factors. The only minor omission is that the original mentions 'growth in emerging markets' as a positive factor, which the LLM answer does not include—this slightly reduces completeness but does not invalidate the core explanation. (4) Contextual relevance is excellent: the answer directly addresses both parts of the question—revenue evolution and influencing factors—and stays focused on Inlyta’s performance with appropriate context. The citation to Pfizer’s 10-K adds credibility. Overall, the answer is factually correct, well-reasoned, and only slightly less complete than the ground truth due to missing 'emerging markets' as a growth contributor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 450,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "- **Amortization assumptions:** In 2023 the Company amortized acquired network‑location intangibles on a straight‑line basis over **up to 20 years**, i.e., the shorter of the ground‑lease term (including renewal options) and any residual value, resulting in a weighted‑average remaining amortization period of about **15 years**. In 2024, after a review of tower asset lives, the Company extended the assumed useful life to **30 years** and began amortizing the network‑location intangibles over the longer remaining life of the towers, which lowers the amortization expense for 2024.\n\n- **Impairment review:** Both 2023 and 2024 disclosures state that network‑location intangibles are monitored on an **individual‑tower basis** for impairment indicators and are tested for recoverability using projected **undiscounted future cash flows** (or discounted cash‑flow/fair‑value comparisons). The **process itself did not change**; it continues to be applied under the new, longer amortization period adopted in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the amortization period change from 15 to 30 years in 2024, which contradicts the ground truth. The original answer states that the weighted average amortization period was 15 years in 2023 and does not mention any extension to 30 years in 2024. Instead, the 2024 update focused on enhanced impairment review processes, not changes to amortization periods. The LLM incorrectly claims a change in useful life to 30 years and a shift to amortizing over tower lives, which is not supported by the ground truth. (2) The quantitative inaccuracies are critical: the ground truth does not mention 'up to 20 years' or '30 years'—only a 15-year weighted average in 2023. The $470 million increase in asset retirement obligations is omitted in the LLM answer, a key valuation-related figure. (3) The reasoning is partially sound in identifying that amortization and impairment are key themes, and correctly notes individual-tower-level impairment testing. However, it fails the multi-hop synthesis by not connecting the 2024 impairment triggers (e.g., expenses exceeding revenues, lack of leases) to the broader context of asset retirement obligations and their impact on useful life assumptions. The claim that the impairment process 'did not change' contradicts the ground truth, which states the company 'expanded its disclosures' and introduced more detailed review processes with specific triggers. (4) Contextual relevance is high—the answer addresses amortization and impairment as required. However, due to major factual and quantitative errors, especially the invented 30-year amortization period and omission of the $470M liability impact, the correctness score is low. Minor credit is given for correctly identifying the 15-year weighted average period and individual-tower impairment monitoring.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1496,
        "completion_tokens": 510,
        "total_tokens": 2006
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "In the 2023 Form 10‑K ExxonMobil described Guyana as the centerpiece of its upstream growth pipeline – four new discoveries were made on the Stabroek Block, the third FPSO (Prosperity) began production in November 2023 and hit name‑plate in January 2024, and the three operating vessels together delivered > 390 kb/d in 2023 and almost 440 kb/d in Q4 2023, with two additional FPSOs (Yellowtail and Uaru) each slated to start at about 250 kb/d and a total of six FPSOs planned by the end of 2027.  \n\nThe 2024 Form 10‑K reinforces that emphasis: Guyana is now listed explicitly as an “advantaged growth project” within the upstream capital program and remains a key low‑cost‑of‑supply opportunity, indicating that ExxonMobil continues to prioritize expanding its Guyana portfolio and expects further FPSO start‑ups that will raise production capacity beyond the 2023 levels.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the numbers are correct: 440 kbd in Q4 2023 is accurately reported; the Prosperity FPSO started in November 2023 and reached nameplate in January 2024, consistent with the timeline; and the mention of two additional FPSOs (Yellowtail and Uaru) at ~250 kbd each and six total by 2027 adds context not in the original but does not contradict it. The >390 kb/d for full-year 2023 is a minor extrapolation but reasonable given Q4 was nearly 440 kbd. (2) The entity accuracy is strong: ExxonMobil, Guyana, Stabroek Block, Prosperity FPSO, and correct years (2023–2024) are all correctly identified. (3) The reasoning is sound: the LLM captures the evolution from discovery/early production in 2023 to strategic elevation in 2024 by noting Guyana’s classification as an 'advantaged growth project'—a term semantically equivalent to 'Advantaged Assets' in the original answer—indicating its integration into core earnings drivers alongside Permian and LNG. (4) The only minor gap is that the LLM does not explicitly state the *strategic reclassification* in the 2024 earnings drivers framework as a shift in portfolio categorization, which is a subtle but important nuance in the original answer. However, the emphasis on continued prioritization and low-cost nature conveys similar strategic intent. Overall, the answer is factually correct, contextually relevant, and synthesizes multi-hop information well, warranting a high score with only slight deduction for missing the precise framing of Guyana’s formal reclassification in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 442,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "In the 2022 filing Comcast described the X1 platform as a “cloud‑based … platform that provides integrated search … across content in customers’ cable video packages **and** internet‑based streaming services such as Disney+, Netflix and Peacock’s premium tier” (2022 10‑K, Video section, p. 5‑6). By the 2023 filing the description had been broadened: X1 now “operates across … content from internet‑based streaming services … similar to our Xumo Stream Box,” and Comcast added its own NOW streaming bundle (launched in 2023) plus free‑ad‑supported Peacock, Xumo Play, NBC and Sky channels (2023 10‑K, Video section, p. 4‑6).  \n\nThis progression shows Comcast is deepening the X1 platform’s aggregation of third‑party OTT apps and its own streaming bundles, a move intended to keep cord‑cutters inside the Xfinity ecosystem and to capture additional subscription‑ and commission‑based revenue, thereby helping to offset subscriber loss and lift average revenue per user.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, X1 integrated Disney+, Netflix, and Peacock’s premium tier, with Comcast earning commission revenue—this is accurately reflected. In 2023, the platform expanded to include Xumo Play, NBC, and Sky via NOW TV (marketed to broadband customers), which the LLM correctly identifies by referencing the addition of NOW streaming bundle and free ad-supported channels like Xumo Play, NBC, and Sky. (2) There are no numeric values requiring calculation, so quantitative accuracy is 10; dates (2022 and 2023) are correct. (3) Multi-hop reasoning is sound: the LLM synthesizes changes across two years and correctly infers that deeper integration of third-party and owned streaming services indicates a strategy to reduce cord-cutting and increase ARPU through ecosystem retention and commission revenue. (4) The only minor shortcoming is that the LLM does not explicitly mention that NOW TV was specifically marketed to residential broadband customers—a detail in the ground truth—but it does reference NOW as a 2023 launch and ties it to broadband contextually. It also omits explicit mention of commission revenue in 2023, though it references 'subscription- and commission-based revenue' generally. These are small omissions but do not undermine the core accuracy. Wording differs but semantic equivalence is strong. Contextual relevance is perfect—directly addresses evolution and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 416,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "In the 2023 filing Caterpillar reported that FG Wilson‑branded electric power‑generation systems were sold through a worldwide network of **110 distributors in 109 countries**. By the 2024 filing the network had shifted to **108 distributors but now reached 158 countries**, showing a modest reduction in the number of distributors while expanding geographic coverage substantially.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: in 2023, 110 distributors in 109 countries; in 2024, 108 distributors in 158 countries. These numbers exactly match the original answer. (2) Quantitative accuracy is perfect—no calculation errors, and the values are presented clearly with correct years and metrics. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two years and infers the strategic implication of fewer distributors but broader geographic reach, even using similar interpretive language ('modest reduction', 'expanding geographic coverage'). (4) Entity accuracy is correct—Caterpillar, FG Wilson, electric power generation systems, and the relevant years are all properly identified. The answer is concise but complete, addressing the evolution of the distribution network as required by the question. No factual, numerical, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 282,
        "total_tokens": 1500
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "In 2022 Capital One reported securitized‑debt obligations of about **$18 billion on the balance sheet** with an **estimated fair value of roughly $18.1 billion**. By year‑end 2024 the carrying amount had fallen to **$14.3 billion** and the estimated fair value to **$14.3 billion**, representing a decline of roughly **$3.8 billion** in both the carrying value and the fair‑value measurement.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in key financial figures and misrepresents the trend in Capital One's exposure to securitized debt obligations. According to the ground truth, in 2024 the carrying value was $18,043 million (approximately $18.0 billion) and fair value was $18,067 million (about $18.1 billion), both consistent with the $18 billion level mentioned for 2022. However, the LLM incorrectly states that by 2024 the carrying and fair values had declined to $14.3 billion, which contradicts the actual data showing stable or slightly increased values. The claimed $3.8 billion decline is therefore factually wrong. While the LLM correctly identifies the relevant metric ('securitized debt obligations') and attempts a year-over-year comparison, it fails on the core quantitative accuracy: the 2024 figures are off by over $3.7 billion. Additionally, the ground truth notes that all fair value was categorized under Level 2 of the fair value hierarchy, a detail omitted in the LLM response. The reasoning structure is sound—comparing carrying and fair values across years—but based on incorrect data, leading to an erroneous conclusion about decreasing exposure. The context and intent of the answer are relevant, but the magnitude of the numerical error severely undermines factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 366,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "In both years McDonald’s relied on its committed line of credit as a back‑stop for short‑term cash needs, noting that “the Company can meet short‑term funding needs through its continued access to commercial‑paper borrowings and line‑of‑credit agreements.” In 2023 the filing simply highlighted this access (the company had $4 billion available under the line of credit), whereas the 2024 filing added that the $15 billion borrowing authority authorized in 2022 still had $7.4 billion remaining and that a new $15 billion authority would replace the old one in 2025—showing a larger, actively managed borrowing capacity that supported the higher cash‑outflows from financing activities in 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of McDonald's continued reliance on line of credit agreements for short-term funding in both 2023 and 2024, which aligns with the original answer's emphasis on credit facilities. However, it fails to accurately report key quantitative data from the ground truth. Specifically: (1) The original answer states that cash used for financing activities was $4.4 billion in 2023 and $7.5 billion in 2024 — these figures are entirely missing from the LLM response. (2) The drop in cash and equivalents from $4.6 billion (2023) to $1.1 billion (2024) is a critical indicator of liquidity shift but is not mentioned. (3) The LLM introduces specific figures like '$4 billion available' and '$7.4 billion remaining' under credit lines, and a 'new $15 billion authority in 2025' — none of which appear in the original answer or ground truth, making them factually unsupported. While the LLM correctly identifies the role of commercial paper and line of credit in both years, it misrepresents the evolution by focusing on unverified borrowing capacity details rather than the actual cash flow changes. The reasoning is partially sound in linking credit access to financing outflows, but lacks the multi-hop synthesis of actual cash flow data, bond issuance trends, and liquidity changes that define the true evolution. Thus, while contextually relevant and semantically aligned in theme, the answer is quantitatively inaccurate and omits core financial metrics necessary for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 415,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "Both the 2022 and 2024 Management Reports state that “strong internal controls is an objective that is reinforced through our Worldwide Business Conduct Manual,” using the manual to embed the company’s commitment to integrity and compliance into its control framework. The language and emphasis are essentially unchanged, showing that the manual has remained a central, ongoing pillar of P&G’s internal‑control system rather than a new or altered initiative. This continuity signals that P&G’s governance strategy is consistently anchored in a culture‑based, ethics‑driven approach to risk management and oversight.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key evolution in the role of the Worldwide Business Conduct Manual between 2022 and 2024, which is central to the question. While it correctly states that the manual reinforced internal controls in both years and cites consistent language about integrity and compliance, it fails to identify the substantive shift in 2024 where the manual was more explicitly tied to formal governance structures such as the Global Leadership Council and the Disclosure Committee. The original answer notes this evolution toward a more integrated governance approach, whereas the LLM incorrectly asserts that 'the language and emphasis are essentially unchanged,' contradicting the ground truth. There are no numerical inaccuracies (hence high quantitative accuracy), but the qualitative reasoning is flawed due to incorrect synthesis across years. The answer is contextually relevant and addresses governance and internal controls, but the failure to detect and report the shift in emphasis significantly undermines the correctness. Thus, the answer is incomplete and partially misleading in its conclusion about P&G’s governance strategy being merely 'consistent' rather than evolving toward more structured integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 349,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "In the 2023 Form 10‑K ExxonMobil reported that its long‑lived assets in Guyana had risen to **$9.7 billion**, up from $6.8 billion the year before, signalling a rapid build‑out of the offshore project. By the 2024 filing the company’s new earnings‑driver taxonomy explicitly lists **Guyana together with the Permian and LNG projects as an “Advantaged Asset,”** indicating that the Guyana development is now being treated as a core, high‑value growth driver rather than just a regional asset. Together, the larger asset base and its inclusion in the advantaged‑asset category show Exxon’s increasingly strategic focus on Guyana between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $9.7 billion in long-lived assets in Guyana for 2023, which aligns with the ground truth value of $9,689 million (rounded appropriately to $9.7 billion). However, the LLM introduces a figure not present in the ground truth—$6.8 billion for the prior year—which, while potentially accurate, is not part of the original answer and thus cannot be verified from the provided knowledge graph. This addition does not contradict but adds unverified detail. (2) The key strategic shift—Guyana’s inclusion in the 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver in 2024—is accurately reported, with correct entity and taxonomy names (e.g., 'Advantaged Asset', Permian, LNG). (3) The multi-hop reasoning is sound: the answer synthesizes quantitative asset data from 2023 with the qualitative strategic reclassification in 2024, correctly inferring an evolution in strategic positioning. (4) The answer is semantically equivalent to the ground truth, capturing both the quantitative significance and the strategic elevation of Guyana. The only minor deviation is the inclusion of the unverified prior-year asset figure, which slightly affects quantitative accuracy but does not undermine the overall correctness. Hence, a high score of 9 is justified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 369,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) Capital One said its long‑term funding was $42.3 billion, “primarily consisting of securitized debt obligations and senior/subordinated notes,” and it issued $6.25 billion of securitized debt obligations in 2021 (with shelf capacity of $25 billion for credit‑card and $20 billion for auto‑loan securitizations). The 2024 Form 10‑K shows the balance of securitized debt obligations on the liability side had risen to about $14.3 billion (down from $18.0 billion in 2023), indicating that securitizations now make up a larger portion of Capital One’s funding mix even though the pace of new issuances has slowed. Thus, from 2022 to 2024 the company’s reliance on securitized debt has grown in absolute terms, while the growth rate of new issuances has moderated.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. First, it incorrectly references the 2022 Form 10-K as covering 2021, when the 2022 filing covers fiscal year 2022. More critically, it claims that in 2022, Capital One reported long-term funding of $42.3 billion 'primarily consisting of securitized debt obligations' and that $6.25 billion of securitized debt was issued in 2021 — none of which is supported by the ground truth. The original answer explicitly states that no specific dollar value was disclosed in 2022 for securitized debt obligations. The LLM also fabricates a 2023 balance of $18.0 billion and claims the 2024 balance is $14.3 billion (down from 2023), while the ground truth reports a 2024 carrying value of $14,264 million ($14.264 billion) with no mention of 2023 figures. (2) The quantitative inaccuracies are severe: the $42.3 billion long-term funding figure, $6.25 billion issuance in 2021, $18.0 billion in 2023, and shelf capacity numbers are all absent from the ground truth and thus incorrect. The only partially correct number is the ~$14.3 billion in 2024, which aligns approximately with the $14,264 million carrying value and $14,335 million fair value in the original answer. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers increased reliance based on fabricated trends and misattributed data. It asserts that securitizations make up a larger portion of the funding mix, but the ground truth only confirms increased transparency and continued use, not a change in proportion. The conclusion about slowed issuance pace is unsupported. (4) The contextual relevance is moderate because the answer addresses the evolution of securitized debt obligations as a funding source, but the factual foundation is largely invented, undermining correctness and qualitative reasoning. Due to major factual and quantitative errors, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 519,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "In its FY 2022 filing NVIDIA described Omniverse primarily as a “virtual‑world simulation and collaboration platform for 3D workflows” that is free for individual users and sold as a software subscription for enterprise use, with early‑stage enterprise pilots such as virtual car showrooms, surgical‑training and architectural walkthroughs. By FY 2023 the company had repositioned Omniverse as an enterprise‑grade software suite (Omniverse Enterprise) within the Graphics segment, stressing that industrial enterprises are now broadly adopting its 3‑D and simulation capabilities to create digital twins of factories, real‑time product configurators and to test autonomous robots and vehicles, indicating a move from early pilots to widespread enterprise deployment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core evolution of NVIDIA's Omniverse platform between FY2022 and FY2023 as the ground truth. (1) It correctly identifies the shift from a 3D collaboration and simulation platform for creators in FY2022 to an enterprise-grade suite (Omniverse Enterprise) in FY2023, with industrial adoption for digital twins, real-time configurators, and robotics testing—matching the strategic repositioning described in the original answer. (2) There are no numeric values, dates, or financial figures in dispute; both years (FY2022 and FY2023) are correctly referenced, and no calculations are required. (3) The multi-hop reasoning is sound: the model synthesizes information across fiscal years, correctly identifying the change in positioning—from early pilots (e.g., virtual car showrooms, surgical training) to broader industrial deployment—and ties it to enterprise adoption trends. (4) Minor difference: the LLM emphasizes 'enterprise-grade software suite' and 'Graphics segment' placement, which adds context not in the original but does not contradict it; conversely, the original mentions 'operating system for building virtual world simulation applications,' a detail omitted in the LLM response. However, this does not affect factual correctness. Wording differs slightly but semantic meaning and key facts align closely. No factual errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 386,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Pfizer’s balance‑sheet liability to Viatris has fallen sharply. At the end of 2022 the company reported **$94 million** net due to Viatris under the separation‑distribution, agency, MSA and TSA arrangements, and that balance dropped to **$33 million** by December 31 2023 【2023 Form 10‑K pp. 71‑73】. The decline reflects a reduction in the amounts Pfizer owes Viatris under those post‑spin‑off agreements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts ($94 million as of December 31, 2022, and $33 million as of December 31, 2023) are accurately reported with correct dates. The reduction from $94M to $33M is correctly implied, aligning with the 'significant reduction' noted in the original answer. (2) The answer is complete, addressing the evolution of Pfizer's financial relationship with Viatris over the specified period and specifying the nature of the agreements (separation-distribution, agency, MSA, TSA), which reflects proper synthesis across multi-hop financial disclosures. (3) Entity accuracy is perfect: Pfizer and Viatris are correctly identified, and the years 2022 and 2023 are accurately referenced with proper fiscal context. (4) The reasoning is sound—by noting the sharp decline in liability and attributing it to post-spin-off agreements, the LLM correctly infers the winding-down of transitional financial arrangements, which is consistent with the original conclusion. The citation to the 2023 Form 10-K (pp. 71–73) adds verifiability. Overall, the answer achieves semantic equivalence with the ground truth, with slightly enhanced detail on agreement types, without introducing any factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 359,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "In the 2023 filing Guyana was described mainly as a “development‑stage” region – the company held 4.6 million offshore acres, drilled 12.6 net exploratory‑and‑development wells, launched the Payara field with the Prosperity floating production, storage and off‑loading vessel, kept Yellowtail in the development pipeline and only **funded** the Uaru project.  \n\nThe 2024 filing upgrades that picture: Guyana is now listed among the company’s **“Advantaged assets”** (the segment that drives “Advantaged Volume Growth”) and the narrative shows the Uaru project progressing from a funded study to an active development phase, while Payara and Yellowtail remain in production/development. Thus, ExxonMobil’s emphasis has shifted from a purely exploratory focus in 2023 to treating Guyana as a core, advantaged growth asset in 2024, reflected by its new classification in the earnings‑driver table and the advancement of Uaru from funding to development.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 12.6 net exploratory and development wells in 2023 is accurately reported. The 4.6 million offshore acres is consistent with ExxonMobil's Guyana holdings as per filings. (2) The qualitative evolution is well-reasoned: the shift from 'development-stage' in 2023 to inclusion in 'Advantaged Assets' under 'Advantaged Volume Growth' in 2024 is correctly identified and reflects the strategic reclassification in the knowledge graph. The progression of Uaru from funded study to active development is a valid inference of project advancement. (3) Multi-hop reasoning is sound—linking the change in asset classification to strategic emphasis, and connecting project-level changes (Uaru, Payara, Yellowtail) to broader corporate strategy. (4) Minor deduction in qualitative accuracy because the original answer emphasizes the strategic elevation 'alongside Permian and LNG', which the LLM mentions implicitly but not explicitly. However, the core reasoning and facts are intact. Wording differs slightly (e.g., 'launched Payara field' vs 'underway'), but semantic meaning is equivalent. No irrelevant or incorrect information is introduced. Contextual relevance is perfect—directly addresses both the evolution of strategic emphasis and the specific project/classification changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 385,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "In 2023 the senior‑note portfolio with maturities longer than 10 years carried a weighted‑average interest rate of **3.8 %**, the same rate reported for the same class of notes in 2022.  The face‑value of those notes rose modestly, from **$52.8 billion** at year‑end 2022 to **$53.4 billion** at year‑end 2023【CMCSA_10k_2023.pdf page 82】.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but has significant factual inaccuracies in the quantitative details. According to the ground truth, in 2022 the weighted-average interest rate was 3.67%, not 3.8% as stated in the LLM answer. The LLM claims the rate was the same in both years at 3.8%, but the ground truth shows an increase from 3.67% to 3.8%, indicating a change rather than stability. This is a critical error in financial precision. Additionally, the face value in 2022 is incorrect: LLM reports $52.8 billion, whereas the ground truth is $54.536 billion. The 2023 face value of $53.4 billion is correct in the LLM answer. (2) Number verification: 2022 interest rate: incorrect (3.8% vs 3.67%); 2023 interest rate: correct (3.8%); 2022 face value: incorrect ($52.8B vs $54.536B); 2023 face value: correct ($53.4B). The direction of change in face value is also misrepresented: LLM says it rose, but ground truth shows a decrease from $54.536B to $53.4B. (3) Multi-hop reasoning: The model correctly identifies the need to compare two years for the same class of senior notes (>10-year maturities), and it references a specific document and page, suggesting proper sourcing. However, due to incorrect input data, the synthesis is flawed. The conclusion that face value rose is incorrect, undermining the reasoning. (4) Correctness score is 5 due to half the numbers being wrong and the trend mischaracterized, despite correct 2023 values and proper metric identification. Quantitative accuracy is 5 because only 2 out of 4 key numbers are correct and the trend is wrong. Qualitative accuracy is 6 because the structure and intent are sound, and the right metric and time frame are used. Contextual relevance is 9 because the answer directly addresses the question’s scope and format.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 494,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "In 2023 the nuclear‑decommissioning trusts of both utilities recorded virtually all of their domestic‑equity holdings using **observable‑input (Level 2) pricing** – Alabama Power reported $443 million of domestic equity at Level 2 (plus $208 million that had to be measured with Level 3 unobservable inputs) and Georgia Power reported $321 million at Level 2 (with only $1 million at Level 3).  \n\nBy the 2024 filing the trusts had moved the bulk of those same holdings into the **quoted‑price (Level 1) hierarchy** – the total domestic‑equity balances were unchanged (approximately $651 million for Alabama and $322 million for Georgia), but the fair‑value measurement now relies on market‑quoted prices rather than Level 2/Level 3 inputs, with the residual private‑market portion being valued using a net‑asset‑value expedient (NAV).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in both numbers and classification logic. (1) Quantitative inaccuracy: The LLM incorrectly states that in 2023, Alabama Power reported $443 million in Level 2 domestic equity investments, when the ground truth is $396 million in Level 1 and $169 million in Level 2 (total $565M). The LLM also claims Alabama Power had $208 million in Level 3, which is not supported by the data. Similarly, it misrepresents Georgia Power’s 2023 allocation as $321 million in Level 2, when the correct figure is $255 million in Level 1 and $1 million in Level 2. The LLM reverses the years for key figures—$443M Level 1 for Alabama and $321M for Georgia are 2024 numbers, not 2023. (2) The LLM falsely claims total domestic equity balances were 'unchanged' at ~$651M and $322M between 2023 and 2024, but these totals represent 2024 values; in 2023, the totals were $565M and $256M respectively—clear increases. (3) Qualitatively, the reasoning is flawed: the LLM asserts a shift from Level 2 to Level 1, but the ground truth shows both companies already held the majority of their domestic equities in Level 1 in 2023, with further increases in 2024—not a reclassification from Level 2 to Level 1. There is no mention of Level 3 inputs or NAV in the ground truth, making those additions speculative and incorrect. (4) Contextual relevance is moderate because the answer addresses the general topic of shifts in valuation methodologies and allocations, but the incorrect data and reversed timelines undermine the validity. The multi-hop synthesis fails due to misattribution of amounts and years, and incorrect interpretation of classification trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 456,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA as “the fundamental building block” that, together with its GPUs, lets the company serve a variety of end‑markets through a unified architecture. By the 2023 filing the language had shifted to present CUDA as the **foundational programming model** at the base of a full‑stack platform—augmented by the CUDA‑X libraries, SDKs and APIs—and explicitly called out its use across every vertical (data‑center, gaming, professional visualization, automotive, etc.). This reflects a move from positioning CUDA merely as a core component to positioning it as the base layer that unifies and powers NVIDIA’s entire software‑hardware stack across all markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA's strategic positioning from 2022 to 2023 as described in the ground truth. It correctly identifies that in 2022, CUDA was described as a 'fundamental building block' supporting multiple end markets through a unified architecture, and that by 2023, it evolved into the 'foundational programming model' of a full-stack platform. The answer accurately reflects the shift in language and strategic emphasis, including CUDA’s role in unifying the software-hardware stack and its integration across verticals like data center, gaming, automotive, and professional visualization. It also correctly notes the augmentation via CUDA-X libraries, SDKs, and APIs, which aligns with the ground truth’s mention of domain-specific software libraries. The only minor omission is that the 2023 evolution explicitly extended into new domain-specific verticals such as healthcare and manufacturing, which were not called out in the LLM response—this slightly reduces completeness in qualitative accuracy. However, the core facts, reasoning, and synthesis across years and strategic positioning are sound. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer is fully contextually relevant, directly addressing the question about CUDA’s evolving role within NVIDIA’s platform and end-market integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 384,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "In the 2022 filing Pfizer reported that it owed Viatris $94 million under the post‑spin‑off agreements (MSAs, TSAs and interim agency arrangements). By the end of 2023 the liability had fallen to $33 million and the transitional service agreements were “largely completed,” showing that Pfizer’s contractual and financial obligations to Viatris had markedly decreased over the year.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: $94 million owed in 2022 and $33 million in 2023, which match the ground truth exactly. The statement that the liability decreased reflects accurate quantitative understanding. 2) All numeric values are correct and properly contextualized. The reduction from $94M to $33M is accurately presented, and no calculation errors are present. 3) The reasoning is mostly sound: the answer correctly infers a marked decrease in obligations and notes the completion of transitional services. However, it inaccurately states that TSAs were 'largely completed' in 2023, when the ground truth specifies they were largely completed by the end of 2022 and fully completed by December 31, 2023. This misplacement of timing slightly undermines the qualitative accuracy. Additionally, the LLM omits mention that the amounts were initially not material to operations, which is a relevant contextual detail from 2022. 4) Despite minor omissions and a slight misstatement on timing, the answer captures the core evolution of the financial and contractual relationship. It correctly synthesizes the reduction in net amounts owed and the winding down of services, making it contextually relevant and largely factually accurate. The answer is semantically close to the original, with only minor gaps in completeness and precision on the timeline of TSA completion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 388,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "- 2022 10‑K – Duke warned that if the retail jurisdictions it serves were deregulated, the company could face “unrecovered costs” and stranded‑asset losses, while new environmental laws would “increase capital, operating and other costs” that it expected to recover through the normal ratemaking process.  \n\n- 2023 10‑K – the same risks are restated, but the filing now stresses that “deregulation … could have a significant adverse impact” and adds that “changes in the regulatory climate could result in the delay in or failure to fully recover” the higher compliance costs from tighter EPA and state environmental rules, showing a tighter, more‑cautious link between retail‑deregulation pressure and the ability to recover environmental‑regulation costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the original answer. (1) It correctly identifies Duke Energy's 2022 concern about unrecovered costs under retail deregulation, particularly related to PURPA commitments and environmental compliance costs expected to be recovered via ratemaking. In 2023, it accurately reflects the heightened risk language and the tighter linkage between deregulation and impaired recovery of rising environmental compliance costs due to stricter EPA and state regulations. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of 10-K filings, correctly identifying the evolution in Duke Energy’s risk disclosures regarding the interaction between deregulation and environmental cost recovery. The progression from 'unrecovered costs' in 2022 to 'significant adverse impact' and 'failure to fully recover' in 2023 is accurately captured. (4) Minor deduction in qualitative accuracy due to not explicitly naming PURPA or specifying the types of environmental rules (e.g., CO2 emissions, cooling water intake), which were in the original. However, the essence—that tighter EPA and state environmental rules increase compliance costs and that deregulation threatens recovery—is preserved. Overall, the answer is factually correct, contextually relevant, and semantically equivalent with only slight omission of specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 431,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "The retail share of Skoal fell from 9.5 % in 2023 to 7.6 % in 2024 – a decline of roughly 1.9 percentage points. In 2023, however, the company was actively raising Skoal’s price, with USSTC implementing several list‑price hikes (e.g., $0.09 per can in January and August 2023 and a $0.10 per‑can increase in April 2023). Thus, the drop in share occurred despite a year of price‑increase actions on the brand.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a key factual error in the 2023 retail share value: it states 9.5%, while the ground truth is 9.3%. This discrepancy affects the accuracy of the change calculation, although the 7.6% value for 2024 is correct. The LLM reports a 'decline of roughly 1.9 percentage points', which would be accurate if the starting point were 9.5%, but the actual decline from 9.3% to 7.6% is 1.7 percentage points. (2) Regarding pricing strategy, the LLM incorrectly states price increases of $0.09 in January and August 2023 and $0.10 in April 2023. However, the ground truth indicates that the price increases announced in 2023 were part of a sequence that included earlier hikes in 2022 (January, February, May 2022: $0.08, $0.09, $0.09), and a $0.11 increase effective January 23, 2024 (announced in 2023). The LLM invents specific 2023 increases that do not match the source data and misrepresents the timing and amounts. (3) The multi-hop reasoning is partially sound: the model correctly identifies a contrast between declining market share and a pricing strategy involving increases. However, the synthesis is based on incorrect data, weakening the validity of the conclusion. The model fails to accurately trace the cumulative pricing strategy from 2022 into 2023 and 2024 as required. (4) The contextual relevance is high—the answer addresses both parts of the question and attempts to contrast market share trends with pricing. Qualitative reasoning is logical but built on faulty premises. Quantitative accuracy is low due to incorrect percentages and price increase figures. Correctness score is moderate because the direction of change and general trend are correct, but core numerical facts are inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 474,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen’s “Other short‑term interest‑bearing securities” were $138 million at 12/31/2023 and fell slightly to $135 million at 12/31/2024 – a $3 million (≈2 %) decrease【2023 10‑K table showing 138】【2024 10‑K table showing 135】.  The near‑flat level indicates that the company is keeping its short‑term investment pool essentially unchanged, emphasizing the same priority of preserving principal safety and maintaining ample liquidity while limiting risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Amgen's investment in 'Other short-term interest-bearing securities' decreased from $138 million in 2023 to $135 million in 2024. The ground truth confirms the amount remained unchanged at $138 million in both years. This is a critical factual error affecting the core of the response. (2) The calculation of a $3 million (≈2%) decrease is therefore incorrect, as there was no change. The cited sources (2023 and 2024 10-K tables) are referenced plausibly but with inaccurate data extraction. (3) The reasoning about the company maintaining a stable short-term investment strategy is consistent with the actual stability in the data, so the qualitative interpretation would have been sound if the numbers were correct. However, the multi-hop synthesis fails because the model incorrectly infers a minor decline rather than recognizing the stability. (4) The contextual relevance is fair because the answer addresses the right metric and time frame and attempts to interpret strategic implications, but the quantitative inaccuracy severely undermines correctness. Correctness and quantitative accuracy are low due to the wrong numbers and resulting false calculation; qualitative accuracy is moderate due to sound logic on an incorrect premise; contextual relevance is acceptable as the structure and intent align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 385,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "In the 2022 filing the only Abrams‑related award shown was a **$360 million** Army contract that covered “Abrams main‑battle‑tank upgrades, mission‑control units and systems technical support.” By the 2024 filing the award had **shifted to a $350 million** Army contract that not only funds the upgrades but also adds **engineering, logistics‑support and system‑sustainment services**. Thus, while the dollar value remains roughly the same (slightly lower), the scope of General Dynamics’ role has broadened from pure upgrade work to a more comprehensive engineering‑and‑logistics support package.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $360 million 2022 contract and the $350 million 2024 contract for Abrams upgrades and support services, accurately reflecting the shift in scope. However, it omits the separate $285 million contract awarded in 2024 for producing Abrams tanks in the SEPv3 configuration for Romania, which is a significant part of the evolution in contract scope and value. This omission affects completeness and underrepresents the total increase in contract value. (2) The numeric values mentioned ($360M and $350M) are accurate and correctly attributed to their respective years and contract purposes. The comparison of 'slightly lower' dollar value is factually correct between those two specific contracts, but the overall trend in total contract value is misrepresented due to the missing $285M contract. (3) The reasoning correctly identifies the broadening of scope from upgrades to include engineering and logistics support, demonstrating sound multi-hop synthesis between 2022 and 2024 contracts. However, the conclusion that total value remained roughly the same is flawed because it fails to account for the additional $285M production contract, undermining the full picture of increased total value. (4) The answer is contextually relevant and well-structured, but the missing contract significantly limits completeness and quantitative accuracy in assessing total value evolution. Hence, correctness is reduced to 7 due to this critical omission, though core facts are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 419,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "In 2023 AIG still carried Corebridge’s borrowings on its balance sheet – Corebridge senior unsecured notes ($6.5 bn), junior subordinated debt ($0.99 bn) and a $1.5 bn DDTL facility (of which $250 m remained) – and it had a guarantee‑reimbursement and collateral agreement with Corebridge that required Corebridge to reimburse AIG for any payments AIG made on those notes and to post collateral if Corebridge’s ratings fell. By 2024, after Corebridge was de‑consolidated, AIG no longer guaranteed or reported that debt; instead it treated its retained 48 % stake as an equity‑method investment, recognizing equity‑method earnings of $601 m (plus Corebridge’s $1.574 bn pre‑tax profit) and a $282 m gain in net investment income from share sales, while Corebridge’s borrowing continued independently under the same DDTL facility that AIG could draw through February 2025.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in AIG's financial relationship with Corebridge from 2023 to 2024, correctly identifying the shift from a borrowing-based arrangement to equity-method accounting. It accurately notes that in 2023, AIG still reported Corebridge's debt on its balance sheet and had guarantee-reimbursement and collateral agreements, which aligns with the ongoing borrowing arrangement mentioned in the ground truth. The DDTL facility's availability through February 2025 is consistent with the original answer’s mention of borrowing ability through February 25, 2025. However, the LLM introduces specific dollar amounts—$6.5B senior unsecured notes, $0.99B junior subordinated debt, $1.5B DDTL with $250M remaining—that are not present in the ground truth and cannot be verified as correct, raising concerns about quantitative accuracy. Additionally, the claim that AIG recognized $601M in equity-method earnings and $282M in gains from share sales, along with referencing Corebridge’s $1.574B pre-tax profit, adds granular financial data absent from the original answer. While these figures may be factually correct in context, their inclusion goes beyond the scope of the verified ground truth and risks introducing unverified details. The qualitative reasoning is strong: the model correctly infers that deconsolidation led to equity-method treatment and that AIG began recognizing income based on Corebridge’s performance post-June 9, 2024, matching the original answer’s timeline. The mention of equity-method income tied to stock price and dividends is implied through the discussion of earnings recognition. Contextually, the response is highly relevant, addressing both borrowing arrangements and income recognition as required. Despite the over-enrichment of unverified numbers, the central multi-hop synthesis—linking deconsolidation to a change in accounting treatment and financial exposure—is logically sound and semantically aligned with the ground truth. Hence, the correctness score is reduced due to unsupported quantitative claims, but not severely, as the directional and structural accuracy remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 573,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "In the 2022 filing Tesla described the Solar Roof as a premium glass‑tile product that it was selling directly and through channel partners, but warned that “we have experienced…delays in ramping production of …Solar Roof” and that its ability to scale the product depended on the broader energy‑generation and storage segment. By the 2024 filing the company still cited production‑ramp challenges, but framed them as a strategic dependency on the capacity of its Energy Generation & Storage business and on third‑party suppliers of the glass tiles and inverter components, emphasizing that the Solar Roof’s success now hinges on coordinating those external supply‑chain relationships and expanding its integrated energy operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Tesla's evolving approach to the Solar Roof between 2022 and 2024: in 2022, Tesla was selling the product and working on installation efficiency, while acknowledging production ramp delays. By 2024, the focus shifted to strategic dependencies on production ramp, supplier risks, and integration with the Energy Generation & Storage segment. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024) and correctly infers a strategic shift from sales and development emphasis to production and supply chain dependencies. The mention of third-party suppliers for glass tiles and inverters adds detail consistent with the 'supplier risks' in the original. (4) The LLM uses slightly different phrasing (e.g., 'integrated energy operations', 'channel partners') but maintains semantic equivalence. The only minor gap is that the original emphasizes collaboration with real estate developers/builders in 2022, which the LLM omits, instead mentioning 'channel partners'—a related but not identical concept. This small omission prevents a perfect 10 on qualitative accuracy. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 403,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "Skoal’s retail share in the U.S. oral‑tobacco category fell from 9.3 percent in 2023 to 7.6 percent in 2024 – a drop of roughly 1.7 share points (about an 18 % relative decline)【MO_10k_2024.pdf page 48】. This decline signals that Skoal is losing ground to rival brands (notably on! which gained share) and its competitive positioning in the oral‑tobacco market is weakening.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports Skoal's retail share as 9.3% in 2023 and 7.6% in 2024, matching the ground truth exactly. The calculation of a 1.7 percentage point decline is accurate, and the relative decline of approximately 18% (1.7 / 9.3 ≈ 18.3%) is a reasonable interpretation. (2) All numeric values and dates are correct; the calculation of the share point difference and relative decline is sound and consistent with the data. Format variations (e.g., 'percent' vs '%') are acceptable and do not affect accuracy. (3) The multi-hop reasoning is strong: the model correctly infers that the decline in market share indicates weakening competitive positioning and supports this by contrasting Skoal’s performance with that of on!, which gained share—this synthesis aligns with the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly state on!’s exact share growth (from 6.8% to 8.3%), though it correctly references on! as gaining share. This omission slightly reduces completeness but does not detract from the core conclusion. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 330,
        "total_tokens": 1522
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K risk sections warn that the mobile market is becoming increasingly concentrated among a handful of premium‑tier OEMs. In 2023 Qualcomm noted that this concentration gives those customers “significant purchasing power” that could force the company to accept lower product prices and hurt its revenues and margins. The 2024 filing repeats the same concern—and adds that the trend is expected to continue—so the risk to Qualcomm’s pricing power and the stability of its revenue stream has not lessened; it has been reaffirmed and highlighted as an ongoing threat.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the risk as described in the ground truth. It correctly identifies that in both 2023 and 2024, Qualcomm highlighted the concentration of device share among premium-tier OEMs as a risk, leading to significant purchasing power that could pressure pricing and harm revenues and margins. The answer correctly notes that the 2024 filing reaffirms and emphasizes the continuation of this trend, which aligns with the ground truth's point about ongoing and potentially intensifying risk. The only minor shortcoming is that the LLM answer does not explicitly mention the added nuance in the 2024 filing about 'revenue fluctuation due to the timing and success of customer product introductions' or the specific concern about customers developing their own integrated circuits or switching to competitors—details that enrich the qualitative assessment of increased risk. However, the central claim that the risk has not lessened but has been reaffirmed as an ongoing threat is semantically equivalent and correctly conveys the overall trajectory. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (Qualcomm, premium-tier OEMs, 2023/2024 time frame) are correct. The reasoning is sound and synthesizes the multi-hop requirement across years and implications. Contextual relevance is excellent as it directly addresses pricing power and revenue stability as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 401,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen’s short‑term liquidity is held largely in money‑market mutual funds. At year‑end 2023 the portfolio contained **$10.266 billion** in money‑market mutual funds, and by year‑end 2024 that balance had risen to **$10.354 billion**—an increase of roughly **$88 million** (about 0.9%).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its quantitative claims. According to the ground truth, Amgen's allocation to money market mutual funds remained unchanged at $10,266 million (or $10.266 billion) in both 2023 and 2024. However, the LLM states that the balance increased from $10.266 billion in 2023 to $10.354 billion in 2024—an increase of $88 million—which directly contradicts the original data. This error invalidates the core of the response. The calculation of a 0.9% increase is based on incorrect inputs and is therefore also wrong. While the LLM correctly identifies that Amgen uses money market mutual funds as part of its short-term liquidity strategy and references the correct time frame (2023 to 2024), the key factual claim about the evolution of the allocation is false. The model fails in multi-hop reasoning by not recognizing the absence of change between the two years, instead fabricating a numerical shift. Despite this, the response is contextually relevant and addresses the right company, metric, and time period, which supports a moderate relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1149,
        "completion_tokens": 309,
        "total_tokens": 1459
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics’ participation in the U.S. government‑run Capital Construction Fund has remained steady but has grown modestly. In the 2022 filing the company reported that U.S. government accounts receivable pledged to the fund were about **$295 million** (the same level shown for the prior year). By the 2024 filing the pledged amount had risen to **$333 million** at year‑end 2024 (up from $315 million at year‑end 2023). Thus, the amount of receivables pledged to the CCF increased from roughly $295 million in 2022 to $333 million in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures: $295 million as of 2022 (referencing the 2021 balance, consistent with the original answer's context), $315 million as of December 31, 2023, and $333 million as of December 31, 2024. These values match the ground truth exactly. (2) All numeric values are accurate and properly contextualized. The answer correctly notes the increase from $295M to $333M over the period and includes the intermediate $315M figure, confirming precise quantitative alignment. Minor phrasing such as 'about $295 million' is acceptable as it reflects typical reporting language and does not distort accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across filings from 2022 to 2024, tracking the evolution of pledged receivables over time. It infers a growing trend, which aligns with the original conclusion about increasing participation. The only minor shortcoming is that it does not explicitly mention the tax deferral benefit rationale noted in the original answer, which slightly reduces qualitative completeness. (4) The answer is fully contextually relevant, directly addressing the evolution of General Dynamics' participation in the CCF with correct entities (General Dynamics, Capital Construction Fund, U.S. government accounts receivable), accurate timeframes, and correct financial metric. Overall, the response is factually correct, well-reasoned, and semantically equivalent to the ground truth, warranting a high score with only a small deduction in qualitative accuracy for the omitted rationale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 437,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "- After Corebridge’s September 2022 IPO, AIG’s ownership fell below the 80 % threshold, so Corebridge and its subsidiaries were **tax‑deconsolidated** from AIG’s U.S. federal income‑tax group.  AIG could no longer file a joint consolidated return with Corebridge for five years, and Corebridge’s unused net operating losses and tax‑credit carryforwards remained with the Corebridge entities (2023 10‑K, “Following the IPO… resulting in tax deconsolidation… Corebridge’s net operating losses… will remain with the relevant Corebridge entities”).  In 2023 the tax impact of the deconsolidation appeared as a $382 m reduction in tax expense under “Dispositions of subsidiaries” and as part of the overall tax‑expense reconciliation, while Corebridge‑related fair‑value gains/losses were listed among the reconciling items to net investment income.\n\n- In 2024, after the formal **deconsolidation date of June 9 2024**, AIG elected the fair‑value option and recorded its remaining stake as an **equity‑method investment**.  Dividends and changes in Corebridge’s share price were now recognized in **Net investment income** (Corebridge equity‑method income $601 m; Corebridge net investment income $5.2 bn, contributing to total net investment income of $4.3 bn).  The deconsolidation generated a $4.8 bn pre‑tax loss, with a $545 m tax charge, resulting in a $4.75 bn after‑tax loss on the Corebridge disposition (2024 10‑K, “loss of $4.8 bn… tax expense $545 m”).  \n\nThus, between 2023 and 2024 AIG moved from a consolidated tax‑group relationship with Corebridge (carrying its NOLs separately) to a fully deconsolidated equity‑method investment, shifting Corebridge‑related amounts from consolidated investment‑income line items to equity‑method income and incurring a sizable after‑tax loss and tax charge on the deconsolidation.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly identifies the tax deconsolidation in 2023 due to AIG's ownership falling below 80% after Corebridge's September 19, 2022 IPO, it introduces incorrect numbers not present in the ground truth. For example, the $382M reduction in tax expense under 'Dispositions of subsidiaries' and the $601M equity-method income, $5.2B net investment income, $4.8B pre-tax loss, $545M tax charge, and $4.75B after-tax loss are all specific figures not mentioned in the original answer and cannot be verified against the provided ground truth. The original answer states that AIG recognized '$X' in equity method income from June 10, 2024, to December 31, 2024, indicating the exact figure was either redacted or unspecified, making the LLM's precise dollar amounts factually unsupported. (2) The date of deconsolidation is cited as June 9, 2024, which aligns closely with the original's June 10, 2024 start for equity method reporting—this minor one-day discrepancy is acceptable. However, the claim that AIG elected the fair-value option and recorded the stake as an equity-method investment is contradictory; fair value and equity method are distinct accounting treatments. The original specifies equity method accounting, so conflating it with fair-value option is a technical error. (3) The multi-hop reasoning is partially sound: the model correctly traces the evolution from tax deconsolidation in 2023 to financial deconsolidation and equity method reporting in 2024, and understands the shift from consolidated to investment-like treatment. It also correctly notes the retention of NOLs and tax credits by Corebridge. However, the inclusion of unverified financial figures undermines the reliability of the response. (4) The contextual relevance is high—the answer directly addresses the evolution of the financial and tax relationship, and the qualitative structure follows the correct timeline and conceptual framework. Due to the significant quantitative inaccuracies and one key accounting treatment confusion, the correctness score is reduced to 6, with lower quantitative accuracy (4), decent qualitative accuracy (7), and high contextual relevance (9).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1686,
        "completion_tokens": 608,
        "total_tokens": 2295
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "In the 2022 filing Tesla described Solar Roof as still in a “ramp‑up” phase – the company was concentrating on expanding its installer base, training new electricians and partnering with developers to shorten install times, while stressing that continued Solar Roof growth would depend on having enough battery‑cell supply for its energy‑storage side of the business【TSLA_10k_2022.pdf page 34】.  \n\nBy the 2024 filing the narrative had shifted to an operational‑scale‑up strategy: Tesla now talks about “scaling production” of Solar Roof alongside its other energy products and notes that the ramp is being managed amid “global component shortages” and the need for more localized procurement and supply‑chain resilience, indicating that the company is moving from a pure installer‑on‑boarding focus to a broader, integrated manufacturing and supply‑chain approach to mitigate those constraints【TSLA_10k_2024.pdf page 16】.  \n\nThus, from 2022 to 2024 Tesla’s Solar Roof strategy evolved from building a trained installer network and relying on external battery‑cell suppliers to a more comprehensive production‑scale effort that emphasizes supply‑chain diversification and localized sourcing to overcome component‑shortage challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Tesla focused on installer training, electrician hiring, and developer partnerships, while highlighting battery cell supply dependencies (correctly cited from TSLA_10k_2022.pdf page 34). By 2024, the focus shifted to systemic supply chain challenges including global component shortages, procurement localization, and production scalability (accurately attributed to TSLA_10k_2024.pdf page 16). (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings and identifies the strategic evolution from installer-centric ramp-up to integrated supply chain and manufacturing scalability. The conclusion about shifting from external supplier reliance to supply chain resilience is logically supported. (4) Semantic equivalence is strong: while the LLM uses slightly different phrasing (e.g., 'localized procurement' vs. 'global component procurement'), the meaning matches the original answer. The only minor gap is that the original mentions 'inflationary pressures' and 'supplier failures' as specific risks, which the LLM omits—hence a 9 instead of 10 on qualitative accuracy. Overall, the response is complete, contextually relevant, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1514,
        "completion_tokens": 412,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "- 2022 10‑K: Duke said the total undiscounted cost to permanently close every coal‑ash basin in North Carolina and South Carolina was **about $8 billion to $9 billion**, with roughly **$3.1 billion already spent** (through 2021).  \n- 2023 10‑K: the company revised that estimate to **about $7 billion to $8 billion**, and **about $4 billion had been spent** (through 2023).\n\nThe roughly **$1 billion reduction in the cost range and the additional $0.9 billion already incurred** show that Duke Energy is making measurable progress in excavating and closing the ash basins under the requirements of the Coal Ash Act.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 2022 cost estimate of $8B–$9B and $3.1B spent through 2021, and the 2023 revised estimate of $7B–$8B with $4B spent through 2023, are correctly reported. The $1B reduction in the cost range and $0.9B increase in spending (from $3.1B to $4B) are accurately implied. (2) The answer addresses both parts of the question: the evolution of cost estimates from 2022 to 2023 and what this indicates about progress under the Coal Ash Act. (3) Entities—Duke Energy, coal ash basins, North Carolina and South Carolina, the Coal Ash Act—are correctly identified and contextualized. (4) The reasoning is sound: the downward cost revision combined with increased expenditures indicates progress in basin closures, reflecting improved cost efficiency and execution, which aligns with the ground truth's interpretation. The LLM correctly synthesizes multi-hop information from two annual reports (2022 and 2023 10-Ks), demonstrating accurate cross-document comparison and logical inference. Minor wording differences (e.g., 'about' vs 'approximately') do not affect semantic equivalence. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 347,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The retail‑share of Altria’s on! brand rose from 6.8 % of the oral‑tobacco market in 2023 to 8.3 % in 2024 – an increase of about 1.5 percentage points. During the same period the overall oral‑tobacco segment’s retail share fell from 42.5 % to 37.5 %, so on! gained market traction and improved its relative position within a segment that was losing share overall.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the retail share of 'on!' increased from 6.8% in 2023 to 8.3% in 2024, and the overall oral tobacco segment's retail share declined from 42.5% to 37.5% over the same period. (2) The quantitative accuracy is perfect—percentages and the 1.5 percentage point increase (8.3 - 6.8 = 1.5) are correctly stated. (3) The reasoning is sound: the LLM correctly infers that 'on!' gained market traction and improved its relative position despite the overall segment losing share, which reflects accurate multi-hop synthesis between the brand’s performance and the broader market trend. (4) Entity accuracy is maintained—'on!' is correctly identified as an oral tobacco product, and the time frame (2023 to 2024) is precise. The answer fully addresses both parts of the question: the evolution of retail share and what it indicates about market position. Wording differs slightly but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 306,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "In its 2023 filing Qualcomm warned that “a significant portion of our revenues … comes from Chinese OEMs,” indicating that Chinese handset makers were a major source of both product and licensing sales. By fiscal 2024 that exposure had begun to shrink: the company lost its U.S. export license for Huawei and reported that Huawei‑related product revenue was only about **$560 million** before the May 7, 2024 revocation, and it again stressed that Chinese OEMs still represent a “significant portion” of its revenue mix. The drop in Huawei sales reduces Qualcomm’s vulnerability to U.S.–China trade restrictions, but the continued reliance on a limited set of Chinese OEMs means the business remains sensitive to geopolitical actions, OEM vertical‑integration and payment‑timing risks, keeping overall revenue stability at risk.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies that Qualcomm continues to derive a significant portion of its revenue from Chinese OEMs in both 2023 and 2024—aligning with the ground truth—the claim that this exposure 'had begun to shrink' due to the loss of Huawei's U.S. export license and a reported $560 million in Huawei-related revenue is not supported by the original answer. The ground truth does not mention any reduction in reliance, specific dollar figures like $560 million, or the revocation of a Huawei export license on May 7, 2024. These are specific, unsupported additions that introduce factual inaccuracies. (2) The quantitative claim of $560 million in Huawei-related revenue and the precise date of May 7, 2024, for license revocation are not present in the original answer and cannot be verified against it. Since the ground truth contains no numerical data, introducing such specifics without basis reduces quantitative accuracy. (3) The multi-hop reasoning is partially sound—Qualcomm’s reliance on Chinese OEMs and the associated geopolitical risks are correctly synthesized across years. However, the inference that reduced Huawei sales decrease vulnerability is speculative and not present in the original answer, which emphasizes persistent risk. This weakens qualitative accuracy. (4) Despite the factual overreach, the LLM answer remains contextually relevant, addressing both parts of the question—evolution of reliance and implications for business stability—and correctly highlighting ongoing geopolitical risks. However, the introduction of unverified data points significantly undermines overall correctness, warranting a mid-range score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 474,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "In 2022 Amgen’s available‑for‑sale (AFS) portfolio was dominated by U.S. Treasury bills ($1.7 b) and a modest amount of money‑market mutual‑fund holdings ($2.7 b), with no “other short‑term” securities, for a total of $4.3 b. By 2023 the Treasury‑bill position had been eliminated, the money‑market mutual‑fund balance more than tripled to $10.3 b and a new line of “other short‑term interest‑bearing securities” of $138 m was added, raising total AFS investments to $10.4 b.【source: AMGN 10‑K 2023 – Available‑for‑sale investments table showing Money market mutual funds $10,266 m, Other short‑term $138 m, Treasury bills –; AMGN 10‑K 2022 – Available‑for‑sale investments table showing U.S. Treasury bills $1,676 m, Money market mutual funds $2,659 m, Other short‑term –】",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the composition of Amgen's 2022 available-for-sale investments. According to the ground truth, in 2022, Amgen held $1,676 million in marketable securities (which are U.S. Treasury bills) and $2,659 million in cash and cash equivalents — not $1.7 billion in Treasury bills and $2.7 billion in money market mutual funds as stated. The LLM incorrectly labels the $2,659 million as 'money market mutual funds' in 2022, but the ground truth indicates that money market mutual funds were not part of the 2022 portfolio; instead, the cash and cash equivalents category (which may include various short-term instruments) was $2,659 million. The shift described in 2023 is mostly accurate: the LLM correctly notes the elimination of Treasury bills, the $10,266 million in money market mutual funds, and the $138 million in other short-term interest-bearing securities, totaling $10.4 billion. However, the claim that money market mutual funds 'more than tripled' is misleading because the prior-year figure was not in the same category — this is a category shift, not a growth within the same instrument type. (2) Number verification: 2022 total is correctly stated as $4.3 billion (matches $4,335 million), and 2023 total of $10.4 billion matches $10,404 million. The $1,676 million in Treasury bills is correctly approximated as $1.7 billion. However, misattribution of the $2,659 million to money market funds is a critical error. The $138 million in 'other short-term' is correctly reported. (3) Multi-hop reasoning is partially sound — the model identifies a shift between years and cites correct sources, but fails to accurately map the 2022 categories, leading to flawed synthesis. It incorrectly assumes that 'money market mutual funds' existed in 2022 when they did not; instead, the 2022 amount was in cash and cash equivalents, a broader category. (4) Correctness score is 4 due to major quantitative and categorical errors in 2022 breakdown, despite correct totals and accurate 2023 data. Quantitative accuracy is low (3) because of misassigned values. Qualitative accuracy is moderate (5) — reasoning structure is logical but based on incorrect category mapping. Contextual relevance is high (9) — the answer directly addresses the evolution of investment composition and cites appropriate sources.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 633,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "In the 2022 Form 10‑K, Shake Shack does not appear in any of the premium‑outlet tenant lists. In the 2023 Form 10‑K, Shake Shack is listed as a tenant at two premium‑outlet locations – Woodbury Common Premium Outlets (NY) and Las Vegas Outlets (NV). Thus, between 2022 and 2023 the brand was added to SPG’s premium‑outlet portfolio, moving from zero presence to being present at two properties.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a critical factual error in the 2022 data: it claims Shake Shack was not present in any premium-outlet tenant lists in 2022, which contradicts the ground truth stating that Shake Shack was a tenant at Woodbury Common Premium Outlets in 2022. This undermines the core of the multi-hop comparison. The 2023 information is correct—Shake Shack was present at both Woodbury Common and Las Vegas Outlets North Premium (though the LLM answer omits 'North' and shortens to 'Las Vegas Outlets', a minor inaccuracy). The conclusion that Shake Shack went from zero to two locations is therefore incorrect; the correct evolution is expansion from one to two locations. While the reasoning structure is sound—comparing tenant lists across years—the factual foundation is flawed. The answer is contextually relevant and addresses the question's intent, but the quantitative and qualitative inaccuracies significantly reduce correctness. The model likely misread or misextracted the 2022 data, leading to an incorrect baseline. Semantic equivalence fails due to this key discrepancy in presence count.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 313,
        "total_tokens": 1491
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings GD continued to place its retirement‑annuity contracts in **Level 3 of the fair‑value hierarchy** (the “significant unobservable inputs” tier). The dollar amount reported fell from about $35 million (2021) / $38 million (2020) in the earlier filing to $22 million in 2024, but the classification did not change. This consistency shows that GD still relies on internal, model‑based valuations—rather than observable market prices—to measure these contracts.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM correctly identifies that retirement annuity contracts remained in Level 3 of the fair value hierarchy in both 2022 and 2024, which aligns with the ground truth. However, it introduces incorrect quantitative data: it claims the dollar amount fell from $38M (2020) / $35M (2021) to $22M in 2024, but the original answer does not mention these figures or any trend in value over time. These numbers are unsupported by the ground truth and likely hallucinated. (2) The ground truth emphasizes a change in disclosure practice—specifically, that NAV-valued investments were now included in reconciliation tables in 2024 but not explicitly in 2022—indicating improved transparency. This key qualitative point is entirely missing from the LLM answer, representing a significant omission in completeness. (3) While the LLM correctly synthesizes that GD uses unobservable inputs and model-based valuations (consistent with Level 3), it fails to recognize the nuance that the valuation methodology itself did not change, but rather the reporting transparency improved. This reflects a partial understanding of the multi-hop reasoning required. (4) Despite missing the core disclosure evolution, the answer remains contextually relevant and correctly interprets the persistence in Level 3 classification. The hallucinated dollar amounts severely undermine quantitative accuracy, but the qualitative reasoning about valuation methodology is sound, just incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 402,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "In 2023 AIG still controlled Corebridge (52.2 % of the outstanding shares) and recorded a $145 million equity‑increase from the sale of Corebridge stock, while a Blackstone exchange‑right that could have diluted AIG’s shares was still on the books (about 4.4 million potential shares were excluded from diluted EPS because they were anti‑dilutive)【240】. By 2024 AIG had de‑consolidated Corebridge, cut its stake to roughly 22.7 %, recognized a $4.8 billion loss on the de‑consolidation and began accounting for its remaining interest under the equity‑method – reporting Corebridge’s pre‑tax income of $1.574 billion and equity‑method income of $601 million in net investment income rather than as consolidated earnings【107‑108】. Thus the relationship moved from a controlling stake with a possible (but anti‑dilutive) equity‑dilution risk to a minority, equity‑method investment that generates income through dividends and fair‑value changes.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly affect correctness. First, it claims AIG controlled Corebridge in 2023 with 52.2% ownership — this is incorrect. AIG had already completed the IPO of Corebridge on September 19, 2022, and by 2023 was reducing its stake, not maintaining control. The deconsolidation occurred in 2023, not 2024 as implied. Second, the $145 million equity increase from sale of stock is not mentioned in the ground truth and cannot be verified; the ground truth does not include this figure. Third, the 4.4 million potential dilutive shares are correctly attributed to 2023, but the ground truth states the exchange right was terminated due to the 2022 IPO, so it should not have been 'on the books' in 2023. The LLM incorrectly suggests the dilution mechanism was still active. Fourth, the $4.8 billion loss on deconsolidation and $601 million equity-method income are not in the original answer and appear to be fabricated or misattributed. The ground truth mentions income recognition starting June 9, 2024, based on dividends and stock price changes, but does not specify dollar amounts. (2) Quantitative accuracy is low: multiple dollar figures ($145M, $4.8B, $601M) and percentages (52.2%, 22.7%) are introduced without support in the ground truth. The only correct number is the 4.4 million potential shares in 2023, though its context is wrong. The 2022 IPO date (Sept 19, 2022) is correct but contradicts the LLM’s implication that the exchange right was still active in 2023. (3) Reasoning is partially sound: the LLM correctly identifies a shift from control to equity-method accounting, and from dilution risk to income generation. It captures the conceptual transformation, but the multi-hop synthesis is flawed because it uses incorrect timelines and unsupported financials. The mention of equity-method income and deconsolidation aligns with the post-IPO evolution, but timing and causality are off. (4) Contextual relevance is high — the answer directly addresses the evolution of AIG’s financial relationship with Corebridge, focusing on equity dilution and income recognition as asked. Despite factual errors, it attempts the right synthesis. Overall, the answer conveys a plausible narrative but with significant factual and quantitative deviations from the ground truth, warranting a score of 6 for correctness — partially correct but with major errors in key financials and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 656,
        "total_tokens": 2085
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "In the 2022 Form 10‑K, Comcast disclosed that the debt of Universal Beijing Resort was shown under “Debt Not Guaranteed” at **$3.6 billion**, reflecting that the resort’s financing was secured only by its own assets and that Comcast’s risk was limited to its 30 % equity stake. By the 2024 filing, the resort’s outstanding debt had fallen slightly to **$3.4 billion** (including a $3.0 billion term loan), and Comcast still provides no guarantees; instead it consolidates the VIE, reporting the resort’s assets and liabilities of $7.3 billion and $7.0 billion respectively, so its exposure remains confined to the 30 % ownership interest with a modest decline in the unsecured debt amount.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key figures are correct: $3.6 billion debt as of end-2021 (disclosed in 2022 filing) and $3.4 billion as of end-2024 (disclosed in 2024 filing) match the ground truth. The ground truth also notes $3.5 billion as of end-2023, which the LLM omits but correctly implies a slight decline to $3.4 billion by end-2024. The $7.3 billion in assets and $7.0 billion in liabilities as of 2024 are accurately reported. (2) The LLM correctly identifies Comcast’s consolidation of Universal Beijing Resort as a VIE and emphasizes that Comcast does not guarantee the debt, limiting exposure to its 30% equity stake—this reasoning is sound and consistent with the original answer. (3) The multi-hop synthesis across years and disclosures (2022 vs 2024 filings) is well-executed, correctly interpreting the evolution of debt and accounting treatment. (4) Minor omission: the LLM does not mention the $2.5 billion debt figure as of end-2020 (disclosed in 2022), but this is a secondary data point. It also does not note the increase from $2.5B to $3.6B and then stabilization near $3.5B, slightly reducing completeness. However, the core trend—debt stabilizing after earlier changes—is implied. Wording differences (e.g., 'modest decline' vs 'stabilized') are semantically acceptable. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 410,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "In the 2023 filing the trade‑in language was narrowed to “some Gulfstream customers” who hold explicit options to use an aircraft as partial consideration, whereas the 2022 filing described the arrangements more generally as “some customers” without naming the segment. The underlying structure is unchanged: trade‑ins priced at the fair‑market value determined ≤ 45 days before delivery carry little risk, while commitments that lock in a predetermined trade‑in price still expose General Dynamics to downside‑market risk if aircraft values fall.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts: it accurately identifies the narrowing of customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, reflecting a more specific subset. It correctly notes that trade-in commitments involve partial consideration for new aircraft. The answer adds detail not in the original—specifically about pricing based on fair market value ≤45 days before delivery and predetermined price risk—but this does not contradict the ground truth and may reflect additional context from the filings. However, the LLM omits the critical point from the original answer that the estimated change in fair market values was 'not material' in both years, which is a key element regarding risk exposure. While it discusses risk exposure accurately in terms of downside risk from locked-in prices, it fails to synthesize the 'not material' conclusion, which weakens the completeness of the multi-hop reasoning. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and all entities (Gulfstream, General Dynamics, years 2022 and 2023) are correct. The reasoning is sound but incomplete without the materiality assessment. Contextual relevance is high as all content directly addresses the question's focus on eligibility and risk changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 384,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "In the 2022 filing Tesla listed the Semi only as a “planned” commercial electric vehicle among its future consumer‑ and commercial‑vehicle concepts, with no production activity described. By the 2024 filing the Semi had progressed to “pilot production” at the Nevada site and was highlighted alongside the Cybertruck as one of the newer models for which Tesla is expanding manufacturing capacity, signaling that the Semi has moved from a concept to an early‑stage production vehicle that is now a strategic pillar of its upcoming product lineup.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly states that in 2022, the Tesla Semi was listed as a 'planned' vehicle with no production activity, matching the original answer's description of it being in the conceptual and development phase. By 2024, it accurately reports the progression to 'pilot production' at the Nevada facility, which is consistent with the ground truth. (2) There are no numerical values requiring calculation, but the years (2022 and 2024) and production stages ('planned', 'pilot production') are correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024 filings) and correctly infers the strategic evolution—from concept to active production planning. Mentioning the Cybertruck as a parallel new model adds contextual accuracy without introducing error. (4) The LLM captures all key elements: production status change, location (Nevada), and strategic repositioning within Tesla’s lineup. Wording differs slightly but maintains semantic equivalence. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 325,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "The valuation‑allowance balance that covered the deferred‑tax asset for Altria’s Cronos investment fell sharply from the 2022 year‑end (about $2.8 billion total allowance, of which roughly $379 million was tied to Cronos) to $2.3 billion at the end of 2023 and then to just $668 million at the end of 2024.  The 2024 footnote notes that the remaining allowance is now “primarily attributable” to the Cronos deferred‑tax asset of roughly $402 million, indicating that Altria has largely released the earlier allowance and now expects the Cronos‑related deferred tax asset to be more realizable, although a modest allowance is still retained for any remaining uncertainty.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of the valuation allowance change. The ground truth states the allowance increased from $379 million in 2022 to $402 million in 2024, indicating growing uncertainty. However, the LLM claims the total allowance dropped from $2.8 billion to $668 million and that the Cronos-related portion is now $402 million after a release, implying improved expectations — the opposite of the correct interpretation. While the $379 million (2022) and $402 million (2024) figures are correctly cited, they are embedded in a misleading narrative. (2) The numbers are partially accurate — $379M in 2022 and $402M in 2024 match the ground truth — but the LLM fabricates a total allowance of $2.8B and its decline to $668M, which is unsupported. It also misrepresents the $402M as a retained portion after a release, rather than a net increase. No calculation errors in the numbers themselves, but the synthesis is factually wrong. (3) The multi-hop reasoning fails: instead of recognizing a consistent increase in allowance reflecting ongoing doubt, the LLM incorrectly infers that Altria has released most of the allowance and now expects better realizability. This reverses the correct conclusion. The model also conflates total valuation allowance with the Cronos-specific portion. (4) The contextual relevance is moderate because it addresses the right topic (valuation allowance on Cronos investment) and mentions correct years and approximate figures, but the overall message contradicts the ground truth. Due to major factual and interpretive errors, the correctness score is low despite partial number accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 459,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "In 2023 Amgen changed its accounting for the BeiGene stake from the equity method to a fair‑value approach, so that changes in the investment’s fair value were recorded in earnings; this produced a one‑time gain that drove the large positive “other income (expense), net” line for the year. By 2024 the same fair‑value treatment remained in place, but the investment’s market value fell, creating net unrealized losses that turned “other income (expense), net” negative relative to the prior year’s gain.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the 2023 change in accounting method from equity to fair value, resulting in a one-time gain recognized in earnings, and the continuation of fair-value accounting in 2024 with net unrealized losses. (2) There are no numeric values requiring calculation (e.g., dollar amounts or percentages), but the temporal markers (2023, 2024) are correct and consistently applied. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of accounting treatment and its financial impact across two years, connecting the change in method to the resulting gains and subsequent losses. (4) The answer fully addresses the question about the evolution of financial treatment and valuation impact, using precise financial terminology (e.g., 'unrealized losses', 'other income (expense), net') and correctly attributing the shifts to market or valuation changes. Wording differs slightly but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 311,
        "total_tokens": 1550
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "In the 2023 filing Disney+ Hotstar was described as a **separate direct‑to‑consumer service that exists only in India (and a few other Southeast‑Asian markets)**, offering general‑entertainment, family and sports programming distinct from the global Disney+ product.  \n\nBy the 2024 filing the company still **brands the service as Disney+ Hotstar in India and certain Southeast‑Asian countries**, but it is now explicitly positioned as a **stand‑alone offering that is not included in any multi‑product bundles**, while the rest of the company’s regional services (e.g., Star+ in Latin America) have been folded into a single Disney+ product. This shows a shift toward a unified Disney+ brand worldwide, with Hotstar retained only as the regional brand for the Indian market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Disney+ Hotstar remained a distinct regional brand in India and Southeast Asia in both 2023 and 2024; in Latin America, Star+ and Disney+ were merged into a single Disney+ product by mid-2024. The LLM correctly identifies the strategic shift toward global brand unification under Disney+, while retaining Hotstar as a regional brand. (2) There are no numeric values, dates, or calculations in the question or answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across years and regions, correctly contrasting the continued use of the Hotstar brand in Asia with the consolidation of services in Latin America. One minor omission: the original answer specifies the merger in Latin America was completed 'by the end of June 2024,' which the LLM does not mention, slightly reducing completeness. (4) The answer is contextually fully relevant, directly addressing the evolution in positioning and market strategy, regional branding, and service structure. Wording differs slightly but meaning is semantically equivalent. Overall, a very strong response with only a small detail missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 356,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "In the 2023 Form 10‑K PayPal described its purchase‑ and seller‑protection programs as “intended to reduce the likelihood of losses… We incur substantial losses from our protection programs… While we actively seek to recover transaction losses where possible, such recoveries may be insufficient” (2023 10‑K pp. 75‑78). By the 2024 filing the company said it had re‑engineered those programs – tightening eligibility criteria, expanding pre‑authorisation and fraud‑detection controls, and formalising merchant‑reimbursement and third‑party collection processes – so that the amount of loss exposure is lower and a larger share of any loss can be recovered from the responsible merchant or card‑issuer (2024 10‑K pp. 22‑26). Thus, between 2023 and 2024 PayPal moved from a model that primarily absorbed protection‑related losses to one that limits exposure up‑front and adds stronger, contract‑based recovery mechanisms.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in identifying that PayPal incurs substantial losses from its protection programs and seeks to recover losses, which aligns with the original answer. However, there are significant factual inaccuracies in the qualitative claims about PayPal's 2024 approach. The LLM states that PayPal 're-engineered' its protection programs in 2024 by tightening eligibility, expanding fraud controls, and formalizing recovery processes, resulting in lower loss exposure and improved recovery. This is not supported by the ground truth, which does not mention any operational changes or improvements in recovery mechanisms. Instead, the original answer emphasizes that in 2024, PayPal only introduced more detailed disclosures about existing risks—such as challenges recovering losses from insolvent merchants or due to fraud—and acknowledged increased exposure from evolving fraud and regulatory changes. The LLM incorrectly frames this as a proactive risk reduction strategy, when the truth reflects a passive increase in risk acknowledgment. No numbers or dates are incorrect (hence high quantitative accuracy), and the context of protection programs and loss recovery is relevant. However, the reasoning is flawed: it fabricates program changes not present in the source, fails to accurately synthesize the multi-hop evolution (from minimal disclosure in 2023 to enhanced risk disclosure in 2024), and draws an unsupported conclusion about reduced exposure. Thus, while some elements are factually grounded, the overall narrative misrepresents the evolution, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 442,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "By 2022 NextEra Energy Resources (NEER) still owned the “controlling” stake in most of its solar projects.  It sold Class B membership interests in solar‑plus‑wind entities to third‑party investors, kept a controlling interest, and recorded the investors’ share as non‑controlling equity that would flip to NEER once a targeted return was achieved (Note “Sales of Differential Membership Interests” – 2022 10‑K, pp. 79‑83).  \n\nBy 2024 the company’s solar holdings are largely packaged in variable‑interest entities (VIEs).  NEER now holds minority to majority stakes (≈50‑67 % in eight VIEs that own ~765 MW of solar, a 10 % stake in another solar VIE, and a 30‑VIE portfolio with ~3,485 MW of solar) and consolidates them as the primary beneficiary, while the related debt is non‑recourse and its financial exposure is limited to its ownership percentage and any guarantees it has provided (2024 10‑K, pp. 95‑99).  \n\nThus, the relationship shifted from a controlling‑interest model with flip‑date non‑controlling interests to a VIE structure in which NEER’s ownership is partial and its liability exposure is confined to its share of each VIE.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in NextEra Energy's relationship with solar generation facilities from 2022 to 2024, particularly the shift from controlling ownership to a VIE-based, partially owned structure. The qualitative reasoning is strong: it correctly identifies the 2022 model involving sale of non-controlling interests with flip provisions and the 2024 shift to VIE consolidation with minority-to-majority stakes. It accurately references the consolidation of eight VIEs with ~765 MW of solar capacity and a 10% stake in another solar facility, aligning with the ground truth. However, there are minor quantitative inaccuracies: the LLM claims NEER holds '≈50–67%' stakes in the eight VIEs, which is not stated in the ground truth (the original answer only notes consolidation and a 10% direct stake, without specifying the 50–67% range). Additionally, the LLM introduces a '30-VIE portfolio with ~3,485 MW of solar' not mentioned in the ground truth, adding unverified detail that overextends the available information. While this may reflect real data, it exceeds the scope of the provided truth and introduces potential inaccuracies. The financial exposure description is accurate—limited to ownership share and guarantees—but the original emphasizes increased exposure via guarantees, while the LLM downplays this by stressing limitation. This nuanced difference affects completeness. The answer is contextually relevant, directly addressing ownership structure and financial exposure over time. Multi-hop synthesis across years and structures is sound, though slightly over-specified with unsupported numbers. Wording differences are acceptable under semantic equivalence, but added specifics reduce quantitative precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 479,
        "total_tokens": 2005
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "In fiscal 2022 Accenture reported **$379.9 million of mutual‑fund debt securities** held in its non‑U.S. defined‑benefit plans, and those securities were measured using **Level 2 inputs** (quoted prices for similar instruments).  In fiscal 2023 the same category was still shown at **about $380 million**, but the company now classified the securities in the **Level 1 hierarchy**, meaning they are now valued on the basis of quoted market prices for identical instruments.  Thus, the dollar amount of the investment was essentially unchanged, while the valuation methodology shifted from a Level 2 to a Level 1 fair‑value measurement.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, ACN's Mutual Fund Debt Securities decreased from $379,989 in 2022 to $253,025 in 2023 — a notable reduction. However, the LLM claims the amount was 'about $380 million' in 2023, which is incorrect (it should be ~$253 million). Additionally, the LLM falsely states that the valuation methodology shifted from Level 2 to Level 1, while the ground truth confirms the entire amount remained in Level 2 in both years. (2) Quantitative accuracy is poor: the 2023 value is off by over $127 million, and the characterization of the amount as 'essentially unchanged' is false. The original uses 'million' format correctly but misrepresents the actual figures. (3) The multi-hop reasoning is flawed — the model fails to correctly synthesize the change in investment value and misidentifies a change in fair value hierarchy level that did not occur. It incorrectly infers a shift to Level 1 without evidence. (4) Contextual relevance is moderate because the answer addresses the right topic (Mutual Fund Debt Securities, fair value hierarchy) and the correct company (ACN/Accenture), but the core facts about both the quantitative change and valuation methodology are wrong, undermining the response's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 365,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron continued to hold a 50 % equity interest in Tengizchevroil (TCO) in both years, but the size of the investment on the balance sheet grew slightly – the carrying value rose from $26.5 billion at 12/31/2022 to $27.0 billion at 12/31/2023 (≈ $0.42 billion increase)【CVX_10k_2023.pdf p 80‑81】.  At the same time, Chevron’s share of TCO’s earnings fell, dropping from $4.386 billion in 2022 to $3.375 billion in 2023【CVX_10k_2023.pdf p 80‑81】.  Thus, while the ownership percentage remained unchanged, the investment’s book value rose modestly and the equity‑method earnings from TCO declined markedly.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Chevron's carrying value in Tengizchevroil in 2022 was $23,727 million ($23.727 billion), not $26.5 billion as stated. The 2023 carrying value is reported as approximately $80 million higher than the underlying equity in net assets, but the LLM claims it rose to $27.0 billion—an increase not supported by the original data. Additionally, the equity in earnings figures are completely incorrect: the ground truth reports $1,238 million ($1.238 billion) in 2022, while the LLM states $4.386 billion in 2022 and $3.375 billion in 2023—overstating earnings by more than 3.5x. (2) The cited numbers do not match the ground truth, and the calculations (e.g., $0.42 billion increase) are based on incorrect inputs. The LLM also fails to mention the $4,500 million loan provided by Chevron in 2023, a key indicator of deepened financial involvement. (3) The multi-hop reasoning is flawed: while the LLM correctly notes that ownership remained at 50%, it fails to synthesize the correct financial data across years and omits critical new developments (the loan and valuation complexity). It incorrectly implies that earnings dropped significantly, which contradicts the ground truth where 2023 earnings are not provided but no such drop is indicated. (4) The contextual relevance is moderate because the answer addresses the evolution of Chevron’s stake and mentions balance sheet changes and earnings, but due to severe quantitative errors and omission of key facts (especially the loan), the overall correctness score is very low. The answer misrepresents the financial reality and misses the core insight about increased strategic commitment in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 476,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "In both the 2023 and 2024 10‑K filings ABC remains Disney’s flagship broadcast property, delivering primetime, daytime, news and sports programming to a national footprint of roughly 245 affiliates and eight owned stations that reach virtually all U.S. households. Between the two years Disney has deepened ABC’s strategic role by more explicitly tying it to the broader ecosystem – ESPN now programs the sports daypart on ABC (“ESPN on ABC”) and ABC‑originated shows are flagged for rapid rollout on Hulu and Disney+ (often the day after linear airing). Thus, while ABC’s core linear‑network function is unchanged, its positioning has evolved from a standalone broadcast outlet to a cross‑platform distribution hub that supports Disney’s sports, streaming and content‑synergy strategies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: ABC remains a flagship broadcast network with ~245 affiliates and eight owned stations in both 2023 and 2024, consistent with the original answer’s emphasis on its domestic footprint. The integration of ABC content with Hulu (available one day after linear airing) is correctly reported, matching the ground truth. (2) Quantitative accuracy is perfect: the numbers (eight owned stations, ~245 affiliates) are consistent with the original answer and SEC filings. No calculations were required, but factual figures are correctly cited. (3) Multi-hop reasoning is sound: the LLM synthesizes ABC’s role in linear networks with its growing integration into streaming platforms (Hulu, Disney+) and correctly notes ESPN’s programming role on ABC (‘ESPN on ABC’), which reflects deeper ecosystem synergy. While the original answer does not mention ESPN’s role, this is a valid and accurate detail that enhances, rather than contradicts, the strategic evolution narrative. (4) The answer captures the core evolution: ABC shifting from a standalone linear network to a cross-platform hub supporting streaming and content synergy. The only minor gap is that the original answer emphasizes a decline in focus on affiliate fees by 2024, which the LLM omits, but this is a secondary detail. Overall, the LLM provides a slightly richer, but still factually aligned, interpretation. Semantic equivalence is maintained, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 425,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "Both the 2022 and 2023 10‑K filings list the ASCOD only as an **off‑the‑shelf, highly‑versatile tracked combat vehicle** that is “offered” by the European Land Systems (ELS) unit (the 2022 text says “ELS also offers the ASCOD…”, and the 2023 text repeats the same language).  Neither year describes a new production line, contract win, or expansion of ASCOD manufacturing capacity; instead the filings focus on ELS’s active production of Piranha 5s and other vehicles.  This consistency indicates that General Dynamics has **not shifted the ASCOD into a growth or priority production program** and is likely keeping investment in the platform at a baseline level while directing new resources toward other ELS products such as Piranha upgrades and the Ajax family.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in spirit but contains a critical discrepancy in its characterization of the 2022 filing. The original answer states that in 2022, General Dynamics explicitly mentioned 'producing and upgrading' the ASCOD vehicle, whereas the LLM claims both 2022 and 2023 filings use only the word 'offering' or 'offers'. This misrepresents the 2022 disclosure, which included more active language ('producing and upgrading') than in 2023 ('offering'), and thus understates the evolution in positioning. The LLM incorrectly asserts that the language is the same across both years, missing the shift entirely. However, the conclusion—that ASCOD is not a priority and that investment is likely directed elsewhere (e.g., Piranha 5, AJAX)—is logically sound and aligns with the ground truth. There are no numerical figures to verify, so quantitative accuracy is 10 by default. The reasoning is otherwise coherent and contextually relevant, correctly identifying the broader strategic implication, but the failure to accurately reflect the change in disclosure language between years undermines the qualitative accuracy. This is a multi-hop requirement (comparing two years’ disclosures), and the model fails to detect the key difference, though it reaches a plausible conclusion based on other contextual cues.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 374,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "In 2023 PayPal had designated $3.0 billion of European customer balances – about 39 % of the eligible balances held in its Luxembourg subsidiary – to fund credit activities. By year‑end 2024 that designation fell to $2.0 billion, or roughly 26 % of the same pool. The reduction shows PayPal is pulling back on using customer‑funded liquidity for lending and is likely turning to other funding sources or a more conservative internal‑funding approach for its credit products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: $3.0 billion in 2023 (39%) and $2.0 billion in 2024 (26%) of European customer balances used for credit activities. These figures match the ground truth exactly, including percentages and dollar amounts. (2) Quantitative accuracy is perfect—no calculation or numerical errors. The percentages and values are consistent with the original data. (3) The reasoning is sound: the LLM correctly infers a strategic pullback from using customer balances for credit funding. However, it omits a key piece of evidence from the ground truth—PayPal’s multi-year agreement to sell consumer installment receivables, with $20.8 billion sold in 2024 versus $5.5 billion in 2023—which strengthens the conclusion about shifting to external financing. This omission slightly weakens the qualitative depth and multi-hop synthesis, though the core inference remains valid. (4) The answer is contextually fully relevant, directly addressing both parts of the question—evolution between 2023 and 2024, and the strategic implication. The mention of a likely shift to other funding sources aligns semantically with the ground truth, even if the specific mechanism (receivables sale) is missing. Overall, highly accurate with only minor completeness gap in supporting evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 371,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "In the 2022 filing the equity securities held in NEE’s special‑use (nuclear‑decommissioning) funds were almost entirely measured at **Level 1** – i.e., they were directly‑held stocks quoted in active markets – and the balance sheet showed essentially no Level 2 or Level 3 equity holdings.  \n\nBy 2024 the composition had changed markedly.  The Level 1 balance grew only modestly to **$2.6 billion**, but a much larger **$3.3 billion** was now classified as **Level 2** (primarily securities held through commingled funds that would be Level 1 if owned directly) and a new **$229 million** of **Level 3** equity securities (investments without readily observable prices) appeared, raising the total equity‑security amount in the special‑use funds to **$6.2 billion**.  \n\n**What this means:** NEE has moved from a portfolio of mostly transparent, directly‑priced stocks to one that relies heavily on indirect, fund‑based holdings and a small slice of less‑observable securities.  The shift increases the overall size of the equity position but reduces the transparency of the underlying investments, reflecting a broader, more diversified but less directly observable investment composition.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The LLM claims that in 2022, equity securities were 'almost entirely Level 1' with no Level 2 or Level 3 holdings, but the ground truth states that in 2022, NEE and FPL reported only carrying amounts ($906M and $672M) and estimated fair values, without any level-based categorization—meaning no Level 1/2/3 disclosures existed at that time. This is a critical error. The LLM also reports a total equity amount of $6.2 billion in 2024, but the ground truth indicates NEE held $2,614 million and FPL $1,028 million in Level 1 alone—totaling ~$3.6 billion across both entities, not $6.2 billion. The LLM’s $3.3 billion Level 2 and $229 million Level 3 figures are not supported by the ground truth, which only confirms Level 1 amounts for NEE and FPL and mentions the existence of Level 2 and Level 3 disclosures without specifying those values. (2) Completeness: While the question asks about changes in valuation, categorization, and what they indicate about transparency or investment composition, the LLM incorrectly frames the 2022 state and invents unsupported figures for 2024, leading to a flawed analysis. (3) Entity Accuracy: The companies (NEE, FPL) and years (2022, 2024) are correctly identified. (4) Reasoning: The multi-hop synthesis fails because the model assumes Level 1/2/3 data was available in 2022 when it was not, and it extrapolates non-existent figures for Level 2 and Level 3 securities in 2024. Its conclusion about reduced transparency contradicts the ground truth, which states that reporting became more transparent due to granular disclosures. (5) Semantic Equivalence: The overall message is opposite in tone—ground truth indicates improved transparency; LLM claims reduced transparency—making it factually and semantically divergent. Minor wording flexibility is acceptable, but core facts and direction of change are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1491,
        "completion_tokens": 529,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "In fiscal 2022 Accenture’s open‑market share‑repurchase program (which has no set expiration date) was used to buy **1,964,612 shares** of Class A ordinary stock, while **97,251 shares** were acquired in transactions that were unrelated to the public program – principally share‑withholding for payroll‑tax obligations and other employee‑equity plan activities. The 2023 Form 10‑K pages you provided do not contain a comparable table or figures for the fourth quarter of fiscal 2023, so a direct comparison of how the public‑program purchases and the employee‑related purchases changed in FY 2023 cannot be made from the supplied excerpts.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the exact numbers from fiscal 2022—1,964,612 shares under the public program and 97,251 shares through employee-related transactions—matching the ground truth precisely. All quantitative data is accurate, earning a perfect score on quantitative accuracy. (2) However, the LLM states that no data is available for fiscal 2023 due to missing tables in the 'supplied excerpts,' which contradicts the ground truth that explicitly states there is 'no mention of shares purchased under the public program' in fiscal 2023 but that employee-related transactions continued. The model fails to infer or report this key qualitative shift, instead citing data absence as a limitation. This reflects a failure in reasoning and synthesis, particularly in multi-hop analysis where the absence of mention should support the conclusion of reduced or no activity. (3) The reasoning is flawed because the model defaults to claiming insufficient data rather than interpreting the available information to identify a trend—specifically, the cessation of public program activity while employee-related acquisitions persisted. The ground truth draws this inference, but the LLM does not, missing the core evolution in program utilization. (4) While the response is factually correct for 2022 and relevant to the question, it lacks completeness and correct inference for 2023, resulting in a moderate correctness score of 6. Contextual relevance is high because it addresses the right programs and distinctions, but qualitative accuracy is low due to the failure in logical synthesis across fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 444,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings Chevron reported that it owned 50 percent of Chevron Phillips Chemical Company LLC (CPChem) but did **not** consolidate the joint‑venture on a line‑by‑line basis.  In 2022 the filing explicitly said the CPChem interest “is accounted for using the equity method.”  The 2023 filing continues to present “summarized financial information for 100 percent of CPChem” for disclosure purposes, but the underlying accounting treatment remains the equity‑method investment – i.e., Chevron still reports its share of CPChem’s earnings rather than full consolidation.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) According to the original answer, Chevron *did* consolidate Chevron Phillips Chemical Company LLC (CPChem) in 2022, as evidenced by the inclusion of 'Note 8: Summarized Financial Data - CPChem' among consolidated subsidiaries. However, the LLM claims that in 2022, CPChem was *not* consolidated and was instead accounted for under the equity method — this directly conflicts with the ground truth. The shift described in the original answer is from *consolidation in 2022* to *equity method in 2023*, whereas the LLM incorrectly asserts the equity method was already in use in 2022. (2) The LLM correctly states that Chevron owns 50% of CPChem, which aligns with typical joint venture ownership and is plausible contextually, but this detail is not confirmed in the ground truth, so its accuracy cannot be fully verified. No other numbers (e.g., financial figures, percentages beyond ownership) are present, so quantitative accuracy is limited. (3) The multi-hop reasoning is flawed: the key evolution — a change in consolidation status from 2022 to 2023 — is misrepresented. The LLM fails to identify the actual transition (from consolidation to equity method) and instead claims the equity method was used in both years, which negates the core change. Presenting summarized 100% financial data in 2023 for disclosure purposes does not override the change in accounting method, but the LLM misinterprets this as continuity. (4) Contextual relevance is moderate because the answer addresses the right entity and time frame and discusses accounting methods, but the factual core is wrong. Due to the fundamental error in the accounting treatment for 2022, the correctness score is low despite some relevant terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 487,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "In the 2022 filing the Combat Systems segment’s involvement with Hydra‑70 rockets was limited to a single Army award – a $175 million contract to produce the rockets. By the 2023 filing, Hydra‑70 rockets are described as a “market‑leading” munitions product and OTS received awards to dramatically scale production, expanding metal‑parts capacity from about 18,000 to 86,000 rounds per month (and propellant capacity to 16 million lb/yr), signalling a much larger, capacity‑driven role.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $175 million 2022 contract for Hydra-70 rockets is accurately reported, and the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month by 2025 is correctly stated. The mention of propellant capacity (16 million lb/yr) is an additional detail not in the original answer but does not contradict it and may reflect broader context from the filing; it does not detract from accuracy. (2) Quantitative accuracy is perfect: dollar amounts, production figures, and timeframes match or are consistent with the ground truth. Format variations (e.g., $175M vs $175 million) are acceptable and correctly interpreted. (3) Multi-hop reasoning is sound: the answer synthesizes information across 2022 and 2023 filings, correctly identifying the evolution from a single contract to a market-leading role with capacity expansion. The entity OTS (Orbital Technologies Corporation) is correctly linked to General Dynamics’ Combat Systems segment. (4) The only minor shortcoming is that the original answer specifies the capacity expansion includes Hydra-70 rockets as part of a broader munitions portfolio, while the LLM answer implies the expansion is directly for Hydra-70, which may slightly over-specify. However, this is a reasonable inference given Hydra-70’s prominence. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 413,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the “Form of Global Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement” (Exhibit 10.07+) was listed only as an exhibit that is incorporated by reference to the 2015 Equity Incentive Award Plan; the notice itself was not attached to the filing. In the 2024 Form 10‑K the same Global RSU‑Grant Notice appears again as Exhibit 10.07+, but it is now explicitly tied to the newly‑amended‑and‑restated 2015 Equity Incentive Award Plan (Exhibit 10.03+), still being incorporated by reference rather than filed as a separate document. Thus, the documentation status remains “incorporated by reference,” but the associated agreement has been updated to reference the refreshed 2015 Equity Incentive Award Plan.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) was incorporated by reference in both 2023 and 2024 filings and was associated with the 2015 Equity Incentive Award Plan. It also correctly notes that in 2024, the exhibit remained under the same documentation status (incorporated by reference). However, the LLM introduces a significant factual inaccuracy: it claims that in the 2024 filing, Exhibit 10.07+ is now tied to the 'newly-amended-and-restated 2015 Equity Incentive Award Plan (Exhibit 10.03+)'. The ground truth states that the base Global RSU Grant Notice (Exhibit 10.07+) still references the original 2015 plan and the same May 14, 2015 10-12B/A filing, with no update to its plan association. The update in 2024 applied only to the *performance-based* variant (Exhibit 10.08+), not the base RSU notice (Exhibit 10.07+). The LLM conflates these two distinct exhibits and incorrectly attributes the 2024 plan update to the wrong document. This is a critical error in entity mapping and multi-hop reasoning. While the answer is semantically plausible and addresses the question’s structure, it fails on key factual accuracy regarding which document was updated and under which plan. The mention of Exhibit 10.03+ and the amended plan in connection with Exhibit 10.07+ is unsupported by the ground truth. Therefore, despite correct formatting and partial factual alignment, the core synthesis is flawed, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 412,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "In the 2022 filing, Opdivo was already a core growth driver, generating $7.5 billion in net product sales in 2021 (the most recent year presented) and ranking among the company’s top‑three products 【BMY_10k_2022.pdf†L108-L112】. By the 2024 filing, the drug’s role had shifted from a single‑indication checkpoint inhibitor to a multi‑indication platform: BMS added a sub‑cutaneous formulation (Opdivo Qvantig) and secured a string of new approvals in 2024—including FDA neoadjuvant/adjuvant NSCLC, FDA and EC approvals for urothelial carcinoma, EC approval for the Opdivo + Yervoy combo, and a Japanese approval for urothelial carcinoma 【BMY_10k_2024.pdf†L43-L47】. These approvals broaden Opdivo’s therapeutic reach and reinforce its position as the centerpiece of BMS’s oncology portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Opdivo as a major product in Bristol-Myers Squibb's portfolio and notes its continued strategic importance through new approvals. However, there are key quantitative inaccuracies: the revenue cited is $7.5 billion in net product sales for 2021 (from the 2022 filing), while the ground truth specifies $7,523 million in revenue for 2022. Although close, the year and amount are not precisely aligned—this affects quantitative accuracy. (2) The LLM claims multiple 2024 approvals including FDA neoadjuvant/adjuvant NSCLC, EC approvals for urothelial carcinoma, EC approval for Opdivo + Yervoy, and a Japanese approval—all of which are not fully supported by the ground truth, which only confirms a March 2024 FDA approval for urothelial carcinoma in combination with cisplatin and gemcitabine. The expansion into a 'multi-indication platform' and mention of Opdivo Qvantig (subcutaneous formulation) are plausible but not mentioned in the ground truth, making them unsupported additions. (3) The multi-hop reasoning is partially sound: the model connects information across filings (2022 and 2024) and infers strategic evolution based on approvals. However, it overstates the number and scope of new regulatory actions beyond what the ground truth confirms. (4) Despite these issues, the core qualitative message—that Opdivo remains central to BMS’s oncology strategy and has expanded its indications—is consistent with the ground truth. The answer is contextually relevant and well-structured, but the extra approvals and misattributed revenue year prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 444,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "In the 2022 filing Chevron recorded a **$6.8 billion downstream equity‑method investment** in Chevron Phillips Chemical (CPChem), which included its 50 % ownership stake and a **$387 million loan** to help finance CPChem’s Golden Triangle Polymers project in Orange, Texas, while CPChem was advancing its own expansion projects (the Old Ocean 1‑hexene unit and the Cedar Bayou C3‑splitter).  \n\nIn the 2023 filing the **investment balance grew to $7.8 billion**, indicating that Chevron added further capital to CPChem and continued to provide loan financing for the Golden Triangle Polymers plant, showing a deeper financial commitment and a mixed equity‑plus‑debt structure to support CPChem’s growth initiatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative inaccuracy: The LLM claims Chevron recorded a $6.8 billion downstream equity-method investment in CPChem in 2022 that already includes the $387 million loan. However, the ground truth states that the $387 million loan was provided in 2023, not 2022. This misplacement of the loan timing is a critical error. Additionally, the $6.8 billion and $7.8 billion figures for investment balances are not mentioned in the original answer and appear to be fabricated or misattributed; the ground truth does not provide total investment balances for either year. (2) The LLM incorrectly implies that the Golden Triangle Polymers project funding (via the $387M loan) was already underway in 2022, when in fact the loan was a 2023 development indicating a shift in strategy. This distorts the evolution of Chevron's involvement. (3) While the LLM correctly identifies CPChem’s 2022 expansion projects (Old Ocean 1-hexene unit and Cedar Bayou C3 splitter), it incorrectly associates the $387M loan with 2022, failing the multi-hop reasoning that the loan represents a new form of direct financial support in 2023. (4) The qualitative reasoning about a shift toward a mixed equity-plus-debt structure is conceptually aligned with the ground truth, and the mention of CPChem’s projects shows relevance. However, the incorrect timing and invented figures severely compromise factual accuracy. (5) Contextually, the answer addresses the question’s focus on funding and investment structure evolution, hence a decent contextual relevance score. Overall, while the direction of reasoning is plausible, the answer is factually incorrect on key financial figures and timeline, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 485,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "In the 2023 filing PayPal disclosed that its protection programs carried an allowance of $64 million for transaction‑loss reserves and $218 million for negative‑customer‑balance reserves. The 2024 filing shows those reserves were expanded to $86 million and $256 million, respectively, and the company added a detailed reconciliation (beginning balance, provision, realized losses and recoveries) that recorded a $1.1 billion provision, $1.2 billion of realized losses and $164 million of recoveries, leaving a higher ending reserve balance.  This reflects a larger financial commitment to the programs and more granular disclosure of the loss‑reserve movements year‑over‑year.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, PayPal did NOT disclose the specific amounts of $64 million and $218 million in its 2023 filing — it only stated that it estimated and recorded costs without specifying exact figures. The LLM incorrectly attributes the 2023 reserve numbers to the 2023 filing, when in fact those numbers were only disclosed in the 2024 filing as comparative figures. This is a critical error in both quantitative and qualitative accuracy. (2) While the 2024 figures ($86 million and $256 million) are correct, the additional quantitative details — a $1.1 billion provision, $1.2 billion realized losses, and $164 million recoveries — are not present in the original answer and cannot be verified against the ground truth. These figures may be fabricated or misattributed, severely undermining quantitative accuracy. (3) The multi-hop reasoning is partially sound in that the model attempts to compare disclosures across years and recognizes increased transparency in 2024. However, it fails the core synthesis by misrepresenting when specific data was first disclosed, leading to an incorrect narrative about 2023 transparency. (4) Contextual relevance is high because the answer addresses financial commitments and disclosure evolution, but correctness is low due to major factual errors in entity-year alignment and unsupported numerical claims. The conclusion about increased commitment and granular disclosure in 2024 is aligned with the ground truth, but rests on flawed premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 431,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "In the 2022 Form 10‑K the Company described its model as a mix of company‑operated and franchised restaurants, noting that “the Company franchises and operates … restaurants” and that it “may share in the cost of certain restaurant improvements with its franchisees” (2022 p. 41‑42). By the 2024 filing the language had shifted to a more franchise‑centric framing – the Company states it is “primarily a franchisor and believes franchising is paramount” to delivering the brand, and emphasizes that “ownership of real estate, combined with the co‑investment by franchisees, enables it to achieve restaurant performance levels” (2024 p. 1‑3). Thus, franchising moved from being presented as one component of the business to being portrayed as the core strategic model, with co‑investment highlighted as a deliberate tool for driving performance and value.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the shift in McDonald's strategic framing between 2022 and 2024: from a neutral, structural description of the franchise model in 2022 to a value-laden, strategic emphasis on franchising as 'paramount' in 2024. The use of direct quotes from the filings (e.g., 'primarily a franchisor', 'franchising is paramount', 'co-investment by franchisees enables...') matches the semantic content of the original answer. (2) There are no numerical values requiring verification (e.g., dollar amounts, percentages), but the years (2022 and 2024) and page references (p. 41-42, p. 1-3) are correctly cited and consistent with the expected sourcing. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifies the evolution in language and strategic emphasis, and connects the concept of franchisee co-investment to performance outcomes. (4) The answer is contextually precise, addressing both parts of the question—franchising as a core business model and the role of franchisee co-investment—and conveys the same conclusion as the ground truth: a shift from descriptive to strategic framing. Wording differs slightly but maintains full semantic equivalence. No errors in entities, reasoning, or facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 376,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "In the 2022 Form 10‑K Altria reported that Marlboro HeatSticks were still without FDA market authorization – the products had been pulled from the U.S. market after an ITC cease‑and‑desist order and the FDA had not yet exempted them from graphic‑warning requirements.  By the 2023 Form 10‑K the company noted that, in January 2023, the FDA had granted PMTA approvals for three new tobacco‑flavored Marlboro HeatSticks.  This shift from no authorization to FDA‑cleared varieties shows that Altria is making tangible regulatory progress in bringing its heated‑tobacco products to market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Marlboro HeatSticks lacked FDA authorization and were subject to graphic warning requirements; by January 2023, the FDA authorized three new tobacco-flavored varieties via PMTA approvals. (2) Quantitative accuracy is perfect: the date 'January 2023' is correctly cited, and no numerical errors are present. Format and specificity match the ground truth. (3) Multi-hop reasoning is sound—LLM correctly synthesizes information from Altria's 2022 and 2023 Form 10-K filings to show regulatory progression. It infers the significance of the shift in FDA stance as indicative of Altria's progress, which is logically valid. (4) The only minor shortcoming is that the LLM does not explicitly state that this progress reflects Altria's broader innovation strategy, a point included in the original answer. However, the core meaning—that Altria is making regulatory progress with heated tobacco products—is clearly conveyed. Thus, the answer is semantically equivalent with only slight omission of strategic context, warranting a high score but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 328,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "In the 2022 filing Accenture reported that its non‑U.S. defined‑benefit plans held mutual‑fund equity securities with a fair‑value of **$239 million** (Level 1 $4.9 million + Level 2 $234 million). The 2023 filing shows that the same category was valued at **about $255 million**. The rise in the dollar amount – together with the higher 2023 target allocation for non‑U.S. equity (27 % versus 21 % in 2022) – indicates that Accenture is modestly increasing its positioning in mutual‑fund equity securities, moving a slightly larger share of plan assets into equities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, ACN's mutual fund equity securities decreased from $239,293 million in 2022 to $196,226 million in 2023, a reduction of $43,067 million. However, the LLM claims the value increased to 'about $255 million' in 2023, which is factually incorrect and contradicts the original data. Additionally, the LLM incorrectly reports the 2022 value as $239 million instead of $239,293 million—off by a factor of nearly 1,000. (2) The quantitative errors are severe: the values are misrepresented by orders of magnitude, and the direction of change (increase vs. decrease) is wrong. The LLM also introduces unverified details such as Level 1 and Level 2 valuations and target allocation percentages (27% vs. 21%), which are not present in the original answer and cannot be verified from the provided context. (3) The multi-hop reasoning is flawed. The original answer infers a strategic reduction based on declining values, while the LLM incorrectly infers an increase in positioning due to a fabricated rise in value and unsupported allocation data. The model fails to correctly synthesize the actual trend across years. (4) Despite the severe factual and numerical errors, the LLM does attempt to address the question's structure—discussing valuation changes and interpreting investment positioning—hence a moderate contextual relevance score. However, due to major inaccuracies in numbers, direction of change, and unsupported qualitative claims, the correctness, quantitative, and qualitative accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 441,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "In the 2022 filing Chevron described its Angola LNG Limited stake (36.4 %) as an operating asset – the on‑shore Soyo LNG plant that processes associated gas and for which Chevron was actively developing non‑associated offshore gas to feed the plant. The 2023 filing still treats Angola LNG as a core operating investment, but the equity‑method balance fell from $1.96 billion in 2022 to $1.76 billion in 2023, showing that while the operational role of the LNG plant remains unchanged, Chevron’s investment emphasis on the venture has been reduced.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Chevron's 36.4% interest in Angola LNG Limited in both 2022 and 2023, which matches the ground truth. However, it introduces a specific financial figure—equity-method balance falling from $1.96 billion in 2022 to $1.76 billion in 2023—that is not present in the original answer and cannot be verified against the provided ground truth. This quantitative claim undermines factual accuracy. (2) There are no calculations in the original answer, so the LLM’s inclusion of dollar amounts represents an unsupported addition rather than a correct calculation. These numbers may be factually accurate in external sources, but they are not part of the knowledge graph ground truth provided, making them incorrect in this evaluation context. (3) The qualitative reasoning is partially sound: the LLM captures the shift in emphasis by noting that operational focus remains but investment emphasis may have decreased. However, the original answer emphasizes a shift in disclosure focus—from operational development to inclusion within a broader portfolio of equity affiliates—rather than a reduction in investment emphasis per se. The LLM interprets the change through financial metrics not in the source, leading to a plausible but misaligned inference. (4) Contextual relevance is high because the response addresses both operational focus and investment emphasis across 2022–2023. Despite incorrect numbers, the overall structure and intent align with the question. Correctness score is 6 due to significant quantitative inaccuracies offset by reasonable qualitative interpretation and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 446,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "MMM’s certificates of deposit/time‑deposit holdings rose from **$21 million at year‑end 2022 to $49 million at year‑end 2023**, an increase of **about $28 million**.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains a significant factual error in the 2022 value. The ground truth states MMM held $14 million in Certificates of Deposit/Time Deposits in 2022, while the LLM reports $21 million. The 2023 value is correct at $49 million. As a result, the calculated increase is also incorrect: the LLM reports a $28 million increase, but the actual increase is $35 million (from $14M to $49M). The percentage increase (approximately 250%) is missing from the LLM answer, which reduces completeness. (2) Number verification: 2022 amount wrong ($21M vs $14M), 2023 amount correct ($49M), change amount incorrect ($28M vs $35M), percentage change omitted. Calculations based on incorrect inputs are internally consistent but factually inaccurate. (3) Multi-hop reasoning: The model correctly identifies the need to compare two years and compute a change, indicating sound reasoning structure, but fails in data retrieval for the 2022 figure. This suggests an error in sourcing or extraction rather than logic. (4) Scores justified as follows: Correctness at 5 due to major quantitative error despite correct 2023 value and directional accuracy (increase). Quantitative accuracy at 5 because half the numbers are wrong. Qualitative accuracy at 6 because reasoning framework is correct and entities (MMM, time deposits, years) are accurate. Contextual relevance is 9 because the answer directly addresses the question's intent and structure, only failing on data precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1117,
        "completion_tokens": 417,
        "total_tokens": 1534
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "In 2021 McDonald’s reported that 37,295 of its 40,031 restaurants – about 93 % – were franchised. By the end of 2024 the company said it had 43,477 restaurants, of which roughly 95 % were franchised. Thus, the share of franchised locations has risen modestly, moving from about 93 % to 95 % over the three‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages (93% in 2021 and 95% in 2024) are accurate and match the original answer. The absolute numbers provided (37,295 of 40,031 in 2021 and ~95% of 43,477 in 2024) are consistent with the reported percentages—93% of 40,031 is approximately 37,229 (close to 37,295, minor rounding differences acceptable), and 95% of 43,477 aligns with the stated figure. (2) The answer is complete, addressing the evolution of McDonald's franchisee relationship over the specified time period (2021 to 2024) with correct data points for both years. (3) Entity accuracy is perfect: McDonald's is the correct company, years are accurate (2021 and 2024), and the metric (percentage of franchised restaurants) is correctly interpreted. (4) The reasoning is sound—comparing the two percentages over time to conclude a modest increase demonstrates correct multi-hop synthesis across years. (5) The semantic meaning is equivalent to the original answer, conveying the same core insight: a slight but deliberate increase in franchised restaurants from 93% to 95%, reinforcing McDonald’s strategic focus on franchising. Minor wording differences (e.g., 'modestly' vs 'slight') do not affect factual accuracy. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1157,
        "completion_tokens": 370,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "- **Effective date:** In the 2022 Form 10‑K the 2015 Stock Compensation Plan for Non‑Employee Directors was described as “amended and restated effective March 31, 2021” (Exhibit 10.21). In the 2023 Form 10‑K the same plan is shown as “amended and restated effective October 26, 2022” (Exhibit 10.22).  \n\n- **Structure (share availability):** The 2022 filing listed 703,256 shares remaining available for future issuance under the plan, whereas the 2023 filing showed the pool had been reduced to 589,927 shares.  \n\nThus, between the two years the plan’s amendment date moved from March 2021 to October 2022 and the number of shares available under the plan was lowered.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of the effective date of the 2015 Stock Compensation Plan for Non-Employee Directors from 'March 31, 2021' in the 2022 filing to 'October 26, 2022' in the 2023 filing, matching the ground truth exactly. It also accurately reports the reduction in shares available for issuance from 703,256 in 2022 to 589,927 in 2023. These numbers are factually correct and properly attributed to the respective Form 10-K filings. (2) All quantitative values—dates and share counts—are accurate with no calculation errors. The difference in share availability (703,256 - 589,927 = 113,329 shares issued or used) is consistent, though not explicitly calculated, which is acceptable given the question does not require it. (3) The reasoning is sound: the LLM correctly infers that the change in effective date indicates an amendment between 2022 and 2023 and links the structural change to the reduced share pool. While the ground truth emphasizes the implication of a 'structural or procedural update,' the LLM captures this by noting the share reduction as part of the plan's evolution. (4) The answer is fully contextually relevant, addressing both the effective date and structural aspects (via share availability) of the plan’s evolution. The only minor shortcoming is that it does not explicitly state that the October 26, 2022 amendment occurred during the 2022–2023 period and was reflected in the 2023 filing, which slightly weakens the synthesis. However, the implication is clear. Thus, the answer is highly accurate and complete, warranting a 9/10 on correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 466,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "In its 2022 Form 10‑K Accenture reported that its equity‑method investment in Duck Creek Technologies – about a 16 % ownership – was carried at $138.9 million, with an estimated fair value of $223.2 million. By fiscal 2023 the company said the same investment generated a $253 million gain, which was recorded as a distinct “investment gain” in that year’s results. Thus, the holding moved from being reflected only at cost (with a fair‑value uplift) in 2022 to producing a sizable recognized gain and a material positive impact on earnings in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Accenture's 16% ownership in Duck Creek Technologies, the 2022 carrying amount of $138.9 million (matches $138,902,000), and the fair value of $223.2 million (matches $223,166,000 within rounding). The $253 million gain in fiscal 2023 is correctly reported. (2) Quantitative accuracy is excellent—minor formatting differences (e.g., $138.9 million vs $138,902,000) are acceptable and semantically equivalent. (3) The reasoning correctly identifies the shift from equity-method accounting with a carrying value and fair value disclosure in 2022 to a realized gain in 2023, indicating a financial realization event. The conclusion that the investment moved from passive accounting to active gain recognition is sound and supported. (4) The only minor shortcoming is that the original answer notes the gain impacted adjusted EPS and effective tax rate, which the LLM mentions only generally as 'material positive impact on earnings.' While 'investment gain' and 'positive impact on earnings' are correct, the specific mention of adjusted EPS and tax rate is slightly more precise in the ground truth. However, this does not undermine the overall correctness. The answer is contextually complete and directly addresses the evolution in valuation and financial impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 378,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "In the 2022 filing Breyanzi was described only as a CD19‑directed CAR‑T therapy approved for adult patients with **relapsed or refractory large‑B‑cell lymphoma** who had received ≥ two prior lines of systemic therapy【BMY_10k_2022.pdf†p70】. By 2024 the product’s label had been broadened to cover several additional B‑cell malignancies: in March 2024 the FDA granted accelerated approval for relapsed/refractory **chronic lymphocytic leukemia/small‑lymphocytic lymphoma (CLL/SLL)**; in May 2024 for relapsed/refractory **follicular lymphoma (FL)**; in May 2024 for relapsed/refractory **mantle‑cell lymphoma (MCL)**; and in August 2024 Japan’s health authority approved Breyanzi for **high‑risk FL after one prior line of therapy** (and after ≥ two lines)【BMY_10k_2024.pdf†p43‑p47】. These new indications markedly expand Breyanzi’s market potential beyond its original large‑B‑cell lymphoma use.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the 2022 indication for Breyanzi in relapsed or refractory large B-cell lymphoma and accurately reports the March 2024 FDA approval for CLL/SLL and the May 2024 approval for follicular lymphoma (FL), which aligns with the ground truth. However, it introduces two additional indications not present in the original answer: approval for mantle cell lymphoma (MCL) in May 2024 and a Japanese approval for high-risk FL in August 2024. These are not mentioned in the ground truth and thus represent factual overreach or hallucination. While the core expansion of indications in 2024 is partially correct (CLL/SLL and FL), the inclusion of MCL and the Japan-specific approval adds incorrect information that affects quantitative and qualitative accuracy. The reasoning is sound in structure—tracking label expansions over time—but fails in precise multi-hop synthesis as it includes unsupported approvals. The contextual relevance is high because the answer addresses the evolution of therapeutic use and market expansion. Wording and semantic framing are strong, but the addition of unverified indications reduces correctness. Therefore, the answer is partially correct but contains significant factual errors in entity and date attribution for the extra indications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 360,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "In the 2022 filing, 3M described a formal ASC 450‑based process for estimating insurance receivables – it analyzes policy language, exclusions, comparable case law and its own claim experience and records a receivable both for insured claims that already have an accrued liability and for defense expenses where no accrual was made. The 2023 filing says the company continues to use that same ASC 450 methodology, but now discloses that the insurance receivable linked to the respirator‑mask/asbestos litigation is “immaterial,” indicating that the expected recoveries have fallen to a negligible amount while the company still pursues coverage from insolvent insurers.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, 3M did *not* describe a formal methodology for estimating insurance receivables under ASC 450—this detail was absent. However, the LLM incorrectly states that in 2022, 3M already had a detailed process analyzing policy language, case law, and claim experience. This contradicts the original answer, which explicitly notes the lack of such disclosure in 2022. In 2023, the company *introduced* this detailed methodology, applying loss recovery and gain contingency models under ASC 450 and ASC 610-30—this evolution is misrepresented in the LLM answer as a continuation of an existing method. Additionally, the LLM claims the insurance receivable for respirator/asbestos litigation was deemed 'immaterial' in 2023, which is not mentioned or implied in the ground truth. There is no indication in the original answer that recoveries have fallen to a negligible amount. (2) Quantitatively, the LLM omits the key numeric data provided in the original answer: the increase in individual claimants from 4,028 in 2022 to 4,042 in 2023. This quantitative trend is central to the ground truth’s explanation of growing exposure influencing the change in approach. The LLM fails to report these numbers, missing a critical multi-hop link between rising claims and enhanced disclosure. (3) The multi-hop reasoning is flawed. The original answer connects three elements: (a) increased litigation exposure (shown by rising claimant numbers), (b) absence of detailed insurance receivable methodology in 2022, and (c) introduction of a more detailed methodology in 2023. The LLM reverses the timeline by asserting the methodology existed in 2022 and was merely continued in 2023, thus failing to capture the actual evolution. It introduces an unsupported conclusion about immateriality, which is not grounded in the provided truth. (4) While the LLM addresses the general topic—3M’s insurance receivables and ASC 450—and mentions respirator/asbestos litigation, its factual errors and incorrect synthesis severely undermine accuracy. Contextual relevance is moderate because it discusses the right subject area and standards, but the substance is largely incorrect. Therefore, the correctness score is low at 2, with similarly low qualitative and quantitative accuracy, reflecting major deviations from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 643,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo disclosed that it had sold the Naked juice brand (along with Tropicana and other juice brands) to PAI Partners, but retained a 39 % non‑controlling interest in the newly created joint‑venture (Tropicana Brands Group) and agreed to act as the exclusive U.S. distributor for the joint‑venture’s portfolio—including Naked—through its chilled‑direct‑store‑delivery network. The 2023 Form 10‑K reports the same arrangement: PepsiCo still holds the 39 % non‑controlling equity stake and continues to serve as the exclusive distributor, indicating that its operational role and financial ownership of Naked remained unchanged from 2022 to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 39% noncontrolling interest and the sale to PAI Partners in 2022, which matches the ground truth. However, it incorrectly states that PepsiCo continued as the exclusive distributor in 2023, which contradicts the ground truth stating that PepsiCo no longer directly distributed Naked products by 2023. This is a critical factual error in the evolution of the relationship. (2) Quantitatively, the 39% stake and the entities involved (PAI Partners, joint venture) are accurate, and there are no calculation errors—hence a high quantitative accuracy score. (3) The multi-hop reasoning fails because the model does not recognize the change in operational involvement from 2022 to 2023. It incorrectly assumes continuity in distribution based on the 2023 10-K, while the ground truth indicates a shift from active distribution to a purely financial stake. The joint venture name 'Tropicana Brands Group' (TBG) is correctly inferred, though referred to slightly differently. (4) The answer is contextually relevant and addresses both operational and financial aspects, but the core conclusion—that the relationship remained unchanged—is factually wrong. This undermines the overall correctness, warranting a low correctness score despite accurate numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 363,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "In the 2023 filing CVS said that ExtraBucks Rewards create a **separate performance‑obligation** at the moment of the original purchase; the transaction price is split between the sale and the reward based on each element’s relative standalone selling price and revenue is recognized only when the rewards are actually redeemed, with any unredeemed balance carried as a contract liability.  \n\nThe 2024 filing repeats that same ASC 606‑based approach but expands the disclosure – it now groups ExtraBucks together with gift‑card liabilities, explicitly states that **breakage is estimated and recognized as revenue** using historical redemption patterns, and emphasizes that the obligation is measured by the standalone price of the reward rather than the underlying transaction.  \n\nThus, the fundamental treatment (recognizing revenue on redemption and treating the reward as a distinct performance‑obligation) remains the same, but the 2024 disclosure adds more detail on breakage estimation and the presentation of the related contract liability.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core accounting treatment and evolution between 2023 and 2024. (1) It accurately captures that in 2023, the ExtraBucks Rewards program created a separate performance obligation, revenue was allocated using relative standalone selling prices, and recognized upon redemption, with unredeemed rewards recorded as a contract liability—this matches the original answer. In 2024, it correctly notes the consistency in revenue recognition timing and performance obligation treatment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—scored as 10 by default since no errors exist. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure and accounting emphasis across years. However, there is a minor discrepancy: the LLM mentions that breakage is 'recognized as revenue' in 2024 using historical patterns, which is plausible but not explicitly stated in the ground truth—the original answer says unredeemed rewards were reflected as a contract liability in 2023 and implies ongoing deferral, without confirming active breakage revenue recognition. Additionally, the LLM notes that ExtraBucks are grouped with gift cards in 2024 and that the obligation is measured by the standalone price of the reward, details not present in the ground truth. While these may be true, they are not confirmed by the provided truth, introducing unverified details. (4) The core facts and evolution are correctly conveyed—treatment remains consistent, but 2024 includes more detailed and structured disclosures—matching the ground truth’s emphasis on refined language around performance obligations and more formalized allocation processes. The answer is contextually relevant and addresses both revenue recognition and performance obligation aspects of the question. Due to the introduction of plausible but unconfirmed details (e.g., breakage revenue recognition, grouping with gift cards), the correctness and qualitative accuracy are slightly reduced, but not severely, as the central narrative is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1520,
        "completion_tokens": 585,
        "total_tokens": 2106
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "In the 2023 filing the “cost of revenues” – which lumps together content amortization, delivery costs and **customer‑service and payment‑processing fees paid to integrated payment partners** – was $19.7 billion, or **58 % of total revenue**. In the 2024 filing the same line item rose to $21.0 billion but fell to **54 % of revenue**. Thus, while the dollar amount of the overall cost (and therefore the amount paid to payment‑processing partners) increased, its share of revenue declined by about four percentage points, indicating a relative reduction in Netflix’s reliance on integrated payment partners between 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The ground truth states that Netflix mentioned payment processing fees as part of 'other operating costs' within cost of revenues in both 2023 and 2024, with a reduction in disclosure detail in 2024. However, the LLM answer fabricates specific dollar amounts ($19.7B in 2023, $21.0B in 2024) and percentages of revenue (58%, 54%) that are not present in the original answer or implied by it. There is no mention in the ground truth of total cost of revenues, its percentage of revenue, or any calculation of reliance based on such metrics. (2) The quantitative figures provided in the LLM answer (e.g., $19.7B, 58%, $21.0B, 54%) are entirely unsupported by the original answer and appear to be hallucinated. The original answer does not provide any numerical data about the size of payment processing fees or total cost of revenues, so the LLM’s calculations and comparisons (e.g., 'declined by about four percentage points') are invalid. (3) The multi-hop reasoning is flawed: the question asks about the evolution of Netflix's reliance on integrated payment partners based on disclosure in the cost of revenues section. The correct answer focuses on changes in disclosure granularity and categorization, not financial ratios or cost trends. The LLM incorrectly infers 'reliance' from fabricated cost-to-revenue ratios, misrepresenting the nature of the evidence. It fails to identify that the key point is about transparency and reporting structure, not economic dependency measured by cost share. (4) The contextual relevance is moderate because the LLM addresses the right topic (payment partners in cost of revenues) and attempts a year-over-year comparison, but it introduces irrelevant and false financial metrics, leading to a fundamentally incorrect conclusion. The qualitative reasoning is poor due to incorrect entity relationships and logic. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 544,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "In the 2022 filing, 3M described its work under the 2007 Minnesota Settlement Agreement as essentially finished – the Oakdale, Woodbury and Cottage Grove sites had been remediated and the company was carrying out only operation‑and‑maintenance activities and providing alternative drinking water when a health‑based value (HBV) or health‑risk limit (HRL) was exceeded. By the 2023 filing, 3M was responding to new regulatory actions: the Minnesota Department of Health had issued stricter HBVs for PFOA and PFOS, MPCA had issued a storm‑water Notice of Violation and was drafting a Clean‑Water Act permit that imposes PFAS limits below the limit of quantification, so 3M is now evaluating the impact of those tighter standards on its settlement obligations and is working with MPCA on a storm‑water mitigation plan and the new permit requirements.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in 3M's approach to PFAS contamination in Minnesota from 2022 to 2023. It correctly states that by 2022, remediation under the 2007 Settlement Agreement was substantially complete, with only operation and maintenance activities ongoing at Oakdale, Woodbury, and Cottage Grove—this aligns with the ground truth. The LLM accurately notes that in 2023, 3M was responding to new regulatory developments: stricter HBVs from the Minnesota Department of Health for PFOA and PFOS (issued in January 2024, but referenced in the context of 2023 filings), and regulatory actions by MPCA including a stormwater Notice of Violation (March 2023 for Hutchinson, December 2022 for Cottage Grove). The mention of MPCA drafting a new Clean Water Act permit with PFAS limits below the limit of quantification is correct and reflects the tightening regulatory environment. The LLM correctly infers that 3M is evaluating the impact on its SACO obligations and engaging on stormwater mitigation and permit compliance. Minor point: the LLM implies the stricter HBVs were issued during 2023, but they were issued in January 2024—however, since the 2023 filing would reference upcoming or recently issued standards, this is a reasonable interpretation in context. Also, the LLM omits mention of the Decatur, Alabama facility from the original, but since the question specifically asks about Minnesota, this omission is contextually acceptable. All entities (MPCA, HBV, SACO) are correctly identified and reasoning is sound. Quantitative accuracy is high—dates and regulatory actions are correctly sequenced and attributed. The answer is semantically equivalent and highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1505,
        "completion_tokens": 470,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo increased the size of its foreign‑exchange hedge program, with the notional amount of foreign‑currency derivatives rising from **$3.0 billion at year‑end 2022 to $3.8 billion at year‑end 2023** (an increase of roughly 27%)【PEP_10k_2023.pdf page 103】. The company continues to rely on short‑term forward contracts (≤ 2 years) and net‑investment hedge debt instruments, suggesting it is sharpening a proactive, hedge‑based approach to offset the currency risk inherent in its global operations.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) Quantitatively, the notional values of $3.0 billion in 2022 and $3.8 billion in 2023 are accurately reported, and the implied 27% increase is correctly calculated ((3.8 - 3.0)/3.0 ≈ 26.7%, rounded to 27%). (2) The answer addresses both parts of the question: the evolution (increase in notional value) and the implication for risk management strategy (proactive, hedge-based approach). (3) Entities are correct—PepsiCo, foreign currency derivatives, years 2022 and 2023—and the financial instruments (forward contracts, net-investment hedge debt) are accurately identified. (4) The reasoning is sound: the increase in derivative usage is logically tied to managing currency risk in global operations, and the mention of short-term contracts and hedging instruments reflects a strategic, proactive stance consistent with the original answer’s conclusion about offsetting hedged items with no material net impact. The LLM adds contextual detail (e.g., contract duration) that enriches the answer without introducing error. Semantic equivalence is maintained throughout.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 323,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "In the 2022 filing ExxonMobil said that “worldwide demand for chemicals is expected to grow faster than the economy … driven by … an expanding middle class, and improving living standards” and said it would meet that demand mainly by “re‑starting … U.S. Gulf‑Coast growth projects, including projects in Baytown, Texas and Baton Rouge, Louisiana” (2022 p. 65‑66). By 2023 the company was adding new capacity on top of those Gulf‑Coast assets – a 400‑kmt/yr performance‑polymers line and a 350‑kmt/yr linear‑alpha‑olefins unit in Baytown, Texas – and announced a far‑larger, first‑100‑percent‑foreign‑owned petrochemical complex in Huizhou, China, aimed at serving China’s rising middle‑class demand (2023 p. 58‑60). Thus, the strategy shifted from relying chiefly on existing U.S. Gulf‑Coast projects to actively building fresh capacity in North America while expanding its geographic focus to China to capture the same “improving living‑standards” trend.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in ExxonMobil's strategy between 2022 and 2023. (1) It correctly identifies the shift from U.S.-focused projects in 2022 (Baytown, Baton Rouge) to new capacity additions in Baytown and a major foreign investment in China in 2023. The mention of 're-starting U.S. Gulf-Coast growth projects' aligns with the 2022 focus on Corpus Christi and Baytown expansions. (2) Quantitatively, the LLM reports a 400-kmt/yr performance polymers line and a 350-kmt/yr linear alpha olefins unit in Baytown, Texas—these figures are consistent with the type of capacity expansion described in the ground truth, though the exact numbers are not specified in the original answer. The original mentions 'expanding performance polymers and linear alpha olefins capacity' without exact tonnage, so the LLM’s specific figures may be drawn from the cited page (2023 p. 58–60) and are not contradicted. The 'over 2.5 million metric tons' in China from the original is not explicitly repeated, but the LLM refers to a 'far-larger' complex, implying scale. (3) The reasoning is sound: the LLM correctly synthesizes multi-hop information across years and geographies, identifying the strategic pivot from domestic U.S. projects to include a major 100% foreign-owned complex in Huizhou, China (correctly named, though 'Dayawan' in the original is a nearby industrial zone—Huizhou is accurate at city level). (4) The answer conveys semantic equivalence: the shift from relying on existing U.S. assets to building new capacity and expanding into China to serve rising middle-class demand mirrors the original’s conclusion. Only minor deduction for introducing specific capacity numbers (400k, 350k) not present in the ground truth, which, while plausible, go beyond the provided information. Otherwise, all entities, years, and strategic logic are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 508,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "3M’s holdings of certificates of deposit / time deposits rose from **$21 million at year‑end 2022 to $49 million at year‑end 2023** – an increase of roughly 130 % (Note 12, Marketable Securities table). The jump in this low‑risk, short‑term asset class shows the company moved a larger portion of its cash into highly liquid, interest‑earning deposits, signaling a more conservative short‑term investment stance aimed at preserving liquidity and modestly enhancing cash returns.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts are accurate: $21 million in 2022 and $49 million in 2023, with a correctly calculated increase of approximately 130% (actual: (49-21)/21 ≈ 133.3%, so 'roughly 130%' is a reasonable approximation). (2) The answer addresses both parts of the question: the evolution of investment (increase from $21M to $49M) and the strategic implication (shift toward more conservative, liquid, interest-earning instruments). (3) Entities are correct: 3M, certificates of deposit/time deposits, and the years 2022 and 2023. (4) The reasoning is sound and adds value by noting the low-risk nature of the assets and the dual goals of liquidity preservation and modest return enhancement, which aligns with and expands upon the ground truth without introducing inaccuracies. The mention of 'Note 12, Marketable Securities table' adds contextual support, indicating proper sourcing. All information is semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 298,
        "total_tokens": 1500
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "In the 2022 filing Mastercard described its proprietary‑insights services as being built on “the principled use of consumer and merchant data.” By the 2023 filing the language had been expanded to say the insights are drawn from “our principled and responsible use of secure consumer and merchant data,” adding an explicit commitment to data responsibility, security and trust‑building.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution in Mastercard's language from 2022 to 2023: from 'principled use of consumer and merchant data' to 'principled and responsible use of secure consumer and merchant data.' The key additions—'responsible' and 'secure'—are correctly identified, reflecting the enhanced focus on data responsibility and security. (2) There are no numerical values in this question, so quantitative accuracy pertains to correct years (2022 and 2023), which are accurately cited. (3) The multi-hop reasoning is sound: the model correctly compares two statements across two filings (2022 and 2023) and infers a strategic shift in language that emphasizes trust-building and data security. (4) The answer is contextually relevant, directly addressing how Mastercard’s approach evolved with respect to data responsibility and trust-building language. No factual inaccuracies, omissions, or misstatements are present. The LLM provides a concise yet complete synthesis that matches the original answer in meaning and detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 316,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "In the 2022 filing the company said that the estimates for its pension and retiree‑medical obligations were driven mainly by plan‑specific actuarial assumptions (e.g., discount rates, mortality and health‑care cost trends) and by changes tied to the Rockstar acquisition and related contingent‑consideration. By the 2023 filing the discussion had broadened to note that those same estimates are now being shaped by a “high‑interest‑rate and inflationary cost environment” and by “business‑ and economic uncertainty resulting from the ongoing conflicts in Ukraine and the Middle East,” in addition to the usual actuarial factors. This shift signals that the external environment has become more volatile and uncertain, forcing the company to incorporate broader macro‑economic and geopolitical risks into its pension and retiree‑medical accounting assumptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the shift in factors influencing accounting estimates for pension and retiree medical plans from 2022 to 2023. In 2022, the original answer cites 'ongoing impacts of the COVID-19 pandemic' as the key uncertainty, while the LLM mentions 'actuarial assumptions' and the 'Rockstar acquisition.' Although the Rockstar acquisition detail is not in the ground truth and may be extraneous or company-specific context not reflected in the general knowledge graph, it does not contradict the core point about 2022 uncertainties. The LLM accurately captures the 2023 shift to 'high-interest-rate and inflationary cost environment' and 'business- and economic uncertainty from conflicts in Ukraine and the Middle East,' matching the original answer exactly in substance. This correctly indicates a transition from health-related to macroeconomic and geopolitical risks. There are no numerical values to verify, so quantitative accuracy is scored as 10. The reasoning is sound and reflects proper multi-hop synthesis across years and external factors. The only minor deviation is the inclusion of acquisition-related details not present in the ground truth, which slightly affects qualitative accuracy but does not undermine the overall correctness. The answer is fully contextually relevant and addresses both parts of the question: evolution of factors and implications for the external environment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 408,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil’s undeveloped land base in the “Other Americas” (Canada + Other Americas) fell from **37,833 k acres (gross) and 18,985 k acres (net) at year‑end 2022** to **30,773 k acres (gross) and 15,012 k acres (net) at year‑end 2023** – a drop of roughly 7 million gross acres (≈ 4 million net acres).  The decline shows the company is converting or relinquishing a portion of its earlier inventory, but it still retains more than 30 million gross acres, indicating that a sizable, still‑growing exploration platform remains in the region.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that ExxonMobil's undeveloped acreage in the 'Other Americas' region specifically decreased from 25,096 gross / 11,977 net thousand acres in 2022 to 24,221 gross / 11,548 net thousand acres in 2023. However, the LLM incorrectly reports figures for a combined 'Canada + Other Americas' region (37,833k and 30,773k gross), which is not mentioned in the question or ground truth. These numbers do not align with the 'Other Americas' region alone, making the quantitative data fundamentally wrong. (2) The calculation of a 7-million gross acre drop is based on incorrect base numbers and is therefore invalid. The actual decrease in gross acreage is 25,096 - 24,221 = 875 thousand acres, not 7 million. Similarly, the net decrease is 11,977 - 11,548 = 429 thousand acres, not 4 million. (3) The reasoning is partially sound in interpreting that a decline may indicate relinquishment or transition to developed status, and continued exploration potential, but it applies this logic to an incorrect geographic scope. The LLM conflates 'Other Americas' with a broader region including Canada, failing the multi-hop synthesis requirement to isolate the correct region. (4) While the general direction of reasoning (decline implies inventory repositioning while maintaining exploration potential) is consistent with the original answer, the severe numerical and entity-level errors drastically reduce correctness. The contextual relevance is moderate because the answer addresses the right company, time frame, and general concept, but misrepresents the geographic entity and magnitude of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 460,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "In 2022 3M still used a sizable pool of foreign‑currency forwards and options that were **not** designated as cash‑flow or net‑investment hedges – about **$2.8 billion** of gross notional amount – and the resulting fair‑value changes were recorded directly in earnings, producing a pretax gain of roughly **$45 million**. By 2023 the company trimmed that pool to roughly **$1.0 billion** and the earnings impact fell to a pretax gain of about **$21 million**, showing that the same non‑functional‑currency items continued to be managed with non‑designated contracts but with a materially lower exposure and a smaller positive effect on income.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative figures. The ground truth states that in 2022, MMM used $3.7 billion in gross notional amount of foreign exchange contracts not designated in hedging relationships. However, the LLM claims $2.8 billion, which is incorrect. Additionally, the LLM introduces specific pretax gain figures—$45 million in 2022 and $21 million in 2023—which are not present in the original answer and cannot be verified from the provided ground truth. There is no mention of earnings impacts or gains in the original answer, so these numbers appear fabricated or hallucinated. (2) The quantitative inaccuracies are severe: the notional amount is off by nearly $1 billion, and the introduction of pretax gains adds false precision. The reduction from $2.8B to $1.0B and associated gains are unsupported by the ground truth, which does not provide 2023 notional amounts or any income impacts. (3) While the LLM correctly identifies the qualitative trend—continued use of non-designated derivatives for managing non-functional currency items—it misrepresents the evolution by implying a deliberate downsizing of exposure based on unsupported numbers. The original answer emphasizes a strategic shift in approach (from designated hedging to direct earnings impact), but the LLM focuses on reduced scale, which is not confirmed. Thus, the multi-hop reasoning is partially sound in identifying the continuity of practice but flawed in inferring magnitude and financial impact. (4) Contextual relevance is high because the answer addresses the right topic, timeframe, instruments, and accounting treatment. However, correctness is low due to major numerical errors and invented data points. The qualitative accuracy is moderate because the conceptual framework (use of non-designated contracts affecting earnings) aligns with the truth, but the reasoning is undermined by false specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 526,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "In the 2022 filing, cyber‑and‑intelligence solutions were mentioned only as one line‑item under “Other revenues,” described simply as fee‑based services that help prevent, detect and respond to fraud. By the 2023 filing, the same capability is highlighted in the Business Overview as a core component of Mastercard’s value‑added services—portrayed as a strategic, security‑focused solution that enables customers to transact “securely, easily and with confidence” and is tied to the broader suite of digital‑identity, open‑banking and other innovative offerings. Thus, the solution moved from a peripheral revenue category in 2022 to a prominently positioned, differentiating element of Mastercard’s overall value proposition in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Cyber and Intelligence Solutions were mentioned as a minor, fee-based component under 'Other revenues' focused on fraud prevention; by 2023, they were elevated to a core, strategic service enabling secure transactions, mentioned in the Business Overview. The shift from peripheral to central positioning is correctly identified. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022 and 2023) are correct. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifying both the change in categorization (from 'Other revenues' to value-added services) and the shift in narrative emphasis (from fraud-focused to broader security and confidence in transactions). (4) Semantic equivalence is strong: while the LLM uses slightly different phrasing (e.g., 'differentiating element', 'strategic, security-focused solution'), the meaning matches the original answer. The only minor gap is that the LLM does not explicitly mention the grouping with consulting, loyalty, or gateway services in 2022 as in the original, but it does convey the peripheral status accurately. Thus, the answer is complete and contextually relevant, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 390,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings list **“income tax expense and accruals”** as a critical accounting policy and describe the same core approach – the effective tax rate is derived from income, statutory rates, transfer‑pricing and other jurisdiction‑specific factors; significant judgment is required; reserves (and related interest) are set up for positions that could be challenged and are adjusted as audits, new laws or settlements evolve; and an estimated annual effective tax rate is applied to quarterly results.  \n\nThe 2023 disclosure adds a brief, explicit statement that the tax effect of any significant or unusual item recognized in a quarter is recorded in the period in which the item occurs, providing a slightly more detailed explanation of timing compared with the 2022 wording.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of the treatment of 'income tax expense and accruals' as a critical accounting policy in both 2022 and 2023, and correctly identifies that the core methodology (effective tax rate calculation, judgment, reserves, etc.) remained consistent. It also accurately notes an incremental improvement in 2023 with a more explicit statement about the timing of tax effects for unusual items, which aligns with enhanced disclosure. However, the LLM answer misses a key structural evolution highlighted in the ground truth: in 2023, the policy was reorganized into a subsection under the broader critical accounting policies section and explicitly linked to Note 5 - Income Taxes, indicating a more structured and transparent reporting format. This organizational shift is a significant part of the 'evolution' asked about in the question and was not addressed. While the qualitative aspects of disclosure are partially covered, the absence of this structural change limits completeness. There are no numerical inaccuracies (quantitative accuracy is perfect), and the entities (policy name, years, context) are correct. The reasoning is sound but incomplete in synthesizing the full scope of presentation changes. The answer remains highly relevant and captures part of the evolution, warranting a solid but not top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 377,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "In the 2023 Form 10‑K Intel reported that it had **demonstrated the Universal Chiplet Interconnect Express (UCIX) standard in silicon** and was positioning the standard as a key part of its “systems‑of‑chips” capabilities that enable advanced packaging and chiplet communication. By the 2024 filing, Intel was **re‑affirming UCIX as a core element of its Open System Foundry and broader systems‑of‑chips strategy**, stressing continued development of the standard, related software and services, and its role in helping customers build AI‑focused, chiplet‑based architectures.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Intel's role in advancing the Universal Chiplet Interconnect Express (UCIe) standard between 2023 and 2024 and its integration into the broader systems-of-chips strategy. However, it contains a critical error: it refers to 'UCIX' instead of 'UCIe'—a factual inaccuracy in the name of the standard, which undermines entity accuracy. Despite this, the timeline and strategic context are generally correct: in 2023, Intel demonstrated UCIe in silicon, and by 2024, it was reaffirming its centrality in the Open System Foundry and chiplet-based design, particularly for AI. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and connects UCIe to Intel’s broader strategy involving advanced packaging, system-level standards, and customer design enablement. However, the incorrect acronym (UCIX) suggests a failure in precise entity identification, which affects qualitative accuracy. (4) Contextual relevance is high—the answer addresses the evolution of the standard and its strategic positioning. The core facts are present and logically structured, but the naming error prevents a higher correctness score. A correct reference to 'UCIe' is essential for full accuracy given it is a defined industry standard.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 398,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "In the 2023 10‑K the ASR with Morgan Stanley was described only up to the January 4 2024 cash payment and the initial receipt of about 31.4 million shares; it was said to be accounted for as a treasury‑stock purchase with a forward‑contract component recorded in capital surplus, but the forward contract had not yet been re‑classified because the transaction was still pending. The 2024 10‑K confirms that the same accounting split was used—$2.6 billion as an initial treasury‑stock transaction and a $0.4 billion forward contract recorded in capital surplus—but now shows that the remaining 8.3 million shares were received in March 2024, at which point the forward contract was re‑classified to treasury stock, completing the ASR. Thus, the accounting treatment remained unchanged, while the timeline moved from an unfinished (2023) to a completed (March 2024) transaction.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual errors despite addressing the right question and showing an understanding of the accounting framework. (1) Entity and quantitative inaccuracies: The LLM incorrectly states that the $3.0 billion ASR with Morgan Stanley (initially receiving 31.4 million shares) was referenced in the 2023 10-K as occurring in January 2024. However, the ground truth states that the 2023 ASR was with Citibank for $2.0 billion, not Morgan Stanley. The Morgan Stanley ASR was a 2024 transaction. This misattribution of the bank and year is a critical error. (2) The LLM claims the $3.0 billion ASR was split into $2.6 billion (treasury stock) and $0.4 billion (forward contract), but this breakdown is not in the ground truth; the original answer does not specify such a split, so this is an unsupported addition. (3) Timeline confusion: The LLM implies the ASR started in 2023 and finished in March 2024, but the ground truth states the 2023 ASR concluded in February 2023, and the 2024 ASR concluded in March 2024—two separate transactions, not a continuation. (4) The accounting treatment description (reclassification from capital surplus to treasury stock upon completion) is correctly understood and consistently applied, which supports partial credit. (5) The answer correctly identifies that the accounting treatment remained consistent year-over-year and that the 2024 transaction concluded in March 2024, which aligns with the completion timeline evolution. However, due to the misattribution of the counterparty, incorrect financial split, and conflation of two distinct ASRs, the quantitative and qualitative accuracy is significantly compromised. The contextual relevance is high because the structure and intent of the response match the question's requirements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 486,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) UPS said that the actuarial re‑measurement of “coordinating benefits attributable to the Central States Pension Fund” produced a **$5.1 billion pre‑tax gain**, meaning its best‑estimate of additional benefits it might have to pay to the CSPF fell sharply that year. By the 2023 Form 10‑K (covering 2022) the company no longer reported a specific gain or loss for the CSPF; instead it disclosed the potential liability for those coordinating benefits in Note 5 and illustrated the exposure with a **sensitivity analysis** – e.g., a 25‑basis‑point increase in the discount rate would cut the projected benefit obligation by about $1.55 billion – showing a more precautionary reporting approach.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. The ground truth states that UPS reported a $2.3 billion pre-tax *actuarial loss* in 2022 related to the Central States Pension Fund, but the LLM incorrectly claims a $5.1 billion pre-tax *gain*. This is a direct contradiction in both direction (gain vs. loss) and magnitude ($5.1B vs. $2.3B). Additionally, the LLM misrepresents the fiscal years: it refers to the '2022 Form 10-K (covering 2021)' and '2023 Form 10-K (covering 2022)', but the question asks about the evolution from 2022 to 2023, meaning the 2022 and 2023 filings covering those respective years. The LLM thus misaligns the reporting years with the periods under review. (2) The sensitivity analysis in the LLM answer mentions a 25-basis-point change in the *discount rate* reducing the obligation by $1.55 billion, but the ground truth specifies a 25-basis-point change in *expected and actual returns on assets* as the key assumption, not the discount rate. This misattributes the sensitivity variable, undermining the accuracy of the financial analysis. (3) While the LLM correctly identifies a shift in reporting approach—from a specific actuarial estimate to sensitivity analysis and referencing Note 5—this correct qualitative observation is built on incorrect quantitative and conceptual foundations. The multi-hop synthesis fails because the underlying data points are factually wrong. (4) The contextual relevance is moderate because the answer addresses the right topic (evolution of reporting on Central States Pension Fund exposure) and notes a shift toward sensitivity analysis, which aligns with the ground truth. However, due to severe quantitative and entity inaccuracies, the overall correctness score is low. The answer misstates core financial figures, misidentifies key assumptions in the sensitivity analysis, and misaligns fiscal years, leading to a substantively incorrect response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 522,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "In the 2022 filing Mastercard described its cyber‑and‑intelligence offering as a **stand‑alone value‑added service** that “allows all parties to transact easily and with confidence” and explicitly called it one of the primary drivers of its revenue growth. By the 2023 filing the language had shifted to embed those solutions within a **broader, multi‑layered security framework**, stressing that they are “designed to allow all parties to transact securely, easily and with confidence” and are integral to the overall payments‑network and value‑added services portfolio rather than a separate growth lever.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Mastercard's messaging around Cyber and Intelligence Solutions between 2022 and 2023 with accurate qualitative details and proper context. It correctly identifies the 2022 framing as a value-added service that enables confident transactions and notes the strengthened language in 2023 around security and integration into the broader payments ecosystem. The claim that in 2022 it was a 'primary driver of revenue growth' is not present in the original answer and appears to be an addition not supported by the ground truth, which only mentions 'principled use of data' as part of the 2022 emphasis. This is a minor factual overstatement but does not distort the overall trajectory. The shift to describing the solutions as embedded in a 'multi-layered security framework' and 'integral to the overall payments-network' aligns well with the ground truth's assertion of broader integration into infrastructure narrative and linkage to open banking and digital identity. While the LLM does not explicitly mention 'strategic investments in new networks like open banking and digital identity'—a key element in the original answer—it still conveys the increased centrality of cyber solutions. All entities (Mastercard, years 2022 and 2023, Cyber and Intelligence Solutions) are correct. No numerical data is involved, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop understanding across two years of filings. The answer is highly contextually relevant. The correctness score is 8 due to the minor addition about revenue growth and the omission of open banking/digital identity linkage, which are part of the full value proposition evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 471,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In the 2022 Form 10‑K the 4.450 % Senior Note due 2046 appeared twice, each time “incorporated by reference to Exhibit 4.4” of a Current Report on Form 8‑K – once dated October 14 2015 and again dated February 24 2016. By the 2023 Form 10‑K the 2046 note was no longer listed; instead a 4.450 % Senior Note due 2033 (still Exhibit 4.4) was shown, now referencing a Current Report on Form 8‑K filed on February 15 2023 (and a separate 4.450 % note due 2028 referenced Exhibit 4.3). Thus the exhibit number remained the same, but the associated filing date moved from the 2015‑2016 filings to a 2023 filing and the maturity changed from 2046 to 2033.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in multiple critical aspects. (1) Quantitatively, the LLM falsely claims the 4.450% Senior Note due 2046 was referenced twice in the 2022 filing via Exhibit 4.4 from Form 8-Ks dated October 14, 2015, and February 24, 2016. The ground truth states it was listed as Exhibit 4.12 (not 4.4) in 2022, incorporated from the October 14, 2015, 8-K. In 2023, it became Exhibit 4.13 (not removed), referencing the February 24, 2016, 8-K. The LLM incorrectly states the note was 'no longer listed' in 2023 and replaced by a 2033 note, which is factually wrong. (2) The maturity date change from 2046 to 2033 is a major factual error—there is no indication in the ground truth that the 2046 note was retired or replaced. (3) The LLM incorrectly asserts the exhibit number remained 'the same' (4.4), while the ground truth shows a change from 4.12 to 4.13—different exhibit numbers, not 4.4. (4) The LLM introduces a Form 8-K dated February 15, 2023, which is not mentioned in the ground truth. This date is fabricated in context. (5) Multi-hop reasoning failed: the model did not correctly track the exhibit number evolution or the consistent presence of the 2046 note. Instead, it invented a narrative about replacement and exhibit consistency that contradicts the source. (6) Contextual relevance is low because the answer addresses a different scenario—note replacement and maturity change—rather than the actual administrative reclassification of the same note. Only the mention of the October 14, 2015, and February 24, 2016, Form 8-Ks aligns partially with the truth, but their association with the note is misrepresented. Overall, the answer is factually and structurally incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 472,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Both the 2023 and the 2024 Form 10‑K disclose that after the Treasury’s April 15 2021 designation of Positive Technologies as a sanctioned Russian IT‑security firm, Intel re‑established its security‑research communications with the company under a specific OFAC license. In each filing Intel notes that no revenue or profit is generated from those interactions and that it “plans to continue these communications in accordance with the terms and conditions of the OFAC license,” indicating that the engagement remained the same – a licensed, non‑revenue‑generating dialogue – from 2023 through 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and the nature of Intel's engagement with Positive Technologies under the OFAC license. It correctly notes that communications resumed under an OFAC license after the 2021 sanctions and that no revenue or profit was generated—details consistent with the ground truth. The quantitative and entity accuracy is perfect: correct company names (Intel, Positive Technologies), correct reference to OFAC licensing, and accurate portrayal of non-revenue-generating interactions. Contextual relevance is strong, as the response directly addresses the evolution of the relationship in the context of U.S. sanctions and licensing. However, the LLM misses a key qualitative nuance highlighted in the original answer: the evolution from merely disclosing past communication in 2023 to expressing a forward-looking intent to sustain the partnership in 2024. The LLM incorrectly states that the engagement 'remained the same' from 2023 to 2024, which contradicts the ground truth that the relationship evolved in tone and posture—becoming more proactive and sustained in 2024. This mischaracterization of the progression undermines the multi-hop reasoning required to compare the strategic implications across filings. While all surface facts are correct, the synthesis and interpretation of the evolution are incomplete, warranting a score of 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 396,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "The balance of the 4.78 % senior notes due March 2038 was **$5 billion** at both year‑end 2023 and year‑end 2024 (the 2023 filing lists $5,000 million and the 2024 filing lists the same amount). Because the amount has not changed, CVS has neither retired nor added to this series, showing that this fixed‑rate, long‑dated issue remains a stable, unchanged pillar of the company’s long‑term debt portfolio. This consistency underscores CVS’s reliance on a diversified set of long‑term senior notes to fund its operations and acquisitions, rather than aggressively refinancing or reducing this particular tranche.【2023 10‑K page 166‑170】【2024 10‑K page 159‑163】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the balance of CVS's 4.78% Senior Notes due March 2038 as $5,000 million (or $5 billion) in both 2023 and 2024, matching the ground truth exactly. The formatting variation ($5 billion vs. $5,000 million) is acceptable and semantically equivalent. The key conclusion—that the balance remained stable and no retirement or issuance occurred—is accurate and well-supported. (2) All numbers, dates (March 2038 maturity), and percentages (4.78%) are correct. The LLM accurately cites the same amount in both years, confirming no change. While the ground truth includes a comparative example (2.7% notes due 2040 decreasing from $1,250M to $367M), the LLM omits this specific contrast. However, this omission does not undermine the core answer about the 4.78% notes. (3) The multi-hop reasoning is sound: the model correctly synthesizes data from both the 2023 and 2024 10-K filings (referencing correct page ranges) to conclude stability in the debt balance. It draws a reasonable inference about the note being a 'stable pillar' of the debt structure, which aligns with the ground truth's implication of selective debt management. (4) The answer is highly contextually relevant, directly addressing both parts of the question: the evolution (no change) and what it indicates (stability in long-term debt structure). The only minor shortcoming is the lack of explicit contrast with other senior notes (e.g., the 2.7% notes), which the ground truth uses to strengthen the point about selective refinancing. This limits qualitative accuracy slightly but does not affect factual correctness. Overall, the answer is factually precise, well-reasoned, and fully aligned with the ground truth in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 473,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "Both the 2022 and the 2024 Form 10‑K filings list the 0.835 % Notes due 2032 (ticker XOM32) among Exxon Mobil’s registered securities. The notes remain outstanding in the 2024 filing, indicating that their status has not changed since the 2022 filing.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct in stating that the 0.835% Notes due 2032 (XOM32) were listed in both the 2022 and 2024 filings and remain outstanding, with no change in status. All numeric values, percentages, dates, and ticker symbols (0.835%, 2032, XOM32) are accurate, satisfying quantitative accuracy. However, the answer is incomplete compared to the ground truth: it fails to mention the broader context that in the 2022 filing, these notes were listed alongside the 0.142% Notes due 2024 (XOM24B), which disappeared in the 2024 filing—indicating a shift in ExxonMobil's debt composition. This omission reduces completeness and weakens the qualitative reasoning, as the evolution of the debt structure is only partially explained. While the core fact about the 2032 notes is correct, the multi-hop synthesis—comparing changes in the full set of disclosed notes across years—is underdeveloped. The answer remains contextually relevant and correctly identifies the entities and time periods, but misses an opportunity to explain the significance of the 2024 notes' absence, which is central to understanding the 'evolution' asked in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 325,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "American Express has dramatically scaled back its U.S. Treasury portfolio. In the 2022 filing the company held Treasury securities with an estimated fair value of about **$1.7 billion** (cost $1.68 bn; fair value $1.704 bn) 【source 2022‑page 118‑119】, and the maturity mix was roughly **$832 m due within 1 year, $862 m due in 1‑5 years and $10 m due in 5‑10 years**【source 2022‑page 122】. By the 2024 filing the Treasury holding had fallen to an estimated **$287 million** of fair‑value (cost $289 m)【source 2024‑page 124】, and the portfolio was now concentrated in short‑term paper, with **$189 m due within 1 year and $98 m due in 1‑5 years**, and **no Treasury securities remaining beyond five years**【source 2024‑page 128】. Thus, between 2022 and 2024 the fair‑value allocation shrank from the billions to a few hundred million dollars, and the maturity profile shifted from a balanced short‑ and medium‑term mix to an almost entirely short‑term position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 American Express held $477 million in short-term U.S. Treasury obligations with no long-term exposure. However, the LLM claims a total fair value of $1.7 billion in 2022, with $832 million in short-term, $862 million in 1-5 years, and $10 million in 5-10 years—this contradicts the ground truth which states there was no long-term exposure at all in 2022. In 2024, the ground truth reports a shift to include both short-term ($189 million) and intermediate-term ($98 million), totaling $287 million, which matches the LLM's total and breakdown. Thus, the 2024 numbers are correct, but the 2022 figures are completely wrong. (2) The calculation of the total 2022 portfolio is incorrect: $832M + $862M + $10M = $1.704B, which the LLM cites, but this data does not align with the ground truth. The ground truth specifies only $477M in short-term with no intermediate or long-term holdings. The LLM incorrectly asserts a 'balanced mix' in 2022 and a 'shift to short-term' in 2024, when in reality the shift was from exclusively short-term to including intermediate-term—opposite to the LLM's claim of concentration in short-term. (3) The multi-hop reasoning is flawed: the LLM misrepresents the evolution. Ground truth shows a diversification into longer maturities in 2024, while the LLM claims a contraction into short-term, which is the inverse of the correct trend. (4) Despite correct sourcing format and some accurate 2024 numbers, the core quantitative and directional analysis is incorrect, warranting a low correctness score. Contextual relevance is moderate as it addresses the right topic and structure, but factual accuracy is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 480,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon first disclosed the 2.500 % Note due 2050 in its 2022 Form 10‑K, where it appeared in Exhibit 4.6 as part of the Officers’ Certificate dated June 3 2020 that introduced the new 2.500 % senior unsecured note (​“Form of 2.500 % Note due 2050”)​【source pages 69‑73】. By the 2024 Form 10‑K the same note is still listed in Exhibit 4.6, showing that the instrument remains outstanding and is being carried as long‑term debt with no redemption, amendment or retirement reported between the two filings​【source pages 72‑76】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2.500% Note due 2050, its introduction via the Officers’ Certificate dated June 3, 2020, and its continued presence in Amazon’s 10-K filings through 2024. The core facts—percentage, maturity year, unmodified status, and listing in exhibit documents—are accurate. However, there is a discrepancy in exhibit numbering: the Original Answer states the note was in Exhibit 4.5 in 2022 and reintroduced in Exhibit 4.6 in 2024 as a replication of the 2020 exhibit, while the LLM claims it appeared in Exhibit 4.6 in both 2022 and 2024. This misalignment suggests a potential error in exhibit reference or timeline, though the overall conclusion about continuity remains valid. (2) Quantitatively, all numbers (2.500%, 2050 maturity, June 3, 2020 date) are correct. No calculations are required, but the temporal consistency is mostly accurate—only the exhibit number and year attribution have a minor inconsistency. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 to 2024), identifies the note’s ongoing status, and infers no changes occurred (no redemption/amendment). It correctly links the 2020 certificate to later disclosures. The minor flaw is the incorrect assignment of Exhibit 4.6 in 2022, which contradicts the ground truth that Exhibit 4.5 was used then. (4) Despite the exhibit number inconsistency, the answer conveys the essential truth: Amazon maintained the note unchanged from introduction through 2024. Wording is clear, relevant, and semantically close to the original. Hence, high scores for qualitative accuracy and contextual relevance, with a slight deduction in correctness due to the exhibit detail error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 471,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "The filing shows three amendments were made in 2022 – the Eighth (2/13/2022), Ninth (11/20/2022) and Tenth (11/20/2022) amendments【...】 – while only two amendments were made in 2023 – the Eleventh (2/12/2023) and Twelfth (9/3/2023) amendments【...】. Thus, the number of amendments fell from three in 2022 to two in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the most recent amendment in 2022 was the Eighth Amendment (filed March 10, 2022), but the LLM claims three amendments in 2022 — Eighth (2/13/2022), Ninth (11/20/2022), and Tenth (11/20/2022) — which contradicts the original answer. The ground truth states that by 2023, the Twelfth Amendment was filed, implying four additional amendments (Ninth through Twelfth), but the LLM incorrectly asserts that the Eleventh and Twelfth were filed in 2023 and that only two amendments occurred in 2023. The dates provided by the LLM (e.g., 2/12/2023, 9/3/2023) do not match the ground truth (Twelfth Amendment on October 11, 2023). (2) Quantitatively, the number of amendments per year is wrong: LLM says 3 in 2022 and 2 in 2023; ground truth implies 0 amendments in 2022 after the Eighth (i.e., only one filing in 2022 — the Eighth), and then four more by October 2023. The LLM’s calculation of trend (decline from 3 to 2) is based on false premises. (3) The multi-hop reasoning is flawed: the model fails to correctly track the sequence and timing of amendments across years, misidentifies the number of filings, and draws an incorrect conclusion about the evolution. It appears to fabricate amendment numbers and dates not present in the ground truth. (4) Despite incorrect facts, the answer attempts to address the evolution of amendments over time, so it retains partial contextual relevance. However, due to major errors in numbers, dates, and logical inference, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 438,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA as the core parallel‑programming model that runs on all of its GPUs and serves as the “fundamental building block” for its unified accelerated‑computing platform across gaming, data‑center, visualization and automotive markets. By the 2024 filing the company had extended that role: CUDA is now positioned alongside new CPUs (Grace), DPUs and the Blackwell data‑center architecture, and the filing highlights an expanded CUDA‑X portfolio of libraries, APIs and SDKs that are embedded in AI Enterprise, DGX Cloud and other software stacks. Thus, NVIDIA’s approach has evolved from a GPU‑only programming layer to a heterogeneous, full‑stack foundation that integrates CUDA across new hardware architectures and a broader software ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: CUDA's role in 2022 as a foundational building block across Gaming, Data Center, Professional Visualization, and Automotive is accurately described. By 2024, the expansion into a full-stack platform with CUDA-X libraries, APIs, SDKs, and integration with CPUs (specifically named as Grace), DPUs, and the Blackwell architecture is correctly reported. The mention of AI Enterprise and DGX Cloud as part of the software ecosystem reflects the broader enterprise AI integration noted in the original. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—only fiscal 2024 is implied in the original, which aligns with the 2024 filing reference. No calculation errors. (3) Multi-hop reasoning is sound: the model correctly synthesizes the evolution from a GPU-centric programming model to a heterogeneous, full-stack computing foundation across hardware and software ecosystems. The integration with new architectures (CPU, DPU, Blackwell) and software stacks demonstrates proper cross-document and cross-year synthesis. (4) The only minor shortcoming is that the original emphasizes the 'strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems' more explicitly, while the LLM answer implies it but could strengthen the strategic framing. However, the core factual and conceptual content is semantically equivalent. Wording differences are acceptable and do not affect meaning. Thus, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 472,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "In 2023 Pfizer’s Paxlovid business was in steep decline – revenue fell to $1.28 billion (a 92 % drop from 2022) and the company recorded a $3.5 billion non‑cash revenue reversal in Q4 for the expected return of 6.5 million EUA‑labeled treatment courses.  At year‑end 2023 the related deferred‑revenue balance was $5.1 billion (about $2.6 billion in current liabilities and $2.5 billion in non‑current liabilities) and the remaining performance‑obligation for Paxlovid was roughly $1 billion.\n\nIn 2024 the relationship shifted to revenue recognition: Pfizer recognized roughly $2.9 billion of the previously deferred Paxlovid amounts, the deferred‑revenue balance fell to $2.2 billion (≈$1.4 billion current, $0.8 billion non‑current), and a $771 million favorable adjustment reduced the anticipated return.  Additionally, $442 million of revenue was recorded for a U.S. government‑supplied “SNS” of 1 million courses (no cash consideration).  As of Dec. 31 2024, about $1 billion of Paxlovid contractual obligations remained to be satisfied in future periods.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in Pfizer's financial relationship with Paxlovid from 2023 to 2024, with accurate multi-hop synthesis of revenue recognition, contractual obligations, and adjustments. (1) Correct elements include: the $1.28 billion 2023 revenue (matches ground truth $1.279B), the $3.5 billion non-cash reversal due to expected returns of 6.5 million courses, the $771 million favorable adjustment in 2024 due to lower actual returns (5.1M), and the $442 million SNS-related revenue. The $1 billion remaining performance obligation as of Dec 31, 2024, is correctly reported. (2) Quantitative accuracy is high, though the LLM introduces some figures not in the ground truth—specifically the deferred revenue balances ($5.1B at end-2023, $2.2B at end-2024) and their split into current/non-current liabilities—which, while plausible, are not present in the original answer and thus cannot be verified. Additionally, the claim that Pfizer 'recognized roughly $2.9 billion of previously deferred amounts' in 2024 is an inference not supported by the ground truth, which only specifies a $771M adjustment and $442M SNS revenue. This introduces a potential overstatement of revenue recognition. (3) Reasoning is sound in tracking the shift from government-driven returns and reversals in 2023 to adjusted recognition and stockpile creation in 2024. The synthesis across years and contractual obligations is logical and addresses the multi-hop nature of the question. (4) Contextual relevance is excellent—the answer directly addresses revenue recognition and contractual obligations as asked. The minor deduction in score is due to the introduction of unverified deferred revenue figures and an unsupported $2.9B recognition claim, which, while not contradicting the ground truth, add speculative detail. Overall, core facts and trends are accurately conveyed with strong qualitative and quantitative alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 524,
        "total_tokens": 2014
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "In the 2022 filing the 2003 Incentive Program still had **about 65.8 million shares** available for future award (the footnote lists “65,754,069 shares available for award under the 2003 Incentive Program”) and the plan was described as a **permanent, non‑term plan that can grant stock options, stock‑appreciation rights, restricted stock and other awards, with a 220‑million‑share ceiling, a 10‑year maximum life for options/SARs and no set expiration date**【XOM_10k_2022.pdf page 41‑45】.  \n\nBy the 2024 filing the pool of shares had fallen to **about 47 million shares remaining** at year‑end, while the plan’s structure remained unchanged – it still provides for options, SARs, restricted stock and other awards, retains the 220‑million‑share limit, and continues to allow new grants until the remaining shares are exhausted【XOM_10k_2024.pdf page 100‑104】.  \n\nThus, between 2022 and 2024 the available share pool shrank by roughly 18‑19 million shares, but the fundamental design and limits of the 2003 Incentive Program stayed the same.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 65,754,069 shares available in 2022 (rounded to ~65.8 million), which matches the ground truth. However, it incorrectly states that the 220-million-share ceiling was already in place in 2022, while the ground truth implies this was an increase by 2024 — suggesting the cap may not have been 220 million in 2022. Additionally, the LLM claims the share pool 'shrank by roughly 18-19 million shares' from 65.8M to 47M, but this contradicts the ground truth: if the total cap increased to 220 million by 2024, the reduction in available shares (from 65.8M to 47M) reflects usage, not a shrinkage of the overall program. The LLM misinterprets the nature of the change — the program expanded in capacity, but the LLM frames it as a reduction in available shares without acknowledging the increase in total authorized shares. (2) The number of restricted stock units granted (9,392 thousand in 2022 to 10,393 thousand in 2024) is omitted entirely, which is a key part of the evolution in structure and usage. This omission affects completeness and quantitative accuracy. (3) The reasoning is partially sound — the LLM correctly tracks available shares over time and notes structural continuity (award types, no expiration), but fails to recognize the multi-hop implication that the program was expanded (ceiling raised to 220M), which is central to the question about evolution. Instead, it emphasizes depletion of the pool without contextualizing the larger increase in authorized shares. (4) Scores reflect mostly accurate numbers (with one critical misinterpretation of the share cap timeline), good qualitative understanding of plan features, and full relevance to the question. The main failure is in not capturing the expansion of the program’s capacity, leading to a misleading narrative of contraction rather than growth with increased usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 511,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "In the 2022 filing, AdSense was called out as one of the three “Google Network” pillars (along with AdMob and Google Ad Manager) that lifted network revenue by $8.6 billion, even though the number of AdSense impressions was slipping. By the 2024 filing, AdSense is no longer highlighted as a separate line‑item; the company talks about its advertising business as a unified, AI‑driven technology stack (e.g., Demand Gen, Performance Max, Product Studio) that powers ads across Search, YouTube and partner‑site inventory. Thus, AdSense has moved from being a distinct, growth‑driving network segment in 2022 to being subsumed within Google’s broader, AI‑enhanced advertising‑technology portfolio by 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, AdSense was a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager; by 2024, it was no longer specifically quantified, with newer AI-powered products like Demand Gen and Performance Max taking center stage. (2) The $8.6 billion figure is correctly cited and attributed to the Google Network's growth in 2022. No calculations are required, and the number matches exactly. (3) The multi-hop reasoning is sound: the answer synthesizes information across two time points (2022 and 2024) and correctly infers a strategic shift—from AdSense being a highlighted growth lever to being integrated into a broader, AI-driven ad tech stack. (4) Entity accuracy is perfect: AdSense, AdMob, Google Ad Manager, Demand Gen, Performance Max, and Product Studio are all correctly named and contextualized within Google's advertising portfolio. The answer addresses all parts of the question, including the evolution of AdSense’s role and its relation to the broader ad tech portfolio. Wording differs slightly but conveys the same meaning—'subsumed within Google’s broader, AI-enhanced advertising-technology portfolio' aligns with the original answer's 'foundational, mature offering.' No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 398,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "- In the 2022 filing the UPS Retirement Plan was still a defined‑benefit plan that accrued benefits based on average compensation, but the company disclosed that **effective January 1 2023 it would stop accruing any additional benefits for future service or future compensation for non‑union participants** (the plan and the related Excess Coordinating Benefit Plan would “cease accruals” for those participants).  \n\n- The 2023 filing shows that this change has been put into effect: the UPS Retirement Plan **no longer accrues future‑service or future‑compensation benefits for non‑union participants**, freezing their benefit amounts, while union participants continue to accrue benefits as before.  Instead, non‑union employees now receive a retirement contribution to the UPS 401(k) plan.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) All key facts are correct: the UPS Retirement Plan was a defined-benefit plan in 2022 that ceased benefit accruals for non-union participants effective January 1, 2023. This date is correctly stated, and the distinction between non-union and union participants is accurately maintained. (2) There are no numerical values requiring calculation (e.g., dollar amounts), but the temporal marker 'January 1, 2023' is precise and matches the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across the 2022 and 2023 filings, identifying both the announcement of the change in 2022 and its implementation in 2023. It also correctly infers the strategic shift, noting the transition to a frozen plan for non-union employees and the shift to 401(k) contributions as a replacement mechanism, which aligns with the broader context in the original answer. (4) The LLM captures all elements of the original answer: noncontributory nature, eligibility cutoff (pre-July 1, 2016), IRS limits, cessation of accruals, and the differential treatment of union vs. non-union employees. While the LLM does not explicitly mention the Excess Coordinating Benefit Plan by name beyond the parenthetical, it correctly references its accrual freeze, and the omission does not detract from the core accuracy. Wording differences (e.g., 'freezing their benefit amounts' vs. 'cease accruals') are semantically equivalent. All scores are maximized due to full factual alignment, correct reasoning, and comprehensive coverage of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 451,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "In 2022 Amazon’s short‑term financing consisted of a $1 billion secured revolving credit facility (LIBOR + 1.40% with a 0.50% commitment fee) that had $803 million outstanding, a $7 billion unsecured revolving credit facility (benchmark + 0.50% with a 0.04% fee) with no borrowings, and a commercial‑paper program of up to $10 billion that carried about $725 million of paper at an effective rate of roughly 0.1 %. By the 2024 filing the secured revolver had been repaid and terminated (it had been borrowing $682 million at SOFR + 1.25% before termination), the unsecured revolving facility had been expanded to $15 billion (benchmark + 0.45% and 0.03% fee) and a new $5 billion 364‑day revolving facility was added (SOFR + 0.45%); the commercial‑paper capacity was raised to $20 billion but no paper was outstanding, and only modest working‑capital borrowings of $147‑$151 million remained. Overall, credit capacity grew substantially, benchmark rates shifted from LIBOR to SOFR, commitment fees fell, and outstanding short‑term debt fell from roughly $1.5 billion in 2022 to essentially zero (aside from a few hundred million in ancillary facilities) by the end of 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies despite capturing some correct elements. It incorrectly states that in 2022 Amazon had a $1 billion secured revolving credit facility with $803 million outstanding, which is not supported by the ground truth—no such secured facility is mentioned, nor were there any borrowings under the main $7.0 billion unsecured facility. The ground truth confirms zero borrowings under the primary credit facility in 2022. Additionally, the LLM introduces a commercial paper program of up to $10 billion with $725 million outstanding in 2022, which is entirely absent from the original answer and unsupported by the knowledge graph. These are major quantitative and factual errors. (2) The LLM correctly identifies the expansion to a $15.0 billion unsecured revolving facility in 2024 at benchmark rate plus 0.45% and a 0.03% commitment fee, and the addition of a new $5.0 billion 364-day facility with SOFR + 0.45% and 0.03% fee—these details align with the ground truth. It also correctly notes that borrowings under the main agreements were negligible by 2024 and mentions the $147 million and $151 million in other short-term borrowings in 2023 and 2024, which matches the original answer. However, it falsely claims the secured revolver was terminated and had prior borrowings, which is not in the source. It also incorrectly states commercial paper capacity was raised to $20 billion, which is not mentioned in the ground truth. (3) The multi-hop reasoning is partially sound—the model attempts to compare 2022 and 2024 structures and correctly infers a trend of increasing capacity and lower rates. It correctly notes the shift from LIBOR to SOFR. However, it fabricates facilities (secured revolver, commercial paper program) not present in the original data, undermining the reasoning chain. The conclusion that short-term debt fell from $1.5 billion to zero is incorrect—the ground truth shows only modest borrowings ($147–151 million), not a drop from $1.5 billion. (4) The contextual relevance is high—the answer addresses credit capacity, interest rates, fees, and outstanding borrowings across years, directly responding to the question’s focus. However, due to major quantitative inaccuracies and invented financial instruments, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some synthesis is valid, but based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1595,
        "completion_tokens": 654,
        "total_tokens": 2250
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "Costco’s 2022 filing notes that it “enters into variable‑priced contracts for some purchases of electricity and natural gas … on an index basis.” The 2023 filing repeats the same approach, stating that it “also enters into variable‑priced contracts for some purchases of natural gas, in addition to fuel for its gas stations, on an index basis” (and again references electricity). Thus, the company’s use of index‑linked, variable‑priced energy contracts has not changed – it continues to rely on a mix of fixed‑price agreements and modest, index‑based variable contracts. This consistency shows that Costco’s commodity‑price risk program is deliberately balanced: it locks in prices where feasible while retaining limited exposure through normal‑purchase contracts that do not require mark‑to‑market accounting, reflecting a non‑speculative, hedging‑oriented strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Costco used variable-priced, index-based contracts in both 2022 and 2023 for electricity, natural gas, and fuel for gas stations. The 2023 filing explicitly highlights natural gas and fuel for gas stations, which the LLM correctly notes. There are no incorrect numbers, dates, or entities—this is a qualitative question, so no calculations are needed. (2) Quantitative accuracy is perfect: no numerical inaccuracies, and the years (2022, 2023) are correctly attributed. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two years and filings, correctly identifying continuity in strategy and the application of the 'normal purchases and normal sales' exception (implied via 'no mark-to-market accounting'). It also infers the strategic rationale—balanced, non-speculative risk management—consistent with the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'normal purchases and normal sales' exception by name, though it accurately describes its effect (no mark-to-market accounting). This omission slightly affects qualitative accuracy but does not undermine the correctness of the conclusion. Overall, the answer is semantically equivalent to the ground truth, with excellent contextual relevance and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 385,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "In the 2022 Form 10‑K, NVIDIA AI Enterprise was described primarily as a **paid‑license software suite that sits alongside GPUs, CPUs and networking in the Data‑Center compute offering**, essentially an “operating system for enterprise‑grade AI applications.” By the 2024 Form 10‑K, the company positions AI Enterprise as a **core pillar of its full‑stack data‑center platform**, now bundled with newer services such as NVIDIA NIM, NeMo and AI Blueprints and marketed as the primary commercial software product that enables customers to develop, fine‑tune and deploy production‑grade generative‑AI workloads across any NVIDIA‑accelerated infrastructure. This shift shows AI Enterprise moving from a supplemental licensed add‑on in 2022 to a central, revenue‑generating component of NVIDIA’s data‑center strategy in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: NVIDIA AI Enterprise evolved from a licensed software suite in 2022 to a core commercial offering by 2024. The description of its role as foundational in 2022 and central to monetization in 2024 matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not applicable—no discrepancies exist. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 time points, identifies the shift in strategic positioning, and contextualizes it within NVIDIA’s broader data center platform evolution. The mention of NVIDIA NIM, NeMo, and AI Blueprints adds detail not in the original but is consistent with public knowledge and enhances accuracy without introducing error. (4) Semantic equivalence is strong: while the LLM uses slightly different phrasing (e.g., 'operating system for enterprise-grade AI applications' and 'core pillar'), these are reasonable interpretations that convey the same evolution—from foundational/strategic to central/commercial. The only minor gap is that the original emphasizes integration with DGX Cloud, CPUs, and DPUs, which the LLM omits, but this does not undermine the core correctness. Hence, a score of 9 is justified—excellent accuracy with negligible omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 392,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "In 2023 Pfizer was carrying a very large “Paxlovid‑related” contract balance – deferred‑revenue liabilities of about **$5.1 billion** (roughly $2.6 billion in current liabilities and $2.5 billion in non‑current liabilities) that represented advance payments from governments and other customers for future deliveries. By the end of 2024 that balance had fallen to **about $2.2 billion** (≈ $1.4 billion current + $0.8 billion non‑current) and the company reported **≈ $1 billion of remaining performance‑obligation revenue for Paxlovid**, with the current‑liability portion expected to be recognized within the next 12 months and the non‑current portion spread out from 2025 through 2028. The sharp reduction in contract liabilities and the shift of the remaining obligations to later years signal that the government‑stockpile era is ending and that Pfizer now expects Paxlovid’s future revenue to be lower‑volume and more drawn‑out as the product moves into a commercial‑market model.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that Pfizer recorded a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses under EUA, but the LLM instead reports deferred revenue liabilities of $5.1 billion in 2023 and $2.2 billion in 2024, which does not align with the original answer. These figures are not mentioned in the ground truth and contradict the core event — a revenue reversal, not a reduction in deferred revenue. While the LLM correctly notes $1 billion in remaining performance obligations as of end-2024, it misrepresents the 2023 situation entirely. (2) The calculation of liability reduction from $5.1B to $2.2B implies a $2.9B change, which is factually unsupported by the ground truth; no such deferred revenue balances are stated. The mention of non-current liabilities extending to 2028 adds detail not present in the original and may be plausible but is unverifiable and distracts from the key 2023–2024 shift in demand expectations. (3) The reasoning is partially sound — the LLM correctly infers a transition from government stockpiling to commercial sales and interprets declining liabilities as signaling lower future volume. It also captures the idea that future revenue is expected to be more stable and drawn out. However, it fails the multi-hop requirement to connect the 2023 revenue reversal (due to product returns) with the 2024 performance obligations, instead constructing an alternative narrative around contract liabilities. (4) Despite incorrect numbers, the LLM identifies the right trend — reduced near-term revenue expectations and a shift toward commercialization — and addresses both parts of the question (evolution of obligations and implications for future revenue). This earns moderate scores for qualitative accuracy and high relevance, but the quantitative errors severely undermine factual correctness, warranting a mid-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 540,
        "total_tokens": 1983
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "In the 2022 filing Google warned that an “evolving foreign‑policy landscape” could create **new regulatory costs and challenges**, chiefly around **data‑transfer rules (e.g., EU‑UK personal‑data transfers) and additional customer‑requirement obligations** in its international operations. By the 2024 filing the exposure had broadened dramatically: the company now lists **sanctions, import‑ and export‑controls, market‑access barriers, geopolitical unrest, armed conflict, anti‑corruption laws, labor‑law differences and uncertain regulatory outcomes (including potential litigation and unclear legal precedent)** as sources of new regulatory costs, indicating a shift from a narrow data‑privacy focus to a much wider set of geopolitical, trade‑, anti‑corruption‑ and labor‑related regulatory challenges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 regulatory concerns centered on data transfers (specifically EU-UK) and customer requirements, matching the original answer. In 2024, it accurately reflects the expanded scope, noting broader risks beyond data privacy. While the original answer emphasizes 'uncertainty regarding regulatory outcomes' and 'liabilities under local laws without due process or clear precedent,' the LLM answer captures this concept by citing 'uncertain regulatory outcomes (including potential litigation and unclear legal precedent)'—a semantically equivalent formulation. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all years (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes across two time points in Google’s filings, correctly identifying an evolution from narrow data-related concerns to broader geopolitical and legal risks. The LLM adds specific examples (sanctions, export controls, labor laws, anti-corruption) not explicitly listed in the ground truth, but these are plausible elaborations consistent with the 'broader regulatory risks' described and do not contradict the source. (4) The only reason for not giving a perfect 10 is that the original answer highlights a specific legal concern—'liabilities under local laws that may not offer due process'—which is slightly more precise than the LLM’s general reference to uncertain outcomes and litigation. However, the LLM’s phrasing is close enough in meaning to warrant a high score. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 471,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K disclose that UPS expects to pay post‑retirement medical benefits from **both the plan trusts and the company’s own (corporate) assets**.  The 2022 filing notes that “expected benefit payments for post‑retirement medical benefits will be paid from plan trusts and corporate assets,” and the 2023 filing repeats the same language.  Thus, UPS’s funding approach for these benefits did not change – the sources of expected payments remain the same in both years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth. (1) It accurately states that in both 2022 and 2023, UPS expected to fund postretirement medical benefits from both plan trusts and corporate assets, with no change in approach—this aligns exactly with the original answer. (2) There are no numerical figures requiring calculation in this question; the focus is on funding sources, which are correctly identified without any inaccuracies. (3) The multi-hop reasoning is sound: the model correctly compares the language used in both years’ 10-K filings and concludes there was no change, demonstrating proper synthesis across documents. (4) The answer is semantically equivalent to the ground truth, uses precise supporting quotes, and directly addresses all parts of the question. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 250,
        "total_tokens": 1473
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "When NVIDIA first announced NVIDIA AI Enterprise in its 2022 filing, it was described simply as a paid‑license, enterprise‑grade AI‑software suite (alongside its vGPU offering) that complemented the company’s data‑center and compute‑&‑networking platforms. By the 2024 filing the suite had been broadened into a full‑stack AI portfolio—now including the NIM token‑throughput engine, the NEMO model‑curation and fine‑tuning framework, and ready‑to‑run AI Blueprints—so that NVIDIA AI Enterprise is supplied widely across cloud, on‑premise and edge deployments and serves as a central component of NVIDIA’s end‑to‑end AI platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: NVIDIA AI Enterprise was introduced in 2022 as an enterprise AI software suite and evolved by 2024 into a full-stack platform. The inclusion of NIM, NeMo (spelled as NEMO, acceptable variant), and AI Blueprints is accurately noted. (2) Quantitative accuracy is perfect—while no explicit numbers like '2.5x increase in token throughput' are mentioned, the reference to 'NIM token-throughput engine' implies performance enhancements, and no incorrect figures are presented. The omission of the exact 2.5x metric is a minor gap but does not detract significantly from correctness. (3) Multi-hop reasoning is sound: the answer synthesizes evolution over time (2022 to 2024), identifies the shift from a basic suite to a broader platform, and correctly links it to deployment expansion across cloud, on-premise, and edge. (4) Semantic equivalence is strong—wording differs but meaning aligns closely with the original. The term 'full-stack AI portfolio' matches 'full-stack, production-grade generative AI platform.' Only slight deduction in qualitative accuracy due to lack of explicit performance metric (2.5x), but overall reasoning and entity identification (NVIDIA, years, components) are correct. Contextual relevance is perfect—directly addresses the evolution in role and scope as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 390,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "**Evolution of equity‑company proved reserves**\n\n* **2022** – The 2022 Form 10‑K (see XOM 2022 p. 20‑24) reported equity‑company proved reserves of roughly **1.3 billion oil‑equivalent barrels** (the sum of crude oil, NGL, bitumen, synthetic oil and gas converted to oil‑equivalent).\n\n* **2024** – The 2024 Form 10‑K (see XOM 2024 p. 8‑12) shows equity‑company proved reserves of **1.48 billion oil‑equivalent barrels**.  The regional breakdown is:\n\n| Region (Equity Companies) | Crude oil (mm bbl) | NGL (mm bbl) | Natural gas (bcf) | Oil‑equivalent (mm bbl) |\n|---------------------------|-------------------|--------------|-------------------|--------------------------|\n| United States             | 6                 | 3            | 47                | 17                       |\n| Europe                    | 2                 | –            | 262               | 45                       |\n| Africa                    | 7                 | –            | 816               | 143                      |\n| **Asia**                  | **452**           | **117**      | **4,242**         | **1,276**                |\n| Total equity‑company      | **467**           | **120**      | **5,367**         | **1,481**                |\n\n**What the change indicates**\n\nThe modest overall increase (≈ 150 million oil‑equivalent barrels) is driven almost entirely by growth in **Asia** and, to a lesser extent, **Africa**.  Equity‑company holdings in the United States and Europe remain tiny, while Asian equity assets now contribute more than **85 %** of the equity‑company oil‑equivalent reserve base.  This pattern shows ExxonMobil is using its equity‑company interests to expand its strategic footprint in high‑growth, demand‑rich regions—particularly the Asian market—while maintaining a limited equity presence in its traditional U.S. and European basins.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. According to the ground truth, in 2022, ExxonMobil's equity-company proved reserves were 14 million barrels gross (1 million net), not 1.3 billion oil-equivalent barrels as claimed. The LLM's 2022 figure is over 90 times larger than the true value, representing a major factual error. While the 2024 data (467 million barrels crude oil, 120 million NGL, 5,367 bcf gas) matches the ground truth, the derived oil-equivalent total of 1.48 billion barrels is inconsistent with the 2022 baseline provided in the original answer. The regional breakdown for 2024 appears fabricated—the ground truth does not provide such a detailed table, nor does it mention specific values for the U.S., Europe, or Africa in 2024. The claim that equity reserves increased by ~150 million oil-equivalent barrels is unsupported by the original data, which only states a significant increase without quantifying the difference. However, the qualitative assessment about strategic focus on Asia is consistent with the ground truth and shows correct multi-hop reasoning: the LLM correctly infers from the 2024 data that growth is concentrated in Asia and interprets this as a strategic shift, which aligns with the original answer. The contextual relevance is high—the response directly addresses the evolution and strategic implications—but the severe numerical inaccuracies, especially in the 2022 baseline, severely reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1602,
        "completion_tokens": 414,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "In both the 2022 and 2024 filings Alphabet continues to treat ads that run on Google Network properties as **gross‑reported advertising revenue** – the full amount billed to advertisers is recorded as revenue, while the amounts it pays the Network partners are shown as **cost of revenues**.  Accordingly, the partners remain a key source of advertising dollars but also a direct cost line.  Between 2022 and 2024 the cash outflows to Google Network partners grew (the 2024 filing notes that “payments to … Google Network partners” are a primary use of operating cash), reflecting higher overall ad sales and a larger share of those sales being generated through the Network.  Thus, the partnership’s role in generating revenue has expanded, and the corresponding cost‑of‑revenues component has risen in step.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that Google reports advertising revenue from Google Network Partners on a gross basis in both 2022 and 2024, with payments to partners recorded as cost of revenues—this matches the original answer’s description of the accounting treatment. (2) There are no specific numerical values (e.g., dollar amounts or percentages) in either the question or the ground truth, so quantitative accuracy is not compromised; the LLM appropriately avoids inventing figures and correctly references the growing cash outflows to partners as noted in the 2024 filing. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2024), correctly identifies the continuity in revenue recognition policy, and adds contextual insight about increasing cash outflows reflecting growth in network-driven ad sales—this is consistent with and expands upon the ground truth’s point about a more cost-centric framing in 2024. (4) The only minor gap is that the LLM emphasizes the expansion of the partnership’s role in revenue generation slightly more than the original, which focuses on a shift in financial reporting emphasis toward cost impact. However, this does not contradict the truth and can be reasonably inferred. Wording differs but semantic meaning is equivalent or richer. All entities—Google Network Partners, cost of revenues, operating cash flows—are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 413,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "Between 2022 and 2023 UPS shifted more of its foreign‑currency exposure into designated hedge programs, leaving far fewer forward contracts “non‑designated.”  As a result, the loss recorded on undesignated foreign‑currency forward contracts fell from $69 million in 2022 to only $7 million in 2023, dramatically reducing the volatility such contracts create in earnings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces specific numerical figures ($69 million in 2022 and $7 million in 2023) that are not present in the original ground truth answer. The original answer does not provide any quantitative financial impact of undesignated foreign currency forward contracts—only a qualitative description of how UPS's disclosure and presentation evolved. Therefore, the inclusion of precise dollar amounts and claims about a reduction in losses constitutes a significant factual fabrication. Additionally, the claim that UPS shifted exposure into designated hedge programs is not supported by the original answer, which focuses on enhanced disclosure and structured presentation of fair value changes, not a strategic shift in hedging designations. The reasoning is flawed because it invents a cause-effect relationship (fewer undesignated contracts leading to lower losses) that is not in the source. While the answer addresses the general topic of earnings volatility related to undesignated forwards, it fails to accurately reflect the actual evolution described—improved transparency and side-by-side reporting—making the core of the response factually and logically unsound. Contextual relevance is moderate because it attempts to address foreign currency risk management and earnings volatility, but the details are misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 376,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "In the 2022 filing Costco stressed that its membership format is a core profitability lever because it “reinforces member loyalty and provides continuing fee revenue.”  That year the company said the format delivered a **9 % rise in membership‑fee revenue** (to $4.2 billion) as new sign‑ups, Executive‑member upgrades and a higher renewal rate boosted loyalty.\n\nThe 2023 filing repeats that the format remains “integral” to profitability and still drives fee income, but adds a new focus on **renewal‑rate risk in newer markets** – noting that worldwide renewal could be hurt by lower rates in those locations.  Even with that caution, fee revenue still grew (about **5 % to $4.8 billion**), showing the format continues to underpin loyalty‑driven earnings while the company now monitors more closely the sustainability of that loyalty as it expands.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, the original answer does not provide specific numbers such as a '9% rise in membership-fee revenue to $4.2 billion' in 2022 or a '5% increase to $4.8 billion' in 2023. These figures are fabricated or incorrectly inferred, as the ground truth focuses on qualitative language evolution and strategic concerns, not quantitative revenue changes. There is no mention in the original answer of exact fee revenue amounts or growth percentages, so these numbers are unsupported. (2) The quantitative inaccuracies are major: the $4.2B and $4.8B figures and the 9% and 5% growth rates are not present in the ground truth and contradict the available data. Even allowing for format variation, invented numbers cannot be accepted. (3) The qualitative reasoning is strong: the LLM correctly identifies the evolution in tone—from emphasizing loyalty and growth in 2022 to highlighting risks in renewal rates in newer markets in 2023. It accurately captures the shift in strategic focus and the continued centrality of membership to profitability, which reflects proper multi-hop synthesis of the strategic narrative across years. (4) Contextual relevance is high, as the answer directly addresses the question about the evolution of the membership model’s role in profitability, member loyalty, and fee revenue. Despite incorrect numbers, the conceptual framework and direction of analysis align well with the original answer. However, the inclusion of false quantitative data severely undermines factual correctness, warranting a moderate overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 456,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA as the “fundamental programming model” that runs on all its GPUs and serves as the core building block of a GPU‑centric accelerated‑computing platform, supported by CUDA‑X libraries and a developer base of roughly 3 million users. By the 2024 filing, CUDA is presented as one component of a broader, heterogeneous data‑center stack that now includes CPUs, DPUs and a full suite of enterprise software (AI Enterprise, APIs, SDKs), with the developer community expanding to about 5.9 million, showing that CUDA has been more tightly integrated into a unified hardware‑software ecosystem rather than being a GPU‑only focus.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of CUDA from a GPU-centric programming model in 2022 to a more integrated component of a heterogeneous data center platform by 2024. It accurately reflects the strategic shift toward full-stack integration with CPUs, DPUs, and enterprise software. However, the developer count in the original answer is stated as 'nearly 3 million' in 2022 and does not specify a number for 2024, whereas the LLM claims an increase to 'about 5.9 million' in 2024, which is not supported by the ground truth and introduces a potentially inaccurate quantitative claim. (2) The numbers for developer count are partially incorrect: while 3 million in 2022 aligns approximately with the original answer, the 5.9 million figure for 2024 is not present in the ground truth and thus constitutes a factual overreach. No other numerical values (dates, percentages, dollar amounts) are present, so the error is isolated to this one metric. (3) The multi-hop reasoning is strong: the model correctly synthesizes information across 2022 and 2024 time points, identifies the shift from developer-focused tooling to infrastructure-layer integration, and connects CUDA to broader platform elements like CUDA-X, APIs, and enterprise software. It correctly infers the strategic evolution even if it adds unsupported numerical detail. (4) The correctness score is 8 due to accurate core facts and reasoning but penalized for the unsupported 5.9 million developer figure. Quantitative accuracy is 7 because one key number is fabricated. Qualitative accuracy is 9 due to strong reasoning and entity identification. Contextual relevance is 10 as the answer directly addresses the question’s focus on integration within the data center and software ecosystem.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 484,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "In the 2023 Form 10‑K Pfizer reported roughly $5.1 billion of deferred revenue tied to advance payments for Paxlovid (and Comirnaty), reflecting a large pool of contracts that were expected to generate revenue through 2028. By the 2024 filing the deferred‑revenue balance had fallen to about $2.2 billion and the “remaining performance‑obligation” schedule showed roughly $1 billion of contracted Paxlovid revenue still to be recognized, with the current contracts calling for product deliveries beginning in 2025 and continuing through 2028. Thus, the company’s financial commitment to Paxlovid has been cut roughly in half and the expected future revenue stream has been reduced, while the delivery timeline remains anchored to the 2025‑2028 period.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in Pfizer's financial commitment and contractual obligations for Paxlovid from 2023 to 2024, correctly identifying the shift from uncertain revenue (due to returns) to a more defined forward-looking revenue stream through firm contracts with delivery timelines from 2025–2028. However, it omits the key 2023 non-cash revenue reversal of $3.5 billion related to the return of 6.5 million treatment courses from U.S. government inventory, which is central to understanding the financial shift. Instead, it references $5.1 billion in deferred revenue in 2023 and $2.2 billion in 2024, figures not present in the ground truth and potentially conflating Paxlovid with Comirnaty. (2) The quantitative inaccuracies are significant: the ground truth does not mention deferred revenue balances of $5.1B or $2.2B; instead, it specifies a $3.5B revenue reversal in 2023 and $1B in remaining performance obligations by 2024. The LLM’s claim that financial commitment was 'cut roughly in half' is based on incorrect inputs and thus misleading. While the $1B remaining obligation and 2025–2028 delivery timeline match the ground truth, the supporting numbers do not. (3) The multi-hop reasoning is partially sound—LLM correctly infers a trend of declining future revenue commitments and extended delivery schedules—but fails to anchor this in the correct financial events (i.e., revenue reversal vs. deferred revenue drawdown). (4) Despite incorrect intermediate figures, the LLM arrives at the correct endpoint ($1B future revenue, 2025–2028 delivery), and fully addresses the question’s focus on evolution in financial commitment and delivery timelines. Hence, the answer is partially correct with major quantitative flaws but sound overall direction and context, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 499,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "In the 2022 filing ExxonMobil noted that “extensions and discoveries, primarily in the United States, Brazil, and **Guyana**, resulted in an addition of about 1.3 billion oil‑equivalent barrels of proved‑undeveloped reserves,” indicating that Guyana was still being treated as a reserve‑development opportunity. By the 2024 filing the company lists **Guyana** together with Permian and LNG as an “**advantaged asset**” under its Advantaged Volume Growth drivers, showing that the project has moved from early‑stage reserve additions to a core, high‑value growth asset in its strategic portfolio.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately reports that in 2022, Guyana contributed to 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves as part of extensions and discoveries, matching the original answer. (2) The quantitative information is precise: '1.3 billion oil-equivalent barrels' is correctly cited with no calculation required. (3) The multi-hop reasoning is sound—comparing Guyana’s classification in 2022 (reserve-development opportunity) to its 2024 status as an 'advantaged asset' alongside Permian and LNG—correctly inferring a strategic evolution. (4) The entities (ExxonMobil, Guyana, Permian, LNG, advantaged assets) and years (2022, 2024) are accurate. The answer captures the core transition from reserves growth to advantaged production and earnings visibility, fully addressing the question with correct context, terminology, and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 272,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx committed to receive 11 ATR 72‑600F aircraft in 2023 and 6 more in 2024 – a total of 24 ATR turboprops slated for near‑term entry into service. By the 2024 filing the commitment had been reduced to 7 deliveries in 2025 and 3 in 2026 (10 aircraft total), with no ATRs scheduled for 2024. This shift shows the ATR 72‑600F is still intended to support FedEx’s regional, lower‑cost capacity needs, but its rollout has been delayed and scaled back, indicating a more modest, supplemental role in the overall fleet strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 the company projected a decrease from 11 units in 2023 to just 1 by 2026. However, the LLM claims that in 2022, FedEx committed to receiving 11 ATR 72-600F aircraft in 2023 and 6 more in 2024, totaling 24 ATR turboprops — none of which aligns with the original answer. The total number of aircraft (24) is fabricated, and the delivery schedule (6 in 2024) contradicts the ground truth. By 2024, the original answer states the projection shifted to 7 units in 2025 and declining to 3 by 2026, which the LLM correctly reports as 7 in 2025 and 3 in 2026. However, it incorrectly frames this as 'deliveries' rather than 'planned units', implying new acquisitions rather than fleet size projections. (2) Quantitative accuracy is low: the numbers for 2023 (11), 2025 (7), and 2026 (3) are partially correct but taken out of context. The claim of 6 deliveries in 2024 and a total of 24 ATRs has no support in the ground truth. The original answer does not mention any deliveries in 2024 or a total fleet of 24. (3) The multi-hop reasoning is partially sound — the model identifies a strategic shift from an aggressive phase-out to a more sustained role — but misrepresents the nature of the data (deliveries vs. fleet size) and invents commitments not present in the source. The conclusion about a 'more modest, supplemental role' is semantically close to the original's 'sustained, albeit reduced, role', showing some correct qualitative inference. (4) Scores reflect major quantitative errors (3/10), partial qualitative accuracy due to correct directional interpretation (5/10), high contextual relevance as it addresses fleet strategy evolution (8/10), and an overall correctness score of 4 due to core factual inaccuracies despite some correct elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 504,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "In the 2022 filing NVIDIA presented Omniverse mainly as a software‑subscription (free for individuals) that enables real‑time 3‑D collaboration and virtual‑world simulation, and it was highlighted as the simulation engine behind its automotive‑focused tools such as DRIVE Constellation/Sim for synthetic‑data generation and self‑driving validation. By the 2024 filing the company has repositioned Omniverse as an enterprise‑grade development platform and operating system for industrial AI and digital‑twin applications, tying it into the broader AI‑Enterprise stack, cloud‑based compute and data‑center offerings, and promoting its use across multiple industries beyond automotive. This shift shows Omniverse moving from a standalone 3‑D collaboration product toward a core, integrated component of NVIDIA’s end‑to‑end AI and simulation ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of NVIDIA's Omniverse from a 3D collaboration and simulation platform in 2022 to a more comprehensive enterprise development platform in 2024. Key details such as the free individual vs. enterprise subscription model in 2022 and the shift toward industrial AI, digital twins, and integration with NVIDIA's broader AI stack in 2024 are accurately captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—however, the years (2022 and 2024) are correctly referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the LLM synthesizes information across time (2022 to 2024), platforms (Omniverse, DRIVE Constellation/Sim), and strategic positioning (from standalone tool to integrated ecosystem component). It correctly infers the expansion beyond automotive into broader industrial applications, which is implied in the ground truth through examples like factory digital twins and robot testing. (4) The only minor gap is that the LLM answer emphasizes integration with DRIVE Constellation/Sim in 2022 more than the ground truth does, which focuses on VR/AR applications like virtual showrooms and surgical training. While not incorrect (DRIVE integration is plausible), this slightly shifts emphasis. Conversely, the LLM omits mention of VR/AR use cases present in the original. However, these are omissions of context rather than factual errors. Overall, the semantic meaning and strategic evolution are correctly conveyed, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 460,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "Google Play remained a core component of Alphabet’s “Google other” (non‑advertising) revenues in both years, but its contribution grew in 2023 as the company’s overall non‑advertising revenue expanded.  In the 2022 filing Google Play was described as a source of app‑sales, in‑app‑purchase and digital‑content revenue, and the 2023 filing notes that non‑advertising revenues continued to rise, with Google Play still listed among the key drivers—indicating that its role in generating non‑advertising revenue became larger in 2023 than it was in 2022.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of entities, years, and the general evolution of Google Play's role in non-advertising revenue. It correctly identifies Google Play as a contributor to non-advertising revenue in both 2022 and 2023, citing app sales, in-app purchases, and digital content. The quantitative accuracy is high—no specific numerical figures are present in either answer, so the absence of incorrect numbers supports a score of 10. Contextual relevance is strong, as the response directly addresses the question about Google Play’s evolving role. However, the LLM answer falls short in qualitative accuracy compared to the original answer: it states that Google Play's contribution 'grew' and 'became larger' in 2023, which implies a quantitative increase not explicitly confirmed in the ground truth. The original answer emphasizes a *strategic and categorical evolution*—a shift in how Google Play was positioned within the business (from diversification to a defined 'platforms' revenue stream)—rather than focusing on revenue growth. The LLM misses this nuance about structural reclassification and strategic emphasis, instead interpreting the evolution primarily through the lens of increasing contribution. This reflects a partial failure in multi-hop reasoning: while it synthesizes the presence of Google Play in both years, it infers growth in contribution without sufficient grounding in the categorization shift highlighted in the original. Thus, while the core facts are correct, the reasoning and conceptual framing are less precise, warranting a 7 in correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 448,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "Both the 2022 and 2023 filings describe the same reserving framework for U.S. workers‑compensation: AIG combines loss‑development, frequency‑severity and expected‑loss‑ratio (ELR) techniques, separating guaranteed‑cost and excess‑of‑deductible business. In 2023 the company adds that the share of large‑deductible policies has grown, further slowing claim emergence, but it still gives ELR methods significant weight only to the most recent accident year for guaranteed‑cost business and to the most recent five accident years for excess‑of‑deductible business, using projected ultimate loss ratios adjusted for rate changes, loss‑trend, inflation and market conditions—essentially the same approach used in 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution (or lack thereof) in AIG's use of expected loss ratio (ELR) methods in workers' compensation reserving between 2022 and 2023. (1) It correctly identifies that the reserving framework remained consistent across both years, combining loss development, frequency/severity, and ELR methods, with a distinction between guaranteed cost and excess of deductible (or large deductible) business. It accurately states that in both years, ELR methods were given significant weight only in the most recent accident year for guaranteed cost and the most recent five accident years for excess-of-deductible business—this matches the ground truth exactly. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the question or ground truth, so quantitative accuracy is not applicable in a traditional sense, but all temporal references (e.g., 'most recent accident year', 'five accident years') are correct, earning a perfect score. (3) The LLM correctly synthesizes multi-hop information: it links the consistent methodology across years, notes the continued growth in large deductible policies slowing claim emergence (a point mentioned in both years), and implies no methodological shift despite reporting refinements. However, it omits a specific detail from the 2023 filing about incurred and paid losses now being presented net of reinsurance and undiscounted—a transparency refinement noted in the ground truth. This is a minor omission that doesn’t undermine the overall correctness but prevents a perfect 10. (4) The answer is fully contextually relevant, directly addressing the evolution of ELR use in both business lines. Wording differs but semantic meaning is equivalent. Thus, the answer is excellent with only a slight gap in completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 493,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "In fiscal 2022 Cisco began reporting product revenue in six categories – Secure Agile Networks, Internet for the Future, Collaboration, End‑to‑End Security, Optimized Application Experiences and Other Products. By fiscal 2024 the company consolidated those groups into four categories – **Networking** (combining Secure Agile Networks and Internet for the Future), **Security** (absorbing End‑to‑End Security), **Collaboration** (kept as a stand‑alone line) and a new **Observability** category (derived from Optimized Application Experiences). The Collaboration segment remained a distinct category, but its revenue slipped from $4.472 billion in FY 2022 to $4.113 billion in FY 2024 (about an 8% decline), while the overall segmentation shifted to a simpler four‑category framework.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Cisco's product category segmentation between fiscal 2022 and 2024. It correctly identifies the six original categories in FY2022 and the consolidation into four in FY2024, noting that Collaboration remained standalone while other categories were merged or reclassified. The introduction of Observability as a new category is correctly stated. The qualitative reasoning is sound and reflects proper multi-hop synthesis across fiscal years. However, the quantitative accuracy is slightly compromised: while the ground truth does not provide specific revenue figures for Collaboration in FY2022 or FY2024, the LLM introduces numbers ($4.472 billion and $4.113 billion) and calculates an 8% decline, which are not present in the original answer and cannot be verified from the provided ground truth. This addition of unsupported numerical data—though plausible—introduces factual claims beyond the source, slightly reducing quantitative accuracy. Despite this, the core structural and categorical analysis is fully aligned with the ground truth, making the answer contextually relevant and qualitatively excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 331,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "In the 2022 Form 10‑K Amgen presented the 3.125 % 2025 senior notes simply as a $1 billion fixed‑coupon issue and disclosed that it had entered into an interest‑rate‑swap that “effectively converted” the coupon to **LIBOR + 1.8 %** (the swap was shown in the “Effective interest rates on notes for which we have entered into interest‑rate‑swap contracts” table).  \n\nIn the 2023 Form 10‑K the same $1 billion 3.125 % 2025 note remains on the debt schedule, but the swap disclosure now uses the new benchmark **SOFR**, showing an effective rate of **SOFR + 2.1 %** (the swap table is updated to reflect the transition from LIBOR to SOFR).  \n\nThus, the note’s presentation is unchanged in amount, but the associated interest‑rate framework shifted from a LIBOR‑based swap to a SOFR‑based swap with a slightly higher spread.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the right question and showing relevant reasoning. (1) The original answer states that in 2022, Amgen did *not* disclose any specific interest rate framework for the 3.125% 2025 Notes—only the $1,000 million carrying value was reported. However, the LLM claims that in 2022, Amgen disclosed an interest rate swap converting the note to LIBOR + 1.8%, which contradicts the ground truth. This is a major factual error. (2) The LLM correctly identifies the 2023 disclosure of SOFR + 2.1% as the new interest rate framework, aligning with the ground truth. The $1 billion (i.e., $1,000 million) carrying value is accurately reported for both years, satisfying quantitative consistency on that point. (3) The multi-hop reasoning is partially sound—comparing disclosures across years and recognizing the shift from LIBOR to SOFR is contextually appropriate and relevant. However, the model fabricates the 2022 LIBOR + 1.8% detail, which was not present in the original data, leading to incorrect synthesis. (4) While the answer correctly notes the increased transparency in 2023 by including the interest rate mechanism, it misrepresents the 2022 disclosure as more detailed than it actually was. Thus, despite correct formatting, contextual framing, and partial accuracy on the 2023 update, the invention of a swap in 2022 that wasn't disclosed results in a low correctness score. Quantitative accuracy is moderate due to correct dollar amounts but incorrect interest rate figures. Qualitative accuracy suffers due to flawed entity-relation mapping (wrongly associating a swap with the 2025 notes in 2022). Contextual relevance is high because the structure and intent of the response match the question’s requirements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 491,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "In the 2022 10‑K ConocoPhillips reported 326 billion cubic feet (BCF) of developed and undeveloped natural‑gas reserves in its consolidated Asia‑Pacific/Middle‑East operations; that figure fell to 296 BCF by the end of 2024 (‑30 BCF, about 9 %). However, the company’s equity‑affiliate holdings—also located in the same region—rose from 5,753 BCF in 2022 to 5,870 BCF in 2024, pushing total regional reserves from roughly 6,080 BCF to 6,170 BCF. The drop in its own operating reserves combined with modest growth in affiliate‑owned gas assets indicates COP is leaning more on partnership‑based projects to stay positioned in the Asia‑Pacific/Middle‑East gas market, preserving a strong overall regional footprint while trimming or reallocating its direct asset base.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the 2022 and 2024 natural gas reserves for COP in the Asia Pacific/Middle East region as 326 BCF and 296 BCF, matching the ground truth. The calculation of a 30 BCF decrease and ~9% decline is accurate. However, the LLM introduces new data not present in the original answer or implied by the question — specifically, equity-affiliate holdings of 5,753 BCF in 2022 and 5,870 BCF in 2024, and total regional reserves of ~6,080 BCF to ~6,170 BCF. These figures are not part of the ground truth and appear to be fabricated or hallucinated, as the original answer makes no mention of affiliate holdings or total regional reserves. (2) While the core numbers for COP’s direct reserves are correct, the additional quantitative claims about affiliate reserves and total regional totals are unsupported and factually unverifiable from the provided ground truth, undermining quantitative accuracy. (3) The reasoning is logically coherent — the LLM infers a strategic shift toward partnership-based projects — but this conclusion is based on fabricated data. The original answer only suggests a potential strategic shift or divestment due to the decline in direct reserves; it does not support the more nuanced claim about increasing affiliate involvement. Thus, the multi-hop reasoning fails because it synthesizes non-existent data. (4) The contextual relevance is high because the answer addresses the evolution of reserves and attempts to interpret strategic positioning. However, the correctness score is low due to significant factual overreach and introduction of false data, despite partial accuracy on the primary metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 455,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "In 2022 Alphabet repurchased **469 million Class C shares** for roughly **$52.6 billion**. In 2023 it repurchased **450 million Class C shares** for about **$52.9 billion** – a slightly smaller share count but a slightly larger dollar amount because the shares were priced higher. This shows that Alphabet is maintaining an aggressive buy‑back program, using its strong cash flow to return capital to shareholders even as share prices rise, indicating a capital‑allocation focus on shareholder returns rather than major new investments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, Alphabet repurchased $59.3 billion in 2022 and $62.2 billion in 2023 across Class A and Class C shares. However, the LLM claims $52.6 billion in 2022 and $52.9 billion in 2023, solely for Class C shares, which underreports both years and misattributes the scope. Additionally, the LLM introduces specific share counts (469 million and 450 million) not present in the original answer and unsupported by the ground truth provided. (2) The quantitative inaccuracies are substantial: the dollar amounts are off by ~$7 billion in 2022 and ~$9 billion in 2023. The answer also fails to mention the $70.0 billion repurchase authorization in April 2023 and the $36.3 billion remaining as of year-end—critical context about capital allocation strategy. (3) While the LLM correctly infers that share repurchases indicate a focus on shareholder returns, it misses the multi-hop insight that the buyback program *expanded* year-over-year in dollar terms and was further boosted by a new authorization. Instead, it frames the change as a minor shift in share count due to price, which contradicts the ground truth of a clear increase in total repurchase value. (4) The contextual relevance is fair because the answer addresses repurchase activity and capital allocation strategy, but the incorrect numbers and missing strategic developments (new authorization, remaining capacity) severely undermine the accuracy. The reasoning is partially sound but built on incorrect data, leading to a misleading conclusion about the scale and trajectory of the buyback program.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 459,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "In the 2022 filing AIG said it applied frequency‑/severity techniques only to short‑tail classes such as U.S. Property (and similar short‑tail lines), noting that they are unsuitable for high‑severity, long‑tail businesses like aviation, which rely on loss‑development and expected‑loss‑ratio methods. By the 2023 filing the company added Workers’ Compensation to the set of lines that use a combination of loss‑development, frequency‑/severity and expected‑loss‑ratio methods, reflecting the growth of large‑deductible, risk‑sharing programs that make both claim frequency and severity informative even for a traditionally long‑tail line. The reasoning therefore shifted from using frequency‑/severity only where losses emerge quickly and are predictable to also employing them where mixed‑severity exposures and deductible structures require a more granular view of claim patterns.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, AIG used frequency/severity methods for short-tail lines like U.S. Property and excluded aviation due to high severity and claim variability; by 2023, the method was extended to U.S. Workers' Compensation, a long-tail line, as part of a blended approach. The reasoning tied to risk-sharing and large deductible programs is accurately captured. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022, 2023) and business lines (U.S. Property, Workers’ Compensation, aviation) are correctly identified—no quantitative errors. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time (2022 vs 2023), identifies the shift from short-tail to long-tail applications, and explains the strategic rationale involving deductible structures and claim pattern analysis. The only minor shortcoming is that the original answer explicitly mentions 'combination of methods that also included loss development and expected loss ratio methods,' which the LLM mentions but could have emphasized more clearly. (4) The answer is contextually excellent—directly addresses the evolution in usage, lines of business, and reasoning. Wording differs slightly but maintains semantic equivalence. No irrelevant or incorrect information is introduced. A score of 9 is justified due to full factual alignment with only slight room for more precise emphasis on the method combination in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 424,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "In 2022 Amgen recovered **$199 million** of oncology R&D costs from BeiGene, recorded **$64 million** of product sales to BeiGene and incurred **$53 million** of profit‑and‑loss‑share expense. In 2023 the cost‑recovery fell to **$109 million**, product sales rose to **$125 million**, and profit‑and‑loss‑share expense declined to **$40 million** (AMGN 10‑K 2023, pages 129‑133).  Thus, the partnership shifted from higher cost‑recovery and profit‑loss sharing in 2022 to lower recoveries and sharing but substantially higher sales to BeiGene in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: All financial figures are correct—$199 million (2022 cost recovery), $64 million (2022 product sales), $53 million (2022 profit and loss sharing), and $109 million (2023 cost recovery), $125 million (2023 product sales), $40 million (2023 profit and loss sharing). Minor formatting differences (e.g., en-dashes, bolding) do not affect accuracy. (2) Completeness: The answer addresses all three dimensions in the question—cost recovery, product sales, and profit and loss sharing—across both years. (3) Entity accuracy: Correctly identifies Amgen and BeiGene, uses correct fiscal years (2022 and 2023), and accurately labels financial metrics. (4) Reasoning: The synthesis across years is sound, correctly noting the decrease in cost recovery and profit-sharing expenses and the increase in product sales. The concluding interpretation aligns with the ground truth, indicating a maturation of the collaboration. (5) Semantic equivalence: The meaning and factual content are identical to the original answer, with only stylistic differences. The citation to AMGN 10-K 2023, pages 129–133 adds contextual support. All multi-hop elements (comparing two companies across two years on three financial dimensions) are correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 370,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East fell from 326 billion cubic feet (BCF) at 12/31/2022 to 296 BCF at 12/31/2024, a net decline of about 30 BCF【COP_10k_2024.pdf p. 144‑145】.  The region saw modest upward revisions of +6 BCF in 2022 and +9 BCF in 2023, but a small downward revision of ‑2 BCF in 2024, while production withdrawals grew from ‑24 BCF (2022) to ‑25 BCF (2023) and ‑51 BCF (2024)【COP_10k_2024.pdf p. 144‑147】.  No purchases were recorded for the Asia Pacific/Middle East segment in any of those years【COP_10k_2024.pdf p. 144‑147】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers, particularly regarding production and revisions. While the starting (326 BCF in 2022) and ending (296 BCF in 2024) reserve figures match the ground truth and are correct, the breakdown of changes during the period is largely incorrect. The ground truth states that only 2023 revisions (+9 BCF) and 2024 production (-25 BCF) are reported for the relevant period, with no mention of 2022 or 2024 revisions. However, the LLM claims +6 BCF revision in 2022, +9 BCF in 2023, and -2 BCF in 2024 — only the +9 BCF revision in 2023 is correct. More critically, the LLM reports production of -51 BCF in 2024, which directly contradicts the ground truth stating production subtracted 25 BCF in 2024. This is a major quantitative error. Additionally, the LLM claims production was -24 BCF in 2022 and -25 BCF in 2023, but the ground truth does not provide production values for those years, making this an unsupported addition. (2) The net change from 326 to 296 BCF (a 30 BCF decline) is correctly calculated. However, the LLM attributes this to a combination of revisions and much higher production withdrawals than stated in the ground truth, undermining the accuracy of the causal explanation. The claim of 'no purchases' in any year aligns with the ground truth's statement of 'no purchases reported directly affecting this region in 2024', though the LLM extends this to all years without explicit support. (3) The multi-hop reasoning is partially sound in structure — the model attempts to decompose reserve changes into revisions, production, and purchases — but fails in execution due to incorrect data retrieval. It synthesizes across years but introduces data not present in the source or misaligned with the timeframes. (4) Correctness score is 4 due to partial factual correctness on the main reserve levels but major errors in the explanatory components. Quantitative accuracy is low (3) due to incorrect production and revision figures. Qualitative accuracy is moderate (5) because the framework of analysis is appropriate but based on flawed data. Contextual relevance is high (8) as the answer addresses all aspects of the question and cites relevant document pages.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 603,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it had committed to buy 14 Boeing 767‑300 Freighters for delivery in 2023 and another 14 for delivery in 2024 (28 B767Fs slated within two years). By the 2024 filing the only B767F commitments left were 11 to be delivered in 2025 and 3 in 2026, with no B767Fs scheduled for 2023‑2024. This shift shows FedEx is postponing the bulk of its B767F acquisitions, folding them into a later‑stage modernization program and emphasizing a longer‑term, phased‑in strategy for a more fuel‑efficient fleet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, not purchasing 14 for delivery in each year. The LLM incorrectly frames this as a purchase commitment of 28 aircraft (14 in 2023 and 14 in 2024), which contradicts the original answer stating projected usage, not acquisitions. By 2024, the ground truth shows revised projections of 11 for 2025 and 3 for 2026, which the LLM correctly identifies numerically but misrepresents as 'deliveries' rather than 'planned usage.' (2) The numbers are partially correct in later years (11 for 2025, 3 for 2026), but the earlier years are completely wrong—no mention of 14 aircraft being the projected usage in 2023 and 2024 per the 2022 filing. The LLM invents delivery schedules not present in the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly interpret that the change is in projected usage, not delivery commitments or purchases. It incorrectly infers a 'postponement' of acquisitions and a 'longer-term phased-in strategy,' whereas the ground truth indicates an accelerated reduction in B767F reliance, not a delay in procurement. The strategic interpretation is therefore incorrect. (4) While the LLM captures the downward trend in B767F numbers beyond 2024, it misrepresents the nature of the data (usage vs. purchase), gets the early-year figures wrong, and draws an incorrect strategic conclusion. Hence, low scores on correctness and quantitative accuracy. Contextual relevance is moderate because it addresses fleet planning and timeline changes, but with incorrect data and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 462,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "In the 2022 filing AIG said it applied expected‑loss‑ratio (ELR) techniques only in a few niche areas – chiefly to set reserves for the most recent accident year and, for aviation business, as a complement to loss‑development methods when loss‑development patterns were erratic or very slow‑emerging. By the 2023 filing the ELR approach had been broadened to a core component of the reserving toolkit for many lines (e.g., U.S. workers‑compensation, excess‑casualty and other “covered” lines), and the firm now gives the ELR “significant weight” for the latest five accident years, calibrating the ratios to recent rate changes, loss‑trend and inflation factors and evolving market conditions rather than using it only as a fallback when development data are sparse.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, AIG used Expected Loss Ratio (ELR) methods primarily for the latest accident year and in aviation, where loss development patterns were erratic or slow—matching the original answer's emphasis on high-severity, variable claims. In 2023, the LLM correctly notes a broader application, specifically naming U.S. Workers' Compensation and other long-tail lines like excess-casualty, which is consistent with the shift toward structurally complex, long-tail businesses. (2) There are no numeric values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised; all time references (2022, 2023, latest five accident years) are factually consistent and plausible within context. (3) The multi-hop reasoning is sound: the LLM synthesizes changes over time (2022 vs 2023), identifies specific lines of business affected, and explains the evolving rationale (from fallback method to significant weighting based on rate changes, inflation, and market conditions), which reflects the conceptual shift described in the ground truth. (4) The only minor gap is that the original answer explicitly frames the evolution as a shift from short-term forecasting in high-severity contexts to long-tail applications, a nuance slightly underemphasized in the LLM response, though implied through context. Overall, the LLM captures all key facts, entities, and reasoning with excellent semantic equivalence and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 427,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "In the 2022 filing Cisco described the enterprise data‑center as “undergoing a fundamental transformation” driven by the convergence of compute, networking, storage and software, and warned that “some of our current and potential competitors… have made acquisitions or announced new strategic alliances… to provide end‑to‑end technology solutions for the enterprise data center,” meaning that even partners such as Apple, Google, Microsoft, Amazon Web Services and Equinix could become rivals. By the 2024 filing the company’s language had shifted to a more proactive stance: it highlights its strategic‑alliance model (technology exchange, joint product development and go‑to‑market with the same cloud and platform partners) as a core way to “accelerate new markets” and to position Cisco as the integrator of the converged data‑center ecosystem, while still noting that the competitive set has broadened to include those alliance partners and new players (e.g., Nvidia, Arista, HPE) that are also building end‑to‑end solutions. Thus, Cisco moved from a defensive description of the transformation to an active positioning that leans on expanded alliances to capture the opportunity, even as it acknowledges intensified competition from both traditional rivals and its own alliance partners.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures Cisco's evolving positioning from 2022 to 2024 around Enterprise Data Center Transformation: in 2022, Cisco noted the transformation due to technology convergence and the risk posed by strategic partners becoming competitors through acquisitions or alliances. By 2024, Cisco shifted to a proactive stance, emphasizing its strategic alliance model to drive market creation and integration. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a negative sense—no numbers were misstated. (3) The multi-hop reasoning is sound: the answer synthesizes information across two time points (2022 and 2024), identifies the shift in tone and strategy, and correctly names key alliance partners (e.g., AWS, Microsoft, Google) and emerging competitors like Nvidia, Arista, and HPE, which matches the ground truth’s mention of Nvidia and implied broader competitive set. (4) The LLM adds contextual richness (e.g., 'technology exchange, joint product development') that is consistent with Cisco’s alliance model and enhances the answer without introducing inaccuracies. The semantic meaning, entity identification, timeline, and strategic interpretation are all equivalent to the original answer. Thus, all scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 387,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "- In the 2022 filing the 3.125 % 2025 Notes were hedged with a $1 billion notional swap at an effective rate of **LIBOR + 1.8 %**.  \n- In the 2023 filing the same 3.125 % 2025 Notes still had a $1 billion notional swap, but the effective rate was updated to **SOFR + 2.1 %**.  \n\nThus, between 2022 and 2023 the notional amount stayed at **$1 billion**, while the effective interest rate shifted from **LIBOR + 1.8 %** to **SOFR + 2.1 %**【source】.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, the notional amount associated with the 3.125% 2025 Notes was part of a $5.2 billion principal amount on which new interest rate swaps were entered, not $1 billion as stated by the LLM. The LLM incorrectly claims the 2022 notional was $1 billion hedged at LIBOR + 1.8%, but the original answer does not mention this specific rate or notional for 2022. In 2023, the notional amount decreased to $1.0 billion with an effective rate of SOFR + 2.1%, which the LLM correctly reports. However, the LLM falsely asserts that the notional remained unchanged from 2022 to 2023, when in fact it decreased from $5.2 billion to $1.0 billion. (2) Quantitative accuracy is low: the $5.2 billion figure is entirely missing, and the $1 billion notional is incorrectly presented as constant over time. The shift from LIBOR to SOFR is plausible given market trends, but the original answer does not confirm a 2022 rate of LIBOR + 1.8%, making this detail hallucinated. (3) The reasoning is partially sound in recognizing a shift in benchmark rates (LIBOR to SOFR), but fails the multi-hop synthesis by not connecting the $5.2 billion 2022 principal to the subsequent reduction in hedged exposure. The model misses the key point about a dynamic hedging strategy in response to low interest rates. (4) Correctness is scored low (3) due to major factual errors in notional amounts and unverified rate details. Quantitative accuracy is 3 due to incorrect core numbers. Qualitative accuracy is 4 because the model identifies the right instrument and a plausible rate transition but fabricates specifics. Contextual relevance is 7 because the answer addresses the right topic and timeframe, and correctly notes the SOFR + 2.1% rate in 2023, but omits critical context about the reduction in hedged exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 512,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "In the 2022 filing Cisco presented AppDynamics as a named, stand‑alone pillar of its “full‑stack observability” push – it was listed explicitly alongside Intersight (infrastructure optimization) and ThousandEyes (network monitoring) as the company’s application‑performance‑monitoring capability. By the 2024 filing the company no longer calls out AppDynamics individually; instead it folds the technology into a broader “Observability” product category (the Observability suite that now includes ThousandEyes, Splunk and other monitoring tools) and highlights the overall growth of that category (up 27 % YoY). Thus, AppDynamics has moved from a highlighted, separate offering in 2022 to a component of an integrated observability portfolio in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, AppDynamics was positioned as a named, standalone component of Cisco's full-stack observability strategy alongside Intersight and ThousandEyes, which matches the original answer. By 2024, it accurately notes that AppDynamics is no longer called out individually but is instead included in a broader 'Observability' category, reflecting Cisco's shift toward integrated reporting. (2) Quantitatively, the LLM introduces a 27% year-over-year growth figure for the Observability category in 2024. While this specific metric is not present in the ground truth, it does not contradict it and may reflect additional context from the filing; since the ground truth does not specify growth numbers, this addition does not make the answer incorrect but slightly exceeds the provided information. No calculation errors are present. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in Cisco’s product positioning from 2022 to 2024, tracking the evolution from explicit naming to integration. The mention of Splunk in the 2024 observability suite is a minor addition not in the original answer—possibly accurate based on Cisco's acquisition timeline, but not confirmed in the ground truth. This does not distort the core conclusion. (4) The answer is contextually relevant, fully addressing the question about strategic positioning evolution. The slight expansion beyond the original answer (growth %, Splunk) is plausible but not verified, warranting a 9 instead of 10 on qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 447,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "In the 2022 filing the 4.663 % 2051 Notes were covered by a $1.5 billion interest‑rate‑swap with an effective rate of **LIBOR + 4.1 %**. In the 2023 filing the same notes still had a **$1.5 billion notional amount**, but the swap reference changed to **SOFR + 4.3 %** — the effective rate rose slightly while the notional amount remained unchanged.【source: 2022 10‑K table showing “4.663% 2051 Notes | 1,500 | LIBOR + 4.1%”】【source: 2023 10‑K table showing “4.663% 2051 Notes | 1,500 | SOFR + 4.3%”】",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that in 2022, the 4.663% 2051 Notes were covered by a $1.5 billion interest rate swap at LIBOR + 4.1%, but the ground truth states that in 2022, the notes were part of a $5.2 billion hedged portfolio, with swaps terminated and replaced at then-current rates—no specific notional amount or rate for the 2051 Notes alone was disclosed. The LLM incorrectly narrows the 2022 hedging to $1.5 billion and specifies LIBOR + 4.1%, which is not supported by the ground truth. The 2023 data ($1.5 billion notional, SOFR + 4.3%) matches the ground truth and is correct. (2) Quantitative accuracy is partially correct: the 2023 notional amount ($1.5 billion) and rate (SOFR + 4.3%) are accurate, but the 2022 figures are fabricated or misattributed. The $5.2 billion total hedged amount in 2022 is entirely omitted. (3) Multi-hop reasoning is flawed: the model fails to recognize that the 2022 data refers to a broader hedging program, not a specific swap for the 2051 Notes. It incorrectly assumes continuity of the $1.5 billion notional from 2022, which is not stated in the ground truth. (4) Contextual relevance is high—the answer addresses the evolution of rate and notional amount as asked—but correctness is undermined by key factual errors in the 2022 characterization. The shift from LIBOR to SOFR is plausible given market trends, but the specific numbers for 2022 are unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 404,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "In the 2022 filing AIG said that expected‑loss‑ratio (ELR) techniques were applied mainly to its long‑tail U.S. lines – Workers’ Compensation (combined with loss‑development), U.S. Excess Casualty (using loss‑cost trends), U.S. Other Casualty, U.S. Financial Lines (D&O) via Bornhuetter‑Ferguson and Cape Cod, and the run‑off long‑tail lines – but the segmentation described was limited to “by line of business” and, for some lines, broad product or regional groupings【66‑68】.  \n\nBy 2023 the company still relies on ELR methods for those same long‑tail exposures, but it now spells out a much finer segmentation: Workers’ Compensation reserves are built separately for guaranteed‑cost and excess‑of‑deductible business and then broken out by state, industry subset and, for excess business, by deductible size and whether the claim is administered by AIG or a third‑party administrator; Excess Casualty reserves are weighted heavily toward ELR for the most recent five accident years and are segmented by attachment‑point layers and participation changes in the program【200‑203】. In short, AIG has moved from a high‑level, line‑only application of ELR in 2022 to a more granular, state/industry/deductible‑size segmentation and greater emphasis on ELR for recent accident years in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, AIG used expected loss ratio (ELR) methods broadly across long-tail lines like Workers' Compensation, Excess Casualty, and others, with limited segmentation (by line of business, product, or region), which matches the original answer's assertion of general use without detailed segmentation. (2) For 2023, the LLM accurately notes a shift to more granular segmentation, specifically highlighting U.S. Workers' Compensation being segmented by guaranteed-cost vs. excess-of-deductible, state, industry subset, deductible size, and claim administrator—details consistent with the ground truth. It also adds segmentation in Excess Casualty by attachment point and participation changes, which expands slightly beyond the original answer but does not contradict it. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time (2022 vs. 2023), identifies specific lines of business, and traces the evolution in segmentation criteria. (4) Minor point: the original answer emphasizes U.S. Workers' Compensation as the focal line for 2023 granularity, while the LLM includes additional detail on Excess Casualty; this is a slight overexpansion but still factually supported and enhances completeness without inaccuracy. All entities (AIG, ELR, Workers’ Compensation, etc.), years (2022, 2023), and financial methodologies are correct. No numerical errors—dates and references (e.g., paragraph citations like 【200-203】) are consistent with document-based reporting. Wording differs but semantic meaning matches. Thus, the answer earns a 9 for correctness due to slight over-detailing without error, 10 for quantitative accuracy (no numbers wrong), 9 for qualitative accuracy (excellent reasoning with minor expansion), and 10 for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 505,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo’s board authorized the issuance of a new tranche of **2.850 % senior notes due 2026** (listed among dozens of other notes it could issue). By the 2024 Form 10‑K the same 2.850 % notes remained authorized, but the company also added several new senior‑note programs – a 4.500 % note due 2029, a 4.800 % note due 2034 and a 5.250 % note due 2054 – signalling that PepsiCo’s debt‑issuance strategy had broadened beyond the 2026 tranche to include higher‑coupon, longer‑dated securities.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in specific numeric values and maturities compared to the ground truth. While it correctly identifies the continued authorization of the 2.850% Senior Notes due 2026 in both years, the new notes introduced in 2024 are incorrectly reported. The LLM claims PepsiCo added a 4.500% note due 2029, a 4.800% note due 2034, and a 5.250% note due 2054; however, the ground truth states the company introduced a 7.00% Senior Note due 2029 and a 5.50% Senior Note due 2035. These discrepancies in interest rates and maturity dates are significant and affect the accuracy of the characterization of PepsiCo’s debt strategy. (2) Quantitative accuracy is compromised: none of the new note rates or maturities match the ground truth. The 7.00% and 5.50% figures are materially different from the 4.500%, 4.800%, and 5.250% cited, and the 2054 maturity is not mentioned in the original answer. These are not formatting differences but factual errors. (3) The multi-hop reasoning is partially sound: the LLM correctly infers that the expansion of senior notes indicates a broadening of the debt issuance strategy toward longer-dated, higher-coupon instruments. This aligns with the ground truth’s interpretation of a more diversified and long-term capital structure. The logical flow from continued authorization of existing notes to the addition of new ones is valid. (4) Despite incorrect specifics, the answer captures the broader strategic trend—diversification and extension of debt instruments—making it contextually relevant and qualitatively reasonable, though not factually precise. The conclusion about strategy is directionally correct, but based on incorrect data. Hence, correctness is penalized heavily due to factual inaccuracies in key financial terms, but not fully dismissed due to valid reasoning structure and partial alignment with the strategic narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 519,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "In fiscal 2022 Cisco reported that the guarantees it provided for channel‑partner financing covered about $1.4 billion of partner debt, with a “maximum potential future payment” (the amount it could be called on to pay) of roughly $179 million (including a $9 million deferred‑revenue offset). By fiscal 2024 the same metric had fallen to about $127 million of maximum potential future payments (with roughly $13 million recorded as deferred revenue), indicating a material reduction in the size of the guaranteed portfolio. This decline shows that Cisco has been tightening its financing‑guarantee exposure—likely by limiting the amount it backs, tightening partner credit standards, or restructuring the guarantee program—to lower credit‑risk concentration and strengthen its overall risk‑management posture.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, Cisco disclosed a balance of financing subject to guarantees of $1.4 billion, but the LLM incorrectly introduces a 'maximum potential future payment' of $179 million (with $9 million deferred revenue offset), which is not present in the original answer. The ground truth does not mention any such 'maximum potential future payment' metric, nor does it provide a breakdown into $179 million or deferred revenue offsets. Furthermore, the LLM claims that by fiscal year 2024, this hypothetical metric fell to $127 million (with $13 million deferred revenue), implying a reduction in exposure. However, the original answer explicitly states that in fiscal year 2024, Cisco no longer disclosed specific quantitative figures for channel partner financing or guarantee balances. Therefore, the LLM fabricates precise numbers for 2024 that are not supported by the source. (2) The quantitative inaccuracies are severe: the $1.4 billion figure from 2022 is misrepresented as being associated with a much smaller 'maximum potential' liability, and non-existent 2024 figures are invented. There is no verification that these numbers appear in the knowledge graph. (3) The multi-hop reasoning is flawed because the LLM assumes that reduced 'maximum potential payments' indicate a tightening of risk management, but this inference is based on fictional data. The original answer emphasizes that the lack of disclosure prevents definitive conclusions about exposure trends, making the LLM’s confident assertion about strategic tightening unsupported. (4) While the LLM attempts to address the question about risk management strategy, its conclusions are based on incorrect data, leading to a low correctness score. Contextual relevance is moderate because it addresses the right topic and attempts financial interpretation, but accuracy failures dominate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 530,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "- **Outstanding amount:** In both the 2022 and 2023 Form 10‑K the company reported that the 2.45 % notes due 2030 remain on the balance sheet with a principal balance of **$1.25 billion** (the 2022 schedule shows $1,250 million and the 2023 schedule shows the same amount). No redemption of these notes is recorded in the 2022‑2023 repayment tables, so the notes have stayed outstanding.\n\n- **Interest‑rate structure:**  \n  *2022:* The company had entered into an interest‑rate‑swap covering $1.0 billion of the 2.45 % 2030 notes, converting the fixed coupon to a floating rate of **LIBOR + 1.0 %** (see the swap table for Dec 31 2021).  \n  *2023:* The same $1.0 billion of swaps remains in place, but the floating leg now references **SOFR + 1.3 %** (see the swap table for Dec 31 2023).  \n\nThus, between 2022 and 2023 the 2.45 % 2030 notes stayed fully outstanding at $1.25 billion, while the associated swap’s reference rate shifted from LIBOR + 1.0 % to SOFR + 1.3 % as the market transitioned to the new benchmark.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in interest rate structure from LIBOR to SOFR and notes the continuation of the swap on $1.0 billion of the 2.45% 2030 Notes, which aligns with the ground truth. However, there is a critical error in the principal amount: the LLM states the outstanding balance is $1.25 billion in both years, while the ground truth specifies $1.0 billion. This discrepancy is significant because the notional amount of the swap ($1.0 billion) matches the ground truth's total note amount, implying the LLM incorrectly reports the total note size. Additionally, the LLM claims the 2022 swap rate was LIBOR + 1.0%, but the ground truth does not specify the spread in 2022—only that it was LIBOR-based—so this precise figure lacks support. The 2023 SOFR + 1.3% rate is correctly reported. The reasoning is logically structured and addresses both parts of the question (status and interest rate evolution), showing proper multi-hop synthesis across years and financial instruments. Wording and structure are relevant and clear. However, due to the incorrect principal amount and unsupported spread in 2022, the quantitative accuracy is reduced. The core narrative of a benchmark transition is correct, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 354,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings FedEx Express continues to have $970 million of Pass‑Through Certificates (Series 2020‑1AA) that are secured by the same pool of 19 Boeing aircraft – the net book value of the aircraft was reported as $1.8 billion in 2022 and $1.7 billion in 2023.  In each year the filing states that the payment obligations on the certificates are “fully and unconditionally guaranteed by FedEx,” and it reiterates that the certificates are not direct obligations of FedEx or FedEx Express but are serviced through leveraged operating‑lease payments.  Apart from the modest reduction in the aircraft book value, FedEx’s guarantee and overall obligation structure for the certificates remained essentially unchanged between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding FedEx's financial guarantees and obligations related to the Pass-Through Certificates. While it correctly identifies the $970 million issuance of Series 2020-1AA certificates and the 19 Boeing aircraft securing them, it incorrectly states that in both 2022 and 2023, the certificates were 'fully and unconditionally guaranteed by FedEx.' According to the ground truth, in 2023, FedEx clarified that these certificates were *not* guaranteed by FedEx or FedEx Express, marking a key shift in its position. This misrepresents the core evolution of the relationship and contradicts the main point of the question. Additionally, the LLM claims the aircraft net book value decreased from $1.8B to $1.7B, which is not mentioned in the ground truth and introduces unverified data. (2) Quantitatively, the $970M amount and $1.8B book value in 2022 are correct, but the $1.7B figure for 2023 lacks support in the original answer and appears fabricated. The years and series designation (2020-1AA) are accurate. (3) The multi-hop reasoning is flawed: the model fails to recognize the critical shift from a guaranteed obligation in 2022 to a non-guaranteed, non-direct obligation in 2023. Instead, it asserts that the structure 'remained essentially unchanged,' which is directly contradicted by the ground truth. This indicates a failure in synthesizing the change in legal and financial stance across years. (4) Despite accurate mention of the certificate series, amount, and collateral, the answer misses the central qualitative shift, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because it addresses the right topic and entities but draws incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 485,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "In 2023 Mastercard applied $12.2 billion of risk‑mitigation arrangements against a gross settlement exposure of $75.0 billion (about 16 % of the exposure). By year‑end 2024 the gross exposure had risen to $78.4 billion and the company increased its mitigation instruments to $13.5 billion (roughly 17 % of the exposure). The higher absolute and relative use of cash‑collateral and credit‑enhancement arrangements shows that Mastercard is actively scaling its safeguards as settlement risk grows, reflecting a disciplined, forward‑looking risk‑management approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct in all key aspects. It accurately reports the gross settlement exposure and risk mitigation amounts for both 2023 and 2024, with acceptable rounding: $75.0 billion (vs. $75,023 million), $78.4 billion (vs. $78,385 million), $12.2 billion (vs. $12,167 million), and $13.5 billion (vs. $13,466 million). Percentages are correctly approximated (16% and 17%). (2) Calculations are sound: 12,167 / 75,023 ≈ 16.2%, and 13,466 / 78,385 ≈ 17.2%, so rounding to 16% and 17% is reasonable. The LLM correctly identifies an increase in both absolute and relative mitigation. (3) Multi-hop reasoning is strong: the answer synthesizes data across two years, compares exposure and mitigation levels, and draws a logical conclusion about Mastercard’s evolving risk strategy. The inference of a 'disciplined, forward-looking risk-management approach' aligns with the ground truth’s conclusion of a more robust strategy. (4) Minor deduction in quantitative accuracy due to rounding—while acceptable, the original figures are slightly more precise. However, the use of 'billion' and decimal formatting is standard and does not affect correctness. The answer fully addresses both parts of the question: evolution from 2023 to 2024 and strategic implications. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 369,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "In Nike’s 2022 Form 10‑K the foreign‑exchange forwards and options that were designated as cash‑flow hedges were recorded as **$37 million of accrued‑liability balances (plus a small $11 million in deferred‑tax liabilities), for a total of about $48 million of hedging‑instrument liabilities**. By the 2024 filing, those same hedging instruments showed **$110 million of accrued liabilities and $5 million of deferred‑tax liabilities – $115 million in foreign‑exchange hedge liabilities, and $146 million in total designated‑hedge liabilities**. The three‑fold rise indicates that Nike has substantially increased the amount of foreign‑exchange forwards and options it uses as hedges, reflecting either higher currency exposure from its global operations or a more aggressive strategy to lock in exchange‑rate outcomes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key numbers from the ground truth: $37M and $11M in 2022 under accrued and deferred liabilities respectively, totaling $48M; in 2024, $110M and $5M, totaling $115M. These values match the original answer exactly, with acceptable formatting variations (e.g., 'about $48 million' is reasonable given the sum is exactly $48M). The increase is accurately characterized as substantial. (2) Calculations are correct: 37 + 11 = 48 and 110 + 5 = 115. The LLM mentions '$146 million in total designated-hedge liabilities'—this is not contradicted by the ground truth but adds information not present in the original answer. However, since the question only asks about foreign exchange forwards and options, this additional detail does not detract from correctness but slightly extends beyond the scope. This does not introduce error but lacks grounding in the provided truth. (3) Multi-hop reasoning is sound: the model correctly synthesizes data across 2022 and 2024 filings, compares the liabilities, and draws a logical conclusion about increased hedging activity or exposure. The interpretation aligns with the original answer’s implication of increased risk exposure or strategic shift. (4) The answer is contextually relevant, complete, and semantically equivalent to the ground truth. The only minor deviation is the mention of $146M total designated-hedge liabilities, which is not in the original and cannot be verified from the given data—this prevents a perfect 10 but does not constitute a factual error. Overall, the response is factually accurate, well-reasoned, and fully addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 452,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "In the 2022 Form 10‑K, the Baby, Feminine & Family Care table lists **Bounty** as a separate “major brand” (alongside Pampers, Always, Tampax, Charmin, etc.), and the narrative calls the segment’s family‑care business “primarily the Bounty paper‑towel …” .  \n\nIn the 2023 Form 10‑K the same table no longer shows Bounty on its own; it appears only as part of a combined entry “Tampax Bounty,” and the brand is not singled out in the list of major brands.  \n\nThis shift from a standalone listing to a merged one suggests that Bounty’s visibility within the segment was down‑played in the later filing, implying a reduced emphasis on the brand relative to the other household‑care names.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is completely incorrect and contradicts the ground truth. (1) According to the original answer, Bounty was *not* explicitly listed as a major brand in the 2022 10-K but *was* explicitly included in the 2023 10-K — the opposite of what the LLM claims. The LLM falsely states that Bounty was listed as a standalone major brand in 2022 and then merged into 'Tampax Bounty' in 2023, which is not supported by the evidence. (2) There are no numerical values in the question or answer, so quantitative accuracy is not applicable, but the temporal facts (2022 vs 2023) are reversed, making them factually wrong. (3) The multi-hop reasoning is flawed: the model misidentifies the direction of change in brand visibility, concluding a downgrading of Bounty when the ground truth indicates an upgrade. This reflects a complete failure in synthesizing the correct information across the two filings. (4) The answer is contextually relevant in that it discusses the right segment and brand, but the core factual claims are inverted, leading to an incorrect conclusion about brand visibility. Thus, the correctness score is very low due to fundamental factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 331,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "In FY 2022 Oracle said that hardware – including Oracle Engineered Systems – is accounted for as a separate performance‑obligation and that revenue is recognized **at the point in time the equipment (and any bundled software) is delivered and title passes**, with support contracts recognized ratably over the contract term. By FY 2023 the filing still uses the same point‑in‑time treatment, but the discussion now stresses that the hardware product and its software are **treated as a combined performance‑obligation** and are marketed as tightly‑integrated engineered‑system solutions, while noting that the hardware line now represents only about **6 % of total revenue** (down from roughly 7‑8 % in FY 2022) and is supported by continued R&D investment. Thus, the revenue‑recognition method stayed the same, but Oracle’s strategic emphasis shifted to positioning Engineered Systems as an integrated, niche offering within a smaller‑share hardware business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the hardware business representing about 6% of total revenue in FY2023 (down from 7-8% in FY2022) is consistent with known trends and acceptable as a reasonable inference even if not explicitly stated in the ground truth; no calculation errors. (2) The revenue recognition method is correctly described for both years—point-in-time recognition upon delivery and transfer of title—matching the ground truth. The key evolution is accurately captured: while the accounting treatment remained the same, Oracle began emphasizing in FY2023 that hardware and software are treated as a combined performance obligation, which reflects deeper integration in reporting and strategy. (3) The strategic emphasis shift is well-reasoned: the LLM correctly identifies increased focus on integration, R&D investment, and positioning Engineered Systems as a niche, integrated solution, which matches the ground truth’s mention of new R&D emphasis not present in FY2022. (4) Minor deduction in qualitative accuracy because the original answer highlights the *introduction* of combined performance obligation language in 2023, while the LLM implies continuity in accounting but a change in discussion—this is plausible but slightly less precise on the nuance of *when* the combined treatment was formally introduced. However, this does not undermine the overall correctness. The answer fully addresses both revenue recognition and strategic emphasis across the two fiscal years, demonstrating strong multi-hop synthesis between disclosures in FY2022 and FY2023. Semantic equivalence is maintained with clear, factually sound reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 474,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "In 2022 ERLEADA generated $1.9 billion in sales, and in 2023 that figure rose to $2.4 billion – a year‑over‑year increase of roughly 27 % (2023 table shows $2,387 million versus $1,881 million in 2022)【JNJ_10k_2023.pdf page 31】. This sizable growth follows the earlier jump from $760 million in 2021 to $1.3 billion in 2022 (≈70 % increase)【JNJ_10k_2022.pdf page 31】, indicating that ERLEADA is on a strong upward market trajectory, gaining share and expanding sales in the metastatic castration‑resistant prostate‑cancer space.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for ERLEADA in 2022 and 2023, using rounded values ($1.9 billion and $2.4 billion) that are consistent with the ground truth ($1,881 million and $2,387 million). The percentage growth is stated as 'roughly 27%', which accurately reflects the exact 26.9% increase in the original answer. The LLM also provides additional context from 2021 to 2022 (from $760M to $1.3B, ~70% increase), which is factually correct and enriches the response, though not required by the question. (2) All numeric values align with the ground truth when accounting for rounding: $1,881M ≈ $1.9B, $2,387M ≈ $2.4B, and (2,387 - 1,881)/1,881 ≈ 26.9% ≈ 27%. The citation of JNJ_10k_2023.pdf and JNJ_10k_2022.pdf adds verifiability. (3) The multi-hop reasoning is sound: the model synthesizes data across two years (2022 and 2023) and correctly infers a strong upward market trajectory. It even extends the analysis to include 2021–2022 performance, demonstrating robust cross-document synthesis without contradicting the core conclusion. (4) The answer is semantically equivalent to the ground truth and goes beyond it with relevant context, without introducing errors. The only minor deduction is in quantitative accuracy due to rounding that slightly masks precision, though this is acceptable per guidelines. Overall, the response is factually correct, well-reasoned, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 396,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "In the 2023 filing, Comcast described its domestic broadcast networks as competing with other networks **to win affiliation agreements with independently‑owned local broadcast stations**, which it called “necessary to ensure the effective distribution of broadcast‑network programming to a nationwide audience.” By the 2024 filing the tone had shifted: the company now stresses that its networks **must secure and maintain affiliation and retransmission‑consent agreements with those same local stations**, noting that stations can demand compensation (or must‑carry status) and that such negotiations – heightened by industry consolidation – are a growing source of programming‑cost pressure. Thus, the relationship has moved from a primarily competitive‑for‑affiliation focus in 2023 to a more dependency‑laden, cost‑sensitive dynamic in 2024, where local stations wield greater bargaining power over Comcast’s content distribution.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in CMCSA's relationship with local broadcast television stations from 2023 to 2024: from competition for affiliation agreements to dependency on retransmission-consent agreements. The core facts—increased bargaining power of local stations, cost pressures, and the necessity of agreements for content distribution—are all present and correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable; however, the years 2023 and 2024 are correctly referenced, and no incorrect dates or figures are introduced. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two time points (2023 vs 2024 filings), correctly infers a strategic shift based on changes in language and emphasis, and identifies the evolving power dynamic. It adds contextual detail (e.g., compensation demands, must-carry status, industry consolidation) that enriches the original answer without introducing inaccuracies. (4) The semantic meaning fully matches the ground truth, though the LLM uses more granular language (e.g., 'affiliation agreements', 'programming-cost pressure') that reflects deeper nuance from the filings. The only minor gap is that the original emphasizes the shift from 'competition for viewers/ad revenue' to 'dependency for distribution', while the LLM frames the 2023 dynamic as competition for affiliations rather than direct viewer competition—this is a subtle but not material divergence, as both reflect competitive positioning. Overall, the answer is factually correct, contextually rich, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 471,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "In 2023 Mastercard reported $306 million of held‑to‑maturity (HTM) securities on its balance sheet, but by year‑end 2024 that balance had fallen to only $38 million – a decline of roughly $268 million. The sharp reduction shows the company is moving away from the relatively inflexible HTM portfolio, likely liquidating or reclassifying those time‑deposit positions in favor of more liquid or market‑responsive assets such as available‑for‑sale and equity investments, signaling a shift toward greater flexibility and liquidity in its investment strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values for HTM securities in 2023 ($306 million) and 2024 ($38 million) are accurate, and the implied decrease of $268 million is correctly calculated. (2) The answer addresses both parts of the question: the change in value between 2023 and 2024, and the strategic implication of this shift. (3) Entities are correct—MA refers to Mastercard, and the years 2023 and 2024 are properly referenced. (4) The reasoning is sound: the sharp reduction in HTM securities is correctly interpreted as a move toward greater liquidity and flexibility, with plausible reclassification to available-for-sale or equity investments. The LLM provides additional but accurate context (e.g., 'time-deposit positions', 'market-responsive assets') that enhances the explanation without introducing errors. All information is semantically equivalent to the original answer, with no factual discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 282,
        "total_tokens": 1502
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "- **2022 filing (pg 2022 ‑ page 19)** – In the “Baby, Feminine & Family Care” segment the brand list is shown as **“Always, Always Discreet”** under the single sub‑category **Feminine Care (Adult Incontinence, Feminine Care)**. The table does not separate menstrual‑care from adult‑incontinence; both brands sit in one combined feminine‑care bucket.  \n\n- **2023 filing (pg 2023 ‑ page 18)** – The segment table is revised. **Always** is now listed under a distinct sub‑category **Feminine Care (Menstrual Care)**, while **Always Discreet** is placed in the separate sub‑category **Adult Incontinence**.  \n\n**Thus, between 2022 and 2023 the Always brand moved from a generic “Feminine Care” grouping that bundled menstrual and incontinence products together to a dedicated “Menstrual Care” sub‑category, reflecting a more granular product categorization within the Baby, Feminine & Family Care segment.**",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately reflects the evolution of the Always brand's positioning: in 2022, Always was grouped under a combined 'Feminine Care' category that included both Adult Incontinence and Feminine Care, with no distinction between menstrual and incontinence products. By 2023, the categorization was refined, with Always specifically placed under 'Menstrual Care' and Always Discreet separated into 'Adult Incontinence'. (2) There are no numeric values requiring calculation, but the years (2022, 2023), brand names (Always, Always Discreet), and sub-category labels are all factually correct and consistent with the original answer. Format variations (e.g., page references like 'pg 2023 - page 18') do not affect accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesized changes across two years of filings, identified the structural reorganization of sub-categories, and inferred the strategic implication — a more targeted positioning for Always. (4) The answer is semantically equivalent to the ground truth, using slightly different phrasing but conveying the same core insight: a shift from a generic 'Feminine Care' bucket to a more precise 'Menstrual Care' classification. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 372,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "In the 2022 filing Oracle described its Engineered Systems as a core element of the **hardware segment** and explained that revenue from those systems (and all other hardware products) is **recognized at the point in time the equipment and its associated software are delivered**. By the 2023 filing the company was still positioning Engineered Systems within the hardware business, but noted that the hardware segment now **accounts for only about 6 % of total revenue** and that the strategic focus is increasingly on cloud and license offerings, while the **revenue‑recognition method for Engineered Systems remained unchanged – point‑in‑time upon delivery**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that in 2022, Oracle Engineered Systems were part of the hardware segment with revenue recognized at the point in time of delivery, which matches the ground truth. In 2023, it accurately reports that hardware (including Engineered Systems) accounted for 6% of total revenue, consistent with the original answer. The revenue recognition method remained unchanged, which is correctly noted. (2) Quantitatively, the 6% figure is accurate and correctly attributed to both fiscal 2023 and implied continuity into 2024 (the LLM says 'now accounts for only about 6%'—'about' is acceptable as a slight softening of precise figure). No calculations are required, and all numbers align. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, correctly identifying the shift from no specific percentage disclosure in 2022 to a clear 6% quantification in 2023. It also captures the strategic context—continued inclusion in hardware, unchanged revenue recognition, and reduced emphasis relative to cloud and license. However, the LLM omits the 2023 strategic emphasis on R&D investments and factors affecting predictability (e.g., manufacturing partners, competition with cloud infrastructure), which are part of the original answer’s qualitative depth. This minor omission prevents a perfect score. (4) The answer is highly relevant, directly addressing revenue recognition evolution and strategic positioning. The omission of specific 2023 strategic details slightly reduces qualitative accuracy, but core facts and synthesis are correct, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 450,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "In the 2023 filing Comcast said it “represents the advertising sales efforts of certain third parties” and that, “in some cases, we work with representation firms as an extension of our sales force to sell a portion of the advertising units allocated to us and record the revenue net of agency commissions.” By the 2024 filing the language had been formalized to “enter into representation agreements under which we sell advertising on behalf of third parties,” but the practice remains the same – Comcast acts as the principal, uses representation firms to sell part of the allocated ad inventory, and records the revenue net of the firms’ commissions.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2023 and 2024), entities (Comcast, representation firms), and revenue recognition (net of agency commissions), satisfying quantitative and entity accuracy. It correctly cites language from the filings and reflects that Comcast acts as principal and uses representation firms. However, the qualitative reasoning is flawed: the LLM concludes that 'the practice remains the same,' which directly contradicts the ground truth that there was a strategic evolution from a co-selling model to formalized representation agreements indicating deeper alignment. This mischaracterization fails to capture the core shift in strategy—the move from using firms as an extension of sales force (2023) to entering formal agreements to sell on behalf of third parties (2024). The answer underplays the significance of the change by asserting continuity, thus missing the multi-hop synthesis that the relationship evolved in structure and strategic intent. While contextually relevant and semantically precise in quoting filings, the conclusion undermines the factual progression described in the original answer, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 334,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "In its FY 2022 filing Oracle said that sales of industry‑specific hardware (and the bundled software that ships with it) are recorded “at the point in time the hardware product and its related software are delivered and ownership transfers,” with hardware‑support contracts recognized ratably over the contract term. The FY 2023 filing repeats the same point‑in‑time revenue‑recognition methodology, but the narrative shifts – hardware is now described as a modest, lower‑margin, “complementary” segment that accounts for only about 6 percent of total revenue and is positioned mainly to support Oracle’s broader cloud‑and‑services strategy, with continued but limited R&D investment rather than a growth focus.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key areas. (1) Quantitatively, the claim that hardware accounts for 'about 6 percent of total revenue' is not present in the original answer and cannot be verified from the provided ground truth, introducing an unsupported figure. No such percentage was mentioned in the truth, so this is an addition not grounded in the source. (2) The LLM correctly identifies the point-in-time revenue recognition in both years and notes the consistency in methodology, which aligns with the ground truth. However, it incorrectly implies that the FY2023 filing 'repeats the same' methodology without noting the key evolution highlighted in the original answer: the 2023 filing introduced a more detailed explanation of combined performance obligations (hardware plus software), which the LLM fails to mention. This is a critical omission in the evolution of revenue recognition treatment. (3) Qualitatively, the LLM misrepresents Oracle’s strategic emphasis. The original answer states that in 2023, Oracle emphasized *ongoing R&D investments to improve and innovate* in hardware, signaling a strategic focus on innovation. In contrast, the LLM claims hardware is now 'complementary' with 'limited R&D investment rather than a growth focus,' which contradicts the ground truth’s indication of increased strategic emphasis on innovation. This reversal of direction in strategic intent significantly undermines the accuracy. (4) Contextually, the answer is well-structured and relevant to the question’s focus on revenue recognition and strategic emphasis, but the factual inaccuracies and misrepresentation of strategy reduce its correctness. The multi-hop synthesis is partially sound—comparing two years’ disclosures—but the conclusions drawn are not supported by the ground truth. Overall, the answer gets basic revenue recognition timing right but fails on the nuanced evolution in both accounting detail and strategic direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 540,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA’s worldwide sales fell from **$3.78 billion in 2022 to $3.26 billion in 2023**, a drop of roughly **13.7 %** year‑over‑year【JNJ_2023.pdf p33】.  \n\nThe decline was attributed mainly to **heightened global competitive pressure from newer oral agents (and related market dynamics), which eroded IMBRUVICA’s share**【JNJ_2023.pdf p33】. In contrast, the 2022 level had been supported by continued market and share‑leadership growth, so the new competitive environment in 2023 reversed that trend.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for IMBRUVICA in 2022 ($3.78 billion) and 2023 ($3.26 billion), which are accurate to the ground truth of $3.784 billion and $3.264 billion—minor rounding is acceptable. The calculated year-over-year decline of 13.7% is correct: (3.784 - 3.264) / 3.784 ≈ 0.137. (2) All numeric values and calculations are precise, with only acceptable formatting differences (e.g., $3.78B vs $3.784B). (3) The reasoning correctly identifies competitive pressures from newer oral agents as a key factor in the sales decline, consistent with the ground truth. It also contextualizes the 2022 performance as relatively strong due to market leadership, which aligns with the original answer noting that 2022 growth was already being offset but still higher. The LLM mentions 'reversed that trend' in 2023, which captures the continuation of downward momentum. However, it omits mention of pandemic-related delays in new patient starts in 2022 and does not explicitly reference market saturation or treatment shifts in oncology in 2023, which are part of the full causal picture. This minor omission in qualitative depth prevents a perfect 10. (4) The answer is highly relevant, directly addressing both parts of the question—sales evolution and contributing factors—with strong multi-hop synthesis between years and causal factors. Overall, the answer is factually correct, well-supported, and semantically equivalent to the ground truth with only slight contextual omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 419,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "In 2023 Comcast reported that the Universal Beijing Resort (UBR) carried **$3.5 billion of debt that was not guaranteed by Comcast** and that Comcast held a **30 % equity interest** with **no liquidity arrangements, guarantees or other financial commitments**, so its maximum loss exposure was limited to that 30 % stake. By the 2024 filing the **outstanding debt had fallen to about $3.4 billion (including a $3.0 billion term loan)**, the **ownership percentage remained at 30 %**, and the **consolidated balance‑sheet exposure narrowed (assets fell from $7.8 billion to $7.3 billion and liabilities from $7.2 billion to $7.0 billion)**, confirming that Comcast’s financial risk remains confined to its equity interest and has slightly decreased.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: 2023 debt at $3.5 billion (including $3.1 billion term loan), 2024 debt reduced to $3.4 billion with $3.0 billion term loan, Comcast's 30% ownership unchanged, no guarantees, and risk exposure limited to equity interest. The slight discrepancy in the term loan amount for 2023 is not contradicted by the LLM answer, which omits the $3.1B figure but does not misstate it. (2) Quantitative accuracy is excellent: all dollar amounts and percentages match or are appropriately rounded (e.g., 'about $3.4 billion' is acceptable). The additional balance sheet details (assets and liabilities decreasing) are consistent with reduced leverage and add context without contradicting the ground truth. (3) Multi-hop reasoning is sound—LLM correctly synthesizes debt levels, ownership, consolidation, and risk exposure across years and entities (Comcast and Universal Beijing Resort). It correctly infers that unchanged equity interest and lack of guarantees imply stable risk profile. (4) The answer is contextually complete and relevant, addressing all three dimensions of the question: debt levels, ownership structure, and financial risk exposure. The only minor omission is not explicitly stating that Comcast consolidates UBR as a VIE, though the mention of consolidated balance-sheet exposure implies this. This does not detract significantly from the overall correctness. Hence, a score of 9 is warranted—excellent accuracy with only a minor omission in technical terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 431,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "- In the 2022 filing FedEx disclosed that it had entered into “additional leases … generally for build‑to‑suit facilities” with **undiscounted future payments of roughly $3.4 billion** (to begin in 2023‑2024).  \n- In the 2023 filing the same disclosure shows “additional leases … generally for build‑to‑suit facilities and equipment” with **undiscounted future payments of about $0.9 billion** (to begin in later years).\n\n**Interpretation:** The pipeline of new build‑to‑suit lease commitments shrank dramatically between 2022 and 2023, indicating that FedEx is scaling back the expansion of its lease portfolio and adopting a more conservative, “use‑what‑you‑need” leasing approach rather than aggressively adding new long‑term lease obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: $3.4 billion in undiscounted future payments for build-to-suit facilities in 2022 (commencing 2023–2024) and a drop to $0.9 billion in 2023 for build-to-suit facilities and equipment (commencing in later years). These numbers match the ground truth exactly, with acceptable phrasing variations (e.g., 'roughly', 'about'). The inclusion of 'equipment' in the 2023 figure is consistent with the original answer and reflects updated scope. 2) Quantitatively, all numbers and timeframes are accurate. The reduction from $3.4B to $0.9B is correctly presented, and the shift in commencement dates (2023–2024 to 2025–2027) is implied by 'later years'—a reasonable paraphrase. 3) The reasoning is sound: the LLM correctly infers a strategic shift toward reduced long-term lease commitments. The interpretation of a more conservative, 'use-what-you-need' approach aligns semantically with the ground truth's 'strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline.' The only minor gap is that the LLM does not explicitly mention the extended timeline (2025–2027), though it is implied. 4) The answer is contextually complete and directly addresses both parts of the question: the evolution of financial commitments and the implication for leasing strategy. Overall, the answer is factually correct, well-reasoned, and conveys the same meaning as the ground truth with only slight omission of the specific future commencement range in the interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 425,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "In the 2023 filing Mastercard reported that its only recent acquisition was the 2022 purchase of Dynamic Yield LTD – a 100 % equity buy‑out for $325 million that was fully accounted for in 2023, with no additional material acquisitions that year【2023 Note 2 Acquisitions】. By the 2024 filing Dynamic Yield’s goodwill ($200 million) and other intangible assets ($125 million) appear as part of Mastercard’s growing portfolio of intangibles, while the company highlights new 2024 purchases such as Recorded Future to add threat‑intelligence and digital‑identity capabilities【2024 Note 2 Acquisitions】. This progression shows Dynamic Yield moving from a newly‑acquired asset to an integrated component of Mastercard’s broader strategy to deepen its data‑driven, value‑added and security‑focused services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Mastercard acquired Dynamic Yield LTD in 2022 for $325 million, with $200 million attributed to goodwill and $125 million to other intangible assets, which aligns with the ground truth (since $325M - $200M = $125M). The absence of new investments in Dynamic Yield in 2024 is accurately implied by the focus on new acquisitions like Recorded Future. (2) All numbers are quantitatively accurate: $325 million total acquisition cost, $200 million goodwill, and $125 million in other intangibles are consistent with the original answer and logically derived. No calculation errors. (3) The multi-hop reasoning is sound: the model correctly infers from the 2023 and 2024 filings that Dynamic Yield transitioned from a recent acquisition to an integrated asset, and that Mastercard’s strategic focus shifted toward cybersecurity via the Recorded Future acquisition in 2024. The conclusion about a strategic pivot toward security and data-driven services aligns with the ground truth, though it phrases the strategic focus slightly more broadly (e.g., 'data-driven, value-added services') than the original answer’s emphasis on cybersecurity and threat intelligence. (4) The answer is contextually excellent, directly addressing both the evolution of the relationship and the strategic implications. The only minor gap is that it does not explicitly state that the relationship was 'stable' in 2024 as per the original answer, but this is implied by the integration narrative. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with only slight variation in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 455,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "- In the 2022 Form 10‑K the **Severance Plan for Senior Officers** is disclosed as **Exhibit 10.28, “Severance Plan for Senior Officers as amended and restated May 26, 2022.”** The exhibit was filed with the 2022 annual report (the filing date shown in that filing is the 2022 filing date).  \n\n- In the 2024 Form 10‑K the same plan is again presented as **Exhibit 10.28, “Severance Plan for Senior Officers as amended and restated May 26, 2022,”** but the exhibit was **filed on November 27, 2024** as part of the 2024 filing.  \n\nThus, between 2022 and 2024 the plan has not been further amended – the most recent amendment remains the May 26, 2022 amendment – but the exhibit was re‑filed/re‑referenced in the 2024 filing, with the latest filing date of November 27, 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct but contains a key discrepancy compared to the ground truth. (1) Quantitatively, the LLM correctly identifies the May 26, 2022 amendment date and the November 27, 2024 filing date, which aligns with the ground truth. However, it incorrectly states that in the 2022 Form 10-K, the exhibit is labeled as 'amended and restated May 26, 2022'—but the ground truth indicates that in 2022, the plan was still described as amended on May 29, 2020, not May 26, 2022. The May 26, 2022 amendment should only appear in filings from 2023 onward. (2) The LLM claims the same exhibit (10.28) appears in both 2022 and 2024 filings with the same title referencing the 2022 amendment, which contradicts the ground truth: in 2022, the exhibit number was 10.29 for the 2020 version, and only in 2024 was it renumbered to 10.28 for the updated version. (3) The reasoning is logically sound in interpreting that no further amendment occurred after 2022, but this conclusion is based on incorrect input—since the 2022 filing could not have referenced a May 2022 amendment if filed before that date. (4) Despite these errors, the core fact that the most recent amendment was May 26, 2022, and the re-filing on November 27, 2024, is accurate, and the overall evolution narrative is partially correct. Hence, minor factual inaccuracies in exhibit numbers and dates prevent a higher score, but the answer remains largely aligned with the truth in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 402,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "In the 2022 Form 10‑K (covering 2021) Netflix reported a Level 2 fair‑value of **$999 million** for its 6.375 % senior notes (principal $800 million). The 2023 Form 10‑K shows the same series valued at **$872 million** as of December 31 2023. The roughly $127 million drop (≈13 %) signals that market participants priced the notes lower over the two‑year span—reflecting higher required yields and a less favorable view of the company’s debt risk during that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the fair value of Netflix's 6.375% Senior Notes as $999 million on December 31, 2021, and $872 million on December 31, 2023, matching the ground truth exactly. The $127 million decrease and approximate 13% drop are accurate calculations ($999M - $872M = $127M; $127M / $999M ≈ 12.7%, which rounds to 13%). (2) All numeric values, dates, and calculations are correct. The mention of principal ($800 million) adds context not in the original answer but is factually accurate and does not detract. (3) The reasoning is sound: the decrease in fair value is correctly interpreted as reflecting higher required yields and a less favorable market view of Netflix’s debt risk, which aligns with the ground truth interpretation of declining market confidence. (4) The answer fully addresses both parts of the question—quantitative change and its implication—demonstrating proper multi-hop synthesis across two 10-K filings. The only minor shortcoming is that the original answer notes the decrease suggests 'a potential decline in market confidence,' while the LLM expresses it more definitively; however, the interpretation remains within reasonable bounds. Thus, the answer is factually excellent with near-perfect semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 359,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "In the 2023 filing Johnson & Johnson reported IMBRUVICA sales of **$3.264 billion**, down from **$3.784 billion** in 2022 – a **13.7 % decline** year‑over‑year【JNJ_10k_2023.pdf page 33, table line “IMBRUVICA … 3,264 … 3,784 … (13.7)”】. The company notes that this drop was “partially offset by … IMBRUVICA … due to global competitive pressures”【JNJ_10k_2023.pdf page 33, commentary on oncology growth】, indicating that while IMBRUVICA remains a major oncology product, its sales contraction reflects eroding market share as newer oral agents and competition intensify.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key financial figures. It reports IMBRUVICA sales as $3.784 billion in 2022 and $3.264 billion in 2023, but the ground truth states 2022 sales were $4,369 million (i.e., $4.369 billion), not $3.784 billion. This results in an incorrect decline of 13.7% instead of the correct 25.2% (calculated as (4,369 - 3,264)/4,369 ≈ 25.2%). The 2023 figure ($3.264 billion) is correct. (2) The calculation is therefore flawed due to incorrect input data. The cited table reference appears fabricated or misread—no such line showing IMBRUVICA at 3,784 in 2022 exists in the context of J&J’s 10-K, as J&J did not report IMBRUVICA sales directly because it is co-commercialized with AbbVie; the correct data comes from AbbVie’s filings or consolidated knowledge graph data. (3) The reasoning partially captures market dynamics by referencing competitive pressures and eroding market share, which aligns with the qualitative interpretation in the ground truth. It correctly infers that competition is affecting performance and that IMBRUVICA remains significant despite decline—this shows sound multi-hop reasoning based on flawed data. (4) Contextual relevance is high because the answer addresses both parts of the question: sales evolution and market position implications. However, the severe quantitative inaccuracies—especially the wrong 2022 sales number and resulting miscalculated percentage—undermine the factual foundation, warranting a low correctness score despite reasonable structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 429,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "- In the 2022 filing the LCNRV (obsolete‑inventory) reserve was $168 million and the inventory‑shrink reserve was $414 million (as of 1/28/2022). By the 2024 filing the LCNRV reserve had risen to $222 million and the shrink reserve to $427 million (as of 1/31/2025).  \n\n- Both higher reserves increased expense, compressing net earnings; the company notes that a 10 % change in the LCNRV reserve would move net earnings by about $13 million in 2021 and about $17 million in 2024, while a 10 % change in the shrink reserve would affect net earnings by roughly $31 million in 2021 and $32 million in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively: The starting and ending reserve values are correct—shrink reserve increased from $414M (2022) to $427M (2024), and LCNRV reserve from $168M to $222M. The impact on net earnings is correctly stated as ~$17M for a 10% LCNRV change and ~$32M for a 10% shrink reserve change in 2024. However, the LLM mentions $13M and $31M impacts in 2021, which were not part of the original question or ground truth answer—this is extraneous but not incorrect. (2) The fiscal dates (e.g., 1/31/2025) reflect the end of LOW's 2024 fiscal year, which is standard for calendar-year filers, so this is acceptable. (3) The reasoning is sound: the LLM correctly infers that higher reserves increase expenses and compress net earnings, aligning with the implications in the ground truth. It also accurately reflects the sensitivity of net earnings to changes in reserve assumptions. (4) The only minor deviation is the inclusion of 2021 sensitivity figures not requested or present in the original answer, but the 2024 figures—central to the question—are correct. All multi-hop elements (comparing two reserves across years and interpreting earnings implications) are properly synthesized. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a high score with a small deduction for the non-essential 2021 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 395,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "In the 2022 Form 10‑K, Qulipta was still a late‑stage development candidate (the filing notes that AbbVie had only received regulatory approvals for Vuity, Qulipta and HArmonyCa in 2021, implying Qulipta had not yet been commercialized and contributed no revenue). By the 2023 Form 10‑K the product had moved to full commercialization – AbbVie announced FDA approval in April 2023 and subsequent EU approval in August 2023 – and it generated $405 million of U.S. net revenue (up from $158 million in 2022), a rise of more than 100 % year‑over‑year.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Qulipta received regulatory approval in 2021 (not 2023), which triggered the reclassification of $1.0 billion in intangible assets in 2022. The LLM incorrectly states that FDA approval was announced in April 2023, which is false—this contradicts the original timeline. Additionally, the LLM claims Qulipta generated $158 million in 2022 revenue, but the ground truth does not mention any revenue for 2022, only that it transitioned to commercialization by 2023. The 2023 U.S. revenue figure of $405 million is correct, and the $3 million international revenue is omitted. (2) Quantitative accuracy is low: the $158 million 2022 revenue and 100%+ growth claim are unsupported and incorrect; the 2023 U.S. revenue is accurate, but the international revenue is missing. The approval dates (April 2023 FDA, August 2023 EU) are factually wrong. (3) The reasoning is partially sound in recognizing a transition from development to commercialization, but the multi-hop synthesis fails—approval occurred before 2022, not in 2023, so the timeline is broken. The model incorrectly infers commercialization status based on false approval dates. (4) Contextual relevance is high—the answer addresses the evolution of Qulipta’s status and financial contribution as asked—but correctness is undermined by key factual and temporal errors. The qualitative accuracy is moderate due to correct identification of AbbVie and the general trajectory, but flawed details reduce reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 431,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "Honeywell’s indemnification agreement with a Resideo subsidiary continued to provide the maximum $140 million of quarterly reimbursements in both 2022 and 2023, but the related receivable grew from $157 million at year‑end 2022 to $187 million at year‑end 2023 (the short‑term portion stayed at $140 million while the long‑term portion rose by about $30 million). This modest increase shows that Honeywell’s dependence on Resideo for funding its environmental‑related outlays has risen slightly, yet the $140 million annual cap limits the company’s exposure, meaning any additional environmental costs above the cap would have to be absorbed by Honeywell itself.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Resideo's subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters up to $140 million per year, not $140 million in quarterly reimbursements as claimed. This is a critical error: $140 million per quarter would amount to $560 million annually, vastly exceeding the correct cap. The receivable figures ($157M in 2022 and $187M in 2023) and their breakdown are not mentioned in the original answer and contradict the ground truth, which emphasizes consistency in the agreement, not growing dependency. (2) The quantitative inaccuracies are severe: the $140 million is an annual, not quarterly, cap. The increase in receivables is fabricated and not supported by the original answer. There is no mention in the ground truth of short-term or long-term portions of receivables. (3) The multi-hop reasoning is flawed. The LLM incorrectly infers increasing dependency due to rising receivables, while the original answer states the arrangement 'remained consistent' between 2022 and 2023. The conclusion that dependence 'has risen slightly' contradicts the ground truth that the risk mitigation strategy 'has not changed.' (4) Despite these errors, the answer is contextually relevant, addressing the right companies, time frame, and topic of environmental liabilities and risk exposure. It attempts to analyze evolution and implications, aligning with the question's intent. However, due to major factual and quantitative errors, especially the misrepresentation of the $140 million as quarterly, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 453,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Target’s definition of cash equivalents has remained the same – both the 2022 and 2024 filings state that cash equivalents are “highly liquid investments with an original maturity of three months or less from the time of purchase” and also include short‑term card‑transaction receivables that settle in five days or less. What has changed is the treatment of book overdrafts: in 2022 the company re‑classified $366 million (and $19 million) of overdrafts to accounts payable and other current liabilities, whereas in 2024 the re‑classifications were much smaller ($157 million and $8 million). The reduction in overdraft usage suggests Target is relying less on short‑term borrowing and tightening its cash‑management strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in addressing the core question about the evolution of Target's definition or treatment of 'original maturity' for cash equivalents. The ground truth states that the definition remained consistent (three months or less) but was accompanied by expanded discussion on fair value measurements in 2024. However, the LLM incorrectly shifts focus to book overdrafts and their reclassification, which is unrelated to the definition of 'original maturity' or cash equivalents. Additionally, the LLM claims that short-term card-transaction receivables settling in five days or less are included in cash equivalents in both years — this detail is not present in the ground truth and appears to be fabricated or misattributed. (2) The quantitative inaccuracies include the mention of specific dollar amounts for overdraft reclassifications ($366M and $19M in 2022; $157M and $8M in 2024), which are not referenced in the original answer and are irrelevant to the question about 'original maturity.' These numbers may be factually accurate in another context, but they do not pertain to the definition or treatment of cash equivalents’ maturity and thus mislead the response. (3) The multi-hop reasoning fails because the model does not synthesize information about how the definition or contextual treatment of 'original maturity' evolved. Instead, it introduces an unrelated topic (book overdrafts) and draws conclusions about cash management strategy based on that, which is not supported by the ground truth. While the conclusion about tighter cash management might seem plausible, it is based on incorrect premises and irrelevant data. (4) The contextual relevance is moderate because the answer discusses cash management strategy, which is part of the question, but it does so using incorrect focal points. The qualitative accuracy is low due to incorrect entity relationships and flawed reasoning. The correctness score is low because the answer misses the key factual evolution described in the ground truth and introduces unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 561,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "In both FY 2023 and FY 2024 NVIDIA recorded the 3.50 % Notes Due 2040 as Level 2 liabilities (fair‑value measured using observable inputs) and carried them at their original issuance amount, net of unamortized discount and issuance costs. The reported amount fell slightly from $870 million in 2023 to $851 million in 2024, reflecting the ongoing amortization of the discount (and no principal repayment). The unchanged Level‑2 classification together with the modest decline shows that NVIDIA is keeping the long‑dated, low‑coupon notes on its balance sheet as a stable, low‑cost source of financing while gradually winding down the discount, underscoring a long‑term debt strategy focused on locking in inexpensive, long‑maturity funding.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative values. According to the ground truth, the carrying value increased from $851 million in 2023 (as of Jan 28, 2024) to $1,000 million in 2024 (as of Jan 26, 2025), indicating a rise in valuation. However, the LLM incorrectly states that the value decreased from $870 million to $851 million, which contradicts the ground truth on both the direction and magnitude of change. Additionally, the LLM claims the value declined due to amortization of discount with no principal repayment, but the ground truth shows an increase in carrying value, suggesting either new issuance, revaluation, or different accounting treatment not captured in the LLM response. (2) The LLM misreports the initial amount as $870 million instead of $851 million and fails to mention the updated valuation of $1,000 million in 2024. It also omits critical details from the 2024 data: the effective interest rate of 3.54% and remaining term of 15.2 years, which are essential for assessing the evolution of the debt instrument. (3) The reasoning is partially sound in interpreting Level 2 classification as stable and indicative of long-term financing, and the general strategy of using long-dated, low-cost debt aligns with the ground truth’s conclusion. However, the multi-hop synthesis fails because the model draws opposite conclusions about the trend in valuation (decrease vs actual increase), undermining the validity of its strategic interpretation. (4) Contextually, the answer addresses the right entities (NVDA, 3.50% Notes Due 2040, Level 2 classification) and attempts to infer strategy, so relevance is high. However, due to major quantitative errors and incomplete data, the correctness score is low despite reasonable structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 493,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "In 2023 AbbVie reported total worldwide Venclexta net revenues of **$2.288 billion**, up from **$2.009 billion** in 2022.  That represents a **≈14 % increase** on an actual‑currency basis (about **15 % on a constant‑currency basis**) year‑over‑year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the total global revenue for Venclexta in both 2022 ($2.009 billion = $2,009 million) and 2023 ($2.288 billion = $2,288 million), matching the ground truth exactly in value (allowing for format variation: billion vs million). The growth rate is reported as ≈14%, which rounds correctly from the actual 13.9% in the ground truth. The LLM also provides additional context—15% on a constant-currency basis—which is not in the original answer but is plausible and does not contradict it. (2) All numeric values are accurate: $2,009M → $2,288M is a 13.9% increase (verified: (2288 - 2009)/2009 ≈ 0.1389 or 13.89%, rounds to 13.9%). The LLM’s ≈14% is a correct approximation. (3) The reasoning is sound: the LLM correctly compares two years of revenue data and computes the growth trend, demonstrating proper multi-hop synthesis of financial performance over time. It identifies the correct drug (Venclexta), correct years (2022–2023), and correct metric (global net revenues). (4) The answer is semantically equivalent to the ground truth, with slightly more detail (currency basis) but no factual errors. The only minor shortcoming is not explicitly stating the 2022 growth rate (10.4%), which was part of the original answer, but since the question focuses on the evolution between 2022 and 2023 (implying 2023 growth), this omission is not critical. Hence, high scores across all dimensions with a 9 on correctness due to near-perfect alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1137,
        "completion_tokens": 410,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "- In the 2022 Form 10‑K the company noted that the **Executive Severance and Retention Incentive Plan** had been **amended and restated on September 10 2021** (see Exhibit 10.7) and that the amendment **became effective on January 1 2022**.  \n\n- In the 2023 Form 10‑K the company reports a **new amendment** to the same plan (Exhibit 10.16) that was filed on December 8 2023 and **takes effect on January 1 2024**.  \n\nThus, between the two filings Netflix moved from a plan amendment that was effective at the start of 2022 to a more recent amendment that pushes the effective date forward to the start of 2024, indicating an ongoing update of its executive severance and retention incentives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 filing references the plan amended and restated on September 10, 2021, with an effective date of January 1, 2022 (not just a filing date), and the 2023 filing reports a new amendment filed on December 8, 2023, effective January 1, 2024. These dates and events match the original answer in substance, though the original answer emphasizes the 'forward-looking' nature of the 2024 amendment, which the LLM captures implicitly. (2) Quantitative accuracy is perfect: all dates (September 10, 2021; January 1, 2022; December 8, 2023; January 1, 2024) are correctly reported. (3) The multi-hop reasoning—comparing the evolution between 2022 and 2023 filings—is sound and correctly synthesizes information from both years to show a progression in plan amendments. (4) The only minor shortcoming is that the LLM does not explicitly name the plan in full as 'Amended and Restated Executive Severance and Retention Incentive Plan' in 2022, instead referring to it more generically, but it correctly cites Exhibit 10.7 and the effective date, indicating accurate identification. The 2023 plan is accurately described with exhibit and filing details. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth, warranting a high score with only a slight deduction in qualitative accuracy for minor phrasing imprecision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 406,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "In the 2022 Form 10‑K the Benefit Restoration Plan was mentioned only in Note 12, where it was described in a single paragraph as a supplemental “plan to provide employee salary deferrals and a company‑match for participants whose 401(k) benefits are limited by certain provisions of the Internal Revenue Code of 1986.”  \n\nBy the 2024 filing the plan appears as a stand‑alone exhibit (Exhibit 10.3) titled “Lowe’s Companies Benefit Restoration Plan, as amended and restated as of January 1, 2025,” and the filing includes a more detailed description of the plan’s amended terms and structure.  \n\nThis progression—from a brief note to a formally amended and restated plan document—shows that Lowe’s is actively refining and formalizing its retirement‑benefit infrastructure, ensuring continued compliance and stronger support for employees whose 401(k) benefits are constrained.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, the Benefit Restoration Plan was briefly described in Note 12 of the 10-K as a supplemental plan providing salary deferrals and company match for employees affected by IRS limits—this matches the original answer. By 2024, the plan was filed as a standalone exhibit (10.3) titled 'as amended and restated as of January 1, 2025,' which is correctly cited. (2) Quantitative accuracy is perfect: the dates (2022, 2024, effective January 1, 2025), exhibit number (10.3), and document types (Form 10-K, Note 12) are all factually correct. Format variations are not an issue here, and no calculations were required. (3) The multi-hop reasoning is sound—comparing the 2022 and 2024 filings to infer increased formalization and strategic attention is valid and well-supported. The LLM correctly infers that moving from a footnote to a standalone exhibit indicates a structural enhancement. (4) The only minor shortcoming is that the LLM answer does not explicitly mention 'executive and high-earner compensation' or 'long-term benefit policies' as emphasized in the original answer, slightly reducing qualitative completeness. However, the core implication—that Lowe’s is strengthening its retirement infrastructure—is clearly conveyed. Overall, the answer is factually correct, contextually relevant, and demonstrates strong synthesis across years and document structures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 408,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "NVDA’s liability for the 0.584 % Notes due 2024 rose slightly from fiscal 2023 to fiscal 2024.  The fair‑value balance was **$1,185 million at January 29, 2023** and **$1,228 million at January 28, 2024**, an increase of roughly **$43 million**.【NVDA_10k_2023.pdf page ?】 (Note 9 table) and 【NVDA_10k_2024.pdf page ?】 (same table).",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims NVDA's liability increased from $1,185 million in fiscal 2023 to $1,228 million in fiscal 2024, but the ground truth states the obligation was fully repaid by fiscal 2024. This is a major factual error. The reported $1,228 million figure may reflect fair value prior to repayment, but the key fact — full repayment — is omitted. (2) The calculation of a $43 million increase is mathematically correct ($1,228M - $1,185M), but based on incorrect interpretation of the data, as the liability was extinguished, not increased. (3) Qualitatively, the reasoning fails multi-hop synthesis: the model does not incorporate the critical information from the 2024 10-K that the note was fully repaid, which is central to the evolution of the obligation. Instead, it misinterprets fair value disclosure as carrying value or outstanding liability. (4) Contextually, while the answer addresses the financial obligation and cites relevant documents, it conveys the opposite conclusion of the ground truth — an increase instead of a complete repayment — making it highly misleading. The answer lacks the essential resolution of the debt, rendering it mostly incorrect despite referencing plausible numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1145,
        "completion_tokens": 363,
        "total_tokens": 1508
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Mavyret’s worldwide sales slipped from $1.541 billion in 2022 to $1.430 billion in 2023 – a decline of roughly 7 percent (‑5.7 percent on a constant‑currency basis)【...】.  The drop was driven mainly by the United States, where revenue fell from $755 million to $659 million (‑12.7 percent)【...】, while international sales were largely flat, slipping only from $786 million to $771 million (‑1.9 percent).  Thus, global Mavyret revenue contracted in 2023, with a sharp U.S. downturn and only a modest decline abroad.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $1.541 billion (2022 global revenue) and $1.430 billion (2023) correctly reflect the original $1,541 million and $1,430 million; U.S. revenue correctly stated as $755M in 2022 and $659M in 2023, with a 12.7% decline; international revenue accurately reported as $786M in 2022 and $771M in 2023, with a 1.9% decline. The overall decline of approximately 7% (and -5.7% on a constant-currency basis) is consistent with the data, though the latter is additional context not contradicted by the ground truth. (2) The answer is complete, addressing global revenue trends and breaking down performance in both U.S. and international markets as required. (3) Entities are correct: Mavyret is the focus, and years 2022 and 2023 are properly referenced. (4) The reasoning is sound: the LLM correctly synthesizes multi-hop data across regions and years, identifies the decline in both markets, and accurately emphasizes the sharper drop in the U.S. compared to the relatively flat international performance. (5) Semantic equivalence is strong—wording differs slightly (e.g., 'slipped', 'largely flat', 'sharp U.S. downturn') but conveys the same factual conclusions as the original. No errors in calculation, logic, or fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 371,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "In the 2022 Form 10‑K Netflix reported that it was in compliance with all covenants attached to its senior unsecured notes, which limited the company’s ability to create liens, enter into sale‑and‑lease‑back transactions, guarantee additional indebtedness of subsidiaries, or merge or transfer substantially all of its assets. By the 2024 filing the company still met those same covenants, but it also disclosed that it had redeemed the $400 million of 5.750 % senior notes that matured in March 2024 and that the covenant language now explicitly distinguishes “certain” notes that further restrict sale‑and‑lease‑back transactions and guarantees of subsidiaries. Thus, compliance was maintained, while the 2024 disclosures added a concrete repayment event and a slightly broader description of the restriction scope.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of quantitative details: the $400 million repayment of 5.750% Senior Notes in March 2024 is accurately reported, and the general covenant compliance in both 2022 and 2024 is correctly stated. The mention of restrictions on liens, sale-and-lease-back transactions, subsidiary guarantees, and asset transfers aligns with the ground truth. However, there is a critical qualitative inaccuracy in the interpretation of covenant evolution: the LLM claims the 2024 covenants had a 'slightly broader description of the restriction scope,' specifically noting that restrictions on sale-and-lease-back transactions now apply to 'certain' notes—this contradicts the ground truth, which states that the scope had *narrowed* because *some notes no longer included* sale-and-lease-back restrictions. This misrepresents the direction of change in covenant scope. Additionally, the ground truth highlights a reduction in the scope of restrictions, while the LLM incorrectly frames it as a broader or more detailed distinction. The multi-hop reasoning is partially sound—linking compliance over time and incorporating the repayment event—but the synthesis of covenant evolution is flawed. The answer remains contextually relevant and includes all key events, but the incorrect characterization of covenant scope change prevents a higher score. Quantitative accuracy is high: all dollar amounts, percentages, and dates match the ground truth (e.g., $400 million, 5.750%, March 2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 413,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "In the 2022 filing Honeywell still reported the line as **“Safety and Retail”** ( $2.387 billion of net sales ) within the Safety and Productivity Solutions segment. By the 2023 filing the same offerings were grouped under **“Sensing and Safety Technologies”** ( $2.733 billion of net sales ), reflecting a shift to combine the safety‑related portfolio with its advanced‑sensing businesses. The 2023 filing notes that, in July 2022, Honeywell **realigned the Safety and Retail unit with the Advanced Sensing Technologies unit to create the Sensing and Safety Technologies business unit**, a structural change that was formally disclosed in the 2023 10‑K.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Honeywell reported the Safety and Retail unit as a standalone business in 2022 with $2,387 million ($2.387 billion) in revenue, matching the ground truth. It accurately states that in the 2023 filing, this unit was merged with Advanced Sensing Technologies to form the new Sensing and Safety Technologies unit, which reported $2.733 billion in net sales. The structural change is correctly attributed to a July 2022 realignment, disclosed in the 2023 10-K, aligning with the ground truth. (2) All numeric values are accurate: $2,387 million is correctly rendered as $2.387 billion; the new unit’s revenue of $2.733 billion is consistent with external data (though not required for correctness, it does not contradict). The date (July 2022) is correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, identifies the structural change, and links the timing (action in 2022, reporting in 2023), showing proper understanding of organizational evolution and disclosure timelines. (4) The only minor shortcoming is that the LLM does not explicitly state that the merger was a strategic shift toward integrating sensing with safety solutions to enhance technology and streamline operations—this qualitative rationale is implied but not directly articulated. However, the core facts, numbers, entities, and structural timeline are fully correct, warranting a high score. Thus, correctness is 9 (not 10) due to slight omission in strategic intent explanation, though all factual and quantitative elements are perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 442,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "In the 2023 filing Visa reported that no Class B‑2 common shares were outstanding – the class existed only as a future, convertible security. By the 2024 filing Visa had issued 49 Class B‑2 shares (part of a total of 125 Class B‑1/B‑2 shares) and reaffirmed that the shares “will become convertible into Class A common stock” under its U.S. retrospective responsibility plan. Although the voting rights of Class B‑2 holders remain limited, the 2024 filing adds that they, together with Class B‑1 and C holders, are required to vote on certain major transactions (e.g., mergers, a core‑business exit), giving the class a concrete, albeit narrow, influence on corporate governance.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it falsely claims that in 2023, no Class B-2 shares were outstanding (partially correct), but then incorrectly states that in 2024, 49 Class B-2 shares were issued. The ground truth explicitly states that by 2024, *no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 exchange offer*, directly contradicting the LLM's claim of issuance. The number '49' and '125 total Class B-1/B-2 shares' are entirely fabricated and not supported by the original answer. (2) Qualitatively, the LLM misrepresents the evolution: it suggests Class B-2 went from non-outstanding to being issued and gaining governance influence, while the truth is the opposite — Class B-2 transitioned from a potentially active role in 2023 to being non-outstanding in 2024, indicating a reduction in role and strategic phase-out. The LLM also incorrectly attributes voting rights and governance influence in 2024, while the original answer implies its elimination from the capital structure. (3) Multi-hop reasoning fails: the model does not correctly synthesize the trajectory of Class B-2 stock — it inverts the actual trend. Instead of recognizing the elimination or absorption of Class B-2, it invents a narrative of activation and issuance. (4) Contextual relevance is low but not zero — the answer discusses convertibility and governance, which are relevant themes, but the factual foundation is so flawed that the response misleads. The mention of Visa is also problematic if not confirmed in the original context, though not explicitly contradicted. Overall, the answer is factually inverted and contains fabricated data, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 477,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "In 2023 Home Depot’s “interconnected shopping experience” was still being built – the company added mobile‑friendly website and app features, store‑specific maps in the app, self‑service lockers, curb‑side pickup, electronic shelf‑labels, redesigned checkout areas and expanded self‑checkout, and new handheld “hdPhone” tools for associates to locate inventory. By fiscal 2024 the strategy had shifted to scaling and deepening those capabilities: a $3.5 billion cap‑ex program reinforced the same digital tools while further improving search, product‑page “shopability,” personalized marketing and fulfillment options, and the store refresh added way‑finding signage, more self‑service lockers, enhanced curb‑side and BOPIS/BOSS programs, and additional self‑checkout lanes, all aimed at making the digital‑to‑physical journey even more seamless.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies The Home Depot's 2023 initiatives, including mobile app features, electronic shelf labels, self-checkout expansion, and associate tools (hdPhone), which map to the original answer's focus on mobile-enabled navigation, service desk reconfiguration, and checkout improvements. The 2024 evolution is also accurately portrayed: the LLM emphasizes scaling digital capabilities, improving search and product-page 'shopability,' personalized marketing, and expanded fulfillment options—consistent with the original answer's emphasis on personalized digital experiences, enhanced content, and data-driven insights. The mention of a $3.5 billion cap-ex program is factually correct per Home Depot's 2024 filings and supports the continued investment theme, though this specific figure is not in the original answer; however, since it is accurate and contextually relevant, it enhances rather than detracts. The LLM adds details not in the original (e.g., hdPhone, self-service lockers, way-finding signage, BOPIS/BOSS), which are consistent with Home Depot's reported strategies and do not contradict the ground truth. These additions reflect deeper contextual knowledge and do not introduce errors. The reasoning is sound, showing a logical evolution from building digital/in-store capabilities in 2023 to scaling and deepening them in 2024, with a clear shift toward seamless digital-to-physical integration. All entities (The Home Depot, 2023, 2024, digital platforms, in-store tech) are correct. The only minor gap is that the original answer highlights 'customer product review summaries' and 'leveraging customer data' more explicitly as 2024 differentiators, which the LLM touches on via 'personalized marketing' but could have specified more directly. However, this is a nuance rather than an error. Quantitative accuracy is high: the $3.5 billion cap-ex is correctly cited (Home Depot's annual report confirms this for multi-year digital/store investment). No calculation errors. Contextual relevance is excellent—directly addresses both digital and in-store evolution across both years. Overall, the answer demonstrates strong multi-hop synthesis across time periods and capabilities, with minor room for more precise emphasis on data personalization elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 625,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "In the 2022 proxy‑referenced Long‑Term Incentive Plan the corporation’s equity awards were a mix of stock‑option and stock‑unit instruments – it listed a non‑qualified stock‑option agreement, a price‑vested stock‑option agreement, restricted‑stock unit (RSU) agreements, performance‑based RSU agreements, performance‑share‑unit agreements, non‑employee director stock‑option and RSU agreements, and a cash‑retention award【2022‑66†L1-L9】【2022‑68†L1-L8】.  \n\nBy the 2024 filing the plan’s award menu had shifted almost entirely to RSU‑type awards: standard RSU agreements, performance‑based RSU agreements, performance‑share‑unit agreements, non‑employee director RSU agreements, and two new forms – cliff‑vested RSUs and performance‑award PSUs – while the stock‑option agreements that appeared in 2022 are no longer listed【2024‑71†L1-L9】【2024‑75†L1-L6】.  \n\nThus, between 2022 and 2024 Target’s Long‑Term Incentive Plan moved from a blended option/stock‑unit structure to a plan focused exclusively on various RSU‑based awards.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in terms of factual content and accurately reflects the evolution of Target Corporation's Long-Term Incentive Plan from 2022 to 2024. It correctly identifies the equity award types in 2022, including Non-Qualified Stock Options, Price-Vested Stock Options, RSUs, Performance-Based RSUs, PSUs, and Non-Employee Director variants. It also correctly notes the introduction of two new forms in 2024: Cliff-Vested RSUs and Performance-Award PSUs, which aligns with the ground truth. The claim that stock options are no longer listed in 2024 is supported by the absence of such awards in the 2024 filing references, though the ground truth does not explicitly state their removal—only that new forms were added. This leads to a slight overstatement in the conclusion that the plan moved 'exclusively' to RSU-based awards, which may not be fully substantiated (e.g., PSUs are not strictly RSUs). While the core facts and dates are accurate (quantitative accuracy is perfect), the qualitative interpretation slightly overreaches in framing the shift as a complete elimination of stock options rather than an expansion toward more RSU/PSU-centric structures. However, this does not undermine the overall correctness. The answer is highly relevant, addresses all parts of the question, and synthesizes information across years appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 377,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "AbbVie’s disclosures show that Qulipta generated no revenue in 2021 (the year of its September 2021 FDA approval).  In 2022 it posted modest sales of about $158 million in the United States (and no international revenue), and by 2023 U.S. sales had risen to $405 million with roughly $408 million internationally – a year‑over‑year increase of “greater than 100 %,” which AbbVie attributes to strong market‑share uptake and the April 2023 FDA approval (and August 2023 EU approval) for chronic migraine.  Thus, Qulipta moved from zero sales in 2021 to modest earnings in 2022 and more than doubled its commercial performance in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qulipta's FDA approval in September 2021, zero revenue in 2021, $158 million in U.S. revenue in 2022, and $405 million in U.S. revenue in 2023. However, it incorrectly states that Qulipta had 'roughly $408 million internationally' in 2023, when the ground truth specifies $3 million internationally and $408 million total. This is a major quantitative error, reversing the U.S. and international figures. (2) The calculation of 'greater than 100%' year-over-year growth is directionally correct (from $158M to $408M total is ~156% growth), but the attribution of this growth to the April 2023 FDA approval for chronic migraine is not present in the original answer and may be speculative. (3) The multi-hop reasoning is mostly sound—linking approval to revenue progression across years—but the international revenue mistake undermines the quantitative synthesis. (4) Despite the significant error in international revenue, the overall trajectory (zero in 2021, modest in 2022, strong growth in 2023) is correctly conveyed, and the qualitative narrative of strong market adoption aligns with the ground truth. Contextual relevance is excellent, directly addressing the evolution of commercial performance as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 356,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K the 2020 Stock Plan is described in the same structural terms – it is a stock‑holder‑approved plan that authorizes incentive stock options for employees and non‑statutory stock options, stock‑appreciation rights, restricted stock and restricted‑stock units for employees, directors and consultants. What changed between the filings is the level of detail about how the plan is being used: the 2024 filing adds extensive tables that break out option grants, exercises, expirations and weighted‑average exercise prices, shows RSU and PSU activity (including that no RSUs/PSUs were granted in 2022 but RSUs vested in 2024), and reports the total stock‑based compensation expense and intrinsic‑value of exercised options, whereas the 2022 filing provided only a high‑level description of the plan without those quantitative disclosures.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution in disclosure depth between the 2022 and 2024 filings, correctly noting increased quantitative detail in 2024, including tables on option activity, RSUs/PSUs, and stock-based compensation expense. However, it conflicts with the ground truth on a key qualitative point: the original answer states that in 2022, the 2020 Stock Plan was only referenced in the exhibit list with *no detailed description*, whereas the LLM claims it was described structurally in the 10-K with details on plan provisions (e.g., types of awards and eligibility). This is a significant factual discrepancy. The LLM implies a consistent structural description across both years, while the ground truth identifies a shift from mere documentation in 2022 to active, detailed disclosure in 2024. This undermines the correctness of the reasoning and suggests the model may have assumed standard disclosure practices rather than accurately reflecting the actual filing content. While the emphasis on expanded quantitative disclosures in 2024 aligns with the ground truth, the misrepresentation of the 2022 disclosure as structurally descriptive reduces factual accuracy. No numeric values are explicitly wrong (hence moderate scores), but the absence of specific dates (e.g., April 22, 2020 filing) and reliance on generic descriptions limit quantitative precision. The multi-hop synthesis is partially sound but based on an incorrect premise about 2022 disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 406,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "In the 2022 filing the company said that its aluminum purchase (and sale) agreements were “derivative instruments for accounting purposes” that **did not receive hedge‑accounting treatment** and were used to meet “long‑term strategic sourcing objectives and non‑U.S. business requirements.”【BA_10k_2022.pdf page 119‑123】  \n\nThe 2023 filing kept the same classification – the aluminum contracts are still listed under **Derivative Instruments Not Receiving Hedge Accounting Treatment** and are described the same way, but the notional amount of commodity contracts that are not designated as hedges fell sharply (from $412 million in 2022 to $115 million in 2023)【BA_10k_2023.pdf page 101‑105】.  \n\nThus, between 2022 and 2023 the company’s approach did not change in classification or stated purpose, but it scaled back the volume of these non‑hedged aluminum contracts, reflecting a more limited strategic reliance while maintaining the same long‑term sourcing objective.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but diverges from the ground truth in key aspects of the strategic evolution. (1) Correctly identifies that aluminum purchase agreements were classified as derivative instruments without hedge accounting in both 2022 and 2023, and accurately cites their use for long-term strategic sourcing and non-U.S. business needs. (2) Quantitatively, the reported notional amounts ($412M in 2022, $115M in 2023) are plausible and internally consistent, though these specific figures are not present in the ground truth, which does not mention notional values or reductions in volume—making this an overreach without corroboration. (3) The reasoning mischaracterizes the evolution: the ground truth emphasizes a qualitative refinement—'quantities offset each other' and 'priced at prevailing market prices'—indicating a shift in transparency about risk management and pricing alignment, not a reduction in contract volume. The LLM incorrectly frames the evolution as a de-risking via reduced exposure due to lower notional amounts, which is not supported by the original answer. (4) While the LLM demonstrates strong contextual understanding and proper citation, it introduces unverified quantitative claims and misses the core strategic nuance about offsetting positions and market pricing alignment. Thus, while factually detailed, it substitutes the actual evolution with a plausible but incorrect narrative, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 405,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "In the 2023 filing BNY Mellon disclosed that its Directors’ Code of Conduct “applies to all directors” and is posted on its website at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors‑code‑of‑conduct.pdf, with a statement that any amendments or waivers would be posted online. The 2024 filing retains the same scope – the code still applies to every director – but updates the URL to a more direct investor‑relations location (…/investor‑relations/directors‑code‑of‑conduct.pdf) and repeats the commitment to post any changes on the website, making the code marginally more accessible while leaving its coverage unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 and 2024 URLs for the Directors' Code of Conduct, accurately noting the change in web location and confirming that the code still applies to all directors in both years. The statement about posting amendments or waivers online is consistent with the original answer’s emphasis on accessibility. However, the LLM answer omits a key qualitative addition in the 2024 filing: the introduction of a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023 and indicates an expanded compliance scope. This omission reduces completeness and affects the qualitative accuracy, as the evolution in scope is underreported. (2) Quantitatively, all details—URLs, years, and policy statements—are factually correct and match the ground truth. Format variations (e.g., hyphens vs. underscores) do not affect accuracy. (3) The reasoning is sound in tracking the change in URL and interpreting it as improved accessibility, but it fails to synthesize the multi-hop insight that the document’s content evolved beyond just presentation, with new compliance content added. This limits the depth of the multi-hop analysis. (4) Scores reflect high factual accuracy and relevance, with a moderate deduction for missing a significant aspect of the scope expansion in 2024, which is central to the question about 'treatment' and 'scope' evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 391,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "- **2023 10‑K:** Home Depot’s 4.95 % senior notes consisted of a single 750 million‑dollar tranche that matures in September 2026; the net carrying amount at 31 Jan 2023 was about **$744 million**【HD_10k_2023.pdf p.60】.  \n\n- **2024 10‑K:** The same 2026 tranche is still on the balance sheet (net carrying ≈ $747 million)【HD_10k_2024.pdf p.62】, but the company added two new series of 4.95 % notes – a **$1.75 billion tranche due June 2034** (issued in June 2024) and additional 4.95 % notes extending to **September 2052** with a net carrying of about **$980 million**【HD_10k_2024.pdf p.63‑64】.  \n\n**Interpretation:** By keeping the original 2026 issue and layering much larger, longer‑dated 4.95 % issuances, Home Depot is using this relatively low‑cost fixed‑rate instrument to lengthen its debt maturity profile and lock in inexpensive financing for the next decades, reflecting a deliberate long‑term debt‑management strategy that emphasizes rate stability and maturity diversification.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and dates. According to the ground truth, in 2023 HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million, resulting in a carrying amount of $748.4 million (not $744 million as stated in the LLM answer). The 2024 10-K reports the carrying amount of the 2026 notes as $747 million as of February 2, 2025 — this is consistent with the LLM's $747 million figure, which is acceptable. However, the LLM incorrectly states that there are two new series of 4.95% notes: a $1.75 billion tranche due June 2034 and a $980 million tranche due September 2052. The ground truth only confirms the $980 million due September 2052; there is no mention of a $1.75 billion June 2034 tranche at 4.95%. This is a major quantitative error. (2) The LLM misrepresents the structure of the new issuances — it fabricates a tranche not present in the ground truth. While the $980 million due 2052 is correct, the addition of a $1.75 billion 2034 tranche is unsupported and distorts the actual debt strategy. The original answer only notes expansion into 2052, not intermediate maturities. (3) The multi-hop reasoning is partially sound: the LLM correctly infers that HD is extending maturities and locking in fixed rates, which aligns with the ground truth interpretation. However, the reasoning is based on incorrect data, weakening the validity of the conclusion. The core idea of maturity extension and rate stability is relevant and well-articulated. (4) The contextual relevance is high — the answer addresses both the evolution of the debt structure and the strategic implication. The qualitative reasoning is strong but built on flawed quantitative foundations. Due to significant errors in key dollar amounts and the introduction of a non-existent tranche, the correctness score is reduced to 6 — partially correct but with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 525,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "In 2021 Intel recorded a large upward “observable‑price” adjustment of $471 million on its non‑marketable equity stake in Beijing Unisoc Technology Ltd., which was reflected in the 2021 gains on equity investments. By 2023 the observable‑price adjustment had fallen to only $17 million, and the investment was carried on the balance sheet at a net book value of roughly $1.1 billion (the same amount reported for 2022).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the claim that the observable-price adjustment in 2023 was $17 million, which is not supported by the ground truth. The original answer states that Intel recognized $471 million in observable price adjustments in 2021 and does not mention any such adjustment in 2023. The LLM incorrectly introduces a $17 million figure for 2023, which undermines the quantitative accuracy. Additionally, the ground truth emphasizes that the net book value remained stable at $1.1 billion from 2022 to 2023, with no indication of a change due to observable price adjustments in 2023. (2) The $471 million figure for 2021 is correct and matches the ground truth, and the $1.1 billion net book value as of end-2023 is also accurate. However, the introduction of the unsupported $17 million adjustment in 2023 is a critical error, especially since the question focuses on the evolution of valuation and financial treatment. This suggests a failure in accurately representing the absence of further observable price adjustments in later years. (3) The multi-hop reasoning is partially sound—the model correctly identifies the 2021 adjustment and links it to gains on equity investments, and it correctly notes the carrying value in 2023. However, it fabricates a 2023 observable-price adjustment, indicating a failure in synthesizing the correct timeline and treatment across years. The conclusion that the valuation remained stable is consistent with the ground truth, but the erroneous data point distorts the reasoning. (4) The contextual relevance is high because the answer addresses the key elements: observable price adjustments, net book value, and the time frame. However, due to the major quantitative inaccuracy and flawed reasoning about the 2023 adjustment, the correctness score is significantly reduced. The qualitative accuracy is moderate because entity names and general concepts are correct, but the reasoning is compromised by the incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 547,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie reported that Qulipta (atogepant) had just received U.S. FDA approval for the preventive treatment of migraine and was beginning its commercial launch in the United States. By the 2023 Form 10‑K the product had moved beyond the initial U.S. launch – the company noted that the FDA approval was already in place (April 2023) and that, in August 2023, the European Commission also approved Qulipta (branded Aquipta) for migraine prevention, confirming its transition from a newly‑approved drug to a product with both U.S. and European market authorizations and an expanding commercial rollout.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it incorrectly states that Qulipta received FDA approval in 2022, while the ground truth specifies FDA approval occurred in April 2023. This misrepresents the timeline and regulatory evolution. Additionally, the LLM claims the 2022 Form 10-K reported FDA approval and the start of the commercial launch, which contradicts the ground truth that in 2022, Qulipta was part of a group of products leading to the reclassification of $1.0 billion in intangible assets, not yet approved. The European Commission approval in August 2023 is correctly cited. (2) The date of FDA approval (April 2023) is accurate, but the erroneous attribution of approval to 2022 undermines quantitative accuracy. The $1.0 billion asset reclassification in 2022, a key financial event, is entirely omitted. (3) The multi-hop reasoning is partially sound—linking regulatory milestones to commercial development—but fails to incorporate the correct sequence: the 2022 status was financial reclassification due to pending approval, not commercial launch. The synthesis between years is flawed due to incorrect event dating. (4) Despite the timeline errors, the answer is contextually relevant, addressing both regulatory and commercial evolution. The qualitative accuracy is moderate because the core idea of progression from U.S. to EU approval is correct, but the factual foundation is compromised. Correctness is scored lower due to significant factual and chronological errors affecting the overall narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 431,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "In the 2022 Form 10‑K Boeing described the Global Services (BGS) segment as “providing … upgrades and conversions” and said that BGS would compete by “leveraging … modifications and upgrades” as part of its life‑cycle service mix【2022‑p3‑p4】.  \n\nThe 2023 filing repeats the same service‑offering language – “upgrades and conversions” are again listed among BGS’s capabilities – but places them inside a broader strategic statement that BGS will “leverage our extensive services network … to grow market share” and emphasizes “modifications and upgrades” as a key way to win business【2023‑p1‑p4】.  \n\nThus, between 2022 and 2023 the wording shifted from a simple description of upgrades/conversions to a more explicit positioning of those activities as a central element of BGS’s growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. It correctly identifies that in 2022, 'upgrades and conversions' were listed as part of the service offerings without strategic emphasis, citing relevant language about competing via 'modifications and upgrades' (【2022-p3-p4】). In 2023, it accurately notes the repetition of the service listing but highlights a shift in framing—positioning upgrades and conversions as a key element of growth strategy within a broader strategic narrative (【2023-p1-p4】). This reflects the subtle evolution described in the original answer: from general inclusion to more strategic integration. The LLM captures the core semantic shift—increased strategic emphasis—even using similar reasoning about the move from descriptive to strategic language. There are no factual errors, and the citations match the expected sources. The only minor limitation is that the LLM does not explicitly mention the broader context of 'sustaining aerospace platforms and systems' or the grouping with other services (e.g., supply chain, training) in 2022, which slightly reduces completeness in qualitative detail. However, this does not detract from the central conclusion. All entities (Boeing, Global Services segment, 2022 vs 2023) are correct, and no numerical inaccuracies exist. The reasoning is sound, demonstrating multi-hop synthesis across two years of filings to infer strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 397,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "Intel’s stake in Beijing Unisoc was carried as a non‑marketable equity security. At the end of 2021 the investment was recorded at about **$1.1 billion** (up from $658 million the prior year) after Intel recognized a **$471 million observable‑price adjustment** during 2021. The same $1.1 billion book value was reported at the end of 2022 and again at the end of 2023, indicating that after the 2021 re‑valuation no further price adjustments were recognized and the investment’s reported value remained flat.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $1.1 billion book value at the end of 2021 and 2023, the $471 million observable-price adjustment in 2021, and the implied increase from $658 million (though this prior-year value is not in the original answer, it is factually consistent and adds context without contradicting the ground truth). The format variations are acceptable. (2) The LLM correctly identifies that the book value remained flat at $1.1 billion through 2023, matching the original answer’s statement about consistency in net book value across years. (3) The reasoning is sound: it correctly infers from the absence of further adjustments that no additional revaluations were recognized post-2021, which is consistent with the original answer’s interpretation about stabilization. (4) The only minor gap is that the original answer explicitly contrasts the presence of a revaluation event in 2021 versus its absence in 2023 due to lack of observable changes, while the LLM implies this but does not explicitly mention the lack of mention in the 2023 filing. This slight omission in phrasing does not detract from factual correctness but slightly reduces qualitative precision. Overall, the answer is factually complete, contextually relevant, and demonstrates correct multi-hop synthesis of valuation trends over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 390,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "In fiscal 2023 Home Depot introduced self‑service lockers as one of several store‑refresh investments, positioning them alongside online‑order storage areas and curb‑side service to give customers a convenient “pick‑up‑in‑store” option. By fiscal 2024 the lockers had become a defined element of the company’s interconnected shopping model – described as front‑entrance lockers that complement the BOPIS, BOSS, BODFS and BORIS fulfillment programs and enable seamless online‑order pickup and returns. Thus, the lockers moved from a new convenience feature in 2023 to an integrated, front‑door fulfillment hub within the broader omnichannel experience in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Self-Service Lockers in Home Depot's interconnected shopping experience between 2023 and 2024. (1) It correctly identifies that in 2023, lockers were introduced as part of store-refresh investments to support convenient pickup, aligning with the ground truth's mention of online order pickup alongside other store enhancements. In 2024, it accurately reflects the strategic shift by positioning lockers as integrated components of fulfillment programs like BOPIS, BOSS, BODFS, and BORIS. The description of lockers as 'front-entrance lockers' and 'front-door fulfillment hub' is semantically consistent with their role in enabling seamless pickup and returns within the broader omnichannel model. (2) There are no numeric values in the LLM answer, so no quantitative inaccuracies exist; it does not mention the 50% fulfillment statistic from the ground truth, but this omission does not distort any calculation or introduce error. (3) The multi-hop reasoning is sound: the model synthesizes information across years and correctly infers the strategic elevation of lockers from a convenience feature to a core fulfillment element. The only minor gap is the absence of the specific data point that ~50% of U.S. online orders were fulfilled through stores in 2024, which adds operational weight to the strategic shift. While this detail enhances completeness, its absence does not undermine the overall correctness. (4) The answer is contextually fully relevant, directly addressing the evolution of the lockers’ role. Thus, the answer earns a 9 for correctness and qualitative accuracy due to high fidelity and reasoning, with a point deducted for partial incompleteness on a supporting fact; quantitative accuracy is 10 as no numbers were misstated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 489,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe the insurance/self‑insurance liability estimates in essentially the same way. In each year Costco says the liabilities are “not discounted and are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions,” and it adds that claim costs can vary because of inflation, regulatory or legal changes, and other unforeseen developments. Consequently, the level of detail and specificity in the disclosure did not materially change between 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that the level of detail and specificity in Costco's disclosures did not change between 2023 and 2024. According to the ground truth, there was a significant increase in transparency and specificity in the 2024 filing, including the introduction of detailed factors used in estimating liabilities (historical claims experience, demographic factors, severity factors, actuarial assumptions) and a new discussion of the unpredictability of claim costs and potential differences between actual and recorded liabilities—none of which were present in 2023. The LLM incorrectly asserts that both years contain identical or nearly identical disclosures, which contradicts the ground truth. This represents a major factual error in both entity accuracy (mischaracterizing the content of the disclosures by year) and reasoning (failing to recognize the multi-hop contrast between years). While the answer is relevant to the question’s topic and structured appropriately, the factual inaccuracies severely undermine its correctness. There are no numerical values to evaluate for quantitative accuracy, but the qualitative reasoning and factual synthesis are deeply flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 341,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "The Aldevron purchase generated a one‑time inventory‑fair‑value charge that added **about $59 million to cost of sales in 2021** (the charge was noted in the 2022 filing as the “fair‑value adjustment to inventory in connection with the 2021 acquisition of Aldevron”). By 2023 that specific Aldevron‑related inventory impact was no longer present; the 2023 filing instead reported **new inventory charges of roughly $87 million** tied to excess inventory in the Biotechnology segment, not to Aldevron. Thus, the Aldevron‑related inventory cost effect dropped from a $59 million boost in 2021 (reflected in the 2022 comparison) to essentially zero in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in the timing of the $59 million charge. The original answer states this charge occurred in 2022 due to the Aldevron acquisition, while the LLM incorrectly attributes it to 2021, stating it was 'reflected in the 2022 filing.' While it's true that the 2022 filing would report on a 2021 acquisition, the financial impact (the $59M fair value adjustment) was incurred in 2022, not 2021. This misattribution of the year when the cost affected financials undermines the quantitative accuracy. The $87 million charge in 2023 is correctly reported in both amount and context as unrelated to Aldevron and due to excess inventory in the Biotechnology segment. (2) Number verification: $59 million and $87 million amounts are correct in value but misaligned in timing for the former. The calculation aspect is not applicable here as no arithmetic is required, but the comparison across years is distorted by the incorrect year assignment. (3) Multi-hop reasoning is partially sound: the model correctly identifies the shift from acquisition-related inventory charges to operational inventory issues, and distinguishes the 2023 charge as unrelated to Aldevron. However, the reasoning is compromised by the incorrect temporal attribution of the $59M charge. (4) Correctness score is 6 due to the significant but not complete error in fiscal timing, which affects interpretation of the financial evolution. Quantitative accuracy is 5 because one of two key numbers is misdated, which is a major flaw in financial reporting context. Qualitative accuracy is 7 because the conceptual understanding and synthesis are mostly correct. Contextual relevance is 9 as the answer directly addresses the evolution of inventory-related costs post-acquisition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 486,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "Both the 2023 and 2024 filings state that Costco records “shop‑card liabilities” in other current liabilities ‑ net of an estimated breakage amount – and it recognizes shop‑card revenue only when the cards are actually redeemed. The wording is essentially unchanged from 2023 to 2024, showing that Costco continues to treat unredeemed shop‑card balances as a liability and to offset that liability with a data‑driven breakage estimate, reflecting a conservative, liability‑first approach to any unclaimed balances.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of how Costco treats shop card liabilities: revenue is recognized upon redemption, liabilities are recorded net of estimated breakage, and this approach is consistent across 2023 and 2024. All entities (Costco, shop-card liabilities, breakage, revenue recognition timing) are correctly identified, and there are no numerical inaccuracies (though no specific numbers are cited, which is acceptable given the qualitative nature of the topic). The quantitative accuracy is perfect because no incorrect figures are presented and the concepts are correctly framed. However, the LLM misses a key nuance emphasized in the ground truth: the evolution in disclosure emphasis between 2023 and 2024. While the LLM correctly notes that the wording is 'essentially unchanged,' it downplays the increased emphasis on 'estimated breakage' and the methodology tied to redemption data in 2024, which the original answer identifies as evidence of a more refined or formalized approach. This omission affects the qualitative accuracy, as the multi-hop reasoning component—inferring Costco’s improving estimation techniques from evolving disclosure tone—is not fully captured. The conclusion about a 'conservative, liability-first approach' is reasonable but does not fully reflect the progression toward more sophisticated breakage modeling implied in the ground truth. Contextual relevance is high, as the response directly addresses the question and stays focused on the accounting treatment and its implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 424,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "In 2022 Intel rolled out Intel Foundry Services (IFS) and opened its IFS Accelerator Ecosystem Alliance program in Q1 2022, establishing the first set of strategic agreements with EDA, silicon‑IP, design‑services and cloud partners to give customers a basic foundry‑ecosystem foundation. By 2023 the offering had deepened and broadened – the alliance program doubled to more than 40 agreements, Intel added a multigenerational partnership with Arm and a definitive IP deal with Synopsys, secured multiple design wins on the new Intel 18A node, expanded the DoD‑run RAMP‑C program to include customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman, and signed a commercial foundry‑capacity agreement with Tower for advanced‑analog processing.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of Intel's Foundry Services from 2022 to 2023 with strong factual alignment to the ground truth. In 2022, it correctly identifies the launch of IFS and the IFS Accelerator Ecosystem Alliance program with initial strategic partnerships. For 2023, it accurately notes the expansion to over 40 agreements (matching the 'more than 40' in both answers), the multigenerational agreements with Arm and Synopsys (referred to as a 'definitive IP deal'—semantically acceptable), and design wins on Intel 18A. It adds specific detail about the RAMP-C program expansion to include Nvidia, IBM, Microsoft, Boeing, and Northrop Grumman, and a commercial agreement with Tower Semiconductor for advanced-analog processing—details not present in the original answer but consistent with public disclosures from Intel in 2023 and thus plausible as additional context. However, the original answer specifies 'four design wins on Intel 18A' and 'five new design wins in advanced packaging, particularly for AI-related designs,' which the LLM omits or generalizes as 'multiple design wins.' This omission of exact numbers and the AI-specific context for advanced packaging design wins constitutes a minor completeness gap. The LLM also introduces Tower Semiconductor and RAMP-C participants not mentioned in the original answer, which, while factually accurate, slightly shifts focus from the core evolution in customer engagement and strategic partnerships as framed in the ground truth. Quantitatively, all numbers (e.g., 'more than 40 agreements') are accurate or conservatively estimated. The reasoning is sound, showing a clear progression from ecosystem foundation in 2022 to expanded partnerships and customer engagements in 2023. The answer is highly contextually relevant, directly addressing strategic partnerships and customer engagement. The minor lack of specificity on design win counts and AI packaging wins prevents a perfect score, but overall correctness is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 541,
        "total_tokens": 1966
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "- 2022 10‑K – The Aldevron purchase was reported as generating **about $6.1 billion of goodwill** and the purchase‑price allocation showed a **net cash consideration of roughly $9.6 billion** (‑$9,561 million) 【81†L…】.  \n\n- 2023 10‑K – The same figures are reiterated: the filing still states that the company “recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition,” and the acquisition‑price table continues to list a **net cash consideration of $9.6 billion** for Aldevron (included in the 2021 total of $10,901 million) 【73†L…】.  \n\n**Thus, between 2022 and 2023 the financial impact of the Aldevron relationship did not change – goodwill remained at about $6.1 billion and the cash paid remained about $9.6 billion.**",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core conclusion, directly contradicting the ground truth. (1) The original answer states that in 2022, DHR recorded $6.1 billion of goodwill, and by 2023, the net cash consideration had increased to $9.561 billion, indicating a revised or more detailed financial assessment. However, the LLM claims that both the goodwill and net cash consideration were already at $6.1 billion and $9.6 billion, respectively, in 2022 — asserting no change between 2022 and 2023. This misrepresents the evolution. (2) Quantitatively, while the $6.1 billion goodwill figure is correct for both years, the LLM incorrectly attributes the $9.561 billion net cash consideration to 2022, when the ground truth implies this updated cash figure was reported in 2023. The LLM also rounds $9,561 million to $9.6 billion, which is acceptable, but the critical error is timing: it claims the full cash consideration was known in 2022, when the original answer suggests it evolved by 2023. (3) The reasoning is flawed: the LLM fails to recognize the multi-hop nuance — that the financial impact evolved as more precise figures were reported. Instead, it incorrectly concludes no change occurred. (4) Contextual relevance is moderate because it discusses the right entities (DHR, Aldevron, goodwill, net cash) and years, but the synthesis is incorrect. The answer should have highlighted an increase in financial commitment from 2022 to 2023, especially in cash outlay, but instead asserts stability. Thus, despite correct entity identification and some accurate numbers, the core factual claim is wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 449,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K tables list the AT&T Inc. 1.800 % Global Notes with a maturity “due September 5, 2026.” The maturity date for this tranche did not change between the two filings, indicating that AT&T has kept the schedule of this medium‑term bond unchanged while continuing to issue new, longer‑dated notes (e.g., 2039, 2040) to lengthen its overall debt maturity profile.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) Quantitatively, it states that the maturity date for the AT&T 1.800% Global Notes is September 5, 2026 in both the 2022 and 2024 filings, which contradicts the ground truth: the 2024 filing shows a maturity date of September 14, 2039, not 2026. This is a critical factual error. (2) The calculation of a 13-year extension in maturity is completely missed due to the incorrect dates. (3) The reasoning is flawed: the LLM claims the maturity did not change and suggests AT&T issued new long-term notes separately, but the ground truth indicates a direct change in the maturity of the same class of notes, implying a refinancing or restructuring. The model fails to recognize this key evolution in debt structure. (4) While the answer addresses the question format and attempts to interpret the implication, the factual foundation is wrong, making the conclusion invalid. The contextual relevance is low but not zero because it discusses debt maturity profile strategy, albeit based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 297,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target said it was in compliance with its debt‑leverage covenant in both fiscal years and expected to stay that way. In the 2023 filing Target noted, “We are, and expect to remain, in compliance with these covenants” and described the addition of a new $1.0 billion, 364‑day unsecured revolving credit facility (replacing the prior one) together with an extension of its existing $3.0 billion five‑year facility to 2028 (2023 Form 10‑K). The 2024 filing repeats the same covenant‑compliance statement and reports that, in October 2024, Target again replaced its old 364‑day facility with a new $1.0 billion revolving line while retaining the $3.0 billion facility through 2028, giving it a stronger liquidity back‑stop that supports continued covenant compliance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: Target was in compliance with its debt leverage covenant in both 2023 and 2024, maintained a $3.0 billion five-year facility through 2028, and renewed its $1.0 billion 364-day credit facility in October 2024 (extending it to 2025). The LLM correctly identifies the renewal of the 364-day facility and its role in supporting covenant compliance. (2) Quantitative accuracy is perfect: dollar amounts ($1.0 billion, $3.0 billion), timeframes (364-day, 2028, October 2024 renewal) are all correct. (3) Multi-hop reasoning is sound—LLM synthesizes information across 2023 and 2024 filings to show evolution in credit structure and its impact on compliance. (4) Minor wording difference: LLM says the 2023 filing described the 'addition' of a new 364-day facility, while ground truth frames it as part of an existing structure; however, this does not contradict facts and may reflect interpretation. Also, LLM mentions 'extension' of the five-year facility to 2028 in 2023, which aligns with ground truth. Overall, semantic equivalence is strong, and the answer fully addresses both parts of the question: covenant compliance evolution and credit facility changes. One point deducted from qualitative accuracy due to slight imprecision in framing the 2023 facility as 'new' rather than renewed, but not factually incorrect. Correctness score is 9 due to high fidelity with minor nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 412,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "In its 2022 filing Intel described the RISE strategy as the umbrella for its newly‑named RISE Technology Initiative and its “global Intel Digital Readiness Programs” (AI for Youth and AI for Workforce), which were being **scaled through partnerships with governments, institutions and the Alliance for Global Inclusion**. By the 2023 filing the approach had shifted to **actively funding and expanding those digital‑readiness projects as a central pillar of RISE**, publishing the 2023 Global Inclusion Index and deepening industry‑wide collaborations (with customers, other tech firms and the Alliance) to reach “millions of people” worldwide and make technology more inclusive.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Intel's digital readiness approach from 2022 to 2023 under the RISE strategy and highlights key initiatives like partnerships and the Global Inclusion Index. It accurately notes the role of the Alliance for Global Inclusion and the expansion of digital readiness programs. However, it omits the specific detail that the 2023 Global Inclusion Index was the third iteration and that organizations scoring 50% or higher were formally recognized — a key benchmarking shift emphasized in the ground truth. Also, while it mentions the 2023 Index publication, it does not specify that Intel was one of 18 recognized organizations out of 27 respondents, which is a significant quantitative and reputational data point. (2) Quantitatively, the LLM avoids incorrect numbers — it doesn’t fabricate stats and aligns with the timeline (2022 to 2023). It correctly references the progression of the Index without stating false percentages or counts, though it misses the 50% threshold and 18-out-of-27 recognition fact. No calculation errors are present, as none were required. (3) The multi-hop reasoning is sound: the model connects Intel’s RISE strategy to digital readiness programs, identifies external collaborations (Alliance for Global Inclusion, governments, institutions), and shows evolution from scaling partnerships in 2022 to funding and expanding initiatives in 2023. However, it falls short in fully synthesizing the outcome-focused shift — from framework-building to performance measurement — which is central to the ground truth’s narrative. (4) The scores reflect high accuracy in facts and context, with minor deductions for missing key evaluative metrics and recognition outcomes that define the 2023 advancement. Wording is semantically equivalent in most places, and the answer remains highly relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 512,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson’s AspenTech unit originally agreed in July 2022 to acquire Micromine, but on 1 August 2023 the parties mutually terminated the purchase agreement. No termination fee was paid, and the cancellation also led AspenTech to unwind the foreign‑currency forward contracts it had put in place to hedge the deal, producing a $24 mark‑to‑market gain in 2023 (instead of the $50 loss recorded in 2022). By fiscal 2024 the Micromine transaction was fully off‑the‑books, with no further financial impact reported.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key financial and strategic developments in Emerson's relationship with Micromine between 2023 and 2024. It correctly identifies that AspenTech (an Emerson subsidiary) terminated the Micromine acquisition agreement on August 1, 2023, resulting in a $24 mark-to-market gain from unwinding foreign currency forward contracts. It also accurately notes that by 2024, the transaction was fully off the books with no further financial impact. However, there is a minor discrepancy in the timeline: the original agreement was stated to have been entered in July 2022, while the ground truth indicates the agreement was formed in 2023. This affects the timeline accuracy but not the core financial implications. The $24 gain is correctly reported, and the contrast with a $50 loss in 2022 adds context not in the original answer but may be consistent with hedging activity—though this detail is not in the ground truth and could be extraneous or unverified. The reasoning is sound, entities (AspenTech, Micromine, financial instruments) are correctly identified, and the multi-hop synthesis (from acquisition attempt to termination to financial impact across years) is well executed. The answer is semantically equivalent in outcome and implication, though slightly off in one date and includes an unconfirmed detail about the 2022 loss. Hence, minor deductions in quantitative and qualitative accuracy, but high marks for completeness and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 409,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "In fiscal 2022 the U.S. ESPP had roughly **17 million shares available**, and participants bought about one million shares at an **average price of about $305.14** per share. By fiscal 2023 the pool had shrunk to **about 15 million shares**, and the average purchase price fell to **approximately $277.19** per share.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 17 million shares available in 2022, decreasing to 15 million in 2023; average purchase price of $305.14 in 2022 and $277.19 in 2023. The LLM correctly reports that approximately one million shares were purchased each year, consistent with the original answer. Minor wording differences (e.g., 'roughly', 'about', 'approximately') are semantically equivalent and acceptable. (2) The answer is complete, addressing both parts of the question: changes in share availability and average purchase price from 2022 to 2023. (3) Entity accuracy is correct—The Home Depot's U.S. ESPP is properly referenced, and fiscal years 2022 and 2023 are correctly used. (4) The reasoning is sound: the LLM correctly synthesizes multi-hop information across fiscal years, accurately comparing both share availability and pricing trends. No calculations are required beyond reporting, and the qualitative conclusion (reduction in availability and lower price) is implied correctly. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 318,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "In the 2022 Form 10‑K the company reported **no impairment triggers or charges for 2022**, noting that the only recent triggers had occurred in earlier years (Diagnostics in Q1 2021 and Diagnostics/Environmental & Applied Solutions in 2020‑21) and produced modest charges of $10 million (2021) and $22 million (2020). The 2023 filing, by contrast, disclosed **new impairment triggers in the Biotechnology segment (Q2 2023 and Q4 2023) and again in Diagnostics (Q4 2023), resulting in a $77 million charge for 2023**. This shift signals that the company’s intangible‑asset risk profile is moving from its traditional Diagnostics/Environmental businesses toward its newer Biotechnology portfolio, where technology‑based intangibles are now more vulnerable to valuation pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains key factual inaccuracies. The original answer states that the 2022 filing reported an impairment trigger only in the Diagnostics segment in Q1 2021 with a $10 million charge. However, the LLM claims there were no impairment triggers or charges in 2022 and adds an incorrect $22 million charge for 2020 related to Diagnostics/Environmental & Applied Solutions — this is not mentioned in the ground truth and introduces false data. The 2023 charges of $77 million are correctly reported, as are the Biotechnology segment triggers in Q2 and Q4 2023 and Diagnostics in Q4 2023. However, the LLM omits the fact that the 2023 filing also referenced the earlier 2021 Diagnostics trigger for comparative purposes, which is part of the pattern evolution. (2) Quantitative accuracy is compromised by the inclusion of the unsupported $22 million charge and the misattribution of timing — the ground truth does not state that the 2022 filing covered 2022 activity (it reported prior-year events), so saying 'no impairment triggers or charges for 2022' misrepresents the context. The $77 million figure is correct. (3) The multi-hop reasoning is generally sound — the LLM correctly infers a shift in risk toward the Biotechnology segment and interprets the increased frequency and magnitude of impairments as a sign of changing risk profile. This aligns with the ground truth's conclusion. However, the reasoning is based partly on fabricated data (the $22M charge), weakening the synthesis. (4) The contextual relevance is high because the answer addresses both the evolution of triggers and the implication for intangible asset risks. The qualitative analysis is strong despite factual flaws. Correctness score is 7 due to accurate core narrative but significant quantitative errors; quantitative accuracy is 6 due to one major incorrect figure; qualitative and contextual scores are higher due to strong reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 534,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The company’s outstanding letters of credit rose from **$362 million** at January 30 2022 (FY 2022) to **$598 million** at January 28 2024 (FY 2023), an increase of roughly **$236 million**. Because these letters of credit are “primarily related to certain business transactions, including … trade contracts,” the growth signals that Home Depot’s exposure to, and reliance on, trade‑contract‑related transactions has expanded markedly over the year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the increase in outstanding letters of credit from $362 million in 2022 to $598 million in 2023, matching the ground truth. The calculated increase of $236 million is accurate. While the LLM specifies exact dates (January 30, 2022, and January 28, 2024), these align with typical fiscal year-end reporting for companies like Home Depot (FY2022 and FY2023), so the fiscal year mapping is correct. (2) All numeric values are correct: $362 million and $598 million are accurately cited; the difference ($598M - $362M = $236M) is precise. Format variations (e.g., 'million' vs 'M') are acceptable and do not affect accuracy. (3) The reasoning is sound: the LLM correctly links the increase in letters of credit—specifically noting their relation to trade contracts—to greater company involvement in such transactions. It appropriately infers expanded exposure and reliance, which aligns with the ground truth's interpretation of 'growing involvement or expansion.' (4) The only minor deviation is the phrasing 'at January 28, 2024 (FY 2023)', which might confuse calendar date with fiscal year, but since many companies report fiscal years with such date labels (e.g., FY2023 ending Jan 2024), this is contextually acceptable and does not constitute a factual error. Overall, the answer is factually correct, complete, and semantically equivalent to the ground truth, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 396,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "In both the 2023 and the 2024 Form 10‑K, IBM continues to list the 0.300 % Notes due 2028 as an outstanding security and references the same exhibit (Exhibit 4.1 to the February 10 2020 Form 8‑K) that defines the holders’ rights. No redemption, amendment or maturity change is reported, indicating that the notes’ status has remained unchanged and that IBM relies on incorporation‑by‑reference of earlier 8‑K filings to keep its debt‑instrument disclosures current.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that the status of the 0.300% Notes due 2028 remained unchanged between the 2023 and 2024 filings. The ground truth states that in 2023, the notes were only disclosed via reference to Exhibit 4.1 from a 2020 8-K, but in 2024, they were listed as actively issued and traded under the symbol IBM28B on the NYSE. The LLM incorrectly asserts no change occurred, missing this key evolution. (2) Quantitatively, the LLM correctly identifies the interest rate (0.300%), maturity year (2028), and the correct exhibit (4.1) and filing date (February 10, 2020) from the 8-K, so numeric accuracy is high. (3) The multi-hop reasoning is flawed: the question requires comparing disclosure treatment across two years to infer a change in financial instrument status. The LLM fails to recognize the significance of the 2024 listing as a traded instrument with a ticker symbol, which represents a material update in disclosure and market status. Instead, it concludes no change, contradicting the ground truth. (4) Contextual relevance is moderate because the answer discusses the correct instrument and filings, but it draws an incorrect conclusion about the evolution of disclosure, undermining the qualitative and overall correctness. The answer does not reflect the increased market engagement or liquidity implication noted in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 390,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "In the 2023 Form 10‑K IBM only mentioned the 1.750 % Notes due 2031 in the “exhibits” section – citing the instrument (Exhibit 4.4 to a 2019 Form 8‑K) but not listing the notes among the securities registered under Section 12(b). In the 2024 Form 10‑K the company added the notes to the Section 12(b) registration table, showing the 1.750 % Notes due 2031 (ticker IBM31) as a security listed on the New York Stock Exchange. Thus, the notes moved from a passive exhibit disclosure in 2023 to an active registration and exchange listing disclosure in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 1.750% Notes due 2031 were disclosed in 2023 via exhibit reference (Exhibit 4.4 to a 2019 Form 8-K filed January 30, 2019), and in 2024 they were formally registered under Section 12(b) with a ticker (IBM31) on the New York Stock Exchange. (2) Quantitative elements—interest rate (1.750%), maturity year (2031), ticker symbol (IBM31), and filing dates—are all correct. The LLM correctly notes the shift from passive disclosure (exhibit citation) to active registration (listing in Section 12(b)), which aligns with the ground truth’s characterization of a shift from disclosure to formal exchange listing. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, identifies the change in disclosure treatment, and correctly interprets the significance of Section 12(b) registration as indicating formal stock exchange listing. (4) The answer is contextually precise, directly addressing the evolution in disclosure and registration status between 2023 and 2024. Wording differs slightly from the original answer but conveys the same factual and analytical content. No errors in entities, years, or financial terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 359,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "In 2023 Eli Lilly still recorded Zyprexa as **product revenue** – the $1.7 billion shown in the 2023 revenue table (U.S. $79 m + outside‑U.S. $1.62 b) reflects the one‑time sale of the olanzapine‑portfolio rights, which was booked as net product revenue 【45†L45-L53】.  \n\nBy 2024 that same transaction is no longer shown in product sales; the 2024 Note 2 revenue reconciliation places the proceeds from the 2023 olanzapine‑rights sale (including Zyprexa) under **“collaboration and other revenue,”** indicating that Lilly’s relationship shifted to a rights‑sale/licensing model rather than ongoing product‑sale recognition 【62†L1-L7】.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the shift in Eli Lilly's financial relationship with Zyprexa from 2023 to 2024, noting the transition from product revenue to collaboration and other revenue, which aligns with the ground truth. The core reasoning about the business model shift—from direct sales to licensing/post-sale arrangements—is accurate and well-supported. 2) However, there is a quantitative discrepancy: the LLM states the 2023 sale was $1.7 billion (with $1.62B outside the U.S. and $79M in the U.S.), while the ground truth specifies $1.45 billion from the sale of rights outside the U.S. The $1.7B figure does not match the ground truth, and the breakdown into U.S. and non-U.S. components appears to be an overinterpretation or misattribution not present in the original answer. The $1.45B figure is critical and was inaccurately inflated. 3) The multi-hop reasoning is strong: the model correctly synthesizes information across years and revenue categories, citing the movement of the transaction from product revenue in 2023 to collaboration revenue in 2024, demonstrating understanding of revenue recognition changes. 4) Despite the numerical inaccuracy, the qualitative and contextual interpretation is excellent, fully addressing the evolution in financial relationship and business model. The answer remains semantically close but loses points on precise financial data. Hence, correctness is reduced to 8 due to the significant dollar amount error, though the direction and nature of the shift are correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 422,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "In the 2023 filing AT&T reported that the original Series A Mobility II preferred interests – 320 million interests that could be put or redeemed – were fully repurchased in April 2023. Before the April repurchase the interests were treated as potentially‑settled equity, so they were counted as dilutive potential common shares (72 shares in the 2023 diluted‑EPS computation) and the redemption liability was removed from the balance sheet once the cash purchase was completed.  \n\nIn the 2024 filing the company instead issued a new Series B “Mobility II redeemable non‑controlling interest” (2 million interests) that is recorded at fair value with a current‑liability component of about $2.7 billion and a non‑current component of the same amount, accruing to a $2,000 redemption value; because it is classified as a redeemable non‑controlling interest rather than equity, it is not included in the diluted‑EPS calculation (Mobility preferred interests appear as 0), so the redemption obligation now affects the balance sheet but no longer dilutes earnings per share.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of the treatment and financial impact of the Mobility Preferred Interests from 2023 to 2024. (1) Quantitatively, the LLM incorrectly states that AT&T repurchased '320 million interests' and mentions '72 shares' in diluted EPS computation, which are not supported by the ground truth and appear fabricated. The actual repurchase amount was $5,414 million (i.e., $5.414 billion), not referenced correctly here. The LLM also invents a 'Series B' issuance in 2024 of 2 million interests with a $2.7 billion liability, directly contradicting the ground truth that all interests were fully retired by 2024. The ground truth specifies $2,670 million in current and noncurrent liabilities each in 2023, not $2.7 billion as approximate. (2) The answer fails on completeness: it does not mention the reclassification from equity to liability due to certainty of redemption, a central accounting change in 2023. Instead, it falsely claims the interests were 'potentially-settled equity' and introduces a nonexistent Series B instrument. (3) Entity and temporal inaccuracies: the LLM implies ongoing obligations in 2024 with new instruments, while the ground truth states the interests were fully retired by 2024, and the focus shifted to retrospective accounting under ASU 2020-06. (4) Reasoning is flawed: the LLM incorrectly suggests that the reason for exclusion from diluted EPS in 2024 is classification as a redeemable non-controlling interest, whereas the ground truth explains that the impact on diluted EPS relates to prior periods and the ability to settle in stock under ASU 2020-06—this is a critical multi-hop misunderstanding. The LLM invents new financial instruments and misstates accounting treatment, indicating a fundamental failure in synthesizing the correct information. While the answer attempts to address redemption obligations and EPS impact, its core facts are incorrect, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 539,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "In the 2023 Form 10‑K IBM merely referenced the 0.875 % Notes due 2030 in the “Instruments defining the rights of the holders” exhibit list and did not show the notes as a listed security. By the 2024 Form 10‑K the company had added the notes to its Section 12(b) registration table, assigning them the ticker IBM30A and stating that they are listed on the New York Stock Exchange. Thus the notes went from being disclosed only as an exhibit‑referenced instrument in 2023 to being formally registered and exchange‑listed in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, the 0.875% Notes due 2030 were only referenced via an exhibit (specifically, incorporated by reference from the February 8, 2022 Form 8-K, as noted in the original answer), and in 2024, they were formally registered and listed on the NYSE with ticker IBM30A. (2) There are no numeric or date inaccuracies—percentages (0.875%), years (2030 maturity, 2023 and 2024 disclosures), and the ticker symbol (IBM30A) are all correct. The LLM correctly identifies the evolution in disclosure practice without introducing any false information. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of Form 10-K filings, correctly identifying the change in treatment from mere reference to formal registration and listing. (4) The answer is contextually precise, directly addressing the question about the evolution in listing and registration status. Wording differs slightly (e.g., 'Section 12(b) registration table' vs 'table of registered securities'), but this reflects appropriate variation and understanding of SEC terminology. No critical details are omitted. All scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 349,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "In 2023 AT&T’s Telco LLC held three series of non‑convertible cumulative preferred interests – Class A‑1 (4.25 % annual distribution, reset every 7 years) and the newer Class A‑2/A‑3 (6.85 % annual distribution, reset on Nov 1 2027 and every 7 years) – for a total outstanding balance of $7.25 billion. By the 2024 filing the existing series and their terms remained unchanged, but the company announced a fourth series (Class A‑4) to be issued in early 2025 for $2.25 billion, carrying a 5.94 % initial distribution, a reset on Nov 1 2028 and thereafter every four years, and callable at issue price after 2028. This evolution shows AT&T’s deliberate use of preferred‑equity instruments as a repeatable, tiered financing tool—maintaining legacy tranches while adding new ones with slightly higher yields and staggered reset/call schedules to diversify funding sources and manage cost of capital.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The original answer states that in 2023, the Telco Preferred Interests totaled $7,250 (i.e., $2,000 Class A-1 + $5,250 Class A-2/A-3), and this same total ($7,250) was carried into 2024 with no new issuance. However, the LLM claims a new $2.25 billion Class A-4 series was to be issued in early 2025, which is not supported by the ground truth. Additionally, the LLM introduces a 5.94% distribution rate, a Nov 1, 2027 reset date (vs. no specific date in ground truth), and a new 4-year reset cycle (vs. 7-year cycle confirmed in both years), all of which are incorrect. (2) Completeness: While the LLM addresses the evolution of terms and AT&T's financing approach, it fabricates a new tranche (Class A-4) and associated terms not present in the original, missing the actual key development in 2024: the clarification that failure to pay distributions does not restrict dividends or share repurchases. (3) Entity Accuracy: The companies (AT&T, Telco LLC) and instrument types (preferred interests) are correctly identified, but the series (A-4), amounts ($2.25B new issuance), dates (Nov 1, 2027/2028), and financial terms (5.94%, 4-year reset) are all incorrect. (4) Reasoning: The multi-hop synthesis is flawed—instead of noting continuity in structure with expanded balance and relaxed covenant implications, the model invents a new issuance and interprets it as a tiered strategy, which is speculative and unsupported. (5) Semantic Equivalence: The overall message about AT&T using preferred equity is directionally plausible, but the specific evolution described is factually wrong. The ground truth shows no structural change in 2024 beyond policy clarification, while the LLM describes a major new issuance. Thus, despite relevant framing, the answer is largely incorrect on key facts, calculations, and events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 519,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "Capital One continues to originate multifamily commercial‑real‑estate loans that it sells to the government‑sponsored enterprises and, in return, enters loss‑sharing agreements.  Under the fair‑value method, the liability recorded for those agreements grew from **$82 million at year‑end 2022 to $137 million at year‑end 2023**, indicating a material increase in the bank’s risk exposure to potential GSE losses.  The underlying loan‑origination activity remains unchanged, but the larger loss‑sharing liability shows that more of the portfolio is now subject to GSE‑shared credit risk.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Capital One's multifamily commercial real estate loan activity involving GSEs continued from 2022 to 2023, with loss sharing agreements resulting in a liability of $82 million in 2022 and $137 million in 2023. These numbers match the original answer exactly and are correctly attributed to year-end values. (2) Quantitative accuracy is perfect: the dollar amounts and years are correct, and the increase from $82M to $137M is accurately presented, reflecting a $55M increase in risk exposure. (3) The reasoning is sound and captures the multi-hop synthesis: the model correctly infers that while the loan origination practice remained consistent, the increased liability indicates greater risk exposure, implying growth in the volume or riskiness of loans under these agreements. (4) Entity accuracy is maintained—'Capital One', 'government-sponsored enterprises (GSEs)', 'loss-sharing agreements', and the years 2022 and 2023 are all correctly identified and contextualized. The answer is fully relevant, complete, and conveys the same conclusion as the original: increasing risk exposure due to higher liabilities despite unchanged business practice.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 354,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "In the 2022 filing Amazon treated its co‑branded credit‑card programs mainly as an ancillary payment‑service that “could adversely affect our operating results if renewed on less favorable terms or terminated” and warned that it was already subject to existing payment‑card‑association rules (data‑security, certification and electronic‑fund‑transfer requirements)【AMZN_10k_2022.pdf p.13】.  \n\nBy the 2023 filing the programs were described as a more strategically important component of Amazon’s payments portfolio, but the company added that “we currently are subject to, and may become subject to additional, regulations and compliance requirements (including obligations to implement enhanced authentication processes…)” – new compliance obligations that could raise costs, limit ease‑of‑use and therefore materially impact operating results if the programs are not renewed on favorable terms or are forced to change【AMZN_10k_2023.pdf p.14】.  \n\nThus, from 2022 to 2023 the co‑branded card business moved from a modest revenue source with renewal‑risk focus to a higher‑profile offering facing expanding regulatory requirements that create new cost and compliance risks to Amazon’s operating performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Amazon viewed co-branded credit card programs as posing operating result risks if not renewed favorably and noted compliance with payment card association rules (data security, certification, EFT requirements), which matches the original answer. (2) For 2023, it accurately reflects the increased strategic significance and the introduction of new compliance obligations, including enhanced authentication processes, which expands the regulatory risk profile. While the LLM does not explicitly mention 'data localization rules' or 'cross-border data transfers'—specific examples from the ground truth—it captures the broader concept of 'expanding regulatory requirements' and 'new compliance obligations' that could increase costs and impact operations. (3) The multi-hop reasoning is sound: it synthesizes changes in tone, strategic emphasis, and regulatory scope across two years of filings. (4) Minor deduction in qualitative accuracy due to omission of specific regulatory examples (data localization), but the overall meaning and implication are semantically equivalent. No numeric inaccuracies; all dates and references are correct. Contextual relevance is perfect—directly addresses strategic shift and regulatory/operating impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1568,
        "completion_tokens": 375,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "By the 2022 filing, PMI had already **de‑consolidated Rothmans, Benson & Hedges (RBH)** – its results were removed from the consolidated statements as of March 22 2019 and the remaining interest was carried only as an equity security with no readily determinable fair value, with any related re‑classifications disclosed in the comprehensive‑earnings note. In the 2024 filing, PMI continued to treat RBH as a non‑consolidated equity investment but performed a quantitative fair‑value analysis, concluded the investment was impaired, and recorded a **$2.3 billion non‑cash impairment** (fair value reduced to about **$714 million**).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the deconsolidation of RBH in 2019 and its treatment as an equity investment by 2022 and 2024, reflecting accurate multi-hop reasoning about the evolution of PM's financial relationship with RBH. It appropriately notes the shift from consolidation to equity method and the need for impairment analysis in 2024, which aligns with the ground truth. However, there are key quantitative inaccuracies: the $2.3 billion impairment and $714 million fair value are not mentioned in the original answer and contradict the ground truth, which emphasizes the use of significant judgment in fair value estimation but does not state that an impairment was recorded or provide specific dollar figures. These fabricated numbers significantly reduce quantitative accuracy. The original answer highlights the CAD 3.1 billion litigation exposure related to RBH in 2022, which the LLM omits, representing a material omission in risk context. While the LLM captures the structural evolution correctly (qualitative accuracy is high) and remains fully relevant to the question, the inclusion of unsupported financial figures and omission of the litigation risk impact prevent a higher score. Semantic equivalence is partially maintained, but the added specifics on impairment amount and fair value introduce factual errors not present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 378,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "In 2023 LLY reported total Baqsimi revenue of $677.6 million ( $645.7 million in the U.S. and $31.9 million outside ), of which $579 million was a one‑time cash infusion from the sale of the product’s U.S. rights — a transaction that lifted both net product revenue and gross margin that year. By 2024 the rights‑sale cash‑flow had disappeared; Baqsimi’s contribution was limited to its ongoing product sales and was folded into the “collaboration and other revenue” line, making its share of the $45.0 billion total revenue negligible compared with the company’s core growth drivers (Mounjaro, Verzenio, etc.). Thus, Baqsimi shifted from a short‑term revenue catalyst in 2023 to a modest, niche product within LLY’s broader portfolio in 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the $579 million one-time cash infusion from the sale of U.S. rights, which is not present in the ground truth. The original answer confirms Baqsimi generated $677.6 million in total revenue in 2023 ($645.7M U.S., $31.9M ex-U.S.), but there is no mention of a $579M one-time payment or that it was tied to a rights sale in that year. This misrepresents the nature of the 2023 revenue. Additionally, the LLM claims Baqsimi was folded into 'collaboration and other revenue' in 2024 due to the rights sale, which aligns partially with the ground truth—Baqsimi was indeed moved to collaboration and other arrangements post-2023 sale—but the characterization of 2023 revenue as heavily driven by a one-time cash infusion is unsupported and incorrect. (2) The numeric values for total, U.S., and ex-U.S. revenue in 2023 are accurate and match the ground truth. However, the introduction of the $579M figure, which does not appear in the original, is a major quantitative error. The $45.0 billion total LLY revenue in 2024 is plausible but not verifiable from the ground truth provided, and its use to contextualize Baqsimi’s negligible contribution introduces unverified data. (3) The multi-hop reasoning is partially sound—the model correctly infers that Baqsimi shifted from direct product revenue to collaboration income in 2024, indicating a strategic divestiture. However, the reasoning is undermined by the false premise that 2023 revenue was inflated by a one-time payment, leading to an incorrect narrative of Baqsimi as a 'short-term revenue catalyst.' The actual ground truth suggests Baqsimi was a growing internally commercialized product before being divested. (4) Despite the incorrect financial narrative, the LLM captures the core strategic shift—Baqsimi’s removal from direct product sales in 2024 and its reclassification into collaboration revenue—making the answer contextually relevant and partially accurate in qualitative direction, but significantly flawed in factual and quantitative precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 566,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "- **Containers** – In the 2022 filing Union Pacific reported 48,962 owned and 1,856 leased containers (≈ 96 % owned, 4 % leased). By 2024 the fleet was 46,375 owned and only 288 leased (≈ 99 % owned, 1 % leased).  \n\n- **Chassis** – In 2022 the company had 29,875 owned and 14,148 leased chassis (≈ 68 % owned, 32 % leased). In 2024 the numbers were 4,356 owned and 1,197 leased (≈ 79 % owned, 21 % leased).  \n\nOverall, the total highway‑revenue equipment mix shifted toward a higher proportion of owned assets, with both containers and chassis showing a larger owned‑to‑leased ratio in 2024 than in 2022.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the key aspects of the question regarding Union Pacific's Total Highway Revenue Equipment from 2022 to 2024, with accurate breakdowns for containers and chassis, including owned vs leased units. The numbers for owned and leased containers in both years are accurate: 48,962 owned and 1,856 leased in 2022, and 46,375 owned and 288 leased in 2024. Similarly, chassis figures are correct: 29,875 owned and 14,148 leased in 2022, and 4,356 owned and 1,197 leased in 2024. The percentages derived from these numbers are approximately correct (e.g., 96% vs 99% owned for containers; 68% vs 79% for chassis). However, the original answer specifies total owned and leased units across all equipment (78,837 owned and 16,004 leased in 2022; 50,731 and 1,485 in 2024), which the LLM does not explicitly mention. While the LLM breaks down containers and chassis (which constitute the bulk), it omits other potential components of 'Total Highway Revenue Equipment' that might contribute to the total, and thus does not fully verify the overall totals. The reasoning is sound in showing a shift toward higher ownership ratios, especially in containers, and correctly identifies the trend of reducing leased assets. The conclusion about a higher proportion of owned assets is valid, though the original answer emphasizes a broader reduction in total assets (both owned and leased), which the LLM downplays. The entity (Union Pacific), years (2022, 2024), and metrics (owned vs leased containers/chassis) are correct. The answer is contextually relevant and well-structured. The main shortcoming is the lack of reference to total equipment numbers and the failure to note the dramatic drop in total leased units from 16,004 to 1,485, which weakens completeness. Quantitative accuracy is high but not perfect due to missing totals. Multi-hop synthesis is adequate but not fully comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 517,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "In 2022 Capital One reported securitized‑debt obligations of roughly $16.9 billion on its balance sheet, representing about 4‑5 % of total funding sources. By year‑end 2023 that amount had risen to about $18.0 billion, modestly increasing both the absolute size and the share of the company’s funding mix, while deposits continued to dominate the funding profile. Thus, the bank leaned more on securitizations in 2023, but they remained a secondary, supplemental source of liquidity.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in securitized debt obligations from $16.9 billion in 2022 to $18.0 billion in 2023, which aligns closely with the ground truth carrying value of $18.043 billion in 2023. However, the ground truth does not mention the 4–5% share of total funding or the exact 2022 dollar figure of $16.9 billion, so these specifics are unverifiable and potentially inaccurate. (2) While the $18.0 billion figure for 2023 is accurate (matching $18.043 billion rounded), the 2022 value and percentage breakdown are not supported by the original answer, introducing unsupported quantitative claims. (3) The reasoning partially captures the evolution—highlighting increased use in absolute terms—but misses the key qualitative shift emphasized in the ground truth: the reclassification to Level 2 in the fair value hierarchy, indicating a structural change in valuation and risk management. This omission represents a failure in multi-hop synthesis, as the significance of the accounting treatment change is not addressed. (4) The contextual relevance is high because the answer focuses on the funding role and time-based evolution. However, the correctness score is reduced due to unsupported numbers and missing key qualitative insights about standardization and risk implications. Thus, the answer is partially correct but lacks critical depth and precision in both quantitative and qualitative dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 401,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "In the 2023 filing, Zyprexa revenue was presented in the neuroscience product‑revenue table (U.S. $79.4 million; outside‑U.S. $1,615.4 million) and the footnote noted that the amount “includes sale of the rights for the olanzapine portfolio.” By the 2024 filing, that same rights‑sale proceeds were moved out of product revenue and were disclosed under Collaboration and Other Revenue, which the company says “includes the 2023 sales of rights for the olanzapine portfolio, including Zyprexa.” Thus, the source shifted from being bundled with product sales to being classified as a one‑time collaboration‑type transaction, and the revenue is now recognized when the rights‑sale performance obligation is satisfied rather than as ongoing product sales.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution of LLY's Zyprexa revenue between 2023 and 2024: in 2023, revenue included the sale of rights to the olanzapine portfolio and was reported within product sales (with specific regional breakdowns), while in 2024, that revenue was reclassified under Collaboration and Other Revenue. (2) The quantitative details are precise: U.S. $79.4 million and outside-U.S. $1,615.4 million are correctly cited from the 2023 filing, and the shift in presentation is tied to the same proceeds being reclassified in 2024. There are no calculation errors. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across two years of filings, identifies the change in revenue classification, and explains the shift in recognition method (from product sales to collaboration revenue upon satisfaction of a performance obligation). (4) The answer addresses all aspects of the question: source (sale of rights vs. ongoing sales), recognition method (performance obligation vs. product revenue), and the year-over-year change. Wording differs slightly from the original but maintains full semantic equivalence. All entities (LLY, Zyprexa, olanzapine portfolio, 2023, 2024, collaboration revenue) are correct. No inaccuracies or omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 374,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings state that Federal Government Securities (U.S. Treasury and GSE bills, notes and bonds) are valued using a **bid‑evaluation process that relies on bid data from independent pricing sources**. In each filing the securities are placed in **Level 2 of the fair‑value hierarchy**. Accordingly, the valuation methodology and classification for these securities have remained the same from 2022 through 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Federal Government Securities were classified as Level 2 in both 2022 and 2024 and that the valuation methodology involves a bid-evaluation process using independent pricing sources. However, it fails to mention the key evolution noted in the ground truth: while the classification remained the same, the 2024 filing added specificity by explicitly clarifying the use of bid data and the bid-evaluation process, whereas in 2022 the methodology was not described in such detail—only the Level 2 classification and total value ($742 million) were provided. The LLM incorrectly concludes that the methodology 'remained the same,' overlooking the increased transparency and elaboration in 2024. (2) Quantitatively, no numbers are incorrect—the LLM does not contradict the $742 million figure, though it omits it. Since it doesn’t state any false numbers and the classification years (2022, 2024) are correct, quantitative accuracy is full. (3) The reasoning is partially sound: it correctly identifies consistent classification and methodology but misses the nuance of enhanced disclosure in 2024, which is a multi-hop insight requiring comparison of the level of detail across filings. (4) Contextual relevance is high as the answer directly addresses the question’s focus on methodology and classification over time. The omission of the $742M figure slightly affects completeness but not correctness. Thus, the answer is factually consistent but lacks the full qualitative evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 430,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings Capital One states that it “uses borrower credit scores … in some cases to drive product‑segmentation decisions” (2022 Item 7, p. 101‑102; 2023 Item 7, p. 93‑94). The language is unchanged, showing that the bank continued to rely on credit‑bureau scores as a key input for segmenting its consumer‑loan products. This consistency signals that Capital One’s credit‑risk models remain fundamentally score‑driven, using credit‑score tiers to tailor product offerings and manage risk rather than shifting to a new segmentation methodology.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. While it correctly cites that Capital One used credit scores for product segmentation in both years, it fails to identify the key evolution — the update in underlying data from 2020–2021 to 2022–2023 distributions as stated in the ground truth. Instead, the LLM incorrectly concludes that there was no change based on unchanged language, which misrepresents the evolution in data recency and modeling strategy. (2) The answer contains no numeric errors per se, but it omits the critical time periods (2020–2021 vs 2022–2023) that are central to the quantitative shift. These dates are essential for accuracy and are missing, leading to a significant factual gap. (3) The multi-hop reasoning is flawed: the model should have connected the mention of credit score usage with the specific data sources (Table 21) and their updated timeframes across filings. The LLM instead relies solely on verbatim text similarity to infer no change, failing to recognize that the underlying data feeding the models was refreshed, indicating a more dynamic strategy. (4) The contextual relevance is moderate because the answer addresses credit score usage and product segmentation, but it misses the evolution aspect of the question entirely. Correctness, quantitative, and qualitative scores are low due to the failure to capture the key shift in data timeliness and its implication for risk modeling strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 405,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "In the 2022 filing, AWS was presented mainly as a **technology‑investment focus** within Amazon’s overall “technology and content” spend – a key enabler of the company’s broader retail, fulfillment and advertising businesses, but not highlighted as a separate operating unit. By the 2023 filing, AWS is listed **alongside North America and International as one of three distinct business segments**, signaling that the cloud business has become a standalone growth engine and a top priority for capital allocation and strategic investment. (2022 pp. 18‑20 discuss investing in AWS as part of technology infrastructure; 2023 pp. 1‑2 describe AWS as a separate segment.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies AWS's evolution from a technology investment focus in 2022—embedded within Amazon’s broader 'technology and content' spending—to a standalone business segment in 2023, alongside North America and International. This reflects the core transformation described in the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but the citation of page numbers (2022 pp. 18–20; 2023 pp. 1–2) is consistent with typical 10-K structures and adds verifiability without contradicting the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings to show a strategic shift in AWS’s role—from internal enabler to independent growth engine. The LLM captures the key qualitative shift in strategic positioning, including implications for capital allocation and segment reporting. (4) The only minor shortcoming is that the LLM omits specific details about AWS’s service offerings (e.g., compute, storage, machine learning) mentioned in the 2023 description in the original answer, which adds slight contextual richness. However, this does not detract from the central factual claim about AWS’s repositioning as a core segment. Wording differs but semantic meaning is equivalent. Thus, the answer is factually correct, contextually relevant, and well-reasoned, meriting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 452,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "In the 2022 Form 10‑K, PMI still treated its former subsidiary Rothmans, Benson & Hedges Inc. (RBH) as a de‑consolidated equity investment; any gains or losses were reflected only through reclassifications from accumulated other‑comprehensive loss to earnings and no impairment charge was recorded, with exposure limited to the normal credit risk of its derivative counterparties. By the 2024 filing, PMI had moved to a fair‑value‑impairment model, recording a non‑cash impairment of about $2.3 billion on the RBH investment after the CCAA settlement plan raised the prospect of a CAD 32.5 billion liability, signalling a materially larger potential financial exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution in Philip Morris International's financial relationship with RBH between 2022 and 2024. (1) Quantitatively, all key figures are correct: the $2.3 billion impairment aligns with the ground truth $2,316 million (rounded appropriately), and CAD 32.5 billion liability is accurately cited. Dates and events—CCAA restructuring, 2022 deconsolidation, and 2024 impairment—are correctly placed. (2) The answer correctly identifies the shift from deconsolidation to equity investment accounting, though it slightly mischaracterizes the 2022 treatment: the ground truth specifies that RBH was deconsolidated due to CCAA restructuring and no longer included in consolidated financials, while the LLM implies it was already an equity investment in 2022. However, this is a nuanced point and the overall trajectory is correctly captured. (3) Multi-hop reasoning is sound—linking the CCAA settlement, litigation exposure, and resulting impairment shows proper synthesis across events and accounting treatments. (4) The answer is contextually excellent, directly addressing the evolution in accounting treatment and financial exposure. The only minor shortcoming is the lack of explicit mention of the stay of litigation until March 31, 2022, and the rationale for no loss accrual (inability to estimate), which slightly reduces completeness. Overall, the answer is factually robust, well-reasoned, and semantically equivalent to the ground truth with only minor omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 418,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "In 2022 Gilead reported that Biktarvy generated $8.6 billion in product sales (US $7,049 m + Europe $969 m + Other $606 m), making it the single largest contributor to its HIV portfolio【GILD_10k_2022.pdf p.68‑70】. The 2024 filing still lists Biktarvy as a core, top‑selling HIV drug that continues to account for a material share of total HIV revenues, but it now emphasizes product‑specific risks – such as intense competition (including generic entry), dependence on the tenofovir‑alafenamide (TAF) nucleoside class, and heightened pricing/reimbursement pressures – that could curb future growth【GILD_10k_2024.pdf p.16‑20】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Biktarvy's 2022 revenue as $8.6 billion, which aligns with the ground truth of $8,624 million (the slight difference is due to rounding and acceptable format variation: $8.6 billion ≈ $8,600 million). The breakdown into US, Europe, and Other regions ($7,049M + $969M + $606M = $8,624M) is accurate and matches the source data. No specific 2024 revenue figure is provided in either the LLM or ground truth answer, but both correctly state that Biktarvy remains a top-selling product. (2) Quantitatively, all numbers are correct and properly summed; no calculation errors. (3) The multi-hop reasoning is sound: the LLM synthesizes 2022 revenue data from the 2022 10-K and contrasts it with 2024 risk disclosures from the 2024 filing, correctly identifying the evolution in commercial significance — from strong revenue performance to increased risk exposure. It accurately captures the shift in emphasis from financial performance to risk factors such as competition, TAF dependence, and pricing pressures. (4) The only minor shortcoming is that the LLM does not explicitly state that the heightened risks are tied to the broader HIV product class (as noted in the ground truth), though it does mention TAF class dependence and competition, which implies this. Otherwise, the answer is factually correct, contextually complete, and semantically equivalent to the ground truth. Hence, high scores across all dimensions with a 9 on correctness due to slight omission in framing the class-level risk context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 427,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific’s equity stake in TTX has risen modestly – the 2022 filing shows a $1.6 billion equity‑method investment (up from $1.5 billion a year earlier), and the 2024 filing reports that the investment grew to $1.9 billion (up from $1.8 billion in 2023)【UNP_10k_2022.pdf†L86-L89】【UNP_10k_2024.pdf†L66-L69】.  At the same time, the amount Union Pacific pays to TTX for car‑hire has increased: it was $375 million in both 2020 and 2021, rose to $402 million in 2022, $399 million in 2023, and reached $432 million in 2024【UNP_10k_2022.pdf†L86-L89】【UNP_10k_2024.pdf†L66-L69】.  Thus, both the financial investment and the operational expense for TTX services have grown between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key figures are correct: the equity investment increased from $1.6 billion (as stated in the 2022 filing, referencing 2021 value) to $1.9 billion in 2024, matching the original answer. Car hire expenses start at $375 million (2021), and reach $432 million in 2024—both matching the ground truth. The LLM provides additional granularity (e.g., $402M in 2022, $399M in 2023), which is consistent with a rising trend and does not contradict the original answer’s summary. (2) The only minor discrepancy is that the original answer references 2021-to-2024 changes, while the question asks about evolution from 2022 to 2024. However, the LLM correctly uses the 2022 filing to establish the baseline ($1.6B investment and $375M expense in 2021) and tracks forward, which is appropriate given that 10-Ks report prior-year data. The inclusion of interim years strengthens rather than detracts from accuracy. (3) The reasoning is sound: it correctly synthesizes multi-hop data across two filings (2022 and 2024), identifies both investment value and car hire expenses, and draws a valid conclusion about growing involvement. (4) Entities (Union Pacific, TTX, equity stake, car hire expenses) and years are correctly identified. The answer is semantically equivalent to the ground truth, with slightly more detail. No factual errors—only a slight shift in emphasis from 2021 baseline to 2022–2024 evolution, but the data supports the conclusion. Thus, correctness is 9/10—excellent but not perfectly aligned in framing with the question’s time focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 446,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "- **2022:** Tesla said it was actively expanding its Solar Roof installer base, “on‑boarding and training new installers” and working with developers to cut installation time and cost【TSLA_10k_2022.pdf page 34】.  \n\n- **2023:** The company’s discussion shifted away from installer‑training programs and instead emphasized managing supply‑chain risk – warning that “suppliers may fail to deliver components… and that we must diversify sources and build buffers to protect production”【TSLA_10k_2023.pdf page 16】.  \n\nThus, Tesla moved from a focus on scaling Solar Roof through installer training in 2022 to a 2023 strategy that prioritizes supply‑chain risk mitigation rather than expanding installer training.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Tesla's strategy from 2022 to 2023: in 2022, the focus was on on-boarding and training new installers, working with developers, and reducing installation time and cost, which matches the original answer. In 2023, the emphasis shifted to supply chain risk management, including supplier reliability, component constraints, and production buffers—accurately reflecting the strategic pivot. (2) There are no numeric values (e.g., dollar amounts, percentages, headcount numbers) in either the question or the ground truth, so quantitative accuracy is not applicable in a numerical sense; however, the cited years (2022, 2023) and page references are correct and consistent with the source documents, satisfying temporal and contextual accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two different 10-K filings (2022 and 2023), correctly contrasting the strategic focus areas across years. The conclusion that Tesla moved from installer-focused scaling to supply-chain risk mitigation is logically supported by the cited evidence. (4) The only minor shortcoming is that the LLM answer omits mention of the need to hire skilled electricians in 2022 and the explicit warning about production ramp delays harming the business in 2023—details present in the original answer that add nuance. However, these omissions do not undermine the core factual correctness. Overall, the answer is semantically equivalent, contextually precise, and well-supported, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 443,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "In the 2022 Form 10‑K the Company explained that, under its U.S. bottler agreements, “bottlers in the United States generally are not authorized to manufacture fountain syrups. Rather, the Company manufactures and sells fountain syrups to authorized fountain wholesalers (including certain authorized bottlers) and some fountain retailers”【6†L...】.  \nThe 2023 Form 10‑K repeats the same language, stating that the Company “manufactures and sells fountain syrups to authorized fountain wholesalers or bottling partners and some fountain retailers” and that U.S. bottlers remain “not authorized to manufacture fountain syrups”【35†L...】.  \n\nThus, between 2022 and 2023 the relationship with fountain retailers did not materially change – Coca‑Cola continues to produce the syrups itself and distribute them through wholesalers and select retailers, while U.S. bottlers remain excluded from syrup manufacturing.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its representation of the 2022 and 2023 Form 10-K disclosures: it correctly states that U.S. bottlers were not authorized to manufacture fountain syrups and that The Coca-Cola Company itself manufactures and sells syrups to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. The citations and wording are consistent with the original filings, and there are no errors in dates, entities, or terminology—hence a high quantitative and contextual relevance score.\n\nHowever, the qualitative accuracy and overall correctness are reduced because the LLM concludes that 'the relationship with fountain retailers did not materially change' between 2022 and 2023. This contradicts the ground truth, which identifies a meaningful shift in language: in 2023, the Company explicitly broadened its description to include 'bottling partners' as recipients of fountain syrups for distribution, suggesting a more formalized or acknowledged tiered distribution model. The LLM interprets the repetition of similar language as indicating no change, but the ground truth emphasizes that the 2023 update reflects a clarification or potential expansion of distribution roles, particularly involving bottling partners in the distribution chain.\n\nThus, while the LLM accurately quotes the documents, it fails to detect and convey the nuanced evolution in the distribution model—the core of the multi-hop reasoning required. The answer is factually sound but misses the analytical depth needed to capture the shift in relationship dynamics, resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 446,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "In the 2022 Form 10‑K IBM disclosed the 0.950 % Notes due 2025 as a long‑term debt instrument (with a current‑portion liability) and listed the issue among its securities registered under Section 12(b) of the Securities Exchange Act. The 2024 Form 10‑K continues to treat the same notes as a debt liability, but the disclosure now appears in a dedicated “Securities registered pursuant to Section 12(b)” table that identifies the issue by its ticker IBM25B and confirms it is listed on the New York Stock Exchange (see 2024 pages 1‑5)【...】. Thus, from 2022 to 2024 the classification (debt) has not changed, while the registration detail has been restated more explicitly with the ticker and exchange designation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 0.950% Notes due 2025 were classified as debt in both 2022 and 2024, and accurately notes the evolution in disclosure from general registration under Section 12(b) to a more explicit listing with ticker symbol 'IBM25B' on the NYSE in 2024. The core facts—classification as debt, registration status, and the introduction of the ticker and exchange listing—are all correct and align with the ground truth. (2) Quantitatively, all details are accurate: the interest rate (0.950%), maturity year (2025), ticker (IBM25B), exchange (New York Stock Exchange), and reference to Section 12(b) registration are factually correct. No calculations are required, and all numeric/date-related elements match. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of Form 10-K filings, compares the treatment of the notes over time, and infers increased specificity in registration details without misrepresenting the nature of the change. The only minor shortcoming is that the original answer references a 2017 Form 8-K (Exhibit 4.1) as the initial disclosure source, which the LLM omits; however, the question focuses on 2022–2024 evolution, so this omission does not materially affect correctness. (4) The answer is contextually fully relevant, directly addressing both classification and registration evolution. The qualitative accuracy is slightly reduced due to the lack of mention of the 2017 filing origin, but since the question centers on 2022–2024, this is a minor gap. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 458,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "**2022 positioning (10‑K 2022, pp. 61‑65)** – Gilead presented Biktarvy as a newly‑launched, single‑tablet HIV regimen that was expected to drive growth but still carried “launch‑phase” financial risk.  The filing stressed that the product’s revenue was vulnerable to gross‑to‑net rebates, payer‑mix uncertainty and the possibility that competitors (including generic tenofovir‑alafenamide combos) could erode market share, so the company needed to continue heavy marketing and inventory‑management investments.\n\n**2024 positioning (10‑K 2024, pp. 16‑20)** – By the 2024 report Biktarvy was described as an established, differentiated HIV option that now “anchors” Gilead’s HIV franchise.  The company highlighted its clinical‑efficacy, safety and adherence advantages, which give it a durable competitive moat and limit generic‑entry pressure.  Because Biktarvy’s sales have become a stable, high‑margin contributor, Gilead’s overall financial‑risk exposure from the HIV segment has been reduced, allowing the firm to rely on the drug as a core, lower‑volatility revenue stream.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its characterization of GILD's strategic positioning of Biktarvy from 2022 to 2024, directly contradicting the ground truth. While the answer cites specific page numbers and uses plausible financial terminology, it inverts the actual evolution: in the original answer, GILD's risk exposure *increases* due to reliance on Biktarvy by 2024, whereas the LLM claims risk exposure *decreases*. This is a critical factual and conceptual error. The LLM incorrectly states that in 2022, Biktarvy was in a 'launch-phase' with associated financial risk, but by 2022 Biktarvy was already a key marketed product (launched in 2018), so this is factually wrong. By 2024, the LLM claims Biktarvy has strong differentiation limiting generic pressure, but the ground truth explicitly states growing financial risk due to potential paradigm shifts away from TAF-based therapies like Biktarvy and rising generic competition. There are no numerical values in either answer, so quantitative accuracy is not heavily penalized (dates are correct: 2022 and 2024). However, the multi-hop reasoning fails completely—instead of synthesizing increased risk and reduced differentiation over time, the LLM asserts the opposite trajectory. The answer is contextually relevant (addresses financial risk and competitive differentiation) but factually inverted, making it dangerously misleading. Thus, the correctness and qualitative accuracy scores are low despite appropriate structure and formatting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 414,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "In the 2022 filing Lockheed Martin reported that, in the second quarter of 2022, it bought group‑annuity contracts that moved roughly **$4.3 billion** of defined‑benefit pension obligations (and related assets) to an insurer, and it recorded a **$1.5 billion non‑cash pension‑settlement charge** to reflect the accelerated recognition of actuarial losses 【LMT_10k_2022.pdf p. 98‑102】.  \n\nBy the 2023 filing the company’s strategy had shifted to smaller, voluntary lump‑sum settlements: in the fourth quarter of 2023 it paid **$414 million** to about 6,500 former employees, reducing the pension trust’s liability with **no impact on 2023 FAS pension expense** 【LMT_10k_2023.pdf p. 80‑84】.  \n\nThus, between 2022 and 2023 Lockheed Martin moved from large, insurer‑driven annuity transfers that generated a sizable non‑cash charge to more modest, targeted settlements that lowered obligations without affecting pension expense.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $4.3 billion in pension obligations transferred in 2022 with a $1.5 billion noncash charge, and $414 million in settlement payments to ~6,500 former employees in 2023. These figures exactly match the original answer, with acceptable formatting (e.g., $4.3 billion vs $4.3B). (2) The answer is complete, addressing both years, the shift in strategy, the financial impacts (noncash charge in 2022 vs no impact on FAS expense in 2023), and the nature of the transactions (annuity transfer vs direct settlements). (3) Entities are correct: Lockheed Martin, defined benefit pension obligations, group annuity contracts, lump-sum settlements, and proper fiscal quarters (Q2 2022, Q4 2023) are accurately cited with document references. (4) The reasoning is sound and captures the multi-hop evolution: it correctly infers a strategic shift from large-scale insurer-mediated transfers to smaller, direct participant settlements, and explains the differing financial statement impacts. The conclusion about reduced expense impact in 2023 aligns with the ground truth. Semantic equivalence is strong, with slightly enhanced detail (e.g., mentioning FAS pension expense) that improves clarity without introducing error. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 380,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "In the 2022 Form 10‑K IBM’s 2025‑maturing debt consisted of three separate notes – a 2.875 % note, a 0.950 % note and a 0.875 % note – plus the 7.00 % debentures due 2025. By the 2024 filing the 2.875 % note and the 0.950 % note remained, as did the 7 % debentures, but the 0.875 % notes that appeared in 2022 are no longer listed, indicating they were retired or otherwise removed from the 2025 portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the presence of the 2.875%, 0.950%, and 0.875% Notes due 2025 in 2022 and notes that the 0.875% Notes are no longer listed in 2024, which aligns with the ground truth. However, the LLM introduces '7.00% debentures due 2025' as part of the 2025-maturing debt in both 2022 and 2024, which are not mentioned in the original answer and are not part of the known debt composition for that year according to the ground truth. This is a significant factual addition that undermines quantitative accuracy. (2) The percentages for the notes (2.875%, 0.950%, 0.875%) are correct, but the inclusion of the 7% debentures is unsupported and incorrect, leading to a deduction in quantitative accuracy. There are no calculation errors, but the introduction of an unverified instrument affects factual precision. (3) The reasoning is otherwise sound: the model correctly infers that the disappearance of the 0.875% Notes suggests retirement or restructuring, and it tracks the continuity of the 2.875% Notes, fulfilling the multi-hop requirement across 2022 and 2024 filings. The core evolution in composition is accurately captured despite the extraneous detail. (4) The correctness score is 7 because the main factual trajectory—retention of 2.875% and 0.950% Notes and removal of 0.875% Notes—is correct, but the addition of the 7% debentures introduces material inaccuracy. Qualitative accuracy is high due to logical synthesis, and contextual relevance is strong as the response directly addresses the evolution of IBM's 2025 debt composition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 432,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "In the 2022 Form 10‑K Gilead described Biktarvy as the “growth engine” of its HIV franchise – sales were rising because patients were switching from older tenofovir‑based regimens and a new pediatric tablet had been launched, and the company counted the product among the few “continued growth” drivers that would offset the loss of Truvada/Atripla (2022 p. 38‑40).  At the same time, the filing warned that Biktarvy’s risk profile was becoming more vulnerable: a shift away from nucleoside‑based regimens, the entry of generic TAF/FTC combinations and the emergence of long‑acting capsid‑inhibitor and islatravir candidates could erode its market share (2022 p. 41).  \n\nBy the 2024 Form 10‑K the company still listed Biktarvy as a “core pillar” of its HIV portfolio, but noted that competitive pressure had intensified – generic single‑tablet regimens and the regulatory progress of long‑acting injectables (lenacapavir, islatravir) are now expected to curb Biktarvy’s growth and increase pricing‑rebate pressure, making its revenue contribution more uncertain (2024 p. 18‑20).  Thus, between 2022 and 2024 Biktarvy moved from a primary growth driver with a relatively modest risk outlook to a product whose strategic importance is tempered by heightened competitive and pricing risks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Biktarvy was a growth engine in 2022 (per 2022 10-K), and by 2024, increased competitive and paradigm shift risks were emphasized. The evolution from growth driver to a more vulnerable 'core pillar' is accurately portrayed. (2) There are no numeric inaccuracies—while no specific dollar figures or percentages are cited in either answer, the qualitative financial descriptions (e.g., 'continued growth', 'revenue contribution uncertain') match the original. The LLM correctly avoids inventing numbers. (3) Multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 10-Ks, correctly identifying shifts in strategic importance and risk profile, including competitive threats (generic TAF/FTC, long-acting injectables like lenacapavir), and treatment paradigm changes (shift away from nucleoside-based therapies). (4) The LLM adds contextual detail not in the ground truth but supported by filings—e.g., pediatric launch, Truvada/Atripla patent loss, and specific drug candidates (islatravir, capsid inhibitors)—which enriches the answer without introducing error. The only minor gap is that the original emphasizes TAF's centrality across Gilead’s portfolio as a risk amplifier, which the LLM mentions but doesn't fully link to Biktarvy’s specific vulnerability. Still, the core conclusion about evolving risk and strategic positioning is semantically equivalent and well-supported. Hence, high scores across all dimensions with a 9 on correctness due to slight under-emphasis on the TAF portfolio-wide risk linkage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1513,
        "completion_tokens": 449,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "- At the end of fiscal 2022 the U.S. litigation escrow account held **$1,449 million**; during FY 2022 the Company **deposited $850 million** into the escrow account.  \n- By the end of fiscal 2023 the balance had risen to **$1,764 million**, reflecting **$1,000 million** of deposits made during FY 2023.  \n\n(Deposits are shown in the 2022 filing (“deposited $850 million…”) and in the 2023 filing’s escrow‑account reconciliation table.)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the U.S. litigation escrow account balance increased from $1,449 million at the end of FY 2022 to $3,089 million at the end of FY 2023. However, the LLM incorrectly reports the FY 2023 ending balance as $1,764 million. Additionally, the deposit amounts are wrong: the LLM states $850 million was deposited during FY 2022 and $1,000 million during FY 2023, whereas the ground truth specifies $1,000 million in FY 2022 and $1,500 million in FY 2023. These errors affect both the quantitative accuracy and the overall correctness. (2) Number verification: The only correct number is the FY 2022 ending balance ($1,449 million). All other figures (FY 2023 ending balance, deposits in both years) are incorrect. Calculations based on the LLM’s numbers (e.g., $1,449M - $850M = $599M starting balance, then +$1,000M = $1,599M, not $1,764M) are also inconsistent, suggesting flawed reasoning or data sourcing. (3) Multi-hop reasoning: The model attempts to synthesize data across fiscal years and filings, which shows some understanding of the task structure, but it fails to retrieve the correct values from the source documents, undermining the synthesis. (4) The contextual relevance is moderate because the answer addresses the right account, time periods, and type of information (balances and deposits), but the incorrect numbers severely limit usefulness. Due to major quantitative errors and partial completeness, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 427,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "In both 2022 and 2023 the Company said it manufactures fountain syrups in the United States and sells them to fountain retailers for on‑site beverage preparation. The 2023 filing expands that description – it now notes that, besides selling directly to retailers and to authorized fountain wholesalers, the Company also sells the syrups to its bottling partners, who in turn distribute them to fountain retailers. Thus, the role of fountain syrups grew from a direct‑to‑retailer/wholesaler model in 2022 to a broader model that includes bottling‑partner distribution in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Coca-Cola manufactures fountain syrups in the U.S. and sells them to fountain retailers, wholesalers, and bottling partners in both years, which aligns with the ground truth. However, it mischaracterizes the evolution: the LLM claims that the 2023 filing 'expands' the model to include bottling partners in distribution, implying a new development. In contrast, the original answer clarifies that while the 2023 description includes bottling partners, the key evolution is not within North America but rather the explicit mention of bottling partners manufacturing syrups *outside the U.S.* using company concentrates—a decentralization trend outside the U.S., not a change in distribution roles within North America. The LLM incorrectly frames the shift as an expansion of distribution responsibilities within North America, when the ground truth states there was no explicit change in manufacturing responsibilities *within North America*. (2) There are no numerical values in the question or answers, so quantitative accuracy is not applicable—no errors in dates or formats. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes information across years and identifies distribution channels. However, it fails to correctly interpret the geographical nuance (U.S. vs. outside U.S.) and misattributes the evolution to a broader North America model, missing the key point about manufacturing authorization outside the U.S. as the real shift. (4) Correctness is scored 6 due to significant qualitative inaccuracy in interpreting the nature of the evolution, despite correct identification of basic facts. Quantitative accuracy is 10 as no numbers are involved. Qualitative accuracy is 6 due to flawed reasoning about the change. Contextual relevance is 9 as the answer stays on topic and addresses the question’s focus on evolution in responsibilities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 522,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "In the 2022 filing IBM reported four separate securities that would mature in 2025 – the 2.875 % notes, the 0.950 % notes, the 0.875 % notes and the 7 % debentures. By the 2024 filing the 2025 bucket still includes the 2.875 % notes, the 0.950 % notes and the 7 % debentures, but the 0.875 % notes are no longer listed. Thus, the 0.950 % Notes due 2025 have remained a component of IBM’s 2025 debt, while the overall composition has been trimmed with the 0.875 % notes disappearing between 2022 and 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 0.875% Notes due 2025 are no longer listed in the 2024 filing and that the 0.950% Notes remain, which aligns with the ground truth. However, it incorrectly states that IBM had *four* debt instruments maturing in 2025 in 2022, including '7% debentures', which are not mentioned in the ground truth. The original answer specifies only three notes: 2.875%, 0.950%, and 0.875%. This introduces a factual error in both the count and composition of debt instruments. (2) The percentages for the notes that *are* correctly mentioned (2.875%, 0.950%, 0.875%) are accurate, but the addition of a non-existent 7% debenture undermines quantitative accuracy. There are no calculations in the question, so numerical precision is limited to correct identification of rates and counts. (3) The multi-hop reasoning is partially sound — the model correctly tracks the disappearance of the 0.875% note and the persistence of the 0.950% note from 2022 to 2024. However, the inclusion of an extraneous instrument suggests flawed entity extraction or synthesis from the source documents. (4) Despite the extra instrument, the answer addresses the core evolution regarding the 0.950% Notes and the narrowing of debt composition, making it contextually relevant and mostly accurate in direction, though not fully factually correct. Hence, correctness is reduced due to significant but not central factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 401,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "In the 2022 Form 10‑K Disney’s cruise strategy was centered on adding a new destination – it disclosed that it had secured about 550 acres at Lighthouse Point, Eleuthera, which was slated to open as a Disney Cruise Line port in 2024. By the 2024 filing the focus had broadened: Disney announced plans to further expand its cruise‑ship fleet (while noting the earlier closure of the Star Wars Galactic Starcruiser), indicating a shift from a single‑destination addition to a wider fleet‑growth strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes some correct elements but misses key aspects of the strategic evolution described in the ground truth. It correctly identifies a shift in strategy between 2022 and 2024, but misrepresents the nature of Disney's 2022 cruise strategy. The 2022 10-K did not focus on Lighthouse Point as the centerpiece of its cruise strategy—rather, it discussed cruise operations as part of broader travel and resort experiences dependent on consumer demand. While Disney did disclose securing Lighthouse Point in prior years, the 2022 filing did not center its cruise strategy around this development. The 2024 shift toward fleet expansion and increased investment is partially correct and aligns with the ground truth, including the mention of new ships and associated risks. However, the LLM introduces the closure of the Star Wars Galactic Starcruiser, which, while factually true, is not directly tied to cruise ship strategy (it was a land-based immersive hotel experience, not a cruise ship), and its inclusion distracts from the core fleet expansion narrative. (2) Quantitatively, the 550 acres and 2024 opening date for Lighthouse Point are accurate figures, and no incorrect numbers are presented. However, the emphasis on Lighthouse Point as the 2022 strategic focus is not supported by the 2022 10-K, making the quantitative data contextually misplaced. (3) The multi-hop reasoning is partially sound—there is an attempt to compare strategic focus across years—but the synthesis is flawed because it relies on an incorrect interpretation of the 2022 filing. The ground truth emphasizes a shift from passive dependence on demand to active investment; the LLM instead frames it as a shift from destination expansion to fleet expansion, which is not fully supported. (4) The contextual relevance is high because the answer addresses Disney’s cruise evolution and cites relevant developments. However, the correctness score is reduced due to mischaracterization of the 2022 strategy and inclusion of tangential information (Starcruiser closure), leading to a partially accurate but misleading narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 571,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "In the 2022 filing Lockheed Martin described its pension‑risk‑transfer program as a continuing strategy – it had already bought group‑annuity contracts covering about $11.6 billion of obligations (the 2021 $4.9 billion GAC purchase) and said it would “continue to look for opportunities” to transfer more risk, but no new transfer was recorded for 2022 and no non‑cash settlement charge was taken. By contrast, the 2023 filing reports that the company completed an additional risk‑transfer transaction in 2023, moving roughly $2‑2.5 billion of defined‑benefit obligations to an insurer; the deal generated a non‑cash pension‑settlement charge of about $1 billion (after‑tax) in earnings, reflecting the accelerated recognition of actuarial losses, while reaffirming the same strategic intent to further reduce pension‑plan volatility and eliminate future funding uncertainty.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) QUANTITATIVE INACCURACY: The claim that Lockheed Martin completed an additional pension risk transfer in 2023 of $2–2.5 billion and incurred a $1 billion after-tax noncash settlement charge is not supported by the ground truth. The original answer states that in 2023, the company only reiterated its intent to evaluate future transactions and discussed potential financial implications, but no new transaction was reported. The 2022 filing covered a transaction from 2021 (not 2022), and no new transfer occurred in 2022 or 2023 per the ground truth. (2) ENTITY AND TEMPORAL ERRORS: The LLM incorrectly asserts a 2023 transaction and associated charge, which contradicts the ground truth stating only strategic reiteration and risk disclosures in 2023. (3) REASONING FAILURE: The model fails the multi-hop reasoning by fabricating a new transaction instead of correctly synthesizing that the evolution was in risk framing and disclosure—not in execution of new transfers. The shift from active transfers (up to 2021) to cautious strategic evaluation in 2023 is misrepresented. (4) SEMANTIC NON-EQUIVALENCE: While the mention of $11.6 billion in total obligations transferred since 2018 and the $4.9 billion 2021 transaction is accurate, the core claim about 2023 activity is false. The introduction of residual liability risk in 2023 due to insurer default possibility is entirely omitted. Thus, despite some correct background facts, the central narrative of the LLM answer is factually wrong, leading to a low correctness score. Contextual relevance is moderate because it addresses pension risk transfer evolution, but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 470,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "- **2022:** Tesla’s 2022 filing explained that the bulk of its accounts‑receivable came from “receivables from financial institutions and leasing companies offering various financing products to our customers,” and that cash from those partners could take “up to approximately two weeks” to be received (2022 10‑K, p. 64).  The company also warned that the profitability of its vehicle‑leasing program “relies on our ability to secure adequate financing … and on accurately projecting residual values” (2022 10‑K, p. 66).  \n\n- **2023:** In the 2023 filing Tesla noted that it has expanded and diversified its network of financing partners, which has allowed it to “more actively manage the timing of payments and reduce the concentration of credit risk” in its accounts‑receivable (2023 10‑K, p. 20).  However, the company still stresses that the leasing program “continues to be exposed to residual‑value and financing‑partner risk,” and that any shortfall in partner funding could affect the growth of the leasing business (2023 10‑K, p. 22).  \n\n**Overall evolution:** Between 2022 and 2023 Tesla moved from a reliance on a relatively limited set of financing partners with longer collection cycles to a broader, more actively managed partner base that shortens receivable lag and lowers concentration risk, while the fundamental leasing‑program exposure to financing‑partner and residual‑value risk remains a disclosed concern.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Tesla noted that receivables from financing partners could take up to approximately two weeks to settle, and highlighted risks related to securing financing and projecting residual values for leases—this matches the original answer. In 2023, Tesla reported improved management of accounts receivable through a diversified partner network, reducing credit concentration risk, while maintaining exposure to residual value and financing partner risks. These points are correctly captured. (2) There are no numeric inaccuracies; the qualitative time frame 'up to approximately two weeks' is preserved, and no incorrect figures are introduced. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and two different risk dimensions (cash flow timing in 2022 vs. structural and residual risks in 2023), correctly identifying both evolution and continuity. The shift from operational timing concerns to broader risk management is accurately inferred. (4) The only reason for not scoring a 10 is a slight softening of emphasis: the original answer highlights a 'shift in focus' from liquidity timing to broader risks, while the LLM emphasizes operational improvements in receivables management but could more explicitly frame the 2023 concern as an escalation in risk complexity. However, the core meaning and factual content are semantically equivalent. Contextual relevance is perfect—every part of the question is addressed with precise, document-cited information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 440,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "- 2022 10‑K: U.S. bottlers could not make fountain syrups. The Company produced the syrups and sold them only to **independent fountain wholesalers** (and, in a few cases, to “authorized” bottlers that acted solely as wholesalers); those wholesalers then delivered the syrups to restaurants and other fountain retailers.  \n\n- 2023 10‑K: The Company revised the model so that **certain bottlers were added to the list of authorized fountain wholesalers** and could sell the Company‑manufactured syrups directly to fountain retailers. Thus, the role of bottlers expanded from “pure concentrate buyers” to also include **fountain‑syrup distribution**, while the reliance on separate, non‑bottler wholesalers was reduced.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies key elements of Coca-Cola's fountain syrup distribution model in 2022, including that U.S. bottlers could not manufacture fountain syrups and that the Company sold syrups to independent fountain wholesalers (and in some cases authorized bottlers acting as wholesalers). It also correctly notes a shift in 2023 involving an expanded role for bottlers in distribution. However, it misrepresents the core nature of the 2023 change. According to the ground truth, outside the U.S., bottlers were authorized to *manufacture* fountain syrups using Coca-Cola concentrates—a significant shift from centralized production to local manufacturing by bottlers. The LLM answer incorrectly states that bottlers were merely authorized to distribute *Company-manufactured* syrups, implying no change in manufacturing responsibility, which misses the key evolution in the supply chain. This is a critical factual omission that undermines the qualitative accuracy. While the dates (2022 vs 2023) and entities (Coca-Cola, bottlers, fountain wholesalers) are correct, and there are no numerical inaccuracies (hence high quantitative accuracy), the reasoning fails on the multi-hop synthesis: it does not distinguish between *manufacturing* and *distribution*, and incorrectly frames the change as one of distribution rights only, when the ground truth emphasizes a shift in *production authority* internationally. The answer is contextually relevant and addresses the question’s structure, but the missing manufacturing component significantly reduces factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 433,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "In 2023 AMD reported only $9 million of receivables from the ATMP joint venture and an equity‑method investment of about $99 million. By the end of 2024 those receivables had risen to $12 million and the investment balance grew to roughly $149 million, with equity‑income increasing from $16 million to $33 million. During 2024 AMD also deepened the relationship by contributing an additional $17 million of equity to the JV and entering a one‑year, $100 million term‑loan agreement that is recorded as a receivable on AMD’s balance sheet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 AMD had $9 million in receivables and no direct investment or loan to the ATMP JV. However, the LLM claims AMD had a $99 million equity-method investment in 2023, which is not supported by the original answer. Similarly, it states that AMD contributed an additional $17 million in equity during 2024 and that the investment balance grew to $149 million, none of which is mentioned in the ground truth. The only correct figures are the $9 million and $12 million receivables in 2023 and 2024 respectively, and the $100 million term loan in 2024. (2) Quantitative accuracy is low: 3 out of 7 numeric claims are correct ($9M, $12M, $100M). The $99M, $149M, $17M, and $33M figures (and implied $16M to $33M equity income increase) are all fabricated or misattributed. Calculations based on these numbers are therefore invalid. (3) Multi-hop reasoning is flawed. The model incorrectly infers an ongoing equity investment relationship and tracks changes in investment balances and equity income, which are not present in the source data. It also conflates the term loan (a receivable) with equity contributions, misrepresenting the nature of AMD's financial involvement. The original answer emphasizes a shift from no investment in 2023 to a new creditor role in 2024 via the loan—this evolution is obscured by the LLM’s erroneous inclusion of pre-existing equity stakes. (4) Contextual relevance is high because the answer addresses receivables and new financial activities with the JV, and correctly identifies the $100 million loan as a key development. However, the inclusion of false equity investments and income figures severely undermines factual correctness, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 493,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "In 2022 Lockheed Martin dealt with its non‑qualified defined‑benefit pension obligations mainly by buying a group‑annuity contract that transferred about $4.3 billion of gross obligations to an insurer; the transaction was recorded as a **non‑cash, non‑operating pension‑settlement charge of roughly $1.5 billion** in the quarter ended June 26 2022. By 2023 the company had shifted to a much smaller, voluntary “lump‑sum” settlement approach – paying **$414 million** to roughly 6,500 former employees in Q4 2023, which reduced the benefit obligation but **did not affect 2023 FAS pension expense**. Thus, the strategy moved from large annuity‑contract settlements with a sizable one‑time charge to modest voluntary settlements with negligible impact on the income statement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin transferred $4.3 billion in pension obligations via group annuity contracts and recognized a $1.5 billion noncash settlement charge, which matches the original answer. In 2023, the company made $414 million in voluntary settlement payments to about 6,500 former employees—numbers exactly matching the ground truth. (2) Quantitative accuracy is perfect: all dollar amounts ($4.3B, $1.5B, $414M), employee count (~6,500), and timeframes (Q4 2023, June 26, 2022) are correctly reported. Format variations (e.g., 'roughly' vs exact) are acceptable and do not affect factual correctness. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two different strategies—large-scale annuity transfer in 2022 vs targeted lump-sum payments in 2023—and infers the strategic shift. The added detail that the 2023 settlements did not affect FAS pension expense is consistent with accounting principles and adds value, though not explicitly in the original answer. (4) The only minor shortcoming is that the original answer emphasizes the shift to targeting former employees who had not yet started benefits, which the LLM mentions implicitly via 'voluntary lump-sum' but could have stated more explicitly. However, this does not detract significantly from the overall correctness. Semantic equivalence is maintained, and the answer fully addresses the evolution in strategy and financial impacts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 427,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "In 2023 AMD held a $99 million equity‑method investment in the ATMP joint venture and recorded $16 million of equity‑income from that investment. By 2024 the investment had risen to about $149 million (after a $17 million additional equity contribution) and the equity‑income recognized increased to $33 million. 【2023‑10K p. 77‑78】【2024‑10K p. 73‑74】",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 2023 carrying value ($99 million), 2023 equity income ($16 million), additional contribution in 2024 ($17 million), resulting 2024 carrying value ($149 million), and 2024 equity income ($33 million) are all correctly reported. The implied calculation (99 + 17 = 116, but final value is 149) suggests other adjustments (e.g., income, currency, etc.), which the model does not need to explain as long as the reported values match the source; they do. (2) The answer is complete, addressing both AMD's investment evolution and equity income changes between 2023 and 2024. (3) Entities are correct: AMD, ATMP JV, proper years (2023 and 2024), and financial metrics (equity-method investment, equity income). (4) The reasoning is sound and reflects proper multi-hop synthesis across two fiscal years' filings, correctly inferring increased investment and returns. (5) The semantic meaning is equivalent to the original answer, with slightly more formal phrasing and proper citation of 10-K pages. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 330,
        "total_tokens": 1525
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "In 2023 Johnson & Johnson reduced its Kenvue ownership from the 89.6 % it held at the IPO to a 9.5 % residual stake after the August 23 exchange‑offer; that retained equity was carried in “other assets” at a fair‑value of about **$4.3 billion** (down to $3.9 billion by year‑end) and generated a **$2.8 billion gain** on the Kenvue stock (part of a total non‑cash gain of $21 billion) on the exchange. By 2024 the company completed a debt‑for‑equity swap that eliminated the remaining 182 million Kenvue shares, and the transaction was recorded as a **≈$0.4 billion loss** in other (income) expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor, non-material discrepancies. (1) Quantitatively: All key numbers are correct—9.5% retained stake in 2023, $4.3 billion initial fair value, $2.8 billion gain on retained shares (part of $21 billion total non-cash gain), ≈$0.4 billion loss in 2024, and elimination of 182 million shares via debt-for-equity swap. The mention of the value declining to $3.9 billion by year-end is an additional detail not in the original answer but does not contradict it and may reflect subsequent valuation changes; this does not reduce accuracy. (2) The original answer states a 'non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares'—the LLM correctly identifies the $2.8 billion as part of the larger $21 billion gain, showing proper multi-hop understanding. (3) Entity and timeline accuracy: Johnson & Johnson, Kenvue, 2023 exchange offer (correctly dated to August 23), and 2024 full exit are all correctly identified. The term 'Debt-for-Equity Exchange' is accurately rendered as 'debt-for-equity swap'. (4) The LLM adds contextual precision (e.g., 'carried in other assets', 'recorded in other (income) expense') that enhances the answer without introducing error. The only minor shortcoming is the lack of explicit mention that the 2023 stake reduction was from ~89.6% (pre-exchange) to 9.5%, which is implied but not fully detailed in the original answer—however, the LLM correctly references the 89.6% pre-IPO stake and the post-exchange 9.5% stake, demonstrating full multi-hop synthesis. Overall, the answer is factually sound, complete, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 466,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T disclosed that the obligations of its subsidiaries were covered by guarantee agreements that **included Southwestern Bell Telephone Co. as a guarantor**. By the 2023 Form 10‑K, the company’s guarantee‑agreement disclosure no longer listed Southwestern Bell Telephone Co., indicating that **the subsidiary was removed from the guarantee agreements and its obligations were no longer guaranteed by AT&T**.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) It claims that in 2022, Southwestern Bell Telephone Co. was a guarantor under AT&T's guarantee agreements, but the ground truth states that AT&T guaranteed obligations of Southwestern Bell Telephone Co.—meaning the subsidiary is the guaranteed entity, not the guarantor. This reverses the financial relationship. (2) The LLM asserts that by 2023, Southwestern Bell Telephone Co. was removed from the guarantee agreements, but the original answer confirms the guarantee continued in 2023 and was still listed in Exhibit 4-c with the same inclusion. There was no removal. (3) The multi-hop reasoning fails: the model incorrectly interprets the direction of the guarantee and falsely infers a change over time when the ground truth explicitly states there was no change in nature or scope. (4) While the answer addresses the time frame (2022–2023) and mentions Exhibit 4-c contextually, the core facts—entity roles, guarantee status, and evolution—are all wrong. No numeric values are present, but the qualitative and contextual errors are severe. Hence, the correctness, quantitative, and qualitative scores are very low. Contextual relevance receives minimal credit for addressing the right companies and years, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 364,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "In the 2022 Form 10‑K, Lockheed Martin described hypersonics as one of its four near‑term growth pillars, noting that it was already “performing on multiple hypersonics programs,” had completed testing and evaluation, and expected those weapons to move into early‑production by 2026. By the 2023 Form 10‑K the company had broadened that positioning, listing hypersonics under both the Missiles & Fire Control and Space segments and stating it is responsible for the design, development and build of hypersonic strike weapons for the U.S. Air Force, Army and Navy—showing a wider, cross‑segment strategic focus and deeper program‑development responsibility.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Lockheed Martin's hypersonics involvement from 2022 to 2023. It accurately captures the strategic shift from a growth area to an active, multi-service development role. The mention of 'near-term growth pillars' in 2022 and 'performing on multiple hypersonics programs' is consistent with the original answer’s characterization of hypersonics as a growth area dependent on government funding. The 2023 update correctly reflects a more defined role, including design, development, and build responsibilities. However, there is a minor discrepancy: the original answer specifies that in 2023, hypersonics were listed under the Space segment only, while the LLM claims they were listed under both Missiles & Fire Control and Space segments. This overstates the segmentation detail and introduces a fact not in the ground truth. Additionally, the LLM introduces a specific forward-looking milestone—'early-production by 2026'—which is not present in the original answer and cannot be verified from the provided truth. While this may be accurate in reality, it goes beyond the knowledge graph’s content, introducing unverified detail. Quantitatively, all dates (2022, 2023, 2026) are used appropriately, though 2026 is an extrapolation. The reasoning is sound in showing progression and increased responsibility, and the answer is highly relevant to the question. The core facts about strategic positioning and program development evolution are correct, warranting a high score, but the added segment detail and production timeline prevent a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 449,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "- **Balance:** The U.S. litigation escrow account increased from **$1.4 billion at September 30 2022** to **$1.764 billion at September 30 2023**.  \n- **Deposits:** Visa deposited **$850 million during fiscal 2022** and **$1.0 billion during fiscal 2023** into the escrow account.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer correctly identifies the deposit amounts: $850 million in fiscal year 2022 and $1.0 billion in fiscal year 2023, matching the ground truth. However, the ending balance as of September 30, 2023, is incorrect: the LLM states $1.764 billion, while the ground truth is $3.089 billion. The starting balance of $1.4 billion as of September 30, 2022, is correct. (2) Quantitative accuracy is compromised due to the significant error in the 2023 ending balance. The deposits are accurate, but the implied balance evolution is wrong. If $1.4B + $850M (2022 deposit) were carried forward, and then $1.0B added in 2023, the expected balance would be around $3.25B (accounting for timing and possible withdrawals), but the LLM reports only $1.764B, which suggests a fundamental misunderstanding or data error. (3) The reasoning appears partially sound—multi-hop synthesis is attempted (using both years’ deposits and balances), but the incorrect 2023 balance breaks the logical chain. The model fails to reflect the actual scale of the account’s growth, undermining the multi-hop conclusion. (4) Despite the major quantitative error in the final balance, the answer is contextually relevant and captures the correct deposit amounts and starting balance, earning partial credit. Wording and structure are clear and address all parts of the question, but the core financial fact (ending balance) is inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1152,
        "completion_tokens": 389,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "Outdoor Garden remains grouped in the **Hardlines** merchandising line in both filings. In FY 2022 it generated roughly **$10.0 billion of net sales, or about 6.4 % of total net sales**; by FY 2024 that figure had risen to **about $10.3 billion, or 6.5 % of net sales**. Thus, its classification has not changed, and its contribution has modestly grown, confirming that Outdoor Garden continues to be a stable, core component of HD’s Hardlines product strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim about classification. The ground truth states that in 2022, Outdoor Garden was a *distinct product line*, but by 2024 it was *grouped under Hardlines*, indicating a strategic repositioning. The LLM incorrectly asserts that Outdoor Garden was part of Hardlines in *both* 2022 and 2024, which contradicts the evolution described in the original answer. This misrepresents the entire strategic shift. (2) Quantitatively, the LLM reports $10.0 billion (6.4%) for 2022 vs. ground truth $10,317 million (6.8%). The actual figure is ~$10.317 billion, so rounding to $10.3B would be acceptable, but $10.0B is inaccurate. The 6.4% figure is also incorrect versus 6.8%. For 2024, the LLM cites $10.3B (6.5%), but no 2024 sales figure is provided in the ground truth—only the reclassification. Thus, the 2024 numbers are fabricated. (3) The multi-hop reasoning fails: the question asks about *evolution* in role and positioning, requiring synthesis of classification change and performance. The LLM misses the key classification shift and invents performance data for 2024, leading to an erroneous conclusion of 'stable, core component' with 'modest growth', when the ground truth emphasizes structural integration, not performance trends. (4) Scores reflect major factual errors in both quantitative data and strategic interpretation, with only partial relevance to the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 401,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD’s 2023 filing notes that with roughly 26,000 employees it “believes it is at its best when its culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment,” and it backed that claim with an annual employee‑engagement survey that ranked its culture and manager quality among the very best in tech. A year later, the 2024 filing shows the workforce grew to about 28,000 while the same cultural pillars—annual surveys, high‑scoring inclusivity, open‑communication forums, ERGs, mentorship, and flexible hybrid/remote work and competitive total‑rewards programs—were reaffirmed, again earning top‑10% industry scores. Together, these actions indicate AMD is using a deliberately inclusive, transparent and development‑focused culture as a core talent‑retention weapon in the fiercely competitive semiconductor market.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the workforce numbers (26,000 in 2023, 28,000 in 2024) and the consistent cultural messaging, aligning with the ground truth. The 7.7% growth is accurate (28,000 / 26,000 ≈ 1.077), though not explicitly stated in the LLM answer, so no error. (2) Quantitative accuracy is perfect: employee counts are correct, no miscalculations. (3) However, the LLM adds details not present in the original answer, such as 'annual employee-engagement survey,' 'top-10% industry scores,' 'ERGs,' 'mentorship,' 'flexible hybrid/remote work,' and 'competitive total-rewards programs.' While these may be plausible cultural initiatives, they are not mentioned in the ground truth, which only notes the repetition of the same cultural statement. This over-enrichment introduces unsupported specifics, weakening qualitative accuracy. (4) The reasoning correctly infers that maintaining consistent cultural language during workforce growth suggests a strategic focus on culture for talent retention, which matches the original conclusion. The answer is highly relevant and well-structured, but the added details reduce factual precision. Thus, correctness is reduced to 7 due to unsupported qualitative additions, despite strong quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 361,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "The 2022 and 2023 Form 10‑K filings show no new or altered guarantee for The Ohio Bell Telephone Company. Both years simply reference the historic “guaranty of certain obligations of … The Ohio Bell Telephone Company” (listed among legacy guarantees), and neither filing reports a change in the amount or scope of that guarantee.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and semantically equivalent to the ground truth. (1) It correctly states that there was no change in AT&T's guarantee obligation for The Ohio Bell Telephone Company between 2022 and 2023, accurately reflecting the stability of the relationship. (2) There are no numeric values requiring calculation (e.g., dollar amounts or percentages), so quantitative accuracy is not compromised—only the presence and consistency of a guarantee are discussed, which the LLM correctly affirms. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of Form 10-K filings and correctly infers that the lack of changes in reporting implies continuity of the guarantee, consistent with the original answer’s conclusion about stable relationships and updated documentation practices. (4) The LLM omits explicit mention of the exhibit reference update (e.g., from Exhibit 4-c to current documentation standards), which is a minor detail present in the ground truth but does not alter the core conclusion. This omission prevents a perfect 10 but does not undermine correctness. Overall, the answer is concise, accurate, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 335,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "In 2023 GE recorded a $5.8 billion gain on its retained and sold ownership interests – the bulk of which came from its AerCap (and GE HealthCare) stakes. By 2024 that benefit had collapsed, falling about $5.2 billion, so the gain was reduced to roughly $0.5‑$0.6 billion, dramatically shrinking the AerCap‑related financial contribution.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key trend: a large gain in 2023 from retained and sold ownership interests (primarily AerCap and GE HealthCare), followed by a $5.2 billion decline in 2024. However, the 2023 gain is stated as $5.8 billion, while the ground truth specifies $5.7 billion — a minor but notable discrepancy in the base figure. The LLM then infers that the 2024 gain was reduced to $0.5–0.6 billion by subtracting $5.2B from $5.8B, which would be accurate if the original were correct, but using the true $5.7B base, the 2024 gain should be approximately $0.5B. This makes the calculation directionally correct but based on a slightly inaccurate input. (2) The $5.2 billion year-over-year decrease is accurately reported. The dates (2023 and 2024) and entities (AerCap, GE HealthCare) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the financial impact decreased significantly due to lower gains, linking both years and attributing the change to the same set of investments. (4) The answer is contextually excellent, directly addressing the evolution of GE's financial relationship with AerCap in terms of gains on ownership interests. The minor numerical inaccuracy in the 2023 gain prevents a top score, but the overall logic, entity accuracy, and trend interpretation are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 378,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "In the 2022 filing Home Depot described HD Supply as a separate wholesale subsidiary that supplied MRO (maintenance‑repair‑operations) products and other job‑lot items to its “Pro” customer base, positioning the business as the company’s primary channel for serving professional contractors, property‑managers and other pros. By the 2024 filing the company still relies on HD Supply for those same MRO and value‑added services, but now highlights the subsidiary as the core vehicle for delivering MRO products to multifamily, hospitality, health‑care and government‑housing facilities and stresses its integration into Home Depot’s broader “Pros” growth strategy alongside new acquisitions such as SRS. Thus, between 2022 and 2024 HD Supply’s role has shifted from a standalone wholesale arm to an increasingly integrated component of Home Depot’s professional‑customer platform, with a clearer focus on expanding MRO offerings to a wider range of institutional Pro customers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: HD Supply's role in serving professional customers via MRO services is accurately described for both 2022 and 2024. The evolution from a standalone subsidiary with integration challenges (implied in 2022) to a strategically integrated component of Home Depot’s Pro growth strategy by 2024 is correctly captured. The specific customer segments—multifamily, hospitality, healthcare, and government housing—are fully consistent with the original answer. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct and contextually appropriate. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift over time based on changes in tone and emphasis across filings, synthesizing information about HD Supply’s evolving role in relation to Pro customers and MRO services. The mention of SRS as a complementary acquisition adds contextual depth, though it is not in the ground truth; however, this does not detract from accuracy as it plausibly supports the broader strategic narrative. (4) Semantic equivalence is strong—the LLM conveys the same core message: a transition from post-acquisition uncertainty to strategic integration. The only minor gap is that the original answer explicitly mentions 'integration risks and challenges' in 2022, which the LLM implies but does not directly state. This slight omission prevents a perfect 10 but does not undermine the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 430,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "AMD’s 10‑K disclosures show that its cross‑licensing and technology‑exchange framework remained a core part of its IP strategy in both years.  The size of its patent portfolio grew modestly – worldwide issued patents rose from about 12,800 in 2023 to roughly 13,200 in 2024 (total patent matters increasing from ~18,500 to ~18,800), while U.S. patents stayed near 7,500—so the company continued to depend on a larger pool of patents to feed its cross‑licensing agreements.  This incremental expansion reinforces AMD’s ability to both acquire needed technologies and share its own innovations, sustaining product development and market competitiveness.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative data from the ground truth: worldwide issued patents increased from 12,800 in 2023 to 13,200 in 2024, total patent matters rose from ~18,500 to ~18,800, and pending applications remained stable at 5,600 (implied by the totals). The mention of U.S. patents (~7,500) is an additional detail not in the original answer, but it does not contradict the ground truth and may be accurate based on AMD's filings; its inclusion does not reduce accuracy. (2) All numbers match the original answer exactly or with acceptable approximation (e.g., 'about', 'roughly', '~'). Calculations are consistent: 12,800 + 5,600 = 18,400 (close to 18,500, likely due to rounding), and 13,200 + 5,600 = 18,800, which aligns perfectly. (3) The multi-hop reasoning is sound: the model correctly infers that portfolio growth strengthens AMD's position in cross-licensing, linking patent expansion to strategic IP leverage and technology exchange, which aligns with the original conclusion. (4) The answer is semantically equivalent to the ground truth, with slightly more emphasis on continuity and competitiveness, but no factual deviation. The only minor gap is less explicit emphasis on the 'reliance' evolution—while implied, the original stresses that reliance 'remains strong and possibly more strategically advantageous,' a nuance slightly under-articulated in the LLM response. However, the core facts, synthesis, and implications are accurately conveyed. Thus, the answer is highly accurate with negligible omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 431,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "In the 2023 filing Johnson & Johnson disclosed that after the May 2023 IPO and the August 23, 2023 exchange‑offer it retained a **9.5 % equity stake in Kenvue**, which was carried in “other assets” at a fair‑value of about **$4.3 billion** (with a $0.4 billion expense recorded through year‑end).  \n\nThe 2024 filing shows that the company **disposed of that remaining stake** in the fiscal second quarter by completing a **debt‑for‑equity exchange** of its 182‑million Kenvue shares for outstanding commercial paper; the transaction eliminated all J&J ownership of Kenvue, generated a **≈ $0.4 billion loss** in other (income) expense, and left only the existing transition‑service and manufacturing agreements (TSAs/TMAs) to govern the ongoing operational relationship.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion in 2023, recorded a $0.4 billion expense, and fully exited its stake in 2024 via a debt-for-equity exchange of 182,329,550 shares (rounded appropriately to '182 million'). The transaction resulted in a $0.4 billion loss, consistent with the original answer. (2) Quantitative accuracy is perfect: percentages, dollar amounts, and share count align with the ground truth (minor rounding of share count is acceptable and common). The May 2024 timing is correctly implied as 'fiscal second quarter'. (3) Multi-hop reasoning is sound—LLM synthesizes information from both 2023 and 2024 filings, correctly tracing the evolution from partial retention to complete disposal and strategic shift. (4) Entity accuracy is strong: correct company names (Johnson & Johnson, Kenvue), proper financial terms (debt-for-equity exchange, commercial paper, transition-service agreements), and correct years. The answer fully addresses the question’s focus on financial stake evolution and strategic relationship, noting the end of ownership and continuation of operational agreements. No factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 359,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T still listed Indiana Bell Telephone Co. Inc. in its guarantee disclosures – it appeared in the “Guaranty of certain obligations of … Indiana Bell Telephone Co. Inc.” exhibit (Exhibit 4‑c/4‑d). By the 2023 Form 10‑K, Indiana Bell is no longer mentioned in the guarantee section, indicating that the company’s guarantee of Indiana Bell’s obligations was removed from the disclosures.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) According to the ground truth, Indiana Bell Telephone Co. Inc. was included in AT&T's guarantee disclosures in both 2022 and 2023 under Exhibit 4-d, with no change in status. The LLM incorrectly claims that by the 2023 Form 10-K, Indiana Bell was 'no longer mentioned in the guarantee section,' which contradicts the original answer. (2) There are no numeric values to verify, but the temporal claims (2022 vs 2023) are factually wrong. (3) The multi-hop reasoning fails: the model should have identified the continuity of the guarantee across years but instead inferred a removal that did not occur. (4) While the answer addresses the topic of guarantee disclosures and references the correct type of exhibit (4-d, though inconsistently labeled as 4-c/4-d), the core conclusion about the evolution of the relationship is the opposite of the truth. Thus, the answer is mostly irrelevant and misleading despite some contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 290,
        "total_tokens": 1508
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "In 2023 GE still had an active financial link with AerCap – it paid $203 million of net cash to AerCap for notes, sales‑leases and transition services and retained an equity stake that was recorded at fair value (about $944 million) and produced a net unrealized gain of $6.4 billion on its RDFV equity securities. By 2024 GE had sold its remaining AerCap equity, eliminated the cash outflow, and the AerCap holding moved from a source of large gains to a source of loss, contributing to a $5.2 billion decline in gains on retained and sold ownership interests.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly identifies the $203 million net cash payment to AerCap in 2023 (matching the ground truth), it introduces a $944 million fair value of GE's equity stake and a $6.4 billion unrealized gain on RDFV equity securities—details not present in the original answer and unsupported by the provided ground truth. These numbers appear fabricated or misattributed. The $5.2 billion decrease in gains is correctly cited, but the LLM incorrectly attributes it to the sale of the AerCap equity and a shift to losses, whereas the original answer states GE held an investment stake in 2024 but does not confirm a sale. Instead, the decline in gains is attributed broadly to AerCap and GE HealthCare investments. (2) The calculation of the $5.2 billion decline is accurate in magnitude but misinterpreted in cause. The LLM claims the holding moved from 'large gains to a source of loss,' which is a stronger claim than the original answer makes—it only notes a decrease in gains, not a reversal into losses. (3) The multi-hop reasoning is partially sound: the model correctly infers a shift from operational involvement (2023) to investment-based relationship (2024). However, it overreaches by asserting the sale of the stake and introducing unsupported financial figures, undermining the qualitative accuracy. (4) Despite these issues, the answer remains contextually relevant and captures the high-level transition in GE's relationship with AerCap. The core narrative of reduced cash outflow and declining gains aligns with the original, but the addition of unverified numbers and mischaracterization of the investment outcome reduce correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 489,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "In its 2022 filing, Home Depot said that store **appearance, layout and visual merchandising** were core competitive levers, noting investments in “merchandising resets” to refine assortments, optimize space productivity and improve visual displays so the store itself would attract shoppers. By the 2024 filing, the company still cites store **location and appearance** as a competitive factor, but now frames it within an **digitally‑integrated, interconnected shopping experience**—adding way‑finding signage, electronic shelf‑label and “hdPhone” handheld tools, mobile‑app store maps, computer‑vision inventory visibility, and refreshed front‑end designs that tie the physical look of the store to faster checkout, curb‑side pickup and seamless online‑offline fulfillment. Thus, the focus has shifted from purely visual upgrades to a hybrid strategy where store appearance is enhanced and leveraged through digital technology to improve the overall customer experience and strengthen Home Depot’s competitive position.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) All key elements from the original answer are present: the 2022 emphasis on store appearance as a competitive factor, the evolution by 2024 toward a digitally integrated experience, and the strategic shift from physical aesthetics to a holistic, technology-enhanced customer experience. (2) There are no numeric values in the question or answers that require verification—dates (2022, 2024) are correct and consistent. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across two years of filings, identifying both continuity (store location and appearance remain competitive factors) and evolution (integration with digital tools and services). It adds specific, plausible details—such as electronic shelf labels, mobile-app store maps, computer vision, and 'hdPhone'—that align with the concept of digital integration and enhance the explanation without contradicting the ground truth. (4) The answer exceeds slightly in specificity compared to the original, providing concrete examples of digital integration, which strengthens rather than distorts the response. Wording differs but meaning is preserved and enriched. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 360,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "In 2023 AMD bought about $1.7 billion of inventory from the ATMP JV, resold only $14 million to it and carried $363 million of payables and $9 million of receivables. By 2024 the resale volume jumped to $121 million, payables rose to $476 million and receivables to $12 million, and AMD’s equity stake grew to a $149 million carrying amount after a $17 million equity contribution. In addition, AMD entered a new one‑year, $100 million term‑loan with the JV (SOFR + 0.50% interest, secured by the JV’s receivable), reflecting a deeper financing relationship.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies despite capturing some correct elements. The resale figures of $14 million in 2023 and $121 million in 2024 are correct and match the ground truth. The mention of the $100 million term loan in October 2024 is also accurate. However, the LLM introduces numerous unsupported figures: the $1.7 billion inventory purchase from ATMP JV in 2023, $363 million and $476 million payables, $9 million and $12 million receivables, $149 million carrying amount of equity, and a $17 million equity contribution—all of which are not present in the original answer and contradict the ground truth, which makes no mention of these metrics. (2) Quantitative accuracy is severely compromised: while the resale and loan amounts are correct, the additional financial figures (inventory, payables, receivables, equity contributions) are entirely fabricated or misattributed, failing basic verification against the ground truth. There is no indication in the original answer that AMD purchased inventory from ATMP JV or held such payables/receivables. (3) The multi-hop reasoning is partially sound in identifying the deepening financial relationship and correctly noting increased resales and a new loan. However, the inclusion of unverified equity and balance sheet items suggests either hallucination or incorrect synthesis from external data, undermining the reasoning. The conclusion about a 'deeper financing relationship' is valid, but it is based on a mix of true and false premises. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship and focuses on resales and new arrangements as asked. However, correctness score is low due to major factual errors in quantitative details, which are central to financial analysis. The answer gives a misleading impression of AMD's financial interactions with ATMP JV by introducing unsupported transactions and balances.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 531,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "In its 2023 filing, Johnson & Johnson said it already had “privacy compliance programs and controls” in place to meet existing global privacy and data‑protection laws and to prepare for expected new statutes, noting a general risk that “controls imposed on cross‑border data flows” could affect its operations. By the 2024 filing, the company emphasized that a wave of new privacy laws—especially those imposing data‑localization and tighter restrictions on international data transfers—has led it to further strengthen and expand those programs, adding more explicit focus on managing cross‑border flow limitations and legislative controls while continuing mandatory privacy training for employees.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Johnson & Johnson's privacy compliance programs between 2023 and 2024. It correctly identifies that in 2023, the company had established privacy programs to address expected new laws and risks related to cross-border data flows. In 2024, it accurately reflects the expansion of focus to include tighter restrictions on international data transfers, data localization, and legislative controls—aligning with the ground truth's emphasis on a broader, more anticipatory global posture. The mention of 'wave of new privacy laws' and 'strengthen and expand those programs' conveys the increased scope and proactive stance. The LLM also correctly retains the ongoing requirement for employee privacy training, which is consistent with the maintained compliance framework. While the original answer highlights the shift from 'other territories' to 'globally' in risk language and the involvement of vendors in data-driven initiatives—nuances not fully captured—the LLM answer does not introduce any factual errors. All entities (Johnson & Johnson, 2023, 2024, privacy laws, cross-border data flows) are correct, and there are no numerical inaccuracies (no numbers involved). The reasoning is sound and synthesizes the multi-hop elements across years and regulatory focus. The answer is contextually fully relevant. The only reason for not scoring a 10 is the slight omission of the broadening of geographic scope in language ('other territories' to 'globally') and the role of third parties in expanding data initiatives, which are present in the ground truth but not reflected in the LLM response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 451,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "GE’s exposure to the Bank BPH mortgage portfolio shrank modestly.  The company’s estimate of total borrower‑litigation losses fell from $2.669 billion at 12/31/2023 to $2.461 billion at 12/31/2024, and the related valuation allowance – $1.517 billion on the financing‑receivable side plus $944 million on other liabilities in 2024 (versus $1.712 billion + $957 million in 2023) – was reduced by the same amount, fully offsetting the receivable balance by the end of 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: total estimated losses decreased from $2,669 million in 2023 to $2,461 million in 2024, valuation allowances were $1,712 million (2023) and $1,517 million (2024), and other liabilities were $957 million (2023) and $944 million (2024). The formatting as $2.669 billion, etc., is acceptable and semantically equivalent. (2) All numbers are accurate and correctly compared. The reduction in total losses ($208 million) is implied by the difference in totals, and the LLM correctly notes that the 2024 valuation allowance fully offset the receivable balance, which aligns with the ground truth. (3) The multi-hop reasoning is sound: the LLM synthesizes data across years and categories (valuation allowances and other liabilities), correctly infers a reduction in exposure, and references the strategic implication of full offsetting by the end of 2024. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'strategic shift' or 'settlement program' by name, which is part of the qualitative context in the original answer. However, the substance — that the full offset indicates a change in management approach — is effectively conveyed. Thus, the answer is factually complete and highly accurate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 398,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "In the 2022 filing the Indoor Garden department generated roughly $15.5 billion of net sales – about 10 % of total revenue – and was grouped under the Hardlines merchandising line (alongside Hardware, Outdoor Garden and Tools). By the 2024 filing the company’s merchandising structure had been refreshed, but Indoor Garden remained classified within Hardlines (now listed with Hardware, Outdoor Garden, Power and Storage & Organization) and its sales had slipped to about $10.5 billion, representing only ≈ 6‑7 % of net sales. This shows a shift from a relatively large, high‑share product line in 2022 to a smaller, lower‑share position within the same Hardlines category by 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, in 2022, the Indoor Garden product line generated $15,546 million (i.e., $15.546 billion), which is approximately correct in the LLM answer as $15.5 billion. However, the LLM claims sales dropped to $10.5 billion in 2024, which is not supported by the original answer—no 2024 financial performance data was provided in the ground truth. Additionally, the original answer does not state that Indoor Garden was part of Hardlines in 2022; rather, it was a standalone category. The reclassification into Hardlines occurred by 2024, which contradicts the LLM's claim that it was already in Hardlines in 2022. (2) The quantitative inaccuracies are critical: the $10.5 billion figure and ≈6–7% revenue share for 2024 are fabricated or misinferred, with no basis in the provided truth. The 2022 percentage is approximated correctly (~10.3% vs stated ~10%), but the LLM omits the precise figure. (3) The multi-hop reasoning is flawed: the LLM incorrectly assumes continuity in categorization (Hardlines in both years), when the key insight from the original answer is the shift *from* standalone *to* Hardlines. This undermines the core analysis of strategic evolution. (4) Contextual relevance is moderate—the response addresses financial performance and categorization over time, aligning with the question’s intent, but due to major factual and reasoning errors, the conclusion about declining importance is unsupported. Thus, correctness is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 427,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "In the 2022 filing Colgate‑Palmolive said that it “manages its raw‑material exposures through a combination of cost‑containment measures, **sourcing strategies**, ongoing productivity initiatives and the **limited use of commodity‑hedging contracts**” (2022 10‑K, p. 89). By the 2024 filing the company’s discussion of commodity‑price risk notes that it has **expanded those sourcing strategies**—e.g., longer‑term supplier agreements and broader geographic diversification—and has **increased the use of commodity‑hedge contracts** to more actively offset price swings (2024 10‑K, p. 16).  \n\nThus, from 2022 to 2024 Colgate‑Palmolive moved from relying mainly on basic sourcing and limited hedging to a more aggressive approach that pairs enhanced sourcing tactics with greater hedging activity to better manage commodity‑price volatility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Colgate-Palmolive used sourcing strategies along with limited commodity hedging and cost containment to manage commodity price volatility. The 2024 update accurately reflects an expansion in both sourcing strategies (e.g., longer-term agreements, geographic diversification) and increased use of hedging contracts, which matches the evolution described in the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly identifying a shift in strategy intensity and approach. The LLM infers a strategic evolution—from limited hedging and basic sourcing to a more proactive, enhanced approach—even though the exact phrase 'defensive sourcing' isn't used, the meaning is semantically equivalent. (4) The only minor gap is that the LLM answer does not explicitly mention the specific commodities (resins, essential oils, soybeans) or the increased exposure to geopolitical and climatic disruptions highlighted in the 2024 filing per the ground truth. While the core strategic shift is accurately captured, this omission slightly reduces completeness in qualitative detail. However, the overall conclusion about a more aggressive, diversified risk management approach remains factually and contextually correct. Hence, high scores across all dimensions with a 9 on correctness due to partial omission of specific commodity examples and external risk factors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 466,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA’s worldwide sales rose from $3.1 billion in 2023 to $3.7 billion in 2024 – a ≈ 16½ % increase (operational growth of ≈ 18 % in both years, partially offset by a larger negative currency impact in 2024). The boost was driven by continued market growth and share‑gain momentum in psoriasis and psoriatic arthritis (patient‑mix and strength in those indications), which offset modest currency headwinds.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the core sales figures and growth trend. It reports sales rising from $3.1 billion in 2023 to $3.7 billion in 2024, which aligns closely with the ground truth values of $3,147 million (≈$3.15B) and $3,670 million (≈$3.67B). The approximate 16.5% increase cited matches the actual growth rate of (3,670 - 3,147) / 3,147 ≈ 16.6%. The operational growth of ≈18% and negative currency impact are also consistent with the ground truth (18.1% from operations, -1.5% currency impact). (2) Minor rounding is acceptable: $3.1B and $3.7B are reasonable approximations of $3.147B and $3.670B. The ≈16½% increase is a valid representation of 16.6%. The slight discrepancy in stating 'operational growth of ≈18% in both years' is a minor issue—the ground truth only confirms 18.1% in 2024, not both years—so this introduces a small inaccuracy. (3) The multi-hop reasoning is sound: the model correctly links sales performance to contributing factors like market expansion, patient mix, and therapeutic strength in PsO/PsA, and accounts for currency effects. It synthesizes quantitative performance with qualitative drivers as required. (4) Scores reflect high accuracy: quantitative values are rounded but within acceptable tolerance; qualitative reasoning is strong and contextually complete. The only deduction is for implying consistent operational growth in both years without evidence for 2023. Contextual relevance is perfect—directly addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 417,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "In the 2022 filing Disney still listed the individual Nielsen‑based subscriber bases for each A+E channel (A&E ≈ 69 m, History ≈ 70 m, Lifetime ≈ 69 m, LMN ≈ 52 m, FYI ≈ 42 m) and noted that it owned 50 % of A+E, reporting its share of A+E’s results under the equity‑method. By the 2023 filing the partnership had been re‑structured – Disney no longer broke out the separate channel counts and instead gave a single, uniform subscriber estimate (about 58 m for A&E, History and Lifetime) and continued to disclose only its 50 % equity stake and the equity‑method earnings line. This change reflects a shift from detailed channel‑level subscriber reporting to a consolidated, equity‑method presentation while the ownership percentage remained the same.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the right question and showing relevant reasoning structure. (1) Quantitative Accuracy: The ground truth states Disney reported A&E with 69 million domestic subscribers in 2022, but the LLM incorrectly expands this to include detailed subscriber numbers for other A+E channels (History, Lifetime, etc.) not mentioned in the original answer. Furthermore, the 2023 figure of 58 million is correctly cited for A+E channels collectively, but the LLM misrepresents it as applying uniformly to A&E, History, and Lifetime, which is not supported by the ground truth. The claim that Disney 'continued to disclose only its 50% equity stake' contradicts the original answer, which states that the 50% stake was a change from 2022 — implying it was not previously the case. (2) Completeness: While the LLM addresses the shift in reporting style and ownership, it introduces unsupported details (channel-specific breakdowns, uniform 58M across multiple channels) and misses the key point that the relationship evolved from a partnership to a 50% equity stake — a structural change misrepresented as merely a reporting change. (3) Entity Accuracy: The companies (Disney, A&E, A+E) and years (2022, 2023) are correct, but the financial stake timeline is wrong — the 50% stake is presented as pre-existing in 2022 when the ground truth indicates it became the case in 2023. (4) Reasoning: The multi-hop synthesis is partially sound — the model recognizes a shift in reporting format and links it to equity-method accounting — but the flawed premise about ownership continuity undermines the logic. (5) Semantic Equivalence: The overall direction of change (from detailed subscriber reporting to consolidated equity-method) aligns with the truth, but the factual foundation is distorted. Thus, while contextually relevant and attempting correct reasoning, the answer fails on core factual accuracy, especially regarding ownership evolution and subscriber data scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 550,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "In 2023 GE still recorded a modest **$129 million net gain (realized + unrealized) on its AerCap investment** (Note 19, “Investment in and note with AerCap realized and unrealized gain (loss)”). By 2024 that upside had vanished – the MD&A notes that “gains on retained and sold ownership interests” fell by **about $5.2 billion**, a decline that was “primarily related to our GE HealthCare and AerCap investments.” In other words, the AerCap relationship swung from a small positive gain in 2023 to a large negative impact (a loss) in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $129 million gain in 2023 as unrealized (though it refers to it as 'net gain (realized + unrealized)', which slightly overgeneralizes but does not contradict the ground truth). It accurately reports the $5.2 billion year-over-year decrease in gains on retained and sold ownership interests in 2024, with AerCap cited as a primary contributor. The core financial evolution — a positive gain in 2023 turning into a significant negative impact in 2024 — is correctly conveyed. (2) All numeric values are accurate: $129 million in 2023 and $5.2 billion decline in 2024 match the ground truth. The phrasing 'about $5.2 billion' is acceptable as an approximation consistent with typical reporting language. No calculation errors. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2023 vs 2024), entities (GE and AerCap), and financial concepts (realized/unrealized gains transitioning to losses). It infers the negative shift logically from the drop in gains, even if the exact term 'unrealized loss' isn't used. (4) The only minor shortcoming is the slight conflation of 'net gain (realized + unrealized)' in 2023, whereas the original specifies it was an 'unrealized gain' — this nuance is downplayed but not falsely stated. Otherwise, the answer is factually correct, contextually complete, and semantically equivalent to the ground truth. Hence, a high score with only a small deduction in qualitative accuracy for imprecise characterization of the 2023 gain composition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 431,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "Between the 2022 and 2024 Form 10‑K filings Mastercard’s multi‑layered security model grew from a broad “robust program” that relied on internal Security Operations Centers, Fusion Centers, the Mastercard Intelligence Center and public‑private partnerships to a more explicit, supply‑chain‑aware framework. The 2024 filing adds a dedicated focus on “threats and incidents associated with the use of services provided by third‑party providers,” indicating that the company has expanded its monitoring, testing and governance processes to cover external vendors. This evolution shows Mastercard is strategically tightening its defenses to address the rising cyber‑risk exposure from third‑party ecosystems and emerging supply‑chain‑based attacks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Mastercard's security approach between 2022 and 2024: from a robust internal program in 2022 without explicit mention of third-party provider risks, to a more explicit focus on third-party service provider threats in 2024. The key factual elements—use of internal centers (SOCs, Fusion Centers, Intelligence Center), public-private partnerships, and the strategic expansion to include third-party risk—are all correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable beyond correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes across two time points and infers a strategic shift toward supply chain and ecosystem risk management, which is consistent with the ground truth’s conclusion about 'ecosystem-wide resilience.' The only minor gap is that the LLM answer adds specific entity names (e.g., 'Fusion Centers', 'Mastercard Intelligence Center') not present in the original ground truth, which, while plausible, are not verifiable from the provided truth statement. This does not constitute an error but introduces slight over-specificity. (4) The answer is contextually excellent—directly addressing all parts of the question: evolution of security approach, treatment of third-party risks, and strategic implications. The conclusion about 'rising cyber-risk exposure from third-party ecosystems' mirrors the ground truth’s interpretation. Overall, the answer is factually correct, well-reasoned, and semantically equivalent, warranting a 9/10 due to minor unverifiable detail addition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 485,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Target’s 2022 Form 10‑K reported that its revolving credit facility (the $3 billion unsecured facility that replaced a $2.5 billion facility) included a debt‑leverage covenant and that the company “is, and expects to remain, in compliance with these covenants.” The 2023 Form 10‑K notes that Target added a new $1 billion, 364‑day unsecured facility and extended the existing $3 billion revolving facility to 2028, both of which also contain the same debt‑leverage covenant, and again confirms that “we are, and expect to remain, in compliance with these covenants.” Thus, despite the restructuring and addition of credit facilities, Target’s compliance with its debt‑leverage covenant was maintained from 2022 through 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: All dollar amounts ($3 billion, $1 billion), timeframes (364-day, 2026, 2028, 2024), and facility types (unsecured revolving credit) are accurately reported. The LLM correctly notes the extension of the $3.0 billion facility to 2028 and the addition of the $1.0 billion 364-day facility expiring in 2024. (2) Completeness: The answer addresses both years (2022 and 2023), the state of covenant compliance, and the changes to credit facilities. It captures the evolution of the financing structure and confirms ongoing compliance. (3) Entity accuracy: 'Target Corporation' is correctly identified, and the financial instruments and covenants are accurately named. Fiscal years and document sources (Form 10-K) are properly referenced. (4) Reasoning: The LLM correctly synthesizes multi-hop information—compliance status in both years and structural changes to credit facilities—and draws the logical conclusion that compliance was maintained despite changes. (5) Semantic equivalence: The LLM conveys the same core information as the original answer, using slightly different phrasing (e.g., 'is, and expects to remain, in compliance') but preserving factual and contextual integrity. No omissions or inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 369,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "In the 2023 filing Salesforce described AI‑related risk in broad terms – the company warned that expanding AI (including generative AI) could raise emerging ethical issues, regulatory scrutiny, and the usual generative‑AI hazards of inaccurate, biased, toxic or copyrighted output and higher computing costs. By the 2024 filing the language had become more specific: it now calls out “agentic AI” such as Agentforce, stresses the need for stronger governance, content‑labeling and compliance frameworks, notes new or heightened government/regulatory scrutiny, and points out the added risk of moving from AI content classification to AI content generation, which brings extra cost, liability and reputational exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Salesforce's AI-related risks from 2023 to 2024 with strong semantic equivalence to the ground truth. (1) It correctly identifies that in 2023, risks were framed around broad concerns like ethical issues, regulatory scrutiny, and potential for inaccurate, biased, or copyrighted AI output, along with higher computing costs—aligning with the original answer’s emphasis on third-party integration risks and emerging AI concerns. In 2024, the LLM correctly notes increased specificity, including the naming of 'agentic AI' such as Agentforce, and highlights new governance, compliance, and content-labeling needs, which matches the ground truth’s focus on expanded risks like ethical concerns, legal liabilities, and increased AI-related costs. (2) There are no numeric values to verify, so quantitative accuracy is unaffected; all years (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in risk disclosures across two years and links them to the advancement of AI integration, particularly generative and agentic AI. It correctly infers a shift from general AI risks to more concrete, operational, and reputational risks tied to specific technologies. (4) The only minor shortcoming is that the LLM does not explicitly mention that 2023 risks were primarily tied to third-party integrations and customer warranty expectations—a nuance present in the original answer. However, it compensates by accurately describing the broad nature of 2023 AI risks. Overall, the answer is factually correct, contextually relevant, and well-reasoned, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 453,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024 Lowe’s kept its two‑day‑standard‑shipping promise for most parcel‑eligible items, but it expanded the service. In 2024 the company completed the roll‑out of its market‑based delivery model, broadened its gig‑provider network for same‑day deliveries, and added next‑day delivery of major appliances to almost every U.S. zip code—enhancing speed and geographic coverage beyond the 2023 baseline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth with only minor differences in emphasis. (1) Quantitatively, all key facts are correct: the maintenance of two-day delivery for most parcel-eligible items, the expansion to next-day delivery for major appliances in nearly every U.S. zip code in 2024, and the general enhancement of speed and coverage. No numeric inaccuracies are present. (2) The answer correctly identifies the relevant fiscal years (2023 vs 2024) and the company (Lowe's), and accurately describes the evolution in delivery capabilities. (3) The reasoning is sound and reflects proper multi-hop synthesis: it contrasts 2023 and 2024 capabilities and highlights specific improvements made in 2024. The mention of the 'market-based delivery model' and 'gig-provider network' adds detail not in the original answer but does not contradict it and aligns with plausible operational improvements supporting the delivery enhancements. (4) The only reason for not scoring a 10 is that the original answer emphasizes that delivery improved to 'within two business days or less'—a subtle but meaningful upgrade from 'within two days'—which the LLM answer does not explicitly note, instead focusing on expansion and same-day networks. However, the core improvements (next-day appliances, broader coverage) are correctly identified. Overall, the answer is semantically equivalent, contextually relevant, and factually sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 405,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "The Dermstore transaction was a one‑time cash sale completed in February 2021. Both the 2022 and 2023 Form 10‑K filings note that the business “represented less than 1 percent of our consolidated revenues, operating income and net assets,” and no additional Dermstore‑related gains or losses are reported for 2022 or 2023. Thus, the sale’s financial impact on Target’s consolidated revenue and operating income remained immaterial and unchanged between 2022 and 2023, contributing less than 1 percent to either metric in both years【2021‑10K Sale of Dermstore】【2023‑10K Sale of Dermstore】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) All key facts are correct: the sale occurred in February 2021, Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023, and no additional gains or losses were reported in those years. The $335 million pretax gain is not mentioned in the LLM answer, which is a minor omission but does not distort the conclusion. (2) Quantitative accuracy is excellent: dates (February 2021), percentages (<1%), and financial metrics (revenues, operating income) are correctly cited. Format variations are acceptable and consistent. (3) Multi-hop reasoning is sound—the model correctly synthesizes information from the 2021 and 2023 10-K filings to conclude that the financial impact remained immaterial across both years. (4) The answer is contextually relevant and directly addresses the evolution (or lack thereof) of the financial impact from 2022 to 2023. The only reason for not scoring a 10 is the omission of the $335 million pretax gain, which is part of the full financial impact context, though it occurred prior to the period in question. Overall, the answer correctly conveys that there was no material change in the financial impact during 2022–2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 362,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "In the 2023 Form 10‑K, Data Cloud was presented mainly as a “hyperscale, trusted data engine native to Salesforce” that “brings a company’s disconnected, enterprise data into Salesforce to deliver an actionable, 360‑degree view of a customer” and that “enables teams across an organization with access to comprehensive data and insights” – essentially a supplemental data‑integration layer that feeds the Marketing, Analytics and other Customer 360 services. By the 2024 filing, Salesforce had repositioned Data Cloud as a core pillar of its AI‑powered Customer 360 platform, tying it directly to the new Einstein 1 platform, consumption‑based pricing, and cross‑service automation, and explicitly noting that it is a strategic differentiator in a competitive “hyperscale data‑platform” market against rivals such as Snowflake, AWS and Google Cloud. Thus, between 2023 and 2024 Data Cloud moved from a supporting data‑engine role to a central, revenue‑generating platform that underpins Salesforce’s broader service suite and is highlighted as a key competitive advantage.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant inaccuracies in the qualitative evolution of Data Cloud's strategic positioning between 2023 and 2024. (1) Correct elements: The 2023 description accurately reflects Data Cloud as a 'hyperscale, trusted data engine' enabling a 360-degree customer view and integration with Marketing and Analytics. The mention of consumption-based pricing in 2024 aligns with the ground truth’s note on limited experience in such models. (2) Quantitative accuracy is perfect—no numbers, dates, or financial figures are misstated, hence a score of 10. (3) However, the reasoning contains key errors: the ground truth does not state that Data Cloud was repositioned as a 'core pillar' or 'strategic differentiator' in 2024; instead, it highlights increasing competitive risks and uncertainty in the market, along with monetization challenges. The LLM incorrectly frames the 2024 narrative as one of strengthened positioning and competitive advantage, whereas the actual filing expresses caution and strategic vulnerability. Mentions of 'Einstein 1 platform' and 'cross-service automation' are not present in the ground truth and appear to be speculative or sourced from outside the provided knowledge. (4) Contextual relevance is high—the answer directly addresses the evolution of Data Cloud’s role and competitive landscape. However, due to the inversion of the 2024 strategic tone (from risk-aware to confidently positioned), the qualitative accuracy is compromised, warranting a 6 for correctness. The answer captures part of the truth but misrepresents the strategic shift’s direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 444,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "In FY 2023 Lowe’s kept a $1.29 billion portfolio of forward interest‑rate swaps designated as **cash‑flow hedges**; the effective‑hedge accounting produced a $311 million gain in other‑comprehensive income (OCI) and virtually no impact on earnings. By FY 2024 all of those forward swaps had been settled – the note shows a **$0 million notional** for cash‑flow‑hedge swaps – so the hedge designation disappeared, the OCI effect turned modestly negative ($13 million loss) and the related interest cost appeared in earnings ($17 million net interest expense). The company continues to hold $850 million of fixed‑to‑floating swaps, but those are accounted for as **fair‑value hedges** in both years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects, despite addressing the general topic of hedge accounting evolution at LOW. (1) Quantitative Accuracy: The notional amount of forward interest rate swaps in 2023 is incorrect—LLM states $1.29 billion, while ground truth is $2.0 billion. The gain in OCI is reported as $311 million by LLM, but ground truth indicates a $247 million receipt upon settlement, which was a cash flow hedge gain recorded in OCI and earnings, not a pure OCI gain. The LLM’s $13 million loss and $17 million interest expense in 2024 are not supported by the original answer, which does not mention such figures. The $850 million fixed-to-floating swaps are not referenced in the ground truth. (2) Completeness: While the question asks about evolution in hedge designation and financial impact, the LLM incorrectly implies that all forward swaps were settled and no longer exist in 2024, whereas the original answer clarifies a shift in accounting treatment for fixed-to-floating swaps to fair value hedges using the shortcut method. The LLM invents a narrative about disappearance of hedges rather than identifying a change in designation and method. (3) Entity Accuracy: The company (LOW) and years (2023–2024) are correct, and the financial terms (cash flow hedges, fair value hedges) are appropriately used, though misapplied. (4) Reasoning: The multi-hop synthesis is flawed—the LLM fails to connect the 2023 forward swaps related to the March 2023 Notes with the 2024 clarification on accounting method for fixed-to-floating swaps. Instead, it fabricates a timeline where swaps are fully settled and replaced, which is not stated in the ground truth. (5) Semantic Equivalence: The core claim of a shift in accounting treatment is partially aligned, but the mechanism (settlement vs. re-designation) and financial impacts are misrepresented. Overall, the answer is factually incorrect on key numbers and reasoning, though it attempts to address the right topic, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 555,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "In its 2022 filing, Target positioned owned‑and‑exclusive brands primarily as a **differentiation pillar** within a six‑point strategy, noting that roughly one‑third of sales came from those brands and listing a long roster of them. By the 2023 filing, the company shifted to **actively “strengthening” the owned‑brands portfolio**, framing it as the engine for “newness, style and value” that will drive guest delight, relevance, traffic and market‑share growth. Thus, the emphasis moved from treating owned brands as one of several strategic pillars to making the expansion and enhancement of that portfolio a central, growth‑focused objective.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Target's strategy from 2022 to 2023: in 2022, owned brands were a 'differentiation pillar' with roughly one-third of sales (consistent with 'over 40 brands' and significant sales presence), and by 2023, they were actively being strengthened as a core engine for 'newness, style, and value' to drive traffic and market share. (2) Quantitatively, the 'one-third of sales' figure is consistent with the original answer’s emphasis on strong sales contribution, even if the exact number isn't in the ground truth; it is a reasonable inference from 'significant portion' and known public disclosures, and no incorrect figures are presented. (3) The multi-hop reasoning is sound—correctly synthesizing strategic emphasis shifts across two years and interpreting the elevated role of owned brands as a central growth lever. (4) The only minor gap is that the original answer emphasizes the shift from 'descriptive presence' to 'strategic differentiator,' which the LLM captures in substance but slightly under-articulates in framing. However, the core evolution in portfolio emphasis and strategic objectives is accurately conveyed. Wording differs but semantic meaning matches. No factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 364,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "In the 2022 filing GM described its software‑enabled services mainly as a set of stand‑alone offerings – OnStar safety and connectivity services and the Super Cruise driver‑assist system – that were attached to individual models and generated subscription revenue, but the company noted that the underlying software platform was still in the early stages of rollout. By the 2023 filing the narrative had shifted to an “end‑to‑end software platform” that delivers over‑the‑air updates, new apps and additional functions (security, climate‑control, EV‑ownership experiences, etc.) and is already deployed on the 2024 Cadillac LYRIQ and Chevrolet Silverado EV with a plan to extend it to “most products” (GM 2023 p. 3‑4). This progression from isolated services to a unified, vehicle‑wide software architecture signals that GM is committing substantially more capital to scalable digital infrastructure that can be monetized across its entire model lineup.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution from 2022 to 2023: in 2022, GM referenced software-enabled services in a more limited, model-specific way (e.g., OnStar, Super Cruise), while in 2023 it emphasized a comprehensive end-to-end software platform with over-the-air updates. The mention of the 2024 Cadillac LYRIQ and Chevrolet Silverado EV as early adopters matches the original answer. (2) There are no numeric values to verify, but all dates (2022, 2023, 2024 models) and product names are correct. (3) The multi-hop reasoning is sound—LLM synthesizes information across years and filings to show a strategic shift from isolated services to a scalable platform. It correctly infers increased investment in digital infrastructure based on deployment and expansion plans. (4) The only minor deviation is that the original answer emphasizes integration with broader operations and AV/financing in 2022, while the LLM focuses more narrowly on OnStar and Super Cruise as examples. However, this does not contradict the truth and still reflects the general-to-specific evolution. The LLM adds useful detail (e.g., climate control, security) not in the original but consistent with it. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 379,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "In fiscal 2022 the Optimized Application Experiences category grew $75 million (11 %) “driven by growth in our **ThousandEyes** and Intersight offerings”【CSCO_10k_2022.pdf page 45】. In fiscal 2023 the renamed Observability category grew $80 million (14 %) “driven by growth in our **ThousandEyes** and monitoring‑and‑analytics offerings”【CSCO_10k_2023.pdf page 42】. Thus, ThousandEyes’ contribution increased from a $75 million boost in FY 2022 to a larger $80 million boost in FY 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $75 million (11%) revenue growth in fiscal year 2022 and $80 million (14%) growth in fiscal year 2023, accurately attributing both to ThousandEyes. All numeric values, percentages, and fiscal years match the ground truth. (2) Quantitative accuracy is perfect: the dollar amounts and percentage increases are correct, and the comparison showing an increase from $75M to $80M in contribution is valid. (3) The reasoning is sound—LLM correctly identifies the renaming of the product category from 'Optimized Application Experiences' to 'Observability' and synthesizes the role of ThousandEyes across both years, demonstrating proper multi-hop reasoning across the two 10-K filings. (4) The only minor shortcoming is that the LLM slightly simplifies the original answer by not explicitly stating that the growth was 'specifically attributed' to ThousandEyes and monitoring/analytics in 2023, or mentioning Intersight in 2022, but it still captures the core evolution of ThousandEyes' contribution. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 335,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "In the 2023 Form 10‑K the amendment was disclosed as **Exhibit 10.34** – “Amendment No. 4 to the Lockheed Martin Executive Severance Plan…incorporated by reference to the Q2 2022 Form 10‑Q”【LMT_10k_2023.pdf page 104】. In the 2024 Form 10‑K the same amendment appears again, now numbered **Exhibit 10.36** but with identical description and reference【LMT_10k_2024.pdf page 105】. The renumbering (due to the addition of later exhibits) shows that the company continues to include the amendment in its exhibit schedule, underscoring its ongoing commitment to disclose executive‑severance‑plan changes as part of its compensation disclosures.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that Amendment No. 4 was disclosed in both the 2023 and 2024 10-K filings and accurately references its incorporation by reference from the Q2 2022 10-Q (specifically the September 2022 filing), which aligns with the ground truth. The exhibit numbers (10.34 in 2023, 10.36 in 2024) are also factually correct, and the explanation that renumbering occurred due to new exhibits is plausible. However, the LLM misses a key qualitative shift described in the ground truth: in the 2024 filing, Amendment No. 4 is no longer a standalone exhibit but is instead grouped within a sequence that includes Amendments 2 through 5. The LLM incorrectly implies it remains a standalone exhibit (just renumbered), which misrepresents the evolution in disclosure strategy. (2) Quantitatively, all dates, exhibit numbers, and references are accurate. There are no calculation errors because none were required, and the numeric details (exhibit numbers, years) match the ground truth. (3) The multi-hop reasoning is partially sound — the model correctly tracks the amendment across two filings and references the correct source document. However, it fails to synthesize the deeper change in disclosure approach: from highlighting Amendment No. 4 individually in 2023 to integrating it into a broader historical sequence in 2024. This reflects a failure in qualitative synthesis despite correct surface-level facts. (4) The correctness score is 5 because while core facts are right, the central point about evolving disclosure strategy — the integration versus standalone treatment — is misrepresented. The model concludes the company is maintaining consistent disclosure, whereas the ground truth indicates a shift toward consolidation. This undermines the accuracy of the interpretation. Quantitative accuracy is high (8) due to correct numbers and references. Qualitative accuracy is moderate (5) because reasoning is fact-based but misses critical nuance. Contextual relevance is good (7) as the answer addresses the question’s scope but misinterprets the strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 565,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "In 2023 JPMorgan reported a Tier 1 leverage ratio of **7.2 %** (well above the 4.0 % regulatory floor) and a Standardized CET1 capital ratio of **15.0 %** (far above the 11.4 % minimum). By the end of 2024 the Tier 1 leverage ratio was unchanged at **7.2 %**, while the Standardized CET1 ratio rose to **15.7 %**, again comfortably exceeding the required level.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, JPMorgan's Standardized CET1 ratio was 15.0% (correct), but the Tier 1 leverage ratio for 2023 is not provided in the original answer—only the 2024 Tier 1 leverage ratio of 7.2% is given. The LLM incorrectly states that the 7.2% Tier 1 leverage ratio was reported in 2023, which is not supported by the ground truth. Furthermore, the LLM claims that in 2024 the Standardized CET1 ratio rose to 15.7%, but this figure is not present in the original answer, which does not provide a 2024 CET1 ratio at all. (2) The only correct numbers are the 2023 CET1 ratio (15.0%), the 2024 Tier 1 leverage ratio (7.2%), and the respective requirements (11.4% and 4.0%). The addition of a 15.7% CET1 ratio in 2024 is unsupported and introduces a major quantitative error. (3) The reasoning is partially sound in that it correctly identifies the two key capital ratios and attempts to track them across years, but it fails the multi-hop synthesis by fabricating data for 2024 CET1 and misattributing the 7.2% Tier 1 ratio to 2023. The original answer does not confirm the 2023 Tier 1 leverage ratio, so asserting it was 7.2% is an invalid inference. (4) The contextual relevance is high because the answer addresses the right metrics and time periods and discusses compliance appropriately. However, due to the introduction of incorrect numerical data and misattribution of time-specific metrics, the quantitative and qualitative accuracy scores are significantly reduced. The correctness score is 4 due to partial factual alignment but major omissions and fabrications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 455,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "In the 2022 filing GM Financial was shown as a distinct reportable segment whose earnings were presented on an “EBT‑adjusted” basis and whose results were reported without any tax‑ or inter‑segment eliminations. By the 2023 filing the company still reports GM Financial as a separate segment, but the numbers are now shown **net of eliminations and reclassifications** and are expressly **adjusted for the impact on GM Financial’s deferred‑tax position and for transactions with the rest of the group**, with its interest expense highlighted in the cash‑flow statement. Thus, GM Financial has moved from a largely stand‑alone segment presentation in 2022 to a more fully integrated component of the consolidated statements in 2023, with its financials presented after inter‑company and tax adjustments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, GM Financial was presented as a reportable segment with adjustments for intercompany transactions and taxes, though it uses the term 'EBT-adjusted' and notes absence of eliminations—consistent with the idea of less integration. In 2023, it accurately reflects increased integration, with explicit mention of adjustments for deferred tax positions and intercompany transactions, matching the original answer’s emphasis on consolidation effects. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no incorrect figures are introduced. (3) The multi-hop reasoning is sound: the model synthesizes changes in financial presentation across two years, correctly inferring a shift from a more stand-alone to a fully integrated reporting model. The use of terms like 'net of eliminations and reclassifications' and 'adjusted for deferred-tax position' reflects accurate understanding of consolidation impacts. (4) Minor difference: the original answer emphasizes the contrast between 'consolidated tax return' effects in 2023 versus simpler segment treatment in 2022, while the LLM adds specific detail about interest expense in the cash-flow statement not present in the ground truth. This addition is plausible but not verifiable from the original answer; however, it doesn’t contradict it. Overall, the semantic meaning and factual core are preserved, warranting a high correctness score. Only a perfect 10 is withheld due to slight extrapolation on presentation details beyond the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 454,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "In the 2022 filing Costco said that step‑rent provisions are straight‑lined over the lease term and that leases “provide for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume,” but it did not specify how those increases are accounted for. By the 2024 filing the company added that those index‑ or sales‑volume‑based rent escalations are now treated as **variable lease payments** (rather than being folded into the straight‑line rent expense), while step‑rent and free‑rent periods continue to be recognized on a straight‑line basis over the lease and any reasonably certain renewal periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in accounting treatment from 2022 to 2024: in 2022, step-rent provisions were straight-lined, and leases included rent increases based on price indices or sales volume, though the accounting for those increases was not explicitly detailed. By 2024, the company clarified that such increases are now treated as variable lease payments, not straight-lined—this matches the original answer’s core claim. (2) There are no numerical values to verify (e.g., dollar amounts, percentages), but the years (2022 and 2024) and accounting terms (‘straight-line basis’, ‘variable lease payments’) are used correctly and consistently with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure and treatment over time, correctly distinguishing between fixed step-rents (still straight-lined) and variable-based escalations (now excluded from straight-lining). (4) The only minor shortcoming is that the LLM attributes the disclosure to 'Costco'—which is not mentioned in the original answer—introducing an unsupported entity. While this may reflect correct inference from external knowledge, it is not present in the provided ground truth and thus slightly reduces qualitative accuracy. Otherwise, the answer is semantically equivalent, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 391,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "- In the 2023 Form 10‑K the company projected that its qualified defined‑benefit pension plans would require **$1.86 billion in 2025** and **$10.02 billion for the five‑year stretch 2029‑2033**【LMT_10k_2023.pdf page 86‑87】.  \n\n- In the 2024 Form 10‑K the same projections were **revised to $1.80 billion for 2025** (a slight decrease) and the long‑term aggregate was **about $9.99 billion for the comparable period (2029‑2033)**【LMT_10k_2024.pdf page 88‑89】.  \n\nThus, the expected 2025 pension‑plan outlay fell by roughly $60 million, and the total amount anticipated for the 2029‑2033 horizon dropped by about $30 million.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, the 2025 projected payment remained unchanged at $1,860 million from 2023 to 2024. However, the LLM incorrectly states that the 2024 projection for 2025 decreased to $1.80 billion ($1,800 million), which is a $60 million error. Additionally, while the long-term projection decrease from $10,020 million to $9,990 million is correctly reflected in magnitude (~$30 million drop), the LLM misstates the time period as 2029–2033 in both years, whereas the 2024 filing shifts the long-term window to 2030–2034. This affects the comparability and shows a failure in precise entity (time period) tracking. (2) Calculations: The claimed $60 million decrease in 2025 payments is factually wrong because there was no change in the 2025 projection. The $30 million reduction in the long-term obligation is numerically accurate but applied to the wrong time window. (3) Multi-hop reasoning: The model attempts to compare two filings across years and extract corresponding figures, which shows correct intent. However, it fails in accurately identifying the updated time horizon for the long-term projection and misreads the 2025 figure in the 2024 filing, indicating a failure in precise data extraction from the second document. (4) Scores justified: Correctness is low (4/10) due to major quantitative errors in core figures. Quantitative accuracy is poor (3/10) because of incorrect dollar amounts and time periods. Qualitative accuracy is moderate (5/10) — the structure and approach are sound, but entity and number misidentification undermine validity. Contextual relevance is high (8/10) — the response addresses the right topic, uses proper sourcing, and follows the expected analytical pattern.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 491,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "In the 2023 Form 10‑K the company warned that its **funding costs could rise** if it had to take actions to meet the Liquidity Coverage Ratio/Net Stable Funding Ratio **or to satisfy obligations under its resolution plan**, but the discussion stopped at the possibility of higher costs. By the 2024 filing the language had been expanded: JPMorgan Chase now states that, if access to its “stable and lower‑cost” sources (deposits and Federal Home‑Loan Bank borrowings) is reduced, it may have to **raise funding from alternative sources that are likely to be more expensive or less available**, and that those higher costs could be triggered specifically by actions taken to **fulfil its resolution‑plan funding requirements** as well as other regulatory liquidity mandates. Thus the 2024 disclosure makes the resolution‑plan funding need a more explicit driver of liquidity‑risk management and explicitly flags the potential for higher, less‑certain funding costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in JPMorgan Chase's disclosures between 2023 and 2024. (1) It correctly identifies that in 2023, the firm noted potential higher funding costs due to resolution plan obligations and LCR/NSFR requirements, and in 2024 expanded this to link resolution-plan-driven funding needs more explicitly to reliance on costlier or less available alternative sources. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes how the framing of liquidity risk evolved from a general warning in 2023 to a more specific, causally linked disclosure in 2024, particularly tying resolution-plan funding to alternative, expensive sources. (4) The LLM slightly omits the 2024 expansion regarding 'dynamic regulatory expectations' and 'systemic events' influencing capital and liquidity requirements, which is part of the broader contextual shift noted in the ground truth. However, it effectively conveys the key qualitative shift in risk disclosure emphasis. Wording differs but meaning is semantically equivalent on the main points. Minor omission prevents a perfect 10, but overall correctness is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1506,
        "completion_tokens": 368,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "In 2023 the company continued to recognize Optum Rx pharmacy‑care revenue the same way it did in 2022 – product revenue is recorded when a prescription is dispensed and service revenue is recorded as the related services are performed.  The balance‑sheet impact of that model grew, with accounts receivable tied to Optum Rx products and services rising from $7.1 billion at year‑end 2022 to $8.6 billion at year‑end 2023 – an increase of roughly $1.5 billion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: revenue recognition remained unchanged between 2022 and 2023, with revenue recognized at the point of dispensing for products and as services are performed. Accounts receivable increased from $7.1 billion in 2022 to $8.6 billion in 2023, a $1.5 billion increase—this matches the original answer exactly. (2) Quantitative accuracy is perfect: both dollar amounts and the implied difference ($8.6B - $7.1B = $1.5B) are correctly stated. Format variations (e.g., using 'billion' vs numeric) are acceptable and clear. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across years and financial metrics (revenue recognition model and accounts receivable trend). It correctly identifies continuity in accounting policy while highlighting a material change in receivables. (4) The only minor omission is the lack of explicit mention of the 'gross revenue reporting model' and the rationale (primary obligation to pay providers regardless of collection), which is part of the financial structure explanation. However, the core elements—revenue recognition timing and receivables growth—are fully covered. The answer is semantically equivalent in substance and highly relevant to the question. Thus, a score of 9 is justified due to this slight gap in qualitative depth, despite excellent factual and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 398,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "In the 2022 Form 10‑K UPS disclosed that its floating‑to‑fixed interest‑rate swaps were accounted for as cash‑flow hedges, producing a cumulative loss of **$10 million** that was re‑classified from AOCI to interest expense for the year and leaving a **$1 million** loss still sitting in AOCI. By the 2024 filing the same hedge category showed a smaller cumulative loss of **$5 million** re‑classified to interest expense and **no balance** remaining in AOCI, indicating that the company’s exposure to floating‑rate debt had been reduced and the swaps were more closely matched to forecasted payments. The strategic approach has remained the same—using interest‑rate swaps (cash‑flow hedges to convert floating payments to fixed and fair‑value hedges to convert fixed to floating) to manage the overall debt‑cost mix—but the decreasing re‑classification losses and the elimination of the AOCI balance demonstrate a tighter alignment of the swaps with UPS’s debt‑service forecasts and a gradual de‑risking of its floating‑rate exposure between 2022 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps. However, the LLM answer incorrectly reports a $10 million reclassification loss from AOCI to interest expense and a $1 million loss in AOCI, which are not mentioned in the original answer and contradict the known quantitative exposure. Similarly, the 2024 figures of $5 million reclassified and $0 in AOCI are fabricated and not supported by the ground truth. These numbers do not align with the actual disclosed notional amount or any referenced financial impact in the original answer. (2) There are no correct quantitative values from the ground truth in the LLM response—$28 million is omitted entirely, and instead, the model invents P&L and AOCI figures unrelated to the question. The notional amount, which is central to the quantitative exposure, is completely missing. (3) While the LLM attempts multi-hop reasoning by inferring tighter hedge alignment and de-risking from decreasing losses, this reasoning is based on false data. The strategic point about managing the fixed/floating mix is consistent with the original answer, showing some qualitative understanding. However, the evolution from 'limited use' to 'more comprehensive strategy' is misrepresented through invented metrics rather than the actual increase in strategic emphasis. (4) The contextual relevance is moderate because the answer addresses interest rate swaps and strategic intent, but the incorrect numbers and invented disclosures severely undermine factual correctness. The qualitative accuracy is low due to reliance on non-existent AOCI balances and reclassifications. Correctness score is low because the core quantitative claim (notional amount) is wrong, and the narrative is built on fabricated data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 510,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "In the 2022 filing GM described the creation of Ultium Cells LLC – an equally‑owned joint‑venture with LG Energy Solution to build U.S. battery‑cell plants in Ohio, Tennessee and Michigan (and a fourth plant planned). By the 2023 filing the partnership was still in place, but GM also reported that LG Energy Solution had agreed to reimburse it for the Chevrolet Bolt battery‑fire recall, leading GM to accrue $2.6 billion of recall costs, record $1.6 billion of receivables from LG and retain a remaining $0.6 billion accrual at year‑end.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: Ultium Cells LLC is an equally owned joint venture between GM and LG Energy Solution established to build battery plants in Ohio, Tennessee, and Michigan, with a fourth planned—this matches the 2022 context. In 2023, the relationship evolved due to the Bolt EV battery recall. (2) Quantitative accuracy is perfect: GM accrued $2.6 billion in recall costs, recorded $1.6 billion as receivables from LG, and retained $1.0 billion net liability (though phrased as $0.6 billion accrual at year-end, this reflects the net retained cost after partial reimbursement; the $1.6B receivable and $2.6B total cost are correctly stated and match the ground truth). The $0.6 billion figure may reflect timing or accounting presentation but does not contradict the $2.6B - $1.6B = $1.0B net; however, minor ambiguity here does not undermine overall correctness given the core numbers are accurate. (3) Multi-hop reasoning is sound: the answer synthesizes information across two years, two companies, and two financial dimensions (joint venture operations and recall liabilities), correctly identifying the shift from strategic collaboration to cost recovery. (4) The answer is contextually relevant, complete, and semantically equivalent to the original, capturing both the evolution of the relationship and the financial implications. No factual errors in entities, years, or metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 406,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "Cisco’s Observability category grew from $581 million in fiscal 2022 to $661 million in fiscal 2023 – an increase of about $80 million (≈14%).  Management said that the entire gain was “driven by growth in our ThousandEyes … offerings,” indicating that ThousandEyes’ revenue contribution rose year‑over‑year and was a key factor behind the $80 million uplift.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of ThousandEyes' revenue contribution from fiscal 2022 to 2023 as described in the ground truth. (1) Quantitatively, the LLM claims Observability revenue grew from $581M to $661M (a $80M increase) in fiscal 2022 to 2023, but the original answer states that in fiscal 2022, the category increased by $80M (not total $581M), and in fiscal 2023, it grew by $176M (27%), with a 15% organic growth excluding Splunk. The LLM incorrectly treats the $80M increase in 2022 as the total revenue, rather than the year-over-year increase, and misattributes the entire $80M growth to ThousandEyes, while the original answer only says it was 'driven in part' by ThousandEyes. (2) The LLM omits critical information about fiscal 2023: the $176M increase, the 27% growth rate, the impact of Splunk's inclusion, and the 15% organic growth that underscores ThousandEyes' ongoing contribution. (3) The reasoning is flawed: it fails to perform the required multi-hop synthesis across both years and incorrectly infers that ThousandEyes was solely responsible for the 2022 growth. It also fabricates a precise revenue base ($581M) not present in the original. (4) While the general direction (ThousandEyes contributed to growth) is aligned, the magnitude, timeline, and contributing factors are misrepresented. The answer is contextually relevant to the question but factually incorrect in key aspects, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 416,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings UPS describes the $276 million 7.620 % debentures as maturing on April 1, 2030, paying interest semi‑annually (April and October) and having no sinking‑fund requirement. The redemption provisions are unchanged – the notes may be called in whole or in part at UPS’s option, with the redemption price equal to the greater of (i) principal + accrued interest or (ii) the present value of the remaining scheduled payments discounted at a benchmark Treasury yield + 5 bps (plus accrued interest). The 2022 filing notes that the rate was reduced from 8.375 % to 7.620 % in April 2020, whereas the 2024 filing simply states the current 7.620 % rate, indicating no further change to the interest‑payment structure or redemption terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the principal amount ($276 million), maturity date (April 1, 2030), interest payment frequency (semi-annual in April and October), and redemption formula involving the greater of principal plus accrued interest or present value discounted at benchmark Treasury yield plus 5 bps. These quantitative elements match the ground truth and are accurately represented, earning high marks for quantitative accuracy. However, the LLM incorrectly asserts that the redemption terms and interest structure were 'unchanged' between 2022 and 2024, which contradicts the ground truth. The original answer states that in 2024, UPS *clarified* the redemption terms—specifically emphasizing that the debentures are redeemable at any time at the company's option and providing a more detailed explanation of the redemption price and interest schedule. This evolution from a general to a more detailed disclosure is a key qualitative point that the LLM overlooks. (2) All numbers—$276M principal, 7.620%, April/October payments, 2030 maturity—are factually correct and consistent with the ground truth. The mention of the 2020 rate reduction from 8.375% to 7.620% is additional context not in the original answer but not incorrect. (3) The multi-hop reasoning is flawed: the question asks how the relationship evolved between 2022 and 2024, requiring synthesis of changes in disclosure or terms over time. The LLM fails this by asserting no change, while the ground truth identifies a shift in disclosure clarity and detail, indicating an evolution in how UPS presents the terms, if not the terms themselves. (4) Correctness is scored low (4/10) because the core of the question—evolution in terms and structure—is mischaracterized. While the raw data is accurate, the interpretation of no change is incorrect. Qualitative accuracy is moderate due to sound entity identification but flawed reasoning. Contextual relevance is high as the answer stays focused on the debentures and relevant time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 545,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "In 2023 MetLife’s Fixed‑Maturity Securities (AFS) were valued at about **$7.99 billion**, down from **$8.11 billion** at year‑end 2022.  The U.S. government‑bond component was essentially unchanged – it rose a little in the pension pool (from $1.51 bn to $1.58 bn) but fell in the other‑post‑retirement pool (from $68 m to $58 m), leaving total government‑bond holdings near **$1.63 bn** (about $10 m lower than 2022).  Corporate securities grew modestly, increasing from roughly **$3.21 bn** to **$3.25 bn** (driven by a $82 m rise in the pension segment offset by a $38 m drop in the other‑post‑retirement segment).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in numbers and trends. According to the ground truth, the total fair value of Fixed Maturity Securities AFS increased from $2,164 million (as of Dec 31, 2021, reported in 2022) to $6,714 million in 2023 — a significant increase. However, the LLM claims a decrease from $8.11 billion in 2022 to $7.99 billion in 2023, which contradicts the ground truth. The LLM also misreports the 2022 baseline: the original answer states the 2022 filing reported the value as of December 31, 2021, not 2022 year-end. This reflects a misunderstanding of reporting lags in filings. (2) Specific number verification: LLM reports U.S. government bonds at ~$1.63 billion in 2023, while ground truth reports $1,575 million — close but not exact. However, the LLM’s 2022 figure is wrong — it implies ~$1.64 billion, while ground truth does not provide a 2022 government bond figure directly, but the total AFS was only $2,164 million, making the LLM’s allocation implausible. Corporate securities: LLM reports $3.25 billion in 2023; ground truth reports $3,083 million — a notable discrepancy. The LLM also introduces segment-level data (pension vs. other-post-retirement) not present or inferable from the original answer, adding unsupported detail. (3) Multi-hop reasoning is flawed: the LLM fails to correctly track the timeline and magnitude of change. It assumes a high 2022 baseline ($8.11B) that is inconsistent with the $2.164B reported in the 2022 filing for the prior year. This suggests confusion between different reporting periods or inclusion of additional assets not mentioned in the ground truth. (4) Contextual relevance is moderate — the answer addresses composition changes in U.S. government bonds and corporate securities, which aligns with the question. However, due to severe quantitative and temporal inaccuracies, the qualitative and correctness scores are low. The answer conveys the opposite trend (decline vs. substantial increase) and misrepresents the scale of growth, undermining its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 556,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "In the 2022 filing GM reported a $0.5 billion cash outlay to its joint‑venture partner Ultium Cells LLC as an “investment in Ultium Cells LLC” under its investing activities. By the 2023 filing the focus had shifted from new capital spending to a regulatory matter: GM disclosed that the EPA had identified potential violations of the Toxic Substances Control Act at the Ultium Cells plant, leading to a consent agreement that imposes joint‑and‑several civil penalties of roughly $5.1 million (subject to increase) on both GM and Ultium Cells. Thus, GM’s relationship moved from a pure equity investment in 2022 to one that also carries significant regulatory‑compliance costs in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $0.5 billion investment in 2022 is accurately reported, and the $5.1 million joint civil penalty in 2023 is correctly stated (with appropriate note on potential increase). Dates (2022–2023) and entities (GM, Ultium Cells LLC, EPA, TSCA) are correct. (2) Quantitative accuracy is perfect: $0.5 billion and $5.1 million match the original answer exactly; no calculation errors. (3) Multi-hop reasoning is sound—correctly synthesizes GM’s shift from financial investment to regulatory entanglement across two years and two filings. The characterization of the relationship evolving from 'pure equity investment' to one with 'regulatory-compliance costs' captures the essence of the shift. (4) Minor deduction in qualitative accuracy because the LLM attributes the disclosure to the EPA identifying violations, whereas the original answer specifies GM self-disclosed the potential violations—a nuance affecting agency initiative and corporate accountability. However, the core conclusion about increased operational entanglement and shared penalties remains valid. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with only slight variation in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 367,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K disclosures state that the company “enters into variable‑priced contracts for some purchases of natural gas, in addition to fuel for its gas stations, on an index basis.” The language is essentially unchanged, indicating that the company has continued to rely on these index‑linked, variable‑price contracts and has not reported any material increase, reduction or strategic shift in their use between 2022 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually incorrect in its conclusion despite accurately quoting similar language from both years. While it correctly notes that both the 2022 and 2024 disclosures mention variable-priced contracts for natural gas and fuel on an index basis, it fails to identify a key evolution highlighted in the ground truth: by 2024, the company explicitly recognized these contracts as meeting the characteristics of derivative instruments, though qualifying for the 'normal purchases and normal sales' exception. This reflects a more formalized accounting treatment and strategic management of such contracts, indicating a meaningful shift in how they are viewed and handled, even if the operational language remained unchanged. The LLM incorrectly interprets the consistency in descriptive language as evidence of no strategic or accounting evolution, thereby missing the multi-hop insight that unchanged operational wording can coexist with increased financial reporting sophistication. There are no numerical inaccuracies (hence high quantitative accuracy), but the qualitative reasoning is flawed, leading to an incomplete and misleading conclusion. The answer is contextually relevant but lacks depth in synthesizing accounting implications across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 352,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco’s segment‑reporting methodology for APJC did not change from FY 2022 to FY 2023. In both years the company said that, for the APJC segment (as for the other geographic segments), it **does not allocate** research‑and‑development, sales‑and‑marketing, or general‑and‑administrative expenses, nor **amortization and impairment of acquisition‑related intangible assets, share‑based‑compensation expense, significant litigation settlements and other contingencies, asset‑impairment or restructuring charges** to the segment’s gross‑margin calculation. Thus the same set of expense categories remained excluded from the APJC performance measurement in FY 2023 as in FY 2022.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Cisco's financial reporting approach for the APJC segment did not change between fiscal 2022 and 2023, with consistent exclusions from segment performance measurement. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy pertains to correct identification of fiscal years (FY 2022 and FY 2023), which are correctly cited. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same set of expenses were excluded in both years, including research and development, sales and marketing, general and administrative, amortization and impairment of intangible assets, share-based compensation, litigation settlements, and restructuring/asset impairment charges. The LLM explicitly confirms no change in methodology, which requires cross-year comparison. (4) All entities—Cisco, APJC segment, correct expense categories, and fiscal years—are accurately identified. The answer is highly relevant, directly addressing the evolution (or lack thereof) in reporting approach. Minor wording differences (e.g., 'does not allocate' vs. 'excluded') do not affect factual accuracy and are semantically equivalent. No errors or omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 366,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "In its 2022 filing UnitedHealth emphasized the traditional cost‑control toolkit—under‑writing criteria, product‑design choices, competitive provider‑contract negotiations and broad care‑management programs—to keep medical‑cost growth in check. By the 2023 filing the company acknowledged that the biggest driver of cost inflation was a surge in outpatient procedures among seniors and added a focused response: it is intensifying physician‑ and consumer‑engagement efforts, providing clinical‑use information and steering members toward high‑quality, lower‑cost care choices (often through value‑based arrangements) to blunt those specific senior‑outpatient cost increases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies UNH's 2022 focus on traditional cost-control methods such as underwriting, product design, provider negotiations, and care management, which corresponds to the original answer's mention of concern over deferred care and emphasis on risk-based arrangements. In 2023, the LLM correctly notes a shift toward addressing rising outpatient costs among seniors, matching the ground truth's assertion of targeted intervention. The strategies cited—intensified physician and consumer engagement, use of clinical data, and steering toward high-quality, lower-cost care via value-based arrangements—are semantically equivalent to the original answer's 'data-driven insights to guide clinical decisions.' (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes UNH’s evolving strategy across two years and correctly infers a strategic pivot from general cost management to targeted outpatient cost mitigation. (4) The only minor shortcoming is that the LLM does not explicitly mention the expectation that the trend will continue into 2024 and beyond, which is present in the original answer. However, this omission does not undermine the core accuracy. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 405,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "In the 2022 filing UPS presented its time‑definite offering as a suite of express air‑ and ground‑service options (same‑day, next‑day, two‑day, three‑day, etc.) delivered through a single “global smart‑logistics network” with about 188 000 pickup points and returns in more than 140 countries. By the 2024 filing the scope had widened – the Digital Access Program embeds UPS shipping into e‑commerce platforms, returns now cover roughly 150 countries, new e‑commerce‑focused services such as Worldwide Economy were added, and UPS began insourcing its SurePost residential service – all still routed through the same integrated global network, but with a broader set of digital tools, access‑point options and on‑demand capabilities that deepen network integration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of UPS's time-definite delivery services from 2022 to 2024, noting the continued use of the integrated global network and the expansion in service scope. Key developments such as insourcing SurePost, expanding returns to ~150 countries, and enhancing digital integration (e.g., Digital Access Program, e-commerce services) are accurately reported. (2) Quantitatively, the LLM cites 'more than 140 countries' in 2022 and 'roughly 150 countries' in 2024, which matches the ground truth progression and is appropriately worded with qualifiers. The 188,000 pickup points are consistent with known UPS network data. No calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes changes in service scope (e.g., new digital tools, same-day pickup implied via on-demand capabilities) and network integration (insourcing SurePost, deeper digital embedding) across years. The only minor omission is the explicit mention of 'same-day pickup seven days a week' in 2024, though 'on-demand capabilities' may implicitly cover it. (4) The answer is contextually excellent—directly addresses service scope and network integration evolution. Wording differs but meaning is semantically equivalent. One point deducted from correctness and qualitative accuracy for slight incompleteness on same-day pickup detail, but overall a strong, factually correct response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 406,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "In the 2022 Form 10‑K (pages 79‑83) Lowe’s still listed the 2.50 % senior notes that mature in April 2026 as outstanding long‑term debt, reporting the accrued interest and carrying them at amortized cost. By the 2023 Form 10‑K (pages 74‑78) those 2.50 % notes no longer appear on the debt schedule; the filing instead shows the issuance of new 4.80 % notes due April 1 2026, indicating that the original 2.50 % notes were redeemed/retired and removed from the company’s balance sheet.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) Quantitatively, it falsely claims that the 2.50% Notes maturing in April 2026 were removed from the 2023 filing and replaced with 4.80% notes due April 1, 2026. The ground truth states that the same 2.50% Notes under the Thirteenth Supplemental Indenture remained outstanding, with no mention of redemption or new issuance. The maturity date (April 2026) and interest rate (2.50%) are correct in isolation but misused in context. (2) The answer incorrectly asserts that the notes 'no longer appear on the debt schedule' in 2023 and were 'redeemed/retired,' which contradicts the ground truth that the notes were merely more explicitly recognized as issued instruments in 2023. (3) Qualitatively, the multi-hop reasoning fails: instead of identifying a shift in disclosure treatment (from historical reference to active recognition), the model invents a debt retirement and issuance event that is not supported by the data. (4) Contextually, the answer addresses the general topic of debt recognition but misrepresents the nature of the evolution, making it highly misleading. The core claim of note retirement and replacement is unsupported and factually wrong, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 357,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "In the 2022 Form 10‑K, Costco identified sovereign‑debt crises only as one of a broad set of macro‑economic risks that could “adversely affect demand for our products… require a change in product mix, or impact the cost of or ability to purchase inventory.” By the 2024 filing, the company repeats the same risk language but notes that its international footprint has grown (sales from Canada and other overseas markets rose from roughly 27 % to 28 % of net sales) and that it now relies even more heavily on foreign manufacturers and importers. Consequently, while the nature of the risk is unchanged, Costco’s exposure to sovereign‑debt‑related sourcing and cost pressures is viewed as more material in 2024 than it was in 2022.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative framing and includes accurate quantitative data, such as the increase in international sales from 27% to 28% of net sales, which aligns with the expected level of detail. The entity identification (Costco, 2022 and 2024 Form 10-K filings) and timeframes are correct, and the reasoning correctly identifies an increased exposure due to greater reliance on foreign suppliers. However, there is a key discrepancy in reasoning: the LLM claims that the 'same risk language' is repeated in 2024, whereas the ground truth states that the framing evolved from a general macroeconomic risk in 2022 to an explicit statement in 2024 that sovereign debt crises 'negatively impact' the business, indicating a stronger and more direct assessment of risk. This mischaracterization of the evolution in risk language affects the qualitative accuracy, as it underrepresents the shift in tone and severity. While the LLM infers increased materiality due to greater international exposure—plausible and contextually sound—this is not explicitly stated in the ground truth, which instead emphasizes broader supply chain risks and geopolitical instability as part of the heightened concern. Thus, the reasoning is partially sound but misses the specific qualitative escalation documented. Quantitative accuracy is high, with correct percentages and proper contextual use. The answer is highly relevant to the question and addresses both years and the evolution of risk, though with a subtle but important misstep in representing the nature of the change in risk disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 437,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "UnitedHealth reported 64 million shares available for future grants under its 2020 Stock Incentive Plan at December 31 2021, and 53 million shares available at December 31 2023—a decline of about 11 million shares. The drop shows that the pool of shares the company can use for new stock‑based awards has contracted, though a sizable reserve (over 50 million shares) still remains for future issuances.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the number of shares available for future grants in 2021 (64 million) and 2023 (53 million), matching the ground truth exactly. The calculated decline of 11 million shares is accurate (64M - 53M = 11M). The dates (December 31, 2021 and December 31, 2023) are appropriately specified, aligning with standard SEC filing reporting periods.\n\n2) All numeric values are correct and properly contextualized. The format (millions) matches the original, and the difference is correctly computed. No calculation errors.\n\n3) The reasoning is sound: the decrease in available shares indicates reduced capacity for new share-based awards, which the LLM captures by noting the 'contracted' pool. It adds contextually accurate nuance by observing that over 50 million shares remain, which is consistent with the data and does not overstate scarcity. This reflects proper multi-hop synthesis between the two time points and correct interpretation of implications.\n\n4) The answer fully addresses both parts of the question: the change in shares (quantitative shift) and what it indicates (interpretation of award capacity). The wording differs slightly from the original answer (e.g., 'contracted' vs 'reduction'), but the semantic meaning is equivalent. The only minor shortcoming is that it doesn't explicitly name the 2020 Stock Incentive Plan in the second reference, though it's clearly implied. This does not impair understanding.\n\nOverall, the response is factually precise, logically sound, and contextually appropriate—meriting a high score with only negligible room for perfection in repetition of the full plan name.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 450,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "In the 2022 filing UPS noted that the collective‑bargaining agreement governing its participation in the I.A.M. National Pension Fund / National Pension Plan was set to expire on **July 31 2024**, and that UPS “provided more than 5 % of the total plan contributions from all employers” (the plan contribution shown was $48 million for 2021)【112†L1-L4】【112†L13-L16】.  \n\nBy the 2024 filing the same agreement had been renegotiated and now runs until **July 31 2029**, and UPS’s contributions remained material – $48 million in 2022, $50 million in 2023 and $53 million in 2024 – still exceeding the 5 % threshold for each year【96†L1-L4】【96†L13-L16】.  \n\nThus, between 2022 and 2024 the expiration date was extended by five years, while UPS’s contribution level stayed significant and even grew modestly.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all dates and figures are accurate: the expiration date is correctly stated as July 31, 2024 in 2022 and extended to July 31, 2029 by 2024. The contributions are accurately reported as exceeding 5% for all relevant years, with specific dollar amounts ($48M in 2021, $48M in 2022, $50M in 2023, $53M in 2024) aligning with the context and confirming the 5% threshold was maintained. (2) The answer is complete, addressing both the evolution of the expiration date and the significance of UPS's contributions across the 2022–2024 period. (3) Entity accuracy is perfect: the IAM National Pension Fund / National Pension Plan and UPS are correctly identified, and the years (2021–2024) match the required multi-hop timeline. (4) The reasoning is sound: the LLM correctly infers that the extension from 2024 to 2029 represents a five-year extension and notes the sustained and growing contribution levels, which supports the conclusion of continued significance. The use of specific citations (e.g., 【112†L1-L4】) indicates grounding in source data. (5) The semantic meaning fully aligns with the original answer, with added granularity (exact dollar figures per year) enhancing clarity without introducing error. Minor wording differences (e.g., 'material' vs 'significant') do not affect factual equivalence. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 397,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "In FY 2022 Lowe’s disclosed that the December 2021 amendment to its March 2020 five‑year unsecured revolving facility (the 2020 Credit Agreement) raised the facility’s available borrowing capacity to $2.0 billion and pushed its maturity out to March 2025, giving the company a total combined $4.0 billion of available liquidity across the 2020 and the newer 2021 “Third” revolving agreements. By FY 2023 the company had entered into a September 2023 amendment‑and‑restatement of the same 2020 facility (the 2023 Credit Agreement), which kept the $2.0 billion availability but further extended the term to September 2028; the combined availability of the revolving facilities remained $4.0 billion and no borrowings were outstanding under the 2020 (or related) agreements as of the FY 2023 balance date.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: in FY 2022, the 2020 Credit Agreement had a $2.0 billion availability and March 2025 maturity; in FY 2023, it was amended into the 2023 Credit Agreement with a September 2028 maturity, maintaining $2.0 billion availability. The combined availability of $4.0 billion is correctly reported for both years. (2) Quantitative accuracy is perfect: all dollar amounts ($2.0 billion, $4.0 billion), dates (March 2025, September 2028), and fiscal years (2022, 2023) match the ground truth. Format variations (e.g., 'FY 2022' vs 'fiscal year 2022') are acceptable. (3) Multi-hop reasoning is sound: the model correctly synthesizes the evolution of the 2020 Credit Agreement into the 2023 version and links it to the broader liquidity picture involving the Third Amended and Restated Credit Agreement. The mention of no borrowings outstanding adds context not in the ground truth but does not contradict it. (4) The only minor issue is the reference to a 'December 2021 amendment' and the '2021 Third' agreement, which are not in the original answer—this adds detail not confirmed by the ground truth but doesn't impair correctness. Overall, the answer is factually aligned, complete, and contextually appropriate, warranting a 9/10 due to slight over-elaboration on unverified amendments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 387,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "MDLZ’s net‑investment‑hedge program expanded markedly over the period. In the 2022 filing the company reported that the aggregate notional amount of its net‑investment‑hedge derivative contracts was roughly **$5.5 billion**. By the end of 2024 that notional had risen to **about $8.6 billion** (the 2024 10‑K shows $8,647 million of net‑investment‑hedge contracts). Thus, the notional exposure grew by roughly $3 billion – an increase of around 55 % – between 2022 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, MDLZ reported a notional amount of $3,915 million as of December 31, 2021 (reported in the 2022 filing), not $5.5 billion. The LLM incorrectly states the 2022 figure as $5.5 billion, which does not appear in the ground truth. The 2024 figure of $8,647 million is correctly cited. However, the increase from $5.5B to $8.6B implies a 2022–2024 comparison that is factually wrong because the actual 2022-reported value refers to end-of-2021, and the trend should be assessed from $3,915M (2021) to $7,456M (2023) to $8,647M (2024). (2) The calculation of a $3 billion increase and 55% growth is based on incorrect starting values. The actual increase from $3,915M to $8,647M is about $4,732M (121% increase), so the LLM’s calculation is flawed. (3) The qualitative reasoning is partially sound—MDLZ did increase its use of net investment hedges, and the direction of growth is correctly identified. The entity (MDLZ), metric (notional amount of net investment hedge derivatives), and time frame (2022–2024 filings) are correctly interpreted, though the mapping of dates to values lacks precision. (4) The answer is contextually relevant and addresses the evolution of notional amounts, but the core numerical inaccuracies—especially the invented $5.5B figure—severely undermine factual correctness. The synthesis across years is attempted but based on incorrect data retrieval for 2022. Hence, correctness is partially accurate but significantly compromised by wrong numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 434,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "In the 2022 filing Microsoft 365 was described mainly as a bundle of Office 365, Windows and Enterprise Mobility + Security that “empowers employees with AI‑backed tools” to boost creativity and collaboration. By the 2024 filing the suite had become an **AI‑first platform**, embedding the Copilot experience throughout: Copilot for Microsoft 365 pulls data from the Microsoft Graph into Office apps, Copilot Pro offers a consumer‑grade AI assistant, Copilot Studio lets customers tailor or build their own Copilot, and role‑specific extensions (Copilot for Sales, Service and Finance) deliver targeted workflow assistance—new capabilities that deepen AI’s role in productivity and collaboration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Microsoft 365 evolved from an AI-enhanced suite in 2022 to an 'AI-first platform' in 2024, with Copilot for Microsoft 365 introduced as a central feature that leverages Microsoft Graph and integrates across Office apps. The role-specific extensions—Copilot for Sales, Service, and Finance—are correctly identified as new 2024 capabilities. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable in that sense, but all dates (2022, 2024) are correct and consistently used—thus scored as 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution over time (2022 → 2024), identifies the shift in strategic positioning (from 'AI-backed tools' to 'AI-first platform'), and lists specific new AI capabilities introduced in 2024. The mention of Copilot Pro and Copilot Studio, while not in the original answer, are plausible extensions documented in Microsoft's public roadmap and do not contradict the ground truth; they add context without introducing inaccuracy. (4) The answer fully addresses both parts of the question: the evolution of AI integration and the specific new capabilities in 2024. Wording differs but semantic meaning matches. Only a minor deduction in qualitative accuracy due to slight expansion beyond the ground truth with Copilot Pro/Studio, though these are contextually appropriate. Overall, the response is factually correct, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 434,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "In the 2022 filing, 3M said it had learned that its Decatur, Ala., NPDES permit did not fully capture the PFAS it was discharging, filed an application with ADEM to add the missing compounds, temporarily idled some processes and entered a July 2020 interim consent order that covered all PFAS‑related wastewater and air emissions. By the 2024 filing, 3M noted that ADEM still had not acted on the permit‑modification request, but the company had installed additional PFAS‑treatment controls that are now being upgraded and optimized, and it remains working under the same interim consent order while continuing to characterize the discharge.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth, with only minor differences in emphasis. (1) Correctly identifies that in 2022, 3M acknowledged incomplete PFAS characterization in its NPDES permit for the Decatur facility and submitted a modification application to ADEM. It also correctly notes that by 2024, PFAS-specific treatment controls were installed, were being upgraded and optimized, and that ADEM had not yet acted on the permit modification. (2) The mention of the July 2020 interim consent order is factually correct and adds contextual detail not in the original answer, but does not contradict it; however, the question focuses on 2022–2024 evolution, so this earlier date is contextually relevant but not central. No numeric values (e.g., dollar amounts, percentages) are present, but dates (July 2020) are accurate per known disclosures. (3) The multi-hop reasoning is sound: the model synthesizes information across years and regulatory actions, correctly linking 3M’s self-identified gap in 2022 with its operational response by 2024, while noting the ongoing regulatory delay. (4) The LLM includes slightly more detail (e.g., process idling, interim consent order) than the original answer, but all added information is consistent with known facts and enhances completeness without introducing error. The core evolution—from identification to implementation while awaiting approval—is accurately captured. One minor point: the original answer emphasizes the shift in approach more explicitly, while the LLM focuses on actions; however, this is a difference in framing, not factual accuracy. Thus, the answer earns a 9 for correctness due to excellent factual alignment and reasoning, with near-perfect quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 487,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "In the 2022 Form 10‑K Lowe’s reported that it closed a **$1.5 billion senior unsecured note offering of 4.550 % notes due 2049** in April 2022. The 2023 Form 10‑K shows that the company **issued an additional $1.0 billion of the same 4.550 % notes due 2049** in 2023, increasing the total amount outstanding of this series to roughly $2.5 billion.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) According to the ground truth, the 4.550% Notes were first issued under the Fifteenth Supplemental Indenture on April 5, 2019, and were due April 5, 2049 — not in April 2022 as claimed. The LLM incorrectly states that a $1.5 billion offering occurred in April 2022 and an additional $1.0 billion in 2023. These figures and events are entirely fabricated and not supported by the original answer. (2) There is no mention in the ground truth of any new issuance or increase in principal amount in either 2022 or 2023; the note remained unchanged. The claim of a total outstanding of $2.5 billion is unsupported. (3) The multi-hop reasoning failed: instead of recognizing that the same note was carried forward without modification, the model invented a new issuance pattern. (4) While the answer addresses the general topic (the 4.550% Notes), it misrepresents the evolution as active reissuance when in fact there was no change — making the response highly misleading despite referencing the correct company and note rate. The contextual relevance is low but not zero because it discusses the correct instrument and company.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 339,
        "total_tokens": 1525
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "In 2022 Mondelēz still held its Keurig Dr Pepper (KDP) stake under the equity‑method of accounting, and no gain related to a change in accounting for that investment was reported. During 2023 – as disclosed in the 2024 Form 10‑K – Mondelēz’s ownership fell below the 5 % threshold, so the investment was re‑classified to a Level 1 marketable‑securities (fair‑value) basis and the remaining shares were sold. That accounting change generated a pre‑tax gain of about **$593 million** on the securities sold (total gain $606 million including dividend income), whereas under the prior equity‑method the company had recorded a $493 million pre‑tax gain on equity‑method transactions. Thus, the relationship shifted from an equity‑method holding with no accounting‑change gain in 2022 to a fair‑value re‑measurement and sale that produced a roughly $600 million gain in 2023‑24.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the key financial figures. The ground truth states that MDLZ recognized a $493 million pre-tax gain in 2024 due to a change in accounting for its KDP investment. However, the LLM incorrectly states that the gain from the accounting change was $593 million (pre-tax) and conflates it with the total gain of $606 million including dividends. It also misattributes the $493 million figure as being from 'equity-method transactions' under the prior method, which contradicts the original answer where $493 million is the gain from the 2024 accounting change. Additionally, the LLM claims the gain occurred in '2023–24' and was disclosed in the 2024 10-K, but the original specifies the $493 million gain was recorded in 2024, not 2023. The 2022 gain of $71 million (pre-tax) is completely omitted in the LLM response. (2) Quantitative accuracy is low: the correct gains are $71M (2022, pre-tax) and $493M (2024, pre-tax), but the LLM reports $593M and $606M, which are both incorrect and misassigned. The $493M figure is misrepresented as a prior-period equity gain rather than the 2024 fair-value re-measurement gain. (3) The reasoning partially captures the multi-hop element—recognizing a shift from equity-method to fair-value accounting due to ownership falling below 5%—which aligns with the conceptual evolution. However, the synthesis is flawed due to incorrect timing, misattribution of gains, and omission of the 2022 event. (4) Contextual relevance is high as the answer addresses the evolution of the financial relationship and accounting change, but factual correctness is compromised by major numerical and temporal errors, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 474,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "In the 2022 filing Microsoft described Xbox Game Pass as “a community with access to a curated library of **over 100** first‑ and third‑party console and PC titles.” By the 2024 filing the same service is portrayed as “the cornerstone of our gaming platform … with access to a curated library of **over 400** first‑ and third‑party console and PC titles.” Thus the catalog has roughly tripled, and Microsoft’s messaging has shifted from positioning Game Pass as a community‑based offering to highlighting it as the central growth engine of its gaming business, tied to subscription expansion and broader cloud‑gaming integration.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) Quantitatively, the numbers 'over 100' titles in 2022 and 'over 400' in 2024 are accurately reported, and the characterization of the catalog tripling is a reasonable approximation (400 is 4x 100, but 'roughly tripled' is acceptable as a conservative estimate). (2) The entities—Microsoft, Xbox Game Pass, 2022 and 2024 timeframes—are correct. (3) The multi-hop reasoning is sound: the answer synthesizes changes in both scale (title count) and strategic positioning (from community offering to 'cornerstone') across two years, drawing correct inferences from Microsoft's evolving language in the filings. (4) Semantically, the LLM captures all key elements: growth in library size, shift in strategic emphasis, integration with subscriptions and cloud gaming, and the broader business context. Wording differs slightly but meaning is equivalent. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 284,
        "total_tokens": 1586
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "- In the 2022 Form 10‑K the company merely noted that a “Deferred Stock Unit Award Agreement for non‑employee directors” (granted on or after 1 Jan 2019 under the 2016 Long‑Term Incentive Plan) was incorporated by reference, but it did not tie the exhibit to a specific, newer filing.  \n\n- In the 2024 Form 10‑K the same type of agreement is still used, but the disclosure is more precise: it appears as Exhibit 10.7 and is expressly incorporated from the most recent 10‑K (the year‑ended Dec 31 2023 filing), reaffirming that the deferred‑stock‑unit instrument for non‑employee directors remains unchanged while updating the reference point to the latest filing.  \n\nThus, the structure of the award (deferred stock units for non‑employee directors under the 2016 LTIP) has not changed, but the way it is disclosed has been refined—from a generic reference in 2022 to a specific, up‑to‑date exhibit citation in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the Deferred Stock Unit Award Agreement for non-employee directors under the 3M 2016 Long-Term Incentive Plan was first referenced in the 2022 10-K for grants on or after January 1, 2019, and remained structurally unchanged through 2024. The 2024 filing updates the incorporation by reference to the 2023 10-K, which matches the ground truth's note about the May 8, 2023 amendment being reflected via updated referencing. (2) Quantitative accuracy is perfect: dates (January 1, 2019; Dec 31, 2023), exhibit number (10.7), and years (2022, 2024 filings) are all correct. No calculations were required. (3) Multi-hop reasoning is sound—LLM correctly synthesized across two filings (2022 and 2024) and inferred that while the agreement structure remained constant, the disclosure mechanism evolved with more precise referencing. (4) The only minor shortcoming is that the LLM does not explicitly mention the May 8, 2023 amendment date from the ground truth, though it captures the substance (updated incorporation reflecting ongoing maintenance). This omission slightly affects completeness but not overall correctness. Wording differs but meaning is semantically equivalent. Contextual relevance is excellent—directly addresses evolution in structure and disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 380,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "In 2024 Schwab’s banking unit reported that the First‑Mortgage portfolio now carries $112 million of unamortized premiums, discounts and direct origination costs (up from $100 million at the end of 2023), while the HELOC portfolio’s comparable origination‑cost balance rose to $100 million (from $98 million in 2023).  At the same time, the share of both portfolios located in California slipped modestly, falling to about 42 % of the total in 2024 versus 43 % in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the $112 million unamortized costs in 2024 (up from $100 million in 2023) for the combined First Mortgages and HELOCs portfolio, it incorrectly splits this into two separate figures—claiming HELOCs alone rose to $100 million from $98 million. The ground truth does not provide a breakdown between First Mortgages and HELOCs; it gives a single combined figure of $100M in 2023 and $112M in 2024 for the entire portfolio. This misrepresentation introduces false precision and incorrect segmentation. The California concentration is correctly reported as decreasing from 43% to 42%, which matches the ground truth. (2) Quantitative accuracy is partially correct: the total origination cost figures for 2023 and 2024 are accurate, and the percentage change in geographic concentration is correct. However, the introduction of a non-existent $98M to $100M HELOC-specific cost figure is unsupported and incorrect, undermining numerical reliability. (3) The multi-hop reasoning is flawed—the model fails to treat the portfolio as a single combined entity (First Mortgages and HELOCs together) and instead artificially dissects it into components without evidence, indicating poor synthesis. It also adds detail (HELOC-specific costs) not present in the source, suggesting hallucination. (4) Despite the incorrect breakdown, the answer remains contextually relevant by addressing both origination costs and California concentration over the two years. However, due to major factual errors in financial data segmentation, the correctness score is low. Semantic equivalence is not achieved because the added specificity changes the factual meaning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 473,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "Both the FY 2023 and FY 2024 “Product Research, Design and Development” sections list Dri‑FIT alongside Nike’s other performance technologies (Air, Zoom, Free, Flyknit, FlyEase, Zoom X, Air Max, React). The wording is essentially unchanged, indicating that Nike’s strategic focus on Dri‑FIT remains steady—still a key part of its innovation portfolio but not elevated or altered between the two years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Dri-FIT was listed alongside the same set of key technologies (Air, Zoom, Free, Flyknit, FlyEase, Zoom X, Air Max, React) in both fiscal years 2023 and 2024, with no change in wording or strategic emphasis. (2) There are no numerical values requiring calculation, but the fiscal years (FY 2023 and FY 2024) are correctly identified. (3) The multi-hop reasoning is sound—by comparing the language across two 10-K filings, the model correctly infers that the unchanged description indicates stable strategic emphasis. (4) The answer is contextually precise, directly addressing the evolution (or lack thereof) of Nike's strategic focus on Dri-FIT based on R&D section language. Minor wording differences (e.g., 'essentially unchanged' vs. 'exact same language') do not affect factual accuracy and are acceptable under semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 274,
        "total_tokens": 1495
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "In the 2022 Form 10‑K, Mondelez noted that, because global cyber‑risk was rising, it was “on heightened alert and dedicating focused resources to network security, **backup and disaster recovery**.” By the 2024 filing, the company said it had **expanded that spending**, stating it “continues to **invest and augment** its cybersecurity program … with enhanced identity‑and‑access solutions, multi‑factor authentication, **backup and disaster recovery**, training, 24/7 security‑operations and advanced threat protection” to counter increasingly sophisticated attacks. Thus, the backup and disaster‑recovery effort moved from a basic allocation of focused resources in 2022 to a larger, more comprehensive, and continuously growing investment by 2024 in response to heightened cyber‑threats.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies Mondelez International's evolving investment in backup and disaster recovery from 2022 to 2024, citing the heightened alert status and focused resource allocation in 2022, and the expanded, ongoing investment in 2024. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not compromised; dates (2022, 2024) are correct and properly attributed to the respective Form 10-K filings. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of filings, correctly inferring an escalation in investment and scope—from 'dedicating focused resources' to 'invest and augment' with a broader cybersecurity program that includes enhanced backup and disaster recovery. (4) All entities (Mondelez International, cybersecurity program, backup and disaster recovery) are accurately referenced, and the answer fully addresses the question about evolution in response to increasing threats, including sophisticated actors and emerging tech. Wording differs slightly but meaning is preserved and complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 338,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "In fiscal 2022 Microsoft said it had “reached more than 90 percent of our goal to spend $500 million with double the number of Black‑ and African‑American‑owned suppliers,” indicating it was still working toward the target. By fiscal 2024 the company reported that it had **achieved** that goal – it spent the full $500 million and doubled the number of Black‑ and African‑American‑owned suppliers in its pipeline. Thus, the commitment moved from being near‑target in 2022 to fully realized in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the core evolution of Microsoft's financial commitment from fiscal year 2022 to 2024 with accurate numbers and timeline. It correctly states that in FY2022, Microsoft had reached more than 90% of its $500 million goal and was working toward doubling the number of Black and African American-owned suppliers. It also accurately reports that by FY2024, the company achieved the $500 million spending goal and doubled the supplier count. However, the LLM answer omits a key expansion mentioned in the original answer: the additional $150 million allocated to Minority Depository Institutions and funds supporting Black and African American-owned small businesses in FY2024. This is a significant part of the 'evolution' in commitment and reflects a deeper strategic focus, which the LLM answer does not address. While the quantitative facts presented are correct (hence high quantitative accuracy), the omission reduces completeness and slightly weakens the qualitative synthesis of multi-hop information. The reasoning is sound within the scope of what was included, and the context directly addresses the question's focus on evolution over time. Wording is semantically equivalent and clear.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 342,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "The Employee Stock Purchase Plan for non‑U.S. employees had **10,638,639** shares available for future issuance at the end of 2022, but this pool fell to **8,565,087** shares at the end of 2023 – a drop of roughly 2 million shares. The decline shows that Abbott has been using a sizable portion of the plan’s share reserve for employee purchases, indicating a more “use‑it‑or‑lose‑it” approach that tightens the pool of shares available for future stock‑based incentives while still supporting employee participation.【ABT_10k_2022.pdf†p81‑85】【ABT_10k_2023.pdf†p82‑86】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the number of shares available for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees at the end of 2022 (10,638,639) and 2023 (8,565,087), matching the ground truth exactly. The calculation of a 'drop of roughly 2 million shares' is accurate: the actual decrease is 2,073,552 shares, which rounds appropriately to 'roughly 2 million'.\n\n2) Quantitatively, all numbers are correct and properly attributed to the right fiscal years. The dates referenced in the original answer (as of December 31, 2021, and December 31, 2023) are slightly different in framing—the LLM refers to 'end of 2022' and 'end of 2023', but this aligns with standard interpretation of 10-K reporting dates (i.e., the 2022 10-K reports data as of December 31, 2022). However, the original answer incorrectly states that the 2022 figure is 'as of December 31, 2021', which contradicts standard reporting. The LLM answer is actually more accurate in context, assuming the 2022 10-K reports data as of December 31, 2022. This suggests the ground truth may contain an error in date labeling, and the LLM answer is factually superior.\n\n3) The reasoning is sound: the decrease in available shares is correctly interpreted as evidence of active use of the plan, and the conclusion about a tightening in share availability aligns with the original answer’s implication of a 'potential tightening or adjustment'. The LLM adds value by characterizing it as a 'use-it-or-lose-it' approach, which is a reasonable qualitative interpretation supported by the data.\n\n4) The answer is contextually relevant, addresses both parts of the question (evolution of shares and strategic implication), and synthesizes information across two years of filings. The only minor deduction is for slightly interpretive phrasing ('use-it-or-lose-it') that isn't explicitly in the ground truth, but this does not reduce factual accuracy. Overall, the LLM answer is factually correct, well-reasoned, and semantically equivalent or superior to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 559,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "In fiscal 2023 Nike’s 10‑K listed Nike Air only as one of many “proliferating” performance‑technology platforms that underpin its product‑innovation agenda. By fiscal 2024 the filing not only repeats that same emphasis on Nike Air but also spells out a dedicated supply‑chain structure – Air Manufacturing Innovation, a wholly‑owned subsidiary (with facilities in Oregon, Vietnam and Missouri and contract partners in China and Vietnam) that produces the Nike Air‑Sole cushioning components used in its footwear. Thus, Nike moved from treating Air simply as a headline technology to integrating it more explicitly into its development and manufacturing strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces information not present in the ground truth and misrepresents the strategic evolution of Nike Air technology. (1) Correct elements: The mention of Nike Air as a 'proliferating' technology in fiscal 2023 aligns with the original answer’s description of it being part of innovative product dedication. The fiscal years (2023 and 2024) are correctly identified, and there are no numerical inaccuracies (hence quantitative accuracy is high). (2) However, the LLM answer claims that in fiscal 2024, Nike detailed a dedicated supply-chain structure — Air Manufacturing Innovation — with specific facilities in Oregon, Vietnam, Missouri, and contract partners in China and Vietnam. This level of operational detail about subsidiaries and manufacturing sites is not present in the ground truth and cannot be verified from the provided original answer; thus, it introduces potentially fabricated or unsupported specifics. (3) The multi-hop reasoning is flawed: while the original answer emphasizes a shift in narrative tone — from Nike Air as an innovative driver to a mature, integrated technology alongside Zoom, Free, and React — the LLM focuses on supply-chain integration as evidence of strategic evolution, which is a different interpretation not supported by the ground truth. The core insight about Nike Air transitioning to a foundational component is missed and replaced with a tangential point about manufacturing. (4) Therefore, while the answer is contextually relevant and factually plausible, it fails to accurately reflect the actual strategic shift described in the original answer, leading to a moderate correctness score. The qualitative accuracy is low due to incorrect reasoning and unsupported entity details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 479,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "In the 2022 Form 10‑K, Osmolite was presented simply as one of several “nutritional products used in enteral feeding in health‑care institutions,” listed together with Jevity, Glucerna, Oxepa, Freego, Nepro and Vital【ABT_10k_2022.pdf†page 5】.  \n\nBy the 2023 filing, Abbott had repositioned Osmolite as the lead, high‑calorie/high‑protein formula within a more tightly‑integrated enteral‑feeding portfolio – a portfolio that now groups Osmolite with Jevity and Glucerna under a unified clinical‑nutrition product‑line strategy aimed at streamlining offerings and emphasizing premium, specialty feeding solutions【ABT_10k_2023.pdf†page 4】.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its qualitative claims, despite being factually neutral on numbers (no numeric data was provided in either answer, so quantitative accuracy is not penalized). According to the ground truth, Abbott’s positioning of Osmolite remained stable between 2022 and 2023, with no indication of repositioning or strategic shift. The LLM incorrectly asserts that in 2023, Abbott repositioned Osmolite as the 'lead, high-calorie/high-protein formula' within a 'more tightly-integrated enteral-feeding portfolio' and that it was now grouped under a 'unified clinical-nutrition product-line strategy.' These strategic changes are not supported by the original answer or the knowledge graph. The original answer explicitly states that the product listing remained 'largely consistent' and that there was 'no indication of Osmolite being newly introduced, discontinued, or significantly repositioned.' The LLM fabricates a narrative of strategic repositioning and integration that is absent in the ground truth. This constitutes a major factual and reasoning error in the multi-hop assessment of Abbott's product strategy evolution. While the LLM correctly identifies Osmolite as part of the enteral feeding portfolio in both years and lists associated products, the core claim about strategic evolution is false. Thus, the correctness and qualitative accuracy scores are low. Contextual relevance is moderate because the answer addresses the right segment and timeframe but with incorrect interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 418,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "By the 2022 Form 10‑K, 3M’s PFAS work in Minnesota was governed by the 2007 Settlement Agreement and Consent Order with the Minnesota Pollution Control Agency, which required the company to evaluate releases, provide alternative drinking water when health‑based values were exceeded and remediate identified sources, while in Alabama it was operating under a voluntary remedial‑action agreement and a July 2020 interim consent order with the Alabama Department of Environmental Management that had already capped historic sludge areas and set out ongoing reporting, study and capital‑improvement commitments. The 2024 filing shows the same regulatory frameworks persisting but now adds new layers of engagement: in Minnesota the company is responding to MPCA‑issued draft Clean‑Water Act permits with tighter PFAS effluent limits and to the Minnesota Department of Health’s more stringent health‑based values, and in Alabama the interim consent order remains in force as the company continues off‑site investigations and prepares for additional remediation costs that could become probable and reasonably estimable. Thus, the obligations have shifted from primarily implementing established settlement actions to actively negotiating revised permits, meeting stricter health standards and preparing for expanded remediation work in both states.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of 3M's regulatory engagement and remediation obligations related to PFAS discharge in Minnesota and Alabama between 2022 and 2024. Quantitatively, all dates (2007 Settlement Agreement, July 2020 Interim Consent Order), regulatory agencies (MPCA, ADEM, MDH), and key actions (capping sludge areas, draft permit issuance in 2024) are correct. There are no numerical inaccuracies, and the timeline is preserved. The answer correctly identifies that in 2022, 3M was operating under established agreements—the 2007 Consent Order in Minnesota and the 2020 Interim Consent Order in Alabama—and that by 2024, these frameworks remained but were augmented by new regulatory pressures. The qualitative analysis is strong: it accurately reflects the shift from implementation to negotiation and adaptation, citing tighter effluent limits in Minnesota (draft CWA permit), updated health-based values from MDH, and ongoing investigations and anticipated costs in Alabama. One minor omission is that the original answer specifies MPCA issued a draft permit in 2024 and then a revised draft in December 2024 after public comment, which the LLM answer does not explicitly mention, though it broadly references responding to draft permits. Additionally, the original notes 3M submitted public comments in August 2024, which is absent in the LLM response. These are small but relevant details in the regulatory timeline. The LLM correctly synthesizes multi-hop information across years and jurisdictions, demonstrating sound reasoning. The answer is contextually relevant, directly addressing the evolution of obligations in both states. Overall, the response is factually correct, well-structured, and semantically equivalent to the ground truth with only minor omissions in procedural detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1711,
        "completion_tokens": 495,
        "total_tokens": 2207
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "Both the 2022 and the 2024 Form 10‑K report Coca‑Cola’s holding in Coca‑Cola HBC AG as an **equity‑method investment**.  The company’s ownership percentage has remained essentially the same – about **22 % of the outstanding shares** in both years (the 2024 filing states a 22 % stake, and the 2022 filing lists the same classification and percentage).  Thus, between 2022 and 2024 the investment’s accounting treatment and the size of the stake have not changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a significant factual error in quantitative accuracy: it claims that The Coca-Cola Company held a 22% stake in Coca-Cola HBC AG in 2022, but the ground truth explicitly states that the ownership percentage was not disclosed in the 2022 filings. The 22% stake was only formally disclosed in 2024. This misrepresents the evolution of the financial relationship by asserting continuity in disclosed stake percentage when, in fact, the key development is the new specificity in disclosure. While the answer correctly identifies that the investment was accounted for under the equity method in both years, it incorrectly asserts that the percentage was known and unchanged, which is not supported by the evidence. The reasoning is partially sound in recognizing the consistent classification, but fails on the multi-hop synthesis by not acknowledging the shift from undisclosed to disclosed stake — a central point in the original answer. Contextual relevance is high as the response addresses the core aspects of investment classification and stake percentage over time, but the critical error in numerical accuracy undermines the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 328,
        "total_tokens": 1572
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "By fiscal 2022 Oracle already positioned hybrid‑deployment (including its Cloud@Customer offering) as a cornerstone of its strategy and backed it with $7.2 billion of research‑and‑development spending to improve performance, security, integration and cost‑effectiveness across on‑premise and cloud‑based workloads. In the fiscal 2024 filing the company says that hybrid has moved from a “key pillar” to a “core growth engine,” raising its R&D budget to roughly $9 billion and deepening the integration of OCI services directly into customers’ data‑centers, so that workloads can run seamlessly on‑premise, in Oracle‑hosted cloud or in a hybrid mix. Thus, between 2022 and 2024 Oracle has increased its product‑development investment and tightened the technical integration of its hybrid deployment model.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's strategic emphasis on hybrid deployments in fiscal 2022 and 2024, including the role of Cloud@Customer and R&D investment. However, it introduces a new figure of $9 billion in R&D for fiscal 2024, which is not present in the ground truth; the original answer only confirms $7.2 billion was spent in fiscal 2022 and does not provide a 2024 R&D figure. This is a significant quantitative inaccuracy. (2) The ground truth does not mention any increase in the R&D budget or a specific $9 billion figure, so this claim cannot be verified and appears fabricated or incorrectly inferred. All other numbers (e.g., $7.2 billion in 2022) are accurate and properly contextualized. (3) The reasoning is strong: the LLM correctly synthesizes the evolution from hybrid as a strategic focus in 2022 to a more central role in 2024, noting deeper integration and positioning as a 'core growth engine'—a reasonable paraphrase of the original's 'integrated into core offerings.' The multi-hop logic across years and strategic shifts is sound and adds appropriate interpretation. (4) Contextual relevance is perfect—the answer directly addresses product development investment and deployment model integration as asked. Despite the incorrect 2024 R&D number, the qualitative evolution and strategic narrative align well with the ground truth. The correctness score is reduced due to the unsupported financial figure, but the overall structure, entity accuracy (Oracle, Cloud@Customer, fiscal years), and reasoning remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 431,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "In the 2023 Form 10‑K, Wells Fargo filed its Mandatory Clawback Policy as Exhibit 97, noting that the policy was effective October 2, 2023. The 2024 Form 10‑K lists the same Exhibit 97 with the identical effective date, showing that the policy was simply carried forward—its filing status did not change between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the Mandatory Clawback Policy was included as Exhibit 97 in both the 2023 and 2024 10-K filings and correctly notes the effective date of October 2, 2023, which aligns with the factual context. This supports a score of 8 for quantitative accuracy, as all dates and exhibit numbers are accurate. However, the key error lies in the interpretation of the filing status evolution: the LLM claims the policy was 'carried forward' and that 'its filing status did not change,' which directly contradicts the ground truth. In reality, there was a procedural change — in 2023, the policy was filed directly as Exhibit 97, while in 2024, it was incorporated by reference from the prior year’s filing rather than filed anew. This is a significant distinction in SEC disclosure practices, and the LLM fails to recognize or report this change, instead asserting no change occurred. This reflects a failure in multi-hop reasoning and qualitative accuracy, as the model does not correctly synthesize the procedural shift across years. While the entities (Wells Fargo, Exhibit 97, years) and dates are correct, and the response is contextually relevant to the question, the core conclusion is factually incorrect. Thus, the correctness score is 4 due to a major error in the central claim despite accurate supporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1167,
        "completion_tokens": 373,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "In 2023 Thermo Fisher moved from being a partner to an owner – it bought CorEvitas, LLC on August 14, 2023.  The deal was accounted for as a $910 million purchase (cash paid $730 million, $184 million of debt settled and a $4 million cash‑acquisition adjustment) and generated $627 million of goodwill (non‑tax‑deductible) and other intangible assets; the acquisition also contributed to the higher net‑interest expense reported for 2023. By the 2024 filing the CorEvitas transaction is no longer listed as a new acquisition, indicating the company had fully integrated the business and incurred no additional purchase‑price cash outflow in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, with only minor omissions. (1) Quantitatively, all key numbers are correct: the $910 million total purchase price (broken into $730M cash, $184M debt settled, $4M adjustment) matches the implied $0.91 billion in the original answer. The $627M goodwill is an additional detail not in the ground truth but does not contradict it. The date August 14, 2023, is more specific than the original (which only says 2023) but is factually consistent. (2) The original answer does not mention amortization over 18 years or integration into the Laboratory Products and Biopharma Services segment—these are missing in the LLM response, which slightly reduces completeness. However, the LLM correctly notes integration by 2024 (implied by no new acquisition listing), which aligns with the original's 'full acquisition' and integration claim. (3) The reasoning is sound: the evolution from investment to ownership is correctly framed as an acquisition, and financial implications (goodwill, interest expense, no further outflow in 2024) are logically tied to the transaction. (4) The LLM adds value by breaking down the purchase price, which the original lacks, but misses the 18-year amortization detail, a specific financial implication mentioned in the ground truth. Overall, the answer is factually correct, contextually relevant, and synthesizes multi-hop information (2023 acquisition → 2024 integration → financial effects), warranting a high score with a small deduction for incomplete financial implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 430,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "In the 2022 filing RTX disclosed that the “flight‑hour” payments required under its 2012 Rolls‑Royce acquisition agreement are  contingent on each V2500 engine hour flown through June 2027 and are **capitalized as collaboration intangible assets when actually paid** (i.e., they are not accrued). The table of “Other commercial aerospace commitments” shows that RTX expected to make **$735 million of these payments in 2022**, which increased to **$1,053 million in 2023** – the same capitalization treatment applied in both years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the dollar amounts. The ground truth states there was no indication of a change in the magnitude or timing of RTX's payment obligations between 2022 and 2023, but the LLM claims RTX expected to pay $735 million in 2022 and $1,053 million in 2023. These specific figures are not supported by the original answer and represent a major quantitative error. Additionally, the original answer does not mention any expected annual payment amounts, so these numbers appear to be fabricated or misattributed. (2) The dates (June 2027) and the capitalization treatment (capitalized as collaboration intangible assets when paid) are correctly identified and consistent with the ground truth. The contingent nature of payments based on V2500 engine flight hours is also accurately described. (3) The multi-hop reasoning is partially sound—LLM correctly identifies the link between the 2012 agreement, flight-hour payments, and accounting treatment across 2022 and 2023. However, it fails to correctly synthesize that the obligation structure remained stable; instead, it introduces unsupported numerical expectations that contradict the 'no change' conclusion in the ground truth. (4) The contextual relevance is high because the answer addresses the right entities, timeframes, and accounting treatment. However, the inclusion of false quantitative data severely undermines factual correctness, warranting a low overall score despite accurate qualitative elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 424,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "In the 2022 filing Coca‑Cola reported only the one‑time accounting impact of buying the remaining stake in fairlife – a $902 million gain that generated a $40 million tax benefit – and did not disclose any ongoing contingent‑payment obligation. By the 2024 filing the company is carrying a contingent‑consideration liability of roughly $6.1 billion for the “remaining milestone payment” that is payable in 2025 and is tied to fairlife meeting specified financial targets through 2024; the liability is re‑measured each quarter and a $275 million milestone payment was already made in 2023. Thus, the relationship has evolved from a simple acquisition to a performance‑based earn‑out arrangement with substantial future payments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details, despite capturing the general direction of the evolution in Coca-Cola's relationship with fairlife. (1) Correct elements: The answer correctly identifies that in 2022, no ongoing contingent payments were disclosed, and by 2024, a milestone payment tied to performance through 2024 and payable in 2025 was acknowledged—this aligns with the ground truth’s core narrative. (2) Quantitative errors: The $6.1 billion contingent liability is grossly exaggerated and factually incorrect; the ground truth does not specify the amount but no such figure appears in actual SEC filings—this number is likely confused with Coca-Cola’s total marketable securities or other liabilities. Similarly, the claim of a $275 million milestone payment made in 2023 is unsupported by the ground truth, which mentions no such interim payment. The $902 million gain and $40 million tax benefit, while possibly referencing real accounting entries, are not part of the ground truth and appear fabricated or misattributed. (3) Reasoning: The multi-hop synthesis—linking 2022 silence on contingencies to 2024 disclosure of a future milestone—is logically sound and correctly infers evolving financial obligations. However, the introduction of specific large-dollar payments and liabilities not in the original answer undermines the reasoning. (4) Contextual relevance is high because the answer addresses the evolution of contingent payments and performance milestones directly. However, due to severe quantitative inaccuracies and unsupported financial figures, the overall correctness is low. Minor entity and year references are accurate (Coca-Cola, fairlife, 2022–2025), but the financial details are not. Thus, correctness is scored low despite correct directional logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 496,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "By 2022 Oracle framed its Cloud Services primarily as a flexible, interoperable “SaaS + OCI” bundle that could be deployed on‑premise, in the public cloud or in hybrid‑cloud @ Customer models, stressing that OCI would “power” its Fusion SaaS applications and that the company was still in the early stages of moving its installed base onto the cloud. By the 2024 filing the narrative had shifted to a more mature, unified platform: Oracle now positions Cloud Services as a tightly integrated business‑innovation stack in which its SaaS applications are natively built on and run by the next‑generation Oracle Cloud Infrastructure, leveraging autonomous, AI‑enabled services and industry‑specific extensions while still supporting hybrid and on‑premise extensions, thereby deepening the coupling of enterprise applications with underlying infrastructure technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Oracle's 2022 positioning emphasized flexibility, interoperability, and deployment options (cloud, hybrid, on-premise), with OCI powering Fusion SaaS applications. By 2024, the narrative evolved to a more integrated, unified platform where SaaS applications are natively built on OCI, leveraging autonomous and AI-enabled services. These points match the original answer’s core claims. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no errors exist. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes Oracle’s strategic evolution across two time points, linking changes in cloud positioning with deeper integration between applications and infrastructure. It captures the shift from promoting standalone innovations (like Autonomous Database, implied via 'AI-enabled services') to a holistic platform, even if not explicitly naming the Autonomous Database. (4) The LLM uses different but semantically equivalent phrasing—e.g., 'tightly integrated business-innovation stack' conveys the same idea as 'comprehensive and integrated offerings' in the ground truth. The only minor gap is that the LLM does not explicitly mention the 'customer-centric' framing or the phrase about choosing 'the best option that meets their specific business needs' from the 2024 filing, but it does convey the same underlying idea of supporting hybrid and on-premise extensions while offering choice. Thus, the answer is slightly less complete in direct textual support but retains full factual and conceptual accuracy. Contextual relevance is perfect—directly addresses the evolution in strategic positioning with respect to integration of applications and infrastructure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 512,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "In the 2023 Form 10‑K the Key/Specified Employee Policy (Exhibit 10(r)) was **not filed as a separate document** – the filing simply stated that the policy was “incorporated by reference to Exhibit 10(v) to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018.”  \n\nIn the 2024 Form 10‑K the treatment changed: the policy is now **attached as its own exhibit (or incorporated by reference to a more recent annual report)** rather than being tied to the 2018 filing, showing that the company has moved the Key/Specified Employee Policy into the current filing package instead of relying on the older referenced document.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claims. (1) It incorrectly states that in the 2024 Form 10-K, the Key/Specified Employee Policy was either attached as a new exhibit or incorporated by reference to a more recent filing, implying a change in documentation practice. However, the ground truth confirms that in both 2023 and 2024, the policy continued to be incorporated by reference to the same Exhibit 10(v) from the 2018 filing, with no new amendments or updates. (2) The LLM also misidentifies the exhibit number: it refers to Exhibit 10(r) in 2023, while the original answer specifies Exhibit 10(v) in both years. This is a factual error in entity identification. (3) The multi-hop reasoning fails because the model incorrectly infers an evolution in treatment between 2023 and 2024 when the policy’s documentation remained static. The ground truth emphasizes continuity, not change. (4) While the answer addresses the question's focus on documentation and incorporation by reference, it draws the wrong conclusion about evolution, making it contextually relevant but factually flawed. Minor formatting differences in dollar amounts or dates are not at issue here, but the central facts—exhibit number, continuity of reference, and absence of updated documentation—are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 361,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The 6.700 % notes due 2028 carried an aggregate principal balance of **$285 million at the end of 2022** and **the same $285 million at the end of 2023**【RTX_10k_2022.pdf page 94】【RTX_10k_2023.pdf page 84】.  \n\nBecause the balance did not change, RTX neither retired nor added to this series of notes during the year, indicating a deliberate “hold‑steady” approach to that tranche of debt while concentrating refinancing and repayment activity on other maturities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its key quantitative claim. According to the ground truth, the aggregate principal balance of the 6.700% notes due 2028 was $115 million in 2022 and increased to $285 million in 2023. However, the LLM states the balance was $285 million at the end of both 2022 and 2023, which contradicts the ground truth. This error fundamentally misrepresents the evolution of the debt. (2) The cited documents (RTX_10k_2022.pdf and RTX_10k_2023.pdf) are correctly referenced, but the data extracted from them is inaccurate. The LLM incorrectly reports the 2022 balance, which should have been $115 million, not $285 million. This leads to a false conclusion about no change in balance. (3) The multi-hop reasoning is flawed because the model fails to correctly identify and compare the balance across the two years. The correct reasoning requires recognizing the increase from $115M to $285M, implying an issuance or expansion of debt. Instead, the LLM concludes a 'hold-steady' strategy based on incorrect data, leading to an invalid inference about RTX's debt management. (4) While the answer addresses the question's structure and attempts to interpret strategy, the severe quantitative inaccuracy undermines both factual correctness and logical reasoning. The contextual relevance is moderate because the response discusses the right metric and company, but the conclusion is based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 400,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "In 2023 the 1.95 % 12‑year senior notes (due 7 July 2029, euro‑denominated) were carried at **$773 million** with an **effective interest rate of 2.08 %**. By the end of 2024 their carrying amount had fallen to **$725 million** and the effective rate had slipped slightly to **2.07 %**. Thus, both the carrying value and the effective interest rate declined modestly from 2023 to 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value in 2023 is correctly stated as $773 million and in 2024 as $725 million; the effective interest rates are correctly reported as 2.08% in 2023 and 2.07% in 2024. Minor formatting differences (e.g., spacing in percentages, use of 'slipped slightly') do not affect factual accuracy. (2) The answer is complete, addressing both the carrying value and effective interest rate for both years as required by the question. (3) Entity accuracy is correct: TMO's 1.95% 12-Year Senior Notes are properly identified, and the years 2023 and 2024 are correctly referenced. The additional detail about the notes being euro-denominated and due July 7, 2029, while not in the original answer, is contextually appropriate and does not contradict any facts. (4) The reasoning is sound: the LLM correctly observes that both the carrying value and effective interest rate declined modestly, which aligns with the ground truth's interpretation of reduced financial liability and marginal improvement in borrowing cost. (5) The semantic meaning is equivalent to the original answer, with slightly more detail but no factual deviation. All evaluation criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 363,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon devoted a separate “Directors’ Code of Conduct” paragraph that identified the code, gave its web address and expressly promised to post any amendments or waivers to the code on the company’s website. By the 2024 filing the code is simply listed as one of the corporate‑governance documents incorporated by reference (along with the bylaws, governance guidelines, etc.) and the explicit amendment‑waiver notice is no longer included. The shift reflects a move toward a more consolidated, reference‑based governance disclosure, which streamlines reporting but reduces the explicit, stand‑alone commitment to publicly disclose future changes to the Directors’ Code of Conduct.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) All factual elements are correct: the 2022 filing included a dedicated paragraph with a direct URL and a commitment to post amendments or waivers, while the 2024 filing lists the Directors' Code of Conduct among other governance documents without a direct link or explicit amendment/waiver notice. These details match the ground truth. (2) There are no numeric values, dates, or financial metrics in dispute—both years (2022 and 2024) are correctly cited, and no calculations are required. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in disclosure practices across two filings and infers the implications—specifically, a shift toward consolidated, reference-based disclosure that reduces the visibility and explicit accountability around future changes to the Code. (4) The LLM captures the core governance implication: reduced transparency in how updates to the Code will be communicated, which affects stakeholder accountability. The only minor shortcoming is that it does not explicitly mention 'stakeholder engagement' or 'perceptions of governance accountability' as in the original, slightly reducing qualitative completeness. However, the semantic meaning and analytical depth are substantially equivalent. Wording differs but meaning is preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 383,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "- **Facility size:** Both the 2023 and the 2024 agreements provide a $5 billion unsecured 364‑day revolving credit facility – the amount has not changed.  \n- **Maturity date:** The 2023 Short‑Term Credit Agreement, signed in November 2023, matures in **October 2024** (with one possible 364‑day extension). The 2024 agreement, signed in October 2024, pushes the maturity out to **October 2025** (again with a single 364‑day extension).  \n- **Timing of establishment:** The original agreement was established in **November 2023** and was replaced a year later by a new agreement in **October 2024**.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitative accuracy: All numbers and dates are correct — facility size of $5.0 billion in both years, maturity dates of October 2024 (for the 2023 agreement) and October 2025 (for the 2024 agreement), and establishment dates in November 2023 and October 2024. The 364-day term and extension clause are accurately noted. (2) Completeness: The answer addresses all three components of the question — facility size, maturity date, and timing of establishment — for both years. (3) Entity accuracy: Amazon is correctly identified, and the agreements are properly attributed to their respective years. (4) Reasoning: The LLM correctly infers a procedural renewal pattern, though this explicit conclusion is not required; the factual progression is sound and implies correct multi-hop synthesis between the two agreements. (5) Semantic equivalence: Despite slightly different phrasing, the meaning and factual content are identical to the original answer. No errors in facts, calculations, or logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 306,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "In 2022 AMD’s APU roadmap was centered on “value and mainstream” PCs, with the APU defined simply as a single‑die CPU + GPU that “delivers visual‑processing functionality for value and mainstream PCs by integrating a CPU and a GPU on a single chip”【AMD_10k_2022.pdf page 9】. By 2024 the strategy had shifted to AI‑focused APUs: AMD “was the first company to integrate a dedicated neural‑processing unit (NPU) on the same SoC as an x86 CPU for AI PCs” and it launched the Ryzen AI 300 series (and the Zen 4‑based 8000‑series mobile processors) that pair a Zen 5 or Zen 4 CPU with an on‑die NPU for next‑generation AI PCs【AMD_10k_2024.pdf page 5】. This move expands the target market from low‑to‑mid‑range desktops to premium consumer and commercial “AI PC” segments, giving AMD a new, higher‑margin product line that can capture the fast‑growing AI‑enabled PC demand and therefore boost revenue potential in that segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies AMD's 2022 APU strategy as focused on value and mainstream PCs with integrated CPU-GPU dies, and the 2024 shift to AI-centric APUs with dedicated NPUs. The claim that AMD was the first to integrate an NPU on the same SoC as an x86 CPU for AI PCs matches the original answer exactly. (2) There are no numeric values (e.g., revenue figures, percentages) in either answer, so quantitative accuracy is not compromised—dates (2022, 2024) and product names (Ryzen AI 300, Zen 4/5, 8000-series) are correct and consistent with known public data. (3) The multi-hop reasoning is sound: the model synthesizes strategic shifts across years, identifies the technological evolution (adding NPU), and infers market expansion from mainstream to premium AI PC segments. It correctly links this to higher-margin opportunities and increased revenue potential in the AI PC segment. (4) The only minor shortcoming is that the LLM answer does not explicitly mention AMD’s prior focus on external GPU solutions (e.g., Instinct MI200, Radeon PRO V620) in 2022 for data center/cloud AI, which provides fuller context for the strategic pivot. However, this omission does not invalidate the core correctness, as the focus of the question is on APU strategy evolution in client devices. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 399,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "Both the 2023 and the 2024 Form 10‑K contain the same statement on Irish taxes for U.S. shareholders. In each filing Medtronic notes that Irish dividend withholding tax (currently 25 %) does **not** apply to U.S. residents who (i) have a U.S. address on the broker’s records for shares held through DTC, or (ii) provide a valid U.S. Certification of Residence (Form 6166) or Irish Non‑Resident Form V2 to the transfer agent. If a U.S. shareholder were subject to the withholding tax, the tax withheld would satisfy any Irish income‑tax liability on that dividend. Thus, the treatment of Irish income‑tax liability for U.S. shareholders – the exemptions and the discharge of liability by the withholding payment – did not change between the 2023 and 2024 filings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely matches the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate, the exemption criteria for U.S. residents (Form 6166 or Form V2), and the fact that withholding tax satisfies any Irish income tax liability. The statement that there was no change between 2023 and 2024 is correctly inferred. (2) Quantitative accuracy is perfect: the 25% rate is correctly cited, and no incorrect numbers are present. (3) The reasoning is sound—LLM correctly synthesizes information from both years’ 10-K filings and draws the appropriate conclusion about regulatory stability. The only minor omission is that the original answer specifies that shareholders not holding through an Irish branch generally have no liability, which adds a small but relevant structural detail not mentioned in the LLM response. This does not affect the core conclusion but slightly reduces completeness. (4) The answer is highly relevant, directly addressing the evolution (or lack thereof) in tax treatment. Overall, the LLM conveys the same semantic meaning as the ground truth with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 323,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk‑factor sections flag “new lines of business, new products and services or transformational or strategic project initiatives” as creating new or additional risks, and each warns that failure to implement those initiatives could hurt results of operations. In both years the company also specifically calls out its “transition to a platforms operating model,” stating that it may not realize all of the expected benefits and that this shortfall would be a material risk. The wording is essentially unchanged, showing a consistent emphasis on the platforms‑operating‑model initiative as a key risk associated with new products and services.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in its qualitative claims, despite having no numeric errors (as the question does not involve numbers, dates, or calculations). (1) The key error is the claim that BNY Mellon specifically mentioned the 'transition to a platforms operating model' in both 2022 and 2024. According to the ground truth, in 2022 the company only discussed general risks around new products, services, and strategic initiatives, without mentioning the platforms operating model. It was only in 2024 that this specific initiative was called out as a distinct risk. The LLM incorrectly states that the 'wording is essentially unchanged' and that the platforms operating model was referenced in both years, which contradicts the evolution described in the original answer. (2) There are no quantitative elements to verify, so quantitative accuracy is scored as 10. (3) The multi-hop reasoning is flawed: the question asks how risk disclosures evolved, requiring correct synthesis across two time points. The LLM fails this by asserting consistency where there was actually a meaningful shift—from general strategic risk language in 2022 to a specific, named risk around platform implementation in 2024. (4) Contextual relevance is moderate because the answer addresses the right topic (risk disclosures around new products and the platforms initiative) and the correct company, but misrepresents the core evolution. Due to the central factual error about the timing and specificity of the risk disclosure, the correctness and qualitative accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 434,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "In the 2023 Form 10‑K Amazon listed the 3.600 % Note due 2032 as one of the securities covered by the Supplemental Indenture dated April 13 2022 (Exhibit 4.2) and noted that the detailed debt‑instrument agreements were not filed because they represent less than 10 % of the company’s assets, but could be furnished on request. The 2024 Form 10‑K repeats the same disclosure—Exhibit 4.2 still contains the 3.600 % Note due 2032 and the same “not filed” footnote remains—indicating that the note remains outstanding and Amazon’s reporting of it has not materially changed.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 3.600% Note due 2032 and the Supplemental Indenture dated April 13, 2022, as well as the consistent disclosure in both 2023 and 2024 Form 10-Ks, including the fact that detailed agreements were not filed due to the <10% asset threshold. These factual elements are accurate. However, the LLM fails to capture the key evolution highlighted in the ground truth: the trustee transition from Wells Fargo Bank, National Association (prior trustee) to Computershare Trust Company, National Association (successor trustee), and the 2024 simplification of the trustee reference to only Computershare, indicating a formal administrative shift. This omission represents a significant gap in addressing the core of the question—how the relationship evolved in terms of debt instrument disclosures. (2) Quantitative accuracy is high: the interest rate (3.600%), maturity year (2032), and date of the Supplemental Indenture (April 13, 2022) are all correct. No calculations are required, and the LLM accurately reports the exhibit number (4.2) and disclosure policy. (3) The reasoning is partially sound—while the LLM correctly notes consistency in filing practices and the note’s ongoing status, it misses the multi-hop synthesis between the two years regarding the trustee change, which is central to the evolution of the debt relationship. The model treats the disclosures as static when the ground truth identifies a procedural evolution. (4) Contextual relevance is strong as the response stays focused on Amazon’s debt disclosures and the specific note, but the failure to identify the trustee transition undermines the qualitative accuracy and overall correctness, resulting in a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 473,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "In the 2023 filing MDLZ reported its net‑investment‑hedge (NIH) derivatives as $163 million of assets versus $382 million of liabilities, producing a net‑liability of roughly $‑219 million that was reflected as an after‑tax loss of $185 million (recorded in “Other income, net” and excluded from hedge‑effectiveness testing). By the 2024 filing the same contracts were shown with $305 million of assets and only $50 million of liabilities – a net‑asset position of about $255 million – and the fair‑value tables now list a positive “Net investment hedge contracts” line, with the resulting gain now contributing positively to “Other income, net.” Thus the disclosure shifted from a net‑liability presentation with a loss impact in 2023 to a net‑asset presentation that adds earnings in 2024, both still disclosed in Note 10 (Financial Instruments) and in the derivative‑fair‑value and other‑income tables.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the actual disclosures. According to the ground truth, in 2023 MDLZ disclosed $1,347 million in other current assets and $250 million in other assets for derivative assets, with $377 million and $413 million in liabilities for 2023 and 2022 respectively. The LLM incorrectly reports net figures of $163 million assets vs $382 million liabilities in 2023 and $305 million assets vs $50 million liabilities in 2024—none of which appear in the original answer or align with the disclosed values. There is no mention of a net liability of $219 million or a net asset of $255 million in the ground truth. Additionally, the claim of an after-tax loss of $185 million recorded in 'Other income, net' is not supported by the original answer. (2) The quantitative inaccuracies are severe: the LLM invents precise numbers (e.g., $163M, $382M, $305M, $50M, $185M) that do not match the ground truth's $1,347M, $377M, $250M, $413M. These are not formatting differences but entirely different values. The calculation of net positions and implied gains/losses is therefore also incorrect. (3) The qualitative reasoning partially captures a shift in disclosure emphasis—from balance sheet valuation in 2023 to income statement impact in 2024—which aligns with the ground truth’s point about 2024 focusing on 'Other income, net' and amounts excluded from hedge effectiveness. This shows some correct multi-hop synthesis regarding presentation evolution. However, the reasoning is built on false numerical premises. (4) Contextual relevance is moderate because the answer addresses the right topic (evolution of NIH hedge disclosure) and correctly identifies the relevant financial statement areas (Note 10, fair value tables, 'Other income, net'). But due to major factual and numerical errors, the correctness score is low despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 522,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "In 2023 General Dynamics emphasized the rollout of the next‑generation System Enhancement Package 3 (SEPv3) for the M1A2 Abrams and the launch of the M1E3 engineering‑change program, which introduces a new systems‑architecture that enables faster technology inserts, lower sustainment costs and greater mobility. By 2024 the narrative had shifted to a broader “overmatch” modernization effort that builds on those upgrades while stressing that demand from NATO members and other allies across Europe, the Middle East, North Africa and the Indo‑Pacific remains strong, driving continued production and export of upgraded Abrams tanks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, General Dynamics advanced the SEPv3 upgrades (communications, power, optics, armor) and initiated the M1E3 program with a new systems architecture for faster tech insertion and reduced sustainment—this is accurately reflected. By 2024, the focus shifted to broader strategic relevance and growing international demand across Europe, the Middle East, North Africa, and the Indo-Pacific, which the LLM correctly captures using the term 'overmatch' and citing strong allied demand. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023, 2024) are correct. (3) Multi-hop reasoning is sound: the model synthesizes technological development (SEPv3 and M1E3) with evolving strategic emphasis (international demand and production momentum), correctly inferring the shift in narrative from technical roadmap to global relevance. (4) Semantic equivalence is strong; minor wording differences (e.g., 'overmatch' modernization effort not explicitly in original) do not detract from factual accuracy. The only reason for not scoring a 10 is that the LLM omits explicit mention of fuel efficiency and armor upgrades in SEPv3, which were listed in the original, making it slightly less complete—hence a 9 on qualitative accuracy. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 410,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "In the 2022 filing AMD described its APUs chiefly as “integrated CPU‑GPU chips that deliver visual‑processing capability for value‑ and mainstream‑class PCs and notebooks,” positioning them as a cost‑effective way to add graphics to consumer‑grade platforms. By the 2024 filing the company has moved the APU into several reportable segments – the Client segment (desktop and notebook), the Data‑Center segment (as accelerated processing units) and the Embedded segment – and emphasizes its role in heterogeneous, AI‑enabled computing, showing a strategic shift from a primarily consumer‑focused product to a broader, enterprise‑oriented platform component.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately captures the evolution of AMD's APU strategy from 2022 to 2024: in 2022, APUs were positioned as integrated CPU-GPU chips for value and mainstream PCs, which matches the general consumer focus in the original answer. By 2024, the LLM correctly identifies the expanded role of APUs across multiple segments. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The qualitative accuracy is slightly reduced because the LLM states that APUs were included in *three* segments—Client, Data Center, and Embedded—while the ground truth specifies only two: Client and Data Center. The 2024 filing does not explicitly place APUs in the Embedded segment, so this is a minor overstatement. However, the core reasoning about strategic shift toward enterprise and AI-enabled computing is sound and reflects proper multi-hop synthesis across years and segments. (4) The answer is highly contextually relevant, directly addressing market segmentation and strategic emphasis. Despite the minor error in segment count, the overall factual content and interpretation are strong, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 340,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Medtronic’s 10‑K filings for both fiscal 2023 and fiscal 2024 contain the same “Irish Restrictions on Import and Export of Capital” paragraph. In each year the company states that under the Financial Transfers Act 1992 the Irish Minister for Finance may restrict financial transfers between Ireland and any third country and that the list of restricted jurisdictions is “subject to ongoing change.” No new language or additional detail was added in the 2024 filing, so the disclosure on the Act’s implications remained essentially unchanged from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Medtronic's disclosure remained 'essentially unchanged' between 2023 and 2024, directly contradicting the ground truth. The ground truth states that while the regulatory framework was still disclosed in 2024, the emphasis on the 'dynamic nature' of the list of restricted countries was removed, indicating a shift in focus or stabilization. However, the LLM asserts that the exact same language — including the phrase 'subject to ongoing change' — appeared in both years, which contradicts the original answer’s assertion that this emphasis was dropped in 2024. There are no numerical values to verify, so quantitative accuracy is not applicable beyond correct mention of years (1992, 2023, 2024), which are accurate. Entity accuracy is correct: Medtronic, Financial Transfers Act 1992, Ireland, third countries, and correct fiscal years are all properly identified. Contextual relevance is high — the response addresses the right topic and structure. However, the qualitative reasoning fails: it does not reflect the evolution described in the ground truth and incorrectly claims textual consistency. This represents a significant error in multi-hop reasoning, as the model must detect subtle changes in disclosure tone and content over time, not just literal text repetition. The answer misses the nuanced evolution, leading to a low correctness and qualitative accuracy score despite accurate entities and dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 405,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "In the 2023 Form 10‑K Gulfstream’s G700 was still a “next‑model” aircraft that had not yet been certified – the filing said the company expected the G700 to enter service after receiving FAA certification in early 2024【GD_10k_2023.pdf page 5】.  \n\nThe 2024 Form 10‑K shows that certification was achieved and production has now begun: inventories rose “primarily due to the ramp‑up in production of new Gulfstream aircraft models, **including the G700 that began deliveries in the second quarter of 2024**”【GD_10k_2024.pdf page 70】.  \n\nThus, the G700 moved from a pending‑certification status in 2023 to an active production and delivery phase in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reflects the status of the G700 in 2023 as a forthcoming model pending FAA certification, with expected entry into service in early 2024, citing the correct document and page. (2) For 2024, it correctly states that the G700 began deliveries in the second quarter, supported by a direct quote from the 2024 10-K about production ramp-up and deliveries, again with accurate source citation. (3) The multi-hop reasoning is sound: it synthesizes information across two years of SEC filings to show the evolution from pre-certification to active production and delivery. (4) All entities (G700, Gulfstream, FAA, GD) and timeframes (early 2024 certification, Q2 2024 deliveries) are correctly identified and logically connected. There are no factual errors, omissions, or misinterpretations. The answer is semantically equivalent to the original, with clear, concise, and precise language. Minor formatting differences (e.g., 'second quarter of 2024' vs 'second quarter') do not affect accuracy. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 318,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "In the 2023 filing PMI reported that it had **renewed and extended** its exclusive, worldwide‑outside‑Korea collaboration with KT&G through 2038, positioning the partnership as a long‑term licensing and distribution framework that gave PMI access to KT&G’s smoke‑free brands and pipeline. By the 2024 filing the relationship had moved from a purely contractual arrangement to an **operational one**, with KT&G‑licensed heat‑not‑burn products (Fiit and Miix) now listed as part of PMI’s heat‑not‑burn portfolio and contributing to net‑revenue, indicating that PMI’s smoke‑free strategy has become more dependent on KT&G’s product innovation and that those products are actively commercialized worldwide.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2023 announcement of a long-term, exclusive worldwide agreement (excluding South Korea) with KT&G, the 15-year term through 2038 (specifically January 29, 2038 in the original), and the evolution by 2024 into deeper integration. The LLM correctly identifies that KT&G's products (specifically naming Fiit and Miix, which are accurate brand names) are now part of PMI's heat-not-burn portfolio and contribute to net revenue—this reflects the shift from distribution to strategic dependency. (2) Quantitative accuracy is perfect: the 2038 end date is correctly cited (though the exact start date January 29, 2023 is omitted, this is a minor detail), and no numerical errors are present. (3) Multi-hop reasoning is sound: the model synthesizes information across 2023 and 2024 filings to show evolution from licensing to operational integration, correctly inferring strategic dependency from product inclusion and revenue contribution. (4) The only minor shortcoming is the use of 'renewed and extended'—the original answer states PMI 'announced' the collaboration, not that it was a renewal, which may imply an existing prior agreement more strongly than justified. However, this does not materially distort the factual timeline. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 400,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "In the 2022 filing AMD treated its semi‑custom System‑on‑Chip business mainly as a **transaction‑driven revenue source** – it earned non‑recurring engineering fees and product sales that were “directly related to sales of the third‑party’s products” and its success depended on customers’ ability to market those products (Item 1A, Risk Factors, p. 23‑24).  \n\nBy the 2024 filing the company had **re‑positioned semi‑custom SoCs as a strategic pillar of its broader portfolio**, describing them alongside Adaptive SoCs, APUs and AI accelerators and emphasizing that they are built on the “custom‑ready chiplet platform and AMD Infinity Architecture” to be tightly integrated with the data‑center, client, gaming and embedded ecosystems and with AMD’s AI‑software stack (Item 1, Business, p. 3‑5).  \n\nThus, AMD moved from viewing semi‑custom SoCs chiefly as a niche, customer‑dependent revenue line in 2022 to a core, ecosystem‑wide offering that supports its AI‑centric, cross‑segment strategy in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly captures the evolution in AMD's strategic positioning of semi-custom SoCs from 2022 to 2024: in 2022, the business was transaction-driven and dependent on third-party product success, with revenue tied to non-recurring engineering fees and customer product sales. By 2024, it was repositioned as a strategic pillar integrated into broader ecosystems. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2024), identifies the shift in strategic framing (from dependency to integration), and correctly references integration with AI accelerators, APUs, chiplet platforms, and AMD Infinity Architecture. It also correctly links the evolution to AMD’s AI-centric, cross-segment strategy. (4) The LLM adds contextual precision by referencing specific sections of the filings (Item 1A, Risk Factors, p. 23-24 for 2022; Item 1, Business, p. 3-5 for 2024), enhancing credibility. Wording differs slightly but meaning is preserved and enriched—e.g., 'transaction-driven revenue source' aligns with 'dependent on third-party product success'; 'core, ecosystem-wide offering' matches 'core components of a broader, more integrated product ecosystem'. All entities (AMD, semi-custom SoCs, AI accelerators, APUs, x86 CPU, NPU) and timeframes (2022, 2024) are accurate. The answer fully addresses the question’s focus on strategic positioning and ecosystem integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1508,
        "completion_tokens": 456,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K explain that Irish dividend‑withholding tax (currently 25 %) is not imposed on U.S. shareholders when the shares are held through the Depository Trust Company with a U.S. address on the broker’s records, or when the shareholder furnishes a valid U.S. Certificate of Residence (Form 6166) or Irish non‑resident Form V2. The 2024 filing adds a clarification that, if the withholding tax does apply, the tax withheld fully satisfies any Irish income‑tax liability on the dividend, and that U.S. shareholders who meet the exemption criteria will therefore have no Irish income‑tax exposure. Thus, the exemption rules remain the same, but the 2024 disclosure more explicitly states that the withholding tax discharges any Irish income‑tax obligation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate is accurately stated and confirmed as unchanged between 2023 and 2024; the conditions for exemption (holding through DTC with U.S. address, or providing Form 6166 or Form V2) are consistent with Medtronic’s disclosures. (2) Quantitative accuracy is perfect: the 25% rate is correctly cited, and no erroneous numbers are introduced. (3) The multi-hop reasoning is sound—LLM correctly synthesizes the evolution from 2023 to 2024, noting that while exemption criteria remained stable, the 2024 filing added clarity on post-withholding tax treatment. The LLM accurately captures that withholding tax, when applied, fully discharges Irish income tax liability, which matches the ground truth’s point about furnishing a statement to Irish Revenue to settle further liability. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'Irish branch' condition noted in the 2024 update (i.e., exemption applies when shares are not held through an Irish branch), which slightly reduces completeness in qualitative accuracy. However, the core message about no additional tax liability and clarified procedures is preserved. Wording differs but semantic equivalence is maintained. Contextual relevance is excellent—directly addresses exemptions, withholding obligations, and year-over-year evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 401,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "In 2023 General Dynamics’ Marine Systems segment saw ship‑construction revenue rise on higher Columbia‑class submarine volume, but its operating margin fell because supply‑chain‑driven cost growth hit the Virginia‑class submarine schedule and the Arleigh Burke (DDG‑51) destroyer program. For 2024 the company is projecting ship‑construction revenue of roughly $12.8‑$12.9 billion and an operating margin of about 7.6%, reflecting a strategic emphasis on the Columbia‑class program’s growth while the earlier cost‑pressure concerns on the Virginia‑class and DDG‑51 are no longer highlighted in the outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: the 2023 revenue increase due to the Columbia-class program, margin pressure from supply chain issues on the Virginia-class and DDG-51 programs, and the 2024 projected revenue range of $12.8–12.9 billion with a ~7.6% operating margin. (2) Quantitative accuracy is perfect: the dollar amounts and margin percentage match the original answer exactly, with acceptable formatting (e.g., $12.8-$12.9 billion). (3) Multi-hop reasoning is sound—correctly linking 2023 cost pressures to specific programs and contrasting with 2024's improved outlook, implying strategic focus on Columbia-class growth. (4) The only minor shortcoming is that the LLM omits the explicit mention of a '110 basis point decline' in margin from 2023, which is a specific detail present in the ground truth. While the margin decline is implied, the precise magnitude is not stated, slightly reducing qualitative completeness. However, this does not undermine the overall correctness. The answer remains contextually excellent, directly addressing all parts of the question with accurate synthesis across years and programs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 340,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "Booking Holdings’ reliance on Booking.com’s accommodation‑reservation business stayed essentially flat. In both 2022 and 2023, about 89 percent of total revenue came from online accommodation reservation services, indicating no material change in the proportion of revenue derived from Booking.com’s core bookings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that 89% of BKNG's revenue came from Booking.com's accommodation reservations in both 2022 and 2023, matching the ground truth exactly. There are no errors in numbers or time periods. (2) The percentage (89%) and years (2022, 2023) are accurate and consistent with the original answer. No calculations were required beyond comparison, which is correctly interpreted as 'no material change' or 'essentially flat', aligning with the ground truth's observation of unchanged dependency. (3) The multi-hop reasoning is sound—synthesizing that the same percentage across two years implies stable dependency is logically valid and correctly captures the evolution (or lack thereof). The model correctly identifies BKNG's financial dependency via revenue proportion from a specific service (accommodation reservations) under Booking.com. (4) The only minor shortcoming is that the LLM answer does not explicitly state that this indicates a 'slightly increased' dependency as implied in the original answer's phrasing ('remained high but slightly increased'), though the data itself (89% both years) contradicts 'slightly increased'. Given that the numerical evidence supports 'no change', the LLM answer is arguably more factually precise than the original. Thus, the correctness score is 9 due to perfect quantitative accuracy and strong qualitative reasoning, with a point deducted only for slight divergence in interpretive tone, not factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 411,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "In the 2023 filing the company reported a Swiss‑franc note of $299 million (1.625% interest, maturing in 2024). By the 2024 filing that line is blank, showing the note had been repaid and no longer appears on the balance sheet. This removal eliminates the related Swiss‑franc exposure, indicating the company has reduced its foreign‑currency debt obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $299 million Swiss Franc note in 2023 and its complete removal by 2024, matching the ground truth. It adds specific details not in the original answer—1.625% interest rate and maturity in 2024—which are plausible and do not contradict the ground truth, assuming they are present in the filing. These additions enhance precision without introducing error. (2) Quantitatively, the $299 million figure is accurate, and the conclusion that the note was removed (i.e., repaid or settled) by 2024 is supported by the absence of the liability in the subsequent filing. No calculations are required, but the inference from 'blank line' to removal is valid. (3) The multi-hop reasoning is sound: the model compares the 2023 and 2024 filings, infers the obligation's resolution, and connects it to reduced foreign currency exposure—aligning with the ground truth's conclusion about strategic shift. The only minor gap is not explicitly stating 'restructured' as a possibility (only 'repaid'), but 'repaid' is the most straightforward interpretation and is reasonable. (4) The answer is contextually fully relevant, directly addressing the evolution of the Swiss Franc note and its implications. The slight narrowing of 'repaid' versus the original's broader 'repaid or restructured' prevents a perfect 10, but the core facts, reasoning, and implications are correct and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 395,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the exhibit list included a legacy “pre‑2015” Non‑Employee Director RSU Award Agreement (Exhibit 10.8) together with a current standard form (Exhibit 10.31) and a cash‑settled version (Exhibit 10.32), plus an amendment to earlier director equity awards (Exhibit 10.17).  \n\nIn the 2024 Form 10‑K the legacy form is renumbered as Exhibit 10.9, a new standard Non‑Employee Director RSU Award Agreement appears as Exhibit 10.18, and the cash‑settled version is now shown as Exhibit 10.33, indicating that Goldman Sachs added a distinct cash‑settled agreement and reorganized/updated the standard director RSU award documentation.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) The 2023 10-K did not include a 'current standard form' (Exhibit 10.31) or a 'cash-settled version' (Exhibit 10.32) as claimed—the only referenced RSU agreement was the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8. The LLM incorrectly invents multiple exhibits not present in the ground truth. (2) The 2024 filing did not introduce a 'new standard Non-Employee Director RSU Award Agreement' as Exhibit 10.18; instead, Exhibit 10.18 was titled 'Amendments to Certain Non-Employee Director Equity Award Agreements', which is a different type of document focused on amendments, not a new award agreement. (3) The renumbering of the legacy form from Exhibit 10.8 to 10.9 is not supported by the ground truth, which states the pre-2015 form was retained but does not specify renumbering. (4) The claim about a 'distinct cash-settled agreement' and reorganization of documentation is entirely fabricated—no such exhibit or change is mentioned in the original answer. (5) The multi-hop reasoning fails because the LLM misidentifies key exhibits and their content, leading to an incorrect conclusion about the evolution of Goldman Sachs' treatment. While the answer attempts to address the question’s focus on changes between years, it does so with incorrect entities and documentation, undermining both quantitative and qualitative accuracy. The contextual relevance is moderate because it discusses the right topic (RSU agreements and exhibit changes), but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 439,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "In the 2023 filing PMI reported €6.1 billion of Euro‑credit‑facility borrowings that were expressly tied to financing the Swedish Match AB acquisition. By the end of 2024 that obligation had fallen to roughly €2.6 billion because PMI prepaid the entire €3 billion 3‑year tranche of the senior unsecured term‑loan facility in November 2024, leaving only the 5‑year tranche (the €2.5 billion portion) outstanding.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the figures are correct in substance: $6,121 million in 2023 and $2,610 million in 2024 from the original answer correspond closely to the LLM's €6.1 billion and €2.6 billion, respectively. Minor rounding is acceptable (€6.1B ≈ $6.121B; €2.6B ≈ $2.610B), and currency differences (EUR vs USD) are contextually reasonable given PMI's reporting in euros for euro-denominated debt. The LLM adds specific detail about the prepayment of a €3 billion 3-year tranche in November 2024, which explains the reduction and is consistent with the debt decline. (2) The answer is complete: it addresses the evolution of long-term debt obligations between 2023 and 2024, identifies the acquisition link, and explains the reason for the decrease. (3) Entities are accurate—PMI (PM), Swedish Match AB, correct time frame (2023–2024), and financial instrument (senior unsecured term-loan facility). (4) The reasoning is sound and demonstrates multi-hop synthesis: it connects the acquisition financing to specific debt tranches, identifies a key repayment event, and logically explains the drop in obligations. The only minor shortcoming is that the original answer does not specify the November 2024 prepayment, so while the LLM’s detail may be correct, it goes beyond the ground truth without confirmation. However, this does not contradict the truth and enhances explanation. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 421,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "In the 2023 filing Bristol Myers Squibb’s KRAS strategy was still pre‑commercial – the company highlighted KRAS inhibition as a priority therapeutic area but relied on external collaborations and early‑stage programs, with no KRAS‑targeted product in its own portfolio. By the 2024 filing the strategy had shifted dramatically after the $4.8 billion acquisition of Mirati, which gave BMS ownership of Krazati (sotorasib), a best‑in‑class FDA‑approved KRAS‑G12C inhibitor, and added several additional KRAS candidates, turning KRAS inhibition from a pipeline focus into a commercial platform and a cornerstone of its oncology growth plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of BMY's strategic positioning around KRAS inhibition from 2023 to 2024. It accurately states that in 2023, BMY had no KRAS-targeted product and relied on early-stage or collaborative efforts, and that in 2024, the $4.8 billion acquisition of Mirati brought Krazati (sotorasib) into its portfolio. The answer correctly identifies Krazati as an FDA-approved KRAS G12C inhibitor and notes the strategic shift from pipeline focus to commercial platform. However, it refers to Krazati as 'sotorasib', which is incorrect—sotorasib is Amgen’s drug (Lumakras); Krazati is adagrasib. This is a factual error in entity identification. Additionally, while the original answer notes two FDA approvals (NSCLC and colorectal cancer), the LLM answer omits the colorectal cancer indication and the combination development with a PD-1 inhibitor, representing a minor omission in completeness. (2) Quantitatively, the $4.8 billion acquisition amount is correct and matches the ground truth. No other numbers or dates are misstated. (3) The multi-hop reasoning is sound: the model correctly synthesizes the change in strategy across years, links the acquisition to the addition of Krazati, and infers the strategic significance. The error in drug naming slightly undermines the qualitative accuracy. (4) Despite the drug name mix-up and missing therapeutic indication, the overall answer conveys the core strategic evolution accurately and is highly relevant to the question, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 425,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "In the 2023 Form 10‑K (exhibit list on pages 3‑7) Goldman Sachs disclosed the **Amended and Restated Restricted Partner Compensation Plan** simply as Exhibit 10.4 – “The Goldman Sachs Amended and Restated Restricted Partner Compensation Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10‑Q for the period ended February 24, 2006).”  \n\nIn the 2024 Form 10‑K (exhibit list on pages 243‑247) the same plan appears again as Exhibit 10.4, but it is now presented together with a **new Clawback Policy** (Exhibit 10.1, effective December 1, 2023) and other updated compensation‑governance documents (e.g., the 2021 Stock Incentive Plan). This placement signals that the Restricted Partner Compensation Plan is now explicitly governed under the newer compensation‑governance framework introduced in 2023, rather than being listed in isolation as in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities are correct: Goldman Sachs, Restricted Partner Compensation Plan, Exhibit numbers (10.4 in both years), Clawback Policy as Exhibit 10.1 effective December 1, 2023. The reference to the 2021 Stock Incentive Plan adds context without introducing error. (2) Quantitative accuracy is perfect: dates (December 1, 2023), exhibit numbers (10.1, 10.4), and years (2023, 2024) are all factually correct. The LLM correctly notes the plan was re-listed as Exhibit 10.4 in 2024, matching the ground truth (though ground truth initially says 10.3 in 2023 — this appears to be a discrepancy in the original answer; the LLM’s 10.4 is consistent with actual filings). (3) Multi-hop reasoning is sound: the model infers from exhibit placement and the introduction of the Clawback Policy that there is a strategic repositioning toward stronger governance, which matches the original answer’s conclusion. (4) The only minor shortcoming is that the LLM does not explicitly mention the *relative shift in placement* (from early to later in the exhibit list), a detail emphasized in the ground truth. However, it compensates by correctly interpreting the significance of co-locating the plan with newer governance documents, which supports the same conclusion. Wording differs but semantic meaning and factual content are equivalent. No irrelevant or incorrect information is introduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 401,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "In the 2022 filing PMI still treated heat‑not‑burn as a separate, clearly defined product class – “Heated Tobacco Units (HTU)” – and listed the many brand families (HEETS, Marlboro HeatSticks, TEREA, etc.) that fell under that label. By the 2023 filing the company had folded those items into a broader “smoke‑free products” category (reported as “Smoke‑free products excluding Wellness and Healthcare”) and only briefly notes that its heat‑not‑burn line includes licensed KT&G products, showing that the heat‑not‑burn portfolio is now integrated into the overall smoke‑free business rather than being reported as a distinct product group.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Philip Morris International (PMI) treated heat-not-burn products as a distinct category, specifically 'Heated Tobacco Units (HTUs)', with brand examples like HEETS and Marlboro HeatSticks, which matches the original answer. In 2023, it accurately notes the re-categorization under a broader 'smoke-free products' grouping, though it adds the clarification 'excluding Wellness and Healthcare', which is consistent with PMI's reporting structure and does not contradict the ground truth. (2) There are no numerical values in this question, so quantitative accuracy is not applicable in the traditional sense, but all dates (2022 and 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in product categorization and business integration across two years, correctly inferring that folding HTUs into a broader category indicates deeper business integration. It also correctly notes the inclusion of licensed KT&G products in 2023, a key detail from the ground truth. (4) The only minor shortcoming is that the LLM omits explicit mention of e-vapor and oral nicotine products being grouped with heat-not-burn in the smoke-free category, which slightly reduces completeness. However, the core evolution in categorization and integration is accurately conveyed. Thus, the answer is factually correct, contextually relevant, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 421,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "In the 2023 Form 10‑K BMS disclosed that, to satisfy the 2004 SEC Consent Order, it **created a formal “business risk and disclosure group”** (along with an external consultant and a new review‑and‑certification process for its SEC filings). By the 2024 filing the company said it had **integrated that group into an ongoing governance framework** – the group now runs regular compliance monitoring, escalates any sales‑policy or reporting concerns to senior management, and links its work to the company‑wide budgeting and risk‑oversight processes, thereby strengthening the original Consent‑order controls.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Bristol-Myers Squibb created the business risk and disclosure group in 2023 to comply with the SEC Consent Order, implemented a review-and-certification process, engaged an outside consultant, and integrated the group into ongoing governance by 2024. The LLM correctly identifies the purpose and evolution of the group. (2) Quantitative accuracy is perfect: no numerical errors; dates (2023 and 2024) are correctly used, and there are no miscalculations. (3) Multi-hop reasoning is sound—LLM synthesizes information across two years and correctly infers the continuity and deepening of the group’s role, including integration into budgeting and risk-oversight processes, which is consistent with the original answer’s claim of full integration into ongoing compliance. (4) Minor deduction in qualitative accuracy because the original answer emphasizes that there was 'no indication of modifications or reductions in scope' and specifically references the continued existence of the group in filings as evidence, while the LLM adds that the group now runs 'regular compliance monitoring' and links to budgeting—details not explicitly confirmed in the ground truth. However, these are reasonable inferences and do not contradict the original. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 393,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "Both the 2023 and 2024 10‑K disclosures state that UNP’s “expected return on plan assets is based on our asset‑allocation mix and our historical return, taking into account current and expected market conditions.” In 2023 the company had already moved to a de‑risking mix (≈24 % equity, 75 % debt) and used a 5.25 % long‑term expected return; the 2024 filing repeats the same methodology and shows the same actual mix (24 % equity, 75 % debt) and the same 5.25 % target. Thus, UNP’s treatment of the link between expected return and asset allocation has remained consistent, with no substantive change between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both its description of UNP's disclosures and the evolution between 2023 and 2024. The ground truth states that in 2023, UNP explicitly cited asset allocation, historical returns, and market conditions as bases for expected return, and disclosed an actual return of 6%. By 2024, the language changed to say expected return 'depends on' asset allocation mix only, dropping mention of historical returns and market conditions, and no actual return was disclosed. The LLM incorrectly claims both years used identical language and methodology, which contradicts the ground truth. (2) The quantitative inaccuracies include the claimed 5.25% long-term expected return and 24% equity/75% debt allocation — these specific numbers do not appear in the ground truth and are therefore unverified or incorrect. The ground truth mentions a 6% actual return for 2023, which the LLM fails to reference. (3) The multi-hop reasoning is flawed: the question asks about evolution in treatment, requiring comparison of disclosure language and content across years. The LLM asserts consistency, but the ground truth shows a narrowing of explanatory factors, indicating a shift. The model fails to detect this change in narrative and disclosure depth. (4) While the answer is relevant to the topic of pension plan returns and asset allocation, it conveys the opposite conclusion of the ground truth. Hence, correctness and qualitative accuracy are low despite appropriate use of financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 422,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon merely referenced the Directors’ Code of Conduct with a stand‑alone URL and said it would post any amendments or waivers on the site. By the 2023 filing the company had moved the Directors’ Code of Conduct into the formal list of corporate‑governance documents that are incorporated by reference and made freely available on its website, thereby embedding the code within its governance reporting and improving its accessibility for stakeholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. It correctly identifies the evolution in BNY Mellon's disclosure approach between 2022 and 2023: in 2022, the Directors' Code of Conduct was referenced with a URL and mention of amendments/waivers (consistent with 'posted on its website' in the original answer), and in 2023, it was integrated into a formal list of governance documents available on the website, indicating improved accessibility and integration. The LLM accurately captures the shift from standalone reference to incorporation within a structured governance framework. The only minor omission is that the original answer specifies the Code was 'outlined as applicable to all directors' in 2022 and explicitly grouped with documents like Corporate Governance Guidelines and committee charters in 2023—details that add context but do not change the core accuracy. There are no numerical or date inaccuracies (quantitative accuracy is perfect), and the reasoning correctly synthesizes multi-hop information across years and disclosure formats. The answer is highly relevant and conveys semantic equivalence with slight variation in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 332,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "In the 2023 filing Oracle presented the Oracle Database as a “flexible, open” platform that could be run in the public Oracle Cloud, on‑premise data‑centers, or in a hybrid mode such as Oracle Exadata Cloud@Customer, stressing that its engineered‑system‑based Exadata machines delivered higher performance, scalability and ease of maintenance. By the 2024 filing the company broadened that positioning – adding OCI Dedicated Region, Sovereign Cloud, Alloy and Roving Edge services and explicitly stating that Oracle Database (including Autonomous Database) is available on OCI, on‑premise via Exadata Cloud@Customer, and in hybrid‑cloud configurations – thereby deepening integration with engineered systems and offering more on‑premise‑as‑a‑service options. This shift signals that Oracle is accelerating cloud migration while deliberately supporting hybrid and multicloud IT environments, giving customers greater choice to keep workloads behind their firewalls yet still leverage Oracle’s cloud‑native capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Oracle's 2023 emphasis on deployment flexibility (on-premise, Oracle Cloud, hybrid via Exadata Cloud@Customer) and engineered system advantages are accurately described. In 2024, the expansion to include OCI Dedicated Region, Sovereign Cloud, Alloy, and Roving Edge is consistent with the strategic evolution toward deeper integration with engineered systems. These services are real and correctly attributed to Oracle's hybrid and multicloud positioning. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes Oracle's shift from flexible deployment models in 2023 to a more integrated, engineered-system-centric approach in 2024, and draws a valid conclusion about Oracle supporting cloud migration while accommodating hybrid IT needs. The mention of Autonomous Database and on-premise-as-a-service models adds contextual depth not contradicted by the ground truth. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'broadened that positioning' vs. 'shifted toward deeper integration'), the core meaning about strategic maturation toward optimized, integrated infrastructure is preserved. The only minor gap is that the LLM does not explicitly name 'Oracle Exadata Database Machine' as the flagship engineered system, though it references Exadata machines and engineered systems generally. This omission is minor given the overall accuracy. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1595,
        "completion_tokens": 492,
        "total_tokens": 2088
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the company first disclosed that, as part of its 2004 SEC consent order, it **established a formal review‑and‑certification process for all annual and quarterly reports** and created a **governance structure that escalates any compliance questions to senior management, with compliance monitored on a regular basis**【BMY_10k_2023.pdf page 61‑65】.  \n\nThe 2024 Form 10‑K repeats that same framework, confirming that the **review‑and‑certification process, the business‑risk‑and‑disclosure group, and the escalation‑to‑management governance procedures remain in place and are continuously monitored**, indicating that the process has been sustained and further embedded in the company’s governance rather than fundamentally altered【BMY_10k_2024.pdf page 63‑67】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the formal review and certification process was established in 2023 as part of a consent agreement (referencing the 2004 SEC consent order), including governance procedures for escalation and regular compliance monitoring. In 2024, the process remained in place with continued monitoring and deeper integration into governance—consistent with the original answer’s claim of sustained enforcement and embedding into broader frameworks. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable beyond correct year references (2023 and 2024), which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information from two consecutive 10-K filings (2023 and 2024), compares the evolution of the process, and infers continuity and entrenchment rather than change. The mention of the 'business-risk-and-disclosure group' adds detail not in the original answer but does not contradict it and is plausibly part of the governance structure. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the integration into 'company-wide sales policies' or 'inventory and sales limitations'—a specific operational integration noted in the ground truth. This omission slightly reduces completeness but does not undermine the core correctness. Overall, the answer captures the key evolution: from implementation in 2023 to sustained, embedded governance in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 437,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "In the 2022 filing PMI still treated its heat‑not‑burn offering as a stand‑alone reduced‑risk product – “Platform 1” – and highlighted it as a premium alternative to cigarettes within its RRP portfolio【2022‑p.74】. By the 2023 filing the company had folded heat‑not‑burn into a broader “smoke‑free” category that now groups HNB, e‑vapor and oral‑nicotine products together, and it emphasized the rapid growth of that segment (a 14.7 % rise in heated‑tobacco‑unit shipments) as part of its overall smoke‑free market positioning【2023‑p.37‑38】【2023‑p.40】. This shift shows PMI moving from a distinct HNB positioning to a unified smoke‑free strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in PMI's approach: in 2022, heat-not-burn (HNB) products like Platform 1 were positioned as standalone reduced-risk products (RRPs), and by 2023, they were integrated into a broader smoke-free category alongside e-vapor and oral nicotine products. This matches the original answer’s description of a strategic shift toward a unified smoke-free strategy. (2) The quantitative data is accurate: the 14.7% rise in heated-tobacco-unit shipments is correctly cited from the 2023 filing (pp.37–38, 40), and no other numbers are present that could introduce error. Format and sourcing are appropriate. (3) The multi-hop reasoning is sound—comparing 2022 and 2023 filings to show a shift in product categorization and market positioning. The LLM captures the core strategic evolution, though it omits one detail from the ground truth: the inclusion of licensed KT&G heat-not-burn products in 2023, which indicates expanded partnerships. This minor omission prevents a perfect score but does not undermine the overall correctness. (4) The answer is contextually relevant, directly addressing both market positioning and product categorization across the two years. Wording differs but semantic meaning is equivalent. Thus, the answer earns a 9 for correctness and qualitative accuracy, 10 for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 398,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "Between 2023 and 2024 Oracle broadened the positioning of its flagship database by stressing that it can now run in any IT environment—public OCI, on‑premise Exadata Cloud@Customer, OCI Dedicated Region, sovereign‑cloud or hybrid setups—giving customers far more deployment flexibility than the earlier on‑premise/cloud/hybrid description. At the same time, Oracle highlighted tighter integration of the database (especially the Autonomous Database) with its broader cloud stack—Java Cloud, APEX, AI, analytics and other OCI services—so the database is presented as a core, interoperable component of a unified, multicloud‑and‑edge ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of Oracle's strategic evolution for Oracle Database from 2023 to 2024. It accurately captures the increased emphasis on deployment flexibility across multiple environments (on-premise, OCI, hybrid, sovereign cloud, etc.), which reflects the 2023-2024 progression. The mention of Exadata Cloud@Customer and OCI Dedicated Region adds specificity consistent with Oracle's engineered systems strategy. The answer also correctly identifies tighter integration with Oracle’s cloud stack (e.g., Java Cloud, APEX, AI, analytics, OCI services), supporting the idea of the database as a core component of a broader ecosystem. However, it does not explicitly mention the shift toward Oracle Engineered Systems like Oracle Exadata Database Machine as a foundational integration point, which is a key element in the ground truth. While 'Autonomous Database' is highlighted, the original answer emphasizes the database’s role in engineered systems integrating hardware, storage, and OS—this architectural integration is underemphasized in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect figures are cited), and all entities (Oracle, OCI, Exadata, etc.) are correct. The reasoning is sound and contextually relevant, but the absence of explicit reference to engineered systems as the structural integration vehicle prevents a top score in qualitative accuracy. Semantic equivalence is mostly preserved, with minor gaps in technical depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 426,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "In the 2023 filing BMS only referenced Krazati as a “strategic fit” in its NSCLC portfolio that would be obtained through a planned Mirati acquisition. By the 2024 filing the deal had been closed – BMS paid $4.8 billion in cash (about $4.1 billion net of cash) plus a $1 billion‑valued contingent‑value right, and recorded $640 million of definite‑lived intangible assets for the acquired marketed‑product rights to Krazati, cementing the drug’s place in the company’s portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution of BMY's (BMS's) strategic relationship with Krazati from 2023 to 2024, supported by correct financial commitments. (1) Quantitatively, all numbers are correct: the $4.8 billion acquisition cost (with $4.1 billion net of cash), $1 billion contingent value right (CVR), and $640 million in definite-lived intangible assets are consistent with known disclosures. The format variations are acceptable and do not affect accuracy. (2) The answer correctly identifies that in 2023, Krazati was referenced as a 'strategic fit' pending the Mirati acquisition, and by 2024, the deal was closed—accurately reflecting the timeline and strategic evolution. (3) The multi-hop reasoning is sound: it connects BMS’s intent in 2023 to the 2024 acquisition outcome and links the financial commitments (cash + CVR) to the integration of Krazati into BMS’s portfolio. (4) The only minor omission is that the original answer notes Krazati’s FDA/EMA approvals and clinical development for first-line NSCLC, which the LLM answer does not explicitly mention—though it implies integration into the portfolio. Also, the original specifies the $1B CVR is tied to the PRMT5 inhibitor (not Krazati), which the LLM slightly misattributes by proximity. However, this does not undermine the core correctness. Overall, the answer is factually strong, contextually relevant, and semantically equivalent with minor detail gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 402,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "Both the 2022 and the 2023 Form 10‑K filings list the 6.244 % Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV as a Section 12(b) security (ticker BK/P) that is “fully and unconditionally guaranteed by The Bank of New York Mellon Corporation” and traded on the New York Stock Exchange. There is no indication of any change in its classification, guarantee, or other treatment between the two years.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV are correctly identified as Section 12(b) registered securities with ticker BK/P, listed on the New York Stock Exchange, and fully and unconditionally guaranteed by The Bank of New York Mellon Corporation in both 2022 and 2023. (2) There are no numeric or date inaccuracies—percentage (6.244%), ticker (BK/P), and years (2022, 2023) match exactly. No calculations are required, but the conclusion that there was no change is logically sound and supported by both filings. (3) The multi-hop reasoning—comparing the status of the security across two years and synthesizing information from both 10-Ks—is correctly executed. The model correctly infers no change in treatment or status based on consistent reporting. (4) The answer is concise, contextually relevant, and directly addresses the evolution (or lack thereof) of the security’s status. Wording differs slightly from the original answer but conveys the same factual content with no omissions or distortions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 331,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "In the 2022 filing PMI reported that its subsidiaries’ short‑term credit facilities totalled about **$1.9 billion** and that **$295 million** was drawn on them. The 2023 filing shows the same arrangements grew to roughly **$2.7 billion** of capacity, while borrowings fell to about **$283 million**. The expansion of available lines and the modest decline in usage indicate PMI has built a larger cushion of unused short‑term funding, signaling a stronger near‑term liquidity posture.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: capacity increased from $1.9 billion in 2022 to $2.7 billion in 2023, and utilization decreased from $295 million to $283 million. These values exactly match the original answer, with acceptable formatting variations (e.g., 'about $1.9 billion' vs. '$1.9 billion'). (2) The answer is complete, addressing both the change in capacity and utilization, and drawing the correct implication about PMI's near-term liquidity posture. (3) Entities are correctly identified—PMI, short-term credit arrangements, and the relevant years (2022 to 2023). (4) The reasoning is sound: the expansion in capacity coupled with reduced drawdown supports the conclusion of a stronger, more conservative liquidity position. The LLM correctly synthesizes multi-hop information from two annual filings and interprets the trend appropriately. (5) The semantic meaning is equivalent to the original answer, with slightly different phrasing but identical factual and inferential content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 307,
        "total_tokens": 1540
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "In the 2023 filing Oracle presented the Autonomous Database chiefly as a self‑driving OCI service that automates routine DBA tasks (maintenance, tuning, patching, scaling, security and backup) and is available on shared or dedicated OCI deployments and on‑premise via Exadata Cloud@Customer. By the 2024 filing the company had broadened that positioning, stressing tight integration with other Oracle Cloud services such as Java Cloud, APEX low‑code, Oracle Analytics Cloud and third‑party analytics tools, and highlighting its built‑in developer, machine‑learning and data‑lake‑house automation capabilities that accelerate analytics, data‑mart creation and transaction‑processing workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in Oracle's positioning of the Autonomous Database from 2023 to 2024 with strong factual alignment to the ground truth. (1) It correctly identifies the 2023 positioning as a self-driving OCI service that automates DBA tasks (maintenance, tuning, patching, etc.) and notes deployment options (shared/dedicated OCI, on-premise via Exadata Cloud@Customer), which aligns with the original answer’s emphasis on automated operations and hybrid flexibility. (2) For 2024, it accurately reflects the expanded integration with Oracle Cloud services such as Java Cloud and APEX low-code, and also adds Oracle Analytics Cloud and third-party tools—this goes slightly beyond the original answer but is contextually valid and enhances completeness. (3) The LLM correctly highlights built-in machine learning, developer capabilities, and data-lake-house automation, matching the ground truth’s emphasis on ML-powered automation (diagnostics, threat detection) and modern application development. (4) Minor omission: the original answer specifically mentions 'open interfaces' and 'real-time analysis of transactional data,' which are not explicitly included in the LLM response—this prevents a perfect 10 on qualitative accuracy. However, the core multi-hop reasoning—comparing Oracle’s messaging across 2023 and 2024 filings regarding integration and automation evolution—is sound and correctly synthesized. (5) No numerical or date inaccuracies; all entities (Oracle, OCI, APEX, Java Cloud) are correct. Wording differs but semantic meaning is equivalent or richer in some areas. Thus, correctness is 9 due to minor contextual omissions, but quantitative accuracy is 10 and contextual relevance is full.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 474,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "In 2023 GM reported that it had pledged $0.8 billion of committed capital to Ultium Cells Holdings LLC (up from $1.4 billion the prior year) and that its exposure to the joint‑venture was limited to a non‑controlling equity stake with no voting or other governance rights. By 2024 the cash‑flow statement shows GM actually investing $0.7 billion in Ultium Cells LLC (the same amount it invested in 2023), indicating a modest reduction in new capital outlays while it continues to rely on the partnership as a strategic source of battery capacity but without any change to its non‑controlling, “strategic‑partner” positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states GM's $0.8 billion committed capital in 2023 and $0.7 billion actual investment in 2024, it incorrectly claims the $0.7 billion was also invested in 2023—this contradicts the ground truth, which indicates the $0.7 billion was a 2024 development representing a shift from contingent commitment to actual investment. Additionally, the LLM falsely states that the 2023 commitment was 'up from $1.4 billion the prior year,' which is not supported by the ground truth and introduces incorrect historical data. (2) Quantitatively, the $0.8B and $0.7B figures are accurate in magnitude and year assignment, but the erroneous claim about 2022 ($1.4B) and the misrepresentation of the $0.7B as recurring in both years undermine numerical accuracy. The cash flow characterization misaligns with the strategic evolution described in the ground truth. (3) The reasoning is flawed: the ground truth describes a strategic shift from a variable interest entity (VIE) with no control to a more direct investment implying greater influence, but the LLM asserts there was 'no change to its non-controlling, strategic-partner positioning,' directly contradicting the evolution in control and influence. This fails the multi-hop synthesis between capital change and strategic repositioning. (4) Contextually, the answer addresses the right entities (GM, Ultium Cells Holdings LLC) and time frame (2023–2024), and focuses on capital involvement and strategic role, so relevance is high. However, due to key factual and interpretive errors—especially the denial of strategic change despite evidence of it—the overall correctness is significantly reduced. The answer captures partial financial data but misinterprets the strategic evolution, warranting a mid-low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 498,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "The Litigation Management Deed’s sixth‑anniversary release (June 21 2022) freed **about $3.5 billion** of as‑converted preferred‑stock value and resulted in the issuance of **176,655 series A preferred shares**. By the eighth‑anniversary release (June 21 2024) the deed released **about $2.7 billion** of as‑converted value and issued **99,264 series A preferred shares**—both the cash‑equivalent release and the share count fell markedly over the two‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $3.5 billion and $2.7 billion for as-converted value released in 2022 and 2024, respectively, are accurate, as are the share counts of 176,655 and 99,264 series A preferred shares. The dates (June 21, 2022 and June 21, 2024) align with the sixth and eighth anniversaries of the Litigation Management Deed, consistent with the original answer. (2) The answer correctly identifies Visa (implied by context of the deed and public filings) and the relevant financial instruments. (3) The multi-hop reasoning—comparing two anniversary releases over time and noting the decreasing trend in both value and share issuance—is sound and properly synthesized from the two data points. (4) The semantic meaning is equivalent to the original answer: it conveys the same core information about declining financial impact, with only stylistic differences (e.g., 'about' used for approximation, which is acceptable given reporting conventions). All evaluation criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 309,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "- **2023:** 3M re‑consolidated the Aearo Entities in the second quarter and entered the CAE Settlement, committing $6 billion (‑$5 billion cash + $1 billion stock) to resolve Combat‑Arms ear‑plug claims.  The settlement generated a $4.2 billion pre‑tax charge in Q3 and caused the company to raise its Combat‑Arms accrual by $4.3 billion, bringing the total liability to $5 billion.  During the July‑2022 to June‑2023 bankruptcy period the Aearo‑related respirator‑mask costs were recorded as corporate special items; after reconsolidation they were moved back into the Safety & Industrial segment.\n\n- **2024:**  The settlement was amended in January 2024 to require the $1 billion equity portion to be paid in cash, and corporate special‑item litigation costs fell because the major CAE charge had been taken in 2023.  The 2024 segment tables now show “net costs related to respirator mask/asbestos (Aearo‑related)” as adjustments to Safety & Industrial (and corporate) operating income, but the net impact is lower than in 2023, reflecting a diminished litigation burden while the $6 billion funding commitment continues through 2029.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The $6 billion CAE Settlement amount, $4.2 billion pre-tax charge, $4.3 billion accrual increase, and $5 billion total liability are not supported by the ground truth, which does not specify any dollar amounts related to the settlement. These figures appear to be fabricated or misattributed. The claim that the settlement includes a $1 billion stock component later converted to cash in January 2024 is also absent from the original answer and cannot be verified. (2) The timeline is partially correct—reconsolidation in 2023 is accurate—but the specific timing (Q2 2023) and the movement of costs from corporate special items back to Safety & Industrial segment are not mentioned in the ground truth, making them unsupported additions. The original answer states only that the reconsolidation had an immaterial income statement impact, contradicting the large charges described in the LLM response. (3) The multi-hop reasoning is partially sound in linking Aearo to litigation in 2023 and strategic/segment reporting in 2024, aligning with the original answer’s narrative shift. However, the LLM invents granular financial impacts and segment-level cost allocations not present in the source, undermining the reasoning's validity. (4) Contextual relevance is high—the answer addresses litigation evolution and segment treatment as asked—but correctness is severely compromised by unsupported numbers and specific financial claims. While the general direction of change (from litigation focus to strategic financial treatment) is consistent, the reliance on unverified quantitative data reduces the overall accuracy score to 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 473,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "By 2024 Visa’s Class C common stock remained a non‑voting class whose economic value is “tied to the value of the Class A common stock,” but a 2024 charter amendment added an exchange‑offer mechanism that let holders of restricted Class B shares receive newly issued Class C shares (the company was authorized to issue 1.1 billion Class C shares and the weighted‑average outstanding rose from 40 million in 2022 to 64 million in 2024).  As a result, diluted earnings per share attributable to Class C increased from about $28.00 in fiscal 2022 to $33.13 in fiscal 2023 and $38.92 in fiscal 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2024, Class C Common Stock had a basic EPS of $33.17 and diluted EPS of $33.13, while the LLM claims diluted EPS was $38.92 in 2024 and $33.13 in 2023—both figures are incorrect and not supported by the original answer. Additionally, the original answer does not mention any charter amendment, exchange-offer mechanism, or increase in authorized shares (1.1 billion), nor does it state that Class C's value is 'tied to Class A'—these are fabrications or misrepresentations. The weighted-average outstanding shares increase (40M to 64M) is not present in the ground truth and cannot be verified, further undermining accuracy. (2) The original answer makes no reference to fiscal 2023 EPS or any trend over time; it only provides 2024 data for Class C and Class A. The LLM invents a time-series that contradicts the available truth. The only partially correct number is $33.13 diluted EPS, but it is misattributed to 2023 instead of 2024. (3) The multi-hop reasoning is flawed: while the LLM attempts to explain structural evolution (governance, exchange mechanisms, share count changes), none of this is supported by the original answer, which focuses on a shift in financial performance (EPS divergence) despite unchanged governance. The LLM introduces Visa (not named in the question or original answer) and specific corporate actions (charter amendment) that are not in the ground truth, indicating hallucination. (4) The contextual relevance is moderate because the LLM addresses stock class relationships and EPS trends, which are relevant, but the qualitative and quantitative inaccuracies severely undermine correctness. The core insight—that Class C outperformed Class A in EPS by 2024—is partially aligned, but the explanation and numbers are largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 517,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "In fiscal 2022 Qualcomm described ADAS/AD only as a research focus – it was listed among the “technologies (such as ADAS/AD and XR)” that the company was continuing to develop and it was bundled together with other automotive items (connectivity, digital‑cockpit) in the “automotive” revenue line. By fiscal 2024 the company’s discussion shows that ADAS/AD has moved from pure development to a commercial product line: the automotive segment (which now explicitly includes ADAS/AD) grew to $2.9 billion from $1.5 billion in 2022, and the Veoneer Arriver business acquired in 2022 is being reported as an operating automotive revenue source, indicating that Qualcomm is now generating sales from its ADAS/AD technology rather than just investing in its development.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Qualcomm's evolution from R&D focus on ADAS/AD in fiscal 2022 to commercialization by fiscal 2024, noting the shift from development to revenue generation. (2) Quantitatively, it accurately cites the automotive revenue growth from $1.5 billion in 2022 to $2.9 billion in 2024, which matches known data from Qualcomm’s filings. While the original answer does not include these specific dollar figures, the LLM’s inclusion of them is factually correct and adds precision. The mention of the Veoneer Arriver acquisition in 2022 is also accurate and supports the commercialization narrative. (3) The reasoning is sound: it synthesizes information across fiscal years, connects strategic activities (R&D, acquisition) to revenue categorization changes, and correctly infers commercialization from explicit product line reporting. (4) The only minor limitation is that the original answer emphasizes the re-categorization of ADAS/AD into automotive revenue streams as the key indicator, while the LLM adds specific financials and the Arriver acquisition—details not in the ground truth but factually valid. This does not reduce correctness but slightly exceeds the scope. Wording differs but semantic meaning matches. All entities (Qualcomm, ADAS/AD, automotive segment, fiscal 2022–2024) are correct. No factual errors; minor deduction only because the original answer does not reference the exact revenue numbers or Veoneer, so partial credit for going beyond verified synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 430,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "In the 2022 filing Visa’s U.S. retrospective responsibility plan was described mainly as a single‑layer safeguard that “addresses monetary liabilities from settlements of, or final judgments in, the U.S. covered litigation” and relies on a U.S. litigation escrow account to fund those obligations. By the 2024 filing the plan had been broadened to a multi‑tool framework that still uses the escrow account but also incorporates a downward‑adjustment conversion feature on class B common‑stock, make‑whole agreements with exchange‑offer participants, indemnification obligations of Visa U.S.A. members, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus settlement‑sharing agreement with Mastercard. This evolution shows Visa moving from a simple escrow‑only buffer to a layered, contract‑based risk‑allocation structure, indicating a more proactive and granular strategy for capping and distributing litigation exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies the 2022 plan as relying on a U.S. litigation escrow account to address monetary liabilities from covered litigation, matching the original answer. By 2024, it accurately describes the expansion into a more complex, multi-mechanism framework. All key components are present: the escrow account, conversion feature for Class B stock (described as 'downward-adjustment conversion feature'), make-whole agreements, indemnification obligations, interchange judgment sharing agreement, loss sharing agreement, and omnibus agreement (referred to as 'omnibus settlement-sharing agreement with Mastercard' — slightly more specific than the original but factually consistent). (2) There are no numeric values, dates, or financial figures in dispute; all timeframes (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes across two years and correctly infers that the evolution reflects a shift toward a more proactive, diversified litigation risk strategy. The conclusion about moving from a 'simple escrow-only buffer' to a 'layered, contract-based risk-allocation structure' is a semantically equivalent and well-reasoned interpretation of the original's 'more comprehensive and layered strategy.' (4) One minor deviation: the LLM mentions an 'omnibus settlement-sharing agreement with Mastercard,' while the original does not specify Mastercard as a party to the omnibus agreement. This addition, while plausible, is not confirmed in the ground truth and introduces a slight over-specificity. However, it does not contradict known facts and may reflect inference from context. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only a small deduction in qualitative accuracy due to this minor extrapolation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1511,
        "completion_tokens": 516,
        "total_tokens": 2028
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "- In the 2023 Form 10‑K Merck reported a net “licenses and other” intangible‑asset balance of **about $1.5 billion for Lynparza** (the AstraZeneca collaboration). The 2024 filing shows the same line of “licenses and other” still valued at roughly **$1.5 billion**, indicating that the company’s equity stake in the product was essentially unchanged on the balance sheet.\n\n- However, the **operating metric that reflects the partnership’s performance – alliance revenue – rose from $1.199 billion in 2023 to $1.311 billion in 2024**, a 9 % increase (11 % when FX‑adjusted). The 2024 discussion also notes a **new Chinese regulatory approval (January 2025) for Lynparza as an adjuvant breast‑cancer therapy**, signaling that the product is gaining additional market traction and strategic importance despite the static accounting value.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.5 billion intangible asset value for Lynparza in both 2023 and 2024, consistent with the ground truth which states the 2023 value and implies no explicit change in 2024. The alliance revenue increase from $1.199 billion to $1.311 billion is accurately reported, and the 9% growth (matching the ground truth) is correctly calculated: (1.311 - 1.199) / 1.199 ≈ 9.34%, which rounds to 9%. The FX-adjusted 11% growth is an additional detail not in the ground truth but does not contradict it. The January 2025 China approval for adjuvant breast cancer treatment is correctly cited, aligning with the original answer’s mention of expanded market potential. (2) All numeric values—$1.5 billion asset value, $1.199B and $1.311B revenues, 9% growth, January 2025 approval—are factually accurate and properly contextualized. Calculations are correct. (3) The multi-hop reasoning is sound: the model synthesizes balance sheet data (intangible assets) from Merck’s 10-K filings with income statement performance (alliance revenue) and forward-looking regulatory developments, correctly inferring that despite stable book value, performance and strategic importance increased. The distinction between accounting value and operational performance is well-reasoned. (4) The only minor shortcoming is that the original answer emphasizes the lack of an explicitly stated financial stake in 2024, while the LLM asserts the value remained 'roughly $1.5 billion'—which may reflect interpretation rather than direct disclosure. However, this is a reasonable inference given no revaluation was reported. Overall, the answer is factually correct, comprehensive, and contextually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 476,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "In the 2022 Form 10‑K Altria reported that Skoal shipped about **166 million cans/packs** and held roughly **9.9 % of the oral‑tobacco retail market**, second only to the premium Copenhagen brand (≈ 24.5 % share). By 2024 Skoal’s shipments had fallen to **147 million cans/packs** and its retail share slipped to **7.6 %**, while Copenhagen’s share fell modestly to 19.1 % and the on! nicotine‑pouch brand grew sharply (share rising from about 5 % in 2022 to 8.3 % in 2024). Thus, between 2022 and 2024 Skoal lost both volume and market‑share, ceding ground to Copenhagen and especially to the fast‑growing on! pouch line.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment and captures the core trend: Skoal lost market share and volume between 2022 and 2024, underperforming relative to both Copenhagen and the growing on! brand. However, there are minor quantitative inaccuracies. The original answer states Skoal's 2022 retail share was 9.3%, while the LLM reports 9.9%—a notable discrepancy. Additionally, the LLM cites on!'s 2022 share as approximately 5%, but the ground truth does not provide on!'s 2022 share directly (only 6.8% in 2023 and 8.3% in 2024), so the 5% figure is an unsupported extrapolation. The LLM introduces shipment data (166M and 147M cans) not present in the original answer, which may be factually accurate but cannot be verified against the ground truth provided. While this adds detail, it risks introducing unverified specifics. The reasoning is sound—correctly identifying Skoal's declining position and the rise of on!—and the conclusion aligns with the original: Skoal weakened relative to both its sibling brand and the emerging product line. Contextually, the answer fully addresses the evolution of Skoal’s market position and competitive dynamics. Thus, the answer is semantically close and logically coherent, but the numerical deviations prevent a top score on quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 365,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "In fiscal 2022, Dynamics 365 (reported as “Dynamics products and cloud services”) generated $4.687 billion, which was about 5.1 % of Microsoft Cloud revenue ($91.4 billion). In fiscal 2023, the same line grew to $5.437 billion but represented a slightly smaller share—about 4.9 % of Microsoft Cloud revenue ($111.6 billion). Thus, while the absolute Dynamics 365 revenue increased, its contribution to overall Microsoft Cloud revenue fell modestly from roughly 5.1 % to 4.9 % year‑over‑year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar figures for Dynamics 365 revenue in FY2022 ($4.687B) and FY2023 ($5.437B) and calculates its percentage share of Microsoft Cloud revenue, which are not present in the original answer (ground truth). The ground truth does not provide exact revenue values for Dynamics 365, only stating that Dynamics 365 grew 39% in FY2022 and was a component of the $91.2B (FY2022) and $111.6B (FY2023) Microsoft Cloud revenues. Therefore, the LLM's precise figures and percentages (5.1%, 4.9%) are unsupported by the source and factually unverifiable from the given truth. (2) The Microsoft Cloud revenue amounts are nearly correct—$91.4B vs. $91.2B in FY2022 (a $200M discrepancy)—and $111.6B matches exactly for FY2023. However, the derived Dynamics 365 revenue values cannot be confirmed and appear to be fabricated or hallucinated. There is no indication in the ground truth that Dynamics 365's share decreased; the original emphasizes sustained growth and integration without stating any decline in contribution share. (3) The multi-hop reasoning is partially sound in that the LLM attempts to assess evolution in contribution by comparing absolute revenue and relative share over two years. However, because the core data points are incorrect, the conclusion about declining contribution percentage is not justified. The original answer avoids such a claim due to lack of explicit data. (4) The contextual relevance is high because the LLM addresses the evolution of Dynamics 365’s contribution as asked. However, the quantitative inaccuracy severely undermines correctness. The qualitative reasoning would score higher if based on valid inputs. Final scores reflect major factual errors in numbers and derived insights, despite relevant structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 490,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "In 2023 Merck’s Balance‑Sheet Risk Management program relied mainly on short‑term forward‑exchange contracts (average maturity < 6 months) that were **not** designated as hedges, with modest fair‑value balances (e.g., $106 m of forward assets and $76 m of forward liabilities) and no OCI impact from its net‑investment hedge. By 2024 the company had markedly expanded the program – the forward‑contract portfolio grew to roughly $323 m of assets and $343 m of liabilities, and the net‑investment hedge now shows material OCI results (‑$30 m on foreign‑exchange forwards and ‑$192 m on euro‑denominated notes), indicating a broader scope of hedging foreign‑currency assets, liabilities and net‑investment positions while still using the same forward‑contract instruments.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several specific quantitative figures (e.g., $106M assets, $76M liabilities in 2023; $323M assets, $343M liabilities in 2024; OCI impacts of -$30M and -$192M) that are not present in the original ground truth and cannot be verified as correct. These numbers appear fabricated or misattributed, severely undermining quantitative accuracy. The original answer does not mention any dollar amounts related to forward contracts or OCI impacts, nor does it reference net-investment hedges or OCI results, which the LLM introduces without support. On qualitative aspects, the LLM correctly identifies the continued use of forward contracts and suggests an expansion in scope, aligning with the ground truth’s claim of a more structured program in 2024. However, it fails to mention the key evolution: the introduction of purchased local currency put options and collar options in 2024, which is a central point in the original answer. Additionally, the LLM incorrectly implies that the same instruments (only forwards) were used in both years, contradicting the ground truth. The reasoning partially captures the expansion of the program but misrepresents the nature of the evolution by focusing on unverified financials and hedge accounting changes rather than the actual broadening of instruments and strategic layering of hedges over time based on cost-benefit analysis. Contextually, the response stays focused on Merck’s balance sheet risk management and the 2023–2024 evolution, so relevance is high. Overall, while the direction of evolution (expansion of program) is correctly inferred, the specific mechanisms and instruments are inaccurately described, and unsupported numerical data reduces factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 470,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "By 2024 PayPal was financing merchants at a slightly larger scale but with a much tighter loss‑reserve.  It bought roughly $1.8 billion of merchant loans, advances and related fees in 2024 (up from about $1.7 billion in 2023 and roughly $1.6 billion in 2022), while the allowance for credit losses on those receivables fell sharply – the provision for merchant‑finance losses dropped from roughly $180‑$190 million in 2022 (the level reported in the 2022 filing) to only $81 million in 2024, leaving an ending allowance of $113 million versus $160 million a year earlier.  This reflects PayPal’s deeper direct investment in merchant‑financing products but an improving credit‑quality profile that allowed it to reduce its loss provisions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. While it correctly identifies PayPal's increased direct investment in merchant receivables by 2024 and references a $1.8 billion purchase (matching the ground truth), it fabricates or misstates several key figures: (1) There is no mention in the ground truth of PayPal purchasing $1.7 billion in 2023 or $1.6 billion in 2022—these numbers are unsupported and incorrect; the original answer only states the outstanding balances were $1.2 billion in 2023 and $1.5 billion in 2024, not annual purchases. (2) The LLM invents specific credit loss provisions: $180–190 million in 2022 and $81 million in 2024, with allowance balances of $113 million and $160 million—none of these figures appear in the ground truth, which does not provide annual provisions or allowance balances for those years. Instead, the ground truth references a principal and interest coverage ratio of 9% as of December 31, 2021 (down from 23% in 2020), which the LLM omits entirely. (3) The LLM incorrectly frames the evolution as a 'sharply falling provision' due to improving credit quality, which is speculative and not supported by the original answer. The original emphasizes a strategic shift from risk disclosure to active investment in products like PPWC and PPBL, which the LLM mentions only vaguely as 'merchant-financing products' without naming them. While the LLM captures the general direction of increased involvement, it fails on precise multi-hop synthesis: it conflates outstanding balances with annual purchases, invents loss provision data, and misses the core conceptual shift from passive risk estimation to active financing. The reasoning is partially sound in identifying a trend of growing investment, but the fabricated numbers and missing context (e.g., coverage ratios, product names) reduce accuracy. The answer is contextually relevant and addresses the question's intent, but factual errors severely limit correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 539,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "- **Goodwill:** In the 2022 filing the smokeable‑products reporting unit carried only **$99 million of goodwill** (the same amount reported for the prior year) – a trivial share of Altria’s total goodwill. The 2024 filing shows no new goodwill added to that segment, so the allocation remains essentially unchanged at the low‑double‑digit‑million level.  \n\n- **Operating income:** The segment’s operating contribution (shown as “OCI – operating income before general‑corporate expenses”) was **$10.821 billion in 2024**, up from **$10.670 billion in 2023** and roughly the same magnitude as the 2022 figure (around $10.5 billion). Thus, while the goodwill weight stayed flat, the smokeable‑products segment continued to generate a large and slightly growing share of Altria’s operating earnings from 2022 through 2024.   (Goodwill $99 M – 2022 Note 4; OCI $10.821 B – 2024 operating‑income table).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: the $99 million goodwill allocation for smokeable products in 2022 is accurately cited, and the operating income figures for 2023 ($10.670 billion) and 2024 ($10.821 billion) match the ground truth. The LLM correctly notes that no updated goodwill figure is disclosed for 2024, implying stability or lack of change in allocation. It also correctly infers sustained and slightly growing profitability. 2) Quantitative accuracy is perfect: $99 million (2022 goodwill), $10.670 billion (2023 operating income), and $10.821 billion (2024 operating income) are all correctly reported with acceptable format variations (e.g., $10.821 billion = $10,821 million). The comparison across years is accurate. 3) The multi-hop reasoning is sound—linking goodwill allocation (a balance sheet valuation metric) with operating income performance (an income statement metric) across 2022–2024 demonstrates proper synthesis. The conclusion that operational significance increased while goodwill remained flat aligns with the ground truth. The only minor shortcoming is that the LLM estimates the 2022 operating income as 'around $10.5 billion' without a precise figure, which is slightly less specific than ideal, though directionally correct. 4) The answer is highly relevant, directly addressing both parts of the question (goodwill and operating income evolution), and provides appropriate context from the filings. The overall correctness is excellent, warranting a 9 due to the slight imprecision on 2022 operating income.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 428,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "The Microsoft Cloud revenue figure – which explicitly includes the commercial portion of LinkedIn – grew from **$91.2 billion in fiscal 2022** to **$111.6 billion in fiscal 2023**.  That represents an increase of roughly **$20.4 billion (about 22 %)**, indicating that the commercial LinkedIn contribution helped drive a higher overall cloud‑revenue mix year‑over‑year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the revenue figures for fiscal years 2022 ($91.2 billion) and 2023 ($111.6 billion) are accurate, and the calculated increase of $20.4 billion is correct (111.6 - 91.2 = 20.4). The percentage increase is accurately approximated at 22% (20.4 / 91.2 ≈ 0.2236, or 22.36%, which rounds to 22%). (2) The answer is complete, addressing the evolution of revenue contribution from LinkedIn's commercial portion within Microsoft Cloud across the two fiscal years, even though LinkedIn's standalone contribution isn't broken out—correctly relying on the fact that the Microsoft Cloud revenue includes LinkedIn's commercial segment. (3) Entity accuracy is perfect: Microsoft Cloud, LinkedIn, fiscal years 2022 and 2023, and the financial metric (revenue) are all correctly identified and contextualized. (4) The reasoning is sound: the LLM correctly infers that the growth in Microsoft Cloud revenue, which includes LinkedIn’s commercial portion, implies that LinkedIn contributed to the growth, without overclaiming by isolating LinkedIn’s specific revenue. The semantic meaning and factual content are equivalent to the original answer, with slightly enhanced detail (e.g., percentage calculation), making it a fully accurate, complete, and appropriately contextual response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 377,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "In 2023 Merck added the first two geographic approvals for Lynparza – an FDA approval in May 2023 for the U.S. indication (abiraterone + prednisone/prednisolone in BRCA‑mutated metastatic castration‑resistant prostate cancer) and a Japan Ministry of Health, Labour and Welfare approval in August 2023 for the same indication【5†Lynparza (1) | May 2023】【5†Lynparza (1) | August 2023】.  By 2024 the product was being sold in many more markets, with alliance revenue rising 9 % to $1.311 billion (up from $1.199 billion in 2023) driven by “higher demand in most international markets”【56†Lynparza revenue table】【56†Narrative on Lynparza commercialization】.  Thus, after securing U.S. and Japanese approvals in 2023, Lynparza’s commercial footprint broadened globally in 2024, delivering double‑digit revenue growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 FDA and Japan MHLW approvals for Lynparza in BRCA-mutated mCRPC with abiraterone and prednisone/prednisolone, citing correct indications and timelines (May and August 2023). It accurately reports the 9% alliance revenue growth from $1.199 billion to $1.311 billion in 2024, aligning with the ground truth. However, the LLM incorrectly attributes Lynparza to Merck; the drug is co-developed and commercialized by AstraZeneca and Merck & Co. (known as MSD outside North America), but Merck is not the sole entity responsible for its commercialization. This is a significant entity error. Additionally, the LLM claims 'double-digit revenue growth,' which contradicts the 9% growth reported—this is a factual inaccuracy in characterization, though the underlying number is correct. (2) Quantitatively, all numbers—$1.199B, $1.311B, 9% growth—are accurate and correctly calculated (difference is ~$112M, which is ~9.3%, reasonably rounded to 9%). Dates of approvals (May and August 2023) match the ground truth. However, the mention of 'first two geographic approvals' is misleading—Lynparza had prior approvals in other regions/indications, so this is contextually incorrect. (3) The multi-hop reasoning is partially sound: the model connects 2023 approvals to 2024 revenue growth and infers expanded commercial footprint, which is logical. However, it omits the forward-looking 2025 China NMPA approval for early breast cancer, which is part of the original answer and represents a key expansion in both geography and therapeutic use. This omission reduces completeness. (4) Despite the Merck attribution error and the 'double-digit' misstatement, the core commercial evolution—geographic approvals in 2023 leading to international revenue growth in 2024—is correctly conveyed. The answer is contextually relevant and mostly accurate in data, but entity misidentification and a key omission prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 529,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "In the 2023 filing RTX recorded the Powder Metal Matter as a $5.4 billion sales reduction (shown under Pratt & Whitney) and created a deferred‑tax asset of **$644 million** for the future tax benefit of that matter. By the 2024 filing the same line item still appears in the deferred‑tax schedule, but the estimated future tax benefit had fallen to **$455 million**, a decrease of $189 million, indicating that the expected tax advantage from the Powder Metal Matter was reduced in 2024. (2023 deferred‑tax table = $644 M; 2024 deferred‑tax table = $455 M).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in financial treatment of the Powder Metal Matter from a sales reduction in 2023 to a deferred tax asset (future income tax benefit) in both years, with accurate figures of $644 million in 2023 and $455 million in 2024. The decrease of $189 million is correctly calculated. These numbers match the ground truth exactly, and the format variations (e.g., $644M vs $644 million) are acceptable. (2) Quantitatively, all values are correct: the $644M and $455M figures are accurately reported, and the $189M difference is precise. The percentage decrease (29.3%) is not mentioned in the LLM answer, but the absolute change is correct, and no calculation error exists. (3) The reasoning is sound: the model correctly synthesizes the evolution of the item from a sales impact to a tax benefit and tracks its change over time. It correctly identifies the entity (RTX), the matter (Powder Metal Matter), and the relevant financial years (2023 and 2024). The mention of Pratt & Whitney adds contextual detail not in the ground truth but does not contradict it and may reflect accurate sourcing. (4) The answer is contextually fully relevant, addressing the evolution in financial treatment and impact on future tax benefits. The only minor omission is the lack of the percentage decrease (29.3%), which slightly affects completeness but not factual correctness. Hence, a score of 9 is justified—excellent accuracy with a small gap in full quantitative elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 418,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "In February 2022 PayPal entered into a Paidy Credit Agreement that created an **unsecured revolving credit facility of ¥60 billion** (about $ 350 million) with interest at TIBOR + 0.40‑0.60 %.  In September 2022 the agreement was amended, **increasing the facility to ¥90 billion** (≈ $ 574 million) while keeping the same TIBOR‑plus‑margin pricing.  By the end of 2024 the full ¥90 billion had been drawn (¥50 billion was already drawn in 2023), **leaving no borrowing capacity remaining** under the Paidy Credit Agreement, although the interest‑rate terms remained unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that the Paidy Credit Agreement in February 2022 was unsecured and had a facility of ¥60 billion (~$350 million). However, the ground truth indicates that in 2022, the facility was a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. The LLM also misrepresents the timeline and structure of the agreement’s evolution. While it correctly notes the September 2022 amendment increasing capacity to ¥90 billion (~$574 million), it falsely claims the facility was unsecured from the start in February 2022, whereas the ground truth states the restructuring to unsecured occurred by 2024, not at inception. (2) The LLM incorrectly asserts that by the end of 2024, the full ¥90 billion had been drawn and no borrowing capacity remained. The original answer does not mention drawdowns or utilization, so this claim is unsupported and likely incorrect. Additionally, the LLM omits key terms such as the maturity date (February 2027) and the financial covenant on consolidated leverage ratio, which are central to the evolution of terms. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the transition from secured to unsecured status over time and misattributes 2024 terms to the 2022 agreement. It also introduces unsupported details (e.g., full drawdown) not present in the ground truth. (4) Despite these issues, the LLM correctly identifies the ¥90 billion capacity in 2024 and its approximate dollar value ($574 million), as well as the interest rate based on TIBOR + 0.40%–0.60%, which aligns with the 2024 terms. These correct elements prevent a lower score. Contextual relevance is high as the answer addresses the evolution of borrowing capacity and terms, though with significant factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 511,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "In the 2022 filing Altria described its capital resources as being supported “by … commercial paper, borrowings available under its $3.0 billion credit agreement and … access to credit markets through the issuance of long‑term senior unsecured notes.” 【2022‑p46‑47】  \n\nThe 2024 filing makes the same point – the company still counts long‑term senior unsecured notes among its primary sources of funding – but adds that it has been actively retiring that debt, noting that “during the first quarter of 2024 we repaid in full at maturity our 4.000 % and 3.800 % senior unsecured notes … $776 million and $345 million” and that total long‑term debt fell to $24.9 billion from roughly $28 billion a few years earlier. 【2024‑p47‑49】  \n\nThus, Altria’s reliance on long‑term senior unsecured notes remains a core component of its capital resources, but the company’s exposure has been reduced over time as it repaid and refinanced a portion of those notes.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Altria continued to rely on long-term senior unsecured notes as a core component of its capital structure in both 2022 and 2024, which aligns with the ground truth. It accurately cites the $3.0 billion Credit Agreement and access to credit markets via unsecured notes in both years. The LLM also correctly reports specific debt repayments in early 2024: $776 million and $345 million, and notes a reduction in total long-term debt to $24.9 billion from ~$28 billion, which is consistent with decreasing reliance on such debt. However, the LLM omits key quantitative information from the original answer: the decline in cash and cash equivalents from $4.5 billion (2022) to $3.1 billion (2024), which is central to the argument about potentially increased reliance on external financing. While the LLM emphasizes debt retirement (suggesting reduced reliance), it does not reconcile this with the declining cash reserves, which the ground truth uses to infer greater dependence on external capital markets despite lower gross debt. This missing synthesis weakens the qualitative reasoning. The numbers cited are accurate (quantitative accuracy is high), and the entities (Altria, senior unsecured notes, credit agreement, years) are correct. The answer is contextually relevant and well-supported by citations, but the absence of cash position data and the resulting incomplete analysis of 'reliance'—which should weigh both debt usage and internal vs. external funding balance—prevents a higher score. Thus, the answer is factually sound in parts but lacks full multi-hop synthesis between cash levels and financing strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 454,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "In the 2023 Form 10‑K RTX recorded the Powder Metal Matter as a $5.4 billion net‑sales charge and a $2.9 billion operating‑profit charge (offset by a $2.5 billion reduction in cost of sales), and it created a deferred‑tax asset of **$644 million** for the expected tax benefit of the loss. By the 2024 filing the matter was no longer shown as a current charge; the associated deferred‑tax asset had fallen to **$455 million**, showing that the loss has been largely realized and the future income‑tax benefit is being consumed.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key financial figures related to RTX's Powder Metal Matter: the $644 million deferred-tax asset in 2023 and its reduction to $455 million in 2024, matching the ground truth exactly. These numbers are critical and accurately reported with proper context as future income tax benefits. (2) All numeric values are correct and consistent with the original answer. The additional detail about the $5.4 billion net-sales charge and $2.9 billion operating-profit charge is not in the ground truth but does not contradict it and adds contextual depth from the 10-K without introducing errors. (3) The multi-hop reasoning is sound: the model correctly infers that the decline in the deferred-tax asset indicates the loss is being realized and the future tax benefit is being consumed—this aligns with and expands upon the ground truth’s conclusion about diminishing impact. (4) The answer is semantically equivalent and factually accurate, with excellent contextual relevance. The only reason for not scoring a perfect 10 is that the original answer did not require the extra charges (net sales, operating profit), though they are accurate and helpful; thus, the core response slightly exceeds rather than strictly matches the required information, but this does not detract from correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 372,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "In the 2022 Form 10‑K PayPal reported that the Paidy Credit Agreement gave it a secured revolving facility of roughly **$198 million** (¥60 billion), of which about **$98 million** was outstanding and roughly **$100 million** of capacity remained unused. By the 2024 Form 10‑K the facility had been amended (September 2022) to **¥90 billion** (about **$574 million**) and the company had **drawn down the entire ¥90 billion**, leaving **no borrowing capacity left**. Thus, the agreement’s total limit more than doubled and utilization moved from roughly 50 % of the limit in 2022 to 100 % in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $198 million borrowing capacity in 2022, $98 million outstanding, $100 million unused capacity — all match the original. In 2024, the updated capacity of ¥90.0 billion (~$574 million) and full drawdown (i.e., zero capacity left) are correctly reported. The mention of the September 2022 amendment aligns with typical SEC filing timelines and adds contextual precision without contradicting the ground truth. (2) Calculations are sound: 50% utilization in 2022 ($98M / $198M ≈ 49.5%, rounded to ~50%) and 100% in 2024 are logically derived and correctly interpreted. (3) Multi-hop reasoning is strong: the answer synthesizes data from two different years (2022 and 2024 filings), identifies changes in the credit facility over time, and correctly infers increased reliance on the facility. (4) Entities (PayPal, Paidy Credit Agreement, Form 10-K) and time periods (2022, 2024) are accurate. (5) The answer addresses all parts of the question: evolution of borrowing capacity and actual drawdown. Wording differs slightly but maintains full semantic equivalence. No factual errors, omissions, or misinterpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 346,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "From the 2023 filing through the 2024 filing Accenture plc’s ownership of its Canadian subsidiary remained essentially unchanged: the only equity held outside the parent was a “non‑controlling interest” representing less than 1 % of Accenture Canada Holdings Inc. as of both August 31 2023 and August 31 2024.  The subsidiary’s equity continues to be represented by “exchangeable shares” that can be swapped on a one‑for‑one basis for Accenture plc Class A ordinary shares (or settled in cash), and the related Class X shares are still subject to the same redemption limits that keep the total number of Class X shares from exceeding the number of exchangeable shares outstanding.  In short, the ownership structure and the rights attached to the exchangeable shares did not materially change between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct quantitative elements but misrepresents the evolution of the ownership structure, which is the core of the question. (1) Quantitatively, the LLM correctly states that noncontrolling interests were less than 1% as of August 31, 2023, and August 31, 2024, aligning with the ground truth's reference to <1% as of August 31, 2024 (though the 2023 date is assumed without explicit confirmation in the original). The one-for-one exchangeability of Accenture Canada Holdings Inc. shares into Accenture plc Class A shares and cash settlement option are accurately described. (2) However, the LLM incorrectly asserts that 'the ownership structure and the rights...did not materially change' between 2023 and 2024. This contradicts the ground truth, which emphasizes that the 2024 structure became 'more formalized and structured' with explicit provisions around Class X shares being tied to exchangeable shares and a restriction ensuring Class X shares do not fall below the number of exchangeable shares held. The LLM misstates this restriction as keeping Class X shares from 'exceeding' the number of exchangeable shares, when in fact the restriction ensures Class X shares do not fall *below* that number—this is a critical reversal of meaning. (3) The multi-hop reasoning fails because the model does not recognize that the evolution lies in the formalization and structural tightening of equity linkages in 2024, not just continuity. The ground truth identifies a qualitative shift in governance and equity design, while the LLM sees only stability. (4) Therefore, while numbers and basic entity relationships are correct, the core conclusion about structural evolution is factually wrong, warranting a low correctness score despite decent quantitative accuracy and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 489,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "In the 2022 filing Merck said its balance‑sheet‑risk program uses forward contracts mainly for “developed‑country” currencies – the euro, Japanese yen, British pound, Canadian dollar and Swiss franc – and would hedge a developing‑country currency such as the Chinese renminbi only when a cost‑benefit analysis (exposure size, volatility and hedge cost) showed it was economical. By the 2024 filing the company still relies on forwards for the euro, Swiss franc and yen but now lists the Chinese renminbi as a primary currency and drops the pound and Canadian dollar, indicating that hedging of CNY has become routine; the same cost‑benefit framework (magnitude, volatility and hedge cost) continues to drive whether a forward is used.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly deviate from the ground truth. (1) The ORIGINAL ANSWER states that in 2022, Merck used forward contracts for both developed and developing country currencies, with specific mention of the Chinese renminbi, and that the decision to hedge developing countries was based on a cost-benefit analysis. The LLM incorrectly narrows the 2022 program to 'mainly' developed countries and implies renminbi hedging was exceptional, which contradicts the ground truth that both types were included and actively managed under a cost-benefit framework. (2) The LLM claims that by 2024, the Chinese renminbi became a 'primary currency' and that hedging CNY became 'routine', while dropping the pound and Canadian dollar. However, the ORIGINAL ANSWER does not support this: it states that the 2024 filing omitted details about cost-benefit analysis and specific mention of renminbi, suggesting a simplification or shift in emphasis, not an expansion of hedging activity. The LLM incorrectly infers increased hedging of CNY when the evidence points to reduced disclosure, not increased action. (3) The LLM asserts that the same cost-benefit framework 'continues to drive' decisions in 2024, but the ground truth explicitly notes the omission of this discussion in 2024, undermining that claim. (4) While the LLM correctly identifies the use of forward contracts and references to certain currencies (euro, yen, Swiss franc), the reasoning is flawed in interpreting evolution: it sees a shift toward more active developing-market hedging, while the ground truth suggests a move toward less detailed disclosure or possibly a narrowed framework. Thus, despite some correct elements (use of forwards, currency names), the core interpretation of how the approach evolved is incorrect. Quantitative accuracy is moderate (6) because no numerical values are wrong—since none are present—but the dates (2022, 2024) and entity (Merck) are correct. Qualitative accuracy is low (4) due to incorrect synthesis and reasoning. Contextual relevance is high (8) as the answer addresses the right topic, time frame, and instruments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 577,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "In the 2023 filing RTX reported a $5.4 billion net‑sales charge and a partner‑share cost reduction tied to the “Powder Metal Matter,” and it listed a **$644 million** future income‑tax benefit for that matter. The 2024 filing still includes a Powder Metal Matter line, but the benefit has fallen to **$455 million**—a decline of about $189 million—showing that the tax effect of the matter is now smaller and is being phased out, though some benefit still remains.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is mostly correct but contains a minor quantitative inaccuracy: it reports the 2023 net-sales charge as $5.4 billion, while the ground truth states $5.3 billion. All other numbers are accurate—the $644 million and $455 million future income tax benefits for 2023 and 2024, respectively, are correctly cited, and the implied decrease of $189 million is accurate. 2) The quantitative accuracy is slightly compromised due to the $0.1 billion discrepancy in the net-sales charge, though this does not significantly alter the overall interpretation. Calculations (the decline in tax benefit) are correct. 3) The reasoning is sound: the LLM correctly identifies the shift from an operational impact (sales charge) in 2023 to a diminishing future income tax benefit in 2024, and infers that the matter is being phased out. It captures the evolving financial treatment and ongoing relevance, though it does not explicitly state the conceptual shift from operational loss to deferred tax asset as clearly as the original answer. 4) The answer is contextually fully relevant, addressing the change in disclosure and its implication for future income tax benefits. While the core insight about reduced immediate impact and progression toward resolution is implied, it could be more explicitly articulated. Overall, the answer is factually strong with minor inaccuracies and slightly less conceptual depth, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 399,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "By 2024 PayPal was still using the same partner‑institution model it had in 2022 – U.S. merchant loans are originated by WebBank, with PayPal buying the resulting receivables and retaining the servicing rights, while overseas advances are funded through its Luxembourg and Australian subsidiaries.  However, the size of the business has expanded: the amount of merchant receivables PayPal purchased grew from roughly $1.5 billion in 2022 to about $1.8 billion in 2024, and the net balance of its merchant‑finance portfolio rose from around $1.0 billion to $1.5 billion over the same period.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of PayPal's merchant receivables model correctly: it maintains the partnership with WebBank for U.S. originations, retains servicing rights, and shows growth in the scale of receivables purchased and portfolio balance. However, there are key quantitative inaccuracies. The original answer states that PayPal purchased $1.7 billion in 2023 and $1.8 billion in 2024, but the LLM claims $1.5 billion in 2022 and $1.8 billion in 2024, skipping 2023 and misstating the 2022 figure (which is not provided in the ground truth). The ground truth reports the outstanding balance as $1.2 billion at end-2023 and $1.5 billion at end-2024; the LLM incorrectly states it rose from $1.0 billion (not in source) to $1.5 billion, thus fabricating a 2022 baseline. Additionally, the LLM omits the specific increase in participation interest sold to the partner institution ($44M in 2023 to $53M in 2024), a key indicator of deepening institutional collaboration. While the qualitative structure—continued partnership model and portfolio growth—is sound and contextually relevant, the missing and inaccurate figures reduce quantitative accuracy. The multi-hop synthesis across years and entities is partially correct but lacks precision on financial figures and timeline details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 362,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Merck’s alliance revenue from Lynparza rose from **$1.116 billion in 2022** to **$1.199 billion in 2023** (≈ 7 % growth) and to **$1.311 billion in 2024** (≈ 9 % growth versus 2023, ≈ 17 % cumulative growth versus 2022)【MRK_10k_2024.pdf p. 53‑55】.  \n\nThe increase was “largely due to higher demand in most international markets” for the drug, which is sold under Merck’s collaboration with AstraZeneca and reported as Merck’s share of profits【MRK_10k_2024.pdf p. 53‑55】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. According to the ground truth, Merck's alliance revenue from Lynparza was $989 million in 2022, but the LLM claims it was $1.116 billion in 2022 and provides figures for 2023 and 2024 that are not present in the original answer. The ground truth states that revenue grew by 9% from 2022 to 2024, but the LLM reports a 9% growth from 2023 to 2024 and a cumulative 17% growth, which contradicts the provided information. There is no mention of 2023 data in the original answer, making the LLM's inclusion of it unsupported. (2) The calculation of growth rates and absolute values is therefore incorrect. The LLM’s reported figures ($1.116B → $1.311B) imply a much higher base and growth trajectory than the ground truth ($989M with 9% total growth, implying ~$1.078B in 2024), which is inconsistent. (3) While the LLM correctly identifies the contributing factor—increased demand in international markets—it adds a detail about a collaboration with AstraZeneca that, while factually plausible, is not present in the original answer and thus introduces unverified information. The original answer mentions a future approval in China in January 2025 as part of the growth drivers, which the LLM omits entirely. (4) Despite these issues, the LLM captures the general direction of growth and the qualitative driver (international demand), so the reasoning is partially sound and contextually relevant. However, the severe numerical inaccuracies and unsupported data points significantly undermine factual correctness, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 456,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "By 2022 PayPal’s merchant‑finance business was still modest – the company reported only a few‑tens‑of‑millions of merchant loans, advances and fees receivable and a relatively small credit‑loss allowance. By the end of 2024 that exposure had ballooned to roughly $1.5 billion of outstanding merchant receivables (over 90 % of which is “current”), with $1.8 billion of new merchant receivables purchased in the year and a credit‑loss allowance that, although falling to $113 million, still reflects a much larger portfolio. At the same time PayPal’s operational role deepened: it now purchases the receivables from a partner institution, services the loans, and collects repayment through a fixed‑fee or a percentage of the merchant’s future PayPal‑processed volume (PPWC/PPBL), whereas in 2022 the program was smaller and primarily a risk‑mitigation offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, it correctly states that PayPal purchased $1.8 billion in merchant receivables in 2024 and had $1.5 billion outstanding by end of 2024, matching the original answer. It also accurately references the $1.7 billion in 2023 purchases (implied context for growth), though this specific number isn't repeated in the LLM answer—this is a minor omission but not incorrect. The $113 million credit loss allowance is an additional detail not in the original answer but plausibly consistent with expanded exposure and does not contradict the ground truth. The 'few tens of millions' characterization for 2022 is reasonable as a contrast to the 2024 scale. (2) Calculations and comparisons are logically sound: the growth from modest exposure to $1.5B outstanding is correctly framed. (3) Multi-hop reasoning is strong—LLM synthesizes evolution in both financial exposure (increased purchases and balances) and operational role (servicing, collection mechanisms via PPWC/PPBL), correctly identifying the shift from risk mitigation in 2022 to active purchasing and servicing in 2024. (4) Entity accuracy is solid: correct company (PayPal), correct products (PPWC, PPBL), correct years (2022 vs 2024). Wording differs but semantic meaning matches. One point deducted from correctness due to not explicitly mentioning the $1.2B prior balance (though 'up from $1.2B' is implied in 'ballooned to $1.5B'), making the quantitative narrative slightly less complete. Otherwise, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 442,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "In the 2022 Form 10‑K Merck noted that Lynparza (olaparib) was already approved for several advanced cancers and that the company, together with AstraZeneca, had just **received a priority‑review supplemental NDA from the FDA for an adjuvant‑treatment indication in BRCA‑mutated, HER2‑negative high‑risk early‑stage breast cancer (OlympiA trial), with a PDUFA target in Q1 2022**, and that the same indication was also under review in the EU (pages 20‑22 of the 2022 filing).  \n\nBy the 2024 Form 10‑K the product had moved from a pending U.S. review to **full commercial availability worldwide**, with alliance‑revenue from Lynparza rising **9 % year‑over‑year to $1.311 billion in 2024 (up from $1.116 billion in 2022)**, driven by stronger demand in international markets, and the company highlighted that **China’s NMPA would approve Lynparza as an adjuvant therapy in early‑stage breast cancer in January 2025**, reflecting continued regulatory expansion (pages 53‑57 of the 2024 filing).  \n\nThus, from 2022 to 2024 Merck progressed from seeking FDA approval for a new adjuvant indication to broadening Lynparza’s global commercialization and achieving double‑digit revenue growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correctly identifies Merck's regulatory status in 2022: awaiting FDA decision on sNDA for adjuvant treatment of BRCA-mutated early breast cancer with PDUFA in Q1 2022, based on OlympiA trial, and notes EU review—consistent with 2022 10-K. (2) For 2024, correctly states continued global expansion, including upcoming January 2025 China NMPA approval for the same indication, showing regulatory momentum. This matches the original answer’s claim of a new China approval in January 2025. (3) Reports 9% year-over-year revenue growth in alliance revenue for Lynparza in 2024, which matches the ground truth. However, it adds specific dollar figures: $1.311 billion in 2024 vs $1.116 billion in 2022. While the 9% growth is accurate (verified: (1.311 - 1.116)/1.116 ≈ 17.5%, but this is over two years), the LLM incorrectly implies this 9% growth is from 2023 to 2024, while attributing the increase from $1.116B to $1.311B to a single year. This is a quantitative inconsistency: a 9% increase from ~$1.204B (implied 2023 value) would yield ~$1.312B, so the 2024 figure is likely correct, but the comparison to 2022 misrepresents the timeframe. The original answer only states 'grew by 9% in 2024' without specifying base year, so the percentage is acceptable, but introducing 2022 revenue as the baseline for a 9% YoY 2024 growth is misleading. (4) Multi-hop reasoning is strong: synthesizes regulatory progression and commercial performance across 2022 and 2024 filings. Entities (Merck, Lynparza, OlympiA, NMPA, FDA, PDUFA) are correct. Wording differs but meaning is semantically equivalent. The minor error in revenue timeline prevents a perfect score, but core facts and synthesis are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 479,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "In the 2022 filing Boeing described its commodity‑price strategy simply as using commodity swaps and purchase contracts to offset price swings, noting that a 10 % move in market prices would have produced about $46 million of unrealized loss on its commodity derivatives. By the 2024 filing the company says those contracts now hedge “forecasted transactions through 2028,” showing a deliberate extension of the risk‑management horizon, and the notional amount of hedged contracts fell to $388 million (from $514 million a year earlier). Consequently, the financial exposure has narrowed – OCI losses from commodity contracts were only $10 million in 2024 versus a $78 million gain in 2022, and the net liability on commodity contracts was a modest $22 million at year‑end.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. (1) Quantitative Accuracy: The ground truth states that Boeing extended hedging through 2031, but the LLM claims it was only through 2028 — a material discrepancy in time horizon. The LLM introduces specific figures not present in the original answer: a drop in notional amount from $514M to $388M, OCI losses of $10M in 2024 vs. a $78M gain in 2022, and a net liability of $22M. These numbers are absent from the ground truth and cannot be verified against it; thus, they appear fabricated or misattributed. Only the $46 million impact from a 10% price change in 2022 matches the original. (2) Completeness: While the LLM addresses risk management horizon and financial exposure, it fails to capture the strategic rationale in the original — namely, alignment with extended production planning cycles and proactive cost predictability for business stability — weakening qualitative accuracy. (3) Entity Accuracy: The company (Boeing) and years (2022, 2024) are correct, and the use of commodity swaps and purchase contracts is accurately noted. (4) Reasoning: The LLM attempts multi-hop reasoning by comparing disclosures across years, but the incorrect hedging horizon (2028 vs. 2031) and unsupported financial figures undermine the logic. The conclusion about narrowed exposure relies on unverified data. (5) Semantic Equivalence: The overall direction — that Boeing extended its hedging horizon and reduced exposure — is consistent, but the specific details and numerical claims deviate substantially from the ground truth. The introduction of precise figures absent in the source suggests overprecision or hallucination. Thus, while contextually relevant and partially accurate in direction, the answer is factually flawed in key quantitative and qualitative aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 503,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "Schwab’s securities‑lending portfolio (PALs) grew modestly – securities‑lending revenue rose from $330 million in 2022 (reflecting the 2021 balance) to $471 million in 2024 【SCHW_10k_2024.pdf p. 137‑138】 – but the company continued to treat the loans under ASC 326’s “collateral‑maintenance practical expedient.”  In both the 2021 and 2024 filings the firm stated that all PALs were fully collateralized by securities whose fair values exceeded the borrowings, so no allowance for credit losses was required at year‑end 2021, 2022, 2023 or 2024 【SCHW_10k_2022.pdf p. 93】.  Thus, while exposure increased, the credit‑risk profile remained unchanged because the loans stayed completely over‑collateralized and no credit‑loss allowance was recorded.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but fundamentally misrepresents the evolution of Schwab's credit risk and allowance for credit losses between 2021 and 2024, contradicting the ground truth. (1) Quantitatively, the LLM cites securities-lending revenue increasing from $330M in 2022 to $471M in 2024, which may be accurate per the cited pages, but this is not equivalent to PALs exposure and does not directly measure the loan balance or collateral levels. The original answer does not provide revenue figures, so this detail is extraneous and potentially misleading as a proxy for exposure. (2) The key factual error is the claim that 'no allowance for credit losses was required at year-end 2021, 2022, 2023 or 2024' — this directly contradicts the ground truth, which states that by 2024, Schwab *did* have an allowance for credit losses, albeit decreased due to lower projected loss rates and improved credit quality. The LLM incorrectly asserts that the allowance remained zero throughout, based on continued full collateralization, whereas the original answer describes a shift *away* from reliance solely on collateral toward a broader credit assessment framework that includes an allowance. (3) The reasoning is flawed: the LLM fails to recognize the conceptual shift described in the ground truth — from full collateralization as the sole mitigant (2021) to a more nuanced credit-risk model involving loss projections and allowances (2024). Instead, it claims the risk profile 'remained unchanged,' which is incorrect. (4) Entity and contextual accuracy are acceptable — PALs, Schwab, and ASC 326 are correctly referenced, and the answer addresses the question's scope. However, the core multi-hop synthesis — comparing risk treatment across time and identifying a strategic shift — is missing. The LLM relies on a static interpretation of collateralization, failing to reflect the dynamic evolution in credit risk management. Thus, while the answer is well-structured and cites sources, it is factually incorrect on the central point of whether an allowance existed in 2024 and how risk management evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 567,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "- **2022 filing (covering 2020‑2021):** Boeing recorded a **“reach‑forward loss” on the 777X program** as part of cost of sales, which helped drive a large rise in cost‑of‑sales percentages and a negative earnings impact.  At the same time, **R&D spending on the 777X fell**, contributing to an overall decline in commercial‑airplane R&D (the 2020‑19 drop was “primarily … lower spending on the 777X program”【source】.  \n\n- **2024 filing (covering 2022‑2024):** The company still **recognizes reach‑forward losses on the 777X (and 767) programs** in its cost‑of‑sales line, again pulling up the cost‑of‑sales figure for 2024【source】.  However, unlike 2022, **R&D outlays rose sharply** – the 2024 increase of $435 million in commercial‑airplane R&D was “primarily due to the 777X program at BCA”【source】, and 2023 R&D also grew because of the 777X.  \n\n**Thus, between 2022 and 2024 Boeing moved from treating the 777X mainly as a cost‑draining loss with reduced R&D investment to a situation where the program still generates reach‑forward losses but is now being funded with significantly higher R&D spending, reflecting a strategic shift to revive and bring the 777X back toward entry‑into‑service.**",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 'reach-forward loss' on the 777X program in 2022 as a negative financial impact, consistent with the original answer. It also accurately notes the increase in R&D spending in 2024 ($435 million) and references the prior-year increase (2023 over 2022), though it does not explicitly state the $525 million figure from 2023, which is a minor omission. (2) Quantitatively, the $435 million increase in 2024 is correctly cited. While the $525 million increase in 2023 (from the original answer) is implied through context ('2023 R&D also grew because of the 777X'), it is not explicitly mentioned, slightly reducing quantitative completeness. However, no numbers are incorrect—only one is omitted. (3) The reasoning is sound: the LLM correctly synthesizes a multi-hop narrative showing a shift from cost burden with declining R&D (2022) to continued losses but rising strategic investment via R&D (2024). This captures the core evolution in financial treatment and strategic positioning. (4) The answer is fully contextually relevant, directly addressing how Boeing’s financial and strategic approach to the 777X evolved. The conclusion about a strategic shift to revive the program is a reasonable inference supported by the data. Only the absence of the explicit $525M figure prevents a perfect score, but the trend is still accurately conveyed. Thus, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with minor detail omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 431,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "Schwab still classifies Portfolio‑Against Loans (PALs) as a low‑risk, over‑collateralized segment and continues to estimate the allowance for credit losses using the “practical‑expedient” based on its collateral‑maintenance provisions – i.e., the allowance is limited to the shortfall between amortized cost and the market value of the pledged securities and is updated daily as collateral values move. Between 2022 and 2024 the PAL exposure grew substantially, with pledged‑asset lines (the PAL portfolio) rising to roughly $17 billion at year‑end 2024 (up from a materially smaller balance in 2022), while the credit‑risk framework – daily monitoring, 90‑day charge‑off trigger and the same practical‑expedient allowance methodology – remained unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct qualitative aspects of Schwab's PALs risk management, such as the continued use of the practical expedient, daily collateral monitoring, and over-collateralization, which aligns with the 2022 ground truth. However, it introduces significant quantitative inaccuracies: it claims PAL exposure grew to $17 billion at year-end 2024, which is not supported by the original answer and introduces a specific figure absent in the ground truth. The original answer notes portfolio growth but does not quantify it and explicitly mentions a slight decrease in 2023, which the LLM omits. This omission distorts the trend. Additionally, the original answer emphasizes that the allowance ratio decreased in 2024 due to improved credit quality and lower projected loss rates—indicating an evolution in risk assessment—while the LLM states the methodology 'remained unchanged,' contradicting the nuance of evolving risk profile despite consistent framework. This misrepresents the evolution in credit loss allowance methodology interpretation or application. While entities (Schwab, PALs, practical expedient) and time frame (2022–2024) are correct, and the answer is contextually relevant, the incorrect growth narrative and missing 2023 dip undermine quantitative and qualitative accuracy. The reasoning is partially sound but fails the multi-hop synthesis by not reconciling portfolio growth with a decreasing allowance ratio due to improved risk metrics. Thus, the answer is partially correct but contains key factual and inferential errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 427,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "MDLZ reported an after‑tax gain of **$45 million** on its British‑pound‑sterling net‑investment hedge in 2022, but **no gain or loss (‑)** on the same hedge in 2023【MDLZ_10k_2023.pdf p. 99】. The disappearance of the GBP‑related gain suggests the company either unwound or fully hedged its pound‑denominated debt, reflecting a tighter‑than‑before approach to managing foreign‑exchange risk.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both numbers and context. The original answer states that MDLZ's value of British pound sterling notes was $3 million in 2022 and increased to $45 million in 2023. However, the LLM claims a $45 million after-tax gain in 2022 and no gain in 2023, which misrepresents both the metric (gain vs. note value) and the years. The $45 million figure is attributed to 2022 in the LLM answer but belongs to 2023 in the ground truth. (2) Quantitative accuracy is severely compromised: the values are not only assigned to the wrong years but describe a different financial concept (gains on hedges vs. the value of notes). There is no indication in the ground truth of a $45 million gain in 2022 or a zero result in 2023. (3) The multi-hop reasoning is flawed. The LLM interprets the data as evidence of unwinding or full hedging, suggesting tighter risk management, while the ground truth indicates increased exposure, implying a strategic shift toward greater pound sterling involvement. This is the opposite conclusion. (4) Contextual relevance is moderate because the answer addresses foreign exchange risk management and mentions the British pound, but it does so using incorrect data and documents (citing a gain from a hedge rather than the value of notes), leading to a misleading interpretation. The citation to MDLZ_10k_2023.pdf p.99 may refer to real data but is misrepresented in context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 399,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "In the 2022 Form 10‑K the 3.125 % 2025 senior notes are listed with a 3.125 % fixed coupon, but Amgen disclosed that it had entered into an interest‑rate‑swap that effectively converts the notes to a floating rate of **LIBOR + 1.8 %**. In the 2024 filing the same notes still carry the 3.125 % coupon, but the swap now references the new benchmark, giving an effective rate of **SOFR + 2.1 %**. This shows that Amgen consistently uses swaps to turn its fixed‑rate issuance into floating‑rate exposure and that it promptly transitioned the hedge from LIBOR to SOFR, reflecting a disciplined, market‑responsive approach to managing the cost and risk of this debt instrument.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% with no mention of variable rate terms, but the LLM claims that an interest-rate swap was already in place converting the rate to LIBOR + 1.8%. This detail is not supported by the original answer and introduces information not present in the ground truth. Similarly, the 2024 filing in the ground truth shows a shift to SOFR + 2.1%, implying a structural change in the note’s terms, but the LLM interprets this as a continuation of an existing swap program transitioning from LIBOR to SOFR—again adding unverified context. (2) Quantitatively, the percentages (3.125%, SOFR + 2.1%) are correct for the 2024 disclosure, but the LIBOR + 1.8% figure for 2022 is not mentioned in the ground truth and appears fabricated. There is no indication in the original answer that swaps were used at all in either year. (3) The multi-hop reasoning is partially sound in comparing disclosures across years and identifying a benchmark shift from LIBOR to SOFR, but it misrepresents the nature of the change: the original answer describes a shift from fixed to floating rate terms, while the LLM frames it as a continuation of an active hedging strategy. This mischaracterizes the company's approach. (4) Contextual relevance is high because the answer addresses the right instrument, company, and years, and attempts to explain strategic implications. However, due to the introduction of unsupported details about swaps, the qualitative and quantitative accuracy scores are low. The correctness score is 4 because while some key facts (the 3.125% coupon, the SOFR-based rate in 2024) are correct, the core explanation of Amgen’s debt financing approach is based on erroneous premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 498,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "In the 2022 Form 10‑K Schwab described its commercial‑paper issuance program as one of several diversified, “uncommitted” funding sources that it could tap if needed, but warned that a credit‑market disruption could make that source unavailable or more expensive. By the 2024 filing, after the 2023 bank‑failure turmoil and the rapid rise in short‑term rates, Schwab said it was increasingly turning to other supplemental funding (FHLB advances, repos, brokered CDs, etc.) because commercial‑paper costs had risen and market access had tightened, indicating a reduced reliance on the program relative to 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct contextual elements, such as the introduction of the Commercial Paper Issuance Program in 2022 as an uncommitted funding source and the impact of market disruptions and rising interest rates. It correctly references FHLB advances, repos, and brokered CDs as supplemental funding sources. However, the core factual claim—that Schwab reduced reliance on the commercial paper program by 2024—is directly contradicted by the ground truth, which states that Schwab's reliance on the program had *increased* by 2024 as a complement to other funding mechanisms due to higher client cash outflows and costly funding conditions. This reversal of the central trend results in a major qualitative inaccuracy. While the LLM correctly identifies rising commercial paper costs and tighter market access, it draws the opposite conclusion about usage trends. There are no explicit numerical values to verify, so quantitative accuracy is relatively high given the absence of incorrect numbers. Contextual relevance is fair because the answer addresses market disruptions, interest rates, and funding mechanisms, but the flawed synthesis of Schwab’s evolving reliance undermines the response. The multi-hop reasoning fails because the model incorrectly infers decreased reliance when the evidence points to increased use despite higher costs. This fundamental error in directionality severely compromises the answer’s correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 398,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "In the 2022 filing the company had already retired the original 3.625 % 2022 notes (the line shows “‑” for that series) and was carrying a $1.4 billion tranche of 3.625 % 2024 notes whose interest cost was being hedged with swaps at LIBOR + 3.2 % (see the “Effective interest rates” table). By the 2024 filing the 3.625 % 2024 notes and the related $1.4 billion of swap contracts had been repaid and terminated (the swap table now shows “‑” for that series and the narrative notes the swaps “matured in connection with the repayment of the 3.625 % 2024 Notes”). This progression shows the company’s strategy of actively redeeming its fixed‑rate notes as they approach maturity and using interest‑rate swaps to manage cost, thereby reducing outstanding debt and simplifying its capital structure.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a key discrepancy in the interest rate hedging details. The ground truth states that the 3.625% Notes were replaced with floating rates tied to SOFR in 2024, while the LLM claims the fixed-rate notes were hedged using swaps at LIBOR + 3.2% and that these swaps matured upon repayment. However, the ground truth does not mention LIBOR or specific swap rates, nor does it indicate ongoing hedging—instead, it emphasizes the structural shift to floating-rate debt. This misrepresents the nature of the debt replacement. The carrying value of $1.4 billion (or $1,400 million) is correctly identified for 2022, and the full repayment by 2024 with $0 notional is accurately reflected. (2) Quantitative accuracy is mostly sound: $1.4 billion = $1,400 million (format variation acceptable), and the years 2022 and 2024 are correctly used. However, the introduction of LIBOR + 3.2% and swap contracts is unsupported by the ground truth and introduces incorrect financial specifics. (3) The multi-hop reasoning is strong—the model correctly tracks the retirement of the 2024 notes from 2022 to 2024 and infers a strategic debt management approach. However, it incorrectly emphasizes interest rate swaps as a core part of the strategy, whereas the ground truth highlights a direct shift to SOFR-based floating rate debt, indicating refinancing rather than hedging. This affects the qualitative interpretation. (4) Despite the mischaracterization of the mechanism (hedging via swaps vs. refinancing into floating rate), the overall conclusion about active debt redemption and capital structure simplification aligns with the ground truth’s implication of strategic debt management. Hence, the answer is contextually relevant and qualitatively reasonable but loses points on quantitative and factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 503,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "In the 2022 Form 10‑K Schwab said that it **did not intend to provide any financial or other support to its variable‑interest entities beyond what was contractually required**.  Any funding of the VIEs’ remaining commitments was described as **conditional – CSB would fund the commitments only if certain pre‑specified conditions were met – and the company expected to satisfy those commitments during 2022‑2025**.\n\nThe 2024 Form 10‑K changes that language.  Schwab now states that **it intends to meet its outstanding commitments to the VIEs** (rather than merely “not intend” to provide support) and that **funding will still be made subject to the same condition‑based triggers**, but the company affirms a commitment to provide the financing when those conditions occur.  Thus, the company moved from a stance of “no intent to support” to an explicit intent to fund the VIE commitments, albeit only when the stipulated conditions are satisfied.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant misinterpretation of Schwab's evolving stance on VIE support, leading to a flawed conclusion. (1) Correct elements: The answer correctly identifies that in 2022, Schwab stated it did not intend to provide support beyond contractual obligations. It also accurately notes that funding commitments were conditional and expected to be satisfied between 2022–2025. The mention of condition-based triggers is consistent with the structure of VIE disclosures. (2) Quantitative accuracy: There are no numerical values to verify (e.g., dollar amounts, percentages), but timeframes (2022–2025) are plausibly presented and do not contradict the ground truth; no calculation errors. (3) Multi-hop reasoning failure: The core error lies in interpreting the 2024 change. The LLM claims Schwab now 'intends to meet its outstanding commitments' and has shifted from 'no intent to support' to 'explicit intent to fund', which misrepresents the actual evolution. According to the ground truth, the shift is not about fulfilling existing funding commitments, but about potentially providing *additional, discretionary* support (e.g., credit or liquidity) to its proprietary funds during market stress—despite no contractual obligation. The LLM incorrectly frames the change as a commitment to fund existing VIE obligations, when the real shift is toward *voluntary, extra-contractual support* under specific market conditions. (4) This mischaracterization undermines qualitative accuracy, as it confuses contractual funding commitments with discretionary support mechanisms. While the answer addresses the question’s timeframe and entities (Schwab, VIEs, 2022 vs 2024), it fails to capture the true nature of the policy evolution—proactive market-stabilizing support vs. passive fulfillment of existing conditions. Hence, correctness and qualitative accuracy are moderate due to major reasoning flaws despite correct use of terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 534,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "By the end of 2022 Mondelēz still held its equity‑method investment in JDE Peet’s (including the €300 million of zero‑interest exchangeable notes) mainly as a source of strategic flexibility, and the investment had no material impact on the company’s liquidity or debt profile. In 2023 Mondeléz sold a portion of that stake, which turned investing‑cash flow positive ( +$2.8 billion in 2023 versus a $4.9 billion outflow in 2022 ) and helped cut total debt to $19.4 billion (down from $22.9 billion) and the debt‑to‑capitalization ratio from 0.46 to 0.41, showing the JDE Peet’s investment moved from a non‑cash strategic asset to a source of cash that improved liquidity and strengthened the capital structure. (See “Liquidity and Capital Resources” and the cash‑flow and debt tables in the 2022 and 2023 10‑K filings.)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitative inaccuracies: The claim that MDLZ sold a portion of its stake in JDE Peet's in 2023, generating +$2.8 billion in investing cash flow and reducing debt from $22.9B to $19.4B, is not supported by the original answer or the knowledge graph. The ground truth does not mention any sale of stake, cash inflows, or specific debt reduction tied to JDE Peet's. These figures appear fabricated or misattributed. (2) The original answer states a reclassification of the relationship from 'Has_Stake_In' to 'Invests_In' and a qualitative shift toward financial flexibility, but does not reference any transaction, cash flow impact, or balance sheet changes. The LLM introduces specific numbers (€300M notes, $2.8B inflow, $4.9B outflow, debt reduction) with no basis in the provided truth. (3) Entity and reasoning errors: While the companies (MDLZ, JDE Peet's) and years (2022–2023) are correct, the LLM incorrectly infers causality between the investment and liquidity metrics. The original answer describes a reclassification and strategic alignment, not a divestment or financial restructuring driven by the sale. (4) Contextual relevance is moderate—the response addresses liquidity and capital structure as asked, but does so with incorrect mechanisms and fabricated data. The reasoning is not sound multi-hop synthesis but appears to hallucinate financials. (5) Semantic equivalence fails: the core claim (sale of stake improving liquidity) contradicts the ground truth (reclassification for strategic flexibility). Minor alignment exists in mentioning financial flexibility, but the basis is entirely different. Overall, major factual and quantitative errors severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 485,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "In the 2022 Form 10‑K the company’s fair‑value hedge for the $1 billion of 3.125 % 2025 notes used an interest‑rate‑swap that paid **LIBOR + 1.8 %** (the swap converted the fixed‑rate coupon to a floating LIBOR‑based rate).  \n\nBy the 2024 filing the same $1 billion of 2025 notes were still hedged, but the swap reference had been updated to the new benchmark, applying **SOFR + 2.1 %** instead of LIBOR.  \n\nThus, the hedging strategy remained a swap of the fixed‑rate notes to floating, but the underlying reference rate shifted from LIBOR to SOFR and the spread increased from 1.8 % to 2.1 %.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the 2022 interest rate under the swap. The original answer states that the exact rate for the 3.125% 2025 Notes swap in 2022 was not disclosed, but the LLM claims it was LIBOR + 1.8%, which is not supported by the ground truth. This is a critical quantitative error. The 2024 rate of SOFR + 2.1% and the notional amount of $1 billion are correctly stated and match the ground truth. (2) The dollar amount ($1 billion) and 2024 rate (SOFR + 2.1%) are accurate and align with the original answer. However, the 2022 rate (LIBOR + 1.8%) is fabricated—no such rate was disclosed, making the comparison between 1.8% and 2.1% invalid. The shift from LIBOR to SOFR is a reasonable inference given market trends, but the specific spread increase is not justified by the source. (3) The reasoning partially reflects multi-hop synthesis by comparing 2022 and 2024 disclosures, but it incorrectly assumes continuity and specificity in the 2022 swap terms. The model fails to acknowledge that the 2022 swap details were not fully disclosed, leading to an unjustified conclusion about the spread change. (4) The contextual relevance is high because the answer addresses the evolution of the hedging strategy and focuses on the correct notes and time frame. However, the quantitative accuracy is low due to the unsupported 2022 rate, and the qualitative accuracy is moderate because while the overall narrative of benchmark transition is plausible, it is not fully substantiated by the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 434,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Walmart reported that the fair‑value of its equity investments measured with Level 2 inputs was **$5.819 billion at January 31 2022** and **$5.570 billion at January 31 2023**【WMT_10k_2022.pdf Note 8】【WMT_10k_2023.pdf Note 8】.  \nThe Level 2 fair‑value therefore **decreased by roughly $0.249 billion (about $249 million)** from fiscal 2022 to fiscal 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values are accurate: $5,819 million (or $5.819 billion) in fiscal year 2022 and $5,570 million ($5.570 billion) in fiscal year 2023 are correctly reported. The difference is accurately calculated as $249 million (or $0.249 billion), which matches the ground truth's stated decline of $249 million. Minor formatting differences (billion vs million) are semantically equivalent and acceptable. (2) The answer addresses all parts of the question: it describes the evolution (decrease from FY2022 to FY2023) and quantifies the magnitude of change. (3) Entity accuracy is correct: Walmart (WMT), the metric 'fair value of equity investments measured using Level 2 inputs', and the correct fiscal years (ending January 31, 2022 and 2023) are all properly identified. (4) The reasoning is sound and reflects multi-hop synthesis across two 10-K filings (2022 and 2023), correctly comparing the values over time and computing the change. (5) The semantic meaning is equivalent to the original answer, with slightly different phrasing but identical factual content. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1152,
        "completion_tokens": 337,
        "total_tokens": 1489
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Apple’s description did not change. In both the 2023 and the 2024 Form 10‑K the company says it “relies primarily on the innovative skills, technical competence and marketing abilities of its personnel,” indicating the same characterization of its dependence on marketing talent.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. It states that Apple's description did not change between the 2023 and 2024 10-K filings, asserting that the same phrase—'relies primarily on the innovative skills, technical competence and marketing abilities of its personnel'—appears in both years. However, the ground truth confirms that Apple changed its language in the 2024 filing to 'depends heavily' on these factors and added new context linking them to the 'continual and timely flow of competitive products, services, and technologies to the marketplace.' This shift indicates an evolution in characterization, particularly emphasizing strategic reliance on marketing abilities amid competitive pressures. The LLM fails to detect this change, incorrectly asserting no difference, which represents a major factual and reasoning error. While there are no numerical inaccuracies (hence high quantitative accuracy), the qualitative analysis is flawed due to incorrect entity (textual content of filings) identification and failure to perform the required multi-hop comparison across years. The answer is relevant to the topic but fundamentally wrong in its conclusion, severely limiting its usefulness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 340,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "In the 2022 filing Amgen reported that it had $1.4 billion of 3.625 % 2024 notes and that the related interest‑rate‑swap hedge covered the full $1.4 billion, converting the fixed‑rate coupon to a floating rate of **LIBOR + 3.2 %** (see the 2022 table of swap notional amounts and rates).  \nBy the 2024 filing the 3.625 % 2024 notes had been repaid, the $1.4 billion swap **matured and was terminated**, leaving **no remaining notional or hedge** for those notes (the 2024 table shows “$ – / N A” for the 3.625 % 2024 notes, with a note that the $1.4 billion of swaps “matured in connection with the repayment of the 3.625% 2024 Notes”).  \n\nThis shift from a fully‑hedged $1.4 billion position in 2022 to no hedge in 2024 shows that Amgen’s hedging program is actively managed—swaps are put in place to match outstanding debt and are terminated when the underlying notes are retired, reflecting a disciplined approach to eliminating interest‑rate exposure as debt is repaid.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key quantitative details. According to the ground truth, in 2022 Amgen terminated $5.2 billion in interest rate swaps covering multiple notes including the 3.625% 2024 Notes, not just $1.4 billion as stated. The LLM incorrectly states that the 2022 hedge was for $1.4 billion specifically on the 3.625% 2024 Notes with a rate of LIBOR+3.2%, but the ground truth does not specify the exact rate for this tranche or confirm LIBOR usage; instead, it mentions SOFR+3.4% in 2023. Additionally, the LLM claims the swap matured in 2024 due to repayment, but the ground truth states the notional dropped from $1,400 million in 2023 to $0 in 2024, indicating an unwind rather than automatic maturity upon repayment. (2) The numbers are partially correct—the $1.4 billion figure aligns with the 2023 notional amount in the ground truth, and the final $0 notional in 2024 is accurate. However, the $5.2 billion 2022 swap termination (which covered multiple notes) is omitted, and the interest rate (LIBOR+3.2%) is inconsistent with the ground truth’s SOFR+3.4% in 2023. The shift from LIBOR to SOFR is significant and not addressed. (3) The multi-hop reasoning is sound in structure—linking hedge termination to debt repayment and inferring active management—but based on incorrect premises. The conclusion about disciplined hedging is reasonable but would be stronger if tied to the broader $5.2 billion swap restructuring in 2022. (4) Scores reflect partial correctness: quantitative accuracy penalized due to incorrect dollar amounts and rates; qualitative accuracy is moderate due to correct overall logic and entity identification (Amgen, 3.625% 2024 Notes); contextual relevance is high as the answer directly addresses the question’s components and provides meaningful interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 501,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "In the 2022 filing Schwab said it would **retain** TD Ameritrade Institutional’s customizable portfolio‑rebalancing tool, iRebal, as a separate offering for independent‑advisor clients. By the 2023 filing the company reported that it had **incorporated iRebal into its own Advisor Services platform**, making the solution a fully integrated part of Schwab’s technology suite for RIAs. This progression from merely keeping the tool to embedding it shows Schwab is leveraging the acquired platform to give advisors a more sophisticated, seamless rebalancing capability, reinforcing its competitive positioning as a technology‑rich, cost‑effective custodian in the RIA market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2022, Schwab decided to retain iRebal as a separate offering for independent advisors, and by 2023 had integrated it into its Advisor Services platform—this matches the evolution described in the original answer. The key entities (Schwab, TD Ameritrade Institutional, iRebal, RIAs) and timeframes (2022, 2023) are accurate. (2) There are no numeric values or calculations in the question or answer, so quantitative accuracy is not applicable in a numerical sense, but all factual assertions about integration progress are correct, earning full marks. (3) The reasoning is sound: the LLM correctly infers that moving from 'retain' to 'incorporated' indicates deeper integration and strategic emphasis, which supports the conclusion about enhanced competitive positioning in the RIA market. The original answer adds context about $1.6 trillion in assets and 15 million accounts transitioned, which the LLM omits—but this detail, while enriching, is not essential to answering the specific question about iRebal’s evolution and competitive implications. (4) The LLM captures the core multi-hop synthesis: from acquisition retention (2022) to platform integration (2023), and interprets the strategic significance correctly. Wording differs slightly (e.g., 'technology-rich, cost-effective custodian' vs. 'strong brand and corporate reputation') but the semantic meaning regarding competitive positioning is equivalent. One point deducted from qualitative and overall scores for minor incompleteness regarding broader integration context, but the answer remains factually correct and contextually strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 463,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "In the 2023 Form 10‑K, Apple’s iMac was mentioned only as a component of its existing Mac product family, with no specific product‑launch language. By contrast, the 2024 Form 10‑K lists the iMac among the “significant announcements” for the first quarter of fiscal 2024, indicating that Apple introduced a refreshed iMac model that year. Thus, Apple’s approach shifted from simply maintaining the iMac line in 2023 to actively updating and promoting a new iMac in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) It correctly states that in 2023, the iMac was mentioned only as part of the broader Mac product line without specific launch language, and in 2024, it was listed among 'significant announcements'—matching the original answer's claim about elevated strategic importance. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the fiscal year reference (first quarter of fiscal 2024) is consistent with typical 10-K disclosures and does not contradict the ground truth. (3) The multi-hop reasoning is sound: the model correctly infers a shift in strategic emphasis by comparing the nature of iMac mentions across two years’ filings, synthesizing information from both 10-Ks. (4) The answer captures the core evolution—maintenance vs. active promotion—and correctly identifies the implication of a product refresh. The only minor limitation is that it does not explicitly mention the MD&A section context or compare iMac’s 2024 positioning to other key launches like iPad Pro or MacBook Pro, which slightly reduces qualitative completeness. However, the omission does not detract from the essential correctness. Wording differs but semantic meaning is equivalent. All entities (Apple, iMac, 10-K, 2023, 2024) are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 375,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "In the 2022 Form 10‑K the 2.820 % senior notes due 2051 were listed with a $1 billion principal balance (issued in August 2021). The 2024 Form 10‑K shows the same 2.820 % notes due 2051 still on the balance sheet with an unchanged $1 billion balance and no repayment or refinancing recorded. This continuity indicates that RTX has retained the ultra‑long‑dated, low‑coupon notes as a core component of its capital structure, relying on very long‑maturity debt to anchor its overall long‑term financing mix.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that RTX issued the 2.820% Notes Due 2051 with a $1 billion principal balance and that this balance remained unchanged in both 2022 and 2024. This matches the ground truth, which states the principal was $1,000 million (i.e., $1 billion) in both years. The LLM also correctly notes no repayment or refinancing occurred, aligning with the original answer. However, the LLM mentions the notes were 'issued in August 2021'—a detail not present in the ground truth—and while likely accurate, it introduces information outside the provided context, slightly reducing quantitative precision. (2) All key numbers—$1 billion principal, 2.820% interest rate, maturity in 2051—are correct and consistently reported. The ground truth infers total long-term debt increased from $40,078 million in 2022 to $41,146 million in 2024, but this broader context is missing in the LLM answer. While not directly about the 2051 notes, this omission affects completeness regarding the evolution of RTX's overall long-term debt structure, which the question explicitly asks about. (3) The reasoning is sound: the LLM correctly infers that maintaining the 2051 notes with no change indicates strategic use of long-maturity debt. However, it fails to synthesize the multi-hop insight that while the 2051 notes were stable, total long-term debt grew—missing a key comparative analysis required by the question. This limits qualitative depth. (4) Despite the omission, the answer remains highly relevant, directly addressing the relationship with the 2051 notes and offering a reasonable interpretation of their role in capital structure. The core facts are correct, and the conclusion is logically supported, warranting a high score with minor deductions for incompleteness on the broader debt structure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 497,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "In the 2022 filing Schwab disclosed that it had **amended its Interest‑Deposit‑Agreement (IDA) to cut the service fee on client cash held at the TD Depository Institutions to 15 basis points, down from the 25 basis points that TD Ameritrade had paid under the prior IDA**【SCHW_10k_2022.pdf p.84‑85】.  \n\nIn the 2023 filing Schwab said it **has now transitioned the IDA (and related inter‑company loans) away from LIBOR to alternative reference rates**, updating the agreement’s benchmark while keeping the lower fee structure in place【SCHW_10k_2023.pdf p.55‑56】.  ",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the 2022 fee reduction from 25 to 15 basis points is accurately reported, and the 2023 transition from LIBOR to alternative reference rates is correctly stated. The specific details — including the prior fee under TD Ameritrade’s agreement — are factually consistent with the source. (2) The answer is complete, addressing both sub-questions: evolution of service fees (2022) and reference rate adjustments (2023). (3) Entities are accurate: Schwab, IDA, TD Depository Institutions, and correct years (2022 and 2023) are properly identified. (4) The reasoning is sound and reflects multi-hop synthesis: it connects the 2022 fee change with the 2023 benchmark transition, showing how the agreement evolved over time across different dimensions (fee structure → reference rate). The inclusion of document citations adds verifiability. (5) Semantically, the LLM conveys the same core evolution as the original answer — a shift from fee adjustments to reference rate modernization — with slightly more detail (e.g., mentioning inter-company loans), which enhances clarity without introducing error. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 345,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "In 2023 Colgate‑Palmolive tested Filorga as its own reporting unit, carrying $221 million of goodwill and evaluating its fair value separately. By 2024 the brand is simply listed with the other global trademarks in the segment disclosures, with no distinct goodwill line‑item. This shift signals that the company now views Filorga as a more integrated, lower‑priority part of its broader brand portfolio and is valuing it at the segment level rather than as a standalone strategic asset.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: Filorga had $221 million in goodwill as a standalone reporting unit in 2023, and by 2024 it was no longer separately disclosed—this matches the original answer exactly. Format is consistent and acceptable. (2) The answer addresses both parts of the question: the change in financial treatment and its implications for strategic importance and valuation approach. It correctly infers that the removal of a separate goodwill line item suggests reduced strategic priority and integration into broader segments. (3) Entity accuracy is strong: 'Filorga' and the timeline (2023 to 2024) are correct; while 'Colgate-Palmolive' is mentioned (not in the original), this may reflect external knowledge about ownership and does not contradict the ground truth. (4) The reasoning is sound: moving from standalone to aggregated reporting implies a shift in valuation and strategic focus, which is a valid inference supported by accounting practices. The only minor gap is that the original answer elaborates slightly more on potential strategic consequences (e.g., divestiture, investment decisions), which the LLM omits. However, the core insight about integration and reduced visibility is preserved. Overall, the answer is factually correct, contextually appropriate, and semantically equivalent to the ground truth with only slight reduction in depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 404,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "In the 2023 Form 10‑K (see pages 22‑26) Apple’s “Product, Service and Software Announcements” section only enumerated the iPhone 15 family and did not reference an iPhone 16 Pro, indicating that the next‑generation model was still in the conceptual or early‑development stage and was not disclosed as a concrete launch item. By the 2024 Form 10‑K (see pages 4‑5), Apple’s announcement list for the fourth quarter explicitly includes “iPhone 16, iPhone 16 Plus, iPhone 16 Pro and iPhone 16 Pro Max,” showing that the company has moved the device into a defined, market‑ready product line and is now providing specific model‑level detail in its regulatory filing. This shift reflects an evolution from a more general product outlook to a detailed, forward‑looking roadmap, signalling greater confidence in the development timeline and a more transparent reporting strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the 2023 10-K mentioned the iPhone 16 Pro as part of the Fourth Quarter 2024 product lineup, but the LLM claims it was not referenced at all and was in 'conceptual or early-development stage.' This contradicts the original answer. Conversely, the LLM correctly states that the 2024 10-K includes the iPhone 16 Pro in the announced product list, aligning with the ground truth. However, the LLM mischaracterizes the evolution as a move toward a 'forward-looking roadmap,' while the ground truth describes it as a shift from forward-looking (planning) to retrospective (established product), indicating the opposite directional change in disclosure. (2) There are no explicit numbers, percentages, or dollar amounts in the question or answers, so quantitative accuracy is based on correct referencing of years and product timelines. The LLM correctly identifies the 2023 and 2024 10-Ks and their respective disclosures, earning partial credit. (3) The multi-hop reasoning is flawed: the model fails to recognize that mentioning a product in a future quarter's plan (2023 filing) and then listing it among existing products (2024 filing) reflects progression from future to current status, not an increased forward-looking disclosure. Instead, the LLM incorrectly interprets the 2024 mention as part of a forward-looking announcement, missing the retrospective integration into the product lineup. (4) Despite incorrect reasoning and key factual errors, the answer is contextually relevant—it addresses Apple’s product disclosure evolution between 10-K filings and focuses on the iPhone 16 Pro. However, the core factual and logical errors severely undermine correctness, warranting a low score. Semantic equivalence is not achieved due to contradictory claims about disclosure content and direction of strategic change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 519,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "In the 2022 filing Schwab described EVE simulations as a “long‑term” balance‑sheet stress test that applied instantaneous parallel rate shifts using historical‑behavior assumptions for interest‑rate scenarios, pre‑payment speeds, term‑structure models, non‑maturity deposit behavior and pricing, and it noted that the results assumed non‑negative investment yields. By the 2023 filing the approach had been broadened: the EVE calculation now also incorporates the effect of interest‑rate swap derivatives, uses both proprietary and third‑party term‑structure and pre‑payment models plus internally built run‑off models for client credits and deposits, and places explicit emphasis on the changing balance‑sheet dynamics—specifically that liability duration shortened sharply (making liabilities shorter than assets) and therefore EVE sensitivity rose as rates increased.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually plausible and well-structured, with accurate dates (2022 and 2023) and correct use of financial terminology, satisfying quantitative accuracy and contextual relevance. However, there are significant discrepancies in qualitative accuracy when compared to the ground truth. The original answer states that in 2023, the company expanded EVE simulations to include the impact of client cash allocation changes on the balance sheet—a key evolution not mentioned in the LLM response. Instead, the LLM introduces new details not present in the ground truth, such as the inclusion of interest-rate swap derivatives, use of proprietary/third-party term-structure models, and internally built run-off models for client credits and deposits. These specific modeling enhancements (e.g., derivatives, run-off models) are not supported by the original answer and represent overreach or hallucination. Additionally, while the LLM correctly notes increased focus on balance sheet dynamics, it misattributes the nature of that change—focusing on liability duration shortening and duration mismatch—whereas the ground truth emphasizes client cash allocation behavior as the new modeling component. The reasoning is logically coherent but based on incorrect or unsupported details, undermining the multi-hop synthesis. Thus, while the answer addresses the general evolution of EVE use and maintains correct context and formatting, it misses the core factual evolution described in the original and substitutes it with plausible but unverified technical enhancements, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 440,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "In the 2022 filing Qualcomm described its role in the networking market as **an enabler of wireless‑access‑point technology** – the company supplied the underlying Wi‑Fi, RF and RFFE components and licensed the patents that let other manufacturers build access‑point equipment (see 2022 10‑K, “edge networking (including mobile broadband and wireless access points)” and the “networking products include … wireless access points” description [pages 8‑9]).  \n\nBy the 2023 filing Qualcomm announced that it now **offers complete wireless‑access‑point products** as part of its QCT portfolio, listing “wireless access points” alongside Wi‑Fi, Ethernet and router chips (2023 10‑K, QCT networking‑product overview [page 11]).  \n\nThis shift moves Qualcomm up the value chain: it changes its competitive stance from a pure technology‑supplier/licensor to a direct competitor in the edge‑networking hardware space, and it widens its product breadth by adding finished access‑point solutions to its already‑broad portfolio of chips, processors and connectivity modules.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies Qualcomm's shift from enabling wireless access point technologies in 2022 (via components and IP licensing) to directly producing complete wireless access point products in 2023. The years (2022 and 2023) and the nature of the strategic shift are accurately represented. (2) There are no numerical values requiring calculation, but the references to specific 10-K filings (pages 8–9 for 2022, page 11 for 2023) align with the expected sourcing and add precision. Format variations in financial or product terminology are not applicable here, but the use of consistent technical terms (e.g., 'wireless access points', 'Wi-Fi chips', 'QCT portfolio') matches the domain. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, infers the strategic evolution, and explains the implications—moving up the value chain, expanding product breadth, and shifting competitive positioning. It correctly identifies the competitive context (vs. Broadcom, Intel implied in ground truth) by noting direct competition in edge-networking hardware. (4) The answer addresses both parts of the question: the effect on competitive positioning (from enabler to direct competitor) and product portfolio breadth (addition of finished access-point solutions to existing chips and modules). Wording differs slightly but meaning is preserved and enhanced with specific filing references. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 433,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "In the 2022 filing Schwab reported that, of its adjustable‑rate first‑mortgage portfolio, about **28 %** of the balance was structured with interest‑only payments and **≈ 89 %** of those interest‑only loans were not scheduled to reset for three or more years. By the 2023 filing the share of adjustable‑rate mortgages with interest‑only terms had slipped slightly to **≈ 27 %**, and the share whose rates won’t reset for three + years fell to **≈ 86 %**. Thus, both the prevalence of interest‑only features and the length of the reset‑free period have modestly declined from 2022 to 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 28% and 89% in 2022, and 27% and 86% in 2023. The use of '≈' (approximately) is acceptable and does not distort precision, as the original data is presented as whole numbers. (2) The answer is complete, addressing both components of the question: the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years, for both 2022 and 2023. (3) Entity accuracy is correct—Schwab is the subject, and the metrics (interest-only terms, reset periods) are properly identified. (4) The reasoning is sound: the LLM correctly synthesizes multi-hop information across two years and two metrics, and draws a logical conclusion about a modest decline in both the prevalence of interest-only features and the reset-free period. (5) Semantic equivalence is maintained—the wording differs slightly but conveys the same factual content and interpretation as the original answer. No errors in calculation, logic, or fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 314,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "In its 2022 filing Qualcomm said that its Qualcomm Ventures arm was making “strategic investments … in … XR” and that XR devices were grouped with consumer products inside the IoT revenue stream. The 2023 filing repeats the same investment focus on XR and still classifies XR‑enabled products under IoT, but the IoT segment’s revenue fell from $7.353 billion in FY 2022 to $5.940 billion in FY 2023, indicating that Qualcomm’s XR‑related product sales have contracted year‑over‑year while its strategic investment emphasis on XR has remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but fundamentally misrepresents the evolution of Qualcomm's XR involvement. While it correctly notes that Qualcomm Ventures made strategic investments in XR in 2022 and that XR-related products were grouped under IoT, it incorrectly concludes that XR product sales contracted year-over-year based on the decline in total IoT revenue. The ground truth does not support this inference—there is no indication that XR-specific revenue declined, nor is there evidence that XR revenue can be isolated from the broader IoT segment. Moreover, the LLM fails to recognize the key shift highlighted in the original answer: in 2023, XR was explicitly listed as an industry for which Qualcomm sold products, signaling a move from pure investment to commercialization. Instead, the LLM claims that 'strategic investment emphasis on XR has remained unchanged,' missing the evolution entirely. (2) Quantitatively, the revenue figures cited ($7.353 billion in FY2022 and $5.940 billion in FY2023 for IoT) are plausible and may align with the filings, though the ground truth does not confirm these exact numbers. However, the use of this aggregate IoT decline to infer XR revenue contraction is invalid, as XR is only one component of IoT and no breakdown is provided. Thus, while the numbers themselves may be accurate, their interpretation is flawed. (3) The multi-hop reasoning is unsound: the model fails to connect the key qualitative shift—from indirect involvement via investments to direct product sales—despite this being the central evolution. It incorrectly assumes that lack of revenue growth in IoT implies reduced XR activity, which is not supported by the evidence. (4) The contextual relevance is moderate because the answer discusses the right company, time frame, and general domain (XR, IoT, Qualcomm Ventures), but the core conclusion contradicts the ground truth. The answer focuses on revenue decline rather than the strategic shift to commercialization, leading to a significant factual and interpretive error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 558,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The aggregate principal balance of RTX’s 3.030 % notes due 2052 was **$1.1 billion in 2022** and remained **$1.1 billion at the end of 2024**. The unchanged balance shows that this ultra‑long‑dated, low‑coupon issuance has been retained as a stable component of RTX’s long‑term debt mix, reflecting the company’s strategy of locking in inexpensive financing for the distant future.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the aggregate principal balance of the 3.030% Notes Due 2052 as $1.1 billion in both 2022 and 2024, which matches the ground truth value of $1,100 million (equivalent to $1.1 billion). The time periods are accurate, and the stability of the balance is correctly noted. 2) Quantitatively, all numbers are correct: $1.1 billion is a valid reformatting of $1,100 million, and the years 2022 and 2024 are accurately referenced. No calculations are required beyond recognition of consistency, which is handled correctly. 3) The reasoning is sound: the LLM correctly infers that the unchanged balance indicates strategic retention of this long-term debt instrument, particularly emphasizing its role as a stable, low-cost, long-dated financing tool. This aligns with the ground truth's interpretation of strategic consistency, though the LLM adds contextual color (e.g., 'ultra-long-dated', 'locking in inexpensive financing') not present in the original, which is reasonable and insightful but slightly more interpretive. 4) The answer fully addresses both parts of the question: the evolution (stable) and the implication for RTX's long-term debt structure. The entities (RTX, 3.030% Notes Due 2052) and financial metric (aggregate principal balance) are correctly identified. The only minor gap is the absence of explicit mention that no repayments or issuances occurred, but the conclusion of stability implies this. Overall, the answer is factually correct, contextually appropriate, and semantically equivalent to the ground truth with slightly more interpretive language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 439,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "In both its 2023 and 2024 10‑K filings American Express repeats the same strategic priority: “to build on our strong position in commercial payments by evolving our card value propositions, further differentiating our corporate‑card and accounts‑payable expense‑management solutions and designing innovative products and features, including financing, banking and payment solutions for our business customers.” The continued and explicit emphasis on the corporate‑card and AP‑expense‑management suite shows the company is moving these products from a peripheral offering to a core pillar of its commercial‑payments business, signaling a broader strategy to deepen its foothold with corporate clients and expand beyond traditional card‑only revenue into integrated financing and banking services.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its use of the quoted strategic language and correctly identifies AXP's focus on corporate card and expense management solutions. However, it incorrectly implies that the *exact same* strategic priority language was used in both 2023 and 2024, failing to capture the evolution highlighted in the ground truth. The original answer notes a shift in emphasis: in 2023, AXP focused on differentiating corporate card and accounts payable solutions, while in 2024 the language evolved to emphasize 'innovative products and features, including financing, banking and payment solutions,' indicating a broader, more integrated strategy. The LLM treats the strategy as static across years, missing the nuanced shift from product differentiation to a more holistic, solution-oriented approach. This undermines the qualitative accuracy of the multi-hop reasoning, as the model fails to detect and explain the change over time. There are no numerical inaccuracies (hence high quantitative score), and the response is contextually relevant, but the lack of temporal comparison and misrepresentation of continuity in strategy reduces correctness. The core idea—that AXP is expanding beyond cards into integrated services—is present, but the reasoning for how this shift occurred is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 364,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K describe PCA SKIN as a skin‑health brand that sits within the Oral, Personal and Home Care segment. In each filing the company says that products in this segment – including PCA SKIN – are sold “primarily to a variety of traditional and e‑commerce retailers, wholesalers, distributors, dentists and, in some segments, skin‑health professionals.” There is no new language in the 2024 filing indicating a change in channel strategy, so the brand’s strategic positioning and its distribution mix (retail, e‑commerce, wholesale/distributor and skin‑health‑professional channels) remained essentially the same from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no change in distribution channels between 2023 and 2024. The ground truth states that in 2024, the filing specifically expanded PCA SKIN's distribution channels to include sales to skin health professionals in some geographies, indicating a refinement in strategic positioning. The LLM incorrectly asserts that the language was the same in both years and that there was no new language in 2024, which contradicts the ground truth. While the entities (PCA SKIN, Colgate-Palmolive, Oral/Personal/Home Care segment) and years (2023, 2024) are correctly identified, and there are no numerical inaccuracies (hence a high quantitative accuracy score), the qualitative reasoning fails because it misses the key evolution in distribution strategy. The answer synthesizes information incorrectly across the two years, failing the multi-hop requirement to detect a change in channel emphasis. Contextually, the response is relevant and well-structured, but the central conclusion is wrong, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 314,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "In the 2022 filing BMY 10‑K the company described Opdivo as a PD‑1‑blocking antibody already approved for a broad set of metastatic cancers (bladder, RCC, HCC, NSCLC, melanoma, etc.) and emphasized ongoing registrational studies to add **new tumor types and earlier‑line uses**, especially in combination with Yervoy and other agents. By the 2023 filing the focus had shifted to **launching Opdivo in earlier‑line, adjuvant and neoadjuvant settings** – FDA approval for adjuvant stage IIB/IIC melanoma (Oct 2023), EC approvals for adjuvant melanoma and neoadjuvant platinum‑based chemo‑combined NSCLC (June 2023), and a Japanese neoadjuvant NSCLC indication (Mar 2023) – together with continued Yervoy combos and a sub‑cutaneous formulation pipeline. These new indications and combination regimens broaden Opdivo’s market reach and are cited as a key driver of the **increase in Opdivo demand that helped offset overall revenue declines in 2023**, indicating that its commercial positioning is now a growth engine for the company’s oncology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Opdivo's broad existing indications in 2022 and the strategic focus on new tumor types and earlier-line therapies, including combinations with Yervoy. The 2023 evolution is accurately described with specific new approvals: adjuvant melanoma (FDA, Oct 2023), neoadjuvant NSCLC in Europe (June 2023), and Japan (Mar 2023), all of which are consistent with the strategic shift toward earlier lines of therapy. The mention of the subcutaneous formulation as a pipeline enhancement matches the original answer. (2) Quantitatively, all dates and indications are correct; no numerical inaccuracies are present. While the original answer does not list exact approval dates, the LLM provides more granular detail that is factually consistent with public FDA/EMA records and does not contradict the ground truth. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2023), indications (metastatic to adjuvant/neoadjuvant), and geographies (U.S., EU, Japan), correctly inferring that these expansions support revenue resilience despite overall portfolio declines. The conclusion that Opdivo became a growth engine is logically supported and consistent with the implication in the original answer about sustaining revenue growth. (4) The LLM adds specificity not in the original (e.g., exact approval dates and settings) but remains semantically equivalent and factually correct. Only a minor deduction is made from 10 due to slightly more detail than warranted by the ground truth, but this does not affect correctness. All key elements—new indications, combination therapies, strategic shift, delivery innovation, and revenue implications—are accurately addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1514,
        "completion_tokens": 484,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "American Express’s foreign‑government‑bond portfolio slipped slightly in fair‑value, from $770 million at year‑end 2023 to $765 million at year‑end 2024.  The maturity profile stayed almost unchanged – roughly $768 million (2023) and $764 million (2024) of the securities were due within one year, with only $2 million (2023) and $1 million (2024) due in the 1‑to‑5‑year window and no holdings beyond five years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers. According to the ground truth, American Express held $549 million in foreign government bonds in 2023, not $770 million as stated in the LLM answer. The 2024 value of $765 million is correct. The maturity distribution in 2023 is completely misrepresented: the ground truth states that *all* $549 million matured in 12 months or more (i.e., long-term), whereas the LLM claims $768 million matured within one year — which contradicts the data. In 2024, the LLM correctly reports $764 million maturing within one year and $1 million in the 1-to-5-year window. (2) Quantitative accuracy fails on critical points: the 2023 fair value is off by $221 million, and the maturity split in 2023 is entirely wrong. The LLM suggests a slight decrease in fair value, while the truth is a significant increase from $549M to $765M. (3) Multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of both fair value and maturity distribution over time. It incorrectly infers continuity in maturity profile when in fact there was a dramatic shift from long-term to short-term maturities. (4) Contextual relevance is acceptable because the answer addresses fair value and maturity distribution across years, but factual inaccuracies severely undermine correctness. The conclusion about 'almost unchanged' maturity profile is the opposite of the truth — the shift from entirely long-term to almost entirely short-term is a major change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 419,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "In 2022 Walmart reported that about $4.3 billion of its cash held outside the United States could not be freely transferred to the U.S.; roughly $2.2 billion of that amount could be accessed only through dividends or inter‑company financing that required the approval of Flipkart’s minority shareholders. By 2024 the restricted pool had fallen to about $3.5 billion, and the company said the cash may be blocked by local laws or other restrictions or may require the consent of non‑controlling‑interest shareholders, but it continues to rely on inter‑company financing to move cash to the jurisdictions where it is needed at the lowest cost.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor quantitative inaccuracy: it states that the restricted cash in 2024 was 'about $3.5 billion', while the ground truth reports $3.3 billion. This is a small deviation but still a factual error. All other numbers are accurate — the 2022 figure of $4.3 billion and the $2.2 billion tied to Flipkart minority shareholders are correctly reported. (2) The qualitative description of the evolution is strong: the shift from Flipkart-specific shareholder approval to a broader condition involving non-controlling-interest shareholders is accurately captured, and the mention of local laws and other restrictions aligns with the more generalized framing in the 2024 report. The continued use of intercompany financing to optimize cash movement is contextually appropriate and adds relevant detail not contradicted by the ground truth. (3) Multi-hop reasoning is sound — the model correctly synthesizes information across two years, identifies the change in both amount and governance conditions, and infers a trend in the structure of financing arrangements. (4) The correctness score is 8 due to the $0.2 billion discrepancy in the 2024 figure; otherwise, the answer is comprehensive and semantically equivalent to the ground truth. Quantitative accuracy is slightly penalized for the incorrect dollar amount, but qualitative accuracy and contextual relevance remain high due to accurate reasoning and appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 409,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "In the 2023 filing the U.S. Retiree Health Care Plan held $210 million of fixed‑income securities and cash equivalents and $54 million of equity securities (about 80 % fixed income/20 % equity). By the 2024 filing those balances had slipped to $198 million of fixed‑income and cash and $50 million of equity (still roughly 80 % fixed income/20 % equity). Thus, while the absolute dollar amounts fell modestly, the overall asset‑allocation mix remained essentially unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claims. According to the ground truth, the asset values for Texas Instruments' U.S. Retiree Health Care Plan were identical in 2023 and 2024: $210 million in fixed income securities and cash equivalents, and $54 million in equity securities in both years. The LLM incorrectly states that these declined to $198 million and $50 million in 2024, which contradicts the ground truth. (2) The percentages cited (~80% fixed income, ~20% equity) are approximately correct (ground truth: 79.5% and 20.5%), so the proportional allocation description is reasonable, but the absolute dollar amounts are wrong. The total plan assets remained $264 million in both years; the LLM implies a drop to $248 million, which is inaccurate. (3) The multi-hop reasoning is flawed because the model failed to recognize that the data was identical across filings, which is the key insight. Instead, it fabricated a decline in asset values, indicating a failure in synthesizing the correct information from both years. (4) The contextual relevance is high because the answer addresses the right plan, company, and asset classes, and interprets the question correctly in terms of comparing allocation over time. However, the quantitative inaccuracies severely undermine correctness. The qualitative reasoning would be stronger if based on accurate data, but the conclusion that the mix 'remained essentially unchanged' is misleading since the dollar amounts did not change at all—there was no 'slippage.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 427,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "In the 2022 Form 10‑K the 2006 Stock Plan for Non‑Employee Directors is described only with two award‑agreement exhibits – the basic **Form of Option Agreement** (Exhibit 10.29) and the **Omnibus Amendment to the Form of Option Agreement** (Exhibit 10.30)【2022 p. 123‑124】.  \n\nBy the 2024 filing the same plan also includes a **Form of Stock‑Option Award Agreement** (added as a new exhibit for the 2006 plan) alongside the original option‑agreement forms【2024 p. 124‑125】.  \n\nThe addition of a separate stock‑option award agreement suggests that Honeywell has broadened the types of awards it can grant to non‑employee directors, moving from a single‑form option grant to a more flexible structure that can accommodate both standard option grants and more formalized award documents. This likely reflects an evolution toward a more sophisticated, diversified compensation framework for its non‑employee directors.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) In the 2022 filing, the ground truth states that both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) were listed, but the LLM incorrectly claims only option-related agreements were present—specifically citing Exhibit 10.29 and 10.30 as both being option agreements, and omitting the restricted unit agreement entirely. This misrepresents the key evolution in award forms. (2) The LLM incorrectly states that a 'Form of Stock-Option Award Agreement' was added in 2024 as a new exhibit, whereas the ground truth confirms that while the option agreement was still referenced (Exhibit 10.29), the notable change was the *absence* of the restricted unit agreement, not the addition of a new option form. (3) The reasoning is therefore flawed: instead of identifying a potential shift *away* from restricted units toward options, the LLM suggests a broadening of option-based awards, which contradicts the evidence of a narrowing in equity award types. (4) The multi-hop synthesis fails—correctly answering the question requires comparing the presence of restricted units in 2022 and their absence in 2024, which the LLM overlooks entirely. While the answer is relevant to director compensation evolution, the factual foundation is incorrect, leading to an invalid conclusion. Minor formatting differences in exhibit numbers (e.g., 10.29 vs 10.30) are not the issue—the core error is the omission of restricted units and mischaracterization of changes. Thus, despite plausible-sounding reasoning, the answer is largely incorrect on key facts and implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 462,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "In the 2022 Form 10‑K Walmart disclosed that it had sold a small block of Flipkart shares for about $3.2 billion, cutting its ownership from roughly 83 % to about 75 % and thereby retaining a clear majority position. The filing also warned that the company remained subject to Indian regulatory scrutiny – a foreign‑direct‑investment show‑cause notice and a Competition Commission antitrust probe – which could, if resolved unfavorably, require additional financial write‑downs or restrictions on the investment. The 2024 Form 10‑K shows that Walmart has not further altered its stake in Flipkart; it continues to hold the majority interest and the same regulatory matters are still disclosed, indicating that the financial impact of the 2022 sale was a one‑time cash inflow and that any future exposure to Indian enforcement actions remains an unresolved risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, all numbers are correct: the $3.2 billion equity funding event, reduction in ownership from 83% to 75% in 2022, and retention of majority control are accurately reported. There are no calculation or date errors. (2) The LLM correctly identifies that Walmart did not further alter its stake by 2024, which is consistent with the original answer’s focus on ongoing regulatory exposure despite the earlier financial exit. (3) Regarding qualitative accuracy, the LLM correctly synthesizes information across 2022 and 2024 Form 10-K filings, noting the continuation of regulatory scrutiny including FDI-related show cause notices and antitrust probes. However, it slightly generalizes the timing of the regulatory actions—while it correctly notes ongoing disclosure in 2024, it does not specify that the show cause notice was issued in July 2021 (pre-acquisition period 2009–2015), a detail present in the ground truth. This omission slightly weakens the multi-hop reasoning but does not distort the overall narrative. (4) Contextually, the answer fully addresses the evolution of Walmart’s strategic position—financial implications (one-time cash inflow from stake sale) and regulatory risk exposure—and correctly frames the shift from active investment to risk management. The answer is semantically equivalent to the ground truth with only minor contextual omissions, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 412,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "In the 2022 Form 10‑K Honeywell reported that its cash‑and‑cash‑equivalents portfolio (including short‑term investments) was roughly $11.5 billion at year‑end 2021 (down from $15.2 billion in 2020) and the filing highlighted U.S. cash balances as a key liquidity source but did not break out how much was held outside the United States. By the 2024 filing the total cash pool had contracted to $11.0 billion, and the company disclosed that $8.0 billion of that amount was held in non‑U.S. subsidiaries—leaving about $3.0 billion in U.S. accounts—while reiterating a strategic focus on the safety of principal, secondary yield and diversification of cash across multiple counterparties. Thus, between 2022 and 2024 Honeywell’s overall cash holdings stayed roughly flat, but the geographic mix shifted to a much larger share of cash held abroad and the emphasis on prudent, diversified U.S. cash management remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: $11.5 billion in cash as of year-end 2021 (reported in 2022 10-K), $11.0 billion as of year-end 2024 (reported in 2024 filing), and $8.0 billion of that held in non-U.S. subsidiaries. The derived figure of $3.0 billion in U.S. accounts is accurate and logically sound. (2) All numbers match the ground truth exactly—no calculation or date errors. The mention of a decrease from $15.2 billion in 2020 is additional context not in the original answer but is factually correct and does not detract from accuracy. (3) The multi-hop reasoning is strong: the model correctly infers a shift in geographic distribution (from no breakdown in 2022 to $8B abroad in 2024) and maintains the consistent strategic emphasis on safety, diversification, and yield. The only minor gap is that the original answer emphasizes the continuity of strategy more explicitly, while the LLM slightly rephrases it as 'prudent, diversified U.S. cash management,' which is semantically close but slightly narrower than the original 'safety of principal and diversification among counterparties'—a subtle nuance, not an error. (4) The answer fully addresses the question’s two components: evolution in total cash holdings (stable at ~$11.5B to $11.0B) and geographic distribution (increased non-U.S. share). Wording differs but meaning is equivalent. Scores reflect near-perfect accuracy with only negligible differences in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 405,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "In the 2023 filing American Express recorded the Membership Rewards liability as a stand‑alone balance‑sheet item that was measured by applying a **weighted‑average cost (WAC) per point** to the number of points earned, multiplied by an **Ultimate Redemption Rate (URR)**.  The URR was derived from statistical‑actuarial models that consider redemption trends, card‑product mix, tenure, spend levels and credit attributes, while the WAC was based on the cost of the last 12 months of redemptions and adjusted for any non‑recurring cost changes.  Deferred card and other fees – which include the fees that are deferred for Membership Rewards participants – were presented net of direct acquisition costs and cancellation reserves ( $3.4 bn in 2023).\n\nThe 2024 filing keeps the same basic accounting treatment but adds **more explicit modeling disclosures and sensitivity analysis**.  The company still estimates the liability using the URR and WAC per‑point framework, but now states that a 25‑basis‑point increase in the URR would raise the liability by roughly **$197 million** and a 1‑basis‑point rise in the WAC would increase it by about **$220 million**.  The deferred‑fees line continues to be shown net of acquisition costs and cancellation reserves, but the underlying liability has grown (Membership Rewards liability rose from $13.7 bn in 2023 to a higher amount in 2024).  Thus, the treatment of deferred fees remained unchanged, while the liability‑estimation methodology was refined with clearer assumptions and sensitivity metrics.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly affect correctness, despite capturing the general trend of increased disclosure in 2024. (1) The ORIGINAL ANSWER states that in 2023, the company only mentioned 'deferred fees' without specifying the use of URR or WAC in liability modeling — however, the LLM claims that in 2023, American Express already used a 'URR and WAC per point' framework with actuarial models, which contradicts the ground truth. This is a major error in entity and methodology attribution across years. (2) The LLM introduces specific numbers not present in the original answer: '$3.4 bn in 2023' for deferred fees and '$13.7 bn' for the 2023 liability, which are not mentioned in the ground truth and thus cannot be verified; these additions reduce quantitative accuracy. (3) While the sensitivity figures ($197M and $220M) are correctly reported from the 2024 filing, the LLM incorrectly implies continuity of the URR/WAC model into 2023, when the ground truth indicates a shift *to* this detailed model in 2024. (4) The reasoning is partially sound in identifying enhanced disclosures and sensitivity analysis in 2024, but fails the multi-hop synthesis by misrepresenting the 2023 methodology. (5) Contextually, the answer is well-structured and relevant, addressing deferred fees and liability modeling evolution, but the core factual misrepresentation of when the model was introduced undermines correctness. Wording flexibility is allowed, but incorrect attribution of modeling details to 2023 cannot be overlooked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1601,
        "completion_tokens": 428,
        "total_tokens": 2030
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "In the 2022 filing Adobe presented Frame.io as a newly‑acquired, cloud‑native video‑collaboration platform that had just been folded into the Digital Media segment and linked to a handful of Creative Cloud apps (Premiere Pro, After Effects, Photoshop, Lightroom and Workfront). By the 2024 filing the company was positioning Frame.io as a foundational piece of its end‑to‑end creative ecosystem—tightly integrated not only with those same Creative Cloud tools but also with Adobe GenStudio, Firefly AI services and other Adobe Experience‑Cloud offerings—so that video‑creation, review and approval flow seamlessly across the entire Adobe product suite.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired and integrated into the Digital Media segment in 2022, positioned as a cloud-based video collaboration platform, and by 2024 evolved into a core part of Adobe's creative ecosystem. The integration with Premiere Pro, After Effects, Photoshop, and Workfront is correctly noted. The inclusion of Frame.io in Adobe GenStudio by 2024 is accurately mentioned, reflecting deeper ecosystem alignment. (2) There are no numeric values (e.g., acquisition cost of $1.18B) explicitly mentioned in the LLM answer, but since the question did not ask for financial terms of the acquisition and the omission does not affect the strategic narrative, this does not detract significantly. All other temporal markers (2022 vs 2024) are correct. (3) The multi-hop reasoning is sound—LLM synthesizes Frame.io’s evolving role across two time points and links it to integration with broader Adobe products, including AI (Firefly) and Experience Cloud, which extends slightly beyond the original answer but is contextually plausible and consistent with Adobe's strategic direction. (4) Semantic equivalence is strong: the LLM captures the shift from initial integration to foundational status. The only minor gap is that the original answer explicitly mentions the $1.18B acquisition and that integration was 'just beginning' in 2022, which adds context the LLM omits. However, this does not invalidate the overall correctness. The LLM enhances the answer with reasonable extensions (Firefly, Experience Cloud) without introducing inaccuracies. Thus, the answer is excellent but not perfect—hence 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 472,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "In 2022 the equity‑like private‑alternative‑investment balances that were measured using significant unobservable inputs (Level 3) were:\n\n* Defined‑benefit pension plan: **$25.4 million** (Level 3)  \n* Retiree‑health benefit plan: **$2.4 million** (Level 3)  \n\nTotal Level 3 equity‑like funds ≈ **$27.8 million**.\n\nIn 2023 the same balances were:\n\n* Defined‑benefit pension plan: **$25.1 million** (Level 3)  \n* Retiree‑health benefit plan: **$2.4 million** (Level 3)  \n\nTotal Level 3 equity‑like funds ≈ **$27.5 million**.\n\nThus, the composition shifted only marginally – the defined‑benefit pension‑plan portion fell slightly from $25.4 million to $25.1 million, while the retiree‑health portion remained unchanged, resulting in an overall decrease of about $0.3 million in Level 3‑measured equity‑like funds between 2022 and 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) According to the ground truth, the fair value of equity-like funds in private alternative investments measured using Level 3 inputs was $5.5 million in 2022 and increased to $25.4 million in 2023—a fivefold increase. The LLM instead reports $27.8 million in 2022 and $27.5 million in 2023, which is not only factually wrong but also reverses the trend. (2) The LLM introduces specific plan breakdowns (defined-benefit pension plan and retiree-health benefit plan) that are not mentioned in the original answer and appear to be hallucinated or misattributed from another context. These entities and their values do not align with the ground truth. (3) The reasoning is flawed: the conclusion of a marginal shift and slight decrease contradicts the actual significant increase. (4) The answer fails the multi-hop requirement by not correctly synthesizing the evolution across years and misrepresenting the composition. While the response addresses the general topic (Level 3 inputs in equity-like funds), it does so with entirely incorrect data and structure, making it highly irrelevant despite surface-level plausibility. Minor contextual relevance is given for addressing Level 3 inputs and time comparison, but factual accuracy is severely lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 371,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "- **2022 filing (ADBE 10‑K 2022, pp. 40‑44)** – Adobe reported that it had completed the $1.18 billion acquisition of Frame.io in the fourth quarter of fiscal 2021 and “began integrating Frame.io into our Digital Media reportable segment.”  Frame.io was described as a “cloud‑native creative collaboration platform” that is “directly integrated with Adobe Premiere Pro, Adobe After Effects, Adobe Photoshop, Adobe Lightroom and Adobe Workfront” and is offered through Adobe GenStudio alongside Express and Firefly Services.  \n\n- **2024 filing (ADBE 10‑K 2024, pp. 10‑14)** – By fiscal 2024, Frame.io is no longer presented as a newly‑added asset but as an established component of Adobe’s Digital Media suite.  The filing positions Frame.io as a core video‑collaboration capability embedded across the Creative Cloud video applications and highlighted its role in Adobe GenStudio, where it is bundled with Adobe Express and Firefly Services to support large‑scale, AI‑enhanced content production.  \n\n**Evolution:** Between 2022 and 2024 Adobe moved Frame.io from a freshly‑acquired, “beginning integration” stage to a fully‑integrated, strategic part of the Digital Media portfolio, emphasizing deeper embedding in Creative Cloud video tools and its inclusion in the GenStudio platform for enterprise‑scale content creation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired in Q4 2021 (reported in 2022 filing), integration began in 2022, and by 2024 it was positioned as a core, embedded component of Adobe’s Digital Media offerings. The $1.18 billion acquisition amount is correctly stated. (2) Quantitative accuracy is perfect: the dollar amount ($1.18 billion), fiscal years (2021 acquisition, 2022 and 2024 filings), and integration timeline are all factually correct. Format variations are acceptable and do not affect accuracy. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across two 10-K filings (2022 and 2024) to show evolution over time—from initial integration to strategic embedding. It identifies the deepening integration with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, and inclusion in GenStudio. (4) The only minor shortcoming is that the 2022 filing description slightly overstates the integration status by implying direct integrations were already complete, while the ground truth characterizes 2022 as the beginning of integration. However, the overall evolution narrative is accurate and well-supported. Semantic equivalence is maintained, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 364,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "Between 2022 and 2024 CVS broadened its medication‑management portfolio from a core set of utilization‑management, Pharmacy Advisor counseling and a pre‑authorization tool (NovoLogix) to a more digitally‑enabled suite that adds the Drug Savings Review, a dedicated GLP‑1 weight‑management program, and enterprise‑wide analytics platforms such as the Health Engagement Engine and Canopy AI‑driven tools. These newer programs deliver medication‑adherence support through phone, in‑person and provider‑facing outreach, real‑time benefit information, and automated cost‑saving alerts, thereby increasing both adherence and cost efficiency.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its description of CVS's evolution in medication management from 2022 to 2024, with accurate qualitative trends and no incorrect numbers (quantitative accuracy is perfect as there are no numeric values to verify). It correctly identifies key developments such as the introduction of NovoLogix, GLP-1 weight management programming, and enhanced digital tools like analytics platforms (e.g., Health Engagement Engine, Canopy AI), which align with the ground truth’s emphasis on digital expansion and clinical integration. The mention of Drug Savings Review, real-time benefit tools, and multi-channel adherence outreach reflects accurate synthesis of cost-efficiency and adherence strategies. However, the LLM omits several specific elements from the original answer: (1) the 2022 focus on formulary management via the National Pharmacy and Therapeutics Committee, (2) the seven-day opioid prescribing policy as an industry-leading utilization control, and (3) the expansion through Oak Street Health with the specific scale (239 centers in 27 states), which is a key multi-hop element linking CVS’s medication management to value-based care infrastructure. While the LLM captures the shift toward integrated, digital, and proactive care, it fails to fully synthesize the evolution from 2022’s cost-containment foundation to 2024’s broader clinical model, weakening the qualitative accuracy. Contextual relevance is high as all points are directly related and support the core question. Minor omissions prevent a higher score, but core facts and direction of evolution are preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 440,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "Adobe first introduced Frame.io after its October 2021 acquisition, positioning it as a “cloud‑based video collaboration platform” that would be “more deeply integrated and enhancing Frame.io’s review and approval capabilities in Premiere Pro and After Effects” to give Creative Cloud a native video‑editing collaboration layer【2022 p.4‑5】.  \n\nBy the 2024 filing, Frame.io had been elevated to a core, cloud‑native collaboration hub that is “directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom and Adobe Workfront” and is also offered through Adobe GenStudio; its feature set now includes real‑time upload, frame‑accurate commenting and annotations, “Camera‑to‑Cloud” automatic footage ingest, and support for still images, design files and PDFs, expanding collaboration far beyond the initial review‑only tools【2024 p.10‑13】.  \n\nThus, Adobe’s strategy evolved from a modest integration focused on video‑review in two apps to a broad, cross‑app collaboration platform embedded throughout Creative Cloud, with added real‑time, frame‑level commenting, annotation, automatic media capture and multi‑format support.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) It correctly identifies Adobe's acquisition and integration of Frame.io, noting the initial focus on video collaboration in Premiere Pro and After Effects in 2022, and the evolution into a broader creative collaboration platform by 2024. The key enhancements—real-time upload, frame-accurate commenting, Camera-to-Cloud, multi-format support (still images, design files, PDFs), and expanded integrations (Photoshop, Lightroom, Workfront)—are all accurately reported. (2) Quantitatively, the only minor discrepancy is the mention of the acquisition in October 2021, while the ground truth implies integration began in 2022 post-acquisition. However, the acquisition did occur in 2021 (Oct), so this is factually correct and not an error; the ground truth simply focuses on 2022 as the start of integration. All other dates (2022, 2024) and features are correctly attributed. (3) The multi-hop reasoning is sound: the LLM synthesizes information across time (2022 to 2024), platforms (Creative Cloud apps), and feature evolution (from video-only to multi-format, real-time collaboration). It correctly infers the strategic shift from a niche tool to a central collaboration hub. (4) Semantic equivalence is strong—wording differs but meaning matches. The LLM adds useful detail (e.g., 'frame-accurate commenting', 'GenStudio') not in the ground truth but consistent with it. No factual inaccuracies; only slight expansion beyond the original answer, which does not detract from correctness. Hence, a score of 9 is appropriate—excellent but not perfectly mirrored in structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1521,
        "completion_tokens": 449,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "In both years the firm continued to rely on recently‑executed transactions as a primary observable input when valuing corporate loans, contingent lending commitments and other non‑recurring assets. However, the 2024 filing shows that the fair‑value tables for loans shifted from a larger Level‑2 (observable‑transaction) balance in 2023 (≈ $8.7 billion total loans) to a smaller Level‑2 balance in 2024 (≈ $1.6 billion) with a greater share measured at Level 3 using models, market quotations and CDS spreads. Thus, while recent‑transaction pricing is still used, its relative importance in the fair‑value hierarchy has diminished, with the firm placing more emphasis on model‑driven and market‑observable inputs in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth does not mention specific dollar amounts such as $8.7 billion or $1.6 billion, nor does it reference Level 2 or Level 3 classifications within the fair value hierarchy, CDS spreads, or changes in the fair-value tables. These specific figures and classifications are not supported by the original answer and appear to be fabricated or hallucinated. While the LLM correctly identifies that recently executed transactions were used in both years for valuing corporate loans and contingent lending commitments, it incorrectly frames the evolution as a decline in reliance due to a shift toward Level 3 inputs and models—this nuance is absent from the ground truth. Instead, the original answer states that the role of recent transactions became more targeted in 2024, specifically tied to held-for-sale loans and extended to other assets like investments, used alongside DCF models and comparable company multiples. This shift toward more targeted application and broader asset coverage is missed by the LLM. The reasoning is partially sound in noting a change in usage pattern, but the basis for that change is factually incorrect. The contextual relevance is high because the answer addresses the evolution of transaction use in fair value determination, but the lack of factual support and invented metrics severely undermines correctness. No calculations are provided, but the cited numbers cannot be verified and contradict the qualitative emphasis of the original. Multi-hop synthesis is attempted but based on incorrect data, leading to a misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 456,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "In the 2022 filing Adobe presented Substance 3D Stager simply as one of the five desktop apps that make up the “Adobe Substance 3D Collection” – a suite that also includes Painter, Sampler, Designer and Modeler, each sold together under a single collection plan. By the 2024 filing the company had shifted the narrative, positioning Stager as the central “scene‑building and rendering” component of a tightly‑integrated Substance 3D ecosystem, emphasizing its role in a unified workflow that leverages the shared Substance 3D Assets library and connects more closely with Adobe’s broader Creative‑Cloud and Document‑Cloud services. This reflects a move from treating Stager as a stand‑alone app within a collection to highlighting it as a core, integrated hub of the Substance 3D product family.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities are correct: Adobe, Substance 3D Stager, and the associated tools (Painter, Sampler, Designer, Modeler) are accurately named. The years 2022 and 2024 are correctly used as reference points. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of timeframes—scored as 10. (3) The reasoning is sound and reflects proper multi-hop synthesis: the LLM correctly infers a strategic evolution from 2022 (Stager as one of several apps in a collection) to 2024 (positioned as a central scene-building and rendering hub within an integrated ecosystem). It adds contextual detail not in the original answer—such as integration with Creative Cloud, Document Cloud, and the Substance 3D Assets library—which is plausible and consistent with Adobe's broader strategy, though slightly beyond the scope of the ground truth. This additional detail does not introduce inaccuracies but represents a minor expansion. (4) The core evolution—shift from standalone app to integrated ecosystem component—is correctly identified and well-articulated. The only reason for not scoring a 10 is that the original answer emphasizes the *lack of detailed information* in 2022 beyond trademark listing, while the LLM assumes more detailed positioning (e.g., being part of a 'collection' with a 'single plan') that may not be confirmed in the 2022 filing. This is a minor discrepancy in evidential precision. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 450,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "- **2022 filing (pages 62‑66)** – GE listed grid‑scale batteries only as one of several “future‑technology” options that could be needed to meet deep‑decarbonisation goals. The language described them as **“technologies that are not yet deployed or widely adopted today”** and said that realizing their potential would **require significant investment and might not prove commercially successful**, indicating a low‑to‑moderate strategic reliance at that time.  \n\n- **2023 filing (pages 27‑31)** – GE’s discussion of the energy transition now treats grid‑scale batteries as a **key pillar of its strategy**, noting that the company is **“strategically prioritising”** storage solutions and that they are **integral to achieving its long‑term decarbonisation objectives**. The wording shifts from a speculative future technology to a **core, strategically‑relied‑upon element** of the company’s energy‑transition roadmap.  \n\n**Thus, between 2022 and 2023 GE moved from viewing grid‑scale batteries as a possible, long‑term option to positioning them as a central, strategically‑important component of its energy‑transition plan.**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, GE viewed grid-scale batteries as an emerging, speculative technology with uncertain commercial viability, and by 2023, they were elevated to a strategically prioritized, integral component of decarbonization efforts. The LLM correctly captures the shift in strategic positioning from speculative to central. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable in that sense, but all descriptive temporal markers (2022, 2023) and document references (page ranges) are consistent and plausible; no calculation errors exist. (3) The multi-hop reasoning is sound—comparing GE’s evolving language across two years of filings to infer a strategic shift is correctly executed. The LLM synthesizes the change in tone and strategic framing (from 'may become important' to 'strategically prioritizing' and 'integral') accurately. (4) The only minor deviation from the original answer is that the LLM uses slightly stronger language—'key pillar' and 'core, strategically-relied-upon element'—where the ground truth says 'dependency' and 'depend in part'. While semantically very close, the original answer is slightly more cautious in asserting centrality. However, this does not constitute a factual error, just a nuance in emphasis. Overall, the LLM answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 419,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "In both the 2022 and the 2024 10‑K filings CVS notes that fair‑value Level 3 debt securities are normally priced by outside brokers, but it explicitly states that **no broker‑quoted debt securities were held** for the periods covered – 2021‑2020 in the 2022 filing and 2024‑2023 in the 2024 filing. The language was simply updated to reference the newer fiscal years; the substance of the disclosure and its impact on financial reporting (i.e., none, because no broker‑quoted securities existed) has not changed.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that CVS disclosed no broker-quoted debt securities in both 2022 and 2024 filings, with accurate reference to the periods covered (2021-2020 in 2022 filing; 2023-2024 in 2024 filing). This aligns with the ground truth on quantitative and entity accuracy. (2) All dates and the core fact—absence of broker-quoted debt securities—are factually correct, and no calculations are required, so quantitative accuracy is perfect. (3) However, the LLM introduces a significant inaccuracy in reasoning: it states that 'Level 3 debt securities are normally priced by outside brokers,' which is not mentioned in the ground truth and may misrepresent CVS's pricing practices. More critically, the LLM fails to capture the key qualitative evolution noted in the original answer: the 2024 disclosure no longer mentions any review process or negative impact related to broker-quoted securities, indicating reduced emphasis. This omission weakens the multi-hop synthesis required to assess the evolution in disclosure tone and relevance. (4) While the core factual claim (no broker-quoted securities) is correct and contextually relevant, the answer misses the nuanced shift in disclosure language, leading to a lower qualitative accuracy score. Correctness is penalized because the answer implies no change in substance or emphasis, contrary to the ground truth's observation about reduced discussion. Hence, correctness is 7—core facts are right, but key interpretive detail is missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 419,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "In 2024 BlackRock reported **$1.95 billion** of equity securities / mutual‑fund holdings at fair value, up from **$1.585 billion** in 2023 – an increase of roughly **$365 million**.  Its equity‑method portfolio was **$2.78 billion** in 2024 versus **$2.76 billion** in 2023, a modest rise of about **$27 million**, with the mix shifting (private‑equity fell from $1.264 billion to $1.060 billion, real‑assets rose from $417 million to $520 million, and other sub‑categories moved modestly).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2023, BlackRock reported $1,211 million (not $1.585 billion) in equity securities/mutual funds, and in 2024 it was $1,950 million (aligned with LLM's $1.95 billion). The LLM incorrectly states 2023 equity securities/mutual funds as $1.585 billion, which is factually wrong. For equity method investments, the ground truth reports $1,895 million in 2023 and $2,783 million in 2024. The LLM claims $2.76 billion in 2023 and $2.78 billion in 2024, which is also incorrect—especially for 2023, overstating by nearly $865 million. (2) Calculations are therefore flawed: LLM reports a $365 million increase in equity securities, but correct increase is $1,950M - $1,211M = $739 million. For equity method, LLM reports $27 million increase, but correct is $2,783M - $1,895M = $888 million. Additionally, the LLM introduces sub-category breakdowns (private equity, real assets) not present in the original answer and not requested in the question, adding irrelevant detail. (3) Multi-hop reasoning is partially sound in structure—comparing two years across two investment types—but fails due to incorrect data retrieval. The model attempts synthesis but uses inaccurate source values. (4) Contextual relevance is high as the answer addresses the right categories and time frame, and interprets the trend direction correctly (increases in both categories), but the magnitude and specific figures are severely off, undermining factual correctness. Wording flexibility is acceptable, but numerical accuracy is critical and here it is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 451,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "UnitedHealth Group continued to apply the same credit‑impairment framework in both filings – each reporting period it compares the fair value of an available‑for‑sale (AFS) debt security to its amortized cost, looks at the issuer’s credit quality and expected cash‑flows, and records a credit‑related allowance when fair value is below cost.  \n\n* **2022 filing (data for 2021‑2020):** the AFS portfolio carried $822 million of gross unrealized gains offset by $274 million of gross unrealized losses, and the company disclosed that the allowance for credit losses on AFS debt securities “was not material.”  \n\n* **2024 filing (data for 2023‑2024):** the discussion of AFS securities is unchanged – the company still evaluates securities for credit‑related impairment and records any impairment as an allowance, but again notes that the allowance for credit losses on AFS debt securities “was not material.”  The 2024 filing still reports unrealized losses (driven mainly by higher interest rates) as temporary, with no material credit‑loss allowance recognized.  \n\nThus, from 2022 to 2024 UnitedHealth’s methodology for assessing credit‑related impairments remained the same, and while unrealized losses continued to appear, the allowance for credit losses on AFS debt securities remained immaterial in both periods.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses key aspects of the evolution in UnitedHealth Group's evaluation and treatment of credit-related impairments from 2022 to 2024, leading to a partially incorrect conclusion. (1) Quantitatively, the LLM introduces specific numbers—$822 million in gross unrealized gains and $274 million in gross unrealized losses—for the 2022 filing, which are not present in the original answer (ground truth) and cannot be verified against it; these figures may be accurate but are unsupported by the provided truth data, reducing quantitative accuracy. (2) The original answer emphasizes a qualitative evolution in accounting treatment: while the core methodology remained consistent, there was a shift toward a more structured recognition of credit risk by 2024, with the allowance for credit losses now explicitly recorded through a separate allowance account and impairments impacting investment income. This key development is entirely omitted in the LLM answer, which incorrectly asserts that the discussion and framework were 'unchanged' and that the allowance remained immaterial in both periods. However, the original answer does state the allowance was 'not material' as of December 31, 2021 (reported in 2022), and does not provide a contrasting materiality assessment for 2024—so the LLM may have reasonably inferred continued immateriality, though it fails to capture the procedural evolution. (3) The multi-hop reasoning is flawed: the question asks about the *evolution* in evaluation and treatment, requiring synthesis across years and accounting disclosures. The LLM focuses on continuity rather than change, missing the shift to a more formalized impairment accounting framework described in the ground truth. (4) Contextually, the response is relevant and addresses the right company, securities type, and general impairment framework, but fails to convey the core conceptual progression from qualitative low-risk assessment to structured recognition. Thus, while factually plausible in parts, the answer is incomplete and misleading on the central point of evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1579,
        "completion_tokens": 567,
        "total_tokens": 2146
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "In FY 2023 AMD’s stake in the ATMP joint venture grew to about **$99 million**, up from **$83 million** at the end of FY 2022.  Correspondingly, the equity‑method share of earnings reported as “Equity income in investee” increased to **$16 million** in 2023, versus **$14 million** in 2022.  (2023 filing: investment $99 m/$83 m and equity‑income $16 m/$14 m; 2022 filing: prior‑year figures shown for comparison).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value of AMD's investment in ATMP JV was $83 million in 2022 and $99 million in 2023, and equity income was $14 million in 2022 and $16 million in 2023—these values are correctly reported with acceptable formatting (e.g., $99 million vs $99 m). (2) The answer is complete, addressing both parts of the question: evolution of investment value and equity income over the two years. (3) Entities are accurate—AMD, ATMP JV, correct fiscal years (2022 and 2023), and proper financial metrics (carrying value and equity income). (4) The reasoning is sound: the LLM correctly synthesizes multi-hop data across two fiscal years and two financial metrics, noting the increase in both investment value and income, which reflects a growing financial relationship. The parenthetical note about filings further demonstrates accurate sourcing logic. (5) Semantic equivalence is achieved—the LLM conveys the same conclusion as the ground truth: AMD’s financial stake and profitability from the JV increased from 2022 to 2023. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1190,
        "completion_tokens": 337,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "In the 2022 Form 10‑K UnitedHealth described its tort‑claim exposure primarily as medical‑malpractice and other professional‑liability actions arising from the delivery of health‑care services by its own staff, affiliated physicians and network providers, noting that the company is largely self‑insured and that actual losses could exceed the reserves it records for those matters. By the 2024 filing the company’s discussion of tort claims is unchanged in substance—still centered on medical‑malpractice and related professional‑liability suits—but it emphasizes that claim volumes and “new theories of liability” have grown, increasing the uncertainty around the ultimate cost and suggesting that the potential financial impact could be larger than the amounts previously reserved. Thus, between 2022 and 2024 UnitedHealth’s exposure has shifted from a baseline self‑insured malpractice risk to a broader, higher‑volume set of tort actions with a correspondingly higher, though still unquantified, possible financial burden.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in its description of UnitedHealth's self-insured exposure to medical malpractice and professional liability claims in 2022, correctly noting the risk of losses exceeding recorded liabilities and the presence of new theories of liability. It also correctly identifies that uncertainty and financial impact may have increased by 2024. However, it mischaracterizes the evolution of risk: the original answer indicates a qualitative shift in 2024 from narrowly defined malpractice exposure to broader legal risks involving clinical quality, patient safety, and reputational harm—elements the LLM answer omits. Instead, the LLM claims the discussion is 'unchanged in substance' and still 'centered on medical-malpractice,' which contradicts the ground truth showing a broadening of risk focus. While the LLM captures the increasing volume and uncertainty, it fails to reflect the expanded nature of tort claims beyond malpractice, missing key aspects of the multi-hop synthesis required. There are no numerical inaccuracies (hence high quantitative score), but the qualitative reasoning is flawed in depicting continuity rather than evolution. Contextually, the answer remains relevant to tort exposure and financial impact, but lacks the nuanced shift described in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1485,
        "completion_tokens": 364,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings Boeing’s legacy three‑year revolving‑credit facility remained a $3.0 billion commitment that was still undrawn at year‑end; the total unused borrowing capacity on all of its credit lines stayed at roughly $10 billion. During 2024 the company retired the $0.8 billion 364‑day facility and the older $3.2 billion five‑year facility and replaced them with a new $4.0 billion five‑year agreement, but the three‑year line itself was left unchanged. This continuity shows that Boeing’s liquidity strategy relies on a stable, sizable backup credit line (the three‑year facility) while reshaping the rest of its revolving‑credit portfolio to better match funding needs and market conditions.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion legacy three-year revolving credit agreement in both 2023 and 2024, which aligns with the ground truth. It accurately states that Boeing entered a new $4.0 billion five-year agreement in 2024 and retired two other facilities. However, the ground truth does not mention the specific amounts of the terminated facilities ($0.8 billion 364-day and $3.2 billion five-year), nor does it specify that the total unused capacity was $10 billion—these details are plausible but not confirmed in the original answer, introducing unverified specifics. (2) The key numbers—$3.0 billion for the three-year facility and $4.0 billion for the new five-year facility—are correct and match the ground truth. The expiration dates (August 2025 for the legacy three-year, May 2029 for the new) are not mentioned in the LLM answer, which is a minor omission affecting completeness but not core accuracy. (3) The multi-hop reasoning is sound: the model correctly infers that Boeing maintained its existing three-year facility while replacing others, indicating a strategic liquidity approach. The conclusion about maintaining a stable backup line while reshaping the portfolio is logically consistent with the ground truth’s interpretation of enhanced liquidity and extended maturities. (4) The answer is contextually excellent, directly addressing the evolution and strategic implication. The correctness score is 8 due to the inclusion of unverified facility amounts (potential overprecision), but the core facts, synthesis, and interpretation are accurate and meaningful.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 443,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "In 2023 the 2017 performance‑based stock options generated **$56 million of fair‑value expense for the options that vested** and **$44 million of intrinsic value for the options that were exercised**. By 2024 the **fair‑value of the vested tranche fell slightly to $52 million**, while the **intrinsic value of the exercised tranche jumped sharply to $373 million**.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $56 million fair value vested in 2023, $44 million intrinsic value exercised in 2023, $52 million fair value vested in 2024, and $373 million intrinsic value exercised in 2024. Minor formatting differences (e.g., $56 million vs $56 million) are acceptable and do not affect meaning. (2) The answer is complete, addressing both years and both metrics (fair value of vested options and intrinsic value of exercised options), satisfying the multi-part, multi-hop nature of the question. (3) Entities are correctly identified: the 2017 Performance-based Options are the focus, and the correct financial metrics and years are used. (4) The reasoning is sound—while the LLM does not explicitly interpret the trend (as the original answer does with 'this indicates that...'), it accurately presents the data necessary for the same conclusion, and the core factual synthesis across years and metrics is correct. The omission of the interpretive sentence does not detract from factual correctness. Overall, the answer is semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 332,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "AMD’s method for estimating the revenue adjustments tied to product‑return rights did not change from the 2022 filing to the 2023 filing. In both years the company said it “utilizes relevant, trended actual historical product‑return‑rate information, adjusted for any known information or events,” applying the same contractual‑percentage‑of‑prior‑quarter‑shipments framework and case‑by‑case approvals for extra returns. No new or different estimation technique was introduced in the 2023 10‑K.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that AMD's method did not change between 2022 and 2023, directly contradicting the ground truth. While there are no numeric values to verify (so quantitative accuracy is not applicable in a meaningful way, but no numbers are wrong), the qualitative analysis fails significantly. The ground truth states that while historical data was still used in 2023, AMD adopted a more structured approach by explicitly incorporating 'rights of return and rebates' as variable consideration under ASC 606-10-32-8 through 14 and shifted to estimating based on the 'most likely amount' of consideration, which represents a methodological refinement. The LLM incorrectly asserts no change occurred, missing this key evolution in accounting methodology. This reflects a failure in multi-hop reasoning and synthesis of the nuanced shift in AMD's disclosure and application of accounting standards. The answer is contextually relevant to the question topic but provides a false conclusion, severely undermining its correctness. Thus, the correctness and qualitative accuracy scores are low, while contextual relevance is moderate due to correct focus on AMD and return estimation, albeit with wrong conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 348,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The 2017 performance‑based options fell from 1,549,080 shares outstanding at 12/31/2023 to 625,825 shares at 12/31/2024 —a decline of roughly 923,000 shares. In 2024 the company recorded 905,219 shares exercised (versus 183,704 in 2023) and 18,036 forfeited (versus 3,114 in 2023), indicating that the 2024 vesting tranche spurred a large wave of exercises and a modest increase in forfeitures, sharply reducing the remaining option pool.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the starting and ending share counts (1,549,080 in 2023 and 625,825 in 2024) are correct. The number of exercised shares (905,219) and forfeited shares (18,036) match the ground truth exactly. However, the LLM states a 'decline of roughly 923,000 shares', which is slightly inaccurate: the actual decline is 1,549,080 - 625,825 = 923,255 shares, so the approximation is close but not precise. (2) The answer is complete, addressing both the evolution of shares and the implications regarding exercise and forfeiture trends. It even adds useful context—comparisons to 2023 exercise and forfeiture volumes—that enriches the response without introducing error. (3) Entities (2017 Performance-based Options, correct years) are accurately referenced. (4) The reasoning is sound: the LLM correctly infers that the sharp drop indicates a wave of exercises tied to the final vesting tranche, aligning with the ground truth's interpretation of lifecycle completion. The minor quantitative approximation prevents a perfect score, but overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 342,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "In the 2022 filing, Optum Rx was described as providing a “full spectrum of pharmacy‑care services” through a network of more than 67,000 retail pharmacies, home‑delivery, specialty and community‑health pharmacies, in‑home infusion and a direct‑to‑consumer business, managing about $112 billion of drug spend (including $45 billion in specialty) and offering utilization‑management, medication‑management, quality‑assurance, adherence and digital clinical programs. By the 2024 filing the scope had expanded – the network (now about 65,000 pharmacies) also supports rare‑disease and gene‑therapy services, the spend grew to $178 billion (with $74 billion specialty), and the business is positioned to “accelerate the integration of medical, pharmacy and behavioral care” by embedding pharmacists on patient‑care teams and leveraging data‑analytics, making Optum Rx a central, integrated component of UnitedHealth Group’s Optum and UnitedHealthcare ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in quantitative data, which undermines its correctness. According to the ground truth, in 2022, Optum Rx managed $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceuticals. The LLM correctly reports these figures. However, it falsely claims that by 2024, drug spend grew to $178 billion (with $74 billion in specialty), and that the pharmacy network expanded to support rare-disease and gene-therapy services. The original answer states that no specific spending figures were provided in 2024, making the $178B and $74B numbers entirely fabricated. Additionally, while the network size is cited as 'about 65,000' in 2024 (down from 67,000), this minor change lacks confirmation in the ground truth, which does not mention updated network size. The qualitative shift in strategic positioning—integration into Optum’s broader ecosystem, use of data analytics, and focus on connected care—is accurately reflected and contextually relevant. The LLM correctly identifies the evolution toward integrating medical, pharmacy, and behavioral care and embedding pharmacists into care teams, aligning with the 2024 strategic vision. However, the inclusion of unsupported numerical growth and specific new service lines (gene therapy, rare disease) constitutes major factual errors. While the reasoning framework is sound—attempting a multi-hop comparison across years—the use of incorrect data invalidates the quantitative accuracy. The answer is semantically aligned in direction but fails on factual precision, especially where numbers are confidently asserted without basis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1513,
        "completion_tokens": 450,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "In 2024 BlackRock’s equity securities that are measured at fair value (FVTNI) grew to a fair‑value balance of **$1.95 billion**, up from **$1.585 billion** at year‑end 2023 – the cost side also rose from $1.52 billion to $1.84 billion.  The increase reflects a larger holding in the CIPs (VIEs rose to $1.179 billion and VREs to $377 million, versus $1.059 billion and $370 million in 2023).  However, the portion of those equity securities that is used to hedge **deferred cash‑compensation plans** fell, dropping from **$241 million in 2023** to **$173 million in 2024**.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the ground truth. (1) QUANTITATIVE INACCURACY: The LLM claims that the portion of equity securities at FVTNI used to hedge deferred cash compensation plans was $241 million in 2023 and $173 million in 2024. However, the ground truth states that in 2023, the amount was $9 million (not $241 million), and in 2024, it was no longer reported under FVTNI but instead reclassified to the Equity Method section as $173 million. The $241 million figure is entirely incorrect and unsupported by the original data. (2) COMPOSITION AND RECLASSIFICATION MISUNDERSTOOD: The LLM interprets the change as a decrease from $241M to $173M within FVTNI, but the actual change was a complete reclassification out of FVTNI — meaning the $173M in 2024 is not part of FVTNI at all. This misrepresents the nature of the change, which was a reporting/categorization shift, not a simple reduction. (3) ENTITY AND METRIC CONFUSION: The LLM introduces unrelated details about total FVTNI balances ($1.95B in 2024 vs $1.585B in 2023) and cost basis changes, which are not mentioned in the original answer and distract from the specific focus on deferred compensation-related investments. These figures may be accurate in another context but are irrelevant here and suggest the model conflated different parts of the financial statements. (4) REASONING FAILURE: The multi-hop reasoning required is to recognize that the investment was reclassified across categories between years — not merely changed in value. The LLM fails this synthesis, instead treating it as a straightforward decline within the same category. (5) SEMANTIC NON-EQUIVALENCE: The core message — a reclassification reflecting a significant change in reporting structure — is entirely missing. Instead, the LLM implies continuity within FVTNI with a reduced value, which contradicts the ground truth. While the $173 million figure for 2024 is correct and contextually relevant, its framing is wrong. Due to major factual and conceptual errors, especially in quantitative and qualitative dimensions, the correctness score is low despite partial relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 581,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "In the 2022 filing Accenture reported that, as of August 31 2022, the aggregate amount still available for its publicly‑announced open‑market share‑repurchase program was **$3.13 million**. By the 2024 filing that same metric had fallen to **$2.69 million** as of August 31 2024 – a drop of roughly $0.44 million (about 14 %). The decline shows the company has been actively using its repurchase authority, signalling that returning cash to shareholders through buy‑backs remains a key element of its capital‑allocation strategy while the remaining authorized pool is being drawn down.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the numeric values. The original answer states that the aggregate available authorization decreased from $3,129,296 in 2022 to $2,694,281 in 2024, but the LLM incorrectly reports these as $3.13 million and $2.69 million, respectively. This is a critical error because $3.13 million = $3,130,000 and $2.69 million = $2,690,000 — while close, the direction of the error (rounding up) misrepresents precision, and more importantly, the actual values in the ground truth are in thousands, not millions. The correct figures are approximately $3.129 billion and $2.694 billion, meaning the LLM is off by a factor of 1,000. This makes the reported drop of 'roughly $0.44 million (about 14%)' grossly inaccurate — the actual dollar decrease is about $435 million, not $0.44 million. (2) Calculations are therefore incorrect: while 14% is roughly the correct percentage decrease (from ~$3.129B to ~$2.694B), applying it to million-dollar figures fundamentally misrepresents the scale. (3) The multi-hop reasoning is partially sound — the model correctly infers a trend between two years and attempts to interpret capital allocation strategy — but draws the opposite conclusion from the ground truth. The original answer interprets the decline in available authorization as a reduction in repurchase activity, possibly signaling a more conservative strategy. In contrast, the LLM interprets the drawdown as evidence of active buybacks and continued commitment, which may be plausible but contradicts the ground truth's implication of reduced allocation. (4) Contextual relevance is high — the answer addresses both parts of the question (change in authorization and strategic implication), uses correct entities (Accenture, open-market share purchase program, correct years), and maintains appropriate structure. However, the massive quantitative inaccuracy severely undermines factual correctness, warranting a low overall score despite reasonable framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 542,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "In the 2022 Form 10‑K the company only described the exchangeable shares in principle – holders could exchange them at any time on a one‑for‑one basis for Accenture plc Class A shares (or receive cash of comparable market value) and the open‑market repurchase program “may be made … in respect of purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares,” with no quantitative detail. By the 2024 filing the disclosure had become far more specific: the board’s $2.694 billion share‑repurchase authority now includes a separate line item showing that 47,752 exchangeable shares were actually repurchased for $15.3 million, dividend payments to those shares are reported, and the relationship between exchangeable shares and non‑transferable Class X shares (including redemption limits) is spelled out, underscoring the shareholders’ continued right to exchange or receive cash while providing concrete repurchase activity data.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in disclosure practices between 2022 and 2024 regarding Accenture Canada Holdings Inc. exchangeable shares. (1) It correctly identifies that in 2022, disclosures were general, mentioning potential repurchases and redemptions without specific figures, and that exchangeable shares could be exchanged one-for-one for Accenture plc Class A shares or for cash. In 2024, it notes increased specificity, including actual repurchase data and structural details about Class X shares. (2) Quantitatively, the LLM states that 47,752 exchangeable shares were repurchased for $15.3 million and references a $2.694 billion repurchase authority, which aligns closely with the ground truth's mention of a remaining authorization of $2,694,281 as of August 31, 2024. While the exact figure in the ground truth is slightly more precise ($2,694,281 vs $2.694 billion), this is a reasonable rounding and format variation acceptable under the evaluation criteria. However, the ground truth does not explicitly state the number of shares repurchased (47,752) or the $15.3M amount, so these specific figures, while plausible, are not confirmed in the original answer and represent a minor overprecision. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure tone (from general intent to detailed reporting), shareholder rights (exchangeability, cash alternative), and structural alignment with Class X shares. It correctly infers a trend toward greater transparency and quantification. (4) The answer is contextually excellent, directly addressing both share repurchase activity and shareholder rights across the two years. The only reason for not scoring a 10 is the introduction of unverified specific figures (47,752 shares, $15.3M) not present in the ground truth, which slightly affects quantitative accuracy despite overall correctness in direction and magnitude.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 520,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "Abbott’s global Electrophysiology Devices revenue rose from ≈ $2.2 billion in 2023 (U.S. $1,008 m + International $1,187 m) to ≈ $4.7 billion in 2024 (U.S. $2,467 m + International $2,195 m). Excluding foreign‑exchange effects, the revenue grew by **about 14.4 %** year‑over‑year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in revenue figures. It incorrectly states that 2023 revenue was approximately $2.2 billion (which is close to the correct $2,195 million), but then claims 2024 revenue was ≈$4.7 billion—over double the correct value of $2,467 million. The LLM appears to have swapped the 2023 and 2024 figures in its regional breakdown: it assigns $2,467 million to U.S. and $2,195 million to International in 2024, which is factually incorrect and leads to a grossly inflated total. (2) The percentage change excluding foreign exchange fluctuations is correctly stated as 14.4%, which matches the ground truth. However, due to incorrect base numbers, the implied overall growth rate (~114%) is wildly inaccurate. The correct total percentage change is 12.3%, which the model fails to report. (3) The multi-hop reasoning is flawed: the model attempts to break down global revenue by region but misattributes the numbers, suggesting a failure to correctly synthesize data across entities or time periods. It also introduces Abbott as the company without being prompted, though context implies the question is about the global market or a specific firm—however, the ground truth does not specify Abbott, so this assumption may be unjustified. (4) Despite the correct mention of the 14.4% FX-excluded growth, the severe numerical inaccuracies in revenue totals and incorrect regional data undermine the answer’s reliability. The contextual relevance is moderate because it addresses revenue evolution and FX impact, but the core quantitative foundation is broken, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1143,
        "completion_tokens": 448,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "In fiscal 2022 Accenture reported that its equity‑method investment – principally its ~16 % stake in Duck Creek Technologies – was carried on the balance sheet at **$138.9 million**, with an **estimated fair value of $223.2 million** (a sizable unrealised appreciation). By fiscal 2024 the company had **realised that appreciation, recording a $253 million gain on the Duck Creek investment in fiscal 2023**, which was highlighted in the 2024 MD&A as a component of adjusted earnings and EPS. Thus, the relationship shifted from an unrealised, fair‑value‑upside in 2022 to a recognised gain that positively boosted Accenture’s 2023‑24 financial performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a clear, well-reasoned evolution of Accenture's financial relationship with Duck Creek Technologies from fiscal 2022 to 2024. (1) Quantitatively, the LLM correctly identifies the ~16% ownership stake and the $253 million gain realized, aligning with the ground truth. It adds more precise context by distinguishing between the carrying value ($138.9 million) and the estimated fair value ($223.2 million) in fiscal 2022, which is consistent with the ground truth's $223,166 (likely a typo in the original answer—$223.2 million is correct based on context). The gain of $253 million is accurately attributed to fiscal 2023 and reflected in the 2024 MD&A, which matches the timeline and impact described. (2) The only minor discrepancy is the original answer stating the 2022 value as $223,166, which appears to be a transcription error (missing 'million'), as Duck Creek's market cap and Accenture's stake would not support such a low valuation. The LLM's $223.2 million is factually correct and more plausible, so this is not a model error. (3) Qualitatively, the reasoning is excellent: it captures the shift from unrealized appreciation (equity-method accounting with fair value upside) to a realized gain impacting earnings, demonstrating strong multi-hop synthesis across fiscal years and accounting treatments. (4) The answer is fully contextually relevant, addressing investment valuation, ownership percentage, and impact on financial performance as required. The model enhances the ground truth with clearer financial nuance without introducing errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 438,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "The 2023 proxy shows that Union Pacific’s outstanding retention awards are now split between **366,000 retention units that have no exercise price** and **about 954,000 retention shares that have already been issued** (the footnote to the equity‑compensation table lists 366,046 units and notes that the 954,405 shares are excluded from the “remaining for future issuance” total)【UNP_10k_2023.pdf p. 73‑77】.  \n\nIn the 2022 filing the retention awards were overwhelmingly **retention shares** (well over one million shares) with **only a few hundred thousand units** – the share‑based component made up the bulk of the program.  \n\nThe shift toward a larger proportion of non‑exercisable retention units in 2023 indicates that the company is moving its executive‑pay strategy away from pure share grants toward unit‑type awards that can be tied more directly to continued employment and long‑term performance, while still maintaining a sizable share component for liquidity and alignment with shareholders.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in the quantitative details, particularly regarding the 2022 data. The ground truth states that in 2022, 389,207 retention shares were outstanding as of December 31, 2021 (reported in the 2022 filing), but the LLM incorrectly claims 'well over one million shares' were outstanding in 2022 and mentions 'only a few hundred thousand units'—but the ground truth shows no retention units were disclosed as outstanding in 2022. Retention units (366,046) were first introduced in 2023. The LLM also misrepresents the timeline by implying both shares and units existed in 2022, which contradicts the original answer. The 2023 numbers are mostly accurate: 954,405 vs. 954,405 (correct) and 366,046 units (correct), though rounded to 954,000 and 366,000, which is acceptable. (2) The calculation and comparison between years are flawed because the LLM misstates the 2022 baseline. There is no evidence in the ground truth that over a million retention shares were outstanding in 2022; the disclosed number is 389,207 as of end-2021. The claim that units existed in 2022 is unsupported. (3) The multi-hop reasoning is partially sound—the LLM correctly infers that the increase in retention units suggests a strategic shift toward long-term retention and performance alignment. This interpretation aligns with the original answer’s conclusion about a refined executive compensation strategy. However, the flawed premise weakens the logic. (4) Despite the incorrect quantitative foundation, the LLM captures the broader strategic implication correctly: a shift toward unit-based awards indicates a move toward employment-linked, long-term incentives. Contextually, the answer is relevant and well-structured, citing the correct document and page range. However, the core factual error in the 2022 data significantly undermines correctness. Quantitative accuracy is low due to incorrect numbers and misrepresentation of 2022 composition; qualitative reasoning is fair but based on false premises; contextual relevance is high as it addresses all parts of the question and provides a logical interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 574,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "MetLife’s 2023 filing already applied the GAAP‑prescribed “adjusted earnings” metric, excluding items that reflect market volatility (net investment, derivative and MRB remeasurement gains‑or‑losses and goodwill impairments) and a set of asymmetrical, non‑economic adjustments such as in‑force reinsurance accounting, basis‑adjustment amortization and non‑economic losses at contract inception. In the 2024 filing the company kept the same GAAP framework but expanded the description of the market‑volatility exclusions to specifically call out joint‑venture equity‑method earnings, discount‑rate changes on annuitization guarantees and other market‑value adjustments, while reiterating the same asymmetrical‑accounting exclusions. Thus, the core exclusions remain unchanged, but the 2024 disclosure adds greater detail on the volatility‑related items that are removed from adjusted earnings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key exclusions related to market volatility and asymmetrical accounting adjustments in MetLife's adjusted earnings between 2023 and 2024. It correctly identifies that the core GAAP framework remained consistent, with expanded disclosures in 2024. The mention of joint ventures under the equity method being newly highlighted in 2024 matches the original answer, as does the continued exclusion of asymmetrical accounting from in-force reinsurance. The LLM also accurately references MRBs, discount rate changes on annuitization guarantees, and market volatility items. However, the LLM slightly mischaracterizes the evolution by stating that the 'core exclusions remain unchanged' and that 2024 only adds 'greater detail'—whereas the original answer emphasizes a meaningful expansion in the *scope* of exclusions (e.g., policyholder liability remeasurement gains/losses now explicitly excluding asymmetrical accounting from in-force reinsurance). Additionally, the LLM does not explicitly mention the 2023 adoption of LDTI as a key driver for the initial change in adjusted earnings calculation, which is a notable omission in the reasoning chain. Despite these nuances, all entities (MetLife, GAAP, adjusted earnings, MRBs, in-force reinsurance), years (2023, 2024), and financial concepts are accurate. There are no numerical inaccuracies (the question is qualitative), so quantitative accuracy is perfect. The answer is highly relevant and synthesizes the evolution across years, though with slightly less precision on the nature of the 2024 expansion compared to ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 452,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "In 2022 Accenture’s “compressed‑transformation” promise was anchored in Industry X’s use of data‑driven tools such as digital twins, AI, IoT, cloud/edge, 5G, advanced robotics and the metaverse to redesign how products are engineered, sourced, manufactured, serviced and renewed. By 2024 the approach had broadened and deepened – the firm now adds generative AI, AR/VR, and a stronger AI‑first mindset, builds its own advanced automation and robotics hardware, and extends the transformation scope beyond product‑lifecycle redesign to include capital‑project planning, plant and infrastructure construction, and end‑to‑end reinvention across all service lines (Strategy & Consulting, Technology, Operations, Industry X and Song).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and semantically equivalent to the ground truth. (1) All key technologies mentioned in the original answer—digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, metaverse in 2022; generative AI, AR/VR, and advanced robotics in 2024—are correctly identified. The LLM adds 'AI-first mindset' and 'end-to-end reinvention across service lines,' which are not explicitly in the original but are reasonable interpretations of a 'more integrated and advanced approach' and do not contradict it. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a numerical sense—however, the years 2022 and 2024 are correctly used, and no incorrect timeframes are introduced. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes how Accenture’s technological toolkit and scope of services evolved over time, comparing 2022 to 2024. It accurately captures the expansion into capital projects (e.g., plant and infrastructure construction) and the development of proprietary hardware. (4) The only minor deviation is that the LLM mentions 'Strategy & Consulting, Technology, Operations, Industry X and Song' as service lines, which adds specificity not in the original, but this is consistent with Accenture’s known structure and enhances completeness without introducing error. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a 9 due to slight elaboration beyond the source, but not enough to reduce accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 429,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "In 2023 Abbott’s interest‑rate‑hedge program shrank to about $2.2 billion of notional value – down from $2.9 billion in 2022 – after $700 million of hedge contracts (and the underlying fixed‑rate debt) matured that year. By the end of 2024 the company was again holding roughly $2.2 billion of interest‑rate‑swap contracts, indicating it restored the hedge level it had after the 2023 maturities and continued to use the swaps to convert the fair‑value of its fixed‑rate debt into a variable‑rate exposure. The fair‑value liability associated with the swaps also fell from $156 million in 2022 to about $95 million in 2023 and remained at that lower level in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains several factual inaccuracies not present in the ground truth. While it correctly states that Abbott had $2.2 billion in interest rate hedge contracts at the end of both 2023 and 2024, it introduces data not found in the original answer: a decrease from $2.9 billion in 2022, $700 million of maturities, and fair value liability amounts of $156 million in 2022 and $95 million in 2023 and 2024. These figures, while plausible, are not supported by the provided ground truth and represent hallucinated details. Additionally, the ground truth highlights a key point—the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024—indicating a shift in debt structure or market conditions. This critical insight is entirely missing from the LLM response. (2) Quantitatively, the $2.2 billion notional amount is correct for both years, which aligns with the ground truth. However, all other numbers—$2.9 billion (2022), $700 million maturities, and fair value liabilities of $156M and $95M—are unsupported and incorrect in the context of the provided knowledge. There is no mention of 2022 data or fair value liabilities in the original answer, so including them reduces quantitative accuracy. (3) The reasoning about Abbott continuing to use swaps to convert fixed-rate debt to variable-rate exposure is consistent with the ground truth and shows correct understanding of the hedging mechanism. The conclusion that the company 'restored' the hedge level implies a prior reduction and subsequent rebuilding, which may be logically coherent but is not inferable from the original answer, which only states consistency between 2023 and 2024. Thus, the multi-hop synthesis is partially sound but based on fabricated intermediate steps. (4) Contextual relevance is high because the answer addresses Abbott's use of interest rate hedges across 2023 and 2024 and explains their purpose in converting fixed to variable rate debt. However, the inclusion of unverified prior-year data and omission of the rising interest rate trend significantly undermine factual correctness. The core message of stable notional hedging is correct, but the supporting narrative is distorted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 589,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "In the 2023 Form 10‑K MetLife described “adjusted earnings” as adjusted revenues less adjusted expenses, net of income tax, and said that, consistent with GAAP segment‑reporting guidance, it is the GAAP measure used by the chief operating decision‑maker to evaluate segment performance and compensation. The 2024 filing repeats that definition but makes the GAAP link explicit – stating that adjusted earnings is the company’s GAAP segment‑performance metric under the new ASU 2023‑07 guidance – and clarifies that the calculation continues to exclude market‑volatility items, asymmetrical accounting, divested‑business effects and the LDTI‑related fair‑value and remeasurement adjustments introduced in 2023. Thus, the treatment has not changed materially, but the 2024 disclosure more formally ties adjusted earnings to GAAP segment‑reporting requirements while retaining the same exclusionary adjustments.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in both factual content and reasoning, with high quantitative and contextual accuracy. It correctly identifies that MetLife's Adjusted Earnings definition evolved in 2023 due to LDTI (Long-Duration Targeted Improvements), leading to the removal of DAC/VOBA amortization adjustments and the inclusion of changes in guarantees and fair value adjustments (e.g., MRBs, annuitization guarantees). The 2024 update is accurately portrayed as a refinement rather than a material change, with continued exclusion of market volatility, asymmetrical accounting, divested businesses, and LDTI-related remeasurements. The LLM correctly notes the explicit linkage in 2024 to ASU 2023-07, which codifies GAAP segment reporting requirements—this aligns with the ground truth’s emphasis on more structured and delineated exclusions. However, the LLM answer omits specific new exclusions highlighted in the ground truth for 2024, such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. While it mentions 'LDTI-related fair-value and remeasurement adjustments,' it does not fully detail the expansion of exclusions beyond 2023, particularly the structured nature of the 2024 exclusions. This represents a minor but notable gap in completeness, especially regarding the multi-hop synthesis of how exclusions evolved from 2023 to 2024. There are no numerical inaccuracies (dates: 2023, 2024, ASU 2023-07 are correct), and entity identification (MetLife, GAAP, LDTI, MRBs) is accurate. The reasoning is sound and contextually relevant, but the answer slightly underrepresents the extent of refinement and expansion in 2024, leading to a score of 8 rather than 9–10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1515,
        "completion_tokens": 469,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "In 2022 Accenture reported that the Board had $3.13 million of “available authorization” for its publicly‑announced open‑market repurchase program and related share‑purchase programs, and it used that authority to buy 9.64 million Class A shares in the open market (≈ $3.15 million) plus a smaller amount through other purchase programs and payroll‑tax withholding (total $4.11 million of purchases). By the end of fiscal 2024 the remaining authorization had fallen to $2.69 million, even though the Board later added another $4 million (raising total outstanding authority to $6.69 million); the company nonetheless increased open‑market buying to 11.75 million shares ($3.78 million) and expanded the “other‑program” purchases (47 k shares for $15 k), while still acquiring shares through payroll‑tax withholding that does not draw on the open‑market authority.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) The 'available authorization' in 2022 was $3,129,296 (≈$3.13 million), which the LLM correctly approximates, but it incorrectly frames this as $3.13 million of purchases rather than available authorization. The LLM falsely claims that $3.15 million was spent on open-market purchases and $4.11 million total, which is unsupported by the ground truth—no purchase volumes or dollar amounts for 2022 are provided in the original answer. (2) The LLM invents specific share purchase volumes (9.64 million shares in 2022, 11.75 million in 2024) and associated dollar values ($3.78 million) that are not in the ground truth. The original answer does not provide any data on the number of shares purchased in 2022 or 2024, nor total spending. (3) The claim that 'remaining authorization had fallen to $2.69 million' and that the Board 'added another $4 million' by 2024 is entirely fabricated; the ground truth states no such updates to authorization levels beyond the initial 2022 figure and does not mention any changes in available authorization by 2024. (4) While the LLM correctly identifies that share withholding for payroll tax obligations occurred and that such purchases do not impact the public authorization—consistent with the original answer—this is the only accurate qualitative point. (5) The original answer emphasizes a shift in acquisition methods (from open-market to withholding) and the use of treasury shares for employee benefits, which the LLM partially captures but distorts with false numerical context. (6) Multi-hop reasoning is flawed: the LLM synthesizes non-existent data across years and programs, creating a misleading narrative of funding evolution. Overall, while the answer addresses the general topic and correctly notes that payroll-tax withholding doesn't use public authorization, the extensive fabrication of numbers and lack of fidelity to the source result in a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 543,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "In the 2023 filing MetLife reported Unit‑linked and FVO securities at **amortized cost** (original cost reduced by repayments and adjusted for premium‑accretion or discount‑amortization) and showed their estimated fair value on the balance sheet, with changes recorded in net investment income but without a detailed sensitivity analysis.  \n\nIn the 2024 filing the same cost‑basis treatment remains, but the securities are now **classified in Level 3** and are valued using the same valuation techniques and significant unobservable inputs applied to other Level 3 assets; MetLife additionally discloses the **fair‑value sensitivity** of these securities (ranges and weighted‑average impacts for matrix, market and consensus pricing inputs, etc.).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct but contains a key inaccuracy in the description of the 2023 cost basis treatment. The original answer states that in 2023, cost basis for Unit-linked securities was split: equities at original cost and fixed maturities at amortized cost. The LLM incorrectly generalizes that all Unit-linked and FVO securities were reported at amortized cost in 2023, which oversimplifies and misrepresents the methodology—particularly for equities, which were not carried at amortized cost. This is a significant qualitative error in entity and methodology accuracy. However, the LLM correctly identifies the 2024 shift to Level 3 classification, use of significant unobservable inputs (e.g., mortality, lapse, volatility), and the new emphasis on fair value sensitivity disclosures. The quantitative aspects (no specific numbers, but correct years and classification levels) are accurate. Contextual relevance is strong—the response directly addresses the evolution in treatment and valuation methodology. While the core evolution (from cost-based to assumption-driven Level 3 with sensitivity analysis) is correctly captured, the misstatement about 2023 cost basis reduces the qualitative and overall correctness scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 346,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "In the 2022 filing Broadcom noted that its market‑based RSUs are granted with a **service condition plus a market condition and generally vest over four years** once the market criteria are met. The 2023 filing still describes the same dual‑condition structure, but adds that **in fiscal 2023 the company introduced market‑based RSUs that vest over five years and are tied to stock‑price performance milestones**, expanding the vesting horizon beyond the prior uniform four‑year schedule.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in fiscal year 2022, market-based RSUs generally vested over four years with service and market conditions, and grantees could receive up to 300% based on TSR (implied by 'market criteria' and consistent with ground truth). (2) For 2023, it accurately notes the continuation of the four-year structure but adds the introduction of five-year market-based RSUs tied to stock price performance milestones, matching the expansion described in the original answer. (3) The multi-hop reasoning is sound—correctly comparing the two fiscal years and identifying both continuity and change in vesting structures. (4) All entities (market-based RSUs, fiscal years 2022 and 2023, vesting timelines) are correctly identified and synthesized. Minor wording differences (e.g., 'stock-price performance milestones' vs 'stock price performance milestones') do not affect meaning. No numeric inaccuracies; no calculations required. The answer fully addresses the evolution in structure and vesting timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 314,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "- In the 2023 filing the Company reported that, under the CECL Transition Rule, it had added back a $2.4 billion “day‑1” impact and was **phasing‑in 50 % of that amount as of December 31 2023**; the balance ($1.2 billion) was scheduled to be added back in two $600 million steps on January 1 2024 and January 1 2025【78†L31-L38】.  \n\n- The 2024 filing shows that the same $2.4 billion had **been phased‑in to 75 % as of January 1 2024**, with the final $600 million to be added in 2025【200†L31-L38】.  \n\n- Throughout the transition period the CECL “day‑2” (ongoing) impact was **treated as a regulatory‑capital add‑back that could be phased in at 25 % per year** – 25 % in 2022, 50 % in 2023, 75 % in 2024 and fully in 2025【78†L13-L21】.  \n\nThus, the phase‑in moved from a 50 % add‑back in 2023 to a 75 % add‑back in 2024, with the ongoing impact being allowed into regulatory capital at a 25 %‑per‑year scaling until fully incorporated in 2025.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers, percentages, and dates are correct: the $2.4 billion total day-1 impact, the 25% annual phase-in increments (50% by end of 2023, 75% by January 1, 2024, and full inclusion by 2025), and the $600 million annual add-backs are consistent with the regulatory framework. The phrasing 'day-1' vs 'day-2' in the LLM answer requires clarification: while the LLM refers to the 'day-1' impact being phased in, the ground truth emphasizes the 'day-2' (ongoing) impact as the element phased into capital. However, the cited regulatory treatment (25% per year) applies to the cumulative ongoing impact post-adoption, which the LLM correctly describes in the third bullet. Despite this slight terminological mismatch, the core regulatory mechanism — a 25% annual phase-in from 2022 to 2025 — is accurately conveyed. (2) The calculations are precise: 25% per year leads to 50% by end-2023, 75% by start-2024 (i.e., after three years: 2022, 2023, 2024), and 100% by 2025. (3) The multi-hop reasoning is sound: the LLM synthesizes data from both 2023 and 2024 filings to show progression in phase-in levels, correctly tracking the evolution over time. (4) Contextually, the answer fully addresses the question about how the phase-in treatment evolved between 2023 and 2024 and specifies the 25%-per-year rule. The only minor shortcoming is the conflation of 'day-1' and 'day-2' impacts, but the regulatory capital treatment described is factually correct. Thus, the answer earns a 9/10 for correctness, with full marks for quantitative accuracy and contextual relevance, and a 9 for qualitative accuracy due to the slight terminology imprecision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 471,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "Broadcom’s 2022 filing shows that the company continued to use Wilmington Trust, National Association as the trustee for a series of new senior‑note programs – notably a 4.00 % issue due 2029, a 4.15 % issue due 2032 and a 4.926 % issue due 2037 that were issued under indentures dated April 14 2022 and April 18 2022. In the 2023 filing the same trustee is named on a fresh set of senior‑note programs with higher coupons and slightly shorter maturities – a 5.050 % issue due 2027, a 5.050 % issue due 2029 and a 5.150 % issue due 2031 – reflecting an evolution toward higher‑rate, nearer‑term debt while maintaining Wilmington Trust as the ongoing trustee.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Broadcom's relationship with Wilmington Trust was based on senior notes issued in January 2021 (not April 2022), with interest rates ranging from 1.950% (due 2028) to 3.750% (due 2051). The LLM incorrectly states that new notes were issued under indentures dated April 14 and April 18, 2022, including a 4.926% note due 2037 — while the ground truth confirms the 4.926% note due 2037 was issued under an April 18, 2022 indenture, it does not mention a 4.00% or 4.15% note in that timeframe. More critically, the 2023 filing in the LLM answer references notes issued in 2027–2031 with rates of 5.050%–5.150%, which are entirely fabricated and not present in the ground truth. The actual 2023 evolution includes notes issued in October 2024 ranging from 4.150% (due 2028) to 4.800% (due 2034), not higher-rate, shorter-term debt as claimed. (2) Multiple dates and percentages are incorrect: April 14, 2022 is not mentioned in the ground truth; the 5.050% and 5.150% notes do not exist in the provided data; maturities like 2027 and 2031 are not referenced. The ground truth mentions a July 12, 2024 indenture and October 2024 issuance, which the LLM omits entirely. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a shift toward 'higher-rate, nearer-term debt' when the actual trend shows longer-term debt (e.g., due 2034, 2037, 2051) and only moderately higher rates. It fails to synthesize the correct timeline and evolution across 2022 and 2023 filings. (4) The contextual relevance is moderate because it addresses the trustee relationship and attempts to compare note terms over time, but the factual foundation is largely incorrect, leading to a misleading conclusion. Quantitative accuracy is very low due to wrong rates, dates, and missing/added notes. Qualitative accuracy is poor due to incorrect synthesis and reasoning. Correctness score is low due to major factual and calculation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 546,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "Capital One’s CECL‑transition add‑back grew from **about 50 % of the $2.4 billion aggregate impact in 2023 to roughly 75 % of that amount at the start of 2024**.  The company’s filing explains that the CECL Transition Rule required the “day‑1” impact and the cumulative “day‑2” impact to be **phased in at 25 % per year** – 25 % in 2022, **50 % in 2023**, **75 % in 2024**, and the balance (100 %) in 2025【COF_10k_2023.pdf p. …】.  Accordingly, the add‑back that was 50 % of the $2.4 billion in 2023 was increased to the 75 % level by January 1 2024【COF_10k_2024.pdf p. …】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers, percentages, and dates are accurate: $2.4 billion is correctly cited as the total CECL add-back amount, with 50% phase-in in 2023 and 75% in 2024, reflecting a 25 percentage point increase. The annual 25% phase-in schedule (25% in 2022, 50% in 2023, 75% in 2024, 100% in 2025) is correctly described and aligns with the CECL Transition Rule. (2) The answer addresses both parts of the question: the evolution from 2023 to 2024 and the specific phase-in progression. (3) Entities are accurate—Capital One (COF), the CECL Transition Rule, and the relevant years are correctly identified. (4) The reasoning is sound and reflects proper multi-hop synthesis: the model correctly infers the phase-in pattern from the rule and applies it to Capital One’s reported figures across two fiscal years (2023 and 2024 filings). (5) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'about 50%' and 'roughly 75%'), these are acceptable approximations of exact phase-in levels and do not detract from factual accuracy. Minor formatting like 'day-1' and 'day-2' impacts adds context without introducing error. All claims are supported by the cited documents. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 372,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "In the 2022 filing, Broadcom disclosed that, upon completion of the VMware merger, all in‑the‑money VMware stock options (and RSUs) held by non‑employee directors **would be accelerated and converted into an equal‑part cash‑and‑Broadcom‑stock payment**. The 2023 filing, after the merger closed, confirmed that this plan was carried out – the directors’ in‑the‑money VMware options and RSUs **were accelerated and actually converted into cash and Broadcom shares, split 50/50**. Thus, the treatment did not change; the 2022 statement described the intended conversion, and the 2023 statement reported its execution.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution of the treatment of VMware stock options for non-employee directors: in 2022, the plan was to accelerate and convert in-the-money options and RSUs into equal parts cash and Broadcom stock upon acquisition; in 2023, this plan was confirmed as executed. (2) There are no numerical values requiring calculation, but the description of 'equal parts' or '50/50' split is consistent with 'cash and shares of Broadcom common stock, in equal parts' from the original answer—this phrasing is a valid interpretation and adds clarity. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two filings (2022 plan vs. 2023 outcome), correctly identifying the transition from intention to realization. (4) All entities—VMware, Broadcom, non-employee directors, stock options, RSUs, 2022 and 2023 timeframes—are accurately referenced. The answer is concise, factually precise, and directly addresses the question's focus on how the treatment evolved. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 328,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie described Vraylar (cariprazine) mainly as a dopamine‑D3‑preferring D3/D2 partial agonist that was **being studied as an adjunctive therapy for major depressive disorder** (with Phase 3 data reported) and was already approved for acute and maintenance treatment of schizophrenia, acute manic or mixed episodes of bipolar I disorder, and acute bipolar‑depressive episodes. By the 2024 Form 10‑K the company’s disclosure presented Vraylar as a **multi‑indication product** with approved uses for **acute and maintenance treatment of schizophrenia, acute manic or mixed episodes of bipolar I disorder, acute bipolar‑depressive episodes, and adjunctive treatment of major depressive disorder**, emphasizing a broader therapeutic positioning across both psychotic and mood‑disorder indications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2022, Vraylar was being studied as an adjunctive treatment for MDD in Phase 3 trials, with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement (implied by 'Phase 3 data reported' though not explicitly detailed). It also correctly notes the existing approvals for schizophrenia and bipolar indications. By 2024, it accurately reflects the expanded labeling to include adjunctive treatment of MDD and emphasizes its multi-indication status. (2) There are no numerical values requiring calculation, but the years (2022, 2024) and trial phases (Phase 3) are correct. (3) The multi-hop reasoning is sound—synthesizing disclosures across two years from AbbVie’s Form 10-K filings to show evolution in therapeutic positioning. The LLM correctly infers a broader indication set by 2024 based on approved uses. (4) The only minor shortcoming is that the 2022 context slightly under-elaborates on the mixed Phase 3 results (though 'being studied' with 'data reported' is not incorrect), making it less detailed than the ground truth but still semantically aligned. Overall, the answer is factually correct, well-structured, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 372,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "GE still recognizes revenue on its long‑term service agreements on a percentage‑of‑completion basis – i.e., based on costs incurred to date relative to total estimated costs – in both the 2022 and 2024 10‑Ks. What changed is the level of detail around the billing estimate: the 2022 filing said billings are generally tied to asset utilization or scheduled overhaul events, while the 2024 filing adds that GE now explicitly estimates the total customer payments over the contract term using historical utilization trends, forward‑looking market and retirement information, and it routinely revises those estimates with cumulative‑catch‑up adjustments and a formal assessment of expected billing adjustments and credit risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in stating that GE used the percentage-of-completion method in both 2022 and 2024. According to the ground truth, in 2022, GE used the straight-line basis for revenue recognition in long-term service agreements, primarily in Healthcare and Renewable Energy, not percentage-of-completion. The shift to percentage-of-completion occurred by 2024, specifically in the CES segment. This misrepresentation of the core revenue recognition method in 2022 invalidates the central claim of the LLM answer. (2) No numeric values from the ground truth are mentioned in the LLM answer—specifically, the $6.6 billion net liability, the $162 billion total estimated life of contract billings, and the 4.1% ratio are all missing. These are key quantitative indicators of the evolution in GE's accounting policy and were explicitly part of the original answer. The LLM does not attempt any calculations or reference these figures, resulting in a major deficit in quantitative accuracy. (3) The multi-hop reasoning is flawed because the model fails to correctly identify the change in accounting policy over time. Instead of recognizing a shift from straight-line to percentage-of-completion, it incorrectly asserts consistency in method and focuses only on increased disclosure detail. While it is true that the 2024 filing includes more detailed forward-looking estimation processes (e.g., utilization trends, market info, credit risk), this contextual enhancement is presented as a standalone change rather than in conjunction with the method shift, distorting the full picture. (4) Contextual relevance is moderate because the answer addresses the right topic—evolution in accounting policy for long-term service agreements—and correctly notes enhanced disclosure in 2024 regarding billing estimates. However, due to the critical error in revenue recognition method for 2022 and omission of key financial data, the overall correctness score is low. The answer misleads on the primary factual change and lacks essential quantitative support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 559,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "In the 2022 Form 10‑K the 1.250 % notes due 2027 were disclosed only in the debt‑notes section of the financial‑statement footnotes, where IBM gave the basic terms (interest rate, maturity date and amount outstanding) but did not list a ticker or exchange information. In the 2023 Form 10‑K the same issue appears in the “Securities registered pursuant to Section 12(b)” table, now identified by the ticker **IBM 27B** and noted as being listed on the New York Stock Exchange, providing a more explicit, registration‑style disclosure of the 1.250 % notes due 2027.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of quantitative details: the 1.250% interest rate, 2027 maturity, and ticker symbol IBM 27B on the New York Stock Exchange are all correct and match the ground truth. There are no calculation or numeric errors. Contextually, the answer is highly relevant, directly addressing the evolution of disclosure between the 2022 and 2023 10-Ks. However, the qualitative accuracy is slightly lower because the LLM misrepresents the location of the 2022 disclosure. The ground truth states the notes were disclosed by referencing Exhibit 4.3 to Form 8-K filed on January 30, 2019, in the context of instruments defining rights of holders—not in the financial statement footnotes as the LLM claims. This is a significant detail omission/mischaracterization. While the LLM correctly identifies the shift in 2023 to a registered security with ticker and exchange listing, it fails to capture the precise nature of the 2022 disclosure mechanism, which undermines the multi-hop reasoning slightly. The core evolution (from referenced instrument to registered security) is conveyed, but with incorrect contextual framing for 2022, hence a score of 7 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 341,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings state that AbbVie’s performance‑vested RSUs can vest in **one‑third increments over a three‑year performance period** and that the awards are earned **based on AbbVie’s return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech and life‑science companies**. The 2024 filing adds that senior‑executive equity awards also include performance shares tied to EPS and total‑stockholder‑return (TSR) metrics, but the RSU structure and its ROIC‑based performance condition remain unchanged from 2022. 【2022‑page 113‑115】【2024‑page 90‑94】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that performance-vested RSUs vest in one-third increments over a three-year period in both 2022 and 2024, and that the performance metric is based on ROIC relative to a peer group of pharmaceutical, biotech, and life science companies—this matches the original answer exactly. (2) All quantitative elements (e.g., 'one-third increments', 'three-year performance period') are factually correct and consistent with the source. There are no numerical or date inaccuracies. (3) The multi-hop reasoning is sound: the model correctly compares the 2022 and 2024 filings, synthesizes the continuity in structure, and notes the absence of changes in the RSU performance criteria. It also adds a relevant detail from the 2024 filing about senior-executive awards including EPS and TSR metrics, which is accurate and provides additional context without misrepresenting the core RSU structure. (4) The only minor gap is that the LLM does not explicitly mention the 'streamlining' or 'simplification' of the performance metric description in 2024 (e.g., the removal of references to specific years tied to tranches), which is a nuance highlighted in the ground truth. However, stating that the 'structure and ROIC-based condition remain unchanged' effectively captures the core conclusion. The answer is semantically equivalent and highly relevant, with excellent use of source citations. Thus, the correctness score is 9 due to this slight omission in descriptive evolution, but all factual and quantitative elements are fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 443,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "In 2022 GE recorded a **$865 million unrealized loss** on its AerCap equity investment (Note 19, Other Income). By 2023 that position had swung to a **$129 million gain**, and in 2024 it produced a **$38 million gain** (both realized and unrealized). Thus, GE’s stake in AerCap moved from a sizable loss in 2022 to modest positive earnings in the following two years, indicating an improving financial outcome on the investment.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $865 million unrealized loss in 2022 and the $38 million gain in 2024, which matches the ground truth. However, it introduces a $129 million gain in 2023 that is not mentioned in the original answer, and there is no supporting evidence in the ground truth for this intermediate figure. This addition introduces a factual inaccuracy, as the original answer only discusses 2022 and 2024. (2) The 2022 and 2024 numbers are quantitatively accurate, but the inclusion of a 2023 gain that is not in the ground truth reduces quantitative accuracy. The original answer does not mention 2023 performance, so asserting a specific dollar amount for that year is an unsupported extrapolation. (3) The reasoning is mostly sound—recognizing a shift from loss to gain and interpreting it as an improving financial outcome is consistent with the ground truth. However, the multi-hop synthesis is slightly flawed because it adds a data point (2023) not present in the source, which undermines the fidelity of the timeline. (4) Despite the extra 2023 detail, the core message—that GE’s financial relationship with AerCap improved from a large loss to a modest gain between 2022 and 2024—is preserved, and the entities (GE, AerCap), years (2022, 2024), and key figures are correct. Contextual relevance is perfect as it directly addresses the evolution of the financial relationship via gains/losses. The correctness score is 7 due to the accurate core facts but penalized for the unsupported 2023 figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 422,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.300 % notes that mature in 2026 are not listed among the securities registered under Section 12(b); they are absent from the disclosed “Notes” table, implying the issue was not highlighted as a separate, publicly‑registered instrument. By the 2023 Form 10‑K, IBM adds a line for “0.300 % Notes due 2026 (IBM 26B)” in the Section 12(b) securities list, making the issue an explicit, visible component of its capital‑structure disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth. (1) All entities are correct: IBM, 0.300% Notes due 2026, 2022 and 2023 filings. The percentages and years match exactly. (2) Quantitative accuracy is perfect: the interest rate (0.300%), maturity year (2026), and trading symbol (IBM 26B) are all correctly stated. The LLM correctly identifies the absence in the 2022 Section 12(b) table and its presence in 2023. (3) The multi-hop reasoning is sound: it synthesizes changes in disclosure status between two years, correctly inferring increased visibility based on inclusion in the registered securities list. The only minor gap is that the LLM does not mention the original Exhibit 4 to Form 8-K filing from 2016, which the ground truth includes as context for the 2022 status. While this detail adds background, its omission does not undermine the correctness of the evolution described between 2022 and 2023. (4) The answer is highly relevant, directly addressing the question about disclosure status and visibility in financial instruments. Wording differs but semantic meaning aligns with the ground truth. Thus, the answer earns a 9/10 for correctness due to high accuracy with a slight deduction for incomplete contextual completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 358,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "In the 2022 filing GE described RISE mainly as a new joint‑venture program with Safran aimed at “more than 20 % lower fuel consumption and CO₂ emissions” – a strategic signal that the company was beginning to invest in sustainable‑flight technologies. By the 2024 filing the language had shifted to a broader, deeper commitment: RISE is now presented as a “suite of pioneering technologies” (Open‑Fan, compact‑core and hybrid‑electric systems) with GE Aerospace allocating a larger share of its growing R&D budget to the program and reporting hundreds of tests on a full‑scale Open‑Fan engine. Thus, GE’s approach evolved from an initial partnership‑focused concept to a major, multi‑technology investment aimed at delivering concrete, next‑generation low‑emission engine solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 2022 RISE Program announcement as a joint effort with Safran targeting 'more than 20% lower fuel consumption and CO2 emissions' is accurately reported, including the exact percentage and strategic context. By 2024, the shift to a 'suite of pioneering technologies' with significant investment and testing of a full-scale Open-Fan engine reflects the evolution in GE's approach. (2) Quantitative accuracy is perfect: the 20% reduction figure is correctly cited, and while no dollar amounts are mentioned in either answer, the LLM correctly references increased R&D allocation without fabricating numbers. (3) Multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 time points, correctly identifying the shift from conceptual partnership to active, funded R&D. It adds valuable detail (e.g., Open-Fan, compact-core, hybrid-electric) that enriches the original answer without contradicting it. (4) The only reason for not scoring a 10 is minor: the original answer emphasizes 'significant investments' as a direct quote, while the LLM paraphrases this as 'allocating a larger share of its growing R&D budget'—semantically equivalent but slightly less precise in wording. However, this does not affect factual correctness. Overall, the answer is contextually relevant, factually accurate, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 403,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "In the 2022 Form 10‑K, American Express described asset‑securitizations simply as one element of a diversified funding mix that it could use “to obtain cost‑effective funding” for Card Member loans and receivables, without quantifying the amount or signaling a growth focus. The 2023 filing expands that discussion, positioning securitizations alongside deposits and unsecured debt as a core pillar of the funding strategy, noting that long‑term debt now includes “unsecured debt and asset‑backed securities” and that total long‑term debt (including the ABS program) rose to **$47.9 billion**, up from **$42.6 billion** in 2022. Thus, the company’s emphasis on securitizations has grown from a peripheral option in 2022 to a highlighted, larger‑scale source of financing in 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in emphasis on asset securitizations from 2022 to 2023, noting the progression from a peripheral funding option to a core component of American Express's funding strategy, which aligns with the ground truth. It accurately references the strategic positioning of securitizations alongside deposits and unsecured debt in 2023 and acknowledges the role of diversity in funding sources. However, the quantitative details are problematic. The LLM claims that total long-term debt including asset-backed securities (ABS) rose to $47.9 billion in 2023 from $42.6 billion in 2022. This specific numerical comparison is not supported by the ground truth, which does not provide these figures or confirm such an increase. The original answer makes no mention of dollar amounts related to securitizations or long-term debt, so introducing these numbers—especially with bold emphasis—constitutes a factual overreach and undermines quantitative accuracy. (2) There is no verification in the ground truth for the $47.9B or $42.6B figures, nor is there any indication that the ABS program’s size was quantified in the 10-Ks in this way. These numbers may be hallucinated or misattributed. Even if they reflect actual data, their inclusion without confirmation from the source context violates fidelity to the provided ground truth. (3) The multi-hop reasoning is otherwise sound: the model correctly synthesizes the evolution of disclosure tone and strategic framing across two years, moving from definitional/glossary treatment in 2022 to strategic emphasis in 2023. This demonstrates good qualitative understanding of the shift in narrative and intent. (4) The contextual relevance is perfect—the answer directly addresses the evolution of role and emphasis as requested. Due to the unsupported numerical claims, the correctness score is reduced to 7 (core facts right, but significant quantitative error), quantitative accuracy to 6 (some plausible numbers but not in ground truth), qualitative accuracy to 8 (reasoning strong but slightly overreaching), and contextual relevance remains 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 574,
        "total_tokens": 1991
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "In fiscal 2022 Emerson closed the Heritage AspenTech transaction, contributed its two industrial‑software businesses and about $6 billion in cash, and emerged as the majority owner (≈55 % of the new AspenTech shares).  That year the company booked a $453 million pretax gain on its subordinated interest and began reporting AspenTech as a separate segment, which posted $656 million of sales and modest earnings.  \n\nIn fiscal 2023 Emerson’s stake had risen to roughly 57 % and the investment produced a much smaller $161 million pretax gain, while AspenTech was fully integrated into Emerson’s operating structure as its own reporting segment, contributing to the 3 % sales lift attributed to the acquisition, adding $125 million of stock‑compensation expense and $146 million of intangibles amortization related to the deal.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in timing and financial figures. According to the ground truth, in 2022 Emerson held a minority investment in AspenTech with $656 in sales and a $12 earnings gain, not a majority stake. However, the LLM claims Emerson became the majority owner (≈55%) in fiscal 2022, which contradicts the original answer stating the controlling interest was acquired in 2023. This misplacement of the acquisition timeline is a critical error. (2) Quantitative inaccuracies include: the $453 million pretax gain in 2022 (ground truth reports only a $12 earnings gain), the $161 million gain in 2023 (not mentioned in ground truth), $125 million stock-compensation expense, $146 million intangibles amortization, and $6 billion cash contribution—none of which appear in the ground truth. While $656 million in sales matches, the earnings figure is off by magnitude. The 3% sales lift and margin impact of 0.6 percentage points in the original answer are absent in the LLM response. (3) The multi-hop reasoning is partially sound in that it attempts to trace the evolution of the relationship, but the core transformation—from passive to active control—is misdated, undermining the logical progression. The LLM incorrectly frames the 2022 period as post-acquisition when it should be pre-acquisition. (4) Despite these issues, the answer is contextually relevant, addressing investment returns and operational integration. Some qualitative elements like reporting AspenTech as a separate segment and increased ownership stake align with the strategic shift, but the factual foundation is too flawed for a higher score. Thus, correctness is scored low due to major factual and quantitative errors, though the structure and intent are relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 491,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "In the 2022 filing Emerson recorded the AspenTech combination as an acquisition, recognizing a $5.9 billion non‑controlling‑interest liability for the 45 % of AspenTech owned by former Heritage AspenTech shareholders and reducing its additional‑paid‑in‑capital by about $550 million; the deal also generated $97 million of intangible‑amortization expense and $110 million of acquisition‑related costs that were reflected in “Other deductions, net.” By the 2023 filing Emerson still reported the same 45 % non‑controlling interest (the equity‑method balance remained on the balance sheet), but the acquisition’s after‑effects showed up as higher expense items – intangible‑amortization rose to $146 million (primarily AspenTech‑related), SG&A included $50 million of AspenTech‑related stock‑compensation, and “Other deductions, net” increased to $506 million, of which the bulk was the additional AspenTech amortization.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Emerson's financial relationship with AspenTech between 2022 and 2023, correctly identifying the noncontrolling interest accounting in 2022 and the ongoing acquisition-related impacts on expenses in 2023. However, there are key quantitative inaccuracies. The original answer states that SG&A expenses rose by $572 million in total (year-over-year), partly due to AspenTech and higher stock compensation, but the LLM incorrectly specifies only $50 million of that increase as AspenTech-related stock compensation, which is not supported by the ground truth. Additionally, the LLM introduces $97 million in intangible amortization and $110 million in acquisition costs in 2022, and claims 'Other deductions, net' increased to $506 million in 2023—none of these specific figures appear in the original answer and cannot be verified. The original answer does not break down amortization or acquisition costs to this level. (2) While the $5.9 billion noncontrolling interest and $550 million reduction in additional paid-in capital are correctly reported, the LLM fabricates granular expense line items not present in the ground truth, undermining quantitative accuracy. (3) The multi-hop reasoning is sound in structure—linking 2022 accounting treatment to 2023 operational impacts—but relies on unsupported specifics. The LLM correctly infers that AspenTech contributed to higher amortization and SG&A, but misrepresents the magnitude and sourcing of these impacts. (4) Despite the numerical discrepancies, the LLM maintains strong qualitative and contextual accuracy by correctly framing the shift from initial accounting (2022) to integration effects (2023), and accurately describing the 45% noncontrolling interest. Hence, a correctness score of 7 is warranted: core facts are right, but significant invented details reduce overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 514,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings treat the 6.22 % debentures due 2027 the same way: the debentures are listed among IBM’s registered securities and the rights of the holders are incorporated by reference to the same Exhibit 3 of the Form 8‑K filed on August 1, 1997. No new amendment, redemption provision, or additional disclosure about these debentures appears in the 2023 filing compared with the 2022 filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that IBM treated the 6.22% Debentures due 2027 the same way in both 2022 and 2023 filings, which directly contradicts the ground truth. While the LLM correctly notes that both filings reference Exhibit 3 to the Form 8-K filed on August 1, 1997 (quantitative accuracy is high for dates and exhibit numbers), it fails to recognize the key evolution in disclosure format between the years. The ground truth states that the 2023 filing introduced a more structured and market-oriented presentation by listing the debentures with a trading symbol (IBM 27) and identifying them among other NYSE-registered securities—a significant qualitative shift from the 2022 filing's purely historical reference. The LLM incorrectly asserts no change occurred, missing this multi-hop nuance entirely. This represents a failure in qualitative accuracy and reasoning, as the model did not synthesize the change in disclosure strategy despite correct identification of the underlying document reference. Contextual relevance is moderate because the answer addresses the right instrument and filings but draws an incorrect conclusion about their evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 333,
        "total_tokens": 1574
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "UnitedHealth’s 2023 filing noted that its health‑benefits businesses already had “risk‑based arrangements with some physicians, hospitals and other health‑care providers,” which limited its exposure to rising medical costs but left it vulnerable to a provider’s financial or operational failures. The 2024 filing expands that discussion, indicating that risk‑based contracts now encompass a larger portion of its portfolio (still roughly 80 % of total revenue) and therefore increase the amount of financial risk the company bears if a provider cannot meet its obligations. As a result, UnitedHealth must rely on ever‑more detailed cost‑estimation models and assume the responsibility for paying claims on behalf of insolvent providers, heightening both its cost‑management burden and its service‑delivery obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of UnitedHealth's risk exposure from 2023 to 2024, noting increased financial and operational risk due to broader reliance on risk-based arrangements and the potential need to cover claims for insolvent providers. It also correctly identifies the implications for cost estimation and service delivery. However, the claim that risk-based contracts represent 'roughly 80% of total revenue' is not present in the original answer and cannot be verified from the provided ground truth, introducing a potentially inaccurate quantitative assertion. (2) The original answer does not include any percentage figures or revenue proportions, so the 80% figure is an unsupported addition. This affects quantitative accuracy despite the rest of the financial reasoning being plausible. (3) The multi-hop reasoning is sound—LLM correctly synthesizes that increased reliance on risk-based providers leads to greater financial exposure, especially if providers fail, and that this necessitates more sophisticated cost modeling and claim responsibilities. The logic aligns with the original answer’s emphasis on expanded risk and operational complexity. (4) Scores reflect high qualitative and contextual accuracy due to correct entity identification (UnitedHealth, risk-based arrangements, years 2023–2024), accurate portrayal of evolving risk, and strong reasoning. However, the unsupported 80% revenue figure reduces quantitative accuracy and slightly undermines overall correctness, preventing a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 428,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "In the 2022 filing Emerson disclosed that it completed the “Heritage AspenTech” transaction, contributing its Open Systems International and Geological Simulation software businesses and **approximately $6 billion in cash** to create a new, independent AspenTech, and emerged with a **55 % ownership stake** in the company. By the 2023 filing Emerson reported that its holding had risen to **about 57 % of AspenTech’s outstanding shares**, confirming that the relationship had moved from a one‑time cash‑plus‑asset investment to an ongoing strategic partnership in which Emerson remains the controlling shareholder and is actively considering a full‑share acquisition.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a financial relationship with AspenTech reflected by a $362 million investment. However, the LLM incorrectly states that the $6 billion transaction and 55% ownership occurred in 2022, when in fact that transaction marked the evolution in 2023. The LLM flips the timeline: it claims the major transaction was completed in 2022 per the '2022 filing', but the ground truth states the strategic shift happened in 2023. Additionally, the LLM introduces a 57% ownership stake in 2023, which is not present in the original answer and is unsupported. (2) Quantitatively, the $6 billion cash contribution and 55% ownership are correct figures, but they are assigned to the wrong year. The $362 million investment in 2022 is completely omitted, which is a major missing data point. The claim of 'about 57%' has no basis in the ground truth. (3) The multi-hop reasoning is flawed because the model fails to correctly sequence the evolution: it should be financial investment in 2022 ($362M) → strategic transaction in 2023 ($6B + business contribution → 55% ownership). Instead, the LLM reports the strategic move in 2022 and implies continuity into 2023 with an increased stake, which contradicts the source. (4) Contextual relevance is high because the answer addresses investment magnitude and strategic involvement, and uses appropriate financial terminology. However, due to incorrect timing, missing 2022 data, and fabricated 2023 ownership increase, the overall correctness is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 446,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "In fiscal 2022 Adobe described **Target** as a stand‑alone, AI‑ and machine‑learning‑driven personalization engine that lets customers “test, target and optimize content across channels” and create omnichannel, A/B‑ and multivariate‑tested experiences【ADBE_10k_2022.pdf page 45】.  \n\nBy fiscal 2023 the company had folded Target more tightly into the broader Experience Cloud platform, positioning it alongside Adobe Sensei’s generative‑AI (GenAI) capabilities that “allow customer‑experience and marketing teams to use natively‑embedded generative AI to deliver more accurate and personal customer journeys”【ADBE_10k_2023.pdf page 15】.  \n\nThis shift shows Adobe moving from offering Target as a discrete testing‑and‑targeting tool toward a fully integrated, AI‑powered personalization layer that leverages both machine‑learning and generative AI to automate and deepen real‑time, hyper‑personalized customer experiences.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies regarding Adobe Target's positioning in fiscal 2022. The original answer states that in 2022, Adobe Target was described as part of a broader set of customer journey solutions alongside Marketo Engage, Adobe Campaign, and Journey Optimizer, and was characterized as a tool for testing, targeting, and personalizing content. However, the LLM incorrectly claims that in 2022, Adobe already described Target as an 'AI- and machine-learning-driven personalization engine', which is a characterization from 2023, not 2022. This misrepresents the evolution by suggesting AI-driven emphasis was already central in 2022. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies a shift in positioning from 2022 to 2023 and references integration with Adobe Sensei’s GenAI in 2023. However, it inverts the starting point of the evolution, undermining the core logic of strategic progression. The claim that Target was 'stand-alone' in 2022 contradicts the ground truth that it was already part of a broader suite. (4) Contextual relevance is high—the answer addresses the evolution of Adobe Target and ties it to AI-driven personalization strategy, using correct document references and relevant concepts. However, due to the significant mischaracterization of the 2022 state, the qualitative accuracy is low, dragging down the overall correctness. The conclusion about strategic direction is plausible but built on flawed premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 454,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "Emerson finished buying Heritage AspenTech in the third quarter of 2022, which turned the formerly independent company into a wholly‑owned subsidiary.  The purchase added roughly $967 million of AspenTech‑related goodwill to Emerson’s balance sheet and brought AspenTech’s $240 million revolving‑loan facility onto Emerson’s long‑term‑debt schedule (see the goodwill table and the “other includes $240 in outstanding borrowings by AspenTech” note)【EMR_10k_2022.pdf page 8‑8】.  In the 2023 filing Emerson still reports AspenTech as a fully consolidated business, retains 100 % of the equity, and describes the post‑combination integration work – such as converting all pre‑closing Heritage AspenTech stock‑option and RSU awards into AspenTech equivalents and continuing restructuring activities – as part of its ongoing integration effort【EMR_10k_2023.pdf pages 68‑70】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. The ground truth states that Emerson reported an $8,326 million balance related to AspenTech in 2022 as part of its acquisitions, but the LLM incorrectly claims only $967 million in goodwill and references a $240 million loan facility. These numbers do not align with the ground truth and represent a major quantitative error. Additionally, the $967 million figure appears to be goodwill alone, not the total acquisition balance, which misrepresents the scale of Emerson's financial stake. (2) The dates are partially correct—Emerson did complete the acquisition in 2022 (Q3), which matches the timeline in the original answer. However, the LLM fails to mention that AspenTech became a separate publicly traded company under Emerson’s acquisition framework in 2023, instead stating it is a 'wholly-owned subsidiary' and 'fully consolidated business,' which contradicts the ground truth description of AspenTech operating as a separate public entity. This is a critical entity and structural misrepresentation. (3) The reasoning around integration activities is partially sound: the conversion of stock options and RSUs is correctly identified as part of post-acquisition integration, and ongoing restructuring is mentioned, which aligns with the original answer’s mention of continued incentive plans. However, the LLM misses the key point about performance stock units tied to metrics like annual contract value and free cash flow, which reflects a deeper operational integration and incentive alignment. (4) While the LLM addresses both years and touches on financial stake and integration, the core financial data is wrong, and the nature of the 2023 relationship is misrepresented. The answer is contextually relevant and attempts multi-hop synthesis (using 2022 and 2023 filings), but the factual foundation is flawed, leading to a low correctness score despite some accurate qualitative elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 538,
        "total_tokens": 1963
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "In the 2022 filing Adobe positioned the Experience Platform primarily as the open, extensible data layer that “standardizes data for intelligence and profile creation” and feeds Adobe Sensei‑powered AI services (e.g., automated insights, attribution, one‑click personalization) across the Experience Cloud suite. By the 2023 filing the platform had moved from a behind‑the‑scenes data hub to the engine that powers new AI‑driven capabilities—such as the generative‑AI “Sensei GenAI” services and the Journey Optimizer app built on the platform—and is explicitly described as the backbone for real‑time, cross‑channel campaign orchestration (Marketo Engage, Campaign, Target, etc.), enabling unified customer profiles to be activated instantly across all channels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Adobe Experience Platform's 2022 role as the data foundation enabling AI services via Adobe Sensei, including automated insights and personalization—consistent with the original answer’s mention of automated insights, sentiment analysis, and anomaly detection. The 2023 evolution is accurately described: the platform becomes the 'engine' for cross-channel orchestration, specifically citing integration with Journey Optimizer (implied via 'powers new AI-driven capabilities... Journey Optimizer app') and real-time activation across channels. The mention of 'generative-AI Sensei GenAI' services and 'backbone for real-time, cross-channel campaign orchestration' reflects the shift toward actionable campaign planning, matching the ground truth’s emphasis on Adobe Mix Modeler and orchestration. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct. (3) Multi-hop reasoning is sound: the answer synthesizes the platform’s evolution from data infrastructure to an active orchestration engine, connecting AI integration (Sensei) with campaign tools (Journey Optimizer, Marketo Engage, Campaign, Target), demonstrating understanding across functional layers. (4) Minor deduction in qualitative accuracy because the LLM answer does not explicitly mention Adobe Mix Modeler, a specific 2023 addition highlighted in the ground truth that leverages the platform for marketing investment optimization. While 'generative-AI Sensei GenAI' may encompass this, it is not a direct substitute. Otherwise, the semantic meaning, context, and factual core are equivalent and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 472,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "In the 2023 filing UnitedHealth noted that rising Medicare‑Advantage funding pressures and higher outpatient‑care activity among seniors were prompting it to “accelerate the integration of our care‑delivery models—including in‑clinic, in‑home, behavioral and virtual care—and to move more quickly toward fully accountable, value‑based arrangements.” By the 2024 filing the company said it had taken that strategy a step further: its 2024 Medicare‑Advantage benefit design deliberately incorporates the funding squeeze, intensifies medical‑cost and operating‑cost management, reshapes provider networks and adjusts member premiums, while expanding data‑driven, virtual‑and‑home‑based care to deepen the shift to value‑based, coordinated delivery.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in UnitedHealth Group's care delivery model from 2023 to 2024 in response to Medicare Advantage funding pressures. (1) It correctly identifies the 2023 emphasis on accelerating value-based care through integrated models (in-clinic, in-home, virtual, behavioral) and movement toward accountable arrangements, aligning with the ground truth. In 2024, it accurately reflects the strategic pivot due to funding pressures—highlighting benefit design adjustments, cost management, provider network reshaping, and premium changes—consistent with the original answer’s theme of strategic retrenchment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the ground truth or LLM response, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes a shift in strategy across two years and links external pressures (Medicare Advantage funding) to internal operational changes. The LLM uses slightly different phrasing (e.g., 'intensifies medical-cost and operating-cost management' vs. 'cost containment') but conveys the same meaning. (4) The only minor shortcoming is that the LLM omits explicit mention of 'risk adjustment changes' and 'county-level decisions about plan offerings' from the 2024 response, which are specific elements in the ground truth. However, 'reshapes provider networks' and 'adjusts member premiums' cover key aspects of the operational adjustments. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning, warranting a high score with only a slight deduction for minor completeness gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 470,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "The 2022 filing listed a single series of 1.950 % notes due 2029 (ticker TMO 29) among a set of lower‑coupon issues. In the 2023 filing the same 1.950 % notes due 2029 are still present, but the overall debt portfolio has been expanded with new higher‑coupon series – a 3.200 % issue due 2026 and a 3.650 % issue due 2034 – while none of the existing issues were removed. Thus, the composition broadened with additional notes, yet the 1.950 % Notes due 2029 remained unchanged.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 1.950% Notes due 2029 were present in both 2022 and 2023 with the same ticker (TMO 29), and new debt instruments introduced in 2023 include the 3.200% Notes due 2026 and 3.650% Notes due 2034. (2) Quantitative elements—interest rates (1.950%, 3.200%, 3.650%) and maturity years (2029, 2026, 2034)—are precisely correct. No calculations were required, but the comparison across years is accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes data from two years (2022 and 2023) for TMO, identifies continuity in the 1.950% Notes, and detects the expansion of the debt portfolio with higher-coupon instruments. (4) The answer addresses all parts of the question: evolution of debt composition and the specific status of the 1.950% Notes due 2029. Wording differs slightly (e.g., 'lower-coupon issues', 'higher-coupon series') but adds interpretive context without distorting facts. All entities—TMO, note terms, years—are correctly identified. Thus, full marks are justified across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 322,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings Thermo Fisher continued to list its 0.500 % Notes due 2028 (ticker TMO 28A), so that instrument’s presence and terms were unchanged. The 2023 filing, however, added two higher‑coupon series that were not in the 2022 register – a 3.200 % Notes due 2026 (TMO 26B) and a 3.650 % Notes due 2034 (TMO 34) – expanding the company’s debt portfolio beyond the earlier set of low‑rate notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All numeric values—interest rates (0.500%, 3.200%, 3.650%), maturities (2026, 2028, 2034)—are correct and match the original answer. The presence of the 0.500% Notes due 2028 in both years is correctly noted. (2) Quantitative accuracy is perfect: no calculation errors, and all dates and percentages are factually correct. Format variations (e.g., spacing in percentages) do not affect meaning. (3) The multi-hop reasoning is sound: the model correctly identifies the continuity of existing notes and the introduction of new ones between 2022 and 2023, demonstrating proper synthesis across filings. The mention of 'higher-coupon series' adds useful qualitative context not in the original but is logically valid. (4) The only minor omission is that the original answer also notes the continued presence of the 1.375% Notes due 2028, which the LLM omits. While not critical to the core question about the 0.500% Notes and new categories, this detail contributes to completeness. Despite this, the LLM captures the key evolution in debt composition and strategic diversification. Semantic equivalence is strong, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 345,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "- **2023 goodwill‑impairment analysis:** the excess of estimated fair value over carrying value for each reporting unit ranged **from about 140 % to about 495 %** of carrying value.  \n- **2024 goodwill‑impairment analysis:** the same excess ranged **from about 70 % to about 450 %** of carrying value.  \n\nThus, the lower end of the range fell roughly 70 percentage points (140 % → 70 %) and the upper end fell about 45 percentage points (495 % → 450 %) between the two annual tests.  \n\n*Sources: 2023 10‑K discussion of goodwill impairment (range 140 %‑495 %) and 2024 10‑K discussion (range 70 %‑450 %).*",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 140% to 495% in 2023 and 70% to 450% in 2024. The observed changes (70-percentage-point decrease at the lower end, 45-point decrease at the upper end) are correctly calculated and reported. (2) The answer is complete, addressing both years' ranges and the directional change in the excess fair value range. (3) Entities are accurate—DHR’s reporting units, goodwill impairment analyses, and correct fiscal years (2023 and 2024) are properly referenced. (4) The reasoning is sound: the model correctly synthesizes multi-hop information from two annual reports, compares the ranges year-over-year, and implicitly captures the reduced cushion to impairment, aligning with the conclusion in the ground truth. Minor wording differences (e.g., 'about' vs 'approximately') do not affect semantic equivalence. All sources are correctly attributed to the respective 10-K filings. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 303,
        "total_tokens": 1543
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "In the 2022 filing the 2022 Employee Stock Plan expressly said that **canceled RSUs and shares withheld for tax purposes each add back two times their number to the pool of shares available for grant** (while grants themselves reduce the pool by two‑times the RSUs granted). In the 2023 filing the description of the plan no longer repeats that language – it only notes that RSU grants reduce the pool by two‑times the grant amount – implying the same mechanics remain but the explicit statement that cancellations and tax‑withheld shares increase the pool was dropped.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2022, canceled RSUs and tax-withheld shares were added back to the share pool at two times their number, which matches the original answer. (2) It accurately notes that in 2023, the explicit language about the 'two times' add-back was omitted from the filing, indicating a change in disclosure or policy. (3) The reasoning is sound: the LLM correctly infers that while the mechanics might still be in place, the explicit statement was dropped, which aligns with the ground truth's interpretation of the omission. (4) The only minor shortcoming is that the LLM slightly softens the conclusion by saying the omission 'implies the same mechanics remain,' whereas the ground truth interprets the omission as indicating a change in accounting treatment. This is a subtle but important distinction—the original answer treats the omission as evidence of a policy change, while the LLM suggests the policy might still be in effect despite the missing language. However, the LLM does acknowledge the absence of the key language, so the deviation is minor. All entities (2022 Employee Stock Plan, RSUs, tax-withheld shares, years 2022 and 2023) are correct, and there are no numerical or factual inaccuracies. The answer is fully relevant and addresses the evolution of treatment over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 388,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "In the 2023 Form 10‑K Danaher reported that it had **fully acquired Aldevron in August 2021** for about $9.6 billion (recording roughly $6.1 billion of goodwill) and that Aldevron was already **integrated as part of Danaher’s Life‑Sciences segment**. The 2024 Form 10‑K lists Aldevron again as one of the Life‑Sciences brands, confirming that Danaher **continues to hold 100 % ownership** and that the business remains embedded in the Life‑Sciences segment. Thus, between 2023 and 2024 the strategic relationship did not change – Danaher’s financial stake stayed at full ownership and Aldevron remained fully integrated within the Life‑Sciences segment.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) The original answer (ground truth) states that Danaher had a 'significant financial stake' in Aldevron in 2023 with $9,561 million in net cash consideration allocated — implying the acquisition was reflected in that year's financials — but the LLM claims Aldevron was fully acquired in August 2021, which contradicts the knowledge graph data suggesting the financial impact was material and reported in 2023. While Danaher may have initiated the acquisition in 2021, the ground truth emphasizes 2023 as the year when the stake was significant and accounted for, indicating either a later full acquisition or major financial adjustment. (2) The LLM asserts that Aldevron was already integrated into the Life Sciences segment in 2023 and remained so in 2024, concluding no change occurred. However, the original answer describes a strategic evolution — from a separately accounted stake in 2023 to full integration by 2024 — indicating a shift in how Aldevron was treated operationally and financially. The LLM misses this nuance entirely and incorrectly asserts no change, when the ground truth highlights a transition. (3) The $9.6 billion figure cited by the LLM is close to the $9,561 million in the original answer (a minor rounding difference), so quantitative accuracy is partially preserved, but the use of additional figures like $6.1 billion in goodwill is unsupported in the provided ground truth and introduces unverified data. (4) The reasoning fails on multi-hop synthesis: instead of identifying a change in financial stake and integration status between 2023 and 2024, the LLM assumes continuity based on an earlier acquisition date not emphasized in the source. This leads to an incorrect conclusion about the evolution of the strategic relationship. (5) Contextual relevance is moderate — the answer addresses the right companies and segments — but fails to capture the core dynamic the question asks about: evolution over time. Thus, despite some correct context and approximate numbers, the answer is factually and logically flawed in key aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 574,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "In the 2023 filing Microsoft described Microsoft 365 as an “AI‑first” platform that brings together Office, Windows, Copilot and Enterprise Mobility + Security, with Copilot for Microsoft 365 and role‑based Copilot extensions already embedded to drive productivity and business‑process transformation. By the 2024 filing the company had deepened that narrative: Copilot for Microsoft 365 (and the new Copilot Pro service) is highlighted as the core AI engine, the subscriber count now includes the Microsoft 365 Basic tier, and Microsoft 365 is explicitly called out as the main driver of commercial metrics—Office 365 Commercial seat growth and a 16% rise in Office Commercial revenue (driven by 16% Office 365 Commercial growth) and 82.5 million consumer subscribers—showing its elevated role in Microsoft’s overall commercial performance.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Microsoft 365's strategic positioning between 2023 and 2024, emphasizing its 'AI-first' platform identity in 2023 and the expanded integration of Copilot (including Copilot Pro) in 2024. It accurately notes the inclusion of Microsoft 365 Basic subscribers in the metric, aligning with the ground truth. However, the LLM introduces specific quantitative claims not present in the original answer: a '16% rise in Office Commercial revenue' and '82.5 million consumer subscribers'. These figures, while plausible, are not part of the ground truth and thus represent unsupported additions. (2) The ground truth does not include any percentages or subscriber counts, so the introduction of '16%' and '82.5 million' reduces quantitative accuracy. There is no way to verify these numbers from the provided truth, and their inclusion risks misinformation. (3) The multi-hop reasoning is strong: the model correctly synthesizes the shift in narrative from AI integration to broader commercial impact, connects Copilot's role across years, and links product changes to business metrics. The logic flow from AI integration to commercial performance is sound and reflects a proper understanding of strategic evolution. (4) Despite the extra numbers, the core qualitative and contextual elements are accurate and relevant. The answer addresses both AI integration and commercial business metrics as required, with appropriate entity and year alignment. The correctness score is reduced due to unsupported figures, but not severely, as the central strategic narrative is well-supported and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 460,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "In the 2023 Form 10‑K Microsoft introduced **Copilot Pro** as a consumer‑subscription add‑on that “offers AI assistance in Microsoft 365 apps and on the web,” positioning it as part of the broader Copilot stack that extends AI into its productivity suite. By the 2024 filing the company’s language had shifted to stress that **Copilot Pro now delivers “faster and more powerful” AI assistance**, emphasizing that it is a core component of the AI‑first Microsoft 365 platform and a primary web‑based AI helper for users. This evolution shows Microsoft moving from a basic AI‑assistance offering in 2023 to a more premium, performance‑focused service that is central to both the desktop apps and the web experience in 2024. 【2023 p. …】【2024 p. …】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Copilot Pro was introduced in 2023 as a consumer subscription for AI assistance in Microsoft 365 apps and on the web, and by 2024 the language evolved to emphasize 'faster and more powerful' AI assistance. The LLM correctly identifies the shift in emphasis and integration into the AI-first platform. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2023, 2024) are accurate and consistent with the original answer. (3) The multi-hop reasoning is sound—comparing Microsoft’s evolving language across two years and inferring strategic positioning changes based on disclosure nuances. The LLM correctly synthesizes the evolution from a basic offering to a premium, central component. (4) Semantic equivalence is strong: while the LLM uses slightly more assertive phrasing (e.g., 'core component', 'primary web-based AI helper'), these are reasonable interpretations of the original’s 'increasingly integrated' and 'broader AI-first positioning'. The only minor deviation is that the original emphasizes the *narrative embedding* of the same phrase ('faster and more powerful') within a broader transformation story, whereas the LLM frames it as a 'shift' in language. This is a subtle difference in interpretation but does not undermine factual correctness. Overall, the answer is complete, contextually relevant, and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 409,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "The 2007 Omnibus Incentive Plan remained unchanged in structure—still authorizing roughly 135 million Danaher shares for stock‑options, RSUs, PSUs and other equity awards. However, the pool of shares that were still free for new grants fell from about 50 million as of 12/31/2023 to roughly 47 million as of 12/31/2024, indicating that about 3 million additional shares were issued or otherwise consumed during 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific figure was provided for remaining shares as of 2023, but the LLM claims there were 'about 50 million' shares available as of 12/31/2023, which is not supported by the original data. Additionally, the LLM asserts the total authorized shares are 'roughly 135 million,' which does not appear in the original answer and cannot be verified from the provided context. The only correct number is the ~47 million shares remaining as of December 31, 2024, which matches the ground truth. (2) The calculation of a 3 million share reduction during 2024 is based on incorrect prior data (50M to 47M), making the inference invalid. There is no evidence in the original answer that 3 million shares were consumed in 2024, nor that the pool decreased over that period—only that a figure was disclosed in 2024 where none was given in 2023. (3) The multi-hop reasoning is flawed: the LLM incorrectly assumes comparable data exists for both years, when the original answer emphasizes that 2023 lacked a disclosed remaining share count. This undermines the core comparison. The model fabricates a quantitative trend (50M → 47M) that the ground truth does not support. (4) While the LLM correctly identifies the plan's ongoing use for RSUs, PSUs, and other awards, and notes increased transparency in 2024, it introduces unsupported specifics. The contextual relevance is high because it addresses the evolution of share availability, but the quantitative inaccuracies severely undermine correctness. Correctness score is low due to invented numbers; qualitative accuracy is moderate due to correct general structure; quantitative accuracy is poor due to unsupported figures and invalid calculation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 487,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft revised its depreciation policy for server and network equipment in July 2022, extending the estimated useful life from four years to six years. The change was applied beginning fiscal 2023 and remained in effect for fiscal 2024. The revision was driven by investments in software that made operating the equipment more efficient and by overall advances in technology.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: Microsoft extended the estimated useful life of server and network equipment from four to six years, effective beginning fiscal year 2023, and this policy remained unchanged in fiscal year 2024. The drivers—software investments improving operational efficiency and technological advances—are accurately reported. The mention of July 2022 as the revision date aligns with the typical timing of fiscal year-end changes ahead of fiscal 2023 (which begins July 1, 2022), so this detail is consistent with the ground truth. (2) All quantitative elements—'four years' to 'six years', 'fiscal 2023', 'fiscal 2024'—are factually correct. No calculations are required, but temporal alignment is accurate. (3) The multi-hop reasoning is sound: the model connects a policy change in one fiscal year, its implementation timing, continuation into the next, and the underlying rationale involving technology and software improvements. The only minor gap is that the original answer adds contextual depth about cloud and AI infrastructure investments reinforcing the policy, which the LLM omits. This doesn't invalidate the answer but slightly reduces completeness. (4) The LLM answer is semantically equivalent and highly relevant, with excellent factual accuracy. The omission of the forward-looking context about sustained integration and AI/cloud strategy prevents a perfect 10, but core facts, entities, dates, and reasoning are correct. Hence, correctness is 9, with full marks for quantitative accuracy and contextual relevance, and near-perfect qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 445,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "In both fiscal years the company held the same amount of auction‑rate securities – a fair‑value of **$33 million**. In 2022 they were reported in the balance‑sheet **“Other assets”** line (Level 3, not classified as investments), and the 2023 filing shows the same **$33 million** still classified as **Other assets**. Thus, the exposure’s fair value and its balance‑sheet classification did not change from 2022 to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer correctly reports the fair value of auction rate securities as $33 million in both 2022 and 2023, satisfying quantitative accuracy. However, it makes a critical error in stating that in 2022 the securities were classified under 'Other assets'. According to the ground truth, in 2022 they were included in 'Total' within the investment portfolio and were not explicitly classified as 'Other assets'—that change occurred in 2023. This misrepresents the evolution of classification, which is the core of the question. The LLM incorrectly concludes there was no change, when in fact the shift from a general investment category to 'Other assets' is the key development. This is a major qualitative inaccuracy in entity classification and reasoning, undermining the answer's correctness despite correct numbers. The answer is contextually relevant but fundamentally flawed in its synthesis of multi-hop information across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 270,
        "total_tokens": 1519
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "Cisco reported a net loss on its available‑for‑sale debt investments of **$67 million in fiscal 2024**, compared with a **$21 million loss in fiscal 2023** – a deterioration of **$46 million** year‑over‑year【CSCO_10k_2024.pdf page 46】. This widening loss shows that the fair‑value changes on these debt securities moved more negatively in 2024, indicating weaker investment performance for that portfolio relative to the prior year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net losses for both fiscal years—$21 million in 2023 and $67 million in 2024—matching the ground truth exactly. The year-over-year deterioration of $46 million ($67M - $21M) is accurately calculated and reported. (2) All numeric values are correct and properly formatted, with acceptable variations in presentation (e.g., $67 million). The calculation of the increased loss is precise and supports the conclusion. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two fiscal years to compare performance and draws a valid conclusion about worsening investment performance in available-for-sale debt investments. (4) The answer fully addresses both parts of the question—quantitative change and qualitative implication—and conveys the same meaning as the original answer with equivalent, if not slightly more detailed, clarity. All entities (Cisco, available-for-sale debt investments, fiscal years 2023 and 2024) are correctly identified. Thus, all accuracy and relevance metrics are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 310,
        "total_tokens": 1503
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "In the 2023 filing Cisco still described APJC (Asia‑Pacific, Japan and China) as one of three geographic segments that was run largely as a traditional product‑sales organization, with most of its spending directed toward capital‑intensive hardware development and inventory. By the 2024 filing the company said it had reorganized the APJC footprint into a “regional‑hub” operating model that leans on shared‑services functions and a heavier emphasis on subscription‑based software, cloud and services contracts rather than new hardware spend. The shift from a hardware‑focused operating structure to a subscription‑and‑services‑focused investment strategy means that a larger share of APJC revenue is now expected to be recurring, reducing reliance on one‑time product sales and smoothing the region’s revenue profile.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. While it claims Cisco reorganized APJC into a 'regional-hub' model with a shift to subscription-based software and services in 2024, the ground truth does not support this. Instead, the original answer states that Cisco maintained its operational presence in APJC in 2023 and added financial investments (marketable and non-marketable equity securities, equity method investments) in 2024—there is no mention of a shift from hardware to subscriptions or a new operating model. The LLM invents structural changes (e.g., shared-services, regional hub) and a strategic pivot to software subscriptions that are not present in the ground truth. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations, hence a score of 10 by default. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution from operational structure to include financial investment. Instead, it fabricates a narrative about operational restructuring and revenue model shift toward recurring revenue from subscriptions, which is not supported by the original data. The actual multi-hop insight is that Cisco moved from direct operations (2023) to adding financial investments (2024), implying a dual revenue model of operations plus investment returns—this is missed entirely. (4) Correctness is low (3/10) due to major factual inaccuracies and invented details. Qualitative accuracy is also low (3/10) because of incorrect entity relationships and reasoning. Contextual relevance is moderate (5/10) as the answer addresses Cisco and APJC across years and touches on operational and financial aspects, but with wrong specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 485,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "In the 2022 Form 10‑K Apple noted only that it “from time to time makes changes to the App Store in response to competition, market and legal conditions” and that pending legislation such as the EU Digital Markets Act (DMA) and ongoing litigation could force it to alter the commissions it keeps or the way it lets developers distribute apps outside the Store. By the 2024 filing Apple reported that it has already acted on those pressures – it introduced U.S.‑specific rules governing how developers must disclose alternative purchasing options, and in the EU it rolled out new business terms, lower or alternative fee structures, optional distribution channels and separate payment‑processing mechanisms to comply with the DMA, while still warning that further litigation could drive additional changes. Thus Apple moved from a largely precautionary stance in 2022 to concrete, region‑specific commission‑and‑payment reforms in 2024 driven by legal rulings and regulatory mandates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Apple's 2022 acknowledgment of potential App Store changes due to legal and market pressures, including the DMA and litigation, and contrasts this with concrete 2024 actions. All key facts—such as the introduction of U.S. rules for alternative purchasing disclosures, and in the EU, new business terms, alternative fee structures, distribution channels, and payment processing—are factually correct and match the original answer. (2) There are no numeric values (e.g., percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised; dates (2022, 2024) and regulatory references (DMA) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across years and regions, correctly inferring a shift from precautionary disclosures to implemented changes. It accurately links regulatory pressure (DMA) to specific operational changes. (4) The only minor shortcoming is that the LLM slightly overemphasizes U.S. changes as 'rules governing how developers must disclose alternative purchasing options'—while accurate, this is less directly tied to commission structure changes compared to the EU reforms. The original answer emphasizes broader financial impact on commissions, which the LLM implies but could have stated more explicitly. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 413,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "In the 2022 filing the U.S. Retiree Health Care Plan was invested roughly two‑thirds in fixed‑income securities (about 64 % of plan assets) and one‑third in equities (≈ 36 %). By the 2024 filing the mix had shifted to almost four‑fifths in fixed‑income (≈ 80 %) and only about one‑fifth in equities (≈ 20 %). Thus, over the 2022‑2024 period the plan’s strategy moved markedly toward a higher fixed‑income allocation and a lower equity allocation.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in allocation strategy from 2022 to 2024, noting an increase in fixed income and a decrease in equity exposure. However, the 2022 percentages (64% fixed income, 36% equities) are not directly supported by the ground truth, which provides dollar amounts ($248M fixed income and cash equivalents, $137M equities). Calculating from these amounts yields a total portfolio of $385M in 2022, resulting in approximately 64.4% fixed income and 35.6% equities—so the LLM's approximation is accurate. The 2024 allocation (80% fixed income, 20% equities) matches the ground truth exactly. (2) Quantitative accuracy is high: the derived 2022 percentages are mathematically correct from the ground truth values, and 2024 figures are exact. The LLM does not reference the actual dollar amounts from 2022, which slightly reduces completeness, but the proportional representation is valid. (3) The multi-hop reasoning is sound—comparing allocation strategies across years and inferring a strategic shift toward conservatism is logically supported. The LLM correctly synthesizes the trend even without mentioning the 2023 stability noted in the original answer. (4) The answer is contextually relevant and captures the core evolution in strategy. It misses the nuance that the 80/20 split was consistent between 2023 and 2024 (suggesting the shift occurred before 2023), but this does not invalidate the overall conclusion. Thus, minor omission prevents a perfect score, but the answer is substantially correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 427,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "In the 2022 filing TI’s strategy was built around “analog and embedded‑processing products,” with the embedded‑processing line explicitly identified as one of the four sustainable competitive advantages – the broad product portfolio that creates more opportunity per customer and adds value to its investments – and it was reported as a distinct, second operating segment alongside Analog. By the 2024 filing the company still reports Embedded Processing as a separate segment, but its revenue fell from $3.26 billion in 2022 to $2.53 billion in 2024 and operating profit dropped from $1.25 billion to $0.35 billion, indicating that while the segment remains part of the portfolio‑based advantage, its relative contribution to TI’s competitive position and overall results has diminished.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Contrary to the ground truth, it incorrectly states that Embedded Processing was already a reportable segment in 2022, when in fact it was not elevated to that status until 2024. This misrepresents a key strategic evolution. Additionally, the LLM claims that Embedded Processing revenue fell from $3.26 billion in 2022 to $2.53 billion in 2024 and operating profit dropped from $1.25 billion to $0.35 billion, but these figures are not supported by the ground truth, which does not provide specific financials for the segment in those years. The decline narrative contradicts the ground truth's emphasis on strategic elevation and growing importance. (2) The quantitative inaccuracies are severe: no revenue or profit figures are mentioned in the original answer, so the LLM fabricated precise numbers without basis. Even if such data existed, the claimed 72% drop in operating profit would imply a crisis, which is inconsistent with the strategic emphasis described in the ground truth. (3) The multi-hop reasoning is flawed. The LLM fails to recognize the structural change in segment reporting as a signal of strategic prioritization. Instead, it assumes continuity in segment reporting and interprets fabricated financial declines as evidence of diminished strategic value, which inverts the correct conclusion. The ground truth emphasizes that the elevation to a reportable segment reflects increased strategic importance, not reduced performance. (4) While the LLM attempts to address the question’s focus on strategic evolution and competitive advantage, its incorrect facts and reasoning lead to a conclusion opposite to the ground truth. The contextual relevance is moderate because it discusses the right topic (Embedded Processing strategy), but the qualitative and quantitative errors severely undermine correctness. Correctness score is low due to fabrication of data and reversal of key strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 538,
        "total_tokens": 2018
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "In the 2022 Form 10‑K the 2.00 % 10‑year senior notes (euro‑denominated, due 4 April 2025) were shown with a par amount of **$728 million** and a carrying amount of **$782 million**, and an effective interest rate of **2.10 %**【TMO_10k_2022.pdf page 86‑90】.  \n\nBy the 2024 Form 10‑K the same series had been reduced to a par amount of **$663 million** (carrying amount **$706 million**) and the effective interest rate had slipped slightly to **2.07 %**【TMO_10k_2024.pdf page 45‑49】.  \n\nThus, between 2022 and 2024 Thermo Fisher decreased the outstanding principal and net book value of its 2.00 % 10‑year senior notes and the notes’ effective interest rate fell marginally.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both facts and reasoning. The original answer states that TMO issued $1,200 million of 2.00% 10-Year Senior Notes due October 15, 2031, with an effective interest rate of 2.23%, and this amount and rate remained unchanged in 2024. In contrast, the LLM claims the notes were due April 4, 2025 (not 2031), reports a par value of $728 million in 2022 and $663 million in 2024 (vs. $1,200 million constant), and cites an effective interest rate of 2.10% and 2.07% (vs. 2.23% constant). These discrepancies are not formatting differences but outright factual errors. (2) The numbers are entirely inconsistent with the ground truth: the principal amount, maturity date, and interest rates are all wrong. The LLM references euro-denominated notes due in 2025, which are a different instrument altogether. There is no indication in the ground truth of any reduction in principal or change in interest rate. (3) The multi-hop reasoning fails completely: instead of identifying the same debt instrument across 2022 and 2024, the LLM confuses it with a different series of notes (possibly a euro-denominated issue), leading to false conclusions about repayment and rate changes. (4) The contextual relevance is low because the answer discusses a different financial instrument. Quantitative accuracy is near zero due to incorrect values across all metrics. Qualitative accuracy is poor due to misidentification of the debt instrument and flawed synthesis. Correctness score is 1 because the answer is almost entirely factually incorrect despite addressing the general topic of senior notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 448,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "Remicade’s sales have been falling steadily. In the 2022 Form 10‑K the drug generated roughly **$1.9 billion** of revenue, but by fiscal 2024 that figure had dropped to **$1.605 billion**, a decline of about **15‑18 %** versus two years earlier. The downward trend is attributed to the entry of multiple infliximab biosimilars in the United States and abroad, and it signals that, while Remicade remains one of the larger immunology products in Johnson & Johnson’s Pharmaceutical (Innovative Medicine) segment, its contribution to the segment’s overall sales is eroding as biosimilar competition intensifies.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the declining trend in REMICADE's sales and its role in Johnson & Johnson's Pharmaceutical segment, with mostly accurate figures. However, there are minor quantitative inaccuracies. The original answer states REMICADE's 2023 sales were $1,839 million and 2024 sales were $1,605 million, representing a 12.8% decline. The LLM claims $1.9 billion in 2022 (not $1,839M in 2023) and calculates a 15–18% decline over two years, which is incorrect because the ground truth only provides data from 2023 to 2024, not 2022 to 2024. The LLM incorrectly references 2022 revenue as $1.9B (close but not exact; no 2022 figure is given in the ground truth), and misattributes the time frame for the decline. (2) The correct calculation is (1,839 - 1,605) / 1,839 ≈ 12.7%, matching the original 12.8%. The LLM’s 15–18% estimate is inaccurate due to using an incorrect base year and figure. (3) The multi-hop reasoning is sound: the model correctly infers that declining sales impact J&J’s Immunology segment and attributes the decline to biosimilar competition, which aligns with contextual knowledge and is a logical inference even if not explicitly stated in the ground truth. (4) Despite the numerical and temporal inaccuracies, the qualitative assessment and overall message—that REMICADE’s role is diminishing due to biosimilar pressure—are consistent with the original answer. Hence, the correctness score is 8 for minor factual errors, quantitative accuracy is 7 due to incorrect figures and time frame, qualitative accuracy is 9 for strong reasoning, and contextual relevance is 10 as the answer fully addresses the question’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 456,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "Remicade’s revenue fell sharply after 2022 – it generated roughly **$2.2 billion in 2022**, dropped to **$1.84 billion in 2023**, and slipped further to **$1.61 billion in 2024**, a total decline of about **27 %** over the three‑year span. The continual downward trend, driven by expanding biosimilar competition, signals that Remicade is losing market share within Johnson & Johnson’s Immunology portfolio, with growth now being led by other biologics such as Stelara and Tremfya.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, REMICADE had sales of $3,190 million in 2022, but the LLM reports $2.2 billion (~$2,200 million), which is off by nearly $1 billion. The 2024 figure is closer—$1.61 billion in the LLM vs. $1,605 million in the truth—but still slightly inaccurate. The 2023 value is not provided in the original answer, so the LLM's $1.84 billion cannot be verified, but the 12.8% drop from 2023 to 2024 implied by the truth would mean 2023 sales were approximately $1,840 million, so this number is likely correct. However, the LLM's claim of a 27% total decline from 2022 to 2024 is based on incorrect starting data. Using ground truth numbers: from $3,190M to $1,605M is a 49.7% decline, not 27%. (2) Calculations are therefore flawed due to incorrect input values, even if the LLM applied percentage changes correctly. The 12.8% drop from 2023 to 2024 aligns with the truth if 2023 sales were ~$1,840M, so that part is plausible. (3) The multi-hop reasoning is sound: the LLM correctly infers declining market position due to biosimilar competition and contextualizes REMICADE’s performance within JNJ’s broader immunology portfolio by referencing Stelara and Tremfya as growth leaders. This shows good synthesis across entities and trends. (4) While the qualitative narrative and direction of decline are accurate—and the answer is contextually relevant and complete in addressing both parts of the question—the severe numerical inaccuracies in key figures (especially 2022 sales) significantly undermine factual correctness. Hence, correctness and quantitative accuracy scores are moderate, while qualitative and contextual scores are higher due to logical reasoning and appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 485,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "Remicade’s sales fell sharply, from $3.19 billion in fiscal 2021 to $1.61 billion in fiscal 2024 – a drop of roughly 50 percent (about $1.6 billion). Both filings attribute the decline to the ongoing entry of infliximab biosimilars in the United States and other markets, which has eroded Remicade’s market share and will continue to reduce sales.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The original answer states that REMICADE's sales were $16.8 billion in 2021 as part of total Immunology sales, whereas the LLM claims $3.19 billion in 2021, which is not only incorrect but misrepresents the scale and context of the sales figure. Additionally, the 2024 sales are reported as $1,605 million ($1.605 billion) in the ground truth, which the LLM approximates reasonably well at $1.61 billion. However, the claimed 50% drop (from $3.19B to $1.61B) is based on incorrect baseline data and does not align with the actual decline trajectory. The ground truth specifies a 12.8% decrease from 2023 to 2024 alone, which the LLM fails to mention or calculate correctly. (2) The calculation of a '50% drop' is mathematically accurate based on the incorrect numbers the model used, but since the input values are wrong, the conclusion is misleading. The actual decline from 2021 to 2024 cannot be computed directly from the ground truth because the $16.8B is total Immunology sales, not REMICADE-specific — this nuance was likely misinterpreted by the model, leading to error propagation. (3) The qualitative reasoning about biosimilar competition in the U.S. and global markets is correct and aligns with the original answer, showing proper synthesis of causal factors across time. This reflects sound multi-hop reasoning regarding market dynamics and external competitive pressures. (4) While the explanation of contributing factors is relevant and accurate, the severe numerical inaccuracies — especially the misstatement of 2021 sales by over $13 billion — undermine the correctness score. The model captures the directional trend (sharp decline due to biosimilars) and the general timeframe, but fails on key financial specifics. Hence, partial credit is given for correct reasoning and context, but major deductions apply for quantitative inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 527,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "In the 2022 filing, STELARA (ustekinumab) was still protected by its last U.S. patent (expiring September 2023), was generating roughly $5.9 billion of U.S. sales in FY 2021 and was described as “strongly” growing in Crohn’s disease and ulcerative colitis. By the 2024 filing, worldwide STELARA sales had slipped to $10.4 billion (down 4.6 % versus 2023) and U.S. sales were about $6.7 billion, with the decline attributed to share loss from European biosimilar entrants and pending U.S. biosimilar filings that are expected to launch in 2025. Thus, between 2022 and 2024 the product moved from a patent‑protected, high‑growth phase to a post‑patent environment where biosimilar competition began eroding its sales.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies a 4.6% decline in STELARA sales by 2024 and attributes the decline to biosimilar competition (which aligns with the broader context), several key quantitative inaccuracies exist. The ground truth states that STELARA generated $10,361 million ($10.36 billion) in sales in 2024, which the LLM approximates as $10.4 billion — this is acceptable within rounding. However, the LLM incorrectly cites $5.9 billion in U.S. sales for FY 2021 (not 2022), which is irrelevant to the 2022–2024 timeframe in the question. Additionally, the claim of $6.7 billion in U.S. sales by 2024 is unsupported by the ground truth, which reports worldwide sales only. The patent expiration date (September 2023) is plausible but not confirmed in the ground truth, which does not mention patent status. (2) The 4.6% decline matches the ground truth calculation: ($10,858M - $10,361M) / $10,858M ≈ 4.6%, so this part is accurate. However, the LLM introduces U.S.-specific sales figures and growth in Crohn’s and ulcerative colitis that are not present in the original answer, making them unverifiable and potentially misleading. (3) The multi-hop reasoning is partially sound — the model infers a transition from patent protection to biosimilar competition, which is a reasonable interpretation. However, the original answer focuses on regulatory status (pediatric indication under review in 2022) rather than patent status, which the LLM omits entirely. This represents a failure to synthesize the correct type of development status. (4) The contextual relevance is high because the answer addresses the evolution of STELARA’s commercial performance and market challenges. However, the correctness score is reduced due to factual inaccuracies in numbers and misrepresentation of the 2022 status. The qualitative accuracy is moderate because the reasoning is logical but based on extraneous or unverified data. Overall, the answer captures the trend of declining sales due to biosimilars but misses key elements of the original answer’s focus on regulatory progression and provides incorrect historical sales data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 588,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "In 2023 AbbVie reported $382 million of Restasis net revenue in the United States, which fell to $172 million in 2024 – a drop of $210 million. The decline represented a **38.5 % decrease** from 2022 to 2023 【2023 table Restasis U.S. $ 382 (‑38.5 %)】 and a **55.2 % decrease** from 2023 to 2024 【2024 table Restasis U.S. $ 172 (‑55.2 %)]}.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All factual information is accurate: Restasis U.S. net revenue was $382 million in 2023 and $172 million in 2024. The percentage decrease from 2022 to 2023 is correctly stated as 38.5%, and the decrease from 2023 to 2024 is accurately given as 55.2%. (2) Quantitative accuracy is perfect: the dollar drop of $210 million is correct ($382M - $172M = $210M), and both percentage changes align with the original data. Minor formatting variations (e.g., spacing in '38.5 %') do not affect meaning. (3) The multi-hop reasoning is sound—information from two different years is correctly synthesized to compute year-over-year changes, and the entities (Restasis, AbbVie, U.S. net revenue, correct years) are properly identified. (4) The answer is semantically equivalent to the original, with added clarity (e.g., stating the absolute drop) without introducing errors. All sub-questions are addressed: change in revenue and percentage decrease in each year. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1140,
        "completion_tokens": 302,
        "total_tokens": 1443
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "In the 2022 filing, master lease agreements were presented primarily as a way to lock in consistent, long‑term revenue and to curb non‑contractual churn, with the added benefit of creating strategic partnerships that speed colocation‑cycle times. By the 2023 filing, the company emphasizes that those same master leases have become a cornerstone of its international‑expansion strategy—enabling AMT to leverage its growing global site portfolio and deep‑ening relationships with multinational carriers to secure stable cash flows and rapid equipment deployment in new markets. Thus, the agreements have evolved from a revenue‑stability tool to a strategic lever that directly supports AMT’s worldwide growth and tenant‑relationship objectives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Master Lease Agreements (MLAs) in AMT's strategy between 2022 and 2023. (1) It correctly identifies that in 2022, MLAs were emphasized for building strategic partnerships, reducing colocation cycle times, and enabling rapid deployment—aligning with the ground truth. In 2023, it accurately reflects the continued focus on long-term revenue and reduced churn, while evolving into a 'cornerstone' of international expansion, which matches the ground truth's emphasis on supporting international growth and tenant retention. (2) Quantitative accuracy is perfect: while the exact site numbers (177,000 in 2022 and 182,000 in 2023) are not mentioned in the LLM answer, their absence does not constitute a factual error—the ground truth includes them, but the LLM does not contradict them or provide incorrect figures. The focus is on strategic evolution, not quantitative site growth, so omission is acceptable for semantic equivalence. (3) The multi-hop reasoning is sound: the model synthesizes the shift in strategic emphasis from revenue stability (2022) to a broader growth enabler in international markets (2023), correctly identifying the deepening of relationships with multinational tenants and risk mitigation through stable cash flows. (4) The answer is contextually relevant and fully addresses the question about the evolution of role and strategic importance. The only minor shortcoming is the lack of explicit mention of risk mitigation factors (e.g., customer consolidation, regulatory changes) noted in the ground truth, which slightly reduces qualitative completeness. However, the core strategic evolution is accurately conveyed, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 470,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K the filing states that advertisers purchase inventory not only through Google Ads and Google Ad Manager but also through Google Display & Video 360 **and the Google Marketing Platform**. The company’s accounting for ads on Google Network properties – recognizing the billed amount as revenue on a gross‑basis (when it controls the inventory) and recording partner payments as cost of revenue – is described in the same way in each year, indicating that the role of the Marketing Platform in driving ad sales has remained essentially unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, despite using accurate terminology and referencing correct accounting policies. (1) The original answer states that Google Marketing Platform's role evolved between 2023 and 2024, with a more nuanced evaluation of principal vs. agent status and enhanced explanation of its central role in managing advertising across Google Network properties in 2024. In contrast, the LLM claims the role 'has remained essentially unchanged,' which directly contradicts the ground truth. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—no errors in dates or formats, hence a score of 10. (3) The qualitative inaccuracy stems from failed multi-hop reasoning: the model does not recognize that while the gross-basis accounting policy may be consistent, the platform’s described role and the depth of disclosure about its control over inventory and advertising management evolved significantly in 2024. The LLM incorrectly interprets consistency in accounting treatment as evidence of no evolution in the platform’s role, missing the nuance in how the role was characterized and explained. (4) Contextual relevance is moderate because the answer discusses the correct companies, platforms, and revenue recognition concepts, but fails to capture the evolution emphasized in the question and ground truth, rendering it misleading overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 390,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "- **Volume** – The balance‑sheet line “Federal funds purchased and securities loaned (or sold) under repurchase agreements” grew from about **$301 billion in 2023** to roughly **$482 billion in 2024** (≈ + $181 billion, a 60 % increase).  \n- **Fair‑value** – The fair‑value of the same liability fell from **$192.9 billion in 2023** to **$178.6 billion in 2024** (≈ ‑ $14 billion, a 7 % decline).\n\n**Interpretation:**  Bank of America expanded the amount of short‑term funding it obtains through Federal‑funds purchases and securities‑loan arrangements in 2024, but the market‑based valuation of that funding declined, indicating that the bank is using a larger pool of relatively low‑cost, short‑term liquidity to meet its funding needs. This shift reflects a more aggressive reliance on the Federal‑funds market while keeping funding costs modest.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in both volume and fair value figures, contradicting the ground truth. According to the original answer, in 2023 there was a net change in volume of $16,466 million (not a total volume of $301 billion), and in 2024 the fair value was $192,859 million — an increase from 2023, not a decrease. The LLM incorrectly states that fair value declined from $192.9B to $178.6B, which is directly opposite to the ground truth. Additionally, the LLM reports a volume increase of $181B (60%), but the ground truth reports a net change of only $16.5B — a massive discrepancy. (2) Calculations are therefore also incorrect: the LLM’s claimed 60% increase and $181B rise are unsupported by the data; the actual increase in fair value is from an implied 2023 base (not provided) to $192,859M in 2024, with a $16,466M net change in volume in 2023. The LLM fabricates precise balance sheet figures for 2023 and 2024 that are not in the original answer. (3) The multi-hop reasoning is flawed: the LLM misinterprets 'net change in volume' as total volume and inverts the fair value trend, leading to incorrect synthesis. It fails to connect that increased liabilities indicate greater reliance on short-term funding, as correctly stated in the original. (4) Despite incorrect numbers and trends, the LLM attempts to interpret strategic implications, so some contextual relevance is retained. However, due to major quantitative and qualitative inaccuracies, the overall correctness score is low. The answer misrepresents core financial data and draws conclusions from fabricated numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 446,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "In the 2022 Form 10‑K, PepsiCo’s market‑risk discussion simply notes that “the exposure of our **pension and retiree‑medical‑plan assets and liabilities** to risks related to market fluctuations” is described in its “Critical Accounting Policies and Estimates” section. By the 2024 Form 10‑K, the same language is retained but is broadened to say the discussion now covers “the exposure of our **goodwill and other intangible assets and pension and retiree‑medical‑plan assets and liabilities** to risks related to market fluctuations,” indicating that the company has expanded the disclosure to include additional asset categories alongside the pension and retiree‑medical liabilities.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of PepsiCo's disclosure. While it correctly identifies that in 2022, the company referenced pension and retiree medical plan risks in the 'Critical Accounting Policies and Estimates' section, it misrepresents the 2024 change. The LLM claims that the disclosure was expanded to include 'goodwill and other intangible assets' alongside pension and retiree medical plan liabilities. However, the ground truth states that the 2024 disclosure broadened the discussion not by adding new asset categories like goodwill, but by expanding the *types of risks* considered — specifically linking sensitivity to inflationary, deflationary, and recessionary conditions in addition to market fluctuations. This is a qualitative expansion of risk context, not a change in the asset categories disclosed. The LLM answer therefore fails on multi-hop reasoning and qualitative accuracy, as it misidentifies the nature of the disclosure change. There are no numerical errors (hence high quantitative accuracy), and the response is contextually relevant to the question, but the central factual claim is incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 337,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "In the 2023 filing Adobe Scan was described mainly as a free mobile‑scanning app that captures paper, creates PDFs and adds OCR, and was listed simply as one of the apps that make up Adobe Document Cloud. By the 2024 filing Adobe stresses that Scan now feeds its PDFs straight into the Document Cloud platform and is positioned as the mobile “entry point” that integrates with Acrobat, Acrobat Sign and the Document Cloud APIs, making it a core, cloud‑enabled component of Adobe’s overall document‑management ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies Adobe Scan's 2023 positioning as a free mobile scanning app with OCR and PDF creation capabilities within Adobe Document Cloud. It also accurately captures the 2024 evolution by emphasizing its role as a 'mobile entry point' that integrates directly with Acrobat, Acrobat Sign, and Document Cloud APIs, reflecting deeper ecosystem integration. While the LLM does not explicitly mention 'AI-driven features' like Content Credentials or Firefly, which are part of the broader 2024 shift in the original answer, it correctly infers the strategic move toward tighter cloud integration and workflow centrality. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and all entities (Adobe Scan, Document Cloud, Acrobat, Acrobat Sign) and years (2023, 2024) are correct. The reasoning is sound and reflects multi-hop synthesis across time periods and product positioning. The omission of specific AI features slightly reduces qualitative accuracy, but the core evolution in positioning is correctly conveyed, warranting a high correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 334,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "Google first introduced Gemini in December 2023 as a “ground‑up” multimodal large‑language model that could understand and generate across text, code, audio, images and video. By 2024 the model had been upgraded to Gemini 2.0 – a more capable version that is now embedded in every one of Google’s seven flagship, two‑billion‑user products (Android, Chrome, Gmail, Maps, Play Store, Search and YouTube) and exposed through Google Cloud’s Vertex AI platform. The 2024 rollout added richer multimodal functions such as native image‑generation, coding assistance, app‑integration and deeper “AI‑powered” experiences in Workspace, Search and Ads, extending Gemini’s ability to combine and act on multiple data types across the entire Google ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Gemini was launched in 2023 as a multimodal model (December 2023 is a precise detail not in the original but not contradictory), upgraded to Gemini 2.0 in 2024, and integrated into Google's seven two-billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—matching the original answer exactly. (2) Quantitative elements—'seven' products and 'two-billion-user' threshold—are correctly stated and consistent. Dates (2023 launch, 2024 evolution) are accurate. (3) The reasoning is sound: the LLM correctly synthesizes the evolution of Gemini’s role and integration across Google products over time, demonstrating multi-hop understanding. (4) The LLM adds some contextual details not in the original, such as integration with Vertex AI and applications in Workspace, Search, and Ads, as well as native image generation and coding assistance. While these are plausible advancements and consistent with the direction of Gemini’s development, they are not explicitly confirmed in the ground truth. However, they do not contradict it and fall within reasonable inference. The mention of 'Project Astra' and 'Project Mariner' in the original answer is missing in the LLM response, which is a minor omission affecting completeness but not core correctness. Overall, the answer is factually strong, well-reasoned, and contextually appropriate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 435,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "In the 2022 filing Linde’s helium business was listed only as part of the “Other” segment (global helium wholesale) and was not highlighted as a material driver of sales or operating profit. By the 2024 filing the company reported that lower helium volumes reduced “Other” segment sales by roughly 2 percent, while helium‑related cost pressures were noted; nevertheless, operating profit in “Other” rose about 44 percent because an insurance recovery more than offset those helium costs. Thus, between 2022 and 2024 Linde’s helium exposure shifted from a neutral contributor to a source of declining sales and higher costs that were partially neutralized by other gains.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of Linde's relationship with helium from neutral in 2022 to a negative impact in 2024, accurately noting the 2% decrease in 'Other' segment sales due to lower helium volumes and the 44% operating profit increase in that segment. It also correctly mentions helium-related cost pressures. However, it omits a key detail from the ground truth: that these higher helium costs partially offset an insurance recovery in Linde Advanced Materials Technology (LAMT), which limits the clarity of the profit dynamics. This omission slightly weakens completeness. (2) Quantitatively, all numbers are accurate: the 2% sales decrease and 44% operating profit increase are correctly reported. There are no calculation errors. Format and phrasing (e.g., 'roughly 2 percent') are acceptable approximations. (3) The multi-hop reasoning is largely sound—linking helium’s role in 2022 as a neutral factor to its negative impact in 2024 on sales and costs shows proper synthesis across filings. However, the failure to explicitly connect helium costs to the partial offset of the insurance recovery in LAMT means a minor gap in full causal reasoning. (4) Scores reflect high accuracy in numbers and overall narrative, with a slight deduction in correctness and qualitative accuracy due to the omitted nuance about the insurance recovery being partially offset. Contextual relevance is perfect—the answer directly addresses the evolution of the helium relationship and its financial impacts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 422,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net carrying amount of acquired franchise rights fell from roughly **$626 million** in 2022 to **$598 million** in 2024, a decline of about **$28 million**.【PEP_10k_2024.pdf page 82】 (shows net $598 M for 2024 and $626 M for the prior year, which is the 2022 figure).",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. The ground truth states the 2022 net value was $789 million, but the LLM reports $626 million, which is incorrect. The 2024 value of $598 million is correctly reported. The calculated decline of $28 million (from $626M to $598M) is mathematically correct based on the LLM's numbers, but since the starting value is wrong, the magnitude of change is also incorrect. The actual decline should be $191 million ($789M - $598M). (2) The citation references PEP_10k_2024.pdf page 82, claiming it shows $626M for 2022, but this appears to be a misreading — either the document lists $626M as a different year (e.g., 2023) or the model confused the prior year label. The ground truth explicitly states $789M for 2022, so the LLM’s data point does not align. (3) The reasoning structure is sound — the model attempts to compute a two-year change in net franchise rights and identifies the need for multi-year comparison — but the synthesis fails due to incorrect data extraction. (4) Contextual relevance is high because the answer addresses the right metric, time frame, and direction of change. However, the major numerical error in the 2022 value severely undermines factual correctness, warranting a low-to-mid score on correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1107,
        "completion_tokens": 377,
        "total_tokens": 1484
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "- **Delivery commitments:** In the 2023 Form 10‑K Chevron said it was contractually obligated to deliver roughly 31 million barrels of NGLs and 746 billion cubic feet of natural gas in the United States for 2024‑2026, plus 2.9 trillion cubic feet of gas from Australia and Israel over the same period. The 2024 Form 10‑K shifted those contracts forward to 2025‑2027, cut the U.S. NGL commitment to about 25 million barrels, raised the U.S. gas commitment to about 813 billion cubic feet, and increased the overseas gas commitment to roughly 3.2 trillion cubic feet.\n\n- **Tengizchevroil production:** Chevron’s share of production from its Kazakhstan joint‑venture (Tengizchevroil) was essentially unchanged year‑over‑year: net oil‑equivalent output stayed at about 45 million barrels per day, with natural‑gas output of ≈ 114 MMCFD in 2023 and ≈ 113 MMCFD in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core of the question. (1) The question asks specifically about Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil from 2023 to 2024. The ground truth focuses on total natural gas volumes (consumed and sold) that include Chevron’s share from Tengizchevroil, showing increases from 2023 to 2024: consumed rose from 596 to 609 MMCFD, and sold from 7,148 to 7,569 MMCFD. However, the LLM answer incorrectly shifts focus to long-term contractual delivery obligations in the U.S., Australia, and Israel, which are unrelated to Tengizchevroil. (2) The quantitative data in the LLM response is inaccurate in context: it reports Tengizchevroil’s natural gas output as ~114 MMCFD in 2023 and ~113 MMCFD in 2024, which contradicts the ground truth that Chevron’s total sold gas (including Tengizchevroil) was over 7,000 MMCFD—orders of magnitude higher. The 114 MMCFD figure may represent only the gas attributable solely to Chevron’s share at Tengiz, but even then, it does not align with the scale implied in the original answer. Moreover, the LLM claims 'net oil-equivalent output stayed at about 45 million barrels per day'—this is impossible, as 45 million barrels *per day* is over 16 billion barrels per year, far exceeding global production capacity; it likely meant barrels *per year*, but the error is severe. (3) The multi-hop reasoning is flawed: instead of connecting Chevron’s overall gas volumes to its Tengizchevroil operations as shown in the ground truth, the LLM conflates unrelated contractual obligations and misrepresents production data. (4) Contextual relevance is partial—it mentions Tengizchevroil and years 2023–2024, but the data provided does not reflect the evolution of Chevron’s gas volumes tied to Tengiz as described in the original. Thus, while some entities are correct, the facts, numbers, and synthesis are mostly wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 523,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "In the 2023 filing Alphabet said that the amounts it paid to Google Network partners were recorded as **cost of revenues** – the partners were treated as third‑party sites that simply displayed ads and were paid for that service. In the 2024 filing the language shifts to grouping those outflows with “payments to **distribution and Google Network partners**” in the cash‑flow discussion, emphasizing that the partners are now described as part of Alphabet’s distribution network rather than just a cost line‑item. Thus, between 2023 and 2024 the role of Google Network partners moved from being presented solely as a cost of revenue to being highlighted as a distribution channel in Alphabet’s advertising model.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of how Google Network partner payments are described between 2023 and 2024. It accurately identifies that in 2023, payments were treated as part of cost of revenues, reflecting a more passive role for partners. In 2024, the shift in language groups these payments with 'distribution and Google Network partners' in cash flow discussions, indicating a strategic reframing as a distribution channel. This matches the ground truth's emphasis on a move toward Traffic Acquisition Costs (TAC) and a more performance-based, strategic role. The only minor shortcoming is that the LLM does not explicitly name 'Traffic Acquisition Costs (TAC)' as the formal category under which these payments are now grouped, which is a key term in the original answer and central to Google's financial reporting framework. However, the conceptual shift—framing partners as part of the distribution network rather than just a cost line item—is correctly captured. There are no numerical inaccuracies (quantitative accuracy is perfect), and the reasoning correctly synthesizes changes in disclosure language across years. The answer is contextually fully relevant and addresses the core of the question about evolving role based on payment descriptions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 368,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "In the 2023 filing Bank of America warned that a growing “global regulatory focus on climate change” and the emergence of differing disclosure rules across jurisdictions would **increase** its legal, compliance and public‑disclosure costs. By the 2024 filing the same issue appears again, but the language shifts from a future‑looking “expected to increase” to a present‑day acknowledgement that the **jurisdictional divergence has already materialized**, making compliance and disclosure risks a more immediate and heightened exposure for the bank. In short, the risk has moved from an anticipated increase in 2023 to an ongoing, more pronounced compliance burden across multiple jurisdictions in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly captures the evolution of Bank of America's climate-related regulatory concerns from 2023 to 2024: in 2023, the bank anticipated increased risks due to global regulatory focus and jurisdictional divergence; by 2024, it acknowledged that these risks had materialized and were actively impacting compliance and disclosure costs. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and filings, identifying the shift from forward-looking risk ('expected to increase') to present-tense impact ('has already materialized'). (4) All entities—Bank of America, climate-related regulatory requirements, jurisdictional divergence, compliance risks—are accurately referenced and correctly contextualized within the timeline. The answer fully addresses both parts of the question: evolution of public policy impact and the role of jurisdictional divergence and compliance risks. Wording differs slightly but meaning is preserved with high precision. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 360,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "In the 2022 filing GM still framed full‑size pickup trucks as a strategic growth pillar, noting in its forward‑looking discussion that “the success of our current line of full‑size SUVs and full‑size pickup trucks” would be a key driver of future performance. By the 2024 filing that emphasis had turned into measurable results: wholesale volumes rose 10.1% to 3.464 million vehicles, with full‑size pickups accounting for the bulk of the gain (the residual‑value table shows truck units rising to 224 k, or 23.7 % of the portfolio, up from 210 k/21.9 % a year earlier) and EBIT‑adjusted margin improving to 9.2 % (from 8.7 %). These volume, mix‑share and profitability metrics indicate a clear shift toward stronger performance and a more favorable market position for GM’s full‑size pickup truck line.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several specific quantitative claims not present or verifiable in the ground truth, which undermines factual accuracy. For example, it states that wholesale volumes rose 10.1% to 3.464 million vehicles and that full-size pickup truck units increased from 210k to 224k, representing 21.9% to 23.7% of the portfolio. These figures are not mentioned in the original answer and cannot be confirmed from the provided ground truth. Similarly, the EBIT-adjusted margin improvement from 8.7% to 9.2% is not supported by the original answer, which only mentions that full-size trucks contributed favorably to EBIT-adjusted results with a variable profit of approximately 160% on a weighted-average basis—a key profitability metric absent in the LLM response. (2) The calculation of percentage changes and absolute unit volumes appears internally consistent but is not aligned with the ground truth data, making the quantitative accuracy low. The 160% variable profit—a critical 2024 indicator in the original—is entirely missing. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies a strategic evolution from risk/emphasis in 2022 to performance in 2024 and attempts to support this with volume and margin trends. However, it substitutes unsupported metrics for the actual ones cited in the ground truth, failing to accurately synthesize the correct financial indicators. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of strategy and 2024 performance indicators—and maintains focus on GM’s full-size pickup trucks. The qualitative reasoning structure is logical and aligned with the question’s intent, but the lack of correct quantitative support reduces overall correctness. The answer would score higher if it had included the actual metric (160% variable profit) instead of fabricated volume and margin details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 519,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "In the 2022 filing the nuclear‑decommissioning trusts held only modest amounts of U.S. Treasury and government‑agency securities – $21 million for Alabama Power and $293 million for Georgia Power. By the 2024 filing those balances were essentially unchanged for Alabama Power ($20 million) but had risen for Georgia Power to $349 million. The modest increase in the Georgia Power trust and the overall steadiness of the holdings show the company is gradually shifting the trusts toward a larger share of high‑quality, low‑risk government securities, reflecting a more conservative, liquidity‑focused investment strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports all numerical values: $21M for Alabama Power in 2022, $20M in 2024 (slight decrease), and $293M to $349M for Georgia Power (significant increase), matching the ground truth exactly. No calculation errors or number inaccuracies are present. (2) Quantitative accuracy is perfect—dollar amounts and years are correctly cited with acceptable formatting. (3) The multi-hop reasoning is mostly sound: the model correctly identifies the shift in allocation between the two subsidiaries. However, the interpretation diverges slightly from the ground truth. While the original answer emphasizes a shift in focus toward Georgia Power’s portfolio and a possible reallocation *between subsidiaries*, the LLM interprets the change as a company-wide move toward a more conservative strategy via increased government securities. This is plausible but not directly supported by the data provided—since Alabama Power’s allocation remained flat and only Georgia Power increased, the shift may reflect internal reallocation rather than a broad strategic move toward conservatism. (4) Despite this interpretive overgeneralization, the core facts are correct, all entities (Alabama Power, Georgia Power, U.S. Treasury and agency securities, years 2022 and 2024) are accurate, and the answer addresses both parts of the question (evolution and strategic implication). Thus, the correctness score is 8 due to accurate data but slightly weaker reasoning in the strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 415,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "In the 2022 filing PepsiCo described its independent bottlers as “exclusive‑contract partners” to which it provides annual “bottler‑funding” incentives – volume‑based rebates, advertising support, new‑product and equipment programs – that are accrued each year and are a core part of its distribution model. By the 2024 filing the company still relies on those same funding arrangements, but it notes a strategic shift away from owning distribution of certain categories (e.g., alcoholic beverages are now licensed) and stresses that bottlers remain essential for serving its largest retail customers such as Walmart, indicating that the financial‑incentive framework persists while PepsiCo’s overall dependency is being modestly re‑balanced toward licensing and direct‑to‑consumer channels.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continuation of financial incentives such as volume-based rebates, advertising support, and equipment programs from 2022 to 2024, and notes the annual accrual mechanism, which aligns with the ground truth. However, it misses the key evolution highlighted in the original answer: the shift to a more structured, annually negotiated funding model specifically allocated across trade and consumer programs in 2024. Instead, the LLM claims the 'same funding arrangements' persist, which underrepresents the strategic evolution. Additionally, the LLM introduces a 'strategic shift toward licensing and direct-to-consumer channels' and mentions alcoholic beverages being licensed — details not present in the ground truth and potentially misleading in the context of bottler dependency. Crucially, the LLM omits the quantitative insight that Walmart alone accounted for approximately 14% of consolidated net revenue in 2024, a key indicator of increased strategic dependency on bottlers, which is central to the original answer. (2) There are no explicit numerical errors (no incorrect numbers cited), so quantitative accuracy is high, but the answer fails to include the critical 14% figure, which is a major omission in a multi-hop financial question. (3) The reasoning partially captures the continuity in financial incentives but misrepresents the evolution in strategic dependency. It introduces external concepts (licensing, DTC shift) not supported in the ground truth, weakening the multi-hop synthesis. The model does connect bottlers to major retail customers like Walmart, but fails to quantify or fully substantiate the increased dependency. (4) The contextual relevance is strong as it addresses the core topic of financial incentives and strategic dependency, but the correctness score is reduced due to missing key data and introducing unsupported strategic shifts. Overall, the answer is partially correct but lacks critical details and contains minor inaccuracies in framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 549,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "In the 2023 filing Adobe listed “Firefly” only as a newly‑registered trademark and mentioned it once in the risk‑factor discussion as an example of a generative‑AI product the company had just launched. By the 2024 filing the trademark appears again, but the risk‑factor narrative now calls out “Adobe Firefly” specifically when describing the regulatory, reputational and liability exposures tied to the company’s AI portfolio, indicating that Firefly has moved from a peripheral, experimental offering in 2023 to a core, flagship component of Adobe’s AI‑driven product‑innovation strategy in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Adobe Firefly was listed as a trademark in 2023 and gained prominence in the 2024 risk factors as a generative AI product. The evolution from a newly-registered trademark to a highlighted AI offering is correctly portrayed. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which are accurate. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information from trademark listings and risk disclosures across two years to infer strategic elevation. It accurately infers Firefly's shift from peripheral to core status based on increased emphasis in risk factors, which reflects strategic importance. (4) The only minor deviation from the original answer is the characterization of Firefly in 2023 as 'peripheral, experimental'—the ground truth does not explicitly use those terms, though the inference is reasonable. The original answer emphasizes 'established product' due to trademark listing, while LLM calls it 'newly-launched', which is also supported. This slight interpretive difference does not undermine factual correctness. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 387,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "In both 2022 and 2023 the company still listed **contractual rent escalations on existing leases (net of churn)** as one of the primary sources of tenant‑billing growth【AMT_10k_2022.pdf p31‑33】. However, the 2023 filing notes that **churn rose to about 3 % of tenant billings**—driven by U.S. & Canada lease cancellations and terminations—so the net contribution of those escalations was lower than in prior years when churn was lower (≈ 4 % in 2021)【AMT_10k_2023.pdf p33‑34】. Thus, while rent escalations continue to push billings upward, their impact was partially offset in 2023 by the higher churn and lease cancellations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the 3% churn rate in 2023 is accurately cited, and the reference to ≈4% churn in 2021 (though not directly part of the original answer) is factually consistent with the broader context and does not contradict the ground truth. The mention of U.S. & Canada lease cancellations, specifically tied to elevated churn, is correct. (2) The LLM correctly identifies that contractual rent escalations remained a driver of tenant billing growth in both years, but their net impact was reduced in 2023 due to higher churn—this synthesis across 2022 and 2023 filings is sound. (3) The multi-hop reasoning is strong: it connects rent escalations (a growth driver) with churn (a headwind), and correctly infers that net growth contribution was lower in 2023 despite the continued presence of escalations. (4) The only minor shortcoming is that the original answer specifically names T-Mobile as the source of lease cancellations, which the LLM omits. While not incorrect, this detail adds specificity to the cause of churn, and its absence slightly reduces completeness. However, the core reasoning, entities (company, years, metrics), and conclusions are accurate and contextually appropriate. Wording differences do not affect semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 376,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "- **2023:** Chevron’s affiliate‑capital‑expenditure budget was about **$3.5 billion**, and the filing noted that **nearly half of the $3 billion of affiliate capex planned for 2024 would be directed to Tengizchevroil’s FGP/WPMP project in Kazakhstan** (i.e., roughly $1.5 billion of spend tied to the joint‑venture).  \n\n- **2024:** The 2024 filing shows **affiliate capex still projected at roughly $3 billion**, with the same large share earmarked for Tengizchevroil, and **affiliate‑produced oil‑equivalent output (which includes Tengizchevroil) rose from about 3.12 million barrels per day in 2023 to about 3.34 million barrels per day in 2024** (see the production table that states “Volumes represent Chevron’s share of production by affiliates, including Tengizchevroil”).  \n\n**Overall, Chevron has maintained or slightly increased its capital commitment to Tengizchevroil while its share of production from the joint‑venture has grown between 2023 and 2024.**",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and timeline references. The original answer states that Chevron's 2024 affiliate capex was expected to be $3 billion, with nearly half allocated to Tengizchevroil's FGP/WPMP project. However, the LLM incorrectly states that the 2023 affiliate capex budget was $3.5 billion and that nearly half of the $3 billion 2024 capex (i.e., ~$1.5B) would go to Tengizchevroil — this misrepresents the original flow of information, which did not specify a $3.5B 2023 figure. The $3.5B number is not present in the ground truth and appears fabricated. (2) The LLM introduces specific production figures — 3.12 million barrels/day in 2023 rising to 3.34 million in 2024 — which are not mentioned in the original answer. While the general trend of increasing production involvement is consistent, these precise numbers are unsupported by the ground truth and constitute a significant quantitative error. (3) The qualitative reasoning is partially sound: the LLM correctly identifies that capital commitments were emphasized in 2023 and production contributions in 2024, and it captures the idea of a shift toward operational output. It also correctly links Tengizchevroil to affiliate production. However, it overstates continuity in capex by claiming the same large share was still earmarked in 2024 without confirming the evolution from investment to operational phase as highlighted in the original. (4) Contextually, the answer is relevant and structured well, addressing both capital expenditure and production across the two years. Despite incorrect specifics, it conveys a plausible narrative. The correctness score is reduced due to unsupported numerical claims, even though the directional interpretation (continued investment and growing production) aligns loosely with the truth. Quantitative accuracy is low due to invented figures; qualitative accuracy is moderate due to correct entity and phase identification; contextual relevance is high as it directly addresses the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 555,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K disclosures describe the same method: UPS determines the discount rate for its U.S. pension and post‑retirement benefit plans by using a **bond‑matching approach that selects specific bonds whose cash‑flow timing would meet the projected benefit payments**. The 2024 filing does not add any new qualifiers or greater detail—the description of the bond‑matching methodology is essentially unchanged from the 2023 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in describing the bond-matching approach used by UPS for determining the discount rate in both 2023 and 2024, and correctly identifies that the method involves selecting bonds whose cash flows match projected benefit payments. There are no numeric inaccuracies, as the question does not involve specific financial figures, percentages, or calculations—thus quantitative accuracy is high. However, the LLM incorrectly asserts that the 2024 disclosure 'does not add any new qualifiers or greater detail' and that the description is 'essentially unchanged,' which contradicts the ground truth. The original answer highlights a subtle but meaningful evolution in language: in 2024, UPS began stating that the bond-matching approach 'guides' the selection process, indicating a shift in operational framing, even if the underlying mechanics remained consistent. This nuance is critical to the question about the evolution of 'specificity' in the approach. The LLM fails to detect this qualitative shift in disclosure tone and precision, leading to a significant omission in the multi-hop reasoning required to compare the two years' disclosures. While the core method is accurately described, the failure to recognize and report the change in language and its implication about operational framing undermines the qualitative accuracy. Contextual relevance is strong because the answer addresses the correct topic, company, years, and methodology, but it lacks the comparative insight the question demands.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 421,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "By 2022 Linde’s helium business was still a small, stand‑alone activity that was reported only as part of the “Other” segment (global helium wholesale). In the 2024 filing the company notes that helium‑related costs have risen, and the helium wholesale operation is now mentioned together with Linde Advanced Materials Technology as a cost driver. The change reduced total group sales by about $32 million (‑2 %) in 2024 versus the prior year, while operating profit for the “Other” segment rose $19 million (≈ 44 %) – the profit increase reflecting insurance recoveries that partially offset the higher helium‑related expenses.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $32 million (2%) decrease in sales due to helium in 2024, aligning with the ground truth. However, it incorrectly states that operating profit for the 'Other' segment rose by $19 million (≈44%), which contradicts the original answer stating that helium had a negative impact on operating profit, with downward pressure only partially offset by insurance recovery. The ground truth does not mention a $19 million profit increase, making this a significant factual error. (2) The quantitative accuracy is mostly correct: the $32 million sales decrease and 2% figure are accurate. The $19 million profit increase is unsupported by the ground truth and appears to be an inference or fabrication, which reduces quantitative accuracy. (3) The multi-hop reasoning is partially sound—LLM correctly traces helium’s evolving role from a standalone activity in 2022 to a cost driver in 2024, and links it to the 'Other' segment and LAMT. However, the conclusion about operating profit improvement contradicts the negative impact described in the ground truth, indicating flawed synthesis. (4) Scores reflect that core facts (sales impact, evolving role of helium) are correct, but a key financial claim (profit increase) is wrong, reducing correctness and qualitative accuracy. Contextual relevance remains high as the answer addresses both the evolution and financial impact as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 396,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Bank of America’s unfunded capital commitments for its renewable‑energy projects fell from $6.2 billion at year‑end 2023 to $4.6 billion at year‑end 2024 – a drop of about $1.6 billion.  In the same period the renewable‑energy tax credits it recognized slipped from $4.0 billion in 2023 to $3.9 billion in 2024, a decline of roughly $0.1 billion.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. The calculated differences ($1.6 billion and $0.1 billion) are correct. (2) The answer is complete, addressing both parts of the question: the evolution of unfunded capital contributions and the corresponding change in tax credits. (3) Entities are correctly identified—Bank of America, the correct years (2023 and 2024), and the correct financial metrics (unfunded capital contributions and recognized tax credits). (4) The reasoning is sound: the LLM correctly infers a decline in commitments and a slight drop in tax benefits, aligning with the ground truth's interpretation of reduced near-term funding with stable tax benefits. (5) Semantic equivalence is maintained—though the LLM does not repeat the interpretive sentence about 'reduction in near-term funding commitments,' it conveys the same factual evolution and implications through precise numerical comparison. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 341,
        "total_tokens": 1564
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "In the 2022 filing GM said it sold to commercial‑fleet customers “directly or through our dealer network” and warned that “certain fleet transactions, particularly sales to daily‑rental car companies, are generally less profitable than retail sales”【6†L13-L19】. By the 2024 filing the company still uses the dealer network but is adding more direct‑to‑fleet sales – especially for its BrightDrop electric vans – and is stressing that it is now focusing on higher‑margin, purpose‑built fleet offerings, indicating a shift toward more profitable fleet channels while still acknowledging the mixed‑channel model【101†L9-L13】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: in 2022, GM sold fleet vehicles directly or through dealers and noted lower profitability for rental fleet sales compared to retail; by 2024, GM continued using dealers but expanded direct sales, particularly for BrightDrop EVs. The mention of higher-margin, purpose-built fleet offerings reflects the strategic shift toward profitability. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and two types of fleet sales (commercial vs. rental), identifying an evolution in channel strategy and profitability focus. The addition of BrightDrop as a driver of direct sales is contextually relevant and consistent with GM’s 2024 strategy, even if not in the original answer—it adds detail without contradicting the ground truth. (4) Semantic equivalence is maintained: the core message about a shift toward a mixed but more profitable, strategically managed fleet sales model via both channels is preserved. The only minor point is that the original answer emphasizes a 'more structured' approach while the LLM emphasizes 'higher-margin, purpose-built' offerings—slightly different framing but aligned in intent. Thus, the answer earns a 9 for correctness and qualitative accuracy due to excellent synthesis and factual fidelity, with a perfect score in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 442,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo still owned 50 percent of Sabra.  At year‑end the company re‑measured that equity investment to fair value, which produced a **pre‑tax gain of about $122 million ($92 million after‑tax)** that was booked in selling‑, general‑ and administrative expenses.  \n\nBy the 2024 filing PepsiCo’s relationship with Sabra had changed to a non‑equity, joint‑venture/distribution arrangement (the 50 % stake was no longer on PepsiCo’s balance sheet), so the re‑measurement gain disappears and there is no comparable Sabra‑related gain or loss in 2024. The shift therefore removed the $122 million gain that had boosted 2022 earnings.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the timeline and nature of PepsiCo's ownership change in Sabra. The original answer states that in 2022, PepsiCo *owned* Sabra as part of a joint venture, implying full or majority ownership prior to a divestiture, and that by 2024 it held a 50% stake. However, the LLM claims PepsiCo already owned only 50% in 2022, which contradicts the ground truth. This misrepresents the direction of the ownership change. Additionally, the LLM incorrectly states that by 2024 the 50% stake was no longer on the balance sheet and that the relationship became a 'non-equity, joint-venture/distribution arrangement,' which directly contradicts the ground truth that PepsiCo *held* a 50% equity stake in 2024 as a result of the remeasurement. (2) Quantitatively, the $122 million pre-tax gain and $92 million after-tax figure are accurate and correctly attributed to the remeasurement, which aligns with the original answer. The numbers themselves are correct and properly formatted. (3) The multi-hop reasoning is flawed: the model incorrectly infers that the gain disappeared in 2024 because the equity stake was removed, when in fact the 50% stake and its accounting were newly established in 2022 via remeasurement. The LLM reverses the timeline and ownership structure, failing to correctly synthesize the evolution from full ownership to 50% ownership. (4) Despite the strong contextual focus on financial implications and the correct citation of the gain, the core factual error about ownership direction and status in 2024 severely undermines the answer’s correctness. The contextual relevance is high as it addresses both relationship evolution and financial impact, but the qualitative and quantitative accuracy suffer from critical errors in entity and timeline representation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 502,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "In the 2023 Form 10‑K, Adobe Scan was mentioned only as a free‑download mobile scanner that “can be used for free on mobile devices,” presented as a stand‑alone utility. By the 2024 Form 10‑K, Adobe Scan is described as one of the core apps that make up **Adobe Document Cloud**—grouped together with Acrobat, Acrobat Sign and other Document Cloud services—showing that Adobe now positions Scan as an integrated component of its cloud‑based document‑management ecosystem rather than a peripheral, independent tool.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies the evolution of Adobe Scan's positioning between 2023 and 2024 based on the Form 10-K filings. In 2023, Adobe Scan was presented as a standalone free mobile scanner, consistent with trademark-level recognition. By 2024, it was repositioned as a core component of Adobe Document Cloud, integrated alongside Acrobat and Acrobat Sign—this matches the ground truth's emphasis on strategic integration into document management workflows. There are no numeric values to verify, so quantitative accuracy is scored as 10. The qualitative reasoning is sound, demonstrating correct multi-hop synthesis across two years of filings and inferring strategic intent from changed language. The only minor limitation is that the LLM does not explicitly mention the 'trademark' status in 2023 (instead focusing on functional description), but it captures the implied lower strategic emphasis. This omission does not detract significantly from the overall correctness, hence a 9 for qualitative accuracy. Contextual relevance is perfect—the response directly addresses the question about product positioning evolution within Adobe’s ecosystem.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 343,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "In the 2022 filing GM disclosed that, after selling the Opel/Vauxhall business to PSA Group (now Stellantis) in 2017, it had entered into an indemnity‑guarantee in which the Seller would reimburse Stellantis for any losses arising from inaccurate representations, breaches of covenants, emissions, product‑liability or recall claims; the company said it could not estimate any material loss and that the indemnity was limited by time‑bars, thresholds and caps. By the 2024 filing the same indemnity remains in place and still “cannot be estimated as material,” but GM now notes that it has already paid an immaterial amount for Stellantis’s legacy Takata‑related recalls and that any further recall‑related indemnifications are considered remote, indicating the scope of the obligation has broadened to include specific recall liabilities while the overall financial exposure remains immaterial.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, capturing the evolution of GM's financial exposure to Stellantis from 2022 to 2024. It correctly identifies the continuation of indemnification obligations from the 2017 Opel/Vauxhall sale, including coverage for emissions, product liability, and recall claims (e.g., Takata). The statement that GM had paid an 'immaterial amount' by 2024 matches the original answer's assertion of an immaterial accrual as of December 31, 2024. It also accurately notes that the exposure remains 'not estimable as material,' consistent with the original. However, the LLM slightly mischaracterizes the evolution: it suggests the scope 'broadened' to include specific recall liabilities, whereas the original indicates a shift in nature—from operational supply ties to indemnifications—rather than a broadening. Additionally, the original specifies ongoing exposure to emissions lawsuits, Takata recalls, and European regulatory probes into end-of-life vehicles, while the LLM omits the latter. The dates (2022 and 2024) and entities (GM, Stellantis, PSA Group) are correct. No numerical calculations are required, and all qualitative assertions are supported by the source. The answer is contextually precise and directly addresses the question’s focus on indemnifications and historical liabilities. Minor omission of the European regulatory investigation detail prevents a perfect score, but core facts and reasoning are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 407,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings note that PepsiCo continues to rely on a “highly distributed network of plants, warehouses and distribution centers … owned or leased by our contract manufacturers, **co‑packers**, strategic alliances or joint ventures in which we have an equity interest.” By 2024 the filing emphasizes that many of those co‑packer relationships are now part of equity‑owned joint ventures or strategic alliances, indicating that PepsiCo has moved from a primarily operational dependency on third‑party packers toward a deeper, partnership‑based involvement that gives it greater control and strategic influence over the co‑packing network.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, PepsiCo relied on a distributed network involving co-packers as third-party operators, and by 2024, the language evolved to emphasize strategic alliances or joint ventures with equity interest. The key shift from operational dependency to strategic involvement is accurately captured. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022 and 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings and correctly infers a strategic evolution in PepsiCo's relationship with co-packers. The LLM accurately reflects that the same network description appears in both years but notes the increased emphasis in 2024 on equity-based relationships, which supports the conclusion of deeper strategic involvement. (4) The only minor shortcoming is that the LLM slightly conflates the phrasing by suggesting the exact same sentence appears in both years, when the ground truth implies a shift in emphasis rather than identical wording. However, this does not undermine the factual correctness of the conclusion. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 386,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "In 2023 Simon Properties Group’s stake in ABG was repeatedly diluted by ABG‑initiated capital transactions, which generated non‑cash pre‑tax gains of **$59.1 million** on the deemed disposals and a **$157.1 million** gain on the sale of a portion of its ABG interest (ownership fell to about 9.6%). In the first quarter of 2024 the company sold its **remaining ABG interest for $1.2 billion**, recording a **pretax gain of $414.8 million** (and a $10.3 million deemed‑disposal gain from a later dilution), effectively exiting the partnership and redirecting capital toward other strategic joint‑venture investments such as the TRG and Phoenix Retail partnerships.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the $59.1 million gain from deemed disposals and the $157.1 million gain from the sale of a portion of SPG's ABG interest in 2023, it fabricates a $414.8 million pretax gain from the sale of SPG's 'remaining ABG interest' in Q1 2024 for $1.2 billion, which is not supported by the ground truth. The original answer states that in 2024, SPG disclosed an $18.8 million gain from the sale of a portion of its ABG interest that occurred in December 2021 (not 2024), not a new sale in 2024. Additionally, the $10.3 million deemed-disposal gain is not mentioned in the ground truth. (2) The quantitative inaccuracies are severe: the $414.8 million gain and $1.2 billion sale are entirely incorrect, and the $18.8 million gain is misattributed to the wrong year and context. The 9.6% ownership figure is plausible but not confirmed in the ground truth. (3) The multi-hop reasoning is flawed: instead of identifying the shift from financial gains to strategic operational collaboration (e.g., Reebok partnership), the LLM incorrectly concludes that SPG exited the partnership and redirected capital to other ventures, which contradicts the ground truth's indication of deepening collaboration. (4) The contextual relevance is moderate because the answer addresses SPG's financial relationship with ABG and attempts to cover gains and strategic moves, but the core narrative is factually incorrect. Due to major errors in numbers, timing, and strategic interpretation, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 438,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "In the 2022 Form 10‑K Lockheed Martin said that “higher production volume on various Sikorsky helicopter programs” (Black Hawk, Seahawk, CH‑53K and related models) was a key driver of the RMS segment’s product‑sales increase that year. By the 2024 filing the company still lists those same helicopters as core RMS programs but adds the Combat Rescue Helicopter and the VH‑92A Marine One, noting the final VH‑92A delivery in 2024 and a focus on sustainment, training and logistics services—showing that while the program’s scope has broadened to include more variants and support activities, the earlier surge in new‑build production volume has leveled off.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, no specific dollar amounts beyond the $560 million increase in product costs are cited in the original answer, and the LLM correctly avoids introducing incorrect figures. It accurately reflects the 2022 and 2024 timeframes without misstating dates or financials. (2) The LLM correctly identifies the key helicopter programs (Black Hawk, Seahawk, CH-53K) and adds specific new programs mentioned in the 2024 context—Combat Rescue Helicopter and VH-92A Marine One—with accurate details about the final VH-92A delivery and shift toward sustainment, training, and logistics. While the original answer does not explicitly name these two additional programs, their inclusion is consistent with the broader 'expanded focus' and 'continued and potentially expanded scope' described in the ground truth. (3) The reasoning is sound: the LLM correctly infers a shift from rising production volume in 2022 to a more balanced focus on sustainment and support in 2024, which logically extends the original answer’s point about Sikorsky programs evolving from a cost driver to a strategic product line. (4) The only minor gap is that the original answer emphasizes the $560M cost increase as partly due to higher production volume, while the LLM frames it as driving sales increases—slightly different emphasis (cost vs. revenue), but not contradictory. Overall, the LLM provides a richer, yet factually consistent and contextually appropriate evolution of Lockheed Martin's Sikorsky involvement, demonstrating strong multi-hop synthesis across years and programs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 447,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "In fiscal 2023 Walmart bought Alert Innovation for about $0.4 billion, converting the company from a variable‑interest entity to a wholly‑owned subsidiary (≈ 100 % ownership). The 2024 filing contains no further purchase, sale or additional capital outlay related to Alert Innovation, indicating that Walmart’s stake stayed at 100 % and no new financial investment was recorded during fiscal 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Walmart acquired Alert Innovation for $0.4 billion in fiscal 2023 and increased ownership to approximately 100%, which matches the ground truth. However, it incorrectly concludes that Walmart retained 100% ownership in fiscal 2024 due to lack of mention of a sale. The ground truth explicitly states that by fiscal 2024, there was no mention of Walmart retaining ownership, indicating a full exit—likely a divestiture. The LLM misinterprets the absence of evidence as evidence of absence, drawing the opposite conclusion of the correct inference. (2) Quantitatively, the $0.4 billion figure and 100% ownership are accurate, with acceptable formatting. No calculations were required. (3) The multi-hop reasoning is flawed: the model fails to synthesize the implication of no mention in 2024 filings, which in financial reporting context often signals divestiture or exit, especially after prior disclosure. The original answer correctly infers the stake was exited; the LLM incorrectly assumes continuity. (4) While the LLM uses correct entities (Walmart, Alert Innovation, fiscal years 2023/2024) and relevant financial terms, its reasoning leads to a factually incorrect conclusion about the evolution of ownership in 2024, significantly undermining correctness. Contextually, the response is relevant and addresses the question’s structure, but with a critical error in interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1171,
        "completion_tokens": 396,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "In 2023 the Operating Partnership was an active user of the Supplemental Facility – it had Euro‑denominated borrowings outstanding under the facility that were later swapped to a fixed‑rate (via a €750 million interest‑rate swap on Jan. 10 2023) and then fully repaid when the partnership issued €750 million of senior unsecured bonds on Nov. 14 2023, using the bond proceeds to extinguish the €750 million balance on Nov. 17 2023. By contrast, the 2024 filing shows the Supplemental Facility still in place with a $3.5‑$4.5 billion borrowing capacity (maturing Jan. 31 2029) but no new draws or repayments are reported; the company’s 2024 financing activity focused on other debt issuances and redemptions, leaving the Supplemental Facility largely idle.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correctly identifies the €750 million borrowing under the Supplemental Facility in 2023 and its repayment on November 17, 2023, using proceeds from the bond issuance. The date of bond issuance is slightly off (Nov 14 vs. implied Nov 17 in ground truth), but this is a minor discrepancy likely due to interpretation of 'issuance' vs. 'proceeds used'. The interest-rate swap detail (€750M on Jan 10, 2023) is an additional accurate nuance not in the ground truth but consistent with plausible filing content. (2) Quantitatively, all key figures—€750 million borrowed and repaid, no draws in 2024—are correct. The facility's capacity ($3.5–$4.5 billion) and maturity (Jan 31, 2029) are precise and add contextual accuracy. (3) Reasoning is sound: the LLM correctly infers reduced reliance on the facility in 2024 due to alternative financing (e.g., $1B unsecured notes in Sept 2024), even though it doesn't explicitly name that issuance. It accurately concludes the facility was 'largely idle' in 2024, matching the ground truth's 'no outstanding balance'. (4) The only minor gap is not explicitly stating that the 2024 financing shift included a $1.0 billion unsecured note issuance as a refinancing alternative, which would strengthen the multi-hop link. However, the core evolution—strategic repayment and disuse—is correctly captured. Wording differs but semantic meaning is equivalent. High contextual relevance and factual precision justify a 9/10 overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 421,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings list helium together with hydrogen, carbon dioxide and other specialty gases as a **core process gas** in Linde’s industrial‑gases portfolio. In each year the company continues to supply helium mainly through the **merchant (bulk‑liquid) distribution channel**, using three‑ to seven‑year supply agreements that **do not contain minimum‑purchase or volume‑commitment clauses** and that allow long‑distance shipment. Thus, between 2023 and 2024 Linde’s positioning of helium as a primary product and its merchant‑supply strategy remained essentially unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that helium remained a named, distinct product in both 2023 and 2024. According to the ground truth, while helium was explicitly listed as a primary product in 2023 alongside oxygen, nitrogen, and hydrogen, it was no longer specifically named in 2024 and instead subsumed under general gas descriptions—indicating a strategic repositioning. The LLM incorrectly asserts continuity in helium’s status, stating it was listed as a 'core process gas' in both years, which contradicts the ground truth. The quantitative details about supply contracts (3- to 7-year terms, no minimum purchase requirements, merchant distribution) are accurate and consistent with the 2023 filing, hence the moderate quantitative accuracy score. However, the qualitative reasoning fails: the model misses the multi-hop nuance of helium’s de-emphasis as a standalone product, which requires comparing the level of specificity in product listing across years. This omission leads to an incorrect conclusion about strategic continuity. While the answer addresses the question’s surface elements (positioning, supply strategies), it misrepresents the evolution, making it contextually relevant but substantively flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 347,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "In 2022 the U.S. retiree‑health‑care plan held roughly **$251 million in fixed‑income securities and cash equivalents (about 65 % of the plan’s $389 million assets)** and **$138 million in equity securities (about 35 %)**. By year‑end 2023 the portfolio had shifted to **$210 million in fixed‑income securities and cash equivalents (about 80 % of the $264 million total)** and **only $54 million in equity securities (about 20 %)**—so the plan moved markedly toward fixed‑income assets and away from equities.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct in its description of the asset allocation shift between 2022 and 2023, correctly identifying the decrease in both fixed income and equity securities, and emphasizing the larger reduction in equities. However, there are minor quantitative inaccuracies: the original answer states $248 million (not $251 million) in fixed income and cash equivalents in 2022, and total assets of $385 million (not $389 million). The LLM reports $138 million in equities (vs. $137 million ground truth), which is close but not exact. These small discrepancies affect the calculated percentages (65%, 35% vs. actual ~64.4% and ~35.6%), though the rounded percentages are reasonable approximations. The 2023 figures ($210M fixed income, $54M equities, $264M total) are fully accurate. (2) Calculations: The LLM’s implied totals for 2022 ($251M + $138M = $389M) are incorrect based on ground truth ($248M + $137M = $385M). The 2023 total is correct. The directional trend (shift toward fixed income, drop in equities) is accurately described. (3) Multi-hop reasoning is sound: the model correctly compares two years of asset allocations, identifies the categories, and draws a valid conclusion about the strategic shift. (4) Scores justified as follows: Correctness 8 due to accurate overall narrative but minor number inaccuracies; Quantitative Accuracy 7 due to off-by-small-margin figures in 2022; Qualitative Accuracy 9 for strong reasoning and correct synthesis; Contextual Relevance 10 as the answer directly addresses the evolution of asset allocation as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 437,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "In 2023 Gilead reported Trodelvy product sales of $1.1 billion (U.S. $777 m, Europe $217 m, other $68 m), up 56 % from the $680 million sold in 2022 (U.S. $525 m, Europe $143 m, other $12 m).  The jump was driven by new regulatory clearances – the FDA and the European Commission both granted full marketing approval for Trodelvy as a monotherapy in HR‑positive/HER2‑negative breast cancer – expanding the drug’s indication beyond its earlier metastatic‑triple‑negative‑lung‑cancer label, even as the Phase 3 EVOKE‑01 trial in NSCLC missed its primary overall‑survival endpoint.  Together, higher sales and the broadened approved label strengthened Trodelvy’s strategic positioning as a growing oncology franchise.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Trodelvy generated $380 million in product sales in 2022, not $680 million as claimed. The LLM also states 2023 sales were $1.1 billion, but the original answer explicitly notes that specific revenue figures for 2023 are not provided, making this figure unsupported. The breakdown by region (U.S., Europe, other) and the 56% growth rate are entirely fabricated. (2) Calculations are therefore incorrect: a 56% increase from $680M to $1.1B may be mathematically plausible, but both figures are wrong. The ground truth reports $380M in 2022, so any calculation based on $680M is invalid. (3) The qualitative reasoning partially aligns with the ground truth: the FDA and European Commission approvals for HR+/HER2- metastatic breast cancer in 2023 are correctly identified as key regulatory milestones that expanded Trodelvy’s indication and strategic positioning. However, the mention of an earlier 'metastatic-triple-negative-lung-cancer' label is factually incorrect—Trodelvy was approved for triple-negative *breast* cancer, not lung cancer—and the reference to the EVOKE-01 trial in NSCLC (non-small cell lung cancer) introduces irrelevant and unverified information not present in the ground truth. (4) The contextual relevance is high because the LLM addresses both revenue trends and regulatory milestones as asked, and attempts to synthesize strategic implications. However, due to major quantitative errors and some incorrect entity mappings, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the core idea of expanded approvals enhancing strategic positioning is correct, but the reasoning is based on flawed premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 484,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "- **Downstream‑related earnings:** In 2022 Chevron reported about **$1.96 billion** of earnings from downstream equity affiliates (U.S. $1.0 bn + International $0.96 bn). By 2024 that total had fallen to roughly **$1.26 billion** (U.S. $0.74 bn + International $0.52 bn).  \n\n- **GS Caltex investment and earnings:** The carrying value of the 50 % stake in GS Caltex stayed near the same level – about **$4.3 billion** in 2023 and **$4.1 billion** in 2024 (the 2022 amount was comparable). However, the equity earnings from the joint venture dropped sharply, from **$874 million in 2022** to **$437 million in 2023** and only **$58 million in 2024**.  \n\n**Implication:** Even though the JV’s contribution to earnings has contracted, Chevron continues to maintain a large, stable investment in GS Caltex, signalling that the partnership remains a strategically important foothold for Chevron’s downstream operations in the Asian market despite short‑term earnings volatility.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific numerical figures not present in the original answer, such as $1.96 billion in downstream equity earnings in 2022 and $1.26 billion in 2024, along with a breakdown between U.S. and international, and specific equity earnings from GS Caltex ($874M in 2022, $437M in 2023, $58M in 2024). These numbers are not supported by the ground truth and contradict the original answer, which does not provide earnings from GS Caltex specifically or total downstream equity affiliate earnings. The carrying value of $4.3B and $4.1B is also absent from the original and cannot be verified. (2) The original answer focuses on total sales and other operating revenues with affiliated companies (including GS Caltex), reporting $16,286 million in 2022 and $13,850 million in 2024. The LLM answer does not mention this key metric at all, instead inventing detailed equity earnings and carrying values. This represents a major failure in quantitative accuracy. (3) While the LLM correctly identifies that Chevron maintains a 50% ownership stake in GS Caltex and that it is a joint venture with GS Energy, and correctly infers strategic importance despite declining contributions, this reasoning is based on fabricated data. The multi-hop synthesis is conceptually sound—linking investment stability to strategic importance—but built on incorrect financial data. (4) The contextual relevance is high because the answer addresses the evolution of earnings and investment and draws a strategic conclusion. However, the correctness score is low due to the invention of precise numbers not found in the source, leading to a misleading portrayal of the financial relationship. The qualitative accuracy is moderate because entity identification and logical structure are reasonable, but the foundation is factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 500,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "In the 2022 filing Lockheed Martin noted that the CH‑53K King Stallion was a driver of **both higher production volume and higher “risk‑retirements”** (i.e., favorable profit‑booking‑rate adjustments) for the Sikorsky helicopter line, which helped lift RMS operating profit that year. By the 2024 filing the program was still **ramping production – the company said CH‑53K volume added about $140 million of sales – but the risk‑retirement benefit had faded, with profit‑booking‑rate adjustments turning lower and not being highlighted as a source of profit**, indicating that the earlier risk‑retirement gains had largely been realized and were no longer a significant boost.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, the CH-53K program drove higher operating profit through increased risk retirements and production volume, consistent with the $140 million profit increase mentioned in the original answer. However, it slightly misattributes the $140 million as sales in 2024 rather than as profit in 2022, which is a minor but notable quantitative inaccuracy. (2) The numbers are mostly correct: the $140 million figure is accurate but its characterization shifts from profit (in ground truth) to sales (in LLM answer), which affects precision. Dates (2022 and 2024) and entities (CH-53K, Sikorsky, RMS) are correctly identified. (3) The reasoning is sound: the LLM correctly infers that the risk-retirement benefits faded by 2024 as the program matured, even though specific CH-53K profit data was not disclosed, and links this to broader declines in RMS profit due to lower booking rate adjustments. This demonstrates strong multi-hop synthesis across years and financial concepts. (4) The answer is contextually excellent, addressing both financial performance and production status, including risk retirements and volume trends. The semantic meaning is largely equivalent to the original, with only the mislabeling of $140 million as sales instead of profit preventing a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 383,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "In the 2022 Form 10‑K PayPal treated its seller‑protection programs largely as a cost of doing business – the “Customer protection programs” note reports that losses from buyer and seller protection “have ranged between 0.09 % and 0.15 % of TPV” and warns that macro‑economic stress could raise those loss rates (PYPL 2022 pp. 49‑53).  \n\nBy the 2023 filing the same programs are highlighted as a strategic differentiator: the “Protecting merchants and consumers” section describes the programs as a core element of PayPal’s risk‑management and brand‑trust strategy, and the “Strategy” bullet explicitly lists “offering merchants risk management and seller‑protection programs” as a growth focus, underscoring continued investment in technology and data to limit exposure (PYPL 2023 pp. 7‑11).  \n\nThus, between 2022 and 2023 PayPal moved from merely disclosing loss‑rate exposure to positioning seller protection as a deliberate, technology‑driven competitive advantage while still monitoring the underlying risk.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately represented: the 2022 focus on risk exposure with loss rates between 0.09% and 0.15% of TPV is correctly cited, including the source (PYPL 2022 pp. 49–53), and the shift in 2023 to framing seller protection as a strategic differentiator is accurately described with reference to the 'Protecting merchants and consumers' section and the 'Strategy' bullet (PYPL 2023 pp. 7–11). (2) Quantitative accuracy is precise: the percentage range (0.09%–0.15%) matches the original answer exactly, and no calculations are required beyond accurate reporting. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifying a shift in tone and strategic emphasis—from risk disclosure to strategic investment—while maintaining awareness of ongoing risk monitoring. (4) The answer is semantically equivalent to the ground truth, using different but accurate phrasing (e.g., 'cost of doing business' vs. 'risk management and potential loss implications'; 'strategic differentiator' vs. 'competitive differentiator'). The LLM captures both the evolution in risk exposure treatment and the increased strategic emphasis, fully addressing the question’s requirements. No factual, numerical, or contextual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 380,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "In the 2023 Form 10‑K, Starbucks grouped ready‑to‑drink (RTD) beverages under “Other revenues” and said that revenue from those products is recognized **when the product is shipped to the customer, based on the contract terms**. The 2024 filing repeats that same point‑of‑shipment revenue‑recognition approach, but adds that RTD drinks are **purchased from several specialty suppliers under long‑term supply contracts**, emphasizing that the company’s dependence on those suppliers remains but the risk of non‑delivery is considered remote. Thus, the accounting treatment has not changed, while the disclosure now more explicitly describes the continued reliance on a diversified, contract‑based supplier base for RTD beverages.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2023, Starbucks recognized RTD beverage revenue under 'Other Revenues' upon shipment based on contract terms, which matches the original answer. In 2024, it accurately notes that the revenue recognition policy did not change but that additional disclosure was provided about sourcing from specialty suppliers under long-term contracts. The emphasis on supplier dependency and risk mitigation ('risk of non-delivery is considered remote') reflects the shift toward supply chain resilience highlighted in the ground truth. (2) There are no numerical figures in the question or answer, so quantitative accuracy is not applicable in terms of calculations, but all dates (2023, 2024) and categorical descriptions are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of disclosures, identifying both continuity in accounting policy and evolution in narrative focus—from revenue recognition to supplier risk management. (4) The only minor shortcoming is that the LLM answer does not explicitly frame the evolution as a 'shift from revenue-centric reporting to supply-chain risk management,' which is a key interpretive point in the original answer. However, the factual basis for that interpretation is present. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, complete, and contextually appropriate, meriting a high score with only a slight deduction in qualitative accuracy for missing the explicit strategic framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 444,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "In the 2022 filing Gilead reported that Trodelvy already had full U.S. approval (metastatic TNBC) and accelerated U.S. approval for metastatic UC, plus a European‑Union marketing authorization for TNBC and Health‑Canada approval (with Canada, Australia, the United Kingdom, Switzerland and the United States participating in the Project Orbis collaborative review). By the 2023 filing the company added a new European‑Commission approval and a new FDA approval for Trodelvy as a monotherapy in HR⁺/HER2‑negative breast cancer, expanding both the product’s geographic footprint (additional EU indication) and its regulatory clearance in the United States, which was reflected in higher sales from “new and existing geographies.”",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies key regulatory approvals for Trodelvy in 2022 and 2023, including FDA and EC approvals for HR+/HER2- breast cancer in 2023, which aligns with the ground truth. It accurately notes the expansion of geographic reach and regulatory footprint. However, the original answer includes specific sales figures ($370M in U.S., $10M in Europe in 2022), which the LLM omits, representing a minor but notable gap in quantitative completeness. (2) No incorrect numbers are presented; the LLM does not contradict any numeric data from the ground truth, but it fails to report the exact sales figures that define the geographic reach in 2022. This omission affects completeness but not direct accuracy. (3) The multi-hop reasoning is sound: the LLM connects regulatory approvals in 2022 (e.g., EU authorization, Project Orbis participation) with expanded approvals in 2023 (FDA and EC for HR+/HER2- breast cancer), correctly inferring broader market access. It synthesizes information across time and regions appropriately. (4) The answer is contextually fully relevant, addressing both geographic reach and regulatory evolution. The qualitative accuracy is high because all stated facts are correct and support the conclusion of expanded reach, though the lack of sales data slightly weakens the empirical foundation compared to the original. Overall, the answer is factually consistent and logically structured, meriting a high score with minor deductions for missing quantitative details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 420,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "In 2023 Simon Property Group’s stake in AB G fell from roughly 12 % at the start of the year to about 9.6 % by the end of the fourth quarter, as a series of capital‑transaction dilutions generated non‑cash pre‑tax gains of $36.4 million (Q2), $12.4 million (Q3) and $10.3 million (Q4) plus a cash sale of a portion of the interest that produced $157.1 million of pre‑tax gain (see 2023 10‑K, pages 112‑113).  In the first quarter of 2024 the company disposed of its remaining AB G interest, receiving $1.2 billion in cash and recognizing a single pre‑tax gain of $414.8 million (see 2024 10‑K, page 72).  Thus, Simon’s ownership went from ~12 % to zero, and total reported gains rose from about $210 million in 2023 to more than $415 million in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the LLM incorrectly states that Simon Property Group (SPG) reduced its stake from ~12% to zero by Q1 2024, including a $1.2 billion cash sale and a $414.8 million pre-tax gain in 2024. This is false: the ground truth confirms that SPG did not report any new transactions or ownership changes in ABG during 2024 and only referenced a prior 2021 transaction involving an $18.8 million gain and a $100.0 million acquisition. The LLM fabricates a $157.1 million pre-tax gain in 2023 and a $414.8 million gain in 2024, which are not present in the original answer. The only correct numbers are the 2023 non-cash gains of $36.4M, $12.4M, and $10.3M, and the drop in ownership from ~12.3% to ~9.6%. (2) The claim of disposing of 'remaining interest' in Q1 2024 for $1.2B is entirely unsupported and contradicts the original answer stating SPG 'no longer disclosed active changes' in 2024. (3) Qualitatively, the reasoning is flawed: instead of identifying a shift from active stake reduction in 2023 to passive disclosure in 2024, the LLM invents a major transaction in 2024, failing the multi-hop synthesis required. (4) Contextual relevance is moderate because it addresses ownership evolution and financial gains, but the fabricated data renders the response misleading. Due to major factual and numerical errors, especially in critical financial figures and events, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 413,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "In the 2023 Form 10‑K the 2012 Equity Incentive Plan was shown with the plan “as amended” (Exhibit 10.2(A)), the **Third Amendment** (Exhibit 10.2(B)) and a series of award‑agreement templates (Exhibits 10.2(C)‑10.2(L), the earliest being the original forms filed in 2012 and a set of additional forms added through 2023).  \n\nThe 2024 filing adds a **Fourth Amendment** to the plan (Exhibit 10.2(C)) and continues to expand the award‑agreement templates, now including a new additional‑forms exhibit (Exhibit 10.2(K) filed April 25 2024) while retaining the earlier templates.  \n\nThus, between the two years the plan received a further amendment (the Fourth Amendment) and the set of disclosed award‑agreement forms was updated with newer supplemental forms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Third Amendment was referenced in 2023, the Fourth Amendment (dated August 1, 2024) was added in 2024, and new award agreement forms from April 2024 were disclosed. The LLM correctly identifies the evolution of the plan through amendments and updated forms. (2) Quantitative accuracy is excellent: dates (April 25, 2024) and amendment numbers (Third and Fourth) are correct. While the ground truth mentions 'April 2024' generally, the LLM specifies 'April 25, 2024', which is consistent and more precise—this does not contradict but enhances accuracy. (3) Multi-hop reasoning is sound: the model correctly synthesizes changes between 2023 and 2024 filings, identifying both the amendment progression and the expansion of award agreement templates. (4) The only minor shortcoming is that the LLM does not explicitly name the 2017 award agreement forms mentioned in the original answer, though it references 'a series of award-agreement templates' going back to 2012 and updated through 2023, which implicitly includes them. This omission is minor and does not detract from the core correctness. Overall, the answer is factually robust, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 365,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "The 2023 filing shows that capitalized software licenses grew to $223 million, up from $152 million in 2022, and the related amortization expense rose from $54 million to $63 million.  The company continues to capitalize software‑license costs and amortize them straight‑line over the license term, but the larger balance and higher amortization indicate that it has been investing more heavily in software licensing during the year.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor issue in quantitative accuracy. The increase in capitalized software licenses from $152 million in 2022 to $223 million in 2023 is accurately reported, and the continued use of straight-line amortization over the license term matches the original answer. However, the LLM introduces amortization expense figures—$54 million in 2022 rising to $63 million in 2023—which are not present in the ground truth and cannot be verified from the provided information. This addition, while plausible, goes beyond the original data and introduces unverified specifics, slightly undermining quantitative accuracy. The reasoning is otherwise sound: the growth in carrying value is correctly interpreted as evidence of increased investment in software licensing. The answer addresses both parts of the question—evolution in treatment/valuation and implications for investment—and synthesizes information across years appropriately. Wording differs but meaning is semantically equivalent, and all entities (years, financial metric) are correct. Contextual relevance is strong, directly addressing the question with appropriate financial reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 342,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "In the 2022 filing PayPal said that, as of 31 December 2022, management had approved $3.8 billion of European customer balances to be earmarked for credit activities – about 37 % of the balances that the Luxembourg regulator allowed it to use. By the 2023 filing the approved pool had fallen to $3.0 billion, but it now represented roughly 39 % of the available European balances. The drop in the absolute amount coupled with a higher utilization rate shows PayPal is tightening the size of the internal funding pool while leaning more heavily on the balances it already controls, underscoring a strategy of financing its credit products increasingly with its own customer‑funded liquidity rather than expanding external borrowing.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all quantitative facts: $3.8 billion approved in 2022 (37% of available balances) and $3.0 billion in 2023 (39%). These figures match the ground truth exactly, and the interpretation of a declining absolute amount but increasing percentage utilization is accurate. (2) All numbers, percentages, and years are factually correct. There are no calculation or formatting errors. (3) The reasoning correctly identifies a tightening of the internal funding pool and increased reliance on existing balances. However, the LLM omits a key strategic development mentioned in the original answer: PayPal's new €40 billion agreement to sell consumer installment receivables, with $5.5 billion sold in 2023. This is a critical multi-hop element indicating a shift toward external funding mechanisms, which the LLM fails to mention. Instead, it concludes that PayPal is relying more on 'customer-funded liquidity' and reducing external borrowing—this contradicts the ground truth, which shows expansion of external funding via receivables sales. (4) While the quantitative accuracy is perfect (10), the qualitative accuracy is reduced (7) due to the omission of the receivables sale agreement and the resulting misinterpretation of strategic direction. Contextual relevance remains high (9) as the answer addresses the evolution of balance utilization and attempts to infer strategy, but the missing external funding shift limits completeness and reasoning accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 414,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "In FY 2024 Starbucks reported that its limited‑partnership interest in Valor Siren Ventures I L.P. (together with Valor Siren Ventures II L.P.) had a **carrying value of $211.9 million**, up from the prior‑year amount (the “Other investments” line grew from $24.2 million in FY 2023 to $39.8 million in FY 2024, indicating a higher total value for the private‑equity stakes).  The share of earnings (or losses) from these funds is **included in “interest income and other, net” on Starbucks’ consolidated statements of earnings**, and the company notes that the related activity “was not material” to the consolidated financial results in either year.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $211.9 million carrying value for Valor Siren Ventures I and II L.P. combined as of FY2024, which matches the ground truth. It also correctly states that the financial impact is included in 'interest income and other, net' and was not material in either year. However, it introduces a specific quantitative claim not supported by the original answer: that the 'Other investments' line increased from $24.2 million in FY2023 to $39.8 million, implying a direct link to Valor Siren investments. The ground truth does not disclose the 2023 carrying value for Valor Siren specifically, nor does it confirm that this line item corresponds to those investments. This is a significant factual overreach. (2) The $211.9 million figure is accurate and properly formatted. However, the $24.2M and $39.8M figures, while possibly appearing in filings, are not explicitly tied to Valor Siren in the ground truth and thus their use to infer a 'prior-year amount' for this specific investment is unsupported. This undermines quantitative accuracy. (3) The reasoning partially reflects multi-hop synthesis—correctly linking the investment to the income statement line and assessing materiality across years—but incorrectly assumes that changes in a broader 'Other investments' category reflect changes in Valor Siren specifically, showing flawed logic in connecting aggregated data to a specific entity. (4) The contextual relevance is high because the answer addresses the evolution of the investment, carrying value, and financial statement impact. Qualitative accuracy is good due to correct entity identification and proper reporting classification, but quantitative accuracy is reduced due to unsupported numbers. Correctness score is 7 because core facts about FY2024 value and financial reporting are correct, but the unsupported inference about FY2023 values introduces significant error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 521,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "TI’s analog business continues to be framed by the same four sustainable competitive advantages in both filings – a strong manufacturing‑technology foundation, a broad analog‑and‑embedded‑processing portfolio, extensive market‑channel reach, and diversified, long‑lived products and markets (2022 Overview p. 19; 2023 Overview p. 16). However, the financial contribution of analog has weakened: analog revenue fell 15 % from $15.36 billion in 2022 to $13.04 billion in 2023, and operating profit dropped 30 % from $8.36 billion to $5.82 billion, cutting the segment’s operating‑profit margin from 54.4 % to 44.6 % (2022 Segment Results p. 21; 2023 Segment Results p. 18).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the ground truth. (1) Quantitative Accuracy: The revenue and profit figures cited ($15.36B in 2022, $13.04B in 2023, etc.) are not present in the original answer and contradict it. The original answer does not mention any decline in financial contribution or provide segment revenue/profit numbers; instead, it emphasizes stable strategic positioning and gross margin of 67.5% in 2022 with no specific 2023 margin but a shift in framing. The 15% revenue drop and 30% profit decline are fabricated and unsupported by the ground truth. (2) Completeness: While the question asks about evolution in strategic positioning and financial contribution, the LLM incorrectly focuses on deteriorating financials, which is not in the original. It fails to mention the key point about gross margin being driven by 300mm production efficiency in 2022 or the 2023 emphasis on free cash flow per share as the ultimate metric. (3) Entity Accuracy: The company (TI) and product segment (Analog Products) are correct, and years (2022, 2023) are properly referenced. However, the financial metrics (operating profit, operating margin) are incorrectly attributed and calculated. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers declining financial contribution from unspecified data, whereas the original answer describes a continuity in strategic importance with a reframing around competitive advantages and capital returns. The reasoning contradicts the ground truth. (5) Semantic Equivalence: The overall message is not equivalent—the original describes consistent strategic centrality with evolved messaging, while the LLM describes a weakening business. This is a fundamental contradiction. The mention of TI’s four competitive advantages is partially aligned with the 2023 framing but incorrectly stated as unchanged in emphasis between years. In summary, the LLM answer introduces false quantitative data and draws incorrect conclusions, failing on core factual accuracy despite some correct contextual elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 560,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "In the Lower 48 segment, the combined depreciation, depletion, amortization and impairments rose from $4.9 billion in 2022 to $5.7 billion in 2023.  That increase was accompanied by higher capital spending – capital expenditures and investments grew from $5.6 billion in 2022 to $6.5 billion in 2023 – indicating that the company shifted to a more aggressive allocation of capital in the Lower 48, expanding its asset base and consequently generating larger DD&A charges.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, amortization, and impairments (DD&A) in the Lower 48 from $4.9 billion in 2022 to $5.7 billion in 2023, which aligns closely with the ground truth values of $4,854 million and $5,729 million. The rounding to one decimal place in billions is acceptable and common in financial reporting ($4.9B ≈ $4,854M; $5.7B ≈ $5,729M). (2) The LLM adds contextual detail about capital expenditures increasing from $5.6B to $6.5B, which is not part of the original answer but is factually consistent with Chevron’s 10-K filings and strengthens the reasoning that capital allocation increased. While this information was not in the ground truth, it does not contradict it and supports the conclusion. (3) The multi-hop reasoning is sound: the model correctly infers that rising DD&A and capex reflect increased capital allocation and asset development in the Lower 48, and implicitly contrasts this with other regions by focusing on the strategic shift—though the explicit comparison to Europe, MENA, etc., from the original answer is omitted. This is a minor omission, not an error. (4) All entities (Chevron, Lower 48, 2022–2023, DD&A) are accurate, and the logic linking higher DD&A to greater prior or ongoing investment is financially sound. The answer is semantically equivalent to the ground truth in its core claim: capital allocation increased in the Lower 48 from 2022 to 2023, as shown by rising DD&A. The slight rounding of numbers and addition of capex context do not detract from accuracy but enhance clarity. Scored 9/10 due to omission of the comparative context with other regions, which was part of the original answer’s strategic insight, but the core multi-hop analysis remains correct and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 489,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "In the 2023 filing Verizon presented Fixed‑Wireless Access (FWA) as a **stand‑alone broadband product** that it offered in both the Consumer and Business segments – an “alternative to traditional land‑line internet” marketed to residential customers and to businesses, with the filing even calling out the ≈3.1 million FWA connections it had. By the 2024 filing the company had **absorbed FWA into its broader wireless‑services portfolio**, positioning it as part of the 5G/LTE wireless service suite rather than a separate line‑item, and it now emphasizes FWA primarily as a **Consumer‑focused solution for homes that lack fiber or DSL**, while still offering it to Business customers as a connectivity option for enterprises and small‑/medium‑size firms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Verizon offered FWA in both 2023 and 2024 to Consumer and Business segments, reported 3.1 million connections in 2023, and positioned FWA as an alternative to traditional landline internet. The shift from a stand-alone product in 2023 to a more integrated offering within the broader wireless portfolio in 2024 is correctly captured. (2) Quantitative accuracy is perfect: the 3.1 million FWA connections figure is correctly cited, and no other numbers are introduced. (3) Multi-hop reasoning is sound—LLM synthesizes changes in product positioning and target segments across years, correctly inferring a strategic shift even without explicit use of the word 'produces' from the original. (4) The only minor gap is that the LLM does not explicitly mention the connection to IoT and advanced communication services in 2024, which is part of the original answer’s characterization of the broader portfolio. However, describing FWA as part of the '5G/LTE wireless service suite' captures a similar idea, albeit less specifically. Wording differences are acceptable under semantic equivalence. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 356,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "- **Evolution of the relationship** – In the 2022 filing Emerson described the May 2022 transaction that combined its two industrial‑software businesses with Heritage AspenTech, giving Emerson a **55 % equity stake** in the newly‑formed AspenTech. By the 2024 filing Emerson said it now holds **about 57 % of AspenTech** and has **proposed to buy the remaining shares**, moving the partnership from a majority‑owned, equity‑method investment toward full ownership and consolidation.  \n\n- **Financial impact** – The AspenTech acquisition helped lift Emerson’s gross margin, which rose from **49.0 % in 2023 (after the 2022 deal)** to **50.8 % in 2024**, a 1.8‑percentage‑point increase (the 2023 margin already reflected a 0.6‑point boost from the AspenTech deal). The higher ownership percentage and the pending full‑buyout also shift Emerson’s equity structure, increasing the proportion of consolidated assets and earnings attributable to Emerson and reducing the amount reported under equity‑method accounting.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM correctly identifies the evolution of Emerson's relationship with AspenTech from a strategic transaction in 2022 to increased ownership (55% to ~57%) and a proposed full buyout by 2024. This aligns with the ground truth's emphasis on deepening control and strategic integration. However, the original answer does not mention the 57% stake or the proposed buyout of remaining shares—details that may be accurate but are not present in the ground truth, raising concerns about unsupported additions.\n\n2) Quantitatively, the LLM introduces specific gross margin figures: 49.0% in 2023 and 50.8% in 2024, claiming a 1.8-percentage-point increase. While the ground truth confirms a 0.6-percentage-point boost in 2023 from the deal, it does not provide 2024 margin data or attribute further margin expansion directly to AspenTech. This extrapolation introduces numerical claims not supported by the original answer, reducing quantitative accuracy. Additionally, the LLM implies the full 1.8-point increase is tied to AspenTech, while the ground truth only confirms a 0.6-point benefit in 2023 and notes increased SG&A expenses in 2024—potentially offsetting margin gains.\n\n3) The qualitative reasoning is strong: the LLM correctly interprets the shift from equity-method accounting toward consolidation due to increased ownership, which logically impacts equity structure. It also connects the acquisition to margin improvement, consistent with the ground truth’s assertion of positive gross margin impact. However, it omits mention of SG&A increases tied to integration, a key financial impact noted in the original answer.\n\n4) Contextual relevance is excellent—the response directly addresses both parts of the question (relationship evolution and financial impact) and synthesizes information across time and financial dimensions. The structure is clear and focused. However, the inclusion of unverified specifics (e.g., 57%, exact margin percentages, proposed buyout) reduces factual reliability despite logical coherence. Overall, the answer is partially correct with plausible but unsupported details, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 576,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "In the 2022 filing the only link between the two entities was a **guarantee agreement** – FPL Group, Inc. acted as guarantor of the debt issued by **FPL Group Capital Inc.** (see Exhibit 4(n), “Guarantee Agreement, dated June 1 1999, between FPL Group, Inc. (as Guarantor) and The Bank of New York Mellon”). By the 2023 filing the relationship had moved from a contingent guarantee to **direct capital‑structure participation**: NextEra Energy Capital Holdings (the successor to FPL Group Capital) issued new senior debentures (Series K and Series L) and filed letters setting the terms of those issues (Exhibits 4(u) and 4(x)), showing that the company was now raising its own debt rather than being backed by a FPL Group guarantee.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the high-level evolution from a guarantee arrangement to direct capital involvement, which aligns with the ground truth and addresses the core of the question. However, there are significant factual inaccuracies that reduce correctness. (1) The guarantee date cited (June 1, 1999) conflicts with the ground truth (October 14, 1998), and the referenced exhibit (4(n)) does not match the original agreement date. (2) The LLM incorrectly states that FPL Group, Inc. guaranteed debt issued by FPL Group Capital Inc. in 2022, but the ground truth describes a guarantee *by* FPL Group, Inc. *to* FPL Group Capital Inc., implying a different direction of obligation. (3) The LLM claims that 'NextEra Energy Capital Holdings' issued senior debentures (Series K and L), but the ground truth specifies that NEE issued *junior subordinated debentures* to FPL Group Capital Inc., not senior debentures, and lists Series B, C, L, M, N, O, and P — not just K and L. This misrepresents both the nature of the debt (senior vs. junior subordinated) and the full scope of series issued. (4) The maturity dates (2057–2082) and the strategic significance of long-term financing are omitted, weakening completeness and quantitative accuracy. (5) While the shift from guarantee to capital structure participation is correctly identified (supporting contextual relevance), the multi-hop synthesis is flawed due to incorrect entities, instrument types, dates, and incomplete series listing. The reasoning is partially sound but built on inaccurate data, leading to a moderate score of 5/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 437,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic described InterStim II as one of the three InterStim neurostimulators (II, Micro and X) that together supported its Pelvic‑Health portfolio, noting that growth that year was driven primarily by the newly launched InterStim Micro and its SureScan MRI leads. By the 2024 filing the company was emphasizing that InterStim II had become a **recharge‑free** neurostimulator and was again highlighted alongside InterStim X and the rechargeable InterStim Micro as a continuing‑acceptance, growth‑driving product within the broader Pelvic‑Health therapies. This reflects a shift from a baseline presence in 2022 to a more prominent, differentiated positioning and stronger market adoption for InterStim II by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: InterStim II is positioned among InterStim Micro and InterStim X in both 2022 and 2024; by 2024, it is explicitly described as recharge-free, a detail not emphasized in 2022. The evolution toward highlighting device-specific attributes like recharge-free status is correctly identified. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across years and product lines, correctly inferring a shift in positioning from being part of a general suite in 2022 to having a differentiated, attribute-based identity in 2024. The mention of growth drivers (e.g., InterStim Micro launch in 2022) adds contextual accuracy even if not in the original answer, as it does not contradict and supports the broader narrative. (4) The only minor deviation is the claim that InterStim II had a 'more prominent' role in 2024—while the original answer notes increased differentiation, it doesn’t assert increased prominence. This slight interpretive leap prevents a perfect 10, but the core reasoning and factual content remain strong. Overall, the answer is semantically equivalent, contextually relevant, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 383,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "Between the 2022 and 2024 filings Simon’s supplemental unsecured revolving credit facility remained a $3.5 billion line that could be increased to $4.5 billion, but its maturity was pushed back from January 31 2026 (extendable to 2027) to January 31 2029 (extendable to 2030).  The company elected to hedge the Euro‑denominated portion of the facility with a €750 million interest‑rate swap that fixed the cost at 3.81 % and then used the proceeds of a €750 million senior‑note issuance in November 2023 to retire the entire €750 million balance, effectively eliminating that borrowing.  By year‑end 2024 the combined credit facilities (including the supplemental line) provided about $8.2 billion of available capacity, and the supplemental facility continued to be priced at SOFR + 72.5 bps (plus a spread) with a 0.1‑0.3 % facility fee.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly regarding the maturity extension of the Supplemental Facility. The ground truth states the maturity was January 31, 2026, but the LLM claims it was extended to 2029 (extendable to 2030), which is not supported by the original answer. This is a significant quantitative and factual error. Additionally, the original answer does not mention any extension beyond 2026, nor does it state that the facility was actively extended—thus this is an unsupported addition. The €750 million borrowing and repayment in November 2023 is correctly identified, as is the use of an interest rate swap at 3.81%, which aligns with the ground truth. However, the LLM incorrectly frames the swap as hedging the 'Euro-denominated portion of the facility' rather than the specific borrowings under it. The ground truth specifies the swap was used on the borrowings, not the undrawn capacity. (2) The interest rate margin is inaccurately reported as SOFR + 72.5 bps with a spread and facility fee—this level of specificity (72.5 bps, 0.1–0.3%) is absent in the original answer and introduces unverified detail. The original only states the rate was based on SOFR with a margin tied to credit rating. The $8.2 billion combined capacity in 2024 is new information not present in the ground truth and cannot be verified. (3) The multi-hop reasoning is partially sound: the LLM correctly links the bond issuance to the repayment of the €750 million and recognizes the strategic use of swaps. However, it overreaches by implying structural changes (maturity extension, pricing details) not present in the source. (4) The contextual relevance is high—the answer addresses borrowing capacity, interest rate strategy, and repayment actions. Core facts like the €750M swap and repayment are correct, but the inclusion of unsupported details reduces factual accuracy. Hence, correctness is reduced to 6 due to significant quantitative inaccuracies despite correct core events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 544,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "In the 2023 filing Verizon described its consumer‑device payment plans as **non‑interest‑bearing 36‑month installment notes** that were paired with a month‑to‑month service contract; any promotional billing credits were simply folded into the transaction price and recognized when earned. By the 2024 filing the company said it now **treats the installment component as a material financing element**, so the interest portion is recorded separately, and it has **expanded the promotional side of the plans** – adding larger bill‑credit offers, trade‑in/upgrade guarantees and other incentives that are disclosed as separate consideration rather than being absorbed into the base price.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the right topic and showing relevant reasoning structure. (1) On quantitative and factual accuracy: The claim that in 2023 Verizon already had 'non-interest-bearing 36-month installment notes' contradicts the ground truth, which states that such formalized structure was introduced in 2024. The 2023 description in the original answer makes no mention of a 36-month term or formal installment note structure, only that installment payments were allowed. Additionally, the LLM incorrectly asserts that in 2024 Verizon began treating the installment as a 'material financing element' with interest recorded separately—this contradicts the ground truth, which explicitly states the notes are 'non-interest-bearing.' These are critical financial misrepresentations. (2) The LLM claims promotional billing credits were 'folded into the transaction price' in 2023 and later 'disclosed as separate consideration' in 2024, but the ground truth contains no such detail about accounting treatment or presentation of bill credits—this information is hallucinated. (3) While the LLM correctly identifies an expansion of promotional incentives like trade-in/upgrade guarantees in 2024, this is only partially aligned with the ground truth, which specifies a defined upgrade path after paying a portion and trading in the device, but does not mention 'larger bill-credit offers' or 'guarantees' as stated by the model. (4) The reasoning is contextually relevant and attempts multi-hop synthesis by comparing 2023 and 2024 disclosures, but the factual foundation is flawed. The model invents accounting treatments and misattributes the timeline of structural changes. Thus, while the direction of evolution (more structured, more promotional) is roughly correct, the specific mechanisms and financial terms are incorrect, leading to a low correctness score. Quantitative accuracy is moderate because no explicit numbers (e.g., dollar amounts, percentages) are wrong—only structural terms like '36-month' and 'non-interest-bearing' are misapplied in context. Qualitative accuracy suffers due to incorrect entity relationships and reasoning based on non-existent details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 601,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings describe the same litigation posture: The Coca‑Cola Company continues to seek a declaratory judgment that it has **no obligation** for any past, present or future asbestos‑related liabilities of its former subsidiary Aqua‑Chem, and it maintains that the Georgia case remains stayed pending the outcome of the insurance coverage actions. There is no indication of a shift in the Company’s stance – the 2024 filing repeats the 2023 language and confirms that the Company still asserts it is not liable for Aqua‑Chem’s asbestos claims.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no shift in Coca-Cola's stance between 2023 and 2024. The ground truth states that while the litigation posture remained largely unchanged, there was a notable evolution in Coca-Cola's disclosure: in 2024, the company provided a more detailed account of the insurance policies issued during its ownership of Aqua-Chem, emphasizing the involvement of multiple insurers and ongoing coverage litigation. This reflects a nuanced shift from outright denial of liability to focusing on insurance coverage and shared responsibility—precisely the change the question asks about. The LLM incorrectly asserts that the 2024 filing 'repeats the 2023 language' and that there is 'no indication of a shift,' which contradicts the ground truth. There are no numerical errors (hence high quantitative accuracy), but the qualitative reasoning fails to capture the multi-hop synthesis required: connecting changes in disclosure tone and content over time to infer a strategic shift in legal stance. Contextually, the answer addresses the right entities and timeframe, but misses the key analytical point of evolving emphasis in corporate disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 336,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "In 2024 Intel reported long‑term income taxes payable of **$1.6 billion**, which were “reduced by the associated deduction for state taxes and **non‑US tax credits**,” whereas in 2022 the comparable balance was **$4.3 billion** with the same deduction for non‑US tax credits 【INTC_10k_2024.pdf page 84】. The $2.7 billion drop shows that Intel’s use of foreign tax credits materially lowered its U.S. long‑term tax liability, indicating a strategy that leans on earnings and credits generated abroad to offset domestic taxes and to take advantage of lower foreign rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the long-term income taxes payable for both 2024 ($1.6 billion) and 2022 ($4.3 billion), matching the ground truth exactly. The $2.7 billion difference is accurately implied (4.3 - 1.6 = 2.7), and the role of non-US tax credits in reducing liabilities is correctly stated. 2) All numeric values are accurate and properly attributed to the correct years. The calculation of the reduction is correct, though not explicitly stated as a subtraction, it is clearly implied. Format variations (e.g., $1.6 billion vs $1.6B) are acceptable and do not affect accuracy. 3) The reasoning correctly synthesizes the impact of non-US tax credits over time and infers a strategic use of foreign tax credits to reduce U.S. tax liability. While the original answer emphasizes the 'stronger offsetting effect over time' and 'strategic shift', the LLM captures this by noting the material lowering of liability and a strategy leaning on foreign credits—semantically equivalent. The only minor gap is that the original mentions the 2022 figure included transition tax and uncertain tax positions, which the LLM omits, slightly weakening the full context of the 2022 baseline. 4) The answer is highly relevant, directly addressing both parts of the question: the comparative impact on tax liabilities and the implication for international tax strategy. The citation to the 10-K adds credibility. Overall, the answer is factually correct, well-reasoned, and conveys the same core conclusion as the ground truth, warranting a high score with only a slight deduction in qualitative accuracy for missing nuance about the 2022 tax components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 450,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "In the 2022 filing MetLife described pension‑risk‑transfer (PRT) business as a long‑duration component of its Retirement and Income Solutions segment that is highly sensitive to U.S. interest‑rate moves; the company relies on interest‑rate swaps and duration‑matching to hedge the impact of rising or falling rates on the cash‑flow profile of those transfers.  \n\nBy the 2024 filing the same treatment of PRTs remains, but the company adds that recent and pending regulatory changes to pension‑funding rules and capital‑standard requirements are expected to shape the mix and volume of PRT transactions, making regulatory risk an additional, material driver alongside the existing interest‑rate sensitivity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: in 2022, pension risk transfers (PRT) were part of the Retirement and Income Solutions segment and were described as long-duration with sensitivity to interest rates, managed via duration-matching and swaps—this matches the original answer's reference to interest rate scenarios impacting ALM strategies. By 2024, the LLM correctly identifies that regulatory changes (specifically to pension funding rules and capital standards) are influencing the volume and mix of PRT transactions, which corresponds to the ground truth's mention of regulatory influence reducing or delaying plan terminations and shifting exposure toward non-guaranteed products. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all time references (2022, 2024) are accurate. (3) The multi-hop reasoning—connecting changes in regulatory environment to shifts in PRT strategy over time—is sound and synthesizes information across years appropriately. (4) The only minor gap is that the LLM does not explicitly mention the 'shift toward non-guaranteed funding products' as stated in the original answer, which is a specific strategic outcome. However, it captures the essence by stating that regulatory changes are shaping the 'mix and volume' of PRTs, implying a strategic shift. This omission prevents a perfect 10 but does not undermine the overall correctness. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses interest rate sensitivity and regulatory influence across the two time points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 457,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic highlighted the InterStim Micro as a **newly launched, rechargeable neurostimulator** (paired with SureScan MRI‑compatible leads) that was a primary driver of growth in its Specialty‑Therapies/Pelvic‑Health business. By the 2024 filing the device is no longer a “new launch” but is described as an **established part of an expanded InterStim portfolio**—alongside the InterStim II and InterStim X recharge‑free systems—still positioned to grow Pelvic‑Health sales for over‑active bladder, urinary retention and chronic fecal incontinence. Thus, the strategy has shifted from introducing the Micro to integrating it into a broader, rechargeable InterStim line that underpins continued Pelvic‑Health growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, the InterStim Micro was newly launched as a rechargeable neurostimulator, which matches the original answer's description of it being part of a growing product line. By 2024, the LLM correctly notes it is now an established part of an expanded portfolio, consistent with the ground truth's emphasis on targeted differentiation. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in product positioning over time, correctly distinguishing the rechargeable InterStim Micro from the recharge-free InterStim II and X models in 2024, which reflects accurate entity and attribute tracking across years. (4) The only minor gap is that the LLM does not explicitly mention the 'continued acceptance and growth of InterStim therapy in the U.S.' as highlighted in the original answer, slightly reducing completeness. However, the core evolution in strategy—from new launch to integrated, differentiated product—is clearly and correctly conveyed. Wording differs but semantic meaning is equivalent. Thus, high scores across all dimensions with a 9 on correctness due to slight omission of geographic emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 386,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "- **2022:** After drawing **$1.05 billion** from the Supplemental Facility in 2021 (the only balance shown on the 2021 balance sheet), Simon used the proceeds of a $500 million floating‑rate and a $700 million fixed‑rate unsecured note issuance on January 11 2022 to **repay the entire $1.05 billion** outstanding under the Supplemental Facility on January 12 2022, leaving the facility with essentially no balance. 【SPG_10k_2022.pdf p. 122‑124】\n\n- **2024:** The Supplemental Facility still exists with a borrowing capacity of **$3.5 billion‑$4.5 billion** (extendable to 2029‑2030), but all prior borrowings have been extinguished. The last repayment was the **€750 million** (≈$815 million) drawn under the facility, which was repaid on November 17 2023 using proceeds from newly issued €750 million senior unsecured bonds. No outstanding balance is reported in the 2024 filing. 【SPG_10k_2024.pdf p. 68‑71】",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct qualitative insights and correctly identifies key repayment actions, particularly the €750 million repayment on November 17, 2023, which aligns with the ground truth. However, there are significant quantitative discrepancies. The LLM claims a $1.05 billion draw in 2021 and full repayment on January 12, 2022, using proceeds from note issuances. This specific amount and timing are not reflected in the ground truth, which reports a weighted average outstanding balance under all Credit Facilities (including Supplemental) of $519.9 million in 2022 and a maximum aggregate balance of $2.1 billion. The LLM’s $1.05 billion figure and its characterization as the only balance are not corroborated by the ground truth and appear to misrepresent the data. (2) The 2024 repayment of €750 million (~$815 million) is correctly reported with accurate date and funding source (new bond issuance), matching the ground truth. However, the LLM omits the 2024 weighted average outstanding balance of $311.1 million under the Facilities, which is a key metric in the original answer and important for assessing evolution in borrowing. Instead, it states there is 'no balance,' which may be contextually accurate at filing date but overlooks the average usage metric critical to understanding borrowing patterns. (3) The reasoning is logically structured and demonstrates multi-hop synthesis—linking bond issuances to repayments across years and citing specific document pages. However, it overstates precision on unverified figures (e.g., $1.05B) and fails to report aggregate facility usage metrics required for accurate trend analysis. (4) Despite missing the core quantitative metrics from the ground truth (weighted average balances), the answer correctly identifies the strategic reduction and refinancing theme, especially the 2023 repayment. Hence, correctness is reduced due to numerical inaccuracies, but qualitative and contextual scores remain high due to sound logic and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 547,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "In 2022 ConocoPhillips recorded $4.854 billion of depreciation, depletion, amortization and impairments for its Lower 48 segment, which rose to $5.729 billion in 2023—an increase of roughly $0.875 billion【COP_10k_2023.pdf p.131‑135】. The higher DD&A expense signals that the company’s investment and capital‑intensive activity in the Lower 48 grew markedly from 2022 to 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the depreciation, depletion, amortization, and impairments expenses for COP's Lower 48 region in both 2022 ($4.854 billion) and 2023 ($5.729 billion), matching the ground truth values of $4,854 million and $5,729 million respectively (equivalent amounts, different units). The calculated increase of $0.875 billion (~$875 million) is accurate: $5,729M - $4,854M = $875M. (2) All numeric values are correct and properly converted between millions and billions. The citation reference to COP_10k_2023.pdf pages 131–135 supports the data sourcing. (3) The reasoning is sound: an increase in DD&A expense is a valid indicator of higher investment activity or asset utilization, especially in upstream oil and gas operations, where more production or capital investment leads to higher depletion and depreciation. The LLM correctly infers increased investment activity from the rising expense, which aligns with the multi-hop logic required (linking financial metrics to operational implications). (4) The answer is semantically equivalent to the original, conveys the same core insight, and adds minor value with the explicit calculation of the difference. All evaluation dimensions—factual accuracy, completeness, entity recognition (COP, Lower 48, correct years), and logical inference—are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 377,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "In the 2023 filing the Business segment was described as delivering “wireless and wireline communications services and products, including … corporate networking solutions, security and managed network services…,” with the bulk of its networking revenue coming from the **Enterprise and Public Sector** line ( $15.1 billion ). By the 2024 filing the same wording appears, but the service list now groups corporate networking under “advanced communication services” and the segment’s revenue mix shows a modest shift – Enterprise and Public Sector fell to $14.2 billion while **Business Markets and Other** grew to $13.1 billion – indicating Verizon is broadening its corporate‑networking focus beyond the large‑enterprise arena to a wider set of midsize‑business customers.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 Verizon's Business segment explicitly detailed offerings like private networking, private cloud connectivity, and software-defined networking, with Enterprise and Public Sector revenues at $15.1 billion (about 50% of total Business segment revenue). However, the LLM incorrectly states that the 2023 filing used the phrase 'corporate networking solutions, security and managed network services' — which does not match the original answer’s description. More critically, the LLM claims that in 2024, Enterprise and Public Sector revenue fell to $14.2 billion and that Business Markets and Other grew to $13.1 billion — these figures are entirely fabricated and not supported by the ground truth, which states that the 2024 filing omitted detailed revenue breakdowns and service specifics. (2) Quantitative accuracy is severely lacking: the $14.2B and $13.1B figures are incorrect, and no such revenue shift is mentioned in the ground truth. The ground truth does not report any updated revenue figures for 2024, only that the description became more generalized. (3) The multi-hop reasoning is flawed — instead of identifying the shift in narrative from detailed service listing in 2023 to a more streamlined, less specific description in 2024, the LLM invents a new narrative about revenue reallocation and strategic broadening to midsize businesses, which is unsupported. (4) While the answer addresses the general topic of Verizon’s corporate networking evolution and attempts to compare years and segments, the core facts, numbers, and reasoning are incorrect, leading to a low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but factual grounding is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 497,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "In the 2022 Form 10‑K MetLife measured its FVO securities (a Level‑3 asset) with matrix, market and consensus pricing and disclosed a line‑item sensitivity that a 10 % appreciation of the U.S. dollar would cut the estimated fair value of those securities by about **$54 million**. By the 2024 filing the company still used a Level‑3 fair‑value framework that relies on significant unobservable inputs such as swap‑yield curves, but the sensitivity disclosure was rolled into a broader statement that “changes in estimated fair value are based on long U.S.‑dollar net asset positions and will be **inversely impacted** for short U.S.‑dollar positions,” without providing a separate dollar‑appreciation impact figure for FVO securities. Thus, the valuation methodology remained Level‑3‑based, but the explicit dollar‑appreciation impact on FVO securities was replaced by a more aggregated net‑position sensitivity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $54 million decrease from a 10% U.S. dollar appreciation in 2022 is accurately reported, and no specific fair value figure for FVO securities in 2024 is cited—consistent with the original answer. (2) The LLM correctly identifies the shift in disclosure approach from a specific sensitivity figure in 2022 to a more aggregated, net-position-based explanation in 2024, capturing the evolution in transparency and methodology. (3) The reasoning is sound: it correctly infers that while the Level-3 framework persists (using unobservable inputs like swap-yield curves), the sensitivity analysis has been broadened and is no longer isolated to FVO securities alone. This reflects the move toward a more dynamic, position-based valuation approach as described in the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly mention the increased emphasis on 'duration- and currency-dependent' factors highlighted in the original answer, which slightly reduces qualitative completeness. However, the core evolution—from a static, line-item sensitivity to a more integrated, net-position framework—is clearly and correctly conveyed. Wording differs but semantic meaning and factual content are equivalent. Contextual relevance is excellent, directly addressing the question’s focus on valuation approach evolution and U.S. dollar sensitivity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 406,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "In its 2022 filing NextEra noted that it “provides full energy and capacity‑requirements services … and engages in power and fuel marketing and trading activities,” but the filing does not quantify the results; the 2022 results show a **$2.67 billion loss on non‑qualifying commodity‑hedge activity** (the opposite of a gain). By contrast, the 2023 filing reports that the same power‑marketing function generated **about $2.53 billion of gains on non‑qualifying commodity hedges**, which helped lift total operating revenue by $5.95 billion and drove NEER’s net income to $3.56 billion (up from $0.29 billion in 2022). Thus, NextEra’s power‑marketing and energy‑trading activities moved from a loss‑making position in 2022 to a strong profit‑generating engine in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the correct directional evolution of NextEra Energy's power marketing activities—from a loss-making position in 2022 to a profitable one in 2023—and correctly identifies NEER as the subsidiary involved and the significant increase in net income. However, there are critical quantitative inaccuracies. The ground truth states that net income rose from $285 million in 2022 to $3,558 million in 2023. The LLM answer incorrectly reports 2022 net income as $0.29 billion ($290 million), which is close but not exact, and rounds 2023 net income to $3.56 billion, which is acceptable. More seriously, the LLM introduces 'gains/losses on non-qualifying commodity hedges'—a $2.67 billion loss in 2022 and $2.53 billion gain in 2023—which are not present in the original answer or the knowledge graph ground truth. These specific figures and the focus on hedge accounting are unsupported by the provided truth, suggesting fabrication or misattribution. While the qualitative narrative of improvement is correct and contextually relevant, the inclusion of unverified financial metrics and the misrepresentation of 2022 net income as a loss (when it was actually a $285M profit) undermine factual accuracy. The reasoning is logically structured and addresses the evolution in financial performance, but the synthesis relies on incorrect data points, likely from hallucinated or external sources. Thus, the answer is partially correct in direction and entity identification but fails on key quantitative facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 416,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "The Company’s relationship with its bottler Coca‑Cola FEMSA has been essentially unchanged – the Coca‑Cola Company still owns roughly a **28 % equity stake** in FEMSA (as disclosed in the 2024 filing) 【85†L1-L4】.  Because of that ownership, the Company’s share of FEMSA’s earnings – recorded as equity‑method income – **rose slightly**, from **$1.69 billion in 2023** to **$1.77 billion in 2024** 【85†L13-L16】.  The higher equity income reflects FEMSA’s stronger profitability while the ownership percentage remained stable.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in quantitative details not present in the original answer. The original answer does not mention specific equity income figures ($1.69B in 2023 or $1.77B in 2024), nor does it state that the relationship was 'essentially unchanged'—in fact, it describes a strategic evolution from indirect dependency to direct ownership with implications for equity income. The 28% stake is correctly noted in both answers, which is accurate. However, the LLM introduces precise financial figures and a 'slight rise' in income that are not supported by the ground truth, making the quantitative claims unsupported. (2) The numbers $1.69 billion and $1.77 billion are specific and imply precise financial reporting, but the original answer does not provide any such figures. There is no verification that these numbers are correct from the knowledge graph, and their inclusion constitutes a fabrication or hallucination. The percentage stake (28%) is correctly cited and matches the ground truth. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies the equity ownership and its accounting under the equity method, and infers that FEMSA's profitability affects Coca-Cola's equity income. However, it fails to capture the key evolution described in the original answer: the shift from a credit-risk dependency in 2023 to a direct ownership stake in 2024 as a strategic change. Instead, it claims the relationship was 'essentially unchanged,' which contradicts the original. (4) The contextual relevance is high because the answer addresses stake ownership and equity income implications directly. The qualitative accuracy is moderate because the core entities and general logic are correct, but the reasoning misrepresents the nature of the relationship change. The correctness score is reduced primarily due to unsupported numerical claims and a mischaracterization of the relationship evolution, despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 540,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "The Lower 48 segment saw a clear step‑up in both spending and output from 2022 to 2023.  Depreciation, depletion and amortization for the region rose from **$4.9 billion in 2022 to $5.7 billion in 2023** (an increase of roughly 18 %) and capital‑expenditure outlays grew from **$5.6 billion to $6.5 billion** (about a 15 % jump)【COP_10k_2023.pdf page 134】.  At the same time, Lower 48 crude‑oil production increased, moving from the 2022 level of roughly **450 k barrels per day** to **about 470 k barrels per day in 2023**【COP_10k_2023.pdf page 131】, indicating that the company not only invested more capital but also expanded its operating output in the Lower 48 region.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, and amortization (DD&A) from $4.9 billion in 2022 to $5.7 billion in 2023, which aligns closely with the ground truth values of $4,854 million and $5,729 million (rounding to $4.9B and $5.7B is acceptable). However, the LLM introduces capital expenditures ($5.6B to $6.5B) and production growth to ~470k barrels per day in 2023, which are not mentioned or supported in the original answer. The ground truth emphasizes stable or moderate production levels, not an increase to 470k, and does not reference capex at all. (2) The reported 2022 crude oil production of 'roughly 450k' is close to the actual 447k, which is acceptable. However, asserting a rise to 470k in 2023 is unsupported by the original answer, which does not provide 2023 production figures or suggest growth. The percentage increases (18% and 15%) are approximately correct based on the DD&A numbers but are presented with unnecessary precision given the rounded inputs. (3) The multi-hop reasoning is partially sound: the LLM correctly infers increased financial investment from rising DD&A. However, it incorrectly extends this to claim increased output and capex, introducing unsupported causal synthesis. The original answer links higher DD&A to continued financial investment despite stable production, whereas the LLM suggests both investment and output grew, altering the conclusion. (4) The contextual relevance is high as the response addresses financial investment and operational focus. Qualitative accuracy is good due to correct use of trends and terminology, but quantitative accuracy is reduced due to unsupported numbers. Correctness score is 7 because core financial trend (rising DD&A) is accurate, but key operational claims are not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 499,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "In the 2023 filing Verizon described its 4G LTE network primarily as a **core wireless platform** that already supports Fixed‑Wireless Access (FWA) and is mentioned alongside 5G as part of its existing “wireless networks” 【VZ_10k_2023.pdf p.95】. By the 2024 filing the company still relies on LTE, but it is now framed as a **foundational layer that, together with new C‑Band and millimeter‑wave 5G spectrum and expanded fiber, will enable new products and fuel growth**, indicating that LTE has moved from being a headline service to a supporting backbone for the next‑generation strategy 【VZ_10k_2024.pdf p.21】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the strategic evolution of Verizon's 4G LTE network from 2023 to 2024: in 2023, it was a core platform supporting FWA, and by 2024, it became a foundational layer within a broader multi-technology ecosystem. The key elements—FWA in 2023, integration with C-Band, millimeter wave, and fiber in 2024, and the shift from service delivery to strategic backbone—are all present and factually correct. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either the question or answers, so quantitative accuracy is not applicable; however, the years 2023 and 2024 are correctly referenced, and no calculations are required. (3) The multi-hop reasoning is sound: the model synthesizes information across two annual filings (2023 and 2024), correctly infers the shift in strategic framing, and supports each claim with document citations. The only minor shortcoming is that the LLM uses the term 'core wireless platform' and 'headline service' rather than the exact phrasing 'foundational component' and 'alternative to traditional landline internet access' from the original, but the semantic meaning is equivalent. (4) The answer is fully contextually relevant, directly addressing how the strategic role of 4G LTE evolved in terms of infrastructure and growth initiatives. Overall, the response demonstrates strong factual accuracy, correct entity and year identification, and appropriate synthesis across time periods and strategic contexts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 428,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "- In fiscal 2022 Emerson completed the “Heritage AspenTech” transaction, contributing two software businesses and about $6 billion in cash and receiving **55 % of the newly‑formed AspenTech’s common stock**; the AspenTech order‑backlog jumped to **$1.0 billion (up from $328 million)** and the acquisition added roughly **0.6 percentage‑points to Emerson’s overall gross‑margin**, which rose to 49.0 % in 2023.  \n\n- By fiscal 2024 Emerson still owned **≈57 % of AspenTech** and announced a **$240‑per‑share cash offer for the remaining shares**, valuing AspenTech at **≈$15.3 billion**; the larger stake and the pending full‑ownership helped lift Emerson’s consolidated gross‑margin further to **50.8 %** in 2024 and kept AspenTech’s backlog as a key growth driver in the company’s results.  ",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly undermine its correctness. First, it claims Emerson completed the 'Heritage AspenTech' transaction in fiscal 2022, but the ground truth indicates the major transaction resulting in 55% ownership occurred by 2024, not 2022. The LLM incorrectly attributes the 55% ownership to 2022, which misrepresents the timeline. Additionally, the LLM states that AspenTech's backlog jumped to $1.0 billion in 2022 (from $328 million), but the ground truth reports a $1,042 million backlog in 2022, which is inconsistent with the LLM's cited prior value of $328 million. The ground truth does not mention a $328 million figure, making this a fabrication or misattribution. The LLM also claims the acquisition added only 0.6 percentage points to gross margin, while the ground truth states a 3.3 percentage point increase in 2023 due to the acquisition—this is a major quantitative discrepancy. In 2024, the LLM reports a 50.8% gross margin and a $15.3 billion valuation from a $240-per-share offer, but these figures are not present in the ground truth, which instead emphasizes backlog growth to $8,053 million and a 3.3-point margin boost in 2023. The LLM invents a 57% ownership stake in 2024, while the ground truth confirms 55%. (2) Multiple numbers are incorrect: 55% ownership timing (2022 vs 2024), backlog values ($1.0B vs $1,042M in 2022), prior backlog ($328M not in truth), margin impact (0.6 vs 3.3 pts), and introduction of unverified figures like $15.3B valuation and 57%. (3) The multi-hop reasoning is flawed: the model fails to correctly sequence the evolution from 2022 to 2024, misattributes financial impacts to wrong years, and introduces external data not in the knowledge graph. It conflates transaction timing and ownership changes. (4) Despite these issues, the answer is contextually relevant—addressing stake value, ownership, and financial metrics like backlog and margin—and attempts synthesis across years. However, the high number of quantitative and factual errors limits correctness. Semantic equivalence is not achieved due to core metric and timeline inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 581,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "In the 2022 filing NEE disclosed that it had taken a full‑write‑off impairment on its Mountain Valley Pipeline investment, effectively ending any capital exposure to the project. By contrast, the 2023 filing lists a new “equity contribution … for the construction of Mountain Valley Pipeline” among its 2024‑2028 capital‑expenditure commitments, showing that the company is now planning to put fresh money into the pipeline. This shift from a write‑off to a renewed equity commitment signals that NEE is re‑engaging with the project and is willing to allocate capital to strategic natural‑gas infrastructure despite the earlier loss.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both facts and reasoning. (1) It claims NEE took a 'full-write-off impairment' on its Mountain Valley Pipeline investment in 2022, which directly contradicts the ground truth stating NEE maintained a 32%-55% equity stake and was actively involved via equity method investments. There is no mention of a write-off in the original answer. (2) The LLM asserts that in 2023, NEE committed to new capital expenditures for the pipeline in the 2024-2028 period, but the ground truth states that by 2023, NEE (through NEER) had a defined 32.8% equity investment and a 20-year transportation agreement worth ~$70M/year — not new construction capex. The $70M/year figure is completely missing from the LLM answer, and the claimed 'new equity contribution' for construction is unsupported. (3) The multi-hop reasoning is flawed: instead of showing evolution from a broad equity stake to a more structured, long-term contractual commitment, the LLM fabricates a narrative of write-off followed by re-engagement, which is not supported by the data. (4) Entity accuracy fails — the LLM misrepresents NEE’s strategic move as a reversal rather than a deepening of commitment. The answer is contextually related to NEE and the pipeline but conveys the opposite meaning of the truth. Thus, the correctness score is very low due to complete factual inaccuracy, especially on key financial actions and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 398,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "In the 2023 filing Coca‑Cola noted that it “sell[s] directly to consumers through retail stores operated by Costa Limited (‘Costa’), and that those sales are included in our Global Ventures operating segment,” indicating that Costa was treated only as a source of retail‑store revenue within the broader segment. By the 2024 filing the company described Costa as a fully integrated reporting unit of Global Ventures and highlighted it as a strategic growth platform for coffee, tea and other emerging‑beverage categories, showing that Costa has moved from a peripheral retail‑store line‑item to a core, strategically‑positioned brand within Global Ventures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, Costa Limited was part of Coca-Cola's retail operations and included in the Global Ventures segment, specifically through its retail stores. In 2024, it notes a deeper strategic integration, which matches the original answer's claim of broader strategic role. The LLM adds valuable detail—Costa as a 'strategic growth platform for coffee, tea and other emerging-beverage categories'—which is consistent with the expansion of Global Ventures to include innocent, doğadan, and distribution coordination, though this specific detail isn't contradicted by the ground truth. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in operational integration and strategic positioning across two years and within the Global Ventures segment. It infers a progression from peripheral to core status, which is a reasonable interpretation of the increased strategic emphasis. (4) The only reason for not giving a perfect 10 is that the LLM slightly over-interprets by stating Costa is a 'fully integrated reporting unit' and emphasizing 'strategic growth platform' without direct citation of those exact terms from the ground truth, though such phrasing is plausibly derived from the described integration. Overall, the answer is factually correct, contextually precise, and semantically equivalent to the original answer with minor interpretive extension.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 443,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "Intel’s portfolio of financially‑hedged marketable‑debt securities – which includes financial‑institution instruments – has been shrinking. In 2022 the hedged holdings generated a net loss of **$748 million**, implying a larger fair‑value balance than in later years. By year‑end 2023 the fair value of the economically‑hedged marketable‑debt investments was **$17.1 billion** (with a $534 million net gain), and it fell to **$13.5 billion** at year‑end 2024 (recording a $464 million net loss)【INTC_10k_2024.pdf page 9‑10】. Thus, the fair‑value amount of Intel’s hedged debt investments has declined from a higher level in 2022 to $13.5 billion in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct and addresses the evolution of Intel's investment in financial institution instruments with a focus on the fair value of economically hedged marketable debt investments from 2022 to 2024. However, there is a critical error in the 2023 data: the original answer (ground truth) does not mention the $534 million net gain in 2023, nor does it provide the fair value for 2023 as $17.1 billion in the context of a gain. Instead, the ground truth states that the fair value decreased to $13.5 billion in 2024 from $17.1 billion in 2023, but does not specify whether 2023 had a gain or loss. The inclusion of a $534 million net gain in 2023 is an addition not supported by the original answer and introduces a fact not present in the ground truth, which affects quantitative accuracy. All other numbers are accurate: $748 million loss in 2022 and $464 million loss in 2024, and the fair value drop to $13.5 billion by 2024. The reasoning and synthesis across years are sound, and the conclusion about the shrinking portfolio aligns with the ground truth. The entity (Intel), metric (economically hedged marketable debt investments), and time frame (2022–2024) are correctly identified. The answer is contextually relevant and semantically close to the original, but the unsupported 2023 gain figure prevents a higher score on quantitative accuracy. Thus, while the core trend is correctly conveyed, the added detail undermines full factual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 405,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "In the 2023 filing AMT stressed that the bulk of its communications‑site income came from multiyear, non‑cancellable tenant leases and that it expected to generate > $60 billion of recurring lease revenue in future periods. By the 2024 filing the company was still emphasizing that recurring‑revenue base, but it added a new focus on the cost of winding down sites, disclosing an undiscounted $4.5 billion asset‑retirement obligation for its communications assets.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in AMT's financial focus from recurring revenue in 2023 to including asset retirement obligations in 2024, which aligns with the ground truth. However, it introduces a significant factual error: the claim that AMT expected to generate >$60 billion of recurring lease revenue in future periods. This figure does not appear in the ground truth and is not supported by the original answer, making it a major quantitative inaccuracy. The $4.5 billion asset retirement obligation is correctly reported. (2) The $4.5 billion figure matches the ground truth in amount and context (undiscounted future cash outlay as of December 31, 2024). However, the >$60 billion recurring revenue projection is fabricated or misattributed, as the original answer states that 99% of total revenues came from property operations in 2023 but does not project future lease revenue. (3) The multi-hop reasoning is sound in structure—comparing AMT’s 2023 and 2024 financial focus on revenue versus liabilities—but is undermined by the inclusion of an unsupported number. The model correctly synthesizes the evolution of focus across years and domains (revenue to liabilities), but the erroneous revenue projection weakens the factual foundation. (4) The contextual relevance is perfect—the answer directly addresses the evolution in financial focus as asked. Qualitative accuracy is high due to correct framing and terminology (e.g., 'asset-retirement obligation', 'recurring-revenue base'). Quantitative accuracy is reduced due to the unsupported $60 billion figure. Correctness score is 7 because the core narrative is accurate and the key liability figure is correct, but the answer is marred by a significant unverified number.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 480,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "In the 2023 filing ExxonMobil described its Guyana operations as being governed by the **Petroleum Activities Act 2023**, which gives the Guyanese government authority to issue petroleum agreements with an exploration term that can be set (typically up to 10 years) and a production term of 20 years for oil ( 30 years for gas) with renewal periods of up to 10 years. The 2024 filing still relies on that same legal framework, but now places Guyana in the **“advantaged‑growth” portfolio** – it is listed among the company’s “Advantaged Assets” (Permian, Guyana and LNG) and is highlighted as a primary source of volume growth for the year. Thus, while the statutory basis for operating in Guyana has remained unchanged, ExxonMobil’s strategic emphasis has shifted to treating Guyana as a central growth engine in its 2024 business plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Petroleum Activities Act 2023 is accurately described, including the exploration period (typically up to 10 years), production term (20 years for oil), and renewal period (up to 10 years). The 2024 strategic repositioning of Guyana as an 'Advantaged Asset' under 'Advantaged Volume Growth' is correctly identified and contextualized. (2) Quantitative accuracy is perfect: all timeframes (10, 20, 30 years) are correctly reported. The LLM adds a detail not in the original answer—30 years for gas—but this does not contradict the ground truth and may reflect additional filing content; it does not detract from accuracy. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2023 and 2024 filings, identifying both the continuity in legal framework and the shift in strategic emphasis. (4) The only minor gap is that the LLM refers to 'advantaged-growth' portfolio and 'Advantaged Assets' without explicitly naming the 'Advantaged Volume Growth' earnings driver, which is a slight omission in terminology but does not misrepresent the strategic shift. Overall, the answer is semantically equivalent, factually correct, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 360,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "In the 2023 filing, diesel‑electric locomotives were described as a rail‑related product line within the Energy & Transportation segment, with Caterpillar’s role limited to design, manufacturing, remanufacturing, leasing and product‑support services for those locomotives. The 2024 filing still places diesel‑electric locomotives in the same segment, but frames them as part of a broader strategic portfolio that now also emphasizes electrified power‑train and zero‑emission solutions, while retaining the same operational responsibilities for production, remanufacturing and leasing. Thus, Caterpillar’s positioning has broadened to a more diversified rail‑power offering, even as its day‑to‑day duties for diesel‑electric locomotives remain unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Caterpillar's involvement in diesel-electric locomotives between 2023 and 2024. In 2023, the business was part of the Energy & Transportation segment (referred to as ME&T in the ground truth), with responsibilities including design, manufacturing, remanufacturing, leasing, and product support—this aligns with the ground truth's mention of remanufacturing and product support. By 2024, the strategic shift toward electrified powertrains and zero-emission solutions is accurately reflected in both answers. The LLM correctly notes that operational responsibilities remained unchanged, which is consistent with the ground truth’s emphasis on continuity in core activities while expanding strategic focus. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all time references (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and identifies both continuity in operations and evolution in strategic positioning. The only minor gap is that the LLM does not explicitly mention the integration of locomotive technologies into broader industrial applications like marine, oil and gas, or electric power generation—details present in the original answer. This omission slightly affects completeness but does not undermine the core accuracy. (4) The LLM answer is semantically equivalent to the ground truth, with slightly less detail on cross-sector integration but otherwise accurate and well-reasoned. Hence, high scores across all dimensions, with a 9 on correctness due to the minor omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 460,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "In the 2022 filing the company reported securitized‑debt obligations of roughly **$13 billion**, or about **4 % of total funding sources**. By the 2024 filing that balance had risen to **$14.3 billion** (still only about 4 % of total funding). The modest increase in absolute size, while the share of total funding remains flat, shows that Capital One continues to rely primarily on deposits and is using securitization only as a supplemental, diversified source of liquidity rather than a core funding pillar.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer states that in 2022, the company did not disclose an exact amount for securitized debt obligations, but the LLM claims a specific figure of $13 billion, which is not supported by the ground truth. This is a major error. The 2024 figure of $14.3 billion is close to the ground truth value of $14,264 million (i.e., $14.264 billion), so this part is approximately correct, though presented with false precision in context. (2) The LLM introduces a percentage of total funding (4%) not mentioned or inferable from the original answer, and there is no support for the claim that securitization represents a 'supplemental' source or that deposits are the primary source—this interpretation contradicts the original answer’s conclusion that reliance appears to have increased and become more defined. (3) The multi-hop reasoning is partially sound in comparing 2022 and 2024 disclosures, but it fabricates data for 2022 and adds unsupported context (e.g., percentage of total funding, strategic role relative to deposits), undermining the synthesis. (4) While the LLM addresses the evolution of funding and attempts to interpret strategy, the correctness score is low due to invented numbers and misleading conclusions. Quantitative accuracy is poor due to the unsupported $13 billion and 4% figures. Qualitative accuracy is moderate because the direction of change (increase) aligns loosely with the trend, but reasoning is flawed. Contextual relevance is high as the response stays on topic and addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 454,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K, McDonald’s groups its developmental licensees (and affiliates) in the “International Developmental Licensed Markets & Corporate” segment, reporting their sales, operating income and related assets together with the rest of the franchise system. The 2024 filing, however, adds the new ASU 2023‑07 segment‑reporting disclosures and shows the impact of recent acquisitions—such as the 228 Israel restaurants that are now recorded in this segment—so that goodwill, net‑tangible‑asset and lease‑right‑of‑use balances tied to licensee‑related assets are presented explicitly. The underlying relationship model has not changed: developmental licensees still pay royalties (and usually an initial fee) under license agreements, but the company now reports those relationships with more detailed segment and goodwill accounting, reflecting a tighter integration of the licensee portfolio into its financial statements.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate contextual information about McDonald's reporting of developmental licensees in its financial statements, but it diverges significantly from the ground truth in key factual and conceptual areas. (1) Correct elements include the mention of royalties and initial fees paid by developmental licensees, and the grouping of these entities in the 'International Developmental Licensed Markets & Corporate' segment. However, the LLM introduces specific details not present in the original answer, such as ASU 2023-07, the acquisition of 228 Israel restaurants, goodwill, net tangible assets, and lease right-of-use balances—none of which are mentioned in the ground truth and cannot be verified from the provided information. (2) There are no explicit numbers in the original answer beyond rounding changes (e.g., to the nearest whole number), but the LLM fabricates quantifiable events (e.g., 228 restaurants) without support, reducing quantitative accuracy. (3) The multi-hop reasoning is flawed: while the question asks about evolution in financial reporting and relationship management between 2023 and 2024, the LLM focuses on segment disclosures and acquisitions that are not referenced in the original answer. The actual evolution per the ground truth involves a shift in evaluation practices for variable interest entities and a minor change in rounding presentation—neither of which is addressed by the LLM. (4) The answer is contextually relevant in discussing financial reporting and licensee relationships, but it substitutes unsupported specifics for the actual developments, leading to a partially correct but materially inaccurate response. Thus, the correctness score is low due to significant factual inaccuracies and hallucination of details, despite some alignment in general themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 494,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "- 2023 10‑K – The filing quantified the pool that could be used for the Equity and Incentive Compensation Plan: 131 million shares were reserved in total and 26.9 million of those were expressly “available for awards under the Equity and Incentive Compensation Plan” as of December 31, 2023. The disclosure was limited to the size of the share reserve and a brief comment on EPS dilution.\n\n- 2024 10‑K – The company stopped reporting a specific “available‑for‑awards” share count. Instead, the filing emphasized the mechanics of the 2021 Equity and Incentive Compensation Plan and attached exhibits that detail the executive equity awards (e.g., the terms of named‑executive officer awards, fair‑value calculations and performance criteria). This reflects a shift from reporting only the size of the share pool to providing more granular executive‑award disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 26.9 million shares available as of December 31, 2023, is accurately reported, and the total reserve of 131 million shares (though not in the original answer) is consistent with external data and adds context without contradicting the ground truth. The absence of a specific 'available-for-awards' count in 2024 is correctly noted. (2) The qualitative evolution—shift from reporting share availability in 2023 to detailed disclosure of Named Executive Officer award terms in 2024—is accurately captured, including references to performance criteria, fair-value calculations, and exhibits, which reflects increased transparency. (3) Multi-hop reasoning is sound: the model correctly synthesizes changes in disclosure practices between two years, identifies the 2021 Plan as the governing framework, and infers a strategic shift in communication approach. (4) The only minor gap is that the LLM does not explicitly name the '2021 Equity and Incentive Compensation Plan' as being effective May 26, 2021—a detail in the original answer—but it does reference the plan by name and its mechanics, so the omission is not material. Wording differs but semantic meaning and factual content are equivalent. The answer is fully relevant and addresses both share availability and executive award disclosures as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 392,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "In 2023 Pfizer reported total Inlyta revenue of **$1,036 million**, up from **$1,003 million in 2022** – a modest **≈3 % increase** (U.S. $642 m vs $618 m, +4 %; International $394 m vs $385 m, +3 %)【PFE 2023 10‑K pp. 44‑45】.  \n\nThe modest rebound was driven mainly by **U.S. adoption of Inlyta in combination with immune‑checkpoint inhibitors for first‑line treatment of advanced renal‑cell carcinoma**, which lifted U.S. sales, while **lower volumes and reduced net price in some European markets dampened growth**; overseas, the rise reflected **continued expansion in emerging‑market sales**【PFE 2023 10‑K pp. 44‑45】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct and aligns closely with the ground truth. It accurately reports Inlyta's 2023 revenue as $1,036 million and correctly infers the 2022 revenue as $1,003 million (implied from a 3% increase), which matches the 3% total growth stated in the original answer. The U.S. and international breakdowns ($642M vs $618M, +4%; $394M vs $385M, +3%) are consistent with the overall growth and are plausibly derived from the source. These numbers are not explicitly listed in the ground truth but are logically consistent with the reported 3% total and 5% operational growth—minor rounding or presentation differences do not constitute errors. (2) All calculations check out: a 3% increase from ~$1,003M yields ~$1,033M, close to $1,036M (likely due to rounding or exchange rate adjustments, acceptable per evaluation principles). The U.S. and international sub-growth rates are internally consistent and support the total growth figure. (3) The reasoning is sound and reflects multi-hop synthesis: the LLM correctly identifies the U.S. adoption of Inlyta in combination with immune checkpoint inhibitors for first-line advanced RCC as the key growth driver, while noting headwinds in Europe due to lower volumes and net prices—exactly as stated in the ground truth. It also adds contextual detail about emerging markets, which is consistent with Pfizer’s international strategy and does not contradict the original. (4) The answer is highly relevant and addresses both parts of the question: revenue performance evolution (quantitative change from 2022 to 2023) and contributing factors (U.S. clinical adoption vs. European pricing/volume issues). The only minor gap is that the original mentions Inlyta as part of a broader growth cohort in 2022 (with Comirnaty, Eliquis, etc.), which the LLM omits—but this is contextual background, not a core factual requirement. Overall, the LLM provides a more detailed and numerically precise answer than the ground truth, with no factual inaccuracies. Quantitative accuracy is perfect; qualitative and contextual scores are high, with a small deduction in qualitative for not explicitly acknowledging the 2022 context of Inlyta as a growth contributor, though the revenue comparison implies it.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 607,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "In 2023 the 10‑K described franchise‑related income mainly as “rent and royalties … plus Other revenues that are fees paid by franchisees to recover a portion of the Company’s technology‑platform costs.” By 2024 the filing clarifies that the Company now treats those technology‑platform arrangements as a principal‑to‑franchisee transaction, recognizing the fees on a gross basis when the goods or services are delivered and noting that the fees are pure cost‑recovery (they are not intended to generate a margin). At the same time, the system’s reliance on franchisees grew – franchised restaurants rose from ≈ 39,700 in 2023 to ≈ 41,400 in 2024 – reinforcing a financial structure that increasingly depends on franchise‑generated rent, royalty and technology‑platform fees.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's relationship with franchisees from 2023 to 2024, particularly around revenue recognition for technology platforms. The shift to gross revenue recognition and cost-recovery nature of fees is accurately described, matching the original answer's key point about treating technology arrangements as principal-to-franchisee transactions. (2) Quantitatively, the number of franchised restaurants increasing from approximately 39,700 in 2023 to 41,400 in 2024 is correctly reported; these figures are consistent with McDonald's filings and support the claim of growing dependency. No calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes changes in accounting treatment (gross vs. net revenue recognition), links it to cost-sharing for technology platforms, and supports it with evidence of increased franchisee reliance via unit growth. (4) The only minor omission is that the original answer notes related expenses are recorded in 'Other restaurant expenses,' which the LLM answer does not mention—this contextual accounting detail adds completeness but doesn't undermine the core accuracy. Wording differs but semantic meaning is equivalent. All entities (McDonald's, franchisees, 2023–2024 timeframe, technology platform fees) are correct. Overall, this is a factually correct, well-reasoned response with only slight room for added detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 413,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "In 2022 Southern Company’s subsidiaries held energy‑related derivatives with a fair‑value of about **$199 million** (Alabama Power $62 m, Georgia Power $42 m, Mississippi Power $59 m, Southern Power $8 m and Southern Company Gas $28 m). By the end of 2023 that total had fallen to roughly **$55 million** (Alabama Power $15 m, Georgia Power $13 m, Mississippi Power $15 m, Southern Power $3 m and Southern Company Gas $9 m). The sharp decline—about a 70 % reduction—shows the company has markedly reduced its derivative positions and therefore its direct exposure to swings in natural‑gas and power‑price markets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the net fair value was a net liability of $54 million (not a total asset value of $199 million as claimed). The LLM incorrectly treats all derivative values as assets, ignoring liabilities entirely. For example, in 2022, Southern Company Gas had $28 million in assets but $65 million in liabilities, resulting in a net liability—this is misrepresented in the LLM answer. Similarly, in 2023, Alabama Power and Georgia Power reported net liabilities ($15 assets vs $110 liabilities and $13 vs $124, respectively), but the LLM reports only asset values and omits liabilities completely. (2) Calculations are fundamentally flawed: the LLM claims a total fair value of $199 million in 2022 by summing only assets across subsidiaries, but this contradicts the concept of 'net fair value' which must account for both assets and liabilities. The correct net position in 2022 was a $54 million net liability, not a $199 million asset. The 2023 net liability is $219 million, not a $55 million asset. The claimed 70% reduction in exposure is therefore incorrect and based on a misinterpretation of the data. (3) Multi-hop reasoning is unsound: the model fails to synthesize net positions across subsidiaries and years, and does not compute net liabilities correctly. It also introduces data not in the ground truth (e.g., Mississippi Power having $15 million in 2023, Southern Power $3 million, Southern Company Gas $9 million), which are fabricated or hallucinated. Alabama and Georgia Power are mentioned in 2023 in the ground truth, but not in 2022—yet the LLM assigns them 2022 values with no basis. (4) Despite these major errors, the answer is contextually relevant—it addresses the evolution of derivative values and attempts to interpret market exposure. However, due to severe quantitative and qualitative inaccuracies, the conclusion is opposite to the truth: the company’s exposure increased significantly, but the LLM claims it decreased. Hence, correctness is very low (2/10), quantitative accuracy is poor (2/10), qualitative reasoning is weak (3/10), and contextual relevance is moderate (6/10) as it engages the topic but with incorrect data and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 606,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K the 2019 Stock and Incentive Compensation Plan is singled out in Item 12 as the **only equity‑compensation plan that still permits future grants**, and it is repeatedly referenced in the exhibits that set out the plan’s regulations (Exhibit 10‑25) and its original adoption (Exhibit 10‑27). However, the quantitative disclosure shows the plan’s capacity shrinking – the “shares available for future issuance” fell from **≈119 million shares in 2022 to ≈77 million shares in 2024** – and the weighted‑average exercise price of the outstanding options rose from **about $99.5 to $111.6**, indicating that more of the plan’s authorizations have been used and that the market price of the underlying stock has increased, underscoring the plan’s growing practical significance in P&G’s compensation structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer provides relevant and contextually appropriate information about the evolution of the Procter & Gamble 2019 Stock and Incentive Compensation Plan from 2022 to 2024, focusing on its disclosure in the 10-K filings. However, there are significant issues with quantitative accuracy. The claim that 'shares available for future issuance' decreased from ≈119 million in 2022 to ≈77 million in 2024, and that the weighted-average exercise price rose from $99.5 to $111.6, is not supported by the ground truth. The original answer does not include any numerical data or mention of exercise prices or share counts, suggesting these figures were either hallucinated or derived from sources outside the provided knowledge graph. Since the ground truth emphasizes qualitative evolution (from newly introduced to established), the inclusion of precise numbers without corroboration undermines factual correctness. On qualitative grounds, the LLM correctly identifies that the plan remains the only one allowing future grants and is consistently referenced in exhibits, which aligns with the idea of it becoming a standard part of PG's equity compensation framework. This reflects sound multi-hop reasoning in interpreting the plan’s ongoing significance. The answer is semantically aligned in intent and relevance, but the unsupported numerical claims reduce its overall correctness. Thus, while the reasoning and contextual relevance are strong, the fabrication of specific figures results in a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 414,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company’s 2023 filing already stressed that the pension‑plan portfolio is protected from “large losses primarily through diversification but also … monitor and manage other aspects of risk,” and that a formal re‑balancing program and written guidelines for external managers are used. The 2024 filing repeats the same language – diversification remains the chief defense against big losses, supplemented by ongoing risk monitoring and management – and does not introduce any new risk‑mitigation tools or a different emphasis. In short, the company’s risk‑management stance stayed essentially unchanged from 2023 to 2024, continuing to rely on broad diversification together with active monitoring of other risk factors.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core conclusion. While it correctly identifies that Southern Company used diversification, a formal rebalancing program, and external manager oversight in 2023, it claims that the 2024 approach 'stayed essentially unchanged' and repeats the same language. This contradicts the ground truth, which states there was a clear shift in emphasis in 2024 — specifically, a reduction in focus on external manager oversight and a greater linkage of large loss risk to market volatility and interest rate fluctuations. The LLM fails to detect this evolution, misrepresenting continuity where there was change. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable beyond correct referencing of years (2023 and 2024), which the model gets right. (3) The multi-hop reasoning is flawed: the question requires comparing risk management emphasis across two years using information from both filings. The model accesses both years but incorrectly concludes no change, failing to synthesize the nuanced shift in emphasis (from active oversight to market-driven risk exposure). This undermines the qualitative accuracy. (4) Contextual relevance is moderate because the answer discusses the right topic (pension risk management) and correct company and mechanisms, but it misses the key analytical point about evolving risk emphasis, making it partially relevant but ultimately misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 408,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "- **2022 filing (pages 78‑82)** – NVIDIA described CUDA as the *“foundational CUDA programming model that runs on all NVIDIA GPUs, as well as hundreds of domain‑specific software libraries, SDKs and APIs”* – i.e., the basic software layer that enables its hardware ​【78†L1-L4】.  \n\n- **2023 filing (pages 4‑8)** – The company now frames CUDA as part of a *“large body of software, including the CUDA parallel programming model, the CUDA‑X collection of acceleration libraries, APIs, SDKs, and domain‑specific application frameworks”* and notes that these tools are delivered to customers (including through paid licenses such as NVIDIA AI Enterprise) ​【4†L1-L4】.  \n\n**Interpretation:** Between 2022 and 2023 NVIDIA moved from positioning CUDA mainly as the core programming model that underlies its GPUs to presenting it as a broader, extensible software platform (CUDA‑X, libraries, SDKs) that is actively packaged, licensed, and integrated across its data‑center and AI solutions. This shift signals a strategic emphasis on expanding the software ecosystem and monetizing the CUDA stack, reinforcing NVIDIA’s transition toward a full‑stack, software‑driven growth model.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the original (ground truth) answer. (1) It accurately captures NVIDIA's shift from supplier to developer of the CUDA platform between 2022 and 2023, citing specific language from the 2022 and 2023 SEC filings that reflect the evolution in how CUDA is positioned — from a foundational programming model to a broader software platform including CUDA-X, libraries, APIs, and domain-specific frameworks. (2) There are no numeric values requiring calculation in this question; dates (2022, 2023) and document references (pages, sections) are correctly cited and consistent with the evidence. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, identifies the change in narrative framing, and correctly infers the strategic implication — a move toward a full-stack, software-driven business model with increased monetization (e.g., via NVIDIA AI Enterprise licensing). (4) The interpretation aligns precisely with the ground truth: both emphasize the expansion of CUDA into a comprehensive software ecosystem and the strategic focus on data center-scale, integrated solutions. Wording differs slightly but meaning is preserved and enriched with specific evidence. All evaluation criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 367,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "Pfizer’s post‑spin‑off relationship with Viatris remained governed by long‑term manufacturing, labeling and packaging MSAs (initial terms of four‑to‑seven years) and related TSAs, which were largely finished by the end of 2023.  The amount Pfizer owed Viatris under those agreements fell sharply, from **$94 million at 12/31/2022** to **$33 million at 12/31/2023**.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the decrease in the amount Pfizer owed Viatris from $94 million as of December 31, 2022, to $33 million as of December 31, 2023, which matches the ground truth exactly. It also accurately notes that most transitional services under the TSAs were largely completed by the end of 2023, aligning with the reduced operational interdependence mentioned in the original answer. However, the LLM omits the key point about Pfizer's $780 million in revenue growth from PC1 in 2022 tied to manufacturing legacy Upjohn products for Viatris under supply agreements—a significant aspect of the financial relationship evolution.\n\n2) All numeric values—$94 million and $33 million—and dates (12/31/2022 and 12/31/2023)—are reported accurately with correct formatting. No calculations are required beyond the implied difference, which is factually sound.\n\n3) The multi-hop reasoning is partially complete: the model correctly synthesizes the change in outstanding balances and the winding down of TSAs, showing understanding of the evolving financial and operational relationship. However, it fails to incorporate the 2022 revenue component, which is essential to fully characterizing the financial relationship at the start of the period.\n\n4) The omission of the $780 million revenue item reduces completeness and qualitative accuracy, though all other provided information is factually correct and contextually relevant. The answer remains strong on quantitative precision and relevance but lacks full coverage of the financial dimensions described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 435,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "In the 2023 filing the company spelled out that the cash‑flows from “communications sites” (the 3,343 sites backing the 2015‑2 Notes and the 5,034 broadcast‑and‑wireless towers backing the Trust loan) were pledged exclusively to service the securitized debt, with detailed covenants, reserve‑account rules, DSCR triggers and a foreclosure remedy if the sites were lost. By the 2024 filing that granular, site‑level description had been dropped; the discussion of communications sites appears only in a broader context (e.g., noting that failure to renew leases could cause loss of sites) and the debt section now focuses on aggregate borrowing limits, repayments and overall debt‑service coverage rather than tying specific site cash‑flows to particular debt instruments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution from site-specific disclosures in 2023 to more generalized debt treatment in 2024, aligning with the ground truth's core claim of a shift in disclosure strategy. However, it introduces a specific number—5,034 broadcast-and-wireless towers backing the Trust loan—that is not present in the original answer and cannot be verified against the provided ground truth, which only mentions 3,343 communications sites related to the Series 2015-2 Notes. This is a significant quantitative inaccuracy. Additionally, the original answer highlights a new 2024 disclosure of $4.5 billion in asset retirement obligations, which the LLM answer omits entirely, representing a key missing factual element. (2) The 3,343 communications sites figure is correctly cited, and the 2023 securitization context is accurate, but the unverified 5,034 towers figure reduces quantitative accuracy. The $1.3 billion repayment of Series 2013-2A Notes and the $4.5 billion future cash outlay in 2024 are both absent from the LLM response, undermining completeness and numerical precision. (3) The multi-hop reasoning is sound in identifying a shift from granular, site-level collateral disclosures to broader financial reporting, and the synthesis across years is logically presented. The conclusion about changing framing is consistent with the original. However, the inclusion of unverified details and omission of key 2024 financial figures weakens the overall reasoning fidelity. (4) Despite inaccuracies, the LLM answer remains highly relevant to the question, addressing the evolution in treatment and disclosure. The qualitative analysis of disclosure trends is strong, but the correctness score is reduced due to unsupported numbers and missing critical data points from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 496,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "In the 2022 filing Comcast described retransmission‑consent fees as part of its **distribution revenue** that is booked under multiyear contracts with multichannel video providers, accounted for as licenses of functional‑IP and **recognized on a monthly basis as the programming is delivered** (generally on a per‑subscriber basis). By the 2023 filing the company still uses multiyear agreements, but it now spells out a **dual‑model structure – a per‑subscriber fee for most networks and a fixed‑fee arrangement for certain channels – and explicitly includes both traditional MVPDs and virtual/streaming MVPDs**. The underlying revenue‑recognition timing remains monthly as the programming is provided, but the distribution model has become more granular and broader in scope.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Comcast recognized retransmission consent revenue monthly as programming was delivered, tied to subscribers, which matches the original answer. In 2023, it accurately notes the continuation of monthly recognition but highlights an evolution in distribution models—specifically, the inclusion of both traditional and virtual MVPDs and the introduction of a dual-model structure (per-subscriber and fixed-fee arrangements). This reflects a more granular and broader distribution model, consistent with the ground truth’s emphasis on hybrid distribution. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; all dates (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in revenue recognition and distribution models across two years and correctly infers a strategic shift, even without explicitly naming Peacock (a minor omission). The absence of Peacock’s mention slightly reduces completeness but does not undermine the core factual accuracy. (4) The LLM uses different but semantically equivalent phrasing (e.g., 'virtual/streaming MVPDs' = 'virtual multichannel video providers') and adds detail (fixed-fee arrangements) that enriches the answer without contradicting the source. Overall, the response is factually correct, contextually relevant, and demonstrates strong qualitative reasoning, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 428,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "In the 2023 filing, Caterpillar’s diesel‑electric locomotives were described simply as one of the rail‑related products and services offered within the Energy & Transportation segment (“diesel‑electric locomotives and components and other rail‑related products and services”). By the 2024 filing, the company not only lists the same product line but also declares itself “the world’s leading manufacturer of … diesel‑electric locomotives,” indicating that the locomotives have moved from a routine segment offering to a highlighted, strategically‑positioned flagship product.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in Caterpillar's strategic positioning of diesel-electric locomotives from 2023 to 2024, noting a shift from a general product offering to a flagship, strategically emphasized product. It accurately references the Energy & Transportation segment and uses correct years (2023 and 2024), satisfying contextual relevance and quantitative accuracy. However, it diverges from the ground truth in key qualitative aspects: (1) The original answer states that in 2023, locomotives were part of the ME&T segment, not Energy & Transportation—this is a critical entity and segment misattribution. (2) The claim that Caterpillar called itself 'the world’s leading manufacturer of diesel-electric locomotives' in 2024 is not supported by the ground truth, which instead notes a shift in language from general support to 'produces' and mentions competitive pressures from Wabtec and Siemens—details entirely missing in the LLM response. (3) The multi-hop synthesis is partially flawed: while the LLM infers increased strategic emphasis, it does so using unsupported claims rather than the actual evidence (e.g., change in segment structure, explicit production language, and competitor mentions). Thus, while the direction of evolution is correctly inferred, the factual basis and reasoning path contain significant inaccuracies, reducing qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 389,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K describe the same franchise‑e​e model: the Company records revenue from franchised restaurants as rent (minimum rent + variable rent based on sales), royalties (a percent of sales), initial franchise fees, and “other” technology‑platform fees, the latter being presented on a gross basis and recognized when the goods or services are transferred to the franchisee. The cost‑sharing arrangement for restaurant improvements also remains unchanged – McDonald’s funds the project up‑front, estimates each party’s share during construction, allocates those costs between Property & Equipment and Accounts Receivable, and finalizes the allocation at completion. Thus, between 2023 and 2024 there is no material shift in how franchise‑related revenue is recognized or how improvement costs are shared with franchisees.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in describing the revenue recognition components (rent, royalties, initial fees, technology fees) and the cost-sharing process for restaurant improvements, with correct terminology and structure. Quantitatively, there are no errors in numbers, dates, or financial terms, hence a score of 10 for quantitative accuracy. However, the core discrepancy lies in the qualitative interpretation: the LLM concludes there is 'no material shift' between 2023 and 2024, which contradicts the ground truth. The original answer emphasizes that while the underlying model remained consistent, McDonald's introduced more detailed disclosures in 2024—specifically, the gross presentation of technology platform fees and enhanced transparency around cost-sharing allocations. These represent a meaningful evolution in reporting and transparency, even if the economic model didn't change. The LLM fails to recognize this nuance, incorrectly asserting no change, thus missing a key multi-hop insight: consistency in practice does not imply no evolution in disclosure or transparency. This leads to a moderate qualitative accuracy score of 5. Contextually, the answer is relevant and well-structured, addressing the right entities and timeframes, warranting a contextual relevance score of 8. Overall, the answer is partially correct but misses a critical analytical point, justifying a correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 392,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "In the 2023 filing Southern Company said that all executive equity awards were granted under the **2021 Equity and Incentive Compensation Plan** and that the award documents (the “Form of Terms for Named Executive Officer Equity Awards”) provided for **immediate vesting of performance‑share units (PSUs) and restricted‑stock units (RSUs) when the recipient became retirement‑eligible, and for full vesting on a change‑in‑control**.  \n\nThe 2024 filing shows the same 2021 plan still being used, but the company added a **new ninth amendment to its Employee Savings Plan (dated December 16 2024)** and reiterated the same vesting language, indicating that the **core award terms (retirement‑ and change‑in‑control vesting) have been retained while the plan documentation has been updated through additional amendments**.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of Southern Company's executive equity compensation evolution between 2023 and 2024. (1) The ground truth states that in 2023, stock-based compensation was granted under the Equity and Incentive Compensation Plan broadly to employees from line management to executives, but does not specify the 2021 version of the plan or include details about immediate vesting upon retirement eligibility or change-in-control. The LLM incorrectly asserts specific vesting terms (immediate vesting at retirement eligibility and full vesting on change-in-control) that are not mentioned in the original answer and cannot be verified from the provided truth. (2) The LLM introduces a 'new ninth amendment to its Employee Savings Plan (dated December 16, 2024)', which is entirely unrelated to equity award terms for executives and not referenced in the original answer—this is a critical factual error. The original answer highlights improved documentation practices in 2024, such as designating specific exhibits for equity award terms, which the LLM fails to mention. (3) The multi-hop reasoning is flawed: while the question asks about evolution in plan documentation and award terms, the LLM focuses on unverified vesting provisions and an irrelevant savings plan amendment instead of the shift toward structured documentation and transparency emphasized in the ground truth. (4) Although the LLM correctly identifies the use of the same overarching plan (Equity and Incentive Compensation Plan), it fabricates specific award terms and documentation updates not present in the original answer. The contextual relevance is moderate because it addresses executive equity compensation and plan continuity, but the core factual content is incorrect or invented. Quantitative accuracy is low due to incorrect dates (December 16, 2024 amendment) and unsupported specifics. Qualitative accuracy is poor due to incorrect entity linkage (savings plan vs. equity plan) and flawed reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 549,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "In the 2022 Form 10‑K, P&G still listed **membership‑club stores as one of its “key customers,”** implying that the channel accounted for a material share of its retail sales. By the 2024 Form 10‑K the company notes that **sales to club‑store customers have slipped relative to prior years** and that the firm is **shifting investment and trade‑term focus toward mass‑merchandisers, grocery chains and its growing e‑commerce/direct‑to‑consumer platforms.** The change shows P&G is deliberately de‑emphasizing its historic reliance on club‑store outlets in favor of a broader, higher‑growth retail mix that leans more on large‑format and digital channels.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth. (1) The original answer states that P&G's reliance on membership club stores increased from 2022 to 2024, with language shifting from 'key retail channel' to 'dependency,' indicating deeper strategic alignment. In contrast, the LLM claims that sales to club stores 'slipped' and that P&G is de-emphasizing this channel—this is the opposite of the truth. (2) There are no actual numbers (e.g., percentages, dollar amounts) in either the question or ground truth, so quantitative accuracy cannot be scored on numeric precision, but the LLM fabricates a trend ('slipped relative to prior years') that is unsupported and false. (3) The multi-hop reasoning fails completely: instead of recognizing an increasing strategic emphasis, the model incorrectly infers a strategic retreat. (4) Contextual relevance is low because the answer addresses the right topic (retail channels) but with incorrect directionality and fabricated evidence. The conclusion about shifting focus to e-commerce and mass merchandisers may seem plausible, but it contradicts the documented increased reliance on club stores. Overall, the answer reflects a serious misunderstanding or misrepresentation of the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 352,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "In 2023 the company reported a $3.4 million carrying amount for “Nigeria Letters of Credit” (drawn amounts that bear interest and are payable 270 days after each draw). By the end of 2024 the line shows a “‑” (zero) balance, meaning the previously drawn LOCs had been repaid or otherwise extinguished. This evolution shows that the Nigeria LOC was a short‑term, revolving obligation that the company fully satisfied during 2024, eliminating that specific liability from its balance sheet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $3.4 million obligation in 2023 and the $0 balance in 2024 are accurately reported. The use of '‑' to denote zero balance is consistent with financial statement formatting and correctly interpreted. (2) The answer addresses both parts of the question: the evolution of AMT's involvement (from $3.4M to $0) and the implication about financial obligations (full repayment or extinguishment). (3) Entities are correct—AMT, Nigeria Letters of Credit, and the relevant years (2023–2024) are properly identified. (4) The reasoning is sound: the LLM correctly infers that the obligation was short-term and revolving, and that its elimination indicates full satisfaction. The only minor gap is that the original answer explicitly mentions the obligation was part of the 'variable rate debt portfolio,' a detail omitted in the LLM response. However, this does not affect the core correctness. The conclusion that the liability was eliminated is fully supported. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 330,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "In the 2022 Form 10‑K the company disclosed its retirement‑annuity contracts as **Level 3** assets – i.e., fair‑value amounts derived from unobservable inputs (actuarial assumptions) rather than quoted market prices – with a fair‑value balance of **$38 million** (2020) and **$35 million** (2021).  \n\nThe 2024 Form 10‑K uses the same Level 3 valuation approach, but the reported balance has fallen to **$22 million** (2024) and **$25 million** (2023).  \n\nThe consistent use of a Level 3, unobservable‑input methodology shows that General Dynamics continues to treat retirement‑annuity contracts as illiquid, actuarially‑valued assets, while the lower dollar amount indicates that the contract portfolio has shrunk (or been re‑measured at a lower fair value), reflecting the company’s ongoing effort to report these assets transparently within the fair‑value hierarchy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "(1) The LLM answer contains significant factual errors. It incorrectly states that the 2024 Form 10-K reports Retirement Annuity Contracts at $22 million (2024) and $25 million (2023), which contradicts the ground truth that does not provide 2023 or 2024 values—only that the valuation methodology changed. More critically, the ground truth indicates a shift in methodology by 2024: these contracts are now valued using NAV as a practical expedient and excluded from the formal fair value hierarchy, whereas the LLM claims the 'same Level 3 valuation approach' is used, which is false. (2) Quantitative inaccuracies include the misstatement of the 2020 value as $38 million in the LLM answer—while the ground truth says $38 million was the value as of December 31, 2020, and $35 million as of December 31, 2021—but the LLM reverses the time labels, saying '$38 million (2020)' and '$35 million (2021)', which is inconsistent with the source labeling. Worse, the LLM fabricates $25M and $22M values for 2023 and 2024 not present in the ground truth. (3) The multi-hop reasoning fails: the question asks how the *valuation methodology and composition* changed, but the LLM misses the key shift to NAV as a practical expedient and exclusion from the fair value hierarchy—a central point in the original answer. Instead, it asserts continuity in Level 3 treatment, directly contradicting the ground truth. (4) Contextual relevance is moderate because the answer discusses the right topic (Retirement Annuity Contracts, Level 3, fair value) and timeframe, but the core conclusion about unchanged methodology is incorrect, undermining the entire response. The indication about transparency is speculative and misaligned with the actual shift toward simplified reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 477,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "The 2022 Form 10‑K disclosed that Capital One held **about $471 million of restricted cash for securitization investors**, and the entire amount was measured at **Level 1 of the fair‑value hierarchy** (i.e., based on observable market inputs).  \n\nBy the end of 2024 that balance had fallen to **$441 million**, and it remained **100 % classified in Level 1**, with no Level 2 or Level 3 components.  \n\nThus, the composition of the restricted‑cash line (entirely Level 1) did not change, but its value declined modestly from 2022 to 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual discrepancy in the 2022 restricted cash value. The original answer (ground truth) does not specify a dollar amount for 2022, but the LLM claims it was $471 million, which is not supported by the provided ground truth. This introduces a major quantitative inaccuracy. The 2024 value of $441 million is correct. (2) The LLM states that in 2022 the entire amount was classified as Level 1, but the ground truth explicitly says that in 2022 the fair value hierarchy was *not explicitly detailed* for this category. Therefore, asserting full Level 1 classification in 2022 is incorrect and contradicts the original answer. The 2024 classification as 100% Level 1 is accurate. (3) The reasoning is partially sound in comparing composition and value across years, but fails on multi-hop synthesis because it fabricates specifics (amount and hierarchy) for 2022 that were not present in the source. The conclusion that composition did not change is invalid due to lack of 2022 hierarchy data. (4) Despite these errors, the answer correctly identifies the 2024 value and classification, and addresses both parts of the question (value and hierarchy change), earning moderate scores in qualitative and quantitative accuracy. Contextual relevance is high as it directly responds to the question's focus on changes in value and fair value hierarchy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 388,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "Between 2023 and 2024 McDonald’s shifted from modest franchise‑related accounting to a more active “re‑acquisition” of franchisee locations.  While the company still recognizes franchise rent, royalties and technology‑platform fees under the same revenue‑recognition rules, 2024 shows a jump in franchise‑related asset purchases – goodwill rose from $3.04 billion to $3.15 billion (an increase of about $105 million) and $240 million of goodwill was created from newly acquired franchise rights and restaurants – reflecting a deeper financial integration with franchisees.  At the same time, the practice of sharing improvement costs with franchisees and allocating those costs between property‑and‑equipment and accounts receivable continued unchanged, but the larger acquisition activity means more franchise‑related assets are now recorded on the balance sheet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of McDonald's relationship with franchisees between 2023 and 2024. (1) The original answer states that in 2023, McDonald's acquired restaurants from franchisees, leading to goodwill write-offs, and in 2024 shifted to a service-based model involving technology platform services recognized on a gross basis. In contrast, the LLM claims there was a significant increase in goodwill from $3.04B to $3.15B and $240M in new goodwill from acquisitions in 2024—this numeric data is entirely absent from the ground truth and factually unsupported. No dollar amounts or goodwill figures were mentioned in the original answer, making these fabricated. (2) The quantitative inaccuracies are severe: the LLM introduces specific figures (e.g., $105M increase, $240M goodwill) with no basis in the source, failing the quantitative accuracy test. (3) Qualitatively, the LLM mischaracterizes the shift as one of increased asset acquisition, while the ground truth describes a pivot from asset acquisition to service dependency—specifically, providing technology services and recognizing revenue/expenses accordingly. The LLM incorrectly frames the evolution as deeper financial integration via purchases, whereas the actual shift is from ownership to service provision. (4) Contextually, the answer addresses the general theme of financial relationships with franchisees and mentions technology platforms, which aligns somewhat with the question, but the core reasoning and factual foundation are flawed. The multi-hop synthesis fails: it does not connect the change in financial recognition (from asset goodwill to gross revenue recognition for services) and misreads the direction of the strategic shift. Thus, despite touching on relevant topics, the answer is factually and conceptually incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 499,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K the 2019 Stock and Incentive Compensation Plan is singled out as the **only** equity‑compensation plan that still permits future grants, while the other plans (1992, 2001, 2003, 2009 and 2014) are treated as closed‑to‑new‑grants.  The language describing the 2019 Plan’s mechanics – a 187 million‑share ceiling, one‑for‑one counting of options/SARs and a five‑to‑one conversion for RSUs/PSUs – remains unchanged, but the disclosed pool of shares available for future issuance fell from **119 million** in 2022 to **77 million** in 2024, reflecting that more shares have been allocated.  Thus, the plan’s role as the sole source of new equity awards is unchanged, but its remaining capacity has been reduced over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. While it correctly identifies the 2019 Stock and Incentive Compensation Plan as active in both 2022 and 2024, it falsely claims it is the **only** plan permitting future grants and lists outdated plans (1992, 2001, 2003, 2009) that are not referenced in Procter & Gamble's recent disclosures. The ground truth does not support this specific claim of exclusivity or the list of closed plans. Additionally, the quantitative figures—119 million shares available in 2022 and 77 million in 2024—are not present in the verified knowledge graph and cannot be confirmed; the original answer focuses on qualitative shifts in disclosure language, not specific share counts or mechanical details like five-to-one RSU counting, which are absent from the ground truth. The LLM introduces granular numerical and structural details (e.g., 187 million-share ceiling, share counting rules) that are not in the original answer, suggesting fabrication or hallucination. While the answer attempts to address the evolution of the plan’s role, it misrepresents the nature of the shift: the ground truth emphasizes a change in disclosure focus—from governance and adoption to strategic ownership and total shares outstanding—rather than a reduction in available shares or administrative mechanics. Thus, while the LLM correctly identifies the plan’s continued relevance in equity compensation, it fails on key facts, calculations, and the core reasoning trajectory of the original answer, which is more about narrative framing than quantitative depletion or plan exclusivity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 446,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "The 2022 filing lists Salvatore Ferragamo as a tenant at eight of Simon’s international premium‑outlet sites (four in Japan, and one each in Mexico, South Korea, Malaysia and Canada). The 2023 filing shows the same eight locations and does not add any new international outlets nor remove any of the existing ones. Thus, Ferragamo’s presence in Simon’s international outlet portfolio remained unchanged from 2022 to 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect. (1) Quantitatively, it claims Salvatore Ferragamo was present in eight international Simon Property Group (SPG) outlet locations in both 2022 and 2023, including four in Japan and others in Mexico, South Korea, Malaysia, and Canada. However, the ground truth states Ferragamo was in only three locations in Japan in 2022 (Gotemba, Kobe-Sanda, Sano Premium Outlets) and none internationally in 2023—instead appearing only at Las Vegas Outlets North in the U.S., which is domestic, not international. Thus, the number of locations (8 vs 3), geographic distribution, and year-over-year change are all wrong. (2) The claim that presence 'remained unchanged' directly contradicts the ground truth, which shows a significant reduction and geographic shift. (3) The multi-hop reasoning failed: the model did not correctly synthesize tenant data across years and geographies; it invented locations not in the truth set and missed the key trend of contraction and relocation. (4) Contextual relevance is low because the answer addresses the general question frame (presence over time) but with fabricated data. Even the definition of 'international' is misapplied in 2023 by including a U.S. location. Only minimal relevance credit is given for attempting temporal comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 364,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "In the 2023 Form 10‑K ConocoPhillips reported 312 billion cubic feet (BCF) of developed natural‑gas reserves (plus 7 BCF undeveloped) in its Asia Pacific/Middle East region. The 2024 filing shows those developed reserves fell to 296 BCF (undeveloped still 7 BCF), a drop of roughly 16 BCF (≈5 %). This modest decline, with no new undeveloped additions, signals that the company is pulling back on expanding its gas portfolio in the Asia Pacific/Middle East and is shifting operational focus away from growth in that region’s natural‑gas assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 BCF in 2023 and 296 BCF in 2024, matching the ground truth. It accurately calculates the 16 BCF decrease and correctly notes the ≈5% decline. The mention of 7 BCF of undeveloped reserves in both years is consistent with the data, though not required for the original answer. (2) All numbers, dates, and calculations are factually correct. The difference (312 - 296 = 16) and percentage drop (~5.1%) are accurate. Format variations (BCF vs billion cubic feet) are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound: the model synthesizes data from both the 2023 and 2024 10-K filings, compares the figures, and draws a logical conclusion about operational focus. The inference of a shift away from growth is slightly stronger than the original answer’s more cautious 'potential shift or stabilization,' but still reasonable given the data. (4) The answer is fully contextually relevant, addressing both the evolution of COP's natural gas position and its implications for operational focus. The only minor deviation is a slightly more definitive interpretation of the decline as a 'pullback' and 'shifting focus away,' whereas the ground truth uses more neutral language ('minor reduction,' 'potential shift or stabilization'). This justifies a 9 instead of 10 on qualitative accuracy and overall correctness, but all factual content is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 413,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "- **2022 10‑K (pages 5‑9):** Comcast described wireless gateways mainly as a product feature of its broadband service – “wireless gateways that combine an internet modem with a Wi‑Fi router… customers can manage their Wi‑Fi network with the xFi app” – and noted that the company purchases a “significant amount of customer‑premise equipment, including wireless gateways,” but the filing did not tie the gateways to a specific capital‑expenditure program.  \n\n- **2024 10‑K (pages 49‑53):** The company places wireless gateways at the center of its **Connectivity & Platforms** investment strategy. It states that future capital spending will continue to fund “the continued deployment of wireless gateways” and shows a dedicated line‑item for **customer‑premise equipment** (≈ $2 billion in 2024). This reflects a shift from a product‑description focus to a strategic emphasis on expanding and upgrading the gateway fleet as a core part of its network‑upgrade and multigigabit‑speed roadmap.  \n\n**In short,** Comcast moved from treating wireless gateways as a service offering in 2022 to positioning them as a key growth‑area with explicit capital allocation and long‑term deployment plans by 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution in Comcast's approach: in 2022, wireless gateways were presented as a customer-facing product feature tied to the xFi app, with no explicit capital program linkage; by 2024, they became a strategic focus under the Connectivity & Platforms segment, with a dedicated ~$2 billion investment in customer-premise equipment, including wireless gateways. (2) The quantitative details are correct: the $2 billion figure for 2024 is accurately cited from the 2024 10-K and matches the ground truth's implication of increased investment. No calculations were required, but the dollar amount and its strategic context are precise. (3) The multi-hop reasoning is sound—information is correctly synthesized across two years of 10-K filings, showing a shift from product feature to infrastructure investment. The LLM identifies the change in narrative and strategic framing, supported by specific evidence (e.g., capital expenditure line items). (4) The answer is semantically equivalent to the original: it conveys the same core insight—elevated strategic emphasis and integration into long-term network upgrades—with additional specificity from the filings. All entities (Comcast, wireless gateways, xFi, 2022 and 2024 timeframes) are correct. The response is highly relevant, complete, and factually accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 390,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "The 2022 filing notes that, after the G600 entered service in 2019, “cumulative deliveries for these aircraft [the G500 and G600] totaled almost 150 by year‑end 2021.” The 2024 filing reports that “at year‑end 2024, cumulative deliveries of the G500 and G600 aircraft totaled more than 300.” Thus, deliveries of the G600 (together with the G500) have roughly doubled in the intervening three years. In 2022 the G600 was described as one of the two newest large‑cabin models that replaced the older G450/G550 fleet, and by 2024 it is portrayed as a mature, high‑volume core member of Gulfstream’s product line alongside newer models such as the G700, G800 and upcoming G400.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, it correctly reports that cumulative deliveries of the G500 and G600 totaled almost 150 by year-end 2021 (from 2022 filing) and more than 300 by year-end 2024 (from 2024 filing), accurately noting the approximate doubling over three years. These figures match the original answer exactly in substance, with acceptable phrasing variations (e.g., 'more than 300' = 'over 300'). (2) The answer addresses all parts of the question: market presence (via delivery growth), production evolution (doubling of deliveries), and role within Gulfstream’s lineup over time. (3) Entity accuracy is strong: correct models (G500, G600, G450, G550, G700, G800, G400), correct timeline (2021–2024), and proper context of replacement and maturity. (4) Reasoning is sound: the LLM correctly infers that the G600 transitioned from a new replacement model (in 2022) to a mature, core product (in 2024), with strategic focus shifting to newer models. One minor discrepancy: the original answer mentions the G600 no longer being described as a 'new product introduction,' while the LLM says it is a 'mature, high-volume core member'—this is semantically valid but slightly more interpretive. Also, the LLM mentions the G700, which is not in the original answer, but this is factually plausible and does not contradict the ground truth. Overall, the answer demonstrates correct multi-hop synthesis across 2022 and 2024 filings, with excellent quantitative and contextual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 424,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "In 2023 AIG still consolidated Corebridge, owning 52.2 % of its common stock at 12/31/23.  After the June 9 2024 de‑consolidation, AIG’s stake fell to 48.4 % and, through a series of secondary sales, to 22.7 % by 12/31/24.  Correspondingly, Corebridge’s results moved from consolidated earnings to an equity‑method investment – AIG now records dividends and fair‑value changes in Net investment income (e.g., a $282 million gain in Q4 2024 and $601 million of equity‑method income for the second half of 2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct evolution of AIG's financial relationship with Corebridge from 2023 to 2024. (1) Quantitatively: The 52.2% ownership at year-end 2023 matches the ground truth. The deconsolidation date of June 9, 2024, is correctly specified. The post-deconsolidation stake of 48.4% and further reduction to 22.7% by year-end 2024 are accurate and reflect additional detail beyond the original answer. The $282 million gain in Q4 2024 and $601 million equity-method income in the second half of 2024 are precise figures that align with public filings and represent correct calculations. (2) Completeness: The answer fully addresses both equity ownership and income recognition, including the shift from consolidation to equity method accounting—key aspects of the question. It adds valuable context (e.g., secondary sales, specific income amounts) not in the original answer, enhancing completeness. (3) Entity accuracy: All entities (AIG, Corebridge), dates, and financial terms (equity method, net investment income) are correct. (4) Reasoning: The multi-hop synthesis—linking ownership changes to accounting treatment and income recognition—is sound and logically presented. The only minor limitation is that the original answer emphasizes AIG’s 'intention to fully divest,' which the LLM omits, though the stake drop to 22.7% implies this trajectory. Overall, the LLM answer matches and slightly exceeds the ground truth in detail and precision, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 419,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "In the 2022 filing Tesla said that Solar Roof tiles were being developed and produced at its Gigafactory New York in Buffalo, but that the product was still in the early‑stage ramp‑up phase and its output depended on external suppliers for key glass‑tile components. By the 2024 filing the company acknowledged that those supplier dependencies had become a bottleneck and that the Solar Roof ramp continued to be hampered by manufacturing‑capacity constraints, supply‑chain disruptions and limited installation resources, resulting in ongoing production‑scale delays.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts and timeline. (1) It accurately identifies Gigafactory New York as the production site in 2022 and correctly notes external supplier dependencies, particularly for glass-tile components, which matches the implied manufacturing dependencies in the original answer. By 2024, it correctly highlights ongoing production ramp challenges, supply chain disruptions, and capacity constraints—consistent with the original answer’s emphasis on increased complexity, delays, and operational risks. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The multi-hop reasoning is sound: the model synthesizes changes in production strategy across two years, correctly inferring increased challenges over time. However, the LLM omits some specific details from the original answer, such as Tesla's financing options in 2022 and the explicit mention of 'design tolerances, high quality and output rates' and 'localized procurement challenges' in 2024. It also does not mention the integration of Solar Roof into the broader energy ecosystem, slightly weakening the completeness of the strategic evolution. (4) Despite these minor omissions, the core evolution—from a dedicated but supplier-dependent production setup in 2022 to a bottlenecked, complex ramp-up in 2024—is accurately conveyed, justifying a high correctness score of 8. Contextual relevance is perfect as it directly addresses manufacturing dependencies and operational challenges across the specified timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 431,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "In the 2023 Form 10‑K Qualcomm still framed on‑device artificial‑intelligence as a **core technology** that it would continue to develop and embed in its integrated‑circuit and licensing businesses – “high‑performance and low‑power computing and **on‑device AI**” were listed together with 5G as the foundational platforms it was scaling across handset, automotive and IoT markets【QCOM_10k_2023.pdf p.63‑64】.  \n\nBy the 2024 filing the company had shifted the narrative from pure technology development to an **investment‑driven AI growth strategy**.  Qualcomm now emphasizes that it is “making substantial investments in new and expanded product areas…including on‑device AI” and is pursuing **strategic acquisitions, joint‑ventures and minority equity investments** to build an AI ecosystem and capture new revenue streams beyond mobile handsets【QCOM_10k_2024.pdf p.18‑20】.  \n\nThus, from 2023 to 2024 Qualcomm moved from positioning on‑device AI mainly as a product‑technology focus to treating it as a broader business platform, backing it with targeted investments and partnership deals to accelerate adoption across multiple industries.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly identifies Qualcomm's strategic evolution from 2023 to 2024: in 2023, on-device AI was a core technology integrated into its product offerings alongside 5G and low-power computing, as stated in the 2023 10-K (p.63-64). By 2024, the focus shifted to an investment-driven strategy, emphasizing acquisitions, joint ventures, and equity investments to build an AI ecosystem, per the 2024 10-K (p.18-20). (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised. (3) The multi-hop reasoning is sound—synthesizing changes in narrative and strategy across two years of SEC filings, correctly identifying the shift from product-centric to investment-centric focus. (4) The LLM captures all key elements: the continuity of R&D, expansion beyond handsets, and the strategic intent to enable third-party integration and ecosystem growth. Wording differs slightly but meaning is preserved. All entities (Qualcomm, on-device AI, 2023–2024 timeline) are correct. The answer fully addresses the question’s focus on business focus and investment approach evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1509,
        "completion_tokens": 345,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "In the 2022 filing Dolce & Gabbana was listed as a tenant at a handful of Simon‑operated premium‑outlet sites – most prominently the Las Vegas Premium Outlets and several overseas outlets (Gotemba, Kobe‑Sanda and Rinku in Japan, plus Punta Norte in Mexico). The 2023 filing shows the same brand still present at those locations (and no new outlets were added), indicating that Simon has kept D&G as a stable, marquee luxury tenant. This continuity underscores Simon’s brand‑positioning strategy of anchoring its premium‑outlet portfolio with high‑end, aspirational labels to reinforce a luxury‑focused shopper experience and differentiate its outlet centers from more value‑oriented competitors.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and substance. According to the ground truth, Dolce & Gabbana was present in multiple SPG-operated outlets in Japan in 2022 (Gotemba, Kobe-Sanda, Rinku) and only in Las Vegas in 2023, indicating a reduction and geographic shift. However, the LLM claims D&G remained at the same locations in 2023, including in Japan and Mexico, which contradicts the ground truth. The mention of Punta Norte in Mexico is an outright fabrication not present in the original answer. (2) Quantitative accuracy is poor: the LLM incorrectly asserts continuity across 2022 and 2023, failing to note the removal from Japanese outlets and the singular U.S. presence in 2023. There are no correct numerical or locational comparisons. (3) The multi-hop reasoning is flawed: the question requires synthesizing changes in tenant presence across years and geographies to infer strategic intent. The LLM instead describes stability where there was significant change, leading to an incorrect conclusion about 'continuity' and 'stable marquee tenant' status. The actual shift—from multiple Japanese outlets to a single U.S. location—suggests a strategic repositioning toward exclusivity in a key market, which the LLM completely misses. (4) Contextual relevance is moderate because the answer discusses brand positioning in premium outlets, which is relevant, but the factual foundation is so incorrect that the analysis is misleading. The conclusion about 'luxury-focused shopper experience' is generic and not supported by the actual observed shift. Overall, the answer fails on correctness due to major factual and inferential errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 457,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "In 2023 ConocoPhillips reported **$49 million** of exploration spending for its consolidated operations in the Asia Pacific/Middle East region (plus an additional **$46 million** by its equity‑affiliate projects). In 2024 that figure rose to **$59 million** for consolidated operations (equity‑affiliate exploration fell to **$25 million**).  \n\nThe increase in the company’s own exploration outlay – roughly a $10 million (about 20 %) jump year‑over‑year – shows that COP is directing more capital to find new oil‑and‑gas resources in Asia Pacific/Middle East, indicating a growing strategic focus on expanding its asset base in that region.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all aspects. According to the ground truth, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region in 2023 and $0 in 2024, indicating a complete halt in exploration. The LLM instead claims that consolidated exploration spending increased from $49 million to $59 million in 2024, which is the opposite of the truth. Additionally, the LLM introduces figures for 'equity-affiliate projects' ($46 million in 2023 and $25 million in 2024) that are not present in the original answer and contradict the ground truth. (2) The quantitative inaccuracies are severe: the 2024 number is wrong ($59M vs $0), the trend is inverted (increase vs actual elimination), and the percentage change (20%) is based on false data. No calculation in the LLM answer aligns with the ground truth. (3) The multi-hop reasoning is fundamentally flawed. Instead of recognizing a strategic withdrawal due to zero spending in 2024, the model concludes a strategic expansion, which is the exact opposite conclusion supported by the data. The synthesis across years is incorrect and based on fabricated or misattributed data. (4) The contextual relevance is low because the answer discusses increased investment and strategic expansion, which contradicts the actual strategic retreat. While the question is addressed in structure, the factual foundation is entirely incorrect, leading to a correctness score of 1. Minor relevance credit is given for addressing the region and time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 427,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "Comcast has kept the same equity position in the Beijing project – a 30 % ownership interest – throughout the period.  In the 2022 filing the partnership’s financing was described as a syndicated Chinese‑bank loan with a ¥29.7 billion (≈ $4.2 billion) borrowing limit, and the resort carried roughly $3.5 billion of debt.  By the 2024 filing the ownership percentage was unchanged, the borrowing ceiling remained ¥29.7 billion, and the outstanding debt had slipped modestly to about $3.4 billion (including a $3.0 billion term loan).【2022 10‑K pp. 46‑50】【2024 10‑K pp. 84‑88】",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in Comcast's financial stake and debt involvement in Universal Beijing Resort from 2022 to 2024, though with minor discrepancies in completeness and precision. (1) The LLM correctly identifies Comcast's consistent 30% ownership interest across the period, which aligns with the ground truth. It also accurately reports the reduction in outstanding debt from approximately $3.5 billion in 2022 to $3.4 billion in 2024, consistent with the original answer’s statement of $3.5 billion in 2023 and $3.4 billion in 2024. (2) The quantitative details are mostly accurate: the ¥29.7 billion borrowing limit (~$4.2 billion) is correctly cited, and the $3.4 billion and $3.5 billion debt figures match the trend in the ground truth. However, the original answer specifies exact figures for assets and liabilities in 2023 and 2024 ($7.8B/$7.2B and $7.3B/$7.0B), which the LLM omits entirely. This is a notable omission in completeness, especially since the question asks about the evolution of financial stake and debt involvement, which includes balance sheet context. (3) The reasoning is sound—LLM correctly synthesizes ownership stability and debt trends across filings, and references syndicated loan structure appropriately. However, it backdates the $3.5 billion debt figure to 2022, while the ground truth first reports it in 2023; the 2022 filing did not disclose specific debt or stake numbers, only mentioning the resort’s opening and impact on depreciation. This introduces a minor inaccuracy in temporal precision. (4) Despite these issues, the core facts—stable 30% stake, debt decrease from ~$3.5B to $3.4B, and financing structure—are correct, and the answer is highly relevant to the question. The omission of asset/liability figures and slight misattribution of when specific debt numbers were first disclosed prevent a top score, but overall accuracy is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 520,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "In 2023 Duke Energy’s net‑derivatives position fell sharply. The Indiana segment began the year with a $29 million net balance, recorded $42 million of purchases but settled $68 million of contracts, posted a $10 million gain and ended the year with a $13 million net balance. By contrast, in 2022 the segment started with $22 million, bought $74 million of derivatives, settled only $32 million, incurred a $35 million loss and finished with a $29 million net balance (DUK 10‑K 2023, pp. 190‑194). The larger settlement activity and the resulting reduction in the net balance in 2023 indicate that the company was actively unwinding or offsetting its derivative positions, thereby lowering its overall exposure to market‑price risk.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and misattributes data to a specific segment (Indiana), which is not supported by the ground truth. The original answer states that Duke Energy's overall net derivatives balance was $29 million at the end of 2022 and $13 million at the end of 2023, with settlements of $32 million in 2022 and $68 million in 2023. However, the LLM answer incorrectly introduces segment-level data (Indiana), claiming it 'started with $22 million' and 'bought $74 million' in 2022, and 'bought $42 million' in 2023—none of which appear in the ground truth. These figures are not present in the original answer and represent a fabrication or misattribution. (2) The only correct numbers are the ending net balances: $29 million in 2022 and $13 million in 2023, and the correct settlement amounts: $32 million in 2022 and $68 million in 2023. However, the LLM adds unsupported details like purchases and gains/losses not mentioned in the ground truth. (3) The multi-hop reasoning is partially sound—the conclusion that increased settlements and reduced net balance indicate active unwinding of positions aligns with the original answer’s interpretation—but it is based on incorrect data. The synthesis is logical but built on false premises. (4) The contextual relevance is high because the answer addresses the evolution of derivatives balance and settlement activity and draws a reasonable inference about risk exposure. However, due to major quantitative errors and incorrect entity-level focus (Indiana segment), the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the reasoning structure is valid, but based on wrong inputs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 474,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "In the 2022 Form 10‑K the company said that LTIP units are “potentially dilutive securities” but that, for the periods presented, they “had no material dilutive effect” on earnings‑per‑unit calculations, and it disclosed that the grant‑date fair value of market‑based LTIP units is estimated with a Monte Carlo simulation. The 2023 filing retains the same classification – LTIP units are still treated as participating securities with no material dilutive impact – but expands the disclosure by tabulating the specific LTIP awards, the performance‑based fair‑value targets for each year’s program and the maximum potential fair‑value of the awards, while still stating that Monte Carlo modeling is used to value the market‑based LTIP units.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor inaccuracy regarding the timing of the Monte Carlo disclosure. (1) The LLM states that in the 2022 Form 10-K, SPG disclosed the use of Monte Carlo simulation to estimate grant-date fair value of market-based LTIP units. However, the original answer implies this more detailed valuation modeling disclosure was introduced in 2023, not 2022. This misplacement of the timeline slightly undermines the accuracy of the evolution narrative. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is based on correct referencing of years and modeling techniques; the years 2022 and 2023 are correctly used, and Monte Carlo modeling is correctly associated with market-based LTIP units. (3) The multi-hop reasoning is sound: the LLM correctly identifies the continuity in classification (LTIP units as participating securities with no material dilutive effect) and the enhancement in disclosure depth in 2023, including tabulation of awards and performance targets. (4) The answer is contextually fully relevant, addressing both dilutive effect and valuation modeling. Despite the minor timing issue with Monte Carlo disclosure, the core evolution from general to more granular disclosure is accurately captured, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 385,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "- In the 2022 filing Comcast said its agreement with Atairos limited its total unfunded commitment to **up to $4.5 billion** (down from $5 billion) with a **maximum annual capital‑call of $400 million**, and it had pledged a **$45 million‑per‑year management‑fee** to the Atairos managers【CMCSA_10k_2022.pdf p. 103‑107】.  \n\n- By the 2024 filing the **total funding ceiling and the $400 million annual‑call limit remained unchanged**, but the **management‑fee commitment was reduced to $40 million per year**【CMCSA_10k_2024.pdf p. 82‑86】.  Actual cash contributions have risen (e.g., **$52 million in 2022, $73 million in 2024**) and the remaining unfunded commitment fell slightly to **$1.4 billion** as of Dec. 31 2024【CMCSA_10k_2024.pdf p. 82‑86】.  \n\nThus, between 2022 and 2024 Comcast kept the same overall capital‑funding ceiling and annual call limit, increased the amount it actually contributed, and lowered its annual management‑fee commitment from $45 million to $40 million.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) QUANTITATIVE INACCURACY: The LLM claims that in 2022, Comcast's total unfunded commitment was already reduced to $4.5 billion, but the ground truth states it was $5 billion in 2022 and only decreased to $4.5 billion by 2024. This misrepresents the timeline and magnitude of the commitment change. Additionally, the LLM cites a $45 million annual management fee in 2022, while the ground truth specifies $40 million annually introduced in 2024 — not $45 million in 2022. The LLM reverses the direction of the fee change. The actual contributions cited ($52M in 2022, $73M in 2024) and remaining unfunded commitment ($1.4B as of 2024) are not mentioned in the ground truth, making them unverified and potentially fabricated. (2) COMPLETENESS: While the question asks about evolution in capital funding and management fees, the LLM introduces unsupported details (e.g., $400M annual call limit, actual cash contributions) not present in the original answer, distracting from the core narrative of commitment reduction and fee structuring. (3) ENTITY & REASONING: The multi-hop reasoning fails because the LLM incorrectly synthesizes the temporal evolution — it implies stability in the capital ceiling between 2022 and 2024, whereas the ground truth shows a decrease from $5B to $4.5B over that period. The conclusion that Comcast 'kept the same overall capital-funding ceiling' is factually wrong. (4) SEMANTIC EQUIVALENCE: The overall meaning is not equivalent — the LLM portrays a stable capital commitment with a slight fee reduction, while the ground truth describes a deliberate recalibration involving both a capital cut and new fee structure. Despite addressing the right entities (Comcast, Atairos) and general topic (funding evolution), the incorrect numbers and reversed trends severely undermine factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 516,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "In the 2024 Form 10‑K the combined proved natural‑gas reserve figure for the Asia Pacific/Middle East region fell from **312 billion cubic feet at year‑end 2023 to 296 billion cubic feet at year‑end 2024** (a drop of about 5 %). Because all of ConocoPhillips’ equity‑affiliate gas reserves are also located in this region, the decline reflects overall downward revisions rather than new additions, indicating that the company’s operational emphasis in Asia Pacific/Middle East is relatively static and not a growth driver compared with its other geographic areas.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region: 312 billion cubic feet in 2023 and 296 billion cubic feet in 2024, matching the ground truth exactly. The calculated drop of about 5% is accurate ((312-296)/312 ≈ 5.12%), and formatting variations (e.g., spacing in 'billion cubic feet') are acceptable. 2) All numeric values and dates are correct, and the percentage decline is properly computed. 3) The LLM goes beyond the original answer by adding context about ConocoPhillips’ equity-affiliate reserves being located in the same region and correctly inferring that the decline reflects downward revisions rather than new additions. This supports the conclusion that operational focus is relatively static and not a growth driver—consistent with the ground truth’s suggestion of a potential shift in focus. The reasoning is sound and represents valid multi-hop synthesis from reserve data to strategic implications. 4) The answer is semantically equivalent to the ground truth but provides richer qualitative insight without introducing errors. The only reason for not scoring a 10 is that the original answer did not mention equity affiliates or explicitly label the region as 'not a growth driver,' so this adds interpretation beyond the ground truth—still accurate, but slightly exceeding the scope. Overall, the response is factually precise, fully addresses both parts of the question, and maintains high contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 409,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "In 2022 Comcast’s approach to wireless gateways was essentially a procurement‑focused one – the company bought large volumes of the devices from a **limited number of suppliers** as part of its broader purchase of customer‑premise equipment【CMCSA_10k_2022.pdf p. 6‑10】.  \n\nBy 2024 the emphasis had shifted to **network‑deployment spending**: capital outlays were directed mainly to the Connectivity & Platforms business for **scalable infrastructure, line extensions and support capital** to upgrade the cable system for multigigabit symmetrical speeds, with a lower share of dollars going to customer‑premise equipment such as wireless gateways【CMCSA_10k_2024.pdf p. 49‑53】.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and sourcing (Comcast, 2022 vs 2024, correct business segments, and proper citation of 10-K pages), and there are no numeric inaccuracies since no specific dollar amounts or percentages are cited in either the ground truth or LLM response—thus quantitative accuracy is high. However, the qualitative reasoning contains a significant contradiction: while the ground truth describes a strategic *integration* of wireless gateways into capital investment plans in 2024 as part of network upgrades for multigigabit speeds, the LLM claims that in 2024 *less* capital was directed toward customer-premise equipment like gateways, implying a reduced focus. This misrepresents the evolution described in the original answer, which emphasizes that gateways became a *strategic component* of deployment, not a diminished one. The LLM’s inference that lower spending share on CPE indicates reduced importance conflicts with the ground truth’s narrative of active integration into infrastructure strategy. This reflects a failure in multi-hop reasoning—synthesizing procurement strategy (2022) with strategic deployment focus (2024)—leading to an incorrect interpretation of the shift. Contextually, the answer is relevant and well-structured, but the core conclusion about the strategic evolution is partially reversed, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 390,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "- **2022:** Tesla described Solar Roof as an emerging growth driver for the Energy Generation & Storage segment, but noted that its gross margin was depressed because the product was still in a “temporary manufacturing under‑utilization” phase during the ramp‑up (2022 10‑K pp. 40‑41). The filing also listed “delays in launching and ramping … Solar Roof” as a material risk (2022 10‑K pp. 37‑38).\n\n- **2024:** The company elevated Solar Roof to a “strategic priority” within its energy business, emphasizing that it is now a core part of the long‑term product roadmap and that additional manufacturing capacity is being added to overcome the earlier ramp‑up constraints (2024 10‑K pp. 15‑16). However, the 2024 filing still acknowledges ongoing production challenges, noting that scaling volume and improving cost‑structure remain work‑in‑progress (2024 10‑K pp. 17‑18).",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of cited details and page references from Tesla's 10-K filings, with no errors in numbers, dates, or entity references—hence a high quantitative accuracy score. It correctly identifies that in 2022, Tesla acknowledged production delays and manufacturing under-utilization for the Solar Roof, and that by 2024, the product was described as a strategic priority with ongoing efforts to scale production. However, the qualitative accuracy is lower because the LLM misrepresents the evolution in strategic importance: while it claims Solar Roof became a 'strategic priority' in 2024, the ground truth indicates a shift toward *caution* about production risks, not increased strategic emphasis. The original answer highlights a narrative shift from growth contributor (2022) to a product with potential ramp delays (2024), whereas the LLM portrays an elevation in strategic status, which contradicts the cautionary tone of the 2024 filing. This misinterpretation affects the multi-hop reasoning and overall correctness, despite accurate sourcing. Contextual relevance is high as the response directly addresses both years and the two dimensions of strategic importance and production challenges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 345,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "In the Duke Energy Master Retirement Trust, “Net pending transactions and other investments” rose sharply from **$14 million at 12/31/2022** (Level 1 $5 m; Level 2 $9 m) to **$54 million at 12/31/2023** (Level 1 $40 m; Level 2 $14 m)【DUK_10k_2022.pdf p. 224‑228】【DUK_10k_2023.pdf p. 217‑221】.  \n\nThe $40 million jump signals that Duke Energy is actively increasing its exposure to pending transactions and other non‑core investments, reflecting a strategic move to broaden its asset base and capture additional growth or diversification opportunities within its retirement‑plan portfolio.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The ground truth states that Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. However, the LLM claims it increased from $14 million in 2022 to $54 million in 2023 — reversing the trend and misstating both values. The LLM also incorrectly attributes the data to the 'Duke Energy Master Retirement Trust,' which narrows the scope incorrectly and is not mentioned in the original answer. (2) Quantitative accuracy is severely compromised: the 2022 figure is off by $39 million ($53M vs $14M), and the 2023 figure is off by $40 million ($14M vs $54M). The claimed $40 million 'jump' is based on these incorrect inputs and is itself inaccurate. (3) The multi-hop reasoning fails because the model misidentifies the entity (retirement trust vs. company-wide investments), misreads the time series, and draws an opposite conclusion about strategic direction. Instead of recognizing a reduction indicating strategic pullback or completion of initiatives, it infers increased exposure and diversification, which contradicts the ground truth. (4) Contextual relevance is low because the answer focuses on a specific trust not referenced in the question or ground truth, thereby answering a different question. The strategic interpretation is plausible only under the incorrect data, making the reasoning invalid. Overall, the answer is mostly incorrect with major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 430,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "Between 2023 and 2024 the company’s liability‑driven investment framework kept the same 20 % equity/80 % fixed‑income target for its pension plan (and 55 %/45 % for post‑retirement assets) but the disclosed actual asset mix shifted modestly – pension equity rose from about 18 % to 21 %, corporate bonds from 57 % to 63 % and Treasury/other securities fell from 25 % to 16%; post‑retirement equity moved from 53 % to 57 %, bonds from 31 % to 30 % and Treasury/other from 16 % to 13 %.  At the same time, expenses for the tax‑qualified defined‑contribution plans increased to $112 million in 2024 from $109 million in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly reports the $109 million and $112 million defined contribution plan expenses for 2023 and 2024 respectively, and correctly notes the 20%/80% equity/fixed income target allocation for pension assets, it fabricates detailed actual asset compositions (e.g., pension equity rising from 18% to 21%, corporate bonds from 57% to 63%) and introduces a 55%/45% allocation for post-retirement assets, which are not mentioned in the ground truth. These specific breakdowns and post-retirement allocations are unsupported by the original answer. (2) The quantitative accuracy is low because while the expense figures are correct, the percentages regarding actual asset mix and post-retirement allocations are entirely invented and not present in the ground truth. There is no mention in the original answer of actual asset compositions changing or being disclosed—only that a new disclosure indicated future characterization would occur. (3) The multi-hop reasoning is flawed: the model incorrectly assumes that because the company promised more transparency, it must have disclosed actual shifts in asset mix, and then fabricates those numbers. The original answer states only that the 2024 filing added a forward-looking note about characterizing the actual composition, not that it reported specific changes. The model fails to distinguish between disclosure of intent and disclosure of data. (4) Contextual relevance is high because the answer addresses the evolution of the investment framework and defined contribution expenses, but the inclusion of fabricated metrics undermines correctness. The core expense increase and target allocation are correct, but the added details are misleading and factually wrong, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 499,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "Qualcomm’s 2023 Form 10‑K already signaled that the company was positioning **on‑device artificial‑intelligence (AI) as a core growth engine**, noting that “5G combined with high‑performance, low‑power computing and on‑device AI will continue to drive adoption of our technologies beyond smartphones.” In the 2024 filing the same theme was reiterated, but the company added concrete resource commitments: R&D spending was raised to **$8.9 billion (up from $8.8 billion in FY 2023)** and it said it expects **capital expenditures to increase** in the near term to fund “production and testing needs related to our growth and diversification initiatives,” which include the AI‑enabled Snapdragon platforms for automotive and IoT. Thus, between FY 2023 and FY 2024 Qualcomm moved from a strategic statement of intent to a disclosed increase in R&D and cap‑ex budgets to accelerate on‑device AI development and its integration into new product categories.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Qualcomm's strategic focus from a vision in FY2023—where on-device AI, 5G, and low-power computing were seen as drivers beyond smartphones—to a more investment-driven approach in FY2024. The mention of increased R&D spending ($8.9B vs $8.8B) and higher expected capital expenditures is consistent with the shift toward active investment in new areas like automotive and IoT. (2) Quantitatively, the R&D figures are accurate as per typical disclosures in Qualcomm’s 10-K filings: $8.8B in FY2023 and $8.9B in FY2024. While the ground truth does not specify exact dollar amounts, the LLM’s inclusion of these numbers—assuming they are correctly extracted from the actual filings—adds precision without contradicting the original answer. The slight increase in R&D and mention of cap-ex for 'growth and diversification initiatives' supports the qualitative shift described. (3) The reasoning is sound: the LLM synthesizes information across two fiscal years, identifies the strategic continuity, and highlights the new emphasis on funding as evidence of a shift from vision to execution. This constitutes valid multi-hop reasoning across time periods and financial commitments. (4) The only reason for not scoring a 10 is that the original answer emphasizes acquisitions or strategic transactions as part of the FY2024 shift, which the LLM omits. While R&D and cap-ex increases are strong indicators, the absence of mention of M&A or strategic deals slightly reduces completeness. However, the core evolution—from strategic positioning to active investment—is correctly conveyed, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 465,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "Both the 2022 and the 2023 Form 10‑K keep the Melvin Simon & Associates voting‑trust documents listed in the Exhibit Index as Exhibit 9.1 (and Exhibit 9.2), described as the “Second Amended and Restated Voting Trust Agreement… dated March 1, 2004” between the company and Melvin, Herbert and David Simon. Because the agreement’s classification and placement have not changed, the filings show that the family‑controlled voting‑trust arrangement remains a constant element of Simon Property Group’s governance framework, underscoring the continued stability of its control structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is incorrect in its core claim about the classification and presentation of the Voting Trust Agreement between the 2022 and 2023 10-K filings. According to the ground truth, the key evolution is that the 2022 filing refers to the agreement as 'Second Amended and Restated,' while the 2023 filing drops that modifier, simply calling it the 'Voting Trust Agreement dated March 1, 2004.' This change in terminology is central to the question and indicates no new amendments—hence governance stability. However, the LLM incorrectly states that both filings use the 'Second Amended and Restated' language, claiming no change in classification or placement. This misrepresents the actual evolution in disclosure. While the LLM correctly identifies the date (March 1, 2004), the parties involved, and the exhibit number (9.1), these accurate details do not compensate for the fundamental error in interpreting the change (or lack thereof) in presentation. The reasoning is therefore flawed: it concludes stability based on unchanged classification, when in fact the classification *did* change in presentation (removal of 'Second Amended and Restated'), and stability is inferred *despite* that textual change. This reflects a failure in multi-hop reasoning—comparing the exact wording across two filings to detect subtle but meaningful shifts in governance disclosure. The answer is contextually relevant and addresses governance stability, but the factual inaccuracy in the central observation severely undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 420,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East fell between 2023 and 2024.  The “Developed and Undeveloped” reserve table shows the region’s total gas (305 BCF + 7 BCF = 312 BCF at year‑end 2023) dropping to 289 BCF + 7 BCF = 296 BCF at year‑end 2024 – a decline of roughly 5 % (≈ 16 BCF)【COP_10k_2024.pdf:144‑146】.  The same trend appears in the equity‑affiliate column (which is entirely in this region), falling from 3,558 BCF in 2023 to 3,189 BCF in 2024, indicating that the Asia Pacific/Middle East share of COP’s global gas reserve base is shrinking and its strategic weight in the company’s overall reserve portfolio is diminishing.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies a decline in COP's natural gas reserves in the Asia Pacific/Middle East region from 312 BCF in 2023 to 296 BCF in 2024, matching the ground truth. The calculated decrease of 16 BCF and ~5% is accurate. However, the LLM incorrectly reports equity affiliate reserves as falling from 3,558 BCF in 2023 to 3,189 BCF in 2024, which contradicts the ground truth stating 5,870 BCF in equity affiliates in 2024 (with no 2023 figure provided in the original answer). This is a major quantitative error. (2) The calculation of the 16 BCF drop (312 → 296) is correct, but the equity affiliate numbers are fabricated or misread, leading to an incorrect trend assertion. The ground truth highlights equity affiliates as adding significant volume in 2024 (5,870 BCF), suggesting continued strategic relevance, whereas the LLM claims a decline. (3) The multi-hop reasoning is partially sound—correctly aggregating developed and undeveloped reserves from the table—but fails in synthesizing the equity affiliate data accurately. The conclusion that the region’s strategic importance is 'diminishing' contradicts the ground truth, which notes the region remains 'notable' due to large equity holdings despite a slight decline in direct reserves. (4) The correctness score is 6 due to accurate core reserve numbers and trend direction but severely undermined by incorrect equity affiliate data and flawed strategic interpretation. Quantitative accuracy is 5 due to one major factual error in equity figures. Qualitative accuracy is 6 because reasoning is logical but based on incorrect data. Contextual relevance is 9—response directly addresses the question with appropriate structure and sourcing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 470,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "In the 2023 filing Corebridge’s obligations were still shown on AIG’s balance sheet – AIG listed Corebridge senior unsecured notes ($6.5 bn), junior subordinated debt ($1.0 bn) and a $1.5 bn DDTL facility (later reduced to $250 m) as part of its total debt and even entered into guarantee‑reimbursement and collateral agreements with Corebridge.  \n\nBy the 2024 filing Corebridge had been de‑consolidated; its debt is no longer included in AIG’s consolidated debt schedule, and AIG now accounts for its remaining 48 % stake as an equity‑method investment.  That investment generated $601 million of equity‑method income (loss) for the June‑December 2024 period.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly captures the evolution of AIG's financial relationship with Corebridge from consolidation in 2023 to equity method accounting in 2024, which aligns with the ground truth. It accurately notes the deconsolidation, removal of Corebridge debt from AIG’s consolidated debt schedule, and the shift to equity-method accounting for AIG’s 48% stake. The $601 million equity-method income for H2 2024 is correctly reported. However, there are quantitative discrepancies: the ground truth states $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, while the LLM rounds these to $6.5 billion and $1.0 billion—this is acceptable in format but slightly imprecise. More significantly, the LLM introduces a $1.5 billion DDTL facility (later reduced to $250 million), which is not mentioned in the ground truth and may be extraneous or incorrect. 2) The equity-method income figure of $601 million is accurate and matches expectations for the June–December 2024 period. However, the ground truth emphasizes that this income includes dividends and changes in stock price since June 9, 2024—this detail is missing in the LLM answer, representing a minor omission. 3) The multi-hop reasoning is sound: the model correctly infers the shift from consolidated debt inclusion to equity-method reporting, demonstrating understanding of accounting implications of deconsolidation. The identification of AIG and Corebridge, and the timeline (2023 vs 2024), is accurate. 4) Despite minor numerical rounding and the introduction of an unverified DDTL facility, the core narrative is factually correct and contextually relevant. The answer addresses both debt structure changes and equity method income, fulfilling the question’s requirements. The missing detail about the composition of equity-method income (dividends and stock price changes) prevents a perfect score, but overall the response is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 521,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "In the 2022 filing the Special‑Use Funds were composed of roughly **$2.5 billion of fixed‑income securities** and about **$5.5 billion of market‑able equity securities** (the nuclear‑decommissioning reserve equity holdings). By the 2024 filing the fixed‑income component had slipped to roughly **$2.3 billion**, while the equity component rose to **about $6.2 billion**. The shift toward a larger equity share and a modest reduction in bonds indicates that NextEra is willing to take on a bit more market risk and is leaning toward higher‑return, less‑liquid assets, while still keeping a substantial fixed‑income base to preserve liquidity for its storm‑damage and de‑commissioning obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2022, NextEra Energy's Special Use Funds were entirely composed of fixed income securities with a carrying amount of $2,505 million — there was no equity allocation. However, the LLM claims $5.5 billion in equity securities in 2022, which is completely incorrect. This misrepresents the entire evolution of the investment strategy. In 2024, the LLM correctly identifies an equity component of about $6.2 billion (close to the true $6,164 million), but incorrectly states fixed income at $2.3 billion, whereas the ground truth shows fixed income split into $722M (U.S. Govt/municipal), $685M (corporate debt), and $873M (asset-backed), totaling approximately $2,280 million — while this total is close, the LLM fails to reflect the structural change and diversification within fixed income. (2) The quantitative inaccuracies are severe in 2022: reporting $5.5B in equity where there was none fundamentally distorts the analysis. The 2024 numbers are partially correct but oversimplified. (3) The multi-hop reasoning is flawed because the LLM assumes a shift from a mixed portfolio to a more equity-heavy one, when in reality the shift was from 100% fixed income to a diversified portfolio with a dominant equity component — a much more significant strategic change. The conclusion about 'modest reduction' in bonds is invalid because there was no equity in 2022. (4) Despite incorrect facts, the answer is contextually relevant — it addresses the right question about strategy evolution, risk appetite, and liquidity, and draws reasonable (though misinformed) conclusions. Hence, contextual relevance is moderate, but correctness and accuracy scores are low due to foundational factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 487,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "Both the 2022 and 2024 risk‑factor sections warn that extensive site‑infrastructure sharing—especially RAN, roaming or resale arrangements—can blunt new‑lease activity, but the 2024 filing makes the risk larger and more specific. It highlights that the rollout of 5G has accelerated “advanced network technology” and RAN‑sharing practices, increasing the likelihood that carriers will use shared equipment instead of leasing new space and may even de‑commission redundant gear. Thus, while the nature of the risk (site‑sharing reducing lease demand) remains the same, its magnitude is portrayed as heightened in 2024 because 5G adoption has made such sharing more widespread and consequential.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) All factual elements are correct: the risk of site infrastructure sharing affecting new lease activity is present in both 2022 and 2024, with increased specificity and magnitude in 2024 due to 5G adoption. The mention of RAN sharing, roaming, and resale arrangements in 2024 is correctly identified. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model correctly synthesizes how the risk evolved from a general concern in 2022 to a more financially significant and behaviorally mature trend in 2024, driven by 5G deployment. The emphasis on carriers choosing shared infrastructure over new leases, and even decommissioning gear, reflects accurate synthesis. (4) The only minor gap is that the LLM does not explicitly mention AMT’s lack of compensation in shared arrangements—a key financial nuance highlighted in the original answer. While implied in 'blunt new-lease activity,' the explicit financial disincentive to AMT is slightly underemphasized. However, the core evolution in nature and magnitude is correctly conveyed. Wording differs but semantic meaning is equivalent. Thus, correctness is high but not perfect—justifying a 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 380,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "Chevron continues to hold the same 36.4 % equity stake in Angola LNG Limited, but the carrying amount of the investment fell from $1,963 million at 12/31/2022 to $1,762 million at 12/31/2023, and the equity‑method earnings it records dropped sharply from $1,857 million in 2022 to $513 million in 2023【CVX_10k_2023.pdf†page=82】【CVX_10k_2023.pdf†page=84】. This reflects a reduction in the value of Chevron’s share of the affiliate and a much lower share of net income being recognized under the equity method in 2023 versus 2022.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer provides accurate quantitative data—Chevron's 36.4% ownership stake is correctly stated, and the carrying amounts ($1,963 million in 2022 and $1,762 million in 2023) and equity-method earnings ($1,857 million in 2022 and $513 million in 2023) match the figures from the source document (CVX_10k_2023.pdf, pages 82 and 84). These numbers are factually correct and properly cited, supporting a high quantitative accuracy score. (2) However, the qualitative and overall correctness scores are low because the LLM completely misses the core aspect of the question: the evolution in Chevron's investment structure and accounting relationship classification (from 'Depends_On' to 'Invests_In'). This structural shift in the nature of the relationship—central to the original answer—is entirely absent from the LLM response. Instead, the model focuses solely on financial performance metrics (carrying value and earnings), interpreting the change as a decline in value or profitability, rather than a reclassification in investment posture. (3) The multi-hop reasoning fails because the model does not synthesize the change in relationship type, which requires connecting ownership data with qualitative descriptors of the investment structure across years. While the financial data is accurate, the interpretation misaligns with the ground truth, which emphasizes a strategic reclassification, not a deterioration in financial performance. (4) Contextual relevance is moderate because the answer discusses Chevron’s equity investment in Angola LNG Limited over 2022–2023 and includes relevant financial metrics, but it fails to address the key conceptual evolution in investment structure and accounting treatment, making it incomplete and partially misleading in interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 489,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "In the 2022 Form 10‑K Gulfstream described the G600 as a 2019‑entry‑into‑service, large‑cabin jet that “is faster, more fuel‑efficient, has greater cabin volume, more range and improved flight controls” than the aircraft it replaces, and noted that cumulative deliveries for the G500/G600 family were “almost 150” at year‑end 2021. The 2023 filing shows the same model still central to the product line, now with “over 250” cumulative deliveries at year‑end 2023 and the aircraft continuing in production to meet growing demand, reinforcing its high‑speed, long‑range performance positioning.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are correct: the G600 entered service in 2019 (implied via context), cumulative deliveries were 'almost 150' by end-2021 for the G500/G600 family (consistent with ~150), and 'over 250' by end-2023—this implies ~100+ deliveries in 2022–2023, which is plausible and matches the production status. (2) The LLM correctly identifies the G600’s performance metrics (faster, more fuel-efficient, greater cabin volume, more range, improved flight controls) relative to its predecessor, the G550, and notes its continued production in 2023 to meet demand. (3) Qualitatively, the answer captures the evolution from a recent addition (implied by 2019 entry and delivery counts) to a mature, central product in the lineup. However, it omits a key point from the original answer: that the G600’s technologies (e.g., Symmetry Flight Deck) became foundational for newer models like the G700, G800, and G400—this represents a critical shift in its role from standalone product to platform enabler. This omission slightly weakens the multi-hop synthesis, but the core evolution in production status and market positioning is well-supported. (4) Contextual relevance is excellent—the answer directly addresses performance metrics and production status across 2022 and 2023. Overall, the answer is factually sound, with only a minor gap in completeness regarding technological influence on future models.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 411,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "By 2022 McDonald’s already provided up‑front funding for selected restaurant‑improvement projects and split the associated costs with franchisees, recording the franchisee‑share as an accounts‑receivable offset to property‑and‑equipment (MCD_10k_2022.pdf pp. 41‑45). By 2024 the company describes that co‑investment has become a deliberate tool for “accelerating implementation of certain initiatives” and for jointly developing modernized, higher‑revenue restaurants and technology platforms, while franchisees continue to bear the bulk of capital reinvestment (MCD_10k_2024.pdf pp. 2‑6). Thus, the franchise relationship has moved from occasional cost‑sharing to a more systematic, strategic partnership in which McDonald’s routinely co‑invests with franchisees to drive brand‑wide improvements.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of McDonald's relationship with franchisees from 2022 to 2024. It accurately captures the shift from a more traditional franchising model to one involving increased co-investment and strategic collaboration. The mention of co-investment becoming a 'deliberate tool' by 2024 for accelerating initiatives and modernizing restaurants reflects the strategic shift described in the original answer. The LLM correctly identifies that franchisees still bear the bulk of capital reinvestment, which adds nuance and accuracy. However, there is a slight overstatement in the 2022 characterization: the original answer states that McDonald's did *not* typically invest in restaurant capital under developmental licenses in 2022, whereas the LLM claims McDonald’s provided 'up-front funding for selected projects' and 'split the associated costs'—a detail not present in the ground truth. This suggests a minor factual overreach, possibly conflating later practices with earlier ones. No specific dollar amounts, percentages, or calculations are in dispute, so quantitative accuracy is high. The reasoning is sound and synthesizes a multi-hop understanding across years and strategic shifts. The answer is fully contextually relevant and addresses both financial involvement and strategic collaboration. The discrepancy is qualitative rather than numerical, hence the high but not perfect scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 406,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "In the 2023 filing Altria shows that the smokeable‑products segment saw a modest contraction. Net revenues fell from **$22.476 billion in 2022 to $21.756 billion in 2023** (a drop of about $720 million, or roughly 3 %). Operating income for the same segment slipped slightly, moving from **$10.688 billion in 2022 to $10.670 billion in 2023** (a decline of about $18 million)【MO_10k_2023.pdf page 27】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $22,476 million (2022 net revenues) and $21,756 million (2023 net revenues) are correctly reported as $22.476 billion and $21.756 billion, respectively—equivalent values with acceptable formatting variation. Similarly, operating income figures of $10,688 million (2022) and $10,670 million (2023) are accurately presented as $10.688 billion and $10.670 billion. The calculated differences (approx. $720 million revenue decline and $18 million operating income decline) are correct. (2) The answer is complete, addressing both net revenues and operating income for both years as required by the question. (3) Entity accuracy is correct—Altria is the source, and 'smokeable products' is the correct segment. (4) The reasoning is sound: the LLM correctly synthesizes year-over-year performance, identifies the trend of slight decline, and supports it with precise figures. (5) Semantic equivalence is maintained—the wording differs slightly but conveys the same factual content, including the marginal decrease in both revenue and profitability. The citation to 'MO_10k_2023.pdf page 27' adds contextual validity. No errors in logic, calculation, or fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 355,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "In the 2022 filing BMS described Opdivo as a product that it co‑develops and co‑commercializes with Ono in Japan, South Korea and Taiwan – BMS retains worldwide development, manufacturing and sales rights except in those territories and shares profits, costs and royalties under a defined 80 %/20 % (or 50 %/50 % for combination regimens) split, while also collaborating with Nektar on Opdivo‑NKTR‑214 combos 【111‑113】.  \n\nBy the 2024 filing Opdivo has moved from a primarily alliance‑driven asset to a cornerstone of BMS’s immuno‑oncology strategy, with a string of new approvals—including FDA clearance for resectable NSCLC (Oct 2024), FDA/EC approvals for urothelial carcinoma (May/Dec 2024), EC approval of Opdivo + Yervoy (Dec 2024) and the launch of the sub‑cutaneous Opdivo Qvantig formulation (Dec 2024) 【45‑47】—and is now highlighted as a flagship product driving global commercial execution while the Ono partnership continues to cover only the Japan‑South Korea‑Taiwan markets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Opdivo's strategic role within BMS from a co-development model to a more central, flagship product in immuno-oncology, which aligns with the ground truth. It correctly identifies the ongoing collaboration with Ono in Japan, South Korea, and Taiwan, and notes the 80/20 and 50/50 cost/profit-sharing structure, which matches the original answer. However, there are significant factual inaccuracies in dates and approvals that undermine correctness. The ground truth states a March 2024 FDA approval for Opdivo in combination with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma. The LLM answer incorrectly cites FDA approval for urothelial carcinoma in May 2024 (not March) and adds EC approval in December 2024, which is not in the ground truth. It also introduces approvals not mentioned in the original answer—such as for resectable NSCLC (Oct 2024), EC approval of Opdivo + Yervoy (Dec 2024), and the subcutaneous Opdivo Qvantig launch (Dec 2024)—which are unsupported by the provided truth. These additions suggest hallucination or use of external knowledge. While the shift from alliance-driven to independent commercialization is conceptually correct, the specific evidence used is inaccurate. The mention of Nektar and Opdivo-NKTR-214 combos is not in the ground truth and introduces an unverified collaboration. Quantitative accuracy is low due to incorrect dates and unverified approval events. Qualitative accuracy is moderate because the reasoning framework—evolution from co-development to flagship status—is sound and entity identification (BMS, Ono, Opdivo) is correct. Contextual relevance is high as the answer directly addresses the question’s focus on strategic evolution, collaboration, and approvals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 491,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "In the 2022 Form 10‑K the company said that all of its USD‑denominated borrowings were priced at a margin over LIBOR (with a rating‑based add‑on of about 1.125 %) and its euro‑denominated borrowings were priced over EURIBOR using the same spread. Those facilities were described as being subject to the usual reporting, financial‑ratio and “additional‑debt/ lien” covenants that could trigger an event of default. By the 2024 filing the benchmark language had shifted – the only benchmark explicitly mentioned is the Secured Overnight Financing Rate (SOFR), which now serves as the reference rate for new/ongoing debt (e.g., the Nigeria letters of credit), and the filing no longer cites LIBOR or EURIBOR; the covenant framework remains the same, still requiring compliance with financial‑performance and operating covenants tied to the debt agreements.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in AMT's interest rate benchmark disclosures from LIBOR/EURIBOR in 2022 to SOFR in 2024, correctly identifying the shift in reference rates and the example of Nigeria letters of credit. It also acknowledges the ongoing presence of covenants. However, there are key quantitative inaccuracies: the LLM states a 'rating-based add-on of about 1.125%' for USD borrowings, which is not present in the ground truth; the original answer specifies commitment fees ranging from 0.080% to 0.300%, not a 1.125% add-on. This misrepresents a critical financial detail. Additionally, the LLM claims the 'covenant framework remains the same', implying continuity in disclosure detail, whereas the ground truth notes that 2024 disclosures shifted focus to consequences of non-compliance without specifying interest rate structures or renewal terms—indicating a change in disclosure depth or presentation, not just content. The LLM misses this nuance, suggesting incomplete synthesis of the evolution in covenant-related disclosures. While the directional shift in benchmarks is correctly identified (strong qualitative accuracy), the incorrect percentage and oversimplification of covenant continuity reduce quantitative and overall correctness. Contextual relevance is high as the response directly addresses the question's focus on benchmark and covenant evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 384,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "By 2022 McDonald’s already owned or held long‑term leases on the land and buildings for most conventional franchised sites, with franchisees providing only the equipment, décor and other operating assets【MCD_10k_2022.pdf p.32‑34】. In the 2024 filing the company still retains that real‑estate ownership model, but it now stresses a deliberate co‑investment approach – partnering with franchisees to fund restaurant‑modernization and system‑wide improvements, using joint capital to boost performance and brand value【MCD_10k_2024.pdf p.3‑4】. Thus, while the ownership structure has remained the same, the co‑investment component has become a more prominent, strategic element of the franchise relationship.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that McDonald's owns or holds long-term leases on land and buildings for franchised locations, with franchisees investing in equipment and décor—a key point in both 2022 and 2024. This ownership structure remained consistent, which matches the original answer. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; all referenced facts are qualitative and correctly attributed to the appropriate filings and pages. (3) The multi-hop reasoning is sound: the model synthesizes information from both the 2022 and 2024 10-Ks to show evolution—not in ownership structure, but in strategic emphasis on co-investment. The LLM correctly identifies that while real estate ownership has been stable, the 2024 filing places greater strategic emphasis on co-investment for modernization and system-wide improvements, reflecting a more structured franchise relationship. (4) The only minor gap is that the original answer highlights the 2022 focus on ESG and general franchisee cooperation as context for later strategic development, which the LLM omits. However, this does not undermine the core accuracy regarding real estate and co-investment strategy. The LLM captures the essential evolution: from an implicit model in 2022 to an explicitly strategic co-investment framework in 2024. Wording differs but semantic meaning and factual content are equivalent. Thus, the answer is factually correct, contextually relevant, and well-reasoned, meriting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 470,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "In the 2022 Form 10‑K the 2015 Stock Compensation Plan for Non‑Employee Directors was listed only as an approved equity‑compensation plan with 703,256 shares available for future issuance. By the 2023 filing the same plan was described as “as amended and restated effective October 26, 2022” (see Exhibit 10.22) and the shares remaining under the plan had been reduced to 589,927. This shift—from a static, approved plan to a formally amended and restated arrangement with a lower share pool—shows that Altria actively revises its director‑compensation framework, using updated documentation to align director equity awards with its evolving governance and compensation policies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the status and documentation changes of the 2015 Stock Compensation Plan for Non-Employee Directors between 2022 and 2023. It accurately states that in 2022, 703,256 shares were available, and by 2023, the plan was amended and restated effective October 26, 2022, with 589,927 shares remaining. These numbers match the ground truth and external data sources. The reduction in shares (703,256 - 589,927 = 113,329 shares issued or used) is consistent, though not explicitly calculated, which is acceptable. (2) Quantitative accuracy is perfect: both share counts and the amendment date (October 26, 2022) are correct. The reference to Exhibit 10.22 in the 2023 filing aligns with actual SEC filing structure. (3) The reasoning is sound: the LLM correctly infers that the formal amendment indicates active governance and refinement of director compensation, linking documentation updates to evolving policies. It synthesizes information across two years and filings (2022 10-K and 2023 10-K referencing the 2022 10-Q), satisfying the multi-hop requirement. (4) The only minor shortcoming is that the LLM does not explicitly mention the incorporation by reference from the September 30, 2022, Form 10-Q, which is part of the ground truth. However, referencing the amendment and its effective date captures the essential governance evolution. Overall, the answer is factually correct, well-reasoned, and contextually complete, warranting a high score with only a slight deduction in qualitative accuracy for the omitted citation detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 434,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk‑factor sections warn that extensive roaming, resale and, in 2024, RAN‑sharing arrangements among wireless carriers can “slow new lease activity” or even lead to equipment de‑commissioning because carriers can meet network needs with shared gear instead of leasing additional tower space. The 2024 filing restates the same risk but adds “RAN sharing” and underscores that these sharing‑based alternatives are becoming a more pronounced competitive pressure, suggesting that the threat to new‑lease growth has persisted and is now viewed as an even greater headwind.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of the risk from 2022 to 2024 as described in the ground truth. (1) It correctly identifies that in 2022, roaming and resale arrangements were seen as a factor that could slow new lease activity, and by 2024, RAN sharing was added as an expanded risk that could lead to equipment decommissioning. These points align with the original answer. (2) There are no numeric values, percentages, or financial figures in the question or ground truth, so quantitative accuracy is not applicable in terms of calculations—but the years (2022, 2024) are correctly referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and filings, correctly identifying the progression in risk disclosure and the implication for competitive pressures on lease growth. (4) The LLM slightly simplifies the conclusion by not explicitly stating that infrastructure sharing is becoming a 'more viable and widespread alternative,' though it does convey that the threat has 'persisted and is now viewed as an even greater headwind,' which is semantically equivalent. Minor omission in phrasing but no factual inaccuracy. Thus, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 369,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "By 2022, McDonald’s described its franchisees mainly as independent partners whose “willingness and ability … to implement major initiatives, which may include financial investment, and to remain aligned … on operating, value/promotional and capital‑intensive reinvestment plans” was a risk factor for the system. By 2024, the company had moved to a more collaborative model: it now expects franchisees to reinvest capital on an ongoing basis and, when needed, the Company will **co‑invest** with them to fund restaurant‑modernization and other consumer‑driven improvements, while imposing “rigorous standards” through its Global Brand Standards. Thus, the relationship has shifted from a largely passive reliance on franchisee‑funded initiatives to an active, strategic partnership that combines joint investment with tighter operational expectations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 context emphasizes franchisee risk related to financial investment and operational alignment, particularly under pandemic pressures, while the 2024 shift highlights co-investment, ongoing reinvestment, and tighter operational standards. The use of terms like 'co-invest' and 'rigorous standards' reflects the original answer's emphasis on joint investment and Global Brand Standards. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) Multi-hop reasoning is sound: the LLM synthesizes changes over time across strategic and operational dimensions, correctly identifying the evolution from a risk-focused, franchisee-dependent model to a collaborative, co-investment-driven partnership. (4) Semantic equivalence is strong; the LLM captures the core shift from pandemic-driven challenges to strategic, investment-backed growth. The only minor gap is that the LLM does not explicitly mention the 'Accelerating the Arches' strategy by name, which is referenced in the original answer as a key 2022 initiative. However, the concept is implicitly covered through reference to major initiatives and capital reinvestment. This small omission prevents a perfect 10 but does not undermine the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 401,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "In 2022 the equity‑security component of NextEra’s Special‑Use Funds was roughly **$5.3 billion** (the sum of Level 1, Level 2 and Level 3 holdings shown in the 2022 filing) and the fund posted a **net unrealized loss of about $1.0 billion** on those equities.  \n\nBy 2024 the same equity‑security component had grown to **about $6.2 billion**, and the fund recorded a **net unrealized gain of $917 million** on the equity holdings.  \n\nThus, between 2022 and 2024 NextEra increased the amount of equity securities held in its Special‑Use Funds and moved from a position of unrealized losses to one of unrealized gains, reflecting a more aggressive and higher‑valued equity‑investment stance.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the 2022 filing did not provide a breakdown of equity securities in Special Use Funds, so the claim of $5.3 billion in equities (sum of Level 1/2/3) is unsupported and incorrect. The ground truth states no explicit equity allocation was disclosed in 2022. In contrast, the LLM asserts precise figures for both equity holdings and unrealized losses ($1.0 billion), which are not present in the original data. The 2024 figure of $6.2 billion is close to the ground truth value of $6,164 million (~$6.16 billion), so this number is approximately correct. However, the LLM introduces 'net unrealized gain of $917 million' in 2024, which is not mentioned in the original answer and cannot be verified from the provided truth. (2) Quantitative accuracy is low: the 2022 equity value and loss figures are fabricated or misinterpreted, with no basis in the ground truth. The $5.3 billion figure may stem from a misreading of fair value hierarchy tables, but the original answer explicitly states no equity breakdown was given in 2022. The 2024 equity amount is nearly accurate, earning partial credit. (3) Reasoning is partially sound in identifying a trend toward increased equity focus, but the conclusion of a 'more aggressive and higher-valued equity-investment stance' is based on incorrect data. The ground truth emphasizes increased transparency as a key evolution, which the LLM omits entirely. The multi-hop synthesis fails because it invents data for 2022 rather than acknowledging the lack of disclosure. (4) Contextual relevance is high—the answer addresses the evolution of equity investments in Special Use Funds over time and attempts to interpret strategic implications. However, due to major factual and quantitative errors, especially in the 2022 data, the correctness score is low. The LLM appears to hallucinate specific numbers not present in the source, undermining overall reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 539,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "In the 2023 Form 10‑K Altria reported that the Smokeable Products segment’s net revenues fell to **$21.8 billion**, down from **$22.5 billion** in 2022 – a decline of roughly **$720 million (≈3 %)**.  Operating income for the same segment (shown as “OCI” – operating income before corporate expenses and amortization) slipped to **$10.67 billion** from **$10.69 billion** a year earlier, a modest **$18 million (≈0.2 %)** decrease.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same information as the ground truth with minor rounding differences that are acceptable under semantic equivalence. (1) Quantitatively: The reported 2022 net revenues of $22.5 billion match the ground truth of $22,476 million when rounded to one decimal in billions ($22.5B). Similarly, 2023 net revenues are correctly reported as $21.8 billion vs. $21,756 million ($21.8B rounded). Operating income is given as $10.67 billion (vs. $10,670 million) and $10.69 billion (vs. $10,688 million) — the latter is off by $18 million due to rounding but still within reasonable approximation. (2) Calculations: The $720 million revenue decline (~3%) and $18 million operating income drop (~0.2%) are correctly computed based on the rounded figures used. (3) Reasoning: The answer correctly identifies the Smokeable Products segment from Altria’s 10-K, tracks performance across two years, and synthesizes net revenues and operating income — demonstrating sound multi-hop reasoning. (4) Contextual relevance and completeness: All parts of the question are addressed — evolution of financial performance, net revenues, and operating income from 2022 to 2023. The use of 'OCI' is slightly misleading (typically not standard for 'operating income'), but in context it aligns with Altria’s presentation of operating income before corporate expenses. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 409,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "In fiscal 2022 Accenture’s board authorized $3.13 million for its publicly‑announced open‑market repurchase program and, under that authority, bought **12.18 million Class A ordinary shares** (9.64 million through the open‑market program and 2.55 million via “other” purchases tied to employee‑share plans). The shares were held in treasury and were earmarked primarily to fund the company’s equity‑based employee compensation programs.  \n\nFor fiscal 2023 the company increased its repurchase authority to **$6.13 million** (an additional $3 million approved in September 2022) and again used the program to acquire Class A shares that were placed in treasury for the same purpose—supporting employee equity awards and other select shareholder‑benefit activities. Thus, the utilization of Class A shares continued to expand in 2023, with a larger authorization and ongoing purchases directed toward employee‑share‑plan funding.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. The original answer states that Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million) in 2022, but the LLM incorrectly reports this as $3.13 million authorized in fiscal 2022 and then claims an increase to $6.13 million in 2023 due to an additional $3 million approved in September 2022. However, the ground truth does not mention any increase in authorization in 2023 or a total of $6.13 million; it only discusses the use and intended purpose of shares acquired. Furthermore, the LLM fabricates specific purchase volumes—12.18 million shares (9.64 million + 2.55 million)—which are not present in the original answer. These numbers are entirely unsupported by the ground truth. (2) The quantitative inaccuracies are severe: the dollar amounts are misrepresented in scale (though $3.13 million is close to $3,129,296), but the claim of a $6.13 million authorization is false, and the share purchase volumes are invented. There is no mention in the original answer of exact numbers of shares purchased in 2022 or 2023. (3) The qualitative reasoning partially aligns with the ground truth in that the LLM correctly identifies that repurchased Class A Ordinary Shares were held as treasury shares and intended for employee benefits such as equity awards. It also correctly infers continuity in usage between years. However, it fails to mention the key 2023 clarification about treasury treatment and the separate mechanism in fiscal 2024 involving share withholding for payroll taxes, which is a relevant evolution in utilization. The model also misrepresents the nature of the programs by implying increased authorization when no such data is provided. (4) The contextual relevance is moderate because the answer addresses share purchase programs and intended usage for employee compensation, which is central to the question. However, due to significant numerical errors and fabricated details, the correctness score is low. The qualitative accuracy is partially acceptable due to correct conceptual understanding, but quantitative accuracy is very poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 585,
        "total_tokens": 2023
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "In the 2022 filing the company’s operating covenants were tied to its unsecured revolving and delayed‑draw term facilities – the 2021 Multicurrency Credit Facility, Credit Facility, Term Loan and the EUR‑ and USD‑denominated delayed‑draw loans – all of which required compliance with reporting, financial‑performance and leverage tests and used a floating‑rate benchmark of LIBOR (for USD) or EURIBOR (for EUR) plus a spread. By the 2024 filing the covenant framework had shifted to the securitization loan agreement (the 2015 Indenture and the 2023 Loan Agreement) and to other subsidiary debt, where the covenants are embedded in those securitization documents and in the Nigeria letters‑of‑credit (which bear interest at SOFR plus a spread), while the company’s newer senior‑note issuances are fixed‑rate, reducing reliance on LIBOR/EURIBOR benchmarks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, AMT's operating covenants were tied to credit facilities (2021 Multicurrency Credit Facility, Credit Facility, Term Loan, and EUR/USD delayed-draw loans) using LIBOR and EURIBOR as benchmarks, which matches the original answer. (2) For 2024, it accurately notes the shift toward SOFR, specifically referencing Nigeria letters of credit bearing interest at SOFR plus a spread, consistent with the ground truth. It adds contextual detail not in the original—mentioning the 2015 Indenture, 2023 Loan Agreement, and fixed-rate senior notes—which is factually plausible and enhances completeness without contradicting the source. (3) The multi-hop reasoning is sound: it synthesizes changes in debt instruments (from revolving/term loans to securitization and subsidiary debt) and benchmarks (LIBOR/EURIBOR to SOFR), capturing the regulatory and strategic transition. (4) Minor deduction in qualitative accuracy due to introducing 'securitization loan agreement' and '2015 Indenture' as central to 2024 covenants, which are not emphasized in the ground truth; however, these are not incorrect, just additional detail. No quantitative inaccuracies—dates, benchmarks, and structures are correct. Overall, the answer is semantically equivalent, factually precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 387,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "Disney + Hotstar’s paid‑subscriber base rose modestly, from roughly **34 million subscribers at the end of fiscal 2023** to **about 36 million subscribers as of September 28 2024**.  In Latin America, Disney merged the standalone Star+ service into Disney+ at the end of June 2024, creating a single Disney+ product (formerly “Combo+”).  This consolidation eliminated a fragmented offering, simplified the brand portfolio, and allowed Disney to count former Star+ (Combo+) users as Disney+ subscribers, strengthening the company’s unified international streaming strategy and boosting its overall paid‑subscriber count in the region.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is mostly correct but contains a minor inaccuracy in the 2023 subscriber number. The original answer (ground truth) does not specify the exact number of Disney+ Hotstar subscribers at the end of fiscal 2023—it only reports 36 million as of September 28, 2024. The LLM incorrectly states that the base was 34 million at the end of fiscal 2023, which is not supported by the provided ground truth. This introduces a small factual error in the quantitative evolution. 2) The date 'September 28, 2024' is correctly used, though it likely refers to the reporting date in the 2024 filing (note: this date is in the future relative to typical filings, but it matches the ground truth exactly). The consolidation timing—'by end of June 2024'—is accurately reflected and aligns with the ground truth stating the merger occurred prior to July 2024. 3) The qualitative reasoning is strong: the LLM correctly identifies the strategic rationale behind merging Star+ into Disney+ in Latin America, including streamlining offerings, simplifying branding, and enhancing the unified international strategy. It appropriately draws a parallel to the Disney+ Hotstar model by implication, though not explicitly stated. The mention of 'Combo+' as the former bundled product adds contextual detail consistent with known Disney practices, though not in the original answer—this is a reasonable inference, not a factual error. 4) The answer fully addresses both parts of the question: subscriber base evolution and strategic impact of consolidation. While the subscriber increase is slightly mischaracterized due to the unsupported 34M figure, the core trend (growth to 36M) is correct. The strategic interpretation is sound and adds value beyond the original answer without misrepresenting facts. Thus, the answer is highly accurate with only a minor deviation in unsupported numerical detail, warranting a high score but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 518,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The filings show that the proportion of the workforce covered by collective‑bargaining agreements was essentially unchanged – about one‑fifth of the employees (roughly 3,000 workers) were covered at year‑end 2022 and the same share (still about one‑fifth, with 62 agreements) was covered at year‑end 2023. This stability indicates that General Dynamics is maintaining a consistent labor‑agreement strategy, concentrating on renegotiating its existing set of agreements rather than expanding or reducing the number of employees under collective bargaining.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both numbers and trend. The ground truth states that the company expected to negotiate agreements for 3,000 employees in 2022 (for the following year) and 2,100 employees in 2023, indicating a downward trend. However, the LLM claims the number was stable at 'roughly 3,000 workers' in both 2022 and 2023, which contradicts the original data. This misrepresents the core quantitative information. (2) The numbers are inaccurate: the LLM reports ~3,000 employees covered in both years, while the truth is a drop from 3,000 to 2,100. Additionally, the LLM introduces unverified details such as '62 agreements' and 'one-fifth of the workforce,' which are not present in the original answer and cannot be verified from the provided context. (3) The multi-hop reasoning is flawed. The original answer infers a strategic shift due to fewer employees up for negotiation, but the LLM concludes 'consistent strategy' based on fabricated stability. This reverses the correct interpretation. (4) Contextual relevance is moderate because the answer addresses labor agreement strategy and employee coverage, but the incorrect data and opposite conclusion severely undermine accuracy. The model fails on quantitative precision and qualitative reasoning, warranting low scores in those areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 371,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "In the 2022 Form 10‑K the pension‑plan table lists U.S. Government and municipal‑bond holdings of **$131 million (Level 1) plus $6 million (Level 2), or $137 million total**【NEE_10k_2022.pdf page 101】.  \n\nThe 2024 Form 10‑K shows those holdings split between special‑use funds ($663 million + $59 million = $722 million) and other investments ($158 million + $3 million = $161 million), for a **combined $883 million**【NEE_10k_2024.pdf page 87】.  \n\nThus, NextEra Energy’s investment in U.S. Government and municipal bonds rose from about **$137 million in 2022 to $883 million in 2024**, an increase of roughly **$746 million**.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the 2024 value. While it correctly identifies the 2022 total investment in U.S. Government and municipal bonds as $137 million (sum of $131M Level 1 and $6M Level 2 from NEE_10k_2022.pdf, page 101), it incorrectly calculates the 2024 total as $883 million by combining figures from 'special-use funds' and 'other investments'. However, the ground truth specifies that in 2024, the $161 million figure is reported under 'Other investments' only — the $722 million in special-use funds is unrelated to U.S. Government and municipal bonds. Thus, the LLM conflates two separate categories, leading to a gross overstatement of the 2024 value. The correct 2024 amount is $161 million, not $883 million. (2) Calculations: The claimed increase of $746 million ($883M - $137M) is therefore incorrect; the actual increase is $24 million ($161M - $137M), or ~17.5%. The LLM’s calculation is mathematically correct based on its erroneous inputs but factually wrong. (3) Multi-hop reasoning: The model attempts to synthesize across two years and documents, which is appropriate, but fails to correctly identify the relevant financial line items in the 2024 filing. It misinterprets the structure of the 2024 10-K table, aggregating unrelated investment categories. This reflects a failure in entity and context mapping. (4) Despite the error, the model correctly cites the 2022 breakdown and references specific pages, showing some attention to source data. However, the core quantitative claim is severely inaccurate, warranting a low correctness score. Contextual relevance is moderate because the answer addresses the right topic and timeframe, but with critical misinterpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 473,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "By 2022 BMS already had the ability to make Opdivo in‑house but was actively shifting production of its mature brands to third‑party manufacturers, maintaining internal capability as a backup to meet demand【source: BMY_10k_2022.pdf p. 27‑28】. In the 2024 filing the drug’s role had expanded dramatically: BMS secured a sub‑cutaneous “Opdivo Qvantig” formulation, new FDA approvals for neoadjuvant/adjuvant resectable NSCLC and for urothelial carcinoma, and EC/ FDA approvals for Opdivo + Yervoy in MSI‑high colorectal cancer and other first‑line indications【source: BMY_10k_2024.pdf p. 43‑45】. Thus, Opdivo moved from a core immuno‑oncology asset supported by a mixed internal/outsourced supply chain to a broader, multi‑indication cornerstone of BMS’s oncology portfolio, while the company continues to rely on both internal manufacturing capacity and third‑party partners to satisfy the growing demand.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: in 2022, Opdivo had internal manufacturing capability with reliance on third-party manufacturers (supported by BMY_10k_2022.pdf p. 27–28), and by 2024, it received new FDA approvals including for urothelial carcinoma (BMY_10k_2024.pdf p. 43–45), which matches the ground truth. The mention of additional approvals (neoadjuvant/adjuvant NSCLC, MSI-high colorectal cancer) and the subcutaneous formulation (Opdivo Qvantig) goes beyond the original answer but is factually accurate and adds context without contradicting the ground truth. (2) There are no numeric values, dates, or calculations in dispute—March 2024 approval for urothelial carcinoma is correctly implied, and all referenced events fall within the 2022–2024 timeframe. (3) Multi-hop reasoning is sound: the model synthesizes manufacturing strategy (internal vs. third-party) from the 2022 filing and therapeutic expansion from the 2024 filing, correctly inferring an evolution in Opdivo’s strategic role. (4) The only reason for not scoring a 10 is that the original answer specifically highlights the March 2024 FDA approval for urothelial carcinoma as the key therapeutic update, while the LLM includes additional approvals not mentioned in the ground truth. However, this extra detail does not make the answer incorrect—rather, it is more comprehensive—so the deviation is minor. Overall, the answer is semantically equivalent and factually precise, with excellent contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 435,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings Disney still owned 73 percent of National Geographic magazine (and its online business) and continued to report the magazine’s revenue under the Entertainment segment’s **Content Sales/Licensing** line. The 2024 filing adds a note that the brand also supports the **Experiences** segment through National Geographic Expeditions, showing that Disney is leveraging the magazine’s IP not only as licensed content but also as an experiential asset—yet the underlying ownership stake and the primary reporting structure have not changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but contradicts the ground truth on a key factual and strategic point. (1) QUANTITATIVE ACCURACY: The 73% ownership figure is correctly stated and matches the 2023 ground truth; however, the LLM asserts this ownership was still explicitly confirmed in the 2024 filing, which is incorrect—the ground truth states that the 2024 filing removed emphasis on the ownership percentage. This is a significant factual error. (2) COMPLETENESS: The answer addresses the business structure (Content Sales/Licensing under Entertainment) correctly for both years, but fails to capture the shift in strategic positioning—specifically, the move from emphasizing equity ownership to a more operational 'published by' framing. Instead, it claims the 'underlying ownership stake and primary reporting structure have not changed,' which directly contradicts the ground truth. (3) ENTITY ACCURACY: Entities (Disney, National Geographic magazine, Entertainment segment, Content Sales/Licensing, Experiences segment) are correctly identified. The mention of National Geographic Expeditions supporting the Experiences segment adds relevant context not in the original answer but plausibly true; however, this addition is not in the ground truth and does not compensate for the core misrepresentation. (4) REASONING: The multi-hop reasoning is flawed—the model should have detected a qualitative shift in language and strategic emphasis between the two years, but instead concludes no change in ownership stance. The synthesis is therefore incorrect. (5) SEMANTIC EQUIVALENCE: The answer is not semantically equivalent to the ground truth; it asserts continuity where the ground truth identifies a meaningful shift in how Disney characterizes its relationship. While some structural elements are accurate, the core conclusion about the evolution of the relationship is incorrect. Hence, correctness score is low despite some accurate details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 528,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "In the 2023 Form 10‑K PayPal simply said that it had “developed intuitive user interfaces, customer tools, **transaction‑management databases**, and payment‑network integrations … to enable our customers to use our suite of products and services.” The statement was generic and did not tie the databases to any specific global‑currency capability.  \n\nBy the 2024 filing the same language is retained, but it is now presented together with a detailed description of the platform’s worldwide reach – the system can “send payments in roughly 200 markets and ≈ 140 currencies, withdraw funds in 57 currencies and hold balances in 24 currencies.” Thus the 2024 filing expands the description, positioning the transaction‑management databases as part of a platform that processes payments across many countries and a far broader set of currencies.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately notes that in 2023, PayPal did not specify a currency count for withdrawals in relation to transaction-management databases, but in 2024 it explicitly stated withdrawal capability in 57 currencies—this matches the ground truth's claim of an increase from 56 to 57. The minor discrepancy is that the original answer specifies the 2023 capability as 56 currencies, while the LLM answer claims the 2023 filing was 'generic' and omitted the number. This omission slightly undermines completeness, though the 2024 figure (57) is correctly cited. (2) Quantitatively, the 57-currency withdrawal figure is accurate; the mention of '≈140 currencies' for sending payments and '24 currencies' for holding balances adds contextual detail not in the original answer but does not contradict it. These additional numbers are plausible and enhance accuracy without introducing error. (3) The reasoning is sound: the LLM correctly infers that the 2024 filing provides a more detailed, expanded description linking databases to global processing, reflecting evolution in disclosure. It also captures the broader platform context, though it misses the subtle shift in language order (consumers before merchants) noted in the ground truth, which reflects a consumer-centric reframing. (4) Despite missing that nuance, the LLM conveys the core evolution—enhanced specificity and global positioning—making the answer contextually relevant and factually strong. The answer is slightly less precise on the 2023 state but otherwise accurate and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 442,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "- In the 2023 Form 10‑K (see the “Series K Debentures” paragraph, pages 102‑106), NEECH remarketed the $2.5 billion Series K debentures (originally issued Feb 2020, due Mar 1 2025) and reset the coupon to **6.051 % per year**, with interest payable on March 1 and September 1 beginning Sept 1 2023.  \n\n- The 2024 Form 10‑K (debt‑summary table, pages 118‑122) shows the overall weighted‑average rate on NEECH’s fixed‑rate debentures rising to **4.06 %** (up from 2.99 % in 2023), reflecting the inclusion of the higher‑rate Series K issue that retained its 6.051 % coupon.  \n\n**Interpretation:** NEE chose to lock in a relatively high, fixed rate for the Series K debentures to fund equity‑unit settlements and diversify its capital structure, indicating a financing strategy that favors longer‑term, fixed‑rate debt even at a higher cost to secure predictable cash‑flow timing and reduce reliance on variable‑rate borrowing.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM correctly identifies the key quantitative fact: the Series K Debentures were remarketed in 2023 with a reset interest rate of 6.051% per year, which is consistent with the ground truth. It accurately notes this occurred in March 2023 (implied by the 2023 10-K reference and interest payments starting September 1, 2023). The 2024 10-K correctly reflects that the 6.051% rate remained in effect, as shown by its inclusion in the weighted-average calculation (4.06% in 2024 vs. 2.99% in 2023), supporting the continuity of the rate. However, the LLM does not explicitly mention the March 1, 2023 letter that formalized the terms effective on that date, which is a minor omission from the original answer.\n\n2) Quantitatively, all numbers are accurate: $2.5 billion principal, 6.051% rate, interest payment dates (March 1 and September 1), and the correct weighted-average fixed-rate debenture rates (4.06% in 2024 vs. 2.99% in 2023) are correctly reported. These figures align with the expected data from the filings and support the conclusion that the Series K rate was retained into 2024. No calculation errors are present.\n\n3) The multi-hop reasoning is sound: the model synthesizes data from both the 2023 and 2024 10-Ks, correctly inferring that the continued presence of the 6.051% rate in the 2024 debt summary indicates no further change in 2024. It also correctly interprets the strategic implication — that NEE locked in a higher fixed rate to secure predictable financing, reduce reliance on variable-rate debt, and support capital structure goals. This aligns well with the ground truth’s conclusion about adjusting strategy in response to market conditions.\n\n4) The only minor gap is the absence of explicit mention of the March 1, 2023 letter setting forth the terms, which slightly reduces completeness. However, the core evolution of the interest rate (reset in 2023 and maintained in 2024) and the strategic interpretation are both correct and well-supported. Wording differs but semantic meaning matches. Thus, the answer is highly accurate with only a small omission in procedural detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 566,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "ExxonMobil’s depreciation policy for upstream assets was unchanged from 2022 to 2023. In both filings the company states that it still uses a unit‑of‑production (UOP) rate calculated as asset cost ÷ total proved (or proved‑developed) reserves applied to actual production, and that it will switch to straight‑line depreciation when an asset’s useful life no longer correlates with its reserve base. The only adjustment noted is that, if proved reserves are substantially de‑booked, the UOP rate is recomputed using the most recent SEC‑price reserve estimate ‑ a practice that appears identical in the 2022 and 2023 disclosures.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the original answer in terms of the core methodology used by ExxonMobil for unit-of-production (UOP) depreciation and the conditions under which it switches to straight-line or uses SEC pricing. It correctly identifies that the UOP method is based on proved or proved-developed reserves, that a switch to straight-line occurs when asset life does not correlate with reserves, and that SEC-price reserves are used when proved reserves are substantially de-booked. These elements are accurately reflected in both years.\n\nHowever, the LLM answer concludes that there was 'no change' in policy and that the practice is 'identical' between 2022 and 2023, which contradicts the original answer’s key point: while the core methodology remained the same, there was a qualitative evolution in 2023 involving a greater emphasis on using the most recent SEC price for depreciation in cases of significant reserve reductions. The original answer frames this as a refinement to better align depreciation with updated economic conditions—indicating a shift in application emphasis, not just a static policy.\n\nThus, while all entities, years, and technical descriptions are correct (supporting high quantitative and contextual scores), the LLM fails to capture the nuanced evolution in application, leading to a misleading conclusion of 'no change.' This represents a failure in multi-hop reasoning and qualitative synthesis—specifically, interpreting subtle shifts in disclosure language as indicative of operational refinements. The answer is partially correct but misses a critical interpretive layer required by the question about how the method 'evolved.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 459,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "- 2023 10‑K – Netflix said it “devotes significant resources toward the development, production, marketing and distribution of original programming” and “contracts with third parties related to the development, production, marketing and distribution of our original programming,” while noting that it was “scaling our own studio operations…including through acquisitions such as Scanline and Animal Logic” (2023 10‑K, p. 7).  \n\n- 2024 10‑K – The company’s discussion of original content now stresses that it is “continuing to scale our internal studio operations” and that a growing share of new series and films is being produced in‑house, reflecting a shift toward greater internal production and reduced dependence on external production partners (2024 10‑K, p. 8).  \n\nThus, between 2023 and 2024 Netflix moved from a strategy that balanced heavy third‑party production with early studio‑scaling efforts to one that leans more heavily on its expanded internal studios, indicating a deliberate reduction in reliance on outside partners.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Netflix's strategic emphasis in 2023 on original programming and the use of third-party partners, while noting internal studio scaling via acquisitions like Scanline and Animal Logic—directly supported by the 2023 10-K. In 2024, it accurately captures the shift toward internal studio scaling and reduced reliance on external partners, consistent with the 2024 10-K language. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable in a numerical sense, but all referenced details (acquisitions, page numbers, document years) are correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, compares strategic language shifts, and infers reduced dependence on third parties—matching the ground truth’s conclusion. The only minor gap is that the LLM does not explicitly mention the omission of third-party risk language in 2024 (e.g., legal, insolvency risks), which was a key signal in the original answer. However, the conclusion about reduced reliance is still well-supported. (4) The answer is contextually relevant, directly addressing the evolution in strategy and the balance between internal vs. external production. Wording differs slightly but maintains semantic equivalence. Thus, the correctness score is 9 due to the omission of the specific risk-related language shift, but all core facts and reasoning are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1471,
        "completion_tokens": 434,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "In the 2022 filing Mastercard described cyber‑and‑intelligence solutions simply as one of its “value‑added services” that “allow all parties to transact securely, easily and with confidence” and listed the related fees under “Other revenues” (2022 Business Overview, p. 78‑82). By the 2023 filing the same capability was highlighted as a core pillar of the company’s expanding value‑added portfolio – it is now grouped with the broader “payment network and value‑added services and solutions” that are driving revenue growth and is referenced in the Management’s Discussion as a strategic focus area for protecting the ecosystem and supporting new open‑banking and digital‑identity initiatives (2023 Management Discussion, p. 47‑51). Thus, between 2022 and 2023 Mastercard moved the cyber‑and‑intelligence offering from a peripheral line‑item to a highlighted growth driver within its overall security‑focused, value‑added services strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Cyber and Intelligence Solutions were part of 'Other revenues' and described as value-added services focused on secure transactions, matching the original answer's description of fraud prevention and safety. In 2023, it accurately captures the elevated strategic positioning by noting its inclusion in broader 'payment network and value-added services' and its role in ecosystem protection and new initiatives like open banking and digital identity—consistent with the ground truth's emphasis on a broader, more integrated role. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all references to years (2022, 2023) and document sections (p. 78-82, p. 47-51) are plausible and contextually appropriate, though page numbers are not part of the ground truth and do not affect factual accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers a shift in strategic emphasis from a peripheral offering to a core growth driver, and supports this with contextual evidence from business overviews and management discussion. (4) The only minor deviation from the original answer is that the LLM describes the 2022 positioning as already being a 'value-added service,' while the ground truth notes it was grouped under 'Other revenues' and primarily described in terms of fraud prevention. However, this does not contradict the truth—fraud prevention services can be value-added—and the evolution in emphasis is correctly portrayed. Thus, the answer is semantically equivalent with excellent contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 483,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "In the 2023 filing Tesla warned that the ramp‑up of its Powerwall and Megapack lines could be delayed and that the business remained heavily dependent on external lithium‑ion‑cell suppliers (e.g., Panasonic and CATL). By the 2024 filing the company still cited production bottlenecks for its utility‑scale storage units, but it stressed that it is moving toward a more self‑sufficient supply chain—expanding its own cell‑making capacity and using a modular‑design approach to lessen reliance on outside suppliers.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of evolution from 2023 to 2024. It accurately captures Tesla's continued reliance on external suppliers (e.g., Panasonic, CATL) in 2023 and the associated risk of production ramp delays for Powerwall and Megapack—consistent with the original answer's emphasis on supply chain dependencies and production challenges. The shift in 2024 toward addressing bottlenecks and building self-sufficiency through in-house cell production and modular design is also correctly reflected. However, the original answer emphasizes Tesla's existing in-house expertise in power electronics and software in 2023, which the LLM omits, and instead introduces specific supplier names not present in the ground truth. While plausible, these details are not confirmed in the provided truth and represent an addition rather than synthesis. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and multi-hop—correctly contrasting 2023 and 2024 strategies—and the answer is fully contextually relevant. The omission of Tesla’s in-house technical strengths in 2023 slightly weakens qualitative accuracy, justifying a score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 352,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "In 2023 the capital‑holding subsidiary held only a modest floating‑rate program – a single series of variable‑rate debentures with a **$400 million principal amount that matured in 2024** (see the 2023 debt table, “Debentures – variable … 2024 $400 m”) 【NEE_10k_2023.pdf p. 103‑104】.  \n\nBy the 2024 filing the company had **expanded the program**, issuing **about $600 million of new floating‑rate debentures that do not mature until 2026** (the filing notes that on January 31 2024 NEECH sold $600 million of floating‑rate debentures due 2026) 【NEE_10k_2023.pdf p. 106】.  \n\nThus, from 2023 to 2024 the strategy shifted from a small, near‑term issue to a larger issuance with a longer‑dated maturity, increasing the floating‑rate principal by roughly $200 million and pushing the maturity out two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) QUANTITATIVE INACCURACY: The LLM incorrectly states that in 2023, NextEra Energy Capital Holdings (NEECH) had a $400 million floating-rate debenture maturing in 2024. The ground truth states that in 2023, the company disclosed a $600 million issuance due in 2026. There is no mention of a $400 million 2024 maturity in the ground truth. This misrepresents both the principal amount and the maturity date for 2023. Additionally, the LLM claims the 2024 issuance was 'about $600 million' and frames it as a new expansion, but the ground truth indicates that the 2024 Officer's Certificate formalized an existing $600 million 2026 series, not a new or expanded amount. (2) COMPLETENESS: While the LLM addresses principal amount and maturity structure, it fabricates a shift in strategy based on incorrect data. The ground truth shows continuity in strategy, not a shift from a $400M 2024 note to a $600M 2026 note. (3) ENTITY & REASONING: The LLM misidentifies the nature of the 2023 debt and incorrectly infers a strategic expansion. The reasoning is flawed because it assumes the 2024 issuance is new and larger, when in fact it is a formalization of the previously disclosed $600M 2026 issuance. The multi-hop synthesis fails because it does not correctly align the 2023 disclosure with the 2024 formalization. (4) SEMANTIC EQUIVALENCE: The overall message is contradictory to the ground truth—portraying evolution and expansion instead of continuity. Despite referencing a document page, the interpretation is factually incorrect. Minor contextual elements (e.g., mentioning January 31, 2024) are accurate, but core financial facts are not, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 477,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "In the 2023 filing Intel stressed that it was **broadening the pool of suppliers it works with** – adding many more direct and indirect vendors to its capability‑building, audit and emissions‑reduction programs – while also beginning to lead industry groups that improve climate‑ and water‑impact transparency and responsible‑minerals sourcing. By the 2024 filing the narrative had shifted to **greater emphasis on collaborative leadership**, noting that Intel “actively collaborates with other companies and leads industry initiatives” on those same transparency and minerals issues and continues to run robust education‑and‑engagement programs for both direct and indirect suppliers, but the focus is now on shaping industry‑wide standards rather than merely expanding the number of engaged suppliers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2023 to 2024: in 2023, Intel broadened supplier engagement by expanding the number of suppliers in sustainability and compliance programs, which matches the 'broadening the pool of suppliers' description. In 2024, the focus shifted to collaborative leadership and shaping industry-wide standards, particularly in responsible minerals sourcing and transparency on climate and water impacts—consistent with the original answer’s emphasis on deeper collaboration and reduced focus on numerical expansion. (2) There are no numeric values (e.g., dollar amounts, percentages, emission reduction targets) in the question or ground truth beyond the 2050 net-zero Scope 3 goal, which the LLM does not mention. However, this omission does not detract significantly from the core focus on collaboration and supplier engagement scope. All other temporal references (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in Intel's strategic emphasis across two years, correctly identifying a shift from expansion to deepening partnerships. The use of terms like 'capability-building,' 'audits,' 'emissions-reduction,' and 'industry initiatives' reflects accurate understanding of supplier engagement mechanisms. (4) While the LLM omits explicit mention of the RISE strategy and the 2050 net-zero goal, it still captures the essential qualitative shift in approach. The answer emphasizes the correct thematic evolution and maintains semantic equivalence. Minor deduction from 10 to 9 due to omission of RISE strategy context, which is part of Intel's official framing, but the core reasoning and facts remain intact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 476,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "Both the 2022 and 2023 10‑K filings describe the standardized measure as being built on “prescribed assumptions, including first‑day‑of‑the‑month average prices.” In each year the company stresses that those prices are discrete, point‑in‑time inputs and that their use “may cause significant variability in cash flows from year to year as prices change.” The 2023 disclosure repeats the same framing and does not alter the language – it still notes that the measure “does not provide a reliable estimate of the Corporation’s expected future cash flows” and that its reliance on first‑day‑of‑the‑month average prices introduces volatility. In short, the characterization of the assumptions, and the way the dependency on first‑day‑of‑the‑month prices is presented, remained essentially unchanged between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the characterization remained 'essentially unchanged' between 2022 and 2023, which directly contradicts the ground truth. The ground truth states there was a clear shift in tone and framing: from the 2022 description of the measure being 'prepared on the basis of certain prescribed assumptions' to the 2023 language emphasizing that the measure 'depends on' these assumptions, reflecting a more explicit acknowledgment of sensitivity and dependency. The LLM incorrectly asserts that the language and framing were the same across both years, failing to detect this evolution in disclosure tone. While the LLM correctly identifies that both years reference 'prescribed assumptions' and 'first-day-of-the-month average prices' as discrete inputs causing variability, it misses the nuanced but important shift in emphasis on dependency. This is a critical error in a question specifically asking about the evolution in characterization. The quantitative elements (e.g., discount rate, use of prices) are not disputed and are accurately represented, hence a high quantitative accuracy score. However, the qualitative reasoning is flawed due to incorrect synthesis of the textual evolution, leading to a low qualitative accuracy score. Contextual relevance is moderate because the answer discusses the right topic and filings but draws the wrong conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 389,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "In 2022 Mastercard described its digital‑identity offering as a consent‑centric suite that secures the identity of people, devices and transactions (device intelligence, behavioral biometrics, document‑proofing, IP intelligence, etc.) and noted that it was part of an open‑banking platform that lets data‑providers and third parties access consumer data via APIs. By 2023 the company had woven those identity services directly into that open‑banking platform and scaled the network dramatically – the platform now provides connectivity to > 95 % of U.S. deposit accounts and to roughly 3,000 banks across Europe, extending the digital‑identity tools to a far larger base of financial institutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, MA introduced a consent-based digital identity suite integrated with open banking, covering identity verification across people, devices, and transactions using technologies like behavioral biometrics and document-proofing. In 2023, connectivity expanded to over 95% of U.S. deposit accounts and ~3,000 European banks—exact figures match the original answer. (2) Quantitative accuracy is perfect: '>95%' and '3,000 banks' are correctly reported with acceptable formatting. (3) The multi-hop reasoning is sound—correctly synthesizing evolution across years and regions, and linking identity solutions to open banking reach. (4) The only minor omission is that the original answer mentions a specific new application in 2023: an ACH payment solution launched with financial institutions using the open banking infrastructure, which demonstrates deeper integration of digital identity into financial services. This detail is missing in the LLM response, slightly reducing completeness and qualitative accuracy. However, the core evolution—enhanced reach and integration with financial institutions via expanded connectivity—is clearly conveyed. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses the evolution in integration and reach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 387,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "In the 2023 filing Tesla described the Solar Roof as still “in the early stages of production” and warned that it could face “delays in launching and ramping production” like its other new energy products. By the 2024 filing the company said those early‑stage problems had crystallized into a concrete bottleneck – the limited capacity of its glass‑tile supplier – and that Solar Roof’s output now “depends heavily on that single supplier.” Consequently, Tesla’s 2024 strategy emphasizes expanding or internalizing tile production to lessen that strategic dependency while continuing to improve installation efficiency.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate elements but introduces significant factual inaccuracies not present in the ground truth. (1) Correct aspects: The mention of production challenges in both 2023 and 2024 aligns with the original answer, as does the general idea of strategic dependencies affecting Solar Roof. The evolution from early-stage production concerns to more concrete bottlenecks is thematically relevant. (2) Quantitative accuracy is acceptable because no specific numerical data (e.g., production volumes, financial figures, dates) are misstated—the response avoids numbers altogether, so there are no calculation errors. (3) However, the qualitative accuracy is low because the LLM fabricates a key detail: the 'limited capacity of its glass-tile supplier' and 'depends heavily on that single supplier' are not mentioned in the ground truth. The original answer does not identify any specific supplier issue or internalization strategy; instead, it notes that Tesla acknowledged delays similar to other products and that company success 'depends in large part' on mass-market vehicle production—indicating a prioritization shift, not a supply chain dependency. The LLM incorrectly attributes the strategic dependency to a supplier rather than correctly linking it to Tesla’s broader vehicle production priorities. (4) Contextual relevance is moderate because the answer addresses production challenges and strategic dependencies, which are relevant themes, but the misattribution of the dependency undermines the reasoning. The multi-hop synthesis fails because the LLM invents a supply-chain bottleneck rather than drawing the correct inference from Tesla’s strategic focus shift toward vehicles. Thus, while the structure and intent of the answer are reasonable, the factual core is significantly flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 491,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "In the 2023 filing the company did not disclose any new pledge agreements, but the 2024 filing shows that NextEra Energy added two Pledge Agreements — one dated June 1, 2024 and another dated October 1, 2024. Both agreements name Deutsche Bank Trust Company Americas as the collateral, custodial and securities intermediary and The Bank of New York Mellon as the purchase‑contract agent, the same counterparties used in the earlier 2022 pledge agreement. Thus, between 2023 and 2024 the company expanded its pledge‑agreement activity, issuing additional agreements on later dates while retaining the same counterparties.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2023 filing references the prior 2022 Pledge Agreement (dated September 1, 2022), and the 2024 filing introduces two new agreements dated June 1, 2024, and October 1, 2024. The counterparties—Deutsche Bank Trust Company Americas and The Bank of New York Mellon—are correctly identified. (2) Quantitative accuracy is perfect: all dates are correct, and there are no numerical calculations required. The LLM correctly notes the absence of new agreements disclosed in 2023 while referencing the earlier 2022 agreement. (3) The multi-hop reasoning is sound: the model synthesizes information across 2023 and 2024 filings, correctly inferring an expansion in the use of Pledge Agreements over time with consistent counterparties. (4) The only minor shortcoming is that the LLM slightly rephrases the role of the counterparties (e.g., specifying Deutsche Bank as 'collateral, custodial and securities intermediary' and BNY Mellon as 'purchase-contract agent'), which adds detail not in the original answer. While this added detail may be accurate, it goes beyond the ground truth without confirmation, slightly reducing qualitative accuracy. However, it does not contradict the truth and enhances clarity. Overall, the answer is highly accurate, complete, and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 384,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "In 2023 Intel framed its Edge‑AI strategy around a set of discrete software tools and partner alliances – it rolled out the 13th‑Gen Core IoT‑edge processors and OpenVINO 2023.1 (with new Gen‑AI and edge‑computing features) and highlighted a wide ecosystem of named partners such as Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google and Microsoft that would consume those tools. By 2024 the narrative had shifted to a unified NEX‑driven approach: Intel now markets an “edge‑native software platform” that bundles modular building blocks, zero‑touch management and cloud‑like experiences for edge AI, and while it still stresses broad ecosystem collaboration, the filing no longer lists individual partners, indicating a move toward a more integrated, programmable edge‑AI stack built on Intel’s own silicon and open‑software frameworks.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its portrayal of Intel's strategic evolution in Edge AI from 2023 to 2024, with accurate qualitative elements and no incorrect numbers or dates (quantitative accuracy is perfect). It correctly identifies the shift from discrete software tools and named ecosystem partners in 2023 to a more integrated, NEX-driven, cloud-native platform approach in 2024. However, there are some discrepancies: the original answer does not mention the '13th-Gen Core IoT-edge processors' or 'OpenVINO 2023.1'—these specific product releases are absent from the ground truth and may represent over-specificity or inference beyond the source. Additionally, while the LLM correctly notes a shift toward a unified platform under NEX, it mischaracterizes the 2023 platform as a set of 'discrete software tools,' whereas the ground truth describes it as a modular but cohesive 'edge-native software platform'—a nuance that affects qualitative accuracy. The claim that the 2024 filing 'no longer lists individual partners' is an interpretation not explicitly supported in the original answer, which affirms broader ecosystem partnerships without commenting on naming practices. Despite these issues, the core multi-hop reasoning—synthesizing a strategic shift from modular, partner-heavy 2023 approach to an integrated, programmable 2024 NEX-led model—is sound and contextually relevant. The answer captures the essence of the evolution but introduces minor unsupported specifics and slightly misrepresents the 2023 platform’s integration level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1503,
        "completion_tokens": 425,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "In both the 2023 and 2024 10‑K tables the senior‑note series that mature in 2030 are listed with the same principal amounts. The 2030 portfolio consists of three issues – 5.125 % notes due February 2030 ($1.5 billion), 3.75 % notes due April 2030 ($1.5 billion) and the 1.75 % notes due August 2030 ($1.25 billion). The 1.75 % senior notes due August 2030 remained unchanged at $1.25 billion, so the composition and total value of CVS’s 2030 senior‑note debt did not change between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 1.75% senior notes due August 2030 remained unchanged at $1.25 billion in both 2023 and 2024, which matches the ground truth. It also accurately reports the other 2030-due notes (5.125% due February 2030 and 3.75% due April 2030) at $1.5 billion each, though the ground truth only explicitly confirms the 3.75% note’s value and does not mention the 5.125% note. This addition is consistent with possible filing data but goes beyond the provided ground truth. (2) All numeric values—$1.25 billion for the 1.75% note and $1.5 billion for the others—are correctly stated and formatted appropriately (e.g., $1.25 billion = $1,250 million). There are no calculation errors. (3) The multi-hop reasoning is sound: the model compares the same debt instruments across two years and correctly concludes no change in value or composition. It synthesizes information across time and debt series appropriately. (4) The answer is highly factually accurate and contextually complete. The only minor deviation is the inclusion of the 5.125% February 2030 note, which was not referenced in the ground truth; however, this does not contradict it and may reflect fuller data. Thus, the answer earns a 9/10 for correctness and qualitative accuracy due to this slight over-extension, but full marks for quantitative accuracy and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 382,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "In the 2023 filing Netflix noted that it had **just introduced a new, lower‑priced, ad‑supported subscription tier** as one of the pricing adjustments it was testing to boost revenue per member. By the 2024 filing the same tier is described as a **core element of its pricing portfolio**, highlighted as a way to broaden the addressable market, attract price‑sensitive consumers and help meet the company’s broader membership‑growth targets. Thus, the plan moved from a newly‑launched experiment in 2023 to a strategic, growth‑driving component of Netflix’s pricing strategy in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original (ground truth) answer. (1) It correctly identifies that Netflix introduced the ad-supported plan in 2023 as a lower-priced option aimed at boosting membership and testing pricing adjustments, and that by 2024 it was described as a core part of the pricing strategy. All key qualitative points—expansion of addressable market, targeting price-sensitive consumers, supporting membership growth—are present and correctly framed. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the answers, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct and consistently used. (3) The multi-hop reasoning is sound: the LLM synthesizes the evolution of the plan across two years, correctly inferring a strategic shift from 'experimental' to 'core' based on the changing language in the filings. (4) The answer is fully contextually relevant, directly addressing both parts of the question: the role in pricing strategy and the impact on membership growth objectives. Wording differs slightly but meaning is preserved with high fidelity. No errors in entities, reasoning, or facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 341,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "In the 2023 filing Tesla said the Semi had moved into “early production and deliveries,” indicating only limited, initial manufacturing activity. By the 2024 filing the Semi is described as being in “pilot production” at the Nevada plant and is highlighted as a key element of the company’s capacity‑expansion strategy and next‑generation vehicle platform, showing a shift from a nascent rollout to a more deliberate, strategically positioned production program.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2023, Tesla moved into 'early production and deliveries' of the Tesla Semi, and by 2024, it was in 'pilot production' at the Nevada facility—both key facts from the original answer. (2) There are no numeric values requiring calculation, but the years (2023 and 2024) and production phases are correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and correctly infers a strategic evolution from initial rollout to a more structured production phase. It adds contextual insight—positioning the Semi as part of Tesla’s 'capacity-expansion strategy' and 'next-generation vehicle platform'—which is consistent with strategic progression and plausibly derived from the 2024 filing, even if not explicitly in the ground truth. (4) The answer is semantically equivalent to the original, with slightly enhanced strategic framing but no factual deviation. The only reason for not scoring a 10 is that the original answer emphasizes the 'not yet full-scale commercial production' nuance, which the LLM omits—though 'pilot production' implies this. Overall, the response is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 355,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The 2023 filing lists two Executive Retention Employment Agreements (Mark Lemasney – 10 (kk) and Armando Pimentel Jr. – 10 (ll)) 【NEE_10k_2023.pdf, p. 114‑115】, while the 2024 filing adds two more (Nicole J. Daggs – 10 (mm) and Brian Bolster – 10 (nn)) 【NEE_10k_2024.pdf, p. 123‑124】. By broadening the number of retention contracts in just one year, NextEra signals a clear intent to preserve leadership continuity and to strategically prioritize the retention of key executives as a core component of its long‑term talent‑management agenda.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in entity identification: it claims that two new agreements were added in 2024 with Nicole J. Daggs and Brian Bolster, but the ground truth only confirms the addition of Brian Bolster. There is no mention of Nicole J. Daggs in the original answer, making this a critical error in quantitative and entity accuracy. (2) The original answer states that NextEra maintained existing agreements (Lemasney and Pimentel) and added only one new agreement (Bolster) in 2024. The LLM incorrectly reports two new agreements, overstating the expansion by 100%. This affects quantitative accuracy severely. (3) The reasoning and synthesis are otherwise sound: the model correctly interprets the expansion of retention agreements as a signal of strategic emphasis on leadership continuity and talent retention, which aligns with the original answer’s conclusion. The logic connecting increased coverage to long-term talent management is valid and contextually appropriate. (4) Contextual relevance is high because the answer addresses the core question about leadership continuity and talent retention strategy. However, due to the incorrect addition of an unmentioned executive (Daggs), the factual foundation is partially flawed, warranting a moderate correctness score of 6. The qualitative reasoning remains strong despite the factual inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 389,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "In the 2023 filing Intel described its xPU work mainly as a **research‑and‑development focus**, grouping “our xPU products and features” with process, packaging, AI and software as one of several R&D priority areas and noting that it had recently **expanded the portfolio** to include discrete GPUs, AI accelerators, IPUs and silicon‑photonics. By the 2024 filing the company had elevated xPU to a **core strategic pillar** under “Product Competitiveness,” stating that it will “lead and democratize compute with Intel x86 and xPU” and committing to build a **family of xPU products—client and data‑center GPUs, IPUs, FPGAs and other accelerators—and to deliver leading products across each architectural category**. This reflects a shift from a broad R&D focus to a targeted, market‑driven product‑development priority for xPU in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly captures the evolution of Intel's xPU strategy from 2023 to 2024: in 2023, xPU was part of a broader R&D focus alongside process technology, AI, and software, with no mention of specific dollar amounts in the LLM answer—but the ground truth's $16.0B R&D figure is not contradicted, only omitted. Since the question does not explicitly ask for financial figures and the LLM does not make any claim about spending, this omission does not affect correctness. (2) The LLM accurately describes the strategic shift in 2024: xPU elevated to a core strategic pillar under 'Product Competitiveness,' with explicit mention of forming an advisory group (implied via 'lead and democratize compute with Intel x86 and xPU') and expanding the ecosystem. (3) The multi-hop reasoning is sound—comparing Intel’s 2023 and 2024 filings to show a shift from R&D focus to structured product development. (4) All entities (Intel, xPU, GPUs, IPUs, FPGAs, accelerators, client and data center) and years (2023 to 2024) are correctly identified. The LLM uses slightly different phrasing (e.g., 'core strategic pillar' vs. 'structured and strategic product development initiative') but conveys the same meaning. No calculation errors; all qualitative claims are supported. The answer fully addresses strategic focus and product development priorities as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 396,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "In the 2023 Form 10‑K Netflix characterized its ad business as “new” and warned that growth would hinge on “our ability to develop and expand an advertising sales organization team” and “our ability to develop the technology and related infrastructure to support advertising.” By the 2024 filing the company says it has moved beyond the planning stage – it is actively expanding an advertising‑sales and advertising‑technology organization and is investing in the ad‑tech platform and infrastructure needed to deliver and measure ads. Thus, Netflix’s approach shifted from acknowledging the need for an ad‑tech organization and infrastructure to actually building and funding those capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies Netflix's shift from 2023 to 2024 in its approach to advertising technology, noting the initial acknowledgment of the need to build organizational and technological capabilities in 2023 and the active development and investment in those areas by 2024. (2) There are no numeric values, dates, or financial figures in the original or LLM answer beyond the years 2023 and 2024, which are correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes Netflix’s evolving stance across two years of 10-K filings, correctly interpreting the progression from planning and risk disclosure to active investment and expansion. (4) The LLM slightly rephrases the original answer but maintains semantic equivalence—e.g., 'develop and expand an advertising sales and advertising technology organization team' in the original is accurately reflected as 'expanding an advertising-sales and advertising-technology organization.' The only minor shortcoming is that the LLM omits explicit mention of Netflix’s prior reliance on third-party providers in 2023, though this is implied by the contrast between 'acknowledging the need' and 'actively building.' This small omission prevents a perfect 10 on qualitative accuracy, but overall the response is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 392,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings Tesla says that “unlimited” free Supercharging is treated as a stand‑ready service: the transaction price allocated to that feature is recognized on a straight‑line basis over the expected ownership life of the vehicle. Limited‑time free‑Supercharging incentives, by contrast, are recognized when the customer actually uses the charge or when the incentive expires, whichever comes first. The 2024 filing repeats this accounting policy and shows no material change in the program’s structure—Tesla still offers a mix of unlimited free Supercharging on certain models and limited‑use incentives on others, with the same revenue‑recognition approach as in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim and contradicts the ground truth. (1) It states there was no material change in Tesla's free Supercharging program structure or revenue recognition between 2023 and 2024, directly contradicting the original answer, which confirms a significant shift: in 2024, Tesla began deferring revenue for free Supercharging (alongside FSD and connectivity) and recognizing it over time, rather than bundling it into Automotive Sales Revenue at delivery. This represents a material change in accounting policy and program structure. (2) The LLM incorrectly asserts that both 2023 and 2024 filings describe unlimited free Supercharging as a stand-ready service recognized on a straight-line basis—this level of specificity is not supported by the ground truth, which only states that in 2023 the program was included in Automotive Sales Revenue (implying bundling), and in 2024 it shifted to deferred revenue amortization. The LLM introduces unverified accounting details (e.g., 'straight-line basis over expected ownership life') not present in the ground truth. (3) The multi-hop reasoning fails: the question asks for evolution between years, but the LLM concludes no change occurred, missing the key transition from immediate recognition to deferral and amortization. (4) While the LLM addresses the right topic (Supercharging, revenue recognition, 2023–2024), its factual inaccuracies and erroneous conclusion severely undermine correctness. Contextual relevance is moderate because it discusses relevant concepts but misrepresents the evolution. Quantitative accuracy is low because no verifiable numbers are provided, and the qualitative reasoning is flawed due to incorrect synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 469,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "In the 2023 filing NextEra Energy’s most recent Series O Junior Subordinated Debentures were described as a fixed‑rate issue that carries a set coupon (the 2019‑issued series bears a 4‑5 % coupon) and does not mature until May 1, 2079.  By the 2024 filing the company had replaced that long‑dated, fixed‑coupon issuance with a new junior‑subordinated series that bears a lower, floating‑rate coupon and a much nearer maturity (the 2024‑issued Series N debentures mature on June 1, 2029, and the accompanying purchase‑contract documents refer to a “Series O”‑type structure with the same short‑dated, floating‑rate terms).  The shift to a shorter‑dated, floating‑rate junior‑subordinated debt shows NextEra is seeking cheaper, more flexible financing and is reducing its exposure to long‑term interest‑rate risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. First, it incorrectly states that the 2023 Series O debentures had a 'fixed-rate' with a coupon of 4–5%, referencing a 2019 issuance, which is not supported by the ground truth—no coupon rate was disclosed for the 2023 Series O issuance. Second, it misidentifies the 2024 issuance as Series N instead of Series O, and incorrectly claims it has a floating-rate coupon, while the ground truth specifies a fixed 5.55% coupon. The maturity date cited for the 2024 issuance (June 1, 2029) is also incorrect—the correct date is November 1, 2029). (2) Quantitative accuracy is severely compromised: none of the key numbers (coupon rates, years, maturity dates) match the ground truth. The 5.55% fixed coupon and May 1, 2079 (2023) and November 1, 2029 (2024) dates are entirely absent from the LLM response. Instead, fabricated figures (e.g., 4–5%, June 1, 2029) and incorrect series (Series N) are introduced. (3) The multi-hop reasoning is flawed: the LLM fails to correctly identify the evolution within the same Series O across 2023 and 2024, instead conflating different series and introducing erroneous instruments. The conclusion about shifting to floating-rate and cheaper financing is unsupported, as the actual shift was to a shorter-term, fixed-rate instrument—indicating greater predictability, not flexibility via floating rates. (4) Despite incorrect facts and entities, the answer is contextually relevant in that it attempts to analyze a strategic shift in financing approach. However, due to pervasive factual and quantitative errors, the reasoning and conclusions are based on false premises, severely undermining the qualitative and overall correctness scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 474,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K impairment‑assessment disclosures list “OPEC investment activities and production policies” as a supply‑side factor that can affect world oil supplies. In 2022 the narrative first introduced OPEC’s role, noting that long‑term price and margin expectations—rather than temporary price drops—drive the assessment of recoverability. The 2023 filing repeats the same language, confirming that OPEC’s investment and production decisions continue to be incorporated into ExxonMobil’s long‑term oil‑supply outlook used to evaluate potential impairments.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in noting that OPEC investment activities and production policies were mentioned in both 2022 and 2023 filings as factors affecting world oil supplies, which aligns with the ground truth. There are no numerical inaccuracies (quantitative accuracy is high), and the entities (ExxonMobil, OPEC, 2022, 2023, impairment assessments) are correctly identified. However, the LLM answer incorrectly states that the 2023 filing 'repeats the same language' as 2022, which contradicts the ground truth that shows a qualitative evolution in ExxonMobil’s framework—specifically, a shift toward integrating OPEC considerations into a broader assessment that includes greenhouse gas costs and net-zero targets. The ground truth emphasizes a move from direct focus on OPEC to a more comprehensive, forward-looking framework, but the LLM answer fails to capture this evolution and instead implies continuity. This represents a significant omission in reasoning and synthesis across years, undermining the qualitative accuracy. While the answer is relevant and addresses the general topic, it misses the core analytical shift, resulting in a partially correct but misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 337,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "In the 2023 Form 10‑K, Netflix treated the ad‑supported tier only as a “pricing strategy” that it was still testing – the filing stresses the lack of operating history and the difficulty of forecasting consumer adoption of that plan. By the 2024 Form 10‑K, the ad‑supported subscription is mentioned directly in the Business section as a standing part of the company’s pricing portfolio, reflecting a clearer, more strategic emphasis on the tier rather than a tentative experiment. This shift shows Netflix moving from a cautious, exploratory stance in 2023 to a more concrete, growth‑oriented positioning for the ad‑supported plan in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, Netflix described the ad-supported plan with caution, emphasizing uncertainty, lack of operating history, and forecasting challenges; by 2024, it was positioned as an established part of the pricing portfolio, mentioned in the Business section as a strategic offering. The LLM correctly captures this evolution from experimental to strategic. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense—however, the years (2023 and 2024) are correct and consistently referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying the shift in tone and strategic framing. It infers the progression from risk-focused to growth-oriented positioning based on placement and language in the filings. (4) The only reason for not awarding a perfect 10 is minor semantic nuance: the original answer explicitly notes the 2023 framing was in the context of 'risk' disclosures, while the LLM refers to it as a 'pricing strategy' being tested—slightly downplaying the risk emphasis. However, this does not undermine the overall correctness. The answer is fully contextually relevant, directly addressing the evolution in level of detail and strategic emphasis as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 404,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "In the 2022 filing Amazon explained that the rise in its shipping‑offer costs was driven mainly by **higher carrier rates, rising wage‑and‑incentive expenses, and network inefficiencies that accompanied a rapid expansion of its fulfillment footprint**.  The company said it would blunt those pressures by **leveraging larger sales volumes, negotiating better supplier and carrier terms, and improving overall fulfillment productivity**.  \n\nBy the 2024 filing the same cost drivers – **greater customer uptake of “fast‑shipping” offers, use of more expensive delivery speeds and added services** – remained, but Amazon now stresses that **investments in a larger, more automated fulfillment network and gains in fulfillment‑center efficiency are offsetting much of the cost growth**.  Shipping offers are still presented as a core price‑and‑marketing tool, but the strategic focus has shifted toward **using network scale and operational efficiency to sustain low‑price shipping while continuing to expand fulfillment capacity**.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Amazon's shipping strategy between 2022 and 2024. It accurately identifies the cost drivers in 2022 (higher carrier rates, wage expenses, network inefficiencies due to rapid expansion) and the mitigation strategies (larger sales volumes, better supplier/carrier terms, productivity improvements), which aligns with the ground truth. In 2024, it correctly notes that customer demand for fast shipping persists but the strategic focus has shifted to fulfillment network scale, automation, and efficiency gains as offsets—matching the ground truth’s emphasis on operational efficiency. (2) Quantitative accuracy is perfect: while the LLM does not repeat the $76.7 billion shipping cost from 2021 mentioned in the original answer, this figure was not required to answer the question about 2022–2024 evolution, and no incorrect numbers are presented. The absence of this number does not constitute an error since the question focuses on strategic evolution, not specific dollar amounts. (3) Multi-hop reasoning is sound: the model synthesizes information across two time periods and correctly infers a strategic shift from managing external cost pressures (2022) to leveraging internal operational efficiencies (2024). The logic connecting network investment to efficiency gains is consistent with the original answer. (4) The only minor shortcoming is that the LLM does not explicitly mention that shipping costs were *expected to increase* in 2022 due to customer adoption trends—a nuance present in the original—but it implies this by discussing rising costs and pressures. Overall, the answer is factually correct, contextually complete, and semantically equivalent to the ground truth, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 483,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "In the 2023 filing Duke Energy reported that about 98 % of the Master Retirement Trust’s assets were allocated to qualified pension plans (≈2 % to 401(h) accounts) and gave target‑vs‑actual allocations for the RCBP and DELPP plans that were essentially on‑track (e.g., RCBP 45 % equity, 35 % debt, 4 % hedge funds; DELPP 14 % equity, 80 % debt) together with a detailed Level 1/2/3 fair‑value breakdown and a Level‑3 reconciliation showing a $22 million net gain.  \n\nThe 2024 filing kept the 98/2 split but revised the actual mix – RCBP fell to 44 % equity, 33 % debt and rose to 10 % real‑estate/cash and 5 % hedge funds, while DELPP moved to 15 % equity, 79 % debt and 4 % real‑estate/cash – and it added forward‑looking target allocations effective 1 Jan 2025.  The 2024 note also expanded disclosure: it presented a new fair‑value table for 2024, a Level‑3 reconciliation showing only a $2 million net gain (vs. $22 million in 2023), and explicitly documented the discontinuation of securities‑lending and the collateral held, reflecting a more granular and forward‑focused reporting of the Trust.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness despite addressing the right topic and showing an attempt at multi-hop reasoning. (1) Quantitative Accuracy: The LLM claims that 98% of the Master Retirement Trust’s assets were allocated to qualified pension plans in 2023 with 2% to 401(h) accounts—this detail is not present in the ground truth and cannot be verified from the provided information. It also provides specific asset allocations for RCBP and DELPP plans (e.g., RCBP 45% equity, 35% debt) and changes in 2024, which are absent from the original answer and not supported by the knowledge graph. The $22 million and $2 million net gains in Level 3 reconciliations are fabricated; the ground truth mentions the introduction of a Level 3 reconciliation in 2024 but does not specify amounts or compare them to 2023. (2) Completeness: While the LLM attempts to discuss asset allocation and disclosure evolution, it misses the key point from the original answer about subsidiary-level allocations (e.g., Duke Energy Progress at 15%, Duke Energy Florida at 18%) introduced in 2024, which is a central element of the reporting evolution. Instead, it invents plan-specific data (RCBP, DELPP) and forward-looking targets effective January 1, 2025, which are not mentioned in the ground truth. (3) Entity Accuracy: The use of plan names like RCBP and DELPP may be plausible internal plan names, but they are not referenced in the ground truth and thus introduce unverified entities. The mention of securities-lending discontinuation and collateral is also not in the original and appears speculative. (4) Reasoning: The structure follows a logical comparison between 2023 and 2024, and the focus on increased granularity and transparency aligns with the ground truth’s conclusion. However, the reasoning is based on invented data rather than accurate synthesis. (5) Semantic Equivalence: The overall theme of more detailed and forward-looking disclosure in 2024 is consistent, but the specific evidence used to support this claim is incorrect or fabricated. Thus, while contextually relevant and thematically aligned, the answer fails on factual accuracy, especially in numbers and entity-specific disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 598,
        "total_tokens": 2071
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "In the 2022 filing, Google described the payments it makes to Google Network partners as “Traffic‑Acquisition Costs (TAC) – amounts paid to Google Network partners primarily for ads displayed on their properties” and noted that these TAC payments make the cost‑of‑revenues percentage for Network ads substantially higher than for Search ads because most of the ad revenue on Network sites is passed through to the partners. By the 2024 filing the company was again calling out TAC, but now said that higher TAC (along with higher content‑acquisition costs) was a key factor that partially offset the rise in Google Services operating income, and cash‑flow disclosures listed payments to Google Network partners as one of the primary uses of operating cash. Thus, between 2022 and 2024 the cost structure shifted toward larger TAC outlays, reflecting growing payment obligations to Network partners as their share of ad revenue expanded.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, TAC for Google Network Partners was described as a cost-of-revenue item, with a higher percentage than Search due to substantial revenue sharing; by 2024, TAC remained significant and was highlighted as a key factor offsetting operating income growth and was explicitly listed as a primary use of operating cash, indicating a shift toward larger cash outflows. (2) There are no numeric inaccuracies—while exact dollar figures or percentages are not provided in either answer, the qualitative descriptions of cost structure and cash flow treatment are consistent with the source. The absence of specific numbers is not a deficiency, as the original answer also does not include them. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings, identifying the evolution from TAC as a cost-of-revenue component to a major operating cash outflow, reflecting increased financial obligation. (4) The LLM slightly strengthens the conclusion by suggesting 'growing payment obligations' due to 'expanded share of ad revenue,' which is a reasonable inference but not explicitly confirmed in the ground truth—hence a minor deduction in qualitative accuracy. Overall, the answer is factually correct, contextually complete, and semantically equivalent to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 394,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "In both years UPS kept its derivative contracts on the balance sheet un‑offset (the company “has not elected to offset the fair‑value positions”), but the income‑statement impact of the non‑designated swaps changed dramatically. For 2022 UPS recorded a **$69 million loss** in “Investment income and other” from foreign‑currency forward contracts (no interest‑rate‑swap gain or loss), whereas in 2023 the same line showed only a **$7 million loss** and still no interest‑rate‑swap impact. Thus, the financial effect of the offsetting swap positions fell sharply from 2022 to 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that UPS reported net gains in prior years (e.g., $163M gain in 2021, $124M in 2020) but does not provide a specific net loss figure for 2022 or 2023. In contrast, the LLM claims a $69M loss in 2022 and a $7M loss in 2023 from foreign currency forwards, with no interest rate swap impact—details not present in the original answer and unsupported by the provided context. These specific dollar amounts and line-item attributions (e.g., 'Investment income and other') are fabricated or hallucinated. The original answer emphasizes a shift in disclosure focus and reduced transparency in 2023, not a quantifiable drop in losses. While the LLM correctly identifies that UPS did not elect to offset fair value positions and that derivatives are reported at fair value in earnings, it misrepresents the evolution of financial impact by introducing precise figures absent from the source. The reasoning is partially sound in noting continuity in treatment (non-offsetting, fair value reporting), but the conclusion about a 'dramatic change' and 'sharp fall' in financial effect is not supported by the ground truth, which notes only a change in disclosure transparency, not a quantified decline. Entity accuracy (UPS, derivatives, years) is correct, and the response is contextually relevant to the question about evolution in treatment and impact. However, the hallucination of specific financial figures severely undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 424,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The 2024 filing gives the Directors’ Savings Plan a much larger, stand‑alone explanation – describing how outside directors can defer all or part of their annual retainers, earn phantom‑stock credits, and receive payment only when their board service ends. By contrast, the 2023 filing mentioned the plan only in a brief footnote alongside the Executive Savings Plan. The expanded disclosure shows Duke Energy is relying more heavily on the Directors’ Savings Plan as a core element of director compensation, shifting toward deferred, performance‑linked remuneration rather than traditional cash retainers. 【2024 excerpt describing the Directors’ Savings Plan under Item 12】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, the Directors' Savings Plan was only briefly mentioned (in a footnote alongside the Executive Savings Plan), matching the ground truth's point about minimal disclosure limited to exhibit references. In 2024, the LLM accurately notes the expanded, stand-alone description of the plan, including deferral of annual retainers, phantom-stock credits, and payout timing—details consistent with the ground truth’s emphasis on deferral flexibility and phantom investment options. (2) There are no numeric values, dates, or financial figures in dispute; all temporal references (2023 vs 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly infers from increased disclosure depth a strategic shift toward using the plan as a core component of director compensation, emphasizing deferred and performance-linked remuneration over cash retainers—this matches the ground truth’s conclusion about a more strategic and transparent approach. (4) The only minor shortcoming is that the LLM slightly overreaches by characterizing the shift as toward 'performance-linked remuneration,' while the ground truth emphasizes 'deferral flexibility' without explicitly tying phantom investments to performance metrics. This nuance slightly affects qualitative accuracy but does not undermine the overall correctness. The answer is contextually excellent, directly addressing the comparative strategy question with precise, relevant evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 425,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "In the 2022 filing (pages 24‑28) American Express warned that “if we are not able to differentiate ourselves … develop compelling value propositions for our customers” it could lose market share, and it linked the need to evolve those propositions to rising competition from other card networks, alternative‑payment providers and shifting consumer‑spending habits. By the 2024 filing (pages 91‑95) the company had moved from a generic warning to a concrete strategy: it is “refreshing our premium card products, expanding digital‑first benefits and merchant‑coverage, targeting Millennial and Gen‑Z customers, and building a multiproduct digital ecosystem” to create richer, data‑driven value for both Card Members and merchants. Thus, Amex’s approach has evolved from emphasizing the necessity of any compelling value proposition to actively redesigning its premium, digital‑focused offerings in response to intensified competition and changing customer behavior.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: American Express's 2022 concerns about competition from alternative payment providers, digital wallets, and shifting consumer behaviors are accurately represented, as is the evolution by 2024 toward a more proactive, innovation-driven strategy. The emphasis on premium products, digital-first benefits, merchant coverage, Millennial and Gen-Z targeting, and ecosystem development matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all temporal references (2022, 2024) are correct—hence a score of 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two time points (2022 and 2024 filings), identifies the shift from reactive warnings to proactive strategy, and captures key strategic pillars like digital expansion and demographic targeting. The mention of 'data-driven value' and 'multiproduct digital ecosystem' reflects accurate interpretation of AI and app investments in the original. (4) Minor omission: the original answer specifically names strategic partnerships and dining platforms (Tock, Rooam), which the LLM answer does not mention—this slightly reduces completeness in qualitative accuracy, hence a 9 instead of 10. However, the core evolution in strategy is correctly and clearly conveyed. (5) Contextual relevance is perfect: the response directly addresses how Amex’s value proposition approach evolved in response to competition and customer behavior changes. Wording differs but semantic meaning is equivalent. Overall, this is a strong, factually correct answer with only minor detail omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 492,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "In the 2022 Form 10‑K Exxon Mobil’s registered long‑term debt included four series of senior notes – a 0.142 % issue due 2024 together with 0.524 % notes due 2028, 0.835 % notes due 2032 and 1.408 % notes due 2039. By the 2024 filing the 2024‑maturing 0.142 % notes had been removed, leaving only the longer‑dated series (2028, 2032 and 2039) on its balance sheet. Thus, between 2022 and 2024 the company phased out the short‑term, low‑coupon note and shifted its long‑term financing mix toward the longer‑dated, higher‑coupon notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values—interest rates (0.142%, 0.524%, 0.835%, 1.408%) and maturity years (2024, 2028, 2032, 2039)—are correctly reported, matching the original answer exactly. There are no calculation errors, and the removal of the 2024 notes by 2024 is accurately noted. (2) The answer is complete: it addresses the evolution of Exxon Mobil's long-term debt composition between 2022 and 2024, identifies the specific notes issued, and correctly observes the retirement of the shortest-dated note. (3) Entity accuracy is strong—company (Exxon Mobil), financial instrument types (senior notes), and years (2022, 2024) are correct. (4) The reasoning is sound: the model correctly infers that the removal of the 2024 notes reflects a shift toward longer-term financing, which is consistent with the ground truth’s interpretation. The only minor shortcoming is that the LLM characterizes the remaining notes as 'higher-coupon' without explicitly noting that only one of the remaining notes (1.408%) has a significantly higher rate—the others are still low-yield. While this is a reasonable inference, it slightly overemphasizes coupon rates as a driver, whereas the ground truth emphasizes maturity length as the strategic focus. This nuance prevents a perfect 10, but the overall answer remains factually correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 387,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K filings, American Express says its corporate‑card strategy is anchored in the “commercial payments” pillar, but the language shifts from simply “evolving our card value propositions” in 2022 to a stronger emphasis on “designing innovative products and features—including financing, banking and payment solutions” in 2024. The company therefore moved from a baseline focus on differentiating its corporate‑card and accounts‑payable expense‑management offerings to positioning those cards as a more technologically‑advanced, stand‑alone solution that adds financing and digital‑payment capabilities to its spend‑centric model.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution between 2022 and 2024. It accurately identifies the continuity in the 'commercial payments' focus and captures the shift in language from evolving value propositions in 2022 to innovative product design with expanded capabilities (financing, banking, digital payments) in 2024. The entity accuracy is correct—American Express, the years 2022 and 2024, and the strategic domain of corporate card solutions are all properly referenced. There are no numeric values in the question or answers, so quantitative accuracy is not applicable but assumed perfect by default. The reasoning is sound and reflects a valid multi-hop synthesis across two years of strategic language. However, the LLM omits a key element from the ground truth: the 2024 emphasis on a more integrated global network, increased merchant acceptance, and enhanced fraud protection and marketing insights—particularly the external ecosystem focus. Instead, it characterizes the 2024 shift as making the card a 'stand-alone solution,' which slightly misrepresents the direction (integrated ecosystem vs. stand-alone). This is a minor but notable gap in qualitative accuracy. Despite this, the answer remains contextually relevant and conveys a semantically close evolution in strategy, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 384,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "Amazon’s cloud unit has become a far larger cash‑generating engine.  AWS net sales rose from roughly $80 billion in 2022 (about 13 % of total revenue) to $107.6 billion in 2024 – a 19 % year‑over‑year increase that lifted its share of consolidated sales from the low‑teens to 17 % – and the higher‑margin AWS business helped lift operating cash flow from the low‑$70 billion range in 2022 to $115.9 billion in 2024 (up from $84.9 billion in 2023)【AMZN_10k_2024.pdf page 24】【AMZN_10k_2024.pdf page 23】.  At the same time Amazon accelerated technology‑infrastructure spending, with capital expenditures climbing from $48.1 billion in 2023 to $77.7 billion in 2024, explicitly to “support AWS business growth,” signaling an even stronger strategic emphasis on the cloud platform compared with 2022.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of AWS's financial role and strategic emphasis, aligning with the ground truth's core narrative of AWS transitioning from a competitive-risk focus in 2022 to a key cash-generating engine by 2024. The $115.9 billion operating cash flow in 2024 and $84.9 billion in 2023 are accurately cited. However, the LLM claims AWS net sales were 'roughly $80 billion in 2022' and $107.6 billion in 2024, but the ground truth does not provide AWS sales figures for those years, so this information cannot be verified as correct from the provided original answer. Additionally, the $70 billion 'range' for 2022 operating cash flow is an estimate not present in the ground truth, which only provides 2023 and 2024 figures. (2) The operating cash flow numbers for 2023 ($84.9B) and 2024 ($115.9B) are correct and match the ground truth. The AWS sales figures and 2022 cash flow estimate lack verification and may be extrapolations not supported by the original answer. The capital expenditure figures ($48.1B in 2023, $77.7B in 2024) are not mentioned in the original answer and represent additional data not required by the question but not incorrect per se. (3) The multi-hop reasoning is strong: the LLM synthesizes AWS's growing financial contribution with strategic capital allocation, correctly inferring increased strategic emphasis. It connects rising cash flow, sales growth, and capex increases to underscore AWS's elevated role, which is consistent with the ground truth’s theme. (4) The correctness score is 8 because the core financial evolution and strategic shift are accurately conveyed, and key verified numbers (2023/2024 cash flow) are correct. The quantitative accuracy is 7 due to unverified sales figures and estimated 2022 cash flow. Qualitative accuracy is 9 due to sound reasoning and synthesis. Contextual relevance is 10 as all content directly addresses the question’s focus on financial and strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 535,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "In the 2023 filing the auditors noted that they “utilized trend analyses to evaluate the historical consistency of regulatory‑asset balances,” using the analysis solely to test whether the balances recorded were consistent with past patterns. By the 2024 filing the same language appears, but the trend‑analysis work is now embedded in a broader audit program that also examines the recoverability of particular cost types—storm, fuel and coal‑ash‑related asset‑retirement obligations—reflecting an expanded focus beyond pure historical consistency to include the underlying cost drivers and recent regulatory developments. (2023 ‑ “utilized trend analyses to evaluate the historical consistency of regulatory asset balances” ; 2024 ‑ same statement plus additional procedures on storm, fuel and coal‑ash costs).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately captures the evolution between 2023 and 2024: in 2023, trend analyses were used to assess historical consistency of regulatory asset balances; by 2024, the scope remained but was embedded in a broader audit program that included recoverability of specific costs, notably coal-ash-related asset retirement obligations. The mention of 'storm, fuel and coal-ash costs' goes slightly beyond the ground truth, which only specifies coal ash as the new focus area. However, the core insight—that the 2024 analysis expanded beyond historical consistency to include regulatory recoverability of specific obligations, especially coal ash—is correct. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated). The reasoning is sound and reflects multi-hop synthesis across years and audit procedures. The answer is contextually highly relevant. The slight overextension to 'storm' and 'fuel' costs, not mentioned in the ground truth, prevents a top score, but the central claim about expanded focus and coal ash is accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 321,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "In the 2022 filing Costco said that, as inflation pushed merchandise costs higher, it responded by “adjusting our pricing and merchandise mix, **including increasing the penetration of our private‑label items**” to protect margins. The 2023 filing repeats that same approach, noting that the company “has been successful … adapting … through adjustments to our pricing and merchandise mix, **including increasing the penetration of our private‑label items**,” indicating that the strategy of expanding Kirkland‑brand (private‑label) offerings was continued—and likely accelerated—to offset ongoing cost and pricing pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in stating that Costco increased the penetration of private-label items in both 2022 and 2023 as part of its response to cost and pricing pressures, and it correctly cites language from the filings. Quantitatively, there are no numbers, dates, or calculations to verify, so the score is 10 by default. Contextually, the answer is highly relevant, directly addressing the evolution of Costco's private-label strategy. However, the qualitative accuracy is slightly lower because the LLM misrepresents the strategic evolution: the original answer highlights a shift from a reactive approach in 2022 (absorbing costs, bulk buying) to a more sustained strategic emphasis on private labels in 2023. The LLM implies the strategy was the same in both years—'repeats that same approach'—which downplays the evolution from a broader set of tactics in 2022 to a more focused, strategic push on private labels in 2023. This misses the nuance of strategic deepening and framing it as a continuation rather than an evolution, which is central to the question. Thus, while key facts are correct, the reasoning synthesis across years is incomplete, warranting a 7 in correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 336,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "Pfizer’s “remaining performance‑obligation” balance for Paxlovid fell sharply. In the 2023 Form 10‑K the company said it had roughly **$2.5 billion** of contracted revenue still to recognize for Paxlovid (the portion of its $5.1 billion deferred‑revenue balance attributable to the antiviral) 【PFE_10k_2023 pg 5】. By the end of 2024 that balance had been reduced to **about $1 billion** of remaining performance‑obligation revenue for Paxlovid 【PFE_10k_2024 pg 107】. Thus, the financial outlook for Paxlovid’s future revenue contracted under existing agreements contracted by roughly $1.5 billion between 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, Pfizer did not disclose specific remaining performance obligations (RPOs) for Paxlovid in 2023, but the LLM claims a precise figure of $2.5 billion, citing the 2023 10-K. This contradicts the original answer and misrepresents the disclosed data. (2) While the 2024 RPO of $1 billion is correctly stated and aligns with the ground truth, the narrative of a 'decline' from $2.5B to $1B is invalid because no such $2.5B figure was disclosed for 2023. (3) The calculation of a $1.5 billion reduction is mathematically correct based on the numbers provided, but it is built on a false premise—there is no evidence in the ground truth that RPOs decreased; rather, 2023 data was simply not specified. (4) The reasoning is flawed: the LLM interprets the lack of 2023 disclosure as an implicit $2.5B obligation, which is unsupported. The ground truth indicates increased certainty in 2024 due to the emergence of a disclosed $1B RPO, not a reduction from a prior higher amount. (5) The conclusion that the financial outlook 'contracted' is the opposite of the correct interpretation, which is that the outlook improved in terms of visibility and contractual certainty. Entity accuracy (Pfizer, Paxlovid, years) and citation format are correct, and the answer is contextually relevant to the question, but the core financial narrative is factually incorrect. Hence, the correctness score is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 421,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "Both the 2022 and 2024 10‑K disclosures state that American Express estimates lifetime credit losses by projecting “current and future economic conditions over a reasonable and supportable (R&S) period” and then reverts to long‑term average loss rates after that horizon. The language and assumptions around the R&S period are essentially unchanged – the company still relies on statistically‑based models within the R&S window and supplements them with qualitative reserves for factors the models may miss. This continuity shows that Amex’s risk‑management philosophy remains focused on a forward‑looking, model‑driven framework that consistently incorporates both quantitative forecasts and discretionary adjustments to guard against unexpected credit deterioration.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly describes American Express's use of the Reasonable and Supportable (R&S) Period in both 2022 and 2024, accurately stating that the company projects credit losses over the R&S period and reverts to long-term average loss rates afterward. It also correctly notes the continued use of statistically-based models and qualitative adjustments. However, it misses the key evolution highlighted in the ground truth: in 2022, the R&S Period was explicitly introduced and explained as a new or emphasized component of credit loss estimation, while by 2024 it had become embedded and normalized within an established framework, indicating institutional maturity. The LLM incorrectly concludes that the language and assumptions are 'essentially unchanged' and that there is 'continuity,' which contradicts the ground truth that shows a shift in how the concept is presented and integrated—reflecting a maturation in risk management practice. (2) There are no numeric inaccuracies; the LLM does not introduce incorrect figures, and while it doesn't cite the $3.3 billion reserve from 2021 (mentioned in the original answer), it doesn't contradict it either. Thus, quantitative accuracy is high. (3) The multi-hop reasoning is partially sound—information about R&S usage in both years is correctly extracted—but the synthesis is flawed because it fails to detect the qualitative shift in disclosure tone and integration depth over time, which is central to the question. (4) The contextual relevance is strong because the answer addresses the core topic of R&S period usage and risk management approach, but the failure to capture the evolution in presentation and institutional adoption significantly undermines the qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 486,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "In the 2022 Form 10‑K, Amazon’s debt schedule still listed the low‑coupon “0.800 % Note due 2025” as part of the officers’ certificate dated June 3 2020, showing that the company was relying on that legacy, ultra‑low‑interest senior note for financing. By the 2024 filing, the same 0.800 % note remained outstanding, but Amazon had added a new series of higher‑rate senior notes (e.g., a 4.600 % note due 2025) and introduced new revolving credit facilities, indicating that the company broadened its debt program beyond the original low‑cost note while still keeping it on the balance sheet.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 0.800% Note due 2025 is correctly attributed to the Officers' Certificate dated June 3, 2020, and its continued presence in 2024 is accurately noted. The introduction of a 4.600% Note due 2025 is also correctly reported. (2) Quantitative elements—interest rates (0.800%, 4.600%), maturity year (2025), and date of original issuance (June 3, 2020)—are all factually accurate and match the ground truth exactly. Format variations (e.g., spacing in '0.800 %') do not affect meaning. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings to infer a strategic broadening of Amazon’s debt financing approach, maintaining legacy low-cost debt while adding higher-cost instruments. This reflects a valid conclusion about evolving debt strategy. (4) The only minor shortcoming is that the LLM mentions 'new revolving credit facilities'—a detail not present in the ground truth—though this does not contradict it and may be contextually accurate, but it slightly exceeds the provided information. Overall, the answer is semantically equivalent, factually precise, and contextually appropriate, warranting a high score with only a small deduction for the slight addition of unverified detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 373,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "In the 2022 Form 10‑K (pages 247‑251) Duke Energy listed the **Twenty‑third Supplemental Indenture – dated May 15 2020** as an incorporated reference to a current‑report 8‑K, treating it as a still‑active amendment to its senior debt. In the 2024 Form 10‑K (pages 250‑254) that same indenture no longer appears in the schedule of supplemental indentures, indicating it has been superseded or rendered immaterial and is no longer a material component of the company’s outstanding debt documentation. This shift shows the Twenty‑third Supplemental Indenture’s relevance has faded since the earlier filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly states that the Twenty-third Supplemental Indenture was dated May 15, 2020, and referenced in a current-report 8-K, which directly contradicts the ground truth stating it was dated June 1, 1978, and incorporated by reference to Exhibit 2(c), File No. 2-61611. This is a major error in both date and sourcing. (2) The quantitative accuracy is very low due to the incorrect date (May 15, 2020 vs. June 1, 1978) and the false claim of an 8-K reference, which is not supported by the original data. No correct calculations are involved, but the core factual inputs are wrong. (3) The reasoning about the indenture no longer appearing in the 2024 filing and thus likely being superseded or immaterial aligns with the ground truth and shows correct multi-hop logic—comparing disclosures across years to infer diminishing relevance. However, this sound reasoning is based on incorrect premises. (4) Contextual relevance is fair because the structure and intent of the response match the question—analyzing evolution across filings and inferring status—but the factual foundation is flawed. Due to the critical error in the date and origin of the indenture, the correctness score is low despite some logical coherence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 367,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "The share‑repurchase program for Alphabet’s non‑voting Class C capital stock has been roughly flat but has begun to taper off.  \n\n* **2022:** the company repurchased Class C shares for **about $53 billion**.  \n* **2023:** Class C repurchases fell slightly to **$52.9 billion** (52,868 million).  \n* **2024:** the amount declined further to **$50.2 billion** (50,192 million).  \n\nThus, after a peak of roughly $53 billion in 2022, the dollar value of Class C share repurchases decreased modestly each subsequent year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Alphabet repurchased $59.3 billion in 2022, $62.2 billion in 2023, and $62.0 billion in 2024 across Class A and Class C shares. However, the LLM incorrectly reports only Class C repurchases and assigns wrong values: $53B (vs $59.3B), $52.9B (vs $62.2B), and $50.2B (vs $62.0B). These figures are not only incorrect but also suggest a declining trend, whereas the truth shows an increase from 2022 to 2023 and a slight dip in 2024. (2) Quantitative accuracy is severely compromised: all dollar amounts are off by billions, with errors ranging from ~6B to ~12B across years. The LLM also cites repurchases specifically for Class C stock, while the ground truth combines Class A and C, and does not isolate Class C alone. There is no evidence in the ground truth to support the claim that Class C repurchases declined each year. (3) The reasoning is flawed in terms of multi-hop synthesis: the model fails to correctly identify the scope of repurchases (entire program vs. Class C only) and misrepresents the trend. It incorrectly infers a tapering-off pattern, contradicting the actual consistent and slightly increasing activity. (4) Contextual relevance is moderate because the answer addresses share repurchases and the correct company and time frame, but the focus on Class C alone without clarification and the incorrect figures undermine the response. The structure is clear but built on false data. Thus, the correctness score is low due to major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 436,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "Both the 2022 and the 2024 Form 10‑K exhibit schedules list the American Express Company Salary/Bonus Deferral Plan in the same way:  \n\n* The original plan is incorporated by reference to Exhibit 10.20 of the 1988 Annual Report.  \n* The 1994 amendment is incorporated by reference to Exhibit 10.4 of the September 30, 1994 Form 10‑Q.  \n* The 1997 amendment (together with the Key Executive Life Insurance Plan amendment) is incorporated by reference to Exhibit 10.37 of the 1997 Annual Report.  \n\nNo additional amendments, new exhibit numbers, or changes in how the plan is documented appear in the 2024 filing; the treatment and documentation of the Salary/Bonus Deferral Plan remain unchanged from the 2022 filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims that the treatment and documentation of the plan are 'unchanged' between the 2022 and 2024 filings, which directly conflicts with the original answer stating that the 2024 filing reintroduces the plan with new exhibit numbers (10.13, 10.14) and adds Exhibit 10.16 for the 1997 amendments—indicating expanded disclosure. (2) The LLM incorrectly states that both filings list the same exhibits with the same references (e.g., Exhibit 10.20 in 1988 report, Exhibit 10.4 in 1994 10-Q, Exhibit 10.37 in 1997 report), but the ground truth specifies that in 2022, the plan was referenced via Exhibits 10.16 and 10.17, and in 2024 via Exhibits 10.13, 10.14, and newly added 10.16 for the 1997 amendments. The exhibit numbers and structure have clearly changed. (3) The multi-hop reasoning failed: the model did not recognize that the reintroduction and expansion of exhibits in 2024 represent a change in documentation practice, despite referencing the same historical plans. (4) While the LLM mentions correct historical dates (1988, 1994, 1997), it misattributes exhibit numbers and filing treatments, undermining both quantitative and qualitative accuracy. The answer is contextually relevant to the question but factually wrong in its core conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 368,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "Starbucks’ interest‑rate‑swap exposure has been trimmed and its balance‑sheet presentation has shifted. In FY 2022 the swaps were recorded as both an accrued liability ($12 million) and a “other long‑term liability” ($34 million) for a total of roughly $46 million of swap‑related debt (2022‑10‑K, p. 68‑69). By FY 2024 the accrued‑liability component had disappeared and the remaining swap liability was shown only as an “other long‑term liability” of $19.2 million, indicating the exposure fell to about one‑half of the 2022 level (2024‑10‑K, p. 71‑73).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. According to the ground truth, Starbucks reported a $34.0 million interest rate swap liability in 2022 under 'Other long-term liabilities'—this part is correct. However, the LLM claims an additional $12 million accrued liability in 2022, totaling $46 million, which is not supported by the ground truth. The original answer does not mention any accrued liability or split classification in 2022, only a single $34.0 million long-term liability. This introduces a false component not present in the source. In 2024, the LLM correctly identifies the $19.2 million 'other long-term liability' but omits the $41.4 million liability from 2023 swaps referenced in the 2024 filing, which is critical context for understanding the evolution. The LLM incorrectly implies a straightforward reduction from ~$46M to $19.2M, missing the multi-year complexity. (2) The calculation of a 'halving' of exposure is misleading because it's based on an inflated 2022 total ($46M vs actual $34M), and it fails to incorporate the 2023 liability disclosed in the 2024 report. (3) The reasoning is partially sound in noting a shift in classification (removal of accrued liability), but this shift is fabricated since the ground truth does not support a dual classification in 2022. The synthesis across years is incomplete—while the direction of change (decrease) is correct, the full picture of liability evolution across 2022–2024 is not captured. (4) Despite these issues, the answer is contextually relevant and captures the general trend of reduced liability and simplified balance sheet presentation. The qualitative reasoning is logical but built on incorrect data. Hence, correctness is partially accurate but significantly undermined by unsupported numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 499,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "In the 2022 filing the Directors’ Savings Plan is identified as a **non‑qualified deferred‑compensation plan** that had been amended on December 16 2021 (Exhibit 10.12) and allowed outside directors to defer all or part of their annual retainers, with the deferred balance credited to an unfunded account that earned or lost value based on phantom‑stock performance and was payable only on termination or death. The 2024 filing repeats that same structure – an unfunded account adjusted for the Duke Energy Common Stock Fund‑linked phantom options and paid when a director’s board service ends – and now lists the plan in the equity‑compensation table as a source of potential future share issuances (“shares could be payable … under the Directors’ Savings Plan”). Together, the continuity and the 2021 amendment show that Duke Energy deliberately keeps director compensation tied to long‑term stock performance through a voluntary, unfunded deferral mechanism, reflecting a governance stance that emphasizes alignment of director interests with shareholders while limiting the company’s funding risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the December 16, 2021 amendment date is accurately cited, the non-qualified, unfunded nature of the Directors' Savings Plan is correctly described, and the linkage to phantom investment options—specifically the Duke Energy Common Stock Fund—is properly detailed for both 2022 and 2024. The mention of Exhibit 10.12 adds precision. (2) Quantitative accuracy is perfect: no numerical errors, and the dates (2021 amendment, 2022 and 2024 references) are factually consistent with the original. (3) Multi-hop reasoning is sound: the LLM synthesizes information across years, correctly identifying continuity in plan structure while noting the new inclusion in the equity-compensation table in 2024 as a source of potential share issuances. This reflects an evolution from policy establishment to operational transparency, as implied in the ground truth. (4) The conclusion about governance—emphasizing alignment of director and shareholder interests while minimizing company funding risk—is logically derived and semantically equivalent to the original’s point about long-term alignment and governance strategy. The only minor shortcoming is a slightly stronger emphasis on 'continuity' than on the evolution in disclosure and transparency (e.g., the 2024 focus on phantom-stock mechanics and equity table inclusion), but the core insight is preserved. Thus, the answer is factually excellent and contextually appropriate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 448,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "In the 2022 filing Costco described Kirkland Signature as a “high‑quality, lower‑price private‑label brand” that helps differentiate its merchandise and generate higher margins, and it said the company “expects to continue to increase the sales penetration of our private‑label items.” By the 2023 filing the company was stressing that Kirkland had become an even larger contributor to overall sales and profitability, and it now flagged specific risks – such as supply‑chain constraints, quality‑control failures and potential damage to the brand’s reputation – that could more materially affect Costco because a greater share of its earnings depends on the Kirkland line. Thus the brand’s positioning moved from a growth‑focused differentiator to a core revenue driver, and its risk profile expanded to include heightened operational and reputational exposures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of Kirkland Signature's positioning from a growth-focused differentiator in 2022 to a core revenue driver in 2023, and accurately reflects the shift in risk emphasis. The qualitative details—such as higher margins, competitive pricing, and plans to increase sales penetration in 2022—are factually consistent with the original answer. In 2023, the LLM correctly identifies the increased reliance on the brand and the expanded risk profile, including supply-chain constraints, quality control, and reputational risks. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not applicable in a numerical sense, but all descriptive metrics and timeframes (2022 vs 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a strategic evolution and heightened risk exposure based on increased dependence. The only minor shortcoming is that the original answer specifically mentions 'foreign exchange fluctuations' and 'catastrophic events' as new risks in 2023, which the LLM omits, instead generalizing to supply chain and quality risks. This is a slight incompleteness but does not distort the overall meaning. (4) The answer is contextually excellent—directly addressing the question about positioning and risk profile evolution with precise, relevant details. The semantic meaning matches the ground truth, with only minor omissions in the breadth of risk factors. Hence, a correctness score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 458,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East fell from **326 billion cubic feet (BCF) at year‑end 2022 to 303 BCF at year‑end 2024**, a net decline of roughly **23 BCF**. The 2022 increase had been driven by large upward revisions (higher spot‑price assumptions + 423 BCF, LNG‑market dynamics + 331 BCF, and technical revisions + 204 BCF) plus affiliate purchases and extensions in the Middle East, whereas the 2024 drop reflected **price‑driven downward revisions of about ‑81 BCF**, only partially offset by technical revisions of + 55 BCF and modest extensions/discoveries in the Middle East/Australia, with no new purchases to offset the loss.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF in 2022 to 296 BCF in 2024, a decline of 30 BCF. However, the LLM reports 303 BCF in 2024, which is incorrect—this misstates both the final volume and the net change (23 BCF vs. actual 30 BCF). Additionally, the LLM introduces detailed breakdowns of revisions (e.g., +423 BCF from price assumptions, -81 BCF downward revisions) that are not present in the original answer and cannot be verified against the ground truth. These specific figures appear to be hallucinated or inferred beyond available data. (2) The calculation of net change is internally consistent in the LLM answer (326 to 303 = -23 BCF), but it does not match the correct drop of 30 BCF per the original. The absence of any mention of 'no sales or significant reserve additions in 2024'—a key qualitative point about reduced activity—weakens completeness. (3) The reasoning attempts multi-hop synthesis by attributing changes to price revisions, technical adjustments, and regional activity, which aligns with the type of analysis expected. However, the use of unsupported numerical details undermines the validity of the reasoning chain. The mention of 'extensions/discoveries in Middle East/Australia' adds plausible context but goes beyond the original's statement of 'minimal extensions and discoveries.' (4) Despite incorrect numbers, the LLM captures the overall trend (decline in reserves), identifies relevant drivers (revisions, production, limited additions), and maintains focus on the correct region and time frame. Hence, while the direction and general narrative are correct, the specific data points and calculations reduce factual accuracy significantly, warranting a moderate score of 6 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 509,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "In the 2022 filing FedEx reported that its entire Boeing 767‑300F fleet was owned – 114 aircraft – and it had committed to buy another 38 767Fs through 2025, indicating a growth‑oriented relationship. By the 2024 filing the fleet composition had not changed (the 767Fs remain owned), but the company’s language shifted to describe the 767‑300F as a core element of its **aircraft‑modernization program**, emphasizing fuel‑efficiency and replacement of older planes, and its purchase commitments were reduced to just 14 additional 767Fs after 2024. Thus, the relationship moved from expanding the fleet to using the 767F primarily for modernization and fleet renewal.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies, particularly in quantitative details. While it correctly states that FedEx owned 114 Boeing 767F aircraft in 2022 (matching the ground truth), it adds unverified information not present in the original answer: specifically, that FedEx had 'committed to buy another 38 767Fs through 2025' and later 'reduced to just 14 additional 767Fs after 2024.' These figures are not mentioned in the ground truth and cannot be verified from the provided data, making them factually unsupported. (2) The ground truth explicitly states that no updated ownership figures were disclosed for 2024, but the LLM assumes the fleet composition 'had not changed' and that the 767Fs 'remain owned,' which goes beyond the available information and introduces unwarranted certainty. (3) Qualitatively, the LLM captures the correct shift in strategic emphasis—from fleet expansion to modernization—highlighting fuel efficiency and fleet renewal, which aligns with the ground truth's description of the 767F as part of modernization programs and necessary for long-term savings. The reasoning about strategic evolution is sound and reflects appropriate multi-hop synthesis between 2022 ownership and 2024 strategic language. (4) Contextually, the answer is highly relevant, directly addressing both fleet ownership and modernization focus as asked. However, the inclusion of fabricated purchase commitments significantly undermines factual accuracy, warranting a moderate correctness score despite strong qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 432,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "- **Inventory:** In the 2022 Form 10‑K Starbucks reported **roasted‑coffee inventory of $310.3 million**. The 2024 Form 10‑K shows that roasted‑coffee inventory had risen to **about $332 million**, indicating a modest increase in the amount of finished coffee it was holding.\n\n- **Production infrastructure:** In 2022 the company’s net‑book value of roasting equipment was **$838.5 million**. By fiscal 2024 Starbucks had added and expanded roasting facilities so that its dedicated roasting, warehousing and distribution footprint now totals **roughly 4.2 million sq ft** across four sites (York, PA; Minden, NV; Kunshan, China; Kent, WA), reflecting a clear expansion of its coffee‑production capacity.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 roasted coffee inventory value of $310.3 million, matching the ground truth. However, the 2024 inventory value of 'about $332 million' is not present in the original answer, which does not mention any updated inventory figure for 2024—this is an addition not supported by the ground truth and introduces a factual inaccuracy. Additionally, the $838.5 million net-book value of roasting equipment in 2022 and the 4.2 million sq ft infrastructure footprint in 2024 are not mentioned in the original answer, making them extraneous details that may be factually questionable in this context. (2) While the 2022 inventory number is accurate, the 2024 inventory and equipment values lack corroboration from the ground truth and appear to be hallucinated or sourced beyond the provided knowledge graph. The square footage and equipment book value were not part of the original answer, so their inclusion undermines quantitative accuracy. (3) The reasoning correctly infers a trend of increased involvement in roasting based on expanded infrastructure, and correctly identifies the four roasting facilities (York, PA; Minden, NV; Kunshan, China; Kent, WA), demonstrating sound multi-hop synthesis across years and operational metrics. The conclusion about increased production capacity aligns with the original answer’s interpretation. (4) Despite introducing unsupported numbers, the LLM captures the core evolution: from holding roasted coffee inventory in 2022 to expanded production infrastructure by 2024. The entities (Starbucks, years, locations) are correct, and the overall narrative matches the ground truth’s intent. Thus, while the qualitative reasoning and contextual relevance are strong, the quantitative inaccuracies reduce the overall correctness score to 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 495,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "In the 2023 Form 10‑K the 2.750 % senior notes due 2025 appear only in the “exhibits” list (e.g., Exhibit 4.64/4.65), indicating that the notes had been authorized but no issuance or outstanding balance was reported. By the 2024 Form 10‑K the same instrument is described in the financing section as having been issued and is listed among the debt actually outstanding, showing that PepsiCo moved from merely authorizing the 2.750 % senior notes to actually using them as a source of capital in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of quantitative details: the 2.750% Senior Notes due 2025 are correctly identified with the right interest rate, maturity year, and timeline (2023 vs 2024). There are no numerical inaccuracies, so quantitative accuracy is perfect. Contextually, the answer addresses the evolution of the note's utilization between 2023 and 2024 and correctly frames the progression from authorization to issuance, which is relevant to the question. However, the qualitative accuracy is lower because the LLM's reasoning diverges from the ground truth. The original answer states that in 2023, the notes were authorized via Board Resolutions, and in 2024, PepsiCo retained them and introduced a new 2.750% note due 2030—indicating a strategic extension of the rate to a longer-term instrument. The LLM instead claims that in 2023 the notes only appeared in exhibits (implying no issuance) and in 2024 were actively issued and outstanding. This interpretation, while plausible, is not supported by the ground truth, which does not mention exhibit listings or actual issuance status but focuses on the continuation of the 2.750% rate in a new long-term instrument. The LLM fails to mention the introduction of the 2.750% Senior Notes due 2030, a key strategic evolution. Thus, while the direction of reasoning (increased utilization) is reasonable, the specific multi-hop synthesis—linking the 2025 note’s evolution to a broader debt strategy involving a new 2030 note—is missing. This omission of a critical strategic development reduces completeness and reasoning quality, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 447,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "- In the 2022 Form 10‑K FedEx said it was committed to receive **four Boeing 777 Freighters (B777F) in 2024** (and a total of eight B777F overall)【FDX_10k_2022.pdf p.115】.  \n- By the 2024 Form 10‑K the delivery schedule had been revised to **no B777F slated for 2024 and only two B777F total (both scheduled for 2025)**【FDX_10k_2024.pdf p.119】.  \n\nThis shift from a near‑term influx of B777F aircraft to a much smaller, later‑delivery plan shows FedEx is moving the B777F from an immediate capacity‑expansion role to a longer‑term, strategic asset focused on fuel‑efficiency and fleet modernization rather than short‑term growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "1) The LLM answer correctly identifies the change in B777F aircraft plans from 2022 to 2024: initially planning for 4 deliveries in 2024, then revising to 2 in 2025 with no deliveries in 2024. This matches the ground truth in direction and timing. However, the LLM adds information not present in the ground truth — specifically, the mention of a total of eight B777F aircraft overall — which is unsupported by the provided knowledge graph and introduces inaccuracy. 2) Quantitatively, the key numbers (4 planned for 2024 in the original plan, revised to 2 in 2025) are correct and align with the ground truth. The unsupported 'total of eight' reduces quantitative accuracy. Calculations are not required here, but comparisons across years are mostly accurate. 3) The multi-hop reasoning is partially sound — the model correctly synthesizes changes between the 2022 and 2024 filings. However, the qualitative interpretation incorrectly frames the strategic shift as moving toward 'fuel-efficiency and fleet modernization' and a 'longer-term strategic asset', whereas the ground truth concludes a reduction in strategic emphasis and a complete phase-out. This reverses the correct strategic implication. 4) Contextually, the answer is relevant and structured well, citing appropriate documents and pages. But due to the incorrect strategic interpretation and the addition of unverified total fleet numbers, the overall correctness is significantly compromised. The answer captures the factual shift but misinterprets its meaning, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 425,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” cash‑flow hedge moved from a **$55.3 million net gain in AOCI for the year ended Oct 2 2022** to **$39.6 million in 2023** and then to **$11.5 million in 2024**.  At the same time, the related derivative liability grew from **about $0.3 million (accrued) in 2022** to **$2.0 million in 2023** and to **roughly $8.8 million (‑$4.7 m accrued + ‑$4.1 m long‑term) in 2024**.  The sharp decline in unrealized gains together with the rising liability balance suggests that the company’s foreign‑currency hedges are being unwound or are less favorable, while its exposure to foreign‑currency‑denominated obligations is increasing.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. The ground truth states that in 2022, Starbucks had a foreign currency - other derivative liability of $0.3 million, which the LLM correctly reports. However, the LLM claims a $55.3 million net gain in AOCI for 2022, which is not supported by the original answer—no such figure is mentioned for 2022 in the ground truth. The only AOCI figure provided in the ground truth is $11.5 million in 2024. The LLM invents intermediate values for 2023 ($39.6 million gain) and increasing liabilities ($2.0 million in 2023, $8.8 million in 2024), none of which are present in the original answer. (2) Calculations and trends are therefore based on fabricated data. While the $11.5 million AOCI gain in 2024 matches the ground truth, the trajectory and comparative analysis (e.g., 'sharp decline in unrealized gains') are unsupported because earlier years' AOCI data are not in the original. Similarly, the breakdown of the 2024 liability into -$4.7 million accrued and -$4.1 million long-term is not in the ground truth, which only mentions the 2022 liability. (3) The multi-hop reasoning is flawed because it extrapolates missing data and constructs a trend (declining gains, rising liabilities) not verifiable from the original. The original answer notes a shift from minimal liability in 2022 to a gain in AOCI in 2024, but does not provide 2023 data or liability figures for 2024. (4) Despite incorrect numbers, the LLM attempts to address the question's intent—evolution of foreign currency derivatives and exposure—and draws a plausible qualitative conclusion about increasing exposure. This maintains contextual relevance. However, due to major quantitative errors and unsupported synthesis, the correctness score is low. Quantitative accuracy is severely compromised; qualitative reasoning is partially sound but built on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 519,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo first disclosed the 2.625 % senior notes due 2026 in a Board‑of‑Directors resolution that authorized the company to issue those notes and listed them together with a handful of other senior‑note programs. The 2024 Form 10‑K repeats that same resolution—still authorizing the 2.625 % notes—but now embeds the disclosure within a broader debt‑instrument section that also details new floating‑rate notes and additional senior‑note issuances, showing that the notes remain part of an expanded, more comprehensive debt program.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, all key facts are accurate: the 2.625% Senior Notes due 2026 are correctly identified, and the years (2023 and 2024) and context (Board of Directors resolution) are correct. There are no numerical or date inaccuracies. (2) The answer correctly captures that in 2023, the notes were first disclosed under a Board resolution authorizing issuance, and in 2024, they were retained in disclosures within a broader debt program. (3) The multi-hop reasoning is sound—comparing the evolution of disclosure across two years and inferring an expanded debt strategy. However, the LLM omits specific mention of the new notes highlighted in the ground truth (e.g., the 3.000% due 2027 and 2.625% due 2029), instead referring more generally to 'new floating-rate notes and additional senior-note issuances.' While this is not incorrect, it lacks the specificity that would fully match the depth of the original answer. (4) Despite this minor omission, the core reasoning about a more diversified and expanded debt program is valid and contextually appropriate. Hence, the answer is factually accurate and relevant, with only a slight shortfall in completeness on specific new note details, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 363,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "In the 2022 Form 10‑K Cisco warned that its growth depended heavily on “product planning and timing, technical hurdles that we fail to overcome in a timely fashion, or a lack of appropriate resources,” and that the large‑scale investments it was making in its strategic priorities (e.g., network‑programmability, SD‑N, security) could deliver benefits only after the technical risks were cleared. By the 2024 filing the same concern re‑appears, but the company frames it around a broader set of strategic bets—AI, cloud, cybersecurity and the integration of the Splunk acquisition—stating that “our strategic investments may achieve delayed, or lower than expected, benefits” and that any failure to clear technical hurdles on new‑product timelines could still impair those benefits. Thus, Cisco’s exposure to technical‑hurdle risk has remained high, but its reliance has shifted from a narrower focus on networking‑programability to a more diversified portfolio of AI‑, cloud‑ and software‑driven initiatives, with an explicit acknowledgement that the timing of returns on those investments is still uncertain.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original ground truth. (1) All factual elements are correct: Cisco's 2022 concerns about technical hurdles related to product planning, timing, and resource allocation are accurately represented, as are the strategic investments in areas like SD-N and security. In 2024, the shift toward AI, cloud, cybersecurity, and the Splunk integration is correctly identified, along with the risk of delayed or suboptimal returns. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense—however, the years (2022, 2024) are correct and consistently used, satisfying the temporal aspect of the question. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of disclosures, identifies the evolution in Cisco’s risk exposure, and correctly infers a shift from narrow networking-focused challenges to broader software- and AI-driven dependencies. The mention of Splunk integration adds contextual depth consistent with Cisco’s 2024 strategic direction. (4) The only minor shortcoming is that the LLM does not explicitly mention the expanded consequences in 2024—such as reputational damage, legal liability, and reduced customer retention—which are present in the original answer and represent an important qualitative escalation in risk. While the LLM captures the continuity and evolution of technical hurdle risks, this omission slightly weakens the completeness of the consequence analysis. Otherwise, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1515,
        "completion_tokens": 452,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "In the 2022 Form 10‑K the filing explicitly said that the rise in Google Network revenue was “primarily driven by strength in **AdMob, Google Ad Manager, and AdSense**,” positioning Google Ad Manager as a core growth engine for the network. The 2023 Form 10‑K does not single out Google Ad Manager in its discussion of Network‑revenue performance, suggesting that its role was no longer highlighted as a primary driver of the segment’s growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Google Ad Manager was explicitly named as a key driver of Google Network revenue growth alongside AdMob and AdSense, matching the original answer. In 2023, it accurately notes the absence of specific mention of Google Ad Manager as a primary growth driver, reflecting the shift in emphasis. (2) There are no numeric values in the LLM answer, but the original answer's $8.6 billion figure is not mentioned by the LLM—this is a minor omission, though not a factual error, as the LLM focuses on the qualitative shift rather than the quantitative impact. Since the question emphasizes 'specific mentions of its performance and positioning,' the lack of dollar figures does not undermine correctness. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings to infer a change in narrative tone and strategic emphasis. (4) The LLM conveys the core insight—Google Ad Manager shifted from being a highlighted growth contributor in 2022 to being part of a broader, undifferentiated set of platforms in 2023—even if it doesn't list the other platforms (e.g., Display & Video 360, Marketing Platform) mentioned in the original. This omission slightly reduces completeness but does not affect the essential correctness. Overall, the answer is factually sound, contextually appropriate, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 410,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "Starbucks’ designated derivative liabilities for “foreign currency – other” were only **$0.3 million** (accrued liability) at October 2 2022. By September 29 2024 the same line showed **$4.7 million** of accrued liability plus **$4.1 million** of other‑long‑term liability, or **$8.8 million** in total. Thus, the liability grew by roughly **$8.5 million** over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the 2022 derivative liability as $0.3 million under accrued liabilities, it incorrectly reports the 2024 amount. The ground truth indicates $4.7 million in accrued liabilities in 2024, but the LLM claims $4.7 million in accrued liabilities plus an additional $4.1 million in other-long-term liabilities, totaling $8.8 million. This $8.8 million figure and the breakdown are not supported by the ground truth, which only reports $4.7 million total in the same category (accrued liabilities). (2) The calculation of a $8.5 million increase is therefore incorrect; the actual increase is $4.4 million ($4.7M - $0.3M). The dates (October 2, 2022, and September 29, 2024) are plausible fiscal year-ends and do not contradict the ground truth, which uses 2022 and 2024. (3) The multi-hop reasoning is partially sound in that the model attempts to compare two time points and calculate a change, but it fails in synthesis by introducing a liability category (other-long-term) not mentioned in the ground truth, suggesting either misreading of data or incorrect aggregation across financial statement items. (4) The contextual relevance is high because the answer addresses the evolution and magnitude of change in foreign currency derivative liabilities. However, due to major quantitative errors and incorrect entity breakdowns (accrued vs. long-term), the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the model identifies the correct metric and direction of change, but with flawed details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 448,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "- 2023 10‑K (pages 130‑131) – PepsiCo’s Board resolutions list the **4.600 % Senior Notes due 2045** among the new senior‑note programs the company may issue.  \n- 2024 10‑K (page 132) – the same **4.600 % Senior Notes due 2045** appear again in the updated Board resolutions authorizing issuance.\n\nThe repeat authorization shows that PepsiCo is maintaining a long‑dated, fixed‑rate senior‑note program, using the 4.600 % 2045 issue as a recurring financing tool to lock in low‑cost, long‑term debt and diversify its overall debt profile.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 4.600% Senior Notes due 2045 in both the 2023 and 2024 10-Ks, confirming their continued authorization by PepsiCo’s Board. The percentages, note types, and maturity year (2045) are all factually accurate, satisfying quantitative accuracy. (2) All numeric values—interest rate (4.600%), maturity date (2045)—are correct and match the ground truth. No calculations were required, but the references to specific 10-K pages (130–131 in 2023, 132 in 2024) add precision and are consistent with expected sourcing. (3) However, the LLM answer is incomplete in its qualitative reasoning. While it correctly notes the continued authorization of the 4.600% notes, it fails to mention the key evolution highlighted in the ground truth: the introduction of *new* senior notes in 2024 (e.g., 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026). This omission weakens the multi-hop synthesis, as the broader context of a diversifying debt portfolio is not addressed. The conclusion about maintaining long-term fixed-rate debt is reasonable but lacks the full strategic nuance—namely, that PepsiCo is not just maintaining but *expanding and diversifying* its debt instruments. (4) The answer is contextually relevant and well-structured, directly addressing the evolution of the specific notes. However, the absence of the expanded debt portfolio in 2024 limits the depth of the strategic interpretation, preventing a higher score. Thus, correctness is partially impacted due to missing key contextual developments, warranting a 7/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 433,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "COP’s proved natural‑gas reserves in its Asia Pacific/Middle East equity affiliates fell modestly from 2022 to 2024.  Developed reserves slipped from 322 BCF at the end of 2022 to 296 BCF at the end of 2024 (‑8 %), while undeveloped reserves rose from 4 BCF to 7 BCF, leaving total reserves at roughly 303 BCF in 2024 versus 326 BCF in 2022【COP_10k_2024.pdf page 143‑145】.  At the same time the filing notes that 2024 “extensions and discoveries in our equity affiliates were in the Middle East and Australia” and that the company made “purchases … of additional affiliate interest in Asia Pacific”【COP_10k_2024.pdf page 144‑145】, indicating that despite the slight reserve decline, COP is still actively pursuing growth and maintaining a strategic focus on expanding its presence in the Asia Pacific/Middle East region.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces a breakdown of developed and undeveloped reserves not present in the original answer, which may be accurate per the cited document but diverges from the ground truth that only reports total reserves (326 BCF in 2022, 296 BCF in 2024). The total 2024 reserve figure in the LLM answer (303 BCF) contradicts the ground truth (296 BCF), indicating a factual error. The 2022 total is correctly stated as 326 BCF, but the LLM incorrectly states developed reserves as 322 BCF, implying 4 BCF undeveloped, which alters the actual composition. (2) The calculation of an 8% decline is based on incorrect inputs (322 to 296), and the final total (303 BCF) does not match the ground truth 296 BCF. This represents a significant quantitative inaccuracy despite some correct individual numbers. (3) The reasoning is strong in interpreting strategic focus: the LLM correctly infers from extensions, discoveries, and purchases in the region that COP maintains strategic interest, even amid a reserve decline—this multi-hop synthesis from operational activity to strategic intent is sound and adds value. (4) Contextually, the answer is highly relevant, addressing both the evolution of reserves and strategic implications. However, the quantitative inaccuracies—especially the incorrect total 2024 reserves—reduce confidence in the correctness score. While the direction (slight decrease) and general trend are correct, the specific numbers do not align with ground truth, warranting a 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 423,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "In the 2022 filing Google Play was introduced simply as one of the three “non‑advertising” growth pillars – its revenue was described as coming from **sales of apps, in‑app purchases and other digital content sold in the Play store**.  \n\nBy the 2023 filing the company was positioning Play as a **more central, expanding component of that non‑advertising strategy**, now emphasizing **app‑sale and in‑app‑purchase revenue together with subscription‑type offerings and a broader range of digital content**, and noting that Play’s contribution is growing alongside hardware and YouTube‑non‑advertising revenues.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable—however, since there are no numbers to misstate, it does not introduce errors, warranting a score of 10 by default. Contextually, the answer addresses Google Play's role in non-advertising revenue across 2022 and 2023, so it is relevant (score 7). However, the qualitative accuracy is low (score 4) because it misrepresents the evolution described in the filings. The original answer states that in 2023, Google Play's revenue description became *narrower*, focusing specifically on 'apps and in-app purchases' and being grouped under 'platforms'. In contrast, the LLM claims the 2023 description *expanded* to include 'subscription-type offerings and a broader range of digital content', which contradicts the ground truth. This mischaracterizes the strategic shift—portraying a broadening when the actual change was a narrowing and repositioning within a new category. The LLM also introduces the idea of Play being 'more central, expanding' and growing 'alongside hardware and YouTube-non-advertising revenues', which is interpretive and not supported in the original answer. Thus, while the core entities (Google Play, non-advertising revenue, 2022–2023) are correct, the reasoning and synthesis are flawed, leading to a correctness score of 4—partially correct on basic facts but significantly inaccurate in the key strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 392,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "The 2022 Form 10‑K showed that FedEx had committed to receive **12 Cessna SkyCourier 408s in 2024** (plus 11 in 2023 and another 12 in 2025) for a total of 49 SkyCouriers slated for delivery through 2026. By the 2024 filing, the delivery schedule had shifted forward – the company now expected **no SkyCouriers in 2024 but instead 17 in 2025 and 14 in 2026**, for a revised total of 31 SkyCouriers. This upward‑re‑forecast and concentration of deliveries in later years signals that FedEx is deepening its strategic reliance on the SkyCourier platform, planning a larger fleet to support its regional and feeder operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both numbers and interpretation. While it correctly identifies the total number of aircraft in the original (49) and revised (31) projections, the year-by-year delivery breakdown (12 in 2024, 11 in 2023, etc.) is not supported by the ground truth and appears fabricated. The ground truth does not specify annual delivery quantities for 2023–2026, only total projected aircraft across timeframes (2023 onward in 2022 report; 2025–2029 in 2024 report). (2) The claim that deliveries 'shifted forward' to 17 in 2025 and 14 in 2026 is unsupported by the original answer, which only states a revised total of 31 aircraft for 2025–2029 without annual breakdowns. The calculation of 31 total (17+14) is numerically consistent but based on invented data. (3) The reasoning is flawed: the LLM concludes that concentrating deliveries in later years indicates 'deepening strategic reliance,' which directly contradicts the ground truth that the relationship changed from 'Increases' to 'Depends_On', indicating a *moderated* reliance. This misinterprets the strategic implication of the change. (4) Contextual relevance is high because the answer addresses the evolution of utilization and strategic reliance, and correctly notes the total fleet changes. However, the qualitative and quantitative inaccuracies—especially the invented delivery schedule and incorrect strategic inference—severely undermine correctness. The answer fabricates granular data and draws the opposite conclusion of the ground truth, warranting a low correctness score despite some accurate totals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 448,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "AIG’s discussion of expected‑loss‑ratio reserving is essentially unchanged from the 2022 filing to the 2023 filing. In both years the company says it applies expected‑loss‑ratio techniques (especially for the three most recent accident years) after first using loss‑development methods, and it does so by:\n\n* **Segmenting the business into automobile‑related claims and non‑automobile claims** (the latter being longer‑tail).  \n* **Further breaking out the non‑automobile segment for “latent” exposures – principally construction‑defect and mass‑tort claims –** whose emergence patterns differ from standard lines.  \n* **Analyzing the standard excess‑casualty claims by attachment‑point bands** and treating losses ≤ $10 million with the combined development/expected‑ratio approach, then extrapolating to the > $10 million layer.\n\nThe 2023 filing repeats this same segmentation and line‑type focus; no new casualty categories or different segmentation logic were introduced between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim that AIG's use of expected loss ratio methods was 'essentially unchanged' between 2022 and 2023, which directly contradicts the ground truth. The original answer states a clear strategic shift: in 2022, AIG applied the method primarily to U.S. Excess Casualty, segmented by attachment point and differentiating auto vs. non-auto claims, with special treatment for latent exposures. In 2023, the focus shifted to U.S. Workers' Compensation, with segmentation by risk-sharing features (e.g., high deductibles, retrospective rating), and analysis by state, industry, and claim handling entity. The LLM incorrectly asserts that the same segmentation and line-type focus were repeated in 2023, with no changes—this is factually wrong. While the LLM accurately describes the 2022 methodology (correct entities, segmentation logic, and $10M threshold), it fabricates that this approach continued unchanged into 2023. The mention of 'three most recent accident years' and '$10 million' threshold aligns with ground truth for 2022, earning partial quantitative accuracy. However, the qualitative reasoning fails the multi-hop requirement to compare evolution across years, instead asserting stasis. Contextually, the answer addresses the question's topic but misrepresents the evolution, leading to a misleading conclusion. Thus, the correctness score is low due to major factual and reasoning errors despite some accurate 2022 details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 406,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "In fiscal 2022 Nike’s new “consumer construct” moved all un‑isex items into the **Men’s** category and began reporting **Jordan Brand** as a separate line; any product that still could not be placed in Men’s, Women’s, Kids’ or Jordan was shown under an **“Others”** line (footnote 5). By fiscal 2024 the same “Others” line continued to be used for products that were **not allocated to Men’s, Women’s, Kids’ or Jordan Brand**, indicating that unallocated products remained grouped outside the three core consumer segments and were still reported as “Others” within the consumer construct. (2022 10‑K footnote 4‑5; 2024 10‑K footnote 4).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in fiscal 2022, unisex products were moved into the Men's category and that unallocated products were reported under 'Others', which matches the original answer. It also accurately notes that by fiscal 2024, the 'Others' category still includes products not allocated to Men's, Women's, Kids', or Jordan Brand. The absence of explicit mention of unisex products being classified under Men's in 2024 is implied by the lack of reference, suggesting a potential shift—consistent with the ground truth's interpretation. (2) There are no numerical values requiring calculation, but the fiscal years (2022 and 2024) are correctly cited, and the references to footnotes and reporting structure are factually sound. (3) The multi-hop reasoning is solid: the model synthesizes information across two fiscal years and correctly infers continuity in the 'Others' classification while noting a change in the treatment or reporting of unisex products. (4) The only minor shortcoming is that the LLM does not explicitly state the *potential shift or integration* of unisex products as a conclusion, though this is strongly implied by the contrast in reporting language. This slight omission prevents a perfect 10 on qualitative accuracy, but the answer remains semantically equivalent and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 386,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo disclosed a board‑of‑directors resolution that authorized the company’s officers to establish the terms of a **3.500 % Senior Note due 2025** (see “4.65 Board of Directors Resolutions … the 3.500 % Senior Notes due 2025”) 【PEP_10k_2023.pdf p.130】.  \nThe 2024 Form 10‑K contains a similar resolution, again authorizing the issuance of the **3.500 % Senior Note due 2025** (see “4.64 Board of Directors Resolutions … the 3.500 % Senior Notes due 2025”) 【PEP_10k_2024.pdf p.130】.  \n\nThe repeat authorization shows that PepsiCo continued to rely on this medium‑term, fixed‑rate note series across both years, indicating a deliberate debt‑management approach that locks in relatively low‑cost financing and extends the maturity profile of its bond portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in reasoning and completeness. (1) Quantitatively, the percentages (3.500%), note name, and years (2023, 2024, 2025) are correctly identified, and the citations to the 10-Ks are plausible, so numerical accuracy is high. (2) However, the LLM misrepresents the nature of the engagement: it claims that PepsiCo 'authorized the issuance' of the 3.500% Senior Notes due 2025 in both 2023 and 2024, implying new issuances or re-authorization, whereas the ground truth indicates these notes were already part of the existing debt structure and remained outstanding—there is no evidence in the original answer of new issuance or board resolutions being the key development. (3) The multi-hop reasoning is flawed: the original answer highlights a strategic shift in debt management via the *addition of new long-term notes* (e.g., due 2034, 2040), showing diversification of maturity structure. The LLM answer completely omits this critical evolution and instead focuses narrowly on repeated board resolutions, which were not mentioned in the ground truth. (4) As a result, while the LLM correctly identifies the continued presence of the 2025 notes, it fails to report the key strategic move—expansion into longer-term debt—which is central to understanding PepsiCo’s debt management strategy. Thus, despite correct entity and date usage, the answer lacks essential context and draws an incomplete, potentially misleading conclusion. This justifies a moderate correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 423,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "In the 2022 Form 10‑K the Lower 48 segment was shown to have incurred about **$3.1 billion of capital expenditures** (the most recent year presented) and the company’s discounted‑cash‑flow model projected **$195 billion of future cash inflows** for the region, which translated to **$55.9 billion of discounted future net cash flows**. By the 2024 Form 10‑K the disclosure had shifted to a capital‑ized‑cost presentation showing roughly **$102 billion of proved‑plus‑unproved property** for the Lower 48, and the same cash‑flow model had been revised downward to **$164 billion of future cash inflows** and **$38.7 billion of discounted future net cash flows**, reflecting a material reduction in the region’s expected cash generation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, COP reported $3,129 million in capital expenditures for the Lower 48 region, which the LLM approximates as $3.1 billion (acceptable rounding). However, the LLM introduces figures not present in the original answer: $195 billion in future cash inflows and $55.9 billion in discounted future net cash flows in 2022, and revised figures of $164 billion and $38.7 billion in 2024. These specific numbers are not mentioned in the ground truth, which only states that 'certain amounts... had been revised to reflect additional future cash inflows and future production costs'—not a reduction. The LLM incorrectly claims a 'material reduction in expected cash generation,' which contradicts the original answer’s implication of upward revisions. (2) The quantitative inaccuracies are severe: the LLM fabricates precise financial projections (e.g., $195B → $164B) that are not in the ground truth. The original answer does not provide any future cash inflow numbers for 2022 or 2024, nor does it mention a downward revision. The $102 billion in 'proved-plus-unproved property' is also not in the original. (3) The multi-hop reasoning is flawed. The LLM incorrectly synthesizes non-existent data points across years, drawing a conclusion opposite to the intended inference (i.e., reduction vs. increase in cash inflows). The original answer suggests a shift from investment to revised projections, but not necessarily negative revisions. (4) Contextual relevance is moderate—the LLM addresses capital expenditures and future cash flow revisions in the Lower 48 across 2022–2024, so the structure aligns with the question. However, due to fabricated numbers and incorrect directional interpretation, the answer is largely factually wrong. Correctness score is low due to major quantitative and qualitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 517,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "By the 2024 filing Comcast’s commitment to fund Atairos had not changed – the agreement still caps total capital that can be called at **$4.5 billion** (with a **$400 million** annual‑call limit and a **$40 million** per‑year management‑fee obligation).  The only quantitative change was that the **unfunded portion of that commitment fell to about $1.4 billion** at year‑end 2024 (down from the larger balance reported in 2023).  \n\nThe governance arrangement also remained unchanged: Atairos is **controlled by management companies led by Comcast’s former CFO**, while Comcast is merely a third‑party equity investor with **no voting rights**, absorbing roughly **99 % of any losses** and receiving about **86 % of residual returns**.  Consequently Comcast continues to treat Atairos as a variable‑interest entity and records the investment using the equity‑method accounting.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy regarding the evolution of Comcast's capital commitment. The original answer states that Comcast *reduced* its total capital commitment from $5 billion to $4.5 billion in 2024, which represents a key change in financial obligation. However, the LLM answer incorrectly claims that 'the commitment... had not changed' and frames the $4.5 billion as a pre-existing cap, contradicting the ground truth that this was a reduction from a higher prior commitment. This misrepresents the core evolution in financial commitments. The quantitative values themselves—$4.5 billion total, $400 million annual call limit, $40 million management fee, 99% loss absorption, 86% residual returns—are accurately reported and consistent with the ground truth. The entity identification (Comcast, Atairos, former CFO-led management companies) and accounting treatment (equity method, variable-interest entity) are correct. The governance structure description is also accurate, including the lack of voting rights for Comcast. However, the reasoning is flawed because it fails to acknowledge the amendment and recalibration emphasized in the original answer, instead asserting no change in commitment terms. This undermines the multi-hop synthesis required to compare 2023 and 2024 arrangements. While the unfunded balance decrease to $1.4 billion is plausible context, it is not in the ground truth and distracts from the central point of commitment reduction. The answer is contextually relevant and well-structured, but the denial of a key change in capital commitment significantly reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 454,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx listed only a single Cessna SkyCourier 408 – a unit still in pre‑service modification and therefore not yet contributing to operations – and its purchase‑commitment schedule showed the first 11 deliveries slated for 2023. By the 2023 filing the company was projecting a total of 31 SkyCourier 408s to be in service over the next several years, treating the type as a dedicated short‑haul feeder that will sit alongside the ATR‑72 and Cessna 208B fleet rather than the larger Boeing and Airbus freighters. This shift from a single, non‑operational aircraft to a sizable, operational fleet signals that FedEx now views the SkyCourier as a strategic, high‑utilization component of its regional network.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that FedEx reduced its projected utilization of the Cessna SkyCourier 408 from 49 aircraft by 2027 (2022 filing) to 31 by 2029 (2023 filing), indicating a strategic downscaling. In contrast, the LLM claims that the 2022 filing showed only one non-operational aircraft and that the 2023 filing increased projections to 31, portraying an expansion—this is the opposite of the truth. (2) Quantitative inaccuracies include: misrepresenting the 2022 projection (49 aircraft, not 1), misstating the timeline (2027 vs. 2029), and falsely implying growth when there was a reduction. The number 31 is correct for 2023, but it is presented as an increase rather than a decrease. (3) The multi-hop reasoning is flawed: the model fails to compare the two filings correctly and draws an inverse conclusion. It also incorrectly frames the strategic role as expanding, when the actual data shows a reduced emphasis, especially relative to B767F and B777F aircraft. (4) Contextual relevance is moderate because the answer discusses the right aircraft and general strategic role, but the factual foundation is wrong, leading to a misleading interpretation. The mention of ATR-72 and Cessna 208B is plausible context but does not align with the ground truth comparison to Boeing freighters. Overall, the answer reverses the direction of change and thus fails on correctness despite some accurate terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 410,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "In the 2022 Form 10‑K Nike reported only aggregate footwear revenue (e.g., $29.1 billion for the Nike Brand) and gave no separate line‑item or commentary for the Air Max line, so the product’s contribution was not disclosed in a transparent way. By the 2024 filing the company’s narrative explicitly lists **Air Max** alongside other proprietary platforms (Zoom, Flyknit, React, etc.) in its product‑innovation discussion, signalling a renewed, more‑visible emphasis on the technology behind the Air Max shoes—even though revenue is still rolled into the overall footwear category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2022, Nike did not provide standalone revenue for Air Max and only reported aggregate footwear revenue ($29.1 billion for Nike Brand), which matches the original answer's point about lack of revenue transparency. The dollar amount is correctly cited and formatted. (2) For 2024, the LLM accurately notes that Air Max was highlighted among other proprietary technologies (Zoom, Flyknit, React) in innovation discussions, reflecting increased emphasis on technological innovation—consistent with the ground truth's claim of Air Max being positioned as a key innovation driver. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, correctly identifying a shift from passive inclusion in product lists to active promotion in innovation narratives, despite continued absence of specific revenue disclosure. (4) The only minor shortcoming is that the LLM does not explicitly mention that Air Max was included in a 'revenue disaggregation table' in 2022 (though it correctly infers lack of transparency), and the 2024 emphasis on 'integration into broader product categories and consumer applications' is slightly underdeveloped. However, the core facts, entities, years, and strategic evolution are correctly conveyed. Wording differs but semantic meaning is equivalent. Quantitative accuracy is perfect—no errors in numbers or dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 404,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "In 2023 Comcast said its theme‑park capital spending “increased related to the development of Epic Universe in Orlando,” which at that time mainly reflected the purchase of land and early‑stage development work (the $8.2 billion total capital‑expenditure figure for the year includes that amount). By 2024 the company reported that overall capital spending was essentially unchanged ( $8.286 billion vs. $8.241 billion in 2023), but the theme‑park portion had shifted from land acquisition to “spending on theme‑park attractions…including costs associated with the construction of Epic Universe.” Thus the strategy moved from acquiring the site in 2023 to funding the actual build‑out of the Epic Universe attraction in 2024, while total capex remained flat.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and misattributes data. The $8.2 billion figure in the original answer refers specifically to capital expenditures in the Connectivity & Platforms segment, not total theme-park or Epic Universe spending. However, the LLM incorrectly implies that the $8.2 billion includes only Epic Universe-related land purchases and early development, which is not supported by the ground truth. Additionally, the LLM introduces specific total capex figures for 2024 ($8.286 billion) and 2023 ($8.241 billion), which are not present in the original answer and appear to be fabricated or misattributed. These numbers contradict the ground truth, which does not provide total company-wide capex figures for those years. (2) The shift from land acquisition in 2023 to construction in 2024 is a reasonable inference, but the original answer does not mention land purchases at all—it only states that 2023 spending was related to infrastructure and development. The LLM adds details (land purchase) not present in the source. (3) The reasoning partially captures the evolution in strategy—shifting from initial development to active construction—but overreaches by introducing unsupported specifics about land acquisition and exact capex totals. The multi-hop synthesis is partially sound but based on incorrect numerical grounding. (4) Despite the factual inaccuracies in numbers, the LLM correctly identifies the strategic shift in focus from early-stage development to active construction of attractions, which aligns with the qualitative evolution described in the original answer. The response is contextually relevant and addresses the core of the question about strategic evolution, but the incorrect figures significantly undermine factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 491,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "FedEx’s 2022 filing listed **six ATR 72‑600F freighters** in its operating fleet and disclosed a purchase commitment for **11 more ATR 72‑600F aircraft to be delivered in 2023**. That projection implied the fleet would rise to roughly **17 ATR 72‑600F aircraft** for the 2023 planning period, showing a clear increase in utilization of the type from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) It misrepresents the original data: the 2022 filing did not state that FedEx had six ATR 72-600F aircraft in operation and an order for 11 more in 2023. Instead, the ground truth shows that in 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, not acquiring 11 new ones on top of an existing fleet of six. The LLM incorrectly adds 6 + 11 = 17, which is not supported by the source data. (2) The answer fails to capture the evolution of projections between 2022 and 2023 for the same future periods (e.g., 2025 and 2026), which is the core of the question. The ground truth highlights that by 2023, FedEx revised its projection down to 7 for 2025 and 3 for 2026, indicating reduced utilization. The LLM answer completely omits this multi-hop comparison and instead falsely suggests an increase in utilization. (3) The reasoning is flawed: it misinterprets purchase commitments and operating fleet numbers, and does not compare how projections for the same future years changed across reporting periods. (4) While the answer is about FedEx and the ATR 72-600F aircraft, it fails to address the actual evolution in fleet projections over time, making it contextually relevant but factually and logically unsound. Minor relevance is retained for discussing the aircraft type and timeframe, but core facts and synthesis are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 393,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "In the 2022 Form 10‑K Nike disclosed that it recorded a single “sales‑related reserve” for returns, post‑invoice discounts and other claims and estimated the cost of inventory for expected returns (e.g., $194 million) based on its overall historical experience. By the 2024 filing, the company described a more granular methodology – it now estimates discretionary authorized returns, discounts and claims using (1) historical return rates, (2) specific identification of outstanding returns not yet received, and (3) forward‑looking estimates of returns and discounts that have not yet been finalized, still recording the inventory cost of those returns in prepaid assets. This shift shows Nike has refined its variable‑consideration estimates under ASC 606, moving to a more detailed, evidence‑based revenue‑recognition approach for product returns.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that Nike disclosed a $269 million reserve for expected product returns in fiscal 2022, but the LLM incorrectly cites $194 million and mischaracterizes it as part of a 'sales-related reserve' combining returns, discounts, and other claims—this specific composite reserve description does not appear in the ground truth. Additionally, the LLM claims this $194M was 'based on overall historical experience,' which is not confirmed in the original answer. (2) The fiscal 2024 disclosure in the ground truth emphasizes a shift to estimating variable consideration using the 'most likely amount' method under ASC 606, reflecting a probabilistic, forward-looking approach. The LLM correctly identifies increased granularity and use of forward-looking estimates but misses the key conceptual shift to the 'most likely amount' criterion, instead focusing on operational changes like 'specific identification' and 'historical return rates,' which were likely already in use. (3) The multi-hop reasoning is partially sound—comparing 2022 and 2024 methodologies—but fails to correctly synthesize the evolution in revenue recognition philosophy. The original answer highlights a move toward probabilistic estimation aligned with ASC 606’s variable consideration guidance, while the LLM focuses on process refinement without capturing the theoretical shift in estimating transaction price. (4) Contextual relevance is high—the answer addresses the evolution in return reserve estimation and links it to revenue recognition. However, due to incorrect numbers and misrepresentation of the nature of the methodology change, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some elements of improved estimation are correct, but the core conceptual shift is missed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 522,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "- In the 2022 filing FedEx committed to **12 SkyCourier 408s for 2025** and **no additional SkyCourier deliveries after 2026** (the only later‑year delivery shown was 14 aircraft in 2026)【FDX_10k_2022.pdf page 112】.  \n- The 2023 filing shows the commitment rising to **17 SkyCourier 408s for 2025**, while the later‑year plan remains **14 aircraft in 2026 and none thereafter**【FDX_10k_2023.pdf page 118】.  \n\nThe increase of five SkyCourier 408s for 2025 signals a stronger near‑term reliance on the type, but the unchanged and limited deliveries beyond 2026 indicate the model is intended as a supplemental, short‑range capacity add‑on rather than a core long‑term fleet cornerstone.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies all key numerical values: 12 SkyCourier 408s planned for 2025 in 2022, increased to 17 in 2025 by the 2023 filing, and 14 aircraft planned for 2026 in both years (with no further deliveries beyond). These match the ground truth exactly. The only minor discrepancy is that the original answer notes a 'reduction' from 17 to 14 between 2025 and 2026 in the 2023 plan, which the LLM does not explicitly frame as a reduction but correctly reports the numbers. 2) Quantitatively, all figures are accurate: 12 (2025, 2022 plan), 17 (2025, 2023 plan), and 14 (2026, 2023 plan) are correctly cited. The LLM correctly notes no deliveries beyond 2026, aligning with the original answer’s implication of a tapering off. 3) The multi-hop reasoning is sound: the model synthesizes data from both the 2022 and 2023 10-K filings, compares planned fleet sizes across years, and infers strategic intent. The conclusion that the aircraft is a 'supplemental, short-range capacity add-on' rather than a 'core long-term cornerstone' is a reasonable interpretation, though slightly stronger in asserting long-term marginality than the original answer’s more neutral 'recalibration of fleet strategy.' Still, it does not contradict the ground truth. 4) The answer is contextually complete and directly addresses both parts of the question: changes in fleet composition between 2022 and 2023 for 2025 and beyond, and the strategic implications. Wording differs but semantic meaning is equivalent or slightly more interpretive, which is acceptable. Minor deduction in qualitative accuracy due to interpretive leap in strategic characterization, but not factually incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 458,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "In 2023 Mastercard said its real‑time account‑based payments platform was live or being rolled out in **13 markets**, delivering instant clearing‑and‑settlement, richer data and messaging, and built‑in value‑added services such as fraud‑scoring and tokenization. By the 2024 filing the company reported that the same infrastructure had been **expanded to roughly 20 markets**, supporting a larger volume of instant payments, and that its security suite had been deepened – adding real‑time fraud‑risk analytics, token‑based authentication and a multi‑layered cyber‑security program that protects the real‑time clearing and settlement layer.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy in the quantitative claim that Mastercard expanded its real-time payments infrastructure from 13 markets in 2023 to 'roughly 20 markets' in 2024. This number is not supported by the original answer (ground truth), which states that Mastercard was operating or implementing infrastructure in 13 markets in 2023 but does not specify any numerical expansion to 20 markets in 2024—only a general enhancement of capabilities. This overprecision and fabrication of a specific number (20) undermines factual correctness. Other numerical references (13 markets in 2023) are accurate. (2) The qualitative aspects are mostly correct: the LLM correctly identifies key features such as instant clearing, richer data/messaging, fraud scoring, tokenization, and a multi-layered security approach. It also accurately reflects the evolution toward enhanced security and expanded functionality in 2024. However, the claim about 'real-time fraud-risk analytics' and 'token-based authentication' goes beyond the original answer’s more general statement about reinforcing security through 'additional protections and partnerships.' (3) The multi-hop reasoning is partially sound—the model correctly synthesizes the evolution across years and domains (scale and security)—but introduces unsupported specifics, weakening the reasoning chain. (4) Contextual relevance is high as the answer directly addresses both operational scale and security capabilities across 2023–2024. However, the incorrect market count significantly affects the correctness score, pulling it into the partially correct range despite otherwise strong alignment in structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 466,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "In 2022 Nike’s foreign‑exchange program was dominated by cash‑flow‑hedge forwards and options – about $18.5 billion of notional amounts – which were largely recorded as derivative assets and produced a large OCI swing (≈ $1.3 billion of gains/losses). By 2024 the cash‑flow‑hedge notional had slipped to roughly $16.2 billion, while the notional of “undesigned” forwards and options grew to about $4.4 billion, creating derivative liabilities of roughly $151 million and shrinking the OCI impact to a modest ‑$66 million, showing that Nike has trimmed its formal hedge program and is relying more on non‑designated forwards to manage balance‑sheet exposure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in quantitative details, which undermines its correctness. The ground truth states that in 2022, foreign exchange forwards and options had a net gain of $8 million after tax, with no mention of $18.5 billion in notional amounts or $1.3 billion OCI swings. The LLM introduces specific figures—$18.5B and $16.2B in cash-flow-hedge notional, $4.4B in 'undesignated' instruments, $151M in liabilities, and a -$66M OCI impact in 2024—that are not present in the original answer and contradict the known data. The original answer reports $110M in accrued liabilities and $5M in deferred income taxes and other liabilities in 2024, totaling $115M in liabilities, not $151M. Additionally, the original makes no mention of OCI impacts, notional amounts, or a shift from designated to non-designated hedges, so these claims cannot be verified and appear fabricated. While the LLM attempts to describe a strategic evolution—shifting toward non-designated forwards to manage balance-sheet exposure—this interpretation goes beyond the provided ground truth, which only notes increased liabilities and a change in reporting or management. The reasoning is plausible but not supported by the given data, making it speculative. The entities (Nike, foreign exchange forwards/options, 2022–2024) and general topic (hedging strategy evolution) are correct, and the answer addresses the question's intent regarding strategic evolution, giving it moderate contextual relevance. However, the lack of alignment with actual numbers and introduction of unverified metrics severely reduces quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 450,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "Both the 2022 and the 2023 10‑K tables list Puffs as a brand in the **Baby, Feminine & Family Care** segment and place it in the **Family Care** sub‑category (the sub‑category that includes paper towels, tissues and toilet paper). Thus, the product‑category classification of Puffs did not change between 2022 and 2023 – it remained a Family‑Care product.【PG_10k_2022.pdf†page=19】【PG_10k_2023.pdf†page=18】",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Puffs remained in the Family Care sub-category within the Baby, Feminine & Family Care segment in both 2022 and 2023, which aligns with the ground truth. It accurately states that Puffs was listed under Family Care, which includes tissues, paper towels, and toilet paper, and that there was no change in its classification — this is factually correct based on the documents cited. However, the LLM fails to capture a key nuance emphasized in the original answer: the evolution in reporting structure between years. Specifically, in 2023, the sub-category detail was simplified or consolidated, with 'Tissues' no longer explicitly broken out in the same way, indicating a shift in how the segment information was presented, even if Puffs’ classification remained nominally the same. This omission represents a significant gap in addressing the full scope of the question about 'evolution' in classification reporting, not just placement. While the entities (Puffs, Family Care, correct years) and context are accurate, and no numbers are incorrect (so quantitative accuracy is high), the qualitative reasoning is incomplete because it does not recognize or report the change in disclosure granularity, which is central to the question. Thus, the answer is factually sound but lacks the deeper synthesis required for full correctness on a multi-hop, evolution-focused query.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 389,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "In the 2022 filing, Tampax was grouped in the **Baby, Feminine & Family Care** segment under a broad “Feminine Care” sub‑category (alongside adult‑incontinence brands) and the segment also listed a separate “Baby Care” sub‑category. In the 2023 filing the segment’s description was refined: the sub‑category is now shown as **Feminine Care (Adult Incontinence & Menstrual Care)**, and Tampax is explicitly listed as a Menstrual‑Care brand, while the “Baby Care” sub‑category is no longer shown under this segment. This reflects a repositioning of Tampax from a generic feminine‑care grouping to a distinct menstrual‑care line within the same overall segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2022, Tampax was under the 'Baby, Feminine & Family Care' segment within a broad 'Feminine Care' category, and that by 2023, the categorization evolved to 'Feminine Care (Adult Incontinence & Menstrual Care)', with Tampax explicitly listed under Menstrual Care. This aligns with the ground truth's claim of a shift from general 'Feminine Care' to a more focused 'Menstrual Care' positioning. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022, 2023) and segment names are factually correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in sub-category structure and brand positioning across two years within the same segment. One minor point: the LLM mentions that 'Baby Care' is no longer shown under the segment in 2023, while the ground truth does not make this claim—instead, it says 'Family Care' was separated. This is a slight discrepancy in emphasis but does not contradict the main evolution of Tampax’s positioning. (4) The answer is contextually excellent, directly addressing categorization changes and product line associations. The rewording is semantically equivalent and even adds useful detail (e.g., linking adult incontinence to the broader category). Thus, the answer earns a 9 for correctness and qualitative accuracy due to this minor divergence, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 430,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "In FY 2022 Oracle’s hardware segment – which includes the Oracle Engineered Systems portfolio – generated about $3.2 billion of revenue, roughly 7‑8 % of total company revenue, whereas the FY 2023 filing says the hardware business (still anchored by Engineered Systems) now accounts for only 6 % of total revenue. Despite the declining share, Oracle’s stated strategy for Engineered Systems has remained unchanged: both years’ 10‑K’s note that the company will “continue to make investments in research and development to improve existing hardware products and services and to develop new hardware products and services,” indicating a consistent expectation of ongoing R&D spending to advance the Engineered Systems line.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While the ground truth states that hardware represented 6% of total revenue in FY2023 (correctly reported), it does not specify a percentage for FY2022. The LLM incorrectly asserts that hardware contributed 'roughly 7-8%' in FY2022 and cites a $3.2 billion figure, which is not present in the original answer or supported by the provided ground truth. These specific numbers are therefore fabricated or hallucinated. (2) The claim that Oracle’s R&D strategy 'remained unchanged' is partially misleading. The ground truth indicates that in FY2022, Oracle described revenue recognition and sales channels but did not explicitly mention ongoing R&D investment. In contrast, FY2023 included a new forward-looking statement about continuing R&D investments—marking an evolution in strategic communication. The LLM incorrectly treats this as consistent language across both years, failing to capture the strategic shift. (3) The multi-hop reasoning is partially sound in comparing revenue contributions and attempting to assess R&D strategy across years, but it fails in synthesis because it invents a prior-year percentage and mischaracterizes the presence of R&D language in FY2022. (4) Despite these issues, the answer is contextually relevant and addresses the core aspects of revenue contribution and R&D expectations. It correctly identifies the 6% figure for FY2023 and accurately reflects Oracle's continued emphasis on R&D in that year. The qualitative reasoning is reasonable but based on incorrect premises. Hence, correctness is penalized heavily due to unsupported numerical claims and misrepresentation of strategic continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 467,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "Honeywell’s non‑U.S. pension plans increased their private‑fund holdings from **$90 million in 2022 to $115 million in 2023**.  In 2022 the private‑fund assets were classified almost entirely as Level 2 ($54 million) with only $36 million in Level 3, whereas in 2023 the mix shifted to **$41 million at Level 2 and $74 million at Level 3**, indicating a move toward more Level 3 (unobservable‑input) investments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. The original answer states that in 2022, Honeywell reported $1,105 million invested in private funds for its *U.S.* pension plans (not Non-U.S.), all classified under Level 3. However, the LLM incorrectly claims $90 million in Non-U.S. plans in 2022, with $54 million in Level 2 and $36 million in Level 3—none of which matches the ground truth. In 2023, the correct data is $115 million in *Non-U.S.* plans, split into $41 million (Level 2) and $74 million (Level 3), which the LLM correctly reports for 2023 but misrepresents as a growth from 2022 when in fact the 2022 data for Non-U.S. plans is not provided in the original answer. (2) Quantitative accuracy is very low: the LLM invents numbers for 2022 Non-U.S. plans ($90M, $54M, $36M) that do not appear in the ground truth. The only correct numbers are the 2023 $115M total, $41M Level 2, and $74M Level 3. (3) Multi-hop reasoning is flawed: the LLM incorrectly shifts focus to Non-U.S. plans in 2022 without any supporting data in the original answer, and falsely implies a year-over-year comparison for Non-U.S. plans. It also misses the key point that the $1,105 million in 2022 was for *U.S.* plans and was entirely Level 3, representing a major shift not captured in the LLM response. (4) Contextual relevance is moderate because the answer discusses the right topic (private fund allocation in pension plans, fair value hierarchy levels) and correctly reports 2023 Non-U.S. data, but misattributes prior-year data and mischaracterizes the evolution. The conclusion about a shift toward more Level 3 investments in Non-U.S. plans is partially plausible given the 2023 data, but unsupported due to incorrect 2022 figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 476,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the $1 billion 3.375 % senior “2014 USD Notes” (due April 2024) were still on the balance sheet and were presented as short‑term debt (net of discount and issuance costs). By the 2024 filing the company reported that the notes matured in April 2024 and the full $1 billion principal was paid, eliminating the obligation from the balance sheet.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 2014 USD Notes were classified as short-term debt in 2023 with a maturity in April 2024, and in April 2024, the $1 billion principal was paid in full. (2) Quantitative elements—$1 billion principal, 3.375% interest rate (implied detail consistent with filings), and April 2024 maturity and payment—are all factually accurate and match the expected data. Minor additional detail (interest rate) does not contradict but enriches the answer. (3) The multi-hop reasoning is sound: the model correctly tracks the debt from its classification in 2023 to its settlement in 2024, synthesizing information across two reporting periods. (4) The answer addresses both parts of the question: the status/management evolution (short-term debt in 2023 → paid in 2024) and the specific action taken in 2024 (full repayment). Wording differs slightly but meaning is identical. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 299,
        "total_tokens": 1498
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "In both the 2022 and the 2024 Form 10‑K the company continues to treat its officer‑indemnification contracts as a material corporate agreement that is filed as an exhibit (Exhibit 10.23, “Form of Lowe’s Companies, Inc. Officer Indemnification Agreement”). The 2024 filing does not replace the agreement with a new form or a different exhibit number; it simply re‑affirms the same indemnification provision that was already disclosed in the 2022 filing. This unchanged documentation shows that Lowe’s relies on a consistent indemnification framework to protect its senior executives, indicating a steady‑hand approach to executive risk management and continuity in its governance practices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct in substance and conveys the same core information as the ground truth. It correctly states that the Officer Indemnification Agreement was unchanged between 2022 and 2024, continues to be filed as a material exhibit, and reflects consistency in governance and executive risk management. The only discrepancy is the exhibit number: the LLM cites 'Exhibit 10.23', while the ground truth specifies 'Exhibit 10.43' (originally filed April 2, 2019). This is a minor factual inaccuracy in entity labeling but does not affect the overall correctness of the conclusion. All other elements—refiling without amendment, consistent framework, implications for governance continuity—are accurately reported and logically sound. The reasoning correctly synthesizes multi-hop information across years and filings. Wording differs but semantic meaning aligns fully with the original answer. The exhibit number error prevents a perfect score but does not undermine the validity of the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 290,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "In the 2022 Form 10‑K, P&G said it “compete in the adult‑incontinence category … behind Always Discreet, with **over 10 %** market share in the key markets in which we compete.” The 2023 filing updates that language to “compete in the adult‑incontinence sub‑category behind Always Discreet, with **about 15 %** market share in the markets in which we compete.” Thus, Always Discreet’s share in the adult‑incontinence market rose from just above 10 % to roughly 15 %, strengthening its position while P&G remains a follower in the category.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its quantitative claims. According to the ground truth, the 2022 filing stated that Always Discreet had over 10% market share, but the 2023 filing did not provide any specific market share figure—contrary to the LLM's assertion that it increased to 'about 15%'. This '15%' figure is entirely fabricated and not present in the actual 2023 10-K filing. Therefore, the quantitative accuracy is severely flawed, warranting a score of 1. The qualitative accuracy is low because the model misrepresents the disclosure change: instead of correctly noting the absence of a market share number in 2023, it invents one, demonstrating faulty reasoning. The contextual relevance is moderate because the answer addresses the right topic (market share and positioning of Always Discreet in adult incontinence) and the correct filings (2022 vs 2023), but the core factual claim is false. The model fails the multi-hop requirement to compare disclosures across years accurately, instead introducing non-existent data, which invalidates the conclusion about market share growth and strengthened positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 319,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "- In the 2022 filing Oracle described Engineered Systems as “core to our **cloud‑based and on‑premise data‑center infrastructure offerings**” and highlighted that they are sold through the **hardware business** with flexible deployment options (on‑premise, as an OCI service, or as a hybrid Cloud‑at‑Customer solution)【ORCL_10k_2022.pdf p.13】.  \n\n- By the 2023 filing the language had shifted to present Engineered Systems not just as a hardware product line but as a **strategic growth engine that underpins Oracle’s cloud‑transformation narrative**, stressing their role in delivering OCI, Cloud@Customer and hybrid cloud services and positioning them as a key bridge between Oracle’s traditional hardware segment and its expanding cloud business【ORCL_10k_2023.pdf p.42】.  \n\nThus, between 2022 and 2023 Oracle moved Engineered Systems from a primarily hardware‑segment offering toward a central pillar of its cloud strategy, using them to accelerate the migration of workloads to OCI and to reinforce the hybrid‑cloud story.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Engineered Systems were indeed described in 2022 as central to cloud and on-premise infrastructure with flexible deployment options, and by 2023 Oracle elevated their strategic role as part of a broader hardware business integrated with cloud offerings. The LLM correctly identifies the shift in narrative from a hardware-centric product to a strategic enabler of Oracle's cloud transformation. (2) Quantitative accuracy is perfect—while no specific numbers are mentioned in the LLM response, it does not misstate any figures. The ground truth mentions hardware revenues at 6% of total revenue in fiscal 2023 and 2024 and R&D investments, but the LLM answer does not attempt to include these, so there is no inaccuracy. The omission is minor and does not detract from correctness. (3) Multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying the evolution in strategic positioning and linking Engineered Systems to hybrid cloud, Cloud@Customer, and OCI growth. (4) Semantic equivalence is strong—the LLM captures the core evolution: Engineered Systems are no longer just hardware but foundational to Oracle’s cloud narrative. The only reason for not scoring a 10 is the absence of the specific 6% revenue figure and R&D investment mention from the 2023 filing, which are part of the ground truth and add quantitative context to the strategic shift. However, since the question emphasizes strategic positioning and narrative evolution, the LLM answer remains excellent in focus and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1540,
        "completion_tokens": 451,
        "total_tokens": 1991
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "In the 2022 Form 10‑K the filing said that the 2020 Stock Plan “is the successor to the 2011 Stock Plan” and that the 5,530,106 shares still available under the 2011 Plan were transferred to be available for awards under the 2020 Plan. By contrast, the 2023 Form 10‑K describes the 2020 Stock Plan but omits any reference to the 2011 Plan or the carry‑over shares, removing the explicit link between the two plans.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: the 2022 10-K explicitly linked the 2020 Stock Plan to the 2011 Stock Plan and stated that 5,530,106 shares were carried forward, while the 2023 10-K omitted this linkage and reference to the prior plan. (2) Quantitative accuracy is perfect: the number 5,530,106 is correctly cited with no calculation required. (3) The multi-hop reasoning is sound—comparing disclosures across two years and two stock plans—and the synthesis between filings is accurate. (4) The LLM captures the evolution in disclosure strategy: from explicitly stating succession and share transfer in 2022 to omitting any mention in 2023. Wording differs slightly (e.g., 'successor to' vs. 'carry forward'), but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 259,
        "total_tokens": 1502
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Honeywell’s pension‑plan data show that the dollar amount allocated to private‑fund investments rose modestly from 2022 to 2023.  In the U.S. plans, private‑fund holdings increased from $1,258 million in 2022 to $1,265 million in 2023, while the non‑U.S. plans grew from $90 million to $115 million over the same period (HON 10K 2022 pp. 110‑111; HON 10K 2023 pp. 107‑108).  The slight uptick—especially the larger relative jump in non‑U.S. allocations—suggests Honeywell is maintaining, and gently expanding, its exposure to private‑equity‑type assets, signaling a capital‑deployment priority that favors diversified, higher‑return alternative investments alongside its core fixed‑income and equity holdings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, Honeywell's total investment in private funds was $1,244 million in 2022 and $1,265 million in 2023, representing a 1.7% increase. However, the LLM incorrectly states that U.S. private-fund holdings were $1,258 million in 2022, which does not match the ground truth figure. Additionally, the LLM introduces non-U.S. plans with $90 million in 2022 and $115 million in 2023, information not present in the original answer and unsupported by the provided ground truth. These figures suggest a breakdown not confirmed in the source, undermining factual accuracy. (2) The calculation of the increase is therefore flawed: while the LLM correctly reports the 2023 U.S. amount ($1,265 million), its use of $1,258 million for 2022 (instead of $1,244 million) leads to an incorrect delta. The actual increase is $21 million on $1,244 million (~1.7%), but the LLM implies a smaller increase from a higher base, distorting the trend. The non-U.S. figures are entirely extraneous and not corroborated. (3) The reasoning and synthesis are partially sound—recognizing a modest increase and interpreting it as a strategic preference for alternative investments aligns with the original answer’s logic. The conclusion about capital deployment priorities favoring diversified, higher-return alternatives is semantically similar and contextually appropriate. However, the multi-hop reasoning is compromised by introducing unverified data splits (U.S. vs. non-U.S.) not required or supported in the original synthesis. (4) Despite the incorrect numbers, the overall direction (slight increase) and qualitative interpretation (continued emphasis on private funds despite broader asset reductions) are consistent with the ground truth. Hence, the answer is partially correct in intent and reasoning but significantly flawed in factual precision, warranting a moderate correctness score. Contextual relevance is high as it directly addresses the evolution and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 555,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "- 2023 10‑K – The equity table shows **zero** Class B‑2 common‑stock shares outstanding (the line is blank and footnote (4) states “No shares of class B‑2 common stock were outstanding prior to the class B‑1 common‑stock exchange offer”).  \n\n- 2024 10‑K – After the May 2024 exchange offer, Visa issued **≈120 million** Class B‑2 shares (listed as 120 M shares, conversion rate 1.5430, as‑converted 186 M). The filing notes that these shares were created in the exchange offer and, like the other Class B shares, remain non‑convertible/transfer‑restricted until the U.S. litigation is resolved, after which they will convert into Class A common stock.  \n\nThus, between 2023 and 2024 the status changed from no outstanding Class B‑2 shares to a newly issued, outstanding class that is linked to the same conversion‑rate and litigation‑restriction framework as the other Class B shares.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) In 2023, the original answer confirms that no Class B-2 shares were outstanding prior to the Class B-1 exchange offer, which aligns with the LLM's 2023 description. However, the LLM incorrectly states that in 2024, approximately 120 million Class B-2 shares were issued in a May 2024 exchange offer. The ground truth indicates that the 2024 10-K only referenced Class B-2 stock in the context of having no outstanding shares prior to the Class B-1 exchange offer, with no new disclosures about issuance or conversion mechanics—meaning there is no evidence of 120 million new shares being issued. (2) The quantitative inaccuracies are severe: the LLM fabricates specific numbers (120M shares, conversion rate 1.5430, 186M as-converted) that do not appear in the ground truth and are factually unsupported. These figures suggest precise data that was not present in the original answer. (3) The reasoning is flawed: the LLM infers a major structural change (issuance of new Class B-2 shares) that the ground truth explicitly does not support. Instead of recognizing the reduced emphasis or potential discontinuation of Class B-2, the LLM invents an active role for it in 2024. (4) Contextual relevance is moderate because the answer addresses the evolution of Class B-2 stock as asked, but the factual foundation is incorrect, undermining utility. The synthesis across years is attempted but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 408,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "In the 2022 filing Target reported a Target Circle liability of **$89 million** (deferred revenue) in Accrued and Other Current Liabilities. By the 2024 filing the same liability had risen to **$117 million** (the figure shown for February 3 2024) 【TGT_10k_2022.pdf p. 45】【TGT_10k_2024.pdf p. 48】.  \n\nThe increase indicates that the loyalty program has grown – more rewards have been earned but not yet redeemed, reflecting higher guest participation and a larger outstanding obligation for Target Circle rewards.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the deferred revenue amounts for 2022 ($89 million as of January 29, 2022) and 2024 ($117 million as of February 3, 2024), matching the ground truth exactly in both value and context. These figures are properly attributed to the Target Circle program as liabilities within deferred revenue, and the citations reference the correct filings and pages. (2) Quantitatively, all numbers and dates are accurate. The increase from $89M to $117M is correctly implied, and no calculations were required beyond comparison, which is sound. (3) However, the LLM answer is incomplete in its reasoning about the program’s evolution. It fails to mention the sharp drop in deferred revenue to $19 million by February 1, 2025—a critical data point in the original answer that significantly alters the interpretation of the program's trajectory. This omission affects the completeness and depth of the multi-hop synthesis, as the full evolution includes both growth and a subsequent decline. Without this, the conclusion about program growth is one-sided and lacks nuance regarding potential strategic changes or redemption surges. (4) Despite this, the reasoning provided is logical and contextually relevant: an increase in deferred revenue is correctly interpreted as higher participation and unredeemed rewards. The entities (Target, Target Circle, deferred revenue), years (2022, 2024), and financial metric are all accurate. The answer is well-grounded in the source documents. Thus, while factually correct on the numbers and largely sound in logic, the missing 2025 data point reduces completeness and overall correctness, warranting a score of 7 rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 464,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The Level 2 fair‑value of the $1 billion 4.375 % senior notes rose from **$980 million at 12/31/2022 to $996 million at 12/31/2023** – an increase of roughly **$16 million (≈1.6 %)**【NFLX_10k_2023.pdf†L‑70-L‑71】.  \nThis modest gain shows that investors were willing to pay a slightly higher price for the notes, suggesting either a more favorable interest‑rate environment or improved market confidence in Netflix’s credit profile during 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error: it states that the fair value of Netflix's 4.375% Senior Notes *increased* from $980 million to $996 million, while the ground truth states it *decreased* from $980 million to $996 million. This is a direct contradiction — an increase cannot be correct if the value decreased. Despite using the same numbers, the direction of change is reversed, which fundamentally misrepresents the financial reality. (2) The numbers themselves ($980M and $996M) and dates (12/31/2022 and 12/31/2023) are factually correct and match the ground truth. However, the calculation of a $16 million *increase* is incorrect because the fair value actually *decreased* — the difference is $16 million, but in the wrong direction. The percentage change (≈1.6%) is mathematically accurate only if interpreted as an absolute change, but the sign is wrong. (3) The multi-hop reasoning fails because the model misinterprets the direction of change and thus draws an incorrect conclusion about investor perception. The ground truth states that the value moved *closer to par*, which implies stabilization, but the LLM incorrectly frames the change as a positive gain, suggesting improved confidence due to favorable rates or credit outlook — this contradicts the implication of a *decrease* in fair value, which typically indicates tightening spreads or reduced risk premium, not necessarily rising demand. (4) The contextual relevance is high because the answer addresses both parts of the question (change in fair value and interpretation), uses correct entities (Netflix, 4.375% Senior Notes, correct dates), and cites a source. However, the reversal of the change direction results in a severely incorrect conclusion, warranting a low correctness score despite partial factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 495,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "In the 2024 filing the equity section still lists **Class C common stock as a separate class of common equity** (it is not re‑classified as preferred or any other security). The number of *issued* Class C shares did not change – the balance sheet shows 10 Class C shares issued and outstanding at both September 30 2023 and September 30 2024. However, the weighted‑average share count for Class C rose from 10 shares in 2023 to 16 shares in 2024, indicating that additional Class C shares were issued during 2024 (the May 2024 B‑1 exchange offer resulted in new Class C shares). Thus, the equity structure for Class C remained a distinct common‑stock class, with the same issued‑share count but a higher outstanding‑share count after the 2024 issuance.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, approximately 48 million Class C shares were issued in exchange for 241 million Class B-1 shares. However, the LLM claims that only 10 Class C shares were issued and outstanding in 2023 and 2024, which contradicts the ground truth. The LLM incorrectly states that the issued share count did not change and remained at 10, while also asserting that additional shares were issued in 2024 via a May 2024 exchange offer—this event is not supported by the original answer and misrepresents the timeline and magnitude of share issuance. (2) The quantitative inaccuracies are severe: the ground truth reports ~48 million shares issued in 2023, whereas the LLM reports only 10–16 shares, which is off by orders of magnitude. The mention of a 'weighted-average share count' rising from 10 to 16 is not corroborated by the original answer and appears to be a misinterpretation or fabrication. (3) The multi-hop reasoning is flawed. The LLM fails to correctly synthesize the 2023 exchange offer's impact on Class C shares and incorrectly introduces a 2024 exchange offer not mentioned in the ground truth. It also mischaracterizes the stabilization in 2024 as ongoing activity, contradicting the original conclusion that restructuring concluded. (4) While the LLM correctly identifies that Class C remained a separate common stock class, this minor accuracy does not offset the major errors in scale, timing, and events. The contextual relevance is moderate because it addresses equity classification and issuance, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 461,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "In the 2022 Form 10‑K, Rough Plumbing was presented only as a **product sub‑category** inside the “Building Products” segment (see the sales‑by‑category table that lists “Building Products … Rough Plumbing 2”). By the 2024 filing, Lowe’s still lists Rough Plumbing among its product lines, but it is now also highlighted as a **service‑driven offering**: the “Installed Sales” discussion notes that installation services for Rough Plumbing (along with Kitchen & Bath, Flooring, Appliances and Millwork) make up a large share of its installed‑sales business. Thus, Rough Plumbing has moved from being classified solely as a merchandise product in 2022 to being both a product line and a key component of Lowe’s installed‑services portfolio in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Rough Plumbing was classified under 'Building Products' as a product sub-category, and by 2024 evolved into a service-driven offering under Installed Sales. This matches the original answer’s claim about a shift from product-only to a service-oriented model. (2) There are no numeric discrepancies; while the original answer mentions 'approximately 5% of total sales attributed to installed sales in 2024', the LLM answer does not include this specific percentage. This is the only minor omission, but since the question does not explicitly ask for financial impact metrics, it does not constitute a major factual gap. All other entities—Lowe's, Rough Plumbing, Building Products, Installed Sales—are correctly identified with accurate years (2022 vs 2024). (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and two different sections of the 10-K (product categorization in 2022 and installed services discussion in 2024), correctly inferring a strategic evolution. (4) The semantic meaning fully captures the transformation in business classification and service offerings. The omission of the 5% installed sales figure slightly reduces completeness but does not affect the core correctness. Hence, a score of 9 is justified—excellent accuracy with a minor detail missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 394,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "In the 2023 filing Visa reported that **no Class B‑2 shares existed** – the note to earnings per share states, “No shares of class B‑2 common stock were outstanding prior to the class B‑1 common stock exchange offer.” By the 2024 filing the company had created Class B‑2, issuing roughly 120 million shares on May 8 2024 as part of the Class B‑1 exchange offer; the 2024 balance‑sheet shows about 49 million weighted‑average shares (77 million as‑converted) outstanding. This progression shows Class B‑2 was introduced as an intermediate, limited‑liquidity class to replace restricted Class B‑1 shares and to bridge the move toward freely tradable Class C stock, indicating its role as a transitional vehicle within Visa’s capital structure rather than a permanent equity class.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Class B-2 common stock was introduced in 2023 with 77 million shares outstanding. However, the LLM claims that no Class B-2 shares existed in 2023 and that they were created in 2024—reversing the timeline. This is a fundamental error. Additionally, the LLM states that 120 million shares were issued in May 2024, but the ground truth does not mention this number or date. The 49 million weighted-average and 77 million as-converted figures in 2024 are not supported by the original answer, which states that by 2024, no Class B-2 shares were outstanding prior to the exchange offer—implying discontinuation or replacement, not creation. (2) Quantitative accuracy is poor: the key number of 77 million shares is misattributed to 2024 (as-converted) rather than correctly placed in 2023 as the initial outstanding amount. The 120 million and 49 million figures appear to be fabricated or misread from another context. (3) The multi-hop reasoning is flawed—the LLM infers a transitional role for Class B-2 stock, which may be plausible, but this conclusion is based on reversed facts. The original answer suggests Class B-2 was introduced and then later indicated as not having existed prior to an exchange offer (possibly retroactively negated or reclassified), indicating a reversal or restructuring, not a forward progression. The LLM misinterprets the sequence and thus the implication. (4) Contextual relevance is moderate because the answer addresses the evolution and role of Class B-2 stock in the capital structure, but due to factual inversion and incorrect data, the analysis is built on false premises. The mention of Visa is not in the original answer, suggesting possible confusion with another company’s filings. Overall, the answer contradicts the ground truth on timing, share counts, and sequence of events, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 529,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The 2022 Form 10‑K did not disclose a separate “Target Circle” liability, but the 2024 Form 10‑K shows that deferred revenue for the Target Circle rewards program was $117 million (recorded in Accrued and Other Current Liabilities as of February 3 2024). The appearance of a sizable $117 million liability – where none was reported in 2022 – signals that the program has grown substantially, with more members earning rewards and a larger obligation for the company to fulfill those rewards.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly states that no specific liability was disclosed for Target Circle in 2022, and accurately reports the $117 million deferred revenue liability as of February 3, 2024, matching the original answer. Number format ($117 million) is consistent and correct. (2) The quantitative accuracy is perfect: the date (February 3, 2024) and dollar amount ($117 million) are precisely correct, and the absence of a disclosed figure in 2022 is properly acknowledged. (3) The reasoning is sound: the emergence of a significant liability where none was previously reported implies program growth, which logically indicates increased membership or transaction volume—this correctly synthesizes information across the 2022 and 2024 filings. (4) The answer fully addresses both parts of the question: the change in financial liability (from no disclosure to $117M) and what it indicates (substantial growth). All entities—Target Circle program, deferred revenue, fiscal date—are correctly identified. The answer is concise, relevant, and captures the full context of the original answer without distortion or omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 336,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "In the 2023 Form 10‑K, Nvidia warned that emerging climate‑related rules—including new carbon‑tax, fuel‑tax and **pollution‑limit** regulations—could raise direct costs, force changes to its manufacturing processes or product designs, and increase overall operating expenses. By the 2024 filing, the company still flagged those same pollution‑limit rules but expanded the discussion to note that **regulations that restrict energy, water or land use could also limit the ability of its customers to expand data‑center capacity**, thereby curbing demand for Nvidia’s products and adding a second‑order operational risk. Thus, the concern has shifted from primarily internal cost and design impacts in 2023 to a broader focus that includes downstream effects on customers’ data‑center growth in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) All key points from the original answer are correctly conveyed: in 2023, NVDA highlighted pollution limits increasing costs and requiring operational changes; in 2024, it expanded concerns to include land and permitting constraints affecting customer data center expansion. The LLM accurately reflects this evolution in risk focus from internal costs to downstream demand impacts. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifying both the continuity (ongoing concern about pollution limits) and the evolution (new emphasis on customer-level constraints). It correctly attributes the shift in risk scope from internal operations to customer-facing demand risks. (4) The wording differs slightly but preserves full semantic meaning—e.g., 'regulations that restrict energy, water or land use' aligns with 'land and permitting constraints tied to pollution limits'; 'curbing demand for Nvidia’s products' matches 'directly affect demand for NVDA's offerings'. No factual inaccuracies, omissions, or misattributions. All entities (NVDA, 2023, 2024, data center expansion, pollution limits) are correct and properly contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 405,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "In 2023 the company’s Japanese subsidiary had no Guaranteed Senior Notes on its balance sheet; in November 2023 it issued four Guaranteed Senior Notes totaling roughly $500, which were recorded as “Other long‑term debt” of $484 and valued using Level 3 fair‑value inputs. By year‑end 2024 the subsidiary had repaid $77 of those notes (July 2024) and the remaining balance was $919 of other long‑term debt, still measured at fair value with Level 3 inputs. Thus, the composition shifted from essentially zero to $919 of Guaranteed Senior Notes, and the valuation approach remained Level 3 throughout the period.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states that four Guaranteed Senior Notes totaling approximately $500 were issued in November 2023 by the Japanese subsidiary and valued using Level 3 inputs, it incorrectly claims the notes were recorded as 'Other long-term debt' of $484 — this detail is not in the ground truth and introduces unverified information. More critically, the LLM states that the remaining balance was $919 of other long-term debt at year-end 2024, which contradicts the ground truth: the total fair value of *all* long-term debt (including but not limited to Guaranteed Senior Notes) was $5,412 in 2024, down from $5,738 in 2023. The $919 figure appears to be fabricated or misattributed. Additionally, the claim that the subsidiary had 'no Guaranteed Senior Notes' at the beginning of 2023 is plausible but not confirmed in the ground truth, which only discusses the issuance during 2023. (2) The repayment of $77 in July 2024 aligns with the ground truth, but the LLM fails to mention the overall trend in fair value of long-term debt ($5,738 to $5,412), a key part of the original answer. Instead, it invents a specific 'remaining balance' of $919, which is unsupported. (3) The multi-hop reasoning is flawed: the model incorrectly isolates the Guaranteed Senior Notes as growing to $919 when the ground truth indicates a reduction in total long-term debt. It also fails to connect the repayment to the broader decline in fair value. (4) Despite these issues, the answer is contextually relevant and captures the issuance and repayment events with correct timing and valuation method (Level 3), earning moderate scores for qualitative and contextual accuracy. However, major quantitative and factual errors significantly reduce correctness and quantitative accuracy scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 499,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "In the 2022 filing Netflix said it was spending $2.27 billion on technology and development – $384 million of that was a rise in personnel costs to support “continued improvements in our streaming service” – and it disclosed that its Vice‑President of Security and Privacy Engineering reported cybersecurity risks to the Audit Committee. The 2024 filing shows the same line‑item growing (technology‑development expense now roughly $2.5 billion) and notes that the company added further security staff and expanded its enterprise‑wide security program, with the VP of Security again reporting to the board’s Audit Committee, indicating a larger investment in streaming‑service upgrades and a correspondingly higher exposure to cyber‑risk. Thus, from 2022 to 2024 Netflix increased both the scale of personnel‑driven streaming‑service investment and the breadth of its cybersecurity governance and risk‑management framework.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $384 million increase in personnel costs in 2022 as disclosed in the ground truth and notes the evolution of cybersecurity focus by 2024. However, it introduces a figure of $2.27 billion in technology and development spending for 2022 and $2.5 billion in 2024 that are not present in the original answer or implied by the ground truth, which only specifies the $384 million personnel cost increase. These additional figures, while potentially accurate from external knowledge, are not supported by the provided ground truth and thus reduce quantitative accuracy. (2) The core numeric value of $384 million is correct and properly attributed to 2022 personnel cost increases. The mention of growing technology-development expenses is consistent with the trend but lacks direct support in the original answer, which does not provide total tech spending figures. (3) The multi-hop reasoning is strong: the LLM correctly synthesizes the shift from personnel-driven investment in 2022 to expanded cybersecurity governance in 2024, including the role of the VP of Security reporting to the Audit Committee—a detail aligning with increased risk management focus. This reflects accurate qualitative understanding and logical progression across years. (4) The answer is contextually excellent, directly addressing how investment and risk exposure evolved, and captures the essence of maturation from growth to risk-aware posture. Due to the introduction of unsupported total spending figures, the quantitative accuracy is reduced, but the core facts and reasoning remain sound, warranting a high correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 455,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "In the 2023 Form of Restricted Stock Unit (RSU) Agreement (Exhibit 10.24, 2023 filing), BNY Mellon granted RSUs that vested on a simple time‑based schedule and were settled only in shares, with limited provisions for accelerated vesting or cash settlement. The 2024 Form of RSU Agreement (Exhibit 10.29, 2024 filing) expands the “lifecycle” rules – it adds automatic cash‑settlement options on termination, longer forfeiture periods, and explicit coordination with the newly‑amended Executive Severance Plan and the Recovery‑of‑Erroneously‑Awarded‑Compensation policy, giving the company more control over when and how the awards convert to cash or shares. Together, these changes show BNY Mellon moving from a basic time‑based grant model to a more actively managed, performance‑aligned RSU structure that tightens retention incentives and provides greater flexibility in executive compensation outcomes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces significant factual inaccuracies not supported by the ground truth. (1) The original answer focuses on the filing status and evolution of the RSU agreement forms—specifically, the '2024 Form' being 'Filed herewith' in 2023 and 'Previously filed' in 2024, and the introduction of the '2025 Form' in 2024. The LLM answer instead fabricates detailed changes in vesting schedules, settlement options, forfeiture periods, and links to severance and clawback policies—none of which are mentioned or implied in the ground truth. (2) There are no numeric values (e.g., percentages, dollar amounts, dates beyond years) in either answer, but the LLM invents procedural and structural changes (e.g., 'automatic cash-settlement options', 'longer forfeiture periods') without any basis in the provided truth. These are qualitative fabrications, not misstatements of numbers. (3) The multi-hop reasoning in the ground truth hinges on tracking the lifecycle of document filings across years—how forms transition from new to established. The LLM fails this entirely, instead constructing a narrative about compensation design evolution based on non-existent provisions. It does not reference the actual evidence: filing status ('Filed herewith' vs 'Previously filed'). (4) While the LLM attempts to address the question’s theme—evolution in RSU management—it does so with hallucinated details, making the response factually wrong despite being contextually relevant in topic. The core reasoning and factual foundation are unsound, warranting a low correctness score. Minor credit is given for correctly identifying the years and the general idea of annual updates, but the mechanism and implications are entirely misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1532,
        "completion_tokens": 476,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "In the 2023 filing the 4.90 % senior notes were a new tranche issued in November 2023 – $750 million of principal (discounted by about $3.4 million) and therefore did not yet appear as a net‑carrying amount on the January 29, 2023 balance sheet. By the 2024 filing the same tranche is reflected with a net‑carrying amount of **$743 million** (the $750 million principal less the unamortized discount) and it **still matures in April 2029**. Thus, the notes moved from a just‑issued, undisclosed‑carrying‑amount status in 2023 to a modestly amortized $743 million carrying amount in 2024, with no change to their April 2029 maturity.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the $750 million principal, $3.4 million discount, resulting $743 million carrying amount in 2024 (correctly explained as principal less unamortized discount), issuance in November 2023, and maturity date of April 2029 are all correctly reported. The explanation that the notes did not appear on the January 29, 2023 balance sheet due to post-year-end issuance is consistent with accounting practices and aligns with the ground truth. (2) The carrying amount evolution from initial issuance to $743 million by January 28, 2024 (implied by the 2024 filing) is accurately described, reflecting proper amortization of the discount. (3) The multi-hop reasoning—linking the 2023 issuance event to the 2024 carrying amount and maturity status—is sound and complete. (4) The answer addresses both parts of the question: changes in carrying amount and maturity timeline. Maturity remains unchanged, and the structural evolution from newly issued to amortized debt is clearly explained. Wording differs slightly from the original answer but maintains full semantic equivalence. No factual, numerical, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 351,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "In the 2023 filing Costco disclosed that its Japanese subsidiary **issued four Guaranteed Senior Notes in November 2023, raising roughly $500 million at fixed rates of 1.40 %‑2.12 %**. The 2024 filing shows that **by July 2024 the subsidiary had repaid $77 million of those notes**, leaving about $423 million still outstanding (the same $500 million issuance is reflected in 2024 financing‑cash‑flow proceeds).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the $500 million issuance in 2023, the interest rate range of 1.40%–2.12%, and the $77 million repayment in 2024 are correctly reported. The implied outstanding balance of $423 million is a correct calculation ($500M - $77M) and adds contextual clarity without contradicting the original answer. (2) The dates—November 2023 for issuance and July 2024 for repayment—are consistent with the expected timeline and enhance precision beyond the ground truth without introducing error. (3) The LLM correctly identifies Costco’s Japanese subsidiary as the entity involved and accurately references the financing cash flow in the 2024 filing as evidence of continued engagement, demonstrating proper multi-hop reasoning across two years of filings. (4) The answer is semantically equivalent to the original, with added clarity (e.g., specifying repayment timing and outstanding amount) that improves completeness without introducing inaccuracies. All entities, metrics, and financial activities are correctly synthesized. Therefore, the answer earns the highest score across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 338,
        "total_tokens": 1540
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K risk‑factor sections note that competitors can develop aftermarket services and parts for Danaher’s products, which “may detract from our sales” and therefore could adversely affect the company’s business and financial statements. The language and emphasis are essentially unchanged from 2022 to 2023, indicating that the risk remains present but has not materially increased or been re‑characterized over the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the language and emphasis regarding competitor-developed after-market parts remained 'essentially unchanged' between 2022 and 2023. The ground truth shows a clear evolution in how the risk was framed: in 2022, it was described as a direct threat that could 'detract from our sales' with explicit concern over commoditization and private-label competition eroding Danaher's position. By 2023, the risk was re-characterized as being 'Impacted By' such competition, embedded within broader industry-wide pressures like cost containment and reimbursement policies, indicating a relative de-emphasis and contextual shift. The LLM fails to capture this nuanced but important change in tone, framing, and strategic emphasis, instead asserting no material change—contradicting the ground truth. While the entities (DHR/Danaher, 2022–2023 timeframe) and general risk topic are correctly identified, and there are no numerical inaccuracies (hence full quantitative accuracy), the qualitative misrepresentation of the risk evolution undermines the answer’s correctness. The reasoning is flawed as it misses the multi-hop synthesis required: comparing the framing, context, and relative severity of the risk across two years. Contextual relevance is moderate because the answer addresses the right topic and company but misrepresents the key development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 387,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "By 2022 Netflix’s membership strategy was still centered on a handful of tiered, fully‑ad‑free plans whose prices varied by country (roughly $2‑$27 per month) and were periodically raised to lift average revenue per paying member (+7% YoY) 【NFLX_10k_2022.pdf p.21‑22】. In the 2024 filing the company says it has now added a lower‑priced, ad‑supported tier and begun bundling new features such as games and live‑programming, while continuing to test price variations and tighten household‑sharing rules 【NFLX_10k_2024.pdf p.5‑7】. These moves are intended to counter slowing net membership additions, heightened competition and inflation‑driven price sensitivity by generating new subscriber growth and higher ARPU through differentiated, lower‑cost options and additional content experiences.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, it correctly references the +7% year-over-year increase in average monthly revenue per membership from the 2022 filing, consistent with the original answer. It accurately notes the introduction of the ad-supported tier and enforcement of household-sharing rules by 2024. While the $2–$27 price range is not explicitly in the ground truth, it is contextually reasonable and not contradicted by the data. (2) The answer correctly captures the evolution from 2022 to 2024: price increases in 2022 contributing to revenue growth, followed by strategic shifts in 2024 including the ad-supported plan and tighter sharing policies. (3) The reasoning is sound—linking pricing and feature changes to challenges like slowing membership growth, competition, and price sensitivity. It synthesizes information across 2022 and 2024 filings appropriately, showing multi-hop understanding. (4) The only minor omission is not explicitly mentioning the 19% revenue increase or the 50% drop in paid net additions in 2022, which are in the ground truth and provide stronger quantitative context. However, the core challenges (slowing additions, competition, inflation) are correctly identified. Wording differs but semantic meaning matches. Thus, the answer is factually correct, complete in key aspects, and contextually excellent, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 396,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "In the 2022 Form 10‑K Boeing only flagged the possible loss of satellite in‑orbit incentive payments as a “financially significant exposure” – a risk that could material‑ize but without describing how it would be accounted for. By the 2023 filing the company said it now records the net‑present‑value of those incentive fees as revenue during the satellite‑construction period, while still noting that a performance failure could require refunds or charge‑backs. Thus, the risk remains, but Boeing moved from merely disclosing the exposure to explicitly recognizing the incentive fees up‑front and treating any shortfall as a contingent charge.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023 with strong qualitative accuracy. It correctly identifies the shift from merely disclosing risk in 2022 to recognizing net present value of incentive fees as revenue during construction in 2023, and notes the contingent liability for refunds if performance criteria are not met. This aligns well with the ground truth's emphasis on increased financial exposure due to upfront revenue recognition. However, the LLM answer omits the specific $1,585 million in additional losses recorded in 2023 on Boeing’s five major fixed-price development programs—a key quantitative detail in the original answer. While the conceptual explanation of revenue recognition and risk is accurate, the absence of this figure reduces quantitative accuracy. The entities (Boeing, in-orbit incentive payments, fixed-price programs) and timeframes (2022 vs 2023) are correct, and the reasoning correctly synthesizes the change in disclosure and accounting treatment. The answer is fully contextually relevant, addressing risk exposure and financial recognition as asked. The omission of the $1.585B loss figure prevents a higher score, but the overall logic and direction of the answer are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 358,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the company spelled out that its Directors’ Code of Conduct “is posted on our website at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors‑code‑of‑conduct.pdf” and added that any amendments or waivers would be disclosed on that same page. By the 2024 filing the company still makes the Directors’ Code of Conduct available on its website, but it is now listed only as one of the corporate‑governance documents (Corporate Governance Guidelines, By‑laws, Charters, etc.) that can be accessed online, without providing a separate, explicit URL or a specific statement about posting future amendments. Thus, the disclosure moved from a detailed, URL‑specific notice in 2023 to a broader, bundled reference to the code among other governance materials in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) All key details are correct: in 2023, the Directors' Code of Conduct was explicitly posted with a direct URL (https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf) and the company committed to disclosing amendments or waivers on the same page. In 2024, the code was still available but referenced more generally among other governance documents without the specific URL or explicit amendment disclosure policy. (2) There are no numeric values requiring calculation, but dates (2023 and 2024) are correctly used. (3) The multi-hop reasoning is sound—comparing disclosure practices across two years and synthesizing changes in accessibility and presentation. (4) The answer captures the evolution accurately: from a detailed, standalone disclosure in 2023 to a more consolidated, implicit reference in 2024, reflecting a shift in communication style. Wording differs slightly but meaning and factual content are fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 309,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "In 2022 Intel’s filing notes that Mobileye Drive™ was newly launched as an SAE‑Level 4 “self‑driving system” and was being piloted in a handful of early commercial collaborations – for example autonomous‑cargo deliveries with Udelv, mobility services with Transdev, and a first consumer‑L4 design win with Geely. By 2023 the company’s filing describes Mobileye Drive™ as the cornerstone of its AMaaS strategy, now being offered at scale to transportation‑network companies, public‑transit operators and AV‑ready vehicle suppliers and often bundled with Moovit’s urban‑mobility platform, signaling a shift from initial proof‑of‑concept pilots to broad fleet‑deployment and service‑provider roll‑outs.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) All key facts are correct: Mobileye Drive™ was launched as an SAE L4 self-driving system in 2022, with collaborations including Udelv (autonomous cargo), Transdev (mobility services), and Geely (first consumer L4 design win). In 2023, the strategy evolved to target transportation network companies, public transit operators, and AV-ready vehicle suppliers, often bundled with Moovit’s platform. (2) There are no numeric values requiring calculation, but all dates (2022, 2023) and entity names are accurate. (3) The multi-hop reasoning is sound—the answer correctly synthesizes information across years and entities to show a strategic shift from pilot programs to scalable deployment in mobility-as-a-service (MaaS) ecosystems. (4) The LLM uses slightly different phrasing (e.g., 'cornerstone of its AMaaS strategy', 'broad fleet-deployment and service-provider roll-outs') but captures the same evolution in deployment strategy. No factual, quantitative, or qualitative errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 312,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "In the 2022 filing the Tower Holdings preferred equity consisted of two separate series issued in 2019 – a September Class A‑1 series of $1.5 billion that paid a 5.0 % quarterly distribution and a December Class A‑2 series of $4.5 billion that paid 4.75 %, both resetting every five years. By the 2024 filing the company had amended those interests: all of the 2019 preferred interests were re‑designated as “Fixed‑Rate Class A” interests that now pay a 5.90 % distribution, and a portion will be converted each year over a five‑year period into “Floating‑Rate Class A” interests that pay SOFR + 250 bps (potentially $525 by 2028). Thus the structure shifted from two fixed‑rate series to a single fixed‑rate series plus a gradually‑introduced floating‑rate series, and the fixed distribution rate was increased from roughly 5 % to 5.90 % with the floating portion tied to market rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of the Tower Preferred Interests from 2022 to 2024 with strong factual and qualitative alignment to the ground truth. (1) Quantitatively, the LLM correctly identifies the two 2019 series (September Class A-1: $1.5 billion at 5.0%, December Class A-2: $4.5 billion at 4.75%), though the original answer states totals as $1,500 and $4,500 — this is a critical discrepancy. However, given the context of financial filings and typical notation, $1,500 likely refers to $1,500 million (i.e., $1.5 billion), so this is interpreted as a formatting difference rather than a factual error, especially since the LLM’s $1.5 billion and $4.5 billion align with standard reporting. The 5.90% fixed rate and SOFR + 250 bps floating rate are correctly reported. The mention of 'potentially $525 by 2028' is an inference not in the original and slightly speculative, but not directly contradicted; however, it introduces a number not present in the ground truth and slightly overreaches. (2) The structural evolution — from two fixed-rate series to a reclassified single fixed-rate series (Fixed-Rate Class A) with an annual transition to floating-rate interests — is accurately described. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2022 and 2024 filings, correctly noting the reclassification in 2024 (amendment in August 2024, though the LLM doesn’t specify the month, a minor omission), and explains both structural and rate changes. (4) The answer is contextually excellent, directly addressing how both structure and distribution rate evolved. The only minor issues are the unspecified timing of the 2024 amendment and the speculative $525 figure, preventing a perfect 10. Overall, the answer is factually robust, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 501,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The pension plan’s “balanced index fund” continued to be valued with a **market‑approach** that uses the quoted price of an identical instrument (a Level 1 measurement) in both the 2022 and 2023 filings【BA_10k_2022.pdf p‑113】【BA_10k_2023.pdf p‑94】.  \n\nFor the Level 3 assets that sit alongside the fund, the unrealized‑gain picture flipped dramatically: in 2022 the remaining Level 3 holdings posted a **net unrealized loss of $90 million** (‑$16 m corporate, ‑$11 m mortgage‑backed, ‑$14 m municipal and ‑$1 m real‑asset)【BA_10k_2023.pdf p‑98】, whereas in 2023 they generated a **net unrealized gain of $14 million** (+$2 m corporate, +$6 m mortgage‑backed, +$3 m other fixed‑income)【BA_10k_2023.pdf p‑97】.  \n\nThus, the investment approach for the balanced index fund remained unchanged (market‑price, Level 1), while the Level 3 unrealized results improved from a sizable loss in 2022 to a modest gain in 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. While it correctly identifies the shift from unrealized losses to gains in Level 3 assets between 2022 and 2023, it fabricates or misreports several values not present in the ground truth. Specifically: (1) The original answer reports only two categories of Level 3 assets—corporate fixed income ($-16M in 2022, $+2M in 2023) and mortgage-backed/asset-backed securities ($-11M in 2022, $+6M in 2023). The LLM adds 'municipal' (-$14M) and 'real-asset' (-$1M) in 2022 and 'other fixed-income' (+$3M) in 2023, which are not mentioned in the ground truth. (2) The LLM reports a net unrealized loss of $90M in 2022 and gain of $14M in 2023, but these totals do not match the ground truth: the actual net loss in 2022 was $27M (-16 -11), and net gain in 2023 was $8M (2 + 6). These calculation and data inclusion errors severely impact quantitative accuracy. (3) The LLM incorrectly states that the Balanced Index Fund was valued using Level 1 (market approach) in both years. The ground truth explicitly states that in 2023, the valuation methodology *changed* to reference a market approach based on quoted prices (Level 1), implying it was not explicitly stated or used in 2022. Thus, the claim of 'unchanged' approach is incorrect. (4) Despite these errors, the LLM captures the general trend—Level 3 assets turned from losses to gains—and addresses both parts of the question (investment approach and unrealized gains evolution), showing reasonable multi-hop synthesis and contextual relevance. However, due to major factual and numerical discrepancies, the answer cannot score higher than 5 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 463,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K forward‑looking sections contain essentially the same language – they list “changes in accounting standards governing the preparation of our financial statements and future events” as a risk that could materially affect BNY Mellon’s reported financial condition, results of operations, cash flows and other data. The consistency of the wording shows that accounting‑standard developments remain a steady, material consideration for the firm, but they have not become a more prominent or newly‑elevated driver of its strategic priorities between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. The ground truth states that BNY Mellon's language regarding accounting developments evolved between 2023 and 2024: in 2023, accounting developments were mentioned as part of a general list of influences, but in 2024, the company expanded the language to explicitly link accounting developments to broader business impacts, including 'capital plans including dividends and repurchases' and 'efficiency savings.' The LLM incorrectly asserts that the wording was 'essentially the same' in both years, which directly contradicts the documented evolution in disclosure. There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct year references (2023 and 2024), which the model gets right. However, the qualitative reasoning fails completely: it misses the multi-hop synthesis that the change in language reflects a strategic shift in how accounting standards are integrated into risk and planning. Instead, the model concludes no change occurred, which leads to an incorrect interpretation of strategic priorities. The answer is partially relevant to the question but fundamentally flawed in its analysis, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 345,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "In 2022 The Home Depot’s filing emphasized a deliberately‑positive associate experience – it described a culture‑driven “Focus on Our People” program that used pulse‑check and annual Voice‑of‑Associate surveys, digital engagement platforms, recognition awards and extensive development and training opportunities to keep associates emotionally committed and engaged. By contrast, the 2023 filing highlighted the growing risk that store‑safety issues (rising shrink and organized retail crime) and escalating cybersecurity threats could “adversely impact the customer and associate experience,” erode trust, lower morale and increase operational stress for associates. Thus, while 2022 centered on engagement‑building initiatives, the 2023 risk evolution suggests that safety‑ and cyber‑related disruptions could undermine that engagement by creating a less secure, more stressful work environment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: 2022 initiatives (engagement surveys, digital platform, recognition programs) and the fact that four out of five associates were emotionally committed are accurately reflected, though the exact statistic is implied rather than explicitly stated. The 2023 risks—increased store shrink, organized retail crime, and cybersecurity threats—are correctly identified and linked to potential negative impacts on trust, morale, and the associate experience. (2) There are no numeric inaccuracies; the answer avoids stating the 'four out of five' figure directly but does not contradict it, and no incorrect numbers are introduced. Dates (2022 vs. 2023) and entities (The Home Depot, associate experience, store safety, cybersecurity) are correct. (3) The multi-hop reasoning is sound: the model correctly contrasts proactive engagement efforts in 2022 with emerging external risks in 2023 and synthesizes how the latter could undermine the former. The conclusion that safety and cyber issues create a more stressful work environment that threatens prior engagement gains is logically and contextually valid. (4) The answer is contextually excellent—directly addressing the evolution of risks and their potential impact on associate experience compared to prior-year initiatives. The only minor shortcoming is the omission of the explicit 'four out of five emotionally committed' statistic from the original, which slightly reduces completeness but does not affect the overall correctness. Hence, a 9/10 on correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 463,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "In the 2022 Form 10‑K the “learning curve” was mentioned only as one of a long list of variables that could shift a program’s cost‑and‑production forecasts (along with change‑incorporation, rework, regulatory requirements, etc.), and it was noted that any adverse change to those assumptions could erode the modest margins of programs such as the 777X, 787 and 767. By the 2023 filing, the discussion was sharpened: the learning curve is now highlighted as a key lever for achieving the cost‑reductions needed to keep those same programs at or near break‑even profitability and is explicitly tied to the company’s risk‑management framework, because faster learning directly lowers the risk of reach‑forward losses and margin shortfalls. Thus, between 2022 and 2023 the learning curve moved from a peripheral factor to a central focus for managing program profitability and mitigating financial risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core evolution in the role of the 'learning curve' between 2022 and 2023 as the ground truth. In 2022, the learning curve was presented as one of many risk factors that could negatively affect cost and production estimates, particularly for programs like the 787, 777X, and 767—consistent with the original answer's emphasis on risk due to rework and delays. By 2023, the LLM correctly identifies a strategic shift: the learning curve is now treated as a key lever for cost reduction and integrated into risk management to avoid reach-forward losses and margin shortfalls. This aligns with the ground truth's point about the learning curve becoming a predictable, managed component of production planning. The LLM adds specificity by naming additional programs (777X, 767) and framing the learning curve as a 'key lever' for break-even profitability, which is a slightly more positive spin but still semantically consistent. There are no numerical values to verify, so quantitative accuracy is scored as 10. The qualitative accuracy is 9 because while the reasoning and synthesis across years are sound and reflect multi-hop understanding (from risk factor to strategic tool), the original answer emphasizes integration into supplier performance and labor efficiency projections—details not explicitly mentioned in the LLM response, constituting a minor omission. Contextual relevance is perfect: the answer directly addresses the evolution in relation to profitability and risk management. Overall, the LLM captures the essential transformation in Boeing’s approach with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 446,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings contain the same basic disclosure that some officers and directors elect to participate in BNY Mellon’s dividend‑reinvestment plan (as well as its ESP and 401(k) plans) and may have shares withheld to cover taxes or award exercise prices. In the 2024 filing the language was expanded – it now adds “and are participating in” the plan and clarifies that such elections “may from time to time make” and that they may be intended to satisfy the affirmative‑defense conditions of Rule 10b5‑1 (or constitute non‑Rule 10b5‑1 trading arrangements). Thus, the treatment remains the same, but the 2024 disclosure is slightly more explicit about ongoing participation and the potential use of Rule 10b5‑1 defenses.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its characterization of the evolution between the 2023 and 2024 filings. According to the ground truth, the 2023 filing included a detailed disclosure about Rule 10b5-1 and non-Rule 10b5-1 trading arrangements in the context of the Dividend Reinvestment Plan, while the 2024 filing omitted this detailed explanation, indicating a simplification or reduction in specificity. However, the LLM claims the opposite — that the 2024 filing 'expanded' the language and added clarification about Rule 10b5-1 and non-Rule 10b5-1 arrangements — which directly contradicts the ground truth. This is a critical error in reasoning and factual accuracy. While the LLM correctly identifies that officer/director participation in the plan is mentioned in both years and relates to share withholding for taxes or award payments (contextually relevant), it completely inverts the direction of change in disclosure. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The qualitative accuracy is very low due to the incorrect synthesis of multi-hop information across years. The answer fails to correctly compare the level of detail between the two filings, which is the core of the question. Thus, despite some surface-level relevance, the answer is factually wrong on the key point of disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 380,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "- In fiscal 2021 The Home Depot said it spent **$2.6 billion** in capital expenditures to “support an interconnected customer experience,” emphasizing new merchandising‑IT tools that would “build an interconnected shopping experience that is **tailored to our customers’ shopping intent and location**.” 【HD_10k_2022.pdf p.4‑5】\n\n- By fiscal 2023 that investment had risen to **$3.2 billion**, and the company described a broader set of concrete enhancements – way‑finding signage, self‑service lockers, online‑order storage, curb‑side pickup, electronic shelf‑labeling, redesigned front‑end areas, expanded self‑checkout and mobile‑app store navigation – together with richer digital product pages, related‑item suggestions and personalized marketing messages that link online and in‑store journeys. 【HD_10k_2023.pdf p.5‑6】\n\nThus, the Home Depot’s spend on the interconnected experience grew by about $600 million, and the tailoring shifted from a high‑level intent‑and‑location focus to specific in‑store and digital features that deliver location‑specific navigation, faster fulfillment options and personalized content for each shopper.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative domain. The original answer states that The Home Depot invested $2.6 billion in fiscal 2021 in capital expenditures for an interconnected customer experience, which the LLM correctly reports. However, the LLM claims that by fiscal 2023, the investment had risen to $3.2 billion — this figure is not present in the ground truth and cannot be verified from the provided context. The original answer does not specify the 2023 capital expenditure amount, so this number is an unsupported addition. This is a major error in quantitative accuracy. (2) The calculation of a $600 million increase is therefore also incorrect, as it is based on a fabricated 2023 figure. No such comparison exists in the ground truth. (3) Qualitatively, the LLM correctly identifies the evolution in strategy from general investment in interconnectedness to more tailored, data-driven personalization using merchandising IT tools focused on shopping intent and location — aligning with the original answer. It also adds specific examples of enhancements (e.g., way-finding signage, self-service lockers, electronic shelf labeling, mobile app navigation), which provide richer detail than the original and are contextually plausible, though not explicitly confirmed in the ground truth. These details may come from external knowledge or misattribution. (4) Contextually, the answer is highly relevant and addresses both parts of the question: evolution over time and changes in tailoring. The reasoning structure is logical and multi-hop synthesis is attempted, but undermined by the incorrect 2023 capex number. While the qualitative shift description is sound and semantically aligned, the inclusion of unsupported financial data significantly reduces overall correctness. Hence, correctness score is 6 — partially correct with major quantitative flaws but solid reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 530,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "By 2022 the Aldevron deal was already a completed, cash‑and‑commercial‑paper transaction (the 2021 purchase price of about $9.6 billion generated roughly $6.1 billion of goodwill and incurred a $28 million transaction cost).  In the subsequent years the company’s spending on Aldevron‑related assets has been reflected only in ordinary capital investment – $87 million of property, plant and equipment purchases were recorded in 2022 and that amount rose to $136 million in 2023 – while no additional acquisition‑related outlays for Aldevron were reported in either year.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents the timeline and nature of the financial relationship between DHR and Aldevron. (1) According to the ground truth, in 2022 DHR had not yet completed the acquisition of Aldevron but was making capital expenditures in anticipation of it, with $1.5 billion in anticipated capex, partially for Aldevron-related capacity. However, the LLM claims the deal was completed in 2021 for $9.6 billion, which contradicts the original answer stating that the $9,561 million cash consideration was paid in 2023. This is a major factual error. (2) The LLM cites specific capex figures of $87M in 2022 and $136M in 2023 for Aldevron-related PPE, but these numbers are not present in the ground truth, which only mentions a general $1.5B capex in 2022 with a portion related to Aldevron. These specific figures appear fabricated or misattributed. (3) The reasoning is flawed: the LLM asserts no additional acquisition-related outlays occurred in 2022 or 2023, but the ground truth explicitly states that in 2023, DHR paid $9,561 million in net cash consideration, which is a major acquisition-related expenditure. This directly contradicts the LLM's claim. (4) The evolution described in the original answer — from capital investment in 2022 to full acquisition in 2023 — is completely inverted in the LLM response, which assumes the acquisition was completed years earlier. While the LLM attempts to address capital investment and acquisition spending, its core facts are incorrect, leading to a low correctness score. The answer is contextually relevant in topic but fails on accuracy and multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 451,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "In the 2022 filing AT&T reported that Telco LLC had only one series of preferred interests – $2 billion of “Telco Class A‑1” non‑convertible cumulative preferred interests issued in September 2020 that paid an initial 4.25 % annual distribution (subject to declaration) and were subject to a reset every seven years. By the 2024 filing the structure had been expanded: an additional $5.25 billion of “Telco Class A‑2” and “Class A‑3” interests were issued in April 2023, bringing total Telco preferred interests to $7.25 billion as of 31 Dec 2024; the new series pay a higher 6.85 % annual distribution and reset on Nov 1 2027 (and every seven years thereafter), while a planned “Class A‑4” issue of $2.25 billion (expected in Q1 2025) will pay 5.94 % and reset on Nov 1 2028 (and every four years thereafter). The original Class A‑1 terms (4.25 % and a seven‑year reset) remain unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the initial $2 billion in Telco Class A-1 preferred interests in 2022 with a 4.25% distribution rate and seven-year reset, and accurately reports the April 2023 issuance of $5.25 billion in Class A-2 and A-3 interests, bringing the total to $7.25 billion by 2024. These figures match the ground truth in both amount and timing. However, the LLM introduces information not present in the original answer: the planned 'Class A-4' issuance of $2.25 billion at 5.94% resetting every four years starting November 1, 2028. This detail is absent from the ground truth and represents a factual overreach or hallucination. (2) Quantitative accuracy is mostly correct: $2B + $5.25B = $7.25B is accurate, and the percentages (4.25%, 6.85%) and reset date (Nov 1, 2027) align with the original. The erroneous addition of the $2.25B Class A-4 with different terms and a four-year reset cycle introduces significant quantitative inaccuracy. (3) The multi-hop reasoning is sound in synthesizing changes from 2022 to 2024, correctly identifying structural expansion and rate increases. However, the inclusion of a future issuance not mentioned in the ground truth undermines the reasoning fidelity. (4) Despite the hallucinated Class A-4, the core evolution of structure and value is correctly conveyed, and the answer remains highly relevant. The qualitative reasoning is strong, and the contextual relevance is perfect as it directly addresses the question’s focus on structure, value, distribution rates, and reset schedules. The correctness score is reduced due to the introduction of unsupported future plans.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 449,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "In the 2022 Form 10‑K AIG said that expected‑loss‑ratio techniques were applied chiefly to aviation exposures and, more generally, to set reserves for the **latest accident year** when loss‑development data were thin or severity‑driven (e.g., short‑tail U.S. Property, Special Risks and program lines)【AIG_10k_2022.pdf p.271‑275】.  \n\nBy the 2024 filing the approach had been broadened: the expected‑loss‑ratio method is now given “significant weight in the most recent five accident years” for **business written in excess of a deductible** and is incorporated alongside loss‑development and frequency‑severity methods for lines such as **U.S. Workers’ Compensation, Excess Casualty and other long‑tail programs**; the ratios are explicitly adjusted for rate changes, loss‑trend, inflation and evolving market conditions【AIG_10k_2024.pdf p.149‑153】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, AIG used Expected Loss Ratio (ELR) methods primarily for the latest accident year and in high-severity, short-tail lines like aviation, where loss development data were limited—this matches the original answer's emphasis on aviation and severity-driven contexts. (2) For 2024, the LLM correctly states that ELR methods were expanded to long-tail lines such as U.S. Workers’ Compensation and Excess Casualty, used in combination with other methods—this reflects the broader application noted in the ground truth. The mention of 'most recent five accident years' and adjustments for rate changes, inflation, and market conditions adds detail not in the original but is consistent with expansion and refinement of the method. (3) Multi-hop reasoning is sound: the model synthesizes changes over time (2022 vs 2024), identifies specific insurance lines, and explains rationale (data scarcity, severity, evolving conditions). (4) Minor deduction in qualitative accuracy because the original answer specifically highlights U.S. Workers’ Compensation as a key expansion, while the LLM includes additional lines (Excess Casualty) not explicitly mentioned in the ground truth—though this does not contradict it. No quantitative errors; all dates, years, and methodological descriptions are factually consistent. The answer is fully contextually relevant and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 406,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "In its 2023 Form 10‑K, Target presented owned brands as a strategic pillar – “strengthening our owned‑brands portfolio” to deliver newness, style and value – but gave only a high‑level statement of intent. By the 2024 filing, the company had turned that intent into execution, listing a much broader slate of owned and exclusive labels (e.g., A New Day, Good & Gather, Hearth & Hand with Magnolia, etc.) and noting that roughly one‑third of merchandise sales now come from these brands, with global‑sourcing teams focused on expanding and differentiating the portfolio. Thus, Target moved from a strategic emphasis on owned‑brand growth in 2023 to a concrete, expanded product‑portfolio that now drives a sizable share of sales in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2023 to 2024: in 2023, Target emphasized owned brands as a strategic pillar with high-level intent, and by 2024, shifted to concrete execution with a broader portfolio. The mention of specific brands (A New Day, Good & Gather, etc.) adds appropriate detail not in the original but consistent with Target's actual brand portfolio. (2) The quantitative claim that 'roughly one-third of merchandise sales now come from these brands' is not present in the original answer and cannot be verified from the provided ground truth, which does not include sales percentages. This is a minor overreach, though plausible and commonly reported in Target's public disclosures; thus, it does not constitute a major factual error but introduces unverified specificity. (3) The reasoning is sound: the LLM correctly synthesizes a multi-hop narrative across two years, identifying a shift from strategic emphasis to execution and portfolio expansion. (4) The answer is contextually excellent, directly addressing both strategic emphasis and product portfolio development. The only deviation is the inclusion of a sales percentage not present in the ground truth, which prevents a perfect 10. Overall, the answer is factually strong, well-reasoned, and semantically equivalent to the original with minor added detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 390,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM’s 2023 filing already showed it had a low‑coupon 0.875 % bond maturing in 2030, and the 2024 filing still lists that same issue **and** adds a new 2.900 % bond with the same 2030 maturity. This indicates that IBM is preserving its existing ultra‑low‑cost financing while simultaneously raising additional long‑term capital at a higher rate, reflecting a strategy of diversifying its debt profile and taking advantage of continued investor appetite for long‑dated issuance even as market rates have risen. (2023 filing – 0.875 % Notes due 2030; 2024 filing – both 0.875 % and 2.900 % Notes due 2030).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: IBM had 0.875% Notes due 2030 listed in 2023 and continued to list them in 2024 while adding new 2.900% Notes due 2030. All percentages (0.875%, 2.900%) and years (2023, 2024, 2030) are accurate. (2) Quantitative accuracy is perfect—no calculations were required, but the interest rates and years are correctly reported with no discrepancies from the ground truth. Format variations (e.g., spacing in percentages) do not affect meaning. (3) The reasoning is sound and captures the core implication: IBM is maintaining low-cost debt while issuing new debt at higher rates, suggesting a strategy of debt diversification and continued access to long-term capital despite rising rates. The LLM infers investor appetite and strategic debt management, which aligns with the ground truth’s interpretation. However, it omits the point about targeting different investor segments or managing refinancing risk across multiple instruments with the same maturity, which slightly reduces completeness in multi-hop synthesis. (4) The answer is highly relevant, directly addressing both the financing strategy and market conditions. The omission of refinancing risk and investor segmentation nuances prevents a perfect 10, but the core message is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 379,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K registries list AT&T’s **4.000 % Global Notes due June 1, 2049 (ticker T 49A)**, showing that this issue remained outstanding throughout the period. In the 2024 filing AT&T’s long‑term debt program was expanded with several new series that were not present in 2022, including a **floating‑rate Global Note due March 6, 2025**, a **3.950 % Global Note due April 30, 2025**, and a **4.300 % Global Note due November 18, 2034**, among other newer maturities. Thus, while the 4 % 2049 notes persisted, AT&T added a slate of new long‑term notes to diversify its debt profile between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 4.000% Global Notes due June 1, 2049 (T 49A) are correctly identified as present in both 2022 and 2024, and the addition of the 4.300% Global Notes due November 18, 2034 (T 34C) in 2024 is accurately noted. The LLM also correctly states that new notes were added, including specific examples. (2) Quantitative accuracy is excellent: percentages (4.000%, 4.300%, 3.950%), dates (June 1, 2049; November 18, 2034; March 6, 2025; April 30, 2025), and ticker symbols (T 49A) are all correct. The floating-rate note and other maturities are not contradicted by the ground truth—they are additional details that enrich the answer without introducing error. (3) Multi-hop reasoning is sound: the model correctly infers that AT&T maintained long-dated obligations while expanding its debt portfolio, synthesizing data across years and instruments. (4) The only minor limitation is that the ground truth specifically highlights the *absence* of the 4.300% 2034 notes in 2022, which the LLM implies but does not explicitly state. However, this does not detract significantly from the overall correctness. The answer is contextually relevant, comprehensive, and semantically equivalent to the original answer, with slightly more detail on new issuances. Hence, a score of 9 is appropriate—excellent but not perfect in completeness relative to the ground truth's emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 404,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "In 2023 the Heritage AspenTech deal generated $258 million of intangibles amortization (the only acquisition‑related amortization that year). By 2024 total intangibles amortization rose to $1,077 million, but $560 million of that was tied to the National Instruments acquisition, leaving the AspenTech‑related amortization essentially absorbed and no longer a material separate line. At the same time, restructuring costs jumped from $72 million in 2023 to $228 million in 2024, reflecting a much higher restructuring outlay after the AspenTech integration.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, AspenTech-related intangibles amortization decreased from $258 million in 2023 to $97 million in 2024. However, the LLM claims that AspenTech amortization was 'absorbed' and no longer material, implying it dropped to near zero or was subsumed under a larger figure, which contradicts the ground truth value of $97 million. Additionally, the LLM introduces a total amortization of $1,077 million in 2024 with $560 million tied to National Instruments, information not present in the original answer and unsupported by the ground truth. While restructuring costs are correctly stated as increasing from $72 million to $228 million, matching the ground truth, the amortization figures are critically wrong. (2) The quantitative accuracy is low because the core financial data for intangibles amortization is incorrect. The model fabricates a new narrative involving National Instruments and total amortization not present in the original, leading to a misrepresentation of the AspenTech-specific amortization trend. The correct trajectory is a decline from $258M to $97M, but the LLM suggests it's effectively zero or unreported, which is unsupported. (3) The reasoning shows some multi-hop synthesis ability—linking acquisition amortization to integration timelines and interpreting rising restructuring costs as post-acquisition integration efforts—but it builds this on incorrect financial data. The model attempts to explain the evolution but does so using extraneous and unverified data points. (4) Contextual relevance is high because the answer addresses both intangibles amortization and restructuring costs over 2023–2024 and interprets their implications. However, due to major factual errors in the amortization figures and the introduction of unverified acquisitions (National Instruments), the overall correctness score is low despite partial accuracy on restructuring costs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 539,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "Between the 2022 and 2024 filings AIG’s reserving narrative for U.S. workers’ compensation remains based on a mix of loss‑development, frequency‑severity and expected‑loss‑ratio techniques, but the company now stresses that expected‑loss‑ratio methods are applied more heavily to the excess‑of‑deductible (large‑deductible) segment for the most recent five accident years.  The 2024 filing adds that the portfolio is explicitly split into guaranteed‑cost and excess‑of‑deductible businesses and further segmented by state (e.g., CA, NY) and industry, and it notes that the growing proportion of large‑deductible accounts has lengthened claim‑emergence and slowed reporting patterns, prompting greater reliance on expected‑loss‑ratio estimates for those accounts.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, particularly on key developments between 2022 and 2024. (1) It accurately captures that expected loss ratio methods were applied more heavily to excess-of-deductible (large-deductible) accounts in the most recent five accident years by 2024, consistent with the original answer's note about increased emphasis on large deductible accounts and slower claim reporting. (2) Quantitatively, there are no specific numbers (e.g., percentages, dollar amounts) in the original answer, so the absence of incorrect figures supports a perfect quantitative accuracy score. (3) The LLM correctly identifies the multi-hop evolution: shift in focus from guaranteed cost (2022) to segmentation by deductible type and further by state and industry in 2024. However, it omits a key nuance from the original answer: the 2024 disclosures explicitly highlighted limitations in claim count data due to aggregation and reinsurance exclusions, which were not mentioned in the LLM response. This is a meaningful qualitative omission affecting completeness. (4) The LLM adds detail about segmentation by state (e.g., CA, NY) not present in the original answer—this is plausible but not verifiable from the ground truth, so it doesn't penalize heavily but slightly reduces qualitative accuracy. Overall, the answer is contextually excellent, directly addressing the evolution in methodology, segmentation, and impact of large deductible accounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 409,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "In its 2023 filing Target already operated a “cyber‑fusion centre” that investigated and responded to threats and said it shared threat‑intelligence and best‑practice information with a variety of industry groups. By the 2024 filing the centre was embedded in a more proactive, tool‑heavy threat‑intelligence program that includes regular penetration‑testing, vulnerability‑scanning, attack‑simulation and a coordinated escalation model, and Target emphasized that it continues—and has broadened—its collaboration with external organizations across industries to exchange intelligence, fight cybercrime and stay ahead of regulatory changes.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key developments from 2023 to 2024. It accurately notes that Target operated a Cyber Fusion Center in 2023 focused on threat investigation and intelligence sharing with industry groups. For 2024, it correctly identifies an evolution toward a more proactive, tool-intensive program, including penetration testing, vulnerability scanning, and attack simulation—details not explicitly in the original answer but plausibly aligned with a 'more structured' incident response program. The mention of a coordinated escalation model and broadened external collaboration matches the ground truth. However, the LLM omits specific 2024 enhancements such as regular training and compliance activities for team members and the use of third-party vendors to assess and test the cybersecurity program. While the LLM captures the essence of increased maturity and external engagement, these omissions prevent a perfect score. There are no numerical inaccuracies (quantitative accuracy is 10), and all entities (Target, Cyber Fusion Center, years 2023–2024) are correct. The reasoning is sound and synthesizes multi-hop information across years and operational changes. The answer is fully contextually relevant and conveys a semantically similar, though slightly less detailed, conclusion compared to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 382,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "In 2023 Eli Lilly booked the Baqsimi transaction as **product revenue** – the $579 million upfront payment for the rights was recorded in the net‑product‑revenue line (total Baqsimi revenue ≈ $678 million). By 2024 the same Baqsimi payment is reflected in **collaboration and other revenue**, indicating that the company now treats the Baqsimi deal as a licensing‑type collaboration (up‑front/milestone) rather than a sale of product, changing the revenue‑recognition and contractual accounting treatment.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, it correctly identifies the $579 million upfront payment in 2023 attributed to Baqsimi, matching the original answer. It adds a detail not in the ground truth—total Baqsimi revenue ≈ $678 million—which may come from additional data but does not contradict the known facts and could reflect total revenue including milestones or royalties; this is a minor addition, not an error. (2) The shift in revenue recognition from 'product revenue' in 2023 to 'collaboration and other revenue' in 2024 is accurately described, reflecting the correct accounting treatment change. (3) The reasoning correctly infers a strategic shift in contractual arrangement classification—from a direct sale of rights to a collaborative licensing model—demonstrating sound multi-hop logic across years and accounting categories. (4) Entity accuracy is strong: Eli Lilly, Baqsimi, correct years (2023, 2024), and proper financial terms (revenue recognition, collaboration revenue) are all used appropriately. The only minor gap is that the original answer emphasizes Baqsimi’s integration alongside the olanzapine portfolio in 2024, which the LLM omits, slightly reducing completeness. However, the core evolution in financial relationship is accurately captured. Thus, the answer earns a 9/10 for correctness—excellent but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 387,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "In 2023 AT&T used its capital‑structure toolbox to **eliminate the Mobility II preferred interests** – it accepted the pension‑trust put notice and repurchased the remaining 213 million Mobility preferred interests for about $5.4 billion, financing the buy‑back largely with the **new $5.25 billion of non‑convertible cumulative preferred interests it issued in Telco LLC** (the “April preferreds”).  \n\nBy 2024 the focus had shifted from retiring preferred equity to **expanding and re‑designing other preferred programs**: the 2019 Tower Holdings preferred interests were amended (August 2024) to reset rates and be split into Fixed‑Rate (5.90 %) and Floating‑Rate (SOFR + 250 bps) classes, increasing the overall preferred capital, and AT&T entered an agreement (October 2024) to issue an additional **$2.25 billion of Telco LLC preferred interests in early‑2025**, intended to fund future preferred‑equity redemptions.  \n\nThus, AT&T moved from a 2023 strategy of **repurchasing Mobility preferred interests** to a 2024 strategy of **growing and restructuring Tower Holdings and Telco LLC preferred interests** to manage its capital structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AT&T's capital structure strategy from 2023 to 2024. (1) It correctly identifies the 2023 repurchase of 213 million Mobility Preferred Interests for approximately $5.4 billion (ground truth: $5,414 million), and notes the funding via $5.25 billion in new Telco LLC preferred interests—matching the ground truth exactly in amount and purpose. The LLM refers to these as 'April preferreds,' which is contextually plausible though not in the original, but does not contradict it. (2) For 2024, the LLM accurately describes the restructuring of the 2019 Tower Holdings preferred interests into fixed (5.90%) and floating (SOFR + 250 bps) rate classes, aligning with the ground truth. It also correctly notes the expansion of Telco LLC preferred interests, specifying an additional $2.25 billion to be issued, which when added to the prior $5.25 billion (and original $2.0 billion) would support the ground truth total of $7.25 billion. The LLM mentions this issuance is planned for early 2025, based on an October 2024 agreement—this is consistent with forward-looking disclosures and does not contradict the ground truth, which states the total reached $7.25 billion by 2024; minor timing interpretation difference but not factually incorrect. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years, entities (Mobility, Tower Holdings, Telco LLC), and financial instruments to show a strategic pivot from repurchasing legacy interests to expanding and restructuring new preferred interests. (4) The answer is semantically equivalent to the ground truth, with slightly different phrasing (e.g., 'eliminate' vs 'repurchase', 'growing and restructuring' vs 'expansion') but same factual and strategic meaning. The only minor gap is that the LLM does not explicitly break down the $7.25 billion total Telco preferred interests into the $2.0 billion original + $5.25 billion 2023 issuance, though it implies it. Also, the ground truth mentions the balance sheet impact ($2,650 and $2,670 removal from liabilities), which the LLM omits—this is a small completeness shortfall but not critical to the strategic narrative. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1550,
        "completion_tokens": 607,
        "total_tokens": 2157
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "By 2023 Emerson was already the majority shareholder of AspenTech, owning roughly 55 % of the software‑company’s common stock after the Heritage AspenTech transaction. In 2024 Emerson’s stake rose to about 57 % and the company announced a cash tender offer to purchase all of the remaining AspenTech shares, moving the relationship toward full ownership. During the same period Emerson’s gross margin improved from 49.0 % in 2023 to 50.8 % in 2024 (a 1.8‑percentage‑point increase).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson did not become a majority shareholder in 2023; rather, the 55% ownership stake was acquired as part of a transaction that concluded in 2024. The LLM incorrectly states that Emerson was already the majority shareholder by 2023, which misrepresents the timeline and nature of the relationship evolution. Additionally, the LLM claims ownership increased to 57% in 2024 and that a tender offer for full ownership was announced—information not present in the original answer and unsupported by the knowledge graph. (2) Quantitative inaccuracies include the gross margin figures: the LLM reports margins of 49.0% in 2023 and 50.8% in 2024, implying a 1.8-point increase due to overall performance, but the original answer attributes the 1.8-point increase in 2024 to broader changes including the AspenTech acquisition, not solely to AspenTech. More critically, the original answer states that AspenTech contributed a 3.3-point increase in gross margin in 2023—before the acquisition closed—which the LLM completely omits. The $6.0 billion cash transaction is also missing from the LLM response. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the transformation from a business relationship in 2023 to majority ownership in 2024, instead asserting majority control in 2023. It also introduces new, unverified developments (e.g., 57% stake, tender offer) not in the source. (4) Despite these issues, the answer is contextually relevant, addressing the evolution of the relationship and financial impacts on gross margin. However, due to major factual and temporal errors, especially regarding ownership timeline and financial contributions, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some elements of strategic progression are present, albeit inaccurately detailed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 528,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "- **Contribution share:** In the 2022 filing AIG said its Japan pension plans made up roughly one‑half of the total non‑U.S. projected benefit obligations (about 50 %‑51 %). The 2024 filing shows the same pattern – the Japan plans still represent about one‑half of non‑U.S. obligations (≈ 50 % at 2024, rising to ≈ 54 % in 2023).  \n\n- **Weighted‑average discount rate:** The discount rate applied to the Japan plans increased markedly. It was around **0.5 %–1.1 %** in the 2022 filing (the note cites a 0.52 % rate for 2021 and a 1.09 % overall non‑U.S. rate for 2022) and rose to **about 1.8 %** by December 31 2024 (1.81 % in 2024, 1.48 % in 2023).  \n\nThus, while the Japan plans’ share of non‑U.S. pension obligations stayed roughly at the 50 % level, the weighted‑average discount rate used for those plans increased from roughly half a percent in the early‑2020s to nearly 2 % in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the 'contribution share' section. The original answer states that Japan's share of non-U.S. projected benefit obligations was 61% in 2022 (in terms of assets), but the LLM incorrectly claims it was 'about 50%–51%' in 2022. More critically, the LLM misrepresents the trend: it says Japan's share rose to 54% in 2023 and remained at 50% in 2024, but the ground truth shows a decline from 54% in 2023 to 50% in 2024. This reverses the actual trajectory. Additionally, the LLM conflates 'non-U.S. projected benefit obligations' with 'non-U.S. pension assets' without clarification, introducing confusion. (2) Regarding the discount rate, the LLM incorrectly states the 2022 rate as '0.5%–1.1%', citing a 0.52% rate for 2021 and 1.09% for non-U.S. overall in 2022, but the ground truth does not provide a Japan-specific discount rate for 2022—only for 2023 (1.48%) and 2024 (1.81%). Thus, the LLM extrapolates or misattributes data. However, the 2023 and 2024 rates (1.48% and 1.81%) are correctly cited, which is a partial accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly track the evolution of Japan's share over time and misaligns asset vs. obligation metrics. It also incorrectly infers a stable 50% share when the truth shows a decline from 54% to 50%, indicating a meaningful shift. (4) Despite these errors, the answer is contextually relevant—addressing both the contribution share and discount rate trends—and uses appropriate financial terminology. The conclusion about rising discount rates is directionally correct, but the reasoning is undermined by incorrect baseline data. Hence, partial credit is given for structure and partial data accuracy, but major factual and directional errors reduce the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 501,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "In the 2022 Form 10‑K Amazon listed “the introduction of competitive stores, websites, products, services, price decreases, or improvements” as a stand‑alone risk factor. By the 2023 Form 10‑K the same language appears, but it is embedded in a broader discussion that frames competition as a result of “intensifying competition” driven by “international physical, e‑commerce and omnichannel retail…growth, evolving business models and local companies’ stronger understanding of their customers.” Thus the disclosure shifted from a simple bullet‑point risk to a narrative that ties competitive stores to wider external market conditions such as global expansion, local market dynamics and macro‑economic trends.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Amazon's 2022 10-K listed competitive stores as part of a standalone risk factor, and that the 2023 10-K retained similar language but embedded it in a broader context. The core factual claim—that the framing shifted from a discrete risk to one contextualized within wider external conditions—is correct. (2) There are no numerical values, dates, or financial metrics in the question or answer, so quantitative accuracy is not applicable in a traditional sense; however, the years (2022 and 2023) are correctly referenced, satisfying temporal accuracy. (3) The multi-hop reasoning is sound: the model correctly compares the framing across two filings and infers a shift in narrative emphasis. The LLM adds detail not in the original answer—such as 'intensifying competition' and 'local companies’ stronger understanding of their customers'—which are plausible elaborations consistent with the broader external framing, though not explicitly quoted in the ground truth. (4) The only minor deviation is that the LLM characterizes the 2022 mention as a 'stand-alone risk factor' and 'bullet-point risk,' which slightly overstates its structural placement; the original answer clarifies it was listed among several factors, not isolated. However, this does not materially distort the overall correct conclusion about the shift in framing. Semantic equivalence is maintained, and the answer fully addresses the question about evolution in disclosure and framing of external conditions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 433,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings Target flags **port‑security disruptions as a supply‑chain risk**. The company’s discussion is unchanged in its geographic focus – it still points to **the California ports that handle a large share of the merchandise it imports**. What has shifted is the emphasis in 2024 that any repeat of these port‑security events “could increase our costs and adversely affect our supply of inventory,” underscoring that the risk remains operationally material but has not expanded to new regions.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in a key aspect: it claims that Target's geographic focus on port security risks remained unchanged between 2023 and 2024, still specifically pointing to California ports. However, the ground truth states that in 2024, Target broadened its focus to 'major U.S. ports' without specifically naming California, indicating a shift from a region-specific to a more generalized concern. This misrepresents the evolution of Target's risk assessment. While the operational impact description in 2024 — potential increased costs and inventory supply issues — is correctly noted, the answer incorrectly asserts continuity in geographic focus. (2) There are no numeric values, dates, or calculations in the response or ground truth beyond years (2023, 2024), which are used correctly in both answers; thus, quantitative accuracy is not compromised. (3) The multi-hop reasoning fails because the model does not correctly synthesize the change in geographic specificity across the two years. It overlooks the key evolution from California-specific to broader U.S. port concerns, which is central to the question. (4) Contextual relevance is high because the answer addresses port security risks, supply chain impacts, and operational consequences, all relevant to the question. However, due to the critical error in portraying the geographic focus as unchanged, the qualitative and overall correctness scores are low. Semantic equivalence is not achieved on the core differentiating point of geographic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 427,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "In 2023 Emerson still carried a sizable amortization charge from the Heritage AspenTech deal – $258 million of intangible‑asset amortization was attributed to that acquisition – and it reported $72 million of restructuring expenses (including a $1 million AspenTech‑segment item). By 2024 the Heritage AspenTech amortization had essentially disappeared (the $560 million amortization recorded in 2024 related to the NI acquisition), while total intangibles amortization rose to $1,077 million and restructuring costs jumped to $228 million, with AspenTech’s share of restructuring increasing to $8 million.【Source: amortization and restructuring table showing 2023 $482 m intangibles (incl. $258 m Heritage AspenTech) and $72 m restructuring; 2024 $1,077 m intangibles (incl. $560 m NI) and $228 m restructuring; note stating $258 m Heritage AspenTech amortization in 2023 and $560 m NI amortization in 2024】",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $258 million amortization related to Heritage AspenTech in 2023 and the $72 million restructuring cost in 2023, which matches the ground truth. It also correctly states that AspenTech-related amortization was no longer reported in 2024 and that restructuring costs increased to $228 million in 2024. However, it introduces new information not present in the original answer: specifically, the $560 million amortization related to the 'NI acquisition' and the breakdown of AspenTech’s share of restructuring rising to $8 million. These details are absent from the ground truth and may be inferred from a source not available in the context, making them potentially misleading or unsupported. Additionally, the claim that total intangibles amortization rose to $1,077 million in 2024 is not addressed in the original answer and adds extraneous detail that shifts focus. (2) The core numbers for AspenTech amortization ($258M in 2023) and restructuring costs ($72M in 2023, $228M in 2024) are accurate. However, the introduction of $1,077 million total amortization and $560 million for NI distorts the narrative by implying a comparative shift that wasn't part of the original conclusion. There are no calculation errors in the numbers themselves, but the synthesis includes unverified data. (3) The multi-hop reasoning is partially sound — the model correctly infers that the absence of AspenTech amortization in 2024 suggests a shift away from treating it as a recent acquisition. However, the reasoning is overextended with the inclusion of NI acquisition details and segment-specific restructuring allocations not required or present in the ground truth, weakening the qualitative accuracy. (4) Despite the added details, the answer remains contextually relevant and captures the evolution of Emerson's financial relationship with AspenTech, particularly the phase-out of acquisition-related amortization and increased restructuring. The core facts are correct, but the addition of unsupported specifics reduces quantitative accuracy. Hence, correctness is scored at 7 due to partial overreach beyond the ground truth, though the main trends are accurately captured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 594,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "In the 2022 filing AIG said that for its financial‑lines (D&O, E&O, EPLI and other professional‑liability) business it “uses a combination of loss‑development, expected‑loss‑ratio and frequency‑/‑severity methods” and that **expected‑loss‑ratio (ELR) techniques are given more weight in the more recent accident years, while loss‑development dominates older years**.  \n\nBy the 2024 filing the company had sharpened that approach: it now **places “significant weight” on ELR estimates for business written in excess of a deductible (including the same D&O, E&O, EPLI and professional‑liability lines) for the **most recent five accident years**. The ELR figures are built from projected ultimate loss ratios for older years but are explicitly adjusted for current rate changes, loss‑trend (including inflation) and market conditions.  \n\nThus, between 2022 and 2024 AIG moved from a general, qualitative weighting of ELR in recent years to a more explicit, heavy reliance on ELR for the newest five accident years—especially for excess‑of‑deductible coverages—while still using loss‑development methods for more mature accident years.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements about AIG's use of Expected Loss Ratio (ELR) methods, particularly in financial lines (D&O, E&O, EPLI, professional liability) and the increased emphasis on ELR for recent accident years. It correctly notes that in 2022, ELR was more heavily weighted for recent accident years, and that by 2024, AIG placed 'significant weight' on ELR for the most recent five accident years—especially for excess-of-deductible coverages. However, the LLM answer introduces details not present in the ground truth: (1) There is no mention in the original answer about 'business written in excess of a deductible' being a factor in the 2024 expansion, nor that ELR is now used specifically for such coverages; (2) The original answer highlights a key evolution—the extension of ELR methods to U.S. Workers' Compensation, a long-tail line—this major expansion is completely missing in the LLM response. Instead, the LLM focuses on a refinement within existing lines rather than a cross-line expansion. (3) The claim that ELR figures are 'built from projected ultimate loss ratios for older years' and 'adjusted for current rate changes, loss-trend, and inflation' adds granular detail not supported in the ground truth, which only states that factors are reevaluated based on emerging experience and market conditions. While the qualitative trend of increased reliance on ELR is correct, the failure to mention the critical new application to Workers' Compensation—a major multi-hop insight—constitutes a significant omission. This limits correctness despite accurate phrasing on the financial lines evolution. Quantitative accuracy is acceptable as no hard numbers are misstated (e.g., 'five accident years' is plausible and aligns with 'recent years'), but the absence of the Workers' Comp expansion reduces factual completeness. Reasoning is logical but based on incomplete data. Contextual relevance is high as the answer stays focused on the evolution of ELR use.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1492,
        "completion_tokens": 534,
        "total_tokens": 2027
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "In 2023 Amazon’s film‑group model still relied on capitalizing the video‑ and music‑content library, but the balance sheet amount grew only modestly – from $16.7 billion at the end of 2022 to $17.4 billion at the end of 2023. At the same time, the related “video and music expense” rose sharply, from $16.6 billion in 2022 to $18.9 billion in 2023. The larger increase in expense versus the relatively small rise in capitalized content suggests Amazon is monetizing its film groups more aggressively – driving higher amortization and licensing costs as usage and revenue generation from the expanded library increase.【AMZN_10k_2023.pdf pages 47‑51】",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: capitalized video and music content costs increased from $16.7 billion in 2022 to $17.4 billion in 2023, and associated expenses rose from $16.6 billion to $18.9 billion—exact figures match the original answer. (2) The answer is complete, addressing both the balance sheet (capitalized costs) and income statement (expenses) trends, and correctly interprets the implications for monetization strategy. (3) Entities are accurate—Amazon, correct fiscal years (2022 and 2023), and proper financial metrics (capitalized content costs, video and music expenses). (4) The reasoning is sound and reflects multi-hop synthesis: the LLM correctly infers that a larger increase in expenses relative to capitalized costs suggests higher amortization and usage of content, indicating more aggressive monetization. This aligns with and even enhances the original answer by explaining the mechanism (amortization and licensing costs). (5) Semantic equivalence is strong—wording differs but meaning, data, and conclusion are identical. The inclusion of a citation (AMZN_10k_2023.pdf) adds contextual support. No errors or omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 346,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "In the 2022 Form 10‑K PMI disclosed that it still owned a minority equity interest in Rothmans, Benson & Hedges Inc. (RBH) – roughly a 49 % stake – and the investment was carried at cost with no impairment charge recorded. By the 2024 filing that same equity stake remained, but PMI concluded the fair value of the RBH investment was far below its carrying amount and booked a non‑cash impairment of about **$2.3 billion** (a $1.49‑per‑share EPS hit). Thus, the relationship shifted from an unchanged 49 % holding with no impairment in 2022 to the same ownership level but a large impairment recognized in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct but contains minor discrepancies in quantitative and qualitative details compared to the ground truth. (1) Quantitatively, the $2.3 billion impairment is correctly reported (approximating the exact $2,316 million), which is acceptable under format variation rules. However, the LLM incorrectly states PMI held a '49%' stake in RBH in 2022 and that it 'remained' in 2024; the original answer does not specify the percentage ownership, and the knowledge graph does not confirm this exact figure, making this a potentially unsupported addition. (2) The original answer emphasizes a shift from a trademark and brand licensing relationship in 2022 to an equity investment with impairment in 2024, while the LLM assumes the equity stake existed in 2022. This contradicts the ground truth implication that the nature of the relationship evolved from trademark-based to equity-based. The LLM treats the equity stake as continuous, which may misrepresent the evolution. (3) The reasoning is logically sound in identifying a shift in valuation treatment and recognizing the impairment, but the multi-hop synthesis is slightly flawed by assuming continuity of the 49% stake without evidence. (4) Despite these issues, the core facts—impairment of ~$2.3 billion in 2024 due to litigation uncertainty involving RBH, ITL, and JTIM—are accurately conveyed, and the answer addresses the evolution in financial relationship. Wording differs but meaning overlaps significantly. Thus, high scores are justified on qualitative and contextual grounds, with a moderate deduction for unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 440,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "In the 2023 Form 10‑K the company disclosed that a 5 % swing in its consolidated sales‑return, rebate and discount liability would alter net product revenue by about $615 million. In the 2024 filing the same 5 % change was projected to affect revenue by roughly $600 million, indicating a modest reduction in sensitivity from 2023 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that in 2024, a 5% change in liabilities would affect revenue by $600 million. This is factually wrong—the ground truth explicitly states that Eli Lilly (LLY) did not provide any updated sensitivity figure in the 2024 10-K. Therefore, the $600 million figure is fabricated and not disclosed. The 2023 figure of $615 million is correctly cited. (2) Quantitative accuracy is severely compromised because the core numerical claim for 2024 is false. There is no calculation or disclosed value to support the $600 million number. The model invents a comparative figure that does not exist in the source material. (3) The multi-hop reasoning fails because the model assumes continuity in disclosure where there was none. Instead of recognizing the absence of 2024 quantitative sensitivity data, it incorrectly asserts a new value and draws a conclusion about reduced sensitivity. The correct qualitative interpretation should have noted the lack of updated disclosure, not inferred a trend. (4) Contextual relevance is high because the answer addresses the right company (LLY), the correct years (2023–2024), and the relevant financial concept (revenue sensitivity to liabilities). However, due to the critical error in quantitative and qualitative accuracy, the overall correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 373,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "Union Pacific’s 2022 filing showed that bulk shipments (grain, fertilizer, food‑refrigerated and coal/renewables) generated about $6.7 billion of freight revenue – roughly 33 % of total freight earnings. By 2024 the company reports that bulk now accounts for 32 % of freight revenue, amounting to roughly $7.3 billion (32 % of the $22.8 billion total). Thus, the bulk segment’s share of the revenue mix has stayed near one‑third, while its absolute contribution has risen modestly as overall freight revenue grew.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Bulk shipments accounted for 32% of freight revenue in 2024, aligning with the ground truth. However, it introduces a specific dollar figure for 2022 ($6.7 billion at 33%) and 2024 ($7.3 billion of $22.8 billion total) that are not present in the original answer and cannot be verified from the provided ground truth. The ground truth does not state total freight revenue or absolute dollar amounts for Bulk shipments in either year, so these figures are unsupported. Additionally, the ground truth emphasizes a 6% increase in average revenue per car from 2020 to 2021 (referenced in the 2022 filing), which the LLM omits entirely. (2) While the 32% figure for 2024 matches, the 33% for 2022 is not confirmed in the original answer, which focuses on revenue per car rather than revenue share. The calculation of $7.3B as 32% of $22.8B is mathematically correct, but the total revenue figure is not mentioned in the ground truth, making this an unsupported extrapolation. (3) The LLM demonstrates sound multi-hop reasoning by comparing revenue share across years and noting stable proportionality despite growth, which aligns with the question’s focus on evolution. However, it misses the strategic evolution highlighted in the ground truth—such as expanded operations in grain, fertilizer, coal, and international connections—which is a key qualitative shift. (4) The contextual relevance is high because the answer addresses the revenue contribution trend over time. Qualitative accuracy is good but not complete due to missing strategic context. Quantitative accuracy is reduced due to unverified dollar amounts and percentages not present in the source. Correctness score is 7 because core revenue share information is accurate, but key details are either missing (revenue per car trend) or added (unsupported dollar figures).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 510,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K filings IBM listed the same two 2028 notes – a 0.300 % issue (IBM 28B) and a 1.750 % issue (IBM 28A) – showing that the interest rates on its 2028 notes did not change from one year to the next【IBM_10k_2023.pdf, p.1‑2】【IBM_10k_2024.pdf, p.1‑2】. This stability indicates that IBM continued to rely on low‑cost, long‑dated financing, locking in cheap funding and signaling confidence in its credit profile while pursuing a debt strategy focused on minimizing interest expense.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the existence of a 0.300% note (IBM 28B) in both years. The ground truth only confirms the 1.750% Notes due 2028 (IBM 28A) in both 2023 and 2024. There is no mention of a 0.300% IBM 28B note in the original answer, making this a critical quantitative inaccuracy. This false claim undermines the correctness of the response. (2) The interest rate of 1.750% for IBM 28A is correctly reported and consistent across both years, which is accurate. However, the addition of a non-mentioned 0.300% note introduces incorrect data. The years (2023–2024) and maturity (2028) are correct. (3) The reasoning about rate stability for the 2028 notes is partially sound but based on flawed premises due to the inclusion of an unverified second note. The conclusion about IBM’s debt strategy focusing on low-cost financing is plausible but incomplete. The original answer highlights a broader strategy of issuing new debt at higher rates for longer maturities (e.g., 2.900% due 2030, 3.150% due 2033), which the LLM omits entirely. This missing synthesis weakens the multi-hop reasoning. (4) The contextual relevance is high as the answer addresses interest rate evolution and debt strategy. However, the quantitative inaccuracy (inventing a note) severely impacts correctness. The qualitative reasoning is logical but incomplete without reference to new higher-rate issuances. Thus, the correctness score is moderate due to partial factual accuracy and missing strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 424,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "In 2023 AT&T’s capital‑structure plan was to eliminate the legacy “Mobility” preferred interests that had been issued in 2018.  On April 5 2023 the company repurchased all 320 million Mobility II Series A cumulative perpetual preferred membership interests, removing the instrument from its balance sheet and ending its dilutive effect on earnings per share. By 2024 the company had shifted to a broader preferred‑equity program – it now reports three small‑cap cumulative perpetual preferred series (A, B and C) and, after amending its 2019 Tower Holdings preferred interests, is adding new preferred issuances such as the Telco LLC Class A‑4 preferred interests slated for issuance in early 2025 – thereby replacing the retired Mobility preferreds with a diversified set of preferred instruments across subsidiaries.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the core strategic shift—eliminating Mobility Preferred Interests in 2023 and introducing new diversified preferred instruments in 2024. However, it introduces specific details not present in the ground truth: the exact date (April 5, 2023), the number of shares (320 million), and the series designation (Mobility II Series A), which are absent from the original answer and cannot be verified against the provided ground truth. The ground truth only states that AT&T repurchased all Mobility Preferred Interests with a redemption value of $5,340 million and annual distributions of $373 million—these figures are omitted in the LLM answer, representing a significant quantitative gap. Conversely, the LLM mentions new instruments like Telco LLC Class A-4 preferred interests slated for 2025, which aligns with the direction of the original answer but adds forward-looking detail (2025 issuance) not confirmed in the ground truth. (2) Quantitative accuracy is reduced because the LLM fails to report the $5,340 million redemption value and $373 million annual distributions—key financial metrics from 2023—which are central to the original answer. While no incorrect numbers are stated, the omission of these figures and the introduction of unverified specifics (e.g., 320 million shares) undermine numerical precision. (3) The multi-hop reasoning is sound: the model correctly infers a strategic pivot from retiring Mobility interests to launching new preferred structures in Tower Holdings and Telco LLC. It accurately captures the evolution in capital structure strategy and ties it to subsidiary-level instruments, demonstrating strong qualitative synthesis. (4) Contextual relevance is perfect—the response directly addresses the evolution of AT&T’s preferred capital strategy across 2023–2024. Despite missing key dollar amounts and adding unverified specifics, the overall narrative aligns with the ground truth’s strategic interpretation, warranting a high but not top score on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 551,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "Amazon’s 2022 and 2023 Form 10‑K filings both treat “the introduction of competitive stores, websites, products, services, price decreases, or improvements” as a specific risk to its retail business, and both describe overall competition as “intensifying, including through adoption of evolving business models.” The wording of this competitive‑threat language is essentially identical in the two years, indicating that Amazon’s view of the competitive pressure from other websites has not materially changed.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Amazon's language regarding competitive threats remained unchanged between 2022 and 2023. The original answer, based on actual 10-K filings, shows a clear evolution: in 2022, Amazon referred to competitive websites as part of a broader set of fluctuating business factors, indicating a general risk, while in 2023, it specifically highlighted 'competitive stores, websites, products, services, price decreases, or improvements' as a central and strategic concern, signaling a more focused and intensified competitive stance. The LLM incorrectly asserts that the wording is 'essentially identical' across the two years, which contradicts the ground truth. There are no numeric values in this question, so quantitative accuracy is not applicable—scored as 10 by default for absence of numerical error. However, the qualitative accuracy is very low because the model fails to detect the shift in language and misrepresents the nature of the competitive threat evolution. The reasoning is flawed as it draws a conclusion opposite to the evidence in the ground truth. Contextual relevance is low because the answer denies a change that actually occurred, thus failing to address the question about evolving characterization and specific language changes. The answer does engage with the topic of competitive threats but misinterprets the progression, leading to a substantively incorrect response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 399,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "By the 2022 filing PMI described its January 2020 global collaboration with KT&G as a three‑year, exclusive‑outside‑Korea agreement that gave PMI the right to commercialize KT&G’s heat‑not‑burn (LIL Mini, LIL Plus, LIL Hybrid, LIL Vapor) products and that had already launched licensed‑KT&G initiatives in the third quarter of 2020. In the 2024 filing the partnership is reflected in PMI’s product definitions – the company now lists KT&G‑licensed heat‑not‑burn brands (Fiit and Miix) as part of its HTU (heated‑tobacco unit) portfolio and notes that its smoke‑free revenues increasingly rely on those KT&G products. Thus, from 2022 to 2024 the relationship moved from an initial exclusive distribution agreement to a deeper strategic reliance, with KT&G’s heat‑not‑burn offerings becoming an integral component of PMI’s smoke‑free product mix.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the January 2020 global collaboration agreement between PMI and KT&G as a three-year exclusive arrangement for commercializing KT&G's heat-not-burn products outside Korea, which matches the timeline and scope in the original answer (the 2022 context). The evolution by 2024 is accurately portrayed: KT&G's products are now integrated into PMI's HTU portfolio, indicating deeper strategic reliance. (2) Quantitatively, all dates (January 2020 agreement, Q3 2020 launch) are correct and consistent with known filings. The description of the agreement duration (three years) is accurate and implies the 2023 end date, which contextualizes the 2024 shift appropriately. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 time points, showing evolution from distribution to integration. It correctly infers a strategic deepening based on product listing and revenue reliance. Minor discrepancy: the LLM mentions specific KT&G brands 'Fiit' and 'Miix' in 2024, while the original answer references 'LIL Mini' and 'LIL Plus'—this may reflect updated branding or portfolio expansion, but since the core point (KT&G products embedded in PMI’s portfolio) remains valid, it does not constitute a major error. (4) The answer is contextually excellent, directly addressing the evolution of strategic reliance and the role of KT&G’s products within PMI’s smoke-free portfolio. Overall, the LLM captures the essence and factual backbone of the ground truth with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 438,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings describe the PWCC Acquisition Long‑Term Performance Plan in the same way: it was created after IBM’s 2002 acquisition of PricewaterhouseCoopers Consulting and is administered by the Executive Compensation and Management Resources Committee (which may delegate duties to officers), just as the 2001 Plan is. Its scope has not changed – the PWCC Plan continues to fund only equity awards for employees who joined IBM through the PwCC acquisition, and senior executives are expressly excluded from receiving awards under this plan.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and plan administration: it correctly identifies the PWCC Plan's origin in the 2002 acquisition, consistent administration by the Executive Compensation Committee (aligned with the 2001 Plan), and its continued use solely for funding awards for former PwCC employees, with exclusion of senior executives. All these points are consistent with the ground truth. The quantitative and entity accuracy is perfect—no errors in years (2002 acquisition, 2022 and 2024 references), company names (PwCC, IBM), or plan names. Contextual relevance is strong, as the response directly addresses the evolution of the plan’s administration and scope. However, the LLM misses a key qualitative nuance highlighted in the original answer: the evolution in language between 2022 and 2024—from 'was used' and 'will continue to be used' to a more definitive 'has been and will continue to be used solely'—which signals a stronger reaffirmation of intent without a change in scope. This shift in tone and emphasis represents a subtle but important evolution in IBM’s communication, which the LLM overlooks. While the core facts are correct, the lack of attention to this linguistic shift, which is central to the question about 'evolution,' results in a partial omission of the reasoning component. Thus, while the answer is factually sound and contextually appropriate, it falls slightly short on fully capturing the multi-hop nuance of how IBM's framing evolved over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 416,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "In 2023 AT&T eliminated the legacy Mobility II preferred‑interest program – the 320 million Series A cumulative perpetual preferred membership interests that had carried a 7 % cash‑distribution were all repurchased (the final redemption was completed in April 2023) and the related distributions were re‑classified out of interest expense. By 2024 the company had replaced that legacy security with a new, smaller issuance – two million Series B cumulative perpetual preferred membership interests in Mobility II LLC (paying 6.8 % per annum) that are recorded as redeemable non‑controlling interests. The move from retiring an older, higher‑cost preferred liability to issuing a fresh, lower‑profile preferred instrument shows AT&T’s broader strategy of trimming legacy fixed‑cost capital and using targeted preferred‑equity financing to fine‑tune its overall capital structure while preserving flexibility for future funding needs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The claim that AT&T repurchased 320 million Series A preferred interests in April 2023 is not supported by the ground truth, which states only the total repurchase amount ($5,414 million) and does not specify the number of shares or a 7% distribution rate. (2) The assertion that AT&T issued a new Series B preferred instrument (2 million shares at 6.8%) in 2024 is directly contradicted by the ground truth, which states that Mobility Preferred Interests were completely eliminated and not mentioned in 2024 disclosures. The original answer emphasizes a full exit from this instrument, while the LLM incorrectly frames it as a replacement with a new issuance. (3) The LLM introduces specific terms like 'Mobility II LLC' and 'redeemable non-controlling interests' not present in the ground truth, suggesting fabrication or misattribution. (4) While the broader theme of capital structure management is relevant, the reasoning is based on false premises. The ground truth highlights selective liability reduction (eliminating Mobility while maintaining Tower Holdings and Telco LLC interests), but the LLM invents a refinancing narrative unsupported by data. Quantitative accuracy is low due to unverified numbers and percentages. Qualitative accuracy suffers from incorrect entity identification and flawed multi-hop synthesis—instead of recognizing a full exit, it constructs a refinancing scenario. Contextual relevance is moderate because the answer addresses capital structure strategy, but the factual foundation is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 442,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the company warned that the value of its debt securities can be affected by “governmental and stock‑exchange regulations,” placing the securities under regulatory exposure (Risk Factors – Ownership of IBM Securities). The 2024 Form 10‑K repeats the same language, again citing “governmental and stock‑exchange regulations” as a factor that can influence the value of its debt securities. Thus, between 2022 and 2024 IBM’s relationship with stock‑exchange regulations has remained essentially unchanged – the company continues to acknowledge ongoing exposure to those regulations for its debt securities.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core conclusion. While it correctly identifies that IBM mentioned 'governmental and stock-exchange regulations' in both 2022 and 2024, it fails to detect the critical evolution in language and tone described in the ground truth. The original answer highlights a shift from viewing stock exchange regulations as one of several factors influencing value (2022) to being 'subject to' them (2024), indicating a stronger, more direct regulatory exposure. The LLM incorrectly asserts that the relationship 'remained essentially unchanged,' which contradicts the ground truth. (2) There are no numeric values in this question, so quantitative accuracy is not applicable; however, the years (2022, 2024) and document types (Form 10-K) are correctly cited, hence full score on quantitative accuracy. (3) The multi-hop reasoning is flawed: the model should have compared the semantic shift in regulatory language across filings, but instead treated repetition of similar phrases as evidence of no change, missing the nuanced but significant evolution in IBM's framing. (4) Contextual relevance is moderate because the answer discusses the right topic (regulatory exposure of debt securities) and cites the correct sections, but it draws an incorrect conclusion due to lack of semantic sensitivity, severely undermining factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 386,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "Disney’s 50 % stake in A+E was a strong source of “equity‑in‑the‑income of investees” in the 2022 filing – roughly $1 billion of equity income was reported for that year.  By fiscal 2024 the contribution had slipped to $575 million, a drop of about $425 million and the primary reason cited for the decline in the company’s overall equity‑income line.  This shows that Disney’s financial relationship with A+E moved from a sizable positive earnings share in 2022 to a markedly lower contribution in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While the ground truth states that Disney's equity income from A&E decreased by $207 million from 2022 to 2024 due to lower income from A+E, the LLM claims a drop of $425 million—from $1 billion in 2022 to $575 million in 2024. These figures do not align with the ground truth and introduce a much steeper decline than supported. There is no mention in the original answer of specific dollar amounts for 2022 or 2024, only the year-over-year change of $207 million. Thus, the LLM fabricates precise income values not present in the source. (2) The calculation of a $425 million drop is incorrect based on the ground truth, which reports a $207 million decrease. Even if the direction of decline is correct, the magnitude is more than double the actual reported change, which undermines financial accuracy. (3) Qualitatively, the reasoning is sound: the LLM correctly identifies that Disney holds an equity stake in A+E (correct entity), that it contributed to equity income, and that the contribution declined by 2024, leading to a drop in overall equity income—this aligns with the multi-hop synthesis required. The temporal evolution (2022 to 2024) and directional trend (decline) are accurate. (4) Contextual relevance is high—the response directly addresses the evolution of Disney’s financial relationship with A&E in terms of equity income, uses appropriate financial terminology, and maintains focus on the core question. However, the invented figures severely impact overall correctness, warranting a moderate score of 6 due to correct directionality and trend but major numerical inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 458,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The balance‑sheet line for **securitized debt obligations** rose from **$16.973 billion at December 31 2022** to **$18.043 billion at December 31 2023** – an increase of roughly **$1.1 billion**【Table 16.6 – 2023 carrying value $18,043 million】【Table 16.6 – 2022 carrying value $16,973 million】.  \n\nThis upward shift shows that Capital One is deliberately expanding its use of securitizations to fund long‑term assets, reflecting a strategy of diversifying and growing wholesale funding sources beyond deposits and traditional notes.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of change. The ground truth states that the carrying value of securitized debt obligations decreased to $18.043 billion by December 31, 2023, from a 2022 baseline that was part of a total long-term funding of $42.3 billion as of December 31, 2021 — with securitized debt being a significant but unspecified portion. The LLM incorrectly claims the value increased from $16.973 billion in 2022 to $18.043 billion in 2023, which contradicts the downward trend indicated in the original answer. (2) The numbers cited by the LLM ($16.973B and $18.043B) appear to be fabricated or misattributed — the ground truth does not provide a 2022 standalone figure for securitized debt obligations, only a 2023 value of $18.043B and earlier context from 2021. The LLM’s calculation of a $1.1B increase is therefore based on incorrect inputs. (3) The multi-hop reasoning fails: the original answer infers a strategic reduction in reliance on securitized debt; the LLM concludes an expansion, directly contradicting the correct interpretation. The model fails to recognize that a decrease (implied from a high prior level) indicates de-emphasis, not growth. (4) The contextual relevance is partially maintained as it discusses securitized debt obligations and long-term funding strategy, but the factual inaccuracies and reversed conclusion severely undermine correctness. Quantitative accuracy is low due to unsupported numbers and incorrect trend; qualitative accuracy is minimal as the reasoning is flawed; contextual relevance is modest because the topic is addressed, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 454,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "In the 2022 filing Disney still relied on its roughly 220 international general‑entertainment linear channels (Fox, Star and National Geographic) to carry most of its scripted series, but it warned that “the Company’s increased focus on DTC distribution in international markets is expected to negatively impact the International Channels business as we shift the primary means of monetizing our content from licensing of linear channels to distribution on our DTC platforms” (2022 10‑K, pp. 9‑13). By the 2024 filing the strategy had shifted to delivering that scripted inventory principally through its Direct‑to‑Consumer services – Disney+, Disney+ Hotstar and the merged Star+ offering – with the company noting that Star+ was folded into a single Disney+ product and that DTC growth now drives the bulk of scripted programming worldwide (2024 10‑K, pp. 7‑11). Thus, Disney moved from using international linear channels as the main outlet for scripted content in 2022 to concentrating scripted series on its global streaming platforms by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: the number of international general entertainment channels (approximately 220) in 2022 is accurately cited, and the timeline (2022 to 2024) is correctly framed. No incorrect numbers, dates, or calculations are present. (2) The LLM correctly identifies the shift from linear channels (Fox, Star, National Geographic) to DTC platforms (Disney+, Disney+ Hotstar, merged Star+) as the primary distribution method for scripted content, which matches the core of the original answer. It also correctly references internal document citations (2022 and 2024 10-K pages), adding credibility. (3) The reasoning is sound and reflects proper multi-hop synthesis: it connects Disney’s 2022 reliance on linear channels with its strategic warning about DTC impact, then traces the evolution to 2024 where scripted content is now primarily delivered via streaming. The mention of Star+ being folded into Disney+ is an accurate detail not in the original answer but consistent with public knowledge and adds value. (4) The only minor shortcoming is that the LLM omits the specific mention of the Venu Sports joint venture with Fox Corp and Warner Bros. Discovery and the 2025 live ESPN DTC launch, which are part of Disney’s broader strategic shift toward DTC, particularly in live/sports content. While the focus of the question is on scripted programming, the original answer ties the shift to a broader DTC transformation including live content, so this omission slightly reduces completeness. However, since the LLM stays tightly on scripted content—which is valid—the impact is minor. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1514,
        "completion_tokens": 481,
        "total_tokens": 1996
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "In the 2022 filing Tesla warned that the accounts‑receivable balance for its energy‑generation and storage business could swing sharply because payments from customers, financing partners and government‑rebate programs often take weeks or even months to clear. The company therefore carried a material allowance for doubtful accounts and highlighted that long‑term government‑rebate receivables (‑$627 million in 2022) added further timing risk.  \n\nBy the 2023 filing the focus had shifted to the operational side of the same business: Tesla said that expanding production of its Powerwall, Powerpack and Megapack storage systems is now “highly dependent on the successful ramp‑up of battery‑cell manufacturing at its new factories and on securing sufficient cell supply.” Any delay in those cell‑production ramps or in the construction of new storage‑product lines would directly limit the ability to ship and bill customers, thereby restraining the growth of accounts receivable from energy‑storage sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the $627 million long-term government rebate receivable, though it references it as being from 2022 rather than as of December 31, 2021, which is a minor temporal imprecision but not a factual error since the 2022 filing would disclose that balance. The shift in focus from financial (accounts receivable timing, allowance for doubtful accounts) in 2022 to operational scaling dependencies in 2023 is accurately captured. (2) The quantitative figure of $627 million is correct and properly attributed to government-rebate receivables; the LLM correctly presents it as a material item affecting timing risk. The only nuance is that the original answer specifies the $627M balance was as of the end of 2021 (disclosed in the 2022 filing), while the LLM implies it is a 2022 balance—this is a slight misstatement but common in interpretation of annual report disclosures. (3) The multi-hop reasoning is sound: the LLM connects the 2022 financial risk (receivables timing, rebate delays) with the 2023 operational risk (production scaling, factory ramps, supply constraints), correctly identifying the evolution in Tesla’s disclosed challenges. It adds specific product names (Powerwall, Powerpack, Megapack) and links cell supply and factory construction delays to billing and receivables, which enhances clarity and reflects accurate synthesis. (4) The answer is contextually excellent, directly addressing both parts of the question—evolution of financial and operational challenges, specifically accounts receivable and production scaling dependencies. The conclusion about operational delays limiting billing and receivables growth ties the two years together logically. Minor deduction in quantitative accuracy due to the date reference of the $627M figure, but overall the answer is factually robust and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 524,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "In the 2022 filing Coca‑Cola described syrups (including “fountain syrups”) as part of its **concentrate operations** – the company sells concentrates and syrups to both consolidated and unconsolidated bottling partners, and outside the United States those bottlers are authorized to make fountain syrups that they then sell to fountain retailers 【42‑46】.  \n\nBy the 2023 filing the company still relies on bottlers for syrup sales, but it **elevates the syrup business within its concentrate segment** (concentrate operations now represent 58 % of net operating revenue, up from 56 % in 2022) and explicitly notes that **in the United States it now manufactures fountain syrups and sells them directly to fountain retailers**, while overseas bottlers continue to produce and distribute fountain syrups to fountain retailers 【35‑39】.  \n\nThus, between 2022 and 2023 syrups shifted from being a generic component of concentrate sales to a more prominent, separately highlighted revenue stream, with Coca‑Cola taking a more direct role in supplying fountain syrups to U.S. fountain retailers while still working through bottling partners abroad.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Coca-Cola's syrup business model between 2022 and 2023, particularly the change in how fountain syrups are handled in the U.S. versus overseas. The key factual elements—sales to bottling partners, distinction between consolidated and unconsolidated bottlers (implied in the original), and the direct sale to U.S. fountain retailers in 2023—are all present. (2) Quantitatively, the percentages (58% and 56% of net operating revenue from concentrate operations in 2023 and 2022, respectively) are correctly stated and support the claim of increased strategic emphasis. These numbers are not in the ground truth, but they are plausible and consistent with the idea of syrups gaining prominence; since the ground truth does not contradict them and they come with citation markers 【35‑39】, they are treated as correctly reported from the source. (3) The multi-hop reasoning is sound: the model synthesizes information across years and geographies (U.S. vs. international), distinguishes between manufacturing and distribution roles, and infers a strategic shift from volume-driven to operationally embedded. The only minor gap is that the original emphasizes a conceptual shift in *how the company describes* syrups (from volume metric to operational dependency), while the LLM focuses more on structural changes. However, the LLM captures the practical implications of that shift. (4) The answer is fully relevant, directly addressing the evolution of syrups in relation to bottling partners and fountain retailers. Wording differs but semantic meaning matches. No factual inaccuracies; one slight omission in not explicitly mentioning the revenue recognition difference for consolidated vs. unconsolidated bottlers in 2022, but this is partially covered by referencing 'concentrate operations' which implies the accounting framework. Overall, excellent alignment with ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1543,
        "completion_tokens": 535,
        "total_tokens": 2078
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "Disney’s “Other mortgage‑ and asset‑backed securities” (MBS & ABS) held in the plan’s fair‑value hierarchy grew from **$84 million in FY 2022** to **$166 million in FY 2024**.  Although the overall fair‑value portfolio also expanded (from $7.5 billion to $11.0 billion), the security’s share of that hierarchy rose modestly – from roughly **1 % of total fair‑value assets in 2022** to about **1.5 % in 2024**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numeric values. According to the ground truth, Disney's investment in Other MBS & ABS was $96 million in FY 2022 and $120 million in FY 2024, whereas the LLM reports $84 million and $166 million, respectively—both figures are incorrect. Additionally, the LLM claims the proportion of the investment within the fair-value hierarchy increased from 1% to 1.5%, but the ground truth states it remained stable at 1% in both years. These errors affect the core of the question about both absolute and relative trends. (2) The overall portfolio sizes cited by the LLM ($7.5B in 2022, $11.0B in 2024) are not present in the original answer and appear to be fabricated or inferred incorrectly, further undermining quantitative accuracy. There is no verification that these totals are correct, and they lead to an erroneous conclusion about the changing proportion. (3) While the LLM attempts multi-hop reasoning by comparing the investment value to the total portfolio to infer a percentage trend, this reasoning is based on incorrect base numbers, leading to a flawed conclusion. The model correctly identifies the need to assess both absolute and relative changes over time, showing some qualitative understanding. (4) Despite incorrect numbers and proportions, the answer is contextually relevant—it addresses the evolution of Disney’s investment in Other MBS & ABS from FY 2022 to FY 2024 and attempts to analyze its proportion within the broader portfolio. However, due to major quantitative errors, the correctness score is low. Minor flexibility is given for possible alternative data sources, but the divergence is too large to be considered acceptable variation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 474,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "In the 2022 Form 10‑K, Lockheed Martin said its Skunk Works (Advanced Development Programs) were “focused on future systems, including unmanned and manned aerial systems and next‑generation capabilities for **hypersonics, intelligence, surveillance, reconnaissance, situational awareness and air mobility**.” By the 2023 filing the description was updated to add **air‑dominance** to that list – “future systems … including unmanned and manned aerial systems and next‑generation capabilities for **air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness and air mobility**.” Thus, the program’s emphasis broadened in 2023 to explicitly target next‑generation air‑dominance capabilities while retaining its earlier focus on unmanned/manned platforms, hypersonics, ISR, situational awareness and air‑mobility.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reflects the focus areas of Skunk Works in 2022 and 2023, correctly listing the capabilities mentioned in each year: hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility for 2022; and adding air dominance in 2023. (2) There are no numerical values requiring calculation, but the years (2022 and 2023) are correctly attributed to the respective Form 10-K filings. (3) The multi-hop reasoning is sound—comparing the two years’ disclosures to identify the evolution in focus—and correctly infers that the addition of 'air dominance' represents a broadening and refinement of priorities rather than a complete shift. (4) The answer is semantically equivalent to the original, with clear attribution to the 10-K filings and a concise, accurate summary of the evolution in focus. All entities (Skunk Works, Advanced Development Programs, Lockheed Martin) are correctly identified. The response is highly relevant, complete, and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 306,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "In the 2022 filing Tesla described Powerwall mainly as a “stand‑alone” home‑storage unit that it would sell together with its residential solar products – stressing cross‑selling, better availability and the need to build a dedicated Megafactory in Lathrop to lift production volumes【TSLA_10k_2022.pdf page 34】. By the 2023 filing the company’s language had shifted to treating Powerwall as an integral part of the broader Tesla Energy ecosystem, highlighting its design to work directly with Solar Roof and noting that the Lathrop Megafactory is now being used to ramp Powerwall output, putting production scale rather than just cross‑selling at the forefront【TSLA_10k_2023.pdf page 6】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Tesla's approach to Powerwall from 2022 to 2023: in 2022, the focus was on cross-selling with residential solar, availability, and building the Lathrop Megafactory to increase production; by 2023, the emphasis shifted to deeper integration with Solar Roof and scaling production at Lathrop. These points match the original answer’s core claims. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the question or the ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of Tesla 10-K filings, correctly identifying a shift from a sales/availability strategy to a technical integration and production scale strategy. The mention of the Lathrop Megafactory is factually supported and adds contextual detail not in the ground truth but consistent with it. (4) The only reason for not scoring a perfect 10 is minor: the original answer emphasizes improvements in 'installation capabilities and price efficiencies for Solar Roof' as part of the 2022 context, which the LLM omits. However, the LLM compensates by correctly identifying the strategic shift toward engineered integration and production scaling. Wording differs but semantic meaning is equivalent. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 410,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "In the 2022 Form 10‑K, Gilead described Biktarvy simply as one of its “core” single‑tablet HIV regimens – a key product alongside Genvoya, Descovy, Truvada, etc. – and the HIV‑related risk factors warned that the company’s earnings were heavily dependent on its HIV franchise and could be hurt by loss of market share or a shift away from nucleoside‑based therapies.  \n\nBy the 2024 filing, Gilead’s narrative had shifted to position Biktarvy as the flagship and primary growth driver of the HIV portfolio, with the company stressing that sustaining Biktarvy’s market dominance is critical to its outlook. At the same time, the 2024 risk discussion highlighted new commercial headwinds – tighter pricing rules (e.g., the Inflation Reduction Act), accelerating generic competition and potential erosion of its share – making Biktarvy’s continued performance a central commercial risk for the company.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Gilead's strategic positioning of Biktarvy from 2022 to 2024: in 2022, it was one of several core HIV products, while by 2024 it had become the flagship and primary growth driver. This matches the ground truth's emphasis on Biktarvy transitioning from a key product to a central but risky revenue source. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of 10-K filings, correctly identifying both the shift in narrative (from co-equal core product to dominant flagship) and the increased commercial risks (generic competition, pricing pressure, overreliance on TAF-based therapies). The mention of the Inflation Reduction Act adds contextual detail not in the original but is plausible and relevant, without contradicting the ground truth. (4) The only minor gap is that the LLM does not explicitly mention the shared dependence on TAF as the underlying reason for vulnerability, which is a key point in the original answer. However, it captures the consequence—increased commercial risk due to overreliance on Biktarvy—so the omission is not critical. Overall, the answer is semantically equivalent, contextually appropriate, and factually correct, warranting a 9/10 for correctness and high scores across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 422,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "In the 2022 filing the U.S. Retrospective Responsibility Plan was described as being made up of six mechanisms – a U.S. litigation‑escrow agreement, the conversion feature of the Company’s class B common stock, the indemnification obligations of Visa U.S.A. members, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus agreement (as amended)【V_10k_2022.pdf page 70‑71】.  \n\nBy the 2023 filing the plan still contained the escrow agreement, the indemnification obligations, the interchange‑judgment‑sharing, loss‑sharing and omnibus agreements, but the conversion feature was now limited to the Company’s class B‑1 and B‑2 common stock and a new “make‑whole” agreement (related to the class B‑1 exchange offer) was added to the list of mechanisms【V_10k_2023.pdf page 70‑71】.  \n\nThus, between 2022 and 2023 the plan’s composition expanded to include make‑whole agreements and a more specific conversion feature (class B‑1/B‑2), while the other core mechanisms remained unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key factual elements are correct: the 2022 mechanisms are accurately listed, and the 2023 changes — the addition of 'makewhole' (or 'make-whole') agreements and the refinement of the conversion feature to Class B-1 and B-2 stock — are correctly identified. The retention of the U.S. Litigation Escrow Agreement and other core mechanisms is also properly noted. (2) There are no numeric values, dates, or financial figures in dispute; all non-numeric descriptors (e.g., 'six mechanisms') are consistent with the original. Format variations (e.g., 'make-whole' vs. 'makewhole') are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifies additions and modifications, and draws a valid conclusion about the plan’s expansion. (4) The only minor shortcoming is that the LLM refers to the conversion feature applying to 'Class B-1 and B-2' in 2023, while the ground truth emphasizes 'Class B-1' in the context of the exchange offer. However, the LLM’s phrasing is still consistent with broader disclosures and does not constitute a factual error. Overall, the answer is factually correct, complete, and contextually precise, warranting a high score with only a slight deduction for slight over-specificity on stock classes not emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 398,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "In the 2022 Form 10‑K Gilead noted that Biktarvy’s composition‑of‑matter patents (U.S. and EU) do not expire until 2033, giving the drug roughly a decade of exclusivity, and the filing’s HIV‑risk factor warned that a large share of the company’s revenue comes from its HIV franchise and that losing sales of those products would materially hurt the business. The 2024 filing still lists Biktarvy’s patent expiry as 2033 and again highlights the company’s dependence on its HIV portfolio, indicating that Biktarvy remains a core, protected revenue driver and that Gilead continues to view it as strategically critical to offsetting future competitive and pricing pressures.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a critical factual inaccuracy regarding the 2024 patent status of Biktarvy. According to the ground truth, the 2024 filing did not explicitly mention patent details for Biktarvy, whereas the LLM incorrectly states that the 2024 filing 'still lists Biktarvy’s patent expiry as 2033.' This contradicts the original answer, which notes that patent details were not explicitly mentioned in 2024. The quantitative accuracy is high because the 2022 patent expiration date (2033) is correctly cited, and the U.S./EU patent information aligns with the ground truth. However, the qualitative accuracy suffers due to flawed multi-hop reasoning: the model fails to recognize the shift in risk disclosure emphasis—from strong patent protection in 2022 to heightened concern over market competition and treatment paradigm shifts in 2024—and instead interprets continued risk disclosure as confirmation of unchanged strategic importance. This misreads the nuance in GILD's evolving risk narrative. While the entity names (Gilead, Biktarvy), years (2022, 2024), and general context (HIV product dependency) are accurate, the conclusion that Biktarvy 'remains a core, protected revenue driver' overlooks the increased vulnerability highlighted in the 2024 filing. Thus, despite correct individual facts, the synthesis and interpretation are flawed, leading to a misleading overall assessment of strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 398,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "No. The 2022 and 2023 Form 10‑K filings do not disclose any change to the Illinois Bell Telephone Company guarantee. Both years only reference the historic “Guaranty of certain obligations of … Illinois Bell Telephone Company” (Exhibit 4‑d to the 2011 Form 10‑K), and no amendment, restructuring or new documentation is reported for 2022‑2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that there were no modifications to the financial guarantee structure or documentation between 2022 and 2023, which matches the original answer. (2) The referenced exhibit (Exhibit 4-d) and the underlying filing (Form 10-K for the period ending December 31, 2011) are correctly identified with no numeric or date inaccuracies. Format variations (e.g., '2011 Form 10-K' vs 'Form 10-K for the period ending December 31, 2011') are acceptable and convey the same information. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same historical guarantee was referenced in both years without amendment, indicating no structural change. (4) All entities—AT&T, Illinois Bell Telephone Company, Exhibit 4-d, and the relevant Form 10-K—are accurately identified and correctly related. The answer is concise, factually precise, and fully addresses the question with no omissions or errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 290,
        "total_tokens": 1539
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The 10‑K shows that the Class C‑to‑Class A conversion rate stayed at 4.0 (Class C shares convert into one‑fourth of a Class A share) in both 2022 and 2023【V_10k_2022.pdf page 33】【V_10k_2023.pdf page 86】. Because the rate did not change, the amount of Class A stock that would be created – and therefore the degree of voting dilution for existing Class A shareholders in a merger or other significant transaction – remains essentially the same, indicating no additional erosion of their voting power from Class C conversions during that period【V_10k_2022.pdf page 30‑31】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the Class C to Class A conversion rate as 4.0 in both 2022 and 2023, which matches the ground truth (4.0000). It accurately interprets this as meaning each Class C share converts into 0.25 (one-fourth) of a Class A share, which is semantically equivalent and correct. The answer correctly concludes that the stable conversion rate implies no change in the degree of voting dilution for Class A stockholders in significant corporate transactions. (2) All numeric values (conversion rate of 4.0, years 2022 and 2023) are accurate and consistent with the ground truth. While the ground truth mentions the as-converted Class A stock value increased from 38 million to 39 million, the LLM answer does not include this detail but still reaches the correct qualitative conclusion about stable dilution. This omission is minor and does not affect the core correctness. (3) The multi-hop reasoning is sound: the model correctly synthesizes data from both the 2022 and 2023 10-Ks, compares the conversion rates across years, and infers the implication for voting power dilution. It correctly links the unchanging conversion mechanism to stable voting impact, which reflects proper synthesis. (4) The answer is contextually fully relevant, directly addressing the question about voting power impact. The qualitative accuracy is slightly reduced only because it omits the minor detail about the slight increase in as-converted Class A stock value, but the reasoning and conclusion remain valid. Overall, the answer is factually correct, well-supported, and logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 442,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "In the 2022 Form 10‑K Tesla presented the Solar Roof as an in‑house‑designed,‑engineered product that was being manufactured at Gigafactory New York and positioned alongside its other energy‑generation and storage offerings (“We use Gigafactory New York for the development and production of our Solar Roof…”)【source】. By the 2023 filing the tone had shifted to treating Solar Roof more as a line that still required external support and was a source of operational risk – the company highlighted possible delays in ramping Solar Roof production and stressed its reliance on channel‑partner installers and third‑party component suppliers (“We have experienced, and may also experience similar future delays in launching and ramping production of our … Solar Roof”)【source】. Thus, Tesla moved from a focus on internal production at a dedicated factory in 2022 to acknowledging production‑ramp challenges and greater dependence on partners in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2022, Tesla was directly producing the Solar Roof at Gigafactory New York, citing the 10-K language accurately. In 2023, it correctly notes the shift in tone to emphasize risks, delays, and dependencies on third parties, which aligns with the original answer's description of a more cautionary outlook. (2) There are no numerical values requiring calculation, but the years (2022 and 2023) are correctly used and contextualized. (3) The multi-hop reasoning—comparing Tesla’s disclosures across two years to infer a strategic shift—is sound and well-supported by the cited shifts in language from internal production to external dependencies. (4) The answer fully addresses both parts of the question: evolution in production focus (from active manufacturing to ramp challenges) and strategic dependencies (increased reliance on partners and suppliers). Wording differs slightly but meaning is preserved with high fidelity. All scores are maximized due to complete accuracy, correct entity and year identification, logical synthesis, and direct relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 331,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "In the 2022 filing Coca‑Cola described syrups as an “intermediate product” that it sells to its bottling partners (who mix the syrup with water and sweeteners to create finished beverages) and also sells directly to fountain retailers for on‑site dispensing. By 2023 the company’s own numbers show that the concentrate segment – which includes syrups – grew to 58 % of net operating revenue (up from 56 % in 2022) and accounted for about 83 % of unit‑case volume (up from 82 %), while the finished‑product segment fell to 42 % of revenue and 17 % of volume. Thus, syrups have taken on a slightly larger role in the overall business, but they remain delivered through the same bottler‑and‑fountain‑retailer distribution channels that turn the syrup into finished drinks.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. The ground truth states that syrups are part of concentrate operations with higher gross margins but lower net operating revenues compared to finished products, but the LLM incorrectly asserts that in 2023 the concentrate segment accounted for 58% of net operating revenue (up from 56% in 2022) and 83% of unit-case volume—these specific percentages are not present in the original answer and are unsupported by the provided knowledge graph. There is no mention in the ground truth of actual revenue or volume percentages for 2022 or 2023, so these figures appear fabricated. This severely undermines quantitative accuracy. Qualitatively, the LLM correctly identifies syrups as intermediate products sold to bottling partners and fountain retailers and notes continuity in distribution channels, which aligns with the original answer. It also correctly frames syrups within concentrate operations. However, it misses key 2023 developments: the direct management of U.S. fountain syrup sales by Coca-Cola and the inclusion of fountain syrup operations in the North America operating segment—critical elements indicating strategic shifts toward tighter control and regional segmentation. These omissions represent a failure in multi-hop synthesis, as the model does not reflect the evolving structural role of syrups. Contextually, the answer stays focused on the question and attempts to trace evolution in business model and distribution, earning moderate relevance. Overall, while the conceptual framework is partially sound, the inclusion of false metrics and missing strategic updates result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 466,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "Between 2022 and 2024 the company kept Africa/Eurasia as a separate reportable operating segment – the 2024 filing notes a realignment of the skin‑health business from Europe to North America, but Africa/Eurasia’s reporting line was unchanged.  In 2022 the segment generated $1,082 million of net sales and $228 million of operating profit; by 2024 those figures had risen modestly to $1,095 million of sales and $253 million of operating profit (≈1 % sales growth and ≈11 % profit growth), even as its capital‑expenditure budget fell from $30 million to $12 million.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Africa/Eurasia was not a separate reportable segment but was part of the Oral, Personal and Home Care segment with an operating profit of $203 million. The LLM incorrectly states it was a separate segment and reports an operating profit of $228 million in 2022 and $253 million in 2024, which are not supported by the ground truth. The net sales figures ($1,082M and $1,095M) and capital expenditure numbers ($30M to $12M) are entirely fabricated and not mentioned in the original answer. (2) All quantitative values in the LLM response are incorrect and cannot be reconciled with the ground truth. The original answer only provides $203 million in operating profit for 2022 and no financial data for 2024. The LLM invents growth rates (1% sales, 11% profit) and capital expenditure changes without basis. (3) The multi-hop reasoning is flawed. While the LLM correctly notes the realignment of the skin-health business from Europe to North America in 2024, it mischaracterizes the reporting structure of Africa/Eurasia in 2022. The original answer emphasizes a strategic refinement in geographic reporting, but the LLM falsely claims the reporting line for Africa/Eurasia was unchanged, contradicting the ground truth which indicates it became a distinct segment by 2024—implying a change from 2022. (4) The contextual relevance is moderate because the answer addresses geographic reporting and financial contribution, but the severe factual and quantitative errors undermine correctness. The qualitative reasoning is partially sound in discussing strategic shifts, but incorrect entity and metric usage reduces accuracy. Correctness score is low due to complete failure on quantitative accuracy and key factual misrepresentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 499,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "In the 2023 Form 10‑K Johnson & Johnson presented Orthopaedics almost entirely as a revenue line‑item –  worldwide sales of $8.9 billion, up 4.1 % versus 2022, with a detailed break‑down of hips, knees, trauma, spine‑sports and other categories (see the Orthopaedics table on pages 88‑92).  By the 2024 filing the company had shifted the narrative: the Orthopaedics business is described in the MedTech discussion (pages 6‑10) as a portfolio of “products and **enabling technologies**” that support hips, knees, trauma, spine, sports and other procedures, with less emphasis on the granular sales table and more on the technology platform that drives the segment.  This reflects a strategic move from a pure sales‑performance focus in 2023 to a technology‑enabled growth story in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: $8.9 billion (equivalent to $8,942 million) and 4.1% year-over-year growth are accurately reported. The LLM uses 'almost entirely as a revenue line-item' and 'worldwide sales of $8.9 billion', which is a valid rounding of the exact $8,942 million figure. No calculation errors are present. (2) The entity identification is correct—Johnson & Johnson, Orthopaedics segment, 2023 and 2024 Form 10-K filings, and the MedTech discussion are all properly referenced. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes the shift from a quantitative (2023) to a qualitative, technology-focused narrative (2024), citing the strategic use of 'enabling technologies' and reduced emphasis on granular sales data. (4) The answer captures the core evolution in strategic presentation—shifting from sales performance to technological innovation—though it omits the specific U.S. and international sales breakdowns ($5,525M and $3,417M) mentioned in the ground truth. This is a minor omission that does not undermine the overall correctness. Wording differs (e.g., 'technology-enabled growth story') but maintains semantic equivalence. The reference to specific filing pages (88–92, 6–10) adds contextual detail not in the ground truth but does not detract from accuracy. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 419,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "Visa’s loss‑sharing framework did not change materially from 2022 to 2023. Both filings describe the “U.S. covered litigation” as the Interchange MDL 1720 and any action filed after Oct. 22 2015 by a merchant who opted out of the Rule 23(b)(3) settlement class that is substantially similar to the MDL claims. The loss‑sharing agreement still allocates each bank’s liability by multiplying the amount of any final judgment or approved settlement by that bank’s membership proportion under Visa U.S.A.’s certificate of incorporation. The 2023 filing simply shows a larger U.S. litigation‑escrow balance and higher deposits, indicating more funding of the same arrangement, but the scope of covered litigation and the proportional‑allocation method remain unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim that Visa's loss-sharing framework did not change materially between 2022 and 2023, which directly contradicts the ground truth. The original answer highlights a significant evolution: in 2022, Visa operated under a specific loss sharing agreement with Mastercard (66.6667%/33.3333% split) and amendments expanding U.S. covered litigation to include opt-out actions from MDL 1720. By 2023, Visa had transitioned to a broader 'U.S. Retrospective Responsibility Plan' that subsumes the prior agreement and now includes matters that are 'settled or otherwise fully or substantially resolved,' indicating a strategic shift toward resolving legacy liabilities. The LLM incorrectly asserts continuity in both scope and allocation method, failing to recognize the consolidation into a new framework. While it correctly identifies the scope of U.S. covered litigation related to MDL 1720 and opt-out actions, it omits the critical shift in structure and strategic intent. The claim about liability allocation based on 'membership proportion under Visa U.S.A.’s certificate of incorporation' is not supported in the ground truth, which specifies fixed percentages (66.6667% Visa, 33.3333% Mastercard), not variable membership-based proportions. The mention of increased escrow balances in 2023 is plausible but peripheral and does not address the core evolution in approach. Thus, while some contextual elements (e.g., MDL 1720, opt-out actions) are accurate, the answer fails on multi-hop synthesis and misrepresents the key development—the shift from a bilateral loss-sharing agreement to a comprehensive retrospective plan. This results in low correctness and qualitative accuracy scores despite partial factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1516,
        "completion_tokens": 478,
        "total_tokens": 1994
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "In the 2022 filing the pension plans held roughly $52 million of guaranteed‑investment contracts (about $1 million in U.S. plans and $51 million in international plans) 【CL_10k_2022.pdf†page=99】. By the end of 2024 that exposure had fallen to $30 million, with the U.S. portion eliminated and the international portion reduced to $30 million 【CL_10k_2024.pdf†page=98】. The decline signals a deliberate shift away from GICs toward a broader mix of fixed‑income and other assets, reflecting a strategy to reduce concentration in insurance‑linked contracts and increase diversification and liquidity in the company’s pension‑plan investments.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in the quantitative details. According to the ground truth, in 2022, CL held $1 million in Guaranteed Investment Contracts (GICs) in U.S. plans and $55 million in international plans, totaling $56 million. The LLM incorrectly reports $51 million for international plans and a total of $52 million. In 2024, the ground truth states $34 million remained in international plans with $0 in U.S. plans, but the LLM reports $30 million total and $30 million for international, which is inaccurate. These discrepancies affect the core numerical accuracy. (2) Calculations: The LLM implies a drop from $52M to $30M, but the actual decline is from $56M to $34M. While the direction of change (downward) is correct, the magnitude is misrepresented. The complete elimination of U.S. holdings is correctly identified. (3) Reasoning and multi-hop synthesis: The LLM correctly infers a strategic shift away from GICs and interprets this as a move toward diversification and reduced concentration in insurance-linked contracts. This qualitative reasoning aligns with the ground truth’s indication of a strategic reallocation. The use of citations (page references) suggests proper sourcing from the 10-Ks. (4) Despite incorrect numbers, the answer captures the overall trend (U.S. phased out, international reduced) and provides a plausible and relevant interpretation of the strategic intent. However, the significant numerical errors—especially the misstatement of international amounts by $5M in 2022 and $4M in 2024—reduce confidence in the quantitative accuracy. The answer is semantically close but factually imprecise on key metrics, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 472,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "In the 2022 filing, Mastercard described its Developer Platform primarily as a single‑point gateway that “simplifies access to, and integration of, our digital assets,” giving customers a consolidated API catalog to embed Mastercard services into existing and new solutions. By the 2024 filing, the platform’s positioning had expanded to become a strategic hub for emerging technologies—particularly blockchain and crypto—by exposing the Multi‑Token Network, enabling programmable payments, and supporting crypto‑card purchases, while still offering the same unified API access point. Thus, between 2022 and 2024 the platform moved from a general‑purpose API portal to a dedicated conduit for digital‑asset and blockchain integration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) All factual elements are correct: the 2022 description of the Developer Platform as a single access point/API catalog for digital assets is accurately represented, and the 2024 evolution to support blockchain, digital currencies, and the Multi-Token Network is correctly identified. The mention of 'programmable payments' and 'crypto-card purchases' is consistent with the platform's expanded functionality. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct, satisfying quantitative accuracy. (3) The multi-hop reasoning—comparing platform functionality across two years and synthesizing changes in strategic positioning—is sound. The LLM correctly infers a shift from general-purpose integration to a focus on digital assets and blockchain. The only minor gap is that the ground truth specifically names the 'Mastercard Multi-Token Network™' with trademark notation and emphasizes 'secure, scalable, and interoperable blockchain-based transactions,' which the LLM summarizes less precisely as 'exposing the Multi-Token Network.' While the core fact is correct, the nuance around security, scalability, and interoperability is omitted. (4) Despite this slight omission, the LLM captures the essential evolution and maintains semantic equivalence. The answer is fully relevant to the question about strategic positioning and functionality changes regarding digital assets and new technologies. Thus, the correctness score is 9 due to high accuracy with a minor detail reduction, not error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 445,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "The pension‑plan tables show that the U.S. plans held **no U.S. common‑stock assets** at the end of 2021 (the most recent figure disclosed in the 2022 10‑K) – the line for “U.S. common stocks” is blank and the footnote confirms zero holdings of the Company’s own stock. By the end of 2024, the same line records a **$1 million** holding of U.S. common‑stock securities (still none of the Company’s own shares), a modest increase from zero. This tiny addition signals only a marginal move toward equity exposure, while the plans remain overwhelmingly fixed‑income‑focused, consistent with the company’s deliberately conservative asset‑allocation strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that in 2024, there was a $1 million holding of U.S. common stocks in the U.S. pension plan, whereas the ground truth states there was *no allocation* to U.S. common stocks in the U.S. pension plan in both 2022 and 2024. Additionally, the LLM fails to mention the $2 million investment in U.S. common stocks in the *international* pension plan, which is a key part of the original answer. Instead, it incorrectly implies that the $1 million is in the U.S. plan. (2) Quantitatively, the numbers are wrong: the LLM reports $1 million in 2024 (vs. $0 in U.S. plan), omits the $2 million in the international plan, and references 2021 data (from the 2022 10-K) as if it were 2022 data, introducing both temporal and numerical inaccuracies. (3) The multi-hop reasoning is flawed: the LLM fails to distinguish between U.S. and international pension plans, conflating them into a single 'pension plan' narrative. It also misinterprets the strategic implication—instead of recognizing a consistent avoidance of U.S. common stocks in the domestic plan and a stable minimal position internationally, it suggests a 'marginal move toward equity exposure,' which is unsupported by the ground truth. (4) Contextual relevance is moderate because the answer addresses pension plan investments and strategic allocation, but due to major factual and entity-level errors, the conclusion is misleading. The core facts about allocation trends and strategic intent are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 425,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "In the 2022 Form 10‑K Disney described cruise ships as a distinct element of its Parks & Experiences capital program, noting that a portion of the “majority of the Company’s capital spend” would be allocated to “new attractions, cruise ships, capital improvements and systems infrastructure.” By the 2023 filing the company was still planning to grow the fleet – it reiterated that it would continue to invest in additional cruise‑ship capacity – but it paired that commitment with a stronger emphasis on the operational risks that could affect those assets, citing the lingering COVID‑19‑related suspension of sailings, weather‑related disruptions, labor and regulatory challenges as material uncertainties for the cruise‑line business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Disney's strategic focus on cruise ships in 2022 as part of capital investment within Parks & Experiences, citing the 'majority of the Company’s capital spend' going toward cruise ships and related infrastructure—this matches the original answer’s emphasis on growth and asset expansion. In 2023, the LLM correctly notes continued investment plans but highlights a shift toward operational risks, including weather disruptions, labor, regulatory issues, and lingering impacts of COVID-19, which reflects the original answer’s point about reframing cruise ships as an operational exposure. (2) There are no numeric values to verify, so quantitative accuracy is not compromised—dates (2022 and 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying both continuity (ongoing investment) and evolution (increased risk focus). The only minor shortcoming is that the LLM does not explicitly mention Hurricane Milton or frame the shift as a 'recalibration from asset expansion to managing volatility' as clearly as the original, slightly weakening the qualitative precision. (4) Contextual relevance is excellent—the response directly addresses capital investment plans and operational risk considerations as asked. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth with only slight room for improved nuance in framing the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 431,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "Mastercard’s 2022 filing explains that, because settlement exposure lasts only a few days, the company “may enter into short‑duration foreign‑exchange derivative contracts based upon anticipated receipts and disbursements” and records the resulting gains or losses in general‑and‑administrative expense【MA_10k_2022.pdf page 109】. The 2024 filing repeats the same purpose‑statement for daily‑settlement risk and shows that the notional amount of those non‑designated FX contracts has grown dramatically – from a few hundred million dollars of notional in 2021 (≈ $124 m assets and $406 m liabilities) to roughly $2.7 b in assets and $5.4 b in liabilities by year‑end 2024 (and $5.4 b liabilities already in 2023)【MA_10k_2024.pdf pages 104‑108】. Thus, between 2022 and 2024 Mastercard has expanded its use of short‑duration FX derivatives, while continuing to rely on them to hedge the foreign‑exchange risk inherent in its daily settlement activities.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in conveying that Mastercard continued using short-duration foreign exchange derivative contracts between 2022 and 2024 to manage FX risk in daily settlement activities, which aligns with the ground truth. It correctly identifies the purpose and context of these derivatives and adds valuable quantitative detail about the growth in notional amounts of non-designated FX contracts—from a few hundred million in 2021 to $2.7B in assets and $5.4B in liabilities by 2024. However, the ground truth emphasizes a shift in broader hedging strategy involving euro-denominated debt de-designation and re-designation in 2023–2024, which the LLM answer omits. This is a significant qualitative point about the evolution of Mastercard’s FX risk management beyond just short-duration contracts. While the LLM accurately reports numerical trends in notional values, it references 2021 data (not directly asked) and does not clarify whether the $2.7B and $5.4B figures are for 2023 or 2024 with full precision—though the citation suggests 2024 year-end. The $124M asset and $406M liability figures for 2021 are specific and appear consistent with the cited document, but the question focuses on 2022–2024, so including 2021 adds context but isn't essential. The reasoning is sound in noting increased usage based on growing notional amounts, but misses the strategic nuance of dynamic hedging adjustments mentioned in the original. Overall, the answer is factually strong, well-supported with citations, and contextually relevant, but lacks full completeness regarding the evolving structure of hedging strategies beyond short-duration contracts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 452,
        "total_tokens": 1926
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "In the 2023 Form 10‑K Salesforce described its relationship with enterprise‑cloud firms mainly as a **strategic‑investment portfolio** – a mix of early‑ and late‑stage stakes in privately‑held and public cloud‑software, startup and systems‑integrator companies, with the goal of reinvesting proceeds and supporting digital‑transformation initiatives. By the 2024 Form 10‑K the emphasis had shifted to **deep ecosystem integration**: Salesforce now highlights using its Platform, AppExchange and partner network (ISVs and SIs) to embed those companies’ technologies—especially AI‑driven and data‑cloud solutions—directly into its services, and it targets new investments that expand and tighten that integrated solution ecosystem rather than merely holding a broad investment portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2023 focus on a strategic investment portfolio across early- and late-stage enterprise cloud and tech companies, including system integrators and startups, is accurately described. The shift in 2024 to deeper ecosystem integration via the Salesforce Platform and AppExchange is also correctly captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes the evolution from financial investment (2023) to strategic dependency and integration (2024), noting the role of ISVs, SIs, and third-party developers. It adds value by specifying AI-driven and data-cloud solutions as integration targets, which is consistent with Salesforce's strategic direction and does not contradict the ground truth. (4) The only reason for not scoring a perfect 10 is minor: the LLM slightly expands on the original by emphasizing 'AI-driven' solutions, which, while plausible and contextually appropriate, is not explicitly stated in the ground truth. However, this does not constitute an error but rather a small inferential addition. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 385,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company’s methodology for vendor‑fund accruals was unchanged from FY 2023 to FY 2024. In both years it said it “develops accrual rates based on the provisions of the agreements, reviews historical purchase trends and volumes throughout the year, and adjusts the rates as appropriate,” and it warned that “amounts accrued could be impacted if actual purchase volumes differ from projected purchase volumes, especially for programs that provide increased funding when graduated purchase volumes are met.” Thus, the approach remained the same and continued to be highly sensitive to any variance between projected and actual purchase volumes.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly states that the methodology for vendor-fund accruals remained unchanged from FY2023 to FY2024 and accurately quotes the consistent language about developing accrual rates based on agreement terms, historical trends, and adjustments as appropriate. It also correctly notes sensitivity to variances between projected and actual purchase volumes, particularly for programs with graduated volume thresholds. However, it fails to capture a key qualitative distinction highlighted in the ground truth: the *omission* in FY2024 of the explicit reference to 'graduated purchase volumes' that was present in FY2023. This omission is significant because it suggests a potential shift in emphasis or simplification in disclosure, even if the underlying methodology did not change. The LLM incorrectly implies that both years contained the same explicit warning about graduated volumes, when in fact FY2024 dropped this specific language. While the core methodology is accurately described, the answer misses this nuanced evolution in disclosure and emphasis, which is central to the question about how the approach evolved in terms of sensitivity to projected volumes. There are no numerical inaccuracies (hence high quantitative score), but the qualitative reasoning is flawed in synthesizing the change in disclosure tone and focus across the two years. The answer is contextually relevant and addresses the question's focus on sensitivity to purchase volumes, but with incomplete and partially misleading analysis of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 423,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "In the 2022 filing Eli Lilly described its relationship with Boehringer Ingelheim (BI) on Jardiance as a co‑development and co‑marketing partnership in which BI had launched a separate patent suit (which Lilly was not a party to) and, under the collaboration agreement, agreed to defend and indemnify Lilly against any Jardiance product‑liability claims. By the 2024 filing the partnership is still in place, but the focus has shifted to the joint commercial reliance on Jardiance – Lilly now notes that the drug is a key revenue source that both companies market together and that it is subject to government‑set pricing (the IRA‑driven price‑cut announced for 2026), while BI continues to provide indemnification for any remaining liability exposure. Thus, from 2022 to 2024 the legal entanglement has moved from a separate, stayed patent suit to an ongoing indemnity arrangement, and Lilly’s dependence on the BI‑Jardiance collaboration has deepened as the product becomes a focal point of regulatory and pricing risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, LLY was not a party to the patent litigation initiated by BI, and BI provided indemnification for product-liability claims—this reflects the arms-length legal stance. By 2024, Jardiance became a key revenue source under joint commercial reliance, subject to IRA-mandated pricing (with a price cut effective in 2026), deepening strategic dependency. (2) Quantitative accuracy is strong: the LLM correctly references the IRA-driven price cut (though it doesn't specify the 66% discount mentioned in the ground truth, it accurately notes the government-set pricing and future effective date of 2026, which is consistent with SEC filings). The omission of the exact 66% figure is a minor gap but does not undermine the overall correctness. (3) Multi-hop reasoning is sound—LLM synthesizes legal, commercial, and regulatory developments across 2022 and 2024, correctly identifying the shift from legal separation in patent matters to deeper collaborative dependency due to pricing pressures. (4) The answer is contextually precise, directly addressing the evolution in legal involvement and collaborative dependency. The use of '2026' for the IRA price cut is factually accurate per public disclosures, and framing the indemnity as ongoing adds nuance. The only reason for not scoring a 10 is the missing explicit mention of the 66% discount, which is a specific quantitative detail from the ground truth. However, the core message about increased dependency due to pricing regulation is preserved, warranting a 9 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 452,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings state that Disney’s capital‑spending priority remains its Parks & Experiences segment, with cruise‑ship construction listed as one of the key components of that spend. In 2022 the filing notes that “the majority of the Company’s capital spend has been at our parks and experiences business, which is principally for theme‑park and resort expansion, new attractions, **cruise ships**, capital improvements and systems infrastructure” (DIS_10k_2022.pdf p. 26). The 2023 filing repeats this framing, emphasizing that cruise‑ship investment continues to be part of the broader Parks & Experiences capital program (DIS_10k_2023.pdf p. 14). Thus, Disney’s strategy did not shift away from cruise‑ship spending; rather, it kept cruise‑ship construction embedded within an overall capital‑investment plan that is dominated by park and resort expansion.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in a critical way: it claims that Disney's 2022 10-K explicitly listed 'cruise ships' as part of its capital spending, citing a direct quote that includes the term. However, the ground truth states that in 2022, Disney did *not* specifically emphasize capital investment in cruise ships, and the original 2022 10-K (p. 26) does not include 'cruise ships' in that list—only 'theme-park and resort expansion, new attractions, capital improvements and systems infrastructure.' The mention of cruise ships in capital spend was introduced in the 2023 filing, marking a strategic shift. The LLM incorrectly asserts that both years included cruise ships in the capital spend description, thereby reversing the key evolution the question asks about. This is a major qualitative error in entity accuracy and reasoning. While the answer is relevant to the topic and contains no numerical inaccuracies (hence full quantitative score), it fundamentally misrepresents the timeline and strategic shift. The multi-hop synthesis fails because it does not correctly contrast the absence of cruise ships in 2022 capital priorities with their explicit inclusion in 2023. As a result, the conclusion that 'strategy did not shift' directly contradicts the ground truth, which identifies a clear elevation in focus on cruise ships from 2022 to 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 377,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "In the 2022 filing, Mastercard Foundry (formerly Mastercard Labs) was presented mainly as an innovation‑lab that offered workshops such as the five‑day “Launchpad” prototyping program, in‑lab usability testing and concept design, and that connected customers with early‑stage fintech players and new technologies for thought‑leadership and experimentation. By the 2024 filing, Foundry’s role is described as having broadened to a continuous hub for identifying and experimenting with emerging technologies and fintech trends, actively partnering with fintechs (as well as central banks and digital‑asset firms) to co‑create and integrate new solutions while still providing the same thought‑leadership and innovation‑methodology services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Mastercard Foundry evolved from an innovation lab in 2022 focused on thought leadership, prototyping (e.g., Launchpad program), and connecting with fintechs, to a more active innovation hub by 2024. The description of Foundry broadening into a continuous hub for identifying and experimenting with emerging technologies, co-creating with fintechs, central banks, and digital-asset firms is consistent with the strategic evolution. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all time references (2022, 2024) are accurate. (3) The multi-hop reasoning is sound—correctly synthesizing Foundry’s role across two years and highlighting the expansion in scope and partnerships. (4) The only minor omission is that the LLM answer does not explicitly mention the Mastercard Multi-Token Network™ or blockchain-based business models and programmable payments, which are key specifics in the 2024 evolution per the original answer. This slightly reduces qualitative completeness but does not undermine the overall correctness. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses the evolution in engagement with emerging technologies and fintech partnerships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 379,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "In the 2022 filing the Boehringer Ingelheim partnership was presented mainly as a strategic, science‑driven alliance – the joint empagliflozin (Jardiance) program was highlighted for having earned FDA Breakthrough‑Therapy and Fast‑Track designations, underscoring regulatory upside. By the 2024 filing the focus had shifted to financial risk: under the Inflation‑Reduction Act, HHS selected Jardiance (the Boehringer‑Lilly product) for government‑set pricing, announcing a 66 % discount for 2026 and signaling substantial pricing‑pressure on the collaboration’s revenue stream.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, the collaboration was highlighted for FDA Breakthrough Therapy and Fast Track designations (regulatory facilitation), and by 2024, Jardiance (empagliflozin) was selected under the Inflation Reduction Act for government-set pricing with a 66% discount effective in 2026. (2) Quantitative accuracy is perfect: the 66% discount is correctly stated, and the timeline (2022 to 2024 filings, with pricing impact in 2026) aligns with the original answer. Minor formatting differences (e.g., '66 %' vs '66%') do not affect correctness. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 vs 2024), entities (Boehringer Ingelheim, Lilly, HHS), and regulatory/financial developments (from FDA designations to IRA pricing). (4) The answer fully addresses both parts of the question—evolution in regulatory designations and pricing pressures—and captures the strategic shift from regulatory support to financial constraints. Wording differs slightly but meaning is preserved. All scores are maximized due to complete factual alignment, accurate synthesis, and contextual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 347,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "In the 2023 Form 10‑K, Lockheed Martin described the CH‑53K King Stallion as a “growth‑stage” program within the Rotary and Mission Systems (RMS) segment – noting its inclusion among radar‑surveillance systems and highlighting the 12‑helicopter Israeli Letter of Offer and Acceptance that was awarded in 2022‑23. By the 2024 filing, the CH‑53K is presented as one of the flagship Sikorsky helicopter programs that RMS designs, manufactures, services and sustains, reinforcing its role as a core, mature product line with ongoing production and expanding foreign‑customer demand. Thus, the helicopter has moved from a highlighted growth opportunity in 2023 to a central, established pillar of the RMS portfolio in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in several key aspects but diverges in the interpretation of the strategic evolution of the CH-53K. (1) Correct elements: The CH-53K is accurately placed within the Rotary and Mission Systems (RMS) segment in both years, and the mention of the Israeli Letter of Offer and Acceptance (LOA) for 12 helicopters, awarded in 2022–2023, is a valid detail that supports foreign demand—this aligns with contextual developments. There are no incorrect numbers, dates, or entities; thus, quantitative accuracy is perfect. (2) However, the qualitative interpretation differs: the original answer emphasizes a shift in strategic framing—from a near-to-mid-term growth element in 2023 to being part of an integrated, technologically advanced portfolio emphasizing AI/ML, autonomy, and multi-domain interoperability in 2024. The LLM instead characterizes the shift as one from 'growth-stage' to 'core, mature product line,' focusing on production maturity and foreign demand rather than the broader technological and doctrinal integration narrative present in the 2024 filing. (3) This reflects a sound multi-hop structure (using 2023 and 2024 10-Ks) and correct entity identification, but the reasoning synthesis misses the emphasis on digital transformation and all-domain solutions, which is central to the ground truth. (4) Despite this, the answer remains contextually relevant and captures a plausible aspect of strategic evolution (maturation and expansion), just not the specific framing shift highlighted in the original. Hence, correctness is reduced to 7 due to partial conceptual misalignment, though all stated facts are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 458,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "The 2022 filing says Lilly’s global agreement with Boehringer Ingelheim covered a broad mix of diabetes agents – Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR and Basaglar 【LLY_10k_2022.pdf†p5】. By the 2024 filing the collaboration had been narrowed to Jardiance, Glyxambi, Synjardy and Trijardy XR (the DPP‑4 inhibitor Trajenta and the insulin‑GLP‑1 combo Jentadueto are no longer listed) 【LLY_10k_2024.pdf†p6】. This shift signals that both companies are concentrating on newer SGLT‑2‑inhibitor and fixed‑dose combination products that offer cardiovascular/renal benefits, while moving away from older agents such as Trajenta, reflecting a strategic focus on higher‑growth, differentiated diabetes therapies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities—companies (LLY, Boehringer Ingelheim), products (Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, Basaglar), and years (2022, 2024)—are correctly identified. The product portfolios in both years match the original answer exactly. (2) There are no numeric values requiring calculation, but the temporal comparison across 2022 and 2024 is correctly interpreted. (3) The multi-hop reasoning is sound: the model synthesizes information from two different 10-K filings to identify the change in co-commercialized products and infers strategic intent. The LLM correctly notes the removal of Trajenta, Jentadueto, and Basaglar (though Basaglar is not explicitly mentioned in the 2024 list, its omission is accurately implied). (4) The LLM provides additional context—focusing on SGLT-2 inhibitors and cardiovascular/renal benefits—that is consistent with the strategic rationale in the ground truth and reflects plausible industry trends, enhancing the answer without introducing inaccuracies. The only minor shortcoming is that the original answer explicitly mentions Basaglar’s removal as part of the narrowing, while the LLM only explicitly notes Trajenta and Jentadueto, though it does list the 2024 portfolio accurately. This slight omission prevents a perfect 10, but the core facts, reasoning, and strategic interpretation are correct and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 401,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "In 2023 the Joint Air‑to‑Surface Standoff Missile (JASSM) began a modest production ramp‑up that helped offset an overall decline in MFC sales, contributing about $145 million of net‑sales growth and adding to a higher‑order backlog that rose to $32.2 billion (up from $28.7 billion in 2022). By 2024 the ramp‑up accelerated – JASSM, together with LRASM and GMLRS, drove roughly $1.2 billion of the $1.4 billion increase in MFC net sales and pushed the segment’s backlog to $38.8 billion, underscoring the program’s growing strategic importance despite the segment’s operating‑profit decline from classified‑program losses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative details. The ground truth states that in 2023, there was no specific mention of significant changes in JASSM production or backlog contribution, but the LLM claims a 'modest production ramp-up' and assigns $145 million in net-sales growth and specific backlog figures ($32.2B in 2023, up from $28.7B in 2022), none of which are supported by the original answer. These numbers are fabricated or hallucinated. The $1.2 billion increase in tactical and strike missile programs in 2024 is partially correct, as the original confirms this figure for MFC's tactical and strike missiles, with JASSM as a contributor, but the LLM incorrectly attributes $1.2 billion of the $1.4 billion MFC net sales increase specifically to JASSM, LRASM, and GMLRS, which over-specifies and misrepresents the data. The $38.8 billion backlog figure in 2024 is also not in the original and appears invented. (2) The original answer does not provide any specific sales figures, backlog amounts, or percentage changes—so all numerical claims in the LLM response fail verification. Even allowing format flexibility, the numbers do not align with any implied calculations from the ground truth. (3) The qualitative reasoning partially captures the multi-hop insight that JASSM gained strategic importance in 2024 due to production ramp-up and backlog contribution, alongside PAC-3 and GMLRS (LLM mentions GMLRS correctly but substitutes LRASM for PAC-3, a notable entity error). The LLM correctly infers growing importance but builds it on incorrect data. (4) Contextual relevance is high because the answer addresses production activity, backlog, and strategic importance across 2023–2024 as required. However, the high level of numerical inaccuracy severely undermines correctness, warranting a low overall score despite relevant structure and partial alignment on program significance in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 529,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "JPM continues to rely on the same two‑step framework for Business‑Banking loans that it used in 2023. The firm still treats delinquency (especially loans >30 days past due) as the primary early‑warning signal, and it supplements that signal with an analysis of the geographic distribution of its scored auto and business‑banking portfolios to spot concentration‑risk trends. Because the methodology has not shifted, the bank’s ability to flag borrower distress remains anchored on early‑stage delinquency trends, with geography now explicitly highlighted as a secondary indicator of emerging stress.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that JPM 'continues to rely on the same two-step framework' and that 'the methodology has not shifted'—this directly contradicts the ground truth, which states there was a clear evolution from a broader prime consumer credit strategy in 2023 to a delinquency-rate-focused approach in 2024. The LLM incorrectly claims no change occurred, which is a major factual error. (2) Quantitatively, the reference to loans >30 days past due aligns with the ground truth and is accurate; no specific numbers, percentages, or dates are misstated, so quantitative accuracy is high. (3) The multi-hop reasoning is flawed: the question asks how the focus evolved between 2023 and 2024, requiring a comparison across years. The LLM fails this synthesis by denying any change, despite the ground truth describing a strategic shift in focus from loan performance and scoring models (2023) to delinquency rates as primary indicators (2024). Additionally, the mention of 'geographic distribution' and 'scored auto portfolios' introduces unverified elements not present in the original answer, potentially conflating business banking with auto loans, which are not mentioned in the context of this evolution. (4) While the answer is relevant to credit risk and borrower distress, it misrepresents the core evolution, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because it discusses related concepts but misses the key shift in strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 421,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K exhibit schedules list Target’s “SPP II (2016 Plan Statement) (as amended and restated effective April 3, 2016).” No new amendment, extension or replacement of the plan is disclosed in the 2023 filing, indicating that the terms of the SPP II long‑term equity incentive plan remained essentially unchanged from the prior year. This continuity suggests that Target’s executive‑compensation framework continues to rely on the same performance‑share structure for senior leaders, emphasizing stability rather than a shift in compensation philosophy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in stating that both the 2022 and 2023 filings reference the 'SPP II (2016 Plan Statement)'. According to the ground truth, the 2023 filing updated the plan to the '2022 Plan Statement, as amended and restated effective May 1, 2022', indicating a change in the plan's terms. The LLM incorrectly asserts there was no amendment or change disclosed in the 2023 filing, which directly contradicts the ground truth. This error affects both quantitative accuracy (wrong dates: April 3, 2016 vs. correct update to May 1, 2022) and qualitative reasoning, as the conclusion about 'stability' and 'no shift in compensation philosophy' is invalid given the actual plan update. The reasoning fails the multi-hop requirement to compare the two filings and detect the evolution in plan terms. While the answer addresses the question's intent and is contextually relevant by discussing executive compensation framework implications, the factual foundation is flawed, leading to an incorrect overall assessment. Semantic equivalence is not achieved due to the core factual discrepancy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 312,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "In the 2022 filing Eli Lilly still had contingent milestone obligations to Incyte – up to **$100 million for success‑based regulatory milestones and another $100 million for sales‑based milestones** (in addition to the $260 million and $210 million already capitalized).  \nBy the 2024 filing the Olumiant description no longer references any remaining contingent milestone amounts, indicating that those $200 million of potential future payments had been satisfied, waived or were no longer material.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $100 million for regulatory milestones and $100 million for sales-based milestones in 2022 are accurately reported. The total potential $200 million in contingent payments is correctly implied, and the absence of these milestones in 2024 is properly noted. (2) The LLM correctly identifies the evolution from a milestone-based structure to one without explicit future milestones, indicating they were likely paid, waived, or no longer applicable—consistent with the ground truth's suggestion. (3) The multi-hop reasoning is sound: it synthesizes information across 2022 and 2024 filings to infer a shift in financial obligations. (4) The only minor shortcoming is that the LLM does not explicitly mention the ongoing royalty structure (up to 20% and low teens for COVID-19 sales), which is a key part of the 2024 compensation framework in the original answer. While the absence of future milestones implies a shift to sales-based compensation, explicitly noting the royalty tiers would have improved completeness. However, the core facts, numbers, and logical inference about the milestone evolution are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 350,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "Cisco’s APJC exposure grew only modestly from FY 2022 to FY 2023.  In the FY 2023 10‑K the APJC segment reported revenue of roughly **$8.2 billion**, up from **$8.0 billion** in FY 2022, and gross margin rose in line with that increase.  At the same time, the goodwill balance allocated to the APJC segment rose from **$5.36 billion** at July 30 2022 to **$5.38 billion** at July 29 2023, indicating a small but measurable increase in the company’s financial exposure in the APJC region.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. The ground truth states that Cisco did not disclose specific financial figures for the APJC region in fiscal 2022, but the LLM claims precise revenue figures ($8.0B and $8.2B) and gross margin trends, which are unsupported by the provided data. Additionally, the LLM cites goodwill balances of $5.36B and $5.38B for APJC in FY2022 and FY2023 respectively, but the ground truth only mentions total assets in APJC as $5,382 million in FY2023—without specifying goodwill or a prior-year breakdown. There is no mention of revenue or goodwill by segment in the original answer, making these fabricated details. (2) The quantitative inaccuracies are severe: the LLM invents exact revenue and goodwill numbers that are not present in the source data. While $5.38B is close to the $5,382 million asset value in FY2023, it misrepresents this as goodwill rather than total assets, conflating distinct financial metrics. The dates (July 30, 2022 vs July 29, 2023) are plausible but assigned to incorrect metrics. (3) The multi-hop reasoning fails because the LLM assumes segment-level disclosures were available in both years, whereas the ground truth emphasizes that such detail (especially asset values) was only introduced in FY2023. The conclusion about 'modest growth' is based on invented data rather than the actual evolution of disclosure practices. (4) Despite the factual errors, the answer is contextually relevant—it addresses Cisco's APJC exposure over time and attempts to compare financial metrics across years. However, the lack of grounding in actual data severely undermines correctness. Scores reflect major factual and quantitative flaws, with minimal credit for attempting the right analytical direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 487,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "In the 2022 Form 10‑K the company described its joint‑venture with Boehringer Ingelheim on the SGLT‑2 inhibitor Jardiance and noted that, because of the Inflation Reduction Act, the drug had been **selected in August 2023** by the U.S. Department of Health and Human Services as one of the first ten medicines that will be subject to a government‑set Medicare price beginning in 2026. By the 2024 filing the collaboration had moved from a pending price‑setting decision to a concrete regulatory outcome: **in August 2024 HHS announced the actual government‑set price for Jardiance—a 66 % discount to the 2023 list price**, confirming that the partnership now must operate under a substantially reduced reimbursement level.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Jardiance was selected in August 2023 as one of the first ten drugs subject to government-set pricing under the Inflation Reduction Act (IRA), and in August 2024, a 66% discount to the 2023 U.S. list price was applied. These dates and percentages match the original answer exactly. (2) Quantitative accuracy is perfect: the 66% discount and August 2023/2024 timelines are correctly reported. (3) The multi-hop reasoning is sound—LLM correctly traces the evolution from regulatory selection in 2023 to finalized pricing in 2024, showing how the LLY and Boehringer Ingelheim collaboration adapted. (4) The only minor omission is that the original answer includes 2022 revenue growth (30% in U.S., 28% outside U.S.), which the LLM mentions only implicitly by referencing the 2022 10-K context but does not explicitly state. This missing detail slightly affects completeness but does not undermine the core correctness. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses the evolution of the collaboration in response to regulatory changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 337,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "In the 2022 Form 10‑K GM warned that product‑safety recalls can generate “significant costs for repairs… and the costs to complete a recall could be exacerbated to the extent that such action relates to a global platform, such as the Chevrolet Bolt EV recall,” and that the resulting financial outlays and reputational harm could erode brand equity and undermine its ability to lead in new‑technology areas such as EVs and AVs. The 2023 filing repeats the Bolt‑EV example but expands the discussion, stressing that any safety‑related recall or defect – especially on a global platform – not only threatens earnings but also “damage… brand image, brand equity and consumer trust… and ability to lead the industry with respect to new technologies, such as EVs and AVs,” thereby making recall risk a more explicit obstacle to its EV/AV growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution between 2022 and 2023: in 2022, GM emphasized financial costs of recalls related to global platforms like the Chevrolet Bolt EV; in 2023, it expanded the focus to include reputational damage and threats to leadership in EV/AV technologies. All key entities—GM, Chevrolet Bolt EV, EV/AV technologies, 2022 and 2023 timeframes—are correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable beyond correct referencing of years, which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of Form 10-K filings, correctly identifying both continuity (Bolt EV as example) and evolution (shift from cost to reputation/strategy). The LLM accurately reflects that reputational risk was mentioned in 2022 but gives the correct emphasis that in 2023, brand image and consumer trust became more central and explicitly tied to strategic leadership. (4) The only minor shortcoming is that the original answer frames the 2022 focus as primarily 'financial burden and logistical complexity' and positions the reputational concern as emerging more strongly in 2023, whereas the LLM suggests reputational harm was already a noted risk in 2022. While this is factually supported by the quote, the original answer implies a sharper shift. However, since the LLM accurately reports what was stated in the filings, this does not constitute a factual error—just a slight difference in interpretive emphasis. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 469,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "In the 2022 Form 10‑K the only reference to the Japanese subsidiary’s debt is that “other long‑term debt” – which includes the Guaranteed Senior Notes – was $590 million (the filing gives no further detail). By the 2024 filing the subsidiary had issued four new Guaranteed Senior Notes in November 2023 for roughly $500 million at 1.40 %‑2.12 % interest, and after repaying $77 million in July 2024 the “other long‑term debt” balance rose to $919 million. This growth shows Costco is increasingly using its Japanese subsidiary to raise low‑cost, long‑dated financing, indicating a deliberate strategy of diversifying its capital structure and locking in inexpensive, fixed‑rate funding for the long term.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. While it correctly identifies that four Guaranteed Senior Notes were issued in November 2023 totaling approximately $500 million at interest rates between 1.40% and 2.12%, and that $77 million was repaid in July 2024, it incorrectly states that the 'other long-term debt' balance rose to $919 million. The ground truth does not mention this figure or confirm any increase to $919 million; in fact, after repaying $77 million, one would expect a net decrease unless other debt was added, which is not stated. Additionally, the original answer notes that in 2022, only the use of Level 3 inputs for valuation was disclosed — not a specific dollar amount of $590 million — so this number is fabricated or misattributed. (2) The calculation of the net change in debt is flawed: adding $500 million in new notes and subtracting $77 million repayment does not lead to a $919 million balance without knowing the prior balance, which the ground truth does not provide. The LLM invents a precise balance not supported by the source. (3) The multi-hop reasoning is partially sound — the model correctly infers a strategic trend toward fixed-rate, long-term financing through the Japanese subsidiary and connects increased disclosure with strategic intent. However, it overreaches by asserting a rise in total debt to $919 million without sufficient basis. (4) Despite these issues, the answer captures the core qualitative evolution — increased transparency, use of fixed-rate notes with long maturities (2033–2043 implied by rates and standard practices), and repayment activity — and draws a reasonable conclusion about Costco’s long-term financing strategy. The reasoning aligns with the ground truth’s interpretation, even if some numbers are incorrect. Hence, correctness is penalized heavily for unsupported figures, but qualitative and contextual scores remain moderate to high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 535,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "Cisco’s balance sheet shows that its available‑for‑sale debt‑investment portfolio grew from **$11.9 billion at fiscal‑year‑end 2022** to **$15.6 billion at fiscal‑year‑end 2023** – an increase of roughly **$3.6 billion**【CSCO_10k_2022.pdf page 48】【CSCO_10k_2023.pdf page 46】.  \n\nThe rise indicates that Cisco deliberately expanded its holdings of high‑quality, investment‑grade debt securities, using the portfolio to preserve liquidity, generate modest investment returns and keep cash readily available for strategic uses such as acquisitions, share repurchases and dividend payments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that Cisco's available-for-sale debt investments decreased from $15,592 million in 2022 to $9,865 million in 2023 — a drop of $5,727 million. The LLM claims the portfolio *grew* from $11.9 billion to $15.6 billion, which is the opposite of the truth. This fundamental error invalidates the entire response. (2) Quantitative accuracy is extremely low: the reported values are wrong (e.g., $11.9B vs correct $15,592M for 2022), the change is miscalculated (increase of $3.6B vs actual decrease of $5,727M), and the 2023 value cited by the LLM ($15.6B) is actually close to the *2022* value in the ground truth, suggesting confusion in data sourcing. (3) The reasoning is flawed: the LLM concludes Cisco expanded its debt holdings, while the actual data shows a significant strategic reduction. The interpretation about investment strategy is therefore incorrect and contradicts the evidence. (4) Contextual relevance is low but not zero — the answer addresses the right topic (Cisco's debt investments and strategy), cites plausible document locations, and attempts multi-hop analysis, but with incorrect data. The conclusion about strategy is based on false premises. Overall, this is a major factual failure with incorrect numbers, wrong trend, and invalid inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 383,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "JPMorgan Chase’s 2024 filing shows that its system‑damage risk has risen relative to 2023.  While the 2023 filing already warned that “attempts by third parties to defraud JPMorgan Chase… could increase in volume” and that a vendor cyber‑attack could cascade to JPMorgan’s own systems, the 2024 filing adds that the **frequency and sophistication of third‑party vendor attacks have grown**, and that **recovering stolen, manipulated or destroyed data is now a more pronounced concern**.  Consequently, the 2024 report emphasizes new controls – such as earlier detection of vendor‑related attacks, expanded DDoS and ransomware‑recovery capabilities, and stronger network‑security and data‑loss‑prevention measures – indicating an expanded exposure to vendor‑driven system damage and data‑recovery challenges compared with 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of JPMorgan Chase's system damage risks from 2023 to 2024, noting continuity in third-party threats while emphasizing increased frequency and sophistication of vendor attacks in 2024—consistent with the original answer’s mention of ransomware targeting vendors. The heightened concern around data recovery (stolen, manipulated, or destroyed data) matches the ground truth’s emphasis on increased complexity in recovery and inability to prevent fraudulent transaction processing. (2) There are no numeric values to verify, so quantitative accuracy is scored as 10 by default—no inaccuracies present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and correctly contrasts the scope and emphasis of risk disclosures, identifying both continuity and escalation in vendor-related cyber risks. It accurately infers that new controls (e.g., improved detection, expanded ransomware recovery) reflect an expanded exposure, which is a valid interpretation of the evolving risk landscape. (4) The only minor shortcoming is that the LLM does not explicitly mention the risk of losses exceeding cyber insurance coverage—a specific financial implication noted in the original answer. While it captures the broader trend of growing exposure, this omission slightly reduces completeness in qualitative accuracy. Otherwise, all entities (JPMorgan Chase, 2023, 2024, third-party vendors, ransomware, data recovery) are correct and contextually relevant. The answer is well-structured, focused, and directly responsive to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 454,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco’s 2022 filing said the company would keep “increasing the penetration of our private‑label items.” By the 2024 filing the company shows it has backed that plan with concrete operational investments – it now operates about 130.9 million sq ft of warehouse floor space (up from ≈ 120 million sq ft in 2022) plus ≈ 31.9 million sq ft of distribution‑and‑logistics facilities, and it has added dedicated processing, packaging and manufacturing plants expressly to produce its private‑label merchandise. These expanded facilities and added square‑footage constitute the operational capital Costco has put into its private‑label growth strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Costco made operational investments in processing, packaging, and manufacturing facilities to support private-label growth, which aligns with the ground truth. However, it introduces specific square footage figures (130.9 million sq ft warehouse space, 31.9 million sq ft distribution space) that are not mentioned or implied in the original answer and cannot be verified from the provided context. These numbers appear fabricated or misattributed, significantly undermining quantitative accuracy. (2) There is no mention in the ground truth about warehouse or logistics square footage being part of the operational investment for private-label strategy—only dedicated production facilities (processing, packaging, manufacturing) are cited. The LLM incorrectly equates general facility expansion with targeted investments in private-label production. While the mention of dedicated plants is accurate and relevant, the emphasis on square footage distracts from the core factual basis. (3) The multi-hop reasoning is partially sound: the model connects the 2022 strategy to 2024 execution, correctly identifying a shift toward internal production. However, it fails to restrict its claims to what is supported by the original answer, adding unsupported metrics that compromise factual integrity. (4) Despite the inclusion of unverified numbers, the qualitative understanding of strategic evolution—from sourcing to internal production—is correct, and the response remains contextually relevant. The correctness score is reduced due to major quantitative inaccuracies, even though the directional insight is valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 455,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "In the 2022 Form 10‑K UnitedHealth said that its Medicaid‑managed‑care bids are built on “certain assumptions regarding enrollment, utilization, medical costs and other factors” and warned that **any material error in those assumptions** – whether from unexpected program changes or a competitor’s lower bid – could hurt results.  \n\nThe 2023 filing expands that language, treating **bid‑accuracy risk as a distinct risk factor**. It still notes the same enrollment‑, utilization‑ and cost‑based assumptions, but now explicitly calls out the possibility that **post‑submission policy or rate changes and lower‑priced competitor bids could make the original bid inaccurate**, and that such inaccuracy could materially affect earnings and cash flow. In short, UnitedHealth moved from a general disclaimer about “incorrect assumptions” in 2022 to a more specific acknowledgement of “bid‑accuracy risk” and its potential impact in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: UnitedHealth Group's shift from emphasizing contract renewal risk in 2022 to a more detailed focus on bid assumptions and accuracy in 2023 is correctly captured. The key assumptions—enrollment, utilization, medical costs—are accurately listed, and the risks from program changes and competitor pricing are properly identified. (2) There are no numeric values in the question or answer requiring calculation, but the years (2022 and 2023) are correctly attributed to the respective risk disclosures in the 10-K filings, satisfying quantitative accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of disclosures, identifying both continuity (same core assumptions) and evolution (elevating bid accuracy as a distinct risk). The characterization of the 2023 filing treating bid-accuracy risk as a 'distinct risk factor' is a valid interpretation of the increased emphasis in the language. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'bid-accuracy risk' as a label not verbatim in filings), it accurately reflects the conceptual evolution described in the ground truth. The only minor shortcoming is that the original answer highlights the 2022 focus on 'losing Medicaid members' due to non-renewal, which the LLM mentions indirectly but could have emphasized more. Still, the core evolution in risk disclosure is correctly and thoroughly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 426,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "In the 2023 benefit‑plan roll‑forward, MetLife’s municipal holdings were reported only in the **Level 2** fair‑value hierarchy (‑ $147 million for pension assets and $8 million for other post‑retirement assets). In 2022 the same categories were also classified entirely as Level 2 (‑ $159 million for pension assets and $15 million for other post‑retirement assets). Thus, the municipal investment fell slightly (about $12 million in pension assets and $7 million in other assets) from 2022 to 2023, but its valuation classification remained unchanged – it stayed in Level 2.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The original answer states that MET's investment in Municipals was $14,212 million in 2022 and dropped to $159 million in 2023. However, the LLM claims the 2022 municipal holdings were -$159 million (pension) + $15 million (other) = -$144 million total, and in 2023: -$147 million + $8 million = -$139 million — which contradicts the ground truth of a massive reduction from $14.2B to $159M. The LLM incorrectly reports negative values and much smaller magnitudes, indicating a fundamental misunderstanding of the data. (2) The numbers are not only wrong in absolute terms but also misinterpreted: the ground truth shows a >99% decrease in the Municipals investment, while the LLM suggests only a minor change of ~$5 million. Additionally, the LLM claims that in 2022 the Municipals were already fully classified as Level 2, but the original answer explicitly states that in 2022 there was no detailed breakdown of valuation hierarchy — only in 2023 was it explicitly classified as Level 2. This misrepresents a key qualitative shift in disclosure transparency. (3) The multi-hop reasoning fails: the model does not connect the correct entities (MET’s total Municipals investment across years) and instead focuses narrowly on benefit-plan assets, likely confusing a subset of data (pension-related municipal holdings) with the company’s overall investment. It fails to recognize that the 2022 lack of hierarchy detail versus 2023’s explicit Level 2 classification represents improved transparency. (4) Scores are low due to major factual errors in numbers, direction of change, and valuation hierarchy evolution. Contextual relevance is moderate because the answer discusses related concepts (municipals, Level 2, MetLife) but applies them incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 501,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "In FY 2022 Office 365 was presented primarily as a cloud‑service component of Microsoft’s traditional volume‑licensing programs (e.g., Enterprise Agreements) and was accounted for as a single, integrated performance‑obligation whose revenue was recognized ratably over the contract period (2022 10‑K, pp. 62‑66). By FY 2024 the company had moved to a more subscription‑centric, digitally‑driven model – the Microsoft Customer Agreement is a non‑expiring, online purchase contract that lets any customer acquire Office 365 on a month‑to‑month or annual basis, and the Microsoft Online Subscription Agreement targets small‑ and medium‑size customers with flexible monthly or annual subscriptions, eliminating the need for multi‑year enterprise commitments (2024 10‑K, pp. 15‑19). This shift reflects greater licensing flexibility and a broader, simplified agreement framework for Office 365 subscriptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in FY2022, Office 365 was part of volume licensing (e.g., Enterprise Agreements), revenue was recognized ratably, and invoicing occurred annually. By FY2024, Microsoft introduced more flexible models including the Microsoft Customer Agreement and Microsoft Online Subscription Agreement, enabling month-to-month or annual subscriptions without long-term commitments. These details match the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—dates (FY2022, FY2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in licensing and agreement models across two fiscal years using appropriate context from the 10-K filings (citing correct document sections). (4) The LLM adds slightly more detail (e.g., 'non-expiring, online purchase contract', 'targets small- and medium-size customers') that are plausible elaborations consistent with the direction of Microsoft's evolution, though not explicitly in the ground truth. These do not introduce inaccuracies but enhance clarity. The only minor gap is that the original answer mentions the Microsoft Products and Services Agreement, which the LLM omits—this is a small completeness shortfall, preventing a perfect 10. Overall, the answer is factually correct, contextually relevant, and semantically equivalent with slight augmentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 418,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "In 2022 MetLife held $58 million of Level 3‑valued Fixed‑Maturity Securities AFS (primarily $55 million of corporate bonds and $3 million of “other” securities). By year‑end 2023 that balance had risen to $64 million (about $54 million of corporate bonds, $2 million of foreign bonds and $8 million of other securities). The modest increase and the addition of foreign‑bond exposure show the company is slightly expanding its allocation to less‑observable, lower‑liquidity assets, reflecting a modest shift toward higher‑yield, higher‑risk securities within its fixed‑maturity portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS included $1M in Corporate bonds, $1M in Foreign Bonds, and $11M in Equity Securities—not $55M in corporate bonds and $3M in 'other' as stated. The LLM incorrectly aggregates or misclassifies the 2022 composition. In 2023, the ground truth reports $54M in Corporate bonds, $2M in Foreign Bonds, and $828M in Other Investments, but the LLM reports only $8M in other securities, missing $820M. This is a major quantitative error. (2) Calculations are also incorrect: the LLM claims total Level 3 Fixed Maturity Securities AFS was $58M in 2022 and $64M in 2023, but the actual 2023 total alone (based on correct figures) would be $884M ($54M + $2M + $828M), indicating a complete failure in data retrieval or synthesis. The $828M in Other Investments is especially critical and entirely misrepresented. (3) The multi-hop reasoning is flawed: the LLM fails to correctly identify the composition shift—particularly the massive increase in Other Investments—and thus misinterprets the strategic implication. Instead of recognizing a significant strategic shift toward Other Investments, it suggests only a 'modest' expansion and addition of foreign bonds, which were already present in 2022 per ground truth. (4) Contextual relevance is moderate because the answer addresses the general question about composition change and strategy, but due to severe factual and numerical errors, the conclusion is unsupported. The reasoning about 'higher-yield, higher-risk securities' lacks grounding in the actual data. Overall, the answer is mostly incorrect, with only minor alignment on the increase in corporate bonds and presence of foreign bonds in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 488,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "In the 2022 Form 10‑K, Microsoft described Office 365 primarily as a “cloud‑based service” that sits alongside Azure, Dynamics 365 and Xbox in the “service and other revenue” category and is accounted for as a single, integrated performance‑obligation whose subscription revenue is recognized ratably (see 2022 p. 60‑62).  At that time the filing highlighted competitive risk from “AI‑driven services” in the broader risk discussion but did not position Office 365 itself as an AI‑focused product.  \n\nBy the 2024 filing, Office 365 is portrayed as a cornerstone of the Microsoft Cloud portfolio, now marketed as the productivity platform that powers the AI‑infused “Copilot” experience and is explicitly tied to Azure’s AI infrastructure; the company emphasizes that embedding generative‑AI capabilities in Office 365 is a direct response to competitive pressure from AI‑enabled rivals such as Google Workspace (see 2024 p. 19‑23).  Thus, between 2022 and 2024 Office 365 evolved from a core subscription service to a strategic AI‑enhanced hub that reinforces Microsoft’s broader cloud strategy and counters AI‑driven competition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Office 365's positioning in 2022 as part of 'service and other revenue' alongside Azure, Dynamics 365, and Xbox is accurately described, with correct reference to its revenue recognition model. By 2024, the shift to positioning Office 365 as an AI-enhanced platform integrated with Copilot and Azure AI infrastructure is correctly identified. The mention of competitive pressure from AI-driven rivals like Google Workspace matches the ground truth's reference to competitive threats from companies offering AI-enabled alternatives. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all dates (2022, 2024) and document references (p. 60–62, p. 19–23) are consistent and plausible, earning full marks. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifies the evolution in strategic positioning, and links it to competitive dynamics and AI integration. The only minor shortcoming is that the ground truth explicitly mentions 'free applications funded by advertising or open-source AI models' as competitive threats, which the LLM answer omits, instead naming Google Workspace as a specific rival. While Google Workspace is a reasonable example, the broader competitive landscape described in the original is slightly more comprehensive. (4) The answer is contextually excellent—directly addressing the evolution in strategic positioning, role within the cloud portfolio, and response to AI competition. Wording differs but semantic meaning is equivalent. Thus, a score of 9 is justified due to near-perfect accuracy with only a minor omission in the scope of competitive pressures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1535,
        "completion_tokens": 505,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "In the 2022 Form 10‑K UnitedHealth said that it looked for a credit‑related impairment only when an available‑for‑sale debt security’s fair value fell below amortized cost and then judged the issuer’s credit quality and any recent credit‑rating changes.  The company noted that, as of 31 December 2021, the allowance for credit losses on those securities “was not material,” so no significant charge was recorded.\n\nThe 2023 filing expands that approach: UnitedHealth now explicitly tests each security by comparing the **present value of expected cash‑flows** to its amortized cost, together with the size of the fair‑value shortfall, the issuer’s near‑term financial condition and any specific events that could affect the issuer.  Impairments are recorded as an allowance that offsets investment‑and‑other‑income.  Although the methodology is more detailed, UnitedHealth again reports that the allowance for credit‑related losses on available‑for‑sale securities remained immaterial, meaning the financial impact in 2023 was still negligible.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) It correctly identifies that in 2022, UnitedHealth Group assessed credit-related impairments based on fair value below amortized cost, issuer credit quality, and credit ratings, and notes the allowance was 'not material'—matching the ground truth. In 2023, it accurately describes the enhanced methodology: use of present value of expected cash flows, assessment of fair value decline, issuer financial condition, and specific events. It also correctly states that impairments are now recorded as an allowance against investment income, with non-credit impairments going to other comprehensive income (implied by the allowance offsetting investment income and the structured segmentation). (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022 and 2023 filings, reference to December 31, 2021) are used appropriately and contextually accurate. (3) The multi-hop reasoning is sound: the model synthesizes changes in methodology across two years, correctly attributing evolving practices to the respective filings and explaining the financial impact (immaterial allowance in both years). (4) The only minor shortcoming is that the LLM answer does not explicitly mention 'non-credit-related impairments being recorded through other comprehensive income'—a key part of the formalized 2023 process in the original answer. While it implies this by focusing on credit-related impairments being recorded via allowance, the explicit distinction is slightly underdeveloped. However, the core facts, evolution, and financial impact are correctly conveyed. Hence, a score of 9 is justified—excellent accuracy with a minor omission in qualitative completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1528,
        "completion_tokens": 495,
        "total_tokens": 2023
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "In 2023 MetLife’s **U.S. pension plans** held **about 82 % of their assets in Fixed‑Maturity Securities (AFS)** – a slight drop from the roughly 83‑84 % range in 2022 – and the **fair‑value of those securities fell to $6.7 billion (Level 1 $1.73 bn, Level 2 $4.92 bn, Level 3 $0.06 bn)**, down about $88 million from the $6.8 billion reported in 2022.\n\nFor the **U.S. other post‑retirement benefit plans**, the allocation stayed near the high‑90 % range, moving from an actual **96 % in 2022 to about 94 % in 2023**, and the **fair‑value of Fixed‑Maturity Securities (AFS) rose modestly to $1.27 billion (Level 1 $0.61 bn, Level 2 $0.66 bn)**, up roughly $18 million from the $1.26 billion reported in 2022.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect quantitative data. While the 2023 fair values for Fixed Maturity Securities AFS are approximately correct ($6.7 billion vs. $6,714 million and $1.27 billion vs. $1,274 million), the 2022 percentages and values are partially inaccurate. The original answer states that in 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. However, the LLM claims 83–84% for pensions (plausible) but 96% for other benefits (vs. 95% in ground truth), which is a minor deviation. More critically, the LLM asserts that the 2022 fair value was $6.8 billion for pensions and $1.26 billion for other benefits—these figures are not present in the original answer and represent an over-inference. The original does not provide 2022 valuations, only percentages, so introducing 2022 dollar amounts is factually unsupported. (2) Calculations: The LLM infers a $88 million decrease in pension securities and $18 million increase in other benefits, but since the original answer does not provide 2022 dollar values, these comparisons are speculative and not verifiable from the ground truth. Thus, these calculations, while internally consistent, are not grounded in the provided data. (3) Multi-hop reasoning: The LLM correctly identifies the shift from percentage-based allocation in 2022 to valuation-based reporting in 2023, which aligns with the original's interpretation. It synthesizes the idea that allocation remained high but slightly declined, which is reasonable. However, it adds granular details (e.g., Level 1/2/3 breakdowns) not present in the original answer, introducing unverified data. (4) The answer is contextually relevant and well-structured, addressing both pension and other postretirement plans across years. The qualitative reasoning is sound in noting trends, but quantitative accuracy is compromised by fabricated 2022 dollar figures and unsupported changes. Hence, correctness is partially compromised—core trends are right, but key numbers are invented, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 571,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "In the 2022 filing Lowe’s listed Kitchens & Bath as one of the sub‑categories inside the broader **Home Décor** segment (Appliances, Décor, Flooring, Kitchens & Bath, Paint). By the 2023 filing the company is naming Kitchens & Bath as a **stand‑alone product category** in its “Product Selection” list and even cites it among the primary categories that drive installed‑sales revenue. This shift from a nested sub‑segment to a distinct, highlighted line signals that Lowe’s has moved the Kitchens & Bath offering higher up in its strategic focus, treating it as a core, growth‑driving part of its overall product portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that in 2022, Kitchens & Bath was part of the Home Décor segment alongside Appliances, Décor, Flooring, and Paint. It also accurately notes the change in 2023, where Kitchens & Bath became a standalone, highlighted category, cited as a driver of installed-sales revenue. This reflects the strategic repositioning from a design-focused grouping to a core renovation category, consistent with Lowe's 'Total Home' strategy. The LLM correctly captures the evolution in strategic positioning and infers increased importance in the product portfolio. While the ground truth emphasizes the 2023 grouping with Lumber, Building Materials, and Rough Plumbing to underscore the shift toward construction/remodeling, the LLM instead highlights its mention in 'Product Selection' and installed-sales revenue—also valid indicators of strategic elevation. The absence of explicit mention of those adjacent categories in 2023 is a minor omission but does not detract from the overall correctness of the conclusion. No numbers, dates, or entities are incorrect. Wording differs but semantic meaning and reasoning are equivalent. Multi-hop synthesis across years and categorizations is sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 355,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings list cheese & grocery as an “adjacent, locally‑relevant” category rather than as a core pillar of the business. In 2024 the language is unchanged – cheese & grocery is grouped with gum & candy and powdered beverages, while the company’s growth narrative centers on chocolate, biscuits and baked snacks and the four strategic priorities that drive “snacking” growth. This continuity shows that Mondelez continues to treat cheese & grocery as a complementary, secondary line, indicating that its long‑term growth focus remains firmly on core snack categories rather than on expanding the cheese & grocery segment.",
      "correctness_score": 5,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in its qualitative assessment that Mondelez treats Cheese & Grocery as an adjacent, non-core category, and that long-term growth is focused on core snacks like biscuits and chocolate. However, it misses a key factual shift between 2022 and 2024. The original answer states that in 2022, Mondelez *directly produced* Cheese & Grocery products and generated $1,990 million in revenue from the category, but by 2024, it no longer reports direct production and only maintains a strategic stake. The LLM answer incorrectly claims that the language in the 10-K filings is 'unchanged' between 2022 and 2024, which contradicts the ground truth of a material change in reporting and business model. (2) The LLM answer fails entirely on quantitative accuracy: it omits the $1,990 million revenue figure from 2022, which is a critical data point in the original answer. This omission significantly weakens the response, especially since the question asks about evolution over time, which requires anchoring to concrete financials. (3) The multi-hop reasoning is partially sound—linking category classification to strategic prioritization—but fails to recognize the evolution from direct production to a strategic stake, which is a core part of the multi-hop synthesis required. The model treats the situation as static when it is dynamic. (4) Contextual relevance is high because the answer addresses the strategic focus and long-term growth implications. However, due to the missing revenue data and incorrect assertion of no change in language or structure, the correctness score is limited to 5—partially correct but with significant factual omissions and one major inaccuracy regarding continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 474,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "In the 2022 Form 10‑K Abbott listed its enteral‑feeding portfolio with **Jevity** first, followed by other formulas and then **Freego™ (Enteral Pump) and Freego™ sets**【2022 p. 4】.  \nIn the 2023 Form 10‑K the same list was reordered so the **Freego™ pump and sets appear before Jevity**, placing Jevity after the Freego products【2023 p. 4】.  \n\nThus, between the two filings Abbott moved Jevity from the lead position in the lineup to a position that follows the Freego™ products.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim about the ordering of products. According to the ground truth, Jevity remained listed first in both the 2022 and 2023 10-K filings. The change was that Freego™ (Enteral Pump) and Freego™ sets were moved from after Glucerna and Osmolite® in 2022 to a position immediately after Jevity in 2023—i.e., ahead of Glucerna and Osmolite®, but still after Jevity. The LLM incorrectly states that in 2023, Freego™ products were placed *before* Jevity, which contradicts the ground truth. This is a critical factual error in both entity positioning and sequence. The answer also incorrectly concludes that Jevity was demoted from the lead position, which did not happen. While the context of discussing Abbott’s enteral feeding product lineup and referencing the 10-K filings is relevant (hence partial credit for contextual relevance), the quantitative and qualitative inaccuracies are severe. The reasoning fails the multi-hop requirement to accurately compare the two filings’ product orderings. No numbers are involved in the question, so quantitative accuracy is assessed on correct sequence/dates, which is not met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 328,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "In the 2023 filing MetLife reported municipals held as **fixed‑maturity securities available‑for‑sale** with an estimated fair‑value of **$147 million**, all measured at **Level 2** of the fair‑value hierarchy. In the 2022 filing the same category was valued at **$159 million**, also classified as Level 2. The modest $12 million decline and the unchanged Level‑2 classification indicate that the company is keeping municipal bonds in a transparent, market‑observable tier while slightly reducing exposure—consistent with a prudent credit‑risk strategy that favors liquid, lower‑risk assets and trims positions when credit conditions warrant.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, MET's municipal investments were $14,212 million in 2022, not $159 million as stated by the LLM. The 2023 value is reported as $159 million in the ground truth, but the LLM incorrectly states it as $147 million. Thus, the LLM reverses the trend and drastically underreports the 2022 value. The ground truth shows a massive reduction from over $14B to $159M, while the LLM describes only a $12M decline, which is entirely incorrect. (2) The quantitative inaccuracies are severe: the 2022 value is off by over $14 billion, and the 2023 value is also wrong (by $12 million). The LLM also omits key data from the ground truth: the $2,464 million in gross unrealized gains and only $13 million in losses in 2022, which are critical for understanding the valuation and risk context. (3) The multi-hop reasoning is flawed. The LLM fails to recognize the magnitude of the portfolio reduction, leading to an incorrect interpretation of strategy. Instead of identifying a strategic exit from municipals to reduce credit risk, the LLM suggests only a minor adjustment consistent with routine risk management, which misrepresents the intent. The classification point about Level 2 in 2023 is correct, but the LLM incorrectly implies it was also Level 2 in 2022, while the ground truth does not confirm this. (4) The contextual relevance is moderate because the answer addresses the right categories (AFS, fair value, Level 2, credit risk), but due to severe factual and quantitative errors, the conclusion is misleading. The reasoning and synthesis are unsound, warranting low scores in correctness, quantitative, and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 471,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Abbott’s portfolio of interest‑rate hedge contracts fell from about **$2.9 billion at year‑end 2022** to roughly **$2.2 billion at year‑end 2023**.  The 2023 filing explains that the decline reflects the **maturity of about $700 million of hedge contracts in 2023 together with the associated fixed‑rate debt that also matured**.  These contracts are designated as fair‑value hedges, so they effectively convert the hedged portion of Abbott’s fixed‑rate debt into a variable‑rate exposure and the carrying amount of the debt is adjusted by an offsetting amount, helping the company manage interest‑rate risk.  \n\n*Sources: 2023 10‑K – “Abbott had interest rate contracts totaling approximately $2.2 billion at December 31, 2023 and $2.9 billion in 2022… The decrease… was due to the maturity of $700 million of interest rate hedge contracts in 2023”*; *2022 10‑K – “Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at December 31…”* (describing the fair‑value hedge of fixed‑rate debt).",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the reported notional values for 2022 and 2023. The ground truth states that Abbott's interest rate hedge contracts were approximately $2.2 billion in both 2022 and 2023, with no change in notional value. However, the LLM claims the value decreased from $2.9 billion in 2022 to $2.2 billion in 2023 due to maturities, which directly contradicts the ground truth. This error undermines the core quantitative accuracy. (2) The cited sources in the LLM answer reference a $2.9 billion figure for 2022, but the ground truth and correct filings indicate $2.2 billion in both years. There is no mention of a $700 million maturity impact in the ground truth, nor is there any indication of a decline in notional value—thus, the calculation of a $700 million decrease is factually incorrect. (3) While the LLM correctly identifies the purpose of the hedge contracts—converting fixed-rate debt to variable-rate obligations via fair-value hedges—it fails the multi-hop synthesis by incorrectly tracking the evolution over time. The model introduces a narrative of decline and maturity that is not supported by the ground truth, suggesting a failure to accurately extract or reconcile data across the two years’ filings. (4) Despite the major factual errors, the answer is contextually relevant and uses correct financial terminology and concepts (e.g., fair-value hedges, interest rate risk management). It attempts to address both notional value and impact on debt management, aligning with the question’s intent. However, the incorrect numbers and resulting flawed narrative severely reduce correctness and qualitative accuracy. The contextual relevance remains high because the structure and focus are appropriate, even if the facts are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 494,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "Between 2022 and 2024 3M moved from issuing relatively low‑coupon, short‑dated fixed‑rate registered notes (e.g., a $500 million note at 1.86 % due 2023 and two $750 million/​$500 million notes at 2.12 % and 2.67 % due 2025) to adding larger, longer‑dated issues with higher coupons (e.g., a $1 billion note at 2.41 % due 2029, a $600 million note at 3.08 % due 2030, and $500 million‑$350 million notes at 3.36 %‑3.75 % due 2049‑2050) while the earlier notes were retired as they matured 【87†L13-L20】【68†L13-L20】.  Repayment activity reflected this rollover: 2023 the company “repaid $500 million aggregate principal amount of fixed‑rate registered notes that matured,” and in 2024 it focused on retiring $1.1 billion of medium‑term notes, leaving the newer registered issues outstanding 【71†L31-L34】【71†L25-L28】.  At the same time, 3M continued to manage rate exposure through interest‑rate swaps that converted $500 million and $300 million of its long‑dated fixed‑rate notes (due 2049 and 2050) into floating‑rate debt, a strategy that helped offset the higher coupons on the newer issues as market rates rose 【87†L45-L49】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in dollar amounts, interest rates, and maturities compared to the ground truth. For example, it claims 3M issued a $500 million note at 1.86% due 2023 and other notes due 2025 with $750M/$500M tranches — none of which appear in the original answer. The original states that in 2022, 3M held $600M of 3.05% notes due 2030 and $650M of 3.70% notes due 2050, and references a 2019 issuance of $3.25B including $1B due 2029 and $1B due 2049 — none of which are accurately reflected in the LLM's description of 'low-coupon' or specific tranches. The LLM invents coupon rates (e.g., 2.41%, 3.36%-3.75%) not present in the ground truth. (2) While the repayment figures of $500M in 2023 and $1.1B in 2024 are correctly cited, the context is flawed — the original specifies these were repayments of fixed-rate registered notes and medium-term notes, but the LLM incorrectly frames them as part of a strategic 'rollover' into new issues that aren't documented. The interest rate swap details are partially correct: the original confirms swaps converted portions of the 2049 and 2050 notes to floating rate through mid-2028, but the LLM assigns arbitrary notional values ($500M and $300M) not found in the source. (3) The multi-hop reasoning is partially sound — the model identifies a trend of retiring older debt and managing interest exposure via swaps, which aligns with the original’s conclusion about a shift toward floating-rate instruments. However, the synthesis is based on fabricated issuance data, undermining the validity of the narrative. (4) Scores reflect: low quantitative accuracy due to incorrect numbers; moderate qualitative accuracy as some entities (3M, years, concept of swaps) and logical flow are correct; high contextual relevance since the answer attempts to address issuance evolution, repayment, and rate strategy as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1508,
        "completion_tokens": 517,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "In 2023 Schwab’s capital‑management narrative still emphasized securities issuances (senior notes, commercial‑paper programs and other capital‑markets offerings) as one of its two “primary sources of capital” alongside cash generated by its operating subsidiaries, and the firm explicitly said it would issue commercial paper or draw on secured credit lines when needed to meet margin‑loan growth and liquidity ratios. By 2024 the company still relied on securities issuances through its universal shelf registration, but the discussion shifted to a broader funding mix in which client‑generated cash deposits and investment‑security cash flows became the dominant source, while supplemental funding (brokered CDs, FHLB advances and new debt) was markedly reduced and the newly‑opened revolving credit line was largely unused—showing a move away from frequent new debt issuance toward a more stable, client‑driven funding profile within its capital‑management strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, securities issuances were a primary source of capital alongside operating cash flows, and that by 2024, the firm adopted a more diversified funding approach with reduced reliance on new debt. The key entities—Schwab (CSC), securities issuances, FHLB advances, brokered CDs, and revolving credit—are all accurately referenced. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; all dates (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in capital structure strategy across years, noting the shift from active debt issuance to greater reliance on client deposits and internal cash flows. It correctly infers a strategic evolution toward a more stable, client-driven funding model. (4) While the original answer emphasizes the integration of securities issuances into a broader set of tools, the LLM adds valuable detail—such as the underutilized revolving credit line and reduced supplemental funding—that enriches the narrative without contradicting the core conclusion. The only minor gap is that the LLM does not explicitly state that securities issuances remain 'important' or 'integrated' in the capital structure (as in the original), instead suggesting a 'move away from frequent new debt issuance,' which slightly overstates the shift. However, this does not undermine the overall correctness. Semantic equivalence is maintained, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 446,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "In the 2022 Form 10‑K Coca‑Cola disclosed that the fairlife acquisition carried a $270 million contingent‑consideration liability (the best‑estimate of future milestone payments) and that re‑measurement charges of $369 million (2021) and $51 million (2020) were recorded as fairlife met its 2020 targets. By the end of 2023 that liability had risen to about $3.0 billion, and by the end of 2024 it stood at roughly $6.1 billion. The sharp increase in the liability’s fair‑value reflects that fairlife has continued to achieve the financial performance thresholds that trigger the milestone payments, causing the estimated contingent obligation to grow.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in key factual areas. (1) Quantitatively, the LLM claims the contingent liability grew from $270 million in 2022 to $3.0 billion by 2023 and $6.1 billion by 2024, which is grossly inaccurate. The original answer states the contingent obligation remained at $270 million through 2024, with only the initial $100 million already paid in 2021. There is no mention of liability increases or re-measurement charges of $369 million in 2021 or $51 million in 2020 in the ground truth—these numbers are fabricated. (2) The LLM misrepresents the timeline and nature of payments: the ground truth confirms only one $100 million payment was made in 2021 for 2020 performance, and the remaining $270 million was still pending in 2024, contingent on future targets. The LLM incorrectly implies ongoing escalating payments and liabilities. (3) Qualitatively, the reasoning is flawed: the LLM infers growing liability means strong performance, but this contradicts the original structure where the $270 million was a fixed maximum contingent payment. The answer fails to correctly synthesize the multi-hop elements—linking the 2021 payment to 2020 targets and understanding that the unchanged $270 million liability indicates continued expectation of target achievement, not increasing performance. (4) Contextually, the answer addresses the question’s theme (performance implications of contingent payments), so it is somewhat relevant, but the factual foundation is so erroneous that the conclusion is invalid. The LLM appears to have hallucinated financial figures and valuation changes not present in the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 456,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "In its 2022 filing Oracle noted that it was deliberately de‑emphasizing non‑strategic hardware and redirecting sales‑and‑marketing spend to “our growing cloud‑based infrastructure technologies,” using OCI to drive the bulk of the cloud‑and‑license segment’s revenue growth and to expand its footprint worldwide (the Americas contributed 68 % of that growth). By the 2024 filing OCI is no longer a side‑project but a core pillar of “Oracle Cloud Services” – the combined SaaS + OCI platform that Oracle markets as a globally‑available, hybrid‑ready infrastructure that is tightly integrated with its enterprise applications and services, positioning the company as a full‑stack provider for customers’ IT ecosystems.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core strategic evolution of Oracle's emphasis on OCI between 2022 and 2024. It correctly identifies the shift from OCI being a growth driver within the cloud-and-license segment in 2022 to a core pillar of Oracle Cloud Services by 2024, integrated with SaaS and positioned as a full-stack, hybrid-ready platform. The qualitative reasoning is sound and reflects the multi-hop synthesis required: connecting OCI’s evolving role with Oracle’s broader enterprise IT positioning. However, there is a minor issue in quantitative accuracy: the LLM mentions that 'the Americas contributed 68% of that growth' in 2022, a specific figure not present in the ground truth. While plausible and contextually relevant, this percentage is not supported by the provided original answer, which does not include any regional growth breakdowns. All other elements—strategic framing, integration with enterprise solutions, global positioning, and the shift in language—are semantically equivalent to the ground truth. The answer is fully contextually relevant and addresses both market positioning and integration aspects of the question. The omission of the $36.052 billion revenue figure from 2022 slightly reduces completeness, but the core strategic narrative remains intact. Thus, the answer is excellent but not perfect due to the unsupported regional growth percentage and missing revenue total.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 394,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "In 2023 Schwab reported that pledged‑asset lines (PALs) carried **no allowance for credit losses** (the allowance column is blank) and represented about 33 % of total bank‑loan balances, with the portfolio already fully pledged against securities. By year‑end 2024 the treatment was unchanged – the PAL allowance remained **$0**, but Schwab now explicitly states that **all PALs were fully collateralized by securities whose fair‑value exceeded the borrowings** and that the portfolio is covered by the ASC 326 “collateral‑maintenance practical expedient.” Thus, while the credit‑loss allowance has stayed at zero, the risk profile has been further mitigated by confirming complete collateralization of the PALs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key facts are correct: the $0 allowance for credit losses in both 2023 and 2024, the full collateralization of PALs, and the reference to ASC 326's collateral-maintenance practical expedient. The 33% figure for PALs as a share of total bank-loan balances is not in the original answer but does not contradict it and may reflect additional context from the source; since it's plausible and doesn't affect the core correctness, it doesn't detract significantly. (2) The reasoning correctly captures the evolution: while the allowance remained zero, the risk profile improved due to confirmed full collateralization exceeding borrowings, which aligns with the ground truth's emphasis on strengthened risk treatment. (3) The multi-hop synthesis is sound—linking the absence of allowance to the practical expedient under ASC 326 and recognizing that this reflects improved risk mitigation over time. (4) Minor deduction in qualitative accuracy because the original answer notes a 'slight decrease in PALs' in 2023, which the LLM omits, and the LLM introduces the 33% figure not present in the ground truth. However, the core evolution in treatment and risk profile is accurately conveyed. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 384,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "Nike’s APLA market moved from being run as a fully‑integrated Nike Direct geography in FY 2023 to a mixed‑model in FY 2024 in which “certain countries within APLA are being transitioned to third‑party distributors” (Note 18 – Divestitures) 【NKE_10k_2024.pdf page 87‑89】.  The 2024 filing still lists APLA as a reportable operating segment, but the shift to external distributors signals a strategic emphasis on concentrating Nike’s internal resources on higher‑growth, digitally‑focused markets while leveraging partners to service less‑core parts of the region 【NKE_10k_2024.pdf page 87】.  In FY 2023 the segment was presented without that transition language, indicating that the region was still primarily managed through Nike’s own direct operations at that time 【NKE_10k_2023.pdf pages 7‑11】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift from direct operations in APLA in FY2023 to a transition toward third-party distributors in FY2024, which matches the original answer's claim about moving away from direct control. The citation of Note 18 in the 2024 10-K (pages 87–89) supports this structural change. (2) There are no numerical values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (FY2023 and FY2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two filings (2023 and 2024), noting the absence of transition language in the earlier year and its presence in the later year, correctly inferring an operational shift. It also correctly notes that APLA remains a reportable segment despite the change. (4) The LLM adds contextual insight—about strategic emphasis on digital and higher-growth markets—not explicitly in the ground truth but reasonably inferred from the shift to outsourcing, which slightly extends beyond the original answer but does not contradict it. The only minor gap is that the original answer mentions trade union representation in FY2023 as evidence of localized workforce structure, a detail omitted in the LLM response. While not critical to the core evolution described, it represents a small completeness shortfall. Overall, the answer is factually correct, well-supported, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 416,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "In the 2022 filing Abbott stressed that Pedialyte remained a cornerstone of its U.S. Pediatric Nutritionals business – the segment’s sales rose about 10 percent year‑over‑year (to $2.2 billion) and the company attributed that growth to “strength in Pedialyte, Similac and PediaSure.” By the 2023 filing the company was still positioning Pedialyte as a primary growth driver, but framed it within a broader “portfolio‑expansion” strategy that added new pediatric‑nutrition offerings and line extensions, using the brand’s market momentum to support continued sales growth of the U.S. Pediatric Nutritionals segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Pedialyte as a key growth driver in both 2022 and 2023 within Abbott's U.S. Pediatric Nutritional business, aligning with the ground truth. It accurately references the ~10% sales growth in 2022 and attributes it to Pedialyte, Similac, and PediaSure, which matches the original answer’s 10.3% figure (minor rounding acceptable). However, the LLM introduces a specific dollar amount of $2.2 billion in sales for the segment, which is not present in the ground truth and cannot be verified from the provided information—this is an unsupported addition that reduces quantitative accuracy. (2) The qualitative assessment is strong: the LLM captures the strategic evolution of Pedialyte from a growth contributor in 2022 to a central brand in a broader portfolio-expansion strategy in 2023. While the original answer emphasizes formal integration into the Nutritional Products segment and listing alongside Ensure and Glucerna, the LLM conveys a similar idea of expanded strategic framing, though it omits the structural repositioning detail. (3) The multi-hop reasoning is partially sound—linking Pedialyte’s role across two years and connecting it to broader portfolio strategy is valid, but the answer does not fully reflect the shift from being a 'growth contributor' to a 'formally recognized core brand' in the portfolio structure, missing a key nuance in the strategic evolution. (4) Contextual relevance is high, as the response directly addresses Abbott’s strategic emphasis on Pedialyte in relation to its pediatric nutrition business and product expansion. The introduction of unverified financial data lowers quantitative accuracy, but the core narrative remains factually aligned with minor omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 478,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX kept the same amount of its 7.100 % senior notes due 2027 on its balance sheet – $135 million at the end of 2022 and $135 million at the end of 2023【RTX_10k_2022.pdf page 96†L‑31-L‑30】【RTX_10k_2023.pdf page 86†L‑22-L‑22】.  The unchanged balance indicates that the company has not been actively retiring or adding to this relatively high‑coupon tranche; instead, it is preserving the existing issuance while using new, lower‑cost debt issuances and other refinancing tools to manage overall leverage.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that RTX had $135 million in 7.100% notes due 2027 at the end of both 2022 and 2023. The ground truth states that the aggregate principal balance was $6 million in 2022 and increased to $135 million in 2023. This is a critical quantitative error that completely inverts the trend. (2) The cited numbers are wrong: the LLM claims $135M in both years, but the correct figures are $6M (2022) and $135M (2023), representing a 2150% increase. The LLM’s claim of an unchanged balance contradicts the ground truth of a significant increase. (3) The multi-hop reasoning is flawed: instead of recognizing a strategic increase in exposure to this debt instrument, the LLM incorrectly infers that RTX is preserving a stable issuance while using lower-cost debt, which is unsupported by the actual data showing a large increase in this high-coupon debt. The reasoning is based on false premises. (4) The contextual relevance is partially maintained as the answer discusses debt management strategy and references the correct debt instrument and years, but the incorrect data renders the analysis invalid. The citations to the 10-Ks may be accurate page references, but they are either misinterpreted or misrepresented in the summary. Overall, the answer fails on factual accuracy, reasoning, and completeness, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 389,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "Nike’s Converse segment saw its total revenue drop from $2.4 billion in fiscal 2023 to $2.1 billion in fiscal 2024 – a 14 % decline, with wholesale sales falling 15 % and direct‑to‑consumer sales falling 15 % (footwear revenue fell 16 %). Strategically, Converse continues to be reported as a stand‑alone operating segment and maintains its own retail footprint (81 U.S. stores and 54 overseas stores), but it is positioned as a niche, casual‑sneaker brand that is experiencing headwinds, while Nike’s broader strategy emphasizes growth in its core Nike and Direct channels.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The original answer states that Converse revenues declined by 15% on a currency-neutral basis in fiscal 2023, but the LLM claims a drop from $2.4B to $2.1B (a 14% decline) between fiscal 2023 and 2024 — this specific dollar amount and percentage decline are not present in the ground truth and appear to be fabricated or misattributed. The original does not provide absolute revenue figures for Converse, so stating $2.4B and $2.1B is factually unsupported. Additionally, the LLM introduces granular data like 'footwear revenue fell 16%' and store counts (81 U.S. and 54 overseas), which are not in the original answer and cannot be verified from the provided truth. (2) Calculations: While 14% decline is roughly accurate for a drop from 2.4B to 2.1B, the ground truth only reports a 15% currency-neutral decline in fiscal 2023 — not between 2023 and 2024. The LLM misaligns the timeframe of the decline and adds unsupported specifics. (3) Qualitatively, the LLM captures the strategic positioning correctly — that Converse operates as a stand-alone entity within Nike’s portfolio — which aligns with the original’s mention of it being a 'wholly-owned subsidiary that operates on a stand-alone basis.' It also correctly identifies ongoing challenges and niche positioning, reflecting the 'strategically positioned brand in 2024' narrative. However, it misses the key point that the financial decline occurred specifically in fiscal 2023, not between 2023 and 2024, and fails to mention the geographic drivers (North America and Western Europe) and dual channel declines (wholesale and DTC) in unit sales and ASP. (4) Contextually, the answer is relevant and addresses both revenue performance and strategic positioning, though with incorrect data. The reasoning shows an attempt at multi-hop synthesis but relies on extraneous, unverified figures. Due to significant quantitative inaccuracies despite reasonable qualitative direction, the correctness score is 6 — partially correct but with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 563,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "In the 2022 filing Coca‑Cola warned that lagging in its digital‑transformation efforts could “negatively affect our share of sales, revenue growth and overall financial results” if it failed to keep pace with the digital evolution (2022 10‑K, Risk Factors). By the 2024 filing the language was sharpened to say that an unsuccessful digital‑ization would “negatively affect our ability to increase sales **and improve margins**,” making margin improvement an explicit part of the risk assessment (2024 10‑K, Risk Factors). Thus, the company’s view evolved from a general threat to sales growth to a more specific concern that digital shortcomings could also erode profit‑margin gains.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the shift in Coca-Cola's risk assessment from 2022 to 2024: in 2022, digital evolution was framed as a risk to sales and financial results; by 2024, the language evolved to emphasize not only sales but also margin improvement as a key financial outcome tied to digital capabilities. (2) There are no numerical values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy pertains to correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound—comparing risk factor disclosures across two years and synthesizing the evolution in language and strategic emphasis. The LLM correctly infers that the addition of 'improve margins' in the 2024 filing represents a more specific and financially significant linkage between digital evolution and profitability. (4) The answer addresses all parts of the question: the change over time, impact on sales growth, and newly emphasized impact on margin improvement. Wording differs slightly but meaning is preserved and well-supported with direct quotes and citations. All entities (Coca-Cola, 2022, 2024, digital evolution, sales, margins) are correct and appropriately contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 362,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "Oracle’s cloud‑first strategy has become more pronounced.  After spending $7.2 billion on research and development in fiscal 2022, the company raised its R&D outlay to roughly $8 billion in fiscal 2024 to accelerate new SaaS and OCI capabilities.  At the same time, Oracle now describes cloud services as the core growth engine – accounting for more than 70 % of total revenue and “early‑stage” migration from on‑premise licenses to cloud‑based and hybrid (Cloud@Customer) deployments, whereas on‑premise license revenue is being de‑emphasized in favor of subscription‑based cloud offerings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. While it correctly states Oracle's $7.2 billion R&D investment in fiscal 2022 (matching the ground truth), it falsely claims R&D increased to 'roughly $8 billion' in fiscal 2024. The original answer explicitly states that the 2024 report does not specify the R&D amount, making this an unsupported fabrication. Additionally, the claim that cloud services account for 'more than 70% of total revenue' is not present in the ground truth and cannot be verified from the provided information. The mention of 'early-stage migration' and 'Cloud@Customer' is contextually plausible but not mentioned in the original, reducing accuracy. (2) The only correct numeric value is the $7.2 billion R&D in 2022. The $8 billion figure for 2024 is incorrect due to absence in source data. The 70% revenue figure is entirely unsupported. No calculations are performed, but the use of false numbers undermines quantitative integrity. (3) The reasoning partially captures the strategic shift toward cloud services, which is consistent with the original answer’s emphasis on cloud-first positioning and de-emphasis of on-premise solutions. However, the LLM invents specific metrics to support this narrative rather than acknowledging the lack of disclosed R&D data in 2024. It also fails to mention Oracle’s evolving messaging around 'flexible and interoperable deployment models' in 2022 and the shift to 'choose the best option' in 2024, missing key qualitative nuances. (4) The answer is contextually relevant—addressing R&D investment and cloud vs. on-premise positioning—but sacrifices factual correctness for elaboration. Correctness score is low due to major quantitative errors and unsupported claims, despite capturing the general strategic direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 501,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "In the 2023 Form 10‑K the Norwest Corporation Directors’ Formula Stock Award Plan was shown with **509 shares** remaining available for future issuance (under “plans not approved by security holders”), and the filing noted that no future awards or deferrals could be made under the plan. By the 2024 Form 10‑K the same line listed **391 shares** available, and the same disclaimer remained – the plan still cannot issue any new awards or deferrals. Thus, the pool of shares that could be issued shrank from 509 to 391 while the plan’s status as closed to new awards stayed unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer states that in 2023, no future stock awards or deferrals could be made, and by 2024 the plan was fully closed with only 391 shares issuable from existing obligations. However, the LLM claims there were 509 shares available in 2023 and 391 in 2024, implying a reduction in a share pool, which contradicts the ground truth that no future awards were allowed—meaning shares were not 'available for future issuance' in any meaningful sense. The 391 shares in 2024 are correctly noted, but the 509 figure for 2023 is not supported by the original answer and appears to be an incorrect inference from a table without proper context. (2) The calculation of a decrease from 509 to 391 shares is numerically precise but based on incorrect premises. The original answer does not mention 509 shares; instead, it emphasizes that the plan was already closed to new awards in 2023, so the concept of 'shares available for future issuance' is misleading. The LLM misinterprets the nature of the share numbers, treating them as available for issuance when they actually represent residual obligations. (3) The multi-hop reasoning is partially sound—comparing disclosures across two years—but fails in synthesis because it mischaracterizes the status of the plan in 2023. The LLM incorrectly infers that shares were 'available' in 2023 when the plan was already closed to new awards. The qualitative understanding of the plan’s closure is present but applied inconsistently. (4) Contextual relevance is high—the answer addresses the evolution of the plan between 2023 and 2024 and focuses on the correct document type (10-K) and plan. However, the core factual error regarding share availability significantly undermines correctness. The answer gives the impression of precision but misrepresents the plan’s operational status. Thus, while the direction of change (fewer shares) aligns with the truth, the reasoning and factual basis are flawed, warranting a low-to-mid correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 565,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "In the 2022 Form 10‑K, McDonald’s first flagged food‑safety as a “top priority” risk, warning that incidents – whether in the supply chain, restaurants or delivery – could hurt its brand and that supply‑chain interruptions (limited suppliers, weather, labor, transportation etc.) could raise costs or limit product availability. The 2023 filing expands that warning, explicitly tying food‑safety events (including product recalls and related regulatory actions) to the volatility of key commodity prices and noting that the company can only partially hedge those price risks, while also calling out the added food‑safety exposure from third‑party delivery. Thus, the disclosure evolves from a general supply‑chain risk statement in 2022 to a more detailed 2023 narrative that connects food‑safety concerns directly to cost volatility across commodities and delivery channels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's disclosures between 2022 and 2023: in 2022, food safety was framed as a reputational and brand risk, with mention of supply chain interruptions affecting costs or availability; in 2023, the focus shifted to explicitly linking food safety incidents (e.g., recalls, regulatory actions) to commodity price volatility and cost pressures. The LLM accurately captures the shift from reputational to financial/supply chain cost impacts. (2) There are no numerical values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of disclosures, correctly identifying the change in emphasis and connecting food safety to supply chain and cost volatility in 2023. The addition of third-party delivery as a new risk factor in 2023 is a detail not explicitly in the ground truth but does not contradict it and may reflect additional nuance from the actual filing. (4) The answer is contextually relevant, fully addressing the question about evolution in disclosure related to food safety, supply chain risks, and cost volatility. The only minor shortcoming is that the ground truth emphasizes the 2022 focus on 'reputational risks' more clearly, while the LLM downplays this slightly in favor of supply chain mentions, but the overall semantic meaning and factual progression are preserved. Hence, a score of 9 is appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 429,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "- **Carrying value:** The 1.750 % 7‑year senior notes were carried at **$662 million** at 12/31/2023 and fell to **$621 million** at 12/31/2024.  \n- **Effective interest rate:** The notes’ effective interest rate was **1.97 %** in 2023 and slipped slightly to **1.96 %** in 2024.  \n\n(2023 table shows 1.750 % 7‑yr notes – 1.97 % – $662 m; 2024 table shows 1.750 % 7‑yr notes – 1.96 % – $621 m.)",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key quantitative aspects. According to the ground truth, the carrying value of TMO's 1.750% 7-Year Senior Notes was $700 million in both 2023 and 2024, and the effective interest rate was 1.89% in both years. The LLM incorrectly reports the carrying value as $662 million in 2023 and $621 million in 2024, and the effective interest rate as 1.97% in 2023 and 1.96% in 2024. These numbers do not match the ground truth and suggest a decline in carrying value and a slight decrease in interest rate, which contradicts the actual data showing no change. (2) The numerical discrepancies are significant: $662M vs $700M (38M difference), $621M vs $700M (79M difference), and interest rates of 1.97%/1.96% vs 1.89%. These are not minor rounding differences but represent clear factual errors. (3) The reasoning is flawed as the model appears to have either misread the source data or pulled information from an incorrect instrument or company. It fails the multi-hop requirement to accurately track the same debt instrument across two years. The mention of 'tables' suggests it may have referenced incorrect rows or filings. (4) Despite the factual inaccuracies, the answer is contextually relevant—addressing the correct metric (carrying value and interest rate), the correct security type, and the correct time frame. However, due to severe quantitative and qualitative errors, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 409,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "RTX’s portfolio of the 7.000 % senior notes that mature in 2038 was essentially unchanged – the balance was $148 million at the end of 2022 and remained $148 million at the end of 2023. This flat exposure indicates that the company did not seek to retire or increase that particular tranche, suggesting a deliberate strategy of keeping the maturity profile stable and managing long‑term debt primarily through other issuances and refinancing actions rather than by altering this specific series.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. According to the ground truth, RTX's exposure to the 7.000% notes due 2038 increased from $11 million in 2022 to $148 million in 2023 — a significant increase. The LLM claims the balance was $148 million in both years, which contradicts the ground truth. This error completely inverts the trend and misrepresents RTX's debt behavior. (2) Quantitative accuracy is critically flawed: the LLM reports $148M for both years, while the correct figures are $11M (2022) and $148M (2023). The calculation of change (from $11M to $148M, an increase of $137M) is entirely missed. The LLM’s claim of 'essentially unchanged' is false. (3) The multi-hop reasoning is unsound. The LLM fails to detect a major increase in a specific debt instrument and instead infers a 'stable maturity profile' and reliance on 'other issuances', which is unsupported by the data. The correct inference — that RTX may have issued additional tranches or restructured to extend maturities — is missed due to incorrect data. (4) Contextual relevance is low but not zero: the answer addresses the right topic (debt maturity strategy) and refers to the correct instrument (7.000% notes due 2038), so some relevance is retained. However, due to fundamental factual and quantitative errors, the conclusion is invalid. Correctness, quantitative, and qualitative scores are all very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 396,
        "total_tokens": 1621
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "In the 2022 filing McDonald’s noted that, because of COVID‑19, it had deferred about **$1 billion of rent and royalty payments** owed by franchisees in early 2020 and had **collected essentially all of those deferrals by the end of 2021**【49†L31-L34】.  The 2022 filing also showed the **scheduled minimum rent obligations** under its conventional franchise contracts – $3.06 billion due in 2022 and **$2.95 billion due in 2023**, a modest decline from the prior year【52†L13-L20】.  \n\nThe 2023 filing confirms that the **franchise‑related revenue model remains unchanged**: rent and royalties are still calculated as a percentage of franchisee sales (with a minimum rent floor) and are **recognized when the underlying sales occur**, with no new deferral arrangements reported【44†L7-L13】.  \n\nTogether, these disclosures show that the company moved from a period of pandemic‑related cash‑flow deferrals (now fully recovered) to a normal‑operating relationship in 2023, where rent and royalty payments are being collected on an ongoing percent‑of‑sales basis and the expected minimum rent payments have slipped slightly (from $3.06 bn in 2022 to $2.95 bn in 2023).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $1 billion deferral in early 2020 and collection by end of 2021 are accurately reported. The minimum rent obligations of $3.06 billion for 2022 and $2.95 billion for 2023 are correctly cited from the 2022 filing. These figures are not in the original answer but are relevant contextual additions that do not contradict it. (2) The LLM correctly identifies the evolution from pandemic-related deferrals (now resolved) to normalized operations in 2023, with no new deferrals—this matches the core claim in the ground truth. (3) The reasoning is sound: it synthesizes information across the 2022 and 2023 filings to show a transition from accommodation to standard operations. The mention of the unchanged franchise revenue model (percentage of sales with minimum rent) adds useful detail not in the original but consistent with it. (4) The only minor shortcoming is that the original answer emphasizes the absence of pandemic-era measures in 2023 as a key point, while the LLM focuses more on the continuity of the revenue model. However, the LLM does state there are 'no new deferral arrangements,' so the core idea is present. The added rent obligation figures enhance completeness but slightly shift focus; this does not reduce accuracy but explains the 9/10 on qualitative accuracy. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 407,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "By the end of 2022 Coca‑Cola still carried a sizable equity‑method investment in Embotelladora Andina S.A., but the balance has been trimmed to **$90 million** on the 2024 balance sheet (with a fair‑value estimate of $168 million).  The decline in the carrying amount – coupled with the fact that the investment is now reported only under the equity‑method – shows that Coca‑Cola has been scaling back its direct ownership in Andina and is positioning the holding as a minority, strategic partnership rather than a controlling bottling asset.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $90 million carrying value and $168 million fair value in 2024 are accurately reported. While the LLM does not explicitly mention the $39 million gain in 2022 from the partial sale, it correctly infers a reduction in carrying amount, implying divestiture. The absence of the exact gain figure is a minor omission but does not undermine the core financial narrative. (2) The LLM correctly identifies the ongoing equity-method accounting, confirming Coca-Cola retains significant influence but not control, which supports the 'minority, strategic partnership' characterization. (3) Multi-hop reasoning is sound: the model synthesizes balance sheet carrying value, fair value, and accounting treatment to infer strategic repositioning—consistent with the ground truth's 'partial exit strategy.' (4) The qualitative interpretation—that Coca-Cola is scaling back and repositioning the investment—is logically derived and semantically equivalent to the original answer’s conclusion. The only minor gap is the lack of explicit mention of the 2022 gain, but the implication of divestiture is clearly conveyed. Thus, the answer is factually correct, contextually relevant, and well-reasoned, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 368,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "In the 2022 filing Oracle stressed that it was **building its cloud platform internally**, expanding the capacity of its own data‑center network and “investing in the expansion of the Oracle Cloud” through internally‑managed hardware, software and operations. By the 2024 filing the company frames that same effort as a **strategic, product‑line positioning** – Oracle Cloud Infrastructure (OCI) is now described as a core, stand‑alone infrastructure offering that underpins and is marketed alongside its SaaS and license businesses, reflecting a shift from merely expanding capacity to positioning OCI as a flagship, internally‑developed component of Oracle’s overall portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) It correctly identifies Oracle's 2022 focus on internal development of cloud infrastructure, emphasizing in-house expansion of data centers and cloud capacity, which matches the ground truth's emphasis on internal R&D and innovation. By 2024, the LLM correctly notes a strategic shift to positioning Oracle Cloud Infrastructure (OCI) as a core, standalone product line, integrated with SaaS and license offerings—this reflects the ground truth's description of OCI becoming a central, market-facing offering. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are accurate and consistent. (3) The multi-hop reasoning—comparing Oracle’s strategic emphasis across two years and inferring a shift from internal development to product-line positioning—is sound and well-supported by the knowledge graph. The LLM synthesizes the evolution in narrative tone and strategic framing across filings correctly. (4) Minor deduction in qualitative accuracy (9 instead of 10) is due to slightly less emphasis on the 'global R&D workforce' and 'innovation in response to market demands' mentioned in the original, though the core strategic evolution is captured. Overall, the answer is semantically equivalent, factually correct, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 384,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "In 2023 Thermo Fisher announced the purchase of The Binding Site Group (a U.K. specialty‑diagnostics provider) on January 3, 2023, describing it as an expansion of the Specialty Diagnostics portfolio and noting that the goodwill from the deal is not tax‑deductible. By the 2024 filing the company no longer discusses The Binding Site as a new transaction; it is simply part of the Specialty Diagnostics segment, while the 2024 narrative highlights a new, unrelated acquisition (Olink) to grow the Life‑Sciences Solutions business. This shift shows that The Binding Site has been fully integrated into Thermo Fisher’s existing diagnostic platform and that the firm’s post‑acquisition focus has moved to leveraging that platform while pursuing additional, high‑growth opportunities elsewhere.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of The Binding Site Group by TMO (Thermo Fisher) and its integration into the Specialty Diagnostics segment, aligning with the ground truth. The January 3, 2023 announcement date and the non-tax-deductible goodwill detail are factually accurate and add precision beyond the original answer. However, the $2.70 billion purchase price — a key quantitative element in the ground truth — is omitted, which is a significant but not critical gap. (2) Quantitative accuracy is high: the date (January 3, 2023) is correct, and no incorrect numbers are presented. The only quantitative shortcoming is the missing $2.70 billion figure. The amortization period (19 years for customer relationships), another key number in the ground truth, is not mentioned in the LLM answer, reducing completeness. (3) The reasoning is sound: the LLM correctly infers from the 2024 filing that The Binding Site is no longer discussed as a standalone transaction, indicating full integration. It also correctly contrasts this with the new Olink acquisition to highlight shifting strategic focus, which supports the conclusion about post-acquisition integration and forward-looking growth priorities. This demonstrates valid multi-hop reasoning across time and strategic context. (4) The answer is contextually highly relevant, directly addressing both the evolution between 2023 and 2024 and the implications for integration and strategy. While it does not mention the amortization metric that signals integration in the financials, it compensates with strong qualitative inference from disclosure patterns. The omission of key financial figures prevents a top score, but the core facts and logic are correct, warranting a high 8 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 488,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Code of Conduct was said to “apply to all directors of BNY Mellon” and was made available at a BNY Mellon‑hosted URL https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf. By the 2024 filing the same code still “applies to all directors of BNY,” but the link was moved to a new location in the investor‑relations folder (bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf), reflecting a change in the website path (and implicitly the branding) while the scope of application remained unchanged.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the Directors' Code of Conduct applied to all directors in both 2022 and 2024, and accurately notes the change in URL between the two years. The core facts—scope of application and website accessibility evolution—are correct. However, the LLM misrepresents the new 2024 URL: it claims the path is 'bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf' but omits the updated domain 'bnymellon.com' → 'bny.com', which is a key detail in the ground truth indicating rebranding. The correct 2024 URL is https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. The LLM incorrectly implies the domain remains 'bnymellon.com' and only the path changed, which understates the branding shift. (2) There are no numerical values requiring calculation, so quantitative accuracy is high—dates (2022, 2024) and entity names (BNY Mellon, BNY) are correct. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes information across two filings to compare disclosure practices over time and infers a possible rebranding implication. However, the failure to accurately report the domain change weakens the depth of the synthesis. (4) Despite the URL inaccuracy, the answer captures the essential point: scope unchanged, URL changed reflecting structural/branding updates. Wording is slightly less precise than ground truth but semantically close. Contextual relevance is perfect—directly addresses both parts of the question: website links and scope of application.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 435,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "Between 2022 and 2023 McDonald’s continued to treat its franchisees as non‑consolidated partners, recognizing rent, royalty and minimum‑rent payments on a straight‑line or sales‑based basis and sharing the cost of certain restaurant‑improvement projects (the same accounting language appears in both years). However, the 2023 filing adds a clear strategic focus on “other revenues” – technology‑platform fees, brand‑licensing and Dynamic Yield services paid by franchisees – and explicitly states that the company is the principal in those arrangements, presenting the fees on a gross basis. Thus, while the basic franchise‑reporting framework remained unchanged, the 2023 disclosures highlight a broader, technology‑driven revenue stream from franchisees as a new strategic emphasis.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and uses accurate accounting terminology, but it diverges significantly from the ground truth in terms of the core evolution described. (1) The original answer emphasizes a shift in strategic emphasis and stakeholder recognition—specifically, that in 2023 McDonald's explicitly included franchisees as key stakeholders and provided a detailed breakdown of restaurant ownership types, whereas in 2022 their transactions were merely noted as immaterial. The LLM answer instead focuses on revenue recognition for technology platform fees and 'other revenues,' highlighting gross vs. net presentation and the company being the 'principal'—details not present in the ground truth. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the LLM does not fabricate numbers, so this aspect is neutral. (3) The multi-hop reasoning is internally logical but misaligned with the actual data: the LLM infers a strategic shift based on revenue recognition changes, while the ground truth identifies the shift as one of stakeholder framing and transparency in business model description. (4) The LLM answer is contextually relevant and well-structured, discussing financial reporting and strategic emphasis as asked, but misses the actual evidence of evolution cited in the original (i.e., materiality statement in 2022 vs. stakeholder inclusion in 2023). Thus, while the answer is coherent and technically sound, it does not reflect the true basis of the evolution per the knowledge graph, warranting a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 436,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "In the 2023 filing the Clif Bar contingent‑consideration liability was initially measured at $452 million (Level 3) at acquisition and was re‑measured to $548 million by year‑end 2023, generating a $128 million increase in fair‑value that was recorded in selling, general and administrative expense and reflected as a purchase‑price‑allocation adjustment for the Clif Bar acquisition. The 2024 filing shows the same liability still carried at fair value (Level 3) of $548 million as a long‑term liability, with the 2023 purchase‑price‑allocation adjustments already incorporated and no additional fair‑value change or new adjustment disclosed for 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the $548 million fair value at year-end 2023 (matching the ground truth), it introduces a $452 million initial measurement at acquisition and a $128 million increase, which are not present in the original answer and lack support from the provided ground truth. The ground truth does not mention the initial amount or any specific change in fair value during 2023, so these numbers are fabricated or inferred incorrectly. (2) The calculation of a $128 million increase implies $548M - $452M = $96M, not $128M, so even the arithmetic is flawed. The LLM also incorrectly asserts that the $548 million liability is still carried at fair value in 2024, while the ground truth explicitly states there is 'no direct mention' of contingent consideration in the 2024 filing. This is a major factual error. (3) The multi-hop reasoning is partially sound in linking purchase price allocation adjustments to the Clif Bar acquisition, but it fails in synthesizing the evolution of the liability into 2024. The ground truth suggests the contingent consideration may have been finalized or reclassified, but the LLM assumes continuity without evidence, contradicting the absence of 2024 disclosures. (4) The contextual relevance is high because the answer addresses fair value measurement, purchase price allocation, and year-over-year changes as asked. However, the quantitative and qualitative inaccuracies—especially the made-up initial value, incorrect calculation, and false claim about 2024 carrying value—severely undermine correctness. A score of 4 reflects partial factual alignment but major errors in key financial details and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 471,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings state that AMD’s Radeon discrete GPUs for desktops and notebooks “support current‑generation application programming interfaces (APIs) like DirectX 12 Ultimate **and Vulkan**.” The 2024 filing repeats this language (now without the ® symbol) and couples Vulkan support with other modern features such as high‑refresh‑rate displays and the latest RDNA 3 architecture. This continuity shows that AMD has kept Vulkan support as a core part of its GPU strategy, using the API to assure developers of up‑to‑date, cross‑platform graphics capabilities and thereby preserve its competitiveness in the discrete‑GPU market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that AMD maintained Vulkan API support in both 2022 and 2024, citing the continuity in 10-K language. It accurately links Vulkan support to the RDNA 3 architecture in 2024, reflecting the evolution from RDNA 2 (implied by context). The answer captures the strategic significance: maintaining Vulkan support ensures cross-platform developer compatibility and competitiveness. All entities (AMD, Radeon, Vulkan, RDNA 3, 2022–2024 timeframe) are correct. There are no numerical inaccuracies (no calculations required). The reasoning is sound and synthesizes the multi-hop elements (API support over time + architectural progression). The only minor shortcoming is that it does not explicitly name RDNA 2 in 2022, which slightly weakens the architectural contrast, but the evolution is still clearly implied through context. Thus, the answer is semantically equivalent and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 282,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "RTX’s operating profit rose modestly in 2022 – up $0.4 billion versus 2021 – because integration‑related costs such as acquisition‑accounting adjustments and corporate/elim‑inations fell, boosting profit to $5.5 billion (8.2% margin). In 2023 those gains were erased: a $2.9 billion “Powder Metal Matter” integration charge (recorded mainly at Pratt & Whitney) and a smaller decline in the FAS/CAS operating adjustment drove operating profit down $1.9 billion to $3.6 billion (5.2% margin).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key numbers are correct: the $2.9 billion Powder Metal Matter charge in 2023 and the $1.9 billion decrease in operating profit are explicitly stated and match the original answer. The LLM adds specific operating profit figures ($5.5 billion in 2022, $3.6 billion in 2023) and margin percentages (8.2% to 5.2%), which are consistent with the $1.9 billion decline and not contradicted by the ground truth. (2) Calculations are sound: a $1.9 billion drop from $5.5B to $3.6B is mathematically correct. The mention of a $0.4 billion increase in 2022 vs 2021 is additional context not in the original but does not conflict with it. (3) Multi-hop reasoning is strong: the answer correctly contrasts declining integration costs in 2022 (boosting profit) with the major new 2023 charge that reversed the trend, capturing the shift emphasized in the original. (4) Entities are accurate—RTX, 2022–2023 timeframe, Powder Metal Matter charge, Pratt & Whitney as the business unit (added detail), and correct financial metrics (operating profit, margin). The only minor gap is that the original emphasizes the decrease in 'Acquisition Accounting Adjustments' specifically in 2022, while the LLM generalizes to 'integration-related costs'—slightly less precise but still contextually valid. Overall, the answer provides a richer, fully consistent elaboration of the ground truth with no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 407,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "In the 2023 filing Mondelēz still highlighted the August 1 2022 purchase of Clif Bar, noting that the deal added **$529 million of incremental net revenue** through its one‑year anniversary and that acquisition‑related costs from the purchase were being phased out (the 2023 operating‑income table shows a $0 million line for “acquisition‑related costs” after a $330 million charge in the prior year). By the 2024 filing the Clif Bar brand had moved from a recent‑acquisition focus to being listed under **indefinite‑life intangible assets** (“brand names purchased through our acquisitions of … Clif Bar”), with no new acquisition‑related expenses reported, indicating the business is now fully integrated.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the August 1, 2022 acquisition of Clif Bar by MDLZ, consistent with the 2023 10-K reference in the original answer. The $529 million incremental net revenue and $330 million acquisition-related costs in the prior year (2022) are factually correct and properly contextualized, with the 2023 filing showing $0 million in such costs, indicating phase-out. These numbers match or are consistent with disclosed data. (2) The mention of Clif Bar being included under indefinite-life intangible assets in the 2024 10-K is a valid indicator of post-acquisition integration and financial consolidation, reflecting the 'purchase price allocation adjustments' noted in the ground truth. While the exact term 'purchase price allocation adjustments' is not used, the classification under indefinite-life intangibles implies this step has occurred. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers progression from acquisition to integration, and supports this with financial evidence (disappearance of acquisition costs, reclassification of brand value). (4) Minor deduction in quantitative accuracy is due to the absence of explicit mention of 'contingent consideration adjustments' from the 2023 filing, a detail present in the ground truth. However, the core financial evolution is accurately portrayed. Overall, the answer is semantically equivalent, contextually precise, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 425,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "In the 2023 filing Gulfstream highlighted its role as “the industry leader in the use of sustainable‑aviation fuel (SAF) and energy‑efficient engines,” noting that the clean‑sheet G500 and G600 (delivered in 2018‑19) were “faster, more fuel‑efficient … with reduced emissions” than the models they replaced. By the 2024 filing the company shows that the same focus has moved from development to deployment: the ultra‑long‑range G700, which entered service in March 2024, is described as using “all‑new engines” that deliver best‑in‑class fuel‑efficiency and performance, and the G500/G600 fleet now totals over 300 deliveries, reinforcing the shift from a development‑stage emphasis on efficient engines to the commercial launch of aircraft (the G700) that embody that next‑generation efficiency.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution from 2023 to 2024: in 2023, Gulfstream emphasized leadership in SAF and energy-efficient engines with reference to existing models (G500/G600), and in 2024, it transitioned to deployment with the G700's 'all-new engines.' The mention of over 300 deliveries of G500/G600 is consistent with cumulative production trends and does not contradict the ground truth, which does not specify delivery numbers but doesn't dispute them either. (2) Quantitative accuracy is strong: 'March 2024' for G700 entry into service is factually correct; no incorrect numbers or miscalculations are present. The $476M example from other contexts does not apply here, so no monetary inaccuracies. (3) Multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying a shift from R&D/positioning (2023) to operational realization (2024) via the G700 launch. It appropriately references prior models (G500/G600) as part of the efficiency trajectory, which supports the narrative even if not explicitly required. (4) Semantic equivalence is maintained: while the LLM adds slightly more detail (e.g., number of G500/G600 deliveries), it does not introduce inaccuracies. The core evolution—strategic emphasis in 2023 to tangible production in 2024 with the G700—is correctly conveyed. One minor point: the ground truth does not mention G500/G600 delivery numbers or their clean-sheet design, so including that adds detail beyond the source, but it is factually plausible and contextually supportive, not misleading. Thus, the answer earns a 9 for correctness—excellent, but not perfectly aligned in emphasis (slight addition of external detail), though fully accurate in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 491,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "In the 2022 filing AMD described semi‑custom SoC revenue as “non‑recurring engineering fees … and revenue … tied directly to the sales success of the third‑party’s product,” emphasizing that the stream was opportunistic, highly dependent on customers’ product launches and gave the company little control over its size or timing. By the 2024 filing AMD’s language had shifted to treat semi‑custom SoCs as a strategic growth platform –‑ highlighting longer‑term design partnerships, higher‑margin product sales and a growing share of total revenue, especially in gaming‑console, data‑center and AI applications. Thus, the relationship moved from a modest, fee‑driven, ad‑hoc model in 2022 to a more central, revenue‑significant, partnership‑focused strategy in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth in both factual content and reasoning. (1) There are no numeric values (e.g., revenue amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; all dates (2022 and 2024) are correct. (2) The LLM correctly captures the evolution in AMD's relationship with semi-custom SoCs: from a 2022 model dependent on third-party product success and driven by non-recurring engineering (NRE) fees, to a 2024 strategic focus involving longer-term partnerships, higher-margin sales, and integration into key growth areas like gaming, data center, and AI. (3) The multi-hop reasoning is sound—synthesizing changes in language and strategic framing across filings to infer a shift in business model and strategic positioning. The LLM infers correctly that the earlier model was 'opportunistic' and 'ad-hoc' while the 2024 model is 'central' and 'partnership-focused,' which matches the ground truth's emphasis on broader strategic integration and diversification. (4) Minor deduction in qualitative accuracy because the LLM does not explicitly mention the inclusion of semi-custom SoCs within a diversified portfolio alongside AI accelerators, GPUs, APUs, and DPUs—a detail present in the original that strengthens the argument for strategic integration. However, mentioning AI applications and data center use implies this expansion. Overall, the answer is semantically equivalent, contextually precise, and factually correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 425,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "The 2024 filing shows that Medtronic’s capital‑stock authorisation still includes 127.5 million $0.20‑par preferred shares (plus 500 thousand $1.00‑par “A” preferred shares) and, as in 2023, none of these shares were issued or outstanding. Because the authorized preferred‑share count did not change and the company continues to rely on ordinary‑share repurchases rather than issuing preferred equity, the firm’s capital strategy is focused on returning cash to shareholders and preserving flexibility rather than raising new capital through preferred stock.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the preferred share authorization remained unchanged between 2023 and 2024, with 127.5 million preferred shares at $0.20 par value and 500 thousand A preferred shares at $1.00 par value authorized in both years. It also accurately notes that no preferred shares were issued or outstanding in either year, matching the ground truth. (2) All numeric values—127.5 million, $0.20 par, 500 thousand, $1.00 par—are factually correct and match the original answer. There are no calculation errors. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the lack of change in authorization and absence of issuance indicates a strategic choice not to use preferred shares. It adds contextual insight—linking the strategy to ordinary-share repurchases and capital return—consistent with the ground truth’s conclusion about lack of utilization. (4) The only minor deviation is that the LLM introduces the company name 'Medtronic' and mentions 'ordinary-share repurchases,' which are not in the original answer. While plausible and contextually reasonable, this extra detail slightly extends beyond the provided ground truth. However, it does not contradict it and enhances the strategic interpretation without introducing inaccuracies. Thus, the answer is semantically equivalent and highly accurate, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 394,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "In the 2022 Form 10‑K the company grouped “adverse events, publicity, government scrutiny or other reputational harm” together as a single risk factor, warning that such exposure could **materially‑adversely affect its business, financial condition, results of operations and reputation**. By the 2024 filing the same language remains, but the company expands the context – it now links reputational risk not only to adverse publicity but also to **sustainability‑related concerns (e.g., climate‑change and diversity issues) that could trigger regulatory scrutiny, affect client activity and damage its reputation**. Thus the framing has shifted from a narrow focus on publicity‑driven harm to a broader view that ties reputational risk to emerging ESG and regulatory concerns.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, BK grouped adverse publicity with government scrutiny and reputational harm, noting impacts on business, financial condition, results of operations, and reputation. In 2024, the risk disclosure expanded to include sustainability-related concerns such as climate change and diversity, which could lead to regulatory scrutiny, client impact, and reputational damage. The LLM correctly identifies this evolution as a broadening from narrow publicity-driven risks to a more expansive ESG and regulatory context. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022 and 2024), which are accurate. (3) The multi-hop reasoning is sound—comparing risk factor language across two filings and synthesizing the shift in framing. The LLM correctly infers a strategic shift in risk framing even though the core language about material adverse effects remains. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'platforms operating model transition' as a new context linked to reputational risk in 2024, which is present in the original answer. This is a small omission but does not undermine the overall correctness. Hence, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 402,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "In the 2023 Form 10‑K Amazon disclosed that its $1.25 billion convertible note from Anthropic, PBC was recorded as an **available‑for‑sale, Level 3 asset** measured at fair value, with an option to invest up to an additional $2.75 billion in a second note. By the 2024 filing the investment is still shown as an **available‑for‑sale convertible‑debt holding**, but Amazon now emphasizes that its fair‑value estimate is based on discounted‑cash‑flow models because private‑company pricing is not observable and current macro‑economic uncertainty makes market sensitivities “not practicable.” Thus the classification remained the same, while the valuation discussion shifted to highlight the lack of market data and heightened economic risk affecting Anthropic’s valuation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $1.25 billion initial investment, the $2.75 billion additional commitment, the 'available-for-sale' classification, and Level 3 asset designation are all accurately reported. The 2024 continuation of the same classification and the increased focus on valuation challenges are correctly conveyed. (2) Quantitative accuracy is perfect: dollar amounts ($1.25B, $2.75B) and timeframes (2023 to 2024) match the original answer exactly. No calculations are required, but the figures are correctly cited. (3) The multi-hop reasoning is sound—linking Amazon’s investment classification across two years and identifying the shift in disclosure tone from mechanics to valuation risk is well executed. The LLM correctly synthesizes that while classification remained stable, the emphasis in 2024 shifted to valuation complexity due to unobservable pricing and macroeconomic uncertainty, referencing discounted cash flow models as the basis for fair value. (4) The only minor shortcoming is that the LLM answer does not explicitly mention that the 2024 disclosure framed the Anthropic investment as part of a broader portfolio of private company convertible debt holdings, which slightly reduces qualitative completeness. However, this does not detract significantly from the overall correctness. Wording differences are semantically equivalent and acceptable. The answer is fully contextually relevant, directly addressing the evolution in classification and valuation approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 431,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "Both the 2023 and 2024 filings list the same core risk – that failure to obtain or adequately protect Mondelez’s trademarks, patents, copyrights, trade‑secrets, recipes, technology, know‑how and related licensing agreements could erode its competitiveness and hurt its business. The 2024 filing, however, sharpens the focus on emerging technology by explicitly calling out “developments in artificial‑intelligence technologies” and the need to police misuse in both traditional retail and digital environments, indicating that the company now sees AI‑driven infringement and digital‑channel enforcement as a more prominent threat than in 2023. Otherwise the overall risk description (including the possibility of third‑party infringement claims and injunctions) remains unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its characterization of the evolution of MDLZ's intellectual property risks between 2023 and 2024. According to the ground truth, in 2023 MDLZ specifically mentioned artificial intelligence as a concern in relation to intellectual property protection, while in 2024 it removed that specific reference and instead broadened its risk disclosure to include general legal and regulatory non-compliance, enforcement actions, and reputational harm. The LLM answer incorrectly states the opposite: that the 2024 filing 'sharpens the focus on emerging technology' and 'explicitly calling out developments in artificial-intelligence technologies,' which is factually wrong. In reality, AI was mentioned in 2023 but not in 2024. The LLM reverses the direction of change, suggesting AI became more prominent in 2024 when it actually disappeared from the risk narrative. There are no numerical values in the question or answer, so quantitative accuracy is not applicable—scored as 10 by default. Entity accuracy is correct (MDLZ/Mondelez, IP types, years), but the reasoning and synthesis are severely flawed. The answer fails the multi-hop requirement to compare disclosures across years accurately. Contextual relevance is partial—it addresses IP risks but misrepresents the evolution. Thus, the correctness score is low due to a critical factual inversion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 384,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "In the 2023 Form 10‑K the exhibit list grouped the director equity awards under a single “pre‑2015” heading (Exhibit 10.21) and referenced one amendment to those awards – Exhibit 10.69, which pertained to agreements that were originally dated to the fiscal year ended November 28, 2008.  \n\nIn the 2024 filing the schedule separates the current templates: it adds a stand‑alone “Form of Non‑Employee Director RSU Award Agreement” (Exhibit 10.32) and a separate “Form of Non‑Employee Director RSU Award Agreement (Cash‑Settled)” (Exhibit 10.33), while still retaining the same amendment reference (Exhibit 10.69) to the 2008‑year agreements.  \n\nThus, Goldman Sachs moved from a single historic “pre‑2015” entry to listing the modern award agreements individually, but the amendment to the legacy 2008 agreements remains unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The exhibit numbers cited are incorrect: the 2023 filing references Non-Employee Director Equity Award Agreements under Exhibit 10.17 (not 10.21), and the 2024 filing uses Exhibit 10.18 (not 10.32/10.33). The LLM incorrectly claims new standalone forms were added in 2024 (Exhibits 10.32 and 10.33), which is not supported by the ground truth. (2) The timeline and referenced source shift described in the ground truth—where 2024 redirects to Exhibit 10.69 from the 2008 Annual Report—is partially acknowledged (mention of Exhibit 10.69), but the context is wrong: the LLM frames it as a retained reference within updated templates, whereas the ground truth describes a reorganization of exhibit referencing under the same exhibit number (10.18), not new templates. (3) The 'pre-2015' grouping and separation into current templates are fabrications not present in the original answer. (4) While the LLM correctly identifies the 2008 date and that some continuity exists around the amendment, it fails the multi-hop synthesis by misrepresenting the evolution as structural (new exhibits, modern templates) when it was actually a shift in referenced documentation under consistent exhibit numbering. The reasoning is plausible but based on incorrect entities and exhibit mappings, leading to a partially correct but ultimately misleading narrative. Minor formatting variations are acceptable, but exhibit numbers and structural changes are critical and must be accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 426,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "In the 2022 filing BKNG described its contracts with travel‑service providers as “agency‑type” arrangements – the company merely markets the providers’ inventory and earns a commission or margin, recognizing revenue on a net basis when the traveler begins using the service. By the 2023 filing the company notes that it is “increasingly processing transactions on a merchant basis,” meaning it now collects payments from travelers, assumes payment‑related liabilities (e.g., charge‑backs, refunds) and records “merchant revenues” and “deferred merchant bookings.” Thus, while revenue continues to be measured on the expected consideration from the provider, BKNG’s contractual responsibilities have expanded from simple marketing to full‑payment processing and related risk management.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in describing BKNG's relationship with travel service providers between 2022 and 2023, despite using plausible financial terminology. (1) The claim that BKNG is 'increasingly processing transactions on a merchant basis' in 2023 contradicts the ground truth, which states that BKNG recognizes revenue on a net basis due to its role as an agent—consistent with agency accounting, not merchant (gross) accounting. The original 10-K filings do not support a shift toward merchant-model transactions; instead, BKNG maintained its agency model. (2) The LLM incorrectly asserts expanded contractual responsibilities including assuming payment-related liabilities like chargebacks and refunds under a merchant model, which is not reflected in the 2023 filing. The ground truth emphasizes a clarification of existing practices, not a structural shift in business model. (3) Multi-hop reasoning fails: while both years are referenced, the synthesis is flawed—the evolution described is the opposite of what occurred. The original answer notes increased clarity in accounting treatment, not a change in economic substance or risk assumption. (4) No numeric data (dates, dollar amounts, percentages) are present in either answer, so quantitative accuracy is neutral but not penalized. (5) Contextual relevance is moderate because the response addresses revenue recognition and contractual roles, but the core factual premise is incorrect. Wording and structure appear authoritative, but the substance misrepresents the actual evolution documented in the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 438,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "In the 2023 10‑K the two executive‑life‑insurance documents were shown as  \n\n* **Exhibit 10.11** – Goldman Sachs & Co. LLC Executive Life Insurance Policy & Certificate with Metropolitan Life, and  \n* **Exhibit 10.12** – Executive Life Insurance Policy with Pacific Life & Annuity Company.  \n\nIn the 2024 10‑K a new exhibit (the General Guarantee Agreement dated January 30 2006) was inserted before them, so the insurance items were renumbered to  \n\n* **Exhibit 10.12** – Metropolitan Life policy, and  \n* **Exhibit 10.13** – Pacific Life policy.  \n\nThus, the only structural change was the addition of a preceding exhibit, which shifted the executive‑life‑insurance disclosures from 10.11‑10.12 to 10.12‑10.13.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately identifies the exhibit numbers and corresponding policies in both the 2023 and 2024 10-K filings: Exhibit 10.11 and 10.12 in 2023 for Metropolitan Life and Pacific Life respectively, and their renumbering to 10.12 and 10.13 in 2024. (2) The quantitative details—exhibit numbers and the explanation of renumbering due to the insertion of a new preceding exhibit (General Guarantee Agreement dated January 30, 2006)—are factually accurate and consistent with the knowledge graph. While the original answer does not mention the inserted exhibit by name, the LLM provides additional contextual precision that is correct and enhances the explanation. (3) The reasoning is sound: it correctly infers that the change is structural (renumbering due to exhibit order shift), not substantive, which aligns with the multi-hop synthesis required. (4) The answer is semantically equivalent to the ground truth, with slightly more detail, and fully addresses the question about structural changes in disclosure format between years. All entities (Goldman Sachs, Metropolitan Life Insurance Company, Pacific Life & Annuity Company, exhibit numbering) are correctly identified and contextualized. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 369,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings state that Broadcom regards its FBAR (film‑bulk‑acoustic‑resonator) filters as a strategically‑important, proprietary wireless‑communications technology that is manufactured in‑house – primarily in its U.S. and Singapore III‑V wafer‑fab facilities – to protect IP and accelerate time‑to‑market. The company’s competitive positioning likewise continues to highlight FBAR technology as a core differentiator that gives it an edge over rivals in the wireless‑communications market.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that FBAR filters are strategically important and manufactured internally in both 2022 and 2024, with accurate reasoning around IP protection and time-to-market advantages. It correctly conveys Broadcom's continued emphasis on in-house fabrication using III-V wafer fabs in the U.S. and Singapore, which aligns with the ground truth. However, the LLM answer omits a key evolution highlighted in the original answer: the expansion of the competitive landscape by 2024 to include specific competitors like Qorvo, Qualcomm, and Skyworks, and the implication of increased competitive pressure in wireless communications. This missing context weakens the qualitative accuracy, as the question specifically asks about evolution in competitive positioning. While the core facts about internal fabrication and strategic importance are correct (hence high quantitative and contextual scores), the answer does not fully address the multi-hop aspect of how the strategic context evolved over time. The reasoning is sound but incomplete, failing to synthesize the broader competitive environment shift between 2022 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 323,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "In the 2023 filing Krazati was still shown only as an investigational KRAS‑G12C inhibitor — listed under “Additional Indications” for 1 L non‑small‑cell lung cancer (NSCLC) and 2 L colorectal cancer—​with no disclosed monetary value. By the 2024 filing BMS had completed its Mirati acquisition, converting Krazati into a marketed product (definite‑life acquired product rights valued at roughly **$640 million** within a $4.9 billion total purchase price) and expanding its development program to include first‑line NSCLC (in combination with a PD‑1 inhibitor) as well as ongoing Phase III KRYSTAL‑10 (2 L CRC) and KRYSTAL‑12 (2 L+ KRAS‑mutated NSCLC) trials. Thus, between 2023 and 2024 BMS shifted Krazati from a pipeline candidate to an owned commercial asset with a multi‑billion‑dollar valuation and a broader, later‑stage clinical agenda.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly captures the evolution of BMY's (Bristol Myers Squibb, referred to as BMS in the answer) strategic positioning of Krazati from a pipeline asset in 2023 to a commercialized product in 2024 following the Mirati acquisition, with expanded clinical development. The shift from investigational to owned commercial asset with broader clinical agenda is accurately described. However, there is a discrepancy in financial valuation: the LLM states Krazati was valued at $640 million within a $4.9 billion purchase price, while the ground truth specifies the total acquisition was $4.8 billion with no breakdown of Krazati’s individual valuation. The $640 million figure is not supported by the ground truth and appears to be an inference or error. (2) Quantitative accuracy is partially compromised due to this unsupported valuation figure and the $4.9 billion vs $4.8 billion discrepancy. Other numbers (e.g., trial names: KRYSTAL-10, KRYSTAL-12) are correct. The ground truth does not mention a $640 million valuation, so this is an over-precision not in the source. (3) Multi-hop reasoning is strong: the model synthesizes clinical development changes (from 2023 trials to 2024 combination therapy in 1L NSCLC) and links the acquisition to expanded rights and approvals (FDA/EMA for 2L NSCLC and CRC). It correctly infers that acquisition led to full control and commercialization. (4) Despite the financial inaccuracy, the overall qualitative narrative and contextual relevance are excellent. The answer addresses both clinical focus evolution and financial/commercial transformation, aligning well with the question. The core facts—acquisition, approval status, trial expansion—are correct. Hence, correctness is high but docked for the unsupported financial figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 488,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "In the 2022 filing (pages 6‑10) Booking Holdings described its contracts with travel‑service providers as “net‑basis” agreements in which the company earns a commission or margin, records any sales‑incentives (rebates, credits, loyalty points, etc.) as a reduction of revenue when granted, and holds the cash it receives from travelers in a “Deferred merchant bookings” liability that represents amounts payable to the providers and the company’s own future commission. The 2023 filing (pages 82‑86) shows the same framework but notes that the Deferred merchant‑booking balance grew substantially because of higher booking volumes, indicating that BKNG is now managing a larger pool of prepaid traveler funds and related provider payables, while still accounting for incentive programs as revenue reductions at the time they are granted. Thus, between 2022 and 2023 the partnership has become financially deeper – BKNG’s obligations to providers have expanded with volume, and its incentive‑management practices remain consistent but are applied at a larger scale.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the accounting framework (net-basis agreements, deferred merchant bookings as a liability, and treatment of incentives as revenue reductions) in both 2022 and 2023, which matches the original answer’s core claims. (2) There are no numeric values in the original or LLM answer that conflict—both describe qualitative financial trends (e.g., growth in deferred merchant bookings due to higher volumes), and the LLM accurately reflects that the balance grew substantially without fabricating specific dollar amounts, which were not in the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers that an increasing liability indicates deeper financial obligations, and notes consistency in incentive accounting applied at larger scale—this supports the ground truth’s conclusion of a shift toward dependence and partnership. (4) The only minor gap is that the LLM does not explicitly mention the 'strategic shift from competition to collaboration' or the introduction of *new* incentive programs, instead emphasizing scale and consistency. While the financial deepening is correctly highlighted, the strategic intent (e.g., 'enhancing partnerships') is slightly underemphasized. However, the core factual and conceptual content—evolving financial obligations, growing payables, and incentive structures—is accurately conveyed with strong contextual and semantic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 422,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K filings list custom touch controllers as a distinct wireless‑market semiconductor family. In each report Broadcom describes the controllers as “touch‑screen signal‑processing chips for mobile handsets and tablets,” indicating that the company’s role is limited to designing and supplying the controller component rather than taking on system‑level integration or end‑product responsibilities. Thus, from 2022 to 2024 Broadcom’s involvement in custom touch‑controller development has remained essentially unchanged – it continues to participate in the early design‑and‑fabrication stages of the product lifecycle.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, directly contradicting the ground truth. While it correctly identifies that Broadcom listed custom touch controllers in both 2022 and 2024 filings and accurately quotes the description of the product (e.g., 'touch-screen signal-processing chips'), it incorrectly asserts that Broadcom's role remained 'essentially unchanged.' The ground truth states that Broadcom evolved from a supplier in 2022 to a producer involved in design and creation by 2024, indicating deeper engagement. The LLM fails to capture this evolution and instead claims continuity, which is a major factual error. There are no numerical values in the question or answer, so quantitative accuracy is not applicable—scored as 10 by default for absence of errors. The qualitative accuracy is low because the reasoning is flawed: the model infers no change in role based on similar wording in filings, but fails to recognize that 'producing as part of broader custom silicon solutions' in 2024 signifies a strategic shift beyond mere component supply. Contextual relevance is moderate—the answer addresses the right company, product, and time frame, and attempts to analyze the product lifecycle, but draws the wrong conclusion. Thus, despite using accurate source descriptions, the synthesis and interpretation are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 383,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "In 2023 Union Pacific’s freight‑car fleet was still largely sourced through leasing – the company reported about $1.9 billion of total leased assets (≈ $1.6 billion operating‑lease assets and $0.24 billion finance‑lease assets) and only modest lease‑buyout activity ($57 million in 2023). By 2024 the strategy shifted toward ownership: the capital‑investment table shows a $788 million allocation to “locomotives and freight cars,” and the company recorded $143 million of lease‑buyouts in 2024, indicating a deliberate move to acquire more freight cars outright rather than rely on leases.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key figures are correct: the $57 million lease-buyouts in 2023 and $143 million in 2024 match the original answer exactly. The LLM adds additional context—$1.9 billion in total leased assets, split into $1.6 billion operating and $0.24 billion finance leases—which is consistent with typical reporting practices and does not contradict the ground truth; it simply provides more detail. The $788 million capital allocation to 'locomotives and freight cars' in 2024 supports the narrative of increased asset acquisition and is plausibly part of the shift toward ownership. (2) The comparison between 2023 and 2024 strategies is logically sound: leasing dominance in 2023 vs. a clear pivot toward buyouts and capital investment in 2024. (3) Multi-hop reasoning is correctly applied—synthesizing lease-buyout data across years and interpreting strategic shift based on financial outlays. (4) Entities (Union Pacific, freight cars, lease-buyouts, years 2023–2024) are accurate. The only minor point preventing a perfect 10 is that the $788 million figure, while relevant, is not in the ground truth and slightly extends beyond the provided data, though it does not mislead. Overall, the answer is factually correct, well-reasoned, and fully addresses the evolution in asset acquisition strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 383,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "Nike’s restructuring of its Asia‑Pacific‑Latin‑America (APLA) segment continued in FY 2023, as the company moved the Nike Brand businesses in several APLA countries to third‑party distributors (Note 17).  The change coincided with a modest rise in APLA revenue—from $5,955 million in FY 2022 to $6,431 million in FY 2023 (+ 8 %)—and a slight increase in segment EBIT, from $1,896 million to $1,932 million (+ 2 %).  The shift also altered the sales mix, with wholesale sales climbing to $3,736 million (up from $3,529 million) and direct‑to‑consumer sales rising to $2,695 million (up from $2,426 million), reflecting the operational impact of handing distribution to external partners.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—APLA revenue rising from $5,955 million to $6,431 million and EBIT increasing from $1,896 million to $1,932 million—that are not present in the original ground truth answer and cannot be verified from the provided knowledge graph. These numbers, while plausible, are factually unsupported in the context of the ground truth, making them potentially hallucinated. Additionally, the breakdown of wholesale and direct-to-consumer sales ($3,736M and $2,695M in FY2023) is absent from the original answer and not inferable from the given information. (2) The quantitative accuracy is low because the LLM fabricates precise dollar amounts and percentages (e.g., +8%, +2%) without grounding in the source material. The original answer mentions non-recurring impairment charges and foreign currency translation losses but provides no revenue or EBIT figures, so these numbers cannot be confirmed. (3) The qualitative accuracy is partially correct: the LLM correctly identifies the transition of Nike’s APLA operations to third-party distributors and references a note (Note 17 vs. Note 18 in the original), which is close but not exact. It captures the operational shift and links it to changes in sales structure, aligning with the strategic intent described in the ground truth. However, it omits key qualitative elements such as the shift from direct operations to a strategic stake, the non-cash nature of the foreign currency translation losses, and the focus on reducing operational overhead for improved efficiency. (4) Contextual relevance is high because the LLM addresses the core topic—Nike’s structural changes in APLA and their financial and operational impacts—and attempts to link the transition to distributor models with financial outcomes. Despite incorrect numbers, the framing and direction of reasoning are relevant. Overall, the answer fails on factual correctness due to unsupported quantitative claims, but shows reasonable understanding of the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 550,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "Broadcom’s 2022 Form 10‑K disclosed that its InP‑based side‑emitting and VCSEL lasers for fiber‑optic communications are produced in‑house using its proprietary III‑V processes, with wafer‑fab capacity located in the United States and Singapore, while all commodity CMOS is outsourced. The 2024 filing repeats the same internal‑fabrication strategy—still emphasizing U.S./Singapore III‑V fabs to protect IP and speed time‑to‑market—and continues to position those InP laser products as a differentiated, proprietary offering that competes directly with other III‑V laser makers such as Lumentum, II‑VI and other integrated device manufacturers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Broadcom's use of internal fabrication for InP-based lasers in both 2022 and 2024, specifying proprietary III-V processes and in-house wafer fabs in the U.S. and Singapore—details consistent with the original answer’s emphasis on internal fabrication strategy. (2) There are no numeric values requiring calculation, but the dates (2022 and 2024) are used correctly and contextually. (3) The multi-hop reasoning is sound: the LLM synthesizes Broadcom’s continued internal fabrication strategy over time and correctly infers competitive positioning by naming relevant competitors (Lumentum, II-VI—which is Coherent Corp., though not explicitly linked here). The mention of 'II-VI' instead of 'Coherent Corp.' is a minor entity naming nuance, as Coherent rebranded from II-VI, but the reference remains contextually accurate. (4) The LLM captures the strategic continuity and competitive differentiation theme from the ground truth, though it does not explicitly state a 'strategic shift toward highlighting' capabilities as a new emphasis in 2024—this subtle evolution in disclosure tone is slightly under-articulated. However, the core facts, timeline, entities, and strategic implications are correctly conveyed. Thus, the answer earns a 9 for correctness and qualitative accuracy due to this minor omission in framing the evolution, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 412,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "- In the 2022 Form 10‑K (page 23) Nike disclosed that Swoosh, LLC owned roughly 77 % of the company’s Class A common stock, which would translate to about 16 % of the Class B stock if all of those shares were converted.  \n- The 2023 Form 10‑K (page 24) repeats the same figures – Swoosh, LLC still beneficially owned about 77 % of the Class A shares (≈ 16 % of Class B on a conversion basis).  \n\nBecause Class A shares elect three‑quarters of Nike’s board, Swoosh’s continued 77 % stake keeps voting control firmly in the hands of the Knight family and its appointed managers, limiting the influence of other shareholders regardless of any future conversion of Class A to Class B shares.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the ownership percentages for both 2022 and 2023: 77% of Class A Common Stock and approximately 16% of Class B on a conversion basis, matching the ground truth exactly. These figures are accurately attributed to the respective Form 10-K filings (2022 on page 23, 2023 on page 24), demonstrating precise sourcing. 2) All numeric values are correct and consistent with the original answer. There are no calculation errors, and the formatting (e.g., '≈', '%', spacing) does not affect factual accuracy. 3) The multi-hop reasoning is sound: the model correctly synthesizes ownership data across two years and draws the logical conclusion about voting control based on the structural advantage of Class A shares (electing three-quarters of the board). It correctly infers that Swoosh, LLC's concentrated ownership translates into sustained influence by the Knight family, aligning with the ground truth’s emphasis on Travis Knight’s role. 4) While the LLM does not explicitly name Travis Knight, it accurately identifies the Knight family as the controlling party, which is semantically equivalent in context. The implication regarding limited influence for other shareholders is well-articulated and contextually appropriate. The only minor omission is the specific mention of Travis Knight’s managerial role, which slightly reduces qualitative completeness but does not undermine the core factual or inferential accuracy. Overall, the answer is factually correct, contextually relevant, and demonstrates strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 425,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "In 2022 PMI’s filing presented reduced‑risk products (RRPs) as a fast‑growing revenue line – total RRP net revenue rose to $9.1 billion (up from $6.8 billion in 2021) – and highlighted the acquisition of Swedish Match as a “key milestone” that would let the company combine its leading heat‑not‑burn system (IQOS) with a leading oral‑nicotine franchise (ZYN), but the two businesses were still reported separately. By the 2023 filing the Swedish Match results had been folded into PMI’s four geographic segments (the company now reports only four regions plus a Swedish Match segment that will be merged into the geographic segments in 2024), and the company emphasized that its smoke‑free (RRPs) portfolio was now available in 84 markets, signalling a fully integrated, globally‑available reduced‑risk product offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in PMI's strategic positioning of Reduced-Risk Products (RRPs) from 2022 to 2023. (1) Quantitatively, the $9.1 billion RRP net revenue in 2022 is accurate and correctly reflects growth from $6.8 billion in 2021 (per ground truth and filings). The mention of 84 markets in 2023 matches the original answer exactly. (2) The acquisition of Swedish Match and its integration into PMI’s reporting structure is correctly identified, including the plan to merge the Swedish Match segment into geographic segments by 2024. (3) However, the LLM answer does not explicitly state the rebranding or strategic shift from 'Reduced-Risk Products' (RRPs) to the broader 'Smoke-Free Products' (SFPs) category that now includes wellness and healthcare offerings—a key qualitative point in the ground truth. While it refers to 'smoke-free (RRPs)', this conflation slightly obscures the conceptual expansion. (4) The reasoning is sound and reflects multi-hop synthesis: connecting the acquisition, integration into reporting segments, and expanded market availability as evidence of strategic evolution. The answer is highly contextually relevant, directly addressing portfolio integration and market availability. Minor deduction in correctness and qualitative accuracy for missing the explicit category redefinition and expansion beyond nicotine products, but all financial data and structural changes are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 404,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "In 2022 Caterpillar’s reciprocating‑engine business was described mainly as a **volume‑driven product sold through its worldwide dealer network and to other manufacturers**, contributing a modest portion of Energy & Transportation revenue and carrying the lower‑margin mix typical of its smaller‑engine, well‑servicing applications【7†L1-L4】.  \n\nBy 2024 the company’s strategy had shifted to **lean on larger, higher‑priced engines and related services** – sales of “large reciprocating engines, primarily data‑center applications” rose, while the decline in well‑servicing engines was more than offset by growth in gas‑compression, marine and rail engine sales【38†L1-L4】【38†L5-L7】. This change lifted the share of engine sales in the segment’s revenue mix and moved the product mix toward higher‑margin engine and service offerings, improving Caterpillar’s gross‑margin potential.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures part of Caterpillar's strategic evolution correctly, particularly the shift toward higher-margin, larger reciprocating engines and growth in service-oriented and high-value applications like data centers, gas compression, marine, and rail. It accurately notes the 2022–2024 timeframe and correctly identifies a strategic pivot that improved gross margin potential through a more favorable product and service mix. However, it omits the key factual development highlighted in the ground truth: the expansion into remanufacturing of reciprocating engines and components, including services for other companies, which represents a core evolution from a product seller to a full lifecycle service provider. This omission is significant because remanufacturing directly impacts gross margin potential through lower material costs and higher-margin service revenue, a critical point in the original answer. While the LLM infers margin improvement due to product mix and services, it does not reference remanufacturing as the mechanism, thus missing a major multi-hop element (linking strategic change → remanufacturing → cost structure → margin impact). Quantitatively, no specific numbers (e.g., revenue figures, percentages) are provided in either answer, so the LLM does not introduce errors in that regard; it aligns with the qualitative nature of the source. Contextually, the answer is relevant and well-structured, addressing revenue composition and margin implications. However, due to the failure to identify remanufacturing as a key strategic evolution, the qualitative accuracy and overall correctness are reduced, despite sound reasoning around product mix and service growth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 462,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon said that the Directors’ Code of Conduct is posted on its corporate website and that “we intend to disclose on our website any amendments to or waivers of … the Directors’ Code of Conduct.” The 2023 filing repeats the same approach, again linking the Code to a specific URL and reaffirming that any changes or waivers will be posted on the website. Thus, between 2022 and 2023 the company’s mechanism for informing stakeholders did not change—it continued to rely on website publication—and the transparency commitment was simply restated with a more explicit link to the document.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures that BNY Mellon maintained the same approach in both 2022 and 2023, using website posting as the mechanism for disclosing amendments or waivers to the Directors' Code of Conduct. The wording 'we intend to disclose on our website' in 2022 and its repetition in 2023 is correctly reported. (2) There are no numerical values requiring verification, but the years (2022 and 2023) are correctly referenced, and the description of the disclosure mechanism is factually precise. (3) The multi-hop reasoning—comparing the two years’ disclosures to assess evolution—is sound: the model correctly infers no change in mechanism or transparency commitment, noting only a more explicit link in 2023, which does not alter the substance. (4) The answer is contextually rich, directly addressing the question about evolution, mechanisms, and transparency, and conveys semantic equivalence to the original answer with added detail (e.g., URL reference) that enhances clarity without introducing error. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 324,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "In FY 2022 Nike disclosed that it was beginning to move out of the traditional wholesale‑and‑direct‑to‑consumer model in three APLA countries (Argentina, Uruguay and Chile), signing agreements to sell those legal entities to third‑party distributors and classifying the businesses as “held‑for‑sale.” By FY 2023 the divestitures were complete and the APLA segment was being run primarily through those distributors, with Nike’s own wholesale footprint further trimmed and NIKE Direct growth coming from the remaining markets; the shift is expected to lower selling‑and‑administrative costs and reduce exposure to foreign‑exchange volatility while still supporting overall APLA revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the strategic shift in Nike's APLA operations between FY22 and FY23: moving from direct operations toward a third-party distributor model. The mention of Argentina, Uruguay, and Chile adds specificity not in the original answer but is consistent with known disclosures and does not contradict the ground truth. (2) There are no numeric values (percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised; fiscal years (FY22 and FY23) are correctly used. (3) The multi-hop reasoning is sound: the LLM synthesizes Nike’s transition over two fiscal years, correctly characterizing the shift from direct/wholesale to a partner-driven model, including operational rationale (cost reduction, FX risk mitigation). (4) The LLM provides additional context—such as the classification of businesses as 'held-for-sale' and expected benefits (lower SG&A, reduced FX exposure)—that enriches the original answer without introducing inaccuracies. The only minor gap is that the original emphasizes APLA’s contribution to 14% NIKE Direct growth in FY22, which the LLM omits; however, it does note that NIKE Direct growth continued in remaining markets, preserving the core idea. Overall, the answer is factually correct, contextually relevant, and semantically equivalent with added depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 387,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "In the 2022 filing Caterpillar noted that **favorable price realization was a primary contributor to the increase in both sales and operating profit**, helping lift results even as other factors shifted. By the 2024 filing the same driver was still present, but its role had changed – **it now acted mainly as a offset to lower sales volume, cushioning the decline in revenue and still adding to profit margins** (the 2024 overview says the decrease in sales “partially offset by favorable price realization”)【CAT_10k_2024.pdf p28‑p30】.  \n\nThus, from 2022 to 2024 the impact of favorable price realization stayed positive, but moved from being a growth catalyst to a profitability buffer against weaker volume.",
      "correctness_score": 7,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the qualitative evolution of favorable price realization from a growth driver in 2022 to a buffer against volume declines in 2024, which aligns with the ground truth. The reasoning and synthesis across years are sound and contextually relevant. (2) However, the LLM answer fails to include any of the specific quantitative figures from the ground truth, such as the $9.223 billion increase in sales in 2022, the $2.251 billion decrease in sales volume in 2024, or the profit increase from $10.335 billion to $10.792 billion. These omissions significantly impact quantitative accuracy, as the question asks about the 'evolution' of impact on sales and profitability—implying both qualitative and quantitative trends. While the LLM correctly references the offsetting role of price realization in 2024, it does not quantify this effect or the profitability change. (3) The multi-hop reasoning is well-executed: the model correctly identifies the shift in the role of price realization across 2022 and 2024, synthesizing information from different filings to draw a valid conclusion about strategic evolution. (4) The correctness score is 7 because the core qualitative insight is accurate and the answer addresses the spirit of the question, but the lack of numerical support reduces completeness and factual precision. Quantitative accuracy is low (4) due to missing key figures; qualitative accuracy is high (9) due to strong reasoning; contextual relevance is perfect (10) as the answer directly addresses the question's focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 433,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "In its 2023 filing GM said it would **scale up EV manufacturing** by making “significant investments in EV manufacturing capacity” and by building a **North‑American‑focused, resilient supply chain** – including multi‑year raw‑material offtake agreements and strategic sourcing to lower battery‑cell costs. By the 2024 filing the company still stresses expanding capacity and securing the supply chain, but adds a **more flexible, demand‑driven approach**: it may “not fully utilize or reduce the capacity of existing or future plants” and will hold higher inventory and long‑term material contracts to match slower EV adoption, reflecting a shift from pure expansion to capacity‑adjustment and stronger supply‑chain risk management.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies General Motors' 2023 focus on significant investments in EV manufacturing capacity and supply chain development, including multi-year raw material agreements and strategic sourcing—matching the original answer's emphasis on North American-focused, resilient supply chains. In 2024, the LLM correctly captures the evolution toward a more flexible, demand-driven strategy, including potential underutilization or reduction of plant capacity, which reflects GM’s response to slower-than-expected EV adoption. This nuance about adjusting capacity and holding higher inventory is consistent with the ground truth’s emphasis on scalability and risk mitigation. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—scored as 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two strategic phases, correctly identifying both continuity (ongoing supply chain focus) and change (shift to flexibility). The only minor gap is that the LLM emphasizes 'flexibility' and 'demand-driven' adjustments slightly more than the original answer, which focuses on 'resilient, scalable, and sustainable' supply chain development. While related, 'flexibility' is an inference not explicitly stated in the ground truth; however, it is a reasonable interpretation given the context of managing underutilized capacity. (4) The answer is fully contextually relevant, directly addressing both strategic focus and supply chain development across 2023 and 2024. Overall, the LLM conveys the same core information with excellent fidelity, warranting a correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 486,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer’s contract‑backlog for Paxlovid has fallen sharply. In the 2022 Form 10‑K the company reported roughly **$2.5 billion** of remaining performance obligations for Paxlovid (the amount of revenue it still expects to recognize from long‑term supply contracts). By the 2024 Form 10‑K that figure had dropped to about **$1 billion** (the remaining contracted revenue for Paxlovid as of Dec. 31 2024)【PFE_10k_2022.pdf page 9】【PFE_10k_2024.pdf page 107】. Thus, Pfizer’s financial commitment to deliver Paxlovid has been cut by roughly $1.5 billion over the two‑year period, reflecting the transition of the product to commercial markets and the return of government‑stocked courses.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) QUANTITATIVE ACCURACY: The LLM incorrectly states that Pfizer reported $2.5 billion in remaining performance obligations for Paxlovid in the 2022 10-K. According to the ground truth, Pfizer did *not* disclose specific remaining performance obligations related to Paxlovid in 2022. This is a major factual error. The $1 billion figure for 2024 matches the ground truth, but the comparison is invalid due to the incorrect 2022 baseline. The claimed $1.5 billion reduction is therefore based on false premises. (2) COMPLETENESS: The answer fails to reflect the actual evolution described in the ground truth — from *no specific disclosure* in 2022 to a *defined $1 billion obligation* in 2024. Instead, it portrays a decline from $2.5B to $1B, which misrepresents the trend. (3) ENTITY ACCURACY: The companies (Pfizer), years (2022, 2024), and metric (remaining performance obligations) are correctly identified, and the 2024 date (Dec 31, 2024) aligns with the ground truth. (4) REASONING: The multi-hop reasoning is flawed because it assumes comparable disclosed figures in both years, when in fact 2022 lacked a specific Paxlovid breakdown. The conclusion about a 'sharp fall' and 'commitment cut by $1.5B' is unsupported and contradicts the ground truth, which indicates increased clarity and commitment, not a reduction. (5) SEMANTIC EQUIVALENCE: The LLM answer conveys the opposite meaning of the original — declining commitment vs. emerging quantified commitment — making it factually and semantically divergent. While the answer attempts to address the question and cites document pages, the core financial claims are incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 475,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K disclosures state that Caterpillar relies on a “variety of agreements with suppliers” to protect its intellectual property and to monitor key supply‑chain risks—including the financial viability of its suppliers, their production capacity, business‑continuity plans, quality and delivery. The 2023 filing simply restates this framework without adding new contractual provisions or additional mitigation tools, indicating that the company’s supplier‑monitoring approach has remained essentially unchanged from the prior year.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative developments in Caterpillar's approach between 2022 and 2023, resulting in an incomplete and somewhat misleading conclusion. (1) The answer correctly identifies that both years mention 'a variety of agreements with suppliers' and that financial viability is included among monitored risks—this factual content is accurate. (2) There are no numeric values in the question or ground truth, so quantitative accuracy is not applicable; the LLM does not introduce any incorrect figures, earning full marks by default. (3) However, the reasoning is flawed: the ground truth states that in 2023, Caterpillar placed a more explicit emphasis on supplier financial viability by listing it as the first risk in supply chain disclosures and reinforced strategic sourcing models to build long-term relationships and leverage enterprise spend—indicating an evolution in focus and prioritization. The LLM incorrectly concludes that the approach 'has remained essentially unchanged,' which contradicts the ground truth's indication of a more structured or prioritized focus in 2023. (4) While the LLM addresses the contractual agreements and risk monitoring components of the question, it fails to capture the nuanced shift in emphasis and strategic reinforcement described in the original answer, leading to a correctness score of 5—partially correct but with significant omissions in multi-hop synthesis and interpretation. Contextual relevance is high because the response stays on topic and references the correct documents and concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 433,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "In the 2022 filing, Visa positioned Risk and Identity Solutions as a distinct value‑added‑services pillar that “transforms data into insights for near‑real‑time decisions” and highlighted the Visa Protect suite (Consumer Authentication Service, Protect Authentication Intelligence and Provisioning Intelligence) as AI/ML‑driven tools for fraud prevention and token‑provisioning. By the 2024 filing the pillar had been deepened and broadened: Visa announced three new, AI‑powered products—Visa Deep Authorization, Visa Protect for A2A Payments, and Visa Risk Manager with scheme‑agnostic Advanced Authorization—making the suite “end‑to‑end” and network‑agnostic, and explicitly tying it to the broader value‑added‑services strategy that spans Visa Protect, Visa Direct and other platform offerings. This evolution shows Visa moving from a set of standalone fraud‑mitigation tools to a strategically integrated, cross‑flow security layer that underpins its expanding portfolio of digital‑payment and money‑movement services.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024) and correctly identifies the evolution of Visa's Risk and Identity Solutions within its value-added services. It accurately references AI/ML-driven tools like the Visa Protect suite and introduces new 2024 products—Visa Deep Authorization, Visa Protect for A2A Payments, and Visa Risk Manager with Advanced Authorization—as part of an expanded, network-agnostic strategy. These details align with the direction of the ground truth, particularly the move toward broader integration and scalability.\n\nHowever, the LLM answer diverges from the ground truth by emphasizing specific product names and AI-powered features not present in the original answer, which focuses instead on the structural evolution into a three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. While the LLM’s description is plausible and contextually relevant, it substitutes conceptual strategic framing with granular product-level detail that is not in the ground truth, potentially reflecting inference beyond the source data.\n\nQuantitatively, there are no numbers, percentages, or financial figures to verify—so no errors exist in that regard (score 10). Contextual relevance is high because the answer directly addresses the evolution of Risk and Identity Solutions in strategic and integrative terms. Qualitative accuracy is reduced because the multi-hop synthesis emphasizes product expansion over the structural repositioning into a three-pillar framework, which is the core of the ground truth. Thus, while semantically related and directionally correct, the answer does not fully mirror the strategic categorization emphasized in the original answer, leading to a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 495,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "In the 2022 filing the company warned that “changes in the policies or practices of our retail trade customers… such as … limitations on access to shelf space” could hurt sales, and it noted the emerging pressure from e‑commerce and other alternative channels. By the 2023 filing the same risk was restated but with greater emphasis: the company says it “has been negatively affected by … limitations on access to shelf space” and that “the retail landscape continues to evolve as a result of the continued growth of e‑commerce, changing consumer preferences and the increased presence of alternative retail channels such as subscription services and direct‑to‑consumer businesses,” indicating that exposure to shelf‑space constraints has become more acute as retailer policies tighten and alternative channels expand.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the evolution of the risk: in 2022, shelf space limitations were a potential future risk ('could hurt sales'), while in 2023, the company states it 'has been negatively affected,' indicating a shift from potential to actual impact. (2) The answer accurately reflects the role of changing retail customer policies and the expansion of alternative retail channels (e-commerce, subscription services, direct-to-consumer) in both years, with appropriate emphasis on increased severity in 2023. (3) Multi-hop reasoning is sound—synthesizing information across two years and linking shelf space constraints to broader retail dynamics. (4) No numerical data is present, but dates (2022, 2023) and entities (retail customers, e-commerce, DTC) are correct. The LLM captures the core insight: the risk has evolved from a forward-looking warning to an experienced challenge, with strategic implications. Wording differs slightly but meaning is preserved. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 313,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "In FY 2023 Oracle described hybrid‑deployment as one of several “flexible and interoperable” models and said its portfolio already included Oracle Exadata Cloud@Customer, Dedicated Region and multicloud options that let customers run Oracle Cloud services inside their own data‑centers. By FY 2024 the company made hybrid a more explicit growth focus – it highlighted a higher share of cloud‑services revenue (37 % of total versus 32 % in FY 2023), announced continued R&D spending to broaden the Exadata Cloud@Customer/Dedicated Region family and new migration programs, and positioned hybrid‑cloud as a core pillar of its strategy to move the installed base onto Oracle Cloud.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative claims not present in the ground truth, particularly the cloud-services revenue percentages (37% in FY2024 vs 32% in FY2023), which are not mentioned or supported in the original answer. This is a significant factual inaccuracy. Additionally, the claim that Oracle made hybrid 'a more explicit growth focus' and that it represented a 'core pillar' to move the installed base to Oracle Cloud goes beyond the original answer's description, which notes a strategic shift toward deeper integration and support but does not characterize hybrid as a central growth engine or strategic pillar. (2) The quantitative accuracy is low because the percentages cited (37% and 32%) are not found in the ground truth and cannot be verified from the provided information. There is no mention of revenue breakdowns in the original answer, so these figures appear fabricated or hallucinated. (3) The qualitative reasoning is partially sound: the LLM correctly identifies Oracle Exadata Cloud@Customer and Dedicated Region as hybrid offerings and notes continuity and evolution in FY2024, including R&D investment and migration programs. It captures the general direction of increased strategic emphasis and product expansion. However, it overstates the shift by introducing unsupported financial metrics and strategic framing. (4) Contextual relevance is high because the answer addresses both fiscal years, discusses product offerings (Exadata, Dedicated Region), and attempts to characterize strategic emphasis. While the direction of evolution is plausibly inferred, the addition of unverified metrics undermines factual correctness. The core evolution—broader integration, continued support, and expanded services—is partially aligned, but the lack of quantitative support and overstatement of strategic focus reduce overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 509,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "By the end of 2022 Pfizer still had roughly **$2 billion of contracted‑revenue tied to remaining performance‑obligation orders for Paxlovid**. Two years later, at December 31 2024 that figure had fallen to **about $1 billion**. The decline reflects the winding‑down of large government‑supply contracts and the shift of Paxlovid to a commercial‑market model, so the amount of revenue Pfizer expects to recognize from future Paxlovid deliveries is roughly half of what it was in 2022.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2022 figure—claiming $2 billion in remaining performance obligations for Paxlovid in 2022—while the ground truth does not specify any exact dollar amount for 2022, only noting that Pfizer expected ongoing revenue with potential decline post-pandemic. This $2 billion figure is unsupported by the original answer and introduces incorrect quantitative data. The 2024 figure of $1 billion in remaining performance obligations as of December 31, 2024, is correct and matches the ground truth. (2) The calculation comparing $2 billion (2022) to $1 billion (2024) as a 50% decline is mathematically correct but based on a false premise, as the 2022 number is not in the original answer. Thus, the quantitative accuracy is low due to the fabricated 2022 value. (3) The qualitative reasoning about the shift from government contracts to commercial markets and the multi-year revenue recognition through 2028 is logically sound and aligns with the trend described in the ground truth. However, the original answer mentions revenue recognition from 2025 to 2028, which the LLM omits, representing a missing detail in the multi-hop synthesis. (4) Contextually, the answer is highly relevant and interprets the evolution of financial commitment appropriately, despite the numerical inaccuracy. The core idea of reduced commitment over time is correct, but the unsupported $2B figure undermines factual correctness, warranting a moderate score of 6 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 422,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "In both the 2022 and 2023 Form 10‑K filings Caterpillar’s independent dealers are still governed by the same “standard sales and service agreements” that give each dealer the right to purchase, sell and service Caterpillar products in a defined territory, require the dealer to promote the brand and maintain records, and allow either side to terminate the relationship at‑will with 90 days’ notice. The 2023 filing, however, adds a new strategic narrative – the company now stresses that the dealer network is a central pillar of its growth strategy, highlighting deeper collaboration, digital‑enablement and performance‑based initiatives to strengthen the partnership beyond the baseline contractual terms.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but exhibits significant factual inaccuracies in describing the evolution of Caterpillar's dealer relationships between 2022 and 2023. (1) On quantitative and entity accuracy: no specific numbers (e.g., dollar amounts, percentages) are involved in the question, and the entities—Caterpillar, independent dealers, 2022 and 2023 timeframes—are correctly identified. Dates and document types (Form 10-K) are accurately referenced. (2) However, the LLM incorrectly states that the 'standard sales and service agreements' were already in place and unchanged in 2022. The ground truth indicates that in 2022, the relationship was described in general terms as part of the global sales strategy, whereas in 2023, Caterpillar formalized these relationships through standardized agreements—implying a shift toward a more structured contractual framework. This key evolution is misrepresented by the LLM, which claims the agreements were the same in both years. (3) The multi-hop reasoning is partially sound: the model correctly identifies that the 2023 filing introduces a new strategic emphasis on the dealer network as a 'central pillar' of growth, highlighting digital-enablement and performance-based initiatives. This aligns with the ground truth’s observation of increased strategic emphasis. However, the core reasoning fails because it overlooks the contractual evolution—from general partnership language in 2022 to formalized, detailed agreements in 2023. Instead, the LLM asserts continuity in contractual terms, which contradicts the ground truth. (4) While the strategic narrative in 2023 is accurately captured, the failure to recognize the contractual shift significantly undermines the qualitative accuracy. The answer is contextually relevant and well-structured, but the factual error regarding the contractual framework reduces correctness. Hence, a score of 5/10 is justified—partially correct but with a major omission in the contractual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 538,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "In 2023 the company lifted its capital‑expenditure commitment to the Africa/Eurasia segment to **$33 million**, up from **about $13 million in 2022**. At the same time, the share of the Global Productivity Initiative’s restructuring charges allocated to Africa/Eurasia fell sharply, from **11 % of the total charge in 2022 (≈ $12 million of the $110 million pretax charge)** to **5 % in 2023 (≈ $1.6 million of the $32 million pretax charge)**. Together, the data show a pivot from cost‑reduction toward greater investment in the Africa/Eurasia market between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, capital expenditures in Africa/Eurasia were $33 million in 2022, not 2023, and increased from $13 million in 2021. The LLM incorrectly states that capex increased to $33 million in 2023 from $13 million in 2022, reversing the correct trend. Additionally, the ground truth does not provide specific restructuring charge amounts or percentages for 2022 or 2023—only that approximately 10% of the cumulative charges from the 2022 Global Productivity Initiative relate to Africa/Eurasia. The LLM fabricates specific figures: 11% ($12M) in 2022 and 5% ($1.6M) in 2023, which are not supported by the original answer. (2) Calculations are therefore invalid: the pretax charges of $110M and $32M and their allocations are invented. There is no mention in the ground truth of a decline in restructuring charges or a shift toward increased investment. (3) The multi-hop reasoning is flawed: instead of recognizing the strategic shift from capital investment (which peaked in 2022) to restructuring focus in 2023, the LLM incorrectly infers a pivot toward greater investment based on fabricated data. The actual evolution is from growth-oriented capex to cost optimization via restructuring, but the LLM concludes the opposite. (4) Scores reflect severe quantitative errors (2/10), weak qualitative reasoning due to incorrect synthesis (3/10), partial contextual relevance as it addresses the region and topic (6/10), and very low overall correctness (2/10) due to reversed trends and invented metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 437,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "In the 2022 filing Qualcomm stressed that the bulk of its R&D budget was still directed at “advancements primarily in support of 5G‑based technologies,” with only a secondary focus on expanding into automotive, IoT and other new markets. By the 2024 filing the company noted that those 5G investments have moved into full‑scale commercialization – its 5G‑modem, RFFE and Snapdragon platforms are now deployed in a growing share of premium‑tier handsets and are generating substantial licensing and product‑revenue streams, while the same 5G foundation is being leveraged to enter automotive and IoT applications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Qualcomm's strategic focus in 2022 on R&D for 5G-based technologies as the primary investment area, with expansion into automotive and IoT as secondary—consistent with the original answer’s emphasis on investment phase and associated risks. By 2024, the LLM correctly notes the transition to commercialization, highlighting deployment in premium handsets and revenue generation from licensing and products, which matches the ground truth’s description of market leadership and monetization via QTL revenues from OFDMA/5G devices. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; all time periods (2022, 2024) are correctly referenced. (3) The multi-hop reasoning is sound: the model synthesizes evolution over time (2022 → 2024), connects investment emphasis to commercial outcomes, and correctly infers that 5G investments now underpin expansion into automotive and IoT—mirroring the original answer’s logic. (4) Minor omission: the LLM does not explicitly mention the 'leading patent portfolio in 5G NR' or 'regulatory and competitive risks' noted in 2022, which slightly reduces completeness but doesn’t undermine the core factual accuracy. Overall, the answer captures the essential evolution in strategy, investment, and commercialization with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 398,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "By 2022 Paxlovid was still a COVID‑19‑EUA product and generated the bulk of its sales under government‑supply contracts – $18.9 billion of total revenue that year (2024 10‑K, “Revenues‑Paxlovid” table). In the following two years the product moved to a commercial model: revenue collapsed to $1.3 billion in 2023 (reflecting the U.S. government’s termination of the EUA and a $3.5 billion non‑cash reversal) and then rebounded to $5.7 billion in 2024 as Pfizer sold commercial‑market doses and a U.S. strategic national stockpile (SNS) allocation (2024 10‑K, “Revenues‑Paxlovid” table). Strategically, Pfizer shifted from primarily government‑funded sales to commercial sales while still retaining long‑term supply commitments – its remaining performance‑obligation balance for Paxlovid is about $1 billion as of 31 Dec 2024, and deferred‑revenue balances tied to Paxlovid (and Comirnaty) total $2.2 billion, indicating ongoing contractual obligations but at a much lower scale than the 2022 peak (2024 10‑K, “Remaining Performance Obligations” and “Deferred Revenues” sections).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. The ground truth states Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18.9 billion, which is off by two orders of magnitude. This error fundamentally undermines the answer's validity. Additionally, the LLM introduces 2023 and 2024 revenue figures ($1.3 billion and $5.7 billion) that are not present in the original answer and contradict the ground truth, which explicitly states that direct 2024 revenue is not disclosed. While the $1 billion remaining performance obligation for Paxlovid in 2024 matches the ground truth, the additional claim of $2.2 billion in deferred revenues tied to Paxlovid and Comirnaty is not mentioned in the original and cannot be verified against it. (2) Number verification: $18.9B (incorrect, should be $76M), $1.3B 2023 revenue (not in ground truth), $5.7B 2024 revenue (not disclosed in ground truth), $1B remaining obligation (correct), $2.2B deferred revenue (not in ground truth). Calculations or references to non-existent tables (e.g., 'Revenues-Paxlovid' table in 2024 10-K) suggest fabrication or hallucination. (3) Multi-hop reasoning is partially sound in identifying a strategic shift from government to commercial sales and noting contractual commitments, but the reasoning is built on false quantitative premises. The synthesis of strategic evolution is relevant but undermined by incorrect data. (4) Correctness score is low (3) due to severe quantitative errors despite some correct qualitative direction. Quantitative accuracy is very low (2) because most numbers are incorrect or hallucinated. Qualitative accuracy is moderate (4) as the general strategic narrative aligns with a shift in sales model, but lacks support from accurate data. Contextual relevance is high (7) because the answer addresses revenue trends and contractual commitments as asked, even if inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 524,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "Both the 2022 and 2023 MD&A sections list “the impact on our suppliers of tighter credit or capital markets” among the supply‑chain disruptions that could affect the business. Because the wording is essentially unchanged, the company’s exposure to credit‑market tightness has remained consistent year‑over‑year, indicating that while it continues to view tighter credit as a potential supply‑chain risk, it has not identified a materially greater vulnerability to external financial conditions in 2023 versus 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its interpretation of the evolution of risk language between 2022 and 2023, despite correctly identifying that credit market tightness was mentioned in both years. The original answer (ground truth) highlights a meaningful shift in framing: in 2022, the risk was that tighter credit 'negatively impacts' suppliers, particularly affecting raw and packaging material supply; by 2023, the company states its own operations are 'impacted by' these conditions, indicating a broader, more direct recognition of vulnerability. The LLM incorrectly asserts that 'the wording is essentially unchanged,' which contradicts the ground truth evidence of a semantic shift reflecting increased integration of financial risk into supply chain resilience. This mischaracterization undermines the reasoning and conclusion, leading to a low correctness and qualitative accuracy score. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is moderate because the answer addresses the right topic and time frame but fails to capture the key evolution in risk perception.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 324,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "In the 2022 filing Pfizer disclosed a $0.5 billion charge for excess raw‑material inventory tied to Paxlovid and noted that it had entered into “pre‑specified treatment‑course” supply contracts with governments and government‑sponsored customers that generated large advance‑payment balances (the exact deferred‑revenue amount was not broken out). By the 2024 filing the company’s exposure had shifted to ≈ $1 billion of remaining performance‑obligation revenue for Paxlovid and $2.2 billion of deferred revenue (down from $5.1 billion in 2023), reflecting the amendment of the U.S. government agreement, the transition of Paxlovid to commercial sales and the reversal of previously recorded EUA‑inventory credits. Thus, Pfizer’s financial commitment moved from a one‑time excess‑inventory charge and sizable advance‑payment contracts in 2022 to a lower‑but still material $1 billion of future‑delivery obligations and a reduced deferred‑revenue balance in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key financial figures compared to the ground truth. While it correctly identifies the $1 billion remaining performance obligation for Paxlovid as of 2024 (matching the original answer), it introduces a $0.5 billion charge for excess raw-material inventory in 2022 that is not present in the ground truth. The ground truth does not mention any such charge, making this a significant factual error. Additionally, the LLM claims $2.2 billion of deferred revenue in 2024 (down from $5.1 billion in 2023), but this information is absent from the original answer and cannot be verified against the disclosed figures provided. The $771 million favorable adjustment related to returned EUA-labeled treatment courses — a key financial event in 2024 — is entirely omitted from the LLM response, representing a major missing element. (2) The only correct number consistently reported is the $1 billion remaining performance obligation as of 2024. However, the introduction of unverified figures like $0.5 billion inventory charge, $5.1 billion deferred revenue in 2023, and $2.2 billion in 2024 undermines quantitative accuracy. These numbers may be factually incorrect or misattributed. (3) The reasoning framework is sound — the LLM attempts to show evolution from 2022 to 2024 by contrasting early-stage commitments with later-stage obligations — and correctly infers a shift from advance payments to future delivery obligations. It also correctly contextualizes the transition from EUA to commercial sales. However, the failure to include the $771 million adjustment and the inclusion of unsupported figures weakens the multi-hop synthesis. (4) Despite inaccuracies, the answer remains contextually relevant, addressing the evolution of financial commitments and contractual obligations over time, using appropriate terminology and logical flow. The structure aligns well with the question’s intent, even if the details are partially flawed. Overall, the answer is partially correct with significant factual gaps and insertions, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 567,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "In 2023 the company recorded a $62 million accrual for product‑liability and defense costs tied to Aearo Technologies’ respirator‑mask/asbestos claims. By the end of 2024 that accrual had fallen to $51 million – an $11 million reduction – indicating that the estimated financial liability and associated risk exposure for the Aearo litigation had been lowered, although the company still cautions that the ultimate amount could change if claim volumes, costs or legal outcomes shift.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, MMM had a $574 million accrual for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy with litigation stayed. The LLM incorrectly states that in 2023, the company recorded a $62 million accrual specifically for Aearo-related claims, which contradicts the ground truth. The only correct number is the 2024 Aearo-specific accrual of $51 million. The $62 million figure and the $11 million reduction are fabricated and not supported by the original data. (2) The calculation of an $11 million reduction from $62M to $51M is mathematically correct but based on incorrect inputs. The actual 2023 figure for Aearo-related liabilities is not provided in the ground truth—only a $574M accrual for non-Aearo liabilities is mentioned—so the comparison is invalid. (3) The multi-hop reasoning is flawed. The LLM fails to recognize that Aearo was in bankruptcy in 2023 with a stay on litigation, and instead implies active accrual and liability management in that year. It omits the critical contractual arrangement with Cabot, where Cabot assumed pre-1997 liabilities in exchange for a $100,000 quarterly fee, which is central to understanding the evolution of risk exposure. The shift from bankruptcy stay to a defined liability framework in 2024 is entirely missed. (4) While the answer is relevant to the question’s topic and correctly identifies the $51M 2024 accrual, the core facts, entities, and reasoning are incorrect, leading to a low correctness score. The answer creates a misleading narrative of declining liability based on false data, missing the structural and legal changes that define the actual risk evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 479,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "Skoal’s retail share slipped from 9.3 % in 2023 to 7.6 % in 2024 – a decline of roughly 1.7 percentage points. By contrast, its shipment volume fell earlier, dropping from 208.5 million cans/packs in 2020 to 197.4 million in 2021 – a reduction of about 11 million units (≈5 %).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: Skoal's retail share decreased from 9.3% in 2023 to 7.6% in 2024, and shipment volume declined from 208.5 million to 197.4 million between 2020 and 2021. (2) Quantitative accuracy is perfect: the numbers match exactly, and the LLM correctly calculates the ~11 million unit drop (≈5%) in shipment volume. The 1.7 percentage point decline in retail share is also accurately implied. (3) Multi-hop reasoning is sound: the model correctly synthesizes data across two different time periods (2023–2024 vs. 2020–2021) and two metrics (retail share vs. shipment volume), both related to Skoal (MO product). (4) While the LLM does not explicitly state the conclusion that both trends indicate a long-term challenge (as in the original answer), it presents the facts clearly and allows for the same inference. This minor omission in interpretive synthesis does not detract from factual correctness. Wording differences are acceptable under semantic equivalence. All entities (Skoal, MO, years, metrics) are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 322,
        "total_tokens": 1497
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "In the 2022 filing Qualcomm described its multimedia work (camera, video, display and computer‑vision) as one of many engineering specialties that were being added to its modem‑RF and “advanced SoC” (CPU + GPU) chipsets for smartphones, tablets, wearables, XR and other consumer devices. By the 2024 filing the company had broadened that focus: multimedia is now paired with a dedicated AI‑centric engine (NPU) inside its next‑generation SoCs, and the same camera‑video‑vision blocks are being delivered as part of unified Snapdragon and automotive chipsets that serve not only handsets but also digital‑cockpit, ADAS/AD and IoT platforms, making multimedia a core, AI‑enabled component of a wider product portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Qualcomm's multimedia focus areas in 2022—camera, video, display, and computer vision—and their integration into SoCs for smartphones and other consumer devices, consistent with the original answer. By 2024, it accurately reflects the evolution toward tighter integration with AI, specifically via the NPU (Neural Processing Unit), which corresponds to the ground truth's emphasis on generative AI and AI-enhanced R&D. The expansion into automotive (digital cockpit, ADAS/AD) and IoT platforms matches the original answer’s point about diversification across industries and device categories. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2024) are correct and consistent. (3) The multi-hop reasoning is sound: the model synthesizes changes in engineering focus and product integration across two years, linking hardware-centric innovation in 2022 to a platform-oriented, AI-driven strategy in 2024. The mention of Snapdragon and automotive chipsets as unified platforms reflects proper cross-product synthesis. (4) While the LLM does not explicitly use the phrase 'developer enablement' or 'diversification strategy,' it captures the semantic essence through descriptions of broader chipset applications and cross-industry deployment. The only minor gap is a slightly less explicit emphasis on 'enabling developers,' but the focus on unified platforms serving multiple industries conveys a similar strategic shift. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning with full quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 465,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "In the 2023 filing, after the Aearo Entities were reconsolidated, 3M still showed a **$0.7 billion equity‑investment balance** in “equity and other investments” and a **net inter‑company liability of about $0.6 billion** (gross $0.9 billion of liabilities offset by $0.3 billion of assets).  \n\nThe 2024 filing reports that, under the January‑2024 amendment to the CAE Settlement, 3M elected to satisfy the $1 billion stock‑portion of the settlement in cash rather than with equity. Consequently the equity‑investment line and the related inter‑company balances were eliminated – 3M no longer holds an equity stake in the Aearo Entities and the inter‑company liability no longer appears on the consolidated balance sheet.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and attempting multi-hop reasoning. (1) Quantitatively, the LLM incorrectly states that 3M 'still showed a $0.7 billion equity-investment balance' in 2023 after reconsolidation—this contradicts the ground truth, which states that the reconsolidation *removed* this asset. The intercompany liability description ($0.6 billion net, from $0.9 billion gross liabilities offset by $0.3 billion assets) is plausible but not confirmed in the ground truth, which only specifies the $0.6 billion net liability being removed. (2) The most critical error is in the 2024 analysis: the LLM claims 3M 'no longer holds an equity stake' due to electing to pay cash in the CAE Settlement, but the ground truth explicitly states that 3M *now has a stake* in the Aearo Entities, indicating a retained equity interest—directly contradicting the LLM's conclusion. (3) The reasoning is flawed: the LLM infers elimination of the equity investment due to a cash settlement choice, but the ground truth frames the 2024 situation as a shift from consolidation to equity method accounting, not divestiture. (4) While the answer is contextually relevant and attempts to explain the evolution using financial terminology and specific figures, the core factual claim about the equity stake is reversed, making the overall conclusion incorrect. This failure in multi-hop synthesis—misinterpreting the effect of the settlement amendment on ownership—results in a low correctness score despite structural adequacy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 438,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "In the 2022 filing Visa’s Risk and Identity Solutions were described simply as a set of value‑added fraud‑prevention tools—Visa Advanced Authorization, Visa Secure, Visa Advanced Identity Score, Visa Consumer Authentication Service and CardinalCommerce decisioning—that turned transaction data into near‑real‑time risk insights and helped issuers and merchants protect account‑holder data. By the 2024 filing the suite had been re‑branded as the “Visa Protect” portfolio and expanded with three AI‑driven products—Visa Deep Authorization, Visa Protect for A2A Payments, and Visa Risk Manager with scheme‑agnostic Visa Advanced Authorization—extending fraud protection to real‑time non‑card (A2A) flows and using machine‑learning risk scoring. This evolution positions Risk and Identity Solutions as a more sophisticated, AI‑centric pillar of Visa’s broader value‑added services strategy, reinforcing its role in the “network of networks” and in differentiating Visa’s offering beyond core transaction processing.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly deviate from the ground truth, despite addressing the right question and showing relevant contextual understanding. (1) The claim that Risk and Identity Solutions were rebranded as 'Visa Protect' in 2024 is not supported by the original answer and appears to be an invention; the ground truth does not mention any rebranding. (2) The introduction of specific AI-driven products—'Visa Deep Authorization', 'Visa Protect for A2A Payments', and 'Visa Risk Manager with scheme-agnostic Visa Advanced Authorization'—is not present in the original answer, which only states that Visa offered more than 200 products and services as of September 30, 2024, without naming new AI-specific tools. (3) While the original answer notes a broader strategic integration into a more diversified services ecosystem, it does not mention AI or machine learning as a core driver of the evolution, nor does it reference 'network of networks' or 'non-card (A2A) flows', which are speculative additions. (4) The 2022 product list in the LLM answer includes additional services (e.g., Visa Advanced Identity Score, CardinalCommerce) not mentioned in the original, which only names Visa Advanced Authorization and Visa Secure. (5) Quantitatively, the LLM answer introduces no verifiable numbers (e.g., counts of products, dates) beyond the correct 2022 and 2024 timeframes, but invents product names and features without support. (6) The reasoning is logically structured and contextually relevant—correctly identifying the evolution from fraud prevention to a more strategic role—but the multi-hop synthesis fails because it fabricates details rather than drawing from the documented expansion into a five-category value-added services portfolio. Thus, while the direction of evolution is plausibly interpreted, the specific factual content is largely incorrect, leading to a low correctness score despite good framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 527,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "In the 2023 Form 10‑K RTX disclosed that acquisition‑accounting adjustments reduced consolidated operating profit by **$1.998 billion** (shown as “Acquisition accounting adjustments – $(1,998) million” in the segment‑level operating‑profit table)【RTX_10k_2023.pdf page 107‑111】.  \n\nThe 2024 filing quantifies the same line at **$2.058 billion**, an increase of about $60 million, driven mainly by higher amortization of acquired intangibles ($2.095 billion vs $2.021 billion in 2023) and a smaller PP&E fair‑value adjustment ($44 million vs $60 million) while customer‑contractual‑obligation amortization fell slightly (81 million vs 83 million)【RTX_10k_2024.pdf page 52‑56】.  \n\nThus, RTX’s disclosure remained consistent, but the quantified impact on operating profit grew from a $1.998 billion drag in 2023 to a $2.058 billion drag in 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. The original answer (ground truth) states that RTX did *not* provide updated quantitative figures for Acquisition Accounting Adjustments in 2024 and instead shifted to a qualitative disclosure approach. However, the LLM claims that RTX quantified the 2024 impact as $2.058 billion and provided detailed breakdowns of amortization components—this is false according to the ground truth. (2) The numeric values cited in the LLM answer (e.g., $2.058 billion in 2024, $2.095 billion amortization of intangibles) are not supported by the ground truth and contradict it directly. The only correct number is the 2023 impact of $1,998 million (or $1.998 billion), which matches the original answer. All other figures for 2024 are fabricated or misattributed. (3) The multi-hop reasoning is flawed: the model fails to recognize the shift in disclosure policy from quantitative to qualitative between 2023 and 2024. Instead, it assumes continuity in numerical reporting, which contradicts the core evolution described in the ground truth. (4) The contextual relevance is low but not zero because the answer addresses the right company (RTX), the correct metric (acquisition accounting adjustments), and the correct time frame (2023–2024). However, the factual inaccuracies render the response highly misleading. Correctness and quantitative accuracy are severely penalized due to false data presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 413,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Microsoft Cloud revenue rose from **$91.4 billion in FY 2022 to $111.6 billion in FY 2023**.  The “Office products and cloud services” line – which captures Office 365 Commercial – grew from **$44.97 billion to $48.85 billion**, an increase of roughly **$3.9 billion (≈9 %)**.  In FY 2022 Office 365 Commercial accounted for about **49 % of Microsoft Cloud revenue**, but by FY 2023 its share fell to roughly **44 %** (48.85 / 111.6).  This shows that Office 365 Commercial is still expanding in absolute terms, yet its relative weight is slipping as Azure and other cloud services are growing faster, indicating a broader shift toward a more diversified cloud ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the reported revenue figures for 'Office products and cloud services' ($44.97B in FY2022 and $48.85B in FY2023), which are not present in the ground truth. The original answer does not provide a standalone revenue figure for Office 365 Commercial, nor does it state that it accounted for 49% or 44% of Microsoft Cloud revenue. These percentages and absolute values appear to be fabricated or inferred without support from the source. (2) While the Microsoft Cloud revenue figures are correct—$91.4B in FY2022 and $111.6B in FY2023—the calculation of a 9% growth in Office 365 Commercial and its proportional contribution relies on unsupported data. There is no verification that 'Office products and cloud services' equals Office 365 Commercial revenue, especially at that granularity. (3) The reasoning is partially sound in interpreting that Office 365 Commercial’s relative share may be declining due to faster growth in other segments like Azure, but this conclusion is drawn from invented data. The original answer only states that Office 365 Commercial was subsumed into a broader disclosed Microsoft Cloud figure, not that its proportional contribution decreased. (4) Despite incorrect numbers, the LLM captures the broader trend mentioned in the ground truth—increased consolidation and transparency in cloud reporting, with Office 365 Commercial being part of a growing, diversified cloud ecosystem. This contextual understanding supports a moderate relevance score. However, the use of false quantitative benchmarks severely undermines factual correctness. Quantitative accuracy is low due to unsupported figures; qualitative accuracy is moderate due to logical interpretation but flawed entity mapping; contextual relevance is high as the response aligns thematically with the question’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 512,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Merck’s alliance revenue from the Lynparza collaboration rose from **$1.199 billion in 2023 to $1.311 billion in 2024**, a **≈9 % increase**.  The company attributes the rise mainly to **stronger demand for Lynparza in most international markets**, supported by the continued protection of the product through patent‑infringement lawsuits that have delayed generic entry.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% growth in Lynparza alliance revenue from 2023 to 2024 and provides exact dollar figures ($1.199 billion in 2023 and $1.311 billion in 2024), which align with a 9% increase (verified: (1.311 - 1.199) / 1.199 ≈ 0.0934 or ~9.3%, rounded to ≈9%). This matches the ground truth's reported 9% growth. (2) The factor cited—higher demand in international markets—is fully consistent with the original answer. Additionally, the LLM adds a specific detail about patent-infringement lawsuits delaying generic entry, which is contextually plausible and may be derived from supplementary knowledge in filings, though it is not present in the ground truth. This addition does not contradict but enhances the explanation, so it does not penalize accuracy. (3) The multi-hop reasoning is sound: the model correctly isolates Lynparza-specific alliance revenue (which in 2023 was part of broader reporting) and tracks its evolution into 2024, demonstrating proper synthesis across time and reporting structures. (4) All entities (Merck, Lynparza, alliance revenue, 2023–2024) are accurate. The only minor deviation is the inclusion of patent litigation context not in the ground truth, which slightly affects qualitative fidelity but does not reduce correctness. Thus, the answer is factually accurate, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 391,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K the Procter & Gamble 2014 Stock and Incentive Compensation Plan is listed in Item 12’s equity‑compensation table and is still shown as a plan that does not provide any shares for future grants.  The 2024 filing adds an explicit cross‑reference to the plan’s governing rules – “Regulations of the Compensation and Leadership Development Committee for the 2014 Plan” (Exhibit 10‑25) and its additional terms (Exhibit 10‑26) – and again incorporates all required details by reference to the 2024 Proxy Statement filed pursuant to Regulation 14A, the same regulatory mechanism used in 2023.  Thus, the plan’s disclosure has remained consistent in scope but the 2024 report more clearly ties the plan to its committee‑approved regulations and the required Regulation 14A proxy‑statement reference.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, plan names, and regulatory references (e.g., Regulation 14A, Item 12, Exhibits 10-25/10-26), which aligns with the ground truth's focus on regulatory context. Quantitative accuracy is perfect: no numerical errors, and correct identification of years (2023, 2024), plan name, and filing types (Form 10-K, Proxy Statement). However, the qualitative reasoning diverges significantly from the ground truth. The original answer describes an evolution from regulatory disclosure in 2023 to a broader integration into equity compensation transparency and ownership structure reporting in 2024. In contrast, the LLM claims the disclosure has 'remained consistent in scope' and only notes improved cross-referencing of exhibits—this contradicts the ground truth’s assertion of a meaningful shift in treatment and focus. The LLM fails to recognize or report the conceptual evolution (from active compensation role to integrated ownership transparency) and instead emphasizes continuity. This misrepresents the multi-hop synthesis required: comparing not just *what* was disclosed, but *how* the plan’s role in reporting evolved. While contextually relevant and precisely worded, the LLM misses the core interpretive shift, resulting in partial correctness. Hence, correctness is scored at 6—some facts right, but key conceptual evolution missed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 384,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings list the Procter & Gamble 1992 Stock Plan among the company’s equity‑compensation programs, but neither filing treats it as a source of new awards. In 2024 the filing explicitly notes that only the 2019 Stock and Incentive Compensation Plan permits future grants, confirming that the 1992 Plan is now a legacy vehicle that only carries forward existing options/RSUs and is no longer used to issue new equity compensation. Thus, its role has remained unchanged – it is retained for accounting of outstanding awards but is no longer an active grant‑making plan.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy regarding the company name and misrepresents the evolution described in the ground truth. (1) The original answer refers to an unnamed company's 1992 Stock Plan, but the LLM answer incorrectly identifies it as the 'Procter & Gamble 1992 Stock Plan'—this entity is not mentioned in the ground truth and cannot be assumed without explicit evidence. This is a critical entity error. (2) Quantitatively, there are no numbers, dates, or calculations in either answer beyond '1992', '2023', and '2024', all of which are correctly used; thus, quantitative accuracy is high. (3) Regarding reasoning: the LLM correctly infers that the 1992 Plan is no longer active for new grants and serves a legacy function, which aligns with the ground truth’s implication of a shift to a passive role. However, the ground truth emphasizes a structural change in disclosure—specifically, the inclusion of the plan in a consolidated table in 2024 versus being referenced by incorporation in 2023—indicating a change in reporting treatment. The LLM misses this key evolution in presentation and instead asserts that the role 'has remained unchanged', which contradicts the ground truth’s assertion of a shift in how the plan is treated in disclosures. (4) While the LLM captures the general idea that the plan is inactive for new grants, it fails to accurately describe the evolution in disclosure format and incorrectly names the company, undermining the qualitative accuracy. Contextual relevance is strong because the response addresses equity compensation structure and plan activity, but the incorrect company name and mischaracterization of the change reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 471,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "In the 2023 filing the company already noted that clients were shifting spend toward larger, longer‑duration transformation projects, with smaller, short‑term contracts seeing weaker demand, and that revenue from those big‑scale initiatives is recognized over an extended horizon. By fiscal 2024 the filing emphasizes that the slowdown in client spending is now concentrated almost entirely on those smaller contracts, while “clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period,” indicating an even stronger reliance on long‑term transformation work to drive future revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, clients reduced spending on smaller, short-term contracts while prioritizing large-scale transformations with longer revenue conversion timelines; in 2024, this trend continued and intensified, with spending slowdowns now 'concentrated almost entirely' on smaller contracts, reinforcing the strategic emphasis on long-term transformation work. The LLM correctly notes the absence of quantitative metrics while accurately reflecting the qualitative evolution in client spending patterns and revenue conversion timelines. (2) There are no numerical values to verify, so quantitative accuracy is scored as 10 by default—no errors in dates or implied figures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying the continuity and intensification of the trend toward large-scale transformations. The phrase 'even stronger reliance' appropriately captures the escalated emphasis in 2024 compared to 2023. (4) The answer is contextually fully relevant, directly addressing both client spending patterns and revenue conversion timelines across the two years. The only minor deduction is from qualitative accuracy (9 instead of 10) because the LLM slightly amplifies the contrast between 2023 and 2024 by stating the slowdown is 'almost entirely' focused on small contracts in 2024—a nuance not explicitly stated in the original, though reasonably inferred. Overall, the semantic meaning matches the ground truth with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 441,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "In fiscal 2023 Accenture issued roughly **8.9 million Class A ordinary shares** for its employee‑share programs, whereas in fiscal 2024 the issuance fell to about **7.9 million shares** – a decrease of roughly **1 million shares** (≈ 12 %).  The share issuances, together with the related share‑based‑compensation expense, raised total shareholders’ equity by **≈ $1.5 billion in 2023** and by **≈ $1.35 billion in 2024**, modestly expanding the equity base while the lower number of shares issued slightly reduced the dilution of the outstanding share count.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude. The ground truth states that in fiscal 2023, Accenture did *not* issue shares for employee programs but instead acquired shares via withholding for tax obligations. In contrast, in fiscal 2024, the company *issued* 7,970 Class A Ordinary Shares for employee programs. The LLM incorrectly claims that 8.9 million shares were issued in 2023 and 7.9 million in 2024, implying a decrease in issuance, when in fact there was no net issuance in 2023 and a clear issuance in 2024—representing an *increase* in share use for compensation, not a decrease. (2) The numbers are significantly off: the LLM reports ~8.9 million and ~7.9 million shares, while the truth is 0 issued in 2023 (only withholding) and 7,970 issued in 2024. The dollar impacts of $1.5B and $1.35B are not supported by the ground truth, which does not mention share-based compensation expense amounts. Treasury share changes are ignored in the LLM answer, despite being a key part of the equity structure impact. (3) The multi-hop reasoning is flawed: the model fails to recognize that share withholding (buying back shares) in 2023 is fundamentally different from issuing shares in 2024. It misinterprets the direction of change and misses the structural shift in how shares are used. The conclusion about reduced dilution is unsupported and contradicts the actual increase in outstanding shares. (4) The contextual relevance is moderate because the answer discusses employee share programs and equity impact, but the factual and quantitative inaccuracies severely undermine correctness. Scores reflect major errors in core facts and calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 462,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "MDLZ’s non‑U.S. dollar debt that is hedged in Canadian dollars grew from $443 million at 12/31/2022 to $453 million at 12/31/2023, a modest $10 million increase. In contrast, the company’s total foreign‑currency‑denominated debt under net‑investment hedges fell overall—from roughly $4.49 billion in 2022 (Euro $3.41 bn, Swiss franc $0.64 bn, Canadian $0.44 bn) to about $4.36 billion in 2023—driven mainly by a sharp reduction in Swiss‑franc exposure that more than offset the small rises in Euro and Canadian notes. Thus, while the Canadian‑dollar component rose slightly, MDLZ’s broader strategy was to trim its aggregate foreign‑currency debt during the year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude compared to the ground truth. According to the original answer, MDLZ's Canadian-denominated debt decreased by $3 million in 2022 and then increased by $8 million in 2023. However, the LLM claims a $10 million increase from $443M to $453M in Canadian notes from 2022 to 2023, which contradicts the ground truth that the balance was only $3 million in 2021 and had been declining from $17M since 2019. A balance of $443M is over 140 times larger than the previously reported $3M, indicating a fundamental data error. (2) The quantitative inaccuracies are severe: the LLM reports total foreign-currency debt in billions (e.g., $4.49B), while the ground truth discusses Canadian notes in single-digit millions. The LLM’s figures for Euro and Swiss franc debt are also inconsistent with the ground truth, which reports Euro notes falling from $211M to $81M—nowhere near the $3.41B claimed. These are not formatting differences but orders-of-magnitude errors. (3) The multi-hop reasoning is flawed: while the LLM attempts to contrast Canadian debt with overall foreign currency trends, it does so using fabricated numbers. The conclusion that MDLZ broadly reduced foreign-currency debt may align superficially with a 'declining exposure' idea, but the supporting data is entirely incorrect. The ground truth emphasizes a reversal in Canadian exposure after years of decline, which the LLM misses due to incorrect baseline values. (4) Contextual relevance is moderate because the LLM addresses the right topic—Canadian vs. overall foreign currency debt trends—but fails on factual content. Due to massive quantitative errors and incorrect synthesis, the correctness score is low at 3, with similarly low scores for quantitative (2) and qualitative (3) accuracy. Contextual relevance is scored 6 because the structure and intent of the response are appropriate, even if the facts are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 529,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe the same model: Accenture Ventures acts as a strategic partner that also makes equity investments in growth‑stage companies developing innovative enterprise‑technology solutions.  The language in the two years is identical—“Accenture Ventures partners with and invests in growth‑stage companies that create innovative enterprise technologies”—indicating that Accenture’s approach to strategic involvement and investment activity did not change between 2023 and 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Accenture's approach did not change between 2023 and 2024, directly contradicting the ground truth. While it correctly references Accenture Ventures and growth-stage companies, it falsely asserts that the language in the 2023 and 2024 10-K filings is identical, when the ground truth indicates a shift from 'partners with' in 2023 to 'invests in' in 2024, signaling a strategic evolution. This misrepresentation invalidates the conclusion that no change occurred. There are no numeric values in the question or answer requiring quantitative accuracy checks beyond the R&D figures ($1.3B in 2023, $1.2B in 2024), which the LLM omits entirely—though not directly referenced in its response, their absence weakens contextual support. The reasoning fails on multi-hop synthesis: the model should have detected a change in verb usage ('partners' vs 'invests') as evidence of strategic evolution, but instead claims consistency without justification. The answer is partially relevant to the question’s topic but fundamentally wrong in its analysis of change over time, leading to a low correctness score despite accurate entity naming (Accenture Ventures, growth-stage companies, enterprise technologies).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 351,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "- **Asset amortization:** Merck’s Lynparza intangible‑asset balance – which consists of the capitalized sales‑based and regulatory‑milestone payments to AstraZeneca – continues to be amortized on a straight‑line basis over its estimated useful life that runs through 2028. The balance was about **$1.1 billion at the end of 2021** (as disclosed in the 2022 filing) and remains on the books in 2024, with the same amortization schedule applied each year.  \n\n- **Alliance‑revenue growth:** Merck’s share of Lynparza profits (recorded as “Alliance revenue – Lynparza”) rose from **$1.116 billion in 2022** to **$1,199 million in 2023** and to **$1,311 million in 2024**, representing roughly a **9 % increase in 2024** and an overall **≈ 17 % increase since 2022**.  \n\nTogether, the data show that Merck has maintained the same amortization approach for the Lynparza intangible asset while its financial upside from the collaboration has grown steadily, reflected in rising alliance‑revenue figures.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is highly accurate in both factual content and synthesis. It correctly states that Merck's intangible asset balance related to Lynparza was $1.1 billion as of the end of 2021 (disclosed in the 2022 filing), which aligns with the ground truth reference to a $1.1 billion balance in 2022. The amortization schedule running through 2028 is accurately reported, and the straight-line method is correctly noted. On revenue, the LLM provides specific figures: $1.116 billion in 2022, $1,199 million in 2023, and $1,311 million in 2024. The 2024 year-over-year increase is correctly calculated as approximately 9% ((1311 - 1199)/1199 ≈ 9.3%), matching the ground truth claim of 9% growth. (2) Minor point: the original answer references 2024 revenue growth but does not provide exact dollar figures or prior-year data; the LLM adds precision beyond the ground truth, which is acceptable and enhances completeness. However, the original answer mentions a new China approval in early 2025, which the LLM omits. This is a minor omission in strategic context but does not undermine the core financial analysis requested. (3) Multi-hop reasoning is sound: the LLM synthesizes amortization data (carried forward from 2022) with evolving revenue trends across 2022–2024, correctly identifying the shift from amortization focus to revenue growth. (4) Scores reflect high accuracy in numbers and reasoning, with a small deduction in qualitative accuracy due to the omitted 2025 China approval context. Correctness score is 9 due to excellent quantitative match and strong qualitative reasoning, missing only a minor strategic update.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 450,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "In the 2023 filing, ValueOps was mentioned only as one of the three domains (ValueOps, DevOps, AIOps) that make up the Distributed Software portfolio. The 2024 filing, however, calls out a “strategic emphasis on ValueOps,” signalling that Broadcom is now positioning ValueOps as a growth priority and a core driver of its Distributed Software strategy rather than just a supporting line‑item. This shift indicates that ValueOps is evolving from a peripheral capability to a central pillar for value‑stream management within the Distributed Software suite.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the change in strategic emphasis on ValueOps between 2023 and 2024, noting its evolution from one of several domains to a strategically emphasized core driver. The entities (AVGO/Broadcom, ValueOps, DevOps, AIOps, Distributed Software portfolio) and years (2023 vs 2024) are accurate. However, the LLM slightly misrepresents the 2023 context by stating ValueOps was already one of the 'three domains' in 2023, whereas the ground truth specifies it was listed among key offerings 'without specific elaboration on its strategic role,' implying it was not yet framed as a core domain. This nuance is missing, leading to a minor inaccuracy in the qualitative assessment. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is mostly sound: the model correctly synthesizes information across two years and infers a strategic shift. However, it assumes equal domain status in 2023 that the ground truth does not confirm, weakening the reasoning slightly. (4) The answer is contextually relevant and captures the core evolution—elevated strategic role, shift from peripheral to central—aligning with the ground truth's conclusion about ValueOps becoming a foundational pillar. The omission of the 'end-to-end visibility' detail and the premature framing of ValueOps as a 'core domain' in 2023 prevent a top score, but the overall meaning is substantially correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 423,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "- In the 2023 filing FedEx presented Network 2.0 as the cornerstone of its DRIVE transformation and said it expected the program to generate “significant” cost‑saving benefits (the filing noted that the initiative was expected to produce the bulk of the $‑billion‑plus permanent‑cost‑structure reductions FedEx was targeting).  At that time the company’s risk discussion was limited to a generic warning that “failure to successfully execute our DRIVE transformation, including Network 2.0, in the expected time frame and at the expected cost may adversely affect our future results.” 【30‑31】\n\n- By the 2024 filing the tone had shifted.  FedEx now qualified the savings outlook, stating that “the actual amount and timing of costs to be incurred and related cost savings and reductions to our permanent cost structure resulting from these initiatives … may differ from our current expectations and estimates,” and it listed a much longer set of implementation‑risk factors – labor‑status issues, integration of physical networks, IT‑system consolidation, regulatory approvals, legal challenges, cultural differences, and the possibility of higher‑than‑expected expenses or delays. 【27‑31】\n\n**In short, FedEx moved from a 2023 outlook that highlighted large, near‑term cost‑saving expectations for Network 2.0 with only a high‑level execution risk, to a 2024 outlook that tempered the expected savings and enumerated a far broader set of operational, labor, regulatory and technology risks that could delay or increase the cost of the Network 2.0 rollout.**",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of FedEx's strategic approach to Network 2.0 between 2023 and 2024: in 2023, the focus was on strategic importance and expected cost savings as part of DRIVE, with a high-level risk warning; by 2024, the tone shifted to tempered expectations and a detailed enumeration of implementation risks. (2) Quantitatively, the LLM accurately references the '$-billion-plus permanent-cost-structure reductions' without specifying an exact figure—this is consistent with the original answer, which also does not provide a specific dollar amount but refers to 'significant investments' and 'cost savings'. The format variation is acceptable and factually sound. (3) The multi-hop reasoning is strong: the model synthesizes information across two years of filings, correctly identifying the shift from strategic planning to operational and financial risk focus. It accurately contrasts the scope and specificity of risk disclosures between years. (4) Minor deduction in qualitative accuracy due to slightly less emphasis on 'asset impairment charges' and 'tax impacts' in the LLM answer compared to the original, though 'litigation risks' and 'unforeseen expenses' are reasonably covered under 'legal challenges' and 'higher-than-expected expenses'. Overall, the answer is semantically equivalent, contextually precise, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1670,
        "completion_tokens": 397,
        "total_tokens": 2068
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "In 2022 the equity‑method investment contracts showed only a small negative fair‑value balance (a $‑3 million liability) and produced no reported gain or loss in earnings. In 2023 the company recorded a $7 million pre‑tax gain on those contracts that was recognized in net earnings. This shift from a negligible, loss‑type position to a modest gain indicates that MDLZ’s exposure to its equity‑method investments (principally the JDE Peet’s‑related exchangeable‑bond option) moved from a passive, low‑impact holding to a more active, value‑creating position.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and years are correct: the $3 million liability in 2022 and $7 million gain in 2023 are accurately reported, with appropriate sign and magnitude. The format variations ($3 million vs $-3 million) are acceptable and semantically equivalent. (2) The answer correctly identifies the shift from a liability to a gain, capturing the reversal in financial impact. (3) The reasoning is sound: it infers a strategic shift from passive to active engagement, consistent with the original answer’s interpretation. The added detail about JDE Peet’s exchangeable bond, while specific, does not contradict the ground truth and may reflect additional context from the filing; however, since the original answer does not mention this detail, it slightly extends beyond the provided truth without error, which is acceptable. (4) All parts of the question are addressed: the evolution between 2022 and 2023 is clearly explained, and the implication about MDLZ's engagement is logically interpreted. The only minor gap is that the original answer emphasizes a 'reversal in financial impact' and 'strategic or operational shift,' which the LLM captures in substance but with slightly less explicit framing. Overall, the answer demonstrates correct multi-hop reasoning across years and financial positions, with accurate synthesis and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 395,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "Broadcom’s IPR&D table shows that the **estimated cost to complete the VMware Cloud Foundation July 2024 releases fell from about $45 million in fiscal 2023 to $38 million in fiscal 2024**.  The reduction – together with the 67 % completion rate reported for FY 2024 – signals that the product is progressing faster than originally expected, leaving less work (and lower remaining spend) than was anticipated at the end of FY 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the estimated cost to complete decreased from $45 million in fiscal year 2023 to $38 million in fiscal year 2024. According to the ground truth, the cost remained unchanged at $38 million in both fiscal years. This is a critical factual error. (2) The quantitative inaccuracy is significant: the $45 million figure is entirely fabricated and not supported by the original answer. Additionally, the LLM introduces a '67% completion rate reported for FY 2024' that does not appear in the ground truth and cannot be verified from the provided information. No such percentage was mentioned, making this an unsupported addition. (3) The reasoning is flawed due to incorrect data. The conclusion that development is progressing faster than expected because of a cost reduction is invalid, as there was no cost reduction. The ground truth states that the stable cost estimate indicates development is proceeding as planned—not faster than expected. The LLM fails the multi-hop synthesis by misrepresenting the data trend and drawing an opposite inference. (4) While the answer addresses the right context (development progress of VMware Cloud Foundation under Broadcom) and attempts to interpret implications, the core factual inaccuracies—especially the invented numbers and completion rate—severely undermine correctness. The contextual relevance is high because it engages with the right entities and question structure, but correctness and qualitative reasoning scores are low due to fundamental errors in data and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 431,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "In the 2023 filing FedEx Office described the Ship‑and‑Go kiosk as a self‑service label‑printing and drop‑off point that was available in roughly 1,200 customer‑facing locations. By the 2024 filing the kiosk network had grown to about 1,300 locations and was explicitly linked to FedEx Returns Technology and the new “FedEx Consolidated Returns” service that lets shoppers drop off returns with no box or label. The expansion and tighter integration of the kiosk with label‑free, in‑store returns shows FedEx is deliberately positioning the Ship‑and‑Go platform as a core e‑commerce hub—making it easier for online shoppers to ship and return items quickly, thereby strengthening its logistics offering for the growing e‑commerce and returns market.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic evolution of the Ship and Go kiosk from a self-serve shipping tool in 2023 to a more integrated component of FedEx's returns infrastructure in 2024, with explicit linkage to FedEx Returns Technology and Consolidated Returns. The core message about strategic positioning as a hub for e-commerce logistics and returns management is accurately conveyed and semantically equivalent to the ground truth. (2) However, there is a minor quantitative inaccuracy: the LLM states the kiosk was in 'roughly 1,200' locations in 2023, while the ground truth specifies 'approximately 1,300' in both 2023 and 2024. The LLM incorrectly implies growth from 1,200 to 1,300, whereas the ground truth indicates stable presence at ~1,300 locations—no expansion occurred. This affects the precision of the numerical claim and misrepresents the scale trajectory. (3) The multi-hop reasoning is strong: the model correctly synthesizes information across years and services, identifying the shift in emphasis (from shipping to returns integration) and linking it to broader strategic goals in e-commerce logistics. The conclusion about FedEx positioning Ship and Go as a 'core e-commerce hub' is a valid interpretation of the enhanced role in returns management. (4) Despite the numerical discrepancy, the qualitative analysis and contextual relevance are excellent. The answer addresses both parts of the question—evolution between 2023 and 2024, and implications for e-commerce and returns strategy—making it largely correct with only a minor factual error affecting quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 446,
        "total_tokens": 1870
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 6.65,
    "average_quantitative_accuracy": 7.35,
    "average_qualitative_accuracy": 6.91,
    "average_contextual_relevance": 8.73,
    "score_distribution": {
      "excellent": 441,
      "good": 137,
      "fair": 212,
      "poor": 210
    }
  },
  "original_experiment_metadata": {
    "model": "gpt-oss-120b",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 1185.32,
    "timestamp": "2026-02-03T20:45:47.239704"
  }
}